Scientific Opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs : Executive summary by Bolognesi, Claudia et al.
  EFSA Journal 2015;13(1):3978 
 
Suggested citation: EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 
2015. Scientific Opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs: Executive 
summary. EFSA Journal 2015;13(1):3978, 23 pp. doi:10.2903/j.efsa.2015.3978 
Available online: www.efsa.europa.eu/efsajournal  
© European Food Safety Authority, 2015 
SCIENTIFIC OPINION 
Scientific Opinion on the risks to public health related to the presence of 
bisphenol A (BPA) in foodstuffs: Executive summary
1
 




European Food Safety Authority (EFSA), Parma, Italy 
This Executive Summary of the Scientific Opinion, published on 25 March 2015, replaces the earlier version 
published on 21 January 2015.* 
ABSTRACT 
This opinion describes the assessment of the risks to public health associated with bisphenol A (BPA) exposure. 
Exposure was assessed for various groups of the human population in three different ways: (1) external (by diet, 
drinking water, inhalation, and dermal contact to cosmetics and thermal paper); (2) internal exposure to total 
BPA (absorbed dose of BPA, sum of conjugated and unconjugated BPA); and (3) aggregated (from diet, dust, 
cosmetics and thermal paper), expressed as oral human equivalent dose (HED) referring to unconjugated BPA 
only. The estimated BPA dietary intake was highest in infants and toddlers (up to 0.875 µg/kg bw per day). 
Women of childbearing age had dietary exposures comparable to men of the same age (up to 0.388 µg/kg bw per 
day). The highest aggregated exposure of 1.449 µg/kg bw per day was estimated for adolescents. Biomonitoring 
data were in line with estimated internal exposure to total BPA from all sources. BPA toxicity was evaluated by 
a weight of evidence approach. “Likely” adverse effects in animals on kidney and mammary gland underwent 
benchmark dose (BMDL10) response modelling. A BMDL10 of 8 960 µg/kg bw per day was calculated for 
changes in the mean relative kidney weight in a two generation toxicity study in mice. No BMDL10 could be 
calculated for mammary gland effects. Using data on toxicokinetics, this BMDL10 was converted to an HED of 
609 µg/kg bw per day. The CEF Panel applied a total uncertainty factor of 150 (for inter- and intra-species 
differences and uncertainty in mammary gland, reproductive, neurobehavioural, immune and metabolic system 
effects) to establish a temporary Tolerable Daily Intake (t-TDI) of 4 µg/kg bw per day. By comparing this t-TDI 
with the exposure estimates, the CEF Panel concluded that there is no health concern for any age group from 
dietary exposure and low health concern from aggregated exposure. The CEF Panel noted considerable 
uncertainty in the exposure estimates for non-dietary sources, whilst the uncertainty around dietary estimates was 
relatively low. 
© European Food Safety Authority, 2015 
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BACKGROUND AS PROVIDED BY EFSA 
Bisphenol A (BPA) is used as a monomer in the manufacture of polycarbonates and epoxy resins and 
as an additive in plastics. Polycarbonates are used in food contact materials such as reusable beverage 
bottles, infant feeding bottles, tableware (plates and mugs) and storage containers. Epoxy resins are 
used in protective linings for food and beverage cans and vats. 
BPA is authorised for use as a monomer in plastic food contact materials, in accordance with 
Commission Regulation (EU) No 10/2011/EU on plastic materials and articles intended to come into 
contact with foodstuffs
4
. Its use is subject to a specific migration limit SML of 0.6 mg/kg. In addition, 
Commission Implementing Regulation (EU) No 321/2011
5
 places a restriction on the use of BPA in 
the manufacture of polycarbonate infant feeding bottles. 
EFSA has already issued scientific opinions on BPA in 2006, 2008 and in 2010 (EFSA 2006a, 2008; 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF), 2010). 
In its opinion of 2006, EFSA performed a risk characterisation for BPA, including a dietary exposure 
assessment and a hazard characterisation. In this opinion, EFSA established a tolerable daily intake 
(TDI) for BPA of 0.05 milligram per kilogram (mg/kg) body weight per day, based on the no adverse 
effect level of 5 mg/kg body weight per day in multi-generation rodent studies and applying an 
uncertainty factor of 100. 
A new opinion on the toxicokinetics of BPA was adopted by EFSA in 2008. Here, EFSA reaffirmed 
the TDI established in 2006, concluding that age-dependent toxicokinetics differences of BPA in 
animals and humans would have no implication for the assessment of BPA previously carried out by 
EFSA. 
In 2010, the CEF Panel performed a new hazard characterisation of BPA, based on a comprehensive 
evaluation of more recent toxicity data. The CEF Panel concluded that no new scientific evidence had 
been published since the EFSA opinions of 2006 and 2008 that would call for a revision of the current 
TDI. However, it emphasised that there were uncertainties concerning some BPA-related effects of 
possible toxicological relevance, in particular biochemical changes in brain, immune-modulatory 
effects and enhanced susceptibility to breast tumours emerging from studies on developing animals. 
Given several methodological shortcomings in the studies showing these effects, the CEF Panel 
concluded that the relevance of these findings for human health could not be assessed, but that it 
would reconsider its opinion should any new relevant data became available. A CEF Panel member 
expressed a minority opinion based on those uncertainties. 
In 2011, EFSA was asked to provide scientific advice in relation to possible divergences between the 
conclusions of the EFSA Scientific Opinion on BPA of September 2010 and those in the reports on 
BPA published in September 2011 by the French Agency for Food, Environmental and Occupational 
Health and Safety (ANSES). On 1 December 2011, EFSA published a Panel statement
 
on BPA (EFSA 
Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF), 2011a)
 
in which 
the information in the ANSES report was considered not to change the views that the CEF Panel 
expressed in 2010. However, concerning additional data in recent literature, the CEF Panel stated that 
it would need further time for a more in-depth review of the new studies. The CEF Panel also 
underlined that there are ongoing low-dose studies at National Center for Toxicological Research/FDA 
and at National Toxicological Program/National Institute of Environmental Health Sciences which 
aim to address, at least in part, the current uncertainties regarding the potential health effects of BPA.  
                                                     
4 Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into contact with food. OJ 
L 12, 15.1.2011, p. 1 – 89. 
5 Commission Implementing Regulation (EU) No 321/2011 of 1 April 2011 amending Regulation (EU) No 10/2011 as regards the restriction 
of use of Bisphenol A in plastic infant feeding bottles. OJ L87, 2.4.2011, p. 1 – 2. 
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The ANSES risk assessment of BPA (including exposure assessment from the diet as well as from 
other routes) was finalised during the preparation of this scientific opinion and was published in April, 
2013 (ANSES, 2013).  
After its 2011 scientific advice on BPA, EFSA noted that its latest exposure assessment to BPA 
through dietary sources dates back to 2006, and needed to be updated in the light of the data since then 
available. The relevance of a dietary exposure assessment versus a more general exposure assessment 
via various routes of exposure should also be explored. Also, in line with the 2011 conclusions of the 
CEF Panel, it is advisable for EFSA to undertake a full re-evaluation of the safety of BPA, based on 
all the most recent experimental evidence. 
TERMS OF REFERENCE AS PROVIDED BY EFSA 
In accordance with Article 29 (1) of Regulation (EC) No 178/2002
6
, the European Food Safety 
Authority asks its Scientific Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (CEF) to provide by December 2014 a scientific opinion on the risks for public health related to 
the presence of bisphenol A in foodstuffs.  
In particular, the opinion should: 
 evaluate the toxicity of BPA for humans, including specific (vulnerable) groups of the 
population (e.g. pregnant women, infants and children, etc.) and considering all the relevant 
toxicological information available; 
 carry out an exposure assessment on the basis of the occurrence data available in the public 
domain and other occurrence data that may be available, and quantify as far as possible not 
only dietary exposure but also exposure from non-dietary sources; 
 consider specifically the exposure situation for the supposedly most vulnerable groups of the 
population (e.g. pregnant women, infants and children, etc.) and take into account, if available, 
biomonitoring data when assessing the exposure and compare the results with the calculated 
exposure; and 
 characterise the human health risks of BPA taking into account specific groups of the 
population.  
INTERPRETATION OF THE TERMS OF REFERENCE AS PROVIDED BY EFSA 
A three-step approach has been taken by the CEF Panel in developing this full risk assessment of 
BPA. As a first step, the CEF Panel endorsed its draft exposure assessment in July 2013 and released it 
for public consultation (25 July – 15 September, 2013; http://www.efsa.europa.eu/en/
consultationsclosed/call/140117.htm). Secondly, on 12 December 2013 the CEF Panel endorsed its 
draft assessment of BPA health risks addressing specifically BPA hazard assessment and risk 
characterisation, and subsequently issued it for public consultation (17 January – 13 March, 2014; 
http://www.efsa.europa.eu/en/consultationsclosed/call/130725.htm). Following the comments received 
during the two public consultations the CEF Panel has now completed and adopted the full opinion on 
the risk assessment of BPA. In addition, EFSA has compiled a technical report listing all the 
comments received both on the draft BPA exposure assessment and the draft assessment of BPA 
health risks, and has explained whether and how they have been taken into account in the final 
opinion. 
                                                     
6 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general 
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in 
matters of food safety. OJ L31, 1.2.2002, p. 1–24 
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SUMMARY 
This scientific opinion deals with the assessment - by the EFSA CEF Panel - of the risks to public 
health associated with BPA exposure. It consists of three separate documents:  
 Executive summary, which includes the sections in the opinion relevant to both Parts I and II, 
i.e. abstract, background, terms of reference (ToR), interpretation of the ToR and summary of 
Parts I and II;  
 Part I - Exposure assessment, exposure conclusions, list of references and appendices.  
 Part II - Toxicological assessment and risk characterisation, their conclusions, list of 
references and appendices. 
1. Part I – BPA exposure assessment 
Part I of this opinion addresses the second and third part of the terms of reference. It presents an 
exposure evaluation to BPA based on the occurrence data available in the public domain and other 
occurrence data that have been collected through a call for data. Furthermore it includes a 
quantification not only of the dietary exposure, but also of the exposure from non-dietary sources. 
Particular focus is on the exposure for subgroups in the human population, based on different age 
classes. The opinion also considers biomonitoring data to support the exposure estimates obtained by 
calculation, based on the information on occurrence. 
1.1. BPA uses  
BPA (chemical formula C15H16O2, CAS No 80-05-7 and EC No 201-245-8) is an organic chemical 
used in the manufacture of polycarbonate (PC) plastics, epoxy resins and other polymeric materials 
and also for certain paper products (thermal paper e.g. for cash receipts). PC is used for manufacturing 
food and liquid containers, such as tableware (plates and mugs), microwave ovenware, cookware and 
reservoirs for water dispensers, as well as for non-food applications, such as toys and pacifiers with 
PC shields. BPA-based epoxyphenolic resins are used as protective linings for food and beverage cans 
and as a coating on residential drinking water storage tanks and supply systems. Additionally, BPA 
may be used upstream in the process of manufacturing of some raw materials, which are then used to 
produce food contact materials. BPA is also used in the manufacturing of a number of non-food-
related applications, e.g. epoxy resin-based paints, medical devices, surface coatings, printing inks and 
flame retardants. 
1.2. EU Regulatory framework for BPA 
BPA is authorised for use as a monomer in plastic food contact materials, in accordance with 
Commission Regulation (EU) No 10/2011/EU on plastic materials and articles intended to come into 
contact with foodstuffs
7
. Its use is subject to a specific migration limit (SML) of 0.6 mg/kg. In 
addition, Commission Implementing Regulation (EU) No 321/2011
8
 placed a restriction on the use of 
BPA in the manufacture of PC infant feeding bottles which was introduced in 2011 on the basis of the 
precautionary principle. 
1.3. Potential exposure sources for the general population 
The general population can be exposed to BPA via food/drinking water and/or via the use of non-food 
consumer products such as thermal paper, toys, etc.. Environmental sources can include surface water 
(during swimming) and outdoor air (inhalation of aerosols). In addition, BPA from epoxy-based 
floorings, adhesives, paints, electronic equipment and printed circuit boards may be released into 
                                                     
7 Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into 
contact with food. OJ L 12, 15.1.2011, p. 1 – 89. 
8 Commission Implementing Regulation (EU) No 321/2011 of 1 April 2011 amending Regulation (EU) No 10/2011 as 
regards the restriction of use of Bisphenol A in plastic infant feeding bottles. OJ L87, 2.4.2011, p. 1 – 2. 
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indoor air (including airborne dust) and dust. Environmental sources can potentially contribute to oral 
and dermal exposure, as well as inhalation to BPA. 
1.4. General approach for the exposure assessment 
This opinion presents a detailed analysis of data on food consumption and BPA occurrence in food 
that have become available since the previous EFSA evaluation in 2006. Unlike the opinion adopted in 
2006, the present opinion also addresses the contribution of non-food sources to the overall exposure 
to BPA.  
Average and high total chronic BPA exposures were assessed in different age classes, including 
consideration of those groups that may be more vulnerable: infants, children and women of 
childbearing age (in order to address potential exposure in the fetus and in breastfed infants), whereas 
the assessment of BPA exposure in specific disease states, occupational exposure of workers handling 
BPA containing products, or acute exposure to BPA were not developed in this opinion.  
The exposure assessment involved the estimation of consumer exposure in terms of the following 
three different metrics: 
 External exposure to BPA (in Part I – Exposure assessment) 
The assessment of external exposure considered the different routes (ingestion, inhalation, dermal 
uptake) and sources (e.g. diet, drinking water, air, thermal paper). It estimated the source-specific 
doses reaching the physical barriers in the gastrointestinal and respiratory tracts and of the skin. Route-
specific external exposures to BPA were calculated via the so-called forward modelling approach by 
multiplying source concentrations with the corresponding use frequencies (e.g., food intake, handling 
of thermal paper). 
 Internal exposure to total BPA (in Part I – Exposure assessment) 
The assessment of internal exposure to total BPA considered the route- and source-specific absorption 
fractions to estimate the doses that passed the physical barriers to enter the body. For this purpose 
exposure from all sources and over all routes were combined. 
These internal doses are expressed as doses of total BPA (as no differentiation is made between the 
unconjugated and conjugated BPA). As BPA is completely eliminated via urine, the sum of these 
internal doses is directly comparable to exposure estimates obtained by the so-called backward 
modelling approach from urinary biomonitoring data. 
 
 Aggregated exposure to unconjugated BPA (in Part II – Toxicological assessment and risk 
characterisation) 
The assessment of aggregated exposure used physiologically based pharmacokinetic (PBPK) 
modelling to translate the contributions from the relevant sources (diet and house dust for the oral 
route, thermal paper and cosmetics for the dermal route) into a toxicologically relevant dose metric, 
the area under the curve (AUC) for the serum concentration of unconjugated BPA. A translation into 
AUC is necessary because, in contrast to dermally absorbed BPA, orally (i.e. gastrointestinally) 
absorbed BPA is subjected to the first-pass metabolism before entering the systemic circulation. Based 
on the AUC information, external dermal exposures (thermal paper, cosmetics) were converted to 
equivalent oral exposures which could then be summed up with the external oral exposures (diet, 
house dust) to obtain aggregated exposure estimates. 
1.5. Methods 
Literature sources. A thorough literature search was performed by an independent contractor to 
retrieve scientific studies relevant to the following categories: analytical methods for BPA in food, 
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human biomonitoring of BPA, occurrence of BPA in drinking water, food contact materials, food, 
non-food materials (such as indoor air, dust, thermal printed paper, dental materials and medical 
devices) and in the environment. The search using the terms “bisphenol”, “BPA” alone or combined 
with “food” or “migration” or “water” was conducted on these databases: ISI Web of Knowledge-Web 
of Science, Elsevier Science Direct, Elsevier Scopus, EBSCOhost—OmniFile Full Text Select (H.W. 
Wilson), SpringerLink, Taylor & Francis online, Wiley Interscience. In addition, members of the CEF 
Panel’s Working Group on BPA Exposure searched the scientific literature for additional relevant 
information, e.g. parameters used to estimate skin absorption and physiological data, etc.. 
The publications were then screened against the following eligibility criteria: (i) only primary research 
studies, (ii) language (at least abstract in English), (iii) publication date between January 2006 and 
December 2012 (papers published outside this period were considered only if they provided data in 
areas where no or very few data were available (e.g. data on human milk) or to complete the European 
dataset (e.g. biomonitoring data); (iv) geographical origin of the samples and sample type (only 
European data were used if available); (v) quality of the analytical methods employed. Also grey 
literature was considered as specified in the methodology of Part I of this opinion. 
EFSA call for data. Data were also retrieved through a call for data that EFSA launched in July 2012 
in relation to (i) the occurrence of BPA in food and beverages; (ii) BPA migration from food contact 
materials; and (iii) BPA occurrence in food contact materials. Details on the eligibility and inclusion 
of data received from the call for data are given in Appendix B of Part I of this opinion. 
1.6. Assessment of BPA exposure 
1.6.1. External exposure to BPA  
1.6.1.1. Dietary exposure 
Dietary exposure to BPA has been estimated in different population groups by combining information 
on BPA occurrence in food with the corresponding consumption levels. Average exposure was 
assessed based on average concentration and average consumption data, while high exposure was 
based on average concentration and high consumption.  
A total of 2 516 samples (many of which were pooled samples from the French total diet study) of 
food and beverages were selected as the basis to assess BPA concentrations in the different food 
categories. Data on BPA concentrations from the literature and from the call for data did not show 
major differences and were therefore merged for each food category to be used in the exposure 
calculations. 
Left-censored data, i.e. from samples with concentrations below the limit of detection (LOD) or 
quantification (LOQ), were handled through the substitution method. The lower bound (LB) was 
obtained by assigning a value of zero to all the samples reported as less than the left-censoring limit, 
the middle bound (MB) by assigning half of the left-censoring limit, and the upper bound (UB) by 
assigning the left-censored limit (LOD or LOQ) as the sample result. 
Significant differences in BPA concentration between canned and non-canned food were observed in a 
large majority of food categories, with higher BPA concentrations in the canned food. Seven out of 17 
canned food categories presented a MB average BPA concentration above 30 µg/kg (“Grain and grain-
based products”, “Legumes, nuts and oilseeds”, “Meat and meat products”, “Fish and other seafood”, 
“Herbs, spices and condiments”, “Composite food”, and “Snacks, desserts, and other foods”). Lower 
levels were found in other categories. The average (MB) BPA concentration was lower than 3 µg/kg in 
canned beverages (water, alcoholic and non-alcoholic beverages, fruit and vegetables juices). Among 
the 19 non-canned food categories, the highest levels of BPA were found in the categories “Meat and 
meat products” and “Fish and other seafood” with average (MB) BPA concentrations of 9.4 and 7.4 
µg/kg, respectively. When comparing European with non-European concentration data for food, 
average BPA levels were mostly in the same range. 
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Biomonitoring studies suggested higher levels of BPA in colostrum (produced during the first five 
days after delivery) compared with mature human milk. Due to the very limited availability of 
European data on colostrum, the CEF Panel took into account also the data from a Japanese study, 
despite its severe limitations (analytical determination of BPA by ELISA and long storage time of 
samples). Overall, an average total BPA concentration of 3 µg/L and a modelled high concentration 
estimate of 5.8 µg/L in colostrum were used for exposure assessment during the first five days of life. 
Based on different studies, the average and high concentrations of total BPA in mature human milk 
were estimated to be 1.1 µg/L and 4.0 µg/L, respectively.  
BPA migration data from food contact materials into food simulants, retrieved from the literature and 
EFSA’s call for data, were used to assess the exposure of specific groups of consumers. In particular, 
average BPA migration levels were derived for the following PC articles: water coolers with PC 
reservoirs (0.81 µg/L in water), PC water kettles (0.11 µg/L in warm water), PC filters (0.04 µg/L in 
water), PC tableware and cookware (0.09 and 0.29 µg/L, respectively, in foods that can be consumed 
hot). 
Data from the EFSA Comprehensive European Food Consumption Database (hereafter called the 
Comprehensive Database) were used to assess dietary exposure to BPA in all age groups, excluding 
infants aged 0 to 6 months. Consumption data observed in toddlers were used as an estimate of 
consumption in infants aged 6 to 12 months since no data were available for the latter age class. 
Consumption data from a total of 32 different dietary surveys carried out in 22 different Member 
States covering more than 67 000 individuals are included in the Comprehensive Database. In the 
present assessment the adult age group has been broken down in the following subgroups, comprising 
women from 18 to 45 years (child- bearing age), men from 18 to 45 years, adults from 45 to 65 years, 
and elderly and very elderly (65 years and over). Only a limited number of dietary surveys in the 
Comprehensive Database have information on the type of packaging (canned or non-canned, in 
particular).  
In the case of infants a consumption of 150 g/kg bw per day was used as a standard for both human 
milk and infant formula with the exception of breastfed infants over their first five days of life for 
whom the consumption was assumed to be 75 g/kg bw per day.  
Two scenarios were developed to consider the higher levels of BPA in canned foods compared with 
non-canned foods. In scenario 1 only foods specifically codified as canned in the dietary survey are 
assigned the corresponding occurrence level for BPA. In scenario 2 any food category (at the lowest 
available level of food category classification) which has been codified as canned in at least one 
survey is always considered to be consumed as canned in all dietary surveys included the 
Comprehensive Database.  
Due to a low percentage of left censored samples, in particular among canned foods, the techniques 
used to model data below the LOD or LOQ had a small impact on the average concentration in the 
different food categories and, consequently, on the exposure. Therefore, middle bound average BPA 
concentration values were used in the final exposure assessment. 
Dietary exposure for the population groups older than 6 months  
The modelled dietary exposure (MB) obtained by scenario 2, for infants (6 to 12 months), toddlers (12 
to 36 months) and other children (3 to 10 years) ranged from 290 to 375 ng/kg bw per day for the 
average exposure and from 813 to 857 ng/kg bw per day for the high exposure, respectively. 
Additional dietary exposure from a number of food contact articles was also assessed in specific 
population groups. The highest estimated high exposure from PC tableware and cookware was 
observed for infants and toddlers (14 ng/kg bw per day for PC tableware and 46 ng/kg bw per day for 
cookware). The highest estimated exposures to BPA migrating from water coolers with PC reservoirs 
and PC filters into drinking water were also observed in infants and toddlers (22 ng/kg bw per day for 
water coolers and 3.8 ng/kg bw per day for PC filters). High estimated exposure in residents of 
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buildings with old water pipes repaired with epoxy resins was up to 29 ng/kg bw per day in infants and 
toddlers.  
The modelled dietary exposure obtained by scenario 2, for adolescents, adults (including women of 
childbearing age) and elderly/very elderly, ranged from 116 to 159 ng/kg bw per day for the average 
exposure and from 335 to 388 ng/kg bw per day for the high exposure, respectively. Additional dietary 
exposure from a number of food contact articles was also assessed in specific population groups 
within this population. Estimated exposure from PC kettles ranged from 2 to 3.2 ng/kg bw per day 
with the highest values being observed in adults and the elderly due to their higher consumption of 
coffee and tea.  
Under scenario 1, non-canned “meat and meat products” turned out to be a major contributor to BPA 
average exposure in the large majority of countries and age classes. Canned foods contributed to less 
than 50 % to the average exposure for all age classes. “Vegetables and vegetable products” was the 
only canned food category that contributed up to 25-50 % exposure in some population groups. 
Under scenario 2, canned products dominated in all surveys, with canned “vegetables and vegetable 
products”, “meat and meat products” and “composite food” being the major sources of average BPA 
exposure. The contribution of BPA from non-canned foods ranged from 10 to 25 % exposure, with 
“Meat and meat products” being the major contributor among the non-canned food categories as for 
scenario 1.  
Exposure from non-canned meat and meat products and fish had not been anticipated until the 2013 
report of ANSES on concentrations of BPA in French food. Investigation of these findings is currently 
underway in France (see https://info.agriculture.gouv.fr/gedei/site/bo-agri/instruction-2014-994), but 
until further results are available there is no substantiated explanation for the presence of unconjugated 
BPA in foods of animal origin. It may be due to migration from any food contact materials or from 
articles used in the processing of the product or deconjugation of conjugated BPA occurring during 
processing of the sample. The CEF Panel considered that accumulation of BPA in animal tissues was 
not a likely explanation, given the extensive data showing rapid metabolism and elimination of BPA in 
various animal species. 
Overall, among the population older than 6 months, infants and toddlers presented the highest 
estimated average (375 ng/kg bw per day) and high (857 ng/kg bw per day) dietary exposure. The CEF 
Panel considered that this was mainly due to their higher consumption of foods and beverages per kg 
bw. 
Dietary exposure for infants aged 0-6 months 
For breastfed infants, the estimated average dietary exposure was 225, 165 and 145 ng/kg bw per day 
for infants in the first five days of life, infants from 6 days up to 3 months and infants 4-6 months, 
respectively. The estimated high dietary exposure was 435, 600 and 528 ng/kg bw per day, 
respectively. The CEF Panel noted that, due to the lack of recent European data related to colostrum, 
the estimated dietary exposure in the first five days of life was based on BPA concentration in samples 
collected in Japan in 2000 and generated using ELISA methodology. The CEF Panel noted these 
severe limitations and the resulting uncertainties in the estimates for this age group. 
Average and high additional exposure to infants that would derive from the consumption of herbal tea 
prepared with water heated in a PC kettle would be as low as 6 and 12 ng/kg bw per day, respectively.  
In the case of formula-fed infants (0-6 months), the estimated average and high exposures were 30 and 
80 ng/kg bw per day, respectively. These estimates are based on the assumption that non-PC baby 
bottles and water containing low BPA levels were used to reconstitute the infant formula. Additional 
dietary exposure may occur in specific population groups due to the use of old PC bottles bought 
before the 2011 ban (estimated high exposure: 731 ng/kg bw per day). The percentage of infants to 
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which these cases would apply is unknown. If this percentage was higher than 5 % in some countries, 
it would lead to a high dietary exposure which is significantly higher than 80 ng/kg bw per day.  
Dietary exposure from further sources in other specific population groups of infants was also assessed: 
exposure for infants fed powdered formula reconstituted with water heated in PC kettles was 53 ng/kg 
bw per day (average) and 94 ng/kg bw per day (high).  
Compared with the assessment of dietary exposure to BPA estimated by EFSA in 2006 (up to 11 000 
ng/kg bw per day in infants aged 3 months in one of the scenarios considered), the current estimate in 
the population 0 to 6 months is far lower, due to the improvement of data compared with 2006, which 
previously led to very conservative assumptions in relation to BPA concentration in infant formula and 
to BPA migration from PC bottles.  
1.6.1.2. Non-dietary exposure 
The non-dietary sources considered for this assessment were thermal paper, indoor/outdoor air 
(including air-borne dust), dust, toys and articles which may be mouthed, and cosmetics. An average 
and a high scenario were made for all sources. For the average scenario, average values for all 
parameters, including parameters describing frequency of use, were chosen. For the high scenario, the 
same average parameters were used for absorption rates and occurrence data, but the frequency of use 
parameters was modified to account approximately for the highest 95
th
 percentile among the EU 
population, in line with the methodology used to assess dietary exposure. 
Data on occurrence, migration and transfer of BPA from non-food sources are scarce. The following 
concentration data were selected from the scientific literature and other risk assessment reports to 
calculate exposure in the EU: for air 1 ng/m
3
; for dust 1 460 µg/kg, and for cosmetics (such as body 
wash, and body lotions, etc.) 31 µg/kg. A migration of 0.14 µg/toy product into saliva over a 24 h 
period was assumed. The transfer of BPA from thermal paper to fingers was estimated to be 1.4 
µg/finger considering 10 s of contact with paper. Handling events were assumed as 1 per day for 
adolescents and adults to assess average exposure and as 4.6 per day to assess high exposure. For 
children the handling events were assumed as 0.5 time per day for average exposure and 2 times per 
day for high exposure. The thermal paper was assumed to be handled mainly by the fingertips of three 
fingers of one (average exposure) or two hands (high exposure).  
The estimates of external non-dietary exposure according to source and exposure route are as follows: 
Dust ingestion: for the average scenario the derived exposure values ranged from 0.6 ng/kg bw per day 
in adults to 8.8 ng/kg bw per day in infants. The CEF Panel considered that these are likely to be 
overestimated, because in the original studies soil and dust ingestion rates could not be determined 
separately, and so conservative assumptions were made when deriving the dust ingestion rates. In the 
high exposure scenario the exposure ranged from 1.0 ng/kg bw per day (adults) to 14.6 ng/kg bw per 
day (infants). 
Mouthing of toys: exposure values of 0.2 and 0.01 ng/kg bw per day for the average exposure scenario 
and 0.6 and 0.01 ng/kg bw per day for the high exposure scenario for infants’ and toddlers’ exposure, 
respectively, to rattles (as a proxy for PC mouthing toys) were derived. 
Air inhalation: the average exposure values ranged from 0.2 (adults) to 0.7 ng/kg bw per day (toddlers 
and infants), whereas high exposure levels ranged from 0.3 (adults) to 1.4 ng/kg bw per day (infants). 
Dermal exposure to thermal paper: this scenario applied only to subjects older than 3 years. From 
average assumptions, exposures of 68.8, 93.8 and 58.9 ng/kg bw per day were derived for children, 
adolescents and adults, respectively. For the high exposure, values ranged from 542 (adults) to 
863 ng/kg bw per day (adolescents). 
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Dermal exposure to cosmetics: average exposure ranged from 2.0 (adults) to 4.8 ng/kg bw per day 
(infants). High exposure ranged from 4.0 (adults) to 9.4 ng/kg bw per day (infants). 
The CEF Panel noted that the average values for dust and thermal paper differed by a factor 10 from 
the respective high values. This is due to highly conservative assumption for dust ingestion and 
frequency of and number of fingers handling thermal paper when assessing high exposure. 
1.6.2. Internal exposure to total BPA 
The external exposure values to BPA as derived by forward calculation were transformed into internal 
exposure levels by applying route- and source-specific absorption fractions, namely 100 % absorption 
for both ingestion and inhalation, 10 % for dermal absorption of BPA from thermal paper and 50 % 
for dermal absorption of BPA from cosmetics. The internal levels of total BPA summed up over 
different routes were only used to validate external exposure estimates, by means of a comparison with 
daily urinary excretion of total BPA from biomonitoring studies. Internal levels of total BPA were not 
used for risk characterisation, which only focuses on the toxicologically active unconjugated fraction 
of BPA. 
By forward modelling, the average internal exposure (expressed as ng/kg bw per day) to total BPA 
ranged from 42 to 387 for the overall age class “Infants”, and amounted to 384 for toddlers and 301 
for children 3–10 years old. For the adolescents, women of childbearing age, and all the adult 
populations internal total BPA exposures were estimated to be in the range of 124 to 172 ng/kg bw per 
day. The high internal exposure to total BPA for the overall class of infants ranged from 101 to 
878 ng/kg bw per day, and for toddlers and children 3–10 years old it was estimated around 
870 ng/kg bw per day. Lower levels were estimated for adolescents, women of childbearing age, and 
all the adult populations (between 393 and 473 ng/kg bw per day). 
The estimates for the average and high internal exposure to total BPA in the general population, as 
obtained by the forward modelling approach, were compared with the biomonitoring estimates. The 
focus is on total BPA (conjugated plus unconjugated) in order to provide validation for the external 
exposure levels. 
A relatively large amount of information on urinary BPA concentration was available for Europe 
covering all age classes: children (except 1–3-year-old toddlers), adolescents, and 18–75-year-old 
adults. 
Average and high urinary concentrations of total BPA were multiplied by age-specific urinary output 
rates to obtain estimates of daily urinary excretion for the different age groups. Since absorbed BPA is 
rapidly removed from circulation via conjugation and subsequent renal excretion, the estimates of 
daily urinary excretion can be used as estimates of daily BPA exposure. 
For the average exposure, the following biomonitoring estimates (expressed as ng/kg bw per day) 
were derived: <10 (infants 1–2 months old), 107 (children 3–5 years old), 49 (children 5–10 years 
old), 48 (adolescents), 39 (adults including women of childbearing age), and 56 (the elderly). The 
biomonitoring estimates (expressed as ng/kg bw per day) for high BPA exposure were 161 (infants 1–
2 months old), 676 (children 3–5 years old), 380 (children 5–10 years old), 256 (adolescents), 290 
(adults including women of childbearing age), and 203 (the elderly).  
By comparing estimated internal exposure with biomonitoring data, the forward modelling approach 
gave about 4-fold higher estimates (42–387 vs. <10–107 ng/kg bw per day) than the biomonitoring 
approach for average exposure, and about 2-fold higher for high exposure, demonstrating quite a good 
agreement between these two approaches. The different statistical procedures used to derive central 
tendencies and the scenarios for modelling the dietary and non-dietary exposure may contribute to the 
observed differences. The CEF Panel also noted that there are considerable uncertainties in both 
estimates. 
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1.6.3. Conclusions 
The assessment of external exposure to BPA from all sources showed that diet is the main source in all 
population groups. Specifically, canned food and non-canned meat and meat products are the two 
main dietary contributors to external BPA exposure in the large majority of countries and age classes. 
While canned food as a main source of dietary exposure to BPA is confirmed by the data presented in 
this opinion, exposure from non-canned meat and meat products and fish had not been anticipated 
until the 2013 report of ANSES on concentrations of BPA in French food (see above). Investigation of 
these findings is currently under way, but, until further results are available, there is no substantiated 
explanation for the presence of unconjugated BPA in foods of animal origin.  
Among the population older than six months, infants (6-12 months) and toddlers had the highest 
estimated external average (0.375 µg/kg bw per day) and high (0.857 µg/kg bw per day) dietary 
exposure. This was mainly due to their higher consumption of foods and beverages per kilogram body 
weight. The modelled dietary exposure for adolescents, adults (including women of childbearing age) 
and elderly/very elderly ranged from 0.116 to 0.159 µg/kg bw per day for the average external 
exposure and from 0.335 to 0.388 µg/kg bw per day for the high exposure, respectively. Dietary 
exposure to BPA estimated by EFSA in 2006 in the population older than six months was far higher 
(up to 5.3 µg/kg bw per day in toddlers) compared with the current assessment (up to 0.857 µg/kg bw 
per day for the high exposure of toddlers), owing to the lack of data at that time which led to the use of 
very conservative assumptions in relation to both the level of consumption of canned food and the 
estimated BPA concentration in these foods. 
The current much higher data availability than in 2006 has made it possible for the CEF Panel to carry 
out a more refined dietary exposure assessment for infants. According to the current estimate, BPA 
exposure for infants up to six months (0.03 to 0.225 µg/kg bw per day for average external exposure) 
is much lower than that estimated by EFSA in 2006 for infants within six months of age (≤ 
11 µg/kg bw per day). This was due to the use at that time of very conservative assumptions in relation 
to BPA concentration in infant formula and to BPA migration from PC bottles to account for the lack 
of data. 
Dietary external exposure in women of childbearing age (0.132 and 0.388 µg/kg bw per day for 
average and high exposure, respectively) was similar to that of men of the same age (0.126 and 
0.335 µg/kg bw per day for average and high external exposure, respectively). The minimal 
differences may be related to women consuming different food items, as reported in the individual 
surveys. 
The uncertainty around the estimates of dietary exposure was judged as relatively low compared to 
non-dietary sources of exposure such as thermal paper. 
Thermal paper was the second largest source of external exposure in all population groups above three 
years of age. The modelled estimates for 3–10-year-old children, adolescents, adults (including 
women of childbearing age) and elderly/very elderly ranged from 0.059 to 0.094 µg/kg bw per day for 
the average exposure and from 0.542 to 0.863 µg/kg bw per day for the high external exposure, 
respectively. The CEF Panel considers that more data would be needed for BPA absorption through 
the skin, on skin metabolism and for patterns of thermal paper handling by the general population in 
order to provide a refined estimate of exposure through this source to reduce the uncertainty in the 
estimate. 
In children under the age of three years (except for infants in the first few days of life) dust was the 
second largest source of external exposure to BPA and ranged from 0.009 to 0.015 µg/kg bw per day 
for average and high external exposure, respectively. 
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Average external exposure to BPA from non-dietary sources such as toys and cosmetics was estimated 
to be less than 0.001 µg/kg bw per day and 0.005 µg/kg bw per day, respectively, in all population 
groups. 
For the four age classes covering infants from 1 day up to 6 months, the average internal exposure to 
total BPA, as estimated by forward modelling, ranged from 0.042 µg/kg bw per day to 0.226 µg/kg bw 
per day. The average internal exposure for the population older than six months ranged from 0.301 to 
0.387 µg/kg bw per day in children aged 3 to 10 years and infants aged 6 to12 months and from 0.124 
to 0.172 µg/kg bw per day in the elderly/very elderly and adolescents. 
For the four age classes covering infants from 1 day up to 6 months the high internal exposure to total 
BPA ranged from 0.101 µg/kg bw per day to 0.621 µg/kg bw per day. The high internal exposure for 
populations older than six months ranged from 0.873 to 0.878 µg/kg bw per day in toddlers and infants 
aged 6 to 12 months, and from 0.393 to 0.473 µg/kg bw per day in men and adolescents. 
Internal exposures to total BPA, as estimated by forward modelling, are in good agreement with the 
backward-modelling estimates obtained from urinary biomonitoring, suggesting that it is likely that no 
major exposure sources have been missed for the forward-modelled exposure assessment. It is, 
however, important to highlight the fact that the internal exposure estimation of total BPA includes 
conservative assumptions resulting in likely overestimation of exposure that could in theory have 
hidden other possible sources of exposure. The CEF Panel noted also that there are considerable 
uncertainties in the forward and backward estimates of internal exposure. 
The CEF Panel additionally carried out an assessment of aggregated dietary and non-dietary exposure 
to unconjugated BPA using PBPK modelling. This aggregated exposure assessment included diet and 
house dust (the main oral-route sources) as well as thermal paper and cosmetics (the main dermal-
route sources).  
2. Part II – BPA toxicological assessment and risk characterisation  
Part II of this opinion addresses the first and the fourth part of the terms of reference, i.e. BPA hazard 
assessment, and the risk characterisation for human health associated with BPA exposure. 
2.1. Methods 
Literature sources: A thorough and extensive literature search was outsourced by EFSA to cover the 
period from August 2010 to December 2012. The publications were searched on five online 
databases—namely PubMed, ScienceDirect, Scopus from Elsevier, Web of Knowledge/Science from 
the Institute for Scientific Information, and the Directory of Open Access Journals (DOAJ)—using the 
search strings “bisphenol” or “BPA” (without any additional search terms). Additional sources of 
information were the list of published scientific studies on BPA submitted by Réseau Environnement 
Santé to the European Commission (EC) and received by EFSA on 19 February 2013; pre-(July)2010 
studies previously identified as key studies by various risk assessment bodies including EFSA; pre-
(July)2010 studies not previously evaluated by EFSA because they did not match the inclusion criteria 
established for the 2010 opinion, e.g. non-oral studies, single-dose studies, studies addressing BPA 
exposure only during adult age and genotoxicity studies (searched from 2006 onwards); and some 
studies available in 2013 (as per the literature search carried out by an EFSA contractor) selected on a 
case-by-case basis (based on expert judgement) based on their relevance to critical review questions 
and/or their methodological soundness. The literature cited in the comments of the public consultation 
and therefore published by the closing date of the consultation (17 March 2014) was an additional 
source of evidence. 
The studies used for the hazard identification and characterisation of BPA were then grouped 
according to 10 macro-areas of interest, including toxicokinetics and metabolism, general toxicity, 
reproductive and developmental effects. The studies grouped by macro-area were assigned to the 
working group on BPA toxicology for evaluation, including appraisal of their strengths and 
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weaknesses. In vitro studies and studies on the mechanisms of action of BPA were used primarily as 
supplementary information for the toxicological evaluation. 
2.2. Hazard identification 
For the hazard identification of BPA, the Weight of Evidence (WoE) approach was structured in such 
a way as to facilitate consistent treatment of the evidence and to document this in a tabular format, as 
described in more detail in Appendix A of this opinion. The WoE evaluation for each toxicological 
endpoint was divided into one or several parts addressing different questions considered by the CEF 
Panel to be relevant for hazard identification of BPA, e.g. “Is there an association between BPA 
exposure and reproductive effects in humans?”. As already indicated, the conclusions of earlier 
assessments by EFSA in 2006 and/or 2010 were taken as a starting point for each question. 
Subsequently, for each question, the relevant publications were organised into a number of “lines of 
evidence”, addressing different findings or considerations that provide an answer to the question 
concerned. The strengths and weaknesses of each line of evidence, and of the evidence underpinning 
the earlier assessments, were briefly summarised in a tabular format, to facilitate a conclusion to be 
drawn on the likelihood that exposure to BPA was associated with a particular effect. This conclusion 
was categorised depending on the strength of the overall experimental evidence for the effect, as 
follows. Note that, on this scale, "As likely as not" means a level of likelihood between "Unlikely" and 
"Likely", where it is about equally likely that BPA causes, or does not cause, the effect.  




From “-as likely as not- to likely” 
As likely as not 




The CEF Panel would like to underline that this classification applies solely to BPA hazard 
identification and not to the assessment of human risks from BPA exposure.  
This approach was adopted independently for (1) human studies reporting effects of BPA, (2) animal 
studies and (3) in vitro studies, where considered appropriate. An overall conclusion was then drawn 
regarding the likelihood that BPA could be associated with the effect in question in the human 
population, based on a WoE approach in humans, animals and/or in vitro studies. 
The toxicokinetics of BPA were similarly reviewed using the conclusions of previous evaluations and 
the results of new toxicokinetic studies on BPA published since the 2010 EFSA opinion on BPA. In 
this case, however, a WoE approach was not found to be necessary to reach an overall conclusion on 
the toxicokinetics of BPA in humans and experimental animals. 
The conclusions of the CEF Panel on the hazard identification step for BPA in relation to each 
endpoint considered are summarised in the following sections. 
2.2.1. Toxicokinetics 
 Species- and life-stage dependent differences in the toxicokinetic profile of BPA must be 
considered when comparing toxicokinetic data from different species.  
 Conjugation to BPA-glucuronide is the major metabolic pathway of BPA in humans, non-
human primates and rodents. Glucuronidated BPA is a biologically inactive form of BPA at 
the oestrogen receptors (ERs); however it cannot be excluded that the glucuronidated form 
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may have effects at ER independent sites. BPA can also be conjugated via sulfation to a 
lower extent.  
 The oral systemic bioavailability of unconjugated BPA in adults is: 2.8 % in rats, 0.45 % in 
mice and 0.9 % in monkeys, based on oral versus intravenous toxicokinetic data.  
 Unconjugated BPA and BPA-conjugates are observable at low concentrations in the 
amniotic fluid of rats and monkeys in comparison with serum levels. In early pregnancy 
exposure of the fetus might be greater compared with later pregnancy after i.v. exposure to 
BPA.  
 BPA is present in rat milk from BPA-treated dams in both unconjugated and conjugated 
forms. In rat milk, BPA-glucuronide comprises about 80 % of the total BPA concentration. 
Pup exposure via lactation is low, i.e. about 1/300 of the maternal dose. Unconjugated BPA 
has also been reported in human milk. 
 BPA-conjugating enzymes (UDP-glucuronyl-transferases (UGT) and sulfotransferases 
(SULT)) are polymorphic in humans. The default intraspecies uncertainty factors used to 
derive a health-based guidance value are considered sufficient to account for possible 
differences in rates of metabolism of BPA between human individuals. 
 A solid base of toxicokinetic studies in various laboratory animal species provides internal 
dose metrics for neonatal-to-adult stages and for different routes of exposure. Moreover, 
PBPK models have been developed to predict the internal exposures in laboratory animals 
and humans in a route-specific manner.  
 Overall, this body of information permits extrapolation to humans and the application of the 
human equivalent dose (HED) concept for providing HEDs for points of departure derived 
from critical animal data. This was achieved by estimating human equivalent dose factors 
(HEDF) from the ratio of the Area Under the Curve (AUC) for the test species and AUCs for 
humans.  
 Available experimental evidence indicates a 24-h percutaneous penetration of BPA across 
human skin of 2.3–8.6 %. For exposure scenarios with dermal contact to thermal paper, the 
CEF Panel used a conservative value of 10 % dermal absorption. The CEF Panel did not 
consider skin metabolism (conservative decision). For scenarios with aggregated oral and 
dermal exposures, PBPK modelling was used to estimate the internal dose metrics (AUCs) 
for unconjugated BPA, with which equivalent oral exposures were subsequently calculated. 
2.2.2. General toxicity 
 BPA was found to affect kidney and liver weight in parental animals and in all the 
generations of rats and mice examined in multi-generation studies. These effects were 
considered by EFSA (2006, 2010) as relevant systemic effects for the identification of a 
NOAEL. In mice the increased kidney weight was associated with nephropathy at the 
highest BPA dose. Liver weight was increased in rats (relative weight) and mice (both 
absolute and relative weight). The latter species also showed hepatocellular hypertrophy.  
 The CEF Panel re-confirmed that the changes in the kidney and liver are critical endpoints in 
BPA toxicity and therefore took them forward for hazard characterisation. 
2.2.3. Reproductive and developmental effects 
 Only limited conclusions can be drawn from human studies on the likelihood of associations 
between BPA exposure during pregnancy and disturbed foetal growth, or maternal and infant 
decreased thyroid function. The evidence is not sufficient to infer a causal link between BPA 
exposure and reproductive effects in humans.  
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 Data considered in previous EFSA opinions show that BPA is a reproductive toxicant at high 
dose levels. On balance, the evidence from new lower dose (below 3.6 mg/kg bw per day, 
that corresponds to the NOAEL for general toxicity transformed in HED) animal studies for 
changes in reproductive function arising from in utero exposure to BPA remains 
contradictory and highly variable between studies. Furthermore, the biological relevance to 
humans of some of the effects of BPA exposure observed in some animal studies (e.g. 
reduced ano-genital distance in females) is not well understood. The CEF Panel noted that 
there is some evidence for effects of BPA exposure on several parameters indicative for 
changes in the reproductive system in adult male animals at dose levels below 3.6 mg/kg bw 
per day, although these effects were modest. It is not possible to conclude that these changes 
are reflective of changes in reproductive performance, since the studies rarely included a 
forced/continuous breeding phase in adulthood to establish reduced fertility. However, in 
several multi-generation studies no effects were observed at dose levels as low as 3 g/kg 
bw per day up to at least 50 mg/kg bw per day.  
 The CEF Panel re-confirmed that BPA is a reproductive toxicant at high dose levels.  
 Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to 
reproductive and developmental effects of BPA at low doses (below the HED of 3.6 mg/kg 
bw per day). Since the likelihood level for this endpoint is less than "likely" (see Box 1), this 
endpoint was not taken forward for assessing the toxicological reference point, but was taken 
into account in the evaluation of uncertainty for hazard characterisation and risk 
characterisation. 
2.2.4. Neurological, neurodevelopmental and neuroendocrine effects 
 There are indications from prospective studies in humans that prenatal BPA exposure (BPA 
exposure during pregnancy) may be associated with altered child behaviour in a sex-
dependent manner. However, the associations were not consistent across the studies and it 
cannot be ruled out that the results are confounded by diet or concurrent exposure factors. 
The associations reported do not provide sufficient evidence to infer a causal link between 
BPA exposure during pregnancy or childhood and neurodevelopmental effects in humans.  
 A number of new studies report changes that may indicate effects of BPA on brain 
development (effect on neurogenesis and on gene expression, neuroendocrine effects, effects 
on the morphology of certain brain regions, etc.). Whether such changes are mechanistically 
related to the neurobehavioral responses reported following exposure is attempted addressed 
by some studies but with inconsistent results.  
 Several new animal studies investigated anxiety-like behaviour, learning and memory, social 
behaviour and sensory-motor function. Some studies report changes in anxiety-like 
behaviour after BPA exposure. Some, but not all, studies reported significant impairment of 
either learning and/or memory capacities. A few studies also report effects on social 
behaviour and sensory-motor function. However, the studies present methodological 
shortcomings, such as small sample size, lack of consideration of the litter effect, not 
properly controlled variability of exposure through diet and inadequate statistics. Moreover 
the results from different studies are inconsistent.  
 Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to 
neurological, neurodevelopmental and neuroendocrine effects of BPA. Since the likelihood 
level for this endpoint is less than "likely" (see Box 1), this endpoint was not taken forward 
for assessing the toxicological reference point, but was taken into account in the evaluation 
of uncertainty for hazard characterisation and risk characterisation.  
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2.2.5. Immune effects 
 Based on recent studies, there are indications that BPA exposure may be linked to 
immunological outcomes in humans, although these studies had limitations and confounding 
factors may have been present. A causal link between BPA exposure during pregnancy or in 
childhood and immune effects in humans cannot be established.   
 Studies in animals lend support to the possibility of immunological effects of BPA. 
However, most of these studies suffered from shortcomings in experimental design and 
reporting. Although dose-responses could not be confidently established in most studies, a 
dose-related effect was observed for allergic lung inflammation. 
 Using a WoE approach, the CEF Panel assigned a likelihood level of “-as likely as not- to 
likely” to immunotoxic effects of BPA. Since the likelihood level for this endpoint is less 
than "likely" (see Box 1), this endpoint was not taken forward for assessing the toxicological 
reference point, but was taken into account in the evaluation of uncertainty for hazard 
characterisation and risk characterisation.  
2.2.6. Cardiovascular effects 
 All but one study, among the newly considered human studies in relation to cardiovascular 
effects since the 2010 EFSA opinion, are cross-sectional and thus unsuitable to study BPA 
exposure-disease associations on their own. There are indications from one prospective study 
that BPA may be associated with such effects but overall a causal link between BPA 
exposure and cardiovascular effects in humans cannot be established.  
 There are insufficient animal data to suggest that BPA has an effect on cardiac function or 
causes cardiotoxicity.  
 Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to 
cardiovascular effects of BPA. Since this likelihood level is less than “likely”, this endpoint 
was not taken forward for risk characterisation. It cannot be ruled out that the observed 
association between exposure to BPA and cardiovascular effect in the epidemiological 
studies is confounded by diet or other concurrent exposure factors. This association does not 
provide sufficient evidence to infer a causal link between BPA exposure and cardiovascular 
effects in humans. Since there is also a lack of information on the dose-relationship for this 
association, and since there were only very limited number of animal studies on this 
endpoint, this endpoint was not included in the uncertainty analysis. 
2.2.7. Metabolic effects 
 Of the reviewed human studies on metabolic effects only two were prospective while 22 
were cross-sectional and thus not suitable on their own to study exposure-disease 
associations. Inconsistent with the results of cross-sectional studies one prospective study 
found that a higher BPA concentration in maternal urine during pregnancy was associated 
with a lower level of obesity in daughters. A causal link between BPA exposure and 
metabolic effects in humans cannot be established.  
 A number of studies in pre- and postnatally exposed rats and mice indicate that BPA 
exposure could have an effect on metabolic function as evidenced by effects on glucose or 
insulin regulation or lipogenesis, and body weight gain (short-term studies). However, 
based on the results from other studies with a longer duration (e.g. 90 days) there is no 
convincing evidence that BPA is obesogenic after intrauterine exposure or in longer-term 
studies. 
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 Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to 
metabolic effects of BPA. Since the likelihood level for this endpoint is less than "likely" 
(see Box 1), this endpoint was not taken forward for assessing the toxicological reference 
point, but was taken into account in the evaluation of uncertainty for hazard characterisation 
and risk characterisation.  
2.2.8. Genotoxicity 
 The available data support that BPA is not mutagenic (in bacteria or mammalian cells), or 
clastogenic (micronuclei and chromosomal aberrations). The potential of BPA to produce 
aneuploidy in vitro was not expressed in vivo. The positive finding in the postlabelling 
assays in vitro and in vivo is unlikely to be of concern, given the lack of mutagenicity and 
clastogenicity of BPA in vitro and in vivo. 
 Using a WoE approach, the CEF Panel assigned a likelihood level of “unlikely” to BPA 
genotoxicity.  
2.2.9. Carcinogenicity 
 Very few epidemiological studies published to date have investigated a possible association 
between exposure to BPA and incidence of certain cancers, specifically breast cancer and 
meningioma. These studies do not allow any conclusion to be drawn regarding the 
carcinogenicity of BPA in humans.  
 BPA was not carcinogenic in two standard oral carcinogenicity studies in rats and mice. In a 
more recent study, female but not male mice, exposed to approximately 10 mg/kg bw per 
day BPA from in utero up to postnatal day (PND) 21, developed significantly more 
hepatocellular tumours (adenomas and carcinomas together) with or without preneoplastic 
lesions after a stop-exposure period of 10 months. Additional rodent studies on perinatal 
exposure to BPA investigated the potential carcinogenic effect in mammary gland. Due to 
weaknesses in these studies the results do not provide convincing evidence that BPA is 
carcinogenic to the liver during adult life or in mammary gland following perinatal exposure.  
 Using a WoE approach, the CEF Panel assigned a likelihood level of “unlikely to - as likely 
as not -” to carcinogenic effects of BPA. Since the likelihood level for this endpoint is less 
than "as likely as not” (see Box 1), this endpoint was not taken into account in the evaluation 
of uncertainty for hazard characterisation and risk characterisation. 
2.2.10. Proliferative and morphological changes potentially related to carcinogenesis 
 Earlier evidence for BPA effects on cell proliferation and differentiation in the mammary 
gland and other tissues (e.g. prostate or testis) has been supported by recent studies. The 
proliferative changes in the mammary gland reported in these new studies, including a non-
human primate study, are however insufficient to conclude that there is a link to cancer 
development, although there might be a possible role of BPA in increasing the susceptibility 
to mammary gland carcinogenesis later in life.  
 The proliferative responses and possibly enhanced sensitivity to mammary gland 
carcinogens seen in animal studies might be of relevance for human health and are therefore 
included in the risk assessment.  
 Using a WoE approach, the CEF Panel assigned a likelihood level of “likely” to BPA 
induced proliferative changes in the mammary gland. Therefore, this endpoint was brought 
forward for hazard characterisation and for uncertainty analysis. 
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 The CEF Panel considered that the evidence for proliferative changes induced by BPA in 
other organs (e.g. prostate or testis) is currently too limited to reach any conclusion.  
2.2.11. Mechanistic studies with BPA including epigenetic effects 
 Mechanistic studies published since 2010 continue to support the conclusion that BPA 
affects a number of receptor-dependent and independent signalling pathways, resulting in 
effects on hormone homeostasis and gene expression as well as in cytogenetic and epigenetic 
effects.  
 The CEF Panel confirmed its conclusion in its opinion of 2010 that no single clearly defined 
mode of action of BPA can be identified that can contribute substantially to the 
understanding of the potential effects of BPA in humans.  
2.3. Hazard characterisation 
The WoE approach to hazard identification has been used to identify the critical toxicological effects 
for BPA, following prenatal or postnatal exposure, or both. The subsequent step in the risk assessment, 
namely hazard characterisation, was carried out for only those endpoints for which the overall 
likelihood for the specific effect was considered as “likely”. Dose-response relationships (hazard 
characterisation) were examined for the studies considered by the CEF Panel to be the most reliable, in 
order to provide a reference point for the derivation of a health-based guidance value. 
The CEF Panel considered that the “likely” effects indicative of general toxicity in rats and mice that 
were already described in the EFSA 2010 opinion should be maintained as a critical endpoint for risk 
assessment of BPA. Additionally the CEF Panel concluded that BPA-induced effects on the mammary 
gland of rats, mice and monkeys exposed pre- or perinatally were “likely” effects. These latter 
conclusions resulted from the CEF Panel’s evaluation of new evidence published since EFSA’s 
previous risk assessment in 2010 and of earlier studies using the subcutaneous route of administration 
(not considered in the EFSA 2010 opinion). The CEF Panel also considered that recent scientific 
literature has provided additional indications (compared with its 2010 evaluation) of reproductive and 
developmental effects at doses of BPA below the NOAEL for general toxicity as well as neurological/ 
neurodevelopmental/neuroendocrine, immune-modulatory and metabolic effects. In light of the 
methodological shortcomings identified in the evaluated studies, the CEF Panel considered that none 
of these effects could be considered as “likely” by the WoE approach. Instead, they were considered in 
a thorough and structured uncertainty analysis, the results of which were taken into account in hazard 
and risk characterisation.  
The CEF Panel has carried out dose-response (Benchmark Dose [BMD]) modelling on the data for 
general toxicity and for the proliferative changes in the mammary gland. The analysis of the mammary 
gland data revealed large differences in the BMD estimates obtained with the various models and wide 
BMD confidence intervals obtained with some of the models. These estimates could not be used for 
the derivation of a health-based guidance value. Therefore, the proliferative changes in the mammary 
gland were taken into account in the evaluation of uncertainty for hazard characterisation and for risk 
characterisation. 
The CEF Panel therefore used only the endpoint “general toxicity” for risk characterisation, 
specifically the mean relative kidney weight in a two-generation study in mice, and calculated a 
BMDL10 of 8 960 µg/kg bw per day.  
Subsequent to the 2010 opinion, new toxicokinetic data have become available which allow a more 
accurate substance-specific extrapolation of data from animals to humans, using the human equivalent 
dose (HED) approach. The human equivalent dose factor (HEDF) of 0.068 for oral exposure of adult 
mice was applied to the BMDL10 of 8 960 µg/kg bw per day, which results in a HED of 609 µg/kg bw 
per day. The CEF Panel decided to use the HED value of 609 µg/kg bw per day as the reference point 
for establishing a health-based guidance value for BPA. 
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The CEF Panel also developed criteria
9
 for nonmonotonic dose responses (NMDRs) and reviewed 
studies reporting a NMDR for BPA. None of the studies fulfils these criteria. Overall the CEF Panel 
concluded that the available data do not provide evidence that BPA exhibits a NMDR for the 
endpoints considered (reprotoxicity/development, neurotoxicity/behavioural effects, metabolic effects, 
proliferative changes in mammary gland).  
2.3.1. Uncertainties in hazard characterisation 
The overall uncertainty evaluation included the effects on the mammary gland as well as on the 
reproductive, metabolic, neurobehavioural and immune systems. The CEF Panel concluded that the 
health-based guidance value should cover the lowest dose in the dose range for which the likelihood 
approaches “likely” from the overall uncertainty evaluation, taking into account uncertainty of all the 
evaluated endpoints as well as their relevance and adversity to humans. The uncertainty evaluation 
approached “likely” in the (HED) dose range of 100–1000 µg/kg bw per day. The CEF Panel therefore 
decided that the uncertainty regarding the above mentioned effects at the HED of 100 µg/kg bw per 
day and higher should be taken into account when establishing a health-based guidance value by 
including an extra factor in establishing the TDI. Thus, as the reference point was 609 µg/kg bw per 
day based on the mean relative kidney weight and the lower end of the dose-range for which the 
uncertainty evaluation for other endpoints approached “likely” is 100 µg/kg bw per day, a factor of 6 
was applied.  
2.3.2. Health-based guidance value 
In deriving a health-based guidance value, the CEF Panel used an uncertainty factor of 2.5 for inter-
species differences (1 for toxicokinetics and 2.5 for toxicodynamics, reflecting the fact that 
toxicokinetic differences have been addressed by use of the HED approach) and an uncertainty factor 
of 10 for intra-species differences. In addition, the CEF Panel considered that the extra factor of 6 
should be included to take into account the uncertainty in the database, i.e. mammary gland and 
reproductive, neurobehavioural, immune and metabolic systems.  
The CEF Panel applied, therefore, an overall uncertainty factor of 150 to the HED of 609 µg/kg bw 
per day and established a temporary Tolerable Daily Intake (t-TDI) for external oral exposure to BPA 
in humans of 4 µg/kg bw, based on the mean relative kidney weight effect in mice. The CEF Panel 
designated the TDI as temporary, pending the outcome of the long-term study in rats involving 
prenatal as well as postnatal exposure to BPA, currently being undertaken by NTP/FDA.  
2.4. Risk characterisation 
The following table shows the aggregate exposures figures that were used for the risk characterisation. 
  
                                                     
9 (i) at least two adjacent doses departing from monotonicity or support for the NMDR from a similar study (same species, 
similar treatments, similar sampling time) on the same effect (this criteria is relevant to reduce the chance for an incidental 
finding).  
(ii) a plausible underlying mode of action/overarching concept;  
(iii) the reliability of the study and the relevance of the effect for human health should be considered as medium or high (as 
expressed in Appendix B and C); the reliability of the study results should also include an appropriate statistical treatment of 
the reported data 
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Table 1:  Summary table on average (A) and high (H) exposure (µg/kg bw per day) from 
dietary and non-dietary sources to BPA in the different age groups of the general population. 















Infants 1-5 days 
(breastfed) 
A 0.225 
- - - - 
H 0.435 
Infants 6 days - 3 months 
(breastfed) 
A 0.165 0.009 
- - 
0.009 
H 0.6 0.015 0.015 
Infants 4-6 months (breastfed) 
A 0.145 0.009 
- - 
0.009 
H 0.528 0.015 0.015 
Infants 0-6 months (formula 
fed) 
A 0.03 0.009 
- - 
0.009 
H 0.08 0.015 0.015 
Infants 6-12 months 
A 0.375 0.009 
- - 
0.009 
H 0.857 0.015 0.015 
Toddlers 1-3 years 
A 0.375 0.007 
- - 
0.007 
H 0.857 0.012 0.012 
Children 3-10 years 
A 0.290 0.003 0.053 0.008 0.064 
H 0.813 0.005 0.424 0.016 0.445 
Adolescents 10-18 years 
A 0.159 0.002 0.113 0.015 0.13 
H 0.381 0.003 1.036 0.029 1.068 
Women 18-45 years 
A 0.132 0.0006 0.071 0.012 0.084 
H 0.388 0.001 0.650* 0.024* 0.675* 
Men 18-45 years 
A 0.126 0.0006 0.071 0.012 0.084 
H 0.335 0.001 0.650 0.024 0.675 
Other adults 45-65 years 
A 0.126 0.0006 0.071 0.012 0.084 
H 0.341 0.001 0.650* 0.024 0.675* 
Elderly and very elderly 
65 years and over 
A 0.116 0.0006 0.071 0.012 0.084 
H 0.375 0.001 0.650* 0.024* 0.675* 
* It is assumed that the dermal exposures as expressed as equivalent oral doses for the age group men 18-45 years also are 
representative for the age groups women 18-45 years, other adults 45-65 years, and elderly and very elderly 65 years and 
over, assuming that the toxicokinetics are not significantly different between these age groups.  
 
Comparison of the estimates for high dietary exposure for all age groups with the t-TDI of 4 µg/kg bw 
per day showed that the dietary exposure in all age groups (including the most exposed groups, i.e. 6-
12 months infants and toddlers with levels of 0.857 µg/kg bw per day) was more than 4-fold below the 
t-TDI, indicating no health concern from dietary exposure alone. The additional contribution from 
other oral sources, like dust and toys mouthing (high exposure up to 0.015 µg/kg bw per day), did not 
change this conclusion. 
Comparison of the aggregated estimates for exposure to dietary and non-dietary sources of “children 
3-10 years” and adolescents with the t-TDI showed that even when the high exposure estimates for 
dietary and non-dietary sources are combined, the aggregated exposure for children 3-10 years 
(0.813 + 0.445 = 1.258 µg/kg bw per day) and adolescents (0.381 + 1.068 = 1.449 µg/kg bw per day) 
will be approximately 3-fold below the t- TDI.  
The aggregated high dietary and non-dietary exposures (including oral and dermal sources) for women 
(0.388 + 0.675 = 1.063 µg/kg bw per day) and men (0.335 + 0.675 = 1.010 µg/kg bw per day) are 
mostly identical and they are lower than those for adolescents and children 3-10 years. The CEF Panel 
considered that the exposure estimates (up to approximately 1 µg/kg bw per day) for men and for 
women including pregnant women and prenatally exposed children, will be approximately 4-fold 
below the t-TDI of 4 µg/kg bw per day. 
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Having evaluated the overall uncertainty of this assessment, the upper bound of the uncertainty 
interval for dietary BPA exposure alone did not exceed the t-TDI for any age group. Upper bounds for 
the uncertainty of high but not average aggregate exposure estimates to BPA exceed the t-TDI but the 
lower bounds are considerably lower than the t-TDI. The wide uncertainty intervals are caused by 
uncertainty about the magnitude of external exposure to BPA from thermal paper, about the proportion 
of the amount of BPA which is absorbed through the skin, and about the choice of PBPK model for 
converting dermal exposures to oral equivalents.  
OVERALL CONCLUSIONS 
The CEF Panel concludes that the dietary exposure to BPA for the highest exposed groups, which 
includes infants, children and adolescents, is below the t-TDI of 4 µg/kg bw per day, indicating that 
there is no health concern for BPA at the estimated levels of exposure. These conclusions also apply to 
prenatally exposed children and to the elderly.  
In addition, the CEF Panel concludes that the central estimates for aggregated exposure to BPA via the 
dietary and non-dietary sources (dust, toys, cosmetics and thermal paper) for the highest exposed 
groups, which includes infants, children and adolescents, is also below the t-TDI of 4 µg/kg bw per 
day, indicating that the health concern for BPA is low at the estimated levels of exposure. However, 
the CEF Panel noted that there is a considerable uncertainty in the exposure estimate for the non-
dietary sources. 
RECOMMENDATIONS 
Reflecting the uncertainties surrounding this risk assessment of BPA as outlined in the previous 
Section, the CEF Panel considers that further research in the following areas would be useful:  
 Further work to refine the Human Equivalent Dose approach used in this opinion to 
extrapolate from experimental results in animals to humans, including further refinement 
of the toxicokinetics of unconjugated BPA in mice  
 Further refinement of the human PBPK modelling applied in the opinion 
 Further studies on the frequency and extent of dermal contact with BPA containing 
materials 
 Further studies on the extent of dermal absorption following exposure to BPA by the 
dermal route in humans and the toxicokinetics of BPA following dermal absorption in 
humans and experimental animals 
 Mechanistic studies in the kidney to determine the mode of action of BPA in this organ  
 Further research on the significance of proliferative and morphological changes in 
mammary gland following exposure to BPA and the possible relevance for the 
development of breast cancer 
 Further research on the potential adverse health effects of BPA for which there are 
uncertainties and that were therefore not definitely considered as “likely” in this opinion, 
in particular reproductive, neurobehavioural, immunological and metabolic endpoints, 
using validated, robust methodology  
 Further investigations designed to explore the occurrence of non-monotonic dose 
responses following in vivo exposure to BPA 
 Investigations to clarify the extent and the sources of unconjugated BPA in meat and fish. 
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ASSESSMENT 
1. Introduction  
Bisphenol A (BPA) is an industrial chemical that is widely used as a monomer or additive for the 
manufacture of polycarbonate (PC) plastics and epoxy resins and other polymeric materials and also 
certain paper products (e.g. thermal paper). The properties of PC, e.g. rigidity, transparency and 
resistance, make these plastics particularly suitable for many technical applications. PC is used for 
food and liquid containers, such as tableware (plates and mugs), microwave ovenware and reservoirs 
for water dispensers, and non-food applications such as toys and pacifiers with PC shields. BPA-based 
epoxyphenolic resins are used as protective linings for food and beverage cans and as a coating on 
residential drinking water storage tanks. BPA is also used in a number of non-food-related 
applications, e.g. epoxy resin-based paints, medical devices, surface coatings, printing inks, thermal 
paper and flame retardants and also in plastic materials such as CDs, DVDs and parts of electronic 
products. 
The scientific opinion on BPA deals with the assessment – by the EFSA CEF Panel –- of the risks to 
public health  associated with BPA exposure. It consists of three separate documents: Executive 
summary; Part I – Exposure assessment, Part II – Toxicological assessment and risk characterisation. 
This document refers to Part I. 
For the sake of clarity, it should be noted that when the text makes reference to another section (or 
Appendix) of the opinion, this generally refers to a section included in the same part of the opinion, 
unless otherwise stated. In this latter case, the specific part of the opinion (i.e. Executive summary, 
Part I or Part II), to which the mentioned section belongs, is clearly mentioned. 
 
1.1. EU and national provisions regarding BPA 
BPA was first evaluated in 1984 by the Scientific Committee on Food (SCF, 1986
4
) for use in plastic 
materials and articles intended to come into contact with foodstuffs and established a Tolerable Daily 
Intake (TDI) of 0.05 mg/kg bw. It was subsequently listed as a permitted monomer in Annex II of 
Commission Directive 90/128/EEC
5
 with a specific migration limit (SML) of 3 mg/kg food. In 2002, 
the SCF reduced the TDI (SCF, 2002
6
) and a lower SML total (T) of 0.6 mg/kg was subsequently set 
to reflect this in Commission Directive 2004/19/EC
7
. This Directive was an amendment to the then 
Commission Directive 2002/72/EC
8
 relating to plastic materials and articles intended to come into 
contact with foodstuffs, which also authorised its use as an additive. In 2006, EFSA reduced the 
uncertainty factor, establishing a TDI of 0.05 mg/kg bw, although the SML(T) remained at 0.6 mg/kg.  
In 2011, Commission Directive 2011/8/EU
9
 placed a restriction on the use of BPA in the manufacture 
of PC infant feeding bottles as from 1 March 2011 and the placing on the market of these feeding 
bottles as from 1 June 2011, on the basis of the precautionary principle. This was subsequently 
                                                     
4 Reports of the Scientific Committee for Food (Seventeenth series). http://ec.europa.eu/food/fs/sc/scf/reports/
scf_reports_17.pdf. 
5 Commission Directive of 23 February 1990 relating to plastic materials and article intended to come into contact with 
foodstuffs (90/128/EEC). OJ L 75, 21.3.1990, p. 19 – 40. 
6 Opinion of the Scientific Committee on Food on Bisphenol A (Expressed on 17 April 2002). http://ec.europa.eu/
food/fs/sc/scf/out128_en.pdf 
7 Opinion of the Scientific Committee on Food on Bisphenol A (Expressed on 17 April 2002). http://ec.europa.eu/
food/fs/sc/scf/out128_en.pdf 
8 Commission Directive 2002/72/EC of 6 August 2002 relating to plastic materials and articles intended to come into contact 
with foodstuffs. L 220, 15.8.2002, p. 18 – 58. 
9 Commission Directive 2011/8/EU of 28 January 2011 amending Directive 2002/72/EC as regards the restriction of use of 
Bisphenol A in plastic infant feeding bottles, OJ L 26, 29.1.2011, p. 11–14. 
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reflected in Commission Implementing Regulation (EU) No 321/2011
10
 amending Commission 
Regulation (EU) No 10/2011/EU
11
 on plastic materials and articles intended to come into contact with 
foodstuffs. This latter Regulation was introduced as a replacement to the previous Commission 
Directive 2002/72/EC and continues to authorise BPA for use as a monomer subject to the specified 
restrictions. 
Bans on the use of BPA for food packaging intended for young children (zero to three years old) have 
been proposed by several European Union (EU) Member States. 
In May 2010, Denmark banned the use of BPA in infant feeding bottles and all food contact materials 
of foods particularly intended for children between zero and three years of age and it is now included 
in the Bekendtgørelse om fødevarekontaktmaterialer 579/2011.
12
 
Sweden has decided to ban the use of BPA or compounds containing BPA in varnishes or coatings for 
packaging for food intended for children between the age of zero and three years (Regulation SFS 
2012:991
13
). The ban entered into force on 1 July 2013. 
On 24 December 2012, France adopted a law suspending the manufacturing, import, export and 
putting on the market of all food contact materials containing BPA. This law will apply gradually with 
an application date of 1 January 2013 for food contact materials coming into contact with food 
intended for children between zero and three years of age and an application date of 1 January 2015 
for all food contact materials. In the meantime, once a decree with specifications is adopted, labelling 
requirements for pregnant women, breastfeeding women and small children will apply.
14
 
In September 2012, Belgium published an amendment to its national law concerning the protection of 
consumer health, regarding food commodities and other products, banning the marketing or putting on 
the market and manufacture of containers for food commodities, containing BPA, particularly 
intended for children between zero and three years of age.
15
 This amendment was based on the opinion 
of the Belgium Superior Health Council, issued on 3 November 2012. The law entered into force on 1 
January 2013. 
On 6 October 2011, Austria published a decree forbidding the use of BPA in pacifiers and soothers.
16
 
BPA is listed as entry 1 176 in Annex II (list of substances prohibited in cosmetic products) of 




2. Physical and chemical characterisation  
BPA is an organic chemical synthesised by condensation of 2 mol phenol with 1 mol acetone in the 
presence of an acid catalyst. It has the chemical formula C15H16O2, with a molecular mass of 
                                                     
10 Commission Implementing Regulation (EU) No 321/2011 of 1 April 2011 amending Regulation (EU) No 10/2011 as 
regards the restriction of use of Bisphenol A in plastic infant feeding bottles. 
11 Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into 
contact with food. OJ L 12, 15.1.2011, p. 1–89 
12 Bekendtgørelse om fødevarekontaktmaterialer 579/2011 (§ 8, stk. 2): https://www.retsinformation.dk/Forms/
R0710.aspx?id=136917&exp=1 
13 Regulation No 991/2012 of 20 December 2012 amending the Food Regulation No 813/2006, Svensk författningssamling 
(SFS), 4.1.2013, p. 1. 
14 Regulation No 1442/2012 of 24 December 2012 aiming at banning the manufacture, import, export and commercialisation 
of all forms of food packaging containing bisphenol A. OJ of the French Republic (OJFR), 26.12.2012, text 2 of 154. 
15 Loi du 4 septembre 2012 modifiant la loi du 24 janvier 1977 relative à la protection de la santé des consommateurs en ce 
qui concerne les denrées alimentaires et les autres produits, visant à interdire le bisphénol A dans les contenants de denrées 
alimentaires publiée au Moniteur Belge le 24 septembre 2012  
16 Verordnung: Verbot der Verwendung von Bisphenol A in Beruhigungssaugern und Beißringen: 
http://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2011_II_327/BGBLA_2011_II_327.pdf 
17 Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic 
products, OJ L 342, 22.12.2009, p. 59–209. 
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228.29 g/mol. It has the CAS (Chemical Abstracts Service) No 80-05-7 and EC No 201-245-8 





















BPA is a white solid available as crystals or flakes (Lewis, 2001; O’Neil, 2006). It crystallises as 
prisms from dilute acetic acid and as needles from water (Lide and Milne, 1994) and has a mild 
phenolic odour under ambient conditions (O’Neil, 2006). It has a melting point of 150–158 °C, a 
boiling point of 360–398 °C (at 101.33 kPa, (IUCLID, 2000; Cousins et al., 2002) and a density of 
1.195 kg/dm
3
 at 25 °C (IUCLID, 2000; Lewis, 2001). The vapour pressure is 5.3  10−6 Pa at 25 °C 
(Cousins et al., 2002). 
BPA is a moderately hydrophobic compound with an octanol–water partition coefficient (log Pow) of 
3.32 (Hansch et al., 1995), with a slight polarity owing to the two hydroxyl groups. It is soluble in 
acetic acid (Lide and Milne, 1994) and soluble in aqueous alkaline solution, alcohol, acetone (O’Neil, 
2006), benzene and diethyl ether (Lide, 2004). It is has a fairly low solubility of 120–300 mg/L in 
water at 25 °C (Dorn et al., 1987, Cousins et al., 2002). 
The pKa value of BPA is between 9.59 and 11.30 (Cousins et al., 2002); thus BPA will be present 
mainly in its non-ionised form in liquid media with a pH lower than 7. The BPA molecule has a fairly 
strong fluorophore and it can be detected by its fluorescence. Its chromophore is relatively weak, and 
the sensitivity of ultraviolet (UV) detection is much lower than that of fluorescence detection. 
The Cousins report cited above also summarised environmental information as follows: BPA does not 
persist in the environment, although it is fairly stable in its solid form. Aerobic biodegradation is the 
dominant loss process for BPA in river water and soil, with a degradation half-life of approximately 
4.5 days (Cousins et al., 2002). Its loss process in the atmosphere is due to the rapid reaction with 
hydroxyl radicals, and the photo-oxidation half-life for BPA in air is about four hours (Cousins et al., 
2002). 
3. Potential sources of exposure  
3.1. Materials and uses 
3.1.1. Polycarbonate plastics 
PCs are a group of thermoplastic polymers produced by the condensation polymerisation reaction of 
BPA and carbonyl chloride or by melt-transesterification reaction between BPA and 
diphenylcarbonate. The production of PC is the main use for BPA. PC plastics are amorphous, 
transparent polymers with high levels of impact strength and ductility, stability and heat resistance and 
useful engineering properties over a wide temperature range, as well as good resistance to ultraviolet 
(UV) light (CEH, 2008; IHS, 2013). Because of these properties PC plastics and PC blends with, for 
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example, polybutylene terephthalate and acrylonitrile–butadiene–styrene (ABS) polymers are used in 
numerous applications (BPF, 2013). PC and PC blends may be used in the manufacture of consumer 
products such as CDs and DVDs, jars/containers, identity cards and toys. PC plastics are also used in 
the automotive industry, in glazing (e.g. greenhouses) and in optical media including lenses for 
glasses, as well as in food contact materials and articles and in medical devices. 
Until 2011 PC plastics were used in the manufacture of infant feeding bottles. However, this 
application was withdrawn in the EU following the introduction of Commission Directive 2011/8/EU 
of 28 January 2011, which restricts the use of BPA in these articles
18
. Other PC food contact 
applications include water coolers with refillable PC reservoirs (PC coolers), tableware, chocolate 
moulds, kettles and kitchen utensils. The migration of residual BPA in the polymer, present because of 
incomplete polymerisation and migration of the BPA released by hydrolysisof the polymer from these 
PC materials into the foods and beverages with which they come into contact, has the potential to 
provide a source of dietary exposure to BPA. 
Some toys may be made with PC plastics (KEMI, 2012). Mouthing of the toys by children may result 
in exposure to any BPA leaching from these articles into the saliva (KEMI, 2012). For baby pacifiers a 
large Danish retailer of pacifiers estimated that for 10–20 % on the Danish market in 2010 the shield 
and ring were made of PC plastics (Lassen et al., 2011). Since the saliva of a baby is spread around the 
mouth during sucking and may then be ingested, the shield may represent a source of oral exposure to 
BPA. 
About 3 % of total PC production is reported to be used for the manufacture of medical devices 
(Beronius and Hanberg, 2011). Some BPA-containing medical devices may have direct and/or indirect 
contact with patients (e.g. autotransfusion apparatus, filters, bypasses, tubing, pumps, instruments, 
surgical equipment, blood pathway circuits and respiratory tubing circuits, dialysis equipment). It has 
also been reported that breast milk pumps are made from PC plastics (Beronius and Hanberg, 2011). 
The transfer of BPA from these PC plastics into the biological human matrices with which they come 
into contact or the migration of BPA into human milk to be consumed by an infant can result in 
exposure to BPA. 
3.1.2. Epoxy resins 
Epoxy resins are thermosetting polymers that have good mechanical properties, as well as high 
temperature and chemical resistance. As such, these resins have a wide range of applications, 
including use as coatings applied to metal substrates in food contact materials, in dental fillings, in 
electronics/electrical components, in high-tension electrical insulators, in fibre-reinforced plastic 
materials, in structural adhesives and in the relining of aged water pipes (KEMI, 2013). 
Epoxy resins are produced by the reaction of BPA with BPA diglycidyl ether (commonly abbreviated 
to BADGE, made from BPA and epichlorohydrin), which are the primary chemical building blocks for 
the broad spectrum of materials generally referred to as epoxy resins. Alkoxylated BPA may also be 
used to prepare epoxy resins. 
Epoxy resins represent the second largest use for BPA. Epoxy resins may be cross-linked with 
phenolic resins, amino resins, acrylic resins or anhydride resins producing epoxy phenolic, epoxy 
amino, epoxy acrylic and epoxy anhydride can coatings. All of these are used for can coatings, but 
there are also other coatings not containing epoxy resins, such as polyesters.  
Following a request from EFSA, industry noted that “the content of the statement on epoxy phenolic 
resins in the EFSA opinion of 2006 is still correct, but that BPA based phenolics stopped being used in 
Europe a few years ago.” (email from PlasticsEurope to EFSA on 5 February 2013). As well as canned 
food and beverages, epoxy-based coatings have been reported to be used in other food contact 
                                                     
18 Commission Directive 2011/8/EU of 28 January 2011 amending Directive 2002/72/EC as regards the restriction of use of 
Bisphenol A in plastic infant feeding bottles, OJ L 26, 29.1.2011, p. 11–14. 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 7 
applications including re-usable drinks bottles and wine vats. They may also be used in construction 
products, such as and storage tanks and water reservoirs, or for the restauration of domestic water 
pipes. 
Epoxy resins may also be used as stabilisers (hydrochloric acid scavengers) and as plasticisers in 
polyvinylchloride (PVC) organosol coatings that may be used for cans and metal lids applied to glass 
jars. Residual BPA in the cured coating has the potential to migrate into the food or beverage with 
which it comes into contact, thereby providing a potential source of dietary exposure. 
As for plastic food contact materials and articles, the extent of the migration from the coating, and 
hence the potential exposure, is dependent on contact surface, time and temperature. With the high-
temperature processing conditions and the long shelf life of canned foods the migration of any residual 
BPA will occur, resulting in dietary exposure. 
Epoxy resins may also be reacted with ethylenically unsaturated monocarboxylic acids to form vinyl 
esters, and it has been stated that these too may be used in food contact applications (email from 
PlasticsEurope to EFSA on 5 February 2013). 
Epoxy resins may further be used in non-food contact applications including flooring and non-food 
tanks and pipes. The cross-linking of epoxy resins with phenol gives rise to a higher molecular weight 
solid epoxy resin known as a phenoplast (WUR, 2001). These resins are used as materials in the 
construction sector and as such are considered to constitute a source of exposure through indoor air 
and dust (see Section 4.3.3). 
3.1.3. Thermal paper 
Thermal paper consists of a smooth paper to which a coating is applied. This coating is made from a 
leuco dye and a phenol developer such as BPA. The leuco dye exists in two forms, one of which is 
colourless. On printing, a thermal head causes the coating components to melt and react with each 
other, causing the dye to become dark (Biedermann et al., 2010; Mendum et al., 2011). Exposure from 
this source can occur via dermal contact, in particular for cashiers handling receipts, as BPA can be 
transferred from the paper surface to the skin (Biedermann et al., 2010), but also for consumers. 
Thermal papers containing BPA were identified in different applications, such as bus tickets, airline 
tickets, cash receipts and papers for laboratory use (Liao and Kannan, 2011a, b). The European 
Thermal Paper Association states that BPA is still used in thermal paper and that in 2012 80 % of 
thermal paper used was point-of-sales grades, which are mainly used for supermarket and shop 
receipts and not for tickets for transport (bus/boarding passes) or tickets for lotteries (email from 
European Thermal Paper Association to EFSA from 17 June 2013). 
3.1.4. Recycled paper 
Recycled paper and board may contain BPA if paper products that contain BPA (e.g. thermal papers) 
are included in the recycling feedstock and if the is not removed during the recycling decontamination 
process. Thermal paper was estimated to be a major source for the contamination of recycled paper 
with BPA (Gehring et al., 2004). BPA is listed as an evaluated monomer permitted for use in printing 
inks in the Swiss Ordinance of the FDHA on articles and materials (RS 817.023.21
19
). The use of BPA 
as an ingredient in inks is no longer widespread, but its presence as an impurity in ink formulations 
cannot be excluded (email from PlasticsEurope to EFSA on 5 February 2013). Food contact papers 
and cartons include fast-food and snack wrappers and boxes, paper cups, paper plates and food 
cartons, such as pizza boxes. These may include a recycled component within the food-packaging 
material and so may provide a source of exposure to BPA. BPA was detected in 45 % of the take-away 
food cartons tested with higher levels in cardboard than in paper (Lopez-Espinosa et al., 2007). In this 
study all but one of the 40 samples tested contained recycled fibres. Any migration from the recycled 
                                                     
19 Ordinance No 817.023.21 of 25 November 2005 on materials and articles. Swiss Federal Department of Home Affairs 
(FDHA), 1.4.2013, p. 1–96 
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paper or board into food will result in dietary exposure to BPA. BPA was also detected in toilet paper 
(Gehring et al., 2004) and in kitchen towels (Ozaki et al., 2006) made from recycled paper. 
3.1.5. Polyvinyl chloride 
PVC is the third most widely produced plastic, after polyethylene and polypropylene. PVC is 
produced by polymerisation of the monomer vinyl chloride. BPA has been used historically as (i) a 
production aid to stabilise vinyl chloride monomer; (ii) in the polymerisation of PVC plastics; and (iii) 
as an antioxidant in plasticisers used in PVC. According to the European Council of Vinyl 
Manufacturers, the use of BPA for polymerisation and as a stabiliser for storage of vinyl chloride 
monomer was discontinued in Europe from December 2001 (email from PlasticsEurope to EFSA on 5 
February 2013). Additionally, the use of BPA as an additive for food contact plastics, including PVC, 
is not permitted in the EU according to Regulation (EU) No 10/2011. 
PVC has a very low market share (less than 5%) in polymers used for food packaging (Howick 
2007)". However, BPA may still be used in the production of PVC, e.g. for toys, and, therefore, 
exposure may occur by the transfer of BPA through the saliva. Also, the use of BPA as a production 
aid in PVC cannot be excluded, as such use as a polymer production aid is outside the scope of 
Regulation (EU) No 10/2011. 
3.1.6. BPA methacrylate-containing resins 
BPA-containing resins may be used in dental sealants. BPA is not used directly in dental materials, but 
BPA glycidyl methacrylate (bis-GMA) and other acrylate-based derivatives (BPA dimethacrylate) of 
BPA are used. Any BPA that is present as an impurity in the used methacrylate derivative or is 
released from the dental sealant by degradation of the polymer has the potential to contribute to oral 
exposure to BPA (Van Landuyt et al., 2011). 
3.1.7. Polyetherimides 
Polyetherimides (PEIs) are synthesised by the melt condensation of BPA bis(phthalic anhydride) with 
a diamine, usually m-phenylenediamine. PEIs find use in food contact applications, e.g. microwave 
cookware, in blends with PCs (FAO/WHO, 2011) as a consequence of their high heat stability. PEIs 
may also be used in medical applications, in electronic components and in aircraft interiors. The ether 
linkage of polyetherimides has good thermal and hydrolytic stability and so migration of BPA, if any, 
would be limited to any unreacted BPA in the dianhydride starting substance. 
3.1.8. Polysulphone resins 
Polysulphone resins are made by condensation of the disodium salt of BPA with 4,4-dichlorodiphenyl 
sulphone. They exhibit thermal stability, toughness, transparency and resistance to degradation by 
moisture (FAO/WHO, 2011). They are used in electrical components, appliances, transport, medical 
equipment, pumps, valves and pipes (FAO/WHO, 2011). 
3.1.9. Polyarylates 
Polyarylates are amorphous polymers that may be formed by co-polymerisation of BPA with aromatic 
dicarboxylic acids (mainly terephthalic and isophthalic acids). Polyarylates have excellent thermal 
resistance and toughness, in combination with clarity and stability to UV light, and compete with 
traditionally less expensive engineering plastics for applications in the automotive, electronics, aircraft 
and packaging industries. If used in food packaging applications, the migration of BPA from these into 
food or beverage provides a potential source of exposure. However, according to the FAO/WHO 
report, high cost, poor chemical resistance and a tendency to yellow have prevented polyarylates from 
gaining wider acceptance, and so exposure from these materials is not considered likely (FAO/WHO, 
2011). 
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3.1.10. Flame retardants 
BPA may be used in the production of two flame retardants, tetrabromobisphenol A (TBBPA) and 
BPA bis(diphenyl phosphate) (CEH, 2010). TBBPA is used to impart flame resistance to epoxy resins 
used in printed circuit boards, to PC, to ABS resins and, to a lesser extent, to unsaturated polyester 
resins and other engineering thermoplastics. TBBPA is also used as an intermediate in the production 
of other flame retardants, such as brominated epoxy oligomers and brominated carbonate oligomers. 
BPA bis(diphenyl phosphate) is used as a flame retardant in polyphenylene oxide and PC/ABS blends. 
The latter are not used in food contact applications and so any exposure to BPA from this source will 
occur through dermal contact, air or dust (see Section 3.2). 
3.1.11. Other uses 
The presence of BPA has also been reported in tablecloths and mittens (VKM, 2008). However, the 
material type (other than plastic) was not specified in the report. BPA was also detected in low 
amounts in cosmetics on the European market (Cacho et al., 2013). BPA is not permitted for use in 
cosmetics in the EU,
20
 but it may migrate from packaging materials into the cosmetics or be present as 
an impurity in the cosmetic ingredients. Therefore, cosmetics may constitute a source of exposure 
through dermal contact (see Section 4.3.3). 
Other uses have also been reported, such as the use of BPA in polyester resins such as bisphenol 
fumarates formed by reacting BPA with propylene oxide to form a glycol, which is then reacted with 
fumaric acid to produce a resin mainly used for its exceptional corrosion resistance in a caustic 
environment (e.g. AOC, 2013). Typical applications of bisphenol fumarate resins are fibre-reinforced 
tanks and piping. BPA may also be used as an additive in polyamide materials used mainly in 
electrotechnical applications (ECB, 2010). 
The use of BPA as a monomer in plastic food contact materials other than PC cannot be excluded. 
BPA is subjected to an SML of 0.6 mg/kg food (Regulation (EU) No 10/2011). 
3.2. Environmental sources 
The general population can be exposed to BPA via food or via the use of non-food consumer products 
such as thermal paper, toys, etc. (see Section 3.1). The general population can also be exposed to BPA 
from environmental sources such as surface water (during swimming) and outdoor air (inhalation of 
aerosols). In addition, the release of BPA from epoxy-based floorings, adhesives, paints, electronic 
equipment and printed circuit boards is reported to be a source of contamination of indoor air 
(including airborne dust) and dust (Loganathan and Kannan, 2011). Environmental sources therefore 
can potentially contribute to oral, inhalation and dermal exposure to BPA (see Section 4.3.3). 
4. Exposure assessment 
4.1. Scope of the exposure assessment  
The scope of the exposure assessment is to assess average and high chronic exposure to BPA through 
different sources and routes of exposure in the EU population, in order to inform risk assessment. For 
BPA, the toxicologically relevant form is unconjugated BPA. In the conjugated form (e.g. 
glucuronidated) BPA has no oestrogen receptor affinity and is therefore of less toxicological concern 
if at all (see Part II – Toxicological assessment and risk characterisation of this opinion). The fraction 
of an external dose of BPA that reaches the bloodstream in the unconjugated state is dependent on the 
route (and source) of exposure: after oral uptake first-pass metabolism takes place in the liver where 
BPA is rapidly and extensively conjugated before reaching the systemic circulation. For the dermal 
and inhalation routes, absorbed BPA directly enters the systemic circulation. Therefore, route-specific 
                                                     
20 Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic 
products, OJ L 342, 22.12.2009, p. 59–209. 
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exposure levels have to be used in risk assessment. For the dermal route, source-specific exposure 
levels need to be distinguished as well, because the absorption fractions differ by source (s. below).  
The route/source-specific external exposure levels were calculated by multiplying source 
concentrations with the corresponding use frequency (e.g. intake of amounts of food, handling 
conditions of thermal paper, application of amounts of cosmetics, inhalation of quantity of air), which 
is commonly referred to as source-to-dose modelling or forward exposure modelling (Figure 1A). 
In order to evaluate the reliability of the forward-modelled exposure estimates, they were compared 
with urinary biomonitoring data. For this comparison, the route/source-specific external exposure is 
converted to internal exposure to total (unconjugated plus conjugated) BPA (i.e. the total absorbed 
dose) by applying route- and source specific uptake fractions (Figure 1B). For BPA absorption from 
oral sources and inhalation an absorption fraction of 1 was used. For BPA from thermal paper and 
cosmetics, source-specific absorption fractions of 0.1 and 0.5 were used, respectively (see Section 
4.6.5). Since in humans all BPA that is systemically available will be eliminated via the kidneys, the 
internal exposure to total BPA can be compared with daily excretion rates of total BPA calculated 
from urinary levels of total BPA and daily urinary outputs (backward exposure modelling). 
Note that the estimate of interal exposure to total BPA cannot be used directly for risk assessment, 
because it refers to unconjugated plus conjugated BPA and not specifically and only to the 
toxicologically relevant unconjugated BPA. For the use in risk assessment, these route and source-
specific exposure values have to be transformed to human equivalent oral doses (HEDs), since for oral 
exposure the most extensive toxicological data are available. This transformation uses human-
equivalent oral dose factors that are based on serum levels of unconjugated BPA and is not included in 
the exposure part of the opinion, but is described in Part II of this opinion entitled–Toxicological 
assessment and risk characterisation. 
Another consequence of the route dependency in the toxicology of BPA is that it is not very practical 
to compare exposures via different routes. For example, external oral exposure to BPA could amount 
to 75 mass units/day and dermal exposure could amount to 19 mass units/day, or, in other words, oral 
contributes 80 % and dermal contributes 20 % to the total external exposure. Given the very efficient 
first-pass effect for BPA for the oral route, even under the condition that 100% of an oral dose is 
absorbed, only approximately 0.75 mass unit/day would “count” as toxicologically relevant, while for 
the dermal route (assuming 10 % dermal absorption) 1.9 mass unit/day would “count” as 
toxicologically relevant. In other words, from a toxicological perspective, dermal and oral would each 
count for 28 or 72 % of the toxicologically relevant (internal) exposure to unconjugated BPA, 
respectively. In contrast, when looking at urinary excretion, all 75 mass units ingested, but for the 
dermal route only the 1.9 mass unit that is actually absorbed, will end up in the urine. That means that 
for the urinary excretion of total BPA content 97.5 % (i.e 100*75/76.9 comes from oral exposure and 
1 % (i.e. 100*1.9/76.9) comes from dermal exposure. Hence, a comparison of the contribution of 
routes to exposure to BPA is meaningful only if it is explicitly stated for which kind of exposure 
estimates this comparison is being made (external, internal to total BPA inclujding urinary estimates, 
or internal to the toxicologically relevant unconjugated BPA). Because of this complication, in this 
Part or in Part II of this opinion –Toxicological assessment and risk characterisation, the 
“contributions of the various routes of exposure to the total exposure” have not been calculated. 
Specific scenarios were developed to cover the exposure patterns in the different age classes and 
vulnerable groups (infants and children and pregnant and breastfeeding women). Scenarios to assess 
acute exposure to BPA, BPA exposure in specific disease states or occupational exposure of workers 
handling BPA-containing products were not developed in this opinion. 
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Figure 1:  Difference in route-specific external exposure (A) and internal exposure to total BPA (i.e. 
absorbed dose) by applying route-specific and source-specific uptake fractions (B) 
4.2. Methodology applied for data retrieval and for performing the exposure assessment 
and comparison with biomonitoring data 
The methodology to perform exposure assessment and the comparison with the biomonitoring data are 
explained and summarised in this section. Reference is made to other sections and appendices where 
additional relevant information is given. For the (forward) exposure assessment/modelling, 
analytical/experimental BPA concentrations in food (including human milk) were combined with food 
consumption (including human milk) data to estimate dietary exposure. In addition, 
analytical/experimental BPA concentrations in non-food sources were combined with behavioural 
patterns (associated with the handling of these non-food sources) to estimate non-dietary exposure. For 
the backward exposure modelling via biomonitoring data, analytical/experimental BPA concentrations 
in urine were combined with urinary volumes to determine the excreted BPA levels. 
4.2.1. Approaches followed to collect concentration data for use in the exposure assessment 
and biomonitoring comparison 
Whereas EFSA has created a comprehensive European Food Consumption Database (EFSA, 2011), 
concentration data for BPA in food and non-food sources were not readily available. Following the 
terms of reference, which suggest that an exposure assessment should be carried out on the basis of the 
occurrence data available in the public domain and other occurrence data that may be available, EFSA 
has performed a literature search, as well as published a call for data on its website. The EFSA terms 
of reference also state that biomonitoring data should be taken into account when assessing the 
exposure and the results should be compared with the calculated exposure, and so EFSA has also 
performed a literature search to obtain biomonitoring data. 
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4.2.2. Literature search in bibliographic databases 
A thorough literature search was the basis for retrieving scientific studies reporting occurrence data 
herein. This work was outsourced under Contract NP/EFSA/FIP/2012/05. The search of a number of 
bibliographic databases was conducted from August 2012 to November 2013 by an independent 
contractor, and the following databases were searched: 
 ISI Web of Knowledge—Web of Science (WoS) including: 
o Web of Science (1945 to present) 
o Biological Abstracts (1969 to present) 
o MEDLINE (1950 to present) 
 Elsevier Science Direct (SciVerse) 
 Elsevier Scopus 
 EBSCOhost—OmniFile Full Text Select (H.W. Wilson) 
 SpringerLink 
 Taylor & Francis online 
 Wiley Interscience 
A number of different electronic bibliographic databases was used for the search because (i) no single 
database is fully comprehensive; (ii) despite overlap in coverage of the scientific literature with 
different databases, different search engines potentially may perform differently; and (iii) some 
journals are not accessible through mainstream databases. The above choice ensured that the highest 
coverage for relevant articles was achieved. 
Initially searches were conducted using the search term “bisphenol” and a specific year. In total there 
were 9 649 hits from all databases within Web of Knowledge and 13 062 hits from Science Direct in 
the period of the searches from January 2006 until November 2013 (see Table 1). These hits contained 
mainly articles dealing with toxicological studies and not occurrence data, therefore the search was 
refined by adding additional terms such as “food” or “migration”. This led to fewer hits (see Table 1) 
but excluded publications such as those reporting BPA in urine and BPA in non-food materials such as 
banknotes and environmental samples. It was therefore found necessary for a specified time window 
to scan the titles of all publications containing “bisphenol” within the content of the article. The 
screening using “food” and “migration” as additional terms was useful as a “double check” that all 
publications had been found, but it was not broad enough to be used exclusively. 
This search strategy was very sensitive and led to scanning a large number of titles and abstracts for 
relevance, but this was ultimately judged to be the most reliable way of ensuring that no relevant 
articles were missed. All Elsevier articles that were found in the search using Science Direct in 
principle should also have been found by searching Web of Science. However, the timing of entry of 
articles into the two databases appeared to be different, with articles being available sooner from 
Science Direct, often as “author’s uncorrected” or “in press” articles before their appearance in Web of 
Science. Parallel searches by two individuals in the same time window recovered more or less the 
same relevant articles. 
Abstracts were scrutinised on a yearly basis from 2006 until the end of 2012, and from January until 
November 2013 on a monthly basis, around the 10th of each month. An overview of the number of 
hits using “bisphenol” as a broad search term and subsequent refined searches, by restricting the 
search, is shown in Table 1. 
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 Searching statistics: searching results Table 1: 







Web of Knowledge 
Keyword: BPA 1 010 978 1 175 1 159 1 333 1 450 1 186 1 358 9 649 
Combined with “food” 57 57 75 88 102 128 106 158 771 
Combined with “migration” 21 12 20 22 40 25 21 17 178 
Combined with “water” 257 291 323 371 405 445 352 477 2 921 
Science Direct 
Keyword: BPA 1 030 1 130 1 300 1 372 1 469 1 837 2 302 2 622 13 062 
Combined with “food” 347 342 446 471 529 698 932 1 083 4 848 
Combined with “migration” 105 117 140 139 174 216 288 207 1 386 
Combined with “water” 801 844 1 009 1 074 1 159 1 427 1 809 2 144 10 267 
Summary of number of selected studies 
Contractor—individual I 50 34 40 42 50 72 85 138 511 
Contractor—individual II 53 38 42 40 54 71 87 140 525 
Number of studies 
provided to the CEF 
Panels WG BPA Exposure 
for consideration 
48 32 38 40 50 69 80 136 493 
 
The final numbers of publications selected as containing information potentially relevant for this 
opinion, i.e. those that could be assigned to the eight categories given below ranged from 48 articles 
for the year 2006 to 136 articles for the year 2013. Online versions of articles were increasingly found 
to be published ahead of the cover issue date, and thus in the searches until the end of November 2013 
three relevant articles were found with 2014 publication dates. For the period 2006–2013 a total of 493 
peer-reviewed articles were selected as relevant by the contractor and were passed to the CEF Panel’s 
Working Group on BPA Exposure and were assigned to the eight categories listed below: 
 analytical methods for BPA in food; 
 human biomonitoring of BPA; 
 migration of BPA from food contact materials; 
 occurrence of BPA in drinking water; 
 occurrence of BPA in food contact materials; 
 occurrence of BPA in food; 
 occurrence of BPA in non-food materials such as indoor air, dust, thermal printed paper, 
dental materials and medical devices; 
 occurrence of BPA in the environment. 
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Some articles were found to contain information covering more than one category, e.g. a publication 
describing an analytical method for the determination of BPA in canned foods might also contain 
occurrence data from a small survey and so was assigned to both relevant categories. In total, 611 
publications were assigned by category and by year. 
As mentioned above, all articles from the literature search were screened by two individuals, and if the 
title of an article appeared relevant, then the abstract was examined more closely to confirm this. 
Articles reporting methods of analysis for food and containing survey data for food were rather easy to 
identify. However, there were many method papers relating to BPA in water and environmental 
samples, which were exclusively analytical method related papers and did not contain any relevant 
survey (concentration) data. For these articles, it was frequently necessary to look at them in more 
depth to see whether or not the article should be considered. 
As result of the screening process applying the above-described method of working, two lists of 
articles were produced (one by each individual). They were compared and a final list agreed between 
the two individuals. Differences in the number of articles selected between the two independent 
searches were small and these were easily reconciled by discussion between the two individuals, if 
necessary removing any articles that were of marginal interest. Differences were usually because the 
initial search had failed to remove articles that were not relevant. 
In addition to the literature search carried out by the contractor, members of the CEF Panel’s Working 
Group on BPA Exposure searched the scientific literature for additional relevant information, e.g. 
parameters used to estimate skin absorption and physiological data, etc. 
4.2.3. Eligibility criteria for assessing publication relevance 
The publications provided by the contractor to the Working Group on BPA Exposure were further 
assessed to confirm their relevance to the exposure and biomonitoring assessments. Only primary 
research studies (i.e. studies generating new data) were considered. Language, publication period, 
geographical origin of the samples and sample type were considered, according to the criteria defined 
below. 
4.2.3.1. Language 
The search of scientific literature databases was focused only on scientific studies with at least an 
abstract in English. All papers provided to the CEF Panel’s Working Group BPA Exposure by the 
contractor were in English. However, data and non-English reports from other sources, e.g. Swedish 
data for toys and water pipes and French risk assessment reports, each published in the native 
language were considered, but not in a systematic manner/way. 
4.2.3.2. Publication period 
As a general rule only data published from January 2006 until December 2012 were considered. For 
food, data published before 2006 have already been reviewed in the 2006 EFSA assessment of the 
dietary exposure to BPA. The pattern of use of BPA in food packaging has changed in the meanwhile 
and therefore there was a need to provide an up-to-date assessment of the occurrence of BPA in food 
in order to estimate current dietary exposure. Although they were not considered in the EFSA opinion 
of 2006, the same criterion, i.e. data published from 2006 onwards, was applied to the other fields 
(food contact materials and non-food sources of exposure). This criterion was applied, as in more 
recent years there has been a lot of effort to improve the performance of analytical determinations of 
BPA in terms of increased sensitivity and reduced BPA contamination; therefore, more recent data 
should be of better quality than older data. As mentioned above, the literature search carried out by the 
contractor covered the period January 2006 to November 2013. However, owing to the timing of the 
public consultation, only papers to December 2012 were considered. Papers published after this date 
were considered only if they provided data in areas where no or very few data were available (e.g. data 
on human milk) or to complete the European dataset (e.g. biomonitoring data). 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 15 
Similarly, for biomonitoring, only studies published from January 2006 until December 2012 were 
considered. Since 2006, substantial methodological improvements have been achieved, in terms of 
both sensitivity and specificity, by using mass spectrometry (MS)-based analytical techniques. 
Moreover, increased efforts have been implemented to preserve sample integrity and to reduce 
external contamination; therefore, more recent data should be of higher quality than older data. 
Furthermore, the more recent data will provide an up-to-date indication of the current exposure to 
BPA. Papers published after this date were considered only where there were gaps in the data as a 
consequence of only a small number of publications being available. For the biomonitoring studies 
this included BPA concentration data for colostrum and mature breast milk. 
4.2.3.3. Geographical origin of the samples 
A specific inclusion criterion for data on occurrence in food, food contact materials and non-food 
sources and for migration data from food contact materials reported in the scientific literature was that 
only samples purchased in the European region (EU and non-EU) should be included in the exposure 
assessment. Only for those sample classes for which no or only limited European data were available, 
data from products produced and sold elsewhere in the world, were included in the assessment. 
A specific inclusion criterion for biomonitoring data on urinary BPA was that the studies have been 
performed in the European region to enable the estimation of the daily exposure to BPA for different 
age groups of European populations. In addition, biomonitoring data on BPA concentration in breast 
milk were assessed to provide information for the estimate of dietary exposure in breastfed infants. 
However, as only limited European data for human milk were available, data from samples from 
elsewhere in the world were included in the assessment. Also, in the case of biomonitoring data, for 
which no or only limited European data were available, data from elsewhere in the world were 
included. 
4.2.3.4. Sample type 
Data for composite samples with canned and non-canned food combined together were not included in 
the assessment. 
For food contact materials papers describing migration data for food-packaging materials such as can 
coatings and paper and board were not considered, as exposure from packaged foodstuffs is included 
in the exposure assessment for foods themselves. Publications describing migration from food contact 
articles, specifically those made of PC (PC kettles, water coolers, filters and tableware), and from 
articles to which non-stick coatings had been applied were included in the assessment of exposure 
from food contact materials. 
4.2.4. Methodological appraisal of the included publications 
Appendix I, in which all of the publications provided by the contractor are listed, provides an 
assessment of their evaluation against the above criteria. Those publications that met these criteria 
were further scrutinised to ensure that the methods used to determine the concentration and migration 
data were of acceptable quality. The quality criteria applied to the analytical methods are given in 
Appendix A. The method characteristics and sample descriptions are summarised in Appendix I for all 
papers that met the criteria on language, publication date and geographical origin. A final evaluation 
of whether or not the data reported in the papers are included, and the associated reasoning for that 
(based on all criteria: publication date, origin of samples and method quality), is also given in 
Appendix I. 
4.2.5. Grey literature and other sources of information 
Beyond the thorough search of the primary scientific literature, other sources of information were also 
considered: reviews, journals and books recorded in electronic bibliographic databases; full-text 
journal articles; journal tables of content; and grey literature, e.g. conference proceedings, annual 
reports and poster abstracts. The former and reference lists of previous risk assessments, e.g. by 
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FAO/WHO 2011, ANSES 2013, and review articles were screened as cross-checking quality 
assurance measures to ensure that no publications were missed in the bibliographic database searches. 
Data on urinary levels of total BPA in humans were also retrieved from official websites of national 
health surveys (e.g. NHANES (National Health and Nutrition Examination Survey), CHMS (Canadian 
Health Measures Survey), German Federal Environment Agency, Flemish human biomonitoring 
programme) and from as yet unpublished sources (e.g. European research programme, 
DEMOCOPHES (Demonstration of a study to Coordinate and Perform Human Biomonitoring on a 
European Scale). The methodological quality of these data are assessed and described in the main text. 
4.2.6. The EFSA call for data 
In July 2012, Member States, research institutions, academia, food business operators (e.g. food-
packaging manufacturers and food industries) and other stakeholders were invited by EFSA to submit 
analytical data on (i) the occurrence of BPA in food and beverages intended for human consumption; 
(ii) BPA migration from food contact materials; and (iii) BPA occurrence in food contact materials. 
Details on the eligibility and inclusion of data received from the call for data are given in Appendix B. 
4.2.7. Handling of left-censored data 
Left-censored data, i.e. samples with concentrations below the LOD or LOQ were handled as 
recommended in “Principles and Methods for the Risk Assessment of Chemicals in Food” (WHO, 
2009) and in the EFSA scientific report “Management of left-censored data in dietary exposure 
assessment of chemical substances” (EFSA, 2010) through the substitution method. The lower bound 
(LB) was obtained by assigning a value of zero to all the samples reported as less than the left-
censoring limit, the middle bound (MB) by assigning half of the left-censoring limit and the upper 
bound (UB) by assigning the left-censored limit as the sample result. 
Handling of left-censored biomonitoring data is extensively discussed in Section 4.6.2. 
4.2.8. Calculation of exposure 
4.2.8.1. Dietary exposure to BPA 
Dietary exposure to BPA in infants aged less than six months has been assessed by means of a model 
diet based on a standard level of consumption combined with BPA concentration in human milk or 
infant formula. Average and high BPA concentration values have been used to assess average and high 
chronic dietary exposure. Dietary exposure in 12-month-old toddlers to the elderly has been estimated 
using individual consumption data from the EFSA Comprehensive European Food Consumption 
Database combined with available concentration data derived from the scientific literature or from the 
EFSA call for data. Two scenarios were considered: 1) Only foods specifically codified as canned in 
the dietary survey are assigned the corresponding occurrence level for BPA and 2) At FoodEx level 4, 
any food which has been codified as canned in at least one survey is always considered to be 
consumed as canned in all dietary surveys included in the Comprehensive Database. Chronic exposure 
was estimated by multiplying the average BPA concentration for different food groups and type of 
packaging (canned or non-canned) with their respective consumption amount per kilogram body 
weight separately for each individual in the database, calculating the sum of exposure for each survey 
day for the individual and then deriving the daily average for the survey period. Average and 95th 
percentile exposure was calculated for the total survey population separately for each survey and age 
class. 
Data for migration into food simulants reported in the literature and from the EFSA call were 
indirectly used to estimate the concentration of BPA in the products consumed after being in contact 
with PC food contact materials (namely water coolers, tableware, kettles, filters) and non-stick-lined 
cookware. Estimates were made taking into consideration the relationship between testing conditions 
reported in the studies and real contact conditions of time and temperature in the BPA concentration. 
Further details on this are provided in Section 4.3.1. 
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4.2.8.2. Non-dietary exposure to BPA 
For the calculation of exposure to BPA via non-food sources, occurrence data or - if available - data 
on BPA transfer into human body fluids or tissue were combined with data on the use of certain 
sources. An average and a high scenario were calculated for all sources. For the average scenario, an 
attempt was made to choose average values for all parameters, including parameters describing 
frequency of use. For the high scenario, the same average parameters were used for absorption rates 
and occurrence data, but in line with the methodology used to assess exposure from food, the 
frequency of use parameters were modified to account approximately for a 95th percentile of the 
population. If not mentioned otherwise, the arithmetic mean was used for each parameter, but in some 
cases only medians and percentiles were available. In order to follow a similar approach to that of 
exposure from food, behavioural parameters were derived considering both users and non-users in the 
general population. For calculations for specific population groups (e.g. users of pacifiers with PC 
shields), behavioural data were taken only from the group of users. 
Non-dietary exposure estimates were given per kilogram body weight. For the different age groups, 
different default body weights were used. For infants the default body weight of 5 kg for one- to three-
month-old infants was used (EFSA Scientific Committee, 2012). For toddlers the default body weight 
of 12 kg for 1–3 years old children was used (EFSA Scientific Committee, 2012). For children and 
adolescents default values of 30 kg for nine-year-old children and of 44 kg for 15-year-old adolescents 
were used (van Engelen and Prud’homme de Lodder, 2007). For adults, the default body weight of 
70 kg was used (EFSA Scientific Committee, 2012). 
4.2.8.3. Biomonitoring data 
For biomonitoring, estimation of BPA exposure for the different age classes was based on urinary 
concentration of total BPA (obtained from European studies), the urinary output rate and body weight. 
Estimates of the average and high daily BPA exposure were calculated from the geometric means and 
95th percentiles of the urinary BPA concentrations. Depending on whether body weight was available 
from the studies, either study-specific individual or mean values, or generic values from the literature, 
were used. Literature data were also used for the urinary output rate, except for cases in which study-
specific individual urinary volumes from 24-hour urine sampling were available. 
4.3. Occurrence data  
4.3.1. Data on occurrence in and migration from food contact materials into food simulants 
Values for BPA occurrence in different food contact materials and for BPA migration into food 
simulants reported in the scientific literature and obtained through the EFSA call for data were 
screened. From the scientific literature only studies focusing on samples collected in Europe were 
considered. The quality of data from both sources was assessed according to criteria defined in 
Appendix A. Details on the quality of data received through the EFSA call for data are given in 
Appendix B. The outcome of the assessment of the scientific literature is reported in Tables 63 to 70 in 
Appendix I. 
4.3.1.1. Occurrence data in food contact materials 
Germany submitted BPA occurrence data through the EFSA call for data for different kinds of food 
contact materials (plastic, paper and board, others, aluminium, glass). In all, 545 results were reported 
from 2001 to 2012, the large majority (98 %) originating from accredited laboratories. The packaging 
samples, classified according to EFSA’s standard sample description system and taking into account 
the information provided in the data element “Packaging” and “Product comment”, were: paper and 
board (39.1 %); plastic (38.2 %); plastic/plastic film and combined paper and film packaging (2.8 %); 
tinplate aluminium (2.2 %); glass (0.2 %); no information; and not packed (loose; open) (17.5 %). In 
the standard sample description system it was not always possible to give detailed information, so for 
glass it is most likely that the twist-off lid of a glass jar was analysed and in the case of tinplate 
aluminium the coating was most probably analysed. 
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The majority of the studies published in the scientific literature involved the determination of the 
residual level of the BPA monomer in PC plastics and in particular in baby bottles (Ehlert et al., 2008; 
Mercea, 2009; Alin and Hakkarainen, 2012). Values of residual BPA in PC containers, water coolers 
with PC reservoirs, bottles, baby bottles, trays, etc. reported in the literature ranged from 400 to 
70 000 µg/kg. Values specific for PC baby bottles averaged 9 422 µg/kg with a maximum of 
35 300 µg/kg. Average values for other PC bottles and water coolers with PC reservoirs were 10 224 
and 18 763 µg/kg, respectively. 
BPA content in cookware coatings was detected in 7 out of 26 samples, with values ranging from 0.5 
to 18 µg/dm
2
, with an average value of 3.2 µg/dm
2
 (derived from the concentration in the coating of 10 
224 µg/kg for an average coating weight of 313 mg/dm2) (Bradley et al., 2007). 
BPA content in a small number of recycled paper and board food contact samples was reported 
(Bradley et al., 2008a; Pérez-Palacios et al., 2012). The following average values were found: paper 
cloth—25 400 µg/kg; paperboard box—7 390 µg/kg; paper bag—500 µg/kg; and kitchen paper—
330 µg/kg (Pérez-Palacios et al., 2012). Lopez‐Espinosa et al. (2007) investigated the BPA content in 
40 paper and paperboard containers used for take‐away food. BPA was detected in 47 % of the 
samples, and concentrations ranged from 0.05 to 1 817 µg/kg in paperboard products and from 0.08 to 
188 µg/kg in paper products. All but one of the 40 samples tested contained recycled fibres. 
Residual BPA was detected in metal closure coatings (epoxy phenolic basecoat plus organosol 
topcoat) in the range 2–16 µg/dm2 (Oldring et al., 2013). The authors reported a ratio of surface area to 
food weight for metal closures ranging from 0.2 to 2.2 dm
2
/kg. If a complete migration of residual 
BPA is assumed, an average migration value of 12.5 µg/kg would be obtained. These estimates were 
not used in the present exposure assessment because more adequate occurrence data in food were 
available. 
4.3.1.2. Migration data from food contact materials 
European Economic Area (EEA) countries and Switzerland submitted BPA migration data through the 
EFSA call for data from different kinds of materials: 988 results were reported from 2004 to 2012, the 
large majority (93 %) originating from accredited laboratories. 
The packaging samples analysed and classified according to EFSA’s standard sample description 
system were: PC 82.8 %; polypropylene 3.9 %; aluminium foil/aluminium sheet 2.4 %; packed (no 
additional information provided) 2.2 %; metal 2.1 %; plastic/plastic film 1.4 %; combined aluminium 
and film packaging 1 %; tinplate and varnished/partly varnished 1 %; polyamide 0.8 %; combined 
material 0.4 %; and polyethylene terephthalate (PET) (one sample). No information was sent for 1.8 % 
of the samples including the variables “no information” and “not packed (loose; open)”. 
Polycarbonate (PC) and other plastics used in baby bottles 
BPA can migrate from PC into foods by diffusion of residual BPA present in the polymer after the 
manufacturing process as well as by hydrolysis of ester bonds of the polymer, a reaction that is 
catalysed by hydroxide when the polymer is in contact with aqueous food and simulants (Mountfort et 
al., 1997; Hoekstra and Simoneau, 2013). Some studies indicate that diffusion-controlled migration of 
the residual monomer makes a minor contribution to the release of BPA from polycarbonate articles, 
and that hydrolysis of the polycarbonate polymer chains at the interface with the aqueous media is the 
main release process (Biedermann-Brem et al., 2008; Biedermann-Brem and Grob, 2009; Mercea, 
2009). In fact, BPA migration from PC plastics into aqueous media was found to be essentially 
independent of the residual concentration (Mercea, 2009), indicating that transfer mechanisms other 
than diffusion take place. The migration experiments with food simulants used the conditions foreseen 
in the applicable European legislation (Council Directive 82/711/EEC) at that time
21
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Numerous studies have investigated factors influencing BPA migration from PC plastics. These 
include the effect of temperature, time and repeated use (De Coensel et al., 2009; Kubwabo et al., 
2009; Mercea, 2009). The effect of the pH of the water is important for the release of BPA under 
boiling conditions: heating evaporates carbon dioxide from (hard) tap water, which increases the pH 
up to around 9 and strongly accelerates the release of BPA – which is the reason why simulation with 
distilled water may severely underestimate the migration (Biedermann-Brem and Grob, 2009). The 
effect of PC ageing was investigated by Le et al., 2008, Kubwabo et al., 2009 and Mercea, 2009. 
Although temperature has a major impact on BPA migration no significant difference in migration was 
noted between heating in a water bath and by microwave (Ehlert et al., 2008). Hoekstra and Simoneau 
(2013) have reviewed the studies on the release of BPA from PC. 
In the majority of the reported BPA migration studies PC plastics, particularly baby bottles were 
involved. Results from Simoneau et al. (2011) showed BPA < LOD (0.1 µg/kg) in 32 out of 40 PC 
baby bottles analysed in the European market when tested with 50 % ethanol for two hours at 70 °C 
after boiling for five minutes. The highest migration value was 1.83 µg/kg and most of the bottles did 
not release detectable levels of BPA in the second or third migration test carried out with this simulant. 
Samples of PC baby bottles (72) from 12 different brands collected in the Spanish market were tested 
for BPA migration into 50 % ethanol and 3 % acetic acid, for two hours at 70 °C followed by 24 hours 
at 40 °C. Results were below the LOD (5 µg/kg) in the third migration test in most cases. The highest 
value found in the third migration test was 18 µg/kg into 3 % acetic acid, migrating from one of the 
bottles tested (Santillana et al., 2011). 
Further studies show evidence of increased BPA migration into water due to the effect of residual 
alkaline detergent remaining on the surface of the baby bottle after dishwashing (Biedermann-Brem et 
al., 2008; Maragou et al., 2008; Biedermann-Brem and Grob, 2009; Maia et al., 2009). Results 
highlighted the importance of good practices of rinsing and drying PC baby bottles. 
Kubwabo et al. (2009) carried out a study on the migration from PC and other plastic baby bottles, PC 
reusable drinking bottles and baby bottle liners. Twenty-four baby bottles (polyethersulphone (PES), 
polypropylene (PP), PC), 10 baby bottle liners (high-density polyethylene (HDPE), low-density 
polyethylene (LDPE), vinyl acetate, “BPA-free”), five new re-usable PC bottles and five old bottles 
(six months to 10 years) were tested for BPA migration into water. A range of migration test 
conditions were investigated. After 10 days at 40 °C migration of BPA from PC baby bottles reached a 
concentration of 1.88 µg/kg into water and 2.39 µg/kg into 50 % ethanol. 
Significant differences between BPA migration from new and used PC drinking bottles of 0.01 and 
0.2 µg/kg, respectively, were found (Kubwabo et al., 2009). However, different results were reported 
by Le et al. (2008) that indicated that at room temperature the migration of BPA is independent of 
whether or not the PC bottle has been previously used. After seven days of contact at room 
temperature, the migration values from new (1.0 µg/kg) and used (one to nine years) PC bottles 
(0.7 µg/kg) were not significantly different. 
Migration of BPA from 31 PC baby bottles into aqueous food simulants was studied under realistic 
repetitive use (effect of cleaning in a dishwasher or with a brush, sterilisation with boiling water and 
the temperature). Brushing did not seem to have an impact, whereas temperature was found to be the 
crucial factor, in line with the findings of other studies. All samples released BPA in the concentration 
range of 2.4–14.3 µg/kg when filled with boiled water and left at ambient temperature for 45 minutes. 
Normal repeated use was simulated over 12 cycles, and migration values showed a decrease of BPA 
release in the sterilisation water and in the food simulant (Maragou et al., 2008). 
A survey on potential migrants, including BPA, from non-PC baby bottles was performed by 
Simoneau et al. (2012). BPA was not detected in baby bottles made of PP, PES or silicone but was 
detected in some samples of two models of polyamide baby bottles of one single brand found in 
Switzerland and the Netherlands. Levels ranged from 1 to 329 µg/kg, with an average value of all data 
(including non-detects) of 25 µg/kg in the third migration test. In the first migration test a high 
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migration value of 1 005 µg/kg was found for one bottle. A follow-up investigation indicated an 
incidental illegal presence of BPA.This indicates a sporadic finding. The follow-up given by local 
authorities and industry professional associations established that the incident was limited and under 
control (email from PlasticsEurope and World Association of the Manufacturers of Bottles and Teats 
to the European Commission from 30 May 2013, provided to EFSA on 31 May 2013). 
Potential exposure was calculated based on a hypothetical consumption frequency of six times per day 
for three months (90 days) from bottles found to contain initial detectable BPA. Data showed that 
migration decreased by 80 % from the first to the third migration. A linear decrease was assumed, 
which meant falling below the LOD (0.1 µg/kg) between the third and the sixth use (i.e. day 1). The 
simulation was based on the experimental value from migration into 50 % ethanol as simulant It led to 
an average estimate of 0.45 µg/kg food and the 95
th
 percentile was 1.24 µg/kg (MB). 
Coatings, caps, closures and other 
Migration values from cooking ware coatings were found to be lower than 6 µg/kg after the third reuse 
with olive oil at 175 °C for 30 minutes and with a tendency to decline in sequential contact periods 
(Bradley et al., 2007). 
The migration of BPA into food simulants from 11 common food-packaging materials was assessed 
by Fasano et al. (2012). The packages comprised cans intended for tuna (both packed in brine or oil) 
and caps for marmalade jars, all coated with epoxy resins, as well as several plastic packages/materials 
such as HDPE yogurt packaging, polystyrene (PS) dish, teat, bread bag, LDPE film, PC baby bottle, 
aseptic plastic laminated paperboard carton and two plastic wine tops. 
The results for BPA migration from food-packaging materials retrieved from the literature are 
summarised in Table 2. 
 BPA migration into food simulants Table 2: 
Food contact 
material 





LB MB UB 
Can epoxy 1.26 1.26 1.27 16.00 8/23 Viñas et al., 2010; Cooper et al., 
2011; Fasano et al., 2012 
Can polyester 0.00 0.03 0.05 0.05 4/4 Cooper et al., 2011 
Cookware coating 0.60 0.68 0.76 5.80 21/26 Bradley et al., 2007 
(a)
 
Copolyester bottle 0.00 0.04 0.09 0.09 10/10 Cooper et al., 2011; Simoneau et 
al., 2012 
HDPE cup 0.00 0.02 0.03 0.03 3/3 Fasano et al., 2012 
LDPE film 0.09 0.10 0.11 0.19 3/6 Fasano et al., 2012 
PA baby bottle 
(b)
 25 25 25 329 8/28 Simoneau et al., 2012 
PC baby bottle 0.70 0.91 1.20 14.3 461/588 Biedermann-Brem et al., 2008; 
Cao and Corriveau, 2008a 
(a)
; Cao 
et al., 2008; Ehlert et al., 2008; 
Maragou et al., 2008 
(a)
; De 
Coensel et al., 2009 
(a)
; Kubwabo 
et al., 2009; Santillana et al., 
2011 
(a)
; Simoneau et al., 
2011 
(a),(b)
; Fasano et al., 2012 
(a)
  
PC bottle  0.92 0.92 0.92 7.67 4/44 Cao and Corriveau, 2008a 
(a)
; Cao 
et al., 2008; Le et al., 2008 
(a)
 
Kubwabo et al., 2009 
(a)
; Cooper 
et al., 2011 
(a)
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Food contact 
material 





LB MB UB 
PC container 2.64 2.64 2.64 2.64 0/10 Guart et al., 2011 
(a)
 
PC tableware 0.95 0.95 0.95 1.27 0/4 Oca et al., 2013 
(a)
 
PE/board 0.00 0.02 0.03 0.03 3/3 Fasano et al., 2012 
PS cup 0.00 0.02 0.03 0.03 3/3 Fasano et al., 2012 
Silicone teat 0.00 0.02 0.03 0.03 3/3 Fasano et al., 2012 
PP baby bottle 0.00 0.05 0.10 0.10 149/149 Simoneau et al., 2012 
PES baby bottle 0.00 0.05 0.10 0.10 30/30 Simoneau et al., 2012 
Silicone baby 
bottle 
0.00 0.05 0.10 0.10 5/5 Simoneau et al., 2012 
LB, average (lower bound) BPA concentration (assigning the value 0 when LOD or LOQ is reported); Max., maximum value 
reported (assigning LOD or LOQ when LOD or LOQ is reported); MB, average (middle bound) BPA concentration 
(assigning the value for LOD/2 or LOQ/2 when LOD or LOQ is reported); n, total number of samples; UB, average (upper 
bound) BPA concentration (assigning the value for LOD or LOQ when LOD or LOQ is reported); HDPE, high-density 
polyethylene; LDPE, low-density polyethylene; PA, polyamide, PC, polycarbonate; PE, polyethylene; PS, polystyrene; PP, 
polypropylene; PES, polyethersulphone. 
(a):  Studies used to retrieve data to estimate exposure in Section 4.5.2. 
(b): Migration values in PA bottles refer to a contamination during production. 
The values for migration of BPA from food packaging materials into food simulants retrieved from the 
literature and from the call for data were not used in the exposure assessment of the general 
population. Instead, occurrence values in foods, presented in the following section, were used for the 
general population. However, selected data on migration into simulants from published studies were 
used to assess the exposure of specific groups of consumers: those consuming water from water 
coolers with PC reservoirs and users of PC tableware, PC water kettles, PC filters and cookware. 
Those studies from which data were retrieved are marked in Table 2. 
Water coolers 
Consumers might be loyal to the type of water they consume, and will either consume bottled water or 
tap water (either as such or filtered). Water from water coolers with PC reservoirs would mainly be 
consumed away from home (usually at working places), and also in this case consumers might be 
loyal consumers. 
To determine a BPA concentration for the estimation of exposure from water coolers with PC 
reservoirs, data were retrieved from published literature and were combined with data provided to 
EFSA by PlasticsEurope (email from PlasticsEurope to EFSA on 29 November 2012). 
The data from the literature were from migration experiments conducted at moderate temperature 
(typically 20–40 °C) from all PC products into water for all migration times. Concentration data in 10 
samples of water stored in water coolers with PC reservoirs were available from the literature in Spain 
(Guart et al., 2011). BPA concentrations ranged from 1.6 µg/kg to 4.44 µg/kg. The average BPA 
concentration was 2.64 µg/kg. 
Data from PlasticsEurope (email from PlasticsEurope on 29 November 2012) on migration of BPA 
from 41 samples of water coolers with PC reservoirs (both new and used), collected for different 
periods of use at temperatures from 5 to 36 °C were also provided through the EFSA call for data. 
These data were also subjected to the quality screening protocol applied to all data. The contact 
conditions (temperature and time) used in the study were considered to reflect the most common, 
variable real use contact conditions. BPA concentrations ranged from 0.001 µg/kg to 4.05 µg/kg. 
Average BPA concentration was 0.50 µg/kg. 
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When all data for water coolers with PC reservoirs were pooled (from the literature and the call), the 
average BPA concentration of 0.81 µg/L was derived (see Table 3) and this value was used to estimate 
the exposure of this specific group of consumers. 
The concentration values in water stored in water coolers with PC reservoirs in China (Chen et al. 
2011) and in most samples in Canada (Cao et al., 2008) were in the same range as in the European 
samples. However, the water in two PC carboys in Canada had BPA concentrations of 6.5 µg/kg and 
8.8 µg/kg. The authors suggest that the carboys had been exposed to high temperatures for extended 
periods of time during storage or transport. 
Several earlier opinions have not considered a specific BPA value for water stored in water coolers 
with PC reservoirs (EFSA, 2006a; FAO/WHO, 2011). In the ANSES report (2013) water from water 
coolers with PC reservoirs was found to have an average concentration of 1 µg/L and a 95th percentile 
of 4 µg/L. 
Water kettles, tableware, water filters 
Migration data into water from PC products, tested at temperatures in the range of 70 to 100 °C for 
24 hours, and data obtained from the scientific literature were considered to derive a migration value 
associated with the use of PC kettles. A PC kettle is typically used to warm/boil water to prepare hot 
beverages such as tea and coffee, foods such as soups and other dehydrated products such as infant 
formula. The average migration value for the 24-hour contact time derived from the literature 
(2.55 µg/L) was divided by 24 to reflect the migration occurring during a cycle of one hour of contact 
during which the water is boiled and allowed to cool and fresh water may be added to the water 
remaining in the kettle and a new boiling cycle started. This is considered typical behaviour of a user 
of such kettles. An average value of 0.11 µg/L was derived (see Table 3). However, these assumptions 
may not apply to situations where the same water is repeatedly heated in the kettle, as it would 
underestimate the migration value. 
For PC tableware, migration data from the literature for all PC products, into water, 3 % acetic acid 
and 50 % ethanol, obtained under testing conditions of two hours at 70 °C, were considered. These 
data were combined with data from the EFSA call for data obtained under the same testing conditions. 
The average values ranged from 0.18 µg/L (LB) to 1.31 µg/L (UB). The average values from the two-
hour contact time were divided by eight to reflect a single use of approximately 15 minutes use 
(5 minutes of heating in a microwave + 10 minutes of additional contact during consumption). 
Average migration values of 0.02 µg/L (LB), 0.09 µg/L (MB) and 0.16 µg/L (UB) were derived from 
experiments using any simulants (see Table 3). 
PC filters are most likely used for shorter periods of contact time, compared with water coolers with 
PC reservoirs. The migration was estimated considering the same data as for water coolers with PC 
reservoirs but only for periods of time up to 24 hours. It is reasonable to assume that this condition of 
contact (one hour at room temperature) also covers the potential migration for longer periods of 
contact at the refrigerator temperature. An average value of 0.96 µg/L was derived from the data and 
divided by 24 to simulate a maximum one hour of contact time for this application, assuming a 
constant BPA transfer rate. An average value of 0.04 µg/L was used to estimate exposure. 
For cooking ware coatings, an average value of 0.29 µg/kg (MB) was derived to be used in estimating 
exposure (see Table 3), taking into consideration the decrease in migration observed after the third 
reuse with olive oil at 175 °C for 30 minutes (Bradley et al., 2007) and extrapolating it over a set of 
100 uses. 
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 Estimated migration values for specific PC food contact materials used in the exposure Table 3: 
assessment 





Water cooler with PC 
reservoirs 
0.81 0.81 0.81 4.10 4/100 
PC tableware 0.02 0.09 0.16 0.63 217/232 
PC kettle 0.11 0.11 0.11 0.32 0/6 
PC filter 0.04 0.04 0.04 0.17 2/17 
Cookware 0.20 0.29 0.39 7.60 21/26 
LB, average (lower bound) BPA concentration (assigning the value 0 when LOD or LOQ is reported); Max., maximum value 
reported (assigning LOD or LOQ when LOD or LOQ is reported); MB, average (middle bound) BPA concentration 
(assigning the value for LOD/2 or LOQ/2 when LOD or LOQ is reported); n, total number of samples both from literature 
and the EFSA call for data; UB, average (upper bound) BPA concentration (assigning the value for LOD or LOQ when LOD 
or LOQ is reported(a): MB values were used for exposure estimate. 
4.3.2. Occurrence data in food 
Data on the occurrence of BPA in food were retrieved from both scientific journals and provided 
through the EFSA call for data. 
Governmental institutions, academia, food manufacturers and one association (Fédération romande 
des consommateurs (FRC) submitted in total 2 076 results for BPA occurrence in food and beverages 
to EFSA. These data were obtained from samples collected in the EEA countries (EU, plus Iceland, 
Liechtenstein, Norway and Switzerland). 
The majority of data were provided by France from a total diet study (EAT2). Roughly 20 000 
samples prepared as consumed were combined to pools of 15 foods of similar type, resulting in 1 464 
samples analysed for BPA. They referred mainly to non-canned products, in particular “Drinking 
water” (396 samples)”, “Meat and meat products” (172 samples” and “Milk and dairy products” (139 
samples). France reported BPA results for only 36 samples of canned foods or beverages. Most of the 
data (95 %) originated from accredited laboratories and 5 % of results were submitted from non-
accredited laboratories. Some data were obtained by methods not complying with the quality criteria 
for analytical methods (see Appendix A) and therefore the number of data considered was 1 943. A 
comprehensive description of data from the EFSA call for data can be found in Appendix B. 
One hundred and twenty-three scientific papers reported occurrence data in food and beverages and 
were eligible according to the criteria listed in Section 4.2 (publication period, language, geographical 
distribution). These papers are listed in Tables 63 and 64 of Appendix I. The analytical methods 
reported in the papers were scrutinised according to the quality criteria established in Appendix A. The 
outcome of this process is also documented in Tables 62 and 63. Concentration data were extracted 
from only those papers (n = 72) that matched the eligibility criteria and were found to be produced by 
sufficiently suitable analytical methods. In total, 573 data for occurrence in food and beverages were 
retrieved from the scientific literature. 
A specific, automated process was applied to check and remove double entries of datasets, from the 
call and from the literature. This was ensured by comparing 38 fields for each dataset. Data from the 
literature and from the call for data did not show major differences in BPA concentrations and so have 
been merged to provide one BPA concentration for each food category. 
A total of 2 516 analytical results on BPA in food and beverages from the two sources were then 
inserted in a database. All samples included in the final dataset were considered sufficiently robust and 
were treated equally; no weighting was used based on the accuracy of the analytical results. 
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Most of the information included in the combined dataset referred to foods and beverages sampled in 
2008 and 2012 (Figure 2). Analytical results from a small number of food and beverages sampled in 
2004 and 2005 (n = 11) and received through the call for data were also included in the database, as 
these results would have been published anyway after 2006 and therefore are in line with the 
restriction used for the literature search, where this year was used as a threshold. 
 
Figure 2: Total number of BPA samples from the scientific literature and the EFSA call for data per 
sampling year 
France provided by far the majority of the data on non-canned foods and beverages. The distribution 
of canned samples by country was more homogeneous, with Germany and Portugal being the main 
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Figure 3: Figure 3: Total number of BPA samples from the scientific literature and the EFSA call for data per 
sampling country 
A specific inclusion criterion for data on occurrence in food reported in the scientific literature is that 
only foods purchased in the European region (EU and non-EU) would be included in the exposure 
assessment. The reason for this is that data on BPA occurrence in food are collected in order to assess 
dietary exposure to BPA in Europe. Data from a market basket survey recently conducted in Sweden 
(Gyllenhammar et al., 2012) were not considered in the exposure assessment, as analytical 
determinations were performed on composite samples of non-canned and some canned products. 
These values could therefore not be assigned to either canned or non-canned products, and the 
proportion of canned/non-canned products in each category could not be considered representative of 
other European countries. They have, however, been used for the comparison of BPA levels between 
the market baskets and the occurrence data used in this opinion. The same applies to 99 pooled 
samples, including canned and not canned foods, from the French total diet study. Furthermore, non-
European data are summarised in relation to the descriptions of the food categories (Appendix C, Food 
categories). These data have been used for comparison with European data as a check on the BPA 
concentration levels. 
Most of the information on the occurrence of BPA in food and beverages was available at the level of 
individual samples, both from the literature and from the EFSA call for data. In the case of aggregated 
results, average results have been weighted for the number of samples in order to calculate the overall 
average for the food category. When only a median value was available for aggregated results, it was 
considered as a proxy for the average. 
Where available, the information on the type of packaging (not packaged, canned, glass jar with metal 
lid, etc.) was reported and codified. When this information was not available, but assumptions could 
be made that the food was most probably non-canned (e.g. pizza, coffee), it was assigned to the non-
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Analytical data were grouped according to the type of packaging and food category, with the use of 
EFSA’s food classification and description system, FoodEx. The assumption is that a large portion of 
the variability observed in BPA concentration between samples of the same food category is related to 
the packaging. Thus, in the study by Grumetto et al. (2008) on peeled tomatoes, no BPA could be 
detected in products packaged in glass, whereas BPA could be detected in more than half of canned 
products. Analytical data were grouped by food category, as it was observed that the BPA 
concentration in food with the same type of packaging could vary according to the type of food, i.e. 
lower BPA concentrations were observed in canned beverages than in solid foods (Geens et al., 
2012a). The present opinion presents BPA concentration results for more specific food categories than 
the earlier EFSA opinion on BPA (EFSA, 2006a), and the FAO/WHO opinion (2011). In particular, a 
BPA concentration value was estimated for all food categories. This approach differs from some 
earlier opinions in which, for instance, non-canned foods were not considered. 
Despite the limited number of samples, especially for some of the food categories, consistent 
differences in BPA concentration between canned and non-canned food were observed in the large 
majority of food categories, with higher BPA concentrations in the canned food. However, noteworthy 
differences in BPA levels can also be observed within the canned and the non-canned food categories, 
as illustrated in Table 4 (see column “All—Average BPA”). Seven out of 17 canned food categories 
present have an average (MB) BPA concentration above 30 µg/kg (“Grain and grain-based products”, 
“Legumes, nuts and oilseeds”, “Meat and meat products”, “Fish and other seafood”, “Herbs, spices 
and condiments”, “Composite food” and “Snacks, desserts, and other foods”). Four of the canned food 
categories have average BPA concentrations (MB) between 2.7 and 23.5 µg/kg (“Vegetables and 
vegetable products”, “Fruit and fruit products”, “Fruit and vegetable juices” and “Milk and dairy 
products”), while the remaining six categories have average BPA concentrations (MB) below 
1.2 µg/kg. These differences are probably related to the heating after packaging (the main migration 
occurs during this heating process). Beverages are seldom heated, acidic product merely pasteurized, 
whereas other foods are sterilized. Still other cans are not coated with epoxies. 
Among the 19 non-canned food categories, the highest levels of BPA were found in the categories 
“Meat and meat products” and “Fish and other seafood” with average BPA concentrations (MB) of 9.4 
and 7.4 µg/kg, respectively (Table 4, column “All—average BPA”). The relatively high levels of BPA 
in food of animal origin are mainly based on data from France owing to the very large number of 
samples of non-canned products received from this country. The CEF Panel considers that the French 
results for BPA in food of animal origin (unconjugated BPA) are corroborated by the positive results 
for a limited number of samples from Ireland (in “Pork (grilled)”, “Chicken (oven roasted)” and 
“Offal, kidney (dry fried”) and Spain (in “Mussels”). These results are similar to those reported by 
ANSES in their most recent study of BPA concentrations in food, in which the Agency measured both 
total and unconjugated BPA (the former being measured after enzymatic hydrolysis of the sample). 
ANSES reported average concentrations of unconjugated BPA in fish and meat ranging between 10 
and 15 µg/kg, the levels of total and unconjugated BPA in foods of animal origin being virtually the 
same (ANSES, 2013). The correspondence between the EFSA data and those reported by ANSES 
probably reflects the high preponderance of French data on non-canned food in the EFSA database. 
Any BPA to which food production animals are exposed is likely to be present in their tissues as 
glucuronated BPA, as a result of metabolism primarily to glucuronated (conjugated) BPA (see the 
section on Toxicokinetics, Part II of this opinion – Toxicological assessment and risk characterisation, 
of this opinion). Measurement of unconjugated BPA in food of animal origin (in particular meat and 
fish) might indicate that deconjugation may have occurred owing to the action of glucuronidases 
during processing of the sample. Another potential source of unconjugated BPA in meat products is its 
migration from any food contact materials or from articles used in the processing of the product. The 
fact that elevated levels of unconjugated BPA were observed in meat and fish, but not to the same 
extent in eggs or milk, gives more support to the possibility that BPA is due to contamination. ANSES 
also considered that the detection of unconjugated BPA in the samples could be due to contamination 
(ANSES, 2013). With the exception of the data submitted by France through the EFSA call for data, 
none of the methods, published in the scientific literature or obtained through the EFSA call, described 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 27 
deconjugation steps, and so it was assumed that the BPA concentrations reported were for 
unconjugated BPA only. Therefore, the data on total BPA reported by France were merged with the 
other data from the EFSA call for data. 
For the remaining 17 non-canned food categories, the average BPA concentrations (MB) were all 
equal to or below 1.2 µg/kg, with the exception of “Composite foods”, which includes fish- and meat-
based products and had a BPA average equal to 2.4 µg/kg. 
When comparing European with non-European concentration data, average BPA levels of 
concentration resulted mostly in the same range as the samples from Europe. However, there were 
single non-European foods that were reported to have higher BPA concentrations than those found in 
Europe. For instance some canned beans and peas from the United States of America (USA) had a 
concentration four times above the highest European value, and a sample of canned mango from 
Singapore had a value 10 times higher. It seems, however, that these very high values may be outliers 
and not representative of non-European BPA concentrations. Data presented at the national meeting of 
the American Chemical Society in April 2013 indicated that BPA concentrations in foods that are 
produced and canned in Japan have dropped considerably since 2000. In comparison with imported 
canned food from other countries, the decrease has been of the order of a factor of 10–20. 
Concentration values for Japanese canned food are in the range of some tens of micrograms per 
kilogram (Kawamura et al, 2014). 
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 Summary of average BPA concentrations (g/kg) from the literature and the EFSA call for data Table 4: 
Food category (FoodEx level 1) and 
type of packaging (canned or non-
canned) 

































































































Grains and grain-based products 1 67.4 0 67.4 18 34.9 0 47.5 19 36.6 36.6 36.6 0 67.4 
Vegetables and vegetable products 50 26.0 40 116 73 21.7 18 100 123 22.9 23.5 24.0 27 116 
Legumes, nuts and oilseeds 2 86 0 103 18 28.8 33 137 20 32.6 34.6 36.6 30 137 
Fruit and fruit products 7 15.9 0 24.4 14 12.2 21 107 21 13.1 13.4 13.7 14 107 
Meat and meat products 31 14.7 39 51.1 16 64.2 38 203 47 27.7 31.5 35.4 45 203 
Fish and other seafood  107 39.5 20 169 67 33.0 33 198 174 34.7 37.0 39.2 27 198 
Milk and dairy products 19 2.6 63 15.2 3 19.8 0 35.9 22 4.4 4.9 5.5 55 35.9 
Sugar and confectionery 1 0.2 0 0.2 – – – – 1 0.2 0.2 0.2 0 0.2 
Fruit and vegetable juices 5 2.7 0 4.7 – – – – 5 2.7 2.7 2.7 0 4.7 
Non–alcoholic beverages 54 0.5 26 8.1 11 0.5 27 1.5 65 0.5 0.5 0.5 26 8.1 
Alcoholic beverages 
(f)
 18 0.9 17 4.7 49 0.8 35 4.5 67 0.7 0.8 0.8 30 4.7 
Drinking water (bottled and tap) 1 0 100 0 10 0–0 100 0 11 0.0 0.0 0.0 100 0 
Herbs, spices and condiments – – – – 2 41.4 0 82.1 2 41.4 41.4 41.4 0 82.1 
Food for infants and small children 
(f)
 10 0.3 70 2.2 – – – – 10 0.3 0.3 0.3 70 2.2 
Products for special nutritional use 
(f)
 14 1.2 36 4.8 – – – – 14 1.2 1.2 1.2 36 4.8 
Composite food 6 25.9 17 73.1 25 39.6 20 110 31 34.6 37.0 39.3 19 110 
Snacks, desserts and other foods 1 52.0 0 52.0 – – – – 1 52.0 52.0 52.0 0 52.0 
Non-canned 
Grains and grain-based products 1 0.9 0 0.9 95 1.0 43 11.9 96 0.8 1.0 1.1 43 11.9 
Vegetables and vegetable products 4 0.4 0 1.0 201 1.2 34 5.3 205 1.2 1.2 1.3 33 5.3 
Starchy roots and tubers – – – – 45 0.7 16 2.6 45 0.6 0.7 0.7 16 2.6 
Legumes, nuts and tubers – – – – 5 0.2 60 0.5 5 0.1 0.2 0.3 60 0.5 
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Food category (FoodEx level 1) and 
type of packaging (canned or non-
canned) 
































































































Fruit and fruit products 3 0.5 0 1.3 85 0.3 73 2.1 88 0.2 0.3 0.4 71 2.1 
Meat and meat products  1 0.9 0 0.9 191 9.5 5 395 192 9.4 9.4 9.5 5 395 
Fish and other seafood  8 1.9 75 11.2 68 8.1 2 97.9 76 7.4 7.4 7.4 11 97.9 
Milk and dairy products 1 2.6 100 – 151 0.3 52 6.1 152 0.2 0.3 0.4 52 6.1 
Eggs and egg products – – – – 15 0.9 20 4.5 15 0.8 0.9 0.9 20 4.5 
Sugar and confectionery 1 0.3 0 0.3 19 0.5 42 2.6 20 0.5 0.5 0.6 40 2.6 
Animal and vegetable fats and oils – – – – 26 0.5 46 1.4 26 0.3 0.5 0.7 46 1.4 
Fruit and vegetable juices 2 0.01 100 – 14 0.8 71 6.0 16 0.4 0.7 0.9 75 6.0 
Non-alcoholic beverages 1 0.01 100 – 72 0.2 64 1.7 73 0.1 0.2 0.2 64 1.7 
Alcoholic beverages 59 0.5 22 2.1 35 0.5 71 1.6 94 0.4 0.5 0.6 40 2.1 
Drinking water (bottled and tap) 159 0.2 90 4.4 460 0.2 84 4.5 619 0.2 0.2 0.2 84 4.5 
Herbs, spices and condiments 2 0.3 0 0.3 17 1.3 71 2.5 19 0.2 1.2 2.2 63 2.5 
Food for infants and small children 1 0.9 100 – – – – – 1 0.0 0.9 1.7 100 – 
Composite food 3 0.3 0 0.4 107 2.4 13 25.8 110 2.3 2.4 2.4 13 25.8 
Snacks, desserts and other foods – – – – 31 0.4 68 0.4 31 0.1 0.4 0.7 68 0.4 
(a): n, number of samples. 
(b): MB, average (middle bound) BPA concentration (assigning the value for LOD/2 or LOQ/2 when LOD or LOQ is reported). 
(c): UB, average (upper bound) BPA concentration (assigning the value for LOD or LOQ when LOD or LOQ is reported). 
(d): LB, average (lower bound) BPA concentration (assigning the value 0 when LOD or LOQ is reported). 
(e): % < LOD/LOQ: percentage of samples below limit of detection/limit of quantification. No significant difference between LB and UB BPA mean concentration owing to the relatively low 
LODs or LOQs. 
(f): Food categories at FoodEx level 1 have been used. 
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4.3.3. Occurrence, migration and transfer data from non-dietary sources 
Occurrence, migration and transfer data for BPA from non-food sources were retrieved from scientific 
journals and risk assessment reports (FAO/WHO, 2011; ANSES, 2013); an overview of the literature 
concerning non-food sources considered is given in Appendix D. The quality of each study was 
assessed on the basis of the criteria in Section 4.2 and Appendix A. All available information was 
collected, with a focus on environmental matrices sampled in Europe or consumer articles sold in 
Europe. The term “non-food sources” summarises all sources that contribute to exposure via pathways 
other than the food pathway (food pathway: food itself, migration from food contact materials, 
migration from the lining of water supply pipes). 
Environmental media can be inhaled (airborne dust, vapours) or ingested (water, dust) directly, so that 
occurrence can be directly linked to exposure. Drinking water is not considered as an environmental 
medium, since it is classified as food (see Table 4, Section 4.5.2), but untreated surface water may be 
ingested occasionally during, for example, swimming in a lake. Consumer products and articles are 
included as non-food sources in the present assessment only if they are potentially in close contact 
with the consumer (e.g. dermal exposure, mouthing, hand-to-mouth contact possible) and if migration 
and/or transfer rates have been reported. This is the case for children’s toys, for example (KEMI, 
2012), and indicatively for thermal paper. Consequently, for consumer products, in addition to data on 
occurrence, data for migration into saliva and transfer to skin are also summarised in this section. 
The pathway of exposure via medical devices and medical materials is currently under review by the 
Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) of the Directorate 
General Health and Consumers (DG SANCO). Only dental materials are medical treatments that are 
considered to be applied on a regular basis for a large proportion of the population and therefore 
occurrence data on dental materials are summarised below. 
The known sources of exposure that presumably are the most relevant for the consumers by magnitude 
of exposure and prevalence of sources are discussed below. 
4.3.3.1. Environmental sources (air, dust and surface water) 
Outdoor air 
Data for outdoor air in Europe are available from only two studies, one in Greece and one in France. 
In Greece the presence of BPA was determined in outdoor air in the city of Thessaloniki (Salapasidou 
et al., 2011). From January to February 2007, ambient PM10 (particulate matter < 10 µm) was 
sampled from an urban traffic site and an industrial site. BPA in the particulate phase was collected 
using a low-flow air sampler over 24 hours and analysed by gas chromatography (GC)-MS. BPA 
concentrations measured in the particulate phase ranged between 0.06 and 47.3 ng/m
3
. At the urban 










. The air concentrations as presented above do not discriminate between BPA vapour and 
BPA associated with the airborne particulate phase. It was estimated that 99 % of the BPA is present 
in the airborne particulate phase and only a small fraction is present in the gaseous phase of the air. 
The results from a French study show that BPA was detected in outdoor air in the gaseous phase and 
particulate phase in an urban setting in Paris and in the forest in Fontainebleau at concentrations 
varying from 1 to a few ng/m
3
 (ANSES, 2013). 
Further data for outdoor air are available from the USA. Wilson et al. (2007) collected outdoor air 
samples in children’s homes and daycare centres in two states in the USA (North Carolina and Ohio). 
Outdoor air concentrations (75th percentiles) ranged between 1.0 and 1.5 ng/m
3
 in North Carolina and 
between 0.7 and 0.9 ng/m
3
 in Ohio. The 50th percentile values were below the method detection limit 
(not fully specified, around 0.9 ng/m
3
). These levels were confirmed by Rudel et al. (2010), who 
measured BPA in outdoor air in Richmond and Bolinas (California, USA). Median levels were around 
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0.5 ng/m
3
, the highest level was below 2 ng/m
3
. For Osaka, Japan, Matsumoto et al. (2005) measured 
BPA in urban ambient outdoor air during a six-month period. Samples were collected using a high-
volume air sampler situated on a roof top and analysed with GC-MS. BPA concentrations ranged from 
0.02 to 1.92 ng/m
3
, with an average of 0.51 ng/m
3
. The highest and lowest average concentrations 
were reported for February and October, respectively. Fu and Kawamura (2010) reported that the 
concentrations of BPA in outdoor air ranged over four orders of magnitude in the world (0.001–
17.4 ng/m
3
, aerosol sampling) with a declining trend from the continents to remote sites. The highest 
concentrations were measured in the rural areas (mainly in Asia; no data for Europe were reported). 
The two US studies show that the concentration levels in indoor air are comparable to or even higher 
than those in outdoor air, suggesting that the indoor air in the house contributes more than the outside 
air to exposure to BPA through inhalation in the general population. Furthermore, in Europe most of 
the population spends around 90 % of its time indoors (EuroStat, 2004). For these reasons, no 
distinction was made between time spent indoors and outdoors, but for the calculation only indoor air 
levels were used. 
Indoor air 
Volatilisation and/or abrasion of very small particles from epoxy-based floorings, adhesives, paints, 
electronic equipment and printed circuit boards are a source of contamination of indoor air and dust 
(Loganathan and Kannan, 2011). 
As BPA has a comparatively low vapour pressure, from indoor air it is deposited onto surfaces or dust. 
As a result of the low vapour pressure, concentrations of BPA in air can be expected to be low and it 
will be present mainly in the particulate phase, adsorbed to dust. European data are available only 
from one recent report by ANSES (2013). BPA levels were measured in indoor air of 30 French 
homes with an average of 1.0 ng/m
3
 (median: 0.6 ng/m
3
) in the particulate phase of the air. The highest 
level was 5.3 ng/m
3
. 
US data are in the same range. Wilson et al. (2007) measured indoor air concentrations in 257 US 
homes with an LOD around 0.9 ng/m
3
 (LOD deduced by Beronius and Hanberg (2011)). 
Concentrations in indoor air from homes and daycare centres ranged from < LOD to 193 and 
8.99 ng/m
3
, respectively, with a median and 95th percentile for homes of 1.82 and 11.1 ng/m
3
, 
respectively. A second study from the USA (Rudel et al., 2010) determined the BPA in indoor air of 
50 non-smoking Californian households. BPA was found in only five samples with concentrations of 
0.5 to 20 ng/m
3
; the median for all samples was given as 0.5 ng/m
3 
(which was also the LOD). 
For the exposure calculation, the average level of 1 ng/m
3
 reported by ANSES (2013) was used, as this 
is the only study available for indoor air in Europe. 
Dust 
Ingestion of house dust was reported to be an exposure pathway for BPA in young children owing to 
the use of BPA in a variety of indoor applications and consumer products and because of children’s 
more frequent hand-to-mouth contact and larger intake of dust than adults (Jones-Otazo et al., 2005; 
Calafat et al., 2008). BPA was observed in dust from homes, laboratories (Loganathan and Kannan, 
2011) and offices (Geens et al., 2009a). Data for Europe are available from three studies conducted in 
Germany (Völkel et al., 2008), Belgium (Geens et al., 2009a) and France (ANSES, 2013). They are in 
the same order of magnitude as data from private homes in the USA (Loganathan and Kannan, 2011; 
Rudel et al., 2003). 
Völkel et al. (2008) measured BPA in dust from 12 homes in Germany to investigate potential sources 
of contamination of urine samples in a biomonitoring study. Samples were collected by residents in 
homes using regular vacuum cleaners. BPA concentrations in dust ranged from 117 to 1 486 µg/kg 
with a median of 553 µg/kg. 
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Geens et al. (2009a) measured concentrations of BPA in indoor dust from 18 homes and two offices in 
Belgium. Samples were collected using a vacuum cleaner. BPA concentrations measured in dust from 
homes ranged from 535 to 9 729 µg/kg with a median of 1 460 µg/kg. The concentrations of BPA in 
dust from the two offices were 4 685 and 8 380 µg/kg (but included in the median). The reason for the 
higher concentrations of BPA in offices was not explained by the authors. 
ANSES (2013) measured settled dust in 25 houses in France. The average, median and maximum 
concentrations of BPA were 5 800, 4 700 and 20 000 µg/kg, respectively. 
As no raw data were available from the cited studies, it was not possible to evaluate all data together. 
Instead, for the exposure calculation, the median dust concentration of 1 460 µg/kg was taken from 
Geens et al. (2009a), which is the study that provides the median of the medians reported by the recent 
studies available for Europe. 
Surface water 
In a recent study, the concentrations of BPA in North American and European aquatic environments 
were critically reviewed and statistically characterised (Klecka et al., 2007). A total of 100 papers or 
reports, published between 1991 and 2007, were identified that contained environmental monitoring 
data for BPA in European and North American surface water and sediment. Median BPA 
concentrations in freshwater in Europe were lower than those for North America (0.01 and 0.08 µg/L, 
respectively), although the 95th percentile concentrations were similar (0.35 and 0.47 µg/L, 
respectively). 
Deblonde et al. (2011) reported concentrations of BPA in wastewater treatment plants ranging from 
0.088 to 11.8 µg/L in the influent and from 0.006 to 4.09 µg/L in the effluent. This is in agreement 
with the levels reported by Klecka et al. (2007). 
Data on BPA from surface water were not included in the exposure assessment, as this source 
contributes very little to the overall dermal exposure, as confirmed by ANSES (2013). 
4.3.3.2. Paper products 
BPA is present in thermal papers that are used as cash receipts, airline tickets, bus tickets and papers 
for laboratory use (Liao and Kannan, 2011a). BPA is loosely bound to the paper surface. It has been 
reported that in Europe, thermal paper containing BPA amounts to 72 % (ANSES, 2013) or 80 % 
(Lassen et al., 2011) of total thermal paper. According to the European Thermal Paper Association, 
BPA is still used in thermal paper and, in 2012, 80 % of thermal paper was used for point-of-sales 
grades, which are mainly used for supermarkets and shop tickets and not for tickets for transport 
(bus/boarding passes) and tickets for lotteries (email from European Thermal Paper Association to 
EFSA, 17 June 2013). In Switzerland 11 samples out of 13 investigated thermal papers contained BPA 
(Biedermann et al., 2010). Reported values ranged from 8 to 17 g/kg, with an average of 13.3 g/kg. In 
Sweden, receipt and receipt-like papers contained on average 14 and 16 g/kg, respectively (Östberg 
and Noaksson, 2010). The highest levels in this study were found in car park tickets and bus tickets 
with an average concentration of 32 and 23 g/kg, respectively. In Belgium 73 % of collected thermal 
paper samples had BPA concentrations between 9 and 21 g/kg, the remaining 27 % were < 0.1 g/kg 
(Geens et al., 2012b). Similar values have been reported for the USA. 94 % of all thermal receipt 
papers contained BPA, and the range was from below the LOQ of 1 µg/kg up to 13.9 g/kg (Liao and 
Kannan, 2011a). 
Receipts and bus tickets are commonly stored in wallets in close contact with paper currency. BPA has 
been shown to be transferred from thermal paper to paper currencies at levels ranging from 0.001 to 
82.7 mg/kg for currencies worldwide (Liao and Kannan, 2011b). These levels are considerably lower 
(by a factor of approximately 1 000) than levels of BPA in thermal paper, and the CEF Panel 
considered that this source could be ignored in the exposure. Levels in other paper products are, for 
example, 3.2 to 46.1 mg/kg dry matter for recycled toilet paper (Gehring et al., 2004), with BPA 
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originating from the waste paper used in the recycling process. In this case, BPA is included in the 
bulk of the paper and not readily available from the surface. 
BPA may also be present in some cigarette filters (Jackson and Darnell, 1985). However, no analytical 
data are available for BPA in cigarette filters. 
Consequently, consumers are predominantly exposed to BPA in thermal papers by handling cash 
receipts, tickets, etc. Biedermann et al. (2010) determined the amount of BPA transferred to the 
fingers of one volunteer by touching thermal paper. Different scenarios were tested with regard to the 
moisture and grease content of the finger. BPA transfer increased with wetness and greasiness. For 
what the authors called “standard skin” (slightly greasy skin) five different thermal papers were 
touched for 30 seconds. The average amount transferred by one handling was found to be 1.1 µg BPA 
per finger. In another study, migration from paper receipts from Denmark was investigated (Lassen et 
al., 2011). Eight fingers touched five different receipts for 10 seconds. Migration to dry fingers on 
average was 11 µg, i.e. 1.4 µg/finger, which is similar to the value derived by Biedermann et al. 
(2010). In order to create a conservative average value, the latter was used in this assessment. This 
does not consider crumpling paper before trashing it, which results in contact with most of the hand 
when the printed surface happens to be outside. 
4.3.3.3. Children’s toys and articles intended to be mouthed 
Information on the potential exposure to BPA from toys in children is rather limited. A recent study 
(Viñas et al., 2012) investigated migration of BPA into artificial saliva from articles purchased in 
Spanish supermarkets. Migration from two toys and three pacifiers tested by one minute’s immersion 
without stirring in 100 mL of artificial saliva was in the range of 0.2 to 0.3 µg/L, while the migration 
from a teether was 5.9 µg/L. The contact time of one minute used by Viñas et al. (2012) was 
considered too short to account for real migration, and therefore the data from this study are not used. 
In another migration study, toys and pacifiers from the Swedish market were put into contact with 
artificial saliva at 24 °C for 24 hours (KEMI, 2012) by submersing the toys in the smallest volume of 
artificial saliva needed to completely cover the toys, which was between 100 and 700 mL (pers. 
comm., KEMI, 2013). Migration of < 0.1 µg/L (LOQ) up to 2.1 µg/L was reported with 8 of 14 
toys/pacifiers below LOQ. The maximum levels of 2.1 µg/L were reported for a rattle (0.63 µg BPA 
migration per product) and a pacifier (0.21 µg BPA migration per product). The average values in this 
study were 0.14 µg/product for rattles and 0.11 µg/product for pacifiers. The authors of the study state 
that it had been difficult to find children’s products made of PC. In order to find 14 products that 
contained BPA they had to buy 80 products altogether. 
Migration from pacifiers into artificial saliva was also determined by Lassen et al. (2011). BPA was 
detected in six out of eight migration experiments (LOD: 0.1 µg/kg saliva). The maximal amount 
detected was 1.36 µg migration after 7.75 hours at 37 °C. Average amounts were from 0.28 to 
0.36 µg/product (LB to UB), and the average MB was 0.32 µg/product. 
Exposure was calculated from rattles as a surrogate for any PC toy that can be mouthed (general 
population—children) and pacifiers with PC shields (specific population groups). Migration data for 
rattles from KEMI (2012) were used in the exposure calculation: the average migration (MB) was 
0.14 µg/product. For pacifiers the average MB found by Lassen et al. (2011) was used 
(0.32 µg/product). 
4.3.3.4. Cosmetics 
In Europe, BPA is not permitted as an ingredient in cosmetics (Appendix B of Regulation (EC) No 
1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic 
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products: List of substances prohibited in cosmetic products
22
). However, if BPA was present in the 
packaging (e.g. PC packaging), it could migrate into the cosmetic products. 
European data on BPA in cosmetics are very scarce. A recent study (Cacho et al., 2013) reports levels 
of < LOQ to 88 µg/kg for different cosmetics (shower gel, hair gel, face lotion, make-up remover and 
mouthwash) bought in Spain. Furthermore, worldwide data are scarce. Another recent study reports 
BPA concentrations, banded in the crude range of 1–100 mg/kg in a number of personal care products 
bought in the USA such as bar soap, body lotion, shampoo, conditioner, shaving cream, face lotion, 
facial cleanser, body wash and nail polish (Dodson et al., 2012). No reasoning was given by the 
authors as to why BPA was present in these products. 
As shown by Cacho et al. (2013), BPA can be present in trace amounts in cosmetics. The source could 
be migration from cosmetic packaging or alternatively BPA may be present as an impurity in the 
cosmetic ingredients. The European cosmetics legislation allows impurities to be present in “small 
quantity” (Cosmetics Directive Article 17) as long as it is “safe for human health” (Article 3). Even if 
these data are by no means representative for the EU, nor representative for the wide range of 
cosmetics that are on the market, it can be concluded that cosmetics could contain trace amounts of 
BPA as an impurity. The most important contribution to exposure will be from body lotion, because of 
the large body surface that is treated and because this leave-on product is nearly entirely taken up by 
the skin (Lorenz et al., 2011). Rinse-off products such as shampoos and hair gel that are removed after 
washing contribute comparatively low amounts to exposure. Therefore, to account for a realistic worst 
case, exposure to body lotion was chosen for an exemplary assessment. As no body lotion was 
analysed by Cacho et al. (2013), the concentration of 31 µg/kg found in facial lotion was selected as a 
proxy for body lotion since its matrix, ingredients and use (leave-on) are most similar to body lotion. 
4.3.3.5. Medical devices 
Medical devices are a particular product category in which BPA is found. Examples of these products 
are implants, catheters, and dental devices. BPA-containing medical devices may have direct and/or 
indirect contact with the patients (e.g. autotransfusion apparatus, filters, bypasses, tubing, pumps, 
instruments, surgical equipment, blood pathway circuits and respiratory tubing circuits). The pathway 
of exposure via medical devices is currently under review by SCENIHR of DG SANCO. In the 
present assessment, where the risk of BPA for the general public is assessed, the exposure to these 
medical devices will not be included, as they are used only in specific sub-populations. Dental 
materials are used in the general population, so the occurrence of BPA in dental materials is 
considered here. 
4.3.3.6. Dental materials 
Dental sealants and composite filling materials containing BPA are used in dentistry, especially in 
children (Fleisch et al., 2010). The most commonly used BPA-derived material is BPA glycidyl 
methacrylate (bis-GMA). BPA dimethacrylate (bis-DMA), BADGE and BPA ethoxylate 
dimethacrylate (bis-EMA) are also used. Only bis-DMA, which has an ester linkage, can be 
hydrolysed to release BPA. The ether linkage in bis-GMA is stable (Schmalz et al., 1999). The resins 
are polymerised in situ during placement of dental sealants and unpolymerised material may be 
released into saliva directly after treatment. The release of BPA over time as a result of hydrolysis of 
the resin (Pulgar et al., 2000) was reported. However, other studies describe BPA exposure after dental 
sealant placement as an acute event (Fleisch et al., 2010; Kang et al., 2011). Variability between 
brands and analytical method sensitivity and uncertainty make it difficult to draw conclusions 
regarding exposure from this source (Beronius and Hanberg, 2011). Polydorou et al. (2009a) 
demonstrated that bleaching did not increase the release of BPA from composite materials. 
                                                     
22 Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic 
products, OJ L 342, 22.12.2009, p. 59 209. 
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Van Landuyt et al. (2011) reviewed the release of substances from dental materials into water-based 
solutions, and the highest individual value for BPA was 67 nmol/mm
2
 surface area of material. 
According to Van Landuyt, the value corresponds to a worst-case release of 132 µmol after 24 hours 
on one full crown restoration of a molar. 
Zimmerman-Downs et al. (2010) studied the effect of dental sealants on the BPA concentration in 
saliva in 30 volunteers (with no history with dental sealants or composite material treatment). One 
group of 15 volunteers received one occlusal sealant, the other group received four sealants. One hour 
before treatment, the mean baseline value was around 1 µg/L saliva. In the high-dose group, the mean 
peak value was 6 µg/L (measured 1 hour after treatment) whereas in the low-dose group this mean 
peak value was around 2 µg/L. Sasaki et al. (2005) measured BPA levels in saliva in 21 volunteers 
after restoration with composite resins (from nine different companies). BPA levels in saliva ranged 
from several tens to 100 µg/L but sufficient gargling could remove it from the oral cavity. Both studies 
indicate that BPA levels in saliva return to baseline (1 µg/L saliva) after 24 hours. 
A few studies have also investigated systemic absorption of BPA after placement of dental sealants. 
Measured levels in blood up to five days after sealant placement could not detect any BPA (Fung et 
al., 2000; Zimmerman-Downs et al., 2010). Median urinary levels of BPA increased from 2.4 µg/L 
(pretreatment) to 12.9 µg/L one hour after treatment with one type of sealant but treatment with 
another brand did not result in the same increase in urinary concentrations (Joskow et al., 2006). 
Urinary concentrations of BPA had decreased significantly after 24 hours but were not completely 
back to baseline within this time. 
Kang et al. (2011) reported BPA levels in saliva and urine samples collected from 22 South Korean 
volunteers who received a lingual bonded retainer on their mandibular dentition. Samples were 
collected immediately before placement and 30 min, one day, one week, and one month after 
placement. The only significantly high level of BPA was observed in the saliva collected just after 
placement of the lingual bonded retainer (average 5 µg/L; maximum value 21 µg/L). One day after 
placement, the level decreased to the background level again (average value: 0.5 µg/L saliva). No 
statistically significant increase in BPA in the urine samples at any time point was observed. 
As the baseline level is very low (the level before treatment is the same as about 24 hours after 
treatment), it is probable that this saliva concentration represents exposure to BPA from other sources 
rather than dental material. 
Another exposure assessment of BPA concluded that exposure from dental materials does not 
contribute significantly to the exposure (von Goetz et al., 2010). This is also concluded in a report 
recently published by the Swedish National Board of Health and Welfare (2012) addressing bisphenol 
A in dental materials. This report summarises research on in vitro and in vivo studies related to BPA 
from dental materials and concludes that there is a possibility of low-dose exposure to BPA from 
dental materials, either as a contaminant (very low amounts) or from degradation of bis-DMA. 
Furthermore, as only bis-DMA leaches BPA it is unlikely that the general population is chronically 
exposed to BPA from dental sealants. Therefore, exposure to dental materials was not included in the 
present exposure calculation. 
Based on the assessment of occurrence, migration and transfer data presented above, the data 
presented in Table 5 have been selected for use in the exposure calculation for non-food (see Section 
4.5.3). 
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 Overview of BPA concentrations and sources considered for the present exposure Table 5: 
assessment  






Unit Reference Reasoning 




Single data source 




Direct 1 460 µg/kg 
dust 







Dermal Transfer to 
finger 























Cosmetics Dermal Direct 31 µg/kg Cacho et al., 
2013 
Single data source 
for cosmetics in 
Europe, value for 
face lotion used 
4.4. Food consumption  
Data from the EFSA Comprehensive European Food Consumption Database (hereafter called the 
Comprehensive Database) were used to assess dietary exposure to BPA in all age groups, excluding 
infants aged zero to six months. The Comprehensive Database was built in 2010 from existing national 
information on food consumption at a detailed level. Competent organisations in the European Union 
Member States provided EFSA with data from the most recent national dietary survey in their country 
at the level of consumption by the individual consumer. Survey results for children were mainly 
obtained through the EFSA Article 36 project “Individual food consumption data and exposure 
assessment studies for children” through the EXPOCHI consortium (EFSA, 2011). Results from a 
total of 32 different dietary surveys carried out in 22 different Member States covering more than 
67 000 individuals are included in the Comprehensive Database version 1 as published (EFSA, 2011; 
Merten et al., 2011). 
There are two surveys available for infants, nine surveys available for toddlers, 17 surveys available 
for children 3-10 years, 12 surveys available for adolescents, 15 surveys available for adults, seven 
surveys available for the elderly and six surveys available for the very elderly. Only surveys covering 
more than one day, and thus appropriate for calculating chronic exposure, were selected. For each 
survey, food consumption data are coded according to the FoodEx classification system. 
4.5. Exposure estimation  
4.5.1. General assumptions for exposure calculation 
For each source of exposure (dietary; non-dietary oral, inhalation and dermal) and in each age group 
(infants (0–1 year), toddlers (1–3 years), children (3–10 years), adolescents (10–18 years), women 
(18–45 years), men (18–45 years), other adults (45–65 years), elderly and very elderly (over 65 years) 
(EFSA, 2011), a scenario for average exposure and a scenario for high exposure was developed. 
Average exposures from the different sources have been added together by route to assess average 
exposure. High exposures from the different sources have been added together by route to assess high 
exposure. In order to quantify the relative impact of each source, the assumptions made in the 
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exposure assessments aimed to obtain a similar degree of conservativeness among the different 
sources. 
In the case of infants, owing to their very monotonous dietary pattern, loyalty was considered. Thus, 
high exposure was assessed considering that some infants might be systematically exposed to products 
containing a higher concentration of BPA, e.g. an infant formula containing a high concentration of 
BPA or a baby bottle releasing more BPA than other bottles. In all other age classes, an average BPA 
concentration was considered and high chronic exposure was assessed considering higher levels of 
consumption of products containing BPA, as explained in detail in Section 4.5.2.4 (see “Assessment of 
dietary exposure based on the EFSA Comprehensive Database”). 
As far as possible, exposure to total BPA from dietary and other sources has been calculated. Where 
possible, exposure to conjugated and unconjugated BPA has been assessed separately, i.e. through 
human milk. 
Thus, for non-food sources too an attempt was made to choose average values for all parameters, 
including parameters describing frequency of use. For the high scenario, the same average parameters 
were used for occurrence data, and, in line with the methodology used to assess exposure from food, 
the frequency of use parameters were modified to account for exposure of approximately the 95th 
percentile of the population. For calculating exposure levels for the general population behavioural 
parameters were derived considering both users and non-users. For calculations for specific population 
groups (e.g. users of pacifiers with PC shields, s. Table 24), behavioural data were taken only from the 
group of users (see Table18). Loyalty was assumed in the case of cosmetics. 
Biomonitoring studies have been used to assess how much total BPA is excreted in urine (backward 
modelling), allowing the estimation of exposure from all sources to total BPA. These estimates have 
been compared with the total internal exposure value calculated by forward modelling, as a check of 
plausibility. In addition, biomonitoring studies might be able to identify the existence of unrecognised 
source of exposure. 
4.5.2. Exposure estimation from dietary sources 
Dietary exposure to BPA in infants aged less than six months was assessed by means of a model diet 
based on a standard level of consumption combined with BPA concentration in human milk or infant 
formula. Average and high BPA concentration values were used to assess average and high chronic 
dietary exposure. 
4.5.2.1. Dietary exposure from colostrum and human milk 
Initial human milk (colostrum), which is produced from the first day to approximately five days after 
delivery, differs from mature human milk. The assessment of exposure to BPA in the first few days of 
life has therefore been considered separately. 
The quantity of initial human milk consumed by infants on their very first day of life is very small; it 
was estimated to be 44 ± 71 g (mean ± SD (standard deviation)) by Neville et al. (1988) and as low as 
15 ± 11 g by Santoro et al. (2010). The quantity of initial human milk consumed increases steadily 
each day and reaches around 500 g/day on the fifth day of life (Neville et al., 1988). Taking an average 
consumption of 250 g over the first five days, and assuming an average body weight for a newborn 
infant of 3.25 kg, an average consumption rate of 75 g/kg bw per day (rounded by 5-g steps) is 
obtained. For infants aged five days to three months the average level of consumption of 150 g/kg bw 
per day considered by the US Environmental Protection Agency (EPA, 2011) to derive exposure 
factors in the first month of life was used here. As human milk consumption per kilogram of body 
weight decreases steadily from month 1 to month 3, the level of consumption observed at month 1 
allows a conservative assessment of exposure for this age class up to three months old. For infants 
aged up to three months and breastfed with mature human milk, a level of consumption of 
150 g/kg bw per day, and for breastfed infants aged four to six months, the level of consumption 
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established in the EFSA opinion on default assumptions (132 g/kg bw per day) (EFSA Scientific 
Committee, 2012) was considered. 
Based on data from the scientific literature described in Section 4.6.4, average exposure for infants 
aged one to five days was assessed assuming that initial human milk would contain 3.0 µg of total 
BPA/L whereas high exposure was assessed assuming that initial human milk would contain 5.8 µg of 
total BPA/L. The CEF Panel noted that only very few data from Europe were available and therefore 
decided to take into account data from Japan, reporting the above BPA concentrations. The CEF Panel 
noted, however, that these data had significant limitations, including the use of ELISA methodology 
and the fact that the samples dated back to 2000. The non-specificity of the ELISA method may tend 
to overestimate the BPA concentration in colostrum which, however, would be conservative for the 
exposure assessment of breastfed newborn infants. These limitations were addressed in the uncertainty 
analysis. Results are presented in Table 6. 
 Exposure to total BPA from initial human milk Table 6: 
 Consumption of initial human milk 
(g/kg bw per day) 
Average exposure 








Infants, day 1–5 75 225 435 
(a): Based on an average BPA concentration in initial human milk of 3.0 µg/L assuming a milk density of 1 kg/L. 
(b): Based on a high BPA concentration in initial human milk of 5.8 µg/L assuming a milk density of 1 kg/L. 
Average exposure of breastfed infants from six days of age to six months was assessed considering 
that mature milk would contain 1.1 µg of total BPA/L, whereas high exposure was assessed 
considering that mature milk would contain 4 µg of total BPA/L. Results are presented in Table 7. 
 Exposure to total BPA from mature human milk Table 7: 
 Consumption of mature human  








(ng/kg bw per day) 
Infants, 0–3 months 150 165 600 
Infants, 4–6 months 132 145 528 
(a): Based on an average BPA concentration in mature human milk of 1.1 µg/L assuming a milk density of 1 kg/L. 
(b): Based on a high BPA concentration in mature human milk of 4.0 µg/L assuming a milk density of 1 kg/L. 
4.5.2.2. Dietary exposure from infant formula 
The highest level of consumption per kilogram of body weight is observed during the first months of 
life of formula-fed infants. The level of consumption of infant formula considered is the one that 
would provide a water consumption in infants of 150 g/kg bw per day. This is based on the scenario of 
a 5-kg infant consuming 0.75 L of water per day for the reconstitution of infant formula, as suggested 
by WHO (2003). This is consistent with the approach used in the recent CEF Panel’s opinion on the 
criteria to be used for safety evaluation of recycling processes (EFSA CEF Panel, 2011a). 
Infant formula may be purchased as powder or ready-to-use (liquid). According to the European 
Dietetic Food Industry Association (email to EFSA dated 27 June 2013), canned liquid infant formula 
is not offered in cans in Europe and therefore exposure is not considered here. For powdered infant 
formula, the factor that is generally considered to calculate the quantity of reconstituted infant formula 
based on the quantity of powder (1/7) was used (EFSA, 2010). Thus the total weight of infant formula 
consumed is 150 g  8/7. 
A specific exposure assessment was performed for infants fed with such formulas, based on the 
average and high BPA concentration observed in European samples. 
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In Table 22 and 23, reporting exposure to BPA for the general population, only powdered infant 
formula (canned and not canned) and liquid infant formula (not canned) have been considered. A 
unique value, without distinction between these three types of formula, has been used based on the 
following considerations: 
For powdered infant formula—canned, based on 10 sets of European analytical data, an average 
concentration of 0.3 g/kg and a high concentration of 2.2 g/kg were considered (see Section 4.3.2, 
“Occurrence in food”, and Appendix C). Dietary exposure would amount to 6 ng/kg bw per day in an 
infant fed about 21 g/kg bw per day of infant formula powder (equivalent to 150 g/kg bw per day of 
ready-to-drink liquid infant formula) containing an average concentration of 0.3 µg/kg. As infant 
formula powder is diluted in water, the baseline BPA contamination of drinking water reported in 
Table 3 was also considered MB 0.2 g/kg). Overall, exposure to BPA from the consumption of 
150 mL/kg bw per day of reconstituted formula would be 36 ng/kg bw per day at the average 
(150  0.2 + 150  0.3  1/7) with more estimated BPA deriving from the water than from the powder. 
High exposure would be 77 ng/kg bw per day (150  0.2 + 150  2.2  1/7). 
For powdered infant formula—not canned, only one analytical dataset was available for Europe (under 
the limit of detection, MB 0.9 g/kg) whereas no data were available in Europe for liquid infant 
formula—not canned. Exposure from the consumption of 150 mL/kg bw per day of either 
reconstituted formula or of liquid infant formula—not canned would mainly derive from the 
background contamination of water and, based on an MB value of 0.2 g/kg, would be in the range of 
30 ng/kg bw per day. 
The CEF Panel noted that for these three types of formula, BPA concentration values in formulas and 
water were low and rather uncertain. Overall, no significant difference in exposure is expected 
between canned infant formula powder and non-canned infant formula (either liquid or powder). 
Rough estimates of 30 ng/kg bw per day for average exposure and of 80 ng/kg bw per day for high 
exposure were therefore considered for these three types of products. 
4.5.2.3. Dietary exposure from water coolers with PC reservoirs, PC water filters and old 
waterpipes repaired with epoxy resins 
Water dispensers (also known as water coolers with PC reservoirs) and water filters can be used at 
household level (e.g. fridge water dispensers), at work places and in schools. The water coolers with 
PC reservoirs hold a large bottle (approximately 10 L) on top, which is often made from PC and is 
exchanged for a new bottle when empty. When referring to PC coolers in this opinion the actual bottle 
is meant. Regular consumers of water from these reservoirs are exposed to an additional source of 
exposure compared with the general population. The same is true for households living in buildings 
where old water pipes have been repaired with epoxy resins that release BPA into tap water. 
Additional chronic exposure to BPA in these specific population groups was assessed considering total 
water consumption in each age class, as reported in Table 24. Data on the consumption of drinking 
water was derived from the EFSA Comprehensive Database for all age classes, from toddlers to the 
very elderly, at individual level. The median of average consumption and the highest observed 95th 
percentile are reported and were used to assess average and high exposure.  
For PC water dispensers, only average exposure was assessed, as it is unlikely that high consumption 
of water would derive exclusively from PC dispensers. For PC water filters and water pipes, average 
and high exposure was assessed considering the average and high consumption as described above.  
The use of PC water dispensers and PC filters was not considered for infants, as it was considered 
unlikely that infant formula would be reconstituted with water from such water dispensers. 
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For PC water dispensers and PC filters, migration values of 0.81 µg/L and 0.04 µg/L, respectively, 
were considered (see Table 3 in Section 4.3.1, “Estimated migration values for specific PC food 
contact materials used in the exposure assessment”). For water pipes, the average and high exposure 
was assessed based on average BPA concentration in cold water in those buildings where water pipes 
had been repaired with a two-component technique leading to high release of BPA (see Section 4.3.2, 
“Occurrence in food”, and Appendix B) of 0.1 µg/L. Results are presented in Table 8. 
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 Exposure to BPA from drinking water in specific population groups based on chronic (a) water consumption as reported in the EFSA Table 8: 
Comprehensive Database 
 Median of mean 
water 
consumption 





(g/kg bw per day) 
Average exposure ng/kg bw per day 
(b)
 High exposure ng/kg bw per day 
(c)
 
Water coolers Water pipes PC filters Water pipes PC filters 
Toddlers 26.6 95.6 22 2.7 1.1 10 3.8 
Children 
(3-10 years) 
19.2 68.8 16 1.9 0.8 7 2.8 
Adolescents 10.9 39.4 9 1.1 0.4 4 1.6 
Women 
(18–45 years) 
9.8 39.2 8 1.0 0.4 4 1.6 
Men  
(18–45 years) 
7.7 33.8 6 0.8 0.3 3 1.4 
Other adults 
(45–65 years) 
8.5 32.3 7 0.9 0.3 3 1.3 
Elderly and  
very elderly 
10.5 28.6 9 1.1 0.4 3 1.1 
(a): In order to assess chronic water consumption, only surveys with at least two survey days were considered. 
(b): Considering median water consumption and the following concentration of BPA (µg/kg): water coolers 0.81; water pipes 0.1; PC filters 0.04. 
(c): Considering high water consumption and the following concentration of BPA (µg/kg): water pipes 0.1; PC filters 0.04. 
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4.5.2.4. Dietary exposure from PC kettles, PC tableware, cookware and old PC baby bottles 
BPA may migrate into food and beverages through contact with PC food contact materials such as 
tableware used to heat foods and beverages in microwave ovens, tableware used when the food or 
beverage is eaten (mugs, beakers, plates, bowls) and water kettles used to boil water for preparing hot 
drinks such as coffee, tea or rehydrated soups. As migration increases with temperature, time of 
contact and surface of contact, it is likely to be highest when hot beverages are prepared with water 
heated in a PC kettle or consumed in PC mugs or cups. The case of infant formula reconstituted with 
water heated in a PC water kettle and of infants fed with formula from an old PC baby bottle bought 
before the EU ban must also be considered. PC tableware and PC kettles are used by only a fraction of 
the population, but in this fraction of the population that uses them regularly it needs to be assessed as 
an additional source of exposure to BPA. 
The migration value chosen to represent average potential migration from PC kettles into water was 
0.11 µg/kg. This value is an estimate of BPA concentration in water that would be warmed twice in a 
kettle and left in it for a total of about 50 minutes (see Table 3 in Section 4.3.1.2, “Estimated migration 
values for specific PC food contact materials used in the exposure assessment”). The migration value 
was added to the background level of BPA in water, resulting in combined value of BPA 
concentration of 0.31 µg/kg. It was considered that water heated in a kettle could be used to prepare 
hot beverages such as coffee (espresso excluded) or tea. Individual consumption data from the 
Comprehensive Database have been used to estimate the exposure to BPA from kettles. Average and 
high (95th percentile) exposure have been assessed for each survey and in each age class for exposure 
to BPA from PC kettles. Summary data are presented in Table 9. As expected, the highest estimated 
exposure from PC kettles was observed in adults and the elderly owing to their higher consumption of 
coffee and tea. 
 Exposure to BPA in specific population groups using PC kettles, based on chronic Table 9: 
consumption of beverages that could be prepared with hot water, as reported in the EFSA 
Comprehensive Database 









(g/kg bw per day) 
Average 
exposure ng/kg 










 150 (+ powder contribution) 53 94 
Toddlers 0.4 19.3 0.11 5.98 
Children (3-10 years) 0.4 16.0 0.13 4.96 
Adolescents 1.0 15.4 0.32 4.77 
Women (18–45 years) 3.3 25.8 1.02 8.01 
Men (18–45 years) 1.9 23.6 0.59 7.31 
Other adults 
(45–65 years) 
2.0 29.4 0.63 9.12 
Elderly and very elderly 2.5 27.4 0.77 8.48 
(a): Considering median beverage consumption and the following concentration of BPA: 0.31 µg/kg. 
(b): Considering high beverage consumption and the following concentration of BPA: 0.31 µg/kg. 
(c): Considering the consumption of 150 mL/kg bw per day of water with a BPA concentration 0.31 µg/kg, plus the 
contribution from powder formula. 
For infants fed with infant formula reconstituted from powder, dietary exposure related to the use of 
PC kettles to warm the water was assessed considering a water consumption of 150 mL/kg bw per day. 
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For breastfed infants, the additional exposure from the consumption of herbal tea prepared with water 
heated in a PC kettle was estimated considering the consumption of one small baby bottle (100 mL) 
per day for a 5-kg infant. 
Chronic dietary exposure to BPA from tableware and from cookware was also estimated for age 
classes from toddlers to the elderly with the use of individual consumption data from the EFSA 
Comprehensive Database. In this case, all occasions on which food was consumed and beverages that 
may be consumed hot were assumed to contain a BPA concentration level equal to 0.09 and 
0.29 µg/kg, respectively. These values are the estimated migration during 15 minutes of contact 
between the food and the tableware (see Table 3 in Section 4.3.1.2, “BPA migration into food 
simulants”). All food and beverages, with the exception of “alcoholic beverages”, “drinking water”, 
“fruit and fruit products” and “fruit and vegetable juices”, at the first level of the FoodEx system, were 
assumed to be consumed hot. Average and high (95th percentile) exposure have been assessed for 
each survey and in each age class for the exposure to BPA from tableware. Results are presented in 
Table 10. The highest estimated exposure from PC tableware was observed for toddlers owing to their 
higher consumption of beverages per kilogram of body weight. This age class is also the one in which 
regular use of PC tableware is most likely to occur, as “unbreakable” plastic mugs and beakers are 
often used for toddlers. 
 Exposure to BPA in specific population groups using PC tableware or cookware Table 10: 
containing BPA, based on chronic consumption of food that could be consumed warm, as reported in 
the EFSA Comprehensive Database 










(g/kg bw per 
day) 
Average exposure ng/kg 
bw per day 
(a)
 
High exposure ng/kg 
bw per day 
(b)
 
Tableware Cookware Tableware Cookware 
Toddlers 64.6 156.9 6 19 14 46 
Children  
(3-10 years) 
46.7 96.6 4 14 9 28 
Adolescents 26 54.9 2 8 5 16 
Women  
(18–45 years) 
22.4 52.2 2 6 5 15 
Men  
(18–45 years) 
22.7 49.2 2 7 4 14 
Other adults  
(45–65 years) 
21.8 51 2 6 5 15 
Elderly and  
very elderly 
20.8 49 2 6 4 14 
(a): Considering median food consumption and the following concentration of BPA (µg/kg): 0.09 in tableware and 0.29 in 
cookware. 
(b): Considering high food consumption and the following concentration of BPA (µg/kg): 0.09 in tableware and 0.29 in 
cookware. 
The case of infants fed with formula in old PC baby bottles that would have been bought before the 
EU ban was also considered by combining the consumption level of 150 mL/kg bw per day with an 
average migration of 0.91 µg/L and a high migration of 2.8 µg//L (see Table 2 in Section 4.3.1.2, 
“BPA migration into food simulants”). 
In the 2006 EFSA opinion, a single value of 5 µg/kg was considered for migration from tableware. 
The consumption of food in contact with tableware was extremely conservative, in particular for 
toddlers: 3 kg for a 60-kg adult (50 g/kg bw per day) and 2 kg for a 11-kg toddler (182 g/kg bw per 
day). Estimated exposure from this source was therefore one order of magnitude higher compared with 
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the present assessment, which derives estimates of 250 ng/kg bw per day in adults and 900 ng/kg bw 
per day in toddlers. 
4.5.2.5. Assessment of dietary exposure based on the EFSA Comprehensive Database 
Dietary exposure from 12-month-old toddlers to the elderly has been estimated using individual 
consumption data from the EFSA Comprehensive Database combined with available concentration 
data derived from the scientific literature or from the EFSA call for data. In order to consider 
separately women of childbearing age, in the present assessment the adult age group has been broken 
down into three subgroups, comprising women from 18 to 45 years old, men from 18 to 45 years old 
and other adults from 45 to 65 years old. The subgroups of the elderly and very elderly were merged. 
As food consumption data for infants aged 6 to 12 months in the Comprehensive Database were very 
limited and consequently not used in the present assessment, dietary exposure in toddlers (12–36 
months) was used as an estimate for the dietary exposure in infants aged 6 to 12 months. The CEF 
Panel noted that the consumption pattern in these two age groups is likely to be different, but the 
approach taken was likely to provide a conservative dietary exposure estimate for this age group. 
The average BPA concentration in each food category was assessed by merging data from different 
sources or scientific publications (see Section 4.3.2). Chronic exposure was estimated by multiplying 
the average BPA concentration for each FoodEx level 1 food group (see Appendix E for details) and 
type of packaging (canned or non-canned) with their respective consumption amount per kilogram of 
body weight separately for each individual in the database, calculating the sum of exposure for each 
survey day for the individual and then deriving the daily average for the survey period. Average and 
95th percentile exposure was calculated for the total survey population separately for each survey and 
age class. Details of the surveys are given in Table 11. 
Only a limited number of dietary surveys included in the Comprehensive Database included 
information on the type of packaging (canned or non-canned, in particular). The number and 
percentages of food codes specific for canned products per country and per survey are presented in 
Table 12. 
Two scenarios were therefore considered: 
Scenario 1. Only foods specifically codified as canned in the dietary survey are assigned the 
corresponding occurrence level for BPA. 
Scenario 2. At FoodEx level 4, any food which has been codified as canned in at least one survey is 
always considered to be consumed as canned in all dietary surveys included in the Comprehensive 
Database. A list of all these products is reported in Appendix J. The corresponding average occurrence 
of BPA in canned products is consequently always assigned to these foods. In order to avoid an 
artificial overestimate of exposure to BPA, exceptions have been made for products that are consumed 
in large quantities in many EU countries and would generally not be consumed as canned. For these 
foods, only those effectively codified as canned in the original survey have been assigned the BPA 
occurrence in canned food. The exceptions were as follows: apples, beef, cow’s milk (all types), cream 
(all types), crème fraiche (all types), croissants, mandarins, oranges, potatoes—fried, potatoes and 
potato products, poultry, rice and sour cream (all types). 
4.5.2.6. Presentation of results 
Table 13 presents the minimum, median and maximum values for the average and 95th percentile in 
each age class, for LB, MB and UB, under scenario 1. Table 14 presents the same results under 
scenario 2. The highest levels of exposure were estimated for toddlers and children 3-10 years, up to 
857 and 813 ng/kg bw per day, respectively, for the 95th percentile under the MB scenario. Overall, 
among the population older than six months, infants and toddlers presented the highest estimated 
average (375 ng/kg bw per day) and high (857 ng/kg bw per day) dietary exposure. The CEF Panel 
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considered that this was mainly due to their higher consumption of foods and beverages per kilogram 
of body weight. 
Owing to a very low percentage of left-censored samples, mainly among canned foods, the techniques 
used to model data under the LOD or LOQ had a very small impact on the average concentration in 
the different food categories and, consequently, on the exposure. On average, exposure estimates 
calculated by the MB technique were 4–30 % (scenario 1) and 4–12 % (scenario 2), respectively, 
higher than those calculated by the LB method. Compared with the UB estimates, the MB estimates 
were 4–19 % (scenario 1) and 2–8 % (scenario 2) lower. 
Table 11 reports for each survey age group the average and 95th percentile for each scenario, and it is 
sorted according to the ratio between the 95th percentile exposure in scenario 2 and scenario 1. This 
ratio is lowest in countries where many food codes were available for canned products and/or where 
canned products are largely consumed. It is the case for UK men and women from 18 to 45 years old 
where the ratio is 1.9 and 2.2 at the average and 1.7 and 2.1 at the 95th percentile, respectively. The 
highest difference was noted in Belgian toddlers, with a ratio equal to 5.0 and 6.8 for the average and 
the 95th percentile, respectively. 
Table 15 presents the number of dietary surveys according to the percentage of average dietary 
exposure to BPA per type of packaging (canned vs. not canned) and scenario. Under scenario 1, the 
percentage contribution to BPA from non-canned foods was predominant (but less than 50 %) in the 
most of the dietary survey. Under this scenario, only for one survey (related to males from 18 to 45 
years old) canned foods contributed between 50 % and 75 % of average BPA exposure. Under 
scenario 2, canned products dominated in all surveys, with the percentage contribution to BPA from 
non-canned foods mainly ranging between 10 % and 25 %. Canned foods contributed up to more than 
90 %; this is the result of one dietary survey among toddlers: “Fish and other seafood”. 
The number of dietary surveys according to the percentage of average dietary exposure to BPA per 
type of packaging (canned vs. non-canned), FoodEx level 1 food category and scenario is reported in 
Appendix E for all age groups. Under scenario 1, non-canned “Meat and meat products” turned out to 
be a major contributor to BPA average exposure in the large majority of countries and age classes. 
“Vegetables and vegetable products” was the only canned food category that contributed up to 25–
50 % in some of the population groups. “Meat and meat products” was also the major contributor 
among the non-canned food categories under scenario 2 but never exceeded 10–25 % of the exposure. 
On the other hand, the canned versions for “Vegetables and vegetable products”, “Meat and meat 
products” and “Composite food” were the major sources of average BPA exposure. 
Under scenario 2, dietary exposure in women of childbearing age was slightly higher (132 and 
388 ng/kg bw per day for average and high exposure, respectively) than that of men of the same age 
(126 and 335 ng/kg bw per day for average and high exposure, respectively). This may be due to 
women consuming different food items, as reported in the individual surveys. 
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 Dietary exposure by country survey and age group and scenarios under the middle bound assumption (sorted according to the ratio between the Table 11: 
95th percentile (P95) exposure in scenario 2 and scenario 1) 





(ng/kg bw per 
day) 
Scenario 2 




Mean P95 Mean P95 Mean P95 
United Kingdom NDNS Men (18–45 years) 459 59 109 112 182 1.9 1.7 
United Kingdom NDNS Women (18–45 years) 587 49 91 107 191 2.2 2.1 
Denmark Danish_Dietary_Survey Adolescents 479 64 117 137 248 2.1 2.1 
United Kingdom NDNS Adults (45–65 years) 678 51 94 120 201 2.3 2.1 
Czech Republic SISP04 Men (18–45 years) 446 55 97 120 220 2.2 2.3 
Denmark Danish_Dietary_Survey Men (18–45 years) 781 51 80 109 182 2.1 2.3 
Ireland NSIFCS Adults (45–65 years) 358 48 85 124 203 2.6 2.4 
Italy INRAN_SCAI_2005_06 Children (3-10 years) 193 120 206 267 502 2.2 2.4 
Ireland NSIFCS Men (18–45 years) 282 55 90 126 218 2.3 2.4 
Czech Republic SISP04 Adults (45–65 years) 801 41 75 102 186 2.5 2.5 
Spain AESAN Women (18–45 years) 160 56 126 161 313 2.8 2.5 
Spain AESAN Men (18–45 years) 141 57 100 142 249 2.5 2.5 
Italy INRAN_SCAI_2005_06 Adolescents 247 70 121 169 302 2.4 2.5 
Italy INRAN_SCAI_2005_06 Men (18–45 years) 575 50 83 125 209 2.5 2.5 
Hungary National_Repr_Surv Men (18–45 years) 244 46 85 123 217 2.7 2.5 
Czech Republic SISP04 Adolescents 298 59 109 152 277 2.6 2.6 
Czech Republic SISP04 Children (3-10 years) 389 78 142 198 363 2.5 2.6 
Denmark Danish_Dietary_Survey Elderly and very elderly 329 47 74 111 190 2.4 2.6 
Denmark Danish_Dietary_Survey Adults (45–65 years) 1 117 47 76 115 201 2.4 2.7 
Denmark Danish_Dietary_Survey Women (18–45 years) 924 49 79 119 211 2.4 2.7 
Denmark Danish_Dietary_Survey Children (3-10 years) 490 102 165 253 446 2.5 2.7 
Spain AESAN_FIAB Men (18–45 years) 367 54 92 148 249 2.7 2.7 
Ireland NSIFCS Women (18–45 years) 318 47 82 123 223 2.6 2.7 
Italy INRAN_SCAI_2005_06 Adults (45–65 years) 1 055 47 78 124 219 2.7 2.8 
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(ng/kg bw per 
day) 
Scenario 2 




Mean P95 Mean P95 Mean P95 
Italy INRAN_SCAI_2005_06 Women (18–45 years) 683 52 87 138 242 2.7 2.8 
Spain AESAN_FIAB Adolescents 86 63 101 156 293 2.5 2.9 
Czech Republic SISP04 Women (18–45 years) 419 38 67 97 195 2.6 2.9 
Germany National_Nutrition_Survey_II Adolescents 1 011 41 87 121 252 2.9 2.9 
Germany National_Nutrition_Survey_II Men (18–45 years) 2 517 46 91 127 264 2.8 2.9 
Italy INRAN_SCAI_2005_06 Elderly and very elderly 518 44 70 116 206 2.6 2.9 
Hungary National_Repr_Surv Adults (45–65 years) 503 38 67 113 199 3.0 3.0 
Finland DIPP Toddlers 497 111 228 316 688 2.8 3.0 
Hungary National_Repr_Surv Elderly and very elderly 286 35 60 107 183 3.1 3.1 
Finland FINDIET_2007 Men (18–45 years) 333 37 59 101 184 2.7 3.1 
Sweden Riksmaten_1997_98 Women (18–45 years) 354 42 73 137 228 3.3 3.1 
Spain AESAN_FIAB Adults (45–65 years) 207 52 90 163 283 3.1 3.1 
Sweden Riksmaten_1997_98 Men (18–45 years) 352 41 67 127 209 3.1 3.1 
Finland DIPP Children (3-10 years) 933 87 140 248 440 2.9 3.1 
Spain enKid Adolescents 209 62 111 190 350 3.0 3.2 
Sweden NFA Children (3-10 years) 1 473 79 147 263 476 3.3 3.2 
Hungary National_Repr_Surv Women (18–45 years) 327 41 69 120 224 2.9 3.3 
Spain AESAN_FIAB Women (18–45 years) 407 61 99 182 329 3.0 3.3 
Bulgaria NUTRICHILD Toddlers 428 137 253 431 846 3.1 3.3 
Sweden Riksmaten_1997_98 Adults (45–65 years) 504 43 71 141 238 3.3 3.4 
Finland FINDIET_2007 Adults (45–65 years) 821 33 57 103 194 3.2 3.4 
Spain NUT_INK05 Adolescents 651 61 103 201 352 3.3 3.4 
Germany National_Nutrition_Survey_II Women (18–45 years) 3 285 38 73 124 251 3.2 3.4 
Cyprus Childhealth Adolescents 303 41 77 142 269 3.5 3.5 
Sweden NFA Adolescents 1 018 50 88 163 309 3.2 3.5 
Finland FINDIET_2007 Elderly and very elderly 463 29 51 97 179 3.3 3.5 
Germany National_Nutrition_Survey_II Elderly and very elderly 2 496 38 70 125 247 3.3 3.5 
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(ng/kg bw per 
day) 
Scenario 2 




Mean P95 Mean P95 Mean P95 
France INCA2 Men (18–45 years) 517 37 60 121 211 3.3 3.5 
Bulgaria NUTRICHILD Children (3-10 years) 433 127 223 409 790 3.2 3.6 
Germany National_Nutrition_Survey_II Adults (45–65 years) 4 617 40 75 127 268 3.2 3.6 
Netherlands DNFCS_2003 Women (18–45 years) 398 41 80 142 286 3.5 3.6 
Finland FINDIET_2007 Women (18–45 years) 421 33 56 109 205 3.2 3.6 
Spain enKid Children (3-10 years) 156 96 179 298 668 3.1 3.7 
Spain NUT_INK05 Children (3-10 years) 399 92 148 312 556 3.4 3.8 
Netherlands DNFCS_2003 Men (18–45 years) 352 49 89 175 335 3.6 3.8 
Spain AESAN Adults (45–65 years) 109 50 86 158 331 3.2 3.9 
Netherlands VCP_kids Children (3-10 years) 957 79 160 290 635 3.7 4.0 
Greece Regional_Crete Children (3-10 years) 839 96 165 345 674 3.6 4.1 
France INCA2 Adolescents 973 43 73 156 307 3.7 4.2 
France INCA2 Adults (45–65 years) 947 36 55 138 230 3.8 4.2 
Belgium Diet_National_2004 Men (18–45 years) 365 40 69 158 290 4.0 4.2 
France INCA2 Women (18–45 years) 812 35 55 132 235 3.8 4.3 
Latvia EFSA_TEST Men (18–45 years) 376 42 76 172 333 4.1 4.4 
Germany DONALD_2006_2008 Children (3-10 years) 660 57 86 215 381 3.8 4.4 
Germany DONALD_2006_2008 Toddlers 261 72 108 235 487 3.3 4.5 
France INCA2 Elderly and very elderly 348 34 51 137 231 4.0 4.6 
France INCA2 Children (3-10 years) 482 75 117 314 550 4.2 4.7 
Netherlands VCP_kids Toddlers 322 97 178 375 857 3.9 4.8 
Latvia EFSA_TEST Children (3-10 years) 189 60 112 264 544 4.4 4.9 
Latvia EFSA_TEST Adolescents 470 44 78 187 381 4.3 4.9 
Latvia EFSA_TEST Adults (45–65 years) 547 34 63 161 309 4.7 4.9 
Belgium Diet_National_2004 Adolescents 584 37 65 161 345 4.3 5.3 
Latvia EFSA_TEST Women (18–45 years) 383 33 61 153 328 4.6 5.4 
Belgium Diet_National_2004 Adults (45–65 years) 554 36 61 168 341 4.6 5.6 
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(ng/kg bw per 
day) 
Scenario 2 




Mean P95 Mean P95 Mean P95 
Finland STRIP Children (3-10 years) 250 70 108 362 620 5.2 5.8 
Belgium Regional_Flanders Children (3-10 years) 625 81 131 415 813 5.1 6.2 
Belgium Diet_National_2004 Elderly and very elderly 1 230 35 59 183 375 5.2 6.3 
Belgium Diet_National_2004 Women (18–45 years) 385 34 57 170 388 5.0 6.8 
Belgium Regional_Flanders Toddlers 36 104  551  5.3  
Italy INRAN_SCAI_2005_06 Toddlers 36 145  312  2.1  
Spain enKid Toddlers 17 116  390  3.4  
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 Presence of canned food codes in Comprehensive Database per country and survey Table 12: 
Country Survey Number of national food codes Number of FoodEx codes 
Canned All Percentage Canned All Percentage 
Germany National_Nutrition_Survey_II  1 694 22 387 8 168 817 21 
United Kingdom NDNS 210 3 228 7 87 678 13 
Netherlands VCP_kids  43 1 194 4 39 429 9 
Sweden Riksmaten_1997_98 57 1 055 5 44 487 9 
Denmark Danish_Dietary_Survey  22 315 7 21 233 9 
Spain AESAN 39 709 6 32 366 9 
Sweden NFA 67 1 529 4 46 528 9 
Netherlands DNFCS_2003 177 3 485 5 47 554 8 
Spain AESAN_FIAB 36 572 6 32 381 8 
Spain NUT_INK05 24 602 4 21 293 7 
Ireland NSIFCS 61 1 681 4 38 536 7 
Czech Republic SISP04 28 502 6 19 313 6 
Cyprus Childhealth  10 244 4 9 179 5 
Italy INRAN_SCAI_2005_06 15 1 085 1 13 462 3 
Finland STRIP 10 917 1 9 331 3 
Bulgaria NUTRICHILD 12 511 2 8 308 3 
Spain enKid 6 385 2 6 248 2 
Hungary National_Repr_Surv 10 536 2 8 357 2 
Greece Regional_Crete 6 376 2 5 257 2 
Finland FINDIET_2007 5 1 042 0 5 400 1 
Finland DIPP 5 925 1 5 413 1 
Latvia EFSA_TEST 5 1 300 0 5 488 1 
France INCA2 1 1 251 0 1 570 0 
Belgium Diet_National_2004 0 2 229 0 0 750 0 
Belgium Regional_Flanders 0 940 0 0 360 0 
Germany DONALD_2006_2008 0 3 769 0 0 680 0 
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 Dietary exposure estimates for scenario 1 Table 13: 
Age class Number of 
surveys 
Average 95th percentile 
Minimum Median Maximum Minimum Median Maximum 
Lower bound (ng/kg bw per day) 
Toddlers 7 (4) 55 92 131 94 178 241 
Children (3-10 years) 15 51 73 118 78 135 207 
Adolescents 12 34 51 67 60 89 112 
Women (18–45 years) 15 31 38 58 51 69 119 
Men (18–45 years) 15 34 45 55 56 81 103 
Other adults (45–65 years) 14 30 39 50 52 71 88 
Elderly and very elderly 6 27 33 43 47 57 68 
Middle bound (ng/kg bw per day) 
Toddlers 7 (4) 72 111 145 108 203 253 
Children (3-10 years) 15 57 81 127 86 147 223 
Adolescents 12 37 55 70 65 95 121 
Women (18–45 years) 15 33 41 61 55 73 126 
Men 18–45 years) 15 37 49 59 59 85 109 
Other adults (45–65 years) 14 33 42 52 55 75 94 
Elderly and very elderly 6 29 35 47 51 60 74 
Upper bound (ng/kg bw per day) 
Toddlers 7 (4) 88 126 159 135 223 267 
Children (3-10 years) 15 63 90 135 94 157 235 
Adolescents 12 41 59 74 70 100 127 
Women (18–45 years) 15 35 44 64 58 78 132 
Men (18–45 years) 15 39 53 64 63 90 115 
Other adults (45–65 years) 14 35 45 55 58 79 100 
Elderly and very elderly 6 31 38 50 54 64 78 
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 Dietary exposure estimates for scenario 2 Table 14: 
Age class Number of 
surveys 
Average 95th percentile 
Minimum Median Maximum Minimum Median Maximum 
Lower bound (ng/kg bw per day) 
Toddlers 7 (4) 212 356 516 445 721 817 
Children (3-10 years) 15 184 275 393 337 525 766 
Adolescents 12 114 150 190 237 288 357 
Women (18–45 years) 15 91 125 172 179 225 363 
Men (18–45 years) 15 94 118 164 170 204 314 
Other adults (45–65 years) 14 95 118 158 172 213 321 
Elderly and very elderly 6 90 110 172 169 194 352 
Middle bound (ng/kg bw per day) 
Toddlers 7 (4) 235 375 551 487 767 857 
Children (3-10 years) 15 198 290 415 363 550 813 
Adolescents 12 121 159 201 248 304 381 
Women (18–45 years) 15 97 132 182 191 235 388 
Men (18–45 years) 15 101 126 175 182 218 335 
Other adults (45–65 years) 14 102 126 168 186 224 341 
Elderly and very elderly 6 97 116 183 179 206 375 
Upper bound (ng/kg bw per day) 
Toddlers 7 (4) 257 395 587 504 812 886 
Children (3-10 years) 15 212 306 440 392 584 868 
Adolescents 12 128 168 212 259 320 403 
Women (18–45 years) 15 104 139 192 200 244 413 
Men (18–45 years) 15 108 134 186 193 230 360 
Other adults (45–65 years) 14 109 133 179 198 235 364 
Elderly and very elderly 6 103 122 195 192 216 396 
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 Percentage of average dietary exposure according to the type of packaging and scenario Table 15: 
Age group  Packaging 
type 
Total number of surveys Number of dietary surveys 
Scenario 1 
% average BPA contribution (middle bound) 
Scenario 2 
































































































Toddlers Canned 7 3 0 1 1 2 0 0 0 0 0 0 0 0 1 5 1 
Not canned 0 0 0 0 0 2 1 4 0 0 1 5 1 0 0 0 
Children  
(3-10 years) 
Canned 15 3 0 2 3 4 0 0 0 0 0 0 0 0 1 14 0 
Not canned 0 0 0 0 0 4 3 8 0 0 0 14 1 0 0 0 
Adolescents Canned 12 4 0 1 6 2 0 0 0 0 0 0 0 0 1 11 0 
Not canned 0 0 0 0 0 2 6 4 0 0 0 11 1 0 0 0 
Women  
(18–45 years) 
Canned 15 4 0 2 5 4 0 0 0 0 0 0 0 0 1 14 0 
Not canned 0 0 0 0 0 4 5 6 0 0 0 14 1 0 0 0 
Men  
(18–45 years)  
Canned 15 4 0 1 6 3 1 0 0 0 0 0 0 0 3 12 0 
Not canned 0 0 0 0 1 3 6 5 0 0 0 12 3 0 0 0 
Other adults  
(45–65 years) 
Canned 14 4 0 2 5 3 0 0 0 0 0 0 0 0 1 13 0 
Not canned 0 0 0 0 0 3 5 6 0 0 0 13 1 0 0 0 
Elderly and  
very elderly 
Canned 7 3 0 0 2 2 0 0 0 0 0 0 0 0 0 7 0 
Not canned 0 0 0 0 0 2 2 3 0 0 0 7 0 0 0 0 
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4.5.3. Exposure from non-dietary sources 
For non-food sources in addition to oral exposure, also inhalation and dermal absorption have to be 
considered as routes of exposure. Inhalation is a relevant route for the sources outdoor and indoor air. 
Both ingestion and inhalation can occur for dust. Dermal exposure has to be considered for BPA present 
on the surface of consumer products, such as thermal paper, or in cosmetics. If source concentrations are 
high, dermal exposure may also be relevant for dust and air. As a first step, all possible non-food sources 
of exposure were assessed with regard to their concentrations, migration and transfer potential for BPA 
(see Section 4.3.3). For the quantitative assessment the most important source/route combinations have 
been selected that most probably will contribute to daily exposure. They are listed in Table 16 and the 
relevant population groups are given for each source/route combination. All the equations used to 
calculate exposure from the non-food sources are given in Appendix F. 
  Overview of sources, population groups exposed and routes considered in the quantitative Table 16: 
assessment 
Exposure routes Sources and population groups exposed 
Air Dust Thermal paper Toys Cosmetics 
Inhalation All ages All ages n/a n/a n/a 













Dermal  n/a n/a All ages excluding 
infants and toddlers 
n/a All ages 
n/a, not relevant for this route for all age groups. 
(a): Indirect contact. 
The following sources have not been assessed quantitatively: surface water ingestion, dermal exposure 
from water (both surface and tap water, e.g. during bathing and showering), dermal exposure to toys, dust, 
solid consumer products in which BPA is incorporated into the matrix, cigarette filters (ingestion, 
inhalation), thermal paper mouthed by children and medical devices including dental materials, for the 
following reasons. Surface water ingestion while swimming can be regarded as minor on both an acute 
and a chronic level compared with other sources such as drinking water. In addition, dermal exposure 
through surface water is negligible compared with dermal exposure to, for example, thermal paper. 
Dermal exposure from toys can be considered negligible because very few toys are made from PC (KEMI, 
2012). From the few toys made of PC, migration to sweat was reported to be very low (KEMI, 2012). 
Dermal exposure to dust and solid consumer products (e.g. toilet paper, CDs) other than thermal paper can 
be neglected, because, compared with other dermal sources such as thermal paper, exposure to BPA from 
these sources is extremely low (e.g. 3 g of dust contain the amount of BPA that is transferred by one 
handling of thermal paper to one finger). Cigarette filters are suspected to be a source of exposure (Braun 
et al., 2011), but no evidence could be found that BPA is actually used in cigarette filters. Children 
chewing paper receipts is assumed to occur only sporadically, so that no chronic exposure results. Medical 
devices are dealt with by SCENIHR in a separate opinion and do not represent a chronic exposure 
pathway for the whole population. Dental materials that are commonly used in dental surgery both for 
children and adults, as dental fillers (adults) or as fissure sealants (children) were not found to be a source 
of chronic exposure either (see Section 4.3.3). 
An average and a high scenario were calculated for all sources. For the average scenario, an attempt was 
made to choose average values for all parameters, including parameters describing frequency of use. For 
the high scenario, the same average parameters were used for absorption rates and occurrence data, but, in 
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line with the methodology used to assess exposure from food, the frequency of use parameters were 
modified to account approximately for a 95th percentile of the population. If not mentioned otherwise, the 
arithmetic mean was used for each parameter, but in some cases only medians and percentiles were 
available. In order to follow a similar approach to that of exposure from food, behavioural parameters 
were derived considering both users and non-users in the general population. The estimates for average 
and high exposure are included in Table 22 and 23. 
For calculations for specific population groups (e.g. users of pacifiers with PC shields), behavioural data 
were taken only from the group of users (see Table 18). 
Exposure estimates were given per kilogram body weight. For the different age groups, different default 
body weights were used. For infants, the default body weight of 5 kg for one- to three-month-old infants 
was used (EFSA Scientific Committee, 2012). For toddlers, the default body weight of 12 kg for one- to 
three-year-old children was used (EFSA Scientific Committee, 2012). For children and adolescents, 
default values of 30 kg for nine-year-old children and 44 kg for 15-year-old adolescents were used (van 
Engelen and Prud’homme de Lodder, 2007). For adults, the default body weight of 70 kg was used (EFSA 
Scientific Committee, 2012). 
4.5.3.1. Ingestion 
The non-food sources evaluated for ingestion include dust, toys and other articles intended to be mouthed 
(infants, toddlers) and transfer from hands to food after touching of thermal paper by the parent. For the 
calculation of external exposure only the most significant sources, ingestion of dust and mouthing of toys, 
were used. For ingestion, an absorption fraction of 1 was used. 
Dust 
For the average and the high scenario, the average BPA concentrations (Cdust) derived in Section 4.3.3 
were multiplied with average dust ingestion rates (qdust) according to the Exposure Factors Handbook 
(EPA, 2011) for the average and according to Oomen et al. (2008) for the high exposure (see Table 17), 
respectively, and divided by age-specific body weights (bw) as described above. Newborn infants (0–5 
days) were assumed not to be exposed to dust via ingestion but only to fine dust in air (included in the 
calculation for air). Dust ingestion rates are commonly derived from soil ingestion rates as a proxy and 
thus are considered quite uncertain (Trudel et al., 2008). 
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 Values for dust ingestion (mg/day) according to Exposure Factors Handbook (EPA, 2011) Table 17: 
(average scenario) and according to Oomen et al., 2008 (high scenario) and estimates for exposure from 
dust (ng/kg bw per day) 
Age group Average scenario High scenario 
qdust Edust qdust Edust 
Infants 30 8.8 50 14.6 
Toddlers 60 7.3 100 12.2 
Children 60 2.9 100 4.9 
Adolescents 60 2.0 100 3.3 
Adults 30 0.6 50 1.0 
The derived exposure values range from 0.6 ng/kg bw per day in adults to 8.8 ng/kg bw per day in infants 
for the average scenario. The CEF Panel considered that these are likely to be overestimated, because in 
the original studies soil and dust ingestion rates could not be determined separately, and so conservative 
assumptions have been made when deriving the dust ingestion rates. In the high scenario the exposure 
ranged from 1.0 ng/kg bw per day (adults) to 14.6 ng/kg bw per day (infants). It should be noted, that the 
high scenario is not intended to reflect situations in houses with high BPA concentrations in dust but 
addresses only variation owing to behavioural aspects. 
Toys (rattles) and pacifiers with PC shields 
Data for migration of BPA into saliva from rattles and pacifiers with PC shields was used for this 
assessment (see Section 4.3.3). The amount of substance migrating from pacifiers was adjusted to 
24 hours by linear extrapolation from the incubation time of 7.75 hours. For rattles no extrapolation was 
needed, as the incubation time was 24 hours. The resulting amount of substance that leached over 24 hours 
from a product (qproduct) was used in the equation below: 141.2 ng for rattles and 987.1 ng for pacifiers. 
Then, the migration over 24 hours for the average scenario was corrected by average or high daily sucking 
times, yielding a fraction of the day that the rattle or pacifier is sucked (ftime). 
Sucking times of toys, including pacifiers, were determined for 42 Dutch children by Groot et al., 1998. 
Their findings have been used to develop Dutch reference values reported in Bremmer and van Veen 
(2002), which attempt to calculate exposure for the P75. These are the only data available for Europe and 
thus should be preferred. However, since Bremmer and van Veen report only P75 sucking times, and 
Groot et al. (1998) only observed sucking during the day, their data could not be used for assessing 
average sucking times and sucking times for pacifiers. Therefore, data on a larger study conducted on 385 
US children aged 0–36 months (Juberg et al., 2001) were also considered. For the average exposure from 
plastic toys, sucking times for all participants (users and non-users) as reported by Juberg et al. (2001) 
were used. For the high exposure, P75 daily sucking times reported by Bremmer and van Veen (2002) (see 
Table 18) have been used. To calculate exposure from pacifiers with PC shields for toddlers (specific user 
group), the P75 for the user group was directly taken from Juberg et al. (2001). 
In the migration experiments the toys were completely submersed. Therefore, in order to account for 
realistic exposure situations, it was further assumed that for toys (rattles) only 50 % of the toy surface is 
sucked (fsurface: 0.5). For pacifiers only the shield and ring are made of PC. Therefore, the available surface 
was assumed to be 25 % (fsurface: 0.25; only one side and only parts of the shield that are near to the 
mouth—approach according to Lassen et al., 2011). The following equation was used to assess exposure 
to toys and pacifiers with PC shields: 
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 Values for factors dealing with sucking times, ftime, and estimates for exposure from toys and Table 18: 
pacifiers with PC shields  
Age group Average scenario High scenario 
ftime (per 
day) 








0.012 Juberg et al., 
2001 






0.0014 Juberg et al., 
2001 






0.15 Juberg et al., 
2001 






0.32 Juberg et al., 
2001 




Using this approach, exposure values of 0.2 and 0.01 ng/kg bw per day for the average and 0.6 and 
0.01 ng/kg bw per day for the high scenario for infants’ and toddlers’ exposure to rattles (as a proxy for 
PC mouthing toys) were derived. 
For pacifiers with PC shields, owing to longer sucking times higher exposure was calculated with 7.6 and 
6.6 ng/kg bw per day for the average scenario infants and toddlers, and 9.8 and 10.0 ng/kg bw per day for 
the high exposure scenario. It must, however, be mentioned that only 10–20 % of the shields of pacifiers 
may be made of PC, so that this exposure value is valid only for a specific consumer group (Lassen et al., 
2011). 
Thermal paper: transfer to food 
After touching thermal paper, e.g. during shopping, BPA on the fingers can be transferred to food and 
consequently be ingested, either by the person him- or herself or a child. This may happen, e.g. if a parent 
shops, gets a thermal paper receipt, and directly afterwards eats a fruit or gives a piece of fruit to a toddler 
or child. In Biedermann et al. (2010) the transfer of BPA from contaminated hands back to dry paper was 
investigated and no BPA was detected (< LOD). However, as the same study revealed that transfer to wet 
and greasy fingers was much higher than that to dry fingers, transfer to more lipophilic and/or wet 
surfaces, such as to food, cannot be compared with dry paper. 
No experimental data are available for transfer to food after touching thermal paper. In order to investigate 
this pathway, a transfer of 1 % from skin (ftrans) to food was hypothesised. It was assumed that a fraction of 
1 is available for transfer (favail).These fractions were combined with the assumption that two, two and four 
transfer events (qhandling) for toddlers, children and adults (adults: e.g. one shopping, one canteen meal or 
bus ticket), respectively, occur per week (2/7, 2/7 and 4/7 per day) and that three fingers (nfinger) have 
touched the thermal paper. For the transferred amount of BPA from thermal paper to finger (afinger) the 
mean value given by Lassen et al. (2011) was used, which is 1.4 µg/finger. The following equation was 
used to calculate exposure: 
Etoy =
qproduct × ftime × fsurface
bw
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This calculation yields exposures of 0.7 (toddlers), 0.3 (children), and 0.3 ng/kg bw per day (adults). Since 
there are no data available on the frequency of such unfavourable events, or on transfer rates, this 
exposure estimate was not included in the calculation of exposure for the general public and specific 
consumer groups. It might, however, serve as a benchmark value. 
4.5.3.2. Inhalation 
BPA concentrations in outdoor and indoor air are low, with indoor air levels being slightly higher (see 
Section 4.3.3). For the calculation of an average value, therefore, the assumption was made that people 
spend 24 hours indoors, therefore including outdoor exposure. Average and high intake rates of air (qair) 
are taken from the Exposure Factors Handbook (EPA, 2011, long-term inhalation rates, see Table 19). In 
the calculations it is assumed that airborne particulate matter will fully contribute to the inhalation 
exposure to BPA. The following equation was used for the assessment: 
 
 Values for air intake rates qair from the Exposure Factors Handbook (EPA, 2011) and estimates Table 19: 
for exposure from inhalation 
Age group Average exposure High exposure 
qair (m
3
/day) Eair (ng/kg bw per day) qair (m
3
/day) Eair (ng/kg bw per day) 
Infants 3.6 0.7 7.1 1.4 
Toddlers 8.9 0.7 13.7 1.1 
Children 12.0 0.4 16.6 0.6 
Adolescents 16.3 0.4 24.6 0.6 
Adults 16.0 0.2 21.4 0.3 
 
The average exposure values range from 0.2 (adults) to 0.7 ng/kg bw per day (toddlers). High exposure 
levels range from 0.3 (adults) to 1.4 ng/kg bw per day (infants). 
4.5.3.3. Dermal 
Thermal paper 
In this exposure assessment it was assumed that children (3 - 10 years), adolescents and adults come into 
contact with thermal paper from shopping/canteen receipts, credit card receipts, bus tickets or parking 
tickets. The CEF Panel assumed that infants and toddlers (i.e. children < 3 years old) do not regularly shop 
or ride buses with their own tickets, thus do not regularly come into contact with thermal paper from these 
sources. Therefore, an exposure assessment for these age groups is not needed. The number of handling 
events, qhandling, for adolescents and adults for the high exposure was taken from a usage study by Lassen et 
al. (2011) (4.6 handlings per day). Handling events for the average exposure were assumed to be one per 
day for adolescents and adults, deduced from the credit card receipts handled by Danish consumers over 
the age of 12 years (259 per year) from Lassen et al. (2011). Children were assumed to come into contact 
Etp- food =
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with thermal paper 0.5 times a day in the average exposure and maximally twice a day on a regular basis 
(assessment of chronic exposure). 
The paper is handled mainly by three fingers (nfinger) of one (average exposure) or two hands (high 
exposure). Each finger has a BPA load available for absorption (afinger) of 1.4 µg/handling (Lassen et al., 
2011). Thermal paper is covered with BPA only on one side. However, it is assumed that all fingers that 




The estimates of exposure from dermal contact with thermal paper are summarised in Table 20. 
 Values for qhandling and estimates for exposure from dermal contact with thermal paper Table 20: 
Age group Average exposure High exposure 
qhandling (1/day) Etp-dermal (ng/kg bw per day) qhandling (1/day) Etp-dermal (ng/kg bw per day) 
Children 0.5 68.8 2.0 550 
Adolescents 1.0 93.8 4.6 863 
Adults 1.0 58.9 4.6 542 
 
From these average assumptions, exposures of 68.8, 93.8 and 58.9 ng/kg bw per day were derived for 
children, adolescents and adults, respectively. For the high exposure, exposure ranges from 542 (adults) to 
863 ng/kg bw per day (adolescents). 
Cosmetics 
Exposure to cosmetics in the form of body lotion is possible for all age groups. Medians and 95th 
percentiles for the amounts of body lotion used by adults (qcosmetics) were taken from Hall et al. (2007). For 
infants, toddlers, children and adolescents no data were available for such use of cosmetics. For these age 
groups the amount used was estimated from the amount used by adults by adjusting them using an 
appropriate body surface ratio (see Table 21). Mean body surfaces for adults of 1.85 m
2
 were taken from 
Tikuisis et al. (2001) and for the other age groups from van Engelen and Prud’homme de Lodder (2007) 
(see Table 21). The retention factor, fret, for leave-on cosmetics is 1. A retention factor characterises a 
cosmetic regarding the fraction of the substance remaining on the skin (e.g. for rinse-off cosmetics it is 
0.1). 







Ccosmetics ×qcosmetics × fret
bw
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 Body surfaces, derived parameter values for qcosmetics and estimates for dermal exposure from Table 21: 
cosmetics 
Age group Body surface (m
2
) Average exposure High exposure 
qcosmetics (g/day) Ecosmetics  
(ng/kg bw per day) 
qcosmetics (g/day) Ecosmetics  
(ng/kg bw per day) 
Infants 0.31 0.77 4.8 1.51 9.4 
Toddlers 0.44 1.09 2.8 2.14 5.5 
Children 0.84 2.09 2.2 4.09 4.2 
Adolescents 1.4 3.48 2.5 6.81 4.8 
Adults 1.85 4.60 2.0 9.00 4.0 
Average exposure ranges from 2.0 (adults) to 4.8 ng/kg bw per day (infants). High exposure ranges from 
4.0 (adults) to 9.4 ng/kg bw per day (infants). 
4.5.3.4. Overall external exposures from various routes 
External exposure to BPA was estimated by forward exposure modelling. This involved the assessment of 
chronic exposure (absorbed dose) to BPA through different sources (diet, thermal paper, air, dust, toys, 
cosmetics) and routes of exposure (oral, inhalation and dermal) in the EU population. 
Analytical/experimental BPA concentrations were combined with food consumption (including human 
milk) to estimate dietary exposure and concentration data in and from non-food sources with behaviour 
patterns to estimate non-dietary exposure. For the oral route, an overall external exposure estimate was 
derived by adding up the average estimates from different sources. For dermal exposures, direct addition 
is not appropriate, as absorption depends on the source. For high external exposure, the same procedure 
was followed. Table 22 and 23 list the average and high external exposure to BPA from all sources in the 
general population that are to be used in the risk assessment. 
Exposure to BPA from further sources was assessed in specific population groups or in consumers with 
specific consumption patterns. The aim was to identify possible additional sources of exposure to BPA 
that could lead to levels of exposure significantly higher than those estimated for the general population. 
Average and high exposures from these further sources are presented in Table 24. In a few cases, exposure 
from these further sources was higher, as was the case for infants fed using old PC baby bottles and 
infants living in buildings with old water pipes repaired with epoxy resins and fed with formula 
reconstituted with tap water. For the purpose of risk characterisation, the CEF Panel has carried out an 
assessment of aggregated oral and dermal exposure (the two main routes of exposure) to BPA using PBPK 
modelling (see Section 3.1.7.3. PBPK modelling of aggregated oral and dermal exposure in Part II – 
Toxicological assessment and risk characterisation of this opinion). 
This aggregated exposure assessment included diet and house dust (the main oral-route sources) as well as 
thermal paper and cosmetics (the main dermal-route sources). 
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 Average external exposure to BPA from all sources in the general population (ng/kg bw per day) Table 22: 




































Dust (average)   8.8 8.8 8.8 8.8 7.3 2.9 2.0 0.6 0.6 0.6 0.6 
Toys (average)  0.2 0.2 0.2 0.2 0.01       
Dietary exposure from food 
and beverages (average) 
225 165 145 30 375 375 290 159 132 126 126 116 
Sum of all ingestion 
sources (average) 
225 174 154 39 384 382 293 161 133 127 127 117 
Inhalation 
Air (average)  0.7 0.7 0.7 0.7 0.7 0.7 0.4 0.4 0.2 0.2 0.2 0.2 
Dermal 
Thermal paper (average)       68.8 93.8 58.9 58.9 58.9 58.9 
Cosmetics (average)  4.8 4.8 4.8 4.8 2.8 2.2 2.5 2.0 2.0 2.0 2.0 
 
 High external exposure to BPA from all sources in the general population (ng/kg bw per day) Table 23: 


































Dust (high)  14.6 14.6 14.6 14.6 12.2 4.9 3.3 1.0 1.0 1.0 1.0 
Toys (high)  0.6 0.6 0.6 0.6 0.01       
Dietary exposure from 
food and beverages (high) 
435 600 528 80 857 857 813 381 388 335 341 375 
Sum of all ingestion  
sources (high) 
435 615 543 95 872 869 818 384 389 336 342 376 
Inhalation 
Air (high) 1.4 1.4 1.4 1.4 1.4 1.1 0.6 0.6 0.3 0.3 0.3 0.3 
Dermal 
Thermal paper (high)       550 863 542 542 542 542 
Cosmetics (high)  9.4 9.4 9.4 9.4 5.5 4.2 4.8 4.0 4.0 4.0 4.0 
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 Average and high exposure from further sources in specific population groups (ng/kg bw per day) Table 24: 



































Residents of buildings with old 
water pipes repaired with 
epoxy resins 
Average     2.7 2.7 1.9 1.1 1.0 0.8 0.9 1.1 
High     29 29 21 12 11 8 9 12 
Users of PC tableware Average     6 6 4 2 2 2 2 2 
High     14 14 9 5 5 4 5 4 
Users of PC kettles Average    53 0.11 0.11 0.13 0.32 1.02 0.59 0.63 0.77 
High    94 5.98 5.98 4.96 4.77 8.01 7.31 9.12 8.48 
Consumers of water from PC 
filters 
Average     1.1 1.1 0.8 0.4 0.4 0.3 0.3 0.4 
High     3.8 3.8 2.8 1.6 1.6 1.4 1.3 1.1 
Consumers of water from water 
coolers with PC recipients 
Average     22 22 16 9 8 6 7 9 
Users of PC baby pacifiers Average 8 8 8 8 8 7       
High 10 10 10 10 10 10       
Infants fed with formula in old 
PC baby bottles 
Average    143         
High    426         
Infants consuming herbal tea 
prepared with water warmed in 
a PC kettle 
Average 6 6 6          
High 12 12 12          
Users of cookware Average     19 19 14 8 6 7 6 6 
Users of cookware High     46 46 28 16 15 14 15 14 
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4.6. Biomonitoring and backward exposure calculation  
4.6.1. General introduction 
Biomonitoring denotes the determination of substance concentrations in human body fluids, excrement 
or tissues such as blood, urine, mother’s milk, etc. Measurements in blood and urine are usually used 
as a measure of exposure, whereas measurements in mother’s milk also serve as source concentrations 
for breastfed infants. A number of sensitive analytical methods have been developed to measure low 
concentrations including trace amounts of BPA in biological samples such as urine and blood (Dekant 
and Völkel, 2008; WHO, 2011b; Asimakopoulos et al., 2012), which are by far the most appropriate 
biological matrices for human biomonitoring (Angerer et al., 2007). 
By using toxicokinetic considerations and parameters such as blood volume and/or daily urine 
excretion, biomonitoring measurements can be transformed into human exposure estimates. In contrast 
to source-to-dose modelling this “backward exposure calculation” integrates exposure from all sources 
and via all uptake routes (Angerer et al., 2007; Hengstler et al., 2011). Therefore, it is an appropriate 
tool to validate the external exposure estimates that were derived by forward exposure calculation. In 
the following subsections an overview of biomonitoring of BPA in different matrices will be given 
first and then a comparison of forward and backward exposure calculation will be presented. 
For the translation of biomonitoring data into daily exposure estimates apart from the quantification of 
BPA-related biomarkers in relevant matrices, a detailed understanding of the potential 
analytical/methodological pitfalls (see Appendix A) and of the toxicokinetics of BPA is needed. As a 
non-persistent chemical with an elimination half-life of a few hours, BPA is rapidly removed from 
circulation via conjugation and subsequent renal excretion (Völkel et al., 2002; Doerge et al., 2010c). 
Toxicokinetic studies with oral (gelatine capsule) administration of stable isotope-labelled BPA in 
humans have shown that BPA is almost completely excreted in urine in the conjugated form and that 
the elimination process is essentially complete within 24 hours of exposure (Völkel et al., 2002, 2008). 
Despite still disputed (Vandenberg et al., 2010), these studies show that BPA is metabolized and 
excreted via the urinary pathway. Urine is therefore the matrix of choice for biomonitoring, and the 
urinary concentration of total (unconjugated plus conjugated) BPA is the biomarker of choice to 
estimate BPA exposure (Calafat et al., 2008). Information on the presence and concentration of 
unconjugated and total BPA in serum is useful, and will also be compiled in this section, in order to 
inform toxicological risk assessment. However, given the low exposure in the ng/kg bw range, the 
high first-pass metabolism in the liver after oral exposure, and the elimination characteristics of BPA, 
low serum concentrations of unconjugated and total BPA are to be expected. Also compiled in this 
section is information on unconjugated and total BPA in human milk to enable the estimation of BPA 
exposure in breastfed infants. 
4.6.2. Biomonitoring studies on urinary levels 
4.6.2.1. Methodological aspects 
Data on urinary levels of total BPA in humans were retrieved from scientific journals, from official 
websites of national health surveys (e.g. NHANES, CHMS, German Federal Environment Agency, 
Flemish human biomonitoring programme), and from as yet unpublished sources (e.g. 
DEMOCOPHES). The quality criteria for urinary BPA data were assessed, and a literature quality 
table was developed for the methodical aspects and study aspects. The quality of each study was 
assessed on the basis of the criteria given in Appendix I. 
As a general rule, only data published from 2006 onwards were considered. Since then, substantial 
methodological improvements have been achieved in terms of both sensitivity and specificity by using 
MS-based analytical techniques. Moreover, efforts have been improved/implemented to preserve 
sample integrity and to reduce external contamination; more recent data should therefore be of higher 
quality than older data. Furthermore, the more recent data will provide a more up-to-date indication of 
the current exposure to BPA. 
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A specific inclusion criterion for data on urinary BPA is that the biomonitoring studies have been 
performed in the European region. Only these data are included for estimating daily exposure to BPA 
for different age groups of the European populations. The data from NHANES and CHMS are also 
considered for comparative purposes to provide reference values on average and high concentrations 
of total BPA in urine. 
To compare the distribution characteristics of the urinary concentration of total BPA between the 
different studies, box-percentile plots (Esty and Banfield, 2003) comprising the 5th, 12.5th, 25th, 
37.5th, 50th, 62.5th, 75th, 87.5th and 95th percentiles are used. In contrast to the practice in the food 
area (see Section 4.3.2), the geometric mean (GM) rather than arithmetic mean (AM) was chosen as a 
measure of central tendency of the distribution for several reasons. Firstly, the urinary concentration of 
total BPA is approximately log-normally distributed (Figure 4), so that the GM rather than the AM is 
the most appropriate measure of central tendency. Secondly, since the GM of a log-normal distribution 
equals the median, the median can be used instead in cases when only the median is reported. Finally, 
biomonitoring studies on urinary BPA always report the GM and/or the median, whereas the AM is 
only rarely given. The GM and the 95th percentile of the volume-based total BPA concentrations are 
used to derive estimates of average and high daily BPA exposures. For comparative purposes, daily 
BPA exposures are also calculated from creatinine-based BPA concentrations. 
 
Figure 4: Log-normal distribution shape of urinary BPA concentration. Shown are the histogram 
and density plot of the total BPA concentration in urine for two example datasets. (A) NHANES 
2005–2007 data for the total US population. (B) children of the Duisburg birth cohort study (Kasper-
Sonnenberg et al., 2012). Arrows indicate the location of the geometric mean (GM), arithmetic mean 
(AM), and the limit of detection (LOD). The number of subjects (n) is also given. ND, fraction of non-
detects. 
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Information about the specific distribution characteristics of urinary BPA concentration has 
consequences on how to handle left-censored data, i.e. observations below the limit of detection. 
Using an LB approach (i.e. setting all undetected observations to zero) would make the GM 
calculation unfeasible, whereas the UB approach (i.e. setting them to the LOD) would introduce a 
positive bias and, thereby, would overestimate the average concentration. Hornung and Reed (1990) 
showed that the substitution of non-detectable values by LOD/√2 is most appropriate for log-normally 
distributed data with moderate geometric standard deviations (GSD < 3) and low non-detection rates 
(<30 %). For larger GSD values, the MB approach (i.e. setting the nondetectable values to LOD/2) is 
recommended (Hornung and Reed, 1990). 
The GSD, which is a unit-less multiplicative factor, is only very rarely reported in the biomonitoring 
studies on urinary BPA. However, for the freely available raw data of NHANES (NHANES, online), 
the GSD can be calculated. Using the volume-based urinary BPA concentrations of the survey periods 
from 2003 to 2010 and a grouping in four age classes (Figure 7), the average GSD can be calculated to 
be 2.9 ± 0.2 (mean ± SD, range 2.5–3.1, n = 16 GSD values). Consequently, also taking into account 
the low non-detection rates (2.4–12 %; Figure 7), the replacement of non-detectable values by 
LOD/√2 is recommended according to Hornung and Reed (1990), and this setting has also been 
chosen by NHANES (Lakind et al., 2012). Using a value of LOD/2 instead of LOD/√2 for imputation 
would lower the GMs in Figure 7 by only 2.5 ± 1.2 % (n = 16, range 0.7–4.7 %), which is a negligible 
effect. In conclusion, according to Hornung and Reed (1990) the impact of the imputation procedure is 
negligible as long as the non-detection rates do not exceed 15 %. 
The above decision of using the GM leads to an estimate for the average daily BPA exposure that is 
lower than the AM-based estimate. The reason for this so-called AM–GM inequality is the log-normal 
distribution shape of the urinary BPA data. To convert GM-based estimates into AM-based estimates, 
which are then comparable to those derived from the forward exposure calculation, a multiplicative 
conversion factor of k = exp[0.5 × LN(GSD)] is introduced. Using the GSD values of the NHANES 
data (see above), an average value for k of 1.7 ± 0.1 (n = 16, range 1.5–1.9) is available, which is well 
in line with the directly calculated average AM/GM ratio of 1.9 ± 0.4 (n = 16). Additional information 
on the AM/GM ratio is obtained from CHMS 2007–2009 with an average value of 1.9 ± 0.1 (n = 4) 
and from a few European studies with values of 1.5 from the Duisburg cohort study (Monika Kasper-
Sonnenberg, Ruhr University Bochum, Germany, 2013, personal communication), and 1.8 from the 
German Environmental Survey for Children (GerES IV). A conversion factor of 1.8 is therefore used 
in this opinion to convert GM-based estimates into AM-based estimates. 
For NHANES, descriptive statistics were calculated for specific age classes (see Section 4.5.1) by 
using the statistical computing environment R (R Core Team, 2012) in combination with the R survey 
package (Lumley, 2004, 2012), which was used, for example, by Lakind et al. (2012). The outcome of 
the statistical procedures was checked by comparing the predictions for the default NHANES age 
groups with published data (CDC, 2012). All graphical figures were generated using the R lattice 
package (Sarkar, 2008). 
4.6.2.2. Urinary BPA concentrations (volume-based data) 
Since 2006, a relatively large number of data on total BPA concentration in urine have become 
available in selected populations from various regions, including North and South America, Europe, 
Africa, Asia and Australia (see literature quality table in Appendix I). The studies comprise large-
scaled, population-based cross-sectional studies and a spectrum of smaller scale studies on specific 
population groups, usually from a single location or region, as well as retrospective studies and 
prospective longitudinal studies. The following overview includes only studies performed in the 
European region. Data from the North American Surveys, NHANES and CHMS, are also used for 
comparative purposes. 
As shown in Figure 5, European human biomonitoring (HBM) data on urinary total BPA are available 
from GerES IV (Becker et al., 2009; Kolossa-Gehring et al., 2012), the German Environmental 
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Specimen Bank (ESB) study (Koch et al., 2012; Kolossa-Gehring et al., 2012), the Duisburg birth 
cohort study (BCS) (Kasper-Sonnenberg et al., 2012), two Munich studies (Völkel et al., 2008, 2011), 
the Austrian HBM study (Hohenblum et al., 2012), the Flemish and Liege HBM studies (Milieu en 
Gezondheid, 2010; Pirard et al., 2012; Schoeters et al., 2012), the Generation R (Rotterdam) study (Ye 
et al., 2008a), the Norwegian mother and child birth cohort (MoBa) study (Ye et al., 2009a), the 
Spanish environment and childhood (INMA) project (Casas et al., 2011), the French Elfe pilot study 
(Vandentorren et al., 2011) and the Italian InCHIANTI study (Galloway et al., 2010). Findings from 




Figure 5: Urinary BPA concentrations of European studies (without DEMOCOPHES, see Figure 6). 
Shown are the concentrations of total urinary BPA from different European studies. Box-percentile 
plots (grey-shaded areas) show the distributional characteristics comprising the 5th, 12.5th, 25th, 
37.5th, 50th, 62.5th, 75th, 87.5th, and 95th percentiles. Filled circles with associated values and error 
bars indicate the GMs and the 95 % confidence intervals. The 50th and 95th percentiles are shown by 
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open circles and crosses. The number of subjects is given on the right. Vertical solid and dashed lines 
indicate the LOD and the LOQ, respectively. The proportion of measured values below the LOD (or 
LOQ) is given as a percentage. Also given are the sampling periods and sampling populations, and the 
kind of urine sampling (“?” means that no information on the urine sampling was available). 
The GerES IV is a representative study focusing on the chemical exposure of children (Becker et al., 
2009; Kolossa-Gehring et al., 2012). Morning urine samples were collected from 3- to 14-year-old 
children in 2003–2006. The concentration of total BPA was measured by GC-MS/MS with a LOQ of 
0.15 µg/L. BPA was detected in 98.7 % of the n = 599 samples with a GM of 2.7 µg/L and a 95th 
percentile of 14.0 µg/L (Becker et al., 2009) (Figure 5). The uncertainty in the GM as expressed by the 
95th percentile confidence interval corresponded to a relative margin of error of 8–9 %. An analysis 
by age groups revealed a significantly higher BPA concentration (GM 3.55 µg/L) in the age category 
3–5 years compared with the 6–8 years, 9–11 years and 12–14 years age categories (GM 2.22–
2.72 µg/L). 
By using historical samples from the German ESB, Koch et al. (2012) analysed retrospectively the 
extent of BPA body burden in the German population from 1995–2009 based on a total of 600 24-hour 
urine samples. According to the ESB concept, samples were taken annually from approximately 60 
male and 60 female students (20–30 years old) in each of four university cities. Total and 
unconjugated BPA was determined by high-performance liquid chromatography (HPLC)-MS/MS with 
an LOQ of 0.1 µg/L. In the stored urine samples, total BPA was quantifiable in 99.8 % with a GM of 
1.6 µg/L (relative margin of error 7 %) and a 95th
 
percentile of 7.4 µg/L (Koch et al., 2012) (Figure 5). 
Unconjugated BPA was quantifiable in <15 % of the samples. Total BPA concentrations (GM) 
decreased over time from 1.9 µg/L in 1995 to 1.3 µg/L in 2009, but 24-hour urine volumes (mean) 
increased from 1.6 litres in 1995 to 2.1 litres in 2009. The derived daily exposures therefore remained 
rather constant at a GM of 39 ng/kg bw per day (95 % confidence interval (CI) 37–42 ng/kg bw per 
day) and a 95th percentile of 171 ng/kg bw per day. 
Within the framework of the Duisburg BCS, 208 morning urine samples of 104 mother–child pairs 
(29–49 and 6–8 years old) were collected in 2006–2009 (Kasper-Sonnenberg et al., 2012). Total BPA 
was measured by liquid chromatography (LC)-MS/MS with an LOQ of 0.1 µg/L. Total BPA was 
quantifiable in all samples. The GM concentration was 2.1 µg/L (95 % CI 1.8–2.5 µg/L) in the 
mothers and 2.4 µg/L (95 % CI 2.0–2.8 µg/L) in the children (Figure 5); the relative margin of error 
was 14–19 %. The 95th percentile of total urinary BPA was 8.4 µg/L for the mothers and 9.7 µg/L for 
the children. The BPA concentrations between children and mothers showed a low but significant 
correlation (rSpearman = 0.22, P-value ≤ 0.05). 
In the Munich infants study (Völkel et al., 2011), women who were participating in a birthing class in 
Munich were randomly selected, and 47 mother–infant pairs finally entered into the study. Urine was 
sampled from each infant at one month and two months of age in 2008. Total and unconjugated BPA 
was measured by HPLC-MS/MS with a LOQ of 0.45 µg/L. Unconjugated BPA was detectable in only 
3.3 % of the samples. Total BPA was detected in 35.7 % of the first-month samples and in 43.5 % of 
the second-month samples (Figure 5). The 95th
 
percentile of total urinary BPA for the first-month and 
second-month samples was 2.2 µg/L (n = 42) and 3.4 µg/L (n = 45), respectively. Note that these 95th 
percentile values are different from those reported in the study (9.6 and 5.1 µg/L) in which the subset 
of detectable values was used to derive the 95th percentile. The distributional shape of the total BPA 
concentration was quite unusual with a 95th percentile more than 10- to 15-fold higher than the 
median (Figure 5). A typical range for the 95th to 50th percentile ratio from other studies is 5–6. 
The second Munich study (Völkel et al., 2008) analysed spot urine samples from different sources, 
comprising 62 (multiple) samples from 21 co-workers (19–52 years old) as well as single samples 
from 31 women (18–41 years old) and 30 children (5–6 years old). The samples were collected in 
2005–2008. Total BPA was measured by HPLC-MS/MS with a LOQ of 0.3 µg/L. The median 
concentration and 95th percentile of this heterogeneous dataset was 1.2 and 4.0 µg/L, respectively 
(Figure 5). 
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The first population-based HBM study in Austria (Hohenblum et al., 2012) was performed in 2008–
2011 and included 150 volunteers (6–49 years old) from 50 families from five different Austrian 
regions. Ten woman–child–man groups living in the same household were randomly selected per 
region. Twenty-five out of 100 collected first morning urine samples were analysed for total urinary 
BPA concentration. Questionnaire data were used to pre-select participants who might have a higher 
exposure (e.g. owing to occupation, frequent use of canned food/beverages, use of plastic bottles). 
Total BPA was quantified by HPLC-MS/MS with an LOQ of 0.6 µg/L. Total BPA was detected in 
16 % of the samples; the maximum BPA concentration was 11 µg/L (Figure 5). The detection rate was 
remarkably low compared with the typical rates reported in other European studies. 
The Flemish Environment and Health Survey 2007–2011 cycle 2 (FLEHS II) focused on obtaining 
reference values for a wide range of age-specific biomarkers of exposure in a representative sample of 
the Flemish population (Schoeters et al., 2012). BPA data from FLEHS II were provided by the 
Flemish Center of Expertise on Environment and Health, financed and steered by the Ministry of the 
Flemish Community. BPA was measured in spot urine samples of n = 197 adolescents (14–15 years 
old) by GC-MS with an LOQ of 0.2 µg/L (Milieu and Gezondheid, 2010). Total BPA was detected in 
99.5 % of the samples. After adjusting for age, gender and urinary creatinine, a GM for the total BPA 
concentration of 2.2 µg/L (relative margin of error 12–13 %) was obtained (Figure 5). The 95th 
percentile was 9.5 µg/L. 
The Liege HMB study analysed urinary levels of environmental contaminants of a general Belgian 
population (1–75 years old) living in Liege and surrounding areas (Pirard et al., 2012). Morning urine 
samples were collected in 131 subjects in 2011, and total urinary BPA was quantified by GC-MS/MS 
with a LOQ of 0.50 µg/L. Total BPA was quantifiable in 97.7 % with a GM of 2.6 µg/L and a 95th 
percentile of 9.8 µg/L (Figure 5). BPA levels in urine of people living in the same home and collected 
at the same time were fairly well correlated (rPearson = 0.88). 
The Generation R study is a population-based birth cohort study in Rotterdam (Jaddoe et al., 2007). 
Multiple spot urine samples were collected from 9 778 pregnant women (18–41 years old) at 21–38 
weeks of gestation. BPA was measured in a subset of urine samples collected from 100 women after 
20 weeks of gestation in 2004–2006 (Ye et al., 2008a). BPA was quantified by GC-MS/MS with a 
LOD of 0.26 µg/L. Total BPA was detected in 82 % of the samples with a GM of 1.1 µg/L and a 95th 
percentile of 8.6 µg/L (Figure 5). 
Within the framework of the Norwegian MoBa study, 110 urine spot samples were collected in 2004 
from pregnant women at 17–18 weeks of gestation (Ye et al., 2009a). Urine samples from groups of 
11 subjects each were combined to make 10 pooled samples. As in the Generation R study, BPA was 
quantified by GC-MS/MS with a LOD of 0.26 µg/L. The GM of the total BPA concentration in the 10 
pooled samples was 2.8 µg/L (Figure 5). 
The INMA (Infancia y Medio Ambiente) project is a population-based birth cohort study in Spain. 120 
pregnant women (17–43 years old) were selected at random from four different regions, and 
30 children (4-year-old boys) were selected from a fifth region (Casas et al., 2011). Spot urine samples 
were collected from the women during the third trimester of pregnancy in 2004–2008, and from the 
children in 2005–2006. Urinary BPA was quantified by HPLC-MS/MS with a LOD of 0.4 µg/L. In the 
pregnant women, total urinary BPA was detected in 90.8 % of the samples with a median 
concentration of 2.2 µg/L (Figure 5). The children had a median concentration of 4.2 µg/L; the 
detection rate was 96.7 %. 
The French longitudinal study of children (Elfe: Etude Longitudinale Française depuis l’Enfance) is a 
national cohort study examining the effects of environmental exposure on children’s health 
(Vandentorren et al., 2011). Prior to this study, a pilot survey was conducted in two regions for 
validation purposes, which included the collection of spot urine samples from parturient women 
having a natural delivery (n = 164) or a Caesarean/forceps delivery (n = 79) in hospital maternity 
units. Total and unconjugated BPA was quantified by GC-MS with an LOQ of 0.3 µg/L. Total BPA 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 69 
was quantifiable in 96.9 % of all samples. The GM concentration was 2.0 µg/L (95 % CI 1.6–
2.5 µg/L) in the natural delivery group and 4.5 µg/L (95 % CI: 2.8–7.1 µg/L) in the Caesarean/forceps 
delivery group (Figure 5). The higher values in women who had Caesarean sections (or forceps 
delivery) suggest a contamination from medical devices either from catheterisation or urine probes 
when biomonitoring at delivery (Vandentorren et al., 2011). 
To estimate daily BPA excretion levels in a large European cohort, Galloway et al. (2010) selected 
participants from the InCHIANTI study, a representative population-based study conducted in Chianti. 
24-hour urinary samples were collected from 720 participants (20–74 years old) in 1998–2000. During 
the three days before sample collection, the subjects consumed a diet free of meat and fish. Total BPA 
levels were measured by HPLC-MS/MS with a LOQ of 0.5 µg/L. The GM and 95th percentile of the 
total BPA concentration in urine was 3.6 µg/L (relative margin of error 5 %) and 11.5 µg/L (Figure 5), 
respectively. 
DEMOCOPHES is a pilot study funded by the Directorate General Research in the 7th Framework 
Programme (FP7/2007–2013) and aiming to demonstrate the harmonisation of HBM in Europe (Joas 
et al., 2012). DEMOCOPHES is a cross-sectional study of the European population’s exposure to 
various substances using human biomarker data collected in 17 European countries from a non-
representative sampling of mother–child pairs in 2011–2012 (Joas et al., 2012). It is designed to cover 
an urban and a rural part of each country, involving mother–child pairs comprising an equal number of 
6- to 11-year-old boys and girls and their mothers (Kolossa-Gehring et al., 2012). Urinary BPA was 
measured on a voluntary basis in only a few countries (Sweden, Luxembourg, Denmark, Spain, 
Slovenia, Belgium) using MS-based methods. Sweden recruited 100 mother–child pairs and reported 
GM BPA concentrations of 1.2 µg/L for the mothers and 1.5 µg/L for children (Marika Berglund, 
Karolinska Institutet, Sweden, 2013, personal communication) (Figure 6). In Luxembourg, 60 mother–
child pairs were sampled, and the total BPA concentration was measured by LC-MS with LOQs of 1.0 
and 2.0 µg/L (Arno C. Gutleb, Centre de Recherche Public – Gabriel Lippmann, Luxembourg, 2013, 
personal communication). The GM concentrations were 1.7 (mothers) and 1.8 µg/L (children). 
Denmark recruited 145 mother–child pairs from an urban area near Copenhagen and a rural area near 
Roskilde (Frederiksen et al., 2013). The study was additionally funded by the Danish Health and 
Medicines Authority, the Danish Environmental Protection Agency and the Danish Veterinary and 
Food Administration. The total BPA concentration was measured by LC-MS/MS, and the GM 
concentrations were 2.0 µg/L (mothers) and 1.9 µg/L (children). In Slovenia, 155 mother–child pairs 
were recruited, and the median BPA concentrations were of 0.7 µg/L for the mothers and 2.0 µg/L for 
the children (Milena Horvat, Jožef Stefan Institute, Slovenia, 2013, personal communication). In 
Belgium, 129 mother–child pairs were sampled in the urban region of Brussels and in a rural area in 
the west of the country. GM concentrations of BPA were 2.6 µg/L for the mothers and 2.4 µg/L for the 
children (Covaci et al., 2012). Additional data from Spain became available after the public 
consultation. These last data from the DEMOCOPHES project were included in order to complete the 
European dataset on urinary BPA concentration. BPA was measured in first morning urine samples of 
women aged 18–48 from Madrid and Añover de Tajo (Toledo province) and children aged 6–11 (one 
child per woman; in total 120 mothers and 120 children, half from each location; Argelia Castaño, 
CNSA, Institute of Health Carlos III, Spain, 2013, personal communication). Too diluted and too 
concentrated samples (3 out of 240) were discarded. The Spanish data on urinary BPA concentration 
are in the range of the other DEMOCOPHES data (Figure 6) but were not considered in the estimation 
of daily urinary excretion of BPA (because of their late arrival). Including these data would, however, 
have provided added confidence to the representativeness of these estimates for the European 
population. 
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Figure 6: Urinary BPA concentrations in European mother–child studies from DEMOCOPHES. 
Shown are the concentrations of total urinary BPA in mothers and their 6- to 11-year-old children for 
individual European countries. Filled circles with associated numbers and error bars indicate the GMs 
and the 95 % confidence intervals. The 50th and 95th percentiles are shown by open circles and 
crosses. The number of subjects is given on the right. Vertical solid and dashed lines indicate the LOD 
and the LOQ, respectively. The proportion of measured values below the LOD (or LOQ) is given as a 
percentage. Also given are the sampling periods and the kind of urine sampling (“?” means that no 
information on the urine sampling was available). For references, see main text 
Among the non-European data, the largest datasets on urinary BPA levels have been generated within 
the framework of NHANES and CHMS. Because of their large sample size and their cross-sectional, 
nationally representative, population-based character, these surveys are used here for comparative 
purposes to provide reference values on average and high concentrations of total BPA in urine. 
Both North American surveys used spot urine samples and measured the concentration of total BPA. 
The surveys differed slightly in their analytical procedures (Lakind et al., 2012). For example, 
NHANES analysed the samples by HPLC-MS/MS with a LOD of 0.4 µg/L and a LOQ of 1.2 µg/L; 
measurements below the LOD were assigned a value of LOD/√2. CHMS used GC-MS/MS with a 
LOD of 0.2 µg/L and a LOQ of 0.82 µg/L; missing values (< LOD) were assigned a value of LOD/2. 
Both surveys performed reagent-blank checks, but only CHMS found results slightly above the LOD 
that were subtracted from the reported data. 
In the NHANES surveys, covering the periods from 2003–2004 to 2009–2010, total BPA was detected 
among the different age classes in 88–98 % of the 6 to > 80 years old participants (n = 2 517–2 749 
subjects in total) with a GM of 1.5–3.7 µg/L (relative margin of error 7–27 %) and a 95th percentile of 
8.2–19.4 µg/L (CDC, 2012) (Figure 7). Additional data for the survey period 2011–2012 became 
available after the public consultation. These data continue to show a decreasing trend in the urinary 
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BPA concentration for the USA (Figure 7) but were not included in the estimation of daily urinary 
excretion of BPA (because of their late availability). 
In the CHMS 2007–2009 cycle 1 survey, BPA was detected among the different age classes (Figure 7) 
in 88–94 % of the 6- to 79-year-old participants (n = 5 476 subjects in total) with GMs of 0.9–
1.5 µg/L (relative margin of error 7–18 %) and 95th percentiles of 5.2–8.4 µg/L (Bushnik et al., 2010; 
Health Canada, 2010). These values are somewhat lower than the NHANES values. Recent data from 
the CHMS 2009–2011 cycle 2 survey do not differ from those found in the CHMS 2007–2009 cycle 1 
survey period (Figure 7). 
Given the survey differences in GMs and 95th percentiles of the urinary BPA levels between 
NHANES and CHMS, it can be speculated whether analytical differences such as CHMS-specific 
background subtraction could have led to a bias in the results. Lakind et al. (2012) examined this issue, 
as well as the differences in the survey methodologies (e.g. participant selection, urine sampling, 
fasting time), and concluded that the survey differences are unlikely to have substantial impacts on 
inter-survey comparisons of BPA exposures. 
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Figure 7: Urinary BPA concentrations of the large-sized North American surveys grouped by age 
classes and survey period. Shown are the concentrations of total urinary BPA from the US National 
Health and Nutrition Examination Survey (NHANES) and the Canadian Health Measures Survey 
(CHMS). Box-percentile plots (grey-shaded boxes) show the distributional characteristics comprising 
the 5th, 12.5th, 25th, 37.5th, 50th, 62.5th, 75th, 87.5th, and 95th percentiles. Filled circles with 
associated values and error bars indicate the GMs and the 95 % confidence intervals. The 50th and 
95th percentiles are shown by open circles and crosses. The number of subjects is given on the right. 
Vertical lines indicate the LOD. The proportion of measured values below the LOD is given as 
percentages. Country codes are shown on the right 
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To conclude, a relatively large amount of information on urinary BPA concentration is available for 
the European region. Only a few of the larger-sized European studies, however, can be assumed to be 
representative such as the German Environmental Survey (GerES IV) for a population of children in 
Germany, the Flemish Environment and Health Survey (FLEHS II) for the 14–15 years old 
adolescents of the Flemish population, the INMA project for pregnant women in Spain, and the 
InCHIANTI study for the 20–74 year olds from the Chianti region. All age classes are covered except 
the 1–3 years old toddlers. The analytical sensitivity to detect and quantify BPA varied between the 
different studies with LODs of 0.05–0.4 µg/L and LOQs of 0.1–2.0 µg/L. The distributional 
characteristics of the total BPA concentrations in terms of shape and spread are generally quite 
homogeneous across the different studies. On a log10-transformed scale, the distributions appear 
symmetrical, and the similarity of the GM and the median (P50) indicate that the GM rather than the 
AM is the appropriate measure for the central tendency. For the European studies, the GM of the total 
BPA concentrations is in general localised in the range between 1.1–3.6 µg/L (Figure 5 and 6), which 
is in agreement with the results of the large-sized North-American surveys NHANES and CHMS 
(Figure 7). Exceptions from this general tendency are the Munich infants study and the Austrian HBM 
study with median values far below 0.6 µg/L, the Slovenian DEMOCOPHES study with a median 
value of 0.7 µg/L for the mothers, and the Elfe pilot study on parturient women having a 
Caesarean/forceps delivery (GM = 4.5 µg/L). An additional finding relevant for the estimation of high 
exposures is the 95th percentiles (P95), which, for studies with spot urine sampling, are 5–6-fold 
higher than the “corresponding” median values. The NHANES data covering the period from 2003–
2012 show a decreasing trend in the urinary BPA concentration for the USA. For the European region, 
the German ESB study (Koch et al., 2012) observed a decrease in the urinary BPA concentrations 
between 1995 and 2009 which was accompanied by an increase in the 24-hour urine volumes so that 
the derived daily exposures remained rather constant over time. The remaining data for the European 
region do not allow to draw further conclusion about time trends in urinary BPA concentration. 
4.6.2.3. Creatinine-based BPA concentrations in urine 
Expressing urinary BPA concentration as creatinine-based data (µg BPA/g creatinine) rather than 
volume-based data (µg BPA/L urine) is an alternative that aims to correct for urinary dilution. 
Depending on which basis is chosen, assumptions on daily urinary output (volume) or daily creatinine 
excretion (mass) are required to estimate BPA exposure. Several factors contribute to the daily 
variability in creatinine output, as discussed in detail by Lakind and Naiman (2008) and in Appendix 
G. An important argument in favour of the use of creatinine-based concentrations instead of volume-
based concentrations is the fact that the former is not dependent on drinking behaviour because the 
daily urinary excretion of creatinine depends primarily on the muscle mass of the individual (see 
Appendix G). Creatinine-based BPA concentrations in urine are available only for a few European 
studies comprising the Duisburg Duisburg BCS, the German ESB study, the Flemish and Liege HBM 
studies, the birth cohort study in Rotterdam (Generation R), and the Norwegian MoBa study. The 
descriptive statistics (GM, 50th percentile, 95th percentile) with associated information on gender, age 
and sampling are given in Table 25. The data for the North American surveys, NHANES and CHMS, 
are included for comparative purposes. For the European studies, with the exception of the MoBa 
study, the GMs of the creatinine-based total BPA concentrations are in the range between 1.7 and 
2.5 µg/g creatinine which conforms with the results of NHANES and CHMS (GM 1.3–4.8 µg/g 
creatinine). The MoBa study on pregnant women is distinguished by a considerably higher value of 
5.9 µg/g creatinine. The 95th to 50th percentile ratio for the studies with spot urine sampling is 4.4–5.2 
(European studies) and 3.3–6.7 (NHANES and CHMS), respectively, which is similar to that found for 
the volume-based data. Remarkably, the 95th to 50th percentile ratio for the German ESB study is 
only 3.6, which indicates a reduced variability very likely due to the 24-hour urine sampling design. 
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 Descriptive statistics for creatinine-based BPA concentrations in urine. The table shows Table 25: 
the geometric mean (GM), median (P50), and the 95th percentile (P95) of the creatinine-adjusted 
BPA concentration (µg/g creatinine) for the European studies and for the North American surveys 
NHANES and CHMS 
Study Gender Age 
(years) 
Sampling BPA concentration (µg/g creatinine) 
GM P50 P95 
German ESB MF 20–30 24hU 1.8 1.7 6.2 
Duisburg BCS F 29–49 MU 2.3 2.1 10.0 
Duisburg BCS MF 6–8 MU 1.8 1.7 6.2 
Generation R Pregnant F 18–41 SU 1.7 1.6 8.3 
MoBa Pregnant F  SU 5.9 – – 
Flemish HMB MF 14–16 SU 1.7 1.5 7.5 
Liege HMB MF 7–75 MU 2.5 2.3 13.7 
NHANES03–05 MF 6–9 SU 4.8 4.7 15.7 
NHANES05–06 MF 6–9 SU 3.4 3.0 22.5 
NHANES07–09 MF 6–9 SU 3.6 3.3 20.8 
NHANES09–10 MF 6–9 SU 2.7 2.6 9.9 
CHMS07–09 MF 6–11 SU 2.0 1.9 9.8 
NHANES03–05 MF 10–17 SU 2.9 2.9 12.2 
NHANES05–06 MF 10–17 SU 1.9 1.7 11.9 
NHANES07–09 MF 10–17 SU 2.0 1.8 7.0 
NHANES09–10 MF 10–17 SU 1.7 1.6 7.2 
CHMS07–09 MF 12–19 SU 1.3 1.3 6.4 
NHANES03–05 MF 18–64 SU 2.4 2.4 9.8 
NHANES05–06 MF 18–64 SU 1.8 1.6 8.7 
NHANES07–09 MF 18–64 SU 2.0 1.9 9.1 
NHANES09–10 MF 18–64 SU 1.9 1.8 7.7 
CHMS07–09 MF 20–39 SU 1.5 1.5 6.8 
CHMS07–09 MF 40–59 SU 1.3 1.3 7.5 
NHANES03–05 MF ≥ 65 SU 2.3 2.3 12.1 
NHANES05–06 MF ≥ 65 SU 1.8 1.6 8.8 
NHANES07–09 MF ≥ 65 SU 2.2 2.1 9.3 
NHANES09–10 MF ≥ 65 SU 1.9 1.8 8.4 
CHMS07–09 MF 60–79 SU 1.3 1.3 7.6 
M, male; F, female; 24hU, 24-hour urine; MU, morning urine; SU, spot urine. 
4.6.2.4. Estimation of daily BPA exposure from volume-based urinary BPA concentration 
Estimation of BPA exposure based on volume-based urinary BPA concentration is used in the present 
opinion as a plausibility check for the calculated exposure estimates for BPA uptake via food and non-
food sources. Volume-based urinary BPA data are given preference over creatinine-based data 
because these are supported by a larger number of European studies. Based on measured urinary 
concentration of total BPA CBPA (µg/L), the daily BPA exposure  (ng/kg bw per day) was 
calculated by 
 
where  (mL/day) is the urinary output rate and W (kg) is the body weight (Lakind and Naiman 
2008; UBA, 2012). The CEF Panel noted that, because of the non-persistent nature and short 
elimination half-life of BPA, the CBPA value of an individual spot urine sample cannot be used to 
arrive at a realistic estimate of daily BPA exposure. However, a set of spot urine samples can, when 
taken under certain conditions as detailed below, be used to obtain a reliable estimate of the average 
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24-hour urine collections are preferable, as both CBPA and are measured in 24-hour urine samples 
(in addition to the individual’s body weight), allowing the calculation of 24-hour BPA excretion for 
each individual. The GM (or median) can directly be used as an estimate for the average exposure of 
the (sampling) population, whereas the 95th percentile might tend to overestimate the high exposure, 
as it includes not only the between-person variability but also the within-person between-day 
variation. Spot urine sampling provides information for CBPA only, and only for a single urine sample 
per individual, whereas generic values are generally used for  and W (see below). It may also 
permit estimation of the average BPA exposure of a population, provided that the sampling is at 
random in relation to meal ingestion and bladder-emptying times. However, the high exposure is likely 
to be overestimated because spot urine sampling includes more sources of variability (e.g. within-
person, within-day variability) than 24-hour urine sampling. The collection of first morning urine is a 
non-random, single-sample sampling that is not representative of the daily variability and which bears 
the potential of introducing a bias and may result in an over- or underestimation of average exposure, 
although the sparse evidence available from the literature indicates comparability of the central 
tendency between first morning voids, spot urine samples and 24-hour urine samples (Christensen et 
al., 2012). 
Depending on whether body weight is available from the studies, either study-specific individual or 
mean values, or generic values derived by linear interpolation from body weight vs. age relationships 
taken from the literature, were used. Literature data were also used for the urinary output rate, except 
for cases in which study-specific individual urinary volumes from 24-hour urine sampling were 
available. Lakind and Naiman (2008) provide detailed discussion on the range and variability of age-
/gender-specific body weight and urinary output rate. 
Table 26 shows the body weight and urinary output rate parameters that were used to translate urinary 
BPA concentration into daily exposure. Parameters are given only for European studies and the North 
American surveys. Generic values for body weight were taken from the German National Health 
Interview and Examination Survey 1998 (Bergmann and Mensink, 1999), the German Health 
Interview and Examination Survey for Children and Adolescents (Stolzenberg et al., 2007), the Italian 
National Food Consumption Survey, INRAN-SCAI 2005–06 (Leclercq et al., 2009), and from the 
reference values given by the International Commission on Radiological Protection (ICRP) (Valentin, 
2002). For the urinary output rate, generic values were taken from Valentin (2002) and from Willock 
and Jewkes (2000). For comparative purposes, daily BPA exposures for the large-sized population-
based surveys from North America (NHANES, CHMS) were also calculated, based on the survey-
specific, individual body weights and on the generic urine volumes taken from ICRP reference tables 
(Valentin, 2002). 
Estimates for the average and high levels of daily BPA exposure were calculated by using the GM, the 
median (50th percentile) and the 95th percentile of the urinary BPA concentration of spot urine 
samples, first morning urine samples, and 24-hour urine samples. Because of BPA’s short elimination 
half-life, spot urinary concentrations primarily reflect the exposure that occurred within a relatively 
short period before urine collection (WHO, 2011a). Nevertheless, the single spot-sampling approach 
may adequately reflect the average BPA exposure of a population, provided the samples are collected 
from a large number of individuals and at random in relation to meal ingestion and bladder-emptying 
times. 
The 95th percentile of urinary BPA concentration is used to obtain estimates for high BPA exposures. 
It is, however, noted that the 95th percentile has different interpretations depending on whether spot 
urine samples, first morning urine samples or 24-hour samples are used. For spot urine samples, the 
95th percentile is related to the 95 % probability that a single, randomly collected sample from a 
randomly selected subject has a urinary BPA concentration not exceeding the 95th percentile. This is 
important as urinary BPA concentrations of repeated urine collections from individuals may vary up to 
two orders of magnitude (Teeguarden et al., 2011; Ye et al., 2011; Christensen et al., 2012). The 
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called nested random-effects models (Braun et al., 2011; Ye et al., 2011), which can adequately reflect 
the hierarchical structure of the main sources of variability: (i) between persons; (ii) within 
person/between days; and (iii) within person/within day. The study by Ye et al. (2011) revealed that 
the total variance in spot urine collections could be subdivided into 70 % within-day variability, 21 % 
between-day variability and 9 % between-person variability. The substantial within-day variability is 
expected to be lacking in 24-hour urine samples, so that the 95th percentile should be closer to the 
average concentration (GM, median) than in spot urine samples and first morning urine samples 
(Aylward et al., 2012). However, the sparse evidence available for the European region (cf. German 
ESB study with other European studies for adults in Figure 5) and for the USA (Christensen et al., 
2012) indicates that this effect is less pronounced. 
 Body weight and urinary output rate parameters for the considered European and North Table 26: 
American Studies. The table provides the parameters for body weight (W), urinary output rate ( ) 
and the specific urinary output rate (spec. ), which were used to translate urinary BPA 
concentration into daily BPA exposure. Gender and age were taken into account when deriving 
generic parameter values from published parameter–age relationships by linear interpolation. Study-
specific parameters are set in italic font. The references from which these parameters were taken are: 
[1] Koch et al. (2012); [2] Bergmann and Mensink (1999); [3] Valentin (2002); [4] Stolzenberg et al. 
(2007); [5] Willock and Jewkes (2000); [6] Ye et al. (2009a); [7] Leclercq et al. (2009); [8] Galloway 
et al. (2010); [9] CDC (2012); [10] Health Canada (2012); [11] Monika Kasper-Sonnenberg (Ruhr 
University Bochum, Germany, 2013, personal communication); [12] Elly Den Hond (Flemish Institute 
for Technological Research [VITO], Belgium, 2013, personal communication); [13] Arno C. Gutleb 
(Centre de Recherche Public – Gabriel Lippmann, Luxembourg, 2013, personal communication); [14] 
Frederiksen et al. (2013) 




(mL/day) spec.  (mL/kg 
bw per day) 
Reference 
German ESB MF 20–30 24hU 72 1 790 25 [1] 
Duisburg BCS F 29–49 MU 71 1 200 17 [11, 3] 
Duisburg BCS MF 6–8 MU 24 600 25 [11, 3] 
DEMOCOPHES 
SE 
F 28–46 ? 70 1 200 17 [4, 3] 
DEMOCOPHES 
SE 
MF 6–11 ? 27 600 22 [4, 3] 
DEMOCOPHES 
LU 
F 33–44 MU 65 1 200 17 [13, 3] 
DEMOCOPHES 
LU 
MF 6–11 MU 29 600 22 [13, 3] 
DEMOCOPHES 
DK 
F 31–52 MU 67 1 200 17 [14, 3] 
DEMOCOPHES 
DK 
MF 6–11 MU 31 600 22 [14, 3] 
DEMOCOPHES 
SI 
F ? ? 70 1 200 17 [4, 3] 
DEMOCOPHES 
SI 
MF 6–11 ? 27 600 22 [4, 3] 
DEMOCOPHES 
BE 
F ≤45 ? 70 1 200 17 [4, 3] 
DEMOCOPHES 
BE 
MF 6–11 ? 27 600 22 [4, 3] 
GerES IV MF 3–5 MU 16 475 30 [4, 3] 
GerES IV MF 6–8 MU 24 580 25 [4, 3] 
GerES IV MF 9–11 MU 34 700 21 [4, 3] 
GerES IV MF 12–14 MU 49 1 000 20 [4, 3] 
Munich Infants MF 1/12 ? 4 194 48 [3, 5] 
Munich Infants MF 2/12 ? 5 237 48 [3, 5] 
Generation R Pregnant 
F 
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(mL/day) spec.  (mL/kg 




 SU 74 2 000 27 [6] 
Flemish HMB MF 14–16 SU 57 1 200 19 [12, 3] 
Liege HMB MF 7–11 MU 34 600 18 [2, 3] 
Liege HMB MF 12–19 MU 65 1 200 19 [2, 3] 
Liege HMB MF 20–39 MU 75 1 400 19 [2, 3] 
Liege HMB MF 40–59 MU 79 1 400 18 [2, 3] 
Liege HMB MF 60–75 MU 78 1 400 18 [2, 3] 
INMA Pregnant 
F 
17–43 SU 74 2 000 27 [6] 
INMA MF 4 SU 18 475 26 [2, 3] 
Elfe pilot study Parturient 
F 
 SU 74 2 000 27 [6] 
InCHIANTI MF 20–40 24hU 70 1 530 22 [7, 8] 
InCHIANTI MF 41–65 24hU 70 1 690 24 [7, 8] 
InCHIANTI MF 66–74 24hU 70 1 540 22 [7, 8] 
NHANES MF 6–>65 SU 29–83 600–1 400 17–21 [9, 3] 
CHMS MF 6–79 SU 33–80 650–1 400 18–19 [10, 3] 
M, male; F, female; 24hU, 24-hour urine; MU, morning urine; SU, spot urine, ?, not available. 
The results for daily BPA exposure for the European studies and for the North American surveys 
(NHANES, CHMS) are shown in Figure 8. The data were grouped by the age classes defined in 
Section 4.5.1. Age-specific estimates were available for all age classes except the one- to three-year-
old toddlers. As no data are available for this age group, an estimate was derived by extrapolation 
from 3- to 5-year-old children to be able to make a comparison with the forward exposure-modelling 
estimate. Section 4.5.1 defined the age classes “women (18–45 years)”, “men (18–45 years)” and 
“other adults (45–65 years)”, which could not be matched by the available biomonitoring data. As a 
surrogate, the age class “Adults (18–65 years)” and a subgroup “Women of childbearing age” (i.e. 
mothers and pregnant and parturient women) were used. 
The GM and median values for average daily BPA exposure (as derived from volume-based BPA 
concentrations) are in good agreement among the European studies (Figure 8). Age classes with a 
relatively large coverage of European countries, such as children and adults, indicate a notable 
variability across the countries with the lowest exposures in Sweden (DEMOCOPHES SE) and 
Slovenia (DEMOCOPHES SI), and elevated exposures in Italy (InCHIANTI), Germany (GerES IV), 
and Spain (INMA). The CEF Panel noted that the urine collection periods cover a wide range from 
1998–2000 (InCHIANTI) to 2011–2012 (DEMOCOPHES). 
For the infants, only one study is available with an average BPA exposure of < 10 ng/kg bw per day 
for on- to two-month old infants (Munich infants study). For the children, there is a tendency to higher 
values in younger (3–5 years old) children (107 ng/kg bw per day) compared with older (5–10 years 
old) ones (49 ng/kg bw per day). In adolescents, adults and women of childbearing age, the estimated 
daily BPA exposure is 48 ng/kg bw per day, 39 ng/kg bw per day and 36 ng/kg bw per day, 
respectively. For the elderly, only sparse data are available from the Liege HBM study and the 
InCHIANTI study, with a daily BPA uptake of 56 ng/kg bw per day. Essentially no data are available 
for the very elderly (≥ 75 years old). In comparison with the North American surveys, the European 
data for the children, adolescents and adults appear to be more similar to the NHANES data than to the 
CHMS data. Table 27 summarises the age-specific daily BPA exposures, which are used as estimates 
of average BPA exposure. 
To obtain estimates for high BPA exposure, the maximum of the reported 95th percentiles from the 
different studies were used. The estimates for high BPA exposure were 161 ng/kg bw per day for 
infants, 676 ng/kg bw per day for children three to five years old, 380 ng/kg bw per day for children 
5–10 years old, 256 ng/kg bw per day for adolescents, 290 ng/kg bw per day for adults, 234 ng/kg bw 
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 Average daily BPA exposure as estimated from urinary BPA levels in different European Table 27: 
studies. Estimates of average daily BPA exposure were calculated from the GMs of the volume-based 
urinary concentrations of total BPA. For each age class, the minimum, median and maximum was 
obtained from the data available in each age class. Studies with multiple subgroups per age class were 
merged by calculating the mean of the GMs and by summing up the sample sizes of the subgroups. 
The number of studies and the sample size range of participants is given for each age class. The age 
class “women cba” represents women of childbearing age (i.e. mothers and pregnant and parturient 
women) 




Average daily exposure (ng/kg bw per 
day) 
Minimum Median Maximum 
Infants 0–1 1 88 n/a <10 n/a 
Toddlers 1–3 0 n/a n/a n/a n/a 
Children 3–5 2 30–137 105 107 109 
Children 5–10 8 21–152 33 49 67 
Adolescents 10–18 3 22–317 47 48 55 
Adults 18–65 13 45–569 13 39 95 
Woman cba 18–52 10 60–164 13 36 76 
Elderly 65–75 2 23–452 40 56 73 
Very Elderly ≥ 75 0 n/a n/a n/a n/a 
 
 High daily BPA exposure as estimated from urinary BPA levels in different European Table 28: 
studies. Estimates of high daily BPA exposure were calculated from the 95th percentiles of the 
volume-based urinary concentrations of total BPA. For each age class, the minimum, median and 
maximum was obtained from the data available in each age class. Studies with multiple subgroups per 
age class were merged by calculating the mean of the 95th percentiles and by summing up the sample 
sizes of the subgroups. The number of studies and the sample size range of participants is given for 
each age class. The age class “women cba” represents women of childbearing age (i.e. mothers and 
pregnant and parturient women) 
 




High daily exposure (ng/kg bw per day) 
Minimum Median Maximum 
Infants 0–1 1 88 n/a 161 n/a 
Toddlers 1–3 0 n/a n/a n/a n/a 
Children 3–5 1 137 n/a 676 n/a 
Children 5–10 6 60–152 118 204 380 
Adolescents 10–18 2 197–317 200 228 256 
Adults 18–65 8 60–569 85 184 290 
Woman cba 18–52 6 60–155 85 182 234 
Elderly 65–75 1 452 n/a 203 n/a 
Very Elderly ≥ 75 0 n/a n/a n/a n/a 
n/a, not available. 
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Figure 8: Daily BPA exposure as estimated from volume-based urinary BPA concentrations. The 
age-specific estimates for daily BPA exposure from the different studies are grouped by the age 
classes defined in Section 4.5.1. Filled circles with associated numbers and error bars indicate the 
GMs and the 95 % confidence intervals. The 50th and 95th percentiles are shown by open circles and 
crosses. The number (n) of subjects is given on the right. Age ranges and specific population groups 
(pregnant and parturient women) are indicated. The studies comprise the European studies, large-sized 
population-based surveys from North America (NHANES, CHMS).  
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4.6.2.5. Estimation of daily BPA exposure from creatinine-based urinary BPA concentration 
The estimation of daily BPA exposure from creatinine-based urinary BPA concentrations leads to 
slightly different values than those obtained from volume-based urinary BPA concentrations (see 
Appendix G). For the few European studies providing information on creatinine-based BPA levels, 
there is a tendency for lower BPA exposures in children, adolescents and adults and a tendency for 
slightly higher exposures for the (very) elderly. These differences are (at least partly) explainable by 
daily urinary output rates that deviate from the generic values reported in literature. For the derivation 
of reference values for comparison with BPA uptake via food and non-food resources, the volume-
based BPA exposures will be used because these are better supported by a larger number of European 
studies. 
4.6.3. Biomonitoring studies on serum levels 
4.6.3.1. Methodological aspects 
Whether, and at which levels, serum BPA can be detected under normal, non-experimental exposure 
situations is one of the most controversial topics in the scientific literature on BPA (Dekant and 
Völkel, 2008; Vandenberg et al., 2010; Hengstler et al., 2011; Teeguarden et al., 2012; vom Saal et al., 
2012; Vandenberg et al., 2013). In order to set the background for the assessment of HBM studies on 
serum BPA levels, the principal findings from the available toxicokinetic studies in humans and non-
human primates, and from a controlled dietary exposure study, are briefly summarised in the following 
paragraphs. 
In several toxicokinetic studies in humans (Völkel et al., 2002) and rhesus monkeys (Doerge et al., 
2010c; Taylor et al., 2011; Patterson et al., 2013), stable isotope-labelled BPA (deuterated) was 
administered to avoid any interference by possible contamination of samples with free BPA from 
environmental sources and medical devices. The administration of oral or intravenous doses of 64–
400 µg BPA/kg bw resulted in a transient increase in the serum concentrations of conjugated and total 
BPA up to 34–190 µg/L within the first hour (Figure 9), which was then followed by an approximately 
linear decrease (on a log-transformed scale) during the next hours. Unconjugated BPA was not 
detectable in the study by Völkel et al. (2002), because of the relatively high LOD, but was 
quantifiable in the three other studies. In these studies, unconjugated BPA contributes 0.2–2.8 % (oral 
administration) and 8–29 % (intravenous injection) to the total BPA concentration during the first four 
hours after dosing. In monkeys, after oral administration, the maximum levels of unconjugated BPA in 
serum did not exceed 1 and 4 µg/L at doses of 100 and 400 µg/kg bw, respectively (Doerge et al., 
2010c; Taylor et al., 2011; Patterson et al., 2013). After intravenous injection of 100 µg/kg bw, 
however, much higher maximum levels of 34–39 µg/L were observed (Doerge et al., 2010c; Patterson 
et al., 2013). The oral dosing studies used different administration procedures and vehicles which 
(apart from different doses, species, and analytical sensitivities) might have contributed to differences 
in the peak level and shape of the serum concentration profiles (see Part II - Toxicology assessment 
and risk characterisation, Section 3.1.2.1). Nevertheless, the CEF Panel considered these studies 
sufficiently reliable and relevant to enable back-and-forth calculations between serum levels and oral 
exposures for the general population in humans (see below). 
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Figure 9: Time course of serum levels of unconjugated, conjugated and total BPA in toxicokinetic 
studies in adult humans and monkeys with oral administration and intravenous (IV) injection of 
isotope-labelled (deuterated) BPA. The serum concentrations of BPA are expressed as µg/L of 
unconjugated BPA. Solid and dashed horizontal lines indicate the LOD and LOQ, respectively. Data 
shown in the columns from left to right were taken from Völkel et al. (2002), Doerge et al. (2010a), 
Taylor et al. (2011) and Patterson et al. (2013), with the applied dose given in each column 
Biomonitoring studies on urinary BPA levels have indicated daily BPA uptakes in the general 
population of 36–676 ng/kg bw per day (average-to-high exposure; see medians in Table 27 and 28), 
which are two to three orders of magnitude lower than the doses administered in the toxicokinetic 
studies mentioned above. Provided that this daily uptake is mainly food related, and knowing that the 
kinetics are linear up to a dose of 100 000 µg/kg bw (Taylor et al., 2011), the CEF Panel noted that 
even peak serum concentrations would be expected to be below 0.1 µg/L for the toxicologically 
relevant, unconjugated BPA. The CEF Panel considered that detection of such low concentrations of 
unconjugated BPA without interference from contamination is an analytical challenge. However, a 
significant uptake through the dermal route would increase the fraction of unconjugated BPA in the 
total BPA serum concentration. Forward modelling of dermal exposure to BPA from thermal paper 
(with consideration of the dermal absorption fraction) revealed estimates for high internal exposure to 
total BPA of <100 ng/kg bw per day (see Table 32). By assuming, as an extreme/unrealistic worst-case 
scenario, that humans would receive this internal dose (i.e. 100 ng/kg bw) at once by IV injection, a 
comparison can be made to the above mentioned toxicokinetic studies in monkeys with IV injection 
(Doerge et al., 2010a; Patterson et al., 2013). Again, since the estimates of high internal exposure to 
total BPA are more than three orders of magnitude lower than the IV doses given in the monkey 
studies, and since the kinetics is linear, even peak serum concentrations would be expected to be 
below 1 µg/L in this unrealistic IV worst-case scenario, and more so in a realistic dermal exposure 
scenario. Also for the conjugated or total BPA, in a general population having average-to-high daily 
BPA uptakes of 50–1 000 ng/kg bw per day, serum concentrations would only be expected to exceed 
rarely a level of 1 µg/L. 
These predictions are supported by the findings of a dietary exposure study, in which 24-hour urine 
and serum profiles of total BPA were measured in 20 human volunteers who received a controlled diet 
and ingested 100 % of one of three specified meals comprising standard grocery store food items for 
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breakfast, lunch and dinner (Teeguarden et al., 2011). Subjects were housed in a clinical facility for 
~36 h and were possibly less exposed to other potential BPA sources of non-dietary origin. The diet 
was rich in canned foods (fruits, vegetables, meat, fish and composite food) and juices to represent a 
potentially high BPA dietary exposure. Table 4 indicates that the canned food items chosen by 
Teeguarden et al. (2011) all belong to food categories characterised by high BPA concentrations. To 
ensure the feasibility of regular urine collections, the volunteers ingested large volumes of water per 
day (5.1 L compared to standard values of 1.2–1.6 L for adults) which resulted in a more diluted urine 
as indicated by the higher percentage (26%) of non-detectable urinary levels for total BPA compared 
with results (7.8%) for general public in the US (18–64 years olds, 2009–2010 NHANES; see Figure 
7). The CEF Panel emphasised that the high proportion of non-detects need not be misinterpreted as 
low BPA exposure since the urinary BPA concentration times urinary output rate is the relevant metric 
to quantify urinary BPA excretion (see below). The study revealed inter- and intra-individual 
variability in the serum and urine profiles of total BPA which was explained by the uncontrolled 
nature of dietary BPA exposures (i.e. the food-derived BPA doses were not determined separately), 
the time it took each volunteer to ingest the meal and the individual variability in absorption, 
metabolism and elimination. Only 6 out of 20 subjects (i.e. 30 %) showed consistently detectable 
serum concentrations of total BPA (unconjugated plus conjugated BPA) within a few hours after food 
uptake (Figure 10). The individual peak serum concentrations in this subset of volunteers ranged from 
0.6 to 1.3 µg/L and occurred within two to three hours of food consumption. These transient elevations 
of serum levels were associated with inter-meal urinary BPA excretion of 183–573 ng/kg bw. Overall, 
total BPA was detected in 27 % of the 320 serum samples collected from the 20 volunteers. The 
concentration of unconjugated BPA was always below the LOD of 0.3 µg/L. Comparing the derived 
doses and the detectable maximum serum concentrations of total BPA of Teeguarden et al. (2011) 
with those of Völkel et al. (2002) suggests conformity with the assumption of linearity of BPA 
kinetics and its conjugated metabolites. 
A recent publication by Gayrard et al. (2013) addressed the possibility of sublingual absorption in 
humans by performing a toxicokinetic study in dogs, in which concentrated BPA solutions (50 mg/ml 
in 40–100% ethanol for a 5 mg/kg bw dose, and 0.5 mg/ml in 1% ethanol in water for a 0.05 mg/kg 
bw dose) were applied under the tongues of anaesthesized dogs. With regards to the study by 
Teeguarden et al. (2011), the authors concluded that “Currently, the results of Teeguarden et al. (2011) 
do not support sublingual absorption as a major contributor of dietary BPA to a much higher than 
expected human internal exposure”. The CEF Panel evaluated the study of Gayrard et al. (2013) (see 
Section 3.1.2.1 of Part II – Toxicological assessment and risks characterisation) and concluded that 
detectable levels of unconjugated BPA in serum are unlikely to occur from sublingual absorption in 
humans for average BPA concentrations in food of <0.1 mg/kg food (see Section 4.3.2.). Obviously, 
chewing on thermal prining paper may release substantial amounts of BPA into the buccal cavity, with 
subsequent absorption via the oral mucosa, but since this is considered a behaviour which is not 
common for the major part of the population, this kind of exposure is not further considered. The CEF 
Panel noted though that very young children may occasionally put thermal paper into their mouth, and 
this might result in an uncontrolled but not chronic exposure situation. 
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Figure 10:  Time course of total BPA serum concentration in human volunteers ingesting a 
controlled diet enriched with canned food. Shown are the data of a subset of volunteers (6 out of 20) 
with consistently detectable concentrations of total serum BPA. Total BPA concentrations below the 
LOD of 0.3 µg/L are set to a value of LOD/√2. Vertical dotted lines indicate the meal times (B, 
breakfast; L, lunch; D, dinner). The per-body-weight amount of total BPA eliminated via urinary 
excretion during each inter-meal period is given. Data were taken from Teeguarden et al. (2011) 
4.6.3.2. Serum BPA concentrations 
Data on serum levels of unconjugated, conjugated and total BPA in humans were retrieved from peer-
reviewed scientific papers (published since 2006) which were identified by a systematic literature 
search. Not included are the biomonitoring data on fetal exposure as this is addressed in Section 
3.1.2.4 of Part II – Toxicological assessment and risks characterisation. The analytical methods for the 
determination of serum BPA comprised LC-UV, LC-FLD (fluorescence detection), LC-ECD 
(electrochemical detection), LC-MS and LC-MS/MS, GC-MS and GC-MS/MS, and RIA (radio-
immunoassay) (see Appendix A for description of the method). Of the 26 HBM studies reporting first-
publication data, one study (Sajiki et al., 2008) was excluded as no information on the proportion of 
values below the LOD/LOQ was available. Also excluded were the patient-related subsets of four 
studies (Cobellis et al., 2009; Kaddar et al., 2009; Yang et al., 2009; Bloom et al., 2011) and one study 
reporting only patient-related data (Shao et al., 2012), because patients could have been in contact with 
BPA-containing medical devices, a scenario not representative for the chronic exposure of the general 
population. 
The study groups comprised the general population (M. Liu et al., 2006; He et al., 2009; Kaddar et al., 
2009; Liao and Kannan, 2012) as well as specific age classes such as children (Ye et al., 2012), 
adolescents (Geens et al., 2009b), adults (Fukata et al., 2006; Dirtu et al., 2008; Genuis et al., 2012; 
Santhi et al., 2012a) and the elderly (Olsen et al., 2012). Additional data were available for more 
specific demographic groups such as students (Koch et al., 2012), male partners of female patients 
undergoing in vitro fertilisation (IVF) (Bloom et al., 2011), healthy women (Cobellis et al., 2009), 
female hospital controls (Yang et al., 2009), nursing women (Gyllenhammar et al., 2012) and pregnant 
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women (Lee et al., 2008; Padmanabhan et al., 2008; Wan et al., 2010; Chou et al., 2011; Kosarac et 
al., 2012; Unal et al., 2012). Blood bank samples were also analysed (Ye et al., 2008b, 2009b). 
Because of the large number of studies on pregnant women, and also taking account of the terms of 
reference to consider specifically this group (among others), this demographic group is considered 
separately from the remaining general population. 
For the assessment of reported serum BPA levels, the following aspects were specifically assessed: 
 the proportion of detectable/quantifiable values in relation to the LOD/LOQ; 
 the fraction of unconjugated BPA in the total BPA serum concentration; 
 the average serum concentrations of unconjugated, conjugated and total BPA for studies 
reporting ≥ 50 % detectable values. 
To provide an overview of the study results, a Cleveland dot plot was used to visualise the average 
serum BPA concentrations and the proportion of detectable values (Figure 11). Pie charts displaying 
the proportion of detectable values were positioned at the respective LOD/LOQ of the study, and the 
average serum BPA concentrations (small geometric symbols) are shown for studies reporting ≥ 50 % 
detectable values. For symbols and pie charts, grey and black filling colours were used for 
unconjugated BPA and conjugated/total BPA, respectively. The serum concentrations of 
unconjugated, conjugated and total BPA combined are expressed in µg/L of unconjugated BPA. 
To show the influence of decreasing analytical limits on the proportion of detectable BPA levels, the 
studies were ordered according to their LOD/LOQ, and the pie charts displaying the proportion of 
detectable values were positioned at the respective analytical limit (Figure 11). Some of the studies 
report an LOD, some of them an LOQ and some report both LOD and LOQ. In the last case, only the 
analytical limit that the study authors considered as a censoring limit for reportable and non-reportable 
concentrations was displayed. Across the different studies, the analytical limit for detecting the 
different BPA parameters (i.e. unconjugated, conjugated and total BPA concentrations) varied by 
almost two orders of magnitude (0.01–0.82 µg/L). In spite of this large variation in analytical 
sensitivity, the CEF Panel noted that a consistent pattern such as an increasing proportion of detectable 
values with decreasing LOD/LOQ did not emerge. Overall, the detection rate for unconjugated and 
conjugated and/or total BPA varied largely from 0 % to 100 %. Given the findings of the controlled 
dietary exposure study in human volunteers (Teeguarden et al., 2011), with unconjugated BPA being 
undetectable and total BPA being detectable in only 27 % of the 320 serum samples collected from the 
20 volunteers, the CEF Panel considered detection rates close to 100 % for conjugated and/or total 
BPA in serum to be an implausible result. High detection rates for unconjugated BPA in serum are 
even more implausible. 
Only a few studies analysed more than one serum BPA parameter (i.e. unconjugated, conjugated and 
total BPA). These studies were used to determine the fraction of unconjugated BPA in the total BPA 
concentration, where both unconjugated and total BPA were detectable and quantifiable in the same 
sample. Gyllenhammar et al. (2012) reported detection rates of 25 % and 21 % (at slightly different 
LODs of 0.5 and 0.8 µg/L) for unconjugated and total BPA, respectively. In 15 % of the samples, the 
authors reported that unconjugated BPA could be detected and accounted for one-half to all of the total 
BPA. Ye et al. (2008b) reported unconjugated and total BPA in only 1 of 15 blood bank samples at a 
similar concentration of 1.5 µg/L (i.e. all BPA present was in the unconjugated form). Koch et al. 
(2012) quantified both unconjugated and total BPA in only 7 of 60 plasma samples, reporting that 
unconjugated BPA accounted for the predominant share (90–100 %) of total BPA. Similarly, Ye et al. 
(2012) detected total BPA in only 3 of 24 pooled serum samples, and unconjugated BPA in only two 
pooled samples. The mean percentage of unconjugated BPA in samples with detectable total BPA was 
67 %. Kosarac et al. (2012) reported detection rates of 67 % and 17 % for unconjugated and 
conjugated BPA, respectively, again implying that serum BPA was essentially unconjugated. 
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The findings of these authors appear to indicate (i) that the detection of total BPA in a sample made 
the parallel detection of unconjugated BPA very likely, and (ii) that all serum BPA (if detected) was 
essentially unconjugated. The CEF Panel considered that this is extremely unlikely given the findings 
of the toxicokinetic studies mentioned above, in which stable isotope-labelled BPA was administered 
to avoid any interference by possible contamination of samples with free BPA from environmental 
sources and medical devices. 
Although also providing information on more than one serum BPA parameter (i.e. unconjugated, 
conjugated and total BPA), the study by Liao and Kannan (2012) is notable for the fact that serum 
concentrations of unconjugated and conjugated (sulphated, glucuronidated) were directly measured via 
solid-phase extraction and LC-MS/MS. The LODs of 0.01 µg/L for unconjugated BPA and 0.05 µg/L 
for conjugated BPA were the lowest reported for all studies reviewed in this opinion (Figure 11). 
Unconjugated, sulphated and glucuronidated BPA were detected in 75 %, 50 % and 50 % of the 
samples with GMs of 0.035 µg/L, 0.065 µg/L and 0.115 µg/L (all concentrations values expressed in 
µg/L of unconjugated BPA). Based on these GM concentrations, unconjugated BPA accounted for 
only 16 % of total BPA. It should be noted that the authors also analysed the serum samples by 
enzymatic deconjugation and liquid–liquid extraction (LLE) for the determination of total BPA. Using 
this method, unconjugated and total BPA were both detected in 100 % of the samples with GMs of 
0.049 µg/L and 0.075 µg/L. The GM of 0.049 µg/L for unconjugated BPA (as obtained by LLE but 
without enzymatic deconjugation) agreed well with the 0.035 µg/L as obtained by solid-phase 
extraction. The value of 0.075 µg/L for total BPA (as obtained by LLE with enzymatic deconjugation) 
was, however, considerably lower than would be expected from the sum of the solid-phase extraction-
derived concentrations for unconjugated and conjugated BPA forms. 
Of the remaining studies not involving pregnant women, six (Dirtu et al., 2008; Kaddar et al., 2009; 
Yang et al., 2009; Bloom et al., 2011; Olsen et al., 2012; Liao et al., 2012) report detection rates of 
≥ 50 % for unconjugated and total BPA and provide statistically feasible descriptive statistics with 
median concentrations up to 3.8 µg/L (Figure 11, upper panel). The results of two of these studies are 
presented below as examples. 
Olsen et al. (2012) studied the serum concentration of total BPA in 1 016 elderly people (all aged 70 
years old) living in the community of Uppsala, Sweden. Blood samples were collected in the morning 
after overnight fast. Total BPA was detected in 98 % of the samples (LOD 0.2 µg/L) with a median 
concentration of 3.8 µg/L. Assuming, as a rough calculation, a blood volume of 5 litres, a serum 
fraction of 0.55 and a body weight of 70 kg, this median concentration would translate into an 
instantaneous body burden of 150 ng/kg bw, the amount of BPA distributed among the other tissues 
not yet included. Given the large sample size, it could be concluded from these data that half of the 
population of elderly people in Uppsala had a body burden of higher than 150 ng/kg bw in the 
morning after an overnight fast. However, taking into account the average-to-high daily BPA uptake 
among the elderly of 60–200 ng/kg bw per day, as estimated from biomonitoring studies on urinary 
BPA, the CEF Panel found it difficult to envisage a community-wide exposure scenario that could lead 
to such a high BPA body burden already in the morning after an overnight fast. 
As a second example, Bloom et al. (2011) studied the serum concentration of unconjugated BPA in 27 
couples undergoing IVF. On the day of oocyte retrieval, fasting and non-fasting blood specimens were 
collected from female patients and male partners, respectively. Unconjugated BPA was detected in 
85 % (women) and 52 % (men) of the samples (LOD 0.3 µg/L) with median concentrations of 
3.3 µg/L (women) and 0.48 µg/L (men). The high serum concentration in the women will not be 
discussed further here, as the female patients could have been in contact with BPA-containing medical 
devices. For the male partners, however, a simple back calculation can be used to put their serum 
concentrations into perspective. According to commonly accepted kinetic concepts, the following 
equation (Renwick, 2008; Mielke and Gundert-Remy, 2009) can be used to calculate the dose rate D 
(ng/kg bw/h) from the steady-state serum concentration, Css (µg/L), the serum clearance, Cl (L/h), the 
fraction absorbed, fa, and the body weight, bw (kg): 
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. 
An estimate for the serum clearance (Cl) of 100 L/h for a 70-kg human can be derived from the 
allometric scaling of clearance values (Figure 8A of Part II – Toxicological assessment and risks 
characterisation). For the steady-state concentration (Css), the value of 0.48 µg/L is taken, assuming 
that this value would be representative of the average serum concentration over an observational 
period of one hour. Assuming further a body weight (bw) of 70 kg and a fraction (fa) of 0.1 of 
systemically available BPA (e.g. 10 % bioavailability via the dermal route for thermal paper), the 
calculation yields a dose rate (D) of 6 900 ng/kg bw/h. In other words, to sustain an average serum 
concentration of 0.48 µg/L over a period of, say, one hour would require a continuous external 
exposure of 6 900 ng/kg bw/h. Considering the strong impact of first-pass metabolism, for oral 
exposure the same calculation would result in an even higher required dose rate (e.g. 69 000 ng/kg 
bw/h at fa = 0.01). According to Bloom et al. (2011), half of the male participants had serum 
concentrations of unconjugated BPA of 0.48 µg/L or higher under non-fasting conditions. Again, the 
CEF Panel considered that it is very difficult to envisage a realistic chronic exposure scenario that 
would lead to exposures equal to or exceeding 6 900 ng/kg bw per hour and even per day through 
dermal exposure, the route of exposure that results in the highest blood levels of unconjugated BPA. 
Given the unrealistic exposure implications for reported serum BPA concentrations in the µg/L range, 
the CEF Panel considered that it is difficult to explain the high detection rates and the average 
concentrations of unconjugated and total BPA in the serum of pregnant women (Figure 11). As 
already discussed elsewhere (Koch et al., 2012), these results may be due to methodological 
differences in terms of detection technique (selectivity), LOD/LOQ (sensitivity), contamination and 
within-laboratory and pre-analytical blank issues causing such results, but this can only be a matter of 
speculation. The CEF Panel noted the specific exposure situation of pregnant women at delivery or 
termination in a hospital setting, which may involve BPA exposure due to medical intervention and 
devices as well as a higher risk for BPA contamination through the handling of samples during sample 
collection. From the data available, it is not possible to differentiate between these two sources 
because mostly either unconjugated or total BPA was measured. To assess the impact of 
contamination, information on both unconjugated and conjugated/total BPA is essential. 
Figure 12 provides an overview of how the included studies on serum BPA biomonitoring took 
account of the possible sources of contamination, e.g., by reporting the use of „BPA-free“ collection 
tubes (glass, polypropylene vials), the inclusion of procedural blanks, or the use of quality assurance 
(QA) and quality control (QC) materials. It is also indicated whether a check for contamination was 
performed at sample collection, sample storage, and/or sample work-up and analysis. The overview 
shows that whilst being aware of sources of contamination in the laboratory only a few studies were 
evaluating the sources of contamination during sample collection. A check for contamination at this 
stage of the process involved only the collection tubes (Bloom et al., 2011; Padmanabhan et al., 2008) 
and was, in one case (Padmanabhan et al., 2008), inappropriate because of the use of spiked serum 
containing 5 µg/L BPA. None of the studies included field blanks and replicate samples as 
recommended elsewhere (Calafat and Needham, 2009). In addition, the type of needles for blood 
collection was reported in only a few studies, but none of these studies checked the needles as a 
possible source of contamination. As already emphasised elsewhere (Markham et al., 2010), it is of the 
absolute necessity to elimininate and continually monitor for background contamination from all 
sources (from collection to analysis). 
Overall, whilst contamination of samples from hospitalised persons (e.g., because of release of BPA 
by medical equipment) is rather likely, because of inappropriate reporting on possible sources of 
contamination, and of improbable analytical results, the CEF Panel decided to give little weight to 
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Figure 11: Cleveland dot plot showing the average serum concentrations for unconjugated and 
conjugated/total BPA (small geometrical symbols) and the proportion of samples with 
detectable/quantifiable values (pie charts). Pie charts displaying the proportion of 
detectable/quantifiable values were positioned at the respective LOD/LOQ. A grey filling is used for 
unconjugated (U) BPA, whereas black filling is used for conjugated (C) and total (T) BPA. Average 
serum concentrations are shown only for studies reporting ≥ 50 % detects. The different geometrical 
symbols indicate the geometric mean (squares), the median (diamonds) and the arithmetic mean 
(triangles). Information on the study groups, the number of subjects (n), the analytical method and the 
percentage of detectable/quantifiable values are given. All serum concentrations are expressed in µg/L 
of unconjugated BPA. For each study, only the first author and the year of publication (in parentheses) 
is given. For complete references, see main text. MS: mass spectrometry, FLD: fluorescence detection, 
ECD: electrochemical detection, RIA: radioimmunoassay, UV: ultraviolet detection 
 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 88 
 
 
Figure 12: Overview of possible sources of contamination and how they were handled in the studies 
on serum BPA biomonitoring. Possible sources contamination and control measures were grouped by 
the different phases comprising sample collection, sample storage, and sample work-up and analysis. 
A circle symbol indicates the reporting of, e.g., a collection/storage device, a check for contamination, 
the inclusion of procedural blanks, or the use of QA/QC materials. For each study, only the first author 
and the year of publication (in parentheses) is given. For complete references, see main text. QA: 
quality assurance, QC: quality control. 
 
4.6.4. Biomonitoring studies in human milk 
Breastfed infants may be exposed to BPA via human milk as a consequence of exposure of lactating 
mothers. BPA may occur in human milk in the unconjugated and conjugated forms by the lactational 
transfer from the maternal plasma compartment to the maternal milk compartment. The distribution of 
both BPA forms between the plasma and milk compartments may vary depending on the milk 
composition, which changes in terms of protein and fat content within the first three to five days of 
delivery (Saint et al., 1984). Profound changes occur also in the milk concentration of sodium and 
chloride during the first 48 hours post partum, which are explained by the closure of tight junctions 
between the mammary epithelial cells that prevent plasma constituents from passing directly from the 
interstitial space into the milk (Neville and Walsh, 1996). It is therefore reasonable to consider initial 
human milk (colostrum), which is collected within the first few days after delivery, and mature human 
milk separately for exposure assessment. As colostrum is produced from around mid-pregnancy until 
parturition (lactogenesis stage I; Neville et al., 2001) and accumulates in the mammary gland until 
being drawn after delivery, the BPA content in colostrum may reflect the pregnant woman’s exposure 
during the second half of pregnancy (Migeot et al., 2013). This contrasts with mature milk, which is 
produced between feedings, so that the BPA content in mature milk reflects the recent exposure of the 
mother. Additional arguments for a separate exposure assessment of newborn infants and infants 
receiving initial and mature human milk are: (i) the three-fold higher activity of a human milk β-
glucuronidase in initial milk compared with mature milk (Gourley and Arend 1986); and (ii) the 
possibility of a treatment-related elevated exposure of mothers staying in the hospital for a few days 
after delivery. 
In the scientific literature covering the period from 2006 until the public consultation, the occurrence 
of BPA in human milk was analysed in six small-scale studies carried out in Europe (Cariot et al., 
2012), North America (Ye et al., 2006, 2008c; Duty et al., 2013) and South-East Asia (Kuruto-Niwa et 
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al., 2007; Yi et al., 2010). After the public consultation, four additional studies on BPA in breast milk 
became available, providing new data for Europe (Migeot et al., 2013), North America (Mendonca et 
al., 2014; Zimmers et al., 2014), and South-East Asia (Yi et al., 2013). Three of these are linked to 
previous studies: Migeot et al. (2013) is a follow-up of the pilot study by Cariot et al. (2012); 
Mendonca et al. (2014) is a companion study of Duty et al. (2013); and Yi et al. (2013) is an extended 
follow-up study of Yi et al. (2010). All studies were assessed according to the inclusion/exclusion and 
quality criteria (see literature quality table in Appendix I). 
4.6.4.1. Colostrum milk 
In the French study by Cariot et al. (2012), unconjugated BPA was quantified in initial human milk by 
isotope-dilution ultra-performance liquid chromatography (UPLC)-MS/MS with a LOD of 0.09 µg/L 
and a LOQ of 0.40 µg/L. Very much care was taken to avoid cross-contamination by environmental 
BPA by using solvents and reagents of high analytical quality as well as pre-treated glassware. The 
milk was drawn manually and directly in pre-treated glass tubes, without any device, materials, wipes 
or gloves. Quality-control materials and standards were prepared from pooled human milk derived 
from samples collected over several days from two donors (A. Cariot, University of Poitiers, France, 
2013, personal communication) who had been breastfeeding for over one month. Unconjugated BPA 
was absent in solvent blanks, and it was detected in only some of the pooled (mature) human milk 
used for standards and quality controls in concentrations (≤ 0.12 µg/L) markedly lower than the LOQ. 
To test the applicability of their analytical method, the authors analysed three samples that were 
collected from three donors within a few days after delivery. Unconjugated BPA was detected in all 
samples in concentrations of 0.80, 3.07, and 3.29 µg/L with a GM of 2.0 µg/L (Figure 13). No 
information is available on whether the three donors stayed in the hospital and underwent medical 
procedures, which might have led to an additional, treatment-related non-oral exposure resulting in 
higher than normal BPA levels in plasma and milk. 
In a follow-up study by Migeot et al. (2013), unconjugated BPA was quantified in initial human milk 
using the same methodology as in Cariot et al. (2012). 21 samples were collected at a hospital in 
France in 2011 from healthy women within three days of delivery. Unconjugated BPA was detected in 
90.5 % (19 out of 21) of the samples, and the concentration ranged from < 0.09 µg/L (i.e. below the 
LOD) to 6.3 µg/L, with a median of 1.5 µg/L (Figure 13). 
Initial human milk (colostrum) was also analysed by Kuruto-Niwa et al. (2007) for the presence of 
total BPA using an ELISA with an LOD of 0.3 µg/L. Milk samples were collected within three days of 
delivery from 101 healthy mothers from a local region in Japan in 2000–2001. Glass bottles were used 
for sample storage to avoid contamination. Total BPA was found in all 101 samples in a concentration 
range of 1.4–7.1 µg/L with a median of 3.0 µg/L (Figure 13). No information is available on the 
possible hospitalisation and medical treatment of the donors to exclude a treatment-related non-oral 
exposure of the mothers. An additional uncertainty comes from the analytical method itself. The 
ELISA was originally developed for the determination of BPA in urine and proved to be sensitive to 
both unconjugated and glucuronidated BPA (Kodaira et al., 2000). A method comparison revealed a 
good correlation between ELISA and HPLC-FLD measurements of BPA in glucuronidase-treated 
urine samples (Kodaira et al., 2000). However, the cross-reactivity was checked only for a limited 
number of BPA-related compounds (Kodaira et al., 2000), so that an overestimation of BPA 
concentration by cross-reactivity with other structurally related compounds cannot be excluded 
(Dekant and Völkel, 2008; FAO/WHO, 2011; Asimakopoulos et al., 2012). Moreover, the ELISA was 
obviously not validated for other biological matrices such as human milk. 
The CEF Panel noted that the study of Kuruto-Niwa et al. (2007) did not meet the inclusion criteria 
owing to the non-European origin of the data and the ELISA method (see literature quality table in 
Appendix I). However, because of the lack of European data for total BPA in colostrum, the CEF 
Panel decided to take into account the data from Japan, in spite of the methodical shortcomings as well 
as the fact that the data represent the situation in Japan in or earlier than 2007. The non-specificity of 
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the ELISA method may tend to overestimate the BPA concentration in colostrum which, however, 
would be conservative for the exposure assessment of breastfed newborn infants. 
 
Figure 13: Summary figure of the study results on BPA in human milk. Shown are the concentrations 
of unconjugated (U) and total (T) BPA on a log10-transformed scale for the eight human studies and 
the single rat study by Doerge et al. (2010a). Individual measurements (open circles) are shown for 
studies with small samples sizes (n = 3–4) For larger-scaled studies (n ≥ 20), box-percentile plots 
(grey-shaded boxes) are used to depict the distributional characteristics comprising the 5th, 12.5th, 
25th, 37.5th, 50th, 62.5th, 75th, 87.5th and 95th percentiles
23
, the median (vertical line within the 
boxes) and the minimum and maximum values (tick marks). Data from studies reporting only the 
median and the range are shown as incomplete boxplots. Vertical lines indicate the LOD. 
Concentrations below the LOD are set to a value of LOD/√2. Numbers associated with the data 
represent either the median value (larger scale studies) or the GM (arrows; small-scale studies). The 
number of subjects and the country codes are shown on the right. All concentrations are expressed 
as µg/L of unconjugated BPA. *Study using ELISA instead of an MS-based method 
                                                     
23 In the moderate-sized studies with n only slightly above 20, the extreme percentiles such as the 95th percentile are 
associated with high uncertainty and depend sensitively on the type of quantile algorithm used. 
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4.6.4.2. Mature human milk 
Five studies are available for the USA (Ye et al., 2006, 2008c; Duty et al., 2013; Mendonca et al., 
2014; Zimmers et al., 2014). The first four of these studies quantified unconjugated and total BPA in 
human milk samples by isotope-dilution HPLC-MS/MS with an LOD of 0.3 µg/L. All analytical 
measurements were performed in the Centers for Disease Control and Prevention (CDC) laboratory. 
Quality control materials for milk blanks were prepared by pooling human milk samples either taken 
from multiple donors (Ye et al., 2006) or purchased from Mother’s Milk Bank between 2002 and 2003 
(Ye et al., 2008c). In the first study, Ye et al. (2006) analysed 20 human milk samples from a group of 
lactating women without known occupational exposure. Unconjugated BPA was detected in 60 % of 
the samples with a median of 0.4 µg/L and a maximum of 6.3 µg/L (Figure 13). Total BPA was 
detected in 90 % of the samples with a median of 1.1 µg/L and a maximum of 7.3 µg/L. Comparison 
of the median concentrations of unconjugated and total BPA yielded a proportion of unconjugated 
BPA of 36 %. In the second study, Ye et al. (2008c) analysed milk samples of only four donors. The 
unconjugated and total BPA concentrations were in the range of 0.41–1.54 µg/L and 0.73–1.62 µg/L 
(Figure 13), respectively. The proportion of unconjugated BPA in the individual samples was quite 
high (50–99 %), and the authors (Ye et al., 2008c) acknowledged that they could not rule out the 
potential for contamination, as information on the collection and storage of these four samples was not 
available. 
In the third US study, Duty et al. (2013) analysed milk samples that were collected from 30 mothers 
with premature infants in a neonatal intensive care unit in 2009–2010. Sample collection devices were 
pre-screened for BPA, and maternal milk was expressed by mechanical pumping and frozen in BPA-
free storage containers. BPA-free breast pump disposable devices were made available to the mothers; 
however, the use of different systems by some mothers could not be excluded. The analytical 
measurements were performed by the CDC laboratory. Two human milk samples with concentrations 
of total BPA of 222 and 296 µg/L and unconjugated BPA of 189 and 252 µg/L were excluded by the 
authors as statistical outliers. Of the remaining 28 samples, two samples were collected from mothers 
within three to five days of delivery (S. Duty, Simmons College, Boston, Massachusetts, 2013, 
personal communication). The concentrations of unconjugated and total BPA in these two colostrum 
samples were < 0.3 µg/L (i.e. below the LOD) and 0.67 µg/L (GM), respectively. The remaining 26 
mature milk samples had median concentrations of < 0.3 µg/L (unconjugated BPA) and 1.3 µg/L (total 
BPA) with unconjugated BPA accounting for less than 30 % (median value) of total BPA. 
Remarkably, the box-percentile plots for unconjugated and total BPA (Figure 13; percentiles kindly 
provided by S. Duty) revealed quite a large variability, which appears to be driven by unconjugated 
BPA. This variability may be related to the different conditions in the hospital and home 
environments. 
The fourth US study by Mendonca et al. (2014) is a companion study of Duty et al. (2013), which used 
the same methodology. 23 samples were collected from mothers with healthy infants 3–15 months old 
at the mothers’ home between 2006 and 2008. A breast milk specimen was either hand expressed or 
obtained using a breast pump after the infant had been fed. The storage containers were of PP and 
were reported to be not known to contain BPA. The samples remained on ice until processing in the 
CDC lab. Within the laboratory, rigorous quality control measures were used to ensure valid BPA 
concentrations (Ye et al., 2006, 2008c). The analysis of the raw data (kindly provided by S. Duty) 
revealed that about 20 % of the samples did not have detectable concentrations of free and total BPA; 
in ~ 65 % of the samples the total BPA concentration exceeded that of free BPA, and in 13 % of the 
samples the situation was reversed. The maximum concentrations of free and total BPA of 23.6 and 
22.6 µg/L, which were observed in the same sample, were almost an order of magnitude higher than 
the next highest values. The CEF Panel regarded this sample as an outlier, proposed to be due to 
contamination. The next four highest values showed some kind of alternation with total BPA slightly 
exceeding free BPA and vice versa, but the CEF Panel expected the values for free and total BPA for 
these four samples, and also those for the excluded sample, to be within the measurement uncertainty 
of the analytical method. There is a likelihood that, in addition to the values of the excluded sample, 
the next four highest values could also be outliers and may contain a contribution from contamination; 
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the CEF Panel included these four values to be on the conservative side. Based on the 22 data points 
included, box-percentile plots were calculated (Figure 13) and median concentrations of < 0.3 µg/L 
(unconjugated BPA) and 0.8 µg/L (total BPA) were obtained. 
The fifth US study by Zimmers et al. (2014) focused on developing a sensitive method to detect free 
BPA in human breast milk. BPA was isolated from mature breast milk by solid-phase extraction, 
derivatised to improve sensitivity and analysed by isotope-dilution UPLC-MS/MS with an LOD of 
0.22 µg/L. 21 samples were selected from an archive of a larger national study for a secondary 
analysis of environmental contaminants. The sample selection was based on the body mass index of 
the donors, who lived in 14 different states and were of different race. The breast milk samples were 
drawn by breast milk pumps of different brands, collected in acid-washed glass bottles, shipped on ice 
to the laboratory and stored at –20 °C until analysis. All necessary precautions were reported to be 
taken to avoid background BPA contamination during sample preparation. Unconjugated BPA was 
detected in 62 % of the milk samples (range < 0.22–10.8 µg/L) with a median of 0.68 µg/L (Figure 
13). The authors reported a significant influence of race on BPA concentration with Caucasian women 
having higher levels of unconjugated BPA in their breast milk than non-Caucasian women. The CEF 
Panel noted that no confirmation was provided that the different breast milk pumps were BPA free. 
Given that, and given the lack of information on total BPA concentration, no inference could be made 
about the possible contamination of the samples during milk collection. As only the total BPA 
concentration in breast milk is used in the present opinion for deriving exposure estimates for 
breastfed infants, this study was not taken into consideration for deriving exposure estimates for 
breastfed infants. 
The two remaining studies on BPA in human milk were carried out in South Korea (Yi et al., 2010, 
2013). These studies were excluded because they did not meet the method/quality inclusion criteria 
(see literature quality table in Appendix I). 
To put the data on BPA in human milk in perspective, the results from animal studies should be taken 
into consideration. Valuable information on the lactational transfer of BPA and on the relative 
proportion of unconjugated BPA in animal milk is available from a controlled study in rats (Doerge et 
al., 2010a), in which dams were administered a daily oral dose of 100 µg/kg bw of stable isotope-
labelled BPA. The isotope-labelled BPA was used to avoid contamination problems, and the dose was 
selected to be within the linear pharmacokinetic range at a level as close as possible to the range of 
proposed human exposure, yet high enough to measure both BPA forms (Doerge et al., 2010a). The 
analysis of milk samples, which were collected on day 7 post partum at one hour after dosing when 
BPA serum levels are maximal (Doerge et al., 2010b), revealed median concentrations of 0.19 µg/L 
and 1.6 µg/L for unconjugated and total BPA, respectively (Figure 13). The proportion of 
unconjugated BPA in the individual samples was low (8.7–12 %). So for an oral dose of 
100 µg/kg bw, which is very high for humans, the median concentration of total BPA in rat milk is, 
unexpectedly, of the same order of magnitude as that in human milk. Physiological differences 
between rats and humans cannot be excluded. For unconjugated BPA, the median concentration is an 
order of magnitude lower in rat milk compared with that reported for initial human milk (colostrum). 
Finally, the proportion of unconjugated BPA in rat milk is markedly lower than the reported 
proportions of < 40 % (Mendonca et al., 2014), < 30 % (Duty et al., 2013), ~ 36 % (Ye et al., 2006), 
and 50–99 % (Ye et al., 2008c) for mature human milk. 
To conclude, although anti-contamination measures have been taken during sample work-up and the 
analytical procedure, the issue of potential contamination during the collection and storage of human 
milk samples is not completely solved. Even if the collection procedure is under strict control, an 
uncertainty about a possible hospitalisation and medical treatment-related non-oral exposure of the 
mothers remains. The measurement of only unconjugated BPA introduces an additional uncertainty 
about the concentration of conjugated BPA that should be taken into consideration in the exposure 
assessment. Given the presence of intestinal β-glucuronidases of bacterial origin in rats (Koldovský et 
al., 1972; Rød and Midtvedt, 1977; Gadelle et al., 1985) and of a β-glucuronidase in human milk 
(Gaffney et al., 1986; Gourley and Arend 1986; Grazioso and Buescher 1996), there may be 
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glucuronidase activity in the infant gut that may lead to a deconjugation of ingested glucuronidated 
BPA. Even if the infant’s gut microflora is not fully developed and the ingested β-glucuronidase in 
milk is inactivated by the acidic conditions of the infant’s stomach, there is the additional possibility 
that the β-glucuronidase is already active before the milk is consumed. There are several possible 
reasons why the proportions of unconjugated and conjugated BPA in collected human milk samples 
may vary. The first is the differences in the production of colostrum and mature milk that are 
associated with changes in the blood-to-milk transfer (Neville and Walsh, 1996), milk composition 
(Saint et al., 1984) and the activity of the milk β-glucuronidase (Gourley and Arend 1986). The 
elevated β-glucuronidase activity in initial milk compared with mature milk (Gourley and Arend 1986) 
is remarkable in so far as colostrum is produced (and accumulates in the mammary gland) from around 
mid-pregnancy until parturition (Neville et al., 2001), a period during which the β-glucuronidase 
activity in serum was found to be substantially increased compared with the first half of pregnancy and 
the postpartum period (McDonald and Odell, 1947; Lombardo et al., 1984). Another possibility is the 
maternal exposures via non-oral routes which, for toxicokinetic reasons, may result in higher plasma 
fractions of unconjugated BPA. 
To cover both average and high exposures, estimates of the central tendency and of a UB level should 
be derived. Estimates of the central tendency were obtained from the average BPA concentrations of 
selected human studies (Table 29). For initial human milk, the average concentration of 1.5 µg/L for 
unconjugated BPA was taken from the French study by Migeot et al. (2013). For total BPA, an 
average concentration of 3.0 µg/L was taken from the Japanese study by Kuruto-Niwa et al. (2007), 
being aware that the non-specificity of the ELISA method may tend to overestimate the BPA 
concentration. For unconjugated and total BPA in mature human milk, sample size-weighted means of 
~ 0.3 µg/L and 1.1 µg/L, respectively, were calculated from the moderately sized US studies of Ye et 
al. (2006), Duty et al. (2013) and Mendonca et al. (2014). 
 Database of average BPA concentrations (µg/L) in human milk used for exposure Table 29: 




Study/Author Type of milk No of 
samples 
Average BPA concentration (µg/L) 
Unconjugated Total 
Cariot et al. (2012) Initial 3 2.0 n/a 
Migeot et al. (2013) Initial 21 1.5 n/a 
Kuruto-Niwa et al. (2007) Initial 101 n/a 3.0 
Duty et al. (2013) Initial 2 < 0.3 0.7 
Ye et al. (2006) Mature 20 0.4 1.1 
Ye et al. (2008c) Mature 4 0.7 1.0 
Duty et al. (2013) Mature 26 < 0.3 1.3 
Mendonca et al. (2013) Mature 22 < 0.3 0.8 
Zimmers et al. (2014) Mature 21 0.7 n/a 
n/a, not available. 
A concentration estimate for high exposure to unconjugated and total BPA in initial breast milk was 
obtained by using the 95th percentile of 3.7 µg/L from Migeot et al. (2013) and 5.8 µg/L from Kuruto-
Niwa et al. (2007), respectively. The CEF Panel noted that the 95th percentile is not a reliable estimate 
for moderately sized studies such as Migeot et al. (2013), as the estimate may sensitively depend on 
the type of the quantile algorithm that is implemented in the statistical software package used 
(Hyndman and Fan, 1996). An alternative solution circumventing this problem was not chosen, as the 
95th percentile for total BPA, which finally entered the exposure assessment of breastfed newborn 
infants, was derived from the larger sized study of Kuruto-Niwa et al. (2007). For total BPA in mature 
milk, however, an alternative solution was chosen based on the more robust interquartile range (IQR) 
estimates of the moderately sized studies of Duty et al. (2013) and Mendonca et al. (2014). By noting 
that the log10-transformed BPA concentrations approximately follow a normal distribution (Figure 13), 
and that the standard deviation (σ) of a normal distribution is related to the IQR by IQR = 1.35 × σ, 
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individual estimates for σ of 0.29 and 0.39 could be derived (which agreed well with the parametric 
estimates for σ of 0.32 and 0.40). These individual estimates yielded an average σ of 0.34 on the log10-
transformed scale. A naive 95 % one-sided confidence interval was finally obtained by calculating a 
factor, k = 10
1.64 × σ
 = 3.6, which was then multiplied with the average concentration of 1.1 µg/L to 
yield a high concentration estimate of 4.0 µg/L for total BPA in mature breast milk. For unconjugated 
BPA in mature breast milk, a high-concentration estimate could not be derived in a reliable way, given 
the potential bias owing to the possible contribution from contamination. 
Table 30 summarises the derived estimates for the average and high concentration of total BPA in 
initial and mature breast milk. These estimates were used for the exposure assessment of breastfed 
newborn infants and infants. 
 Average and high values used (µg/L) to estimate exposure to BPA from human milk Table 30: 




Initial 3.0 5.8 
Mature 1.1 4.0 
(a):  Individual median or mean of medians. 
In the 2006 opinion, EFSA used a concentration of unconjugated BPA of < 1.0 µg/L in human milk as 
a conservative estimate of potential dietary exposure to BPA. 
In conclusion, the estimates for the average concentration of unconjugated and total BPA in mature 
breast milk are supported by several medium-sized studies from the USA. A high concentration 
estimate was derived from the same studies for total BPA only because this estimate is potentially less 
biased by sample contamination than an estimate for unconjugated BPA. The high concentration 
estimate for total BPA in mature milk was used for the exposure assessment of breastfed infants which 
is a conservative decision, given the uncertainty about the extent by which the conjugated BPA 
becomes deconjugated in the infant’s gut. For initial breast milk, concentration estimates for 
unconjugated and total BPA were obtained from a medium-sized study from Europe and a larger sized 
study from Japan, respectively. The uncertainty in these estimates results from the low number of 
studies and, in the case of the Japanese study, from the past sampling period (2000–2001) and the non-
specificity of this ELISA method, which may tend to overestimate the BPA concentration. The high 
concentration estimate for total BPA in initial breast milk was used for the exposure assessment of 
breastfed newborn infants, which again is a conservative decision. The uncertainty in the estimates for 
initial breast milk is further increased by the fact that milk production during the first days after 
delivery is of a transitional character owing to the transition from stage I of lactogenesis to stage II 
(Neville et al., 2001). The milk production rate increases more or less linearly during the first days 
after delivery, reaching a plateau of ~ 600 mL/day on day 5 (Neville and Walsh, 1996). This process is 
accompanied by compositional changes in protein and fat content (Saint et al., 1984) and in β-
glucuronidase activity (Gourley and Arend 1986), which may affect the proportion of unconjugated to 
total BPA of maternal origin. Last but not least, there is the possibility of exposure from medical 
devices of mothers staying in hospital for a few days after delivery. 
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4.6.5. Comparison of results from backward with forward exposure calculation  
The exposure part of the opinion focuses on the route-specific external exposure of consumers to BPA. 
In order to compare this external exposure derived by forward calculation with the internal exposure 
levels derived by backward calculation, the external exposure values have to be transformed to 
internal exposure levels summed up over all routes. The focus is on total BPA (conjugated plus 
unconjugated) in order to provide validation for the external exposure levels. In order to sum up the 
internal exposure to total BPA over routes, different absorption factors have to be considered for the 
different routes of exposure. These absorption factors are further described below. The CEF Panel 
notes that the exposure levels here summed up over different routes are valid only for comparison with 
biomonitoring. As the information on the proportion of unconjugated and conjugated BPA is not 
included, they cannot be used for risk assessment. For deriving sound estimates for the internal levels 
of unconjugated and conjugated BPA for the different routes a more complicated procedure is 
necessary, which is described in detail in Section 3.1.7 of Part II of this opinion – Toxicological 
assessment and risk characterisation. 
The opinion also systematically evaluates the uncertainty in both forward and backward internal 
estimates for total BPA (Section 4.7.2). 
4.6.5.1. Absorption factor for ingestion  
For ingestion it is assumed that 100 % is absorbed, i.e. the absorption fraction of 1 was used. 
4.6.5.2. Absorption factor for inhalation  
For inhalation the same absorption factor as for ingestion, i.e. 1, was assumed. 
4.6.5.3. Absorption factors for dermal uptake  
Dermal absorption studies are discussed in detail in Appendix D of Part II – Toxicological assessment 
and risk characterisation. It has been shown that only studies with pig or human skin are useful for 
deriving human dermal absorption fractions. From an in vitro study with human skin exposed in Franz 
cells, where the scenario of dermal exposure to thermal paper was simulated (Demierre et al., 2012), 
an absorption fraction of 0.1 was derived for dermal exposure to thermal paper. 
For exposure to BPA in cosmetics, however, this study cannot be used, as BPA was applied in 
Demierre et al. (2012) in aqueous solution, i.e. without a vehicle that may enhance absorption. 
Therefore, for BPA in cosmetics a different approach was used. 
In Biedermann et al. (2010), an attempt is reported to investigate dermal penetration by exposing 
living humans. Here, not the transfer to blood (i.e. absorption) was assessed, but BPA was applied in 
different forms to the fingertips of a human volunteer (e.g. by pressing thermal paper, or by applying 
BPA in ethanolic solutions). Recovery from the fingertips was determined for different exposure times 
by measuring BPA in the ethanolic extraction solution. The calculated amounts that remained in the 
skin after extraction can be seen as a UB for dermal absorption, even if not all BPA remaining in the 
skin will finally reach the bloodstream. 
In one experiment BPA was dissolved in ethanol (10 mg/mL) and 1 µL of this solution was applied 
directly to the skin of the fingertips. For this experiment a recovery of 40 % after 1.5 hours was 
reported (determined by extraction from skin with ethanol over 30 seconds), from which a maximal 
dermal absorption fraction of 0.6 can be deduced. Another experiment with the same amount of BPA 
in a larger volume of solvent (10 µL, 1 mg/mL) showed a recovery < 5 %, which implies that the 
maximal dermal absorption of BPA can reach 95–100 % if BPA is applied dissolved in ethanol. 
Ethanol may act as a transport mediator for BPA into the skin, thus enhancing the absorption fraction. 
Therefore, the dermal absorption fraction derived for BPA in ethanol may be used for BPA in 
formulations that have similar vehicle properties as ethanol (e.g. emulsions such as body lotions and 
creams). 
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In emulsions and creams, apart from lipophilic substances, a high percentage of water is also present. 
Therefore, the vehicle effect of ethanol will overestimate the vehicle effect of cosmetic formulations. 
The dermal absorption fraction for non-intentional trace amounts of BPA in cosmetics can be assumed 
to be larger than the 0.1 determined for solid BPA from thermal paper and smaller than the absorption 
fraction of 1 from the recovery study described by Biedermann et al. (2010). For BPA in cosmetics, 
therefore, an absorption fraction of 0.5 was assumed. 
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 Average internal exposure to BPA from all sources in the general population (ng/kg bw per day); for inhalation and ingestion internal Table 31: 
equals external exposure 






































Dust  8.8 8.8 8.8 8.8 7.3 2.9 2.0 0.6 0.6 0.6 0.6 
Toys  0.2 0.2 0.2 0.2 0.01       
Dietary exposure 
from food and 
beverages 
225 165 145 30 375 375 290 159 132 126 126 116 
Sum of all 
ingestion sources 
225 174 154 39 384 382 293 161 133 127 127 117 
Inhalation 
Air 0.7 0.7 0.7 0.7 0.7 0.7 0.4 0.4 0.2 0.2 0.2 0.2 
Sum of all 
inhalation sources 




       6.9 9.4 5.9 5.9 5.9 5.9 
Cosmetics
 (b)
  2.4 2.4 2.4 2.4 1.4 1.1 1.2 1.0 1.0 1.0 1.0 
Sum of all dermal 
sources 
0 2.4 2.4 2.4 2.4 1.4 8.0 10.6 6.9 6.9 6.9 6.9 
Average internal 
exposure to total 
BPA summed up 
over routes for 
comparison with 
biomonitoring 
226 177 157 42 387 384 301 172 140 134 134 124 
(a): Assuming an absorption fraction of 0.1. 
(b): Assuming an absorption fraction of 0.5.  
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 High internal exposure to BPA from all sources in the general population (ng/kg bw per day); for inhalation and ingestion internal Table 32: 
equals external exposure 






































Dust  14.6 14.6 14.6 14.6 12.2 4.9 3.3 1 1 1 1 
Toys  0.6 0.6 0.6 0.6 0.01       
Dietary exposure from 
food and beverages 
435 600 528 80 857 857 813 381 388 335 341 375 
Sum of all ingestion 
sources 
435 615 543 95 872 869 818 384 389 336 342 376 
Inhalation 
Air 1.4 1.4 1.4 1.4 1.4 1.1 0.6 0.6 0.3 0.3 0.3 0.3 
Sum of all inhalation 
sources 




       55.0 86.3 54.2 54.2 54.2 54.2 
Cosmetics
 (b)
  4.7 4.7 4.7 4.7 2.8 2.1 2.4 2.0 2.0 2.0 2.0 
Sum of all dermal 
sources 
 4.7 4.7 4.7 4.7 2.8 57.1 88.7 56.2 56.2 56.2 56.2 
High internal exposure 
to total BPA summed 
up over routes for 
comparison with 
biomonitoring 
436 621 549 101 878 873 876 473 446 393 399 433 
(a): Assuming an absorption fraction of 0.1. 
(b): Assuming an absorption fraction of 0.5. 
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4.6.5.4. Internal exposure levels combined over all routes 
The external exposure values as derived by forward calculation were transformed into internal 
exposure levels by applying the route- and source-specific absorption factors. The Tables 31 and 32 
show the estimates for the average and high internal exposure to total BPA in the general population. 
4.6.5.5. Comparion of results from backward and forward exposure calculation 
The estimates for the average and high internal exposure to total BPA in the general population, as 
calculated by forward modelling, are compared with those calculated by backward modelling. The 
average exposure values are compared in Table 33, the high exposure values in Table 34. 
By forward modelling, the average internal exposure to total BPA for the age class “Infants” ranged 
from 42 ng/kg bw per day (formula-fed, 0–6 months old) via 157 ng/kg bw per day (breastfed, 4–6 
months old), 177 ng/kg bw per day (breastfed, 6 days to 3 months old), 226 ng/kg bw per day 
(breastfed, 1–5 days old) to 387 ng/kg bw per day (6–12 months old). Based on only a single study, 
backward modelling estimated the average internal exposure to total BPA for infants one to two 
months old to be < 10 ng/kg bw per day, which is at least four-fold lower than the modelled estimate 
of 42 ng/kg bw per day for formula-fed infants. 
The average internal exposure of toddlers to total BPA was estimated only by forward modelling, as 
no biomonitoring data were available. Forward modelling gave an estimate of 384 ng/kg bw per day. 
For children 3–10 years old, an average internal exposure to total BPA of 301 ng/kg bw per day was 
obtained by forward modelling. Backward modelling gave estimates of 107 and 49 ng/kg bw per day 
for three- to five-year old children and 5–10 year old children, respectively, which were three- to six-
fold lower than the figure obtained by forward modelling. 
For the adolescents, adults, women of childbearing age and the elderly and very elderly, a decreasing 
trend of BPA exposure from 172 via 134–140 to 124 ng/kg bw per day was observed in the modelled 
estimates. Similarly, backward modelling indicated a decreasing trend with values of 48, 39 and 
36 ng/kg bw per day for adolescents, adults and women of childbearing age. The somewhat higher 
value of 56 ng/kg bw per day for backward modelling in the elderly may be biased towards higher 
values because of the low number (only two) of biomonitoring studies. Again, the estimates from 
backward modelling are two- to four-fold lower than those obtained by forward modelling. 
To summarise, the estimates for the average internal exposure to total BPA, as obtained by forward 
and backward modelling, agree with each other within an order of magnitude. More specifically, 
forward modelling gave estimates that were approximately four-fold higher (42–387 ng/kg bw per day 
vs. < 10–107 ng/kg bw per day) than those obtained by backward modelling. There are two important 
aspects that may contribute to these discrepancies. The first one is the statistical procedure by which 
averages are derived. The second one is the scenario for modelling the dietary and non-dietary 
exposure. 
The exposure estimation by forward modelling (ingestion, dermal and inhalation exposure) was based 
on the calculation of AMs, whereas the backward modelling was based on GMs. In the case of 
backward modelling, the decision to use GMs was justified by the log-normal distribution shape of the 
urinary BPA data (see Section 4.6.2.1). To convert GM-based estimates into AM-based estimates, 
which are then comparable to those obtained by the modelling approach, a multiplicative conversion 
factor of 1.8 was derived (see Section 4.6.2.1). The different statistical procedures for calculating 
central tendencies may at least partly explain the discrepancies between the two approaches. 
The second source for the discrepancies could be the scenario chosen for modelling the dietary 
exposure. Two scenarios (with LB, MB and UB handling of left-censored data) were considered in the 
dietary exposure estimation (see Section 4.5.2.5). In scenario 1, only foods specifically codified as 
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canned in the dietary survey are assigned the corresponding occurrence level for BPA. In scenario 2, 
any food at FoodEx level 4 which has been codified as canned in at least one survey is always 
considered to be consumed as canned in all dietary surveys considered in the Comprehensive 
Database. Scenario 2 and the MB approach was chosen for the exposure estimation. As scenario 2 
might overestimate the dietary exposure, this may also partly explain the discrepancies between the 
estimates from forward and backward modelling. 
An additional source of discrepancy may be related to the conservativeness of the assumptions made 
to assess exposure to non-food sources. 
 Average internal exposure to total BPA, as estimated by forward and backward exposure Table 33: 
modelling. For some age classes, such as infants and children, several values are given which refer to 
subgroups among the age classes 
Age class Age(years) Average internal exposure (ng/kg bw per day) 
Forward modelling 
(a)
 Backward modelling 
(b)
 
Infants 0–1 42/157/177/226/387 < 10 
Toddlers 1–3 384 Not available 
Children 3–10 301 49/107 
Adolescents 10–18 172 48 
Adults 18–65 134/134/140 39 
Women of cba 18– 2 140 36 
Elderly/very elderly ≥65 124 56 
cba, childbearing age. 
(a) Internal exposure assessed by combining exposure over all routes. For some age classes several values are given that 
refer to subgroups among the age class (see Table 31 for details). 
(b) When biomonitoring data were available for more than one age class, several values are given. 
By forward modelling, the high internal exposure to total BPA for the age class “Infants” ranged from 
101 ng/kg bw per day (formula-fed, 0–6 months old) to 549 ng/kg bw per day (breastfed, 4–6 months 
old), 621 ng/kg bw per day (breastfed, 6 days to 3 months old), 436 ng/kg bw per day (breastfed, 1–5 
days old) to 878 ng/kg bw per day (6–12 months old). Based on only a single study, backward 
modelling estimated the high internal exposure to total BPA for infants one to two months old to be 
161 ng/kg bw per day, which was 1.6-fold higher than the forward-modelled estimate for formula-fed 
infants but 3.9-fold lower than the forward-modelled estimate for breastfed infants three months old or 
less. Although the biomonitoring study did not differentiate between formula-fed and breastfed 
infants, the comparison provides a first indication that the forward-modelled estimate for breastfed 
infants three months old or less could possibly overestimate the exposure because the CEF Panel 
assumed, for conservative reasons, that the conjugated BPA in breast milk would become 
deconjugated by milk and intestinal β-glucuronidases. 
The high internal exposure of toddlers to total BPA was estimated only by forward modelling, as no 
biomonitoring data were available. Forward modelling gave an estimate of 873 ng/kg bw per day. 
For children 3–10 years old, a high internal exposure to total BPA of 876 ng/kg bw per day was 
obtained by forward modelling. Backward modelling gave estimates of 676 and 380 ng/kg bw per day 
for three- to five-year old and 5–10 year old children, respectively, which were 1.3- to 2.3-fold lower 
than the figure obtained by forward modelling. 
For adolescents, adults, women of childbearing age and the elderly and very elderly, high internal 
exposures to total BPA of 473, 393–446, and 433 ng/kg bw per day were obtained by forward 
modelling. Backward modelling gave values of 256, 290, 234, and 203 ng/kg bw per day. Again, the 
backward calculated estimates are 1.4- to 2.1-fold lower than those obtained by forward modelling. 
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To summarise, the estimates for the high internal exposure to total BPA, as obtained by forward and 
backward modelling, agree well with each other. More specifically, forward modelling gave estimates 
that were 1.3- to 2.3-fold higher than those obtained by backward modelling. An exception are the 
toddlers, for which no biomonitoring data are available, and the breastfed infants three months old or 
less, for which there are indications from a single biomonitoring study for a higher fold difference 
between the forward and backward-modelling estimates. Again, as discussed above, the statistical 
procedures used for the high exposure estimates and the scenario for modelling dietary exposure may 
explain the discrepancies. 
Both forward and backward modelling use the 95th percentile of the distribution of the dietary daily 
intakes and of the urinary total BPA concentration to derive high-exposure estimates. In the 
biomonitoring, however, the 95th percentile of the urinary total BPA concentration has different 
interpretations depending on whether spot urine samples, first morning urine samples or 24-hour 
samples are used. For spot urine samples, the 95th percentile is related to the 95 % probability that a 
single, randomly collected sample from a randomly selected subject has a urinary BPA concentration 
not exceeding the 95th percentile. This is important, as urinary BPA concentrations of repeated urine 
collections from individuals may vary by up to two orders of magnitude. There are some studies that 
indicate that the total variance can be subdivided into 70 % within-day variability, 21 % between-day 
variability and 9 % between person variability. Thus, taking the 95th percentile of the urinary BPA 
concentration as a measure for deriving high-exposure estimates is a conservative approach, as the real 
long-term average value for high exposure is lower. It can therefore be concluded that the two-fold 
discrepancy between estimates derived by forward and backward modelling could be somewhat 
higher. 
An important source of the discrepancy between the two modelling approaches is probably the 
scenario chosen for modelling the dietary exposure, which is discussed in detail above. Moreover, as 
the biomonitoring studies for the European region are generally not based on a representative sampling 
of the population, one may argue that they have not captured high levels of exposure that may occur in 
specific geographic areas or specific population groups. However, as the European biomonitoring 
estimates (i.e. GMs, 95th percentiles) are quite similar to those of the largest sized US NHANES (see 
Figure 8), which is a nation-wide representative survey and therefore includes highly exposed 
population groups, there is no evidence for assuming the biomonitoring estimates to be less 
conservative or too liberal. Furthermore, as mentioned above, an additional source of discrepancy may 
be related to the conservativeness of the assumptions made to assess high exposure to non-food 
sources. 
 High internal exposure to total BPA, as estimated by forward and backward modelling Table 34: 
Age class Age (years) High internal exposure (ng/kg bw per day) 
Forward modelling approach Backward modelling 
Infants 0–1 101/436/549/621/878 161 
Toddlers 1–3 873 Not available 
Children 3–10 876 380/676 
Adolescents 10–18 473 256 
Adults 18–65 393/399/446 290 
Women of cba 18–52 446 234 
Elderly and very elderly ≥65 433 203 
cba, childbearing age. 
(a): Internal exposure assessed by combining exposure over all routes. For some age classes several values are given which 
refer to subgroups among the age class (see Table 32 for details). 
(b): When biomonitoring data were available for more than one age class, several values are given. 
4.6.5.4. Overall conclusion 
Backward modelled exposure estimates based on urinary BPA concentrations are in good agreement 
with forward modelled estimates of internal exposure to total BPA, suggesting that it is likely that no 
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major exposure sources have been missed for the modelled exposure assessment. It is, however, 
important to highlight that the modelled internal exposure includes conservative assumptions resulting 
in a probable overestimation of exposure that could in theory have hidden other possible sources of 
exposure. The CEF Panel also noted that there are considerable uncertainties in both estimates. 
4.7. Discussion of exposure estimates  
4.7.1. Comparison with values from other exposure assessments 
According to its terms of reference, the present opinion considers only European data on food 
consumption, BPA occurrence and migration and urinary BPA concentration for estimating the 
exposure of the general population in the European region via modelling and biomonitoring 
approaches. The CEF Panel noted that there are other extensive exposure estimations outside Europe 
such as those based on urinary biomonitoring data from the US NHANES and the Canadian CHMS 
surveys (Lakind et al., 2012). For NHANES, which covers the periods from 2003–2004 to 2009–2010, 
there is a pronounced temporal variability in urinary BPA concentration, with indications of a decline 
in urinary BPA concentration (Melzer et al., 2010; Lakind et al., 2012; Wells et al., 2013), especially 
in 6- to 11-year-olds (Wells et al., 2013), which suggests that exposure may have decreased over the 
last decade. However, the EFSA evaluation focuses on European data, where, given the data available, 
detection of trends in changes in exposure (whether decreases or increases) is not yet possible. For the 
purpose of exposure comparison, data on dietary exposure (expressed as external doses and 
distinguished by age group, when possible) from this and other recent assessments are presented in 
Table 35. 
4.7.1.1. FAO/WHO Expert Meeting on Bisphenol A 
The FAO/WHO Expert Meeting on Bisphenol A (FAO/WHO, 2011) estimated dietary exposure to 
BPA in adults by means of model diets based on the budget method and concentration data on canned 
food (average and maximum concentrations) retrieved from the literature or based on expert 
judgement. The Expert Meeting considered a variety of possible scenarios with respect to the 
frequency of consumption of packaged food, from the worst-case scenario (100 %) to the best-case 
scenario (25 %). Consequently, a number of estimates were derived for the mean and 95th percentile 
exposure. The potential dietary exposure for children from 6 to 36 months of age was also based on 
the budget method and considered a variety of food patterns related to the consumption of liquid food 
(human milk or infant formula) and the introduction of solid food (fruits, desserts, vegetables and 
meat), primarily packaged in glass with coated metal lids. Dietary exposure to BPA in infants (0–6 
months of age) was assessed by means of consumption data on infant formula and human milk 
retrieved from the literature. The Expert Meeting assumed a mean consumption of 130 mL/kg bw per 
day and a 95th percentile consumption of 174 mL/kg bw per day for all food consumption patterns 
based exclusively on infant formula or human milk or mixtures of the two. Six scenarios were 
considered in order to cover different patterns with respect to the consumption of human milk (breast, 
glass or PC bottles), liquid infant formula (glass or polycarbonate bottles) and powdered infant 
formula (glass or polycarbonate bottles). Except for human milk, all concentration data used in the 
calculations were expressed as unconjugated BPA. 
The mean exposure of exclusively breastfed babies (0–6 months) to BPA was estimated to be 
0.3 µg/kg bw per day, and exposure at the 95th percentile was estimated to be 1.3 µg/kg bw per day. 
Exposure estimates were generally higher for infants fed with liquid compared with powdered formula 
and for infants fed using PC compared with non-PC bottles. The highest estimated exposure occurred 
in infants zero to six months of age fed with liquid formula out of PC bottles: 2.4 µg/kg bw per day at 
the mean and 4.5 µg/kg bw per day at the 95th percentile. For children older than three years, the 
highest exposure estimates did not exceed 0.7 µg/kg bw per day at the mean and 1.9 µg/kg bw per day 
at the 95th percentile. For adults, highest exposure estimates did not exceed 1.4 µg/kg bw per day at 
the mean and 4.2 µg/kg bw per day at the 95th percentile. 
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Based on the limited published or review data available on exposure to BPA from non-food sources, 
the Expert Meeting considered that the upper range of mean exposure from inhalation of free BPA 
(concentrations in indoor and outdoor air) was approximately 0.003 µg/kg bw per day for the general 
population. Indirect ingestion (dust, soil and toys) was considered to be approximately 0.03 µg/kg bw 
per day in infants and approximately 0.0001 µg/kg bw per day in children and adults. The Expert 
Meeting was unable to provide an estimate of exposure from thermal papers because of insufficient 
data on dermal absorption and observational studies on use patterns. Exposure to BPA from dental 
treatment was not taken into account because it was considered as short term and unlikely to 
contribute substantially to chronic exposure. 
4.7.1.2. ANSES 
The assessment of exposure carried out by ANSES (ANSES, 2013) within its risk assessment of BPA 
is the only assessment quantifying sources of exposure other than the diet in Europe. A systematic 
approach was used here to identify and characterise the sources, routes and levels of exposure, as well 
as the categories of population to be studied. Two groups referred to as the general population 
(including vulnerable populations) and professionals handling end products intended for the general 
public as part of their activities (outside of fabrication, processing, distribution and disposal) were 
investigated. In the former group, children over three years of age, adults and pregnant women were 
classified as three subgroups. In its exposure assessment ANSES took into account the oral route (food 
and beverage, drinking water, dust), inhalation route (indoor and outdoor air) and dermal route 
(thermal paper). 
ANSES analysed 1 319 composite food and beverage samples which were collected in the context of a 
total dietary study conducted between 2007 and 2009 for unconjugated BPA concentrations. 
Concentration data of BPA in matrices other than foods were retrieved from the scientific literature 
and from reports of especially commissioned French studies on indoor air and dust from 30 selected 
homes, on tap water from the water distribution network and bottled water (spring water, natural 
mineral water, waters made drinkable through treatment) and on the frequency and concentration of 
BPA in 50 receipts collected in various French retail stores. 
Total exposure to BPA was estimated by combining exposure levels from the various matrices by 
means of a probabilistic Monte Carlo approach, which also included other variables, such as food 
consumption (in terms of type and quantity), body weight and respiratory volume. In order to 
accommodate for the reduced systemic bioavailability of unconjugated BPA from food, the exposure 
estimates were multiplied by a factor of 0.03 (equivalent to 3 % systemic bioavailability) to give the 
internal exposure from this particular source. The individual estimated exposure values derived from 
air, dust and food were then combined to calculate a total internal dose. In addition, the internal 
exposure caused by handling thermal tickets was calculated separately. 
The dietary source was identified as the major contributor to the total average internal exposure, with 
values of 84 % (pregnant women), 78 % (adults) and 70 % (for children > 3 years). When analysing 
this source further it became apparent that food products packed in cans (representing approximately 
50 % of total dietary exposure), some food items of animal origin (with meat, offal and charcuterie 
representing 17 % of total dietary exposure) and a background level contamination (representing 25–
30 % of total exposure) were responsible for these high levels. ANSES reported that about 85 % of the 
1 207 food samples analysed were reported to be contaminated with a BPA background level of 
< 5 µg/kg. 
The exposure resulting from thermal paper is calculated separately and not included in the total 
exposure because of the high uncertainty. The values are reported as internal exposure but can also be 
taken as external exposure because the conversion factor is 1. For the study population “Consumers—
pregnant women handling thermal receipts”, the internal dose varies from 0.029 to 140 ng/kg bw per 
day, for the exposure model using an absorption flow determination, to 0.009 to 260 ng/kg bw per day, 
for the exposure model using an absorption rate determination. The 95th percentiles used for the 
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comparison with the toxicological points of reference in the risk assessment, are 50 ng/kg bw per day 
and 80 ng/kg bw per day, respectively. The average for both is 20 ng/kg bw per day. 
For the study population “Consumers—adults handling thermal receipts”, the internal dose varies from 
0.017 to 150 ng/kg bw per day, for the exposure model using an absorption flow determination, to 
0.021 to 260 ng/kg bw per day, for the exposure model using an absorption rate determination. The 
95th percentiles are 58 and 89 ng/kg bw per day, respectively, and the averages are 20 and 
30 ng/kg bw per day (ANSES, 2013). 
4.7.1.3. Belgium 
Dietary exposure to BPA was assessed in Belgium (Geens et al., 2010) by means of analytical data 
from 45 canned beverages and 21 canned food items from the Belgian market. Using detailed 
information from the national food consumption survey, the BPA intake of adults through canned 
foods and beverages was estimated to be 0.015 and 0.086 µg/kg bw per day for the mean and the 95th 
percentile, respectively. 
4.7.1.4. FACET 
BPA was also used, as an example, to validate software developed within the Directorate General 
Research-funded project FACET, to assess the exposure to chemical migrants from food packaging. In 
order to estimate exposure to BPA, concentration distributions in foods packed in light metal 
packaging, such as food and beverage cans, metal closures, aerosol cans and tubes, were linked 
probabilistically via the software tool to the amounts of each food item consumed, as recorded in the 
UK National Diet and Nutrient Survey (NDNS) involving 19- to 64-year-olds. The output from the 
FACET tool has also been verified using a semi-deterministic approach using packaging data from the 
UK. 
The estimates of exposure to BPA from foods packed in light metal packaging using the probabilistic 
FACET tool were 0.13 µg/kg bw per day (mean) and 0.59 µg/kg bw per day (97.5th percentile) in UK 
consumers of these foods. The major contributors were canned foods such as beer, soup, cider, 
carbonates, preserved pasta and ready meals, and fruit and vegetables. Values obtained by 
probabilistic modelling were within the minimum and maximum ranges obtained by using a semi-
deterministic approach. 
4.7.1.5. Conclusions 
 Exposure to BPA carried out by the FAO/WHO Expert Meeting on Bisphenol A are far higher 
than others owing to the use of a conservative model diet. 
 Other exposure estimates are of the same order of magnitude. 
 Only EFSA and ANSES estimated exposure to BPA from sources other than foodstuffs. 
 EFSA considered the contribution of all exposure routes (oral, dermal and inhalation), 
whereas ANSES evaluated that provided by the oral and dermal routes. 
 Exposure from canned food is one of the major contributors to dietary exposure to BPA for all 
age groups. 
 Exposure levels are higher in children aged over three years. 
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 Estimates of external exposure to BPA  Table 35: 
Population 
groups 





based on standard 
assumptions 
Adults ANSES , 
2013  
Diet (food, beverages) and 
drinking water) 
40 87  
Children aged  
over 3 years 
56 141  





Human milk only   200 
Infant formula fed with 
glass or non-PC bottle 
  2 300 
Infant formula fed with PC 
bottle 
  11 000 
(b)





Infant formula fed with PC 
bottle and commercial 
foods/beverages 
  13 000 
(b)





2 kg commercial foods/ 
beverages 
  5 300 
Adults 3 kg commercial foods/ 
beverages 










30 80  
Infants  
(6 days to 3 
months) 
165 600  
Infants  
(4–6 months) 
145 528  
Infants  
(6–12 months) 
375 857  
Toddlers  
(1–3 years) 
375 857  
Children  
(3–10 years) 
290 813  
Adolescents  
(10–18 years) 
159 381  
Men  
(18–45 years) 
126 335  
Women  
(18–45 years) 
132 388  
Other adults  
(45–65 years) 
126 341  
Elderly/very 
elderly (65 years 
and over) 
116 375  
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Population 
groups 





based on standard 
assumptions 
Adults FACET Canned food and beverages 130 590  
Adults Geens et 
al., 2010 
Canned food and beverages 15 86  
Adults FAO/WH
O, 2011 
Canned food and beverages 1 400 4 200  
Children  
(6–36 months) 
700 1 900  
Infants  
(0–6 months) 
Infant formula and/or 
human milk 
300 1 300  
(a): Only for adults and pregnant women. 
(b): Based on the upper value of 50 µg BPA/l of infant formula. 
(c): Based on the typical value of 10 µg BPA/l of infant formula..
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4.7.2. Evaluation of uncertainty in internal exposure to total BPA through expert judgement  
It is important to characterise the uncertainties affecting exposure assessment both for transparency 
(EFSA, 2009) and so that they can be taken into consideration in risk management (Codex, 2014).  
Two complementary approaches were used to address uncertainty in the CEF Panel’s exposure 
assessment for BPA. First, independent estimates of exposure from forward modelling and 
biomonitoring were compared to assess the degree of agreement between them: the results of those 
comparisons are presented in section 4.6.5.5. Second, the uncertainty of both the forward modelling 
and biomonitoring estimates was assessed by a combination of expert judgement and sensitivity 
analysis, as reported in the present section. This provides an approximate range around each exposure 
estimate and enables the uncertainties to be taken into account when comparing the forward modelling 
and biomonitoring results (see below).  
Uncertainties affecting the forward modelling estimates for each source of exposure, and the 
biomonitoring estimates, were assessed by expert judgement and presented in a tabular format of the 
type suggested by EFSA (EFSA, 2006b). A detailed description of the approach is provided in 
Appendix H, together with the results. The CEF Panel expressed its judgement of uncertainties 
affecting each estimate using a scale of symbols representing the degree to which the real exposures 
might be higher or lower than the estimate (Figure 14). It is important to note that the scale is used to 
indicate the expected direction and width of the uncertainty, but the relative likelihood of different 
values within the range was not assessed. Thus, if the uncertainty is described with – –/+, it indicates 
that the real value may fall in an interval ranging from five times lower than the estimate to two times 
higher than the estimate; it does not necessarily imply that there is a higher probability that the real 
value has been overestimated than underestimated. 
Results of these assessments are shown in Table 36, for women aged 18-45 years. This group was 
chosen because it represents women of child-bearing age, and therefore includes one of the groups 
specified for attention in the Terms of Reference (pregnant women).  
As in section 4.6.5.5, it is necessary to convert the forward modelling estimates of external exposure to 
internal exposures to total BPA and then combined across sources of exposure in order to compare 
them with the estimate from biomonitoring, as the latter is a measure of internal exposure to total BPA 
including contributions from all sources. It would be possible to assess the uncertainty of the 
combined forward modelling estimates by using expert judgement to combine the uncertainty 
evaluations for each source. However, this requires taking account of the relative magnitude of 
different sources as well as their different degrees of uncertainty, and is difficult to assess reliably by 
expert judgement. Instead, therefore, the CEF Panel combined the evaluations for different sources by 
calculation.  
First, the evaluations of uncertainty in the forward modelling estimates for each source of exposure 
were re-expressed in quantitative terms. This was done by replacing the symbols representing 
uncertainty for each external exposure estimate with quantitative factors corresponding to the lower 
and upper ends of the ranges for those symbols in the scale that was used by the CEF Panel in 
evaluating the uncertainties (Figure 14). This is a conservative approach, tending to over-state the 
uncertainty, because when evaluating uncertainty the CEF Panel always ‘rounded up’, assigning the 
range of symbols that was as large or larger than its assessment of the uncertainty. The factors 
obtained from this conversion were then applied to the CEF Panel’s estimate, producing a range 
representing an upper and lower bound for the uncertainty of that source of exposure. These ranges are 
shown in the top right column of Table 36.  
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Figure 14: Scale used for evaluating the impact of uncertainties on estimates of exposure to BPA. 
To illustrate this conversion, consider the first row in Table 36. The CEF Panel’s estimate of average 
exposure of women aged 18-45 by the dietary route is 0.132 μg/kg bw per day, with an uncertainty 
evaluation (from Appendix H) of –/●. These symbols correspond to a range of factors from ×½ to 
+20%, as can be seen from the scale in Figure 14. Applying these to the estimate of 0.132 gives a 
range from 0.066 to 0.158 μg/kg bw per day, which represents an upper bound of the CEF Panel’s 
evaluation of the uncertainty around the estimated value. The same process was repeated for the 
uncertainty evaluations for all the sources of exposure that were considered, and also for the estimated 
dermal absorption fractions and the estimates of exposure from biomonitoring, as shown in Table 36. 
Estimates of internal exposure to total BPA were calculated using the following equation: 
                                                                                
                   , 
 
For this calculation, Dietary, Dust, Air, Paper and Cosmetic refer to external exposures. For Dietary, 
Dust and Air, absorption factors of 1 are assumed and not shown in the equation.  
As in other parts of this opinion, both ‘average’ and ‘high’ estimates of exposure are considered. In 
order to be protective for the whole of Europe, international calculations should provide exposure 
estimates that are equal to or greater “than the best estimates carried out at national levels” (EFSA, 
2005). It was therefore assumed that the purpose of the high exposure assessment is to estimate high 
BPA exposure in the EU country where this estimate is highest. The 95
th
 percentile was considered as 
an approximate target percentile for each population group assessed. The exposure assessment is 
therefore aimed at estimating the 95th percentile of exposure for each population group in the EU 
country where this is highest. This was done explicitly in the dietary exposure assessment, where the 
highest 95
th
 percentile from different countries was used. Similarly, the highest 95
th
 percentile was 
taken from the available biomonitoring studies. Assessment of non-dietary sources of exposure did not 
distinguish different EU countries, but was aimed at the same objective.  
The uncertainty analyses were therefore aimed at evaluating how much higher or lower than the 
calculated estimate the real 95th percentile of exposure for each population group might be, in the EU 
country where this is the highest. For each individual source of exposure, ‘average’ and ‘high’ 
estimates have been made as approximate estimates for the mean and 95th percentile. The CEF Panel 
explored different exposure combinations of average and high estimates. Air is a very minor 
contribution to the combined exposure: the CEF Panel took the high estimate of inhalation exposure 
for all estimates but it has negligible influence on the total. Tables 36 show four combinations (C1-C4) 
of estimates for each population group: 
1. Averages for both dietary exposure and non-dietary exposure (Combination 1) 
2. High estimates for dietary exposure and averages for non-dietary exposure exposure 
(Combination 2) 
3. Averages for dietary exposure and high estimates for non-dietary  exposure (Combination 3) 
4. High estimates for both dietary and non-dietary exposure  (Combination 4). 
• + ++ +++       
+/ - 20 % x 1/2 x 1/5 2x 5x x 1/10 10x 
Real value  higher than estimate 
(under - estimation) 
Real value  lower than estimate 
(over - estimation) 
++++     
>10x < x 1/10 
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Combination 1 is an approximate estimate of the average combined exposure. It is expected that the 
95th percentile combined exposure will be in the region of the higher of Combinations 2 and 3, and 
below Combination 4, which is expected to approximate a 99th percentile or higher. Together 
combinations C1-C4 provide an indication of where the 95th percentile exposure is likely to be. To 
obtain firmer estimates of 95th percentile combined exposure would require probabilistic exposure 
modelling, as it will depend on the detailed shape and variance of the distributions for each route of 
exposure and any dependencies between them.  
The results of these evaluations for women aged 18-45 years are presented in Table 36, Figure 15 
(individual sources of exposure) and Figure 16 (combined exposure). These show four combinations 
of average and high internal exposure estimates (Combinations C1-C4, as explained above). Estimates 
of internal exposure to total BPA derived from biomonitoring data also shown, for comparison.  
The estimated internal exposures to total BPA from different sources range over several orders of 
magnitude, so are plotted on a log scale in Figure 15. It can be seen from the Figure 15 that: 
1. The forward modelling estimate of average dietary exposure lies between the average and 
high estimates from biomonitoring. The forward modelling estimate of high dietary exposure 
lies above the high estimate from biomonitoring, but their uncertainty ranges overlap and the 
estimate of each lies within the uncertainty range of the other. 
2. The contributions to internal exposure to total BPAfrom thermal paper and cosmetics are 
much more uncertain than those from diet. This is partly due to uncertainty of the external 
exposure estimates for the dermal sources and partly due to uncertainty about the dermal 
absorption fractions. 
3. The biomonitoring estimates represent combined exposure. The fact that the estimates for 
dietary exposure are close to this may suggest that the contributions from thermal paper and 
cosmetics are over-estimated. However, the average estimate for thermal paper and both the 
average and high estimates for cosmetics are an order of magnitude lower than the 
biomonitoring and dietary estimates, but taking into account the uncertainties of all the 
estimates, they do not contradict each other. This is reinforced by consideration of Figure 16.  
The alternative estimates of combined internal exposure to total BPA (i.e. C1-C4) are within a single 
order of magnitude, so are plotted on a natural scale in Figure 16. It can be seen from Figure 16 that: 
1. All of the forward modelling estimates of combined internal exposure to total BPA 
(Combinations C1-C4) lie within the uncertainty range of the biomonitoring data. Thus all the 
forward modelling estimates are consistent with the biomonitoring data, although some 
combinations show a greater overlap of their uncertainty intervals.  
2. Values in the upper part of the uncertainty range for Combination 4 are above the uncertainty 
range for the biomonitoring estimate and therefore less probable. However, this is not a 
surprise, because since Combination 4 combines high exposures (approximate 95
th
 
percentiles) for both oral and dermal sources, it is expected to exceed the true 95
th
 percentile 
for combined exposure.  
3. Combination 2 and 3 would be expected to be closer to the true 95th percentile exposure. They 
lie either side of the high estimate from biomonitoring, and their uncertainty ranges each 
largely overlap with the uncertainty range for the biomonitoring estimate, so both are 
compatible with the biomonitoring estimate.  
4. Although the high biomonitoring estimate is closer to the estimate for Combination 3, values 
up to the estimate for Combination 2 are still plausible because it derives mostly from the high 
dietary estimate, which has lower uncertainty than the other sources (see Figure 15). Overall, 
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therefore, it might be reasonable to conclude that the true 95
th
 percentile (in the EU country 
where this is the highest) is likely to lie in the range between the estimates for Combinations 2 
and 3, which also includes the high biomonitoring estimate. 
The analysis presented in this section relates to women aged 18-45. Comparisons between the 
estimates from forward modelling and biomonitoring for other age groups can be seen in section 
4.6.5.5 (Tables 33 and 34). Although similar uncertainty analyses have not been completed for other 
age groups, it can be expected that the uncertainty ranges around both the forward modelling and 
backward modelling (biomonitoring) estimates would be larger than those for women aged 18-45, as 
they are supported by less (and, in some cases, much less) biomonitoring data and dietary survey data.  
  Evaluation of uncertainties affecting assessment of internal exposure to total BPA for Table 36: 
females aged 18-45. 
 
Source of uncertainty




EXTERNAL EXPOSURE BY EACH ROUTE:
Average Oral exposure 
Average dietary exposure to BPA (μg/kg bw per day) 0.132 –/● 0.066  - 0.158
Average exposure from dust (μg/kg bw per day) 0.0006 – –/● 0.00012  - 0.001
High Oral exposure 
High dietary exposure to BPA (μg/kg bw per day) 0.388 –/● 0.194  - 0.4656
High exposure from dust (μg/kg bw per day) 0.001 – – –/+ 0.0001  - 0.002
Average Dermal exposure
Average exposure from dermal contact with thermal paper (μg/kg bw per day) 0.059 – – –/++ 0.006  - 0.295
Average exposure from cosmetics (μg/kg bw per day) 0.002 – –/++ 0.0004  - 0.010
High Dermal exposure
High exposure from dermal contact with thermal paper (μg/kg bw per day) 0.542 – –/++ 0.108  - 2.710
High exposure from cosmetics (μg/kg bw per day) 0.004 – –/++ 0.0008  - 0.020
High inhalation exposure
Assessment of high exposure from air (μg/kg bw per day) 0.0003 –/++ 0.00015  - 0.0015
Dermal absorption factors
Dermal absorption factor for thermal paper 0.1 – –/+ 0.02  - 0.200
Dermal absorption factor for cosmetics 0.5 – –/+ 0.1  - 1.000
Internal dermal exposures to total BPA after applying absorption factors
Average internal exposure from thermal paper (μg/kg bw per day) 0.006 0.000  - 0.059
Average internal exposure from cosmetics (μg/kg bw per day) 0.001 0.000  - 0.010
High internal exposure from thermal paper (μg/kg bw per day) 0.054 0.002  - 0.542
High internal exposure from cosmetics (μg/kg bw per day) 0.002 0.000  - 0.020
COMBINED INTERNAL EXPOSURES TO TOTAL BPA:
C1. Average Dietary + Average Non-Dietary (μg/kg bw per day) 0.140
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.066  - 0.230
C2. High Dietary + Average Non-Dietary (μg/kg bw per day) 0.396
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.194  - 0.54
C3. Average Dietary + High Non-Dietary (μg/kg bw per day) 0.190
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.068  - 0.72
C4. High Dietary + High Non-Dietary (μg/kg bw per day) 0.446
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.196  - 1.03
Estimate of average internal exposure derived from biomonitoring data 0.036 –/+ 0.018  - 0.072
Estimate of high internal exposure derived from biomonitoring data 0.234 –/+ 0.117  - 0.468
*Using full width of range implied by -/+ symbols
Approximate maximum 
plausible range*
INTERNAL EXPOSURE TO TOTAL BPA ESTIMATED FROM BIOMONITORING DATA
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Figure 15: Analysis of uncertainty affecting comparison of estimated internal exposure to total BPA 
based on biomonitoring data with forward-modelling estimates for the largest individual sources of 
internal exposure for women of child-bearing age (18-45 years). Note the exposures are plotted on a 
log10 scale, with labels in the natural scale. Dashed lines show approximate ranges for the uncertainty 
of the estimates.  
 
Figure 16. Comparison of forward  modelling estimates of combined internal exposure to total BPA 
for females aged 18-45 with estimates from biomonitoring, plotted on the natural scale. Dashed lines 
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FEMALES AGED 18-45Key: circles = forward modelling estimates; 
squares = backward modelling from biomonitoring data
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Key: circles = forward modelling estimates; 
squares = backward modelling from biomonitoring data
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show approximate uncertainty ranges for each estimate. C1-C4 denote the four alternative Combined 
estimates, see text and table 36. 
5. Conclusions 
The exposure assessment involved the estimation of consumer exposure in terms of the following 
three different metrics: 
 External exposure to BPA (in Part I – Exposure assessment)  
The assessment of external exposure considered the different routes (ingestion, inhalation, 
dermal uptake) and sources (e.g. diet, drinking water, air, thermal paper). It estimated the 
source-specific doses reaching the physical barriers in the gastrointestinal and respiratory 
tracts and of the skin. Route-specific external exposures to BPA were calculated via the so-
called forward modelling approach by multiplying source concentrations with the 
corresponding use frequencies (e.g., food intake, handling of thermal paper). 
 Internal exposure to total BPA (in Part I – Exposure assessment)  
The assessment of internal exposure to total BPA considered the route- and source (thermal 
paper/cosmetics)-specific absorption fractions to estimate the doses that passed the physical 
barriers to enter the body. For this purpose the estimates for average and high internal 
exposure to total BPA from all sources and over all routes were combined (Combinations C1-
C4). 
These internal doses are expressed as doses of total BPA (as no differentiation is made 
between the unconjugated and conjugated BPA). As BPA is completely eliminated via urine, 
the sum of these internal doses is directly comparable to exposure estimates obtained by the 
so-called backward modelling approach from urinary biomonitoring data. 
 Aggregated exposure to unconjugated BPA (in Part II – Toxicological assessment and risk 
characterisation) 
The assessment of aggregated exposure used PBPK modelling to translate the contributions 
from the relevant sources (diet and house dust for the oral route, thermal paper and cosmetics 
for the dermal route) into a toxicologically relevant dose metric, the area under the curve 
(AUC) for the serum concentration of unconjugated BPA. A translation into AUC is necessary 
because, in contrast to dermally absorbed BPA, BPA absorbed from the gastrointestinal tract 
is subjected to the first-pass metabolism before entering the systemic circulation. Based on the 
AUC information, external dermal exposures (thermal paper, cosmetics) were converted to 
equivalent oral exposures which could then be summed up with the external oral exposures 
(diet, house dust) to arrive at an aggregated exposure estimate. 
The assessment of exposure to BPA from all sources showed that diet is the main source in all 
population groups for external exposure only  Specifically, canned food and non-canned meat and 
meat products are the two main dietary contributors to external BPA exposure in the large majority of 
countries and age classes. The pattern was different for aggregate exposure (see Section 5 in Part II-
toxicological assessment and risk characterisation). 
While canned food as a main source of external dietary exposure to BPA is confirmed by the data 
presented in this opinion, exposure from non-canned meat and meat products and fish had not been 
anticipated until the 2013 report of ANSES on concentrations of BPA in French food. Investigation of 
these findings is currently under way, but, until further results are available, there is no substantiated 
explanation for the presence of unconjugated BPA in foods of animal origin.  
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Among the population older than six months, infants (6-12 months) and toddlers had the highest 
estimated external average (0.375 µg/kg bw per day) and high (0.857 µg/kg bw per day) dietary 
exposure. This was mainly due to their higher consumption of foods and beverages per kilogram body 
weight. The modelled dietary exposure for adolescents, adults (including women of childbearing age) 
and elderly/very elderly ranged from 0.116 to 0.159 µg/kg bw per day for the average external 
exposure and from 0.335 to 0.388 µg/kg bw per day for the high exposure, respectively. Dietary 
exposure to BPA estimated by EFSA in 2006 in the population older than six months was far higher 
(up to 5.3 µg/kg bw per day in toddlers) compared with the current assessment (up to 0.857 µg/kg bw 
per day for the high exposure of toddlers), owing to the lack of data at that time which led to the use of 
very conservative assumptions in relation to both the level of consumption of canned food and the 
estimated BPA concentration in these foods. 
The availability of more data now, as compared to 2006, has allowed the CEF Panel to carry out a 
more refined dietary exposure assessment for infants. According to the current estimate, BPA 
exposure for infants up to six months (0.03 to 0.225 µg/kg bw per day for average external exposure) 
is much lower than that estimated by EFSA in 2006 for infants within six months of age (≤ 
11 µg/kg bw per day)bw per daybw per day. This was due to the use at that time of very conservative 
assumptions in relation to BPA concentration in infant formula and to BPA migration from PC bottles 
to account for the lack of data. 
Dietary external exposure in women of childbearing age (0.132 and 0.388 µg/kg bw per day for 
average and high exposure, respectively) was similar to that in men of the same age (0.126 and 
0.335 µg/kg bw per day for average and high external exposure, respectively). The minimal 
differences may be related to women consuming different food items, as reported in the individual 
surveys. 
The uncertainty around the estimates of dietary exposure was judged as relatively low compared to 
other sources of exposure such as thermal paper. 
Thermal paper was the second largest source of external exposure in all population groups above three 
years of age. The modelled estimates for 3–10 years old children, adolescents, adults (including 
women of childbearing age) and elderly/very elderly ranged from 0.059 to 0.094 µg/kg bw per day for 
the average exposure and from 0.542 to 0.863 µg/kg bw per day for the high external exposure, 
respectively. The CEF Panel considers that more data would be needed for BPA absorption through 
the skin, on skin metabolism and for patterns of thermal paper handling by the general population in 
order to provide a refined estimate of exposure through this source to reduce the uncertainty in the 
estimate. 
In children under the age of three years (except for infants in the first few days of life) dust was the 
second largest source of external exposure to BPA and ranged from 0.009 to 0.015 µg/kg bw per day 
for average and high external exposure, respectively. 
Average external exposure to BPA from other sources such as toys and cosmetics was estimated to be 
less than 0.001 µg/kg bw per day and 0.005 µg/kg bw per day, respectively, in all population groups. 
For the four age classes covering infants from 1 day up to 6 months, the average internal exposure to 
total BPA, as estimated by forward modelling, ranged from 0.042 µg/kg bw per day to 0.226 µg/kg bw 
per day. The average internal exposure for the population older than six months ranged from 0.301 to 
0.387 µg/kg bw per day in children aged 3 to 10 years and infants aged 6 to12 months and from 0.124 
to 0.172 µg/kg bw per day in the elderly/very elderly and adolescents. 
For the four age classes covering infants from 1 day up to 6 months the high internal exposure to total 
BPA ranged from 0.101 µg/kg bw per day to 0.621 µg/kg bw per day. The high internal exposure for 
populations older than six months ranged from 0.873 to 0.878 µg/kg bw per day in toddlers and infants 
aged 6 to 12 months, and from 0.393 to 0.473 µg/kg bw per day in men and adolescents. 
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Internal exposures to total BPA, as estimated by forward modelling, are in good agreement with the 
backward-modelling estimates obtained from urinary biomonitoring, suggesting that it is likely that no 
major exposure sources have been missed for the forward-modelled exposure assessment. It is, 
however, important to highlight the fact that the internal exposure estimation of total BPA includes 
conservative assumptions resulting in likely overestimation of exposure that could in theory have 
hidden other possible sources of exposure. The CEF Panel noted also that there are considerable 
uncertainties in the forward and backward estimates of internal exposure. 
The CEF Panel has carried out an assessment of aggregated dietary  and non-dietary exposure  
tounconjugated BPA using PBPK modelling. This aggregated exposure assessment included diet and 
house dust (the main oral-route sources) as well as thermal paper and cosmetics (the main dermal-
route sources).  
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ABBREVIATIONS 
ABS  acrylonitrile-butadiene-styrene 
AM arithmetic mean 
ANSES Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et 
du travail (French Agency for Food, Environmental and Occupational Health 
and Safety) 
BADGE bisphenol A-diglycidyl ether 
BPA bisphenol A 
bw body weight 
CDC (US) Centers for Disease Control and Prevention 
CEF Panel EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids 
CHMS Canadian Health Measures Survey 
CI confidence interval 
DMA dimethacrylate 
ECD electrochemical detection 
EEA  European Economic Area  
ELISA enzyme-linked immunosorbent assay 
EMA ethoxylate dimethacrylate 
EU European Union 
FDA (US) Food and Drug Administration 
FLD fluorescence detection 
GC gas chromatography 
GM geometric mean 
GMA glycidyl methacrylate 
GSD geometric standard deviation 
HBM human biomonitoring 
HDPE  high-density polyethylene 
HPLC high-performance liquid chromatography 
ICRP International Commission on Radiological Protection 
LB lower bound 
LC liquid chromatography 
LDPE  low-density polyethylene 
LLE liquid–liquid extraction 
LOD limit of detection 
LOQ limit of quantification 
MB middle bound 
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MS mass spectrometry 
NHANES (US) National Health and Nutrition Examination Survey 
PA polyamide 
PC polycarbonate 
PEI  polyetherimide 
PES  polyethersulphone 
PET polyethylene terephthalate 
PM10 particulate matter with diameter less then 10 µm 




SCENIHR Scientific Committee on Emerging and Newly Identified Health Risks 
SML specific migration limit 
TBBPA  tetrabromobisphenol A 
TDI tolerable daily intake 
UB upper bound 
UV ultraviolet 
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Appendices 
Appendix A. Sampling and methods of analysis 
This appendix describes the criteria considered for the inclusion of data in the assessment of the 
exposure to BPA, as well as for assessment of the quality of the biomonitoring studies. 
When considering the inclusion of data in the assessment of the exposure to BPA it is essential that the 
methodology used to derive the data is of an appropriate quality. This appendix describes the quality 
criteria applied to ensure, as far as possible, the quality of the data considered in this opinion. 
The criteria for inclusion/exclusion of data (and methodology) for consideration for the opinion for 
BPA are given below and are based on the performance characteristics of the method. Performance 
characteristic means functional quality that can be attributed to an analytical method. This may be, for 
instance, specificity, accuracy, trueness, precision, repeatability, reproducibility, recovery, detection 
capability and ruggedness. The European Commission`s Joint Research Centre (JRC) guidelines on 
performance criteria and validation procedures of analytical methods used in controls of food contact 
materials were used as the basis for defining the criteria for all methods considered in this opinion 
(JRC, 2009). 
In terms of method performance the main criteria to consider are: 
 the recovery of the method; 
 the repeatability of the method; 
 the LOD and/or LOQ. 
Recovery 
Recovery means the percentage of the true concentration of a substance recovered during the 
analytical procedure. For inclusion the recovery should be in a range, as described in Table 37. 
 Ranges of recovery Table 37: 
Concentration Mean recovery ( %) 
≤ 10 parts per billion (ppb, µg/kg) 40–120 
100–10 ppb 60–110 
≥ 100 ppb 80–110 
For the purpose of the exposure assessment in this report, data were not corrected for the recovery. 
Correction for recovery is aimed at reducing the uncertainty in concentration data, but as the technique 
used to estimate it varies among laboratories, such a correction may in the end introduce even more 
uncertainty in the concentration data. Data derived from analytical determinations with recoveries 
outside the above-mentioned criteria were excluded. 
Repeatability 
Repeatability is defined by IUPAC as precision under repeatability conditions (i.e. the same operator, 
instrument and laboratory and within a short time interval). Repeatability (r) is often expressed as a 
relative standard deviation RSDr ( %) derived from replicate analyses of either a certified reference 
material or a fortified material. For inclusion of data the criterion applied was that the repeatability 
(RSDr) should not exceed the level calculated by the Horwitz equation. The Horwitz equation actually 
describes the reproducibility (R) between different labs as a function of concentration and expressed as 
relative standard deviation RSDR (%). Setting the reproducibility measure (RSDR) as the limit for the 
repeatability (RSDr) is explained by the fact that the RSDr is generally one-half to two-thirds of the 
RSDR. For very low concentrations, the reproducibility is somewhat better than expected from the 
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Horwitz equation and approaches a constant value of 33 % (Horwitz, 2003). Similarly, Thompson 
(2000, 2004) concluded that an invariant value for concentrations below 10 ppb was 20–25 %. In 
Table 38, a limit value of 25 % was chosen for concentrations of 1 and 10 ppb. 
 The RSD calculated using the Horwitz equation for a concentration range from 1 ppb to Table 38: 
1 ppm 
Concentration Relative standard deviation (RSDr, %) 
1 ppb 25 
(a) 
10 ppb 25 
(a)
 
100 ppb 22.6 
1 ppm 16.0 
(a): The RSD calculated using the Horwitz equation is > 25 %. However it has been shown (Thompson, 2000, 2004; 
Horwitz, 2003) that at concentrations of less than 10 ppb there is a tendency for an invariant RSD of 20–25 % and so 
25 % was selected as the criterion for acceptable repeatability. 
Limit of detection/limit of quantification 
Analytical LODs are usually expressed as multiples of the signal-to-noise ratio (S:N) of the 
(chromatographic) background signal with the LOD being 3 × S:N and LOQ being 10 × S:N. In some 
biomonitoring studies reporting the unavoidable presence of background BPA contamination (e.g. 
Völkel et al., 2011), somewhat higher multiples of the S:N are used to report only values above the 
background contamination. 
Food samples below the LOQ or limit of reporting (left-censoring limit) were handled through the 
substitution method: the lower bound (LB) value was obtained by assigning a value of zero to all the 
samples reported as less than the left-censoring limit, the midlle bound (MB) value by assigning half 
of the left-censoring limit and the upper bound (UB) by assigning the left-censored limit as the sample 
result (see Section 4.3.2, “Occurrence data in food”). The average BPA concentration in each food 
category was therefore assessed as LB, MB and UB. Therefore, in a study in which all samples give a 
quantifiable BPA concentration, the LOD/LOQ are of no relevance in the assessment of average LB, 
MB or UB BPA concentrations. In a study in which BPA concentrations are reported in some samples 
as < LOD or < LOQ, the MB and UB average BPA concentration of the specific food category will be 
influenced by the left-censoring limits, and this will influence the assessment of exposure to BPA. 
Criteria were therefore set to avoid the possibility that samples with a very high left-censoring limit 
would artificially increase the assessment of average MB and UB BPA concentration in some food 
categories. For occurrence data in food, methods reporting LOD values greater than 15 µg/kg or LOQ 
values greater than 50 µg/kg were excluded from the assessment of average BPA concentration, and 
therefore from the exposure assessment. For biomonitoring data methods reporting LOD values 
greater than 0.4 µg/kg or LOQ values greater than 1.3 µg/kg were excluded from the exposure 
assessment. 
Supplementary criteria to be considered when assessing method performance were: 
 the selectivity of the method, i.e. whether or not interferences had been considered 
(e.g. Ackerman et al., 2010); 
 whether or not measures had been taken to reduce or avoid background contamination; 
 Whether or not the method-performance data described have been derived for an appropriate 
matrix and at a concentration relevant to the levels measured in the samples. 
Specifically for biomonitoring studies, it is necessary to detect and quantify BPA in different 
biological matrices (urine, serum, human milk) in the unconjugated and the conjugated form. 
Complicating problems for all of these matrices are: (i) the artefactual contamination with trace levels 
of unconjugated BPA from environmental sources; and (ii) the instability of BPA conjugates owing to 
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spontaneous or enzymatic hydrolysis during collection, storage and analysis (Vandenberg et al., 2010; 
Hengstler et al., 2011; WHO, 2011a). Therefore, the documentation of measures to preserve sample 
integrity and to reduce external contamination was taken into account when deciding whether a study 
is considered valid and relevant to be included in this opinion. 
Many different approaches have been reported for the determination of BPA and conjugated BPA. 
These are reviewed below.  
Samples 
No quality criteria were established for sampling methods. The country of origin of the samples was 
considered and, in most cases, non-EU data were excluded (see Section 4.2). Where information was 
provided samples taken for determination of BPA concentration or of migration of BPA were 
considered to be representative of those available on the market. However, in many cases this 
information was not given. 
1. Methods of analysis 
The approach used to extract BPA from any sample (including all of the potential sources of exposure 
given in Section 3) is dependent on the matrix being tested. Methodology typically involves extraction 
of the analyte from the matrix and may be followed by clean-up of the extracts to eliminate any 
interferences, concentration to achieve the desired method sensitivity and/or derivatisation to provide 
BPA in a form suitable for analysis. Analytical approaches described in the literature include: LC with 
UV, FLD, ECD, MS or MS/MS detection, GC with MS detection and immunoaffinity methods (e.g. 
ELISA). An overview of the methodology for the determination of BPA in and migrating from food 
contact materials, in foods, in biological samples, in non-food potential sources of exposure (including 
outdoor air, surface water, dust, indoor air, paper products, children toys and pacifiers with PC shield 
and medical devices) is presented below. Ballesteros-Gómez et al. (2009) reviewed methods 
describing the determination of BPA in foods and a WHO/FAO background paper on “Chemistry and 
analytical methods for determination of BPA in food and biological samples” was prepared by Cao 
(WHO, 2011b). 
1.1. Extraction and migration of BPA from food contact materials 
Material types that may contain BPA and that are used in food contact applications include PC 
plastics, epoxy coatings applied to metal substrates and recycled paper and board. To extract all of the 
residual BPA from a material or article requires some degree of interaction between the material and 
the extraction solvent. This interaction, referred to for plastics as swelling of the polymer, allows for 
extraction from the entire material rather than just from the surface. For polar materials such as paper 
and board and PC plastics the greatest interaction occurs with polar solvents. For less polar materials 
such as epoxy resins the greatest interaction occurs with less polar solvents. The solubility of the BPA 
in the extraction solvent must also be considered. BPA is soluble in acetic acid and is very soluble in 
ethanol, benzene and diethyl ether (Lide, 2004). Only a limited number of methods has been reported 
for the determination of BPA in food contact materials and articles, as in most cases a migration test 
into a food simulant or solvent rather than an exhaustive extraction has been carried out. 
1.1.1 Extraction tests 
Mercea (2009) and Ehlert et al. (2008) described the determination of residual BPA in PC by 
dissolution of the polymer in dichloromethane followed by subsequent precipitation with methanol. 
Dissolution of PC in methylene chloride and precipitation with acetone has also been described to 
determine residual BPA concentration in the polymer (Nam et al., 2010). In such studies all of the 
BPA will remain in solution and so is amenable to direct analysis by techniques such as LC-FLD. 
When determining the concentration of residual BPA in a PC plastic, care should be taken to avoid 
hydrolysis of the polymer, as this could lead to an overestimation of the BPA levels present that could 
migrate into a foodstuff under normal conditions of use. Alkaline conditions have been reported to 
hydrolyse the PC polymer, and the hardness of the water has also been postulated to play a role in the 
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degradation (Biedermann-Brem et al., 2008; Biedermann-Brem and Grob, 2009). For epoxy-coated 
metal substrates for which the coating is usually < 10 µm it is generally accepted that acetonitrile 
affords exhaustive extraction. Given the solubility of BPA in ethanol and the polarity of paper and 
board substrates, then extraction in this solvent is conventionally used for the exhaustive extraction of 
this matrix. It is rare that sensitivity is an issue when analysing extracts of PC- or epoxy-coated food 
contact materials and articles, and therefore the extracts generated are usually analysed directly. 
1.1.2 Migration 
Regulation (EU) No 10/2011 (EU, 2011) defines food simulants and migration test conditions for food 
contact plastics and is applicable to PC plastics. These food simulants intended to mimic the migration 
of a given substance that could, under the worst foreseeable conditions of use, migrate into a foodstuff. 
For consumer protection purposes it is the intention that migration into food simulants should exceed 
that which will occur into a food. A CEN Technical Specification was published in 2005 describing 
methodology for the determination of BPA in conventional EU food simulants (CEN, 2005). In this 
procedure aqueous food simulants are analysed directly by LC-UV and oil samples dissolved in 
hexane and extracted into methanol/water. The methanol/water extracts are then analysed directly by 
LC-UV. The aforementioned regulation also permits the substitution of food simulants with more 
severe extraction solvents, provided that the substitution is based on scientific evidence that the 
substitute food simulants (extraction solvent) used overestimate the migration compared with the 
regulated food simulants. The majority of the methods available for food contact materials and articles 
describe the determination of BPA in these regulated or substituted food simulants (solvents). The 
exposed simulants/solvents may be analysed directly by LC-FLD or LC-MS/MS (e.g. Santillana et al., 
2011), analysed using solid-phase micro-extraction and GC-MS (e.g. Cao and Corriveau, 2008b), 
concentrated using solid phase extraction (SPE) and analysed by GC-MS (e.g. Guart et al, 2011; 
Fasano et al., 2012), concentrated using SPE, derivatised and analysed by GC-MS (e.g. Ehlert et al., 
2008; Kubwabo et al., 2009). Direct analysis of water as a food simulant using an ELISA method has 
also been reported (Cooper et al., 2011), however concerns regarding sensitivity, selectivity and cross-
reactivity have been raised for this method of analysis (s. point 2.3). 
1.2. Extraction of BPA from food 
For foodstuffs solvent extraction is the most common technique used for the isolation of BPA from the 
food matrix. The solvent used and the extraction conditions are dependent on the specific food type. 
Acetonitrile is the most commonly used extraction solvent for solid foodstuffs. In addition to the 
extraction of BPA, acetonitrile will also precipitate any proteins that are present, thereby effectively 
performing a clean-up step alongside the extraction. In addition to the removal of proteins from the 
matrix, the separation of the BPA from the fat also facilitates improved analytical performance, and 
this has been reported to be achieved using alkanes (hexane, heptanes and isooctane) along with the 
acetonitrile. For liquid foodstuffs and beverages BPA extraction using ethyl acetate, chloroform or 
dichloromethane has been reported (Ballesteros-Gómez et al., 2009); however, SPE techniques are 
more extensively used to isolate the BPA from these matrices (e.g. Maragou et al., 2006; Ackerman et 
al., 2010; Gallart-Ayala et al., 2011; Bono-Blay et al., 2012). Other extraction techniques reported in 
the literature have been summarised by Ballesteros-Gómez et al. (2009) and include pressurised liquid 
extraction (Ferrer et al., 2011), coacervative microextraction (García-Prieto et al., 2008; Pérez Bendito 
et al., 2009), microwave assisted extraction (Pedersen and Lindholst, 1999; Basheer et al., 2004), 
solid-phase micro-extraction (Cao and Corriveau, 2008b), stir bar sorptive extraction (Magi et al., 
2010), molecularly imprinted polymers (Baggiani et al., 2007, 2010) and matrix solid phase dispersion 
extraction (Shao et al., 2007a). 
Although some methods report the direct analysis of the solvent extracts using LC and GC separation 
techniques, in most cases additional sample clean-up and concentration steps are required to achieve 
the desired selectivity and sensitivity. SPE clean-up is the most commonly reported technique 
(Grumetto et al., 2008; Yonekubo et al., 2008; Cao et al., 2009a); however, some methods describing 
the use of immunoaffinity columns for sample clean-up have also been reported (Brenn-Struckhofova 
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and Cichna-Markl, 2006; Podlipna and Cichna-Markl, 2007), along with others describing gel 
permeation chromatographic methods (Poustka et al., 2007; Gyllenhammar et al., 2012). 
As mentioned in Section 4.3.2 of this opinion, animals that have been exposed to BPA via diet or 
water have the potential to contain conjugated BPA, and furthermore relatively high concentrations of 
unconjugated BPA were observed (average of 9.4 and 7.4 µg/kg in meat and fish, respectively (Table 
4, column “All—average BPA”), and so food products of animal origin may further contribute to BPA 
exposure. The methods used to derive the BPA data for animal products and used in the exposure 
assessment in this opinion were scrutinised to assess whether or not the reported concentration was 
that of unconjugated BPA or total BPA (conjugated + unconjugated). None of these methods, 
published in the scientific literature or obtained through the EFSA call for data, described 
deconjugation steps in the approach. For several methods BPA concentrations were determined after 
derivatisation (Cao et al., 2008; Geens et al., 2010; Cunha et al., 2011; Feshin et al., 2012). In these 
examples it is possible that deconjugation would occur during the derivatisation step, especially if a 
strong acid or base were used. However, no scientific data are available to support this, and therefore it 
was assumed that the reported BPA concentrations for all data are for unconjugated BPA only. Given 
the rapid elimination and the short half-live of BPA, it seems unlikely that significant concentrations 
of the conjugates will accumulate in animals intended for food following exposure during their 
lifetime. ANSES (ANSES, 2013) reported that the levels of unconjugated BPA and total BPA 
(conjugated + unconjugated) were similar in the meat products that they tested. 
1.3. Extraction of BPA from biological samples 
A number of sensitive methods have been developed to quantify low concentrations of BPA in blood 
and urine samples from unintentionally exposed human subjects (Dekant and Völkel, 2008; WHO 
2011b; Asimakopoulos et al., 2012). In biological samples BPA can exist in both the conjugated and 
the unconjugated form. BPA glucuronide is the most commonly found BPA conjugate along with 
lower levels of BPA sulphate. Consequently, methods to determine total BPA in biological samples 
include an enzymatic deconjugation step using β-glucuronidase and sulphatase. Even if a study is 
focused only on unconjugated BPA, the information on total or conjugated BPA is needed for quality 
control purposes. Additional quality criteria include the information on extraction recovery and the use 
of surrogate standards to monitor the extent of the deconjugation reaction. In addition to the 
deconjugation step, sample work-up procedures comprise the clean-up, which is generally based on 
SPE and/or LLE. The most common solvent used for the extraction of BPA from biological samples is 
acetonitrile. As discussed above for foodstuffs, one advantage of using acetonitrile as the extraction 
solvent is the simultaneous precipitation of endogenous proteins in the matrix (Völkel et al., 2011). 
Recent trends for biomonitoring of BPA have been described by Asimakopoulos et al. (2012) and 
include an overview of the methodology applied to these matrices. The authors summarise that “ethyl 
acetate (Schöringhumer and Cichna-Markl, 2007), chloroform (Kuroda et al., 2003), diethyl ether 
(Ouchi and Watanabe, 2002), isopropanol (Atkinson et al., 2002) and ammonium hydroxide (Kaddar 
et al., 2009) were also reported for analyte(s) extraction or/and protein precipitation purposes. n-
Hexane, ethanol and petroleum ether were particularly used for lipid removal from matrix (Sajiki, 
2003; Lin et al., 2009).” As for liquid foodstuffs SPE extraction can be applied to liquid matrices 
(usually following dilution with water and deconjugation with enzymes) or it can be applied as a 
clean-up and concentration step to achieve the sensitivity required for these matrices. Examples of the 
use of SPE in sample extraction, clean-up and concentration include BPA determination in urine 
(Moors et al., 2007; Calafat et al., 2008; Teeguarden et al., 2011), human colostrom (Kuruto-Niwa et 
al., 2007) and human milk (Cariot et al., 2012). Additional information is given in Section 4.6 of the 
opinion. 
1.4. Extraction of BPA from non-food sources 
1.4.1 Environmental samples—outdoor air 
To determine the concentration of BPA in air samples, the sample is first collected onto a filter and the 
filter is extracted using solvent. Sample clean-up methods, concentration and derivatisation steps are 
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then all similar to other matrices. Fu and Kawamura (2010) used an aerosol sampling technique to 
obtain the samples. The resulting filters were ultrasonicated in dichloromethane/methanol (2:1, v/v), 
evaporated to dryness and derivatised with BSTFA with 1 % trimethylsilyl chloride in pyridine. 
Following dilution with hexane the derivatives were analysed by GC-MS. Sangiorgi et al. (2013) 
compared indoor and outdoor BPA in particulate matter. The filter samples were extracted with 
methanol and analysed directly by LC-MS/MS. Wilson et al. (2007) described methodology for the 
sampling of outdoor air using a 10 mm inlet, to collect targeted chemicals in a glass cartridge 
containing a quartz fibre filter followed by XAD-2 resin. Soxhlet extraction of the filter was done with 
dichloromethane, sample concentration by SPE using fluorisil and analysis by GC-MS. 
1.4.2 Environmental samples—surface water 
Many of the extraction techniques described for the determination of BPA in surface water are 
consistent with those reported and described above for food and beverages and for food simulants. 
Other examples include the extraction of BPA with coacervates made up of decanoic acid reverse 
micelles with analysis using LC-FLD (Ballesteros-Gómez et al., 2007), SPE methodology using 
magnetic multiwalled carbon nanotubes followed by GC-MS/MS to determine BPA in river water, as 
well as in snow and drinking water (Jiao et al., 2012) and detection via inhibition of luminol 
chemiluminescence (CL) by BPA on the silver nanoparticles (AgNPs)-enhanced luminol-KMnO4 CL 
system (Chen et al., 2011). Krapivin et al. (2007) reviewed a range of ELISA methods for the 
determination of BPA in surface water samples. 
1.4.3 Indoor air 
Methods described for the determination of BPA in indoor air are consistent with those for outdoor air. 
1.4.4 Dust 
Wilson et al. (2007) described the collection of house dust using a high-volume surface sampler 
(HVS3) (ASTM, 1997). Dust samples were sonicated with 10 % diethyl ether/hexane to extract the 
BPA from the matrix. Sample concentration and analysis was consistent with the air samples. Geens et 
al. (2009a) reported similar methodology for dust samples, with the BPA being extracted into 
hexane:acetone (3:1), clean-up by SPE using fluorisil but with analysis by LC-MS/MS. Völkel et al. 
(2008) measured BPA in dust collected by residents in homes using regular vacuum cleaners. 
Sonication of the dust in methanol released the BPA and, following the addition of water, the extracts 
were analysed using SPE-LC‐MS/MS. Loganathan and Kannan (2011) determined BPA in house dust. 
The BPA was extracted into ethyl acetate, solvent swapped into methanol and analysed by LC-
MS/MS. 
1.4.5 Paper products (including thermal papers) 
As mentioned above, paper is a polar matrix and so to ensure exhaustive extraction polar solvents are 
generally used to extract the BPA. Biedermann et al. (2010) extracted BPA from thermal paper 
samples by immersion in methanol overnight at 60 °C, extracts were then diluted prior to analysis by 
LC-FLD. Liao and Kannan (2011a, b) and Geens et al. (2012b) also used methanol to extract BPA 
from paper samples. Mendum et al. (2011) used ethanol as the extraction solvent for thermal receipts. 
Another study reported the use of pyrolysis GC-MS to determine BPA in paper samples (Becerra and 
Odermatt, 2012) although the authors state that “The reliability of quantification with an internal 
standard should be further investigated.” 
1.4.6 Children’s toys and teats 
Methods of analysis reported for the determination of BPA in plastic toys are consistent with those for 
the extraction of BPA from plastic food contact materials, e.g. dissolution in a solvent with subsequent 
polymer precipitation, solvent extraction using microwave digestion and solvent extraction. Atkins 
(2012) described the dissolution of PVC toys in tetrahydrofuran with polymer precipitation using 
hexane and compared the extraction efficiency with that of a simpler microwave digestion method. 
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Another method for determination of BPA released from toys described the use of water and 0.07 M 
hydrochloric acid. The contact conditions were 24 hours at 40 °C for water according to EN 14372 and 
24 hours at 37 °C for the acidic medium. In this study the extraction methods used were intended to 
mimic the exposure of children to BPA from this source (Troiano and Goodman, 2010). In this the 
transfer of BPA to water or to a saliva simulant to determine exposure from these articles was 
considered, as well as the concentration of BPA in the plastic portion of the toys itself. Methods of 
analysis for the determination of BPA in saliva simulant include ultrasound-assisted emulsification 
liquid–liquid microextraction (Viñas et al., 2012). The methodology for the determination of BPA in 
plastic toys and in physiological saline solution was described by KEMI (2012). Ground plastics were 
soxhlet extracted with either methanol or dichloromethane and analysed directly by GC-MS. The toys 
were also exposed to physiological saline solution (37 °C, 10 minutes, 30 minutes and 2 hours with 
stirring) and the extract analysed by GC-MS. Other samples were exposed to artificial saliva (24 °C, 
24 hours). 
1.4.7 Medical devices (dental sealants) 
The extraction media used for the determination of BPA in resin-based dental materials are included in 
the review of the exposure from these sources (Van Landuyt et al., 2011). The extraction solvents 
included water, acetonitrile, ethanol, ethanol/water, artificial saliva or saliva simulant, phosphate 
buffer or citrate/phosphate buffer. 
2. Instrumental analysis 
The analytical methods reported to be used for the determination of BPA in all matrices described 
above include: LC-UV, LC-FLD, LC-ECD, LC-MS and LC-MS/MS, GC-MS and GC-MS/MS and 
ELISA. 
2.1. GC methods 
Although some methods describe the direct analysis of solvent extracts containing BPA by GC-MS or 
GC-MS/MS, many involve derivatisation to achieve repeatable data. Cao (WHO, 2011b) concluded 
that “derivatisation is always recommended for quantitative analysis by GC-MS”. Improved accuracy 
and sensitivity can be achieved by the derivatisation of the free hydroxyl functional groups on BPA 
(WHO, 2011b). Silylation using BSTFA (Fu and Kawamura, 2010; Viñas et al., 2010) or MTBSTFA 
(Becker et al., 2009) and acetylation using acetic anhydride (Cao and Carriveau, 2008b, Cao et al., 
2009a, b; Viñas et al., 2010; Cunha et al., 2011) are the most common derivatisation techniques used 
for BPA. The use of isopropyl chloroformate to form diether derivatives (Feshin et al., 2012), 
pentafluorobenzylbromide (Kuklenyik et al., 2003), pentafluorobenzoylchloride (Geens et al., 2009b, 
2012b), pentafluoropropionic anhydride (Dirtu et al., 2008) and trifluoroactic anhydride (Varelis and 
Balafas, 2000) has also been described. 
2.2. LC methods 
The majority of the LC methods reported using reverse phase chromatography for the determination of 
BPA. More recently the use of UPLC methods has also been described (Lacroix et al., 2011; Xiao et 
al., 2011; Cariot et al., 2012; Pérez-Palacios et al., 2012) for the determination of BPA in biological 
samples. Although BPA is a weak chromophore and so can be detected by UV, the sensitivity of the 
analysis is low when compared with other detectors. The CEN technical specification for the 
determination of BPA (CEN, 2005) uses UV detection at 280 nm to determine BPA concentrations in 
food simulants; however, none of the more recently developed methods use this detector. LC-FLD 
methodology with excitation wavelengths in the range 224 to 235 nm or 275 nm and emission 
wavelengths in the range 300 to 320 nm have been described and reviewed by Cao (WHO, 2011b). 
Although BPA is a relatively strong fluorophore (owing to the conjugation) the addition of a stronger 
fluorophore to BPA using 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (Watanabe et al., 2001; 
Sun et al., 2002; Kuroda et al., 2003) or p-nitrobenzoyl chloride (Mao et al., 2004) prior to analysis by 
LC-FLD has also been proposed to improve the method sensitivity. The lack of selectivity of these 
methods compared with MS methods means that the data derived may overestimate the concentration 
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of BPA present in the samples. Although ECD affords better selectivity than UV and FLD methods (it 
is electrically specific for phenolic compounds) there are only limited applications described in the 
literature. Sajiki et al. (2007) used LC-ECD and LC-MS for the detection of BPA in canned foods and 
concluded that although LC-ECD is specific for phenols and MS for the mass of BPA the best 
selectivity is afforded by the tandem MS/MS techniques and so this is preferred for quantifying BPA. 





C) BPA as an internal standard is considered as the most specific, selective, 
accurate and precise detection method for measuring trace levels of BPA (WHO, 2011b). 
2.3. ELISA methods (Fukata et al, 2006) 
Commercial ELISA kits for the determination of BPA are available and have been used to determine 
BPA in biological samples. ELISA cannot differentiate between conjugated and unconjugated BPA 
and therefore is not selective for the unconjugated form and so concentrations measured using this 
technique are for total BPA. It has also been reported that cross-reactivity occurs with other 
structurally similar substances. In this evaluation, data generated for biological samples derived using 
ELISA methodology were included only where there was a data gap, and in all cases the data derived 
using this technique were considered with caution. 
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Appendix B. EFSA call for data 
This appendix contains details on the quality of data received through the EFSA call for data, for the 
following categories: food and beverages intended for human consumption; migration data from food 
contact materials; and occurrence data in food contact materials. 
In total 3 609 results were submitted to EFSA, 2 076 results for BPA occurrence in food, 988 results 
for BPA migration from food contact materials and 545 results for BPA occurrence in food contact 
materials. 
These data were obtained on samples collected in the EEA countries (European Union, plus Iceland, 
Liechtenstein, Norway and Switzerland). The vast majority of the samples were collected from 2006 
(some food samples from 2004) to 2012. 
Data were sent by governmental institutions (3 115 results), academia (417 results), food 
manufacturers and two associations (Fédération romande des consommateurs (FRC) and 
PlasticsEurope) (77 results). 
1. Food and beverages intended for human consumption 
Regarding the 1 592 results submitted on unconjugated BPA determination the method was accredited 
by ISO/IEC 17 025 procedure for 71 % of the results and internally validated for 29 %. Regarding the 
484 results submitted on determination of bisphenol total, the method was accredited by ISO/IEC 
17 025 procedure for 12 % of the results, the procedure was internally validated for 42 % and not 
validated for 12 %, no information was provided for 33 % of the results (12 % of results submitted 
from accredited laboratories and 21 % of results submitted from non-accredited laboratories). 
Information about the method of analysis was provided for 100 % of the results. The following 
methods were reported for the determination of bisphenol unconjugated in 1 592 samples analysed: 
GC-MS-MS (71 % of the samples); and LC-MS/MS (29 % of the samples). The following methods 
were reported for the determination of bisphenol total in 484 samples analysed: LC-MS/MS (48.1 % 
of the samples); GC-MS (18.4 % of the samples); HPLC-FD (12.8 % of the samples); HPLC-UV 
(8.5 % of the samples); GC-MS-MS (6.4 % of the samples); and HPLC with standard detection 
methods (5.8 % of the samples). 
For the determination of bisphenol unconjugated, LODs were reported as below the limit of 15 µg/kg 
for 693 results (ranging from 0.008 to 13.9 µg/kg) and greater than 15 µg/kg for one result 
(29.8 µg/kg). LOQs were reported as below the limit of 50 µg/kg for 717 results (ranging from 0.024 
to 41.7 µg/kg) and greater than 50 µg/kg for one result (89.4 µg/kg). 
For the determination of bisphenol total, LODs were reported as below the limit of 15 µg/kg for 344 
results (ranging from 0.0003 to 3.667 µg/kg) and greater than 15 µg/kg for 34 results (ranging from 
16.67 to 105 µg/kg). LOQs were reported as below the limit of 50 µg/kg for 396 results (ranging from 
0.001 to 50 µg/kg) and greater than 50 µg/kg for 33 results (210 µg/kg). 
The food samples across food groups classified according to the FoodEx classification system level 1 
were: drinking water (23 %); vegetables and vegetable products (15 %); meat and meat products 
(10 %); composite food (8 %); milk and dairy products (7 %); grains and grain-based products (7 %); 
fish and other seafood (7 %); fruit and fruit products (5 %); alcoholic beverages (4 %); non-alcoholic 
beverages (4 %); legumes, nuts and oilseeds (3 %); starchy roots and tubers (2 %); snacks, desserts, 
and other foods (2 %); animal and vegetable fats and oils (1 %); herbs, spices and condiments (1 %); 
sugar and confectionery (1 %); eggs and egg products (1 %); and fruit and vegetable juices (1 %). 
The vast majority of the samples at the second level of the FoodEx classification were: tap water 
(13 %); bottled water (9 %); fruiting vegetables (4 %); fish meat (4 %); and livestock meat (4 %). 
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Some of the analysed foods were canned, in tinplate varnished or partly varnished (5 %), in metal 
(4 %) and tinplate (2 %). 
2. Migration data from food contact materials 
The method for the determination of BPA was accreditated by ISO/IEC 17 025 procedure for 34 % of 
the 988 submitted results, the procedure was validated internally for 30 % (including results from non-
accreditated laboratories) and accredited by a different third-party quality assessment procedure for 
36 %. 
Information about the method of analysis was provided for 100 % of the results. The following 
methods were reported: HPLC-FL (52 % of the samples); HPLC with standard detection methods 
(23 % of the samples); HPLC-UV (11 % of the samples); GC-MS (6 % of the samples); LC-MS-MS 
(6 % of the samples); and LC-MS (2 % of the samples). 
LODs were reported as below the limit of 15 µg/kg for 748 results (ranging from 0.006 to 15 µg/kg) 
and greater than 15 µg/kg for 92 results (ranging from 20 to 40 µg/kg). LOQs were reported as below 
the limit of 50 µg/kg for 872 results (ranging from 0.018 to 50 µg/kg) and greater than 50 µg/kg for 
103 results (ranging from 60 to 500 µg/kg). 
All the data and results are converted to µg/kg. If the result of the overall migration in the original 
results was expressed as mg/dm
2
, the conversion rate was 1 mg/dm
2
 equal to 6 mg/kg of packaged 
food, as reported in Consideration No 26 of Regulation EU No 10/2011. 
3. Occurrence data in food contact materials 
The method for the determination of BPA was validated internally for 1 % of the samples analysed. 
No information was provided on the accreditation of the method for the remaining 99 % of the sample 
analysed. 
Information about the method of analysis was provided for 43 % of the 545 submitted results. The 
following methods were reported: HPLC with standard detection methods (25 % of the samples); GC-
MS (16 % of the samples); and HPLC-FL (1 % of the samples). Classification of the method of 
analysis was not possible for 57 % of the samples (submitted as “EG-Referenzmethode” and “Nicht in 
einer offiziellen Sammlung enthaltene Methode”). 
LODs were reported as below the limit of 15 µg/kg for 321 results (ranging from 0.0033 to 10 µg/kg) 
and greater than 15 µg/kg for 212 results (ranging from 20 to 10 000 µg/kg). LOQs were reported as 
below the limit of 50 µg/kg for 330 results (ranging from 0.01 to 40 µg/kg) and greater than 50 µg/kg 
for 203 results (ranging from 90 to 42 800 µg/kg). 
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Appendix C. Food categories 
This appendix provides a comprehensive description of all data made available in relation to BPA 
concentration in food and beverages. Data are described separately for “Canned food categories” and 
“Non-canned food categories”, making use of the EFSA FoodEx categories. European data from the 
literature and from the EFSA call for data are first described separately and then pooled. Non-
European data are then described for comparison only. Note that in this appendix the term “BPA” 
means unconjugated BPA. 
1. Canned food categories 
For canned food, the overall number of samples was 633, of which 327 samples were from the 
literature and 306 samples were from the call for data. 
1.1.  “Grains and grain-based products”, canned 
One sample for “Grains and grain-based products” was available from the literature in Belgium 
(Geens et al., 2010). The maize grain sample had a BPA concentration of 67.4 µg/kg. 
Concentration data from “Grains and grain-based products” was provided through the call for data by 
France and Ireland, with a total of 18 samples. The samples were mainly maize grains. The BPA 
concentrations ranged from 23.1 µg/kg (maize grain, France) to 47.5 µg/kg (maize grain, France). 
Mean BPA concentration (MB) was 34.9 µg/kg. 
When all European data for canned grains and grain-based products were pooled, average BPA 
concentration (MB) was 36.6 µg/kg. 
Concentration values for samples from Singapore (Sun et al., 2006), Japan (Sajiki et al., 2007), Korea 
(Lim et al., 2009a, Kawamura et al, 2014, Canada (Cao et al., 2011), China (Niu et al., 2012) and Iran 
(Ahmadkhaniha et al., 2013) were within the same range as the samples from Europe. 
The FAO/WHO opinion (2011) assigned an overall BPA value of 36.7 µg/kg to the solid canned food, 
while in the EFSA opinion (2006a) 50 µg/kg was used for canned solid foods. 
1.2.  “Vegetables and vegetable products”, canned 
Concentration data from 50 samples of canned “Vegetables and vegetable products” were available 
from the literature in Russia (Feshin et al., 2012), Belgium (Geens et al., 2010), Spain (García-Prieto 
et al., 2008) and Italy (Grumetto et al., 2008). Most of the analysed samples referred to canned tomato 
products (Grumetto et al., 2008). The BPA concentrations ranged from below LOD/LOQ (40 %) to 
116.3 µg/kg (mushrooms, Geens et al., 2010). Mean BPA concentration (MB) was 26.0 µg/kg. 
Concentration data for canned “Vegetables and vegetable products” were provided through the call for 
data by Germany, Switzerland, Ireland, Finland and Norway for a total of 73 samples. Around half of 
the samples were sweetcorn, while coconut milk, sauerkraut, tomatoes and other vegetable products 
constituted the other half. The BPA concentrations ranged from below LOD/LOQ (18 %) to 
100.1 µg/kg (mushrooms, Germany). Mean BPA concentration (MB) was 21.7 µg/kg. 
When all European data for canned vegetable and vegetable products were pooled, average BPA 
concentration (MB) was 23.5 µg/kg. 
Concentration values for samples from Singapore (Sun et al., 2006), Japan (Sajiki et al., 2007; 
Yonekubo et al., 2008; Kawamura et al, 2014), Korea (Lim et al., 2009a), Iran (Ahmadkhaniha et al., 
2013) and Canada (Cao et al., 2010a) were within the same range as the samples from Europe. 
The FAO/WHO opinion (2011) assigned an overall BPA value of 36.7 µg/kg to the solid canned food, 
while in the EFSA opinion (2006a) 50 µg/kg was used for canned solid foods. 
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1.3.  “Legumes, nuts and oilseeds”, canned 
Concentration data for two samples of canned “Legumes, nuts and oilseeds” were available from the 
literature in Spain (García-Prieto et al., 2008). The peas had a BPA concentration of 69.0 µg/kg and 
the green beans had a BPA concentration of 103.0 µg/kg. The average BPA concentration (MB) was 
120.5 µg/kg. 
Concentration data for legumes, nuts and oilseeds were provided through the call for data by Ireland, 
Germany, France and Finland for a total of 18 samples. The samples were of beans and peas. The BPA 
concentration ranged from below LOD/LOQ (33 %) to 137.0 µg/kg (green peas, Ireland). The average 
BPA concentration (MB) was 28.8 µg/kg. 
When all European data for legumes, nuts and oilseeds samples were pooled, average BPA 
concentration (MB) was 34.6 µg/kg. 
Concentration values for samples from Singapore (Sun et al., 2006), Japan (Sajiki et al., 2007), Korea 
(Lim et al., 2009a) and Canada (Cao et al., 2010a, 2011) were in the same range as the samples from 
Europe. However, one study from the USA (Noonan et al., 2011) showed BPA concentrations of some 
canned beans and peas with BPA values up to 730 µg/kg, while the average BPA concentration in 
canned vegetables in the Noonan et al. (2011) study was 87.8 µg/kg. 
The FAO/WHO opinion (2011) assigned an overall BPA value of 36.7 µg/kg to the solid canned food, 
while in the EFSA opinion (2006a) 50 µg/kg was used for canned solid foods. 
1.4. “Fruit and fruit products”, canned 
Concentration data for seven samples of canned “Fruit and fruit products” were available from the 
literature in Belgium (Geens et al., 2010) and Spain (García-Prieto et al., 2008). The analysed samples 
were from canned fruit. BPA concentrations varied from 7.8 µg/kg (canned mixed fruit, García-Prieto 
et al., 2008) to 24.4 µg/kg (canned mango, García-Prieto et al., 2008). Mean BPA concentration (MB) 
was 15.9 µg/kg. 
Concentration data for fruit and fruit products were provided through the call for data by Ireland, 
Germany, France and Norway for a total of 14 samples. The samples were mostly of canned fruit, in 
addition to two samples of dried prunes and one sample of jam. The BPA concentration varied from 
below LOD/LOQ (21 %) to 107.0 µg/kg (dried prunes, Ireland). Mean BPA concentration (MB) was 
12.2 µg/kg. 
When all European canned fruit and fruit products were pooled, average BPA concentration (MB) was 
13.4 µg/kg. 
Concentration values in fruit and fruit products from Japan (Sajiki et al., 2007; Kawamura et al, 2014), 
Korea (Lim et al., 2009a), Canada (Cao et al., 2011) and the USA (Noonan et al., 2011) and most of 
the concentrations from Singapore (Sun et al., 2006) were within the same range as the samples from 
Europe. However, Sun et al. (2006) reported canned mango with a BPA concentration of 160 µg/kg. 
The FAO/WHO opinion (2011) assigned an overall BPA value of 36.7 µg/kg to the solid canned food, 
while in the EFSA opinion (2006a) 50 µg/kg was used for canned solid foods. 
1.5. “Meat and meat products”, canned 
Concentration data in 31 samples of canned “Meat and meat products” were available from the 
literature in the Czech Republic (Poustka et al., 2007), Russia (Feshin et al., 2012), Spain (Pérez-
Bendito et al., 2009) and Belgium (Geens et al., 2010). The analysed samples were mostly of pâté 
from pork liver (16 samples) and luncheon meat (11 samples). BPA concentrations ranged from below 
the LOQ (39 %) to 51.1 µg/kg (luncheon meat, Czech Republic). Mean BPA concentration (MB) was 
14.7 µg/kg. 
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Concentration data for meat and meat products were provided through the call for data by Ireland, 
Finland and France for a total of 16 samples. The samples were of different meat and meat products. 
The BPA concentration ranged from below the LOQ (38 %) to 203.0 µg/kg (bacon, Ireland). Mean 
BPA concentration (MB) was 64.2 µg/kg. 
When all European data for canned meat and meat products were pooled, average BPA concentration 
(MB) was 31.5 µg/kg. 
Concentration values in meat samples from Singapore (Sun et al., 2006), Japan (Sajiki et al., 2007; 
Kawamura et al, 2014), Korea (Lim et al., 2009a) and Canada (Cao et al., 2011) were in the same 
range as the samples from Europe. 
The FAO/WHO opinion (2011) assigned an overall BPA value of 36.7 µg/kg to the solid canned food, 
while in the EFSA opinion (2006a) 50 µg/kg was used for canned solid foods. 
1.6.  “Fish and other seafood”, canned 
Concentration data for 107 samples of canned “Fish and seafood” were available from the literature in 
the Czech Republic (Poustka et al., 2007), Portugal (Cunha et al., 2012), Belgium (Geens et al., 2010), 
and Spain (Pérez-Bendito et al., 2009). The analysed samples were of tuna, mackerel, sardines and 
other fish and seafood. The BPA concentrations ranged from below LOD/LOQ (20 %) to 169.3 µg/kg 
(tuna in oil, Geens et al., 2010). Mean BPA concentration (MB) was 39.5 µg/kg. 
Concentration data for fish and other seafood were provided through the call for data by Germany, 
Finland, Switzerland, Ireland, Norway and France for a total of 67 samples. The samples were of tuna, 
sardines, mackerel and other fish and seafood. The BPA concentration ranged from below LOD 
(33 %) to 198 µg/kg (cod and whiting, Ireland). Mean BPA concentration (MB) was 33.0 µg/kg. 
When all European data for canned fish and seafood samples were pooled, average BPA concentration 
(MB) was 37.0 µg/kg. 
Concentration values in samples from Singapore (Sun et al., 2006), Japan (Sajiki et al., 2007; 
Yonekubo et al., 2008; Kawamura et al, 2014), Korea (Lim et al., 2009a) and Canada (Cao et al., 
2011) were within the same range as that of the samples from Europe. 
The FAO/WHO opinion (2011) assigned an overall BPA value of 36.7 µg/kg to the solid canned food, 
while in the EFSA opinion (2006a) 50 µg/kg was used for canned solid foods. 
1.7. “Milk and dairy products,” canned 
Concentration data from 19 samples of canned “Milk and dairy products” were available from the 
literature in Spain (Molina-Garcia et al., 2012) and Greece (Maragou et al., 2006). The analysed 
samples were of liquid milk (nine samples), evaporated milk (seven samples), and milk powder (three 
samples). BPA concentrations varied from below the LOD (63 %) to 15.2 µg/kg (evaporated milk, 
Maragou et al., 2006). Mean BPA concentration (MB) was 2.6 µg/kg. 
Concentration data from milk and dairy products were provided through the call for data by Germany 
for three samples. The samples were of liquid milk. BPA concentration varied from 0.7 µg/kg to 
35.9 µg/kg. Mean BPA concentration (MB) was 19.8 µg/kg. 
When all European data for canned milk and dairy products were pooled, average BPA concentration 
(MB) was 4.9 µg/kg. 
The concentration value in evaporated milk from Canada (Cao et al., 2011) was in the same range as 
that in the European samples. 
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The FAO/WHO opinion (2011) and the EFSA opinion (2006a) did not assigned a specific BPA value 
for canned milk and diary products. 
1.8. “Sugar and confectionery”, canned 
The only sample in this food category was available from the literature in Belgium (Geens et al., 
2010). The BPA concentration fruit sauce was 0.2 µg/kg. 
This concentration value was used in the exposure assessment. However, the only foods consumed in 
this category were fruit sauce and molasses, and these foods were not consumed in large quantities and 
do not have an impact on the exposure. 
1.9. “Fruit and vegetable juices,” canned 
Concentration data from five samples of canned “Fruit and vegetable juice” were available from the 
literature in Belgium (Geens et al., 2010). The analysed samples of fruit juice varied in BPA 
concentrations from 0.8 µg/kg to 4.7 µg/kg. The average BPA concentration (MB) was 2.7 µg/kg. 
The FAO/WHO opinion (2011) assigned an BPA value of 23.2 µg/kg to the canned non-carbonated 
liquids, while in the EFSA opinion (2006a) 10 µg/kg was used for canned liquid beverages. 
1.10. “Non-alcoholic beverages”, canned 
The food category “Non-alcoholic beverages” includes canned beverages such as soft drinks, both 
carbonated and non-carbonated, coffee and tea. Concentration data from 54 samples of canned “Non-
alcoholic beverages” were available from the literature in Belgium (Geens et al., 2010), Portugal 
(Cunha et al., 2011) and Spain (Gallart-Ayala et al., 2011; Cacho et al., 2012). The samples were of 
canned soft drinks (49 samples) and canned tea (5 samples). The BPA concentrations ranged from 
below LOD (26 %) to 8.1 µg/kg (citrus soda, Geens et al., 2010). Mean BPA concentration (MB) was 
0.5 µg/kg. 
Concentration data on “Non-alcoholic beverages” were provided through the call for data by Germany 
and Norway for a total of 11 samples. Two of the samples were coffee and the rest soft drinks. BPA 
concentration ranged from below the LOD (27 %) to 1.5 µg/kg (in coffee, Germany). Mean BPA 
concentration (MB) was 0.5 µg/kg. 
When all European data for canned non-alcoholic beverages were pooled, average BPA concentration 
(MB) was 0.5 µg/kg. 
From the literature outside Europe, Lim et al. (2009a) found high BPA concentrations in seven out of 
eight samples of canned coffee and tea from Korea. The highest BPA concentration was 136.14 µg/kg, 
and six of the samples were in the range 10.64–38.28 µg/kg (Lim et al., 2009a). Concentration values 
in samples from Canada (Cao et al., 2009b, 2010a, 2011) and Japan (Kawamura et al, 2014) were in 
the same range as that of the samples from Europe. 
Based on these data, the FAO/WHO opinion (2011) assigned a different BPA concentration to 
carbonated beverages (cola, beer, soda, tonic) and non-carbonated beverages (tea, coffee, other), 
owing to high values in canned tea and coffee in the Korean study (Lim et al., 2009a). The carbonated 
beverages were given a BPA concentration of 1.0 µg/kg in the exposure assessment, while the non-
carbonated beverages were given a higher BPA concentration of 23.2 µg/kg. The EFSA opinion 
(2006a) used 10 µg/kg as the BPA concentration for canned beverages. 
The CEF Panel observed that the high values in canned tea and coffee in the Korean study were not 
confirmed by any other study. Contrary to FAO/WHO (2011), the CEF Panel decided not to 
distinguish between carbonated and non-carbonated soft drinks. 
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1.11. “Alcoholic beverages”, canned 
Concentration data in 18 samples of canned alcoholic beverages were available from the literature in 
Portugal (Cunha et al., 2011), Belgium (Geens et al., 2010), and Spain (Gallart-Ayala et al., 2011; 
Cacho et al., 2012). The analysed samples were all of beer. BPA concentrations ranged from below the 
LOD (17 %) to 4.7 µg/kg (beer, Cunha et al., 2011). Mean BPA concentration (MB) was 0.9 µg/kg. 
Concentration data in 49 samples of canned alcoholic beverages were provided through the call for 
data by United Kingdom and Germany. The samples were mostly of beer. The BPA concentration 
ranged from below the level of qunantification (35 %) to 4.5 µg/kg (beer, Germany). Mean BPA 
concentration (MB) was 0.8 µg/kg. 
When all European data for canned alcoholic beverages were pooled, average BPA concentration 
(MB) was 0.8 µg/kg. 
The concentration values in alcoholic beverages from Canada (Cao et al., 2010a, 2011) and Japan 
(Kawamura (personal communication, 2013) were within the same range as the European samples. 
The FAO/WHO opinion (2011) assigned a BPA value of 23.2 µg/kg to the canned non-carbonated 
liquids, while the EFSA opinion (2006a) used 10 µg/kg for canned beverages. 
1.12. “Drinking water”, canned 
There was one European sample of canned drinking water available from the literature. The BPA 
concentration (MB) was 0.004 µg/kg. However, there was no reported consumption of canned water, 
and the concentration value has therefore not been used in the exposure assessment. 
1.13. “Herbs, spices and condiments”, canned 
Concentration data from two samples of canned “Herbs, spices and condiments” were provided 
through the call for data by Germany. The samples were of dressing and curry sauce, and the BPA 
concentrations were 0.6 µg/kg and 82.1 µg/kg, respectively. The average BPA concentration (MB) 
was 41.4 µg/kg. 
The two widely differing values imply a high uncertainty about the average concentration for this food 
category. However, this will have little impact on the assessment because the foods in this category 
were not consumed in large quantities. 
The FAO/WHO opinion (2011) assigned an overall BPA value of 36.7 µg/kg to the solid canned food, 
while in the EFSA opinion (2006a) 50 µg/kg was used for canned solid foods. 
1.14. “Food for infants and small children”, canned 
Concentration data from 10 samples of canned “Food for infants and small children” were available 
from the literature in Portugal (Cunha et al., 2011), Spain (Molina-Garcia et al., 2012) and Russia 
(Feshin et al., 2012). The analysed samples were of infant formula powder. The BPA concentrations 
ranged from below the LOQ (70 %) to 2.2 µg/kg (Feshin et al., 2012). Mean BPA concentration (MB) 
was 0.3µg/kg, and the highest BPA concentration was 2.2 µg/kg. 
The European Dietetic Food Industry Association has confirmed that canned liquid infant formula is 
currently not used in Europe (email to EFSA dated 27 June 2013) but is used in other parts of the 
world. Values from European manufactured canned infant formula were therefore not included in the 
opinion. 
Cao et al., 2008 (Canada) analysed 16 samples of infant formula from USA and Canada. BPA 
concentration ranged from 2.27 µg/kg to 10.23 µg/kg. Mean BPA concentration was 5.98 µg/kg. 
Ackerman et al. (2010, USA) provided BPA concentrations in 71 samples of canned infant formula. 
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The infant formulas were both ready-to-feed and concentrated liquid. The BPA concentrations in 
liquid formula ranged from 0.56 to 11 µg/kg, with an average BPA concentration of 5.74 µg/kg. In 
addition Ackerman et al. (2010, USA) detected BPA in 1 sample of 14 powder formula products 
(0.40 µg/kg). 
Earlier opinions have chosen different BPA concentrations for exposure from infant formula. The 
FAO/WHO report (2011) uses two average BPA concentration values for liquid infant formula of 
4 µg/kg for the ready-to-feed formula and 3.5 µg/kg for the concentrated liquid formula. 
The EFSA opinions (2006a) assumed a very conservative value BPA concentration of 100 µg/kg for 
both beverages and solid canned food consumed by infants. 
1.15. “Products for special nutritional use”, canned 
Concentration data from 14 samples of canned “Products for special nutritional use” were available 
from the literature in Portugal (Cunha et al., 2011), Belgium (Geens et al., 2010), Spain (Gallart-Ayala 
et al., 2011) and Russia (Feshin et al., 2012). All the 14 samples for special nutritional use from the 
European literature were canned soft drinks. The BPA concentration ranged from below LOD/LOQ 
(36 %) to 4.8 µg/kg (energy drink, Geens et al., 2010). The average BPA concentration (MB) was 
1.2 µg/kg. 
The FAO/WHO opinion (2011) assigned a BPA value of 23.2 µg/kg to the canned non-carbonated 
liquids, while the EFSA opinion (2006a) used 10 µg/kg for canned beverages. 
1.16. “Composite food”, canned 
Concentration data from only six samples of canned “Composite food” were available from the 
literature in Belgium (Geens et al., 2010) and Spain (Bendito et al., 2009). The analysed samples were 
soups and other dishes. The BPA concentrations ranged from below the LOQ (one sample) to 
73.1 µg/kg (in ravioli, Geens et al., 2010). Mean BPA concentration (MB) was 25.9 µg/kg. 
Concentration data from 25 samples of canned composite food were provided through the call for data 
by Germany, Ireland, Finland, Norway and France. The samples were of soups, bean-based meals, 
pasta and other composite foods. The BPA concentrations ranged from below the LOQ (20 %) to 
110 µg/kg (meat balls, Ireland). Mean BPA concentration (MB) was 39.6 µg/kg. 
When all European data for canned composite foods were pooled, average BPA concentration (MB) 
was 37.0 µg/kg. 
The concentration values in composite foods from Singapore (Sun et al., 2006), Japan (Sajiki et al., 
2007; Yonekubo et al., 2008; Kawamura et al, 2014), Canada (Cao et al., 2010a) and the USA 
(Noonan et al., 2011) were within the same range as that of European samples. However, Sajiki et al. 
(2007) reported a canned creamed soup with a value of 156 µg/kg and canned brown sauces with very 
high BPA concentrations (428, 547 and 842 µg/kg). Yonekubo et al. (2008) reported a canned gratin 
sauce with a BPA concentration of 235 µg/kg. 
The FAO/WHO opinion (2011) assigned an overall BPA value of 36.7 µg/kg to solid canned food, 
while in the EFSA opinion (2006a) 50 µg/kg was used for canned solid foods. 
1.17. “Snacks, desserts, and other foods”, canned 
Concentration data from one sample of canned “Snacks, desserts, and other foods” were provided 
through the call for data by Ireland. The sample was of starchy pudding, and the BPA concentration 
was 52.0 µg/kg. This BPA concentration was used in the exposure assessment. 
There are few concentration data in this food category. However, the foods in this category were only 
custard and undefined snacks, and neither was consumed in large quantities. 
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The FAO/WHO opinion (2011) assigned an overall BPA value of 36.7 µg/kg to the solid canned food, 
while in the EFSA opinion (2006a) 50 µg/kg was used for canned solid foods. 
2. Non-canned food categories 
For non-canned food, concentration data from the literature were scarce, with only 246 samples 
overall, of which 159 were water samples. However, the call for data provided 1 637 samples of non-
canned food, to which France is the main contributor with 1 433 samples (88 % of the total non-
canned food samples). 
2.1. “Grains and grain-based products”, non-canned 
Concentration data from one sample of non-canned “Grains and grain-based products” were available 
from the literature in Belgium (Geens et al., 2010). The maize grain sample had a BPA concentration 
of 0.9 µg/kg. 
Concentration data for grains and grain-based products were provided though the call for data by 
France, Ireland and Norway for a total of 95 samples. The samples were of grains, bread, cakes, 
breakfast cereals and other grain products. The BPA concentration ranged from below LOD/LOQ 
(43 %) to 11.9 µg/kg (flan, France). Mean BPA concentration (MB) was 1.0 µg/kg. 
When all European data for non-canned grains and grain-based products were pooled, average BPA 
concentration (MB) was 1.0 µg/kg. 
A market basket study from Sweden (Gyllenhammar et al., 2012) observed a BPA concentration from 
cereal products within the same range as that of the European data. 
Concentration values in samples from Japan (Sajiki et al., 2007) and Canada (Cao et al., 2011) were 
within the same range as that of the samples from Europe. However, one sample of cookies from 
Japan (Sajiki et al., 2007) had a BPA concentration of 14 µg/kg. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) assigned a BPA value to non-
canned food. 
2.2. “Vegetables and vegetable products”, non-canned 
Concentration data from four samples of non-canned “Vegetables and vegetable products” were 
available from the literature in Belgium (Geens et al., 2010). The BPA concentration in the varied 
vegetables ranged from 0.1 µg/kg to 1.0 µg/kg. Mean BPA concentration (MB) was 0.4 µg/kg. 
Concentration data for non-canned “Vegetables and vegetable products” were provided through the 
call for data by France (199 samples), Norway (1 sample) and Ireland (1 sample) for a total of 201 
samples. The BPA concentrations for the varied vegetables ranged from below LOD/LOQ (34 %) to 
5.3 µg/kg (leaf vegetables, France). Mean BPA concentration (MB) was 1.2 µg/kg. 
When all European data for canned vegetables and vegetable products were pooled, average BPA 
concentration (MB) was 1.2 µg/kg. 
A market basket study from Sweden (Gyllenhammar et al., 2012) observed a BPA concentration from 
vegetables within the same range as the European data. 
Concentration values in samples from Canada (Cao et al., 2011), and USA (Noonan et al., 2011; Lu et 
al., 2012, 2013) were within the same range as the samples from Europe. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) did assign a BPA value to non-
canned food. 
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2.3. “Starchy roots and tubers”, non-canned 
No BPA concentration data for non-canned “Starchy roots and tubers” were found in the European 
literature. 
Concentration data for non-canned starchy roots and tubers were provided through the call for data by 
France (44 samples), and Ireland (one sample) for a total of 45 samples. All the samples were of 
potatoes. The BPA concentrations ranged from below LOD/LOQ (16 %) to 2.6 µg/kg (fried potatoes, 
France). 
The average BPA concentration (MB) for starchy roots and tubers was 0.7 µg/kg. 
A market basket study from Sweden (Gyllenhammar et al., 2012) observed a BPA concentration from 
potatoes within the same range as that of the European data. 
Concentration values in samples from Canada (Cao et al., 2011) were within the same range as the 
samples from Europe. Potatoes from the USA (Lu et al., 2012, 2013) had a BPA concentration of 
4.3 µg/kg. 
2.4. “Legumes, nuts and oilseeds”, non-canned 
No BPA concentration data were found in the European literature. 
Concentration data for non-canned “Legumes, nuts and oilseeds” were provided through the call for 
data by France (three samples), and Ireland (two samples) for a total of five samples. The samples 
were of oilseeds, beans, tree nuts and other seeds. The BPA concentration ranged from below 
LOD/LOQ (60 %) to 0.5 µg/kg (beans, France). 
The average BPA concentration (MB) for legumes, nuts and oilseeds was 0.2 µg/kg. 
Concentration values in samples from Singapore (Sun et al., 2006) and Japan (Sajiki et al., 2007) were 
within the same range as the samples from Europe. However, one sample of shelled seeds from 
Canada (Cao et al., 2011) had a BPA concentration of 0.7 µg/kg. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) did assign a BPA value to non-
canned food. 
2.5. “Fruit and fruit products”, non-canned 
Concentration data in three samples of non-canned “Fruit and fruit products” were available from the 
literature in Belgium (Geens et al., 2010). The BPA concentration in pineapple and olives ranged from 
0.1 µg/kg to 1.3 µg/kg. Mean BPA concentration (MB) was 0.5 µg/kg. 
Concentration data for non-canned “Fruit and fruit products” were provided through the call for data 
by France (79 samples), and Ireland (six samples) for a total of 85 samples. The samples were of 
different fruits, dried fruits and jam. The BPA concentration ranged form below the LOQ (73 %) to 
2.1 µg/kg (grapefruit, France). Mean BPA concentration (MB) was 0.3 µg/kg. 
When all European data for non-canned fruit and fruit products were pooled, average BPA 
concentration (MB) was 0.3 µg/kg. 
A market basket study from Sweden (Gyllenhammar et al., 2012) observed a BPA concentration from 
fruits in the same range as that of the European data. 
Concentration values in samples from Japan (Sajiki et al., 2007) were within the same range as that of 
the samples from Europe. Fruit samples from the USA (Lu et al., 2012, 2013) had a BPA 
concentration above the European level, with the highest BPA concentration for citrus of 9.0 µg/kg. 
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Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) did assign a BPA value to non-
canned food. 
2.6. Glucuronated BPA in food of animal origin 
Any BPA to which food production animals are exposed may conjugate and so may be present in their 
tissues as glucuronated BPA (ANSES, 2013). When BPA is measured in food of animal origin (e.g. 
meat, milk, eggs), it is possible that deconjugation occurs. Another potential source of unconjugated 
BPA in meat products is its migration from any food contact materials or from articles used in the 
processing of the product. With the exception of the data submitted by France through the EFSA call, 
none of the methods, published in the scientific literature or obtained through the EFSA call, described 
deconjugation steps and so it was assumed that the BPA concentrations reported were for 
unconjugated BPA only. The levels of total and unconjugated BPA in foods of animal origin were 
reported by ANSES to be virtually the same (ANSES, 2013). Therefore, the data on total BPA 
reported by France were merged with the other data from the EFSA call for data. 
2.7. “Meat and meat products”, non-canned 
Concentration data from one sample of non-canned “Meat and meat products” were available from the 
literature in Belgium (Geens et al., 2010). The BPA concentration of sausages was 0.9 µg/kg. 
Concentration data for non-canned meat and meat products were provided through the call for data by 
France (172 samples), Ireland (12 samples) and Norway (seven samples) for at total of 191 samples. 
The samples were of meat types, sausages and pâtés. The BPA concentration ranged from below the 
LOQ (5 %) to 394.8 µg/kg (edible offal, France). The BPA concentration (MB) was 9.5 µg/kg. 
When all European data for non-canned meat and meat products were pooled, average BPA 
concentration (MB) was 9.4 µg/kg. 
A market basket study from Sweden (Gyllenhammar et al., 2012) observed a BPA concentration from 
meat within the same range as that of the European data. 
Concentration values in samples from China (Shao et al., 2007b), Canada (Cao et al., 2011 and Japan 
(Sajiki et al., 2007) were within the same range as that of the samples from Europe. Neither the EFSA 
opinion (2006a) nor the FAO/WHO opinion (2011) assigned a BPA value to non-canned food. 
2.8. “Fish and other seafood”, non-canned 
Concentration data from eight samples of non-canned “Fish and other seafood” were available from 
the literature in Spain (Salgueiro-Gonzalez et al., 2012a) and Belgium (Geens et al., 2010). Most of 
the analysed samples were of mussels. The BPA concentrations ranged from below LOD/LOQ (75 %) 
to 11.2 µg/kg (mussels, Salgueiro-Gonzalez et al., 2012a). The BPA concentration (MB) was 
1.9 µg/kg. 
Concentraton data for non-canned fish and other seafood were provided through the call for data by 
France (66 samples), and Norway (2 samples) for a total of 68 samples. The samples were mostly of 
mussels, shrimps, salmon and trout. The BPA concentration ranged from below LOD/LOQ (3 %) to 
97.9 µg/kg (salmon and trout, France). The BPA concentration (MB) was 8.1 µg/kg. 
When all European data for non-canned fish and other seafood were pooled, average BPA 
concentration (MB) was 7.4 µg/kg. 
A market basket study from Sweden (Gyllenhammar et al., 2012) observed a BPA concentration from 
fish within the same range as that of the European data. 
Concentration values in samples from China (Shao et al., 2007a, Wei et al., 2011), and Canada (Cao et 
al., 2011) were within the same range as the samples from Europe. Some fish and seafood samples 
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from Malaysia (Santhi et al., 2012b) had a BPA concentration above the European level, with the 
highest BPA concentration for squid of 729.0 µg/kg dry weight. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) assigned a BPA value to non-
canned food. 
2.9. “Milk and dairy products”, non-canned 
Concentration data from one sample of non-canned “Milk and dairy products” were available from the 
literature in Greece (Maragou et al., 2006). The BPA concentration was below LOD/LOQ, and the 
MB value was 2.6 µg/kg. 
Concentration data for non-canned milk and dairy products were provided through the call for data by 
France (139 samples), Ireland (eight samples), and Norway (four samples) for a total of 151 samples. 
The samples were mostly of yoghurt, cow’s milk and other cheeses and types of milk. The BPA 
concentration ranged from below LOD/LOQ (52 %) to 6.1 µg/kg (Chantal cheese, France). The BPA 
concentration (MB) was 0.3 µg/kg). 
When all European data for non-canned milk and dairy products were pooled, average BPA 
concentration (MB) was 0.3 µg/kg. 
A market basket study from Sweden (Gyllenhammar et al., 2012) observed a BPA concentration from 
dairy products within the same range as that of the European data. 
Concentration values in samples from China (Shao et al., 2007a; Liu et al., 2008), Canada (Cao et al., 
2011) and Japan (Sajiki et al., 2007) were within the same range as that of the samples from Europe. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) did assign a BPA value to non-
canned food. 
2.10. “Eggs and egg products”, non-canned 
No BPA concentration data for non-canned “Eggs and egg products” were found in the European 
literature. 
Concentration data for non-canned eggs and egg products were provided through the call for data by 
France (13 samples), Ireland (one sample) and Norway (one sample) for a total of 15 samples. The 
samples were mostly whole eggs. The BPA concentration ranged from below LOD/LOQ (20 %) to 
4.5 µg/kg (whole eggs, France). 
The BPA concentration (MB) of non-canned eggs and egg products was 0.9 µg/kg. 
A market basket study from Sweden (Gyllenhammar et al., 2012) observed a BPA concentration from 
eggs within the same range as that of the European data. Concentration values in samples from China 
(Shao et al., 2007a) were within the same range as the samples from Europe. However, one in ten egg 
samples from China (Shao et al., 2007a) had a BPA concentration of 10.45 µg/kg. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) assigned a BPA value to non-
canned food. 
2.11. “Sugar and confectionery”, non-canned 
Concentration data from one sample of non-canned “Sugar and confectionery” was available from the 
literature in Belgium (Geens et al., 2010). The BPA concentration was 0.3 µg/kg. 
Concentration data for non-canned sugar and confectionery were provided through the call for data by 
France (14 samples), Ireland (four samples) and Norway (one sample) for a total of 19 samples. The 
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samples were mostly chocolate and sugars. The BPA concentration ranged from below LOD/LOQ 
(42 %) to 2.6 µg/kg (molasses and other syrups, France). The average BPA concentration (MB) was 
0.5 µg/kg. 
When all European data for non-canned sugar and confectionery were pooled, average BPA 
concentration (MB) was 0.5 µg/kg. 
Concentration values in samples from Japan (Sajiki et al., 2007) and Canada (Cao et al., 2011) were 
within the same range as that of the samples from Europe. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) assigned a BPA value to non-
canned food. 
2.12. “Animal and vegetable fats and oils”, non-canned 
No BPA concentration data for non-canned “Animal and vegetable fats and oils” were found in the 
European literature. 
Concentration data for non-canned animal and vegetable fats and oils were provided through the call 
for data by France (20 samples), Ireland (four samples) and Norway (two samples) for a total of 26 
samples. The samples were mostly butter and vegetable oils. The BPA concentrations ranged from 
below LOD/LOQ (46 %) to 1.4 µg/kg (margarine and olive oil, France). 
The BPA concentration (MB) of non-canned animal and vegetable fats and oils was 0.5 µg/kg. 
A market basket study from Sweden (Gyllenhammar et al., 2012) observed a BPA concentration from 
fats within the same range as that of the European data. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) assigned a BPA value to non-
canned food. 
2.13. “Fruit and vegetable juices”, non-canned 
Concentration data from two samples of non-canned “Fruit and vegetable juices” were available from 
the literature in Belgium (Geens et al., 2010). The BPA concentrations were below LOD/LOQ of 
0.01 µg/kg. 
Concentration data for non-canned fruit and vegetable juices were provided through the call for data 
by France (12 samples), Ireland (one sample) and Norway (one sample) for a total of 14 samples. The 
samples were all fruit juices. The BPA concentrations ranged from below LOD/LOQ (71 %) to 
6.0 µg/kg (orange juice, France). The average BPA concentration (MB) was 0.8 µg/kg. 
When all European data on non-canned fruit and vegetable juices were pooled, average BPA 
concentration (MB) was 0.7 µg/kg. 
Concentration values in samples from Japan (Sajiki et al., 2007) were within the same range as that of 
the samples from Europe. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) assigned a BPA value to non-
canned food. 
2.14. “Non-alcoholic beverages”, non-canned 
Concentration data from one sample of non-canned “Non-alcoholic beverages” were provided from 
the literature in Belgium (Geens et al., 2010). The BPA concentrations were below LOD/LOQ of 
0.01 µg/kg. 
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Concentration data for non-canned non-alcoholic beverages were provided from the call for data by 
France (68 samples), Ireland (three samples), and Norway (one sample) for a total of 72 samples. The 
samples were mostly from coffee, tea and hot chocolate. The BPA concentration ranged from below 
LOD/LOQ (64 %) to 1.7 µg/kg (black tea infusion, Ireland). The BPA concentration (MB) was 
0.2 µg/kg. 
When all European data for non-canned non-alcoholic beverages were pooled, average BPA 
concentration (MB) was 0.2 µg/kg. 
Concentration values in samples from Japan (Sajiki et al., 2007) and Canada (Cao et al., 2010a) were 
within the same range as the samples from Europe. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) did assign a BPA value to non-
canned food. 
2.15. Alcoholic beverages, non-canned 
Concentration data in 59 samples of non-canned “Alcoholic beverages” were available from the 
literature in Austria (Brenn-Struckhofova and Cichna-Markl, 2006). All the samples were of wine. The 
BPA concentrations ranged from below LOD/LOQ (22 %) to 2.1 µg/kg (wine, Brenn-Struckhofova 
and Cichna-Markl, 2006). The BPA concentration (MB) was 0.5 µg/kg. 
Concentration data for non-canned alcoholic beverages were provided through the call for data by the 
United Kingdom (14 samples), Germany (8 samples), France (8 samples), and Ireland (5 samples) for 
a total of 35 samples. The samples were of beer and wine. The BPA concentrations ranged from below 
LOD/LOQ (71 %) to 1.6 µg/kg (wine, France). The average BPA concentration (MB) was 0.5 µg/kg. 
When all European data for non-canned alcoholic beverages were pooled, average BPA concentration 
(MB) was 0.5 µg/kg. 
Concentration values in samples from Japan (Sajiki et al., 2007) and Canada (Cao et al., 2010a, 2011) 
were within the same range as that of the samples from Europe. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) assigned a BPA value to non-
canned food. 
2.16. “Water”, non-canned 
BPA may be present in drinking water as a result of environmental contamination and/or epoxy resin 
linings in the drinking water distribution network and/or migration from PC water dispensers or water 
filters.  
Concentration data from 159 non-canned samples of “Water” were available from the literature in 
Spain (Guart et al., 2011; Bono-Blay et al., 2012) and Belgium (Geens et al., 2010). The samples were 
from well water, bottled water and water stored in PC carboys. 
BPA was detected in only 6 samples out of 131 samples of well water to be used for bottling water in 
Spain (LOD 0.009 µg/kg; maximum 0.2 µg/kg) (Bono-Blay et al., 2012). BPA was not detected in one 
sample of bottled water from Belgium (Geens et al., 2010). BPA was not detected in any sample of 
bottled water in Spain made of HDPE (n = 7) or PET (n = 10) (LOD = 0.009 µg/kg) (Guart et al., 
2011). However, BPA was detected in all 10 samples of water stored in PC coolers in Spain (Guart et 
al., 2011). The BPA concentrations ranged from below LOD/LOQ (90 %) to 4.4 µg/kg. The average 
BPA concentration (MB) was 0.2 µg/kg. 
Concentration data for non-canned water were provided through the call for data by France (396 
samples), Germany (42 samples), Spain (17 samples), Ireland (two samples), PlasticsEurope (two 
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samples) and Norway (one sample) for a total of 460 samples. All types of non-canned waters where 
pooled, as most consumers drink a variety of water from different sources. The samples were mostly 
from tap water but also from water bottled in PET, glass and PC coolers. The BPA concentrations 
ranged from below LOD/LOQ (84 %) to 4.5 µg/kg (water stored in PC carboy, France). The average 
BPA concentration was 0.2 µg/kg. 
When all European data for non-canned water were pooled, average BPA concentration (MB) was 
0.2 µg/kg. 
Concentration values in samples from Japan (Sajiki et al., 2007) were within the same range as that of 
the samples from Europe. 
The EFSA opinion (2006a) did not assign a BPA value to non-canned water. In its exposure 
assessment, FAO/WHO (2011) observed that most BPA concentrations in tap water were below 
0.01 µg/L, whereas BPA concentrations in water packaged in PC bottles were just below 1 µg/L. This 
last value was used by FAO/WHO in the exposure assessment as a conservative scenario. 
2.17. “Herbs, spices and condiments”, non-canned 
Concentration data in two samples of non-canned “Herbs, spices and condiments” were available from 
the literature in Belgium (Geens et al., 2010). The samples were from pickles and vegetable sauce with 
the same BPA concentration of 0.3 µg/kg. 
Concentration data on non-canned herbs, spices and condiments were provided through the call for 
data by France (eight samples), Ireland (eight samples) and Norway (one sample) for a total of 17 
samples. The samples were mainly soy sauce, dressing and some stock cubes. The BPA concentrations 
ranged from below LOD/LOQ (71 %) to 2.5 µg/kg (dressing, France). The average BPA concentration 
was 1.3 µg/kg.  
When all European data on non-canned herbs, spices and condiments were pooled, average BPA 
concentration (MB) was 1.2 µg/kg. 
Concentration values in samples from Canada (Cao et al., 2011) were within the same range as that of 
the samples from Europe. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) assigned” a BPA value to non-
canned food. 
2.18. “Food for infants and small children”, non-canned 
Concentration data for one sample of non-canned infant formula was available from the literature from 
Greece (Maragou et al., 2006). The BPA concentration was below LOD/LOQ, and the MB BPA 
concentration was 0.9 µg/kg. 
Concentration values in samples of baby foods contained in glass jars with metal lids from Canada 
(Cao et al., 2009a, 2011) were in the ranged below LOD to BPA concentration of 1.7 µg/kg. 
Earlier opinions have chosen different BPA concentrations for exposure from infant formula. The 
FAO/WHO report (2011) used two average BPA concentration values for liquid infant formula of 
4 µg/kg for the ready-to-feed formula and 3.5 µg/kg for the concentrated liquid formula. The EFSA 
opinion (2006a) did not assign a BPA concentration to non-canned food. 
2.19. “Composite food”, non-canned 
Concentration data in three non-canned “Composite foods” were available from the literature from 
Belgium (Geens et al., 2010). The BPA concentration in the vegetable soups ranged between 
0.1 µg/kg and 0.4 µg/kg. The average BPA concentration was 0.3 µg/kg. 
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Concentration data for non-canned composite food were provided through the call for data by France 
(96 samples), Switzerland (seven samples), Ireland (two samples) and Norway (two samples) for a 
total of 107 samples. The samples were of different composite foods and dishes. The BPA 
concentration ranged from below the LOQ (10 %) to 25.8 µg/kg (sandwich, France). The average 
BPA concentration (MB) was 2.4 µg/kg. 
When all European data on non-canned composite foods were pooled, average BPA concentration 
(MB) was 2.4 µg/kg. 
Concentration values in samples from Japan (Sajiki et al., 2007) and Canada (Cao et al., 2011) were 
within the same range as the samples from Europe. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) assigned a BPA value to non-
canned food. 
2.20. “Snacks, desserts and other foods”, non-canned 
No BPA concentration data for non-canned “Snacks, desserts and other foods” were found in the 
European literature. 
Concentration data for non-canned snacks, desserts and other foods were provided through the call for 
data by France (25 samples) and Ireland (six samples) for a total of 31 samples. The samples were of 
potato crisps and desserts. The BPA concentration ranged from below the LOD (68 %) to 0.4 µg/kg 
(potato crisps, France). 
The average BPA concentration (MB) in non-canned snacks, desserts and other foods was 0.4 µg/kg. 
Neither the EFSA opinion (2006a) nor the FAO/WHO opinion (2011) did assign a BPA value to non-
canned food. 
2.21. Foods in glass jars with metal lids 
BPA can be used in the internal coating of metal lids for foods in glass jars, and residues of BPA in 
these coatings can migrate into foods, especially at elevated temperatures (Cao et al., 2009a). 
Migration of BPA from the coating on metal lids into foods is assumed to be low compared with 
canned foods (Cao et al., 2009a). There are not many data available on the BPA concentration in food 
from glass jars with metal lids. 
However, baby foods in glass jars with metal lids are an important part of the diets of children aged six 
months and older. One Canadian study has determined the BPA concentration in 99 baby food 
products in glass jars (Cao et al., 2009a). The BPA levels in 15 % of the samples were lower than the 
average LOD, and 70 % had BPA levels of less than 1 µg/kg. The average BPA level was 1.1 µg/kg. 
Concentration data for 10 samples of fruit, vegetables and anchovies in glass jars were available from 
the literature in the Netherlands (Geens et al., 2010). The average BPA level was 0.60 µg/kg, with a 
range from 0.10 µg/kg in red cabbage to 1.28 µg/kg in pineapple. 
As expected, the concentrations observed in foods in glass jars with metal lids were in line with those 
of non-canned food and lower than those in canned food. Concentration data from foods in glass jars 
with metal lids from the European market were therefore categorised with those of non-canned foods 
in the exposure assessment. 
2.22. Water from water pipes relined with epoxy resins 
Data on BPA in drinking water were available from the literature. A survey performed in Sweden 
(KEMI, 2013) investigated whether any BPA could be released in drinking water from aged water 
pipes relined with epoxy resins. Two different techniques for relining were used in Sweden from 2006 
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to 2011, one so-called one-component method in which the composition of the material is prepared 
industrially and another so-called two-component method in which the components are mixed on the 
spot. Both hot and cold water were collected and analysed. The concentrations in 31 samples of hot 
water ranged from below the LOQ of 0.01 µg/L (19 %) to 60 µg/L. Mean BPA concentration (MB) 
was 6.2 µg/L, and the 95th percentile (MB) was 60 µg/L. 
In general the levels were low in cold water. A total of 19 samples of cold water from water pipes 
relined with the two-component method were analysed for BPA concentration, and the range was from 
below the LOQ of 0.01 µg/L (66 %) to 1.1 µg/L. The average BPA concentration (MB) was 
0.10 µg/L. 
The ANSES opinion (2013) paid special attention to water networks renovated with epoxy resins. 
However, all 46 samples analysed had BPA concentrations below the LOQ of 0.025 µg/L. 
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Appendix D. Summary of the non-dietary sources 
 Overview of the literature concerning non-food sources considered in the exposure assessment Table 39: 




Salapasidou et al., 2011 Greece Urban traffic site ng/m
3
 0.06 18.6 6.78    
Industrial site ng/m
3
 LOD 47.3 13.2    




 1.0 1.5     
Ohio ng/m
3
 0.7 0.9     
Rudel et al., 2010 USA California ng/m
3
  2.0  0.5   
Matsumoto et al., 2005 Japan Urban ambient outdoor air ng/m
3
 0.02 1.92 0.51    
Fu and Kawamura, 2010 Worldwide  pg/m
3
 1 17 400     
Surface water 
Klecka et al., 2007 North America  µg/L    0.08   
Europe  µg/L    0.01   
Air 
ANSES, 2013 France 30 homes ng/m
3
   5.3 1.0 0.6   
Wilson et al., 2007 USA 257 US homes ng/m
3
 0.9 193   1.82 11.1 
Rudel et al., 2010 USA 50 Californian houses ng/m
3
 0.5 20   0.5   
Dust 
Völkel et al., 2008 Germany 12 German homes µg/kg 117 1 486   553   
Geens et al., 2009a Belgium 18 Belgian homes ng/g 535 9 729   1 461  
Geens et al., 2009a Belgium 2 Belgian offices ng/g 4 685 8 380      
ANSES, 2013 France 25 French homes mg/kg   20 5.8 4.7  
Paper products 
Biedermann et al., 2010 Switzerland Thermal papers g/kg 8 17 13.3   
Östberg and Noaksson, 2010 Sweden Receipts g/kg 5 32    
Liao and Kannan, 2011a USA Thermal paper receipts g/kg 0.000001 13.9    
Liao and Kannan, 2011b USA Paper currencies mg/kg 0.001 82.7    
Gehring et al., 2004 Germany Recycled toilet paper mg/kg 3.2 46.1    
Toys 
Viñas et al., 2012 Spain Toys and teats µg/L 0.2 5.9       
KEMI, 2012 Sweden Toys and teats µg/L < 0.1 2.1       
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Author Country Location Unit Min Max Mean Median 95th
 
percentile 
Lassen et al., 2011 Denmark Pacifiers ng/product   1 360 319     
Cosmetics 
Cacho et al., 2013 Spain Various cosmetic products µg/kg < LOQ 88       
Dodson et al., 2012 USA Various cosmetic products mg/kg 1 100       
Dental sealants 
Sasaki et al., 2005  Japan Saliva µg/L   100       
Kang et al., 2011  South Korea Saliva µg/L   21 5     
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Appendix E. Sources of FoodEx level 1 
The chronic exposure was estimated by multiplying the average BPA concentration for each FoodEx level 1 food group(s) and type of packaging (canned or 
non-canned) with their respective consumption (amount per kg bw), separately for each individual in the database, calculating the sum of exposure for each 
survey day for the individual and then deriving the daily average for the survey period. The dietary surveys used, by age class, are given in the tables below. 
 Number of dietary surveys according to the percentage of average dietary exposure to BPA per type of packaging (canned vs. not canned), Table 40: 
FoodEx level 1 category and scenario—Toddlers (total number of surveys = 7) 
Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Canned Alcoholic beverages 7 0 0 0 0 0 7 0 0 0 0 0 
Canned Animal and vegetable fats and oils 7 0 0 0 0 0 7 0 0 0 0 0 
Canned Composite food  5 1 1 0 0 0 0 3 1 2 1 0 
Canned Fish and other seafood  6 1 0 0 0 0 0 5 1 1 0 0 
Canned Fruit and fruit products 6 1 0 0 0 0 3 3 1 0 0 0 
Canned Fruit and vegetable juices 7 0 0 0 0 0 2 2 3 0 0 0 
Canned Grains and grain-based products 6 1 0 0 0 0 6 1 0 0 0 0 
Canned Herbs, spices and condiments 7 0 0 0 0 0 3 3 1 0 0 0 
Canned Legumes, nuts and oilseeds 5 1 1 0 0 0 0 4 2 1 0 0 
Canned Meat and meat products  6 1 0 0 0 0 0 0 2 5 0 0 
Canned Milk and dairy products 7 0 0 0 0 0 5 2 0 0 0 0 
Canned Non-alcoholic beverages  7 0 0 0 0 0 7 0 0 0 0 0 
Canned Products for special nutritional use 7 0 0 0 0 0 7 0 0 0 0 0 
Canned Snacks, desserts and other foods 7 0 0 0 0 0 3 1 0 2 1 0 
Canned Starchy roots and tubers 7 0 0 0 0 0 7 0 0 0 0 0 
Canned Sugar and confectionery 7 0 0 0 0 0 7 0 0 0 0 0 
Canned Vegetables and vegetable products  3 1 1 1 1 0 0 0 0 3 4 0 
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Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Not canned Alcoholic beverages 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Animal and vegetable fats and oils 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Composite food  2 4 0 1 0 0 6 1 0 0 0 0 
Not canned Drinking water 0 5 1 1 0 0 1 6 0 0 0 0 
Not canned Eggs and egg products 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Fish and other seafood  0 5 0 2 0 0 5 2 0 0 0 0 
Not canned Food for infants and small children 0 5 0 2 0 0 4 2 1 0 0 0 
Not canned Fruit and fruit products 0 7 0 0 0 0 7 0 0 0 0 0 
Not canned Fruit and vegetable juices 0 5 2 0 0 0 5 2 0 0 0 0 
Not canned Grains and grain-based products 0 1 6 0 0 0 0 7 0 0 0 0 
Not canned Herbs, spices and condiments 6 1 0 0 0 0 7 0 0 0 0 0 
Not canned Legumes, nuts and oilseeds 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Meat and meat products  0 0 0 2 5 0 0 2 4 1 0 0 
Not canned Milk and dairy products 0 1 5 1 0 0 0 7 0 0 0 0 
Not canned Non-alcoholic beverages  5 2 0 0 0 0 7 0 0 0 0 0 
Not canned Products for special nutritional use 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Snacks, desserts and other foods 6 1 0 0 0 0 7 0 0 0 0 0 
Not canned Starchy roots and tubers 1 6 0 0 0 0 6 1 0 0 0 0 
Not canned Sugar and confectionery 6 1 0 0 0 0 7 0 0 0 0 0 
Not canned Vegetables and vegetable products  0 4 3 0 0 0 7 0 0 0 0 0 
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 Number of dietary surveys according to the percentage of average dietary exposure to BPA per type of packaging (canned vs. not canned), Table 41: 
FoodEx level 1 category and scenario—Children 3-10 years (total number of surveys = 15) 
Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Canned Alcoholic beverages 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Animal and vegetable fats and oils 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Composite food  12 1 2 0 0 0 5 1 2 2 4 1 
Canned Fish and other seafood  9 5 1 0 0 0 0 6 8 1 0 0 
Canned Fruit and fruit products 11 4 0 0 0 0 3 8 4 0 0 0 
Canned Fruit and vegetable juices 12 2 1 0 0 0 3 7 5 0 0 0 
Canned Grains and grain-based products 14 1 0 0 0 0 8 6 1 0 0 0 
Canned Herbs, spices and condiments 15 0 0 0 0 0 6 5 3 1 0 0 
Canned Legumes, nuts and oilseeds 12 3 0 0 0 0 3 7 3 2 0 0 
Canned Meat and meat products  12 2 1 0 0 0 0 0 5 10 0 0 
Canned Milk and dairy products 14 0 0 0 1 0 9 5 1 0 0 0 
Canned Non-alcoholic beverages  15 0 0 0 0 0 15 0 0 0 0 0 
Canned Products for special nutritional use 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Snacks, desserts and other foods 15 0 0 0 0 0 5 5 2 2 1 0 
Canned Starchy roots and tubers 15 0 0 0 0 0 13 2 0 0 0 0 
Canned Sugar and confectionery 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Vegetables and vegetable products  8 3 2 1 1 0 0 0 2 7 6 0 
Not canned Alcoholic beverages 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Animal and vegetable fats and oils 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Composite food  6 3 1 4 1 0 9 6 0 0 0 0 
Not canned Drinking water 1 10 4 0 0 0 5 10 0 0 0 0 
Not canned Eggs and egg products 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Fish and other seafood 0 10 4 1 0 0 12 3 0 0 0 0 
Not canned Food for infants and small children 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Fruit and fruit products 1 14 0 0 0 0 15 0 0 0 0 0 
Not canned Fruit and vegetable juices 0 10 5 0 0 0 13 2 0 0 0 0 
Not canned Grains and grain-based products 0 0 13 2 0 0 0 15 0 0 0 0 
Not canned Herbs, spices and condiments 12 3 0 0 0 0 15 0 0 0 0 0 
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Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Not canned Legumes, nuts and oilseeds 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Meat and meat products  0 0 0 2 11 2 0 6 5 4 0 0 
Not canned Milk and dairy products 0 5 9 1 0 0 2 13 0 0 0 0 
Not canned Non-alcoholic beverages  7 8 0 0 0 0 15 0 0 0 0 0 
Not canned Products for special nutritional use 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Snacks, desserts and other foods 13 2 0 0 0 0 15 0 0 0 0 0 
Not canned Starchy roots and tubers 0 15 0 0 0 0 13 2 0 0 0 0 
Not canned Sugar and confectionery 10 5 0 0 0 0 15 0 0 0 0 0 
Not canned Vegetables and vegetable products  0 8 7 0 0 0 15 0 0 0 0 0 
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 Number of dietary surveys according to the percentage of average dietary exposure to BPA per type of packaging (canned vs. not canned), Table 42: 
FoodEx level 1 category and scenario—Adolescents (total number of surveys = 12) 
Packaging type FoodEx LEVEL 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Canned Alcoholic beverages 12 0 0 0 0 0 12 0 0 0 0 0 
Canned Animal and vegetable fats and oils 12 0 0 0 0 0 12 0 0 0 0 0 
Canned Composite food  9 1 2 0 0 0 4 2 1 2 3 0 
Canned Fish and other seafood  4 4 4 0 0 0 0 3 7 2 0 0 
Canned Fruit and fruit products 11 1 0 0 0 0 1 11 0 0 0 0 
Canned Fruit and vegetable juices 8 2 1 1 0 0 4 6 1 1 0 0 
Canned Grains and grain-based products 12 0 0 0 0 0 7 5 0 0 0 0 
Canned Herbs, spices and condiments 11 1 0 0 0 0 5 2 4 1 0 0 
Canned Legumes, nuts and oilseeds 10 2 0 0 0 0 1 6 3 2 0 0 
Canned Meat and meat products  10 1 1 0 0 0 0 0 0 10 2 0 
Canned Milk and dairy products 12 0 0 0 0 0 11 1 0 0 0 0 
Canned Non-alcoholic beverages  12 0 0 0 0 0 12 0 0 0 0 0 
Canned Products for special nutritional use 12 0 0 0 0 0 12 0 0 0 0 0 
Canned Snacks, desserts and other foods 12 0 0 0 0 0 6 3 2 1 0 0 
Canned Starchy roots and tubers 12 0 0 0 0 0 10 2 0 0 0 0 
Canned Sugar and confectionery 12 0 0 0 0 0 12 0 0 0 0 0 
Canned Vegetables and vegetable products  5 2 2 2 1 0 0 0 1 7 4 0 
Not canned Alcoholic beverages 10 2 0 0 0 0 12 0 0 0 0 0 
Not canned Animal and vegetable fats and oils 12 0 0 0 0 0 12 0 0 0 0 0 
Not canned Composite food  3 3 3 2 1 0 7 5 0 0 0 0 
Not canned Drinking water 1 6 5 0 0 0 3 9 0 0 0 0 
Not canned Eggs and egg products 12 0 0 0 0 0 12 0 0 0 0 0 
Not canned Fish and other seafood  0 4 8 0 0 0 8 4 0 0 0 0 
Not canned Food for infants and small children 12 0 0 0 0 0 12 0 0 0 0 0 
Not canned Fruit and fruit products 2 10 0 0 0 0 12 0 0 0 0 0 
Not canned Fruit and vegetable juices 3 8 1 0 0 0 12 0 0 0 0 0 
Not canned Grains and grain-based products 0 0 10 2 0 0 0 12 0 0 0 0 
Not canned Herbs, spices and condiments 8 4 0 0 0 0 12 0 0 0 0 0 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 175 
Packaging type FoodEx LEVEL 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Not canned Legumes, nuts and oilseeds 12 0 0 0 0 0 12 0 0 0 0 0 
Not canned Meat and meat products  0 0 0 0 9 3 0 2 6 4 0 0 
Not canned Milk and dairy products 0 11 1 0 0 0 5 7 0 0 0 0 
Not canned Non-alcoholic beverages  4 8 0 0 0 0 12 0 0 0 0 0 
Not canned Products for special nutritional use 11 1 0 0 0 0 12 0 0 0 0 0 
Not canned Snacks, desserts and other foods 12 0 0 0 0 0 12 0 0 0 0 0 
Not canned Starchy roots and tubers 0 12 0 0 0 0 12 0 0 0 0 0 
Not canned Sugar and confectionery 12 0 0 0 0 0 12 0 0 0 0 0 
Not canned Vegetables and vegetable products  0 8 4 0 0 0 12 0 0 0 0 0 
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 Number of dietary surveys according to the percentage of average dietary exposure to BPA per type of packaging (canned vs. not canned), Table 43: 
FoodEx level 1 category and scenario—Women (18–45 years) (total number of surveys = 15) 
Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Canned Alcoholic beverages 14 1 0 0 0 0 15 0 0 0 0 0 
Canned Animal and vegetable fats and oils 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Composite food  11 3 0 1 0 0 4 5 1 2 3 0 
Canned Fish and other seafood  5 4 5 1 0 0 0 4 8 3 0 0 
Canned Fruit and fruit products 10 5 0 0 0 0 0 15 0 0 0 0 
Canned Fruit and vegetable juices 12 2 1 0 0 0 3 11 1 0 0 0 
Canned Grains and grain-based products 12 3 0 0 0 0 8 7 0 0 0 0 
Canned Herbs, spices and condiments 13 2 0 0 0 0 4 8 3 0 0 0 
Canned Legumes, nuts and oilseeds 10 4 0 1 0 0 2 8 3 2 0 0 
Canned Meat and meat products  11 2 2 0 0 0 0 0 1 14 0 0 
Canned Milk and dairy products 15 0 0 0 0 0 12 3 0 0 0 0 
Canned Non-alcoholic beverages  14 1 0 0 0 0 15 0 0 0 0 0 
Canned Products for special nutritional use 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Snacks, desserts and other foods 15 0 0 0 0 0 7 6 1 1 0 0 
Canned Starchy roots and tubers 15 0 0 0 0 0 14 1 0 0 0 0 
Canned Sugar and confectionery 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Vegetables and vegetable products  5 2 4 4 0 0 0 0 0 5 10 0 
Not canned Alcoholic beverages 6 9 0 0 0 0 13 2 0 0 0 0 
Not canned Animal and vegetable fats and oils 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Composite food  5 5 2 2 1 0 13 2 0 0 0 0 
Not canned Drinking water  1 7 5 2 0 0 3 12 0 0 0 0 
Not canned Eggs and egg products 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Fish and other seafood  0 9 5 1 0 0 12 3 0 0 0 0 
Not canned Food for infants and small children 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Fruit and fruit products 3 12 0 0 0 0 15 0 0 0 0 0 
Not canned Fruit and vegetable juices 5 9 1 0 0 0 15 0 0 0 0 0 
Not canned Grains and grain-based products 0 2 12 1 0 0 0 15 0 0 0 0 
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Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Not canned Herbs, spices and condiments 9 6 0 0 0 0 15 0 0 0 0 0 
Not canned Legumes, nuts and oilseeds 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Meat and meat products  0 0 0 2 12 1 0 3 9 3 0 0 
Not canned Milk and dairy products 0 14 1 0 0 0 8 7 0 0 0 0 
Not canned Non-alcoholic beverages  4 10 1 0 0 0 8 7 0 0 0 0 
Not canned Products for special nutritional use 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Snacks, desserts and other foods 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Starchy roots and tubers 1 14 0 0 0 0 14 1 0 0 0 0 
Not canned Sugar and confectionery 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Vegetables and vegetable products  0 5 10 0 0 0 15 0 0 0 0 0 
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 Number of dietary surveys according to the percentage of average dietary exposure to BPA per type of packaging (canned vs. not canned), Table 44: 
FoodEx level 1 category and scenario—Men 18–45 years (total number of surveys = 15) 
Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Canned Alcoholic beverages 14 0 1 0 0 0 15 0 0 0 0 0 
Canned Animal and vegetable fats and oils 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Composite food  10 3 2 0 0 0 5 4 1 2 3 0 
Canned Fish and other seafood  5 6 3 1 0 0 0 3 9 3 0 0 
Canned Fruit and fruit products 13 2 0 0 0 0 4 11 0 0 0 0 
Canned Fruit and vegetable juices 12 2 1 0 0 0 6 8 1 0 0 0 
Canned Grains and grain-based products 13 2 0 0 0 0 9 6 0 0 0 0 
Canned Herbs, spices and condiments 13 2 0 0 0 0 4 8 3 0 0 0 
Canned Legumes, nuts and oilseeds 9 4 1 1 0 0 1 8 4 2 0 0 
Canned Meat and meat products  10 3 2 0 0 0 0 0 0 13 2 0 
Canned Milk and dairy products 15 0 0 0 0 0 14 1 0 0 0 0 
Canned Non-alcoholic beverages  14 1 0 0 0 0 15 0 0 0 0 0 
Canned Products for special nutritional use 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Snacks, desserts and other foods 15 0 0 0 0 0 8 5 1 1 0 0 
Canned Starchy roots and tubers 15 0 0 0 0 0 14 1 0 0 0 0 
Canned Sugar and confectionery 15 0 0 0 0 0 15 0 0 0 0 0 
Canned Vegetables and vegetable products  6 0 6 2 1 0 0 0 0 5 10 0 
Not canned Alcoholic beverages 1 11 3 0 0 0 6 9 0 0 0 0 
Not canned Animal and vegetable fats and oils 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Composite food  7 4 2 2 0 0 13 2 0 0 0 0 
Not canned Drinking water 2 9 4 0 0 0 5 10 0 0 0 0 
Not canned Eggs and egg products 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Fish and other seafood  0 9 5 1 0 0 13 2 0 0 0 0 
Not canned Food for infants and small children 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Fruit and fruit products 11 4 0 0 0 0 15 0 0 0 0 0 
Not canned Fruit and vegetable juices 8 6 1 0 0 0 14 1 0 0 0 0 
Not canned Grains and grain-based products 0 2 13 0 0 0 0 15 0 0 0 0 
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Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Not canned Herbs, spices and condiments 10 5 0 0 0 0 15 0 0 0 0 0 
Not canned Legumes, nuts and oilseeds 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Meat and meat products  0 0 0 1 10 4 0 1 7 7 0 0 
Not canned Milk and dairy products 0 14 1 0 0 0 10 5 0 0 0 0 
Not canned Non-alcoholic beverages  4 11 0 0 0 0 8 7 0 0 0 0 
Not canned Products for special nutritional use 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Snacks, desserts and other foods 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Starchy roots and tubers 2 13 0 0 0 0 14 1 0 0 0 0 
Not canned Sugar and confectionery 15 0 0 0 0 0 15 0 0 0 0 0 
Not canned Vegetables and vegetable products  0 10 5 0 0 0 15 0 0 0 0 0 
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 Number of dietary surveys according to the percentage of average dietary exposure to BPA per type of packaging (canned vs. not canned), Table 45: 
FoodEx level 1 category and scenario—Other adults 45–65 years (total number of surveys = 14) 
Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Canned Alcoholic beverages 13 1 0 0 0 0 14 0 0 0 0 0 
Canned Animal and vegetable fats and oils 14 0 0 0 0 0 14 0 0 0 0 0 
Canned Composite food  10 3 0 1 0 0 3 5 2 1 3 0 
Canned Fish and other seafood  5 5 3 1 0 0 0 1 6 7 0 0 
Canned Fruit and fruit products 10 4 0 0 0 0 1 13 0 0 0 0 
Canned Fruit and vegetable juices 12 2 0 0 0 0 8 6 0 0 0 0 
Canned Grains and grain-based products 12 2 0 0 0 0 8 6 0 0 0 0 
Canned Herbs, spices and condiments 14 0 0 0 0 0 7 7 0 0 0 0 
Canned Legumes, nuts and oilseeds 10 2 1 1 0 0 1 7 4 2 0 0 
Canned Meat and meat products  10 3 1 0 0 0 0 0 0 13 1 0 
Canned Milk and dairy products 14 0 0 0 0 0 12 2 0 0 0 0 
Canned Non-alcoholic beverages  14 0 0 0 0 0 14 0 0 0 0 0 
Canned Products for special nutritional use 14 0 0 0 0 0 14 0 0 0 0 0 
Canned Snacks, desserts and other foods 14 0 0 0 0 0 9 5 0 0 0 0 
Canned Starchy roots and tubers 14 0 0 0 0 0 13 1 0 0 0 0 
Canned Sugar and confectionery 14 0 0 0 0 0 14 0 0 0 0 0 
Canned Vegetables and vegetable products  6 0 7 1 0 0 0 0 0 4 10 0 
Not canned Alcoholic beverages 1 12 1 0 0 0 8 6 0 0 0 0 
Not canned Animal and vegetable fats and oils 14 0 0 0 0 0 14 0 0 0 0 0 
Not canned Composite food  7 3 1 3 0 0 12 2 0 0 0 0 
Not canned Drinking water 1 7 6 0 0 0 4 10 0 0 0 0 
Not canned Eggs and egg products 14 0 0 0 0 0 14 0 0 0 0 0 
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Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Not canned Fish and other seafood  0 5 6 3 0 0 11 3 0 0 0 0 
Not canned Food for infants and small children 14 0 0 0 0 0 14 0 0 0 0 0 
Not canned Fruit and fruit products 2 12 0 0 0 0 14 0 0 0 0 0 
Not canned Fruit and vegetable juices 8 6 0 0 0 0 14 0 0 0 0 0 
Not canned Grains and grain-based products 0 2 12 0 0 0 0 14 0 0 0 0 
Not canned Herbs, spices and condiments 12 2 0 0 0 0 14 0 0 0 0 0 
Not canned Legumes, nuts and oilseeds 14 0 0 0 0 0 14 0 0 0 0 0 
Not canned Meat and meat products  0 0 0 1 11 2 0 2 9 3 0 0 
Not canned Milk and dairy products 0 13 1 0 0 0 11 3 0 0 0 0 
Not canned Non-alcoholic beverages  4 9 1 0 0 0 8 6 0 0 0 0 
Not canned Products for special nutritional use 14 0 0 0 0 0 14 0 0 0 0 0 
Not canned Snacks, desserts and other foods 14 0 0 0 0 0 14 0 0 0 0 0 
Not canned Starchy roots and tubers 2 12 0 0 0 0 13 1 0 0 0 0 
Not canned Sugar and confectionery 14 0 0 0 0 0 14 0 0 0 0 0 
Not canned Vegetables and vegetable products  0 5 9 0 0 0 14 0 0 0 0 0 
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 Number of dietary surveys according to the percentage of average dietary exposure to BPA per type of packaging (canned vs. not canned) and Table 46: 
scenario—Elderly and very elderly (total number of surveys = 7) 
Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Canned Alcoholic beverages 7 0 0 0 0 0 7 0 0 0 0 0 
Canned Animal and vegetable fats and oils 7 0 0 0 0 0 7 0 0 0 0 0 
Canned Composite food  7 0 0 0 0 0 2 3 0 1 1 0 
Canned Fish and other seafood  4 2 0 1 0 0 0 1 3 3 0 0 
Canned Fruit and fruit products 6 1 0 0 0 0 1 3 3 0 0 0 
Canned Fruit and vegetable juices 6 1 0 0 0 0 5 2 0 0 0 0 
Canned Grains and grain-based products 7 0 0 0 0 0 5 2 0 0 0 0 
Canned Herbs, spices and condiments 7 0 0 0 0 0 5 2 0 0 0 0 
Canned Legumes, nuts and oilseeds 7 0 0 0 0 0 0 5 1 1 0 0 
Canned Meat and meat products  5 2 0 0 0 0 0 0 0 7 0 0 
Canned Milk and dairy products 7 0 0 0 0 0 4 3 0 0 0 0 
Canned Non-alcoholic beverages  7 0 0 0 0 0 7 0 0 0 0 0 
Canned Products for special nutritional use 7 0 0 0 0 0 7 0 0 0 0 0 
Canned Snacks, desserts and other foods 7 0 0 0 0 0 5 1 1 0 0 0 
Canned Starchy roots and tubers 7 0 0 0 0 0 6 1 0 0 0 0 
Canned Sugar and confectionery 7 0 0 0 0 0 7 0 0 0 0 0 
Canned Vegetables and vegetable products  3 0 3 0 1 0 0 0 0 2 5 0 
Not canned Alcoholic beverages 0 7 0 0 0 0 5 2 0 0 0 0 
Not canned Animal and vegetable fats and oils 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Composite food  5 0 1 1 0 0 7 0 0 0 0 0 
Not canned Drinking water 1 3 3 0 0 0 2 5 0 0 0 0 
Not canned Eggs and egg products 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Fish and other seafood  0 3 2 2 0 0 7 0 0 0 0 0 
Not canned Food for infants and small children 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Fruit and fruit products 0 7 0 0 0 0 7 0 0 0 0 0 
Not canned Fruit and vegetable juices 5 2 0 0 0 0 7 0 0 0 0 0 
Not canned Grains and grain-based products 0 0 7 0 0 0 0 7 0 0 0 0 
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Packaging type FoodEx level 1 category Number of dietary surveys (middle bound) (% average BPA contribution) 









































































Not canned Herbs, spices and condiments 6 1 0 0 0 0 7 0 0 0 0 0 
Not canned Legumes, nuts and oilseeds 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Meat and meat products  0 0 0 0 6 1 0 1 5 1 0 0 
Not canned Milk and dairy products 0 6 1 0 0 0 4 3 0 0 0 0 
Not canned Non-alcoholic beverages  1 6 0 0 0 0 4 3 0 0 0 0 
Not canned Products for special nutritional use 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Snacks, desserts and other foods 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Starchy roots and tubers 0 7 0 0 0 0 6 1 0 0 0 0 
Not canned Sugar and confectionery 7 0 0 0 0 0 7 0 0 0 0 0 
Not canned Vegetables and vegetable products  0 2 5 0 0 0 7 0 0 0 0 0 
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Appendix F. Equations and parameters used in the calculation of exposure from non-dietary sources 
 Overview of the equations and parameters used for calculating exposure from non-food sources Table 47: 






bw: body weight (kg bw) 
Esource: exposure contribution of respective source  
(ng/kg bw per day) 
Ingestion/dust 
 
Cdust: concentration in dust (median) (ng/mg) 







qproduct: total amount of BPA that migrated into artificial saliva (ng) 
ftime: correction factor sucking time per day/duration of migration experiment (1/day) 
fsurface: correction factor for contact surface (–) 
Ingestion/thermal 
paper transfer to 
food 
 
afinger: amount on finger after touching thermal paper (ng) 
nfinger: number of fingers touching thermal paper (–) 
favail: available fraction for transfer to food (–) 
ftrans: transfer fraction to food (–) 
qhandling: handling events with transfer (1/day) 
Inhalation/air 
 
Cair: concentration in air (ng/m
3
) 







afinger: amount on finger after touching thermal paper (ng) 
nfinger: number of fingers touching thermal paper (–) 
qhandling: handling events (1/day) 
Dermal 
uptake/cosmetics  
Ccosmetics: concentration in cosmetics (ng/mg) 
qcosmetics: applied amount per day (mg/day) 





qproduct × ftime × fsurface
bw
Etp- food =









Ccosmetics ×qcosmetics × fret
bw
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Appendix G. Biomonitoring: estimation of daily BPA intake from creatinine-based urinary 
concentration 
For the estimation of daily BPA intake, volume-based BPA concentrations (µg BPA/L urine) are 
generally preferred over creatinine-based urinary concentrations (µg BPA/g creatinine) (Lakind and 
Naiman, 2008; Mahalingaiah et al., 2008; Geens et al., 2012a). The arguments against creatinine-
based data are: (i) the larger variation range of > 1 000 % in urinary creatinine concentration compared 
with up to 300 % variation in daily urinary volume (Boeniger et al., 1993); and (ii) the differences in 
the physiological mode of urinary excretion (active secretion, filtration) between glucuronidated BPA 
and creatinine (Boeniger et al., 1993; Mahalingaiah et al., 2008). Although the large North American 
surveys (NHANES, CHMS) indicate an approximately 10-fold difference between the 5th and 95th 
percentiles in (spot urine) creatinine concentration (Health Canada, 2012), the comparison between 
(spot urine) creatinine concentration and daily urinary volume falls short, because in the latter the 
within-day variation is removed. Moreover, although one may expect an increase in variability by 
dividing one fluctuating variable (BPA concentration) by another (creatinine concentration), there is 
de facto no increase in the 95th percentile to 50th percentile ratio between volume-based BPA 
concentrations and creatinine-based urinary BPA concentrations. An additional argument for the use 
of creatinine-based concentrations instead of volume-based concentrations is the fact that the former is 
not dependent on drinking behaviour. An example of changing drinking behaviour is the retrospective 
study by Koch et al. (2012), who reported an increase in 24-hour urine volume from 1.6 to 2.1 L in 
German students between 1995 and 2009, which was associated with a decrease in mean urinary 
creatinine concentration from 1.2 to 0.8 g/L. The daily urinary excretion of creatinine, in contrast, 
depends primarily on the muscle mass of the individual. A man excretes 14–16 mg/kg bw per day, and 
a woman 11–20 mg/kg bw per day, but the amount is fairly consistent for a given individual 
(McClatchey, 2002). 
Based on creatinine-based urinary concentration of total BPA XBPA (µg/g creatinine), the daily BPA 
exposure  (ng/kg bw per day) was calculated by: 
 
where  (g/day) is the creatinine excretion rate and W (kg) is the body weight (Lakind and 
Naiman, 2008; UBA, 2012). Depending on whether body weight is available from the studies, either 
study-specific individual or mean values or generic values derived by linear interpolation from body 
weight vs. age relationships taken from the literature were used. Age-specific generic values on daily 
creatinine excretion were taken from Valentin (2002), except for cases in which study-specific values 
from 24-hour urine sampling were available. Table 48 shows the body weight and creatinine excretion 
rate parameters that were used to translate creatinine-based BPA concentration into daily BPA 
exposure. Generic values for the creatinine excretion rate were taken from ICRP reference tables 
(Valentin, 2002). 
Age-specific estimates were available only from a few European studies, and only for children, 
adolescents, adults and the (very) elderly. For the children, the creatinine-based BPA intakes tend to 
be lower than the volume-based BPA intakes (e.g. 44 vs. 53 ng/kg bw per day for the Duisburg birth 
cohort study). The same tendency applies for the adolescents and the adults except the German ESB 
study and the MoBa study (Figure 17). In the German ESB study, a significant difference is not to be 
expected because both (creatinine-based and volume-based) exposure estimates were derived from 24-
hour urine and creatinine excretions of the study participants rather than from generic values from the 
literature. For the (very) elderly, the Liege HBM study indicates that the creatinine-based intake is 
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The daily BPA intake, as estimated from creatinine-adjusted urinary BPA concentrations, is shown in 
Figure 17 (red symbols). For comparative purposes, estimates derived from volume-based urinary 
BPA concentrations (black symbols) are also shown. 
 Body weight and creatinine excretion rate parameters for the considered European and Table 48: 
North American studies. Given are the parameters for body weight (W), creatinine excretion rate (
), and the specific creatinine excretion rate (spec. ). Gender and age were taken into 
account when deriving generic parameter values from published parameter–age relationships by linear 
interpolation. Study-specific parameters are set in italic font. References from which these parameters 
were taken are: [1] Koch et al. (2012); [2] Bergmann and Mensink (1999); [3] Valentin (2002); [4] 
Stolzenberg et al. (2007); [5] Ye et al. (2009a); [6] CDC (2012); [7] Health Canada (2012); [8] 
Monika Kasper-Sonnenberg (Ruhr University Bochum, Germany, 2013, personal communication); [9] 
Elly Den Hond (Flemish Institute for Technological Research [VITO], Belgium, 2013, personal 
communication) 












German ESB MF 20–30 24hU 72 1 000 14 [1] 
Duisburg BCS F 29–49 MU 71 1 000 14 [8, 3] 
Duisburg BCS MF 6–8 MU 24 458 17 [8, 3] 
Generation R Pregnant F 18–41 SU 74 1 000 14 [5, 3] 
MoBa Pregnant F  SU 74 1 000 14 [5, 3] 
Flemish HMB MF 14–16 SU 57 1200 21 [9, 3] 
Liege HMB MF 7–11 MU 34 586 17 [2, 3] 
Liege HMB MF 12–19 MU 65 1 200 19 [2, 3] 
Liege HMB MF 20–39 MU 75 1 350 18 [2, 3] 
Liege HMB MF 40–59 MU 79 1 350 17 [2, 3] 
Liege HMB MF 60–75 MU 78 1 350 17 [2, 3] 
NHANES MF 6–>65 SU 29–83 490–1350  16–18 [6, 3] 
CHMS MF 6–79 SU 33–80 650–1 350  17–19 [7, 3] 
M, male; F, female; 24hU, 24-hour urine; MU, morning urine; SU, spot urine, ?, not available. 
The differences between creatinine-based and volume-based BPA exposure estimates among the 
European studies suggest that generic values for the daily urine volume overestimate the true daily 
urine volume in the children, adolescents and adults. In the (very) elderly, the situation seems to be 
reversed. This hypothesis is corroborated by North American surveys (NHANES, CHMS), for which 
explanatory information on urinary creatinine concentration is also available (Table 49). For the 
adolescents and adults in the NHANES survey, the actual creatinine concentrations are higher than the 
generic predictions (e.g. 1.33 vs. 0.92 g/L for the adolescents), which explains the lower creatinine-
based BPA exposure estimates compared with the volume-based BPA exposure estimates (Figure 17). 
In other words, US adolescents and adults produce less urine than expected from data in the literature 
and produce, therefore, a more concentrated urine. Using volume-based urinary BPA concentrations in 
combination with generic values from the literature on daily urinary output will consequently 
overestimate the daily BPA exposures for US adolescents and adults. Explanations for differences 
among the US (very) elderly and among the Canadian population groups can be derived in a similar 
manner. 
In conclusion, the estimation of daily BPA exposure from creatinine-based urinary BPA 
concentrations leads to slightly different values from those obtained from volume-based urinary BPA 
concentrations. For the few European studies (with the exception of the German ESB study), there is a 
tendency for lower BPA exposures in children, adolescents and adults, and a tendency for slightly 
higher BPA exposures for the (very) elderly. These differences are (at least partly) explainable by 
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of reference values for the comparison with BPA uptake via food and non-food resources, the volume-
based BPA intakes will be used because these are more conservative and better supported by a larger 
number of European studies. 
 
Figure 17: Daily BPA exposures as estimated from creatinine-based and volume-based urinary 
BPA concentrations. The age-specific estimates for daily BPA exposure from the different studies are 
grouped by the age classes defined in Section 4.5.1. Filled triangles and circles with associated 
numbers and error bars indicate the GMs and the 95 % confidence intervals for the creatinine-based 
and volume-based data. The medians (P50) are shown by open triangles and circles, and the 95th 
percentiles by plus signs and crosses. The number of subjects is given on the right. Age ranges and 
specific population groups (pregnant and parturient women) are indicated. The studies comprise the 
European studies and large-sized population-based surveys from North America (NHANES, CHMS). 
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 Comparison of study-specific and generic urinary creatinine concentrations. Given are the Table 49: 
(average) median creatinine concentration for different age groups in the NHANES survey (2003–
2004, 2005–2006, 2007–2008, 2009–2010) and the CHMS (2007–2009) survey. Also given are the 
generic values which were obtained from Valentin (2002) by dividing the (age-specific) creatinine 
excretion rate by urinary output rate 
Age group Urinary [Cr] (g/L) Age group 
(years) 
Urinary [Cr] (g/L) 
NHANES Valentin CHMS Valentin 
Children 0.86 0.82 6–11  0.75 0.86 
Adolescents 1.33 0.92 12–19  1.33 1.00 
Adults 1.20 0.96 20–39  1.01 0.96 
(Very) Elderly 0.91 0.96 40–59  0.87 0.96 
  60–79  0.81 0.96 
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Appendix H. Evaluation of uncertainties in the exposure assessment through expert judgement 
This appendix documents the approach taken to evaluating uncertainties affecting the CEF Panel’s 
exposure assessment for BPA and presents the detailed results for different parts of the exposure 
assessment. 
The general approach is adapted from the method for qualitative evaluation of uncertainty that was 
suggested in EFSA guidance on dealing with uncertainties in exposure assessment (EFSA, 2006b). 
The suggested approach comprised the following key steps: 
 systematically examine every part of the assessment for potential sources of uncertainty; 
 list the identified uncertainties in a table; 
 evaluate the impact of each uncertainty on the outcome of the exposure assessment, using a 
suitable scale; 
 evaluate the combined impact of all the uncertainties, considered together, on the outcome of 
the exposure assessment. 
The evaluation of uncertainties is approximate, using expert judgement. EFSA guidance (2006b) 
suggested expressing the evaluation on a qualitative scale, provided the scale was defined, and showed 
an example where this was done with combinations of “+” and “–” symbols. Subsequently it was 
realised that while helpful in indicating the relative magnitudes of uncertainties, a qualitative scale 
does not give any indication how large they are in absolute terms, which is in principle needed for risk 
management. For example, if an exposure estimate is 10, its uncertainty is evaluated as “++” and the 
corresponding TDI is 20, then the risk manager needs to know whether “++” means the true exposure 
could be larger by a factor of 2 or more, because that would imply potential exceedance of the TDI. 
Therefore, some later EFSA opinions provided quantitative scales for the symbols, notably the 
guidance document of the EFSA Panel on Plant Protection Products and their Residues (PPR) on 
probabilistic modelling of dietary exposure (EFSA PPR Panel, 2012). 
The general principles above have been applied to the exposure assessment, but the detailed 
methodology and format of the evaluation have been adapted to suit the differing needs of different 
parts of the assessment, as described below. 
The following sections assess uncertainty for each of the individual sources of exposure, and for both 
average and high estimates of exposure, as both are used in risk characterisation (Section 5.1- Part II-
Toxicological assessment and risk characterisation). . Uncertainties associated with the biomonitoring 
data on BPA in urine are also assessed below, so that they can be taken into account when comparing 
forward modelling estimates of exposure with estimates derived from biomonitoring (section 4.7.2). 
How the uncertainties for different sources of exposure combine is considered in Sections 5.1 in Part 
II-Toxicological assessment and risk characterisation and in Section 4.7.2 of the main opinion, in 
order to reach a conclusion on the overall uncertainty associated with the assessment of aggregate 
exposure. 
Uncertainties affecting the estimation of exposures were evaluated using a tabular format similar to the 
original suggestions of EFSA (EFSA, 2006b). The CEF Panel’s assessment of the impact of each 
uncertainty was expressed using symbols whose meaning is defined on a quantitative scale (Figure 
14). Plus symbols mean that the true value of the exposure could be higher than the estimate; minus 
symbols mean that the true value could be lower; a dot (●) means that the impact of the uncertainty is 
less than +/–20 %. As the evaluation is approximate, each symbol represents a range of possible 
values; for example, “++” means that the true exposure is judged to be between two and five times the 
estimate. Pairs of symbols are used where the uncertainty spans a larger range; for example “–/++” 
would mean that the true value exposure is judged to be between half and five times the estimate. 
However, the relative likelihood of different values within the range was not assessed. 
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It is emphasised that all the evaluations are approximate expert judgements and should not be 
interpreted as precise estimates. 
1. Uncertainties in the assessment of dietary exposure (excluding breastfed infants) 
Uncertainties affecting the estimation of high dietary exposures were evaluated by adding two extra 
columns to the tabular format suggested by EFSA (EFSA, 2006b) (Table 51). The left-hand column in 
Table 51 lists the sources of uncertainty identified, and the right-hand column gives the CEF Panel’s 
evaluation of the impact of those uncertainties on its estimates of high exposure, using symbols from 
the scale in Figure 14. The two additional columns, in the centre of the table, identify the variable that 
is affected by each uncertainty, and the value(s) used for that variable in the CEF Panel’s calculation 
of high exposure. 
The scale in Figure 14 was also used to evaluate the combined impact of all the uncertainties on the 
assessment of high dietary exposures, which is shown in the bottom row of Table 50 together with a 
short explanation of how it was derived. 
 Evaluation of uncertainties affecting the assessment of high dietary exposure. The Table 50: 
evaluations are approximate expert judgements and should not be interpreted as precise estimates. See 
Figure 14 for key to symbols 
Source of uncertainty (high scenario) Parameter 
affected 






The Comprehensive Database includes nine 
surveys for toddlers, 17 surveys for children (3-
10 years), 12 surveys for adolescents, 15 surveys 
for adults, seven surveys for elderly and six 
surveys for very elderly 
Consumption patterns in other Member States 






Food consumption data for women aged from 18 
to 45 years from 15 different surveys have been 
used as a proxy for women of childbearing age 
Younger and older women can still be considered 
in childbearing age 
Women can change their consumption patterns 
when pregnant: it is possible that consumption of 
foods with higher BPA content (e.g. canned) 







Dietary data in the Comprehensive Database have 
been collected by means of different study 
designs, methodologies and protocols that could 
bias their results in a different way for each 
survey 
In particular, the following parameters may affect 
the level of detail and the accuracy of the 
collected data: the dietary assessment method 
used; the description and codification of the food 
consumed; the number of days per subject; the 
sampling design and size; the management of 
under-reporters; the quantification of portion 
sizes; the software applications used; and the 
non-dietary information collected. Furthermore, 
in some of the countries, data provided to EFSA 
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Source of uncertainty (high scenario) Parameter 
affected 






Increasing the number of survey days (for both 
recalls and records) has the advantage of 
reducing the effect of study subjects’ day-to-day 
variation, thus leading to an improved estimation 
of consumption variability. As survey duration 
increases, high percentile consumption decreases. 
This might be particularly important for 
episodically consumed foods, as some kind of 
canned foods could be 
Only food consumption data collected on more 
than one day per subject have been used to assess 
chronic exposure. The number of days per subject 
ranged from two to three in toddlers and from 






Only a limited number of dietary surveys 
included in the Comprehensive Database 
presented information on the type of packaging 
(canned or non-canned, in particular). Two 
scenarios were therefore considered: (i) only 
foods specifically codified as canned were 
considered as such; and (ii) at FoodEx level 4, 
any food that has been codified as canned in at 
least one survey is always considered to be 
consumed as canned in all dietary surveys 
included in the Comprehensive Database 
The ratio between the 95th percentiles calculated 
under scenario 2 and scenario 1 ranged from 4 to 
4.8 in toddlers and from 2.1 to 6.8 among women 







Different methods of analysis have been used to 
quantify BPA in food and beverages, all 
presenting an uncertainty. Occurrence data are 
from different origins, total diet studies (TDS), 
monitoring and literature 
Data on occurrence of BPA in food retrieved 
from scientific journals can be biased towards 
positive results as negative results are not always 
published 
Data from TDS can be biased owing to pooling 
of the food samples 
Data from the literature represent 22 % of the 
samples. It is therefore expected that this bias 






by merging data from 
different sources or 
publications 
● 
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Source of uncertainty (high scenario) Parameter 
affected 






Food samples below the limit of quantification or 
reporting were handled through the substitution 
method: the lower bound (LB) value was 
obtained by assigning a value of zero to all the 
samples reported as less than the left-censoring 
limit, the middle bound (MB) value by assigning 
half of the left-censoring limit, and the upper 
bound (UB) by assigning the left-censored limit 
as the sample result 
At the 95th percentile, MB exposure estimates 
were 4 –20 % (scenario 1) and 2–9 % (scenario 
2) higher than those calculated using the LB 
method and 2–20 % (scenario 1) and 2–8 % 





Average BPA occurrence 
for LB, MB and UB have 
been calculated 
● 
Bias could have been introduced by the limited 
number of samples for some of the categories and 
owing to the large food categories, specific foods 
could present lower or higher levels 
In particular, relatively high levels of BPA in 
non-canned meat and fish have been identified in 
many samples from France and one from Ireland. 
These are difficult to explain, more samples from 
different countries would have been useful. 
However, the relatively low impact of non-
canned food to the 95th percentile exposure in 
scenario 2 makes it unlikely this would change 




Average BPA occurrence 
for each FoodEx level 1 
food group and type of 
packaging (canned or 
non-canned) 
 
 –/+  
Bias could have been introduced owing to the 
limited number of samples and Member States 
represented. Data from France are, for example, 
predominant for non-canned food and beverages. 
BPA levels could be lower or higher in some of 
the Member States 
On average, specific population groups could be 
exposed to systematically lower or higher levels 
than those calculated at EU level, e.g. through the 




Average BPA occurrence 
has been calculated at 
EU level 
 –/+  
In general, analytical determination performed in 
food was aimed at quantifying unconjugated BPA 
and would not allow the detection or 
quantification of conjugated BPA (sulphated, 
glucuronidated). Based on ANSES specific 
analysis, conjugated BPA represents a very minor 
fraction of total BPA. This uncertainty is 
therefore likely to have a minor impact on the 




Total BPA ● 
Data on body weight at subject level was used. 
Direct measurements were taken in some of the 
surveys, while, in the remaining, self-reported 
measures were used  
Body weight Individual body weights ● 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 193 
Source of uncertainty (high scenario) Parameter 
affected 







High levels of exposure have been estimated by 
means of the 95th percentile for the total 
population. A limited number of subjects were 
available for some of the age classes. In 
particular, in the case of toddlers the 95th 
percentile was assessed only for four surveys 
presenting at least 60 subjects per study. 
BPA exposure Highest 95th percentile 
among toddlers from 
four different dietary 
surveys 
 –/+  
Women aged 18–45 
High levels of exposure have been estimated by 
means of the 95th percentile for the total 
population. A limited number of subjects was 
available for some of the age classes. In 
particular, in the case of women aged from 18 to 
45 years the 95th percentile was assessed for 15 
surveys 
BPA exposure Highest 95th percentile 
among women aged from 
18 to 45 years old from 
15 different dietary 
surveys 
–/● 
Overall assessment – high dietary exposure 
The main source of uncertainty in the assessment of dietary exposure to BPA is the result of 
limitations in the representativity of the available information on food consumption and BPA 
occurrence in food. In the case of toddlers, the age group presenting the highest exposure 
estimates, only for four surveys was it possible to calculate the 95th percentile of exposure, 
whereas this was possible for 15 dietary surveys in the case of women aged 18–45 years. 
Uncertainty for other adults and for children aged 3-10 years and adolescents is considered to 
be in the same range as for women aged 18-45 years. Also noteworthy is the fact that food 
consumption data from different surveys presents different levels of bias owing to the different 
study designs, methodologies and protocols used. Exposure could also have been under- or 
overestimated owing to the limited number of analytical BPA samples, mainly available for 
specific food categories and from a scarce number of Member States. A clear overestimation 
has been introduced in the assessment of dietary exposure to BPA by not correcting for usual 
intake and by assuming (scenario 2) that any food that has been codified as canned in at least 
one survey is always consumed as canned in all dietary surveys. 
–/+ 
In toddlers  
 
–/● 
In men and 
women aged 
from 18 to 







Overall assessment – average dietary exposure 
The same uncertainties listed above for high dietary exposure apply also to the assessment of 
average dietary exposure except the overestimation of high exposure when assessed from short-
term surveys, due to day-to-day variation. Uncertainty is therefore reduced for the average 
exposure estimates, but not by enough to bring it within +/-20%, The overall uncertainty 
evaluations for average dietary exposure are therefore the same as those given above for high 
exposure estimates, for all age groups.  
 





2. Uncertainties in the assessment of exposure for breastfed infants 
Exposure of breastfed infants is assessed separately from the rest of the population and involves only 
two variables: (i) the concentration of BPA in human breast milk; and (ii) the consumption of breast 
milk by infants (expressed per kg body weight). Uncertainties affecting this assessment are evaluated 
in Table 52. 
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 Evaluation of uncertainties affecting the estimation of high exposure of breastfed infants Table 51: 
to BPA in human breast milk. The evaluations are approximate expert judgements and should not be 
interpreted as precise estimates. See Figure 14 for key to symbols 










Recovery: Not a problem in studies (7 of 8) using isotope-dilution 
mass spectrometry owing to the implicit recovery correction 
● 
Repeatability: Intra- and inter-day CV < 15 % for MS-based methods ● 
Accuracy: < ±10 % (intra- and inter-day) ● 
Contamination of breast milk samples 
Only three out of eight studies (all from the same lab) measured both 
unconjugated and total BPA. The median proportion of unconjugated 
BPA ranged from < 30 % to 76 %. It is unclear whether the variable 
proportion in unconjugated BPA arises from contamination and/or 
from enzymatic deconjugation by a breast milk β-glucuronidase during 






Number of subjects ranges from n = 3–4 in method development 
studies to n = 20–100 in other studies. The relatively low number of 
subjects per study and the non-representative sampling may result in a 
sampling bias. This affects the study estimates for the central tendency 






Uncertainty about the variability of the population means 
The number of studies (n = 8) is low, and only four studies (the 
moderately sized ones) were finally considered for the estimation of 
average and high concentrations of unconjugated and total BPA. The 
estimate for the average concentration of total BPA in initial breast 
milk (colostrum) is based on the sample mean of one study only. For 
mature breast milk, the estimate is based on taking the average of the 
sample means of three studies only. Based on this low number of 
studies, there is practically no information on variability of the sample 
means across different populations or countries. Information on this 
inter-country variability is especially relevant for the calculation of the 
high BPA concentration in order to capture high levels of exposure 
that may occur in specific geographic areas. The absence of this 
information leads to an uncertainty that is judged to be greater than 






There are generally not enough data per study to directly get a reliable 
empirical (non-parametric) estimate of the 95th percentile. However, 
the available raw data for the moderately sized (n ≥ 20) studies suggest 
a log-normal distribution so that a parametric estimation of the 95th 
percentile appears feasible. Based on two studies on BPA in mature 
milk, a standard deviation was derived which was then used (together 
with a mean value) to estimate the 95 % percentile as a measure for the 
high BPA concentration. In principle, this estimate is conservative, as 
the calculated standard deviation reflects not only the between-
individual variability but also the within-individual variability, which 
would average out in the long term. (Repeated/serial milk collections 
are unfortunately not available to estimate the relative contributions of 
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Uncertainty about regional differences 
In the breast milk database, the European countries are, in essence, not 
covered. However, based on the urinary BPA concentrations, there is 
no reason to assume a considerably different (or higher) BPA exposure 
of European mothers in comparison with the USA, for which five 
studies on breast milk are available, and which have the main impact 
on the calculation of estimates for average and high BPA 





Measurement of breast milk consumption 
Different methods of measurement have been used to quantify human 
milk consumption, all presenting an uncertainty. The uncertainties are 
expected to be relatively small and tend to average out when the 




Variation between individuals 
The average breast milk volume is given per kilogram body weight 
and thereby takes into account the size of the baby. However, after 
correction for body weight there will be some residual variation 
between children in their average consumption per day of colostrum 
and breast milk. EFSA (EFSA CONTAM Panel, 2012) has previously 
used 800 mL as an estimate of average intake of breast milk for three-
month-olds with a body weight 6.1 kg, and 1 200 mL for high intake, 




Variation of consumption in the first days of life 
The volumes consumed increases approximately linearly from a few 
grams on day 1 to around 500 g on day 5. Considering an average 
consumption of 250 g over the first five days, and assuming an 
average body weight for a newborn infant of 3.25 kg, an average 
consumption rate of 75 g/kg bw per day (rounded by 5-g steps) is 
obtained. Because of the transitional character in the milk production 
and consumption rate, this estimate is associated with an uncertainty 
that is judged to be larger than ± 20 % but smaller than ± 200 % 
 –/+ 
Variation of consumption of breast milk in months 0–6 
An estimated value of 150 g/kg bw per day already used in previous 
EFSA opinion has been used. The energy requirement and thereby the 
human milk consumption per kg body weight decreases steadily from 
month 1 to month 6 in exclusively breastfed children. The standard 
breast milk volume can be an underestimate the first months and an 
overestimate when the child reaches six months of age 
 –/+ 
Overall assessment—mature breast milk 
There is no reason to assume all the individual uncertainties to be 
correlated. It is expected that the unidirectional but oppositely directed 
uncertainties on sample contamination and population means 
variability would cancel out. The other bidirectional uncertainties add 
up and increase the overall uncertainty in both directions. However, 
the upwards uncertainties are countered by the uncertainty relating to 
the question of whether the proportion of conjugated BPA in breast 
milk becomes systemically available. As a result, it is expected that 
overall, the true exposures will lie between 20 % and 120 % of the 
estimate 




Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 196 






Overall assessment—initial breast milk (colostrum) 
The above assessment is valid for mature breast milk, for which the 
estimate is supported by several small to medium-sized studies. For 
initial breast milk (colostrum), a reliable estimate could not be derived 
because of the discrepancies between the three available studies and 
the low sample sizes in some of the studies. The uncertainty for initial 
breast milk is further increased by the fact that milk production during 
the first five days is of a transitional character with changes in milk 
production rate and milk composition (protein and fat content). Last 
but not least, there is the possibility of an exposure from medical 




3. Uncertainties in the assessment of exposure in formula-fed infants 
 Evaluation of uncertainties affecting the estimation of high dietary exposure (95th Table 52: 
percentile) of 80 ng/kg bw per day in formula-fed infants. The evaluations are approximate expert 
judgements and should not be interpreted as precise estimates. See Figure 14 for key to symbols 







The assumed consumption value of ready-to-eat infant 
formula (independently of being prepared from a powder 
or liquid) is based on water consumption of 150 g/kg bw 
per day (WHO, 2003), leading to formula consumption of 
171 g/kg bw per day. Variability in the consumption 
between individuals is expected to be low. In its 
assessment of BPA, WHO used as 95th percentile of 




150 g/kg bw 
per day 
● 
Method of analysis—analytical determination CV ≤ 15 % BPA occurrence levels 0  ● 
Sampling: Estimates were based on data from the 
literature and only a small number of samples were 
available (10 for canned powder). The values ranged 
from < LOD/LOQ to 2.7 µg/kg for canned formula; 47 % 
of the samples were below LOQ 





Sampling: Estimates were based on data from the 
literature and only one sample of non-canned formula 
below the LOD/LOQ, with an MB of 0.9 µg/kg. 






Uncertainty owing to deconjugation of conjugated BPA: 
In general, analytical determinations performed in food 
aimed at quantifying unconjugated BPA and would not 
allow the detection or quantification of glucuronated 
BPA. However, according to ANSES data, the proportion 
of conjugated BPA in formula was not significant 
BPA occurrence levels Total BPA is 
assumed 
● 
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BPA level in water: The water used to reconstitute infant 
formula from powder was assumed to contain 0.2 µg/kg 
of BPA (MB of all data on non-canned water), leading to 
an estimated exposure of 30 ng/kg bw per day from 
water. However, the formula could be reconstituted 
systematically with water containing significantly more 
BPA in infants living in flats where old waterpipes have 
been lined with epoxy resins (high exposure from water 
would then be 165 ng/kg bw per day. If the percentage of 
infants in this situation was more than 5 % in one of the 
EU countries, this would lead to a real highest 95th 
percentile in the EU more than twice the estimate of 
80 ng/kg bw per day. Other cases such as water warmed 
in a PC kettle or water filtered with a PC filter would lead 
to very little additional exposure (see Table 24 in 
paragraph 4.5.3.4) 




A dilution factor in powder formula preparation of 7 is 
assumed. This can vary depending on the instruction of 
preparation. 
BPA occurrence levels 1/7 ● 
The value used in the exposure assessment covers the 
most common types of packaging (powder or non-canned 
liquid infant formula) and baby bottles not releasing any 
BPA, whereas other cases can occur leading to a higher 
exposure 
Old PC bottles may still in use and can yield a high 
exposure of 684 ng/kg bw day. If the percentage of 
infants in this situation was more than 5 % in one of the 
EU countries, this would lead to a real highest 95th 
percentile eight times higher than the estimate of 
80 ng/kg bw per day. 
BPA occurrence levels  ●/++ 
Overall assessment 
The main sources of uncertainty in the high level of exposure from infant formula are related to the 
lack of knowledge on the percentage of infants for whom more BPA is present in the water used to 
reconstitute infant formula, for whom old PC bottles bought before the 2011 ban would be used. 
This percentage could be higher than 5 % in some countries, leading to significantly higher 95th 
percentile 
–/+++ 
4. Uncertainties in the assessment of (average and high) non-dietary exposure 
Some sources of exposure were considered to be negligible or zero for toddlers and infants and were 
therefore not included in the exposure assessment. For both infants and toddlers, exposure from 
thermal paper was excluded. For infants in the first five days of life, exposure via toys, cosmetics and 
dust were also excluded. There is high confidence in these assumptions, so their uncertainty is not 
considered further. 
The uncertainty evaluations below relate to the assessments of external non-dietary exposure, prior to 
absorption into the body. Uncertainties associated with assessing the fraction absorbed into the body 
are addressed separately (see Appendix D in Part II-Toxicological assessment and risk 
characterisation).  
4.1. Assessment of average non-dietary exposure 
The estimates of average exposure from non-dietary sources is intended to have the same level of 
conservativeness as the estimate of dietary exposure performed under scenario 2. Thus, in scenario 2 
for dietary exposure all foods that may be canned are considered to be canned. To correspond with 
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this, all thermal paper is assumed to contain BPA. The effect of this on the exposure estimates is 
considered below. 
 Evaluation of variability and uncertainties affecting the assessment of average external Table 53: 
BPA exposure of dust ingestion for all age groups. See Figure 14 for key to symbols 




Value used in 
assessment 
Impact on average 
exposure estimate 
In order not to multiply too many worst case 
parameters (so as to achieve a realistic worst 
case) for this parameter an average (mean) value 
was used. Concentrations in dust are assessed in 
three European studies. The median value was 
used from the study that had the middle median 
value of all considered studies. 
Cdust 1.461 mg/kg + 
Method of analysis: trace analytics +/- 15 % Cdust 1.461 mg/kg  
 
Dust ingestion rates in general are very uncertain. 
They are derived from soil ingestion studies. No 
specific dust ingestion studies are available to 
date. In this assessment values from the exposure 
factors handbook (EPA, 2011) were used. They 
are considered conservative estimates. 






























For infant body weight a value for 1-3 months 
old infants was used (EFSA Scientific 
Committee, 2012). For toddlers also a value on 
the conservative side was used. For children 3-10 
years the average bodyweight for 9 years (RIVM) 
was used as a conservative value. For adolescents 
the average bodyweight for 15 year old 
adolescents was used, which is a less 
conservative value. Adult female body weights 
vary: about 70 % are below the EFSA default 
value of 70 kg. (EFSA Scientific Committee, 
2012) 
body weight 5 kg 
(infants) 
12 kg (toddlers) 


















Conservative dust ingestion rates have been used for the average exposure due to a 
lack of more refined data. Therefore, the average exposure is expected to be largely 
overestimated. 
- - - /  
(infants) 
- - /  
 (toddlers) 
- - /  
 (children 3-10 years) 
- - /  
 (adolescents) 
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 Evaluation of variability and uncertainties affecting the assessment of average external Table 54: 
BPA BPA exposure from toys in infants and toddlers. See Figure 14 for key to symbols 




Value used in 
assessment 
Impact on average 
exposure estimate 
This average amount of leaching from toys was 
derived from one migration study with toys 
bought in Sweden. Toys will vary largely, so this 
value may not be representative. However, toys 
made of PC are not frequent on the market, so the 
true average value is likely to be closer to 0 
qtoy 141 ng – – 
Method of analysis: trace analytics  15 % qtoy 141 ng ● 
The time fraction that the toy is sucked per day 
will be highest for continuous sucking (1) and 
lowest for not sucking. Average sucking times 
have been used that were observed in children of 








The fraction of surface in contact with the mouth 
zone of the baby will be variable depending on 
the toy. Many different sizes of toys are 
available. Here, as an example a rattle was 
assessed: for a rattle approximately 0.5 of the 
rattle will be in contact with saliva. It is assumed 
that all of that saliva is subsequently ingested. 
This may not be true—saliva not ingested may 
reduce the effective surface up to five times. For 
some toys, the fraction could exceed 0.6, hence 
+. 
fsurface 0.5 – –/+ 
For infant body weight a value for infants one to 
three months old was used (EFSA Scientific 
Committee, 2012). For toddlers too a value on 
the conservative side was used 






Because of the small fraction of PC toys on the market this value may be an 
overestimation for average exposure 
– –-/+ 
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 Evaluation of variability and uncertainties affecting the assessment of average external Table 55: 
BPA exposure from air inhalation forall age groups. See Figure 14 for key to symbols. 




Value used in 
assessment 
Impact on average 
exposure estimate 
Concentrations of BPA in indoor air are only 
available for France in a limited study. It is not 
clear whether levels of BPA in indoor air will 
vary between countries in Europe. For this 
assessment it was assumed that people spend 
100 % of their time indoors. Since outdoor 
levels of BPA seem to be slightly lower, this 
may result in a slight overestimation (not much, 
because on average people in industrialized 
countries spend 90 % of their time indoors). 
However, in one study for Greece levels in 
outdoor air were as high as 6 ng/m
3
. People in 
Greece, however, may spend more time 
outdoors than people in Northern Europe. 
Taking into account the high levels in outdoor 
air in Greece (which were not used in the 
assessment), there may be an underestimation 
for Greece and other Southern countries.  
Cair 1.0 ng/m
3
 - / ++ 
Method of analysis and sampling together can 
affect the measurement so that the variation 





Inhalation rates vary  
with the activity profile. Therefore, the highest 
uncertainty is associated with the mix of 
activities during the day. Here, average values 
proposed by EPA, 2011 were used for the 
































For infant body weight a value for 1-3 months 
old infants was used (EFSA Scientific 
Committee, 2012). For toddlers also a value on 
the conservative side was used. For children 3-
10 years the average bodyweight for 9 years 
(RIVM) was used as a conservative value. For 
adolescents the average bodyweight for 15 year 
old adolescents was used, which is a less 
conservative value. Adult female body weights 
vary: about 70 % are below the EFSA default 
value of 70 kg. (EFSA Scientific Committee, 
2012) 
body weight 5 kg 
(infants) 
12 kg (toddlers) 

















Overall assessment.  
The activity profile will be very different for different subpopulations and different 
cultures. Also levels in indoor air are only available for one country in Europe and 
may be different in other countries.  
- - / ++ 
(infants) 
- / ++ 
(all other age groups) 
 
The estimates of average exposure from non-dietary sources is intended to have the same level of 
conservativeness as the estimate of dietary exposure performed under scenario 2. Therefore, all 
thermal paper is estimated to contain BPA. 
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 Evaluation of variability and uncertainties affecting the assessment of average level Table 56: 
external dermal exposure to BPA from thermal paper for children (3-10 years), adolescents and adults. 
See Figure 14 for key to symbols 




Value used in 
assessment 
Impact on average 
exposure estimate 
The amount left on the fingers after handling 
thermal papers depends on the wetness and 
greasiness of the touching skin. If the paper is 
handled very shortly, not pressed and the fingers 
are dry it can be assumed that no BPA is 
transferred at all. The highest amount transferred 
was observed for wet fingers (Lassen et al, 
2011). The average value presumably is on the 
conservative side, since it was derived by 
pressing hardly a thermal paper during 10 s (with 
dry fingers). 
qfinger 1.4 µg - / + 
Method of analysis – analytical determination 
CV ≤ 15%  
qfinger  
 
1.4 µg   
Maximum is 10. Normally people grasp paper 
with thumb and 1 or 2 finger tips. More contact 
can occur for those who fold their tickets, but the 
two little fingers are not involved. Based on the 
limited data available, 3 fingers per handling 
event is thought to be a average case. 
nfinger 3 - / + 
This value is based on the number of credit card 








1 per day 
(adults) 





- - / ++ 
 
- - / ++ 
Not all thermal papers contain BPA. Presumably 
today around 80 % thermal papers contain BPA 








For children 3-10 years the average bodyweight 
for 9 years (RIVM) was used as a conservative 
value. For adolescents the average bodyweight 
for 15 year old adolescents was used, which is a 
less conservative value. Adult female body 
weights vary: about 70 % are below the EFSA 
default value of 70 kg. (EFSA Scientific 
Committee, 2012) 













Overall assessment  
For nfinger and qhandling data are lacking, which is why the assessment is highly 
uncertain. It is not clear, in which direction the true value may lie. 
- - -/++ 
all age groups 
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 Evaluation of variability and uncertainties affecting the assessment of average level of Table 57: 
external BPA exposure from cosmetics from all age groups. See Figure 14 for key to symbols 




Value used in 
assessment 
Impact on average 
exposure estimate 
Only one analytical study on 30 products is 
available to date, from which 6 contained 
BPA. No information was given, whether 
children’s products were included. This data is 
not representative for cosmetic products in the 
EU. The range of possible concentrations of 
BPA in the EU therefore is not known. The 
highest boundary may be 10 ppm, since this is 
an acceptable level for impurities in a product. 
One product concentration was chosen for an 
exemplary worst case assessment: a face 
cream as a proxy for body lotion. 
Ccosmetics 0.031 µg/g --/++ 
Method of analysis: trace analytics +/- 15 % Ccosmetics 0.031 µg/g  
Application rates of body lotion have been 
assessed in a large study on the European 
level for adults. Data is considered as robust. 
For infants , children and adolescents, 
however, use data had to be extrapolated from 
adult data. 























It was assumed that only one cosmetic was 
used (a worst case body lotion). In reality, 
some individuals using body lotion will also 
use other cosmetics leading to some additional 
BPA exposure.  
qcosmetics  + 
 
For infant body weight a value for 1-3 months 
old infants was used (EFSA Scientific 
Committee, 2012). For toddlers also a value 
on the conservative side was used. For 
children 3-10 years the average bodyweight 
for 9 years (RIVM) was used as a 
conservative value. For adolescents the 
average bodyweight for 15 year old 
adolescents was used, which is a less 
conservative value. Adult female body 
weights vary: about 70 % are below the EFSA 
default value of 70 kg. (EFSA Scientific 
Committee, 2012) 
body weight 5 kg 
(infants) 
12 kg (toddlers) 

















Overall assessment  
A large uncertainty is associated with the occurrence of BPA in cosmetics. It is not 
clear whether the study on 30 products is representative for the European market, nor is 
it clear how BPA enters the products (during production or from packaging). 
--/++ 
(all age groups) 
 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 203 
4.2. Assessment of high non-dietary exposure 
 Evaluation of variability and uncertainties affecting the assessment of external exposure Table 58: 
from thermal paper for children (3-10 years), adolescents and adults. Note that evaluations in columns 
4 and 5 of the table are approximate expert judgements and should not be interpreted as precise 
estimates. See Figure 14 for key to symbols 




Value used in 
assessment 
Impact on high 
exposure 
estimate 
The approximation of a 95
th
 percentile was 
performed by combining two average parameter 
values (qfinger and bodyweight) with approximate 
75
th
 percentile values for two other parameters and 
an upper bound for another (BPA occurrence). It is 
uncertain whether this approach leads to the true 
95
th
 percentile. The more parameters introduced as 
the 75
th
 percentile, the higher will be the percentile. 
For two 75
th
 percentile and two average parameters 
the 95
th
 percentile is more likely to be slightly 
underestimated than overestimated. 
(all)  ●/+ 
The amount left on the fingers after handling 
thermal papers depends on the wetness and 
greasiness of the touching skin. If the paper is 
handled very shortly, not pressed and the fingers 
are dry it can be assumed that no BPA is 
transferred from the paper to the fingers at all. The 
highest amount of 30 µg transferred was observed 
for wet fingers (Lassen et al, 2011). In order not to 
multiply too many worst-case parameters (so as to 
achieve a realistic worst case) for this parameter an 
average value was used. However, this average 
presumably is on the conservative side, since it was 
derived by pressing hard on a thermal paper for 10 
s (with dry fingers), which is not always done when 
handling receipts. 
qfinger  
quantity on the 
finger 
1.4 µg (Average 
value) 
- -/++ 




1.4 µg  ● 
Maximum is 10. Normally people grasp paper with 
thumb and 1 or 2 finger tips. More contact can 
occur for those who fold their tickets, but the two 
little fingers are not involved. Based on the limited 
data available, 6 fingers per handling event is 
thought to be an approximate 75
th
 percentile and 
suitable for making an estimate of high exposure 










The used value was determined as a worst case by 
Lassen et al, 2011 from a use study with shopping 
receipts (3.6/day) and added safety value for 
unknown papers, e.g. bus tickets. The frequency of 
handling may occasionally and for special people 
be much higher, but presumably not more than 10 








4.6 / day 
(adolescents) 
 
4.6 / day 
(adults) 
-/+ 
(all age groups) 
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Value used in 
assessment 
Impact on high 
exposure 
estimate 
For children 3-10 years the average bodyweight for 
9 years (RIVM) was used as a conservative value. 
For adolescents the average bodyweight for 15 year 
old adolescents was used, which is a less 
conservative value. Adult female body weights 
vary: about 70 % are below the EFSA default value 
of 70 kg. (EFSA Scientific Committee, 2012) 














Not all thermal papers contain BPA. Presumably 
today around 80 % thermal papers contain BPA 
and the percentage may be declining due to public 
debate. 
Occurrence of 





Overall assessment.  
The largest uncertainty arises from the variability of people’s skin wetness and greasiness, 
and behavioural factors. From the combination of a conservative average for the amount on 
the fingers and approximate 75
th
 percentiles for the both use parameters, a 95
th
 percentile 
was targeted. In order to roughly check the assumptions to achieve a P95, a Monte Carlo 
simulation was performed by applying the full parameter range given above. In this Monte 
Carlo simulation the 95
th
 percentile was estimated to be about 400 ng/kg bw /d in 
comparison to 163 ng/kg bw /d for the deterministic evaluation, meaning that there is the 
possibility of underestimating the 95
th
 percentile. However, the assumption that the 
controlled experiment mimics worst-case touching of thermal paper, may have led to 
overestimation. Overall, it is estimated that the true 95
th
 percentile may be between 2-5 





 Evaluation of variability and uncertainties affecting the assessment of high external Table 59: 
exposure from cosmetics in all age groups. See Figure 14 for key to symbols 




Value used in 
assessment 
Impact on average 
exposure estimate 
The approximation of a 95
th
 percentile was 
performed by combining two average 
parameter values (Ccosmetics and bodyweight) 
with an approximate 95
th
 percentile value for 
one other parameter (qcosmetics). A further 
implicit upper bound parameter is the 
occurrence: it is assumed that all people use a 
BPA-containing body lotion on the whole 
body. However, more cosmetics than just body 
lotion may contain BPA, but since most of the 
other will result in much smaller exposure 
(due to amount applied) their contribution will 
be relatively low. It is uncertain whether this 
approach leads to the true 95
th
 percentile. For 
this combination it is more likely to be 
overestimated than underestimated. 
(all)  -/ 
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Value used in 
assessment 
Impact on average 
exposure estimate 
Only one analytical study on 30 products is 
available to date, from which 6 contained 
BPA. No information was given, whether 
children’s products were included. This data is 
not representative for cosmetic products in the 
EU. The range of possible concentrations of 
BPA in the EU therefore is not known. The 
highest boundary may be 10 ppm, since this is 
an acceptable level for impurities in a product. 
One product concentration was chosen for an 
exemplary worst case assessment: a face 
cream as a proxy for body lotion. 
Ccosmetics 0.031 µg/g --/++ 
Method of analysis: trace analytics +/- 15 % Ccosmetics 0.031 µg/g  
Application rates of body lotion have been 
assessed in a large study on the European level 
for adults. Data is considered as robust. For 
infants and children, however, use data had to 
be extrapolated from adult data by using 
surface ratios. 



















For infant body weight a value for 1-3 months 
old infants was used (EFSA Scientific 
Committee, 2012). For toddlers also a value on 
the conservative side was used. For children 3-
10 years the average bodyweight for 9 years 
(RIVM) was used as a conservative value. For 
adolescents the average bodyweight for 15 
year old adolescents was used, which is a less 
conservative value. Adult female body weights 
vary: about 70 % are below the EFSA default 
value of 70 kg. (EFSA Scientific Committee, 
2012) 
body weight 5 kg 
(infants) 
12 kg (toddlers) 

















Overall assessment  
A large uncertainty is associated with the occurrence of BPA in cosmetics. It is not 
clear whether the study on 30 products is representative for the European market, nor is 
it clear how BPA enters the products (during production or from packaging). 
--/++ 
 
 Evaluation of variability and uncertainties affecting the assessment of high external Table 60: 
exposure from dust ingestion in all age groups. See Figure 14 for key to symbols 




Value used in 
assessment 
Impact on high 
exposure estimate 
The approximation of the 95
th
 percentile was 
performed by combining two average 
parameter values (Cdust, bodyweight) with 
higher percentile values for two other 
parameters. Supposed that these parameters 
would be 75
th
 percentiles the approach would 
likely lead to a 95
th
 percentile. 
  ●/+ 
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Value used in 
assessment 
Impact on high 
exposure estimate 
Concentrations in dust are assessed in three 
European studies. Here the median value from 
the study with the middle median values was 
used.  
Cdust 1.461 mg/kg 
(Average value) 
-/+ 
Method of analysis: trace analytics +/- 15 % Cdust 1.461 mg/kg  ● 
 
Dust ingestion rates are very uncertain. They 
are derived from soil ingestion studies. No 
specific dust ingestion studies are available to 
date. It is assumed that the true value for dust 
ingestion is lower, because pika behavior 
contributes large amounts of data for toddlers. 
In this assessment the rates suggested by 
Oomen et al, 2008 were used.  











- - - / - - 
(infants) 
- - / + 
(toddlers) 
- - / + 
(children 3-10 years) 
- - / + 
(adolescents) 
- - / + 
(adults) 
For infant body weight a value for 1-3 months 
old infants was used (EFSA Scientific 
Committee, 2012). For toddlers also a value 
on the conservative side was used. For 
children 3-10 years the average bodyweight 
for 9 years (RIVM) was used as a conservative 
value. For adolescents the average bodyweight 
for 15 year old adolescents was used, which is 
a less conservative value. Adult female body 
weights vary: about 70 % are below the EFSA 
default value of 70 kg. (EFSA Scientific 
Committee, 2012) 
body weight 5 kg 
(infants) 
12 kg (toddlers) 

















Overall assessment.  
Because of the very uncertain dust ingestion rates, the true value for the 95
th
 percentile 
may be below the calculated values. However, since dust concentrations were shown to 
be higher e.g. for France both uncertainties may level out. 
- - - / + 
 
 Evaluation of variability and uncertainties affecting the assessment of high external Table 61: 
exposure from air inhalation by infants, toddlers and adults. See Figure 14 for key to symbols 




Value used in 
assessment 
Impact on average 
exposure estimate 
The approximation of a 95
th
 percentile was 
performed by combining two average 
parameter values (Cair, bodyweight) with 
the 95
th
 percentile values for qair. It is 
uncertain whether this approach leads to 
the true 95
th
 percentile.  
(all)  - /+ 
Concentrations of BPA in indoor air are 
only available for France in a limited 
study. It is not clear whether levels of BPA 
in indoor air will vary between countries 
in Europe. For this assessment it was 
assumed that people spend 100 % of their 
time indoors. Since outdoor levels of BPA 
seem to be slightly lower, this may result 
in a slight overestimation (not much, 
because on average people in 
industrialized countries spend 90 % of 
Cair 1.0 ng/m
3
 - / +++ 
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Value used in 
assessment 
Impact on average 
exposure estimate 
their time indoors). However, in one study 
for Greece levels in outdoor air were as 
high as 6 ng/m
3
. People in Greece, 
however, may spend more time outdoors 
than people in Northern Europe. Taking 
into account the high levels in outdoor air 
in Greece (which were not used in the 
assessment), there may be an 
underestimation for Greece and other 
Southern countries.  
Method of analysis and sampling together 
can affect the measurement so that the 





Inhalation rates vary  
with the activity profile. Therefore, the 
highest uncertainty is associated with the 
mix of activities during the day. Here, P95 
values proposed by EPA, 2011 were used 
























(all age groups) 
For infant body weight a value for 1-3 
months old infants was used (EFSA 
Scientific Committee, 2012). For toddlers 
also a value on the conservative side was 
used. For children 3-10 years the average 
bodyweight for 9 years (RIVM) was used 
as a conservative value. For adolescents 
the average bodyweight for 15 year old 
adolescents was used, which is a less 
conservative value. Adult female body 
weights vary: about 70 % are below the 
EFSA default value of 70 kg. (EFSA 
Scientific Committee, 2012) 
body weight 5 kg 
(infants) 
12 kg (toddlers) 

















Overall assessment. The activity profile will be very different for different 
subpopulations and different cultures. Also levels in indoor air are only 
available for one country in Europe and may be different in other countries.  
- / ++ 
 (all age groups) 
 
 
5. Evaluation of uncertainties affecting the assessment of high total exposure based on 
biomonitoring data on total BPA concentration in urine 
In this assessment, data for three- to five-year-old children were taken as a surrogate, as no 
biomonitoring data are available for one- to three-year-old toddlers. For women of childbearing age, 
data for mothers, pregnant and parturient women were used. The evaluations are approximate expert 
judgements and should not be interpreted as precise estimates. 
 Evaluation of uncertainties affecting the assessment of high total exposure in women (W) Table 62: 
of childbearing age, toddlers (T), and infants (I) based on biomonitoring data on total BPA 
concentration in urine. See Figure 14 for key to symbols 
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Source of uncertainty Parameter 
affected 






Analytical uncertainty for urinary BPA 
concentrations above LOD 
Recovery: Not a problem as all studies use isotope-
dilution mass spectrometry with recovery correction 
Repeatability: Intra- and inter-day CV < 21 % 
Accuracy: < ±20 % (intra- and inter-day). Taken 
together, the overall analytical uncertainty is regarded as 
being within ± 20 % 
BPA 
concentration 
in urine, CBPA 
(µg/L) 
Range of 95th 
percentiles: 
W: 5–12 µg/L 
T: 23 µg/L 





Contamination of urine samples 
Most studies report only total BPA concentration in 
urine, but only a few studies also report the 
concentration of unconjugated BPA. It can, however, be 
expected that contamination of urine samples during 
collection and storage is generally under control. A 
small proportion of total BPA might be from 
contamination, which would then result in a slight 
overestimation, so it tends to be conservative 
BPA 
concentration 
in urine, CBPA 
(µg/L) 
Range of 95th 
percentiles: 
W: 5–12 µg/L 
T: 23 µg/L 





Number of subjects per study is 60–164 (women), 30–
137 (toddlers), and 46 (infants). The relatively low 
number of subjects in some studies may result in a 
sampling bias. Moreover, only a few European studies 
(GerES IV, INMA) can be assumed to be representative 
for a specific age class and geographical region. The 
database contains 10 studies for women from 10 
different European countries (but only six have reported 
a 95th percentile), two European studies for “toddlers” 
(but only one has reported a 95th percentile), and one 
European study for infants. Biomonitoring studies may, 
therefore, not have captured high levels of exposure that 




in urine, CBPA 
(µg/L) 
Range of 95th 
percentiles: 
W: 5–12 µg/L 
T: 23 µg/L 






Most studies provide the 95th percentile (P95) of the 
distribution of the BPA concentration in individual 
urinary samples. The P95 is used to obtain estimates for 
high BPA exposures. Many studies report data for spot 
urine samples, for which the P95 relates to the 95 % 
probability that a single, randomly collected sample 
from a randomly selected subject has an urinary BPA 
concentration not exceeding the P95. This is important 
as urinary BPA concentrations of repeated urine 
collections from individuals may vary by up to two 
orders of magnitude. Some studies exist that indicate 
that the total variance can be broken down into 70 % 
within-day variability, 21 % between-day variability, 
and 9 % between-person variability. Thus, taking the 
P95 of the reported values will overestimate the P95 of 





Range of 95th 
percentiles: 
W: 5–12 µg/L 
T: 23 µg/L 
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Source of uncertainty Parameter 
affected 






Uncertainty in specific urinary output rate 
The specific urinary output rate (mL/kg bw per day) is 
the urinary output rate (mL/day) divided by body weight 
(kg) For the urinary output rate, generic values were 
generally used to estimate the average urinary output 
rate per population subgroup. These generic values were 
derived by linear interpolation from urinary output vs. 
age relationships taken from the literature. Some studies, 
however, collected 24-hour urine samples and provided 
individual data for daily urinary output. The average of 
these experimental data can be compared with generic 
values to obtain a measure of possible bias. For 
example, the German ESB study (Koch et al., 2012) 
analysed historical 24-hour urine samples of 20- to 30-
year-old male and female students and reported an 
increase in urinary output rate from 1 500 mL/day in 
1995 to 2 000 mL/day in 2009. The generic value for 
adults (averaged over males and females) is 
1 400 mL/day. In this particular case, the deviation of 
the average experimental values from the generic value 
is + 7 % and + 42 %. 
For body weight, too, generic values were generally used 
to estimate the average body weight per population 
subgroup. These generic values were derived by linear 
interpolation from body vs. age relationships taken from 
the literature. Some studies, however, measured the 
individual body weights. The average of these 
experimental data can be compared with generic values 
to obtain a measure of possible bias. The available data 
suggest the uncertainty to be within ± 20 %. 
Taking both parameters together, the range of values for 
the specific urinary output rate for women is 17–
27 mL/kg bw per day. For studies for which the upper 
value was taken, the true value could be lower by a 
factor of 1.6. For studies for which the lower value was 





bw per day) 
Range of values: 
W: 17–27 mL/kg 
bw per day 
T: 30 mL/kg bw 
per day 





Uncertainty about time trends in exposure 
Urinary samples were collected in different time periods, 
i.e. in 2004–2012 (women), 2003–2006 (“toddlers”) and 
2008 (infants). There could be changes in exposure over 
the years in exposure. A retrospective study using 
historical samples of students from the German ESB 
study indicated a gradual decline in the 95th percentiles 
from 1995 to 2001/2003, which, however, did not 
continue from 2003 on and seemed to be reversed to 
some extent from 2003 on (Koch et al., 2012). The 
results of US NHANES suggests a slight decline in the 
95th percentiles of 257 ng/kg bw per day to 
183 ng/kg bw per day for adults over the period from 







Range of 95th 
percentiles: 
W: 85–234 ng/kg 
bw per day 
T: 676 ng/kg bw 
per day 
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Source of uncertainty Parameter 
affected 






Uncertainty in extrapolating from children to 
toddlers 
There is no indication that the exposure of three- to five-
year-old children, which was taken as a surrogate for the 
exposure of one- to three-year-old toddlers, is 
substantially different from that of toddlers. The first 
line of evidence from the biomonitoring study GerES IV 
is that three- to five-year-old children have a higher 
exposure than six- to eight-year-old children (Becker et 
al., 2009). Other biomonitoring studies on four-year-old 
children (INMA) and older children (Duisburg BCS, 
Liege HBM, DEMOCOPHES) provide additional 
support for this age dependency. The second line of 
evidence is that the modelling approach did not indicate 
substantial differences in the high total exposure 
between toddlers and the age class of 3- to 10-year-old 
children. This provides an indirect indication for similar 
exposures between the toddlers and the surrogate group 
of three- to five-year-old children, because this group 
can be expected to be in the upper tail of the modelled 







Range of 95th 
percentiles: 




The main sources of uncertainty in the estimation of high total exposure based on 
biomonitoring data are the sampling uncertainty owing to limitations in the representativity of 
the available information on total BPA concentration in urine, the distribution uncertainty in 
the 95th percentile, and the uncertainty in the specific urinary output rate. The last uncertainty 
is two-sided. The distribution uncertainty in the 95th percentile is one-sided so that the true 
value for high total exposure is likely to be lower than the estimate. The sampling uncertainty is 
also one-sided but orientated in the opposite direction so that the true value for high total 
exposure is likely to be higher than the estimate. Overall, the two uncertainties in opposite 
directions may cancel out to some extent, but the outcome could be positive or negative 
depending on their true magnitudes. Hence, the overall assessment is that the true value could 
be either lower or higher than the estimate 
The estimates for high total exposure are 234 ng/kg bw per day for women (W) of childbearing 
age, 676 ng/kg bw per day for “toddlers” (T) and 161 ng/kg bw per day for infants (I) 
As a control check for the high total exposure estimate for women (which was derived from the 
highest 95th percentile of six studies), a parametric statistic was calculated from the log10-
transformed individual P95 values and, based on that, the value 10
(average + 1.64 × sigma)
 was then 
used as a proxy for a hypothetical European country with the highest P95. This control check 
yielded a value of 296 µg/L, which is 26 % higher than the chosen value of 234 µg/L for 
women. No such control checking is possible for “toddlers” and infants. However, compared 
with the infant study (n = 46), the study for “toddlers” is a large-sized (n = 137) representative 
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Appendix I. Literature quality tables 
 Literature quality table—occurrence in food Table 63: 
Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Determination of bisphenol A in US infant formulas: 
updated methods and concentrations. 
Ackerman, L. K., Noonan, G. O., Heiserman, W. M., 
Roach, J. A, Limm, W. and Begley, T. H. 







Not considered Excluded – samples 
from USA (i.e. did not 
meet geographical origin 
criteria) 
Comparison of Single-walled Carbon Nanotubes, Multi-
walled Carbon Nanotubes and C18 as Adsorbents for the 
Solid Phase Extraction of Bisphenol A and Bisphenol F in 
Canned Food. 
Ahmadkhaniha, R., Salimi, M. and Rastkari, N. 







Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Analytical methods for the determination of bisphenol A 
in food. 
Ballesteros-Gomez, A. Rubio, S. and Perez-Bendito, D. 






Not considered Excluded - analytical 
method review paper - 
no relevant data reported 
for calculation of 
exposure from food 
Migration of cyclo-diBA from coatings into canned food: 





Not considered Excluded – paper 
published after 
                                                     
24
 For inclusion/exlusion criteria see Appendix A. 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 212 
Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
and in silico hazard profiling. 
Biedermann, S., Zurfluh, M., Grob, K., Vedani, A. and 
Brüschweiler, B. J. 
Food and Chemical Toxicology. 2013. 58, 107-115. 
10.1016/j.fct.2013.04.004 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Determination of bisphenol A in wine by sol-gel 
immunoaffinity chromatography, HPLC and fluorescence 
detection. 
Brenn-Struckhofova, Z. and Cichna-Markl, M. 
Food Additives and Contaminants. 2006. 23:11, 1227–
1235. 
10.1080/02652030600654382 
Austria 46 white and 
13 red wine 
samples of 
which 10 were 
taken directly 
from the wine 
vats, 21 had 
been filled 
into glass 










Filtered samples were cleaned-up by sol-gel 
immunoaffinity chromatography, using 
polyclonal BPA rabbit antibodies. Analysis was 
carried out by HPLC-FLD. 
 
LOD (3x Signal:Noise ratio (S:N)) = 0.1 μg/L 
LOQ (6x S:N) = 0.2 μg/L 
Recovery = 74 - 81 % (average of three spiking 
levels: 0.4, 0.8 and 1.2 μg/L) 
Repeatability = not given 
Calibration = external standards 0.3 to 100 μg/L 
in mobile phase 
Measures taken to reduce contamination: No 




NOTE: although no 
measures were described 
to reduce background 
contamination the paper 
described concentration 
data for wine which was 
not available elsewhere 
and so was included 
Stir bar sorptive extraction coupled to gas 
chromatography-mass spectrometry for the determination 
of bisphenols in canned beverages and filling liquids of 
canned vegetables. 












Following degassing and dilution with water the 
BPA was derivatised in situ with acetic 
anhydride, extracted using stir bar sorptive 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 




LOD = 2.5 ng/L in solution (3x st dev of the 
procedural blank) equates to 12.5 ng/L in 
sample (sample was diluted x5 with water prior 
to analysis) 
LOQ = 8.4 ng/L (10x st dev of the procedural 
blank) equates to 42 ng/L in sample (sample 
was diluted x5 with water prior to analysis)                                                                                     
Recovery = 86-122 % at 0.1 µg/L and 97-105 % 
at 1 µg/L 
Repeatability = 1.9 % intraday and 3.1 % 
interday for water spiked with BPA at 0.5 µg/L. 
< 10 % in matrix (recovery study) 
Calibration = external standards 0.02 to 
2.5 μg/L in water 
Measures taken to reduce contamination: 
Reported repeatable trace background levels of 
BPA of 10 ng/L - background concentration was 
subtracted from reported values. 
Levels of bisphenol A in canned liquid infant formula 
products in Canada and dietary intake estimates. 
Cao, X. L., Dufresne, G., Belisle, S., Clement, G., Falicki, 
M., Beraldin, F. and Rulibikiye, A. 





Not considered Excluded - samples from 
Canada (i.e. did not meet 
geographical origin 
criteria) 
Migration of bisphenol A from can coatings to liquid 
infant formula during storage at room temperature. 
Cao, X. L., Corriveau, J., Popovic, S. 
Journal of Food Protection. 2009. 72:12, 2571-2574. 
Canada Not 
considered 
Not considered Excluded - samples from 
Canada (i.e. did not meet 
geographical origin 
criteria) 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
DOI not given 
Levels of bisphenol A in canned soft drink products in 
Canadian markets. 
Cao, X. L., Corriveau, J., Popovic, S. 





Not considered Excluded - samples from 
Canada (i.e. did not meet 
geographical origin 
criteria) 
Bisphenol A in baby food products in glass jars with metal 
lids from Canadian markets. 
Cao, X. L., Corriveau, J., Popovic, S., Clement, G., 
Beraldin, F. and Dufresne, G. 





Not considered Excluded - samples from 
Canada (i.e. did not meet 
geographical origin 
criteria) 
Bisphenol A in canned food products from Canadian 
markets. 
Cao, X. L., Corriveau, J., Popovic, S. 
Journal of Food Protection. 2010. 73, 1085-1089. 
DOI not given 
Canada Not 
considered 
Not considered Excluded - samples from 
Canada (i.e. did not meet 
geographical origin 
criteria) 
Sources of low concentrations of bisphenol A in canned 
beverage products. 
Cao, X. L., Corriveau, J., Popovic, S. 
Journal of Food Protection. 2010. 73, 1548-1551. 
DOI not given 
Canada Not 
considered 
Not considered Excluded - samples from 
Canada (i.e. did not meet 
geographical origin 
criteria) 
Concentrations of bisphenol A in the composite food 
samples from the 2008 Canadian total diet study in 
Canada  Not 
considered 
Not considered Excluded - samples from 
Canada (i.e. did not meet 
geographical origin 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Quebec City and dietary intake estimates. 
Cao, X. L., Perez-Locas, C., Dufresne, G., Clement, G., 
Popovic, S., Beraldin, F., Dabeka, R. W. and Feeley, M. 




The contribution of diet to total bisphenol A body burden 
in humans: Results of a 48 hour fasting study. 
Christensen, K. L., Lorber, M., Koslitz, S., Bruning, T. 
and Koch, H. M. 






Not considered Excluded - 
biomonitoring data only 
- no relevant data for 
calculation of exposure 
from food 
 
NOTE: paper considered 
in the scope of the 
biomonitoring 
assessment 
Simultaneous determination of bisphenol A and bisphenol 
B in beverages and powdered infant formula by dispersive 
liquid–liquid micro-extraction and heartcutting 
multidimensional gas chromatography-mass 
spectrometry. 
Cunha, S. C., Almeida, C., Mendes, E. and Fernandes, J. 
O. 























BPA was extracted from the samples using 
disperse liquid-liquid micro-extraction with 
simultaneous derivatisation with acetic 
anhydride. Analysis was carried out by two-
dimensional GC-MS. 
 
LOD = 0.005 μg/L in canned beverages and 
0.06 μg/L in reconstituted powdered infant 
formula (3x S:N) 
LOQ = 0.01 μg/L in canned beverages and 
0.20 μg/L in reconstituted powdered infant 
formula (10x S:N) 
Recovery = 83 % for beverage spiked at 
Included 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
0.05 μg/L, 93 % for beverage spiked at 0.2 
μg/L; 114 % for powdered infant formula 
spiked at 0.05 μg/L, 93 % for powdered infant 
formula spiked at 0.2 μg/L (six replicates of 
each) 
Repeatability = 8 % for beverage spiked at 
0.05 μg/L, 8 % for beverage spiked at 0.2 μg/L; 
15 % for powdered infant formula spiked at 
0.05 μg/L, 7 % for powdered infant formula 
spiked at 0.2 μg/L (six spiked replicates) 
Calibration = Matrix matched - 0.02-10 μg/L for 
beverages and 0.5-10 μg/L for infant formula 
Measures taken to reduce contamination: BPA 
free bottled beverages and milk samples used as 
method blanks to check for background 
contamination. 
Determination of bisphenol A and bisphenol B in canned 
seafood combining QuEChERS extraction with dispersive 
liquid-liquid microextraction followed by gas 
chromatography-mass spectrometry. 
Cunha, S. C., Cunha, C., Ferreira, A. R. and Fernandes, J. 
O. 























canned eel, 1 
canned 
BPA was extracted from the fish samples using 
acetonitrile with QuEChERS and DLLME 
clean-up. The extracted BPA was derivatised 
using acetic anhydride and the derivative 
analysed by GC-MS. 
 
LOD = 0.2 μg/kg in the foodstuff (3x S:N) 
LOQ = 1 μg/kg in the foodstuff (corresponding 
to the lowest calibration standard) 
Recovery = 68-104 % for tuna, 71-104 % for 
sardines in sauce (spike levels = 1, 5 and 
20 µg/kg) 
Repeatability = 8-21 % for tuna, 11-19 % for 
sardines in sauce (spike levels = 1, 5 and 
Included 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24





Calibration = matrix matched standards in the 
range 1 to 150 µg/kg 
Measures taken to reduce contamination: 
Muffled glassware was used - no plasticware - 
to minimise contamination.  Method blanks 
were prepared periodically to check for 
background contamination 
Assessment of bisphenol A and bisphenol B in canned 
vegetables and fruits by gas chromatography-mass 
spectrometry after QuEChERS and dispersive liquid-
liquid microextraction. 
Cunha, S. C. and Fernandes, J. O. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Endocrine disrupting chemicals in fish bile: A rapid 
method of analysis using English sole (Parophrys vetulus) 
from Puget Sound, WA, USA. 
da Silva, D. A. M., J. Buzitis, J., Reichert, W. L., West, J. 
E., O’Neill, S. M., Johnson, L. L., Collier, T. K. and 
Ylitalo, G. M. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Uptake and accumulation of four PPCP/EDCs in two leafy 
vegetables. 
Dodgen, L. K., Li, J., Parker, D. and Gan, J. J. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
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Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
The investigation of bisphenol A presence in canned tuna 
fish using high-performance-liquid chromatography 
method. 
Er, B. and Sarimehmetoğlu, B. 
Journal of Animal and Veterinary Advances. 2011. 10, 
2859-2862. 







Solvent extracted samples were cleaned-up by 
SPE. Analysis was carried out by HPLC-FLD 
 
LOD = 1.96 μg/L in solution  
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Calibration = Not specified 
Measures taken to reduce contamination: No 
information on prevention of contamination or 
blanks  
Excluded - method 
performance criteria not 
defined and so method 
quality criteria could not 
be confirmed to have 
been met 
Simultaneous determination of bisphenol A, octylphenol, 
and nonylphenol by pressurised liquid extraction and 
liquid chromatography–tandem mass spectrometry in 
powdered milk and infant formulas. 
Ferrer, E., Santoni, E., Vittori, S., Font, G., Manes, J. and 
Sagratini, G. 















BPA was extracted using pressurised liquid 
extraction with a C18 dispersant. Analysis was 
carried out by LC-MS/MS. 
 
LOD (3x S:N) = 5 µg/kg 
LOQ (10x S;N) = 16 µg/kg 
Recovery = 89-92 % for five replicates of infant 
formula and powdered skimmed milk spiked at 
50 μg/kg and 500 μg/kg 
Repeatability =  12 to 14 % or five replicates of 
infant formula and powdered skimmed milk 
spiked at 50 μg/kg and 500 μg/kg  
Calibration = Matrix matched - concentration 
range 3 orders of LOQ 
Measures taken to reduce contamination: No 
measures against contamination reported  
Excluded - the reported 
concentrations were 
described as comparable 
to others in the literature 
however the values 
given in this paper were 
several orders of 
magnitude greater than 
the supposedly 
comparable values 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Determination of bisphenol A in foods as 2,2-bis-(4-
(isopropoxycarbonyloxy)phenyl)propane by gas 
chromatography/mass spectrometry. 
Feshin, D. B., Fimushkin, P. V., Brodskii, E. S., 
Shelepchikov, A. A., Mir-Kadyrova, E. Y. and 
Kalinkevich, G. A.  
Journal of Analytical Chemistry. 2012. 67:5, 460-466. 




One sample of 









Aqueous samples derivatised directly in the 
matrix with isopropyl chloroformate, other 
foods solvent extracts were derivatised 
following sample clean-up by SPE for fat 
containing samples. Analysis was carried out by 
GC-MS. 
 
LOD < 0.05 μg/kg for energetic beverage, 
< 0.1 μg/kg for infant meat puree, infant 
formula feed, canned meat and canned 
vegetables    
LOQ = not given 
Recovery = 103 % when 300 ng added - average 
of triplicate results, 104 % when 600 ng added 
(BPA spiked into apple juice mass of apple 
juice not given) 
Repeatability = 0.005 % given in paper - 
actually 3.8 % using data given (triplicate 
extracts of a meat puree sample at 1.33 μg/kg)  
Calibration = 5 to 1200 ng (in 20 mL water)    
Measures taken to reduce contamination: A 
method blank was prepared in each batch to 
check for contamination    
Included 
Field-amplified sample injection-micellar electrokinetic 
capillary chromatography for the analysis of bisphenol A, 
bisphenol F, and their diglycidyl ethers and derivatives in 
canned soft drinks. 






Not considered Excluded - analytical 
method paper - no 
relevant data reported 
for calculation of 
exposure from food 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Electrophoresis. 2010. 31:9, 1550-1559. 
10.1002/elps.200900606 
Analysis of bisphenols in soft drinks by on-line solid 
phase extraction fast liquid chromatography-tandem mass 
spectrometry. 
Gallart-Ayala, H., Moyano, E. and Galceran, M. T. 








beer, tea and 
energy drinks) 
Beverage samples were analysed directly. BPA 
was concentrated using on-line SPE. Analysis 
was carried out by LC-MS. 
 
LOD = 0.025 μg/L in the cola, 0.015 μg/L in the 
lemon soda and 0.025 μg/L in the tonic water 
(3x S:N)         
LOQ = 0.085 μg/L in the cola, 0.050 μg/L in the 
lemon soda and 0.085 μg/L in the tonic water 
(10x S:N)        
Recovery = 98 % in the cola, 97 % in the lemon 
soda and 97 % in the tonic spiked at 0.5 μg/L, 
98 % in the cola, 96 % in the lemon soda and 
94 % in the tonic spiked at 0.2 μg/L (five 
replicates of each)  
Repeatability = 2.5 % in the cola, 4 % in the 
lemon soda and 3.5 % in the tonic spiked at 
0.5 μg/L, 3 % in the cola, 5 % in the lemon soda 
and 5 % in the tonic spiked at 0.2 μg/L (five 
replicates of each)                     
Calibration = 0.05 to 10 μg/L       
Measures taken to reduce contamination: 
Avoided the use of plastic-ware with on-line 
SPE. Water blank samples were injected 
between sample batches to control carry-over 
and background contamination. 
Included 
Decanoic acid reverse micelle-based coacervates for the 
microextraction of bisphenol A from canned vegetables 
Samples 
purchased in 
1 can of each 
of red peppers, 
BPA was extracted from the foods using 
coacervative microextraction. Analysis was 
Included 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
and fruits. 
García-Prieto, L., Lunar, L., Rubio, S. and Pérez-Bendito, 
D. 






in syrup - all 
from Spain 
and 1 can of 
mango slices 
from Thailand 
carried out by LC-FLD 
 
LOD = 1.3 μg/kg peas (3x S:N) 
LOQ = 9.3 μg/kg (not stated how determined) 
Recovery = 86 % for six replicates of peas 
spiked at 200 μg/kg 
Repeatability = 2.8 % for six replicates of peas 
spiked at 200 μg/kg 
Calibration = 0.14 to 20 ng BPA in acetonitrile 
(not expressed as a concentration) 
Measures taken to reduce contamination: No 
measures against contamination reported  
Intake of bisphenol A from canned beverages and foods 
on the Belgian market. 
Geens, T., Zipora Apelbaum, T., Goeyens, L., Neels, H. 
and Covaci, A. 






50 beverages  
(45 canned, 4 
in PET and 1 
in Tetra Pak) 




soups, fish and 
meat (27 
canned, 1 in 
paper, 2 in 
Tetra Pak, 10 
in glass and 4 
in plastic 
containers) 
After degassing BPA was extracted from the 
beverage sample using SPE. BPA was extracted 
from solid content of canned foods using 
solvent.  The liquid content of canned food was 
filtered. Analysis was carried out by GC-MS 
after derivatisation with 
pentafluorobenzoylchloride. 
 
LOD = not given 
LOQ = 0.02 μg/kg for beverages, 0.10 μg/kg for 
food (calculated from 3x st dev of the 
procedural blanks) 
Recovery = 95 % for beverages spiked at 
4.4 μg/L, 93 % for foods spiked at 10.5 μg/kg 
Repeatability = within day = 0.8 - 5.5 % for 
beverages spiked at 4.4 μg/L and 2.8 % for 
foods spiked at 10.5 μg/kg; between day = 
Included 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
3.0 % for beverages spiked at 4.4 μg/L and 
2.8 % for foods spiked at 10.5 μg/kg 
Calibration = not given 
Measures taken to reduce contamination: 
Method blank prepared to determine any 
contamination through the procedure 
A review of dietary and non-dietary exposure to 
bisphenol-A. 
Geens, T., Aerts, D., Berthot, C., Bourguignon, J. P., 
Goeyens, L., Lecomte, P., Maghuin-Rogister, G., 
Pironnet, A. M., Pussemier, L., Scippo, M. L., Van Loco, 
J. and Covaci, A. 






Not considered Excluded - review paper 
- no relevant data for 
calculation of exposure 
from food 
Determination of bisphenol A and bisphenol B residues in 
canned peeled tomatoes by reversed-phase liquid 
chromatography. 
Grumetto, L., Montesano, D., Seccia, S., Albrizio, S. and 
Barbato, F. 









from Italy, 4 









BPA was extracted from the samples with 
solvent, concentrated and the solvent extracts 
passed down the SPE cartridges. Analysis was 
carried out by LC-UV and LC-FLD (fractions 
were collected and infused into an MS source 
for confirmation) 
 
LOD = 1.1 μg/kg (calculated as 3x st dev of the 
noise) 
LOQ = 3.7 μg/kg (calculated as 10x st dev of 
the noise) 
Recovery = 94.3 % BPA spiked at 100, 200, 
300 and 500 μg/kg into blank tomatoes 
Repeatability = 2.63 % BPA spiked at 100, 200, 
300 and 500 μg/kg into blank tomatoes 
Included 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Calibration = External calibration 50 to 
1000 μg/L 
Measures taken to reduce contamination: 
Control (previously verified as BPA free) 
tomato samples used as method blank matrices 
to determine any contamination through the 
procedure. No plastic ware was used in the 
laboratory 
Determination of five bisphenols in commercial milk 
samples by liquid chromatography coupled to 
fluorescence detection. 
Grumetto, L., Gennari, O., Montesano, D., Ferracane, R., 
Ritieni, A., Albrizio, S. and Barbato, F. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
4-Nonylphenol and bisphenol A in Swedish food and 
exposure in Swedish nursing women. 
Gyllenhammar, I., Glynn, A., Darnerud, P. O., Lignell, S., 
van Delft, R. and Aune, M.  









Not considered Excluded – the samples 
were market basket with 
wide pooled samples. 
Some of the pooled 
samples also had canned 
and non-canned food 
together (i.e. did not 
meet the sample type 
criteria) 
Determination of bisphenol A in Iranian packaged milk by 
solid-phase extraction and HPLC. 
Hadjmohammadi, M. R. and Saeidi, I. 




Not considered Excluded - samples from 
Iran (i.e. did not meet 
geographical origin 
criteria) 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Development of a liquid chromatography-tandem mass 
spectrometry procedure for determination of endocrine 
disrupting compounds in fish from Mediterranean rivers. 
Jakimska, A., Huerta, B., Barganska, Z., Kot-Wasik, A., 
Rodriguez-Mozaz, S. and Barcelo, D. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Human exposure to bisphenol A. 
Kang, J. H., Kondo, F. and Katayama, Y. 






Not considered Excluded - review paper 
from Japan - no relevant 
data for calculation of 
exposure from food 
Optimized extraction method for LC–MS determination of 
bisphenol A, melamine and di(2-ethylhexyl) phthalate in 
selected soft drinks, syringes, and milk powder. 
Khedr, A.  






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Determination of bisphenol-A, 2,4-dichlorophenol, 
bisphenol-AF and tetrabromobisphenol-A in liquid foods 
and their packaging materials by vortex-assisted 
supramolecular solvent microextraction/high-performance 
liquid chromatography. 
Li, Y., Jiao, Y., Guo, Y. and Yang, Y. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Determination of Bisphenol A and Alkylphenols in Soft 





Not considered Excluded – paper 
published after 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
with Fluorescence Detection. 
Li, Y., Zhang, S., Song, C. and You, J. 
Food Analytical Methods. 2013. 6:5,: 1284-1290. 
10.1007/s12161-012-9541-0 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Concentrations and profiles of bisphenol A and other 
bisphenol analogues in foodstuffs from the United States 
and their implications for human exposure. 
Liao, C. and Kannan, K. 







Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Risk assessment of bisphenol A migrated from canned 
foods in Korea. 
Lim, D. S., Kwack, S. J., Kim, K. B., Kim, H. S. and Lee, 
B. M. 
Journal of Toxicology and Environmental Health. Part A. 




Not considered Excluded - samples from 
Korea (i.e. did not meet 
geographical origin 
criteria) 
On-line precolumn enrichment of bisphenol A using 
boronate column in microcolumn liquid chromatography. 
Lim, L. W. and Takeuchi, T. 






Not considered Excluded - analytical 
method paper - no 
relevant data for 
calculation of exposure 
from food 
Elimination of matrix effects in the determination of 
bisphenol A in milk by solid-phase microextraction-high-
performance liquid chromatography. 
Liu, X., Ji, Y., Zhang, H. and Liu, M. 
China Not 
considered 
Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Food Additives and Contaminants. 2008. 25:6, 772-778. 
10.1080/02652030701713921 
Development and comparison of two dispersive liquid–
liquid microextraction techniques coupled to high 
performance liquid chromatography for the rapid analysis 
of bisphenol A in edible oils. 
Liu, S., Xie, Q., Chen, J., Sun, J., He, H. and Zhang, X. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Isotope dilution-gas chromatography/mass spectrometry 
method for the analysis of alkylphenols, bisphenol A, and 
estrogens in food crops. 
Lu, J., Wu, J., Stoffella, P. J. and Wilson, P. C. 






Not considered Excluded - samples from 
USA (i.e. did not meet 
geographical origin 
criteria) 
Determination of bisphenol A in milk by solid phase 
extraction and liquid chromatography–mass spectrometry, 
Maragou, N.C., Lampi, E. N., Thomaidis, N. S. and 
Koupparis, M. A. 












BPA was extracted from the milk samples using 
solid phase extraction. Analysis was carried out 
by LC-ESI-MS  
 
LOD = 1.7 μg/kg milk (3.3×SDn=10)/b) where 
SD is the st dev of the response of 10 replicate 
milk samples spiked at 5 μg/kg, b is the slope of 
the calibration line from 5 to 200 μg/L 
LOQ = 5.1 μg/kg milk ((10×SDn=10)/b) 
Recovery = 83 % for milk spiked at 5 μg/kg, 
101 % for milk spiked at 50 μg/kg and 106 % 
for milk spiked at 500 μg/kg (intra-day, n=6); 
97 % for milk spiked at 5 μg/kg, 97 % for milk 
Included 
Scientific opinion on BPA: Part I – Exposure assessment 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
spiked at 50 μg/kg and 104 % for milk spiked at 
500 μg/kg (inter-day, n=6) 
Repeatability = 12.5 % for milk spiked at 
5 μg/kg, 5.0 % for milk spiked at 50 μg/kg and 
2.1 % for milk spiked at 500 μg/kg (intra-day, 
n=6); 17.6 % for milk spiked at 5 μg/kg, 5.8 % 
for milk spiked at 50 μg/kg and 5.2 % for milk 
spiked at 500 μg/kg (inter-day, n=6) 
Calibration = External calibration 5 to 700 μg/L 
Measures taken to reduce contamination: Water 
and milk blanks were analysed in each batch to 
check for contamination 
Dietary exposure assessment of pregnant women to 
bisphenol-A from cans and microwave containers in 
Southern Spain. 
Mariscal-Arcas, M., Rivas, A., Granada, A., Monteagudo, 
C., Murcia, M. A. and Olea-Serrano, F. 






Not considered Excluded - no relevant 
data for calculation of 
exposure from food 
Selective Molecularly Imprinted Polymer Obtained from a 
Combinatorial Library for the Extraction of Bisphenol A. 
Martin-Esteban, A. and Tadeo, J. L. 
Combinatorial Chemistry and High Throughput 
Screening. 2006. 9, 747-751. 





Not considered Excluded - analytical 
method paper - no 
relevant data for 
calculation of exposure 
from food 
Bisphenol A content in fish caught in two different sites of 
the Tyrrhenian Sea (Italy). 









Solvent extracted samples were cleaned-up by 
SPE. Analysis was carried out by HPLC-UV or 
FLD and in some cases were validated by GC-
Excluded - method 
performance criteria not 
defined and so method 
quality criteria could not 
Scientific opinion on BPA: Part I – Exposure assessment 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
U., Sica, V., Monaco, G., Portaccio, M., Diano, N., 
Colonna, A., Lepore, M., Canciglia, P. and Mita, D. G.  
Chemosphere. 2011. 82, 405-410. 
10.1016/j.chemosphere.2010.09.071 






LOD = not given 
LOQ = not given 
Recovery = not given 
Repeatability = not given 
Calibration = not given 
Measures taken to reduce contamination: 
Samples stored in glass containers but no other 
measures described to reduce background 
contamination 
be confirmed to have 
been met 
Analysis of bisphenol A in milk by using a 
multicommuted fluorimetric sensor. 
Molina-García, L., Fernández-de Córdova, M. L.  and 
Ruiz-Medina, A. 





3 x Powdered 
milk, 2 x 
powdered 
infant formula, 
3 x liquid 
infant formula 
and 6 x liquid 
milk 
Following precipitation of the protein the BPA 
was extracted from the sample using SPE. 
Analysis was carried out using a 
multicommuted fluorimetric sensor 
 
LOD = 0.06 μg/L (paper doesn't describe how it 
was determined) 
LOQ = 0.2 μg/L (0.19 μg/kg) (not described 
how determined) 
Recovery = 93-106 % for four samples spiked at 
0.5, 2.0 and 5.0 μg/L 
Repeatability = Intra-day = 3.4 % at 4 μg/L. 
Inter-day = 5.7 % at 4 μg/L 
Calibration = 0.2 to 5.0 μg/L 
Measures taken to reduce contamination: No 
measures against contamination reported  
Included 
Development of monoclonal antibody-based Not Not Not considered Excluded - analytical 
Scientific opinion on BPA: Part I – Exposure assessment 
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Title 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
immunoassays for the analysis of bisphenol A in canned 
vegetables. 
Moreno, M. J., D'Arienzo, P., Manclus, J. J. and Montoya, 
A.  
Journal of Environmental Science and Health B. 2011. 
46:6, 509-517. 
10.1080/03601234.2011.583871 
considered considered method paper - no 
relevant data for 
calculation of exposure 
from food 
Assessing the quantitative relationships between preschool 
children's exposures to bisphenol A by route and urinary 
biomonitoring. 
Morgan, M. K., Jones, P. A., Calafat, A. M., Ye, X., 
Croghan, C. W., Chuang, J. C., Wilson, N. K., Clifton, M. 
S., Figueroa, Z. and Sheldon, L. S. 







Not considered Excluded - 
biomonitoring data only 
- no relevant data for 
calculation of exposure 
from food 
 
NOTE: paper considered 
in the scope of the 
biomonitoring 
assessment 
Occurrence of endocrine disruption chemicals (Bisphenol 
A, 4-nonylphenol, and Octylphenol) in muscle and liver 
of, Cyprinus Carpino Common, from Anzali wetland, 
Iran. 
Mortazavi, S., Bakhtiari, A. R., Sari, A. E., Bahramifar, N. 
and Rahbarizadeh, F. 
Bulletin of Environmental Contamination and Toxicology. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Development of a multiresidue method for the 
determination of endocrine disrupters in fish fillet using 





Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
Scientific opinion on BPA: Part I – Exposure assessment 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
spectrometry. 
Munaretto, J. S., Ferronato, G., Ribeiro, L, C., Martins, M. 
L., Adaime, M. B. and Zanella, R. 
Talanta. 2013. 116, 827-834. 
10.1016/j.talanta.2013.07.047 
not meet publication 
period criteria) 
Simultaneous determination of bisphenol A and 
alkylphenol in plant oil by gel permeation 
chromatography and isotopic dilution liquid 
chromatography-tandem mass spectrometry. 
Niu, Y., Zhang, J., Wu, Y. and Shao, B. 






Not considered Excluded - analytical 
method paper - no 
relevant data for 
calculation of exposure 
from food 
Analysis of bisphenol A and alkylphenols in cereals by 
automated on-line solid-phase extraction and liquid 
chromatography tandem mass spectrometry 
Niu, Y., Zhang, J., Wu, Y. and Shao, B. 





Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
Concentration of bisphenol A in highly consumed canned 
foods on the US market. 
Noonan, G. O., Ackerman, L. K. and Begley, T. H. 







Not considered Excluded - samples from 
USA (i.e. did not meet 
geographical origin 
criteria) 
Design and implementation of an imprinted material for 





Not considered Excluded – paper 
published after 
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Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
milk. 
O’Mahony, J., Moloney, M., McCormack, M., Nicholls, I. 
A., Mizaikoff, B. and Danaher, M. 
Journal of Chromatography B. 2013. 931, 164-169. 
10.1016/j.jchromb.2013.05.025 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Assessment of PCDD/F, PCB, OCP and BPA dietary 
exposure of non-breast-fed European infants. 
Pandelova, M., Piccinelli, R., Levy Lopez, W., 
Henkelmann, B., Molina-Molina, J. M., Arrebola, J. P., 
Olea, N., Leclercq, C. and Schramm, K.-W. 




















the diet of 
babies aged 5 
to 9 months of 
age (including 
jarred foods) 
BPA was extracted from the infant formula 
samples using acetonitrile. BPA was extracted 
from the freeze-dried solid food samples using 
hexane and acetonitrile. Following solid phase 
extraction the extracts were evaporated to 
dryness and derivatised using BSTFA. Analysis 
was carried out by GC-MS. Chlorinated BPA 
determined as well as BPA 
 
LOD = 0.8 to 1.7 μg/kg for BPA and it's 
chlorinated derivatives in the infant formula and 
1.5 to 3.3 μg/kg for BPA and it's chlorinated 
derivatives in the solid foods and beverages (the 
paper doesn't describe how these were 
determined) 
LOQ = 2.6 to 5.8 μg/kg for BPA and it's 
chlorinated derivatives in the infant formula and 
4.9 to 10.9 μg/kg for BPA and it's chlorinated 
derivatives in the solid foods and beverages (the 
paper doesn't describe how these were 
determined) 
Recovery = average recoveries were: 99.0 % 
(BPA), 101.2 % (ClBPA), 92.9 %, (Cl2BPA), 
93.3 % (Cl3BPA) and 93.5 % (Cl4BPA) 
Repeatability = not given 
Excluded - method 
performance criteria not 
well defined and so 
method quality criteria 
could not be confirmed 
to have been met 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Calibration = not given 
Measures taken to reduce contamination: No 
measures against contamination reported  
Determination of bisphenol A in canned fatty foods by 
coacervative microextraction, liquid chromatography and 
fluorimetry. 
Pérez Bendito, M. D., Rubio Bravo, S., Lunar Reyes, M. 
L. and García Prieto, A. 






1 can of each 









BPA was extracted from the solid portion of the 
foods (the liquid portion was discarded) using 
coacervative microextraction. Analysis was 
carried out by LC-FLD 
 
LOD = 9 μg/kg (3x S:N) 
LOQ = depends on sample mass taken for 
200 mg sample method quantification limit is 
29 μg/kg for tuna in oil; for 400 mg sample 
method quantification limit is 14 μg/kg for tuna 
in oil 
Recovery = 90-99 % for overspiked food 
samples spiked with 50 ng BPA with a mass of 
food of either 200 mg or 400 mg 
Repeatability = 6 % for tuna spiked with BPA at 
concentrations between 0.05 and 1.5 μg/kg 
Calibration = 0.2 to 60 ng BPA in acetonitrile 
(not expressed as a concentration) 
Measures taken to reduce contamination: No 
measures against contamination reported  
Included 
Determination of bisphenol A in canned fish by sol–gel 
immunoaffinity chromatography, HPLC and fluorescence 
detection. 
Podlipna, D. and Cichna-Markl, M. 





7 tuna in 
brine, 5 tuna 
in oil, 5 
sardines in oil, 
1 mackerel in 
brine and 1 
Solvent extracted samples were cleaned-up by 
sol-gel immunoaffinity chromatography, using 
polyclonal BPA rabbit antibodies. Analysis was 
carried out by HPLC-FLD 
 
LOD = 0.4 μg/L in solution, 0.4 μg/kg in tuna, 
Excluded. 
NOTE: The highest BPA 
concentration value was 
obtained by analysing a 
sample after its best 
before date 
Scientific opinion on BPA: Part I – Exposure assessment 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
10.1007/s00217-006-0350-9 mackerel in oil 0.2 μg/kg in sardines, 0.2 μg/kg in mackerel, 
0.9 μg/L in brine, 1.8 μg/L in oil (all 3x S:N) 
LOQ = 0.74 μg/L in solution, 0.8 μg/kg in tuna, 
0.4 μg/kg in sardines, 0.4 μg/kg in mackerel, 
1.9 μ/L in brine, 3.8 μg/L in oil (all 6x S:N) 
Recovery = 45 % in tuna, 97 % in sardines, 
83 % in mackerel, 61 % in brine, 31 % in oil 
Repeatability = Standard deviation of the 
recovery was 5 % in tuna, 12 % in sardines, 
26 % in mackerel, 12 % in brine, 9 % in oil 
Calibration = External calibration 0.5 to 
100 μg/L 
Measures taken to reduce contamination: No 
measures against contamination reported  
Determination and occurrence of bisphenol A, bisphenol 
A diglycidyl ether, and bisphenol F diglycidyl ether, 
including their derivatives, in canned foodstuffs’ from the 
Czech retail market. 
Poustka, J., Dunovská, L., Hajšlová, J., Holadová, K. and 
Poustková, I. 






1 can of each 
of sardines in 
oil, mackerel 
in oil, tuna 




Solvent extracted samples were cleaned-up by 
gel permeation chromatography. Analysis was 
carried out by HPLC-FLD 
 
LOD = 3 μg/kg luncheon meat      
LOQ = 10 μg/kg luncheon meat 
Recovery = 83 % in pork luncheon meat spiked 
at 100 μg/kg 
Repeatability = Coefficient of variation = 3.0 % 
for pork luncheon meat spiked at 100 μg/kg 
Calibration = External calibration 2 to 100 μg/L 
Measures taken to reduce contamination: No 
measures against contamination reported  
Included 
Levels Of bisphenol A and bisphenol F In canned foods in Iran Not Not considered Excluded - samples from 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Iranian markets. 
Rastkari, N., Yunesian, M. and Ahmadkhaniha, R. 
Iranian Journal of Environmental Health Science and 
Engineering. 2011. 8, 95-100. 
DOI not given 
considered Iran (i.e. did not meet 
geographical origin 
criteria) 
Properties, threats, and methods of analysis of bisphenol a 
and its derivatives. 
Rykowska I. and Wasiak W. 
Acta Chromatographica. 2006. 16, 7-27. 





Not considered Excluded - analytical 
method paper - no 
relevant data for 
calculation of exposure 
from food 
Bisphenol A (BPA) and its source in foods in Japanese 
markets. 
Sajiki, J., Miyamoto, F., Fukata, H., Mori, C., Yonekubo, 
J. and Hayakawa, K. 




Not considered Excluded - samples from 
Japan (i.e. did not meet 
geographical origin 
criteria) 
Fast and selective pressurized liquid extraction with 
simultaneous in cell clean up for the analysis of 
alkylphenols and bisphenol A in bivalve molluscs 
Salgueiro-Gonzalez, N., Turnes-Carou, I., Muniategui-
Lorenzo, S., Lopez-Mahia, P. and Prada-Rodriguez, D. 





6 samples of 
molluscs 
BPA was extracted using selective pressurised 
liquid extraction with a simultaneous in cell 
clean up with analysis by LC-MS/MS 
 
LOD = 0.9 μg/kg in the foodstuff (average of 
procedural blanks + 3 x st dev of 10 procedural 
blanks)  
LOQ = 3.3 μg/kg in the foodstuff (average of 
procedural blanks + 10 x st dev of 10 procedural 
blanks)  
Recovery = 93-99 % (BPA spike levels into the 
mussels = 5, 50 and 500 µg/kg, seven replicates 
Included 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
at each level) 
Repeatability = 3-8 % (BPA spike levels into 
the mussels = 5, 50 and 500 µg/kg, seven 
replicates at each level) 
Calibration = Quantification was achieved by 
standard addition. Linearity was demonstrated 
between 0.001 and 10,000 µg/kg 
Measures taken to reduce contamination: Filters 
and sorbents were rinsed with solvent prior to 
use. Procedural blanks were included to ensure 
background levels were low. 
Simultaneous determination of organochlorine pesticides 
and bisphenol A in edible marine biota by GC-MS. 
Santhi, V. A., Hairin, T. and Mustafa, A. M. 




Not considered Excluded - samples from 
Malaysia (i.e. did not 
meet geographical origin 
criteria) 
Analysis of alkylphenol and bisphenol A in meat by 
accelerated solvent extraction and liquid chromatography 
with tandem mass spectrometry. 
Shao, B., Han, H., Li, D., Ma, Y., Tu, X. and Wu, Y. 




Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
Analysis of alkylphenol and bisphenol A in eggs and milk 
by matrix solid phase dispersion extraction and liquid 
chromatography with tandem mass spectrometry. 
Shao, B., Han, H., Tu, X. and Huang, L. 




Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Single laboratory validation of a method for the 
determination of bisphenol A, bisphenol A diglycidyl 
ether and its derivatives in canned foods by reversed-
phase liquid chromatography. 
Sun, C., Leong, L. P., Barlow, P. J., Chan, S. H. and 
Bloodworth, B. C. 






Not considered Excluded - review paper 
from Japan - no relevant 
data for calculation of 
exposure from food 
Determinatıon of bisphenol a migrating from canned food 
and beverages in markets. 
Sungur, Ş., Köroğlu, M. and Özkan, A. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Determination of bisphenol A in water and milk by 
micellar liquid chromatography. 
Szymański, A., Rykowska, I, and Wasiak, W.  
Acta Chromatographica. 2006. 17, 161-172. 







in PC bottles 
BPA was extracted from the water and 
reconstituted powdered milk samples using 
solid phase extraction. Analysis was carried out 
by micellar LC-UV 
 
LOD = 0.3 μg/L (3x S:N) 
LOQ = 1.0 μg/L (10x S:N) 
Recovery = 92.3 % for BPA spiked into water at 
1 μg/L (after the SPE step?) six replicates. No 
recovery data for the matrix. 
Repeatability = 3.97 % for BPA spiked into 
water at 1 μg/L (after the SPE step?) six 
replicates. No repeatability data for the matrix. 
Calibration = External calibration 0.5 to 
100 μg/L 
Excluded - method 
performance criteria not 
well defined and so 
method quality criteria 
could not be confirmed 
to have been met 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Measures taken to reduce contamination: No 
measures against contamination reported  
Human exposure to bisphenol A (BPA). 
Vandenberg, L. N., Hauser, R., Marcus, M., Olea, N. and 
Welshons, W. V. 






Not considered Excluded - review paper 
- no relevant data for 
calculation of exposure 
from food 
Comparison of two derivatization-based methods for 
solid-phase microextraction-gas chromatography-mass 
spectrometric determination of bisphenol A, bisphenol S 
and biphenol migrated from food cans. 
Viñas, P., Campillo, N., Martinez-Castillo, N. and 
Hernandez-Cordoba, M. 




















the can and 
the solid food 
were analysed 
(separately) 
BPA was extracted from the supernatant and 
food samples following dilution/slurrying with 
water using solid phase microextraction. 
Derivatisation with acetic anhydride and 
BSTFA were compared. Analysis was carried 
out by GC-MS 
 
LOD = 0.016 μg/L (derivatisation using acetic 
anhydride), 0.025 μg/L (derivatisation using 
BSTFA) - 3 x S:N of solvent standards (no data 
presented for the matrix) 
LOQ = 0.055 μg/L (derivatisation using acetic 
anhydride), 0.083 μg/L (derivatisation using 
BSTFA) - 10 x S:N of solvent standards (no 
data presented for the matrix) 
Recovery = 84-112 % for BPA spiked into 
supernatant at 0.5 and 5 μg/L six replicates 
Repeatability = 5.12 % (derivatisation using 
BSTFA) and 5.43 % (derivatisation using acetic 
anhydride) - for solvent standards (no data 
presented for the matrix) 
Calibration = External calibration - working 
Excluded - method 
performance criteria not 
well defined and so 
method quality criteria 
could not be confirmed 
to have been met 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
range described as 0.05 to 10 μg/L 
(derivatisation with acetic anhydride) and 0.1 to 
10 μg/L (derivatisation with BSTFA) - reported 
concentrations were outside this range 
Measures taken to reduce contamination: No 
measures against contamination reported  
Bisphenol A: how the most relevant exposure sources 
contribute to total consumer exposure. 
von Goetz, N., Wormuth, M., Scheringer, M. and 
Hungerbuhler, K. 






Not considered Excluded - exposure 
paper - no relevant data 
for calculation of 
exposure from food 
Enhanced screening efficiency for endocrine-disrupting 
chemicals in milk and powdered milk using UPLC/QTOF-
MS by the introduction of dansyl chloride derivatisation. 
Wang, H. X., Zhou, Y. and Jiang, Q. W. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Urinary bisphenol a concentration and thyroid function in 
Chinese adults. 
Wang, T., Lu, J., Xu, M., Xu, Y., Li, M., Liu, Y., Tian, X., 
Chen, Y., Dai, M., Wang, W., Lai, S., Bi, Y. and Ning, G. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Assessment of risk to humans of bisphenol A in marine 
and freshwater fish from Pearl River Delta, China. 
Wei, X., Huang, Y., Wong, M. H., Giesy, J. P. and Wong, 
China Not 
considered 
Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
C. K. 
Chemosphere. 2011. 85:1, 122-128. 
10.1016/j.chemosphere.2011.05.038 
Molecularly Imprinted Nanosilica Solid-Phase Extraction 
for Bisphenol A in Fish Samples. 
Wei, F., Liu, X., Zhai, M., Cai, Z., Xu, G., Yang, J., Du, 
S. and Hu, Q. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
An observational study of the potential exposures of 
preschool children to pentachlorophenol, bisphenol-A, and 
nonylphenol at home and daycare. 
Wilson, N. K., Chuang, J. C., Morgan, M. K., Lordo, R. 
A. and Sheldon, L. S. 






Not considered Excluded - no relevant 
data for calculation of 
exposure from food 
Endocrine disrupting chemicals: human exposure and 
health risks. 
Yang, M., Park, M. S. and Lee, H. S. 
Journal of Environmental Science and Health. Part C. 






Not considered Excluded - review paper 
- no relevant data for 
calculation of exposure 
from food 
Single-step extraction and cleanup of bisphenol A in soft 
drinks by hemimicellar magnetic SPE prior to liquid 
chromatography/tandem mass spectrometry. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
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Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Analytica Chimica Acta. 2013. 778,  31-37. 
10.1016/j.aca.2013.03.025 
Simultaneous determination of steroidal and phenolic 
endocrine disrupting chemicals in fish by ultra-high-
performance liquid chromatography-mass 
spectrometry/mass spectrometry. 
Ye, A., Yang, Y., Zhang, J., Liu, M., Hou, L. and Zhou, J. 
L. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Concentrations of bisphenol A, bisphenol A diglycidyl 
ether, and their derivatives in canned foods in Japanese 
markets. 
Yonekubo, J., Hayakawa, K. and Sajiki, J. 





Not considered Excluded - samples from 
Japan (i.e. did not meet 
geographical origin 
criteria) 
Sensitive gas chromatographic-mass spectrometric (GC-
MS) method for the determination of bisphenol A in rice-
prepared dishes. 
Zafra-Gómez, A., Morales, J. C., Ballesteros, O. and 
Navalón, A. 






Not considered Excluded - analytical 
method paper - no 
relevant data for 
calculation of exposure 
from food 
Analysis of estrogenic compounds in environmental and 
biological samples by liquid chromatography-tandem 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 241 
Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
24
 and reasoning 
Zhang, S., You, J., Ning, S., Song, C. and Suo, Y. R. 
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 Literature quality table—occurrence in drinking water Table 64: 
Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




Alkylphenols and phthalates in bottled waters. 
Amiridou, D. and Voutsa, D. 
Journal of Hazardous Materials. 2011. 185:1, 281-286. 
10.1016/j.jhazmat.2010.09.031 
Greece Bottled waters BPA was extracted from the water samples 
using dichloromethane, dried and evaporated to 
dryness. The extracts were derivatised using 
BSTFA. Analysis was carried out by GC-MS  
 
LOD = range of 2-30 ng/L reported for all 
analytes tested 
LOQ = Not given 
Recovery = 77-92 % (for alkylphenols spiked at 
20, 50 and 100 ng/L) 
Repeatability = Not given 
Calibration = 10 to 200 ng/L (seven levels) 
Measures taken to reduce contamination: 
Glassware, solvents and samples were handled 
carefully to avoid contamination. Method blank 
prepared to determine any contamination 
through the procedure. Results were corrected 
for blank values. 
Excluded – measurable 
BPA for PC water coolers 
only which were 
considered in the 
migration from food 
contact materials section. 
Method performance was 
assessed at concentrations 
below which BPA was 
measured in bottled water 
Relevance of drinking water as a source of human 
exposure to bisphenol A. 
Arnold, S. M., Clark, K. E., Staples, C. A., Klecka, G. M., 
Dimond, S. S., Caspers, N. and Hentges, S. G. 
Journal of Exposure Science and Environmental 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




Chemical compounds and toxicological assessments of 
drinking water stored in polyethylene terephthalate (PET) 
bottles: A source of controversy reviewed. 
Bach, C., Dauchy, X., Chagnon, M. C. and Etienne, S. 






Not considered Excluded – review paper 
- no relevant data for 
calculation of exposure 
from drinking water 
Survey of phthalates, alkylphenols, bisphenol A and 
herbicides in Spanish source waters intended for bottling.  
Bono-Blay, F., Guart, A., de la Fuente, B., Pedemonte, 
M., Cinta Pastor, M., Borrell, A. and Lacorte, S. 











BPA was extracted from the water samples 
using solid phase extraction. Analysis was 
carried out by GC-MS  
 
LOD = 0.009 μg/L in the water (3x S:N) 
LOQ = 0.029 μg/L in the water (10x S:N) 
Recovery = 89 % at 1 μg/L, 93 % at 0.1 μg/L 
(HPLC water spiked with BPA) 
Repeatability = 5.4 % (HPLC water spiked with 
BPA at 0.01 μg/L, 93 % at 0.1 μg/L) 
Calibration = External calibration 5 to 
1000 μg/L  (samples enriched during the 
procedure to be in this range) 
Measures taken to reduce contamination: 
Method blank prepared to determine any 
contamination through the procedure 
Included 
Survey of bisphenol A in bottled water products in 
Canada. 
Cao, X-L and Corriveau, J. 





Not considered Excluded - samples from 
Canada (i.e. did not meet 
geographical origin 
criteria) 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 244 
Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




Determination of bisphenol A in water via inhibition of 
silver nanoparticles-enhanced chemiluminescence. 
Chen, X., Wang, C., Tan, X. and Wang, J. 




Not considered Excluded - samples from 
China  (i.e. did not meet 
geographical origin 
criteria) 
Occurrence and assessment of treatment efficiency of 
nonylphenol, octylphenol and bisphenol-A in drinking 
water in Taiwan. 
Chen, H. W., Liang, C. H., Wu, Z. M., Chang, E. E., Lin, 
T. F., Chiang, P. C. and Wang, G. S. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Ultra-trace analysis of hormones, pharmaceutical 
substances, alkylphenols and phthalates in two French 
natural mineral waters. 
Devier, M. H., Le Menach, K., Viglino, L., Di Gioia, L., 
Lachassagne, P. and Budzinski, H. 







Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Factors affecting the quality of bottled water. 
Diduch, M., Polkowska, Z. and Namiesnik, J. 
Journal of Exposure Science and Environmental 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Quantification of bisphenol A, 353-nonylphenol and their 
chlorinated derivatives in drinking water treatment plants. 
France 8 Drinking 
water samples 
BPA was extracted from the water samples 
using solid phase extraction. Analysis was 
Excluded – method 
performance was assessed 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




Dupuis, A., Migeot, V., Cariot, A., Albouy-Llaty, M., 
Legube, B. and Rabouan, S. 
Environmental Science and Pollution Research 
International. 2012. 19:9, 4193-4205. 
10.1007/s11356-012-0972-3 
collected at 
the outlet of 




carried out by LC-MS/MS.   
 
LOD = 0.5 ng/L (3x S:N– corrected for 
recovery) 
LOQ = 1.5 ng/L (10x S:N– corrected for 
recovery) 
Recovery = 108 % for blank samples spiked at 
20 and 40 ng/L  
Repeatability = 7 % intra-day RSD, 18 % inter-
day RSD 
Calibration = 2 to 40 ng/L (five levels) 
Measures taken to reduce contamination: 
Glassware was baked, high quality solvents and 
teflon seals were used to minimise 
contamination. Method blanks were prepared to 
determine any contamination through the 
procedure.  
at concentrations below 
which BPA was measured 
in treated water 
Bisphenol A Detection in Various Brands of Drinking 
Bottled Water in Riyadh, Saudi Arabia Using Gas 
Chromatography/Mass Spectrometer. 
Elobeid, M. A., Almarhoon, Z. M., Virk, P., Hassan, Z. 
K., Omer, S. A., El Amin, M., Daghestani, M. H. and Al 
Olayan, E. M. 
Tropical Journal of Pharmaceutical Research. 2012. 13, 
455-459. 
10.4314/tjpr.v11i3.15 
Saudi Arabia Not 
considered 
Not considered Excluded - samples from 
Saudi Arabia (i.e. did not 
meet geographical origin 
criteria) 
Detection and occurrence of chlorinated byproducts of 
bisphenol a, nonylphenol, and estrogens in drinking water 





Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
Scientific opinion on BPA: Part I – Exposure assessment 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




Fan, Z., Hu, J., An, W. and Yang, M. 
Environmental Science and Technology. 2013. 47:19, 
10841-10850. 
10.1021/es401504a 
not meet publication 
period criteria) 
The occurrence and distribution of a group of organic 
micropollutants in Mexico City's water sources. 
Felix-Canedo, T. E., Duran-Alvarez, J. C. and Jimenez-
Cisneros, B.  






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Migration of plasticizers phthalates, bisphenol A and 
alkylphenols from plastic containers and evaluation of 
risk. 
Guart, A., Bono-Blay, F., Borrell, A. and Lacorte, S. 
Food Additives and Contaminants Part A. 2011. 28, 676-
685. 
10.1080/19440049.2011.555845 
No details are 
provided on 
the place of 
purchase or 
sampling but 
the authors are 
from Spain 
Bottled water 
packed in 10 
in PET bottles, 
10 in PC 
coolers and 7 
in HDPE 
bottles 
BPA was extracted from the water samples 
using solid phase extraction. Analysis was 
carried out by GC-MS  
LOD = 0.009 μg/L (3x standard deviation of the 
blank samples, n=5) 
LOQ = not given 
Recovery = 97 % for HPLC water spiked at 
1 μg/L 
Repeatability = not given 
Calibration = 10 to 10000 μg/L 
Measures taken to reduce contamination: 
Method blank prepared to determine any 
contamination through the procedure  
Included 
Migration of plasticizers from TritanTM and 
polycarbonate bottles and toxicological evaluation. 
Guart, A., Wagner, M., Mezquida, A., Lacorte, S., 





Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Scientific opinion on BPA: Part I – Exposure assessment 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




Food Chemistry. 2013. 141, 373-380. 
10.1016/j.foodchem.2013.02.129 
Surface plasmon resonance sensor for detection of 
bisphenol A in drinking water. 
Hegnerová, K. and Homola, J 






Not considered Excluded - analytical 
method review paper - no 
relevant data for 
calculation of exposure 
from drinking water 
Sol-gel coated polydimethylsiloxane/beta-cyclodextrin as 
novel stationary phase for stir bar sorptive extraction and 
its application to analysis of estrogens and bisphenol A. 
Hu, Y., Zheng, Y., Zhu, F. and Li, G. 




Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
BPA and environmental estrogen in potable water sources 
in Enugu municipality, South-East, Nigeria. 
Ignatius, C. M., Francis, E. E., Emeka, E. N., Elvis, N. S. 
and Ebele, J. I. 
Bulletin of Environmental Contamination and Toxicology. 




Not considered Excluded - samples from 
Nigeria (i.e. did not meet 
geographical origin 
criteria) 
Direct enrichment and high performance liquid 
chromatography analysis of ultra-trace Bisphenol A in 
water samples with narrowly dispersible Bisphenol A 
imprinted polymeric microspheres column. 
Jiang, M., Zhang, J. H., Mei, S. R., Shi, Y., Zou, L. J., 
Zhu, Y. X., Dai, K. and Lu, B. 
Journal of Chromatography A. 2006. 1110:1-2, 27-34. 
China Not 
considered 
Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 





A novel sol-gel-material prepared by a surface imprinting 
technique for the selective solid-phase extraction of 
bisphenol A. 
Jiang, X., Tian, W., Zhao, C., Zhang, H. and Liu, M. 




Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
Determination of bisphenol A, bisphenol F and their 
diglycidyl ethers in environmental water by solid phase 
extraction using magnetic multiwalled carbon nanotubes 
followed by GC-MS/MS. 
Jiao, Y, Ding, L, Fu, S., Zhu, S., Li, H. and Wang, L. 




Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
Exposure to bisphenol A from bis-glycidyl 
dimethacrylate–based dental sealants. 
Joskow, R., Boyd Barr, D., Barr, J. R., Calafat, A. M., 
Needham, L. L. and Rubin, C. 
Journal of the American Dental Association. 2006. 137, 
253-262. 





Not considered Excluded – dental sealants 
data only - no relevant data 
for calculation of exposure 
from drinking water 
Liquid phase microextraction with in situ derivatization 
for measurement of bisphenol A in river water sample by 
gas chromatography-mass spectrometry. 
Kawaguchi, M., Ito, R., Endo, N., Okanouchi, N., Sakui, 
N., Saito, K. and Nakazawa, H. 
Journal of Chromatography A. 2006. 1110:1-2, 1-5. 
Japan Not 
considered 
Not considered Excluded - samples from 
Japan (i.e. did not meet 
geographical origin 
criteria) 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 





Simultaneous determination and assessment of 4-
nonylphenol, bisphenol A and triclosan in tap water, 
bottled water and baby bottles. 
Li, X., Ying, G. G., Su, H. C., Yang, X. B. and Wang, L. 




Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
Screening of endocrine-disrupting phenols, herbicides, 
steroid estrogens, and estrogenicity in drinking water from 
the waterworks of 35 Italian cities and from PET-bottled 
mineral water. 
Maggioni, S., Balaguer, P., Chiozzotto, C. and Benfenati, 
E. 
Environmental Science and Pollution Research 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Association between water consumption from 
polycarbonate containers and bisphenol A intake during 
harsh environmental conditions in summer. 
Makris, K. C., Andra, S. S., Jia, A., Herrick, L., 
Christophi, C. A., Snyder, S. A. and Hauser, R. 







Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
One-step signal amplified lateral flow strip biosensor for 
ultrasensitive and on-site detection of bisphenol A (BPA) 
in aqueous samples. 





Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




Zheng, L., El-Nezamic, H. S., Wu, Y. and Chen, W. 
Biosensors and Bioelectronics. 2013. 49, 457-461. 
10.1016/j.bios.2013.06.006 
period criteria) 
Online in-tube microextractor coupled with UV-Vis 
spectrophotometer for bisphenol A detection. 
Poorahong, S., Thammakhet, C., Thavarungkul, P. and 
Kanatharana, P.  
Journal of Environmental Science and Health. Part A. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Properties, threats, and methods of analysis of bisphenol a 
and its derivatives. 
Rykowska I. and Wasiak W. 
Acta Chromatographica. 2006. 16, 7-27. 





Not considered Excluded - review paper - 
no relevant data for 
calculation of exposure 
from drinking water 
Occurrence of bisphenol A in surface water, drinking 
water and plasma from Malaysia with exposure 
assessment from consumption of drinking water. 
Santhi, V. A., Sakai, N., Ahmad, E. D. and Mustafa, A. M. 





Not considered Excluded - samples from 
Malaysia (i.e. did not meet 
geographical origin 
criteria) 
Dummy molecularly imprinted polymers as the coating of 
stir bar for sorptive extraction of bisphenol A in tap water. 
Sheng, N., Wei, F., Zhan, W., Cai, Z., Du, S., Zhou, X., 
Li, F. and Hu, Q. 
Journal of Separation Science. 2012. 35:5-6, 707-712. 
China Not 
considered 
Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 





Occurrence and distribution of steroids, hormones and 
selected pharmaceuticals in South Florida coastal 
environments. 
Singh, S. P., Azua, A., Chaudhary, A., Khan, S., Willett, 
K. L. and Gardinali, P. R. 






Not considered Excluded - samples from 
USA (i.e. did not meet 
geographical origin 
criteria) 
Efficiency of conventional drinking-water-treatment 
processes in removal of pharmaceuticals and other organic 
compounds. 
Stackelberg, P. E., Gibs, J., Furlong, E. T., Meyer, M. T., 
Zaugg, S. D. and Lippincott, R. L. 







Not considered Excluded - samples from 
USA (i.e. did not meet 
geographical origin 
criteria) 
Human exposure to bisphenol A (BPA). 
Vandenberg, L. N., Hauser, R., Marcus, M., Olea, N. and 
Welshons, W. V. 






Not considered Excluded - review paper - 
no relevant data for 
calculation of exposure 
from drinking water 
Rapid determination of bisphenol A in drinking water 
using dispersive liquid-phase microextraction with in situ 
derivatization prior to GC-MS. 
Wang, X., Diao, C. P. and Zhao, R. S. 




Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




Contaminant Migration From Polymeric Pipes Used in 
Buried Potable Water Distribution Systems: A Review. 
Whelton, A. J. and Nguyen, T. 
Critical Reviews in Environmental 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Determination of Bisphenol A in Plastic Bottled Drinking 
Water by High Performance Liquid Chromatography with 
Solid-membrane Extraction Based on Electrospun Nylon 6 
Nanofibrous Membrane. 
Wu S. Y., Xu, Q, Chen, T. S., Wang, M., Yin, X. Y., 
Zhang, N. P., Shen, Y. Y., Wen, Z. Y. and Gu Z. Z. 





Not considered Excluded - samples from 
China (i.e. did not meet 
geographical origin 
criteria) 
Electrochemical aptasensor for the determination of 
bisphenol A in drinking water. 
Xue, F., Wu, J., Chu, H., Mei, Z., Ye, Y., Liu, J., Zhang, 
R., Peng, C., Zheng, L. and Chen, W. 






Not considered Excluded – paper 
published after 
December 2012 (i.e. did 
not meet publication 
period criteria) 
Endocrine disrupting chemicals: human exposure and 
health risks.  
Yang, M., Park, M. S. and Lee, H. S. 
Journal of Environmental Science and Health. Part C. 






Not considered Excluded - review paper - 
no relevant data for 
calculation of exposure 
from drinking water 
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 Literature quality table – occurrence in food contact materials Table 65: 
Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




Migration from polycarbonate packaging to food 
simulants during microwave heating. 
Alin, L. and Hakkarainen, M. 







Not considered Excluded - migration data 
rather than occurrence data 
was used for the 
determination of the 
exposure from food 
contact materials 
The BIOSAFEPAPER project for in vitro toxicity 
assessments: preparation, detailed chemical 
characterisation and testing of extracts from paper and 
board samples 
Bradley, E. L., Honkalampi-Hamalainen, U., Weber, A., 
Andersson, M. A., Bertaud, F., Castle, L., Dahlman, O., 
Hakulinen, P., Hoornstra, D., Lhuguenot, J. C., Maki-
Paakkanen, J., Salkinoja-Salonen, M., Speck, D. R., 
Severin, I., Stammati, A., Turco, L., Zucco, F. and von 
Wright, A. 






Not considered Excluded - migration data 
rather than occurrence data 
was used for the 
determination of the 
exposure from food 
contact materials 
Investigation into the migration potential of coating 
materials from cookware products. 
Bradley, E. L., Read, W. A. and Castle, L. 






Not considered Excluded - migration data 
rather than occurrence data 
was used for the 
determination of the 
exposure from food 
contact materials 
Migration and sensory properties of plastics-based nets Not Not Not considered Excluded - migration data 
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Title 
Authors 







Method description and quality parameters Reported data included 
or excluded from the 
calculation of the 




used as food-contacting materials under ambient and high 
temperature heating conditions. 
Kontominas, M. G., Goulas, A. E., Badeka, A. V. and 
Nerantzaki, A. 
Food Additives and Contaminants. 2006. 23:6, 634-641. 
10.1080/02652030600643369 
considered considered rather than occurrence data 
was used for the 
determination of the 
exposure from food 
contact materials 
Oestrogenicity of paper and cardboard extracts used as 
food containers. 
Lopez-Espinosa, M. J., Granada, A., Araque, P., Molina-
Molina, J. M., Puertollano, M. C., Rivas, A., Fernandez, 
M., Cerrillo, I., Olea-Serrano, M. F., Lopez, C. and Olea, 
N. 






Not considered Excluded - migration data 
rather than occurrence data 
was used for the 
determination of the 
exposure from food 
contact materials 
Physicochemical processes involved in migration of 
bisphenol A from polycarbonate. 
Mercea, P. 







Not considered Excluded - migration data 
rather than occurrence data 
was used for the 
determination of the 
exposure from food 
contact materials 
Bisphenol A (BPA) and its source in foods in Japanese 
markets 
Sajiki, J., Miyamoto, F., Fukata, H., Mori, C., Yonekubo, 
J. and Hayakawa, K. 






Not considered Excluded - migration data 
rather than occurrence data 
was used for the 
determination of the 
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 Literature quality table – migration from food contact materials Table 66: 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Migration from polycarbonate packaging to food 
simulants during microwave heating. 
Alin, J. and Hakkarainen, M. 









Not considered Excluded - no relevant data 
for calculation of exposure 
of specific populations from 
food contact materials 
Alkylphenols and phthalates in bottled waters. 
Amiridou, D. and Voutsa, D. 









Not considered Excluded – not relevant - 
occurrence in drinking water 
rather than migration data 
reported 
 
NOTE: paper also 
considered in the scope of 
the drinking water exposure 
assessment 
Release of bisphenol A from polycarbonate baby 
bottles: mechanisms of formation and investigation 
of worst case scenarios. 
Biedermann-Brem, S., Grob, K. and Fjeldal, P. 









Not considered Excluded – no relevant data 
for calculation of exposure 
of specific populations from 
food contact materials. 
Model studies determining 
the worst case migration 
rather than migration under 
actual conditions of use 
Release of bisphenol A from polycarbonate baby 
bottles: water hardness as the most relevant factor. 
Biedermann-Brem, S., Grob, K. 
European Food Research and Technology. 2009 
Samples were 
produced in 






of tap water 
BPA was determined in the 
exposed water samples by direct 




NOTE: although method 
performance data was not 
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Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 




NOTE:  Not identified by contractor as a migration 
from food contact materials paper 
LOD = 0.5 μg/L (5 x S:N) 
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Calibration = Not given 
Measurement uncertainty quoted as 
20 % but no indication is given as 
to how this was calculated 
Measures taken to reduce 
contamination: No information on 
prevention of contamination or 
blanks 
well described the paper 
provided migration data not 
available elsewhere 
How Should the Release of Bisphenol A from Baby 
Bottles be Determined? 
Biedermann-Brem, S. and Grob, K. 








Not considered Excluded - review paper - 
no relevant data for 
calculation of exposure of 
specific populations from 
food contact materials 
Investigation into the migration potential of coating 
materials from cookware products. 
Bradley, E. L., Read, W. A. and Castle, L. 









products , 5 












BPA was determined in the 
exposed 10 % ethanol and 3 % 
acetic acid simulants by HPLC-
FLD. The exposed olive oil was 
diluted with heptane and extracted 
with acetonitrile which was 
analysed by HPLC-FLD 
 
LOD = Not given for all 
simulants/products - 0.026 mg/dm
2
 
in acetic acid for one product tested 
Included  
 
NOTE: although method 
performance data was not 
well described the paper 
provided migration data not 
available elsewhere 
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Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Calibration = Not given 
Measures taken to reduce 
contamination: No information on 
prevention of contamination or 
blanks 
Identification of Potential Migrants in Epoxy 
Phenolic Can Coatings. 
Bradley, E. L., Driffield, M., Harmer, N., Oldring, P. 
K. T. and Castle, L. 
International Journal of Polymer Analysis and 








Not considered Excluded - migration data 
for can coatings was not 
used in the exposure 
assessment. Occurrence in 
canned food data was used 
to determine exposure from 
this source 
Determination of bisphenol A in wine by sol-gel 
immunoaffinity chromatography, HPLC and 
fluorescence detection. 
Brenn-Struckhofova, Z. and Cichna-Markl, M. 









Not considered Excluded – occurrence in 
food data only - no 
relevant data for 
calculation of exposure 
from food contact 
materials 
 
NOTE: paper considered in 
the scope of the food 
exposure assessment  
Migration of Bisphenol A from Polycarbonate Baby 










Following the addition of sodium 
chloride the BPA was extracted 
from the sample using SPME. 
Analysis was carried out by GC-
Included  
 
NOTE: although the samples 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 258 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Cao, X.-L. and Corriveau, J. 





LOD = 0.5 μg/L 
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Calibration = 5 to 600 μg/L 
Measures taken to reduce 
contamination: Method blanks were 
prepared to determine any 
contamination through the 
procedure. Blank levels detected 
were subtracted from the reported 
concentrations 
were from outside Europe 
the comprehensive number 
and range of sample types 
provided data not available 
for European samples 
Determination of Bisphenol A in Water by Isotope 
Dilution Headspace Solid-Phase Microextraction and 
Gas Chromatography/Mass Spectrometry Without 
Derivatization. 
Cao, X.-L. and Corriveau, J. 








and 2 water 
bottles 
25ºC for  
24 hours 
Following the addition of sodium 
chloride the BPA was extracted 
from the sample using SPME. 
Analysis was carried out by GC-
MS 
 
LOD = 0.5 μg/L 
LOQ = Not given 
Recovery = Not given 
Repeatability = 9.7 % (n=6 
replicates at 5 μg/L) and 8.9 % (n=6 
replicates at 20 μg/L) 
Calibration = 2.5 to 40 μg/L 




NOTE: although the samples 
were from outside Europe 
the range of sample types 
provided data not available 
for European samples at the 
tested conditions 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 259 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
glassware was used. Method blanks 
were prepared to determine any 
contamination through the 
procedure  
Determination of the Migration of Bisphenol A from 
Polycarbonate by Dispersive Liquid-Liquid 
Microextraction Combined with High Performance 
Liquid Chromatography. 
Cao, J., Liu, S., Bai, W., Chen, J. and Xie, Q. 








Not considered Excluded – paper 
published after December 
2012 (i.e. did not meet 
publication period criteria) 
Migration of Bisphenol A from plastic containers 
into water. 
Chatzis V., Nikolaidis, A. K. and Achilias, D. S. 
Fresenius Environmental Bulletin 2012. 21: 2506-
2509. 







Not considered Excluded – only abstract 
available – no relevant 
data for calculation of 
exposure from food 
contact materials 
Assessment of bisphenol A released from reusable 
plastic, aluminium and stainless steel water bottles. 
Cooper, J. E., Kendig, E. L. and Belcher, S. M. 

















25ºC for  
5 days 
BPA was determined in the 
exposed water samples by direct 
analysis using ELISA 
 
LOD = 0.05 μg/L  
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Calibration = 0.05 to 10 μg/L 
Measures taken to reduce 
contamination: Method blank 
Included  
 
NOTE: data for PC water 
bottles only was included. 
Although the samples were 
from outside Europe the 
comprehensive number and 
range of sample types 
provided data not available 
for European samples 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 260 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 








prepared to determine any 
contamination through the 
procedure  
Study on the migration of bisphenol-A from baby 
bottles by stir bar sorptive extraction-thermal 
desorption-capillary GC-MS. 
De Coensel, N., David, F. and Sandra, P. 





on the place of 
purchase or 
sampling but 








53, 65, 85ºC)  
BPA was determined using stir bar 
sorptive extraction (SBSE) after in situ 
derivatization with acetic acid 
anhydride followed by thermal 
desorption (TD)-capillary GC-MS.  
 
LOD = 0.12 ng/L  
LOQ = 0.40 ng/L 
Recovery = 65%  
Repeatability = not given 
Calibration = 1 ng/L to 10 mg/L 
Measures taken to reduce 
contamination: control of 
background level (set at 8 ng/L) and 
correction of results 
Included  
Migration of bisphenol A into water from 
polycarbonate baby bottles during microwave 
heating. 
Ehlert, K. A., Beumer, C. W. and Groot, M. C. 











100ºC for  
1 minute 
BPA was extracted from the 
exposed simulant samples using 
SPE. Analysis was carried out by 




LOD = 0.1 μg/L 
LOQ = Not given 
Included 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 261 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Recovery = 95 % (water spiked 
with BPA at 1 μg/L, n = 5) 
Repeatability = 2 % (water spiked 
with BPA at 1 μg/L, n = 5) 
Calibration = 0.05 to 5 μg/L 
Measures taken to reduce 
contamination: No measures 
against contamination reported 
Migration of phthalates, alkylphenols, bisphenol A 
and di(2-ethylhexyl)adipate from food packaging. 
Fasano, E., Bono-Blay, F., Cirillo, T., Montuori, P. 
and Lacorte, S. 
Food Control. 2012. 27:1, 132-138. 
10.1016/j.foodcont.2012.03.005 
Not given Eleven food 
packaging 
materials 
40ºC for  
10 days 
BPA was extracted from the 
exposed simulant samples using 
SPE. Analysis was carried out by 
GC-MS  
 
LOD = 21 to 33 ng/L 
LOQ = Not given 
Recovery = 80 % (from water 
spiked with 100 ng of BPA in 30, 
50 or 100 mL simulant, n = 2) 
Repeatability = Not given 
Calibration = 0.01 to 1 μg/mL 
Measures taken to reduce 
contamination: No measures 
against contamination reported 
Included  
 
NOTE: data for PC baby 
bottles only was included  
 
NOTE: although method 
performance data was not 
well described the paper 
provided migration data not 
available elsewhere at the 
testing conditions 
Are potential sources for human exposure to 
bisphenol-A overlooked? 
Geens, T., Goeyens, L. and Covaci, A. 
International Journal of Hygiene and Environmental 







Not considered Excluded – review paper - 
no relevant data for 
calculation of exposure of 
specific polulations from 
food contact materials 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 262 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
10.1016/j.ijheh.2011.04.005 
Phthalates and bisphenols migration in Mexican food 
cans and plastic food containers. 
Gonzalez-Castro, M. I., Olea-Serrano, M. F., Rivas-
Velasco, A. M., Medina-Rivero, E., Ordonez-
Acevedo, L. G. and De Leon-Rodriguez, A. 
Bulletin of Environmental Contamination and 






Not considered Excluded – samples from 
Mexico (i.e. did not meet 
geographical origin criteria) 
Migration of plasticizers phthalates, bisphenol A and 
alkylphenols from plastic containers and evaluation 
of risk. 
Guart, A., Bono-Blay, F., Borrell, A. and Lacorte, S. 





on the place of 
purchase or 
sampling but 









PC exposed to 
water for 10 
days at 40oC 
40ºC for  
10 days 
BPA was extracted from the water 
samples using solid phase 
extraction. Analysis was carried out 
by GC-MS  
 
LOD = 0.009 μg/L (3x standard 
deviation of the blank samples, 
n=5) 
LOQ = Not given 
Recovery = 97 % for HPLC water 
spiked at 1 μg/L 
Repeatability = Not given 
Calibration = 10 to 10000 μg/L 
Measures taken to reduce 
contamination: Method blank 
prepared to determine any 
contamination through the 
procedure  
Included 
Korean Environmental Health Survey in Children Not Not Not Not considered Excluded – paper 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 263 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
and Adolescents (KorEHS-C): Survey design and 
pilot study results on selected exposure biomarkers. 
Ha, M
.
, Kwon, H.J., Leem, J.H., Kim, H.C., Lee, 
K.J., Park, I., Lim, Y.W., Lee, J.H., Kim, Y., Seo, 
J.H., Hong, S.J., Choi, Y.H., Yu, J., Kim, J., Yu, 
S.D. and Lee, B.E.  
International Journal of Hygiene and Environmental 
Health. 2013. Epub Jun13. 
10.1016/j.ijheh.2013.06.001 
considered considered considered published after December 
2012 (i.e. did not meet 
publication period criteria) 
Release of bisphenol A from polycarbonate: a 
review. 
Hoekstra, E. J. and Simoneau, C. 
Critical Reviews in Food Science and Nutrition. 








Not considered Excluded – paper 
published after December 
2012 (i.e. did not meet 
publication period criteria) 
Sol-gel coated polydimethylsiloxane/beta-
cyclodextrin as novel stationary phase for stir bar 
sorptive extraction and its application to analysis of 
estrogens and bisphenol A. 
Hu, Y., Zheng, Y., Zhu, F. and Li, G. 






Not considered Excluded – samples from 
China (i.e. did not meet 
geographical origin criteria) 
Migration Prediction Model of Residual 
Contaminants from Food Packaging Paper and its 
Experimental Verification. 
Huang, C.-X., Duan, D.-D., Yan, M.-M. and Wang, 
S.-F. 







Not considered Excluded – paper 
published after December 
2012 (i.e. did not meet 
publication period criteria) 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 264 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
10.1002/pts.2005 
Human exposure to bisphenol A. 
Kang, J. H., Kondo, F. and Katayama, Y. 








Not considered Excluded – review paper - 
no relevant data for 
calculation of exposure of 
specific populations from 
food contact materials  
Migration of bisphenol A from plastic baby bottles, 
baby bottle liners and reusable polycarbonate 
drinking bottles. 
Kubwabo, C., Kosarac, I., Stewart, B., Gauthier, B. 
R., Lalonde, K. and Lalonde, P. J. 












40ºC for 8 
hours, 1 day 
and 10 days 
BPA was extracted from the water 
samples using solid phase 
extraction and from the ethanol 
solutions using solid phase 
extraction following acidification. 
Analysis was carried out by GC-




LOD = 0.04 ng/L 
LOQ = 0.11 ng/L 
Recovery = 93 % (simulant spiked 
at 0.25 ng/L, n = 7) 
Repeatability = 9.7 % (simulant 
spiked at 0.25 ng/L, n = 7) 
Calibration = Not given 
Measures taken to reduce 
contamination: Method blank 
prepared to determine any 




NOTE: although the samples 
were from outside Europe 
the comprehensive number 
and range of sample types 
provided data not available 
in Europe 
Bisphenol A is released from polycarbonate drinking Samples were New and used 22ºC for 24, BPA was determined in the Included  
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 265 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
bottles and mimics the neurotoxic actions of estrogen 
in developing cerebellar neurons. 
Le, H. H., Carlson, E. M., Chua, J. P. and Belcher, S. 
M. 








72, 120 and 
168 hours; 
100ºC for 24 
hours 
exposed water samples by direct 
analysis using ELISA 
 
LOD = 0.05 μg/L  
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Calibration = 0.05 to 10 μg/L 
Measures taken to reduce 
contamination: Method blank 
prepared to determine any 
contamination through the 
procedure  
 
NOTE: although the samples 
were from outside Europe 
the comprehensive number 
and range of sample types 
provided data not available 
in Europe 
Voltammetric determination of bisphenol A in food 
package by a glassy carbon electrode modified with 
carboxylated multi-walled carbon nanotubes. 
Li, J., Kuang, D., Feng, Y., Zhang, F. and Liu, M. 






Not considered Excluded – samples from 
China (i.e. did not meet 
geographical origin criteria) 
Simultaneous determination and assessment of 4-
nonylphenol, bisphenol A and triclosan in tap water, 
bottled water and baby bottles. 
Li, X., Ying, G. G., Su, H. C., Yang, X. B. and 
Wang, L. 






Not considered Excluded – samples from 
China (i.e. did not meet 
geographical origin criteria) 
4-Nonylphenol, bisphenol-A and triclosan levels in 
human urine of children and students in China, and 
Not Not Not Not considered Excluded – paper 
published after December 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 266 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
the effects of drinking these bottled materials on the 
levels. 
Li, X., Ying, G. G., Zhao, J. L., Chen, Z. F., Lai, H. 
J. and Su, H. C. 
Environment International. 2013. 52: 81-86. 
10.1016/j.envint.2011.03.026 
considered considered considered 2012 (i.e. did not meet 
publication period criteria) 
Potential risk of bisphenol A migration from 
polycarbonate containers after heating, boiling, and 
microwaving. 
Lim, D. S., Kwack, S. J., Kim, K. B., Kim, H. S. and 
Lee, B. M. 
Journal of Toxicology and Environmental Health. 






Not considered Excluded – samples from 
Korea (i.e. did not meet 
geographical origin criteria) 
Oestrogenicity of paper and cardboard extracts used 
as food containers. 
Lopez-Espinosa, M. J., Granada, A., Araque, P., 
Molina-Molina, J. M., Puertollano, M. C., Rivas, A., 
Fernandez, M., Cerrillo, I., Olea-Serrano, M. F., 
Lopez, C. and Olea, N. 









Not considered Excluded - migration data 
for paper and board was not 
used in the exposure 
assessment, occurrence in 
food data was used 
Effect of amines in the release of bisphenol A from 
polycarbonate baby bottles. 
Maia, J. Cruz, J. M., Sendón, R., Bustos, J., 
Cirugeda, M. E., Sanchez, J. J. and Paseiro, P. 







Not considered Excluded - no relevant data 
for calculation of exposure 
of specific populations from 
food contact materials 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 267 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
10.1016/j.foodres.2010.03.014 
Effect of detergents in the release of bisphenol A 
from polycarbonate baby bottles. 
Maia, J., Cruz, J. M., Sendón, R., Bustos, J., 
Sanchez, J. J. and Paseiro, P. 









Not considered Excluded – no relevant data 
for calculation of exposure 
of specific populations from 
food contact materials. 
Model studies determining 
the worst case migration 
rather than migration under 
actual conditions of use 
Migration of bisphenol A from polycarbonate baby 
bottles under real use conditions. 
Maragou, N. C., Makri, A., Lampi, E. N., Thomaidis, 
N. S. and Koupparis, M. A. 












and leaving to 
stand for 45 
minutes 
BPA analysed by LC-MS 
LOD = 2.4 μg/L (water) and 1.8 
μg/L (3% acetic acid) 
LOQ = Not given 
Recovery = Not given 
Repeatability = 2.9% (water), 4.2% 
(3% acetic acid) at 30 μg/L 
Calibration = 0.18 to 180 μg/L 
Measures taken to reduce 
contamination: information not 
provided 
Included 
Physicochemical processes involved in migration of 
bisphenol A from polycarbonate.  
Mercea, P. 
Journal of Applied Polymer Science. 2009. 112:2, 
579-593. 
10.1002/app.29421 







Not considered Excluded - no relevant data 
for calculation of exposure 
of specific populations from 
food contact materials. 
Studies were carried out 
with tailor made samples or 
at non-standardised 
migration test conditions 
Bisphenol A in "BPA free" baby feeding bottles. Not Not Not Not considered Excluded - letter to the 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 268 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Moghadam, Z. A., Mirlohi, M. and Pourzamani, H. 
Journal of Research in Medical Sciences. 2012. 17: 
1089-1091. 
DOI not given 
considered considered considered Editor – no relevant data for 
calculation of exposure of 
specific populations from 
food contact materials 
Application of ethyl chloroformate derivatization for 
solid-phase microextraction-gas chromatography-
mass spectrometric determination of bisphenol-A in 
water and milk samples. 
Mudiam, M. K., Jain, R., Dua, V. K., Singh, A. K., 
Sharma, V. P. and Murthy, R. C. 







Not considered Excluded – samples from 
India (i.e. did not meet 
geographical origin criteria) 
Bisphenol A migration from polycarbonate baby 
bottle with repeated use. 
Nam, S. H., Seo, Y. M. and Kim, M. G. 






Not considered Excluded – samples from 
Korea (i.e. did not meet 
geographical origin criteria) 
A novel electrochemical sensor of bisphenol A based 
on stacked graphene nanofibers/gold nanoparticles 
composite modified glassy carbon electrode. 
Niu, X., Yang, W. Wang, G., Ren, J., Guo, H. and 
Gao, J. 








Not considered Excluded – paper 
published after December 
2012 (i.e. did not meet 
publication period criteria) 
Optimization of a GC/MS procedure that uses 
parallel factor analysis for the determination of 
bisphenols and their diglycidylethersafter migration 
No details 
were provided 
on the place of 
PC cups 70ºC for  
24 hours 
BPA was determined in the 
simulant 50% ethanol by GC-MS 
after SPE extraction. Procedural 
Included 
 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 269 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
from polycarbonate tableware. 
Oca, M.L., Ortiz, M.C., Herrero, A. and Sarabia, 
L.A. 




the authors are 
from Spain 
blanks were analysed. 
 
LOD = 2.65 µg/L  
LOQ = Not given 
Recovery = 114 % 
Repeatability = 5 % 
Calibration = 0 to 90 µg/l with 
BPA-d16 as internal standard 
Measures taken to reduce 
contamination: No measures 
against contamination reported 
NOTE: although the 
publication date is post-2012 
data for migration from PC 
tableware is reported that is 
not available elsewhere 
Migration of Bisphenol A and Benzophenones from 
Paper and Paperboard Products Used in Contact with 
Food. 
Ozaki, A., Kawasaki, C., Kawamura, Y. and 
Tanamoto, K. 









Not considered Excluded - migration data 
for paper and board was not 
used in the exposure 
assessment, occurrence in 
food data was used 
Determination of bisphenol-type endocrine 
disrupting compounds in food-contact recycled-
paper materials by focused ultrasonic solid-liquid 
extraction and ultra performance liquid 
chromatography-high resolution mass spectrometry. 
Perez-Palacios, D., Fernandez-Recio, M. A., Moreta, 
C. and Tena, M. T. 








Not considered Excluded - migration data 
for paper and board was not 
used in the exposure 
assessment, occurrence in 
food data was used 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 270 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Bisphenol A (BPA) and its source in foods in 
Japanese markets. 
Sajiki, J., Miyamoto, F., Fukata, H., Mori, C., 
Yonekubo, J. and Hayakawa, K. 







Not considered Excluded – samples from 
Japan (i.e. did not meet 
geographical origin criteria) 
Migration of bisphenol A from polycarbonate baby 
bottles purchased in the Spanish market by liquid 
chromatography and fluorescence detection. 
Santillana, M. I., Ruiz, E., Nieto, M. T., Bustos, J., 
Maia, J., Sendon, R. and Sanchez, J. J. 






72 baby bottle 
samples from 
12 brands 
70ºC for  
2 hours 
Aqueous food simulant samples 
were analysed directly by LC-FLD 
 
LOD = 4 to 7 μg/kg 
LOQ = 30 μg/kg 
Recovery = 107-118 % (blank 
spiked with BPA at 0.12, 0.6 and 
1.2 mg/kg, n = 9) 
Repeatability = 3.4 to 5.8 % (blank 
spiked with BPA at 0.12, 0.6 and 
1.2 mg/kg, n = 9) 
Calibration = 0.03 to 1.2 mg/kg 
Measures taken to reduce 
contamination: No measures 
against contamination reported 
Included 
Revision of analytical strategies to evaluate different 
migrants from food packaging materials. 
Sendón García, R., Sanches Silva, A., Cooper, I., 
Franz, R. and Paseiro Losada, P.  








Not considered Excluded - no relevant data 
for calculation of exposure 
of specific populations from 
food contact materials  
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 271 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
10.1016/j.tifs.2006.01.005 
Comparison of migration from polyethersulphone 
and polycarbonate baby bottles. 
Simoneau, C., Valzacchi, S., Morkunas, V. and Van 
den Eede, L.  




purchased in 9 
European 
countries  
40 PC baby 
bottles 
70ºC for  
2 hours  
50% ethanol food simulant samples 
were analysed directly by LC-DAD 
and FLD 
 
LOD = 0.1 μg/kg 
LOQ = 0.3 μg/kg 
Recovery = not given 
Repeatability = not given 
Calibration = not given  
Measures taken to reduce 
contamination: No measures 
against contamination reported 
Included 
 
NOTE: although the method 
performance data was not 
well described the paper 
provided data for a 
comprehensive number and 
range of sample types 
provided data not available 
elsewhere. 
Identification and quantification of the migration of 
chemicals from plastic baby bottles used as 
substitutes for polycarbonate. 
Simoneau, C., Van den Eede, L. and Valzacchi, S. 









Not considered Excluded - no relevant data 
for calculation of exposure 
of specific population from 
food contact materials 
Recycled paper–paperboard for food contact 
materials: Contaminants suspected and migration 
into foods and food simulant. 
Suciu, N. A., Tiberto, F., Vasileiadis, S., Lamastra, 
L. and Trevisan, M. 








Not considered Excluded – paper 
published after December 
2012 (i.e. did not meet 
publication period criteria) 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 272 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Rapid Assay of Bisphenol A Released from Baby 
Feeding Bottles by Adsorptive Stripping 
Voltammetry on a Diphenylether Carbon Paste 
Electrode. 
Symeonidou, A. Economou, A., Efstathiou, C. E. and 
Dousikou, M. 








Not considered Excluded – conventional 
exposure conditions wer not 
used (single sample) and 
method performance data 
was not well defined 
Ultrasound-assisted emulsification microextraction 
coupled with gas chromatography-mass spectrometry 
using the Taguchi design method for bisphenol 
migration studies from thermal printer paper, toys 
and baby utensils. 
Viñas, P., Lopez-Garcia, I., Campillo, N., Rivas, R. 
E. and Hernandez-Cordoba, M. 









Not considered Excluded - no relevant data 
for calculation of exposure 
of specific populations from 
food contact materials. 
Reported studies 
determining the transfer to 
saliva rather than migration 
data for food simulants 
Comparison of two derivatization-based methods for 
solid-phase microextraction-gas chromatography-
mass spectrometric determination of bisphenol A, 
bisphenol S and biphenol migrated from food cans 
Viñas, P., Campillo, N., Martinez-Castillo, N. and 
Hernandez-Cordoba, M. 









Not considered Excluded – no relevant data 
for calculation of exposure 
of specific populations from 
food contact materials 
Sensitive gas chromatographic-mass spectrometric Not Not Not Not considered Excluded – no relevant 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 273 
Title 
Authors 










Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
(GC-MS) method for the determination of bisphenol 
A in rice-prepared dishes. 
Zafra-Gómez, A., Morales, J. C., Ballesteros, O. and 
Navalón, A. 
Food Additives and Contaminants. 2009. 26:8, 1209-
1216. 
10.1080/02652030902939663 
considered considered considered data for calculation of 
exposure of specific 
populations from food 
contact materials 
Electrochemical sensor for bisphenol A based on 
magnetic nanoparticles decorated reduced graphene 
oxide. 
Zhang, Y., Cheng, Y., Zhou, Y., Li, B., Gu, W., Shi, 
X. and Xian, Y. 








Not considered Excluded – paper 
published after December 
2012 (i.e. did not meet 
publication period criteria) 
 
  
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 274 
 Literature quality table—occurrence in non-food matrices Table 67: 
Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Composite restorations may lead to increased 
concentrations of salivary and urinary BPA. 
Akeroyd, J. M. and Maserejian, N. N. 







Not considered Excluded - dental materials 
not included in total 
exposure determination.  
Detection and quantification of traces of bisphenol A 
and bisphenol S in paper samples using analytical 
pyrolysis-GC/MS. 
Becerra, V. and Odermatt, J. 






Not considered Excluded - analytical 
method paper - no relevant 
data for calculation of 
exposure from non-food 
sources 
Interferences in the direct quantification of bisphenol 
S in paper by means of thermochemolysis 
Becerra, V. and Odermatt, J. 






Not considered Excluded - analytical 
method paper - no relevant 
data for calculation of 
exposure from non-food 
sources 
Release of bisphenol A from polycarbonate baby 
bottles: water hardness as the most relevant factor. 
Biedermann-Brem, S. and Grob, K. 









Not considered Excluded - food contact 
material and migration data 
only - no relevant data for 
calculation of exposure from 
non-food sources 
Transfer of bisphenol A from thermal printer paper 
to the skin. 
Biedermann, S., Tschudin, P. and Grob, K. 
Analytical and Bioanalytical Chemistry. 2010. 398:1, 
571-576. 
10.1007/s00216-010-3936-9 








Switzerland BPA was extracted from the paper 
by immersion in methanol 
overnight at 60°C. Analysis was 
carried out by LC-FLD 
 
LOD = Not given 
LOQ = 0.05 µg in 10 mL ethanol 
Recovery = Not given 
Included 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Repeatability = 4 % for repeat (n = 
6) analysis of an extract at 
1.2 µg/mL 
Calibration = 0.1 to 50 µg/mL 
Measures taken to reduce 
contamination: No measures 
against contamination reported 
(levels detected are high and so 
typical background levels would 
not influence the concentrations 
measured in the samples) 
Detection of Bisphenol A on a Screen-Printed 
Carbon Electrode in CTAB Micellar Medium. 
Brugnera, M. F., Trindade, M. A. G. and Zanoni, M. 
V. B. 








Not considered Excluded - environmental 
data only - no relevant data 
for calculation of exposure 
from non-food sources 
Stir bar sorptive extraction with EG-Silicone coating 
for 4 bisphenols determination in personal care 
products by GC-MS. 
Cacho, J. I., Campillo, N., Viñas, P. and Hernández-
Córdoba, M. 
Journal of Pharmaceutical and Biomedical Analysis. 







Spain Following dilution with water the 
BPA was extracted using stir bar 
sorptive extraction, and analysed by 
thermal desorption GC-MS 
 
LOD = 8.7 µg/kg 
LOQ = 29.2 µg/kg 
Recovery = 89-114 % (replicate, 
n=10, analysis of three samples 
spiked with BPA and 40 and 
160 µg/kg) 
Repeatability = 2.1-11 % (replicate, 
n=10, analysis of three samples 
spiked with BPA and 40 and 
160 µg/kg)  
Calibration = 0. 5 - 20 µg/L 
Included 
 
NOTE: although the paper 
was published in 2013 the 
comprehensive number and 
range of sample types 
provided data not otherwise 
available in Europe 
 
NOTE: this paper was not 
included in contractors 
database but the report 
provided data for exposure 
from personal care products 
that was not available 
elsewhere 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Measures taken to reduce 
contamination: No measures 
against contamination reported 
Dental composite fillings and bisphenol A among 
children: a survey in South Korea. 
Chung, S. Y., Kwon, H., Choi, Y. H., Karmaus, W., 
Merchant, A. T., Song, K. B., Sakong, J., Ha, M., 
Hong, Y. C. and Kang, D. 






Not considered Excluded - dental materials 
not included in the 
calculation of exposure from 
non-food sources 
Quantitative analysis of organophosphate and 
pyrethroid insecticides, pyrethroid transformation 
products, polybrominated diphenyl ethers and 
bisphenol A in residential surface wipe samples. 
Clifton, M. S., Wargo, J. P., Weathers, W. S., Colon, 
M., Bennett, D. H. and Tulve, N. S. 
Journal of Chromatography A. 2013. 1273, 1-11. 
10.1016/j.chroma.2012.11.003 
Surface wipes Not 
considered 
USA Not considered Excluded – samples from 
USA (i.e. did not meet 
geographical origin criteria) 
Dermal penetration of bisphenol A in human skin 
contributes marginally to total exposure. 
Demierre, A. L., Peter, R., Oberli, A. and Bourqui-
Pittet, M. 








Not considered Excluded – absorption paper 
- no relevant data for 
calculation of exposure from 
non-food sources 
 
NOTE: This manuscript was 
considered for determination 
of the absorption of BPA, 
but excluded for 
methodological reasons  
Orthodontic materials research and applications: part 
2. Current status and projected future developments 
in materials and biocompatibility. 
Eliades, T.  





Not considered Excluded - dental materials 
not included in total 
exposure determination.  
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 277 
Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Orthopedics. 2007. 131:2, 253-262. 
10.1016/j.ajodo.2005.12.029 
Assessment of bisphenol-A release from orthodontic 
adhesives. 
Eliades, T., Hiskia, A., Eliades, G. and Athanasiou, 
A. E. 
American Journal of Orthodontics and Dentofacial 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
Release of bisphenol-A from a light-cured adhesive 
bonded to lingual fixed retainers. 
Eliades, T., Voutsa, D., Sifakakis, I., Makou, M. and 
Katsaros, C. 
American Journal of Orthodontics and Dentofacial 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
Bisphenol A and related compounds in dental 
materials. 
Fleisch, A. F., Sheffield, P. E., Chinn, C., Edelstein, 
B. L. and Landrigan, P. J. 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
Determination of bisphenol A in thermal printing 
papers treated by alkaline aqueous solution using the 
combination of single-drop microextraction and 
HPLC. 
Gao, L., Zou, J., Liu, H., Zeng, J., Wang, Y. and 
Chen, X. 
Journal of Separation Science. 2013. 36:7, 1298-
1303. 
10.1002/jssc.201201060 
Thermal paper Not 
considered 
China Not considered Excluded – samples from 
China (i.e. did not meet 
geographical origin criteria) 
Assessment of human exposure to Bisphenol-A, 
Triclosan and Tetrabromobisphenol-A through 
Dust Dust from 18 
houses and 2 
Belgium Dust samples were filtered and 
BPA was extracted from the dust 
Included  
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
indoor dust intake in Belgium. 
Geens, T., Roosens, L., Neels, H. and Covaci, A. 







with a mixture of hexane and 
acetone (3:1). Following solid 
phase extraction the samples were 
evaporated to dryness and 
reconstituted in methanol. A 
labelled BPA internal standard was 
used. Analysis was carried out by 
LC-MS/MS 
 
LOD = Not given 
LOQ = 3 µg/kg of dust 
Recovery = Not given (results 
automatically corrected through use 
of labelled internal standard) 
Repeatability = 6 % for repeat (n = 
6) analysis of a homogenised dust 
sample 
Calibration = Range not given 
(seven levels used) 
Measures taken to reduce 
contamination: The procedural 
blank sample was taken into 
account when determining the 
method LOQ 
 
NOTE: although method 
performance data was not 
well described the paper 
provided data for exposure 
from dust that was not 
available elsewhere 
Are potential sources for human exposure to 
bisphenol-A overlooked? 
Geens, T., Goeyens, L. and Covaci, A. 
International Journal of Hygiene and Environmental 
Health. 2011. 214:5, 339-347. 
10.1016/j.ijheh.2011.04.005 




Not considered Excluded – review paper - 
no primary data for 
calculation of exposure from 
non-food sources 
A review of dietary and non-dietary exposure to 
bisphenol-A. 
Geens, T., Aerts, D., Berthot, C., Bourguignon, J. P., 




Not considered Excluded – review paper - 
no primary data for 
calculation of exposure from 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Goeyens, L., Lecomte, P., Maghuin-Rogister, G., 
Pironnet, A. M., Pussemier, L., Scippo, M. L., Van 
Loco, J. and Covaci, A. 




Levels of bisphenol-A in thermal paper receipts from 
Belgium and estimation of human exposure. 
Geens, T., Goeyens, L., Kannan, K., Neels, H. and 
Covaci, A. 







Not considered Excluded - no relevant data 
for calculation strategy of 
exposure from non-food 
sources (i.e exposure was 
calculated using 
concentration data on skin. 
s.4.3.3.2) 
Simultaneous determination of bisphenol A, 
tetrabromobisphenol A, and perfluorooctanoic acid 
in small household electronics appliances of 
"Prohibition on Certain Hazardous Substances in 
Consumer Products" instruction using ultra-
performance liquid chromatography-tandem mass 
spectrometry with accelerated solvent extraction 
Guo, Q., Du, Z., Zhang, Y., Lu, X., Wang, J. and Yu, 
W.H 






China Not considered Excluded – samples from 
China (i.e. did not meet 
geographical origin criteria) 
and not addressing the 
category, i.e. household 
appliances are not 
considered in this opinion 
Salivary bisphenol-A levels due to dental 
material/resin: a case-control study in Korean 
children. 
Han, D. H., Kim, M. J., Jun, E. J. and Kim, J. B. 







Not considered Excluded - dental materials 
not included in total 
exposure determination 
Comment on "High levels of bisphenol A in paper 





Not considered Excluded - no primary data 
for calculation of exposure 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
for dermal exposure. 
Heinze, J. E.  
Environmental Science and Technology. 2011. 
45:21, 9464 
10.1021/es203169y 
from non-food sources 
 
Quantitative Analysis of Bisphenol A Leached from 
Household Plastics by Solid–Phase Microextraction 
and Gas Chromatography–Mass Spectrometry 
(SPME–GC–MS). 
Johnson, B. O., Burke, F. M., Harrison, R. and 
Burdette, S. 









Not considered Excluded – source not 
included in total exposure 
determination 
 
No Dental Dilemma for BPA. 
Josephson, J. 







Not considered Excluded - dental materials 
not included in total 
exposure determination 
Release of bisphenol A from resin composite used to 
bond orthodontic lingual retainers. 
Kang, Y. G., Kim, J. Y., Kim, J., Won, P. J. and 
Nam, J. H. 
American Journal of Orthodontics and Dentofacial 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
Bisphenol A and other compounds in human saliva 
and urine associated with the placement of composite 
restorations. 
Kingman, A., Hyman, J., Masten, S. A., Jayaram, B., 
Smith, C., Eichmiller, F., Arnold, M. C., Wong, P. 
A., Schaeffer, J. M., Solanki S. and Dunn, W. J. 





Not considered Excluded - dental materials 
not included in total 
exposure determination.  
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 




Bisphenol-A and residual monomer leaching from 
orthodontic adhesive resins and polycarbonate 
brackets: A systematic review. 
Kloukos, D., Pandis, N. and Eliades, T. 
American Journal of Orthodontics and Dentofacial 






Not considered Excluded - dental materials 
not included in total 
exposure determination.  
In vivo bisphenol-A release from dental pit and 
fissure sealants: A systematic review. 
Kloukos, D., Pandis, N. and Eliades, T. 






Not considered Excluded - dental materials 
not included in total 
exposure determination.  
High levels of bisphenol A in paper currencies from 
several countries, and implications for dermal 
exposure. 
Liao, C. and Kannan, K. 









Not considered Excluded – samples from 
various countries worldwide, 
obtained in USA (i.e. did not 
meet geographical origin 
criteria) 
Widespread occurrence of bisphenol A in paper and 
paper products: implications for human exposure. 
Liao, C. and Kannan, K. 








Not considered Excluded – samples from 
USA, Japan, Korea and 
Vietnam (i.e. did not meet 
geographical origin criteria) 
Reply to Comment on “High Levels of Bisphenol A 
in Paper Currencies from Several Countries, and 
Implications for Dermal Exposure”. 
Liao, C. and Kannan, K. 






Not considered Excluded - no primary data 
for calculation of exposure 
from non-food sources 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
10.1021/es203380e 
Occurrence of eight bisphenol analogues in indoor 
dust from the United States and several Asian 
countries: implications for human exposure. 
Liao, C., Liu, F., Guo, Y., Moon, H. B., Nakata, H., 
Wu, Q. and Kannan, K. 








Not considered Excluded - samples from 
USA, China, Japan and 
Korea (i.e. did not meet 
geographical origin criteria) 
Bisphenol S, a new bisphenol analogue, in paper 
products and currency bills and its association with 
bisphenol A residues. 
Liao, C., Liu, F. and Kannan, K. 







Not considered Excluded - not related to 
BPA - no relevant data for 
calculation of exposure from 
non-food sources 
Occurrence of bisphenol A in indoor dust from two 
locations in the eastern United States and 
implications for human exposures. 
Loganathan, S. N. and Kannan, K. 
Archives of Environmental Contamination and 




USA Not considered Excluded - samples from 
USA (i.e. did not meet 
geographical origin criteria) 
Bisphenol A in supermarket receipts and its exposure 
to human in Shenzhen, China. 
Lu, S.-Y., Chang, W.-J., Sojinu, S. O. and Ni, H.-G. 




China Not considered Excluded – samples from 
China (i.e. did not meet 
geographical origin criteria) 
Exposure to Bisphenol A (BPA) from dental 
materials is detectable in saliva and urine, and varies 
significantly between material formulations. 
Martin, M. D.  





Not considered Excluded - dental materials 
not included in total 
exposure determination 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
2007. 7:2, 79-80. 
10.1016/j.jebdp.2007.03.008 
Concentration of bisphenol A in thermal paper. 
Mendum, T., Stoler, E., VanBenschoten, H. and 
Warner, J. C. 





USA Not considered Excluded - samples from 
USA (i.e. did not meet 
geographical origin criteria) 
The contribution of dermal exposure to the internal 
exposure of bisphenol A in man. 
Mielke, H., Partosch, F. and Gundert-Remy, U. 








Not considered Excluded – absorption paper 
- no primary data for 
calculation of exposure from 
non-food sources 
 
NOTE: This manuscript was 
considered for determination 
of the absorption of BPA, 
but excluded for 
methodological reasons 
Assessing the quantitative relationships between 
preschool children's exposures to bisphenol A by 
route and urinary biomonitoring. 
Morgan, M. K., Jones, P. A., Calafat, A. M., Ye, X., 
Croghan, C. W., Chuang, J. C., Wilson, N. K., 
Clifton, M. S., Figueroa, Z. and Sheldon, L. S. 









USA Not considered Excluded - samples from 
USA (i.e. did not meet 
geographical origin criteria) 
Long-term release of monomers from modern dental-
composite materials. 
Polydorou, O., König, A., Hellwig, E. and 
Kümmerer, K. 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
Effect of bleaching on the elution of monomers from 
modern dental composite materials. 
Polydorou, O., Beiter, J., König, A., Hellwig, E. and 
Kümmerer, K. 






Not considered Excluded - dental materials 
not included in exposure 
determination 
Release of monomers from different core build-up 
materials. 
Polydorou, O., Hammad, M., König, A., Hellwig, E. 
and Kümmerer, K. 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
Elution of monomers from two conventional dental 
composite materials. 
Polydorou, O., Trittler, R., Hellwig, E. and 
Kümmerer, K. 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
Bisphenol A in dental materials and its estrogen like 
effect 
Rathee, M., Malik, P. and Singh, J. 
Indian Journal of Endocrinology and Metabolism. 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
Indoor airborne particle sources and semi-volatile 
partitioning effect of outdoor fine PM in offices 
Sangiorgi, G., Ferrero, L., Ferrini, B. S., Lo Porto, 
C., Perrone, M. G., Zangrando, R., Gambaro, A., 
Lazzati, Z. and Bolzacchini, E. 






from air at 
four sites 
Italy Not considered Excluded – paper published 
after December 2012 (i.e. 
did not meet publication 
period criteria) 
Occurrence of bisphenol A in surface water, drinking 
water and plasma from Malaysia with exposure 




Not considered Excluded – environment and 
drinking water data - no 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
assessment from consumption of drinking water. 
Santhi, V. A., Sakai, N., Ahmad, E. D. and Mustafa, 
A. M. 
The Science of the Total Environment. 2012. 427-
428, 332-338. 
10.1016/j.scitotenv.2012.04.041 
relevant data for calculation 
of exposure from non-food 
sources 
How much do resin-based dental materials release? 
A meta-analytical approach. 
Van Landuyt, K. L., Nawrot, T., Geebelen, B., De 
Munck, J., Snauwaert, J., Yoshihara, K., Scheers, H., 
Godderis, L., Hoet, P. and Van Meerbeek, B. 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
Systematic review of the chemical composition of 
contemporary dental adhesives. 
Van Landuyt, K. L., Snauwaert, J., De Munck, J., 
Peumans, M., Yoshida, Y., Poitevin, A., Coutinho, 
E., Suzuki, K., Lambrechts, P. and Van Meerbeek, B. 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
Ultrasound-assisted emulsification microextraction 
coupled with gas chromatography-mass spectrometry 
using the Taguchi design method for bisphenol 
migration studies from thermal printer paper, toys 
and baby utensils. 
Viñas, P., López-Garcia, I., Campillo, N., Rivas, R. 
E. and Hernandez-Córdoba, M. 

















Spain BPA was extracted from the paper 
by immersion in water. Toys were 
immersed in saliva simulant. 
Derivatisation with acetic 
anhydride and BSTFA were 
compared. Analysis was carried out 
by GC. 
 
LOD = 0.1 µg/L 
LOQ = 0.3 µg/L 
Recovery = Not given 
Repeatability = 7.6 % (replicate, 
n=10, analyses of samples at 
Excluded – experimental 
setup not appropriate for 
exposure determination 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
1 µg/L) 
Calibration = 0.1 to 3 µg/L 
Measures taken to reduce 
contamination: No measures 
against contamination reported 
Bisphenol a: how the most relevant exposure sources 
contribute to total consumer exposure. 
von Goetz, N., Wormuth, M., Scheringer, M. and 
Hungerbuhler, K. 








Not considered Excluded – modelling paper 
- no primary data for 
calculation of exposure from 
non-food sources 
 
SVOC exposure indoors: fresh look at dermal 
pathways. 
Weschler, C. J. and Nazaroff, W. W. 








Not considered Excluded – modelling paper 
- no primary data for 
calculation of exposure from 
non-food sources 
 
An observational study of the potential exposures of 
preschool children to pentachlorophenol, bisphenol-
A, and nonylphenol at home and daycare. 
Wilson, N. K., Chuang, J. C., Morgan, M. K., Lordo, 
R. A. and Sheldon, L. S. 









USA Not considered Excluded – samples from 
USA (i.e. did not meet 
geographical origin criteria) 
Pt/graphene-CNTs nanocomposite based 
electrochemical sensors for the determination of 
endocrine disruptor bisphenol A in thermal printing 
papers. 
Zheng, Z., Du, Y., Wang, Z., Feng, Q. and Wang, C. 




China Not considered Excluded – samples from 
China (i.e. did not meet 
geographical origin criteria) 
Molecularly imprinted layer-coated silica 
nanoparticles for selective solid-phase extraction of 
Cosmetics Not 
considered 
China Not considered Excluded - samples from 
China (i.e. did not meet 
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Title 
Authors 







Method description and quality 
parameters 
Reported data included or 
excluded from the 
calculation of the exposure 
to bisphenol A and 
reasoning 
bisphenol A from chemical cleansing and cosmetics 
samples. 
Zhu, R., Zhao, W., Zhai, M., Wei, F., Cai, Z., Sheng, 
N. and Hu, Q. 
Analytica Chimica Acta. 2010. 658:2, 209-216. 
10.1016/j.aca.2009.11.008 
geographical origin criteria) 
Bisphenol A Blood and Saliva Levels Prior To and 
After Dental Sealant Placement In Adults 
Zimmerman Downs, J. M., Shuman, D., Stull, S. C. 
and Ratzlaff, R. E. 






Not considered Excluded - dental materials 
not included in total 
exposure determination 
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 Literature quality table—occurrence in the environment  Table 68: 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
Sensitive gas chromatographic-mass spectrometric method for the 
determination of phthalate esters, alkylphenols, bisphenol A and their 
chlorinated derivatives in wastewater samples. 
Ballesteros, O. Zafra, A. Navalon, A. and Vilchez, J. L. 








Not considered Excluded - waste water 
not included in exposure 
determination 
Determination of bisphenols A and F and their diglycidyl ethers in 
wastewater and river water by coacervative extraction and liquid 
chromatography-fluorimetry. 
Ballesteros-Gomez, A., Ruiz, F. J., Rubio, S. and Perez-Bendito, D. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Multiresidue analytical methods for the ultra-trace quantification of 33 
priority substances present in the list of REACH in real water samples 
Baugros, J. B., Giroud, B., Dessalces, G., Grenier-Loustalot, M. F. and 
Cren-Olive, C. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Biologically directed environmental monitoring, fate, and transport of 
estrogenic endocrine disrupting compounds in water: A review. 
Campbell, C. G., Borglin, S. E., Green, F. B., Grayson, A., Wozei, E. and 
Stringfellow, W. T. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Bisphenol A occurred in Kao-Pin River and its tributaries in Taiwan. 
Chen, T. C., Shue, M. F., Yeh, Y. L. and Kao, T. J. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Determination of bisphenol A in water via inhibition of silver Industrial Not Not Not considered Excluded - waste water 
                                                     
27
 For inclusion/exlusion criteria see Appendix A. 
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Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
nanoparticles-enhanced chemiluminescence. 
Chen, X., Wang, C., Tan, X. and Wang, J. 





considered considered and river water not 
included in exposure 
determination 
Hollow fiber liquid-liquid-liquid microextraction combined with high 
performance liquid chromatography-ultraviolet detection for the 
determination of various environmental estrogens in environmental and 
biological samples. 
Chen, B., Huang, Y., He, M. and Hu, B. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Occurrence and assessment of treatment efficiency of nonylphenol, 
octylphenol and bisphenol-A in drinking water in Taiwan. 
Chen, H. W., Liang, C. H., Wu, Z. M., Chang, E. E., Lin, T. F., Chiang, P. 
C. and Wang, G. S. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Alkylphenolic compounds and bisphenol A contamination within a 
heavily urbanized area: case study of Paris. 
Cladière, M., Gasperi, J., Lorgeoux, C., Bonhomme, C., Rocher, V. and 
Tassin, B. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Emerging pollutants in wastewater: a review of the literature. 
Deblonde, T., Cossu-Leguille, C. and Hartemann, P. 









Not considered Excluded - waste water 
not included in exposure 
determination 
Uptake and accumulation of four PPCP/EDCs in two leafy vegetables. 
Dodgen, L. K., Li, J., Parker, D. and Gan, J. J. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 290 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
publication period 
criteria) 
Detection and occurrence of chlorinated byproducts of bisphenol a, 
nonylphenol, and estrogens in drinking water of china: comparison to the 
parent compounds. 
Fan, Z., Hu, J., An, W. and Yang, M. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Gas-liquid chromatography-tandem mass spectrometry methodology for 
the quantitation of estrogenic contaminants in bile of fish exposed to 
wastewater treatment works effluents and from wild populations. 
Fenlon, K. A., Johnson, A. C., Tyler, C. R. and Hill, E. M. 








Not considered Excluded - 
environmental risk paper 
- not relevant for 
occurrence in the 
environment 
Bisphenol A exposure, effects, and policy: a wildlife perspective. 
Flint, S., Markle, T., Thompson, S. and Wallace, E. 








Not considered Excluded - 
environmental risk paper 
- not relevant for 
occurrence in the 
environment 
A national reconnaissance for pharmaceuticals and other organic 
wastewater contaminants in the United States--II) untreated drinking water 
sources. 
Focazio, M. J., Kolpin, D. W., Barnes, K. K., Furlong, E. T., Meyer, M. 
T., Zaugg, S. D., Barber, L. B. and Thurman, M. E. 








Not considered Excluded - waste water 
not included in exposure 
determination 
Ubiquity of bisphenol A in the atmosphere. 
Fu, P. and Kawamura, K. 








Not considered Excluded - outdoor 
atmosphere not included 
in exposure 
determination 
On-line solid phase extraction fast liquid chromatography-tandem mass 







Not considered Excluded - surface water 
not included in exposure 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 291 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
derivatives in water samples. 
Gallart-Ayala, H., Moyano, E. and Galceran, M. T. 
Journal of Chromatography A. 2010. 1217:21, 3511-3518. 
10.1016/j.chroma.2010.03.028 
determination 
Determination of acidic pharmaceuticals and potential endocrine 
disrupting compounds in wastewaters and spring waters by selective 
elution and analysis by gas chromatography-mass spectrometry 
Gibson, R., Becerril-Bravo, E., Silva-Castro, V. and Jimenez, B. 








Not considered Excluded - waste water 
not included in exposure 
determination 
A new method for monitoring oestrogens,N-octylphenol, and bisphenol A 
in wastewater treatment plants by solid-phase extraction–gas 
chromatography–tandem mass spectrometry. 
Gómez, M. J., Mezcua, M., Martinez, M. J., Fernández-Alba, A R. and 
Agüera, A. 









Not considered Excluded - waste water 
not included in exposure 
determination 
Multi-residue analytical method for the determination of endocrine 
disruptors and related compounds in river and waste water using dual 
column liquid chromatography switching system coupled to mass 
spectrometry. 
Gorga, M., Petrovic, M. and Barceló, D. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Simultaneous determination of hexabromocyclododecane, 
tetrabromobisphenol A, and related compounds in sewage sludge and 
sediment samples from Ebro River basin (Spain). 
Guerra, P., Eljarrat, E. and Barcelo, D. 








Not considered Excluded - sewage water 
not included in exposure 
determination 
Occurrence of phenols and phenoxyacid herbicides in environmental 
waters using an imprinted polymer as a selective sorbent. 
Not Not Not Not considered Excluded – paper 
published after 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 292 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
Herrero-Hernandez, E., Rodriguez-Gonzalo, E., Andrades, M. S., 
Sanchez-Gonzalez, S. and Carabias-Martinez, R. 
The Science of the Total Environment. 2013. 454-455, 299-306. 
10.1016/j.scitotenv.2013.03.029 
considered considered considered December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Preparation of magnetic molecularly imprinted polymers for bisphenol A 
and its analogues and their application to the assay of bisphenol A in river 
water. 
Hiratsuka, Y., Funaya, N., Matsunaga, H. and Haginaka, J.  








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Environmental temperature changes uptake rate and Bioconcentration 
factors of bisphenol a in tadpoles of Rana temporaria 
Honkanen, J. O. and Kukkonen, J. V. K. 
Environmental Toxicology and Chemistry. 2006. 25:10, 2804-2808. 







Not considered Excluded - 
environmental risk paper 
- not relevant for 
occurrence in the 
environment 
Bisphenol A (BPA) in China: a review of sources, environmental levels, 
and potential human health impacts. 
Huang, Y. Q., Wong, C. K., Zheng, J. S., Bouwman, H., Barra, R., 
Wahlstrom, B., Neretin, L. and Wong, M. H. 








Not considered Excluded - review paper 
- not relevant for 
occurrence in the 
environment 
BPA and environmental estrogen in potable water sources in Enugu 
municipality, South-East, Nigeria. 
Ignatius, C. M., Francis, E. E., Emeka, E. N., Elvis, N. S. and Ebele, J. I. 




water and  





Not considered Excluded - river water 
and rain water not 
included in exposure 
determination 
Identification of organic xenobiotics in urban aquatic environments using 
time-of-flight mass spectrometry. 
Jernberg, J., Pellinen, J. and Rantalainen, A. L. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 293 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
criteria) 
Direct enrichment and high performance liquid chromatography analysis 
of ultra-trace Bisphenol A in water samples with narrowly dispersible 
Bisphenol A imprinted polymeric microspheres column. 
Jiang, M., Zhang, J. H., Mei, S. R., Shi, Y., Zou, L. J., Zhu, Y. X., Dai, K. 
and Lu, B. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Occurrence, transportation, monitoring and treatment of emerging micro-
pollutants in waste water- A review from global views. 
Jiang, J.-Q., Zhou, Z. and Sharma, V. K. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Determination of bisphenol A, bisphenol F and their diglycidyl ethers in 
environmental water by solid phase extraction using magnetic multiwalled 
carbon nanotubes followed by GC-MS/MS. 
Jiao, Y., Ding, L., Fu, S., Zhu, S., Li, H. and Wang, L. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Bisphenol A in the aquatic environment and its endocrine-disruptive 
effects on aquatic organisms. 
Kang, J. H., Asai, D. and Katayama, Y. 








Not considered Excluded - 
environmental risk paper 
- not relevant for 
occurrence in the 
environment 
Bisphenol A in the surface water and freshwater snail collected from 
rivers around a secure landfill. 
Kang, J. H. and Kondo, F. 









Not considered Excluded - 
environmental risk paper 
- not relevant for 
occurrence in the 
environment 
Distribution and biodegradation of bisphenol A in water hyacinth. Not Not Not Not considered Excluded - 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 294 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
Kang, J. H. and Kondo, F. 
Bulletin of Environmental Contamination and Toxicology. 2006. 77:4, 
500-507. 
10.1007/s00128-006-1092-x 
applicable considered considered environmental risk paper 
- not relevant for 
occurrence in the 
environment 
Liquid phase microextraction with in situ derivatization for measurement 
of bisphenol A in river water sample by gas chromatography-mass 
spectrometry. 
Kawaguchi, M., Ito, R., Endo, N., Okanouchi, N., Sakui, N., Saito, K. and 
Nakazawa, H. 








Not considered Excluded - surface water 
not included in exposure 
determination 
On-line solid-phase microextraction of triclosan, bisphenol A, 
chlorophenols, and selected pharmaceuticals in environmental water 
samples by high-performance liquid chromatography-ultraviolet detection. 
Kim, D., Han, J. and Choi, Y. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Distribution of pesticides and bisphenol A in sediments collected from 
rivers adjacent to coral reefs. 
Kitada, Y., Kawahata, H., Suzuki, A. and Oomori, T. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Exposure Analysis of Bisphenol A in Surface Water Systems in North 
America and Europe. 
Klecka, G. M., Staples, C. A., Clark, K. E., Van Der Hoeven, N., Thomas, 
D. E. and Hentges, S. G. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Pharmaceuticals, hormones and bisphenol A in untreated source and 
finished drinking water in Ontario, Canada--occurrence and treatment 
efficiency. 







Not considered Excluded - surface water 
not included in exposure 
determination 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 295 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
S., Cheung, P. and Whitehead, B. 
The Science of the Total Environment. 2011. 409:8, 1481-1488. 
10.1016/j.scitotenv.2011.01.010 
Characterization of trace organic contaminants in marine sediment from 
Yeongil Bay, Korea: 1. Instrumental analyses. 
Koh, C. H., Khim, J. S., Villeneuve, D. L., Kannan, K. and Giesy, J. P. 






Not considered Excluded - sediment not 
included in exposure 
determination 
Enzyme-linked immunosorbent assay for bisphenol A: Assay optimization 
and its application for surface water analysis. 
Krapivin, A. S., Samsonova, J. V., Uskova, N. A., Ivanova, N. L. and 
Egorov, Al. M. 








Not considered Excluded - surface water 
not included in exposure 
determination 
The potential role of water quality parameters on occurrence of 
nonylphenol and bisphenol A and identification of their discharge sources 
in the river ecosystems. 
Lee, C. C., Jiang, L. Y., Kuo, Y. L., Hsieh, C. Y., Chen, C. S. and Tien, C. 
J. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Development and characterization of an immunoaffinity monolith for 
selective on-line extraction of bisphenol A from environmental water 
samples. 
Li, L., Wang, J., Zhou, S. and Zhao, M. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Determination of Bisphenol A in Landfill Leachate by Solid Phase 
Microextraction with Headspace Derivatization and Gas Chromatography-
Mass Spectrophotometry. 
Li, X., Lin, L., Zou, S., Lan, C. and Luan, T. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 296 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
Dispersive liquid–liquid microextraction based on ionic liquid in 
combination with high-performance liquid chromatography for the 
determination of bisphenol A in water 
Li, Y. and Liu, J. 









Not considered Excluded - surface water 
not included in exposure 
determination 
High sensitivity detection of bisphenol A using liposome chromatography. 
Liu, X. Y., Nakamura, C., Tanimoto, I., Miyake, S., Nakamura, N., 
Hirano, T. and Miyake, J. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Passive sampling and stir bar sorptive extraction for the determination of 
endocrine-disrupting compounds in water by GC-MS. 
Magi, E., Di Carro, M. and Liscio, C. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Selective Molecularly Imprinted Polymer Obtained from a Combinatorial 
Library for the Extraction of Bisphenol A. 
Martin-Esteban, A. and Tadeo, J. L. 









Not considered Excluded - analytical 
method paper - not 
relevant for occurrence 
in the environment 
Simultaneous determination of 76 micropollutants in water samples by 
headspace solid phase microextraction and gas chromatography-mass 
spectrometry. 
Martínez, C., Ramírez, N., Gómez, V., Pocurull, E. and Borrull, F. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Ultrasensitive one-step rapid visual detection of bisphenol A in water 
samples by label-free aptasensor. 







Not considered Excluded – paper 
published after 
December 2012 (i.e. 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 297 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
L. 
Biosensors and Bioelectronics. 2013. 39:1, 26-30. 
10.1016/j.bios.2012.06.027 
did not meet 
publication period 
criteria) 
Physico-chemical pre-treatment and biotransformation of wastewater and 
wastewater sludge--fate of bisphenol A. 
Mohapatra, D. P., Brar, S. K., Tyagi, R. D. and Surampalli, R. Y. 








Not considered Excluded - waste water 
not included in exposure 
determination 
Application of electro-enhanced solid-phase microextraction for 
determination of phthalate esters and bisphenol A in blood and seawater 
samples. 
Mousa, A., Basheer, C. and Rahman Al-Arfaj, A. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Pharmaceutical chemicals and endocrine disrupters in municipal 
wastewater in Tokyo and their removal during activated sludge treatment. 
Nakada, N., Tanishima, T., Shinohara, H., Kiri, K. and Takada, H. 








Not considered Excluded - waste water 
not included in exposure 
determination 
A critical evaluation of the environmental risk assessment for plasticizers 
in the freshwater environment in Europe, with special emphasis on 
bisphenol A and endocrine disruption. 
Oehlmann, J., Oetken, M. and Schulte-Oehlmann, U. 








Not considered Excluded - 
environmental risk paper 
- not relevant for 
occurrence in the 
environment 
Determination of phenolic compounds in river water with on-line coupling 
bisphenol A imprinted monolithic precolumn with high performance 
liquid chromatography. 
Ou, J., Hu, L., Hu, L., Li, X. and Zou, H. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Simultaneous determination of endocrine-disrupting phenols and steroid Sediment Not Not Not considered Excluded - sediment not 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 298 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
estrogens in sediment by gas chromatography-mass spectrometry. 
Peng, X., Wang, Z., Yang, C., Chen, F. and Mai, B. 
Journal of Chromatography A. 2006. 1116:1-2, 51-56. 
10.1016/j.chroma.2006.03.017 
considered considered included in exposure 
determination 
Multiresidue analysis of acidic and polar organic contaminants in water 
samples by stir-bar sorptive extraction-liquid desorption-gas 
chromatography-mass spectrometry. 
Quintana, J. B., Rodil, R., Muniategui-Lorenzo, S., Lopez-Mahia, P. and 
Prada-Rodriguez, D. 








Not considered Excluded - surface water 
not included in exposure 
determination 
A study of parabens and bisphenol A in surface water and fish brain tissue 
from the Greater Pittsburgh Area. 
Renz, L., Volz, C., Michanowicz, D., Ferrar, K., Christian, C., Lenzner, 
D., and El-Hefnawy, T. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Quantification of 17 endocrine disruptor compounds and their spatial and 
seasonal distribution in the Iberian Ave River and its coastline. 
Rocha, M. J., Cruzeiro, C. and Rocha, E.  








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Determination of 17 endocrine disruptor compounds and their spatial and 
seasonal distribution in the Sado River Estuary (Portugal). 
Rocha, M. J., Cruzeiro, C., Reis, M., Rocha, E., Pardal, M., A. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Occurrence of bisphenol a, estrone, 17beta-estradiol and 17alpha-







Not considered Excluded – paper 
published after 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 299 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
Rocha, S., Domingues, V. F., Pinho, C., Fernandes, V. C., Delerue-Matos, 
C., Gameiro, P. and Mansilha, C. 
Bulletin of Environmental Contamination and Toxicology. 2013. 90:1, 73-
78. 
10.1007/s00128-012-0887-1 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Vesicular coacervative extraction of bisphenols and their diglycidyl ethers 
from sewage and river water. 
Ruiz, F. J., Rubio, S. and Perez-Bendito, D. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Determination of alkylphenols and bisphenol A in seawater samples by 
dispersive liquid-liquid microextraction and liquid chromatography 
tandem mass spectrometry for compliance with environmental quality 
standards (Directive 2008/105/EC). 
Salgueiro-Gonzalez, N., Concha-Grana, E., Turnes-Carou, I., Muniategui-
Lorenzo, S., Lopez-Mahia, P. and Prada-Rodriguez, D. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Simultaneous determination of bisphenol A and its halogenated 
derivatives in river water by combination of isotope imprinting and liquid 
chromatography-mass spectrometry. 
Sambe, H., Hoshina, K., Hosoya, K. and Haginaka, J. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Polycarbonate baby bottles: study of the release of Bisphenol A. 
Santillana, M. I., Ruiz, E., Nieto, M. T., Rodríguez Bernaldo de Quirós, 
A., Sendón, R., Cirugeda, M. E. and Sanchez, J. J. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
A direct Capillary Liquid Chromatography with electrochemical detection 







Not considered Excluded - surface water 
not included in exposure 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 300 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
Segovia-Martinez, L., Moliner-Martinez, Y. and Campins-Falco, P. 
Journal of Chromatography A. 2010. 1217:50, 7926-7930. 
10.1016/j.chroma.2010.10.078 
determination 
GC–MS determination of bisphenol A and alkyl phenol ethoxylates in 
river water from India and their ecotoxicological risk assessment. 
Selvaraj. K. K., Shanmugam, G., Sampath, S., D.G. Joakim Larsson D. G. 
J. and Ramaswamy, B. R. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Analysis of endocrine disrupting compounds in wastewater and drinking 
water treatment plants at the nanogram per litre level. 
Stavrakakis, C., Colin, R., Hequet, V., Faur, C. and Le Cloirec, P. 








Not considered Excluded -waste water 
not included in exposure 
determination 
Human health risk on environmental exposure to Bisphenol-A: a review. 
Tsai, W. T. 









Not considered Excluded - review paper 
- not relevant for 
occurrence in the 
environment 
Investigating the estrogenic risk along the river Po and its intermediate 
section. 
Vigano, L., Mandich, A., Benfenati, E., Bertolotti, R., Bottero, S., Porazzi, 
E. and Agradi, E. 









Not considered Excluded - surface water 
not included in exposure 
determination 
Selective determination of bisphenol A (BPA) in water by a reversible 
fluorescence sensor using pyrene/dimethyl ß-cyclodextrin complex. 
Wang, X., Zeng, H., Zhao, L. and Lin, J.-M. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Analysis of estrogens in environmental waters using polymer monolith in- Surface Not Not Not considered Excluded -surface water 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 301 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
polyether ether ketone tube solid-phase microextraction combined with 
high-performance liquid chromatography. 
Wen, Y., Zhou, B. S., Xu, Y., Jin, S. W. and Feng, Y. Q. 
Journal of Chromatography A. 2006. 1133:1-2, 21-28. 
10.1016/j.chroma.2006.08.049 
water considered considered not included in exposure 
determination 
Seasonal and spatial distribution of 4-tert-octylphenol, 4-nonylphenol and 
bisphenol A in the Huangpu River and its tributaries, Shanghai, China. 
Wu, M., Wang, L., Xu, G., Liu, N., Tang, L., Zheng, J., Bu, T. and Lei, B. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Surface-imprinted core-shell Au nanoparticles for selective detection of 
bisphenol A based on surface-enhanced Raman scattering. 
Xue, J.-Q., Li, D.-W., Qu, L.-L. and Long, Y.-T. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Seasonal variation of endocrine disrupting compounds, pharmaceuticals 
and personal care products in wastewater treatment plants. 
Yu, Y., Wu, L. and Chang, A. C. 








Not considered Excluded – paper 
published after 
December 2012 (i.e. 
did not meet 
publication period 
criteria) 
Determination of some endocrine disrupter chemicals in urban wastewater 
samples using liquid chromatography–mass spectrometry. 
Zafra-Gómez, A., Ballesteros, O., Navalón, A. and Vílchez, J. L. 








Not considered Excluded - waste water 
not included in exposure 
determination 
MCX based solid phase extraction combined with liquid chromatography 
tandem mass spectrometry for the simultaneous determination of 31 







Not considered Excluded - surface water 
not included in exposure 
determination 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 302 
Title 
Authors 










Reported data included 
or excluded from the 
calculation of the 
exposure to bisphenol 
A
27
 and reasoning 
Zhang, H. C., Yu, X. J., Yang, W. C., Peng, J. F., Xu, T., Yin, D. Q. and 
Hu, X. L. 
Journal of Chromatography B. 2011. 879:28, 2998-3004. 
10.1016/j.jchromb.2011.08.036 
Optimisation of derivatisation for the analysis of estrogenic compounds in 
water by solid-phase extraction gas chromatography-mass spectrometry. 
Zhang, Z. L., Hibberd, A. and Zhou, J. L. 








Not considered Excluded - surface water 
not included in exposure 
determination 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 303 
 Literature quality table – colostrum and breast milk Table 69: 
Title 
Authors 




Sampling Country of 
origin of 
samples 




Reliable quantification of bisphenol A and its 
chlorinated derivatives in human breast milk using 
UPLC–MS/MS method.   
Cariot, A., Dupuis, A., Albouy-Llaty, M., Legube, 
B., Rabouan, S and Migeot, V.   
Talanta. 2012. 100, 175-182.  
10.1016/j.talanta.2012.08.034 





within a few 
days after 
delivery 
France Samples were precipitated with 
methanol, sonicated and 
centrifuged. Following sample 
concentration unconjugated BPA 
was determined in the samples 
using on-line SPE-UPLC-MS/MS. 
d16-BPA internal standard was used.  
 
LOD = 0.09 ng/mL (3x S:N) 
LOQ = 0.40 ng/mL (lowest 
calibration standard).  
Recovery >80% at 3.2 ng/ml (n=3) 
Repeatability (RSD) = 15% (intra-
day) and 11% (inter-day) at 
0.40 ng/mL and 1% (intra-day) and 
14% (inter-day) at 3.2 ng/mL 
Accuracy = 101% (intra-day) and 
103% (inter-day) at 0.40 ng/mL and 
93% (intra-day) and 98% (inter-
day) at 3.2 ng/mL 
Calibration = 0.4 to 6.4 ng/mL 
using spiked milk standards 
Measures taken to reduce 
contamination: All solvents and 
reagents were tested to ensure the 
absence of contamination, only pre-
treated glassware (500°C, 5 hours), 
teflon seals and high quality 
Included  
Scientific opinion on BPA: Part I – Exposure assessment 
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Title 
Authors 




Sampling Country of 
origin of 
samples 




solvents were used. The milk was 
drawn manually without using any 
device, materials, wipes or gloves. 
Samples were stored at -20°C. 
Chromatograms are presented 
demonstrating that the background 
levels of BPA are less than the 
LOD. 
Potential sources of bisphenol A in the neonatal 
intensive care unit. 
Duty, S. M., Mendonca, K., Hauser, R., Calafat, A. 
M., ye, X., Meeker, J. D., Ackerman, R., Cullinane, 
J., Faller, J. and Ringer, S. 
Pediatrics. 2013. 131:3, 483-489. 
10.1542/peds.2012-1380 







Total and unconjugated BPA 
concentrations were determined. 
Samples were precipitated with 2-
propanol and centrifuged. 
Following acidification of the 
samples clean-up and analysis was 
by on-line SPE-HPLC-MS/MS. 
13
C12-BPA was used as an internal 
standard. Deconjugation used β-
glucuronidase / sulfatase (Helix 
pomatia, H1). 
 
LOD = 0.3 ng/mL(3x S:N) 
LOQ = 0.93 ng/mL (10x S:N) 
Recovery = Not given 
Repeatability = 6.3-8.3% 
Accuracy = 98-108% 
Calibration = 0 to 100 ng/mL 
NOTE: For method details the 
authors refer to Ye et al 2008 
Measures taken to reduce 
contamination Sample collection 
Included. 
 
NOTE: although the samples 
were from the USA this is 
one of only a few studies 
reporting breast milk BPA 
data and so was included 
 
NOTE: two statistical 
outliers were removed by the 
authors – no explanation as 
to why – addressed in the 
uncertainty tables 
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devices were pre-screened for BPA. 
Milk was expressed by mechanical 
pumping and was stored frozen in 
BPA free containers. 
Evaluation of Organic Environmental Pollutants 
Detected in Human Milk. 
Kishikawa, N. and Kuroda, N. 
Journal of Health Science. 2009. 55:1, 1-10. 
None given. 
Review paper Not 
considered 
Japan Not considered Excluded – Review paper 
(no new data reported) 
Measurement of bisphenol A concentrations in 
human colostrum.  
Kuruto-Niwa, R., Tateoka, Y., Usuki, Y. and 
Nozawa, R.   
2007, Chemosphere, 66, 1160-1164.   
DOI: 10.1016/j.chemosphere.2006.06.073 







within 3 days 
after delivery 
in 2000-2001 
Japan Samples were precipitated with 
acetonitrile, sonicated and 
centrifuged. Following sample 
clean-up using SPE analysis was 
carried out using ELISA. 
 
LOD = 0.3 ng/mL  
LOQ = Not given 
Recovery = 102.6% 
Repeatability (RSD) = Not given 
Calibration = 1.56 to 100 ng/mL 
Measures taken to reduce 
contamination: Colostrum was 
directly expressed into and was 
stored in glass bottles at  




NOTE: although samples 
were from Japan and used 
less selective ELISA 
methodology the paper 
provided data that was not 
available elsewhere and so 
was included 
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Bisphenol A and its chlorinated derivatives in human 
colostrum.  
Migeot, V., Dupuis, A., Cariot, A., Albuoy-Llaty, M. 
Pierre, F. and Rabouan, S. 
Environmental Science and technology. 2013. 47, 
13791-13797.  
dx.doi.org/10.1021/es403071a 








France Samples were precipitated with 
methanol, sonicated and 
centrifuged. Following sample 
concentration unconjugated BPA 
was determined in the samples 
using on-line SPE-UPLC-MS/MS. 
d16-BPA internal standard was used.  
 
LOD = 0.09 ng/mL (3x S:N) 
LOQ = 0.40 ng/mL (lowest 
calibration standard).  
Recovery >80% at 3.2 ng/ml (n=3) 
Repeatability = 1-15% (intra-day) 
and 11-14% (inter-day) at 0.4-
3.2 ng/mL with n=5-13 
Accuracy = 93-101% (intra-day) 
and 98-103% (inter-day) at 0.4-
3.2 ng/mL with n=5-13 
Calibration = 0.4 to 6.4 ng/mL 
using spiked milk standards 
Measures taken to reduce 
contamination: All solvents and 
reagents were tested to ensure the 
absence of contamination, only pre-
treated glassware (500°C, 5 hours), 
teflon seals and high quality 
solvents were used. The milk was 
drawn manually without using any 
device, materials, wipes or gloves. 
Samples were stored at -20°C. 
Chromatograms are presented 
Included 
 
NOTE: this paper was not 
included in contractors 
database and was published 
in 2013 but is one of only a 
few studies reporting breast 
milk BPA data and so was 
included 
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demonstrating that the background 
levels of BPA are less than the 
LOD. 
Bisphenol A concentrations in maternal breast milk 
and infant urine. 
Mendonca, K. Hauser, R., Calafat, A. M., Arbuckle, 
T. E. and Duty, S. M. 
International Archives of Occupational and 
Environmental Health. 2014. 87, 13-20. 
10.1007/s00420-012-0834-9 
Breast milk Breast milk 
samples were 
obtained from 
25 mothers of 
infants in the 




Total and unconjugated BPA 
concentrations were determined. 
Samples were precipitated with 2-
propanol and centrifuged. 
Following acidification of the 
samples clean-up and analysis was 
by on-line SPE-HPLC-MS/MS. 
13
C12-BPA was used as an internal 
standard. Deconjugation used β-
glucuronidase / sulfatase (Helix 
pomatia, H1). 
 
LOD = 0.28 ng/mL(3x S:N) 
LOQ = 0.93 ng/mL (10x S:N) 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
NOTE: For method details the 
authors refer to Ye et al 2008 
Measures taken to reduce 
contamination: “Rigorous quality 
control measures were used to 
ensure valid BPA concentrations”. 
Where breast pumps were used they 
were made of polypropylene and 
Included.  
 
NOTE: although samples 
were from the USA and was 
not in the contractors 
database (being published in 
2014) this is one of only a 
few studies reporting breast 
milk BPA data and so was 
included 
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were were reported to be not known 
to contain BPA. QC materials were 
prepared by pooling breast milk 
samples from multiple anonymous 
donors. Samples were stored at -
20°C.  
Measuring environmental phenols and chlorinated 
organic chemicals in breast milk using automated on-
line column-switching-high performance liquid 
chromatography-isotope dilution tandem mass 
spectrometry. 
Ye, X., Kuklenyik, Z., Needham, L. L. and Calafat, 
A. M. 
Journal of Chromatography B. 2006. 831, 110-115. 
10.1016/j.jchromb.2005.11.050 
Breast milk 20 breast milk 
samples from 









Total and unconjugated BPA 
concentrations were determined. 
Samples were precipitated with 2-
propanol and centrifuged. 
Following acidification of the 
samples clean-up and analysis was 
by on-line SPE-HPLC-MS/MS. 
13
C12-BPA was used as an internal 
standard. Deconjugation used β-
glucuronidase (Helix pomatia, H1). 
 
LOD = 0.28 ng/mL(3x S:N) 
LOQ = 0.93 ng/mL (10x S:N) 
Recovery = 93.7% for SPE clean-
up, 97-106% spiked recovery (1, 
10, 50 and 100 ng/mL) 
Repeatability = 8.2-11.4% 
(combined intra- and inter-day 
RSD), n=50 repeated measurements 
of QC materials of 4.8 and 
24.8 ng/mL over 2 weeks 
Accuracy = 97-106% (intra-day) at 
1-100 ng/mL (n=5) 
Calibration = 0.1 to 100 ng/mL, 
similar curves for milk and water, 
Included  
 
NOTE: although the samples 
were from the USA this is 
one of only a few studies 
reporting breast milk BPA 
data and so was included 
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daily calibration using water 
Measures taken to reduce 
contamination: No specific 
measures described. The authors 
state “Since standards and 
unknowns went through the same 
extraction procedure, reagent 
contributions were automatically 
corrected by the calibration curve 
intercept.” Suggesting that any 
background contribution was 
accounted for in this way.  
NOTE: QC materials for milk 
blanks were prepared by pooling 
human milk samples taken from 
multiple donors. Samples were 
stored at -20°C. 
Automated on-line column-switching HPLC-MS/MS 
method with peak focusing for measuring parabens, 
triclosan, and other environmental phenols in human 
milk 
Ye, X., Bishop, A. M., Needham, L. L. and Calafat, 
A. M. 
Analytica Chimica Acta. 2008. 622, 150-156. 
10.1016/j.aca.2008.05.068 

















Total and unconjugated BPA 
concentrations were determined. 
Samples were precipitated with 
methanol and centrifuged. Sample 




BPA was used as an internal 
standard. Deconjugation used β-
glucuronidase / sulfatase (Helix 
pomatia, H1). 
 
LOD = 0.3 ng/mL(3x S:N) 
LOQ = 0.93 ng/mL (10x S:N) 
Recovery = 105% for SPE clean-
Included  
 
NOTE: although the samples 
were from the USA this is 
one of only a few studies 
reporting breast milk BPA 
data and so was included 
 
NOTE: Uncertainty in BPA 
concentrations due to sample 
handing are addressed in the 
uncertainty tables 
 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 310 
Title 
Authors 




Sampling Country of 
origin of 
samples 




procedures. up, 90-109% spiked recovery (0.5, 
1, 5 and 10 ng/mL) 
Repeatability = 6.3-8.3% 
(combined intra- and inter-day 
RSD), repeated measurements of 
QC materials of 9.3 and 22.7 ng/mL  
Accuracy = Not given 
Calibration = 0.1 to 100 ng/mL, 
similar curves for milk and water, 
daily calibration using water 
Measures taken to reduce 
contamination: No measures 
described. The authors note that the 
proportion of free BPA is quite high 
and that as no information on 
collection and storage of the 
samples were available, the 
potential for contamination can’t be 
ruled out. QC materials were 
prepared by pooling breast milk 
samples from Mother's Milk Bank 
(purchased in 2002-2003). Test 
milk samples were collected in 
2007 and stored in glass vials at -
70°C.  
Biological monitoring of bisphenol A with 
HLPC/FLD and LC/MS/MS assays 
Yi, B., Kim, C. and Yang, M. 
Journal of Chromatography B. 2010. 878, 2606-
2610. 
Breast milk 100 
volunteers,          




Korea Total and unconjugated BPA 
concentrations were determined. 
After enzymatic cleavage of one 
part of the sample, the samples 
were extracted with propanol and 
subjected to HPLC/FLD and LC-
Excluded  
 
Note: The study revealed a 
substantial disagreement 
between the two analytical 
methods and the authors 
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10.1016/j.jchromb.2010.02.008 2 weeks MS/MS analysis. 
LOD = 0.6 ng/mL  (3x S:N) 
0.4 ng/ml (LC-MS/MS) 
LOQ = 1.8  ng/ml (10x S:N) 
1.3 ng/ml (LC-MS/MS) 
Recovery = 65–82% (HPLC/FLD) 
68–82% (LC-MS/MS) 
Repeatability = < 15 % for both 
methods 
Accuracy = Not given 
Calibration = 0.98 – 120 ng/ml  
Deconjugation: β-glucuronidase  
Measures taken to reduce 
contamination: capped brownglass-
bottle. Collected breast milk 
specimens were stored at −80◦C 
prior to analyses. 
state: “…the BPA levels in 
the HPLC/FLD were lower 
than those in the 
LC/MS/MS. Thus, to avoid 
error in biological 
monitoring of BPA, we 
recommend severe 
guidelines for identification 
of BPA in the LC/MS/MS 
method and confirmation of 
BPA identification with the 
LC/MS/MS method, 
particularly in high levels of 
BPA, which were obtained 
with the HPLC method” 
Association between Endocrine Disrupting Phenols 
in Colostrums and Maternal and Infant Health  
Yi, B., Kim, C., Park, M., Han, Y., Park, J. Y. and 
Yang, M.  
International Journal of Endocrinology 2013. vol. 
2013, Article ID 282381, 7 pages. 
10.1155/2013/282381 





Korea Total and unconjugated BPA 
concentrations were determined. 
After enzymatic cleavage of one 
part of the sample, the samples 
were extracted with propanol and 
subjected to LC-MS/MS analysis. 
LOD = not given 
LOQ = not given 
Recovery = > 80%  
Repeatability =  
Accuracy = Not given 
Excluded –) 
NOTE: see remarks for Yi et 
al. 2010 
NOTE: study was not in the 
contractors database (being 
published in 2014). 
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Calibration = not given 
Deconjugation: β-glucuronidase  
Measures taken to reduce 
contamination:  
dark glass tubes with glass caps and 
stored −20°C prior to analyses 
Determination of free Bisphenol A (BPA) 
concentrations in breast milk of U.S. women using a 
sensitive LC/MS/MS method  
Zimmers, S. M., Browne, E. P., O’Keefe, P. W., 
Anderton, D. L., Kramer, L., Reckhow, D. A., 
Arcaro, K. F. 
Chemosphere 2014. 104, 237–243. 
10.1016/j.chemosphere.2013.12.085 
Breast milk 21 samples 
from an 








on ice and 





After adding an internal standard 
(
13
C12-BPA) to the sample a 
partitioning step between hexane 
and acetonitrile was utilized prior to 
purification via solid-phase 
extraction. BPA was then 
derivatized with Pyridine-3-
sulfonyl chloride, and subsequently 
analysed with LC-MS/MS 
LOD = 0.22 ng/mL  (3x S:N) 
LOQ = Not given 
Recovery = 20% to 58% for IS 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Measures taken to reduce 
contamination: Glass SPE 
cartridges and glass pipettes. All 
glassware heated for 8 h at 500 °C  
Included 
 
NOTE: although samples 
were from the USA and was 
not in the contractors 
database (being published in 
2014) this is one of only a 
few studies reporting breast 
milk BPA data and so was 
included 
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Title 
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Composite restorations may lead to increased 
concentrations of salivary and urinary BPA. 
Akeroyd, J. M. and Maserejian, N. N. 
The Journal of Evidence-Based Dental Practice. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Conclusions of the French Food Safety Agency 
on the toxicity of bisphenol A. 
Arnich, N., Canivenc-Lavier, M. C., Kolf-
Clauw, M., Coffigny, H., Cravedi, J. P., Grob, 
K., Macherey, A. C., Masset, D., Maximilien, 
R., Narbonne, J. F., Nesslany, F., Stadler, J. and 
Tulliez, J. 
International Journal of Hygiene and 




Not considered Not 
considered 
Not considered Excluded – a review 
paper on BPA 
toxicity – no relevant 
data reported for 
biomonitoring 
Recent trends in biomonitoring of bisphenol A, 
4-t-octylphenol, and 4-nonylphenol. 
Asimakopoulos, A. G., Thomaidis, N. S. and 
Koupparis, M. A. 




Not considered Not 
considered 
Not considered Excluded – an 
analytical method 
review paper – no 
relevant data reported 
for biomonitoring 
Human Risk Assessment of Endocrine-
Disrupting Chemicals Derived from Plastic 
Food Containers. 
Bang, D. Y., Kyung, M., Kim, M. J., Jung, B. 
Review 
paper 
Not considered Not 
considered 
Not considered Excluded – a review 
paper on human risk 
assessment – no 
relevant data reported 
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Y., Cho, M. C., Choi, S. M., Kim, Y. W., Lim, 
S. K., Lim, D. S., Won, A. J., Kwack, S. J., Lee, 
Y., Kim, H. S. and Lee, B. M. 
Comprehensive Reviews in Food Science and 
Food Safety. 2012. 11:5, 453-470. 
10.1111/j.1541-4337.2012.00197.x 
for biomonitoring 
Determination of bisphenol A exposure in rural 
and urban area populations in Mersin City, 
Turkey.  
Battal, D., Cok, I. Unlusayin, I., Aktas, A. and 
Tunctan, B. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
GerES IV: phthalate metabolites and bisphenol 
A in urine of German children. 
Becker, K., Goen, T., Seiwert, M., Conrad, A., 
Pick-Fuss, H., Muller, J., Wittassek, M., 
Schulz, C. and Kolossa-Gehring, M. 
International Journal of Hygiene and 
Environmental Health. 2009. 212:6, 685-692. 
10.1016/j.ijheh.2009.08.002 
Urine German Environmental 
Survey (GerES IV): a 
representative study on the 
chemical exposure in children 
in Germany. Morning urine 
was collected from 599 
children (4 age groups 
covering the age range 3-14 
years) in 2003–2006. It it a 
representative study with 
random sampling stratified by 
age class, community and 
region. 
Germany BPA conjugates were hydrolysed 
enzymatically and the BPA 
derivatised with MTBSTFA. 
Analysis was by GC-MS/MS. d16-
BPA was used as an internal 
standard. 
Total BPA concentration was 
determined. 
 
LOD = Not given 
LOQ = 0.15 µg/L 
Recovery = Not given 
Repeatability = 8.7% 
Accuracy = Not given 
Calibration = Not given 
Included  
 
NOTE: although the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
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Deconjugation: β-glucuronidase (E. 
coli)  
Measures taken to reduce 
contamination: No measures against 
contamination reported. 
Urinary concentrations of environmental 
contaminants and phytoestrogens in adults in 
Israel. 
Berman, T., Goldsmith, R., Goen, T., Spungen, 
J., Novack, L., Levine, H., Amitai, Y., Shohat, 
T. and Grotto, I. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Risk to all or none? A comparative analysis of 
controversies in the health risk assessment of 
Bisphenol A. 
Beronius, A., Ruden, C., Hakansson, H. and 
Hanberg, A. 




Not considered Not 
considered 
Not considered Excluded – an 
overview paper on 
risk assessment – no 
relevant data reported 
for biomonitoring 
Unclear Relationship Prenatal but not 
Concurrent Bisphenol A Exposure Linked to 
Lower Weight and Less Fat. 
Betts, K.S 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Sex differences in the association of urinary Not Not considered Not Not considered Excluded – paper 
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bisphenol-A concentration with selected indices 
of glucose homeostasis among U.S. adults. 
Beydoun, H. A., Khanal, S., Zonderman, A. B., 
Beydoun, M. A. 
Annals of Epidemiology. 2013. 1-8. 
10.1016/j.annepidem.2013.07.014 
considered considered published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Urinary bisphenol A and obesity in U.S. 
children. 
Bhandari, R., Xiao, J. and Shankar, A. 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Serum unconjugated bisphenol A 
concentrations in men may influence embryo 
quality indicators during in vitro fertilization.  
Bloom, M. S., vom Saal, F. S., Kim, D., Taylor, 
J. A., Lamb, J. D., Fujimoto, V. Y. 
Environmental Toxicology and Pharmacology, 
2011. 32, 319–323. 
doi:10.1016/j.etap.2011.06.003  
Serum Study in 27 couples 
undergoing IVF. On the day of 
oocyte retrieval, fasting and 
non-fasting blood specimen 
were collected from female 




Specimens were extracted with 
methyl tert-butyl ether, recombined, 
dried down under nitrogen, and then 
reconstituted in methanol. 
Unconjugated BPA was determined 
by HPLC with Coularray detection. 
 
LOD = 0.3 ng/mL 
LOQ = Not given 
Recovery = 89% 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: Not used 
Measures taken to reduce 
contamination: Blood was collected 
Excluded / included 
 
Note: the authors 
studied female 
patients and male 
partners. The latter 




NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
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into SST serum separator Vacutainer 
tubes; serum was stored in 
polypropylene cryovials and frozen at 
−80 °C. V. Empty serum collection 
tubes and laboratory diluent and 
extraction blanks were reported to not 
containing detectable BPA. 
 
Variability and predictors of urinary bisphenol 
A concentrations during pregnancy. 
Braun, J. M., Kalkbrenner, A. E., Calafat, A. 
M., Bernert, J. T., Ye, X., Silva, M. J., Barr, D. 
B., Sathyanarayana, S. and Lanphear, B. P. 
Environmental Health Perspectives. 2011. 119, 
131-137. 
10.1289/ehp.1002366 
Urine Not considered United 
States of 
America 
Not considered Excluded - samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria)  
NOTE: This study is 
included in respect to 
the discussion of the 
comparison between 
spot sampling, first 
morning urine, and 
24-h collections. 
 
Variability of urinary phthalate metabolite and 
bisphenol A concentrations before and during 
pregnancy. 
Braun, J. M., Smith, K. W., Williams, P. L., 
Calafat, A. M., Berry, K., Ehrlich, S. and 
Hauser, R. 
Environmental Health Perspectives, 2012. 120, 
739-745. 
10.1289/ehp.1104139 
Urine Not considered United 
States of 
America 
Not considered Excluded - samples 
from the USA (i.e. 




Lead and bisphenol A concentrations in the Urine Not considered Canada Not considered Excluded - data on 
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Bushnik, T., Haines, D., Levallois, P., 
Levesque, J., Van Oostdam, J. and Viau, C. 
Health Reports. 2010. 21, 7-18. 
None given 
urinary BPA reported 
here was used but 




Exposure to bisphenol A and other phenols in 
neonatal intensive care unit premature infants. 
Calafat, A. M., Weuve, J., Ye, X., Jia, L. T., 
Hu, H., Ringer, S., Hunter, K. and Hauser, R. 
Environmental Health Perspectives. 2009. 117, 
639-644. 
10.1289/ehp.0800265 
Urine Focus on association between 
urinary BPA and the use of 
medical devices in premature 
infants undergoing intensive 
medical treatments. Spot urine 
was collected in 2003. 
Analysis of 57 archived urine 
samples from 41 low-birth-
weight infants from neonatal 
intensive care units (NICUs) 
in Boston-area hospitals. Spot 
urine collection from a cotton 
gauze placed in the infant’s 
diaper or from the cotton 





SPE, HPLC-MS/MS (method from 
YKN05a), 
13
C12-BPA was used as an 
internal standard., 
Free and total BPA were determined. 
 
LOD = 0.4 ng/mL (3x S:N) 
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase (Helix pomatia, H1)  
Measures taken to reduce 
contamination: No measures against 
contamination reported. 
Excluded 
- Non EU data 
 
 
Human exposure assessment to environmental 
chemicals using biomonitoring. 
Calafat, A. M., Ye, X., Silva, M. J., Kuklenyik, 
Z. and Needham, L. L. 




Not considered Not 
considered 
Not considered Excluded – an 
overview paper on 
biomonitoring – no 
new data reported for 
biomonitoring 
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Exposure of the U.S. population to bisphenol A 
and 4-tertiary-octylphenol: 2003-2004. 
Calafat, A. M., Ye, X., Wong, L. Y., Reidy, J. 
A. and Needham, L. L. 
Environmental Health Perspectives. 2008. 116, 
39-44. 
10.1289/ehp.10753 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA (2003-
2004 NHANES) 
reported here was 
used but was taken 
from the NHANES 
website of the CDC  
Urinary bisphenol A concentrations in pregnant 
women 
Callan, A. C., Hinwood, A. L., Heffernan, A., 
Eaglesham, G., Mueller, J. and Odland, J. O. 
International Journal of Hygiene and 
Environmental Health. 2012. 216, 641-644. 
10.1016/j.ijheh.2012.10.002 
Urine Not considered Australia Not considered Excluded – samples 
from Australia (i.e. 
did not meet 
geographical origin 
criteria) 
Bisphenol a exposure in Mexico City and risk 
of prematurity: a pilot nested case control study 
Cantonwine, D., Meeker, J. D., Hu, H., 
Sánchez, B. N., Lamadrid-Figueroa, H., 
Mercado-García, A., Fortenberry, G. Z., 
Calafat, A. M., Téllez-Rojo, M. M. 
Environmental Health. 2010. 62, 2-7. 
10.1186/1476-069X-9-62 
Urine Not considered Mexico Not considered Excluded – samples 




Bisphenol A in human placental and fetal liver 
tissues collected from Greater Montreal area 
(Quebec) during 1998-2008. 
Cao, X. L., Zhang, J., Goodyer, C. G., 




Not considered Canada Not considered Excluded – tissue not 
considered in 
biomonitoring 
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Chemosphere. 2012. 89, 505-511. 
10.1016/j.chemosphere.2012.05.003 
Polycarbonate bottle use and urinary bisphenol 
A concentrations. 
Carwile, J. L., Luu, H. T., Bassett, L. S., 
Driscoll, D. A., Yuan, C., Chang, J. Y., Ye, X., 
Calafat, A. M. and Michels, K. B. 
Environmental Health Perspectives. 2009. 
117:9, 1368-1372. 
10.1289/ehp.0900604 
Urine Nonrandomized intervention 
study among n=77 Harvard 
college students (18-23 yrs 
old, 53% males, 47% females) 
in 2008. Urine collection after 
a 1-week washout phase, 
during which cold beverages 
were consumed from stainless 
steel bottles. In the 
intervention week, cold 
beverages were consumed 
from PC bottles, and urine was 
collected at the end of the 
week. Urine collection took 
place in the evening hours. 
Urinary BPA concentrations 




Following enzymatic cleavage of the 
conjugates the urine samples were 
subjected to on-line SPE coupled 
with HPLC-MS/MS detection. 
13
C12-
BPA was used as an internal 
standard. 
Total BPA was determined. 
 
LOD = 0.4 ng/mL 
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase (Helix pomatia, H1) 
Measures taken to reduce 
contamination: Samples were 
collected in polypropylene containers 
and stored at -20°C. 
Excluded  - 
controlled 
(intervention) study 
and not a 
biomonitoring study  
 
 
Urinary bisphenol A and obesity: NHANES 
2003-2006. 
Carwile, J. L. and Michels, K. B. 
Environmental Research. 2011. 111:6, 825-830. 
10.1016/j.envres.2011.05.014 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from the  
NHANES website of 
the CDC  
Canned soup consumption and urinary Urine Randomized, single-blinded, 
2×2 crossover design 
United 
States of 
SPE, HPLC-MS/MS (method from 
YKN05a), 
13
C12-BPA was used as an 
Excluded -  
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bisphenol A: a randomized crossover trial. 
Carwile, J. L., Ye, X., Zhou, X., Calafat, A. M. 
and Michels, K. B. 
The Journal of the American Medical 
Association. 2011. 306:20, 2218-2220. 
10.1001/jama.2011.1721 
performed with 75 volunteers 
(student and university staff, 
mean age of 28 years, 68% 
female) in Boston in 2010. 
Preliminary report comparing 
canned-soup and fresh-soup 
consumption (vegetarian). 
America internal standard. 
Free and total BPA were determined. 
 
LOD = 0.4 ng/mL 
LOQ =  
Recovery =  
Repeatability =  
Accuracy =  
Calibration =  
Deconjugation:  





and not a 
biomonitoring study  
Urinary concentrations of phthalates and 
phenols in a population of Spanish pregnant 
women and children. 
Casas, L., Fernandez, M. F., Llop, S., Guxens, 
M., Ballester, F., Olea, N., Irurzun, M. B., 
Rodriguez, L. S., Riano, I., Tardon, A., 
Vrijheid, M., Calafat, A. M. and Sunyer, J. 
Environment International. 2011. 37:5, 858-
866. 
10.1016/j.envint.2011.02.012 
Urine INMA: Infancia y Medio 
Ambiente (Environment and 
Childhood) project: a 
population-based birth cohort 
study in Spain. Recruitment of 
mother-child pairs between 
2004 and 2008. 
Spot urine samples were 
collected from women during 
the 3rd trimester of 
pregnancy (2004– 2008), and 
from the 4-yr old children  
(2005–2006). 
120 pregnant 17-43 yrs old 
women randomly selected 
from four birth cohorts 
(located in different spanish 
regions) and 30 4-yr old boys 
Spain Total BPA was determined. 
HPLC-MS/MS method as described 
by Ye et al. 2005 was used.  
 
LOD = 0.4 ng/mL (3x S:N) 
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase, a deconjugation standard 
was also added 
Measures taken to reduce 
contamination: Samples were 
Included 
 
NOTE: although the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
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from one birth cohort. These 
birth cohorts belong to the 
INMA Project. 
Spot urine samples, Cr 
adjustment 
collected in polypropylene containers 
and stored at -20°C. 
Exposure to brominated flame retardants, 
perfluorinated compounds, phthalates and 
phenols in European birth cohorts: ENRIECO 
evaluation, first human biomonitoring results, 
and recommendations. 
Casas, M., Chevrier, C., Hond, E. D., 
Fernandez, M. F., Pierik, F., Philippat, C., 
Slama, R., Toft, G., Vandentorren, S., Wilhelm, 
M. and Vrijheid, M. 
International Journal of Hygiene and 




Not considered Not 
considered 
Not considered Excluded – a review 
paper on exposure – 
no new data reported 
for biomonitoring 
Dietary and sociodemographic determinants of 
bisphenol A urine concentrations in pregnant 
women and children. 
Casas, M., Valvi, D., Luque, N., Ballesteros-
Gomez, A., Carsin, A. E., Fernandez, M. F., 
Koch, H. M., Mendez, M. A., Sunyer, J., Rubio, 
S. and Vrijheid, M. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Determination of bisphenol-A levels in human 
amniotic fluid samples by liquid 
chromatography coupled with mass 
Amniotic 
fluid 
Not considered United 
States of 
America 
Not considered Excluded – tissue not 
considered in 
biomonitoring 
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Chen, M., Edlow, A. G., Lin, T., Smith, N. A., 
McElrath, T. F. and Lu, C. 
Journal of Separation Science. 2011. 34:14, 
1648-1655. 
10.1002/jssc.201100152 
Simultaneous determination of multiple 
phthalate metabolites and bisphenol-A in 
human urine by liquid chromatography-tandem 
mass spectrometry. 
Chen, M., Tao, L., Collins, E. M., Austin, C. 
and Lu, C. 
Journal of Chromatograpphy B. 2012. 904, 73-
80. 
10.1016/j.jchromb.2012.07.022 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Maternal urinary bisphenol a during pregnancy 
and maternal and neonatal thyroid function in 
the CHAMACOS study. 
Chevrier, J., Gunier, R. B., Bradman, A., 
Holland, N. T., Calafat, A. M., Eskenazi, B. and 
Harley, K. G. 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Biomonitoring of bisphenol A concentrations in 
maternal and umbilical cord blood in regard to 
birth outcomes and adipokine expression: a 
birth cohort study in Taiwan. 
Chou, W. C., Chen, J. L., Lin, C. F., Chen, Y. 
Plasma Study in healthy pregnant 
Taiwanese women (at 
delivery) which were recruited 
in 2006-2007. Maternal blood 
and umbilical cord blood were 
Taiwan Ammonium acetate buffer, hexane 
and diethyl ether were added to the 
samples, mixed, immobilised and 
perchloric acid was added. After 
cenbtrifugation the orgaic extarct was 
Included  
 
NOTE: for serum 
biomonitoring, 
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C., Shih, F. C. and Chuang, C. Y. 
Environmental Health. 2011. 94, 1-10. 
10.1186/1476-069X-10-94 
sampled at full-term delivery. 
97 mother-newborn pairs from 
a hospital in a Taiwan county. 
evaporated to dryness and 
reconstituted in mobile phase prior to 
analysis by HPLC-UV. 
Free BPA was determined. 
 
LOD = 0.13 ng/mL  
LOQ = Not given 
Recovery = 96-103% (blanks) 96.1% 
(samples, RSD: 7.53%) 
Repeatability = 1.99-7.53% 
Accuracy = Not given 
Calibration = 3.9-250 ng/mL 
(r
2
 > 0.99) 
Deconjugation: None 
Measures taken to reduce 
contamination: Samples were 
collected into glass tubes and stored 
at -80°C. Plastics were excluded 
throughout sample preparation. 
QA/QC materials were prepared from 
pooled plasm.a 
studies from all 
geographical regions 




NOTE: the method 
used less selective 
HPLC-UV detection 
Population variability of phthalate metabolites 
and bisphenol A concentrations in spot urine 
samples versus 24- or 48-h collections 
Christensen, K. L., Lorber, M., Koch, H. M., 
Kolossa-Gehring, M. and Morgan, M. K. 
Journal of Exposure Science and Environmental 
Epidemiology. 2012. 22:6, 632-640. 
10.1038/jes.2012.52 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria)  
Note: This study is 
mentioned in the 
main text when 
discussing 
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such as the 
comparability 
between first-
morning voids, spot 
urine samples and 24-
h samples 
 
The contribution of diet to total bisphenol A 
body burden in humans: Results of a 48hour 
fasting study. 
Christensen, K. L., Lorber, M., Koslitz, S., 
Bruning, T. and Koch, H. M. 
Environment International. 2012. 50, 7-14. 
10.1016/j.envint.2012.09.002 
Urine Fasting study, 48-h urine 
collection in 2009. 5 healthy 
volunteers (2 males, 3 
females, 27-47 years old), 
employees of the institute 
conducting the study, Bochum 
area in Germany. 
Germany Following enzymatic cleavage of the 
conjugates clean up of the samples 
was performed by on-line SPE with 
detection by HPLC-MS/MS. d16-BPA 
was used as an internal standard. 
Total BPA was determined. 
Free BPA was determined in the 
same was but without the enzymatic 
cleavage step. 
 
LOD = 0.05 ng/mL 
LOQ = 0.1 ng/mL 
Recovery: 88.5–104% (10 ng/mL in 
urine) 
Repeatability: 6.5% (2.9 ng/mL) and 
3.4% (11.8 ng/mL) for within day 
RSD and 5.6% (2.9 ng/mL) and 3.4% 
(11.8 ng/mL) between day RSD 
Accuracy = Not given 




were subjects were 
forced to fasten for 
48 hour. Therefore, 
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Measures taken to reduce 
contamination: Samples were stored 
in polypropylene containers at -20°C. 
Dental composite fillings and bisphenol A 
among children: a survey in South Korea. 
Chung, S. Y., Kwon, H., Choi, Y. H., Karmaus, 
W., Merchant, A. T., Song, K. B., Sakong, J., 
Ha, M., Hong, Y. C. and Kang, D. 
International Dental Journal. 2012. 62:2, 65-69. 
10.1111/j.1875-595X.2011.00089.x 
Urine Not considered Korea Not considered Excluded – samples 




The impact of bisphenol A and triclosan on 
immune parameters in the U.S. population, 
NHANES 2003-2006. 
Clayton, E. M., Todd, M., Dowd, J. B. and 
Aiello, A. E. 
Environmental Health Perspectives. 2011. 
119:3, 390-396. 
10.1289/ehp.1002883 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from the 
NHANES website of 
the CDC 
Measurement of bisphenol A and bisphenol B 
levels in human blood sera from healthy and 
endometriotic women. 
Cobellis, L., Colacurci, N., Trabucco, E., 
Carpentiero, C. and Grumetto, L. 
Biomedical chromatography. 2009. 23:11, 
1186-1190. 
10.1002/bmc.1241 
Serum Case-control study using 
endometriotic patients (n = 
58) and controls (n=11). 
Groups were formed after the 
operative procedure. 69 
women being submitted to a 
gynaecological department for 
diagnostic or operative 
laparoscopy for the evidence 
of ovarian cysts or to 
Italy Perchloric acid was added to the 
samples, which were then centrifuged 
and filtered prior to analysis by 
HPLC-FLD with confirmation by 
LC-MS/MS. 
Free BPA was determined. 
 
LOD = 0.15 ng/mL 
LOQ = 0.50 ng/mL (10x S:N) 
Included/Excluded 
 
NOTE: serum data 
for healthy women 
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investigate chronic pelvic pain 
and dysmenorrhea. 
Recovery = 85.6% 
Repeatability = coefficient of 
variation < 0.5% 
Accuracy = Not given 
Calibration = 0.5-20 ng/mL 
(r
2
 = 0.989) 
Deconjugation: None 
Measures taken to reduce 
contamination: Glass syringes and 
glass tubes were employed 
throughout the sampling. Samples 




Quantification of free and total bisphenol A and 
bisphenol B in human urine by dispersive 
liquid-liquid microextraction (DLLME) and 
heart-cutting multidimensional gas 
chromatography-mass spectrometry (MD-
GC/MS). 
Cunha, S. C. and Fernandes, J. O. 
Talanta. 2010. 83, 117-125. 
10.1016/j.talanta.2010.08.048 
Urine Not considered Portugal Not conisdered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Bisphenol A: do recent studies of health effects 
among humans inform the long-standing 
debate? 
Dash, C., Marcus, M. and Terry, P. D. 




Not considered Not 
considered 
Not considered Excluded – a 
commentary paper – 
no new data reported 
for biomonitoring 
Human exposure to bisphenol A by Review Not considered Not Not considered Excluded – review 
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biomonitoring: methods, results and assessment 
of environmental exposures. 
Dekant, W. and Völkel, W. 
Toxicology and applied pharmacology. 2008. 
228:1, 114-134. 
10.1016/j.taap.2007.12.008 
paper considered paper on 
biomonitoring – no 
new data reported for 
biomonitoring 
Simultaneous determination of bisphenol A, 
triclosan, and tetrabromobisphenol A in human 
serum using solid-phase extraction and gas 
chromatography-electron capture negative-
ionization mass spectrometry. 
Dirtu, A. C., Roosens, L., Geens, T., Gheorghe, 
A., Neels, H. and Covaci, A. 




Serum 21 samples were collected in 
Belgium as part of other 
studies; they consisted of 7 
individual serum samples (3 
males + 4 females) collected 
in 2007 and 14 pooled 
samples (all females) collected 
in 1999. 
Belgium Free BPA was determined. 
After adition of an internal standard 
(
13
C12-BPA) the sample was acidified 
for protein percepitation, and clean 
using SPE and Florisil. PFPA was 
used as derivatision agent improving 
sensitivity and selectivity of the 
susequent GC-MS analysis.  
 
LOD = Not given 
LOQ = 0.28 ng/mL (3x standard 
deviation of procedural blanks) 
Recovery = 81-83% at 1.56 and 
14 ng/mL 
Repeatability = 1.6-5.1% (within-
day) and 2.4-14% (between-day) at 
1.56 and 14 ng/mL 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: None 
Measures taken to reduce 




NOTE: this paper 
was not included in 
the contractors 
database but provides 
relevant 
biomonitoring data 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
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Prenatal and postnatal bisphenol A exposure 
and asthma development among inner-city 
children. 
Donohue, K. M., Miller, R. L., Perzanowski, M. 
S., Just, A. C., Hoepner, L. A., Arunajadai, S., 
Canfield, S., Resnick, D., Calafat, A. M., 
Perera, F. P. and Whyatt, R. M. 
The Journal of Allergy and Clinical 
Immunology. 2013. 131:3, 736-747. 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Fetal bisphenol A exposure: concentration of 
conjugated and unconjugated bisphenol A in 
amniotic fluid in the second and third 
trimesters. 
Edlow, A. G., Chen, M., Smith, N. A., Lu, C. 
and McElrath, T. F. 




Not considered United 
States of 
America 
Not considered Excluded – tissue not 
considered in 
biomonitoring 
Urinary bisphenol A concentrations and 
cytochrome P450 19 A1 (Cyp19) gene 
expression in ovarian granulosa cells: An in 
vivo human study. 
Ehrlich, S., Williams, P. L., Hauser, R., 
Missmer, S. A., Peretz, J., Calafat, A. M. and 
Flaws, J. A. 
Reproductive Toxicology. 2013. 42C, 18-23. 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Urinary bisphenol A concentrations and 
implantation failure among women undergoing 
in vitro fertilization. 
Ehrlich, S., Williams, P. L., Missmer, S. A., 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
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Flaws, J. A., Berry, K. F., Calafat, A. M., Ye, 
X., Petrozza, J. C., Wright, D. and Hauser, R. 




Urinary bisphenol A concentrations and 
implantation failure among women undergoing 
IVF. 
Ehrlich, S. R., Williams, P., Wright, D., 
Petrozza, J., Calafat, A. M. and Hauser, R. 
Fertility and Sterility. 2009. 92, S136. 
10.1016/j.fertnstert.2009.07.1205 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria)  
Urinary Bisphenol A concentrations and human 
semen quality. 
Ehrlich, S. R., Wright, D., Ford, J. and Hauser, 
R. 
Fertility and Sterility. 2008. 90, S186. 
10.1016/j.fertnstert.2008.07.752 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria)  
Bisphenol-A and chlorinated derivatives in 
adipose tissue of women. 
Fernandez, M. F., Arrebola, J. P., Taoufiki, J., 
Navalon, A., Ballesteros, O., Pulgar, R., 
Vilchez, J. L. and Olea, N. 




Not considered Spain Not considered Excluded – tissue not 
considered in 
biomonitoring 
Bisphenol A and related compounds in dental 
materials. 
Fleisch, A. F., Sheffield, P. E., Chinn, C., 
Review 
paper 
Not considered Not 
considered 
Not considered Excluded – a review 
paper on dental 
sealants – no relevant 
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Edelstein, B. L. and Landrigan, P. J. 
Pediatrics. 2010. 126, 760-768. 
10.1542/peds.2009-2693 
data reported for 
biomonitoring 
Quantitation of free and total bisphenol A in 
human urine using liquid chromatography-
tandem mass spectrometry. 
Fox, S. D., Falk, R. T., Veenstra, T. D. and 
Issaq, H. J. 
Journal of Separation Science. 2011. 34, 1268-
1274. 
10.1002/jssc.201100087 
Urine Not considered United 
States of 
America 
Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Bisphenol A and other phenols in urine from 
Danish children and adolescents analyzed by 
isotope diluted TurboFlow-LC-MS/MS. 
Frederiksen, H., Aksglaede, L., Sorensen, K., 
Nielsen, O., Main, K. M., Skakkebaek, N. E., 
Juul, A. and Andersson, A. M. 
International Journal of Hygiene and 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Urinary excretion of phthalate metabolites, 
phenols and parabens in rural and urban Danish 
mother-child pairs. 
Frederiksen, H., Nielsen, J. K., Morck, T. A., 
Hansen, P. W., Jensen, J. F., Nielsen, O., 
Andersson, A. M. and Knudsen, L. E. 
International Journal of Hygiene and 
Environmental Health. 2013. 216, 772-783. 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
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Comparison of Elisa- and LC-MS-Based 
Methodologies for the Exposure Assessment of 
Bisphenol A. 
Fukata, H., Miyagawa, H., Yamazaki, N. and 
Mori, C. 





Blood (30 mL) and urine (50 
mL) were collected from 52 
volunteers (age 22–51, 21 men 
and 31 women) between July 
and September 2004. 
Japan Total and free BPA were determined 
The urine and blood samples were 
enzymatically cleaved, subjected to 
SPE purification before measurement 
with HPLC/ECD   
 
LOD = 0.2 ng/mL  
LOQ = Not given 
Recovery = 91.6% to 102.3% 
Repeatability = less then 5 % 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase 
Measures taken to reduce 
contamination: the samples were 
stored at –20◦C until use. 
Included  - only for 
serum values 
 
NOTE: although the 
samples were from 
Japan the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
Daily bisphenol A excretion and associations 
with sex hormone concentrations: results from 
the InCHIANTI adult population study. 
Galloway, T., Cipelli, R., Guralnik, J., Ferrucci, 
L., Bandinelli, S., Corsi, A. M., Money, C., 
McCormack, P. and Melzer, D. 
Environmental Health Perspectives. 2010. 
118:11, 1603-1608. 
10.1289/ehp.1002367 
Urine Cross-sectional study using 
data from the InCHIANTI 
Study, a prospective 
population-based study of a 
suburban and rural-town 
(adult) population (20-74 yrs 
old, N=715) in Italy (Chianty 
& Tuscany). 24-h urine was 
collected. 
Italy Free and conjugated BPA was 
measured using the method described 
by Calafat et al, 2008.  
On-line SPE coupled with HPLC-
MS/MS was employed.  
 
LOD = < 0.50 ng/mL 
LOQ = 0.50 ng/mL 
Recovery = Not given 
Repeatability = Not given 
Included 
 
NOTE: although the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
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Accuracy = Not given 
Calibration = 50-100 ng/mL 
Deconjugation: Not given 
Measures taken to reduce 
contamination: No measures against 
contamination reported. 
Determination of urinary bisphenol A by 
coacervative microextraction and liquid 
chromatography-fluorescence detection 
Garcia-Prieto, A., Lunar, M. L., Rubio, S. And 
Perez-Bendito, D. 
Analytica Chimica Acta. 2008. 630:1, 19-27. 
10.1016/j.aca.2008.09.060 
Urine Not considered Spain Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
A review of dietary and non-dietary exposure to 
bisphenol-A. 
Geens, T., Aerts, D., Berthot, C., Bourguignon, 
J. P., Goeyens, L., Lecomte, P., Maghuin-
Rogister, G., Pironnet, A. M., Pussemier, L., 
Scippo, M. L., Van Loco, J. and Covaci, A. 





Not considered Not 
considered 
Not considered Excluded – a review 
paper – no new data 
reported for 
biomonitoring 
Sensitive and selective method for the 
determination of bisphenol-A and triclosan in 
serum and urine as pentafluorobenzoate-
derivatives using GC-ECNI/MS. 
Geens, T., Neels, H. and Covaci, A. 
Journal of Chromatography B. 2009. 877:31, 
Serum,  
Urine 
The method was applied to 20 
serum and 20 urine samples 
from Belgian adolescents 
Belgium Following enzymatic cleavage of the 
conjugates the sample was acidified, 
cleaned-up using SPE and derivatised 
using PFBCl with detection by GC-
MS. 
13
C12-BPA was used as an 
internal standard. 
Included (only for 
serum) 
 
NOTE: for serum 
biomonitoring, 
studies from all 
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Total BPA was determined. 
 
LOD = Not given 
LOQ = 0.5 ng/mL in serum and 
0.2 ng/mL in urine (3x S:N) 
Recovery = : 89-97% (at 0.46 ng/mL) 
and 90-98% (at 2.20 ng/mL) for 
serum; 93-107% (at 0.73 ng/mL) and 
97-103% (at 2.20 ng/mL) for urine 
Repeatability = RSD 14-21% (at 
0.46 ng/mL) and 6-11% (at 
2.20 ng/mL) for serum; 3-14% (at 
0.73 ng/mL) and 1-5% (at 
2.20 ng/mL) for urine 
Accuracy = Not given 
Calibration = 0.46–10.5 ng/mL 
(r
2
 > 0.999) 
Deconjugation: β-glucuronidase/ 
sulfatase 
Measures taken to reduce 
contamination: Procedural blanks 
were used. 
geographical regions 
were included to 
inform toxicological 
risk assessment 
Distribution of bisphenol-A, triclosan and n-
nonylphenol in human adipose tissue, liver and 
brain. 
Geens, T., Neels, H. and Covaci, A. 






Not considered Belgium Not considered Excluded – tissue not 
considered in 
biomonitoring 
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Human excretion of bisphenol A: blood, urine, 
and sweat (BUS) study. 
Genuis, S. J., Beesoon, S., Birkholz, D. and 
Lobo, R. A. 






20 Canadian subjects (10 
healthy and 10 "unhealthy"; 9 
males and 11 females; 45±14 
and 45±10 years old). 
Assessment of relative [BPA] 
in serum, 1st morning urine 
and sweat. 
Canada Following enzymatic cleavage of the 
conjugates the sample was acidified, 
cleaned-up using SPE with detection 
by LC-MS/MS. Labelled BPA was 
used as an internal standard. 
Total BPA was determined. 
 
LOD = 0.2 ng/mL (3x S:N) 
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase, a 
deconjugation standard was also 
added 
Measures taken to reduce 
contamination: Glass vessels were 
used to avoid contamination. Quality 
control materials were used with calf 
serum as a method blank. Samples 
were stored at -20°C. 
Included (only for 
serum) 
 
NOTE: although the 
samples were from 
Canada and the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
4-Nonylphenol and bisphenol A in Swedish 
food and exposure in Swedish nursing women. 
Gyllenhammar, I., Glynn, A., Darnerud, P. O., 
Lignell, S., van Delft, R. and Aune, M. 
Environment International. 2012. 43, 21-28. 
10.1016/j.envint.2012.02.010 
Serum Women were recruited by 
random selection in a hospital 
a few days after having given 
birth in 2008-2009. 100 
nursing women donated blood 
samples at home 3 weeks after 
delivery. 
Sweden The samples were diluted with water 
and labelled BPA was added as an 
internal standard. Samples were 
subjected to enzymatic hydrolysis 
prior to analysis using on-line SPE 
wiith HPLC-MS/MS detection. 
Total BPA was determined. 
Included 
 
NOTE: this paper 
was included in 
contractors database 
but was not classified 
as a biomonitoring 
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Free BPA was determined in the 
same was but without the enzymatic 
cleavage step  
 
LOD = 0.5 ng/g (free BPA) and 
0.8 ng/g (total BPA) 
LOQ = Not given 
Recovery = 76-103% 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase, a deconjugation standard 
was also added 
Measures taken to reduce 
contamination: Samples were 
collected in glass vials and stored at -
20°C. 
paper but provides 
relevant 
biomonitoring data 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
Human biomonitoring of environmental 
chemicals--early results of the 2007-2009 
Canadian Health Measures Survey for males 
and females. 
Haines, D. A. and Murray, J. 
International journal of hygiene and 
environmental health. 2012. 215:2, 133-137. 
10.1016/j.ijheh.2011.09.008 
Urine Not considered Canada Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from tables 
published by Health 
Canada and Statistics 
Canada 
Prenatal and early childhood bisphenol A 
concentrations and behavior in school-aged 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
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Harley, K. G., Gunier, R. B., Kogut, K., 
Johnson, C., Bradman, A., Calafat, A. M. and 
Eskenazi, B. 
Environmental Research. 2013. 126, 43-50. 
10.1016/j.envres.2013.06.004 
(i.e. did not meet 
publication period 
criteria) 
Bisphenol A-glucuronide measurement in urine 
samples. 
Harthe, C., Rinaldi, S., Achaintre, D., de Ravel, 
M. R., Mappus, E., Pugeat, M. and Dechaud, H. 
Talanta. 2012. 100, 410-413. 
10.1016/j.talanta.2012.07.099 
Urine Not considered France Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Bisphenol A levels in blood and urine in a 
Chinese population and the personal factors 
affecting the levels. 
He, Y., Miao, M., Herrinton, L. J., Wu, C., 
Yuan, W., Zhou, Z. and Li, D. K. 




Exposed workers and their 
relatives:  of  the eligible 
participants referred to those 
without occupational BPA 
exposure that should be 
confirmed by worksite visiting 
or consulting the products, 
raw materials, processing and 
their job categories. Anyone 
who had a dental sealant 
application within 1 year was 
excluded 
China Total BPA (conjugated and free) 
The samples were acidified - one part 
subjected to enzymatic cleavage -  
and extracted with ether before 
analysis by HPCL/FL  
 
LOD = Not given 
LOQ = 0.31 and 0.39mg/L for urin 
and serum respectively.  
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase 
Measures taken to reduce 
contamination: All the biological 
Included (only 
serum) –  
NOTE: although the 
samples were from 
China the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
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samples were stored at -70°C in BPA 
free plastic tubes 
Occupational Exposure Levels of Bisphenol A 
among Chinese Workers. 
He, Y. H., Yuan, W., Gao, E., Zhou, Z. and Li, 
D.-K. 
Journal of Occupational Health. 2009. 51, 432-
436. 
None given 
Urine Not considered China Not considered Included – samples 




Critical evaluation of key evidence on the 
human health hazards of exposure to bisphenol 
A. 
Hengstler, J. G., Foth, H., Gebel, T., Kramer, P. 
J., Lilienblum, W., Schweinfurth, H., Völkel, 
W., Wollin, K. M. and Gundert-Remy, U. 





Not considered Not 
considered 
Not considered Excluded – a review 
paper on exposure – 
no new data reported 
for biomonitoring 
Urinary concentrations of bisphenol A in an 
urban minority birth cohort in New York City, 
prenatal through age 7 years. 
Hoepner, L.A., Whyatt, R. M., Just, A.C., 
Calafat, A.M., Perera, F.P. and Rundle, A.G. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Pollution gets personal! A first population-
based human biomonitoring study in Austria. 
Hohenblum, P., Steinbichl, P., Raffesberg, W., 
Urine 2008-2011 Austrian 
population-based HBM study: 
150 volunteers (50 families, 6-
Austria Total BPA was determined. 
The urine samples were purified on a 
SPE column and analysed by HPLC-
Included 
 
NOTE: this paper 
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Weiss,S., Moche, W., Vallant, B., Scharf, S., 
Haluza, D., Moshammer, H., Kundi, M., 
Piegler, B., Wallner, P. and Hutter, H. P. 
International Journal of Hygiene and 
Environmental Health. 2012. 215, 176-179. 
10.1016/j.ijheh.2011.08.015 
49 years) were selected by 
stratified random sampling 
from 5 different Austrian 
regions. 10 woman-child-men 
pairs living in the same 
household were randomly 
selected per region. 1st 
morning urine was collected. 
25 out of 100 urine samples 
were analyzed for total BPA. 
Questionnaire data were used 
to pre-select participants who 
might have a higher exposure 
(e.g. occupation, frequent use 
of canned food/beverages, use 
of plastic bottles). 
MS/MS 
 
LOD = Not given 
LOQ = 0.6 µg/L 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase 
Measures taken to reduce 
contamination: Sample storage in 
glass containers, storage on dry ice 
during transport. 
was not included in 
the contractors 
database but provides 
relevant 
biomonitoring data 
and so was included 
 
Community level exposure to chemicals and 
oxidative stress in adult population. 
Hong, Y. C., Park, E. Y., Park, M. S., Ko, J. A., 
Oh, S. Y., Kim, H., Lee, K. H., Leem, J. H. and 
Ha, E. H. 
Toxicology Letters. 2009. 184:2, 139-144. 
10.1016/j.toxlet.2008.11.001 
Urine Not considered Korea Not considered Excluded – samples 




Impact of urine preservation methods and 
duration of storage on measured levels of 
environmental contaminants. 
Hoppin, J. A., Ulmer, R., Calafat, A. M., Barr, 
D. B., Baker, S. V., Meltzer, H. M. and 
Ronningen, K. S. 
Journal of Exposure Science and Environmental 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 





on the effect of 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 340 
Title 
Authors 




Sampling Country of 
origin of 
samples 








storage duration on 
the stability of BPA 
in urine is reported 
Determination of Bisphenol A and its 
chlorinated derivatives in placental tissue 
samples by liquid chromatography-tandem 
mass spectrometry. 
Jimenez-Diaz, I., Zafra-Gomez, A., Ballesteros, 
O., Navea, N., Navalon, A., Fernandez, M. F., 
Olea, N. and Vilchez, J. L. 





Not considered Spain Not considered Excluded – tissue not 
considered in 
biomonitoring  
A study on bisphenol A, nonylphenol, and 
octylphenol in human urine samples detected 
by SPE-UPLC-MS 
Jing, X., Bing, S., Xiaoyan, W., Xiaojie, S. and 
Yongning, W. U. 
Biomedical and Environmental Sciences. 2011. 
24, 40-46. 
10.3967/0895-3988.2011.01.005 
Urine Not considered China Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Development of a radioimmunoassay for the 
measurement of Bisphenol A in biological 
samples. 
Kaddar, N., Bendridi, N., Harthé, C., de Ravel, 
M. R., Bienvenu, A. L., Cuilleron, C. Y., 
Mappus, E., Pugeat, M. and Déchaud, H. 
Serum 207 plasma samples, randomly 
collected from samples that 
were sent to a clinical analysis 
laboratory, were used for an 
initial screening of serum BPA 
concentrations in the general 
France RIA 
Free BPA was determined 
 
LOD = 0.08 ng/mL (3x S:N) 
LOQ = Not given 
Excluded / included 
 
NOTE: the authors 
studied the general 
population and 
patients undergoing 
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population. Recovery = 94-101% (at 0.5-
1.5 µg/L) 
Repeatability = intra: 5.6-6.9% and 
inter: 5.7-8.6% (at 0.7-1.3 µg/L) 
Accuracy = Not given 
Calibration = r
2
 > 0.93 
Deconjugation: None 
Measures taken to reduce 
contamination: use of polycarbonate-
free collection materials. 
dialysis. The former 
were included, the 
latter were excluded. 
 
 
Release of bisphenol A from resin composite 
used to bond orthodontic lingual retainers. 
Kang, Y. G., Kim, J. Y., Kim, J., Won, P. J. and 
Nam, J. H. 
American Journal of Orthodontics and 









treatment was not 
considered in 
biomonitoring 
Determination of bisphenol a in urine from 
mother-child pairs-results from the duisburg 
birth cohort study, Germany. 
Kasper-Sonnenberg, Wittsiepe, Koch, Fromme, 
Wilhelm 
2012, J Toxicol Environ Health A, 75, 429-437. 
10.1080/15287394.2012.674907 
 
Urine Birth cohort study with 
mother-child pairs, 1st 
morning urine was collected in 
2006–2009. Urine samples 
were collected from 104 
mother-child pairs (29–49 and 
6–11 years old) in Duisburg. 
BPA concentrations were 
given as volume-based and 
creatinine-adjusted 
concentrations 
Germany Total BPA was determined by two 
independent labs by LC/LC-MS/MS 
according to a method using 
enzymatic cleavage and internal 
standard described by Völkel et al. 
(2008; 2011). Free BPA was also 
measured by LC/LC-MS/MS before 
enzymatic treatment but only in one 
laboratory 
LOD = Not given 
LOQ = 0.1 µg/L (total BPA; lab 1), 
Included 
 
NOTE: this paper 
was not included in 
the contractors 
database but provides 
relevant 
biomonitoring data 
and so was included 
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0.15 µg/L (free and total BPA; lab 2) 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation:  
Measures taken to reduce 
contamination: Samples were 
collected in polypropylene containers 
and stored at -20°C. 
Miniaturized hollow fiber assisted liquid-phase 
microextraction with in situ derivatization and 
gas chromatography-mass spectrometry for 
analysis of bisphenol A in human urine sample. 
Kawaguchi, M., Ito, R., Okanouchi, N., Saito, 
K. and Nakazawa, H. 
Journal of Chromatography B. 2008. 870:1, 98-
102. 
10.1016/j.jchromb.2008.06.011 
Urine Not considered Japan Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Bisphenol A and cardiometabolic risk factors in 
obese children. 
Khalil, N., Ebert, J. R., Wang, L., Belcher, S., 
Lee, M., Czerwinski, S. A. and Kannan, K. 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Association between urinary levels of 
bisphenol-A and estrogen metabolism in 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
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Kim, E. J., Lee, D., Chung, B. C., Pyo, H. and 
Lee, J. 




(i.e. did not meet 
publication period 
criteria) 
Association between urinary concentrations of 
bisphenol A and type 2 diabetes in Korean 
adults: A population-based cross-sectional 
study. 
Kim, K. and Park, H. 
International Journal of Hygiene and 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Urinary concentrations of bisphenol A and 
triclosan and associations with demographic 
factors in the Korean population. 
Kim, K., Park, H., Yang, W. and Lee, J. H. 
Environmental Research. 2011. 111:8, 1280-
1285. 
10.1016/j.envres.2011.09.003 
Urine Not considered Korea Not considered Excluded – samples 




Bisphenol A and other compounds in human 
saliva and urine associated with the placement 
of composite restorations. 
Kingman, A., Hyman, J., Masten, S. A., 
Jayaram, B., Smith, C., Eichmiller, F., Arnold, 
M. C., Wong, P. A., Schaeffer, J. M., Solanki S. 
and Dunn, W. J. 
Saliva,  
Urine 
Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
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Journal of the American Dental Association. 
2012. 143, 1292-1302. 
None given 
In vivo bisphenol-A release from dental pit and 
fissure sealants: A systematic review. 
Kloukos, D., Pandis, N. and Eliades, T. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Are urinary bisphenol A levels in men related 
to semen quality and embryo development after 
medically assisted reproduction? 
Knez, J., Kranvogl, R., Breznik, B. P., Voncina, 
E. and Vlaisavljevic, V. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Bisphenol A in 24 h urine and plasma samples 
of the German Environmental Specimen Bank 
from 1995 to 2009: A retrospective exposure 
evaluation 
Koch, H. M., Kolossa-Gehring, M., Schroter-
Kermani, C., Angerer, J. and Bruning, T. 
Journal of Exposure Science and Environmental 




Retrospective study on the 
extent of BPA body burden in 
the German population 
(students) from 1995–2009 
based on a total of 600 24-h 
urine samples. Samples (600 
in total) were taken annually 
from approximately 60 male 
and 60 female students (20–30 
years old) at each of four 
univercity cities (two from 
East Germany and two from 
West Germany). 
Germany Following enzymatic cleavage of the 
conjugates clean up of the samples 
was performed by on-line SPE with 
detection by HPLC-MS/MS. d16-BPA 
was used as an internal standard. 
Total BPA was determined. 
Free BPA was determined in the 
same was but without the enzymatic 
cleavage step. 
 
LOD = 0.05 ng/mL (3x S:N)  
LOQ =0.1 ng/mL (9x S:N) 
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Repeatability: 6.5% (2.9 ng/mL) and 
3.4% (11.8 ng/mL) for within day 
RSD and 5.6% (2.9 ng/mL) and 3.4% 
(11.8 ng/mL) between day RSD 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase 
Measures taken to reduce 
contamination: Samples were stored 
in polypropylene containers at -20°C. 
A novel method for the quantitative 
determination of free and conjugated bisphenol 
A in human maternal and umbilical cord blood 
serum using a two-step solid phase extraction 
and gas chromatography/tandem mass 
spectrometry. 
Kosarac, I., Kubwabo, C., Lalonde, K. and 
Foster, W. 
Journal of Chromatography B. 2012. 898, 90-
94. 
10.1016/j.jchromb.2012.04.023 
Serum Study was performed as a part 
of the FAMILY (Family 
Atherosclerosis Monitoring In 
Early Life) study conducted at 
McMaster University. 
Samples were collected from 
pregnant women in 2004-
2005. Pilot study of 12 
individual human maternal 
serum samples at mid-
pregnancy, at delivery and 
their matching umbilical cord 
blood serum samples. 
Canada Following enzymatic cleavage of the 
conjugates liquid-liquid extraction 
and SPE clean was performed prior to 




used as an internal standard. 
Total BPA was determined. 
Free BPA was determined in the 
same was but without the enzymatic 
cleavage step. 
 
LOD = 0.026 ng/mL 
LOQ = 0.087 ng/mL 
Recovery = 65-88% in spiked sheep 
serum 
Repeatability = intra-day variability 
of 6.2% and inter-day reproducibility 
Included 
 
NOTE: although the 
samples were from 
Canada the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
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of 17.6% (determined using sheep 
serum) 
Accuracy = Not given 
Calibration = 1-100 ng/mL 
(r
2
 > 0.998) 
Deconjugation: β-glucuronidase, 
BPA-d6-β-glucuronide was used to 
optimise the deconjugation reaction 
Measures taken to reduce 
contamination: Solvents, water, 
extraction equipment and method 
blanks were checked for the presence 
BPA. Chemically pre-cleaned glass 
vials, containers and pipettes were 
used. Results were blank corrected. 
Biomonitoring Equivalents for bisphenol A 
(BPA). 
Krishnan, K., Gagne, M., Nong, A., Aylward, 
L. L. and Hays, S. M. 
Regulatory Toxicology and Pharmacology. 
2010. 58:1, 18-24. 
10.1016/j.yrtph.2010.06.005 
Urine Not considered Not 
considered 
Not considered Excluded – no new 
data reported for 
biomonitoring  
Simultaneous quantification of bisphenol A and 
its glucuronide metabolite (BPA-G) in plasma 
and urine: applicability to toxicokinetic 
investigations. 
Lacroix, M. Z., Puel, S., Collet, S. H., Corbel, 
T., Picard-Hagen, N., Toutain, P. L., Viguie, C. 
and Gayrard, V. 
Plasma,  
Urine 
Not considered Not 
considered 
Not considered Excluded - 
toxicokinetic study in 
sheep – no relevant 
data reported for 
biomonitoring 
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Talanta. 2011. 85:4, 2053-2059. 
10.1016/j.talanta.2011.07.040 
Comparing United States and Canadian 
population exposures from National 
Biomonitoring Surveys: bisphenol A intake as a 
case study. 
Lakind, J. S., Levesque, J., Dumas, P., Bryan, 
S., Clarke, J. and Naiman, D. Q. 
Journal of Exposure Science and Environmental 
Epidemiology. 2012. 22:3, 219-226. 
10.1038/jes.2012.1 









Bisphenol A (BPA) daily intakes in the United 
States: estimates from the 2003-2004 NHANES 
urinary BPA data. 
Lakind, J. S. and Naiman, D. Q. 
Journal of Exposure Science and Environmental 
Epidemiology. 2008. 18:6, 608-615. 
10.1038/jes.2008.20 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from the 
NHANES website of 
the CDC 
Daily intake of bisphenol A and potential 
sources of exposure: 2005-2006 National 
Health and Nutrition Examination Survey. 
Lakind, J. S. and Naiman, D. Q. 
Journal of Exposure Science and Environmental 
Epidemiology. 2011. 21:3, 272-279. 
10.1038/jes.2010.9 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from the 
NHANES website of 
the CDC 
Serum Bisphenol A (BPA) and reproductive 
outcomes in couples undergoing IVF. 
Lamb, J. D., Bloom, M. S., vom Saal, F. S., 
Serum Not considered United 
States of 
America 
Not considered Excluded – this is a 
poster abstract; the 
related full paper is 
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Taylor, J. A., Sandler, J. R. and Fujimoto, V. Y. 
Fertility and Sterility. 2008. 90, S186. 
10.1016/j.fertnstert.2008.07.751 




Association of urinary bisphenol A 
concentration with medical disorders and 
laboratory abnormalities in adults. 
Lang, I. A., Galloway, T. S., Scarlett, A., 
Henley, W. E., Depledge, M., Wallace, R. B. 
and Melzer, D. 
The Journal of the American Medical 
Association. 2008. 300, 1303-1310. 
10.1001/jama.300.11.1303 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from the 
NHANES website of 
the CDC 
Temporal variability in urinary excretion of 
bisphenol A and seven other phenols in spot, 
morning, and 24-h urine samples. 
Lassen, T. H., Frederiksen, H., Jensen, T. K., 
Petersen, J. H., Main, K. M., Skakkebæk, N. E., 
Jørgensen, N., Kranich, S. K. and Andersson, 
A.-M. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Changes in steroid metabolism among girls 
with precocious puberty may not be associated 
with urinary levels of bisphenol A. 
Lee, S. H., Kang, S. M., Choi, M. H., Lee, J., 
Park, M. J., Kim, S. H., Lee, W. Y., Hong, J. 
and Chung, B. C. 
Reproductive Toxicology. 2014. 44, 1-6. 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Scientific opinion on BPA: Part I – Exposure assessment 
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Maternal and fetal exposure to bisphenol A in 
Korea. 
Lee, Y. J., Ryu, H.-Y., Kim, H.-K., Min, C. S., 
Lee, J. H., Kim, E., Nam, B. H., Park, J. H., 
Jung, J. Y., Jang, D. D., Park, E. Y., Lee, K.-H., 
Ma, J.-Y., Won, H.-S., Im, M.-W., Leem, J.-H., 
Hong, Y.-C. and Yoon, H.-S. 
Reproductive Toxicology. 2008. 25:4, 413-419 
10.1016/j.reprotox.2008.05.058 
Serum Study on healthy pregnant 
Korean women at delivery. 
Maternal blood and umbilical 
cord blood were sampled at 
full-term delivery. 300 
mother-newborn pairs from a 
hospital in a Korean county 
were analyzed. 
Korea Following enzymatic cleavage of the 
conjugates the serum samples were 
extracted with MTBE, evaporated to 
dryness before recoinstituting in 
acreetonitrile for analysis by HPLC-
FLD. Bisphenol B was used as an 
internal standard. 
Total BPA was determined. 
 
LOD = 0.625 ng/mL 
LOQ = Not given 
Recovery = : 95.3% at 5 ng/mL, 
93.0% at 20 ng/mL and 91.0% at 80 
ng/mL 
Repeatability = 14.8% at 2.5 ng/mL, 
9.4% at 10 ng/mL and 3.6% at 
40 ng/mL 
Accuracy = 99-101% (at 40 ng/mL) 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase (H-2, H. pomatia) 
Measures taken to reduce 
contamination: Plastic wares were 
excluded throughout the entire 
analytic procedure; glassware was 




NOTE: although the 
samples were from 
Korea the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 




Development and comparison of two Not Not considered Not Not considered Excluded – paper 
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competitive ELISAs for the detection of 
bisphenol A in human urine. 
Lei, Y., Fang, L., Akash, M. S. H., Liu, Z., Shi, 
W. and Chen, S. 
Analytical Methods. 2013. 5:21, 6106-6113. 
10.1039/c3ay41023d 
considered considered published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Predictors of urinary bisphenol A and phthalate 
metabolite concentrations in Mexican children. 
Lewis, R. C., Meeker, J. D., Peterson, K. E., 
Lee, J. M., Pace, G. G., Cantoral, A. and Tellez-
Rojo, M. M. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Urine Bisphenol-A Level in Relation to Obesity 
and Overweight in School-Age Children. 
Li, D.-K., Miao, M., Zhou, Z., Wu, C., Shi, H., 
Liu, X., Wang, S. and Yuan, W. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Urine bisphenol-A (BPA) level in relation to 
semen quality. 
Li, D. K., Zhou, Z., Miao, M., He, Y., Wang, J., 
Ferber, J., Herrinton, L. J., Gao, E. and Yuan, 
W. 
Fertility and Sterility. 2011. 95:2, 625-630. 
10.1016/j.fertnstert.2010.09.026 
Urine Not considered China Not considered Excluded – samples 




Relationship between urine bisphenol-A level Urine Not considered China Not considered Excluded – samples 
from China (i.e. did 
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and declining male sexual function. 
Li, D. K., Zhou, Z., Miao, M., He, Y., Qing, D., 
Wu, T., Wang, J., Weng, X., Ferber, J., 
Herrinton, L. J., Zhu, Q., Gao, E. and Yuan, W. 





4-Nonylphenol, bisphenol-A and triclosan 
levels in human urine of children and students 
in China, and the effects of drinking these 
bottled materials on the levels. 
Li, X., Ying, G. G., Zhao, J. L., Chen, Z. F., 
Lai, H. J. and Su, H. C. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Dispersive liquid–liquid microextraction based 
on ionic liquid in combination with high-
performance liquid chromatography for the 
determination of bisphenol A in water. 
Li, Y. and Liu, J. 
International Journal of Environmental 
Analytical Chemistry. 2010. 90:11, 880-890. 
10.1080/03067310903045455 
Water Not considered China Not considered Excluded – paper 
focuses on 
methodology – no 
relevant data reported 
for biomonitoring  
Determination of free and conjugated forms of 
bisphenol A in human urine and serum by 
liquid chromatography-tandem mass 
spectrometry. 
Liao, C. and Kannan, K. 
Environmental Science and Technology. 2012. 
Serum,  
Urine 
Spot urine samples from 31 
healthy volunteers (11-66 
years old) from Albany (NY) 
were collected in 2011. Serum 
were collected from 14 donors 
(27-63 years old). Urinary 




6 different forms of BPA were 
determined: Free BPA, BPA-
glucuronide, BPA-disulfate, BPA-
mono-Cl, BPA-di-Cl, BPA-tri-Cl  
Urine and serum samples were spiked 
with internal standard (
13
C12-BPA), 
purified using SPE and analysed with 
Included (only serum 
data) 
 
NOTE: although the 
samples were from 
the USA the paper 
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adjusted for creatinine. LC-MS/MS. 
Free and total BPA were determined 
separately: after addition of internal 
standard (
13
C12-BPA) one part of the 
the urine and serum samples were 
extracted with ethyl acetate, the other 
part was enzymatically cleaved 
before extraction. Both parts were 
analyses using LC-MS/MS  
LOD = 0.003 ng/mL (free BPA), 
0.02 ng/mL (conjugated / substituted 
BPA) 
LOQ = 0.01 ng/mL (free BPA), 
0.05 ng/mL (conjugated/substituted 
BPA) 
Recovery = spiking of 10-100 ng 
BPA gave values of 96±14% (blank) 
and 105±18% (urine), 87±8% (blank) 
and 80+13% (serum) 
Repeatability = Urine: 5−16% 
(10 ng), 3−11% (50 ng), 2−19% 
(100 ng), Serum: 5−11% (10 ng), 
3−15% (50 ng), 8−18% (100 ng). 
Accuracy = Not given 
Calibration=0.01-100 ng/mL (r>0.99) 
Deconjugation: β-glucuronidase/ 
sulfatase (Helix pomatia) 
Measures taken to reduce 
contamination: Samples were stored 
in polypropylene containers at -20°C. 
Background subtraction was 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
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performed for BPA. 
Bisphenol S in urine from the United States and 
seven Asian countries: occurrence and human 
exposures. 
Liao, C., Liu, F., Alomirah, H., Loi, V. D., 
Mohd, M. A., Moon, H. B., Nakata, H. and 
Kannan, K. 
Environmental Science and Technology. 2012. 
46:12, 6860-6866. 
10.1021/es301334j 
Urine Not considered United 
States of 
America 
Not considered Excluded – this paper 
focuded on bisphenol 
S – no relevant data 
reported for 
biomonitoring  
Validation and Application of a Method for the 
Determination of Bisphenol A in Urine By LC-
MS/MS: Short-term Temperature Stability Test. 
Lim, H., Oh, E., Yaung, M., Kim, S. H., 
Hwang, Y. S., Park, K.-H., Kang, T. S. and Yu, 
S. D. 
Epidemiology. 2011. 22, S246-S246. 
10.1097/01.ede.0000392445.38840.6a 
Urine Not considered Korea Not considered Excluded – paper 
focuses on phthalates 
rather than bisphenol 
A – no relevant data 
reported for 
biomonitoring  
Automated on-line liquid chromatography-
photodiode array-mass spectrometry method 
with dilution line for the determination of 
bisphenol A and 4-octylphenol in serum. 
Liu, M., Hashi, Y., Pan, F., Yao, J., Song, G. 
and Lin, J. M. 
Journal of Chromatography A. 2006. 1133:1-2, 
142-148. 
10.1016/j.chroma.2006.08.009 
Serum Samples were obtained from 
hospital. Samples were 
collected from healthy 
subjects. 
China Serum samples were cleaned up 
using a restricted access media 
column wth on-line LC–DAD–MS 
detection. 
Free BPA was determined. 
 
LOD = 0.05 ng/mL in serum 
(3x S:N) 




NOTE: although the 
samples were from 
China the paper 
provides data not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
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Recovery = intra-day: 88-101% (at 
0.5-500 ng/mL) inter-day: 81-94% (at 
0.5-500 ng/mL) 
Repeatability = intra-day: 2-7% (at 
0.5-500 ng/mL), inter-day: 6-7% (at 
0.5-500 ng/mL) 
Accuracy = Not given 
Calibration = 0.1-500 ng/mL 
(r
2
 > 0.99) 
Deconjugation: None 
Measures taken to reduce 
contamination: No measures against 
contamination reported. Samples 
were stored at -25°C. 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
The concentration of bisphenol A in urine is 
affected by specimen collection, a preservative, 
and handling. 
Longnecker, M. P., Harbak, K., Kissling, G. E, 
Hoppin, J. A., Eggesbo, M., Jusko, T. A., Eide, 
J. and Koch H. M. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Analysis of polyfluoroalkyl substances and 
bisphenol A in dried blood spots by liquid 
chromatography tandem mass spectrometry. 
Ma, W., Kannan, K., Wu, Q., Bell, E. M., 
Druschel, C. M., Caggana, M. and Aldous, K. 
M. 
Analytical and Bioanalytical Chemistry. 2013. 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
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Temporal variability and predictors of urinary 
bisphenol A concentrations in men and women. 
Mahalingaiah, S., Meeker, J. D., Pearson, K. R., 
Calafat, A. M., Ye, X., Petrozza, J. and Hauser, 
R. 
Environmental Health Perspectives. 2008. 
116:2, 173-178. 
10.1289/ehp.10605 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Association between water consumption from 
polycarbonate containers and bisphenol A 
intake during harsh environmental conditions in 
summer. 
Makris, K. C., Andra, S. S., Jia, A., Herrick, L., 
Christophi, C. A., Snyder, S. A. and Hauser, R. 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Development of a method for the determination 
of bisphenol A at trace concentrations in human 
blood and urine and elucidation of factors 
influencing method accuracy and sensitivity. 
Markham, D. A., Waechter, J. M. Jr., Wimber, 
M., Rao, N., Connolly, P., Chuang, J. C., 
Hentges, S., Shiotsuka, R. N., Dimond, S. and 
Chappelle, A. H. 
Journal of Analytical Toxicology. 2010. 34, 
293-303. 
Blood Not considered United 
States of 
America 
Not conisdered Excluded – paper 
focuses on the issue 
of sample 
contamination and 
stability – no relevant 
data reported for 
biomonitoring 
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Distribution, variability, and predictors of 
urinary concentrations of phenols and parabens 
among pregnant women in Puerto Rico. 
Meeker, J. D., Cantonwine, D. E., Rivera-
Gonzalez, L. O., Ferguson, K. K., Mukherjee, 
B., Calafat, A. M., Ye, X., Anzalota Del Toro, 
L. V., Crespo-Hernandez, N., Jimenez-Velez, 
B., Alshawabkeh, A. N. and Cordero, J. F. 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Semen quality and sperm DNA damage in 
relation to urinary bisphenol A among men 
from an infertility clinic. 
Meeker, J. D., Ehrlich, S., Toth, T., L. Wright, 
D. L. Calafat, A. M., Trisini, A. T., Ye, X. and 
Hauser, R. 
Reproductive Toxicology. 2010. 30:4, 532-539. 
10.1016/j.reprotox.2010.07.005 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Urinary bisphenol a concentration and 
angiography-defined coronary artery stenosis. 
Melzer, D., Gates, P., Osborn, N. J., Henley, W. 
E., Cipelli, R., Young, A., Money, C., 
McCormack, P., Schofield, P., Mosedale, D., 
Grainger, D. and Galloway, T. S. 
PLoS One. 2012. 7:8, e43378. 
10.1371/journal.pone.0043378 
Urine 591 patients participating in 
The Metabonomics and 
Genomics in Coronary Artery 
Disease (MaGiCAD) study, an 
angiography referral study 
from Cambridgeshire, UK. 
Subjects provided an urine 
speciment during their their 
1st angiography visit. Urine 
United 
Kingdom 
Not considered Excluded – urinary 
data from UK 
patients with different 
grades of severity of 
coronary artery 
disease 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 357 
Title 
Authors 




Sampling Country of 
origin of 
samples 




collection in 2001-2004. 
Urinary bisphenol A concentration and risk of 
future coronary artery disease in apparently 
healthy men and women. 
Melzer, D., Osborne, N. J., Henley, W. E., 
Cipelli, R., Young, A., Money, C., 
McCormack, P., Luben, R., Khaw, K. T., 
Wareham, N. J. and Galloway, T. S. 
Circulation. 2012. 125:12, 1482-1490. 
10.1161/CIRCULATIONAHA.111.069153 
Urine Nested case-control set within 
the European Prospective 
Investigation Into Cancer and 
Nutrition (EPIC) – Norfolk 
cohort study, which is a 
prospective population study. 
Baseline sample collection in 
1993-1997 during clinical 
examination. Single-spot 
samples were collected. 
United 
Kingdom 
Not considered Excluded – 
although the paper 
was published in 
2012 it contained 
data from 1993-
1997 
Association of urinary bisphenol a 
concentration with heart disease: evidence from 
NHANES 2003/06. 
Melzer, D., Rice, N. E., Lewis, C., Henley, W. 
E. and Galloway, T. S. 
PLoS One. 2010. 5:1, e8673. 
10.1371/journal.pone.0008673 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from the 
NHANES website of 
the CDC 
Bisphenol A levels in blood depend on age and 
exposure. 
Mielke, H. and Gundert-Remy, U. 
Toxicology Letters. 2009. 190:1, 32-40. 
10.1016/j.toxlet.2009.06.861 
Blood Not considered Not 
considered 
Not considered Excluded – paper 
focuses on PBKT 
modelling – no 
relevant data reported 
for biomonitoring  
The contribution of dermal exposure to the 
internal exposure of bisphenol A in man. 
Mielke, H., Partosch, F. and Gundert-Remy, U. 




Not considered Not 
considered 
Not considered Excluded – paper 
focuses on PBKT 
modelling – no 
relevant data reported 
for biomonitoring  
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Urinary bisphenol A concentrations and ovarian 
response among women undergoing IVF. 
Mok-Lin, E., Ehrlich, S., Williams, P. L., 
Petrozza, J., Wright, D. L., Calafat, A. M., Ye, 
X. and Hauser, R. 
International Journal of Andrology. 2010. 33:2, 
385-393. 
10.1111/j.1365-2605.2009.01014.x 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Simultaneous determination of daidzein, equol, 
genistein and bisphenol A in human urine by a 
fast and simple method using SPE and GC-MS. 
Moors, S., Blaszkewicz, M., Bolt, H. M. and 
Degen, G. H. 
Molecular Nutrition and Food Research. 2007. 
51, 787-798. 
10.1002/mnfr.200600289 
Urine Not considered Germany Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Assessing the quantitative relationships 
between preschool children's exposures to 
bisphenol A by route and urinary 
biomonitoring. 
Morgan, M. K., Jones, P. A., Calafat, A. M., 
Ye, X., Croghan, C. W., Chuang, J. C., Wilson, 
N. K., Clifton, M. S., Figueroa, Z. and Sheldon, 
L. S. 
Environmental Science and Technology. 2011. 
45:12, 5309-5316. 
10.1021/es200537u 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Application of electro-enhanced solid-phase 
microextraction for determination of phthalate 
Not Not considered Not Not considered Excluded – paper 
published after 
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esters and bisphenol A in blood and seawater 
samples. 
Mousa, A., Basheer, C. and Rahman Al-Arfaj, 
A. 
Talanta. 2013. 115, 308-313. 
10.1016/j.talanta.2013.05.011 
considered considered December 2012 
(i.e. did not meet 
publication period 
criteria) 
Urinary Free Bisphenol A and Bisphenol A-
Glucuronide Concentrations in Newborns. 
Nachman, R. M., Fox, S. D., Golden, W. C., 
Sibinga, E., Veenstra, T. D., Groopman, J. D. 
and Lees, P. S. 
The Journal of Paediatrics. 2013. 162, 870-872. 
10.1016/j.jpeds.2012.11.083 
Urine Analysis of unconjugated and 
glucuronidated BPA urine 
collected from healthy 
newborns, whose mothers 
were recruited from the 
newborn nursery at the Johns 
Hopkins Hospital. Duplicate 
samples from n=12 healthy 
newborns (7–44 days old). On 
the day of sample collection, 
the newborns had received 
infant formula or breast milk, 




Samples were derivatised with dansyl 
chloride and the derivatives were 
analysed by HPCL-MS/MS. d6-BPA 
and d6-BPA-glucuronide were used 
as internal standards. 
Free BPA and BPA-glucuronide were 
determined. 
 
LOD = 0.02 ng/mL 
LOQ = 0.1 ng/mL 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: None 
Measures taken to reduce 
contamination: BPA-free urine 
collection bags were used. Samples 




NOTE: the samples 
were from the USA, 
and outside the 
publication period 
and the method 
performance was not 
well described  
 
Urinary bisphenol A concentrations in girls 
from rural and urban Egypt: a pilot study. 
Urine Not considered Egypt Not considered Excluded – samples 
from Egypt (i.e. did 
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Nahar, M. S., Soliman, A. S., Colacino, J. A., 
Calafat, A. M., Battige, K., Hablas, A., 
Seifeldin, I. A., Dolinoy, D. C. and Rozek, L. S. 





Social disparities in exposures to bisphenol A 
and polyfluoroalkyl chemicals: a cross-
sectional study within NHANES 2003-2006. 
Nelson, J. W., Scammell, M. K., Hatch, E. E. 
and Webster, T. F. 
Environmental Health. 2012. 11, 1-15. 
10.1186/1476-069X-11-10 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 




Within-person variability in urinary bisphenol 
A concentrations: measurements from 
specimens after long-term frozen storage. 
Nepomnaschy, P. A., Baird, D. D., Weinberg, 
C. R., Hoppin, J. A., Longnecker, M. P. and 
Wilcox, A. J. 
Environmental Research. 2009. 109:6, 734-737. 
10.1016/j.envres.2009.04.004 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Re: Serum Bisphenol-A Concentration and Sex 
Hormone Levels in Men. 
Niederberger, C. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Relationship of urinary bisphenol A 
concentration to risk for prevalent type 2 
diabetes in Chinese adults: a cross-sectional 
Urine Not considered China Not considered Excluded – samples 
from China (i.e. did 
not meet 
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Ning, G., Bi, Y., Wang, T., Xu, M., Xu, Y., 
Huang, Y., Li, M., Li, X., Wang, W., Chen, Y., 
Wu, Y., Hou, J., Song, A., Liu, Y. and Lai, S. 





Circulating levels of bisphenol A (BPA) and 
phthalates in an elderly population in Sweden, 
based on the Prospective Investigation of the 
Vasculature in Uppsala Seniors (PIVUS). 
Olsén, L., Lampa, E., Birkholz, D. A., Lind, L. 
and Lind, P. M. 
Ecotoxicology and Environmental Safety. 2012. 
75:1, 242-248. 
10.1016/j.ecoenv.2011.09.004 
Serum Population-based prospective 
study on serum BPA levels in 
Uppsala seniors. Blood 
samples were taken after 
overnight fast. Population-
based prospective study in 
1016 randomly selected 
Uppsala seniors (70 years old, 
50:50 male:female), random 
selection. 
Sweden Following enzymatic cleavage of the 
conjugates the urine samples were 
subjected to SPE clean up with 
detection by HPLC-MS/MS. 
13
C12-
BPA was used as an internal 
standard. 
Total BPA was determined. 
 
LOD = 0.2 ng/mL (3x S:N) 
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase (E. 
coli K12), a deconjugation standard 
was also added 
Measures taken to reduce 




NOTE: although the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
Maternal bisphenol-A levels at delivery: a Serum As part of standard clinical United LLE, HPLC-MS/MS, butylphenol as Included  
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Padmanabhan, V., Siefert, K., Ransom, S., 
Johnson, T., Pinkerton, J., Anderson, L., Tao, 
L. and Kannan, K. 
Journal of Perinatology. 2008. 28, 258-263. 
10.1038/sj.jp.7211913  
 
hospital procedures, maternal 
blood samples were collected 
at the time of delivery from 40 
pregnant mothers delivering in 




Free BPA was determined. 
 
LOD = 0.5 ng/mL 
LOQ = Not given 
Recovery = 83-89% for sheep whole 
blood, serum and plasma 
Repeatability = Not given 
Accuracy = Not given 
Calibration = 0.2-100 ng/mL 
Deconjugation: None 
Measures taken to reduce 
contamination: Blood samples were 
drawn directly into a vacutainer tube, 
stored in a glass tube and stored at –
80 °C. Trace levels of BPA detected 
in the blanks (< 0.1 ng) were 
subtracted from sample 
concentrations. 
 
NOTE: this paper 
was not included in 
the contractors 
database but provides 
relevant 
biomonitoring data 
and so was included 
 
NOTE: although the 
samples were from 
the USA the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
From cans and containers to amniotic fluid: 
bisphenol a exposure during pregnancy. 
Pasternack, T., Steinauer, J. E., Hunt, P., 
Taylor, J. A., Fujimoto, V. Y. and Woodruff, T. 
J. 
Fertility and Sterility. 2009. 92:3, S43. 
Amniotic 
fluid 
Not considered United 
States of 
America 
Not considered Excluded – tissue not 
considered in 
biomonitoring 
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Urinary levels of bisphenol A, triclosan and 4-
nonylphenol in a general Belgian population. 
Pirard, C., Sagot, C., Deville, M., Dubois, N. 
and Charlier, C. 
Environment International. 2012. 48, 78-83. 
10.1016/j.envint.2012.07.003 
Urine 131 first-morning urine 
samples were collected from a 
non-occupationally exposed 
population (1–75 yr) living in 
Liege area (Belgium) in 2011. 
Small-scale cohort, not fully 
representative population in 
terms socio-economical range 
and geography. 
Belgium Following enzymatic cleavage of the 
conjugates the sample was cleaned-
up using SPE and derivatised using 
PFBCl with detection by GC-
MS/MS. d14-BPA was used as an 
internal standard. 
Total BPA was determined. 
 
LOD = 0.16 ng/mL 
LOQ = 0.50 ng/mL 
Recovery = Not given 
Repeatability = 3-21%  
Accuracy = Not given 
Calibration = 0.5-15 ng/mL 
Deconjugation: β-glucuronidase/ 
sulfatase (Helix pomatia) 
Measures taken to reduce 
contamination: Samples were stored 
in polypropylene containers, which 
were screened for background 





Determinants of urinary bisphenol A 
concentrations in Mexican/Mexican-American 
pregnant women. 
Quiros-Alcala, L., Eskenazi, B., Bradman, A., 
Ye, X., Calafat, A. M. and Harley, K. 
Environment International. 2013. 59C, 152-
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
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Sensitive determination of bisphenol A and 
bisphenol F in canned food using a solid-phase 
microextraction fibre coated with single-walled 
carbon nanotubes before GC/MS. 
Rastkari, N., Ahmadkhaniha, R., Yunesian, M., 
Baleh, L. J. and Mesdaghinia, A. 
Food Additives and Contaminants: Part A. 
2010. 27:10, 1460-1468. 
10.1080/19440049.2010.495730 
Food Not considered Iran Not considered Excluded – paper 
focuses on 
methodology for food 
– no relevant data 
reported for 
biomonitoring  
Bisphenol A and human health: A review of the 
literature. 
Rochester, J. R. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Development and validation of a method for the 
detection and confirmation of biomarkers of 
exposure in human urine by means of restricted 
access material-liquid chromatography-tandem 
mass spectrometry. 
Rodriguez-Gonzalo, E., Garcia-Gomez, D. and 
Carabias-Martinez, R. 
Journal of Chromatography A. 2010. 1217:1, 
40-48. 
10.1016/j.chroma.2009.11.002 
Urine Not considered Spain Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Food packaging and bisphenol A and bis(2-
ethyhexyl) phthalate exposure: findings from a 
Urine Not considered United 
States of 
Not considered Excluded – paper 
describes an 
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Rudel, R. A., Gray, J. M., Engel, C. L., 
Rawsthorne, T. W., Dodson, R. E., Ackerman, 
J. M., Rizzo, J., Nudelman, J. L. and Brody, J. 
G. 
Environmental Health Perspectives. 2011. 
119:7, 914-920. 
10.1289/ehp.1003170 
America intervention study – 
no relevant data 
reported for 
biomonitoring  
Relationship between urinary bisphenol A 
levels and prediabetes among subjects free of 
diabetes. 
Sabanayagam, C., Teppala, S. and Shankar, A. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Occurrence of bisphenol A in surface water, 
drinking water and plasma from Malaysia with 
exposure assessment from consumption of 
drinking water. 
Santhi, V. A., Sakai, N., Ahmad, E. D. and 
Mustafa, A. M. 
The Science of the Total Environment. 2012. 
427-428, 332-338. 
10.1016/j.scitotenv.2012.04.041 
Plasma 101 random samples were 
collected from communities 
living in a Malaysian River-
basin region. 
Malaysia Samples were acidified, cleaned up 
using SPE and the BPA 
wasderivatised with BSTFA. 
Analysis was by GC-MS. d16-BPA 
was used as an internal standard. 
Free BPA was determined. 
 
LOD = 0.25 ng/mL (3x S:N) 
LOQ = 0.75 ng/mL (10x S:N) 
Recovery = 80-97% (0.75-20 ng/mL) 
in plasma 
Repeatability = intraday: 2.9-7.0%, 
interday: 2.7-8.9%,  
Accuracy = bias: −0.4-8.8% 
Included 
 
NOTE: although the 
samples were from 
Malaysia the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
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 > 0.995 
Deconjugation: None  
Measures taken to reduce 
contamination: Use of plasticware 
was avoided with samples collected 
in heparinized tubes using a glass 
syringe. Solvents were distilled. 
Procedural blanks were tested and the 
BPA measured was below the LOD. 
inform toxicological 
risk assessment 
Unexpected results in a randomized dietary trial 
to reduce phthalate and bisphenol A exposures. 
Sathyanarayana, S., Alcedo, G., Saelens, B. E., 
Zhou, C., Dills, R. L., Yu, J. and Lanphear, B. 
Journal of Exposure Science and Environmental 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Bisphenol A (BPA) in U.S. food 
Schecter, A., Malik, N., Haffner, D., Schecter, 
S., Haffner, D., Smith, S., Harris, T. R., Paepke, 
O. and Birnbaum, L. 
Environmental Science and Technology. 2010. 
44, 9425-9430. 
10.1021/es102785d 
Food Not considered United 
States of 
America 
Not considered Excluded – analytical 
method paper for 
food – no relevant 
data reported for 
biomonitoring  
Simultaneous monitoring of seven phenolic 
metabolites of endocrine disrupting compounds 
(EDC) in human urine using gas 
chromatography with tandem mass 
spectrometry. 
Schmidt, L., Muller, J. and Goen, T. 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
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Analytical and Bioanalytical Chemistry. 2013. 
405, 2019-2029. 
10.1007/s00216-012-6618-y 
Sample clean-up with sol-gel enzyme and 
immunoaffinity columns for the determination 
of bisphenol A in human urine. 
Schoringhumer, K. and Cichna-Markl, M. 
Journal of Chromatography B. 2007. 850:1-2, 
361-369. 
10.1016/j.jchromb.2006.12.002 
Urine Not considered Austria Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Relationship between urinary bisphenol A 
levels and diabetes mellitus. 
Shankar, A. and Teppala, S. 
The Journal of Clinical Endocrinology and 
Metabolism. 2011. 96:12, 3822-3826. 
10.1210/jc.2011-1682 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from 
NHANES website of 
the CDC 
Consecutive Online Separation and 
Determination of Polybrominated Diphenyl 
Ethers, Phthalate Esters and Bisphenol A in 
Human Serum by Gas Chromatography-Mass 
Spectrometry. 
Shao, M., Chen, Y.-H. and Li, X.-Y. 
Chinese Journal of Analytical Chemistry. 2012. 
40:8, 1139-1146. 
10.1016/s1872-2040(11)60569-0 
Serum Not considered China Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Urine phthalate concentrations are higher in 
people with stroke: United States National 
Health and Nutrition Examination Surveys 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
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European Journal of Neurology. 2013. 20:4, 
728-731. 
10.1111/j.1468-1331.2012.03862.x 
(i.e. did not meet 
publication period 
criteria) 
The association of bisphenol-A urinary 
concentrations with antral follicle counts and 
other measures of ovarian reserve in women 
undergoing infertility treatments. 
Souter, I., Smith, K. W., Dimitriadis, I., 
Ehrlich, S., Williams, P. L., Calafat, A. M. and 
Hauser, R. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Prenatal exposure to bisphenol A and child 
wheeze from birth to 3 years of age. 
Spanier, A. J., Kahn, R. S., Kunselman, A. R., 
Hornung, R., Xu, Y., Calafat, A. M. and 
Lanphear, B. P. 
Environmental Health Perspectives. 2012. 
120:6, 916-920. 
10.1289/ehp.1104175 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Association between bisphenol A and abnormal 
free thyroxine level in men. 
Sriphrapradang, C., Chailurkit, L., Aekplakorn, 
W. and Ongphiphadhanakul, B. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
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Bisphenol A data in NHANES suggest longer 
than expected half-life, substantial nonfood 
exposure, or both. 
Stahlhut, R. W., Welshons, W. V. and Swan, S. 
H. 
Environmental Health Perspectives. 2009. 
117:5, 784-789. 
10.1289/ehp.0800376 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from the 
NHANES website of 
the CDC 
Analysis of Bisphenol A in Blood and Urine 
Samples: A Mini Review. 
Taskeen, A. and Naeem, I. 





Not considered Not 
considered 
Not considered Excluded – a review 
paper – no new data 
reported for 
biomonitoring 
Twenty-four hour human urine and serum 
profiles of bisphenol a during high-dietary 
exposure. 
Teeguarden, J. G., Calafat, A. M., Ye, X., 
Doerge, D. R., Churchwell, M. I., Gunawan, R. 
and Graham, M. K. 




Measurement of 24-h urinary 
and serum profiles. 20 
randomly selected healthy 
adults (age 18–55 years) were 
recruited in 2009. Probands 





Following enzymatic cleavage of the 
conjugates clean up of the samples 
was performed by on-line SPE with 
detection by HPLC-MS/MS. d16-BPA 
was used as an internal standard. 
Total BPA was determined. 
Free BPA was determined in the 
same was but without the enzymatic 
cleavage step. 
 
LOD = 0.4 ng/mL (urine) and 
0.3 ng/mL (serum) (2x S:N) 
LOQ = Not given 
Recovery = 98-113%  
Included (only serum 




study and and does as 
an intervention study, 
not meet the 
inclusion criteria. 
However, it was 
included in the 
Section 
“Biomonitoring 
studies on serum 
levels” in the 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 370 
Title 
Authors 




Sampling Country of 
origin of 
samples 




Repeatability = 5.3-7.4% 
Accuracy = 98-113% (expressed as 
recovery) 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase. 
Measures taken to reduce 
contamination: Plastics other than 





Temporal variability in urinary concentrations 
of phthalate metabolites, phytoestrogens and 
phenols among minority children in the United 
States. 
Teitelbaum, S. L., Britton, J. A., Calafat, A. M., 
Ye, X., Silva, M. J., Reidy, J. A., Galvez, M. P., 
Brenner, B. L. and Wolff, M. S. 
Environmental Research. 2010. 106:2, 257-269. 
10.1016/j.envres.2007.09.010 
  
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 




Association between urinary bisphenol A 
concentration and obesity prevalence in 
children and adolescents. 
Trasande, L., Attina, T. M. and Blustein, J. 
The Journal of the American Medical 
Association. 2012. 308, 1113-1121. 
10.1001/2012.jama.11461 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from the 
NHANES website of 
the CDC 
Bisphenol A exposure is associated with low-
grade urinary albumin excretion in children of 
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
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the United States. 
Trasande, L., Attina, T. M. and Trachtman, H. 
Kidney International. 2013. 83:4, 741-748. 
10.1038/ki.2012.422 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Associations between socioeconomic status and 
environmental toxicant concentrations in adults 
in the USA: NHANES 2001-2010. 
Tyrrell, J., Melzer, D., Henley, W., Galloway, 
T. S. and Osborne, N. J. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Racial disparity in maternal and fetal-cord 
bisphenol A concentrations. 
Unal, E. R., Lynn, T., Neidich, J., Salazar, D., 
Goetzl, L., Baatz, J. E., Hulsey, T. C., Van 
Dolah, R., Guillette, L. J. Jr. and Newman, R. 
Journal of Perinatology. 2012. 32:11, 844-850. 
10.1038/jp.2012.12 
Serum Nested cross-sectional study 
was performed from a cohort 
of 600 healthy, term 
nulliparous patients treated in 
Medical University. The 
women were enrolled at 
routine office visits at term 
(>=37 weeks of gestation), 
and maternal blood was 
collected. Fetal cord blood 
was collected at the time of 
delivery. 27 patients (8 
Caucasian, 8 African-
American, 11 Hispanic) were 
finally analysed for BPA 





LLE, LC-MS/MS, d6-BPA was used 
as an internal standard. 
Total BPA was determined. 
 
LOD = Not given 
LOQ = 0.14 ng/mL 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase, a deconjugation standard 
was also added 
Measures taken to reduce 
contamination: Serum samples were 
stored in cryovals at -80°C. Glass 
labware was used during sample 
Included 
 
NOTE: this paper 
was not included in 
the contractors 
database but provides 
relevant 
biomonitoring data 
and so was included 
 
NOTE: although the 
samples were from 
the USA the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
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extraction and hydrolysis. No 
constituent parts of the LC-MS/MS 
used were manufactured from 
materials known to contain BPA. 
Water blanks were injected with each 
run to eliminate the possibility of 
BPA contamination from the LC-
MS/MS hardware. No BPA was 
detected in the blanks. 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
Association of urinary bisphenol A 
concentration with allergic asthma: results from 
the National Health and Nutrition Examination 
Survey 2005-2006. 
Vaidya, S. V. and Kulkarni, H. 
The Journal of Asthma. 2012. 49:8, 800-806. 
10.3109/02770903.2012.721041 
Urine Not considered United 
States of 
America 
Not considered Excluded – data on 
urinary BPA reported 
here was used but 
was taken from the 
2005-2006 NHANES 
report 
Prenatal bisphenol a urine concentrations and 
early rapid growth and overweight risk in the 
offspring. 
Valvi, D., Casas, M., Mendez, M. A., 
Ballesteros-Gomez, A., Luque, N.,  
Rubio, S., Sunyer, J. and Vrijheid, M. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Urinary, circulating, and tissue biomonitoring 
studies indicate widespread exposure to 
bisphenol A. 
Vandenberg, L. N., Chahoud, I., Heindel, J. J., 
Padmanabhan, V., Paumgartten, F. J. R. and 
Review 
paper 
Not considered Not 
considered 
Not considered Excluded – a review 
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Environmental Health Perspectives. 2010. 
118:8, 1055-1070. 
10.1289/ehp.0901716 
NOTE: publication is 
cited in introduction 
of the Biomonitoring 
chapter. 
 
Human exposure to bisphenol A (BPA). 
Vandenberg, L. N., Hauser, R., Marcus, M., 
Olea, N. and Welshons, W. V. 




Not considered Not 
considered 
Not considered Excluded – a review 
paper on exposure – 
no new data reported 
for biomonitoring 
Bisphenol-A and phthalates contamination of 
urine samples by catheters in the Elfe pilot 
study: implications for large-scale 
biomonitoring studies 
Vandentorren, S., Zeman, F., Morin, L., Sarter, 
H., Bidondo, M. L., Oleko, A. and Leridon, H. 
Environmental Research. 2011. 111:6, 761-764. 
10.1016/j.envres.2011.05.018 
Urine Pilot study within the 
framework of the French 
longitudinal study of children 
(Elfe: Etude Longitudinale 
Française depuis l’Enfance), a 
national cohort study. Spot 
samples were collected from 
parturient women having a 
natural delivery (n = 164) or a 
Caesarean/forceps delivery (n 
= 79) in hospital maternity 
units. 
France Following enzymatic cleavage of the 
conjugates samples were subjected to 
liquid-liquid extraction with detection 
by GC-MS. d4-BPA was used as an 
internal standard. 
Total BPA was determined. 
Free BPA was determined in the 
same was but without the enzymatic 
cleavage step. 
 
LOD = 0.1 ng/mL 
LOQ = 0.3 ng/mL 
Recovery = Not given 
Repeatability = < 20% 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase (Helix pomatia) 
Included 
 
NOTE: although the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
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Measures taken to reduce 
contamination: Samples were 
collected in polypropylene vials. 
Maternal bisphenol a exposure during 
pregnancy and its association with adipokines 
in Mexican-American children. 
Volberg, V., Harley, K., Calafat, A. M., Dave, 
V., McFadden, J., Eskenazi, B. and Holland, N. 
Environmental and Molecular Mutagenesis. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Determination of free and total bisphenol A in 
human urine to assess daily uptake as a basis 
for a valid risk assessment. 
Völkel, W., Kiranoglu, M. and Fromme, H. 
Toxicology Letters. 2008. 179:3, 155-162. 
10.1016/j.toxlet.2008.05.002 
Urine Spot urine samples were 
collected in Munich from 62 
(multiple) samples from 21 
co-workers (19–52 years old) 
as well as single samples from 
31 woman (18–41 years old) 
and 30 children (5–6 years 
old) in 2005-2008. 
Germany Following enzymatic cleavage of the 
conjugates the samples were 
centrifuged, clened up using SPE and 
analysed by HPLC-MS/MS. d16-BPA 
or 
13
C12-BPA were used as internal 
standards. 
Total BPA was determined. 
Free BPA was determined in the 
same was but without the enzymatic 
cleavage step. 
 
LOD = 0.3 ng/mL 
LOQ = 1.25  ng/mL 
Recovery = Not given 
Repeatability = 10-13% (inter) 
Accuracy = 80-120% 
Calibration = 0.25-6 ng/mL 
Included 
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sulfatase, a deconjugation standard 
was also added 
Measures taken to reduce 
contamination: Samples were 
collected and stored in polypropylene 
or glass vessels at -20°C. 
Determination of free and total bisphenol A in 
urine of infants. 
Völkel, W., Kiranoglu, M. and Fromme, H. 
Environmental Research. 2011. 111:1, 143-148. 
10.1016/j.envres.2010.10.001 
Urine Females who were 
participating in a birthing class 
in Munich were randomly 
selected, and 47 mother-
infants pair finally entered into 
the study. Urine was sampled 
from each infant at one month 
and two months of age in 
2008. 
Germany Following enzymatic cleavage of the 
conjugates the samples were 
centrifuged, clened up using SPE and 
analysed by HPLC-MS/MS. d16-BPA 
was used as an internal standard. 
Total BPA was determined. 
Free BPA was determined in the 
same was but without the enzymatic 
cleavage step and proteins were 
precipitated with acetonitrile. 
 
LOD = 0.15 µg/L 
LOQ = 0.45 µg/L 
Recovery = Not given 
Repeatability = 5-7% (inter) 
Accuracy = 80-120%. 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase  
Measures taken to reduce 
contamination: Use of polyethylene 
urine bags, sample storage at -20°C. 
Inlcuded 
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procedureal blanks gave a 
background concentration of 0.01-
0.03 ng/mL. 
Large effects from small exposures. II. The 
importance of positive controls in low-dose 
research on bisphenol A. 
vom Saal, F. S. and Welshons, W. V. 




Not considered Not 
considered 
Not considered Excluded – focus is 
on animal studies – 
no relevant data 
reported for 
biomonitoring 
Bisphenol A: How the Most Relevant Exposure 
Sources Contribute to Total Consumer 
Exposure. 
von Goetz, N., Wormuth, M., Scheringer, M. 
And Hungerbuhler, K. 
Risk Analysis. 2010. 30:3, 473-487. 
DOI 10.1111/j.1539-6924.2009.01345.x 
Urine Not considered Not 
considered 
Not considered Excluded – no new 
data reported for 
biomonitoring 
Hydroxylated polybrominated diphenyl ethers 
and bisphenol A in pregnant women and their 
matching fetuses: placental transfer and 
potential risks. 
Wan, Y., Choi, K., Kim, S., Ji, K., Chang, H., 
Wiseman, S., Johes, P. D., Khim, J. S., Park, S., 
Park, J., Lam, M. W. and Giesy, J.  
Environmental Science and Technology. 2010. 
44, 5233-5239. 
10.1021/es1002764 
Serum 26 pregnant women were 
recruited at 3 Korean hospitals 
in 2008-2009. With exception 
of 2 subjects whose blood was 
collected during 20-25 wk of 
pregnancy, all blood was 
drawn during the 3rd trimester 
of pregnancy. 
Korea Samples were extracted with solvent, 
extracts were dried and derivatised 
using dansyl chloride, fractionated 
using silica gel, extracted with 
solvent and analysed by LC-MS/MS. 
d16-BPA was used as as internal 
standard. 
Free BPA was determined. 
 
LOD = 0.6 ng/mL (3x S:N) 
LOQ = Not given 
Recovery = 63.5±15.1% 
Included 
 
NOTE: although the 
samples were from 
Korea and the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
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Repeatability = 88-110% 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: None 
Measures taken to reduce 
contamination: Samples were stored 
in polypropylene vials at -70°C, 
Concentrations were blank corrected 
(blanks gave a background 
concentration of 0.3 ng/mL). 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
Blood plasma concentrations of endocrine 
disrupting chemicals in Hong Kong 
populations. 
Wan, H. T., Leung, P. Y., Zhao, Y. G., Wei, X., 
Wong, M. H. and Wong, C. K. 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
High urinary bisphenol A concentrations in 
workers and possible laboratory abnormalities. 
Wang, F., Hua, J., Chen, M., Xia, Y., Zhang, 
Q., Zhao, R., Zhou, W., Zhang, Z. and Wang, 
B. 
Occupational and Environmental Medicine. 
2012. 69:9, 679-684. 
10.1136/oemed-2011-100529 
Urine Not considered China Not considered Excluded – samples 





Rapid and sensitive analysis of phthalate 
metabolites, bisphenol A, and endogenous 
steroid hormones in human urine by mixed-
Not 
considered 
Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
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mode solid-phase extraction, dansylation, and 
ultra-performance liquid chromatography 
coupled with triple quadrupole mass 
spectrometry. 
Wang, H. X., Wang, B., Zhou, Y. and Jiang, Q. 
W. 
Analytical and Bioanalytical Chemistry. 2013. 
405:12, 4313-4319. 
(i.e. did not meet 
publication period 
criteria) 
Widespread occurrence and distribution of 
bisphenol A diglycidyl ether (BADGE) and its 
derivatives in human urine from the United 
States and China 
Wang, L., Wu, Y., Zhang, W. and Kannan, K. 
Environmental Science and Technology. 2012. 
46, 12968-12976 
10.1021/es304050f 
Urine Not considered China Not considered Excluded – the paper 
fcuses on BADGE 
rather than BPA – no 
relevant data reported 
for biomonitoring 
Decline in Urinary Bisphenol A Concentrations 
in the United States. 
Wells, E. M., Jackson, L. W. and Koontz, M. B. 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Association between bisphenol A and waist-to-
height ratio among children: National Health 
and Nutrition Examination Survey, 2003-2010. 
Wells, E. M., Jackson, L. W. and Koontz, M. B. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 379 
Title 
Authors 




Sampling Country of 
origin of 
samples 




Large effects from small exposures. III. 
Endocrine mechanisms mediating effects of 
bisphenol A at levels of human exposure 
Welshons, W. V., Nagel, S. C. and vom Saal, F. 
S. 






Not considered Not 
considered 
Not considered Excluded – 
biomonitoring data 
from before 2006, i.e. 
outside of the 
accepted publication 
period 
Pilot Study of Urinary Biomarkers of 
Phytoestrogens, Phthalates, and Phenols in 
Girls. 
Wolff, M. S., Teitelbaum, S. L., Windham, G., 
Pinney, S. M., Britton, J. A., Chelimo, C., 
Godbold, J., Biro, F., Kushi, L. H., Pfeiffer, C. 
M. and Calafat, A. M. 
Environmental Health Perspectives. 2007. 
115:1, 116-121 . 
10.1289/ehp.9488 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Long-term study of urinary bisphenol A in 
elementary school children. 
Yamano, Y., Miyakawa, S., Iizumi, K., Itoh, H., 
Iwasaki, M., Tsugane, S., Kagawa, J. and 
Nakadate, T. 
Environmental Health and Preventive 
Medicine. 2008. 13:6, 332-337. 
10.1007/s12199-008-0049-6 
Urine Not considered Japan Not considered Excluded – samples 




Urinary concentrations of bisphenol A in 
relation to biomarkers of sensitivity and effect 
and endocrine-related health effects. 
Urine Not considered Korea Not considered Excluded – samples 
from Korea (i.e. did 
not meet 
geographical origin 
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Yang, M., Kim, S. Y., Chang, S. S., Lee, I. S. 
and Kawamoto, T. 
Environmental and Molecular Mutagenesis. 
2006. 47:8, 571-578. 
10.1002/em.20230 
criteria) 
Effects of bisphenol A on breast cancer and its 
risk factors. 
Yang, M., Ryu, J. H., Jeon, R., Kang, D. and 
Yoo, K. Y. 
Archives of Toxicology. 2009. 83, 281-285. 
10.1007/s00204-008-0364-0 
Serum n=167 Study subjects were 
breast cancer patients who had 
visited a clinic in Korea 
between 1994-1997 and were 
diagnosed with breast cancer 
for the 1st time, and the 
hospital controls, who had 
worried about breast cancer, 
visited the same clinic during 
the same period, and not been 
diagnosed with breast cancer. 
Blood sampling occurred 
before breakfest. 
Korea Total and free BPA were determined. 
Liquid-liquid extraction as described 
by Yang et al (2003) was used for 
purification. One part of the sample 
was enzymatically cleaved before 
analysis with HPLC/FD. 
LOD = 0.012 ng/mL (3x S:N) 
LOQ = 0.04 ng/mL (10x S:N) 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase (Helix pomatia, H1) 
Measures taken to reduce 
contamination: No measures against 
contamination reported. 
Included / excluded 
 
NOTE: the authors 
studied breast cancer 
patients and controls. 
The latter were 
included, the former 
were excluded. 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment  
NOTE: although the 
samples were from 
Korea and the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
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and so was included 
Quantitative determination of bisphenol A from 
human saliva using bulk derivatization and 
trap-and-elute liquid chromatography coupled 
to electrospray ionization mass spectrometry. 
Yang, S. H., Morgan, A. A., Nguyen, H. P., 
Moore, H., Figard, B. J. and Schug, K. A. 
Environmental Toxicology and Chemistry. 
2011. 30:6, 1243-1251 
10.1002/etc.498 
Saliva Not considered Not 
considered 
Not considered Excluded – saliva not 
considered in 
biomonitoring 
Bisphenol A exposure is associated with 
oxidative stress and inflammation in 
postmenopausal women. 
Yang, Y. J., Hong, Y. C., Oh, S. Y., Park, M. 
S., Kim, H., Leem, J. H. and Ha, E. H. 
Environmental Research. 2009. 109:, 797-801. 
10.1016/j.envres.2009.04.014 
Urine Not considered Korea Not considered Excluded – samples 




Temporal stability of the conjugated species of 
bisphenol A, parabens, and other environmental 
phenols in human urine. 
Ye, X., Bishop, A. M., Reidy, J. A., Needham, 
L. L. and Calafat, A. M. 
Journal of Exposure Science and Environmental 
Epidemiology. 2007. 17:6, 567-572. 
10.1038/sj.jes.7500566 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Levels of metabolites of organophosphate 
pesticides, phthalates, and bisphenol A in 
pooled urine specimens from pregnant women 
Urine The study was performed 
within the framework of the 
Norwegian mother and child 
Norway Samples were extracted using steam 
distillation followed by SPE clean-
up. Samples were derivatised using 
Included 
 
NOTE: although the 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 382 
Title 
Authors 




Sampling Country of 
origin of 
samples 




participating in the Norwegian Mother and 
Child Cohort Study (MoBa). 
Ye, X., Pierik, F. H., Angerer, J., Meltzer, H. 
M., Jaddoe, V. W., Tiemeier, H., Hoppin, J. A. 
and Longnecker, M. P. 
International Journal of Hygiene and 
Environmental Health. 2009. 212:5, 481-491. 
10.1016/j.ijheh.2009.03.004 
birth cohort (MoBa) study. 
Spot urine samples were 
collected from 110 pregnant 
women at 17–18 weeks of 
gestation in 2004. Urine 
samples from groups of 11 
subjects each were combined 
to make 10 pooled samples. 
MTBSTFA and analysed by GC-
MS/MS. 
Free BPA was determined. 
 
LOD = 0.26 ng/mL 
LOQ = Not given 
Recovery = 105% 
Repeatability = (between-day CV): 
8.3% at 2.8 ng/mL and 4.2% at 
45.4 ng/mL 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: None 
Measures taken to reduce 
contamination: Samples were stored 
in polypropylene containers at -20°C. 
Concentrations were blank corrected 
(blanks gave a background 
concentration of 0.39 ng/mL). 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
Urinary metabolite concentrations of 
organophosphorous pesticides, bisphenol A, 
and phthalates among pregnant women in 
Rotterdam, the Netherlands: the Generation R 
study. 
Ye, X., Pierik, F. H., Hauser, R., Duty, S., 
Angerer, J., Park, M. M., Burdorf, A., Hofman, 
A., Jaddoe, V. W., Mackenbach, J. P., Steegers, 
E. A., Tiemeier, H. and Longnecker, M. P. 
Environmental Research. 2008. 108:2, 260-267. 
Urine Generation R study: a 
population-based birth cohort 
study in Rotterdam (N=9778 
mothers, 18-41 yrs old). 
N=100 randomly selected 
single spot urine samples were 
collected from mothers 
(Rotterdam area) who enrolled 
after Febr 2004, the sample 
were collected during 
pregancy 21-38 wks of 
Netherlands Samples were extracted using steam 
distillation followed by SPE clean-
up. Samples were derivatised using 
MTBSTFA and analysed by GC-
MS/MS. 
Free BPA was determined. 
 
LOD = 0.26 ng/mL 
LOQ = Not given 
Included 
 
NOTE: although the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
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10.1016/j.envres.2008.07.014 gestation. Spot urine was 
taken between 8 am and 8 pm. 
BPA concentrations were 
given as volume-based and 
creatinine-adjusted 
concentrations. 
Recovery = 105% 
Repeatability = (between-day CV): 
8.3% at 2.8 ng/mL and 4.2% at 
45.4 ng/mL 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: Not given 
Measures taken to reduce 
contamination: Samples were stored 
in polypropylene containers at -20°C. 
Concentrations were blank corrected 
(blanks gave a background 
concentration of 0.39 ng/mL). 
Automated on-line column-switching HPLC-
MS/MS method for measuring environmental 
phenols and parabens in serum. 
Ye, X., Tao, L. J., Needham, L. L. and Calafat, 
A. M. 
Talanta. 2008. 76:4, 865-871. 
10.1016/j.talanta.2008.04.034 
Serum 15 commercial serum samples 
(collected between 1998-2003 
from 4 male and 11 female 
donors) were purchased from 




Following enzymatic cleavage of the 
conjugates the samples were acidifed 
and centrifugedClean-up and analysis 
were performed by on-line SPE with 
HPLC-MS/MS. 
13
C12-BPA was used 
as an internal standard. 
Total BPA was determined. 
Free BPA was determined in the 
same was but without the enzymatic 
cleavage step. 
 
LOD = 0.3 ng/mL (3x S:N) 
LOQ = Not given 
Recovery = 108-115% 
Repeatability = 6.2% (9.5 ng/mL) 
and 9.3% (5.6 ng/mL) 
Included 
 
NOTE: although the 
samples were from 
the USA the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
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Accuracy = 108-115% at 0.5-10 
ng/mL 
Calibration = 0.1-100 ng/mL 
Deconjugation: β-glucuronidase/ 
sulfatase (Helix pomatia, H1), 
deconjugation standards were also 
added 
Measures taken to reduce 
contamination: Samples were stored 
in polypropylene vials at -20°C.  
Variability of urinary concentrations of 
bisphenol A in spot samples, first morning 
voids, and 24-hour collections. 
Ye, X., Wong, L. Y., Bishop, A. M. and 
Calafat, A. M. 
Environmental Health Perspectives. 2011. 
119:7, 983-988. 
10.1289/ehp.1002701 
Urine Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 




NOTE: This study is 
included in respect to 
the discussion of the 
comparison between 
spot sampling, first 
morning urine, and 
24-h collections 
Stability of the conjugated species of 
environmental phenols and parabens in human 
serum. 
Ye, X., Wong, L. Y., Jia, L. T., Needham, L. L. 
and Calafat, A. M. 
Environment International. 2009. 35:8, 1160-
1163. 
Serum 16 commercially available 
serum samples collected 
between 1998 and 2003 from 





Following enzymatic cleavage of the 
conjugates the samples were acidifed 
and centrifugedClean-up and analysis 
were performed by on-line SPE with 
HPLC-MS/MS. 
13
C12-BPA was used 
as an internal standard. 
Total BPA was determined. 
Included 
 
NOTE: although the 
samples were from 
the USA the paper 
provides data for 
biomonitoring not 
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10.1016/j.envint.2009.07.011 Free BPA was determined in the 
same was but without the enzymatic 
cleavage step. 
 
LOD = 0.3 ng/mL (3x S:N) 
LOQ = Not given 
Recovery = 108-115% 
Repeatability = 6.2% (9.5 ng/mL) 
and 9.3% (5.6 ng/mL) 
Accuracy = 108-115% at 0.5-
10 ng/mL 
Calibration = 0.1-100 ng/mL 
Deconjugation: β-glucuronidase/ 
sulfatase (Helix pomatia, H1), 
deconjugation standards were also 
added 
Measures taken to reduce 
contamination: Samples were stored 
in glass vials at -70°C. 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
Potential External Contamination with 
Bisphenol A and Other Ubiquitous Organic 
Environmental Chemicals during 
Biomonitoring Analysis: An Elusive 
Laboratory Challenge. 
Ye, X., Zhou, X., Hennings, R., Kramer, J. and 
Calafat, A. M. 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 386 
Title 
Authors 




Sampling Country of 
origin of 
samples 




In-vitro oxidation of bisphenol A: Is bisphenol 
A catechol a suitable biomarker for human 
exposure to bisphenol A? 
Ye, X., Zhou, X., Needham, L. L. and Calafat, 
A. M. 
Analytical and Bioanalytical Chemistry. 2011. 
399:3, 1071-1079. 
10.1007/s00216-010-4344-x 
in-vitro Not considered Not 
considered 
Not considered Excluded – paper 
describes an in-vitro 
study – no relevant 
data reported for 
biomonitoring 
Concentrations of bisphenol A and seven other 
phenols in pooled sera from 3-11 year old 
children: 2001-2002 National Health and 
Nutrition Examination Survey. 
Ye, X., Zhou, X., Wong, L. Y. and Calafat, A. 
M. 
Environmental Science and Technology. 2012. 
46:22, 12664-12671 
10.1021/es303109c 
Serum Samples were collected from 
3-11 year old children 
participating in the 2001-2002 
NHANES. 24 serum pools 
prepared from 936 individual 
samples. Individual samples 
were categorized into 12 
demographic groups, each 
representing a combination of 
age (3-5 yr, 6-11 yr), sex, and 
race/ethnicity. For each 
demographic group, 2 pools 
were prepared that included 
randomly selected 21 (3−5 
years of age) or 57 (6−11 
years of age) individual 
samples. Complex multistage 
probability design with 




Following enzymatic cleavage of the 
conjugates the samples were acidifed 
and centrifuged. Clean-up and 
analysis were performed by on-line 
SPE with HPLC-MS/MS. 
13
C12-BPA 
was used as an internal standard. 
Total BPA was determined. 
Free BPA was determined in the 
same was but without the enzymatic 
cleavage step. 
 
LOD = 0.1 ng/mL (3x S:N) 
LOQ = Not given 
Recovery = Not given 
Repeatability = Not given 
Accuracy = Not given 
Calibration = Not given 
Deconjugation: β-glucuronidase/ 
sulfatase (Helix pomatia, H1), 
deconjugation standards were also 
Included 
 
NOTE: although the 
samples were from 
the USA and the 
method performance 
was not well 
described the paper 
provides data for 
biomonitoring not 
available elsewhere 
and so was included 
 
NOTE: for serum 
biomonitoring, 
studies from all 
geographical regions 
were included to 
inform toxicological 
risk assessment 
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Measures taken to reduce 
contamination: Samples were stored 
in polypropylene vials at -20°C.  
GC-MS analysis of bisphenol A in human 
placental and fetal liver samples. 
Zhang, J., Cooke, G. M., Curran, I. H., 
Goodyer, C. G. and Cao, X. L. 





Not considered Canada Not considered Excluded – tissue not 
considered in 
biomonitoring 
Selective solid-phase extraction of bisphenol A 
using molecularly imprinted polymers and its 
application to biological and environmental 
samples. 
Zhang, J. H., Jiang, M., Zou, L., Shi, D., Mei, 
S. R., Zhu, Y. X., Shi, Y., Dai, K. and Lu, B. 







Not considered China Not considered Excluded – paper 
focuses on method 
development – no 
relevant data reported 
for biomonitoring  
Blood and urinary bisphenol A concentrations 
in children, adults, and pregnant women from 
china: partitioning between blood and urine and 
maternal and fetal cord blood. 
Zhang, T., Sun, H. and Kannan, K. 





Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
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Urinary bisphenol A concentrations and their 
implications for human exposure in several 
Asian countries. 
Zhang, Z., Alomirah, H., Cho, H. S., Li, Y. F., 
Liao, C., Minh, T. B., Mohd, M. A., Nakata, H., 
Ren, N. and Kannan, K. 
Environmental Science and Technology. 2011. 
45:16, 7044-7050. 
10.1021/es200976k 
Urine Not considered Asia Not considered Excluded – samples 




Serum bisphenol-A concentration and sex 
hormone levels in men. 
Zhou, Q., Miao, M., Ran, M., Ding, L., Bai, L., 
Wu, T., Yuan, W., Gao, E., Wang, J., Li, G. and 
Li, D. K. 




Not considered Not 
considered 
Not considered Excluded – paper 
published after 
December 2012 
(i.e. did not meet 
publication period 
criteria) 
Bisphenol A Blood and Saliva Levels Prior To 
and After Dental Sealant Placement In Adults. 
Zimmerman Downs, J. M., Shuman, D., Stull, 
S. C. and Ratzlaff, R. E. 




Not considered United 
States of 
America 
Not considered Excluded – samples 
from the USA (i.e. 
did not meet 
geographical origin 
criteria) 
Vlaams Humaan Biomonitoringsprogramma 
2007–2011. Resultatenrapport: deel 
referentiebiomonitoring. 
2010, Milieu en Gezondheid 
None given 
 
Urine Flemish Environment and 
Health Survey 2007–2011 
cycle-2 (FLEHS II): 
Representative sample of the 
Flemish population with n = 
193 adolescents (14–15 year 
old). Collection of spot urine. 
Belgium GC-MS 
Total BPA was determined. 
 
LOD = 0.1 ng/mL 
LOQ = 0.2 ng/mL 
Included 
 
NOTE: this paper 
was not included in 
the contractors 
database but provides 
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BPA concentrations were 
given as volume-based and 
creatinine-adjusted 
concentrations. 
Recovery = Not given 
Repeatability = Not given 
Calibration = Not given 
Deconjugation:  
Measures taken to reduce 
contamination: Not given 
relevant 
biomonitoring data 
and so was included 
 
NOTE: although the 
paper was not peer 
reviewed it provides 
data not available 
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Appendix J. Food products (FoodEx level 4) that have been codified as canned in at least one dietary survey within the Comprehensive Database 
FoodEx level 1 FoodEx level 2 FoodEx level 3 FoodEx level 4 
Animal and vegetable fats and oils Fish oil Cod liver oil Cod liver oil 
Composite food (including frozen products) Beans-based meals Beans and meat meals Beans and meat meals 
Composite food (including frozen products) Beans-based meals Beans and vegetables meals Beans and vegetables meals 
Composite food (including frozen products) Cereal-based dishes Pasta, cooked Pasta, cooked 
Composite food (including frozen products) Cereal-based dishes Pasta, cooked Pasta, cooked, meat and vegetable filling 
Composite food (including frozen products) Cereal-based dishes Pasta, cooked Pasta, cooked, meat filling 
Composite food (including frozen products) Fish and seafood-based meals Seafood-based meals Seafood-based meals 
Composite food (including frozen products) Meat-based meals Goulash Goulash 
Composite food (including frozen products) Meat-based meals Meat balls Meat balls 
Composite food (including frozen products) Meat-based meals Meat stew Meat stew 
Composite food (including frozen products) Meat-based meals Meat-based meals Meat-based meals 
Composite food (including frozen products) Prepared salads Prepared salads Prepared salads 
Composite food (including frozen products) Ready-to-eat soups Legume (beans) soup Legume (beans) soup 
Composite food (including frozen products) Ready-to-eat soups Meat/poultry soup Meat/poultry soup 
Composite food (including frozen products) Ready-to-eat soups Mushroom soup Mushroom soup 
Composite food (including frozen products) Ready-to-eat soups Ready-to-eat soups Ready-to-eat soups 
Composite food (including frozen products) Ready-to-eat soups Vegetable/herb soup Vegetable/herb soup 
Composite food (including frozen products) Vegetable-based meals Mixed vegetables, boiled Mixed vegetables, boiled 
Composite food (including frozen products) Vegetable-based meals Mixed vegetables, braised Mixed vegetables, braised 
Composite food (including frozen products) Vegetable-based meals Mixed vegetables, fried Mixed vegetables, fried 
Composite food (including frozen products) Vegetable-based meals Vegetable-based meals Vegetable-based meals 
Fish and other seafood Amphibians, reptiles, snails, insects Snail (Helix sp.) Snail (Helix sp.) 
Fish and other seafood Crustaceans Crab (Cancer spp.) Crab (Cancer spp.) 
Fish and other seafood Crustaceans Crayfish (Astacus spp.) Crayfish (Astacus spp.) 
Fish and other seafood Crustaceans Crustaceans Crustaceans 
Fish and other seafood Crustaceans Lobster (Homarus vulgaris) Lobster (Homarus vulgaris) 
Fish and other seafood Crustaceans Prawns (Palaemon serratus) Prawns (Palaemon serratus) 
Fish and other seafood Crustaceans Shrimps (Crangon crangon) Shrimps (Crangon crangon) 
Fish and other seafood Fish and other seafood (unspecified) Fish and other seafood (unspecified) Fish and other seafood (unspecified) 
Fish and other seafood Fish meat Anchovy (Engraulis) Anchovy (Engraulis) 
Fish and other seafood Fish meat Cod and whiting (Gadus spp.) Cod and whiting (Gadus spp.) 
Fish and other seafood Fish meat Eels (Apodes) Eels (Apodes) 
Fish and other seafood Fish meat Fish meat Fish meat 
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Fish and other seafood Fish meat Herring (Clupea) Herring (Clupea) 
Fish and other seafood Fish meat Mackeral (Scomber) Mackeral (Scomber) 
Fish and other seafood Fish meat Perch (Perca) Perch (Perca) 
Fish and other seafood Fish meat Salmon and trout (Salmo spp.) Salmon and trout (Salmo spp.) 
Fish and other seafood Fish meat Sardine and pilchard (Sardina) Sardine and pilchard (Sardina) 
Fish and other seafood Fish meat Sprat (Sprattus sprattus) Sprat (Sprattus sprattus) 
Fish and other seafood Fish meat Tuna (Thunnus) Tuna (Thunnus) 
Fish and other seafood Fish offal Fish roe Fish roe 
Fish and other seafood Fish offal Other fish offal Other fish offal 
Fish and other seafood Fish products Fish balls Fish balls 
Fish and other seafood Fish products Fish paste Fish paste 
Fish and other seafood Fish products Fish products Fish products 
Fish and other seafood Fish products Fish pâté Fish pâté 
Fish and other seafood Water molluscs Clam (Mya arenaria) Clam (Mya arenaria) 
Fish and other seafood Water molluscs Cockle (Cardium edule) Cockle (Cardium edule) 
Fish and other seafood Water molluscs Mussel (Mytilus edulis) Mussel (Mytilus edulis) 
Fish and other seafood Water molluscs Octopus (Octopus vulgaris) Octopus (Octopus vulgaris) 
Fish and other seafood Water molluscs Squid (Loligo vulgaris) Squid (Loligo vulgaris) 
Fish and other seafood Water molluscs Water molluscs Water molluscs 
Fruit and fruit products Berries and small fruits Berries and small fruits Berries and small fruits 
Fruit and fruit products Berries and small fruits Bilberry or whortleberry (Vaccinium spp.) Bilberry or whortleberry (Vaccinium spp.) 
Fruit and fruit products Berries and small fruits Blackberries (Rubus fruticosus) Blackberries (Rubus fruticosus) 
Fruit and fruit products Berries and small fruits Raspberries (Rubus idaeus) Raspberries (Rubus idaeus) 
Fruit and fruit products Berries and small fruits Strawberries (Fragaria × ananassa) Strawberries (Fragaria × ananassa) 
Fruit and fruit products Dried fruits Dried vine fruits (currants, raisins and sultanas) Dried vine fruits (currants, raisins and sultanas) 
Fruit and fruit products Miscellaneous fruits Lychee (Litchi) (Litchi chinensis) Lychee (litchi) (Litchi chinensis) 
Fruit and fruit products Miscellaneous fruits Mangoes (Mangifera indica) Mangoes (Mangifera indica) 
Fruit and fruit products Miscellaneous fruits Miscellaneous fruits Miscellaneous fruits 
Fruit and fruit products Miscellaneous fruits Papaya (Carica papaya) Papaya (Carica papaya) 
Fruit and fruit products Miscellaneous fruits Pineapples (Ananas comosus) Pineapples (Ananas comosus) 
Fruit and fruit products Miscellaneous fruits Table olives (Olea europaea) Table olives (Olea europaea) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit cocktail Fruit cocktail 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, apple (Malus domesticus) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, apricot (Prunus armeniaca) 
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Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, cranberry (Vaccinium 
macrocarpon) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, mandarin (Citrus reticulata) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, mixed fruit 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, peach (Prunus persica) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, pear (Pyrus communis) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, pineapple (Ananas comosus) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, plum (Prunus domestica) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, sour cherry (Prunus cerasus) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit compote Fruit compote, sweet cherry (Prunus avium) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit salad Fruit salad 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, apple (Malus domesticus) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, apricot (Prunus armeniaca) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, cranberry (Vaccinium 
macrocarpon) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, mandarin (Citrus reticulata) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, mixed fruit 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, peach (Prunus persica) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, pear (Pyrus communis) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, pineapple (Ananas comosus) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, plum (Prunus domestica) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, sour cherry (Prunus cerasus) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Canned fruit, sweet cherry (Prunus avium) 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, canned Fruit, canned 
Fruit and fruit products Other fruit products (excluding beverages) Fruit, purée Fruit, purée 
Fruit and fruit products Other fruit products (excluding beverages) Mixed dried fruits Mixed dried fruits 
Fruit and fruit products Other fruit products (excluding beverages) Other fruit products (excluding beverages) Other fruit products (excluding beverages) 
Fruit and fruit products Stone fruits Mirabelle (Prunus domestica var syriaca) Mirabelle (Prunus domestica var syriaca) 
Fruit and vegetable juices Concentrated fruit juice Concentrated fruit juice Concentrated fruit juice 
Fruit and vegetable juices Fruit juice Juice, apple Juice, apple 
Fruit and vegetable juices Fruit juice Juice, grape Juice, grape 
Fruit and vegetable juices Fruit juice Juice, grapefruit Juice, grapefruit 
Fruit and vegetable juices Fruit juice Juice, mango Juice, mango 
Fruit and vegetable juices Fruit juice Juice, orange Juice, orange 
Fruit and vegetable juices Fruit juice Juice, peach Juice, peach 
Scientific opinion on BPA: Part I – Exposure assessment 
 
EFSA Journal 2015;13(1):3978 393 
FoodEx level 1 FoodEx level 2 FoodEx level 3 FoodEx level 4 
Fruit and vegetable juices Fruit juice Juice, pineapple Juice, pineapple 
Fruit and vegetable juices Fruit juice Juice, prune Juice, prune 
Fruit and vegetable juices Fruit nectar Fruit nectar Fruit nectar 
Fruit and vegetable juices Fruit nectar Nectar, orange Nectar, orange 
Fruit and vegetable juices Mixed fruit juice Juice, multi-fruit Juice, multi-fruit 
Fruit and vegetable juices Mixed fruit juice Mixed fruit juice Mixed fruit juice 
Fruit and vegetable juices Mixed vegetable juice Mixed vegetable juice Mixed vegetable juice 
Fruit and vegetable juices Mixed vegetable juice Multi-vegetable juice Multi-vegetable juice 
Fruit and vegetable juices Vegetable juice Juice, carrot Juice, carrot 
Fruit and vegetable juices Vegetable juice Juice, tomato Juice, tomato 
Grains and grain-based products Breakfast cereals Grits Grits 
Grains and grain-based products Breakfast cereals Porridge Rice porridge 
Grains and grain-based products Fine bakery wares Pastries and cakes Sponge cake 
Grains and grain-based products Grains and grain-based products Grains and grain-based products Grains and grain-based products 
Grains and grain-based products Grains for human consumption Maize (corn) grain Maize (corn) grain 
Herbs, spices and condiments Dressing Mayonnaise, < 25 % oil Mayonnaise, < 25 % oil 
Herbs, spices and condiments Dressing Mayonnaise, > 50 % oil Mayonnaise, > 50 % oil 
Herbs, spices and condiments Savoury sauces Meat sauce Meat sauce 
Herbs, spices and condiments Savoury sauces Savoury sauces Savoury sauces 
Herbs, spices and condiments Savoury sauces Vegetable sauce Vegetable sauce 
Herbs, spices and condiments Seasoning or extracts Seasoning or extracts Seasoning or extracts 
Herbs, spices and condiments Spices Capers (Capparis spinosa) Capers (Capparis spinosa) 
Legumes, nuts and oilseeds Legumes, beans, dried Beans (Phaseolus vulgaris) Beans (Phaseolus vulgaris) 
Legumes, nuts and oilseeds Legumes, beans, dried Black-eyed bean (Vigna unguiculata) Black-eyed bean (Vigna unguiculata) 
Legumes, nuts and oilseeds Legumes, beans, dried Broad bean (Vicia faba) Broad bean (Vicia faba) 
Legumes, nuts and oilseeds Legumes, beans, dried Chick pea (Cicer arietinum) Chick pea (Cicer arietinum) 
Legumes, nuts and oilseeds Legumes, beans, dried Legumes, beans, dried Legumes, beans, dried 
Legumes, nuts and oilseeds Legumes, beans, dried Lentils (Lens culinaris syn. L. esculenta) Lentils (Lens culinaris syn. L. esculenta) 
Legumes, nuts and oilseeds Legumes, beans, dried Lima bean (Phaseolus lunatis) Lima bean (Phaseolus lunatis) 
Legumes, nuts and oilseeds Legumes, beans, dried Mung bean (Phaseolus aureus) Mung bean (Phaseolus aureus) 
Legumes, nuts and oilseeds Legumes, beans, dried Peas (Pisum sativum) Peas (Pisum sativum) 
Legumes, nuts and oilseeds Legumes, beans, dried Scarlet runner bean (Phaseolus coccineus) Scarlet runner bean (Phaseolus coccineus) 
Legumes, nuts and oilseeds Legumes, beans, dried Soya beans (Glycine max) Soya beans (Glycine max) 
Legumes, nuts and oilseeds Legumes, beans, green, without pods Beans, green, without pods (Phaseolus 
vulgaris) 
Beans, green, without pods (Phaseolus 
vulgaris) 
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Legumes, nuts and oilseeds Legumes, beans, green, without pods Peas, green, without pods (Pisum sativum) Peas, green, without pods (Pisum sativum) 
Legumes, nuts and oilseeds Legumes, nuts and oilseeds Legumes, nuts and oilseeds Legumes, nuts and oilseeds 
Meat and meat products  Edible offal, farmed animals Tongue (beef, veal, mutton, lamb, pork) Tongue (beef, veal, mutton, lamb, pork) 
Meat and meat products  Livestock meat Pork/piglet meat (Sus scrofa) Pork/piglet meat (Sus scrofa) 
Meat and meat products  Livestock meat Rabbit meat (Lepus cuniculus) Rabbit meat (Lepus cuniculus) 
Meat and meat products  Meat and meat products  Meat and meat products  Meat and meat products  
Meat and meat products  Meat imitates Textured soy protein Textured soy protein 
Meat and meat products  Mixed meat Mixed beef and pork meat Mixed beef and pork meat 
Meat and meat products  Mixed meat Mixed meat Mixed meat 
Meat and meat products  Pastes, pâtés and terrines Meat paste Meat paste 
Meat and meat products  Pastes, pâtés and terrines Pastes, pâtés and terrines Pastes, pâtés and terrines 
Meat and meat products  Pastes, pâtés and terrines Pâté, pork liver Pâté, pork liver 
Meat and meat products  Preserved meat Corned beef Corned beef 
Meat and meat products  Preserved meat Corned pork Corned pork 
Meat and meat products  Preserved meat Ham, beef Ham, beef 
Meat and meat products  Preserved meat Ham, pork Ham, pork 
Meat and meat products  Preserved meat Luncheon meat Luncheon meat 
Meat and meat products  Preserved meat Preserved meat Preserved meat 
Meat and meat products  Sausages Cooked smoked sausage Frankfurters, sausage 
Meat and meat products  Sausages Sausages Sausages 
Milk and dairy products Cheese Quark Quark 
Milk and dairy products Concentrated milk Condensed milk Condensed milk 
Milk and dairy products Concentrated milk Condensed milk Condensed milk, 10 % fat 
Milk and dairy products Concentrated milk Condensed milk Condensed milk, 4 % fat 
Milk and dairy products Concentrated milk Dried milk Dried milk 
Milk and dairy products Concentrated milk Dried milk Milk powder, semi-skimmed 
Milk and dairy products Concentrated milk Dried milk Milk powder, skimmed 
Milk and dairy products Concentrated milk Dried milk Milk powder, whole 
Milk and dairy products Concentrated milk Evaporated milk Evaporated milk 
Milk and dairy products Fermented milk products Buttermilk Buttermilk 
Milk and dairy products Milk and milk product imitates Milk and milk product imitates Milk and milk product imitates 
Milk and dairy products Milk and milk product imitates Soya drink Soya drink 
Milk and dairy products Milk and milk product imitates Soya yoghurt Soya yoghurt 
Milk and dairy products Milk and milk product imitates Tofu Tofu 
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Products for special nutritional use Food for sports people (labelled as such) Carbohydrate-rich energy food products for 
sports people 
Carbohydrate-rich energy food products for 
sports people 
Snacks, desserts and other foods Ices and desserts Custard Custard 
Snacks, desserts and other foods Other foods Other foods Other foods 
Snacks, desserts and other foods Snack food Snack food Snack food 
Starchy roots and tubers Other starchy roots and tubers Other starchy roots and tubers Other starchy roots and tubers 
Starchy roots and tubers Potatoes and potatoe products Mashed potato powder Mashed potato powder 
Sugar and confectionery Dessert sauces Fruit sauce Fruit sauce 
Sugar and confectionery Molasses and other syrups Molasses and other syrups Molasses and other syrups 
Vegetables and vegetable products  Brassica vegetables Brassica vegetables Brassica vegetables 
Vegetables and vegetable products  Brassica vegetables Broccoli (Brassica oleracea var. italica) Broccoli (Brassica oleracea var. italica) 
Vegetables and vegetable products  Brassica vegetables Brussels sprouts (Brassica oleracea var. 
gemmifera) 
Brussels sprouts (Brassica oleracea var. 
gemmifera) 
Vegetables and vegetable products  Brassica vegetables Head cabbage (Brassica oleracea convar. 
capitata) 
Head cabbage (Brassica oleracea convar. 
capitata) 
Vegetables and vegetable products  Brassica vegetables Kale (Brassica oleracea convar. acephalea) Kale (Brassica oleracea convar. acephalea) 
Vegetables and vegetable products  Bulb vegetables Garlic, bulb (Allium sativum) Garlic, bulb (Allium sativum) 
Vegetables and vegetable products  Bulb vegetables Onions, bulb (Allium cepa) Onions, bulb (Allium cepa) 
Vegetables and vegetable products  Fruiting vegetables Aubergines (egg plants) (Solanum melongena) Aubergines (egg plants) (Solanum melongena) 
Vegetables and vegetable products  Fruiting vegetables Chilli pepper (Capsicum frutescens) Chilli pepper (Capsicum frutescens) 
Vegetables and vegetable products  Fruiting vegetables Courgettes (zucchini) Courgettes (zucchini)  
Vegetables and vegetable products  Fruiting vegetables Cucumbers (Cucumis sativus) Cucumbers (Cucumis sativus) 
Vegetables and vegetable products  Fruiting vegetables Gherkins (Cucumis sativus) Gherkins (Cucumis sativus) 
Vegetables and vegetable products  Fruiting vegetables Melons (Cucumis melo) Melons (Cucumis melo) 
Vegetables and vegetable products  Fruiting vegetables Okra, lady’s fingers (Hibiscus esculentus) Okra, lady’s fingers (Hibiscus esculentus) 
Vegetables and vegetable products  Fruiting vegetables Peppers, paprika  Peppers, paprika  
Vegetables and vegetable products  Fruiting vegetables Pumpkins (Cucurbita maxima) Pumpkins (Cucurbita maxima) 
Vegetables and vegetable products  Fruiting vegetables Sweetcorn (Zea mays var. saccharata) Sweetcorn (Zea mays var. saccharata) 
Vegetables and vegetable products  Fruiting vegetables Tomatoes (Lycopersicum esculentum) Tomatoes (Lycopersicum esculentum) 
Vegetables and vegetable products  Fungi, cultivated Cultivated mushroom  Cultivated mushroom  
Vegetables and vegetable products  Fungi, cultivated Fungi, cultivated Fungi, cultivated 
Vegetables and vegetable products  Fungi, cultivated Shiitake mushroom (Lentinus edodes) Shiitake mushroom (Lentinus edodes) 
Vegetables and vegetable products  Fungi, wild, edible Cantharelle (Cantharellus cibarius) Cantharelle (Cantharellus cibarius) 
Vegetables and vegetable products  Fungi, wild, edible Fungi, wild, edible Fungi, wild, edible 
Vegetables and vegetable products  Fungi, wild, edible Morel (Morchella esculenta) Morel (Morchella esculenta) 
Vegetables and vegetable products  Leaf vegetables Spinach  Spinach  
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Vegetables and vegetable products  Leaf vegetables Spinach (fresh) (Spinacia oleracea) Spinach (fresh) (Spinacia oleracea) 
Vegetables and vegetable products  Leaf vegetables Vine leaves (grape leaves) (Vitis euvitis) Vine leaves (grape leaves) (Vitis euvitis) 
Vegetables and vegetable products  Legume vegetables Beans, with pods (Phaseolus vulgaris) Beans, with pods (Phaseolus vulgaris) 
Vegetables and vegetable products  Legume vegetables Peas, with pods (Pisum sativum) Peas, with pods (Pisum sativum) 
Vegetables and vegetable products  Root vegetables Beetroot (Beta vulgaris subsp. vulgaris) Beetroot (Beta vulgaris subsp. vulgaris) 
Vegetables and vegetable products  Root vegetables Carrots (Daucus carota) Carrots (Daucus carota) 
Vegetables and vegetable products  Root vegetables Celeriac (Apium graveolens var. rapaceum) Celeriac (Apium graveolens var. rapaceum) 
Vegetables and vegetable products  Root vegetables Radishes (Raphanus sativus var. sativus) Radishes (Raphanus sativus var. sativus) 
Vegetables and vegetable products  Root vegetables Root vegetables Root vegetables 
Vegetables and vegetable products  Root vegetables Salsify (Tragopogon porrifolius) Salsify (Tragopogon porrifolius) 
Vegetables and vegetable products  Stem vegetables (fresh) Asparagus (Asparagus officinalis) Asparagus (Asparagus officinalis) 
Vegetables and vegetable products  Stem vegetables (fresh) Bamboo shoots (Bambusa vulgaris) Bamboo shoots (Bambusa vulgaris) 
Vegetables and vegetable products  Stem vegetables (fresh) Celery (Apium graveolens var. dulce) Celery (Apium graveolens var. dulce) 
Vegetables and vegetable products  Stem vegetables (fresh) Globe artichokes (Cynara scolymus) Globe artichokes (Cynara scolymus) 
Vegetables and vegetable products  Stem vegetables (fresh) Palm hearts Palm hearts 
Vegetables and vegetable products  Stem vegetables (fresh) Rhubarb (Rheum × hybridum) Rhubarb (Rheum × hybridum) 
Vegetables and vegetable products  Stem vegetables (fresh) Stem vegetables (fresh) Stem vegetables (fresh) 
Vegetables and vegetable products  Vegetable products Mushy peas (Pisum sativum) Mushy peas (Pisum sativum) 
Vegetables and vegetable products  Vegetable products Pickled vegetables Pickled vegetables 
Vegetables and vegetable products  Vegetable products Sauerkraut Sauerkraut 
Vegetables and vegetable products  Vegetable products Tomato purée Tomato purée 
Vegetables and vegetable products  Vegetable products Vegetable products Vegetable products 
Vegetables and vegetable products  Vegetables and vegetable products  Vegetables and vegetable products  Vegetables and vegetable products  
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ASSESSMENT 
1. Introduction 
Bisphenol A (BPA) is an industrial chemical that is widely used as a monomer or additive for the 
manufacture of polycarbonate (PC) plastics and epoxy resins and other polymeric materials. It is also 
used in certain paper products, including thermal paper. The properties conferred by BPA to PC, e.g. 
rigidity, transparency and resistance, make these plastics particularly suitable for many technical 
applications, but also to make food and liquid containers, such as tableware (plates and mugs), bottles, 
microwave ovenware, and reservoirs for water dispensers. BPA-based epoxyphenolic resins are used 
as protective linings for canned foods and beverages and as a surface-coating on residential drinking 
water storage tanks. BPA is also used in a number of non food-related applications, including epoxy-
resin based paints, poly vinyl chloride (PVC) medical devices, surface coatings, printing inks, 
carbonless and thermal paper and flame retardants.  
BPA was authorised in Europe by the Commission Directive 2002/72/EC4 of 6 August 2002, to be 
used as monomer and additive for the manufacture of plastic materials and articles intended to come in 
contact with foodstuffs together with a specific migration limit of 0.6 mg per kilogram food (SML (T) 
= 0.6 mg/kg). This Directive was amended by the Commission Directive 2011/8/EU of 28 January 
20115, placing a temporary ban on the use in the manufacture of polycarbonate infant feeding bottles 
as from 1 March 2011 and the placing on the market of these feeding bottles as from 1 June 2011. The 
definition of ‘infant’ in Directive 2006/141EC6, namely children under the age of 12 months, applies.  
Since May 2011 Directive 2002/72/EC has been replaced by Regulation (EU) No 10/20117, which has 
maintained the ban of BPA in polycarbonate infant feeding bottles and kept the current restriction for 
BPA as a monomer with a specific migration limit (SML) = 0.6 mg/kg food but removed its 
authorisation as an additive in plastic food contact materials and articles. 
The scientific debate on the risks for public health of BPA focusses on its endocrine-active properties, 
which might adversely impact physical, neurological and behavioural development. In addition, other 
perturbations of physiology, both in animals and humans, have been brought in relationship to the 
endocine-active properties of BPA. Among these are e.g. obesity, modification of insulin-dependent 
regulation of plasma glucose levels, perturbation of fertility, proliferative changes in the mammary 
glandpossibly related to the development of breast cancer, immunotoxicity and adverse effects on the 
cardiovascular system (for an overview see NTP-CERHR, 2007, 2008, EFSA, 2006, 2008, EFSA CEF 
Panel, 2010, and ANSES, 2011, 2013). Despite the large number of scientific publications and risk 
assessment reports published on this topic, no scientific consensus has been reached on its risks for 
human health at the currently estimated levels of exposure, mainly due to qualitative and quantitative 
divergences in the outcome and interpretation of animal toxicity studies carried out with this 
compound. Whereas a limited number of large-scale toxicity studies complying with standard/OECD 
test guidelines have consistently indicated that the oral toxicity of BPA is low, many more small-scale 
research studies have reported adverse effects of BPA at levels below the current NOAEL of 5 mg/kg 
bw per day, which was the point of departure for the derivation of the current TDI (for a recent review 
see Vandenberg et al., 2012). Within the scope of the current evaluation by EFSA the papers 
addressing these possible associations and effects will be reviewed for inclusion in the hazard 
identification.  
                                                     
4  Commission Directive 2002/72/EC of 6 August 2002 relating to plastic materials and articles intended to come into contact 
with foodstuffs, OJ L 220, 15.8.2002, p.18-58. 
5 Commission Directive 2011/8/EU of 28 January 2011 amending Directive 2002/72/EC as regards the restriction of use of 
Bisphenol A in plastic infant feeding bottles, OJ L 26, 29.1.2011, p.11-14. 
6  Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending 
Directive 1999/21/EC. OJ L 401, 30.12.2006, p.1-33. 
7  Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into 
contact with food. OJ L 12, 15.1.2011, p.1-89. 
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Assessment of the risks for public health related to the presence of BPA in foodstuffs requires not only 
identification of its possible health hazards, but also assessment of exposure to BPA from dietary 
sources and non-dietary sources.  
As indicated in the Terms of Reference (see Executive summary), a three-step approach was taken in 
developing the scientific opinion on BPA. As a first step, the draft exposure part of the opinion was 
completed and published in July 2013 for public consultation (EFSA CEF Panel, 2013). Secondly, the 
draft assessment of human health risks which covers hazard asssessment and risk characterisation was 
endorsed by the CEF Panel in December 2013 and released for public consultation in January 2014. 
Around 500 comments were received through the two public consultation phases (EFSA CEF Panel, 
2014). As a third step, taking into account the public consultation comments, the CEF Panel has then 
amended the exposure assessment, the hazard assessment and risk characterisation of the opinion and 
completed its full risk assessment opinion for adoption. The final opinion now consists of 3 separate 
documents: (i) an executive summary of the whole opinion (including abstract, summary, background, 
terms of reference, interpretation of the terms of reference, assessment, conclusions and 
recommendations of the exposure and hazard assessments, and the risk characterisation); (ii) Part I – 
Exposure assessment and (iii) Part II – Toxicological assessment and risk characterisation. 
For the sake of clarity, it should be noted that when the text makes reference to another section (or 
Appendix) of the opinion, this generally refers to a section included in the same part of the opinion, 
unless otherwise stated. In this latter case, the specific part of the opinion (i.e. Executive summary, 
Part I or Part II), to which the mentioned section belongs, is clearly mentioned. 
1.1. Previous risk assessments 
In the last decade, the available scientific evidence on the risks for public health of BPA has been 
thoroughly reviewed by a number of risk assessment bodies worldwide (AIST, 2007; 2011; SCF, 
2002; EU-RAR 2003; 2008; EFSA, 2006; 2008; EFSA CEF Panel 2010; Health Canada, 2008; NTP-
CERHR, 2007, 2008;; US FDA, 2010a, FAO/WHO, 2011; ANSES, 2011, 2013). 
European Scientific Committee on Food (SCF) 
In 2002, the SCF set a temporary Tolerable Daily intake (TDI) for BPA, of 0.01 mg BPA/kg body 
weight (bw)/day, by applying an uncertainty factor (UF) of 500 (100 for inter- and intra-species 
differences, and 5 for uncertainties in the database) to the NOAEL of 5 mg/kg bw per day identified in 
a comprehensive three-generation study in the rat by Tyl et al. (2002). 
European Food Safety Authority (EFSA) 
In 2006, the former EFSA Scientific Panel on Food Additives, Flavourings, Processing Aids and 
Materials in Contact with Food (AFC) published a full risk assessment of dietary BPA, encompassing 
both the setting of a TDI and the estimation of dietary exposure to BPA for various groups of the 
populations. A full TDI for BPA was set at 50 µg/kg bw per day, by applying a default UF of 100 to 
the overall NOAEL of 5 mg/kg bw per day from the two multi-generation reproductive toxicity studies 
in rodents by Tyl, where the critical effects were changes in body and organ weights in adult and 
offspring rats and liver effects in adult mice, respectively (Tyl et al., 2002, 2008; the latter is the same 
study as Tyl et al., 2006, cited in EFSA, 2006). For infants, dietary exposure to BPA was estimated to 
range from 0.2 µg/kg bw per day in 3-month-old breastfed babies to 13 µg/kg bw per day in 6-12-
month-old infants, for the worst case scenario (high BPA migration into foodstuffs and high food 
consumption, taking into account breast feeding, feeding formula using PC bottles as well as 
consumption of commercial foods and beverages). For young children and adults, worst case exposure 
estimates to BPA via the diet were 5.3 and 1.5 µg/kg bw per day, respectively, based on high 
migration levels of BPA from cans as well as on migration data from PC tableware or storage 
containers, and on high food and drink consumption. The AFC Panel concluded that exposure to BPA 
through food and drinks was well below the TDI, even for infants and children (EFSA, 2006).  
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The same TDI value of 50 µg BPA/kg bw per day was reaffirmed by the EFSA AFC Panel in its 
subsequent scientific opinion (EFSA, 2008). 
In 2010, the EFSA CEF Panel carried out a comprehensive evaluation of all the recent toxicological 
data on BPA and re-confirmed the TDI of 50 µg/kg bw per day (EFSA CEF Panel, 2010). However, 
the CEF Panel expressed some uncertainties concerning a few BPA-related effects of possible 
toxicological relevance, such as biochemical changes in brain, immune-modulatory effects and 
enhanced susceptibility to breast tumours, emerging from recent low-dose studies on developing 
animals. These studies had several shortcomings and the relevance of these findings for human health 
could not be assessed. Based on such uncertainties a CEF Panel member expressed a minority opinion, 
claiming that the current full TDI should become a temporary TDI. 
In 2011, the EFSA CEF Panel issued a statement on the report on BPA health effects published by the 
French ANSES, relating to possible divergences between the conclusions of EFSA in 2010 and those 
of ANSES in 2011 (ANSES, 2011). In 2011, the ANSES expert group concluded that based on the 
available scientific literature and by all exposure routes BPA has “proven” effects in animals on 
female and male reproduction, mammary gland, metabolism and brain, and also has “suspected” 
effects in humans (reproduction, diabetes and cardiovascular diseases). The CEF Panel overall 
considered that the information in the ANSES report did not change the views that the Panel expressed 
in 2010. The CEF Panel however expressed the need to review more in depth some new studies not 
yet available in 2010, including new data from ongoing low dose studies at NCTR/FDA and at 
NTP/NIEHS8 which are currently exploring many of the uncertainties around BPA. 
European Chemical Bureau of the European Union 
In 2003, the European Chemical Bureau of the European Union published a comprehensive Risk 
Assessment Report (EU-RAR) for BPA in the context of Council Regulation (EEC) No. 793/93 on the 
evaluation and control of existing substances. The key health effects of BPA through different 
exposure routes were considered to be eye and respiratory tract irritation, skin sensitisation, repeated 
dose toxicity to the respiratory tract, effects on the liver and reproductive toxicity (effects on fertility 
and on development). Some of these effects are worker-specific (e.g. eye and respiratory irritation, 
repeated dose toxicity to the respiratory tract) and are not expected to occur in the general population, 
which is predominantly exposed via food or through environmental sources. With respect to human 
health risks, a need for further research was identified, to resolve the uncertainties surrounding the 
potential for BPA to produce adverse effects on neurological and neurobehavioural development at 
low doses (EU-RAR, 2003).  
In 2008, the EU-RAR (EU-RAR, 2008) was updated after evaluation of the two generation 
reproductive study in mice by Tyl et al. (2008) along with the new data on human exposure and effects 
of BPA that had become available since 2003. The Rapporteur came to the conclusion that there was 
no need for further information and/or testing and for risk reduction measures beyond those which 
were already being applied. However, Denmark, Sweden and Norway considered that the results of 
four neurodevelopmental studies (Adriani et al., 2003; Carr et al., 2003; Negishi et al., 2004; Ryan and 
Vandenbergh, 2006) warranted further consideration and expressed a minority view concerning this 
toxicological endpoint (EU-RAR, 2008).  
Japanese Institute of Advanced Industrial Science and Technology (AIST) 
In 2005, the Japanese AIST concluded that BPA was unlikely to pose unacceptable risks to human 
health at current exposure levels. Margins of exposure (MOEs) were calculated as 85,000-1,800,000 
based on realistic exposure scenarios, and as >1,000 for adults and children based on worst-case 
scenarios. For these calculations, the NOAEL or the Benchmark Dose Lower Limit (BMDL) for three 
                                                     
8 See at: http://ntp.niehs.nih.gov/testing/status/agents/ts-10034-y.html 
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critical endpoints, namely lower body weight gain, liver and reproductive effects, were in the 5 to 50 
mg/kg bw per day range.  
AIST updated the Hazard Assessment of BPA in 2011 (AIST, 2011). The oral NOAEL for BPA 
general toxicity was considered to be 3 mg/kg bw per day based on centrilobular hepatocyte 
hypertrophy in the two generation study in mice by Tyl et al. (2008). A total uncertainty factor of 25 
was applied, consisting of 2.5 for inter-species differences (1 for toxicokinetics, and 2.5 for 
toxicodynamics), and of 10 for intra-species differences. According to the BPA exposure estimate in 
Japanese individuals, exposure was highest in 1 to 6 years old children with an estimated 95th 
percentile (in µg/kg bw per day) of 3.9 (males) - 4.1 (females). In adults, the 95th percentile of BPA 
intake (estimated from the amount of BPA excreted in 24-hour urine samples) was 0.037-0.064 µg/kg 
bw per day in men and 0.043-0.075 µg/kg bw per day in women. The relative margins of exposure 
(MoEs, i.e. ratio between the NOAEL and 95th percentile exposure data) were 730-770 for 1-6 yr old 
children and 40,000-81,000 for adults. These values were much larger than both the MoE (25) that 
was considered might possibly result in health effects in humans and the standard (conservative) MoE 
of 100, and thus the AIST concluded that the risk of BPA with regard to human health was very small. 
Health Canada 
In its 2008 risk assessment, the Health Canada’s Food Directorate did not revise the provisional TDI 
for BPA of 0.025 mg/kg bw per day set from the lowest NOEL of 25 mg/kg bw per day for general 
toxicity in a rat 90-day study (NTP, 1982), and concluded that the current dietary exposure to BPA 
through food packaging uses was not expected to pose a health risk to the general population, 
including newborns and young children (Health Canada, 2008). Health Canada then estimated the 
probable daily exposure to BPA to vary from as low as 0.21 µg/kg bw for infants 8-12 months of age 
to as high as 1.35 μg/kg bw for 0-1 month old infants with the maximum formula intake and the 
maximum concentration of BPA migrating from epoxy lined infant formula cans. 
In 2012, a refined (probabilistic) exposure assessment of Canadians was conducted based on the 
collective results of a number of recent Canadian surveys, including results from a Total Diet Study 
(Health Canada, 2012). A mean exposure to BPA of 0.055 µg/kg bw per day was calculated for the 
general population, which is approximately 3 times lower than the exposure calculated in the risk 
assessment of 2008. This updated dietary exposure figure generally aligns with exposure estimates that 
are based on the results of population-based biomonitoring studies. Infants, as an age group, were 
exposed to the greatest amount of BPA. The probable daily exposure to BPA varied from 0.083 µg/kg 
bw (0-1 month of age) to 0.164 µg/kg bw (4-7 months old infants). Collectively, also the BPA 
exposure estimates for infants were, on average, approximately 3-fold lower than those of 2008. 
Health Canada recommended the application of the general principle of ALARA (as low as reasonably 
achievable) to limit BPA exposure of newborns and infants, due to uncertainties for low-dose 
neurodevelopmental and behavioural effects in rodents. 
US National Toxicology Program (NTP) 
In 2008, the US National Toxicology Program (NTP) released its final report on BPA’s potential to 
cause harm to human reproduction or development (NTP-CERHR, 2008). Some concern (“some” is 
the midpoint on a five-level scale, ranging from “negligible” to “serious”) was expressed for effects on 
development of the prostate gland and brain, and on behaviour in infants and children after pre- and 
postanatal exposure to BPA at current human exposure levels. The NTP had minimal concern for 
effects of BPA on the mammary gland development and acceleration of puberty in females at current 
human exposure levels. NTP expressed negligible concern that exposure of pregnant women to BPA 
would result in fetal or neonatal mortality, birth defects, or reduced birth weight and growth in their 
offspring. NTP also expressed negligible concern that exposure to BPA would cause reproductive 
effects in non-occupationally exposed adults and minimal concern for workers exposed to higher 
levels in occupational settings. 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 8 
In the same report, the NTP also provided daily exposure estimates for infants, children and adults 
based on realistic scenarios. For the general population, the highest estimated daily exposure to BPA 
was reported to occur for infants and children. Formula-fed infants (0 to 6 months of age) had 
estimated intakes of 1-11 µg/kg bw per day, 6-12 month-old infants of 1.65-13 µg/kg bw per day, and 
older children (up to 6 years) of 0.04-14.7 µg/kg bw per day. For the general adult population BPA 
intake was estimated as 0.008-1.5 µg/kg bw per day. 
US Food and Drug Administration (US FDA) 
In 2008, the US FDA released a document entitled Draft Assessment of Bisphenol A for Use in Food 
Contact Applications, (US FDA, 2008), which was peer-reviewed during the same year (see report by 
US FDA Science Board Subcommittee on Bisphenol A, 2008). 
Since then, the Center for Food Safety and Applied Nutrition (CFSAN) within FDA has reviewed 
additional studies of low dose toxicity (US FDA, 2010a).  
As of 2013 the US FDA reiterated that at this interim stage it shares the perspective of the National 
Toxicology Program (NTP-CERHR, 2008) that “recent studies provide reason for some concern about 
the potential effects of BPA on the brain, behaviour, and prostate gland of fetuses, infants and 
children.” (US FDA, 2013). FDA has also recognized substantial uncertainties with respect to the 
overall interpretation of these studies and their potential implications for human health effects of BPA 
exposure and, in cooperation with the NTP, FDA’s National Center for Toxicological Research 
(NCTR), is carrying out in-depth studies to answer key questions and clarify uncertainties about the 
risks of BPA (US FDA, 2013).  
Recent evaluation by the FDA’s CFSAN has determined that exposure to dietary BPA for infants, the 
population of most potential concern, is less than previously estimated (US FDA, 2013). The initial 
FDA exposure estimates were 0.185 µg/kg bw per day for adults and 2.42 µg/kg bw per day for 
infants (US FDA, 2008). The new estimate of average dietary exposure, based on increased data 
collection, is 0.2-0.4 µg/kg bw per day for infants and 0.1-0.2 µg/kg bw per day for children and adults 
(US FDA, 2010b). 
Belgian Superior Health Council 
In November 2010 the Belgian Superior Health Council issued a risk assessment that provided the 
scientific ground for adopting a law banning BPA in materials in contact with food for children aged 
0-3 years in 2012. The concern was based on the uncertainties around possible adverse effects of BPA 
at low doses on brain, immune system, development, and mammary cancer promotion in offspring 
exposed during pregnancy or lactation. These uncertainties had also been identified by other national 
or international bodies. This urgent advice mainly consisted of a summary of previous evaluations of 
BPA made by the French AFSSA, the German BfR, EFSA (EFSA CEF Panel, 2010), the Japanese 
AIST, Health Canada, the US NTP and FAO/WHO. In this context the evaluation of original data was 
very limited. The report’s recommendations to take risk management measures to protect young 
children was in line with the application of the precautionary principle.  
Food Standard Australia New Zealand (FSANZ) 
In 2010 the FSANZ9 stated that, after thoroughly considering the toxicological database for BPA, it 
concurred with the hazard assessment previously performed by EFSA, US FDA and Health Canada 
and the established TDI of 50 µg/kg bw per day. FSANZ undertook a survey of BPA in food and 
drinks in the Australian market to determine exposure to BPA from packaging materials and came to 
                                                     
9 http://www.foodstandards.gov.au/science/monitoring/surveillance/documents/BPA%20paper%20October%202010%20FINAL.pdf 
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the conclusion that Australians of all ages are exposed to extremely low levels (in the range of ng/kg 
food to µg/kg food) via such packaged foodstuffs. 
World Health Organization (WHO) 
In 2010 the FAO and WHO jointly held an Expert Meeting on BPA, whose final report was published 
in 2011. The report identified the sub-population with the highest dietary exposure to BPA as that of 
infants of 0-6 months being fed liquid formula out of PC bottles: this accounted for 2.4 μg/kg bw per 
day (mean) and 4.5 μg BPA/kg bw per day (95th percentile). Exposure (in μg BPA/kg bw /day) was 
estimated not to exceed 0.7 (mean) and 1.9 (max) for children >3 years, and 1.4 (mean) and 4.2 (max) 
for adults. Based on limited data, for most subgroups BPA exposure from non-food sources was at 
least one order of magnitude lower than that from food. 
As for hazard characterisation, points of departure were considered to be much higher than human 
exposure for many end-points and thus did not raise health concern. Studies on developmental and 
reproductive toxicity in which conventional end-points were evaluated showed effects only at high 
doses, if at all. However, in a few studies some emerging new end-points (sex-specific 
neurodevelopment, anxiety-like effects, preneoplastic changes in mammary glands and prostate in rats, 
impaired sperm parameters) showed associations at lower levels, i.e. close to the estimated human 
exposure, so there would be potential for concern if their toxicological significance were to be 
confirmed. WHO stated that “while it would be premature to conclude that these evaluations provide a 
realistic estimate of the human health risk, given the uncertainties, these findings should drive the 
direction of future research with the objective of reducing this uncertainty”. 
French Agency for Food, Environmental and Occupational Health & Safety (ANSES) 
In September 2011, ANSES published a report on BPA, including one part concerning its effects on 
human health and the other one on its uses (ANSES, 2011). In the hazard identification report "Effets 
sanitaires du bisphénol A” ANSES classified the effects of BPA on humans and animals as proven, 
suspected, controversial, or inconclusive (ANSES, 2011). Furthermore, it reached the conclusions that 
BPA exposure was associated with proven effects in animals and suspected effects in humans, also at 
levels of exposure below the current regulatory thresholds. These effects were the main focus of the 
subsequent risk assessment that was completed by ANSES in April 2013. Specifically, the 
characterisation of human health risks was conducted for the category “pregnant women” (i.e. 
offspring) considering four toxicological endpoints for which the external threshold doses identified in 
oral studies in developing animals are reported in brackets: neurobehavioural development (NOAEL: 
50 µg/kg bw per day from Xu et al., 2010), female reproductive system (NOAEL: 100 µg/kg bw per 
day from Rubin et al., 2001), metabolism and obesity (LOAEL: 260 µg/kg bw per day from Miyawaki 
et al., 2007) and mammary gland proliferation - changes in the structure that make it more susceptible 
to carcinogens (NOAEL: 25 µg/kg bw per day from Moral et al., 2008). ANSES used a bioavailability 
factor of 3% to convert the external NOAEL/LOAEL from the experimental data into equivalent 
internal doses (internal NOAEL/LOAEL), taking into consideration the impact of first-pass 
metabolism on orally ingested BPA and assuming that only the unconjugated fraction of BPA was 
responsible for the effects observed. To obtain an internal Derived No Effect Level (DNEL) for each 
critical endpoint, ANSES applied an overall assessment factor of 300 to the internal NOAELs (or 900 
if the starting critical dose was a LOAEL), consisting of a factor 100 to account for inter- and intra-
species kinetic and dynamic differences, and an extra factor of 3 to account for uncertainties regarding 
possible low-dose effects of BPA and non-monotonic dose-response relationships (NMDRs). The 
resulting internal DNELs that were used in risk characterisation were 0.01, 0.02, 0.0173 and 0.005 
µg/kg bw per day for neural-, female reproductive-, metabolic- and mammary gland effects, 
repectively. The sources of BPA considered for BPA (probabilistic) exposure assessment were air, 
sedimented dust, food and beverages. Dietary (external) exposure (99th percentile) was estimated to be 
for children (3-17 yrs) 0.31 µg/kg bw per day, for adolescents (11-17 yrs): 0.12 µg/kg bw per day, and 
for pregnant women: 0.24 µg/kg bw per day.  
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The conclusions of the 2013 ANSES risk assessment report that there are risk situations for the fetus, 
associated with maternal exposure to BPA during pregnancy. In detail, a moderate risk for children of 
both sexes relates to the mammary gland with particular reference to an increased number of 
undifferentiated epithelial structures associated with an enhanced susceptibility of the mammary gland 
to tumour transformation. According to the aggregate exposure estimates (expressed in internal dose 
as µg/kg bw per day and summed up from all sources and routes), dietary exposure is the main 
contributor over other sources and routes. Concerning particular exposure scenarios during pregnancy, 
specific risk situations apply to pregnant women handling thermal paper and consuming water from 
refillable polycarbonate containers. The scenario for pregnant women handling thermal paper implied, 
in addition to the effect on the mammary gland, other health risks for the unborn child regarding brain 
and behaviour, metabolism, obesity and/or the female reproductive system. ANSES did not estimate 
the risks for other populations, e.g. infants, children and adolescents, due to insufficient data 
availability (ANSES, 2013). 
1.2. Consideration of low-dose effects and non-monotonic dose-response curves in the risk 
assessment of BPA  
In reviewing the toxicological profile of BPA and other endocrine active substances a particularly 
controversial area has been the reported that not only are there effects at low doses (defined either as 
doses in the range of human exposure, or doses below the NOAEL of 5 mg/kg bw per day (used in 
establishing the current TDI of 50 µg BPA/kg bw per day) but there are also non-monotonic dose-
response curves (NMDRs) (Teeguarden and Hanson-Drury, 2013). The term “low-dose effects” is not 
synonymous with or equivalent to NMDR, but there is particular concern about the possibility that 
non-monotonicity would occur at lower doses than those used in regulatory toxicity studies. The 
NMDR can be characterised by a change in slope direction along the dose interval studied, contrary to 
conventional monotonic dose-response, which shows a consistent increase in (adverse) effects along 
the dose range (Vandenberg et al., 2012). In the papers from Vandenberg and some other authors it is 
suggested that endocrine mechanisms underlying NMDRs are most important during the development 
of an organism which is considered as a sensitive “window of exposure”. Therefore, it has been 
recommended that testing of endocrine-active substances should not only span a wide dose range but 
also encompass the developmental period along with a follow-up later in life to assess potentially 
latent effects (WHO/UNEP, 2012). The view held by some researchers that low-dose effects and/or 
NMDRs cannot be sufficiently captured in internationally agreed protocols for toxicological testing 
challenges the usual practice of setting health-based guidance values. This could particularly apply to 
endocrine-active substances for which complex sex-, tissue- and species-specific mechanisms of 
action could be assumed. These mechanisms may interfere with multiple signalling pathways which 
may influence toxicological outcomes (Watson et al, 2012; Zoeller et al., 2012; Vandenberg et al., 
2013b). The biological activity of endocrine-active substances has been extensively reviewed in the 
scientific literature, most recently by EFSA (EFSA Scientific Committee, 2013), the United Nations 
Environment Programme (WHO/UNEP, 2012) and the EC Joint Research Centre/Institute for Health 
and Consumer Protection (JRC, 2013). More specifically, the possibility that endocrine-active 
substances may display low-dose effects and NMDR has been the subject of several specific reviews 
(Zoeller et al., 2012; Vandenberg et al., 2012; draft report of US EPA, 2013) and has been debated at a 
number of dedicated conferences (EFSA, 2012; JRC/NIEHS, 2013). BPA has frequently been cited as 
an example of a chemical showing such effects, and Vandenberg et al. have recently published 
extensive reviews of the low-dose effects of BPA, based on in vitro, laboratory animal and 
epidemiological studies (Vandenberg et al., 2012, 2013a).  
Of the recent BPA risk assessments conducted by other authorities, described in section 1.1, non-
monotonic (or non-linear) dose-response relationships were specifically discussed in the EU-RAR 
(2008), NTP-CERHR (2008), US FDA (2010a), FAO/WHO (2011) and ANSES (2013).  
The discussion in the EU-RAR (2008) relates to a discrepancy between the results of different studies 
with Xenopus laevis tadpoles, and is therefore not directly relevant to the human health risk 
assessment. The report notes that there were some drawbacks to the methodology used in the study 
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suggesting a NMDR, and the apparent effect could be an artefact. Nevertheless the results could not be 
rejected as invalid and the study was considered as ‘valid with restriction’.  
NTP-CERHR (2008) noted that at low doses effects may be difficult to statistically distinguish from 
background variability. Studies of BPA at low doses could be affected by factors that include 
phytoestrogen content of the animal feed, extent of BPA exposure from caging or water bottles, 
unintentional contamination from adjacently housed animal receiving higher doses of BPA and the 
sensitivity of the animal model to estrogens. In contrast, high-dose studies are less susceptible to these 
types of influences because the toxicologic response should be more robust and less variable. While 
the NTP-CERHR Panel did not necessarily expect a specific effect to display a monotonic dose-
response (e.g. consistently increasing organ size), many members of the panel expected the high-dose 
studies with BPA to detect some manifestation of toxicity (e.g. altered weight, histopathology) in 
tissues reported to be affected at low doses even if the study could not replicate the reported low dose 
effect. Therefore more weight was given to studies that evaluated both low-and high-doses of 
bisphenol A rather than to low-dose-only studies in cases where the target tissues were comparably 
assessed. Specific examples of NMDRs were not identified (NTP-CERHR, 2008). 
US FDA (2010a) noted that in evaluation of non-linear dose-responses, additional lower dose levels 
should be included in a protocol and high doses or a large dose range must also be employed to 
accurately describe the dose-response of the desired endpoint. However they did not specifically 
comment on whether BPA exhibits NMDRs. FAO/WHO (2011) commented that “depending on the 
system studied and the dose, BPA may exert pleiotropic cellular and tissue-type specific effects and 
can exhibit non-monotonic dose–response relationships at cellular and intracellular levels”. 
ANSES (2013) provided a more lengthy discussion of non-monotonic relationships. It notes that 
‘before affirming the existence of a non-monotonic dose-response relationship, the statistical and 
biological plausibility of this non-monotonic relationship must be evaluated’ and proposed a decision 
tree for this purpose. However, overall ANSES concluded that ‘Taking into account non-monotonic 
dose-effect relationships in the quantitative assessment of risks associated with BPA “was not possible 
due to methodological difficulties”. Therefore ‘the "standard" approach based on the choice of a 
starting point associated with a critical effect (NOAEL/LOAEL/BMD)’ was used in the risk 
assessment (ANSES, 2013). 
The EFSA Scientific Committee (2013) has also considered the debate over NMDRs, noting that in 
the assessment of reproducibility of findings that indicate NMDRs it is important to rule out spurious 
results, and that the arguments of Vandenberg et al. (2012) have been questioned by other scientists. 
The CEF Panel noted the conclusions of EFSA Scientific Committee (2013) regarding “the lack of 
consensus in the scientific community as to the existence and/or relevance of low-dose effects and 
NMDRs in (eco)toxicology in relation to endocrine disruption, or other endpoints/modes of actions”. 
The responses to the consultation on this CEF opinion further demonstrate this lack of consensus. 
EFSA Scientific Committee (2013) recommended a follow up activity to clarify NMDRs in the 
broader context and in further detail. As a result, EFSA has commissioned a project to critically 
review the scientific peer-reviewed literature published from 2002 onward  concerning the evidence 
for NMDR hypothesis for substances (other than essential nutrients) in the area of food safety. The 
project was awarded to a consortium of four Organisations (ANSES (leader), AGES, RIKILT and 
Karolinska Institute) and is expected to end in December 2015. 
Whilst it is not in the scope of this risk assessment of BPA to support or to rebut the existence of 
NMDRs for endocrine active substances in general the CEF Panel in its review of the recent BPA 
literature and re-evaluation of earlier papers considered a number of papers describing low-dose 
effects and NMDRs associated with BPA exposure. Considering the limitations of in vitro studies (e.g. 
cytotoxicity, accumulation of toxic metabolites under usual culture conditions) the CEF Panel decided 
to focus its evaluation on in vivo studies with a reported NMDR for an adverse BPA-induced effect. 
For a consistent evaluation of these studies the CEF Panel took into account the considerations of the 
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EFSA Scientific Committee (2013b) and the outcome of discussions in the 2012 EFSA Scientific 
Colloquium (EFSA, 2012) on low dose-responses in toxicology and developed the following criteria: 
(i) at least two adjacent  doses departing from monotonicity or support for the NMDR from a 
similar study (same species, similar treatments, similar sampling time) on the same effect 
(this criteria is relevant to reduce the chance for an incidental finding).  
(ii) a plausible underlying mode of action/overarching concept;  
(iii) the reliability of the study and the relevance of the effect for human health should be 
considered as medium or high (as expressed in Appendix B and C); the reliability of the 
study results should also include an appropriate statistical treatment of the reported data 
For each BPA-induced toxicological endpoint the studies which reported a NMDR were summarised 
in Tables 1 and the evidence for a NMDR was assessed according to the above mentioned criteria. In 
addition for some endpoints a graphical approach was used to get an overview of the possible shapes 
of the dose-responses (section 4.3.2). 
The CEF Panel noted that in two reproductive multi-generations studies covering a broad range of 
BPA doses including very low doses (i.e. 1 and 3 µg BPA/kg bw per day in the Tyl et al. studies from 
2002 and 2008, respectively) and a subchronic study including a prenatal BPA treatment (2.5; 8; 25; 
80; 260; 860 and 2 700 μg/kg bw per day) (US FDA/NCTR, 2013/Delclos et al., 2014) only 
monotonic dose-responses were observed. In contrast, in two reproductive/developmental studies 
NMDRs were reported for sexual behaviour (De Catanzaro et al., 2013) and reduced fertility (fewer 
cumulative pups in a forced breeding study; Cabaton et al., 2011). However, the latter three studies 
were considered too limited to provide sufficient support for the existence of an NMDR event in the 
respective parameters studied. The CEF Panel noted that none of these studies had two adjacent doses 
in the low dose range showing a significant effect. Therefore, the CEF Panel concluded that the 
evidence is not sufficient to support a NMDR in these observations (see Table 1).  
Three studies on neurobehavioural effects report non-monotonicity in the data sets (Jones et al., 2011; 
Jones et al., 2012; Kundakovic et al., 2013). 
Jones et al. (2011) investigated sexual behaviour in adult rats perinatally exposed to BPA and reported 
a non-linear dose–response relationship in males (impaired composite sexual behavior score at 50 
µg/kg bw per day). The CEF Panel noted that the low number of dams per group (3 dams/group) 
implied that littermates were tested. Furthermore that sexual behaviour is in particular sensitive to 
other study factors than dose; that the endpoints measured have interdependence; that the z-score 
approach used by the authors implies that statistically significant differences due to other study factors 
than dose are amplified. The CEF Panel also noted that none of the endpoints looked at had two 
adjacent doses in the low dose range that showed an significant effect.   
Jones et al. (2012) reported non-monotonic dose–response in rats perinatally exposed to BPA as the 
normal sex differences seen in control rats were eliminated in low dose BPA-exposed adults (5 µg/kg 
bw per day) but not at the higher doses in an Elevated plus maze. No significant differences across 
doses of BPA were seen in a Forced Swim test in both males and females, whereas paired comparisons 
indicated that the sex differences seen in controls appeared to varying degree in the different dose 
groups.  In each of these two tests several endpoints were measured. In addition to the use of few dams 
per group (2-3), use of littermates for testing, and reporting NMDR based on t-tests and ANOVA 
results, the CEF Panel noted that none of the endpoints looked at had two adjacent doses in the low 
dose range which showed an effect.  
In the study by Kundakovic et al. (2013) mostly non-monotonic dose-responses were reported on the 
expression of ERα, ERβ and oestrogen receptor-related receptor gamma and on DNA 
methyltransferases (DNMT1 and DNMT3A) in different brain regions of mice prenatally exposed to 
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2, 20 and 200 µg BPA µg/kg bw per day. The CEF Panel noted that in contrast to these sex- and 
tissue-specific biochemical findings of BPA exposure, the large scatter within the dose-groups for the 
behavioural endpoints means that while a large number of different dose-response curves can be fitted 
to the data, it is not possible to conclude on the biological relevance of any of them.   
The CEF Panel concluded that the evidence in Jones et al. (2011, 2012) or Kundakovic et al. (2013) is 
not sufficient to support a NMDR in their observations (see Table 1). 
For metabolic effects six studies reported NMDR (Anderson et al., 2013;  Angle et al., 2013; Bodin et 
al., 2013, Marmugi et al., 2012 Wei et al., 2011; Miyawaki et al., 2007), however, according to the 
above criteria, the evidence provided was not sufficient to confirm NMDR for this endpoint (see Table 
1). Two of them are more frequently cited. Wei et al. (2011) reported increased body weights and 
serum insulin levels in rat offspring after prenatal exposure (oral gavage) only to one dose at 50 µg 
BPA/kg bw per day but not at higher concentrations (250 and 1250 µg/kg bw per day). Marmugi et al. 
(2012) reported increased plasma insulin and triglycerides after 28 day- oral treatment of mice with 
low BPA doses (5-500 µg/kg bw per day) but not at 5000 µg/kg bw per day. No changes in the plasma 
concentrations of glucose or cholesterol were observed after treatment with various BPA doses. In 
addition the authors also report on an accumulation of cholesterol esters and of triglycerides in the 
liver along with induction of hepatic enzymes and transcription factors involved in lipid synthesis with 
NMDRs. The CEF Panel noted that in contrast to these observations no increases in insulin and 
triglycerides and no adverse effects on the liver were observed in the corresponding low dose range in 
the US FDA/NCTR study (2013) and Delclos et al. (2014) or in the Tyl studies (2002, 2008). The CEF 
Panel concluded that the evidence is not sufficient to support a NMDR in these observations. 
In seven studies on proliferative changes in mammary gland, the authors were of the opinion that the 
results indicated BPA-induced, toxicologically relevant, effects and BPA-induced changes in gene 
expression with NMDR (Acevedo et al., 2013; Ayyanan et al., 2011; Jenkins et al., 2011; Markey et 
al., 2001; Murray et al., 2007; US FDA/NCTR, 2013 and Delclos et al., 2014; Vandenberg et al., 
2013c). In evaluating the study results in a WoE approach the CEF Panel acknowledged the overall 
evidence for BPA-induced proliferation as a likely effect. However, the statistically significant 
proliferative effects are observed in each study for only one BPA dose which makes it difficult to rule 
out that the results could be due to chance. The CEF Panel concluded that the evidence is not 
sufficient to support a NMDR in these observations. 
In a tumour-prone transgenic mouse strain, a NMDR was reported by Jenkins et al. (2011) for 
decreased tumour latency and increased tumour multiplicity. Conversely an increase in cell 
proliferation and apoptosis indexes of mammary gland epithelial cells displayed dose-dependent 
(monotonic) trends, while the proliferation:apoptosis ratio showed a NMDR with one statistically 
increased value only. In contrast to the 2011 study, the 2009 Jenkins study in the DMBA mammary 
tumour rat model did not show a non-monotonic dose-response for any of the parameters tested. The 
2009 and 2011 Jenkins studies differed not only in the animal model tested but but also in the period 
of exposure to BPA (lactational versus during adulthood), and the inconsistency in the results make it 
difficult to draw any firm conclusions from these studies.  The CEF Panel concluded that the evidence 
is not sufficient to support a NMDR in these observations. 
In summary, none of the studies fulfill the criteria for a NMDR established by the CEF Panel. Overall 
the CEF Panel concluded that the available data do not provide evidence that BPA exhibits a NMDR 
for the endpoints considered (reproductive and developmental toxicity, neurotoxicity/behavioural 
effects, metabolic effects, proliferative changes in mammary gland).   
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Table 1:   In vivo-studies on BPA  claiming a non-monotonic dose-response relationship for at least one endpoint relevant to reproductive 
toxicity/development, neurotoxicity/behavioural effects, metabolic effects, or  proliferative changes in the mammary gland.  
Reprotoxicity/Development 
 
Author, Year, Title Species Dose range/ 
number of doses 
(µg/ kg bw/ d)  
Dose(s) with 
effect according 
to study report 
(µg/ kg bw/ d) 
Endpoint Evidence for NMDR according to the 
criteria of WG 
Cabaton NJ, Wadia PR, 
Rubin BS, Zalko D, 
Schaeberle CM, Askenase 
MH, Gadbois JL, Tharp AP, 
Whitt GS, Sonnenschein C, 
Soto AM, 2011. Perinatal 
exposure to environmentally 
relevant levels of bisphenol A 
decreases fertility and 
fecundity in CD-1 mice.  
Female mice 0.025 µg/kg bw per 
day  
0.25 µg/kg bw per 
day  
25 µg/kg bw per day 
GD8-PND16 
0.025 µg/kg bw 
per day  
25 µg/kg bw per 
day 
 
Cumulative number of 
pups from forced 
breeding 
This study does not have two adjacent 
doses  in the low dose range showing a 
significant effect   
De Catanzaro D, Berger RG, 
Guzzo AC, Thorpe JB and 
Khan A, 2013 Perturbation of 
male sexual behaviour in 
mice (Mus musculus) with a 
discrete range of bipshenol-A 
doses in the  context of high- 
or low- phytoestrogen diet. 
Male mice 17.5 µg/day 
175 µg/day 
1750 µg/day 




Intromission at day 
85-105: numbers 
reduced 
This study does not have two adjacent 
doses in the low dose range showing a 






17.5 µg/day Ejaculation at day 85-
105: numbers reduced 
 
  
                                                     
10 Significant effects on two adjacent doses (for a single variable only) were observed in animals fed with high soy-diet with BPA, which was not taken into account because they were confounded by the diet.  
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Neurotoxicity/Behavioural effects 
 
Author, Year, Title Species Dose  Dose(s) with effect Endpoint Evidence for NMDR according to the 
criteria of WG 
Jones BA, Shimell JJ, Watson 
NV, 2011.  
Pre- and postnatal bisphenol 
A treatment results in 
persistent deficits in the 
sexual behavior of male rats, 
but not female rats, in 
adulthood 
Rats 5 μg/kg bw per day 
50 μg/kg bw per 
day  
500 μg/kg bw per 
day 5000 μg/kg bw 
per day 
 
GD 7 to PND 14 
50 μg/kg bw per 




sexual behaviour  
 
This study does not have two adjacent 







Jones BA and Watson NV, 
2012 Perinatal BPA exposure 
demasculinizes males in 
measures of  affect but has no 




5 μg/kg bw per day 
50 μg/kg bw per 
day  
500 μg/kg bw per 
day 5000 μg/kg bw 
per day 
 
GD 7 to PND 14 
5 μg/kg bw per day 
 
Anxiety-like 
behaviour in the 
Elevated plus maze: 
-total distance 
moved, time mobile, 
per cent open/closed 
arm entries, nos. of 
hub entries  
Forced swim maze: 
-rotations, latency to 
first immobile 
episode 
This study does not have two adjacent 







Kundakovic M, Gudsnuk K, 
Franks B, Madrid J, Miller 
RL, Perera FP, Champagne 
FA, 2013. Sex-specific 
epigenetic disruption and 
behavioral changes following 
low-dose in utero bisphenol A 
exposure 
















(decreased at low 
dose, increased at 
high dose, male and 
females) 
A  number of different dose-response 
curves can be fitted to the data due to large 
variations in the outcome of the 
measurements of behavioural endpoints.  
It is not possible to conclude on the 
biological relevance of any of them 
The data do not provide sufficient 
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Metabolic effects 
 
Author, Year, Title Species Dose range/number 
of doses 
Dose(s) with effect Endpoint Evidence for NMDR according to the 
criteria of WG 
Anderson OS, Peterson KE, 
Sanchez BN, Zhang Z, 
Mancuso P and Dolinoy DC, 
2013 Perinatal bisphenol A 
exposure promotes 
hyperactivity, lean body 
composition, and hormonal 
responses  across the murine 
life course. 
Mice 




50 ng BPA/kg diet  
50 µg BPA/kg diet  
50 mg BPA/kg diet 
1. All doses had 
effects at 3 and 6 
months. 
But: at 9 months only 
the lowest dose had 
an effect in females 
(higher energy 
expenditure than 
control) but not in 
males 
2. CO2 production 
Females had only an 
effect at 9 months in 
the highest dose 
group. Males had an 
effect at 3 months of 
age in the middle and 
the highest dose 
group. 
3. horizontal activity 
Increase in females in 
the dose group n50 
ng at 3 and 9 months; 
females exposed to 
50 µg or 50 mg had 
an effect only at 9 
months 
In Males: No effect 
of the lowest dose; 
effects of middle and 
higest dose at 3 
months 
4. vertical activity 
1. energy expenditure 









2. CO2 production 









3. horizontal activity 
Lack of biological plausibility: CO2 
production did not parallel energy 
expenditure.   
 
None of the criteria for NMDR were met 
by the study 
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Metabolic effects 
 
Author, Year, Title Species Dose range/number 
of doses 
Dose(s) with effect Endpoint Evidence for NMDR according to the 
criteria of WG 
microgram-exposed 
group 
Angle BM, Do RP, Ponzi D, 
Stahlhut RW, Drury BE, 
Nagel SC, Welshons WV, 
Besch-Williford  CL, Palanza 
P, Parmigiani S, Vom Saal FS 
and Taylor JA, 2013. 
Metabolic disruption in male  
mice due to fetal exposure to 
low but not high doses of 
bisphenol A (BPA): Evidence 
for effects  on body weight, 
food intake, adipocytes, 
leptin, adiponectin, insulin 
and glucose regulation 
Mice 





50,000 µg/kg bw per 
day BPA, 
1. and 2.  5 µg/kg bw 
per day and 5000 
µg/kg bw per day 
increased glucose 
AUC vs control 
3. 500 µg/kg bw per 
day increased in renal 
and gonadal fat 
4. 5 µg/kg bw per day 
and 500 µg/kg bw per 
day increased in 
gonadal and 5 µg/kg 
bw per day and 5000 
µg/kg bw per day in 
renal fat 
5. Insulin level higher 
than control in 5 
µg/kg bw per day 
6. Leptin level higher 
than controll in 500 
µg/kg bw per day 
7. leptin lower than 
control in 5, 50, 5000 
µg/kg bw per day 
8. no consistent doses 
over time different 
from control 
9. 50 µg/kg bw per 
day and 5000 µg/kg 
bw per day increased 






3. Fat cell number 
 
 
















8. body weight 
 
 
9. fat weight of 
gonadal, renal and 
total abdominal fat 
 
No consistent dose-responses e.g. for body 
weight when analysed over time. Effects 
on food consumption and effects on weight 
were not correlated 
Endpoints measured in different animals 
with the exception of body weight 
 
Results of 19 statistical tests were reported 
but even more were performed because 
obviously all the endpoints  were also 
compared to the positive control and the 
doses were compared to each other. 
 
 
In total effects are seen at random. 
 
None of the criteria for NMDR were met 
by the study 
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Metabolic effects 
 
Author, Year, Title Species Dose range/number 
of doses 
Dose(s) with effect Endpoint Evidence for NMDR according to the 
criteria of WG 
regions 
10. 50 µg/kg bw per 
day increased weight 
 
10. liver weight 
Bodin J, Bolling AK, 
Samuelsen M, Becher R, 
Lovik M and Nygaard UC, 
2013 Long-term bisphenol A 
exposure accelerates insulitis 
development in diabetes-
prone NOD mice. 
Mice 1 
100 
mg/l drinking water 
corresponding to  
3 µg/day/mouse 
300 µg/da/mouse 
In the pancreas, 
exposure to both high 
and low dose BPA 
gave increased 
amount of apoptotic 
cells at week 7 and 
12, and reduced 
number of resident 
macrophages at week 
7. However, the more 
severe insulitis 
observed at 12 weeks 
in female NOD mice 
was associated with 
exposure to the 
lowest BPA dose 
only, as was the 
tendency of 
accelerated diabetes. 
 Study in NOD mice  
with questionable relevance for humans. 
 
 
None of the criteria for NMDR were met 
by the study (2 doses only). 
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Metabolic effects 
 
Author, Year, Title Species Dose range/number 
of doses 
Dose(s) with effect Endpoint Evidence for NMDR according to the 
criteria of WG 
Marmugi A, Ducheix S, 
Lasserre F, Polizzi A, Paris A, 
Priymenko N, Bertrand- 
Michel J, Pineau  T, Guillou 
H, Martin PG and Mselli 
Lakhal L, 2012 Low doses of 
bisphenol A induce gene  
expression related to lipid 
synthesis and trigger 
triglyceride accumulation in 
adult mouse liver 





for 4 week(mice 6 
weeks old) 
1. No effect 
2. No effect 
3. 50 increase 
4. 5, 50, 500 increase; 
5 more than 50 and 
500; 50 more than 
500 
5. no effect 
6. elevated TG 500 
7. no effect 
8. no effect 
9. No effect 
1. Body weight gain 
2. Liver weight 







7. total cholesterol 
8. LDL 
9. HDL 
Lack of biological plausibility:high insulin 
along with unchanged glucose levels. 
Accumulation of cholesterol esters and 
triglycerides but no adverse effects on 
liver. 
 
The data do not provide sufficient 
evidence for NMDR. 
 
 
Miyawaki J, Sakayama K, 
Kato H, Yamamoto H and 
Masuno H, 2007 Perinatal 
and postnatal  exposure to 
bisphenol a increases adipose 
tissue mass and serum 
cholesterol level in mice 
Mice  










Males effect only at 
high dose 
2.Females:  increased 
only at low dose 
Males: effects only at 
high dose 
3. Females: 
Elevated at low dose 
Males: no effect 
4. Females: 
Low dose elevated 
TC 
Males no effect 
5. Females: 
No effect 
Males: low dose 
elevated TG 










3. Serum leptin 
 
 








None of the criteria for NMDR were met 
by the study (2 doses only). 
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Metabolic effects 
 
Author, Year, Title Species Dose range/number 
of doses 
Dose(s) with effect Endpoint Evidence for NMDR according to the 
criteria of WG 
6. Females: no effect 
Males: elevated low 
dose 
7.Females no effect 
Males low serum 
glucose at low dose 
6. non-esterified fatty 
acids (NEFA) 
 
7. Glucose serum 
 
Wei J, Lin Y, Li Y, Ying C, 
Chen J, Song L, Zhou Z, Lv 
Z, Xia W, Chen X and Xu S, 
2011 Perinatal Exposure to 
Bisphenol A at Reference 
Dose Predisposes Offspring to 
Metabolic Syndrome in Adult 
Rats on a High-Fat Diet 
Rat 50,  
250  
1250 µg/kg / day 
 
Group A (without fat) 
 
Group B with fat diet 
Effects were only 
seen with 50 µg/kg/d 
Increased body 
weight and insulin 
levels. 
This study does not have two adjacent 





Proliferative changes in mammary gland 
 
Author, Year, Title Species Dose range/number 
of doses 
Dose(s) with effect Endpoint Evidence for NMDR according to the 
criteria of WG 
Acevedo N, Davis B, 
Schaeberle CM, Sonnenschein 
C and Soto AM, 2013 
Perinatally Administered 
bisphenol A acts as a 





120 µg/kg bw/d, sc 
GD9-GD23 
no stat. sign. increase  Atypical ductal 
hyperplasia, tumors 
Lack of statistical significant effects 
compared to control groups 
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Proliferative changes in mammary gland 
 
Author, Year, Title Species Dose range/number 
of doses 
Dose(s) with effect Endpoint Evidence for NMDR according to the 
criteria of WG 
Ayyanan A, Laribi O, 
Schuepbach-Mallepell S, 
Schrick C, Gutierrez, M 
Tanos, T Lefebvre, G  
Rougemont, J Yalcin-Ozuysal 
O and Brisken C, 2011 
Perinatal exposure to 
bisphenol A  increases adult 
mammary gland progesterone 







1200 µg/ kg bw/ d, 
Drinking water 
3 µg/ kg bw/ d  Increase in the number 
of TEBs. 
Progesterone response 
(at 6 µg BPA) and 
proliferation (at 3 µg).  
This study does not have two adjacent 
doses in the low dose range showing a 
significant effect. 
No  supporting study (e.g. Munoz-de-
Torro, 2005).  
Low reliability of the study. 
None of the criteria for NMDR were met 
by the study. 
Jenkins S, Wang J, Eltoum I, 
Desmond R and Lamartiniere 
CA, 2011 Chronic oral 
exposure to  bisphenol A 
results in a nonmonotonic 
dose-response in mammary 
carcinogenesis and metastasis 
in MMTV-erbB2 mice 
Transgenic mice 2.5 
25 
250 
2500 µg/ kg bw/ d, 
drinking water 
25 µg/ kg bw/ d 
and 
 
2.5 and 25 µg/ kg bw/ 
d 
and 
25 µg/ kg bw/ d 
Proliferation apoptosis 
ratio 
and tumors per mouse 
(tumor multiplicity) 
and tumor volume, 
reduced mean time to 
first tumor onset 
MDR for proliferation and apoptosis  
Priliferation:apoptosis ratio increased at 
one dose only; some support in 
Vandenberg et al., 2013c: male mice – 
but at higher HED. 
According to the WoE approach: tumor 
induction is not considered as a likely 
effect. 
Markey et al., 2001 
In Utero Exposure to 
Bisphenol A Alters the 
Development and Tissue 
Organization 










250 ng/kg bw/d, sc 
From GD 9  
25 µg/ kg bw/ d Area of TEBs TEB increase at one dose only. No 
concomitant increase in epithelial 
proliferation. 
None of the criteria for NMDR were met 
by the study. 
Murray et al., 2007 Induction 
of mammary gland ductal 
hyperplasia and carcinoma in 





1000 µg/ kg bw/ d, sc  
2.5 µg/ kg bw/ d 
at PND 95  
(not at PND 50) 
Intraductal hyperplasia  




carcinoma in situ (CIS) 
at the two highest 
doses. 
Increase in intraductial hyperplasia at 
one dose only; but CIS at higher doses 
only. 
Study reliability is considered low. 
None of the criteria for NMDR were met 
by the study. 
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Proliferative changes in mammary gland 
 
Author, Year, Title Species Dose range/number 
of doses 
Dose(s) with effect Endpoint Evidence for NMDR according to the 
criteria of WG 
US FDA/NCTR, 2013 and 
Delclos et al., 2014 Evaluation 
of the toxicity of bisphenol A 
(BPA) in male and female  
Sprague-Dawley rats exposed 
orally from gestation day 6 
through postnatal day 90 
Rats 2.5 – 300,000 µg/ kg 
bw/ d, gavage 
During gestation and 
up to PND 90 
2,700 and 10,0000 
µg/ kg bw/ d  
at PND 21  
(but not at PND 90) 
Ductal hyperplasia The departures from MDR in 
hyperplastic effects (large data variations 
for each dose level)) could also be 
interpreted as chance findings. 
 
This study does not have two adjacent 
doses in the low dose range showing a 
significant effect. 
 
Vandenberg LN, Schaeberle 
CM, Rubin BS, Sonnenschein 
C and Soto AM,  2013c. The 
male mammary gland: a 
target for the xenoestrogen 
bisphenol A. 
Male mice 0.25 
2.5 
25 
250 µg/ kg bw/ d, sc 
GD 9 until PND 16 
25 µg/ kg bw/ d 
and 
0.25 and 2.5 µg/ kg 
bw/ d (3-4 months), 
2.5 and 25 µg/ kg bw/ 
d (7-9 months) 
25 and 250 µg/ kg 
bw/ d (12-15 months) 
Proliferation (Ki67) 
and number of 
branching points and 
ductal area 
Proliferation at one dose only; no other 
supporting study (e.g. Markey, 2001).  
MDR for branching and ductal area at 
latest time point.  
 
Study reliability considered as low. 
 
The data do not provide sufficient 
evidence for NMDR. 
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2. Methodology applied for performing the risk assessment for BPA 
The overall methodology to perform hazard identification and characterisation and risk 
characterisation of BPA is summarised in this introduction and graphically presented in Figs. 1-2. 
More specific details are given in Appendix A. 
Graphical figures showing toxicological data were generated in the statistical computing environment 
R (R Core Team), 2014) in combination with R using the R lattice package (Sarkar et al., 2008). 
The methodology used for BPA exposure assessment is not described here. For such information the 
reader should refer to Part I- Exposure Assessment of this scientific Opinion. 
For hazard identification, studies were retrieved from different sources, as illustrated below, and 
selected for their relevance for this purpose (Appendix A).  
The sources of studies considered for hazard identification and characterisation were: 
Study sources 
Studies that EFSA (EFSA, 2006; EFSA CEF Panel, 2010) or other risk assessment bodies had previously 
identified as crucial for BPA toxicological assessment 
In vitro and in vivo studies on genotoxicity published after the 2006 EFSA opinion  
Studies that were present in the list of the retrieved articles for the preparation of the EFSA opinion of 2010 
(EFSA CEF Panel, 2010), but were not then evaluated because they did not match the inclusion criteria 
established at the time, e.g. non oral studies, exposure during adult age, single dose 
Studies retrieved via a literature search for the period August 2010-December 2012 
Studies included in the report of Réseau Environnement Santé (RES, 2012) on BPA-related risks 
Additional studies becoming available after December 2012 
Studies cited in the public consultation (ended on 13 March 2014) comments and original raw data submitted in 
this context (if relevant to the questions addressed by the opinion) 
 
The studies were then grouped according to macro-areas of interest, e.g. toxicokinetics and 
metabolism, general toxicity, reproductive and developmental effects, and relative study type, i.e. 
human, animal or in vitro study (see Table 1). 
Table 2:  Macro-areas by which the relevant studies for BPA hazard identification were 
grouped and consideration of the studies used for the toxicological evaluation 
Study content How the study was considered 
1. Toxicokinetics and metabolism (human and animal studies) 
2. General toxicity (animal studies) 
Appraisal of strengths and weaknesses (see 
Appendix B) 
3. Reproductive and developmental effects (human and animal 
studies) 
4. Neurological, neurodevelopmental and neuroendocrine 
effects (human and animal studies) 
5. Immune effects (human and animal studies) 
6. Cardiovascular effects (human and animal studies) 
7. Metabolic effects (human and animal studies) 
8. Genotoxicity (in vitro and in vivo studies) 
9. Carcinogenicity (human and animal studies) 
Appraisal of strengths and weaknesses (see 
Appendix B) and inclusion in the Weight of 
Evidence (WoE) approach used for hazard 
identification (see Appendices B and C) 
10. Mechanisms of action of BPA (including epigenetics and 
gene expression studies) 
11. In vitro studies 
Examination and use as supplementary 
information for the toxicological evaluation 
(see Appendix B and Section 3.10) 
 
Then hazard identification was performed as follows: 
1. The studies belonging to the above macro-areas were assigned for review (see description of 
individual studies in Appendix B) to two members of the working group on BPA Toxicology 
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(the rapporteur and co-rapporteur) and further discussed in working group meetings. This led 
to: 
a. Definition of all review questions addressing the association between BPA and the 
toxicological endpoints for macro-areas 2 to 9 listed in Table 1 and, for each review 
question, identification of one or several “lines of evidence” addressing different 
outcomes relevant to the question(s) and grouping of studies relevant to those 
question(s) by lines of evidence; 
b. Appraisal of individual studies against their strengths and weaknesses (see criteria for 
evaluating human and animal studies in Appendix A and the outcome of the study 
appraisal in Appendix B) and inclusion in the Weight of Evidence (WoE) approach 
(Appendix C) used for hazard identification (see below). In vitro and in vivo 
genotoxicity studies were reviewed according to the EFSA scientific opinion on 
genotoxicity testing strategy principles (EFSA Scientific Committee, 2011) and 
submitted to the WoE approach (see Section 3.8). Studies on toxicokinetics and 
metabolism, and general toxicity were appraised but not considered in the WoE 
approach: the conclusions from those studies are reported in sections 3.1 and 3.2, 
respectively. Studies on the mechanisms of action including epigenetics (Section 3.10) 
and all the in vitro studies belonging to the macro-areas defined above excluding those 
on genotoxicity) were examined and used as supplementary information for the 
toxicological evaluation. In vitro studies (not on genotoxicity) using high BPA 
concentrations (equal or above 100 nM, for the reasons explained in Appendix A) 
were excluded a priori from the evaluation. Also excluded were reproductive and 
developmental toxicity studies testing only BPA doses exceeding the (oral) HED of 
3.6 mg BPA/kg bw per day (equivalent to the NOAEL of 5 mg BPA/kg bw per day in 
the rat; see rationale in section 3.3.2.4 and Appendix A) or BPA in mixtures (see list 
of excluded studies in Appendix B).   
2. A WoE approach was used for hazard identification (see Appendix B  and Appendix C). The 
CEF Panel applied a WoE approach to identify the critical toxicological effects ("likely" or 
"very likely" effects) for BPA. In particular, the CEF Panel assessed the likelihood of the 
association between BPA exposure and each relevant toxicological endpoint, taking into 
consideration, for each endpoint, all the lines of evidence (studies in humans and/or 
experimental animals). The conclusions of earlier assessments of BPA by EFSA in 2006 
and/or 2010 were taken as the starting point for the new evaluation. The CEF Panel expressed 
its conclusions in terms of the likelihood that the answer to the question on the association 
between BPA exposure and each endpoint was positive (i.e. an effect of BPA on the endpoint 
could be identified), using the scale of likelihood categories shown in Figure 2 (from "Very 
unlikely" to "Very likely". Note that, on this scale, "As likely as not" means a level of 
likelihood between "Unlikely" and "Likely", where it is about equally likely that BPA causes, 
or does not cause, the effect. For more details, see section 3 of Appendix A. 
It is also important to emphasise that the likelihood assessed by the WoE approach refers specifically 
to hazard identification, i.e. it refers to the likelihood of an association between BPA and the effect 
under consideration. It does not refer to the likelihood or frequency of the effect actually occurring in 
humans, which depend on additional factors including the dose-response relationship for the effect 
(considered in hazard characterisation) and the levels of human exposure to BPA (considered in 
exposure assessment).  
The subsequent step, namely hazard characterisation (identification of a dose-response relationship 
for the effect), was carried out only for those endpoints for which the overall likelihood for the specific 
effect was considered as “likely” or “very likely” in the WoE approach. The studies supporting 
“likely” or “very likely” effects were individually weighed and the most reliable studies were used to 
study dose-response relationships and identify the critical reference point (NOAEL, lowest observed 
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adverse effect (LOAEL) or BMDLs, depending on the suitability of the dataset) for setting a health-
based guidance value.  
Risk characterisation was then performed as described in section 5. 
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Figure 1:  Overview of the steps followed for performing the risk assessment of BPA. 
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Figure 2:  Overview of the steps followed for performing hazard identification and characterisation of BPA.
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3. Hazard identification and characterisation 
3.1. Toxicokinetics and metabolism  
3.1.1. Summary of previous evaluations and introduction of the HED concept 
3.1.1.1. Summary of previous evaluations 
The toxicokinetics of BPA has been reviewed by several risk assessment bodies worldwide (EU-
RAR, 2003, 2008; EFSA 2006, 2008; EFSA CEF Panel, 2010; FAO/WHO, 2011; ANSES, 2011, 
2013). Concerning the routes of exposure, most information is available from studies with oral 
administration, whereas only limited information is available on dermal exposure and essentially none 
on inhalative exposure. 
After oral administration, BPA is rapidly absorbed from the gastrointestinal tract. The analysis of total 
(unconjugated and conjugated) BPA plasma concentration-time profiles after oral and intravenous 
(IV) administration in terms of the area under the curve (AUC) suggests a high degree of absorption 
(up to 85-86% in rats and monkeys) from the gastrointestinal (GI) tract. Similarily, human studies 
have suggested a complete absorption of a relatively low oral BPA dose, based on the urinary 
recovery of labelled BPA-glucuronide (EU-RAR, 2003, 2008).  
Following oral absorption, BPA is rapidly metabolised by polymorphic UDP-glucuronyltransferases 
(UGTs) in the gut wall and the liver (first-pass effect) to BPA-glucuronide, which is a biologically 
inactive form, before reaching the systemic circulation and excreted. In humans, similar to rodents, a 
sulphate conjugation mediated by sulfotransferases has additionally been observed (EFSA, 2008; EU-
RAR, 2003, 2008; ANSES, 2011, 2013; EFSA CEF Panel, 2010). In rodents, the BPA-conjugates are 
partly eliminated (the remaining being eliminated in the urine) via biliary secretion into the intestinal 
tract, where they are cleaved to release BPA which then undergoes enterohepatic recirculation. In rats, 
this enterohepatic circulation results in a slow excretion and prolonged low-level systemic availability 
of unconjugated BPA, which is supported by the observation of urinary excretion of unconjugated 
BPA as an appreciable fraction (1–4%) of the applied oral dose. Due to biliary secretion and 
enterohepatic recirculation, the predominant way of elimination of systemically available 
unconjugated and conjugated BPA in rodents is the fecal excretion of unconjugated BPA. In contrast, 






Bisphenol A-4 sulfate 
 
5-Hydroxybisphenol A 
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In humans there are indications that the metabolic capacity of the UGT forms 2B15 and 1A1 is not yet 
mature at birth (Allegaert et al., 2008; Gow et al., 2001; Miyagi and Collier, 2011; Zaya et al., 2006), 
whereas sulfation enzymes are known to be already expressed at the adult level at birth (Pacifici et al., 
1993; EFSA CEF Panel, 2010). 
Due to the high first-pass effect, peak blood levels of unconjugated BPA in humans after oral 
exposure to BPA are generally reported to be very low (unconjugated BPA is <0.5% of total serum 
BPA in humans and monkeys), even after worst-case dietary exposures (see also Section 4.6.3 in Part 
I – Exposure assessment). In two human studies (Völkel et al., 2002; 2005) unconjugated BPA was 
below the limit of detection in all urine (LOD of 6 nM) and blood samples (LOD of 10 nM) 
(equivalent to a ratio of unconjugated BPA to BPA-glucuronide of < 0.5 %). In humans, 75–85% of 
an oral dose was excreted in urine within five hours post dosing whereas in monkeys 82–85% of the 
dose was eliminated via the urine within 12 hours after oral administration. Thus, the observation of 
higher unconjugated BPA levels in urine of rats compared with non-human primates further supports 
the existence of species differences in blood levels of unconjugated BPA between rodents and 
primates, with higher AUCs for unconjugated BPA in rats (EFSA, 2006, 2008). A similar conclusion 
has been reached in the EU-RAR (2008).  
The BPA conjugates are considered to have no affinity for oestrogen receptors (EFSA, 2006; EFSA 
CEF Panel, 2010; ANSES, 2011, 2013). In addition to the conjugation pathways, in vivo and in vitro 
studies suggest that in the rat, BPA may be subject to oxidation to bisphenol O-quinone by 
cytochrome P450 and to 5-hydroxy-BPA (EU-RAR, 2003, 2008) to a small extent. EFSA (2006) 
reported oxidative BPA metabolites to also occur in mice.   
Previous assessments concluded that BPA is rapidly distributed in all tissues and has no clear affinity 
for one particular organ. Analysis of the fetal compartment shows that BPA is mainly present as its 
conjugates and that only a minor fraction is present in its unconjugated form (EFSA, 2006; ANSES, 
2011, 2013). In rats, fetal exposure to unconjugated BPA changes over the duration of pregnancy, 
based on the apparent development of Phase II metabolic capacity in the fetus: in early pregnancy the 
concentration of unconjugated BPA in fetal tissue is up to three times higher than in the dams, 
whereas later the concentration is about the same (EFSA CEF Panel, 2010). 
In neonatal rats orally administered 1 or 10 mg 14C-BPA/kg bw at postnatal days (PND) 4, 7, or 21, 
the serum levels of both total and unconjugated BPA were considerably higher in younger neonates 
compared to older neonates (Domoradzki et al., 2004). BPA was metabolised to BPA-glucuronide at 
all three ages, although an age dependency in the concentration of glucuronidated BPA was observed, 
consistent with the ontogeny of UGTs (Domoradzki et al., 2004). Differences in the plasma 
concentration-time profiles of unconjugated and glucuronidated BPA between neonatal and adult rats 
additionally suggested a decreased biliary excretion and/or enterohepatic recirculation in neonatal 
rats, which is consistent with a developmental immaturity of hepatic excretory function. Overall, these 
findings indicate a reduced metabolic capacity in early neonatal life, which is however sufficient to 
efficiently metabolise BPA to non-oestrogenic conjugates in rats (EFSA, 2006; EU-RAR, 2003, 
2008). The age-related changes described above after oral administration were not observed after 
subcutaneous (SC) injection, indicating that even in early postnatal pups, which possess lower 
conjugation activity/capacity, the first-pass effect is relevant (EFSA CEF Panel, 2010; FAO/WHO, 
2011). 
Data from an experimental study in rats suggest limited excretion of BPA in the milk. However, the 
data do not allow a reliable quantitative determination to be made (EFSA, 2006; EU-RAR, 2003, 
2008). The CEF Panel estimated that in rats the exposure to total BPA (the major constituent being 
the glucuronide) through lactation is very low. For dams receiving 410 mg/kg bw per day, the 
estimated dose delivered to pups lactationally was approximately 350 µg/kg bw per day (EFSA CEF 
Panel, 2010). This is 1 171-fold lower than the dose administered to the dams (EFSA CEF Panel, 
2010).  
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In monkeys, similar to the rat, the systemic availability of unconjugated BPA is very low after oral 
administration. In adult monkeys, the contribution of unconjugated BPA to the total plasma BPA level 
was higher following intravenous (IV) administration than after oral administration of the same dose 
(Doerge et al., 2010b). Following the same oral dose of BPA (100 µg/kg bw) to adult rats and 
monkeys, unconjugated BPA plasma concentrations in both species were below 1 nM. The only 
notable difference was the longer elimination half-life in rats versus monkeys (3.5 hours versus 0.39 
hours), due to the enterohepatic recirculation in the rat. Comparing newborn animals, PND 3 rats have 
longer elimination half-life and approximately 10 times higher plasma levels of unconjugated BPA 
than PND 5 monkeys, when treated with the same oral BPA dose. These data provide evidence for a 
different developmental profile of hepatic and intestinal conjugation of BPA in rats and monkeys, 
consistent with literature data describing a higher degree of metabolic immaturity of rats at birth as 
compared to primates (Doerge et al., 2010a,b; Doerge et al., 2011b; EFSA CEF Panel, 2010; 
FAO/WHO, 2011). 
Concerning dermal absorption of BPA, the EU-RAR (2008) mentioned an in vitro dermal absorption 
study using human skin that found limited absorption of BPA at millimolar concentrations with the 
extent of absorption being in the region of 10% of the applied dose. Dermal absorption of BPA is 
discussed further in section 3.1.7.. 
3.1.1.2. Introduction of the human equivalent dose (HED) concept 
An understanding of the toxicokinetics and metabolism of BPA is of major importance for its risk 
assessment as it enables quantification of the toxicokinetic relationships between the critical 
exposures in animal experiments and the corresponding (equivalent) exposures in humans. 
Information on how these relationships are modified by factors such as age, gender and pregnancy is 
also essential. Approaches to performing this animal-to-human extrapolation include, among others, 
the internal dose concept recently used by ANSES (2013) and the human equivalent dose (HED) 
concept recommended by the US EPA (2011). 
By making assumptions about route-dependent bioavailability factors, the ANSES approach translates 
external exposures via different routes and sources into internal doses which are then combined to 
give an estimate of the total internal exposure in humans. This internal dose estimate is finally 
compared to internal toxicological benchmarks which are derived from animal experiments and 
adjusted for bioavailability and uncertainties. The US EPA (US EPA, 2011) endorses a hierarchy of 
approaches to derive oral HEDs from data from laboratory animals via factors accounting for the 
toxicokinetic portion of the interspecies differences. This hierarchical framework comprises (i) 
physiologically-based pharmaco-toxicokinetic (PBPK) modelling as the optimal approach, (ii) the use 
of chemical-specific information (e.g. use of internal dosimetrics such as the maximum serum 
concentration, Cmax, or the area under the curve, AUC) as an intermediate approach when the available 
data do not permit PBPK modelling, and (iii) allometric scaling of dose with body weight as the 
default lower-tier approach (see Section 3.1.5 for further details). 
The CEF Panel noted that new data have recently become available from toxicokinetic studies in 
various laboratory animal species (Doerge et al., 2010a,b; Doerge et al., 2011a,b; Doerge et al., 2012). 
These studies provide internal dose metrics for neonatal-to-adult stages and for different routes of 
exposure. Moreover, physiologically-based pharmaco-toxicokinetic (PBPK) models have been 
developed to simulate and predict the internal exposures in laboratory animals and humans in a route-
specific manner. Specifically, a PBPK model has been developed to enable estimation of internal dose 
metrics for the aggregated oral and dermal exposure in humans (Mielke et al., 2011). Overall, this 
body of information permits extrapolation to humans based on the application of human equivalent 
dose factors (HEDFs). The CEF Panel therefore decided to apply the HED concept and to provide 
HEDs for reference points derived from critical animal data. 
The following sections describe the new body of evidence and the PBPK modelling that lead to the 
determination of HEDFs. 
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3.1.2. New information on toxicokinetics (animal and human studies) 
Since the last EFSA evaluation, a consistent body of toxicokinetic information has become available 
for mice, rats and rhesus monkeys at different developmental stages ranging from neonatal to adult 
stages; the routes of administration comprised oral dosing (gavage) as well as intravenous (IV) or 
subcutaneous (SC) injections. The main contribution came from Doerge's group (Doerge et al., 
2010a,b; Doerge et al., 2011a,b; Doerge et al., 2012), who used a consistent methodology with 
identical experimental protocols in all species studied. This methodology included (i) the 
administration of stable isotope-labelled (deuterated) BPA to avoid issues related to contamination of 
samples with BPA from laboratory materials and other sources, (ii) the application of a dose of 100 
µg/kg bw which enables the quantification of unconjugated and conjugated BPA forms in serum  and 
(iii) the use of a specific and sensitive analytical method based on LC/MS/MS, having a method 
detection limit of 0.2 nM (= 45.6 ng/l). The chosen dose of 100 µg/kg bw was demonstrated to enable 
linear pharmacokinetics. The methodology additionally included a consistent toxicokinetic analysis of 
serum concentration-time profiles to estimate the maximum serum concentration, Cmax (mean value 
+s.d.), the area under the curve (AUC) from time zero to infinity, and the elimination half-life (t1/2). In 
the present opinion, the AUC for unconjugated BPA in serum was chosen to derive HEDFs for the 
animal-to-human extrapolation. 
The main body of evidence is summarised in the following sections, starting with animal data on 
adults and neonates and then continuing with human data. This is then followed by in vitro data. A 
detailed description and evaluation of each study are provided separately in Appendix B. 
3.1.2.1. Data in adult animals 
The group of Doerge published several studies in adult CD-1 mice (Doerge et al., 2011b; Doerge et 
al., 2012), SD rats (Doerge et al., 2010a), and rhesus monkeys (Doerge et al., 2010b), using either oral 
administration or IV injection of 100 µg/kg bw d6-BPA (Figure 3). To provide a measure of 
variability, the data on Cmax and AUC given below are expressed as mean ± standard deviation if 
available. 
Following the oral administration of BPA by gavage to mice of both sexes (n = 12) serum 
concentrations of unconjugated BPA were below the LOD (0.2 nM) in the majority of samples at all 
time points (Doerge et al., 2011b). Levels of unconjugated BPA that were above the LOD were 
observed only at the earliest three time points (at 0.25, 0.5 and 1.0 hours after dosing), and only in 
one, two or three samples out of the twelve determinations at each time. By choosing a lower-bound 
approach (i.e. setting all non-detectable observations to zero) and calculating the mean and the 
standard deviation from the few detectable observations and the remaining set-to-zero non-detects, a 
Cmax of 0.18±0.31 nM and an AUC of 0.10 nM×h was obtained (Figure 3A, Doerge et al., 2011b). The 
CEF Panel noted the large standard deviation around the calculated Cmax, which results from setting 
the non-detects to zero. The CEF Panel further noted that, due to the way by which the non-detects 
were handled, the AUC value of 0.10 nM×h needs to be regarded as a lower-bound estimate of the 
true AUC for adult mice with oral administration. Based on additional information and considerations, 
which are detailed in Section 3.1.6.1, the CEF Panel recalculated the AUC to be 0.244 nM×h. 
Under the same dosing conditions as above, female rats (n = 5) showed low but detectable serum 
levels of unconjugated BPA with a Cmax of 0.39±0.19 nM and an AUC of 2.6±2.1 nM×h (Figure 3B, 
Doerge et al., 2010a); the levels of unconjugated and total BPA changed only slightly during the time 
interval from 0.5 to 8 h and elimination occurred mainly between 8 and 24 h, both reflecting the effect 
of enterohepatic recirculation (Doerge et al., 2010a). In female rhesus monkeys (n = 4), the serum 
levels of unconjugated BPA were only detectable within the first 90 min after oral dosing; the Cmax 
was 0.84±0.46 nM and the AUC was 1.5±1.1 nM×h (Figure 3C, Doerge et al., 2010b); the rapid 
decrease in levels of unconjugated BPA was reflected by the short elimination t1/2 of 0.39±0.24 h 
which contrasted with the delayed decrease and the longer elimination t1/2 of 3.0±3.7 h in rats. 
Overall, the internal dose metrics (Cmax, AUC) for unconjugated and total serum BPA revealed a very 
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low proportion of unconjugated BPA in the total BPA serum concentration (<1%) which indicates the 
presence of extensive first-pass metabolism in adult mice, rats, and rhesus monkeys. 
The IV injection in female mice (n = 6) resulted in an initial rapid distribution of unconjugated BPA 
into tissues, followed by a rapid terminal elimination phase with an elimination t1/2 of 0.8 h (Figure 
3D, Doerge et al., 2012). An oral bioavailability of 0.45 % for unconjugated BPA could be derived 
based on the ratio of the oral AUC (= 0.244 nM×h, recalculated value, see Section 3.1.6.1) to that of 
54 nM×h for IV injection. Enterohepatic recirculation was suggested by the presence of an apparent 
"re-entry peak" at 2 h for total, but not for unconjugated BPA (Figure 3D, Doerge et al., 2012). After 
IV injection in female rats (n = 7) a rapid elimination of unconjugated BPA from the serum was 
observed with an elimination t1/2 of 0.66±0.04 h (Figure 3E, Doerge et al., 2010a); in contrast to mice, 
the serum concentration-time data for unconjugated BPA did not indicate a separate distribution 
phase. There was evidence for enterohepatic recirculation being responsible for the extended time 
course of total BPA concentration. In rats, a systemic oral bioavailability of 2.8±3.1 % for 
unconjugated BPA could be derived based on the ratio of the oral AUC (= 2.6 nM×h) to that of 
95±8.8 nM×h for IV injection. In female rhesus monkeys (n = 4), the IV dosing led to a rapid 
distribution of unconjugated BPA from the serum, followed by a slower terminal elimination phase 
(t1/2 = 3.6±1.3 h). A systemic oral bioavailability of 0.94±0.54 % for unconjugated BPA was obtained 
by dividing the oral AUC (= 1.5 nM×h) by the AUC of 180±76 nM×h for IV injection. Overall, the 
experiments with oral and IV administration revealed an oral bioavailability for unconjugated BPA 
ranging from 0.45 % in mice, 0.9% in monkeys to 2.8 % in rats. 
 
Figure 3:  Time course of serum levels of unconjugated and total BPA in adult mice, rats, and 
rhesus monkeys following oral administration or IV injection of a single dose of 
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100 µg/kg bw per day of isotope-labelled (deuterated) BPA. Each symbol represents the mean 
concentration of unconjugated BPA (open circles) and total BPA (filled circles) at a given 
time point. Horizontal arrows indicate the serum concentrations after 24 h. The LOD was 0.2 
nM in all experiments. Additionally given are the pharmacokinetic parameters for 
unconjugated (U) and total (T) BPA, comprising the maximum serum concentration Cmax 
(nM), the area under the curve AUC (nM×h) from time zero to infinity, and the elimination 
half-life t1/2 (h). The data shown were taken from Doerge et al (2011b), Doerge et al (2010a), 
Doerge et al (2010b) and Doerge et al (2012).  
Additional toxicokinetic information on the tissue/serum concentration ratios for unconjugated and 
conjugated BPA and on placental transfer of both BPA forms in rodents and monkeys, available from 
the studies of Doerge et al., are briefly summarised below, together with information from studies by 
other groups. 
In the above mentioned study in adult female CD-1 mice with IV injection, Doerge et al. (2012) 
additionally measured the concentration of unconjugated BPA in adipose tissue and reported a fat-to-
plasma AUC ratio of about 2.2. The levels of unconjugated BPA in adipose tissue rapidly reached a 
maximal level (0.25 h) that did not exceed the plasma Cmax at the initial sampling time (0.08 h). The 
terminal elimination t1/2 of 7.0 h for unconjugated BPA in adipose tissue was similar to that for 
conjugated BPA in serum (t1/2 = 6.6 h), and <0.01% of the administered dose remained in adipose 
tissue after 24 h.  
A study in pregnant rats (after dosing with 100 µg/kg bw deuterated BPA) (Doerge et al., 2011a) 
showed no kinetic differences to non-pregnant rats. After oral administration, unconjugated BPA was 
not detected in the fetal tissue, and the maternal serum levels were close to the LOD (= 0.2 nM). This 
study also showed that BPA crosses the placental barrier, since the BPA conjugates were measurable 
in the fetal tissue of every age. However, no selective affinity of either yolk sac/placenta or 
embryo/fetus for unconjugated and conjugated BPA relative to maternal plasma or tissues was 
observed. After IV injection, in contrast, the concentration of unconjugated BPA at gestational day 
(GD) 12 in the fetal tissue was threefold higher than in the maternal serum, at GD 16 equal to the 
maternal serum, and at GD 20 half the concentration in the maternal serum. The fetal brain at GD 20 
had a 4-fold higher concentration of unconjugated BPA compared to the maternal serum and an 11-
fold higher concentration compared to the fetal serum. At GD 21 after IV administration the amniotic 
fluid contained both unconjugated and unconjugated BPA; the concentrations were 0.35-fold and 0.2-
fold, respectively, of the maternal serum concentrations. The ratios of the amniotic fluid/fetal serum 
concentration at GD 21 were 0.8 for unconjugated BPA and 0.05 for BPA-conjugates (Doerge et al., 
2011a).  
The above mentioned study with pregnant rats additionally measured the distribution of unconjugated 
and conjugated BPA into different tissues in adult female rats after IV injection (Doerge et al., 2011a). 
The tissue/serum concentration ratios for unconjugated BPA were 5 for adipose tissue, 4 for 
mammary gland, 2.8 for brain, 2.7 for muscle, 2.6 for ovary, 1.5 for uterus and 0.73 for liver. For 
conjugated BPA, tissue/serum concentration ratios were below 0.1 for all tissues except the ovary 
(0.2), the uterus (0.3) and the liver (5.4). 
Nishikawa et al. (2010) studied the transfer of glucuronidated BPA across the placenta by uterine 
perfusion in pregnant SD rats (GD 18.5). The uterus was perfused with a solution containing 2 µM 
glucuronidated BPA for 20 min, followed by a 70-min perfusion without glucuronidated BPA, after 
which the perfusate as well as the fetus, amnion, amniotic fluid, placenta, and uterus were collected. 
HPLC and LC/TOF-MS were used for the determination of glucuronidated and unconjugated BPA. 
Almost all of the glucuronidated BPA (113 nmol) was detected in the perfusate leaving the uterine 
vein. Glucuronidated BPA was also detected in the fetus in a small amount (109 pmol, ~0.09% of the 
total amount) but not in the amnion, amniotic fluid, placenta, and uterus. Moreover, unconjugated 
BPA was detected to a small amount in the amniotic fluid (31 pmol) and in the fetus (6 pmol). The 
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findings are in line with results of a toxicokinetic study in pregnant rats (Doerge et al., 2011a) (see 
above). 
In the study of Mita et al. (2012), pregnant adult Balb-C mice were exposed daily to two different 
doses of BPA by subcutaneous injection (100 and 1000 µg/kg bw per day) beginning on GD 1 
through the seventh day after delivery. The dams were sacrificed on day 21 (14 days after the last 
dose) and the offspring at 3 months after delivery. Liver, muscles, hindbrain and forebrain were 
dissected and processed using HPLC with UV and fluorescence detection to measure BPA. The 
authors reported measurable unconjugated BPA levels in the tissues of all animals exposed to BPA. 
The results are, however, questionable due to the analytical limitations known for UV and 
fluorescence detection (the author did not give results for the analytical quality) and implausible since 
>99.9% of BPA is eliminated from mice within 24 h, even in adipose tissue (Doerge et al., 2012).   
In lactating Sprague–Dawley dams, treated by daily gavage with 100 µg/kg bw d6-BPA starting at the 
day of delivery, unconjugated BPA and total BPA was detected in all dam serum (0.55 nM and 126 
nM respectively) and milk (0.87 nM and 7.6 nM respectively) samples (Doerge et al., 2010c). In pup 
serum the concentrations of unconjugated BPA were below the level of detection (<0.2 nM). The dose 
of total BPA delivered to pups lactationally, estimated from milk concentrations and body weights, 
was 0.32±0.12 µg/kg bw per day. This is 300-fold lower than the dose administered to the dams. 
Similarly, serum concentrations of total BPA in pups were at least 300-fold lower than those in their 
dams (Doerge et al., 2010c). 
Taylor et al. (2011) measured unconjugated and conjugated BPA levels in serum from adult female 
rhesus monkeys (n = 11) using isotope-dilution LC-MS (LOQ: 0.2 ng/ml) after oral administration of 
deuterated d6-BPA. The rhesus monkeys received 400 µg/kg bw of d6-BPA (in fruits) per day for 7 
days; the Cmax of unconjugated BPA of 4 ng/ml (= 17.5 nM) was reached 1 hr after feeding and 
declined to low levels by 24 hr (see Figure 9 in Part I – Exposure assessment) with no significant 
bioaccumulation after seven daily doses. In a second experiment with adult female CD-1 mice (n = 5–
7 per blood-sampling time point), the authors used (i) LC with 3H-scintillation counting for a 400 
µg/kg bw dose of 3H-BPA and (ii) LC with electrochemical detection for a 100,000 µg/kg bw dose of 
BPA. The sensitivity of the 3H-scintillation-counting assay was 0.28 ng/ml, which was calculated as 
two-fold above the background counts per minute. The LOD of the LC-ED assay was 9 ng/ml. The 
doses were dissolved in corn oil and were administered into the animal's mouth via a micropipetter 
(oral bolus dosing). The serum-concentration time profiles for unconjugated BPA were subjected to a 
toxicokinetic analysis. The experiment with 400 µg/kg bw dosing yielded a Cmax of 3.28 ng/ml, an 
AUC of 38.72 ng×h/ml, and a terminal elimination half-life (t1/2) of 33.6 h. The experiment with 
100,000 µg/kg bw dosing showed a Cmax of 949 ng/ml, an AUC of 2991 ng×h/ml, and a t1/2 of 4.9 h. 
The Cmax values indicated linear kinetics over the dose range of 100 to 100,000 µg/kg bw per day. 
To compare the toxicokinetic results of Taylor et al. (2011) for adult mice with oral bolus dosing of 
3H-BPA and BPA in corn oil with the results of Doerge et al. (2011b) for adult mice with gavage 
dosing of d6-BPA in aqueous solution (see Figure 4D–F), the doses administered were scaled to the 
common dose of 100 µg/kg bw by multiplying the serum concentrations and the concentration-related 
pharmacokinetic parameters by a factor of 0.25 (= 100/400) and 0.001 (= 100/100.000), respectively. 
In addition, the serum concentrations and the concentration-related pharmacokinetic parameters were 
converted into molar concentration-based values. Compared to the results of Doerge et al. (2011b), 
the dose-adjusted pharmacokinetic parameters of the experiment of Taylor et al. (2011) with 
400 µg/kg bw dosing showed a 20-fold higher Cmax (3.6 vs. 0.18 nM), a 4200-fold higher AUC (42 vs. 
0.1 nM×h), and a 57-fold longer terminal half-life t1/2. The CEF Panel noted that the use of a corn-oil 
dosing vehicle, which is known to influence the kinetics and extent of absorption of chemicals versus 
aqueous dosing solutions (Gallo et al., 1993), and which very likely prolonged the time to reach Cmax 
(Figure 4E), cannot alone explain these large-scale differences. The fact that the Cmax and AUC of 
Doerge et al. (2011b) are lower-bound estimates contributes to the discrepancy but only to a minor 
extent. The pharmacokinetic analysis of Taylor et al. (2011) showed that the AUC (i.e. the AUC0–∞) 
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was 2.3-fold higher than the AUC0–24h, which suggests an analytical problem with the last data point at 
24 h leading to unreliable estimates for t1/2 and AUC (Figure 4E). Also, the use of the corn-oil vehicle 
makes it difficult to deconvolute the kinetics of absorption, distribution, and elimination processes. By 
additionally taking the results on Cmax of the toxicokinetic study of Sieli et al. (2011) in mice (see 
below) into account, the CEF Panel assigned a low reliability to the pharmacokinetic parameters of 
Taylor et al. (2011). 
Sieli et al. (2011) measured unconjugated and conjugated BPA levels in serum from adult female 
C57Bl/6J mice (n = 8 per blood-sampling time point) using isotope-dilution HPLC-MS/MS (LOD: 
0.1 ng/ml) after oral administration of deuterated d6-BPA. Two different oral administrations were 
used. The first group of animals received a dose of 20,000 µg/kg bw per day which was dissolved in 
corn oil and administered into the animal's mouth via a micropipetter (oral bolus dosing). The second 
group was exposed to a dose of ~13,000 µg/kg bw via the diet containing 100 mg d6-BPA/kg feed. In 
the experiment with oral bolus dosing, the Cmax for unconjugated BPA in serum of 21.0 ng/ml was 
observed at the first sampling time at 1 h after dosing. The AUC (i.e. the AUC0–∞) was 210 ng×h/ml, 
and the terminal elimination half-life (t1/2) was 6.4 h. Scaling the administered dose to the common 
dose of 100 µg/kg bw yielded a dose-adjusted Cmax of 0.45 nM (Figure 4G) which was in the range of 
Cmax values of 0.1–1.1 nM for adult and PND21 mice with orogastric administration (Doerge et al., 
2011b) but considerably lower than the dose-adjusted Cmax value of 3.6 nM in the study of Taylor et 
al. (2011). The differences in Cmax between Sieli et al. (2011) and Doerge et al. (2011b) can at least 
partly be explained by the different vehicles (corn oil vs. aqueous solution) and the type of 
administration (oral bolus dosing vs. gavage). These methodical differences also very likely explain 
the apparently higher t1/2 of 6.4 h in Sieli et al. (2011) compared to the lower t1/2 values of 0.2–0.6 h in 
PND21 and adult mice of the study of Doerge et al. (2011b). In the experiment with diet-exposed 
mice, the shape of the serum concentration-time profile for conjugated and unconjugated BPA 
changed in a significant manner as reflected by the delayed time to Cmax of 6 h (Figure 4H). The CEF 
Panel noted that, despite of the change of the serum concentration-time profile due to the diet-related 
exposure to BPA, delaying gastrointestinal absorption processes, the pharmacokinetic parameters Cmax 
and AUC were comparable to those observed in the oral-bolus dosing experiment (Figure 4G/H). 
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Figure 4:  Time course of serum levels of unconjugated and total BPA in newborn (PND3), 
juvenile (PND10, PND21) and adult mice following oral administration. BPA was 
administered by orogastric gavage, oral bolus, or via diet. All serum concentration profiles 
and the pharmacokinetic parameters for the maximum serum concentration Cmax (nM) and the 
area under the curve AUC (nM×h) from time zero to infinity were scaled to a common dose 
of 100 µg/kg bw per day. Additionally given is the elimination half-life t½ (h). Note the effect 
of the administration procedure and the BPA vehicle (aqueous solution, corn oil, food). The 
data shown were taken from Doerge et al (2011b), Taylor et al (2011) and Sieli et al (2011). 
In a study by Tharp et al. (2012) in pregnant rhesus monkeys, an oral dose of 400 µg/kg bw per day of 
deuterated BPA (in fruits) was administered daily during gestational days 100–165. Maternal serum 
samples were taken near the time of spontaneous birth, ≈4 h after oral dosing. The serum samples 
were analyzed for conjugated and unconjugated BPA (LOD: 0.2 ng/ml) as described in Taylor et al. 
(2011). The observed serum concentrations of 0.68 ± 0.312 ng/ml (mean ± SEM, n=3 animals) for 
unconjugated BPA at 4 hours after ingestion agreed with the serum unconjugated BPA concentration 
of 0.6 ng/ml which was measured by Taylor et al. (2011) in adult female rhesus monkeys at 4 hours 
after oral administration of 400 μg/kg bw.  
In the study of Patterson et al. (2013) 100 µg/kg deuterated BPA was given daily to monkeys by the 
intravenous or the oral route to two groups of dams during late pregnancy (days 121–139 of 
gestation). The animals were pre-medicated with glycopyrrolate, buprenorphine or fentanyl prior to 
induction of anesthesia, then sedated with ketamine for intubation, and finally anesthetized with a gas 
mixture of isoflurane and oxygen during the experiment. Concentrations of unconjugated and 
conjugated BPA were measured at 0 min (predose) and after approximately 5, 15, 30, 60, 120, 180, 
240, 480 and 1440 min in the plasma of rhesus monkey dams. Concentrations were similarly 
measured in the plasma of the fetus at 0 min (predose) and approximately 5, 15, 30, 60, 120, 180, 240, 
and 480 min. Furthermore, concentrations of unconjugated and conjugated BPA was also determined 
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in the amniotic fluid and in the placenta. The authors used a validated LC/MS/MS methods for their 
measurements. The kinetics in the dams after the intravenous administration were similar to findings 
in non-pregnant monkeys from a previous study (Doerge et al. 2010b). Plasma concentrations of 
unconjugated BPA were several fold lower in the fetuses than in the dams, and internal exposure as 
measured by AUC was 0.43-fold of the exposure in dams given BPA by the intravenous route. 
Concentrations of unconjugated BPA in the dams were approximately 45.600 ng/ml 5 minutes after 
IV dosing and declined to below 0.0228 ng/ml 24 hours thereafter.  
In this study fetal blood samples were collected from the fetal femoral vein or umbilical cord artery or 
vein at 0 min (predose) and approximately 5, 15, 30, 60, 120, 180, 240 and 480 min following 
maternal IV administration of BPA to the dams. After the 480-min post-dose blood collection, the 
fetuses were extracted from the uterus and euthanized via a pentobarbital overdose. The concentration 
of 0.0228 ng/ml unconjugated BPA in fetal plasma was reached already 8 hours after dosing. In the 
amniotic fluid, concentrations of unconjugated BPA were detectable (less than 0.0228 ng/ml) but 10 
to 100-fold lower than the conjugated BPA. The concentrations of both conjugated and unconjugated 
BPA were two orders of magnitude lower in the amniotic fluid compared to the fetal plasma. In the 
placenta, unconjugated BPA concentration was 2.7 fold higher than in the serum of the dams and the 
tissue-to-serum ratio for conjugated BPA was 4.5. The data show that the fetus is exposed to 
unconjugated BPA, but to a lower extent than the dams. In the fetus, the ratio of the concentrations of 
conjugated to unconjugated BPA in serum was approximately 10 in the first half hour and increased 
with time to a ratio of 300. This is due to the fact that the unconjugated BPA concentration declined 
with a half life of roughly 5 hours whereas the concentrations of conjugated BPA remained constant 
within the observation period, indicating fetal metabolism. Levels of unconjugated BPA in brain were 
analysed in three fetuses, but only one of three brains contained a measurable level of 1.3 pmol/g 
above the LOD of 0.4 pmol/g (0.1 ng/g).  
In the study of vom Saal et al. (2014), isotope-labelled BPA (d6-BPA) and its conjugated metabolites 
were measured in serum in non-pregnant and pregnant female rhesus monkeys, their fetuses and 
amniotic fluid by a reliable isotope-dilution LC/MS analysis. d6-BPA was administered daily by a 
single oral dose injected into a piece of fruit (400 µg/kg bw per day) or by continuous administration 
by SC implantation of silastic capsules. A concentration time profile was obtained in the animals 
orally exposed whereas only one concentration was measured every other day for 12 days in the 
animals with continuous administration. Concentration time profiles and single concentrations were 
measured at different time points in pregnancy. The average serum unconjugated d6-BPA 
concentrations were below 1 ng/ml. Using the AUC of the IV route reported previously in rhesus 
monkeys (Doerge et al., 2010b) for an IV BPA dose of 100 µg/kg bw, the authors estimated the 
absolute bioavailability of d6-BPA by the oral route to be about 7.3% in the non-pregnant animals and 
about 5% for pregnant animals at GD 50. At GD 100, when pregnancy was terminated by 
hysterotomy in a subgroup, the observed serum concentrations of unconjugated dBPA in pregnant 
females were lower relative to pre-pregnancy values. Lower concentrations in fetal serum were 
measured than in maternal serum, 1 hour after oral administration, and levels in fetal serum were 
below LOQ (0.2 ng/ml) at 3 hours after oral administration. No parent BPA was detected in the 
amniotic fluid whereas conjugated BPA was present although in much lower concentration than in the 
fetus. In the maternal deciduas and in the fetal placenta d6-BPA was measured 1 hour after oral 
administration, and levels of parent compound were below LOQ (0.2 ng/ml) in tissues from one 
animal and at a similar concentration in the tissues form the second animal at 3 hours after oral 
administration. The ratio of conjugated BPA-AUC/unconjugated BPA-AUC in serum was several 
fold higher after oral administration (between 35 and 62) than the ratio for the continuous SC 
administration (between 1 and 4). This is in line with high first-pass metabolism. The observed 
differences in pharmacokinetics of d6-BPA, that were evident between pre-pregnancy, early and late 
pregnancy, reflect changes in maternal physiology during pregnancy with a lower absorption rate and 
higher renal clearance.  
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The CEF Panel considered the study of vom Saal et al. (2014) a well performed study that adds to the 
toxicokinetic knowledge on BPA. It demonstrates that BPA concentration in fetus is low (lower than 
the maternal concentration) and is not retained in the fetal tissue as well as in placenta. Furthermore, 
there is only a very low concentration of unchanged BPA in the amniotic fluid which renders study 
results in humans doubtful which has measured high concentrations of unchanged BPA in amniotic 
fluid. It confirms that the fetus is able to conjugate BPA (GD 50 and older) and excrete the conjugate 
into the amniotic fluid. The oral administration was by way of a fruit which was hoarded in the cheek. 
This would explain the higher bioavailability in this study (7.3% in non-pregnant and 5% in pregnant 
animals) compared to the findings of the Doerge et al. (2010b) (0.94%) as by hoarding the contact 
time of a high-concentration BPA point source with the buccal mucosa is prolonged and for the 
absorbed amount first pass is circumvented. 
Gayrard et al. (2013a) performed a toxicokinetic study with sublingual exposure in dogs. They 
reported that application of concentrated solutions of BPA (50 mg/ml in 40–100% ethanol for a 5 
mg/kg bw dose, and 0.5 mg/ml in 1% ethanol in water for a 0.05 mg/kg bw dose) under the tongues of 
anaesthesized Beagle dogs led to concentrations of unconjugated and conjugated BPA in the venous 
blood draining the oral cavity (i.e. jugular vein) similar to those produced by intravenous injection of 
identical doses. The bioavailability values were reported by the authors to be similar for intravenous 
and sublingual administration. The CEF Panel noted however that the choice of jugular blood 
sampling after sublingual administration compromised an accurate evaluation of systemic exposure 
because AUC determination assumes complete mixing of the administered chemical in the blood 
compartment. The authors noted that when blood was sampled from the cephalic vein in the leg, a site 
better reflecting systemic exposure, blood concentrations of unconjugated BPA were lower and less 
variable than those from jugular sampling. Similar to BPA toxicokinetic investigations involving 
bolus gavage in animals (e.g., Doerge et al., 2010ab) or gelatin capsule administration in humans 
(Völkel et al., 2002), Gayrard et al. (2013a) also reported that the absolute bioavailability for 
unconjugated BPA in blood was below 1% after orogastric dosing in dogs. The authors also 
concluded that “Currently, the results of Teeguarden et al. (2011) do not support sublingual 
absorption as a major contributor of dietary BPA to a much higher than expected human internal 
exposure”. 
In response to a commentary by Teeguarden et al. (2013) addressing the possible implications for 
human exposure of the toxicokinetic study in dogs with sublingual BPA administration, Gayrard et al. 
(2013b) clarified that they did not report that “nanograms-per-milliliter serum concentrations of BPA 
resulting from sublingual absorption are plausible in humans.” To further substantiate their statement, 
Gayrard et al. (2013b) applied the elementary pharmakokinetic (PK) computation of Teeguarden et al. 
(2013) to the subpopulation of children 6–11 years of age. By using the 95th percentile of the 
aggregate daily BPA exposure of 0.481 µg/kg bw per day from the 2005–2006 NHANES database for 
the US population (Lakind and Naiman, 2011), and taking into account their own data from dogs on 
the maximum systemic plasma concentration (Cmax) of 64 ng/ml following bolus IV administration of 
50 µg/kg bw, their scaling-by-dose approach yielded a maximum initial plasma concentration of 
0.6 ng/ml. The CEF Panel noted that if the elementary PK computation had been based on the 
maximum mixed-systemic plasma concentration (Cmax) of 20 ng/ml (blood sampling from the 
cephalic vein in the leg) following sublingual administration of 50 µg/kg bw, the scaling approach 
would have yielded a maximum plasma concentration of only 0.2 ng/ml. That the average BPA 
concentration in food of <0.1 mg/kg food (see Section 4.3.2 in Part I - Exposure assessment) is more 
than 3 magnitudes lower than the concentration of 500 mg/L of the sublingually applied solution is a 
further argument against nanograms-per-milliliter serum concentrations in the human population. 
Finally, the CEF Panel further noted that it is hard to imagine a common, chronic exposure scenario in 
which BPA, which is normally and mainly taken up via food, is administered separate from the food 
in concentrated solution to the oral cavity to enable substantial sublingual absorption. 
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3.1.2.2. Data in newborn and immature animals 
The group of Doerge published several studies in neonatal CD-1 mice (Doerge et al., 2011b), SD rats 
(Doerge et al., 2010a), and rhesus monkeys (Doerge et al., 2010b) using an oral administration, IV 
injection, or SC injection of 100 µg/kg bw d6-BPA (Figure 5). 
The oral administration by gavage in mice of postnatal day (PND) 3 (n = 12) resulted in detectable 
serum concentrations for unconjugated BPA with a Cmax of 34±25 nM and an AUC of 26 nM×h 
(Figure 5A, Doerge et al. 2011b). These concentrations were many fold higher than those in adult 
mice, in which the unconjugated BPA levels were essentially below the limit of detection (= 0.2 nM). 
With increasing developmental age from PND 3 to PND 21, the unconjugated BPA levels declined 
progressively to approach adult levels. Under the same dosing conditions, rats of PND 3 (n = 4) had 
serum concentrations for unconjugated BPA with a Cmax of 29±16 nM and an AUC of 56 nM×h 
(Figure 5B, Doerge et al., 2010a) which were several fold higher compared to adult rats. Cmax, AUC 
and the elimination t1/2 decreased with increasing postnatal age to approach adult levels at PND 21, 
again indicating the age-dependent maturation of the metabolic capacity. In rhesus monkeys of PND 5 
(n = 6), the serum levels of unconjugated BPA were within an order of magnitude of the LOD; the 
Cmax of 2.0±2.4 nM and the AUC of 5.7±4.8 nM×h (Figure 5C, Doerge et al., 2010b) were similar to 
those determined for adult monkeys. Overall, the internal dosimetrics (Cmax, AUC) for unconjugated 
and total serum BPA revealed noticeable species-dependent proportions of unconjugated BPA in the 
total BPA serum concentration. The Cmax-derived values for the unconjugated form expressed as a 
percentage of total BPA ranged from 23±17 % (mice) via 6.6 % (rat) to 2.9 % (monkey) and the 
AUC-derived values ranged from 2.2 % (mice) via 1.4 % (rats) to 0.1 % (monkeys). These noticeable 
proportions of unconjugated BPA in neonatal animals contrast with the consistently low proportion of 
<1% in adult animals.The SC injection in mice of PND 3 (n = 12) revealed a concentration-time 
profile for unconjugated BPA which in its initial part was similar to that observed under oral dosing 
(Figure 5D, Doerge et al., 2011b). The similarity was also reflected by SC/oral ratios for Cmax and 
AUC of 1.2 and 1.0, respectively. This apparent similarity in the toxicokinetics in newborn mice 
following SC or oral administration was mice-specific and was explained by the metabolic 
immaturity, rapid oral absorption, and rapid distribution of unconjugated BPA (Doerge et al., 2011b). 
The typical differences in toxicokinetics between the SC route and the oral route developed, however, 
with advancing postnatal age (PND 10 and 21), indicating the maturation of metabolic and 
elimination processes. An oral bioavailability of 100 % for unconjugated BPA in PND 3 mice was 
derived based on the ratio of the oral AUC (= 26 nM×h) to that of 26 nM×h for SC injection.  
In contrast to the toxicokinetic immaturity of neonatal mice, neonatal rats of PND 3 (n = 12) showed 
substantially larger SC/oral ratios for Cmax and AUC of 34 and 17, respectively, indicating the 
presence of a first-pass metabolism in these early postnatal pups (despite some evidence for 
diminished Phase II metabolic capacity) (Figure 5E, Doerge et al., 2010a). Compared to oral dosing, 
there was no statistically significant, postnatal age-related decrease in the unconjugated-BPA fraction 
of the Cmax values from SC administration, which further emphasized the importance of first-pass 
metabolism in neonatal rats following oral administration. An oral bioavailability of 6.0 % for 
unconjugated BPA in PND 3 rats was derived based on the ratio of the oral AUC (= 56 nM×h) to that 
of 930 nM×h for SC injection.  
Compared to newborn animals, in rhesus monkeys of PND 77 (n = 5), the IV dosing revealed a rapid 
elimination of unconjugated BPA (Figure 5F, Doerge et al., 2010b) similar to that in adults. Based on 
the AUC values for orally dosed monkeys of PND 70 and for IV injected monkeys of PND 77, an oral 
bioavailability of 1.9±1.8 % for unconjugated BPA was obtained. Overall, the data for oral 
administration and SC/IV injection show an age-dependent maturation of metabolic capacity of 
different magnitude and rats and mice, and a metabolic capacity in neonatal monkeys that already 
approached adult levels. 
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Figure 5:  Time course of serum levels of unconjugated and total BPA in newborn mice 
(PND3), rats (PND3), and rhesus monkeys (PND70, PND77) following oral administration, 
IV injection, or SC injection of a single dose of 100 µg/kg bw of isotope-labelled (deuterated) 
d6-BPA. Horizontal arrows indicate the serum concentration after 24 h. The LOD was 0.2 nM 
in all experiments. Additionally given are the pharmacokinetic parameters for unconjugated 
(U) and total (T) BPA, comprising the maximum serum concentration Cmax (nM), the area 
under the curve AUC (nM×h) from time zero to infinity, and the elimination half-life t½ (h). 
The data shown were taken from Doerge et al (2011b), Doerge et al (2010a) and Doerge et al 
(2010b). 
Prins et al. (2011) measured unconjugated and total BPA levels in serum from PND3 male SD rats 
using isotope-dilution HPLC-MS-MS (LOD: 0.05 ng/ml) following oral administration and SC 
injection of 10 µg/kg bw of BPA. The doses were dissolved in corn oil and were either administered 
through gentle feeding with a pipette tip (oral bolus dosing) or by SC injection of a ~8–10 µl depot in 
the nape of the neck. Pups were killed by decapitation at 0.5, 1 and 2 h after dosing and blood was 
collected for preparation of serum. Sera from 8–10 pups at each time point and route of exposure were 
pooled, and 3–5 separate sample pools at each time point for both oral and injection exposure routes 
were used for BPA quantitation. The recovery of the internal (deuterated) BPA standard was 
58%±11%, and the mean recovery of native BPA standard spiked to selected sample matrices and 
passed through the entire analytical procedure was 84% (range: 62–114%). In the experiment with SC 
injection, serum Cmax levels seen at 0.5 h were 1.77±0.63 (mean ± s.e.) and 2.00±1.00 ng/ml for 
unconjugated and total BPA, respectively, suggesting 88% of total BPA being in the free bioavailable 
form at this early time point. In the experiment with oral administration, Cmax values for unconjugated 
and total BPA of 0.26±0.04 and 1.02±0.30 ng/ml were observed at 0.5 h and 1 h, respectively; the 
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proportions of unconjugated BPA at these two time points were 29% and 21%, respectively. The 
authors additionally calculated the area under the curve from time zero to 2 h (AUC0–2) for 
unconjugated and total BPA, which was found to be 4.1-fold and 1.8-fold greater, respectively, for SC 
injection compared to oral administration. 
The CEF Panel compared the toxicokinetic results of Prins et al. (2011) for PND3 rats with oral bolus 
dosing and SC injection of BPA in corn oil with the results of Doerge et al. (2010a) for PND3 rats 
with gavage dosing and SC injection of d6-BPA in 10% aqueous EtOH/DMSO solution. Scaling the 
administered dose used by Prins et al. (2011) to the common dose of 100 µg/kg bw, and translating 
the serum levels and AUC values to molar-based values, yielded dose-adjusted Cmax and AUC0–2 
values for unconjugated BPA of 11 nM and 18 nM×h, respectively, which agreed well with the 
respective values (Cmax = 29 nM, AUC0–2 = ~21 nM×h) derived from Doerge et al. (2010a). The 
somewhat larger difference in the Cmax values could be discussed in the context of different types of 
oral administration and the use of the different vehicles (see, e.g., Gallo et al., 1993). Given the good 
correspondence between the AUC0–2 values for unconjugated BPA, it was unexpected to find a large 
discrepancy in the AUC0–2 values for total BPA. The data of Doerge et al. (2010a) showed an AUC0–2 
of ~644 nM×h, whereas an approximately 10-fold lower AUC0–2 of 70 nM×h was obtained for Prins 
et al. (2011). Given that Prins et al. (2011) did not report quality control measures to check the 
efficiency of enzymatic deconjugation (e.g., use of serum containing conjugated BPA, acid hydrolysis 
control), an insufficient deconjugation of the conjugated serum BPA cannot be excluded. The data of 
the SC injection experiment could support this explanation, since Prins et al. (2011) reported 88% of 
the total BPA in serum being still in the unconjugated form after 0.5 h. Again, this high proportion is 
an unexpected result when considering that at 0.5 h the levels of unconjugated BPA are already 
strongly decreasing whereas total BPA has already reached more or less a plateau level. Extrapolation 
of the serum concentration time profiles for unconjugated and total BPA to time points somewhat 
earlier than 0.5 h would lead to the impossibility of unconjugated BPA levels exceeding those of total 
BPA. The CEF Panel noted, however, that alternative explanations for the relatively high proportions 
of unconjugated BPA such as sample contamination and/or inadequate control of de-conjugation 
during sample collection and clean-up can also not be excluded, because critical quality control 
measures (such as used in Doerge et al., 2010a) were not reported, and serum concentration levels at 
time zero (i.e. taken from non-exposed control animals) and at time points >2 h were not available. 
Moreover, the fact that AUC0–2 and Cmax values for unconjugated BPA following SC injection were 
10–13-fold lower than in Doerge et al. (2010a) could indicate an additional problem, the reduced 
systemic absorption of BPA from the injected corn-oil depot. The CEF Panel therefore assigned a low 
reliability to the pharmacokinetic data of Prins et al. (2011). 
3.1.2.3. Summary of BPA Toxicokinetics and Metabolism in animals 
New information compared with previous risk assessments came from several toxicokinetic studies 
using specific and sensitive methods and dosing with deuterated BPA. Data obtained following oral 
versus subcutaneous exposure in rodents indicate low first-pass metabolism in neonates. The results 
indicate maturating metabolic capacity in rodents with age. In monkeys the metabolic capacity was 
similar between adults, juvenile and newborn animals. A study in monkeys and in mice of a second 
research group (Taylor et al., 2011) confirmed the linear kinetics of BPA in mice. However, it also 
showed maximum plasma unconjugated BPA concentrations (normalised by the dose) in mice and 
monkeys that were approximately 5 to 20 fold higher than the levels reported by the group of Doerge. 
Overall the animal data indicate that the systemic availability of unconjugated BPA by the oral route 
varies between the species, being 0.45% of the dose in mice, 0.9% in monkeys and 2.8% in rats 
(Doerge et al., 2010a,b, 2011a,b, 2012; Fisher et al., 2011). 
Studies in pregnant rats indicate that unconjugated BPA does cross the placenta and its glucuronide is 
formed in the fetal compartment. Data in rats indicate that in early pregnancy exposure to the fetus is 
greater compared to later pregnancy based on serum concentrations at GD 20. This finding is 
apparently the result of fetal Phase-II metabolic capacity that increases throughout gestation in rats 
(Doerge et al., 2011a). The concentration in the fetal brain was 4-fold of the concentration in the 
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maternal serum at GD 20. However, also in adult rats the brain concentration is roughly 3-fold of the 
concentration in serum, which reflects the high fat contents of this tissue. Both unconjugated BPA and 
BPA-conjugates can be measured in the amniotic fluid of rats and rhesus monkeys at concentrations 
lower than those in maternal serum (Doerge et al., 2011a; Patterson et al., 2013). However, the levels 
of conjugates consistently exceed those of unconjugated BPA in amniotic fluid from both rats and 
monkeys.   
Unconjugated and conjugated BPA is found in milk of rat dams orally dosed daily with 100 µg/kg bw 
per day (Doerge et al., 2010a). The amount delivered to the pups is so small that the concentrations in 
pup serum are below 0.2 nM (45.6 pg/ml), and therefore pup exposure via lactation is therefore 
extremely low (1/300 of the maternal dose). BPA does not accumulate in the body even though the 
concentration of unconjugated BPA in fat is 5-fold higher than the concentration in serum in rats 2 h 
after injection (Doerge et al., 2011a) and 6.9-fold higher than the serum concentration in mice 1 h 
after injection (Doerge et al., 2012). 
3.1.2.4. Human studies 
BPA in urine and serum in the general population after oral exposure 
A controlled dietary exposure study in 20 healthy volunteers exposed to BPA via food by eating three 
defined meals gives important insight into the internal exposure over a 24-hours period (Teeguarden 
et al., 2011). Although the BPA content of the food was not measured, the exposure to BPA was 
reliably estimated based on total collection of urine over the whole study period. The average daily 
exposures amounted to 0.27 μg/kg bw (range, 0.03-0.86 µg/kg bw). Unconjugated BPA 
concentrations in serum and urine were consistently below the LOD which was 1.3 nM (0.3 ng/ml) in 
the serum and 1.8 nM (0.4 ng/ml) in the urine. Serum samples containing detectable levels of total 
BPA were also analysed independently in a second laboratory in which the LOD varied within the 
range of 0.2-0.7 nM. A serum concentration-time course of total BPA was observable only in six 
individuals with exposures  being 1.3 - 3.9 times higher than the 95th percentile of aggregate US 
exposure. The highest Cmax values for total BPA were always below 1.3 nM. The peak serum 
concentrations for total BPA in serum occurred about one hour earlier than that in urine, which 
occurred at 2.75 hours (range, 0.75-5.75 hours) after a meal. The study results are considered reliable 
as the analytical measurements were performed in two independent laboratories using a validated up 
to date method (on-line HPLC-isotope dilution tandem mass spectrometry) and extensive measures 
were taken to avoid contamination and to identify possibly contaminated samples. 
BPA in urine in a controlled exposure study to BPA in thermal paper 
Ehrlich et al. (2014) performed a pilot study involving the simulation of dermal exposure of human 
volunteers to thermal paper in a cross-over design. In the first simulation experiment, participants 
printed and handled receipts continuously for 2 hours without gloves. After a washout period of at 
least 1 week, a second simulation experiment was conducted in which the participants repeated the 
handling of receipts while wearing nitrile gloves. The participants provided a spot urine sample 
immediately before handling of receipts and 4 hours later. The urine was collected polypropylene 
specimen cups and stored in polypropylene cryogenic vials. The urinary concentration of total BPA 
was measured at the US CDC, and the concentrations of BPA were adjusted for specific gravity to 
account for urine dilution. In the group handling thermal paper without gloves (n=23 participants), the 
geometric mean (GM) concentration of urinary (total) BPA was 1.8 μg/L (95% CI: 1.3-2.4 μg/L) 
before simulation and 5.8 μg/L (95% CI: 4.0-8.4 μg/L) post-simulation; the increase was statistically 
significant (p<0.05). 12 of the 23 participants provided sequential urine samples following the receipt 
handling; the GM concentrations were 2.1 µg/L at baseline, 6.0 µg/L at 6 h, 11.1 μg/L at 8 h, 10.5 
μg/L at 12 h, and 4.7 μg/L at 24 h. In the group handling thermal paper with gloves (n=12 
participants), no significant increase in urinary BPA after the simulation was observed. 
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The CEF Panel noted as a weaknesses that the BPA content in thermal paper and the urinary output 
(i.e. volume) were not measured. Nevertheless, the study results make it possible to obtain a rough 
estimate of the dermal exposure to BPA in thermal paper. From the experiment with sequential urine 
sampling over 24 h, a time-averaged mean concentration for total BPA of 7.7 µg/L can be calculated. 
This level is 5.6 µg/L above the baseline. Assuming a standard urinary output of 1.4 L per day and a 
body weight of 70 kg yields an internal exposure to total BPA of 0,112 µg/kg bw per day resulting 
from the dermal contactto BPA in thermal paper. Although this estimate is representative for 
occupational exposure to BPA in thermal paper, it provides and upper bound or worst case from the 
consumer perspective.  
BPA concentrations in mothers and fetuses in different stages of pregnancy  
 
Total BPA in serum and umbilical cord blood: In the study of Kosarac et al. (2012) total BPA 
concentrations in human maternal serum were measured at mid-pregnancy and at delivery and ranged 
from <0.026 ng/ml to 10.425 ng/ml (median 0.548 ng/ml, n=12) and <0.026 ng/ml to 3.048 ng/ml 
(median 1.461 ng/ml, n=12), respectively. Matching umbilical cord serum concentrations of total 
BPA were in the range of <0.026-2.569 ng/ml (median 1.823 ng/ml; n=12). The CEF Panel 
considered that although the analytical methodology used was sound, the study had some 
shortcomings. The CEF Panel considered that the biomonitoring data reported have low credibility 
due to limited reporting, in particular with respect to sample collection and handling, and 
discrepancies with other studies, in particular with that of Teegarden et al. (2011). In the latter study 
no unconjugated BPA could be measured (LOD 0.3 ng/ml) and total BPA was measurable only in 6 
out of 20 subjects which had peak concentrations of 2.6 - 5.7 nM (corresponding to 0.6 - 1.3 ng/ml) 
(Teeguarden et al., 2011). 
Gerona et al. (2013) used isotope-dilution LC/MS/MS to directly measure concentrations of 
unconjugated, glucuronidated  and sulfated BPA in umbilical cord serum collected from 85 study 
participants during elective second trimester pregnancy terminations. The LODs were 0.05 ng/ml 
(unconjugated and glucuronidated BPA) and 0.025 ng/ml (sulfated BPA), the LOQ was 0.1 ng/ml for 
all three analytes. d16-BPA was used as (surrogate) internal standard for all analytes. Procedural 
blanks and quality control materials at low and high concentrations (0.5 and 20 ng/ml) were included. 
To reduce the likelihood of contamination, the authors used glass/polypropylene containers for sample 
collection, processing, and storage containers. Umbilical cord blood was drained directly into 
collection tubes during the procedure to avoid contact with medical devices and the environment. The 
authors additionally performed a field blank testing by simulating the sample collection, extraction, 
and analytical run using double-charcoal stripped serum and synthetic human serum. No BPA was 
detected ≥ LOD in any of the sample collection and extraction materials or in any of the instruments 
used in the analysis. The possible contamination from the IV equipment (IV bag, needles and tubing) 
and medical equipment (gloves, laminaria) used during the termination procedure was also evaluated. 
The analysis of the umbilical cord serumsamples revealed detection levels of 47%, 76%, and 96% for 
unconjugated, glucuronidated and sulfated BPA. The GM concentrations were 0.16 ng/ml for 
unconjugated BPA (range: <LOD–52.26 ng/mL), 0.14 ng/ml for glucuronidated BPA (range: <LOD–
5.41 ng/mL), and 0.32 ng/ml for sulfated BPA (range: <LOD–12.65 ng/mL). The concentration ratio 
of unconjugated BPA/conjugated BPA ranged from 1:100 to >400:1. The CEF Panel noted that 
extreme concentration ratios such as 400:1 between the unconjugated and conjugated BPA forms are 
not in line with the evidence from toxicokinetic studies in pregnant monkeys (vom Saal et al., 2014) 
and questions the attempts of the authors to have the sample contamination and the exposure to 
BPAfrom medical devices fully under control. The CEF Panel also noted the specific exposure 
situation of pregnant women and fetuses during the termination procedure, which makes an 
extrapolation of the results to pregnant women in general (i.e. outside a hospital setting) questionable. 
Transplacental transfer rate: The transplacental transfer rate in human placentas was measured in ex 
vivo experiments in a multi-centre study (Mose et al., 2012). Based on their results the authors 
concluded that unconjugated BPA has a transplacental transfer rate of 1 (concentration at the fetal 
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site/concentration of the maternal site =1) explained by passive diffusion. The result of the study is 
comparable to a study published earlier (Balakrishnan et al., 2010) also reporting a factor of 1. Thus, 
in late pregnancy the concentration in the fetal blood is unlikely to be higher than in the blood of the 
mother. 
BPA concentrations in amniotic fluid and fetal liver samples: measurements of amniotic 
concentrations of unconjugated BPA and BPA-conjugates by Edlow et al. (2012) were performed 
according to current standards. Unconjugated BPA was detected in 9/20 second trimester samples; 
levels ranged from 0.31 to 0.43 ng/ml (median 0.38 ng/ml) and in 1 out of the 20 samples in the third 
trimester. When detected, unconjugated BPA comprised 83% and 91% of total BPA in second and 
third trimester amniotic fluid, respectively, whilst in experimental human studies less than 10% of 
total BPA in serum is considered to be unconjugated BPA. In addition, it has previously been reported 
that in humans, concentrations of unconjugated BPA after meals with canned food were below the 
level of detection (<0.3 ng/ml) (Teeguarden et al., 2011) and the placental transfer rate in humans is 1 
(Mose et al., 2012; Balakrishnanet al., 2010). In rats, the concentration of BPA in amniotic fluid is 
0.35-fold of the maternal concentration and levels of conjugates consistently exceeded those of 
unconjugated BPA in both rats and monkeys (Doerge et al., 2011a; Patterson et al., 2013). Thus it is 
improbable that high proportions of unconjugated BPA in amniotic fluid, as reported by Edlow et al. 
(2012) can be due to excretion by the fetus. The CEF Panel considered that the observed results might 
be explained by deconjugation of BPA-conjugates excreted in the amniotic fluid or false positive 
responses near the LOQ. 
In a study of Nahar et al. (2013) in 50 first- and second-trimester human fetal liver samples, the 
internal levels of unconjugated BPA and conjugated BPA were measured and gene expression of 
biotransformation enzymes specific for BPA metabolism was evaluated. Both unconjugated BPA and 
conjugated BPA concentrations in the fetal livers varied widely, with unconjugated BPA (GM: 2.26 
ng/g tissue) exhibiting three times higher concentrations than conjugated BPA concentrations (GM: 
0.65 ng/g tissue). As compared to gender-matched adult liver controls, UDP-glucuronyltransferases, 
sulfotransferases and steroid sulfatase genes exhibited reduced expression whereas β-glucuronidase 
mRNA expression remained unchanged in the fetal tissues.The CEF Panel considered that 
shortcomings in the study description with regard to liver sample isolation, procedure of surgery and 
surgical instrument used to avoid contamination and deconjugation of BPA during sample handling, 
hamper the usefulness of the study results.  
BPA concentrations in early life  
Nachman et al. (2013) measured the content of unconjugated BPA and BPA-glucuronide in the urine 
of newborns and young infants (see also Section 4.6.2 in Part I - Exposure assessment)). The study 
population consisted of 11 healthy neonates plus 1 young infant (median age 17 days) born to healthy 
non-smoking mothers. Urine samples were collected using BPA-free pediatric urine collection bags 
during the neonates’ regular well-child care visits. After voiding the urine was transferred on ice to 
the laboratory, transferred to a pre-cleaned glass vial which was stored at -70°C until analysis. The 
average concentration of BPA glucuronide, as measured in all of the duplicate urine samples, was 
0.87± 0.51 ng/ml (median: 0.66 ng/ml). Unconjugated BPA was not found in any of the urine samples 
with the exception of one sample whose replicate sample was a non-detect. With the exception of one 
fully breastfed baby, all babies received infant formula. The study demonstrates that neonates and 
infants are capable of conjugating BPA to the BPA-glucuronide. 
 
The study of Christensen et al. (2012) evaluated the urinary excretion of conjugated BPA in five 
volunteers during a course of a two days fasting (0-48 hrs). In four of the five volunteers the amount 
of conjugated BPA excreted in the urine declined during the fasting period to 5% of the amount on 
day 1 by the second day. In one of the volunteers the urinary excretion increased between 32 and 42 
hours without a defined exposure. According to the authors, the study shows that even after the oral 
exposure to BPA by meals ceases, BPA is still excreted from the body indicating (a) non-food 
exposure to BPA or (b) excretion of BPA from store tissue such as lipid tissues. However, the CEF 
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Panel noted that the conclusion under (b) was inconsistent with the results of well-controlled animal 
studies showing that there is no toxicologically relevant accumulation in fat tissue.  
Other information: 
 
There are several other studies on BPA (Krotz et al., 2012; Cao et al., 2012a; Geens et al., 2012; 
Genuis et al., 2012) which are not relevant or appropriate to be taken into consideration, as explained 
in Appendix B. 
• In reproductive age women undergoing infertility treatments there is little transfer or 
accumulation of BPA into the microenvironment of the human preovulatory oocyte as 
reported by Krotz et al. (2012). However, the low number of subjects in the study (n=5) 
preclude generalization of the results. 
• A high ratio of unconjugated BPA/total BPA in placenta samples and in samples of fetal liver 
is also given in the study of Cao et al. (2012a). As reported by Doerge et al. (2011a) tissue 
samples should be handled deep frozen to avoid that ß-glucuronidase present in the tissue can 
release unconjugated BPA from conjugated BPA. Uncertainties about the handling of samples 
preclude conclusions from the study of Cao et al. (2012a) 
• The study of Geens et al. (2012) used human material obtained by autopsies in deceased 
patients, aged 9-62 years, and measured BPA in brain, liver and fat. They did not find 
metabolites in the liver, in which tissue in animal studies the highest concentrations of the 
metabolites have been measured, explained by the high levels of the conjugating enzymes in 
this tissue. This may point at post-mortem changes.  
• Genuis et al. (2012) reported on concentrations of total BPA in serum, urine and sweat. Their 
results are highly improbable as high concentrations in sweat were reported in subjects 
without a measurable concentration in serum, which is impossible because sweat in humans is 
produced as an ultrafiltrate of the blood. 
3.1.2.5. Summary of BPA Toxicokinetics and Metabolism in humans  
The new data published since 2010 confirm that after oral exposure to BPA the concentrations of the 
unconjugated BPA in plasma and urine of humans are so low that they can only be detected/quantified 
with analytical methods with a LOD of < 1.3 nM (0.3 ng/ml). The transplacental transfer ratio of BPA 
in humans is reported to be 1. Therefore, in late pregnancy the concentrations in the fetal blood are 
expected to be similar to the blood of the mother. Levels of unconjugated BPA were found in the 
livers of first and second trimester fetuses which were 3-fold higher than the concentrations of BPA 
conjugates. The specimens were from induced abortion. As the surgical procedures, the sort of 
surgical instruments used and the liver sample isolation from fetal tissues are not described, it remains 
open whether the results are due to contamination by hospital processing of the samples. In the urine 
of healthy newborn and young infants only conjugated BPA was found. Several other studies showing 
high concentrations of unconjugated BPA in biological fluids have several methodological 
shortcomings, e.g. not avoiding contamination by medical instruments, storage of samples over years 
without confirmation that the samples would be stable, in particular ensuring that no deconjugation of 
BPA conjugates may occur during storage and during thawing the samples (Liao et al., 2012, Krotz et 
al., 2012, Cao et al., 2012a, Geens et al., 2012, Genuis et al., 2012. 
3.1.2.6. In vitro studies 
Native  microsomes were used from rat and from human liver and intestine to study the enzyme 
kinetics of glucuronidation of BPA (Mazur et al., 2010). BPA glucuronidation in liver microsomes 
was sex dependent. Female rat and female human liver microsomes had a higher Vmax values than 
those from males. Km for glucuronidation was much higher in female rats than in humans and male 
rats. The dissimilar Km measured for female rat microsomes together with inhibition studies suggests 
that different UDP-glucuronosyltransferase (UGT) enzyme(s) are involved in BPA glucuronidation in 
rats, UGT2B7 and UGT2B15 being candidates. Human intestinal microsomes (mixed gender) showed 
little BPA glucuronidation activity compared with those from male rat intestine, which in the presence 
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of alamethicin, a membrane-disrupting agent, exhibited a Vmax that was nearly 30-fold higher than that 
for mixed human microsomes.  
In a further study by Mazur et al. (2012), BPA and its major metabolite BPA-glucuronide (BPA-G) 
showed significant interspecies differences in kinetics in vitro. ATP-Binding Cassette (ABC) 
transporter enzymes were considered to play important roles in the physiological processes underlying 
the kinetics. P-glycoprotein (MDR1), multidrug resistance-associated proteins (MRPs), and breast 
cancer-resistant protein (BCRP) were investigated in rat and human tissues.The results reported 
suggest that BPA is likely a substrate for rat mdr1b but not for human MDR1 or rat mdr1a whereas 
BPA is a potential substrate for rat mrp2 and human MRP2, BCRP, and MRP3. BPA-G had the 
highest apparent substrate binding affinity for rat mrp2 and human MRP3. It was not active or even a 
potential inhibitor for human MRP2, MDR1 and BCRP and for rat mdr1a, mdr1b, and bcrp. 
Theauthors suggested that substrate specificity of ABC transporters might be explained by differences 
in amino acid sequences of putative substrate-binding sites and that apical efflux transporters would 
transport unconjugated BPA into the bile and/or into the intestinal lumen, while BPA-glucuronide 
would undergo a similar transport pathway in rat. In humans, due to the basolateral location of the 
MRP3 transporter, BPA-glucuronide would likely enter the hepatic blood.  
The study of Trdan Lušin et al. (2012) aimed to gain insight into intestine, kidney, liver, and lung 
glucuronidation of BPA, human microsomes of all tested organs were used. Human lung microsomes 
did not show glucuronidation activity towards BPA. While the liver intrinsic clearance was very high 
(857 ml min−1 (kg body weight)−1), the tissue intrinsic clearances for the kidney and intestine were 8.0 
and 2.1 ml min−1 (kg body weight)−1. Since BPA is a UGT1A1 substrate, the authors postulated that 
the common UGT1A1*28 polymorphism influences BPA glucuronidation, and consequently, BPA 
detoxification. Hepatic tissue intrinsic clearances for UGT1A1*1/*1, UGT1A1*1/*28, and 
UGT1A1*28/*28 microsomes were 1113, 1075, and 284 ml min−1 (kg body weight)−1, respectively. 
These in vitro results show that the liver is the main site of BPA glucuronidation (Km 8.9 µM, Vmax 
8.5 nmol min−1 mg−1) and BPA metabolism may be significantly influenced by a person’s genotype 
(Km 10.0–13.1 µM, Vmax 3.4–16.2 nmol min−1 mg–1). 
3.1.2.7. Summary of in vitro studies relevant to the toxicokinetics of BPA 
From the in vitro studies of Mazur et al. (2010) and Trdan Lušin et al. (2012) it can be concluded that 
local BPA metabolism in the lung does not play a role. Hence, following this route of exposure, no 
first-pass metabolism has to be taken into consideration. The intrinsic clearance in the intestine is low 
(2.1 ml min−1 (kg body weight)−1) compared to the intrinsic clearance of the liver (857 ml min−1 (kg 
body weight)−1). Hence, the presystemic elimination (first pass) equals the hepatic clearance. 
Glucuronidation of BPA is catalysed by multiple UGT isoforms in the order of catalyic efficiency of 
2B15 > 1A9 > 2B7 > 1A8 > 1A1 > 1A3. Some of the UGTs are polymorphically expressed and are 
expressed at birth at a lower expression level than in the adult (Miyagi and Collier, 2011). 
Transporters may influence absorption in the rat and humans (Mazur et al, 2012).  
The CEF Panel concluded that the in vitro studies contribute to the understanding of the mechanisms 
by which BPA is metabolized in humans. 
3.1.3. Physiologically based pharmacokinetic (PBPK) modelling in humans 
No toxicokinetic study in humans is currently available to inform about the time course of 
unconjugated BPA concentrations in plasma (serum). Experimentally derived internal dosimetrics 
(e.g., AUC) for unconjugated BPA in humans are therefore lacking to support the human-equivalent 
dose (HED) approach (see Sections 3.1.3.4 and 3.1.5). However, several physiologically based 
pharmacokinetic (PBPK) models for oral exposure in humans have been developed to enable 
predictions of serum concentration-time profiles and estimations of internal dose metrics for a given 
oral dose. In the following, an overview on existing PBPK models for humans is given, continued by 
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a description of model predictions on serum BPA levels for adults and newborns, and followed by the 
derivation of PBPK model-based internal dosimetrics for the HED approach. 
3.1.3.1. Overview on PBPK models in humans 
PBPK models for the oral exposure in humans have been developed by Teeguarden et al. (2005), 
Mielke and Gundert-Remy (2009), Edginton and Ritter (2009), and Fisher et al. (2011). Yang et al. 
(2013) developed a PBPK model for neonatal and adult rats with implications for the extrapolation of 
toxicity studies from neonatal rats to neonatal monkeys or infant humans. In addition, Yang et al. 
(2013) used the monkey-based model of Fisher et al. (2011) to predict internal dosimetrics for humans 
with oral exposure. All PBPK models are based on the same general model structure (see e.g. Figure 
6) consisting of a group of tissue compartments.  
 
Figure 6:  Structure of two example PBPK models for oral exposure in humans. Left: Human-
based PBPK model for unconjugated BPA (Mielke and Gundert-Remy, 2009). Right: 
Monkey-based PBPK model which was used for the extrapolation to humans (Fisher et al., 
2011). The compartments "Slow" and "Rich" refer to the slowly and richly perfused tissues. 
These compartments are defined by their volume, blood flow, and tissue-blood partition coefficients, 
and a perfusion-rate-limited kinetics is assumed for describing the distribution of the chemical 
between the blood and the tissues (Andersen, 1981). The PBPK models differ in the number and kind 
of the tissue compartments for unconjugated BPA, in respect to the incorporated ADME processes 
(e.g., consideration of intestinal first-pass metabolism in addition to the hepatic first pass), and in the 
detail of describing the fate of conjugated BPA. Also, the PBPK models originate from either animal-
based or human-based concepts. Common to all PBPK models is the calibration/evaluation against 
toxicokinetic data (i.e. the serum-concentration time course for conjugated BPA and the information 
that the serum-concentration time course for unconjugated BPA is below the LOD of 10 nM) for 
human adults with low-dose oral administration (5 mg d16-BPA, i.e. 54–90 µg/kg bw) (Völkel et al., 
2002). 
Teeguarden et al. (2005) developed a PBPK model consisting of a five-compartment submodel 
(gastrointestinal [GI] tract, liver, blood, uterus, body of remaining tissues) for BPA, a two-
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compartment submodel (volume of distribution, GI tract) for glucuronidated BPA, oral and 
intravenous inputs, and outputs via urinary and fecal excretions of glucuronidated BPA. The model 
was initially developed for rats and incorporated rat-specific toxicokinetic processes such as biliary 
secretion, enterohepatic recirculation (EHR), and predominant fecal elimination of conjugated BPA; it 
was later extended to humans. Hepatic glucuronidation of BPA was assumed to be the only metabolic 
process in the rat and human PBPK models since the experimental data available were insufficient to 
include intestinal first-pass metabolism. However, the authors concluded from rat pharmacokinetic 
data that the ~7-fold greater metabolism Vmax observed for the oral route vs. intravenous was due to 
additional first-pass metabolism in the GI tract. A specific model feature was the consideration of 
protein binding in plasma and the oestrogen receptor binding in uterine tissue. Unknown/uncertain 
parameter values for gastrointestinal absorption, metabolism, excretion, and EHR in rats were 
estimated by fitting to oral gavage data in rats. Other parameter values such as the volume of 
distribution for the conjugated BPA were fitted to human toxicokinetic data and the Michaelis 
constant for glucuronidation was taken from in vitro studies with rat liver microsomes/hepatocytes. 
Extending the model to humans required (apart from adjusting the physiological parameters) to scale 
the parameters for metabolism and elimination to human toxicokinetic data (Völkel et al., 2002). In 
rats, the predicted oral-route blood kinetics were well-described for BPA but less exactly for 
glucuronidated BPA. The human PBPK model accurately simulated the plasma concentration for 
conjugated BPA until 12 hours after dosing but under-predicted the concentration afterwards (24–48 h 
post-exposure). For the plasma concentration of unconjugated BPA, which was not detectable in the 
Völkel et al. (2002) study because of the LOD of 10 nM, the human PBPK model provided an upper-
bound estimate for the concentration-time profile which approached the LOD. 
Mielke and Gundert-Remy (2009) developed a human-based PBPK model for unconjugated BPA 
consisting of eight tissue/organ compartments (including blood), an oral input to the liver via a dosing 
compartment, and an output from the liver as a consequence of the phase II metabolism (Figure 6). 
The authors acknowledged the first-pass effect in the gastrointestinal tract but regarded its 
contribution to the hepatic first pass as low; the first-pass metabolism in the gastrointestinal tract was 
therefore not taken into account in the model. Absorption was set as 90% of the oral dose 
corresponding to the recovery of total BPA in urine in human volunteers (Völkel et al., 2002). The 
liver metabolism included glucuronidation and sulfation pathways, and the metabolic parameters were 
based on in vitro data from human liver cells (Kuester and Sipes, 2007). Parameter sets for different 
age groups ranging from newborns to adults (males) were provided based on age-specific human 
physiological parameters and a set of experimentally determined tissue:blood partition coefficients for 
rats. The glucuronidation activity (assumed to be exerted by the isoform UGT 2B15) in a newborn 
was set at 5% of the activity in adults. The sulfation capacity (assumed to be mediated by the enzyme 
isoform SULT 1A1) in adult humans was assumed to be 15% of the glucuronidation capacity, and the 
expression of sulfation enzymes at birth was considered to be at the same level as in adults. The 
absorption half-life was set based on published peak concentrations of (total) BPA in urine and of 
conjugated BPA in plasma (Völkel et al., 2002). The evaluation of the PBPK model was based on the 
prediction of the blood concentration-time profile for unconjugated BPA after a single oral dose of 5 
mg to an adult, which simulated the exposure scenario used in the Völkel et al. (2002) study. The 
predicted concentration-time profile exceeded only slightly the level of 10 nM (Figure 7A), which 
was consistent with the findings of Völkel et al. (2002) who did not detect unconjugated BPA above 
the LOD of 10 nM in blood taken 40 min after dosing. Accordingly, the predicted serum 
concentration profile for unconjugated BPA is to be regarded as an upper-bound estimate. 
Edgington and Ritter (2009) built a human-based PBPK model for adults and children < 2 years 
which consisted of structurally identical multi-compartment submodels for unconjugated and 
conjugated BPA. Each submodel was comprised of 15 organ compartments and 3 blood 
compartments. The two submodels were coupled by the hepatic glucuronidation of BPA. The input of 
BPA into the portal vein was implemented by a physiologically based model for gastrointestinal 
transit and absorption, and the output was by renal clearance of glucuronidated BPA. 100% of the 
applied BPA dose was modelled as absorbed to the portal vein (i.e. intestinal first-pass metabolism 
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was not considered). The PBPK model additionally included protein binding in plasma as well as sub-
compartments for red blood cells, plasma, interstitial and cellular spaces. The authors considered the 
UDP-glucuronosyltransferase isoform UGT 2B7 as the enzyme responsible for BPA glucuronidation, 
and they used the enzyme ontogeny of this isoform to scale the intrinsic hepatic clearance of BPA to 
glucuronidated BPA from adults to children. In concrete terms, the UGT 2B7 activity in a term 
newborn was assumed to be 5% of the activity in adults. The model was parametrized using 
anatomical and physiological data for adults and children and by using an algorithm for partition 
coefficient estimation based on physicochemical properties. Unknown or uncertain parameter values 
for the clearances, the lipophilicity of glucuronidated BPA (required for calculation of partition 
coefficients), and the intestinal permeability of BPA were estimated for the adult model by fitting the 
predicted plasma concentrations to the toxicokinetic data of Völkel et al. (2002). Specifically, the 
intrinsic hepatic clearance of BPA was set to the lowest integer that maintained the plasma 
concentrations of unconjugated BPA at time points ≥ 51 min below the 10-nM LOD of the Völkel et 
al. (2002) study (Figure 7B). The thus optimized adult model was then scaled to children by means of 
allometric scaling functions for ADME processes. 
 
Figure 7:  Predictions of three PBPK models on the plasma concentrations of unconjugated 
(solid lines) and conjugated BPA (dashed lines) for an adult human male after oral dosing of 
5 mg BPA (corresponding to 63 µg/kg bw). The observed concentrations of glucuronidated 
BPA (filled symbols) were taken from the toxikokinetic study of Völkel et al. (2002), which 
could not detect unconjugated BPA above the LOD of 10 nM in blood taken 40 min after 
dosing. (A) Prediction of a human-based PBPK model for unconjugated BPA with hepatic 
glucuronidation and sulfation (Mielke and Gundert-Remy, 2009). (B) Predictions of a human-
based PBPK model with liver glucuronidation (Edginton and Ritter, 2009). (C) The 
predictions of a monkey-based PBPK model with gastrointestinal and liver metabolism, 
which was extrapolated to humans (Fisher et al., 2011).  
Fisher et al. (2011) developed a PBPK model for the prediction of route-dependent dosimetry of BPA 
in adult and infant rhesus monkeys with extrapolation to humans. The oral-route model consisted of a 
7-compartment submodel for BPA, a one-compartment submodel (volume of distribution) for 
conjugated BPA (i.e. glucuronide + sulphate), an oral dosing compartment (stomach), and two 
compartments (small-intestine) for unconjugated and conjugated BPA (Figure 6). Intestinal first-pass 
metabolism and hepatic metabolism (including first pass) of BPA was incorporated. Additionally 
included was a term for renal reabsorption of conjugated BPA to account for the "lingering residual" 
conjugated BPA in monkey serum. The PBPK monkey model was calibrated against toxicokinetic 
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data for adult and neonatal monkeys with intravenous and oral-bolus administration (Doerge et al., 
2010) to estimate the parameters for gastrointestinal absorption, intestinal and hepatic metabolism, the 
volume of distribution, and renal elimination and reabsorption. The evaluation of the calibrated adult-
monkey model against published kinetic studies in monkeys revealed deviations between the 
predicted and observed data, which were related to study differences in analytical methodology, the 
monkey strains, and the vehicles used for oral administration of BPA. The calibrated adult-monkey 
model was then applied to extrapolate to adult humans using the Völkel et al. (2002) data for model 
evaluation (Figure 7C). For parameterization, human physiological parameters (including a human 
gastric emptying rate) were used together with BPA-specific model parameters derived from the adult 
monkey model. Compared to the predictions of the human PBPK models of Mielke and Gundert-
Remy (2009), and Edginton and Ritter (2009), the calibrated PBPK model by Fisher et al. (2011) 
predicted 10–50-fold lower unconjugated BPA levels in human serum (Figure 7C). A replacement of 
the calibrated model parameters by a set of revised model parameters, which were based on the 
monkey BPA kinetic data of Taylor et al. (2011), increased the unconjugated BPA levels in human 
serum but the concentration-time profile did not exceed the level of 10 nM representing the LOD for 
unconjugated BPA in the Völkel et al. (2002) study. 
Yang et al. (2013) developed a PBPK model for neonatal and adult rats to quantitatively evaluate age-
dependent pharmacokinetics of BPA and its phase II metabolites and to enable a route-dependent 
dosimetry of BPA in rats at different life stages. The PBPK model was calibrated in adult rats using 
studies on BPA metabolism and excretion in the liver and gastrointestinal tract, and pharmacokinetic 
data with BPA in adult rats. For immature rats the hepatic and gastrointestinal metabolism of BPA 
was inferred from studies on the maturation of phase II enzymes coupled with serum time course data 
in pups. The calibrated model predicted the measured serum concentrations of unconjugated BPA and 
BPA conjugates (glucuronide + sulphate) after administration of 100 μg/kg of d6-BPA in adult rats 
(oral gavage and intravenous administration) at postnatal days 3, 10, and 21 pups (oral gavage). The 
observed age-dependent BPA serum concentrations were partially attributed to the immature 
metabolic capacity of pups. A comparison of the dosimetry of BPA across immature rats and 
monkeys suggests that dose adjustments would be necessary to extrapolate toxicity studies from 
neonatal rats to neonatal monkeys or infant humans. 
3.1.3.2. Summary of the PBPK modelling 
To summarise, four PBPK models have been developed for the oral exposure in humans. The models 
originated either from animal-based concepts (which were then extended to humans) or from human-
based concepts. The animal-based concepts offered the opportunity to calibrate the model against a 
training set of animal toxicokinetic data and to then evaluate the calibrated model against a (new) test 
set of data. To parametrize the models for humans required an estimation or optimization of ADME 
parameters, in general by fitting the predicted plasma concentrations to the toxicokinetic data of 
Völkel et al. (2002), specifically to the observed plasma concentration of conjugated BPA and to the 
10-nM LOD for unconjugated BPA. The predicted plasma concentration profiles for unconjugated 
BPA of Teeguarden et al. (2005) and of Edgington and Ritter (2009) have to be regarded as upper-
bound estimates, because ADME parameters were adjusted to allow the profile to approach the 10-nM 
LOD. The predictions of the PBPK model of Mielke and Gundert-Remy (2009), which derived the 
metabolic parameter values from in vitro studies and optimized the absorption parameter against 
"observable" human toxicokinetic data (i.e. urinary BPA excretion), also need to be regarded as an 
upper-bound estimate, even though the metabolic liver parameters were not adjusted to reach a certain 
target level in the serum concentration of unconjugated BPA. Arguments in favour of the Fisher et al. 
(2011) PBPK model are (i) the inclusion of pre-systemic metabolism in the GI tract (i.e. intestinal first 
pass) into the model structure for oral BPA, and (ii) the explicit use of the serum concentration-time 
course data for unconjugated and total BPA in model validation. The CEF Panel therefore decided to 
use the PBPK model of Fisher et al. (2011) to derive internal dosimetrics for oral BPA, as done by 
Yang et al. (2013), for the HED approach. The CEF Panel noted however that due to uncertainty 
around the assumptions used in the different models, there will be uncertainties about the outcome of 
the PBPK modelling. 
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3.1.3.3. Further PBPK model predictions on serum BPA levels in human adults and newborns 
The study of Mielke and Gundert-Remy (2009) further explored the influence of the dosing schedule 
mimicking the age-specific patterns of meals per day (i.e. considering that newborns are usually fed 
more frequently than older children and adults). For an oral exposure of 50 µg/kg bw per day, the 
PBPK model predicted a three times higher steady-state blood concentration of unconjugated BPA for 
newborns in comparison to adults (0.44 versus 0.13μg/l). Edginton and Ritter (2009) predicted a 
children/adult ratio of the steady-state plasma concentration of unconjugated BPA of 2–11 (depending 
on different ages), whereas Yang et al. (2013) predicted a children/adult ratio of the AUC for the 
serum unconjugated BPA concentration of 0.85. The difference in the children/adult ratio of the 
internal dose metrics between the three studies may be explained by the pattern of exposure. The 
simulation by Mielke and Gundert-Remy suggests that the well-expressed sulfation activity in the 
newborn can counteract at least partly a lower glucuronidation activity in neonates associated with 
UGT 2B7 ontogeny, as already highlighted in the EFSA opinion of 2008 (EFSA, 2008). Mielke and 
Gundert-Remy (2009) also calculated in the adult a steady-state concentration of unconjugated BPA 
of 0.0014–0.0026 μg/l, resulting from a daily intake of 0.905 μg/kg bw per day. The value compares 
well with the steady-state concentration of unconjugated BPA of 0.004 μg/l following the oral 
exposure to 1 μg/kg bw per day reported by Edington and Ritter (2009). The derived estimated Cmax 
value was 2–3 orders of magnitude lower than measured mean values reported by some authors. This 
underlines the need for cautious interpretation of data on extremely high concentrations of 
unconjugated BPA, due to the possible background contamination affecting the analytical detection 
(EFSA CEF Panel, 2010). 
Teeguarden et al. (2005) used their PBPK model to simulate an exposure scenario consisting of a 
daily dietary uptake of 1 μg BPA/kg bw per day separated into three meals. The peak concentrations 
of unconjugated (not bound to plasma proteins) BPA in blood were predicted as 0.003 nM in a one-
year-old child and as 0.0037 nM in 50-year-old adults. The PBPK model also permitted the prediction 
of oestrogen receptor binding in uterine tissue. Normalised for the oestrogenic activity of endogenous 
17-ß-oestradiol, the highest increase in the oestrogenic activity induced under the described exposure 
scenario was calculated to be 0.22% for 11-year-old boys (lowest circulating 17-β-oestradiol levels). 
Computational modelling of the possible effects of plasma protein binding of oestradiol and BPA, 
incorporating affinities of oestradiol and BPA to different binding proteins and physiological 
concentrations of these proteins in rodents and in male and female humans, predicts that unless very 
high concentrations (> 100 nM) of BPA are reached in blood, oestradiol binding to the receptor will 
always dominate. Therefore, under realistic blood concentrations expected in humans from oral 
exposure to BPA from diet in the range of up to 0.05 nM, only a very small fraction of the oestrogen 
receptor will be occupied by BPA (Teeguarden et al., 2005). 
Occupancy of the oestrogen receptor by BPA is predicted to be further decreased when the rapid 
elimination of BPA is incorporated into the modelling (EFSA 2006, EU-RAR, 2003/2008). 
Edgington and Ritter (2009) used their PBPK model to simulate a repeated daily oral dosing of 1 
μg/kg bw (given once per day) in adults and young children (0–2 years of age). The average steady-
state plasma concentration of unconjugated BPA in newborns and 3 months-old infants were 11 and 2 
times greater than in adults, because the authors included a much less efficient BPA conjugation in 
newborns and children of very young age. For breast-fed newborn exposure, unconjugated BPA 
average plasma concentration at steady state in newborns and in breastfed 3 month-old infants were 
estimated to be 1.8 and 0.26-fold that in adults (0.004 μg/L), while in formula-fed 3 and 6 month-old 
infants the modelled plasma concentrations were approximately 5 times greater than those in adults. 
The CEF Panel noted that the PBPK models of Edgington and Ritter (2009) and Mielke and Gundert-
Remy (2009) assumed an intestinal absorption of 100% and 90%, respectively, BPA in humans, 
irrespective of age, but no presystemic (first-pass) metabolism of BPA in the GI tract. The assumption 
of (almost) complete absorption is consistent with the quantitative excretion of total BPA in urine 
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(Völkel et el al., 2002; Teeguarden et al., 2011); however, the assumption that no pre-systemic 
metabolism occurs in the GI tract is overly conservative, although direct experimental data to estimate 
the magnitude of this gastro-intestinal first-pass effect in humans are not currently available. The 
results from the human-based PBPK models underline the importance of taking into account both 
metabolic pathways (i.e. glucuronidation by multiple UGT isoforms and sulfation) for dietary BPA in 
both liver and the GI tract at different ages. Simulations taking into account both age-dependent 
metabolic differences and specific pattern of exposure predict for newborns a 3-fold greater steady-
state blood concentration of unconjugated BPA as compared with the adult (0.44 μg/L versus 0.13 
μg/L) after exposure to the same quantity of 50 µg BPA per kg bw (Mielke and Gundert-Remy, 
2009). The two new PBPK models are based on lifestage-specific kinetic data (monkey and rat), 
which are scaled up to the human situation (Fisher et al., 2011; Yang et al., 2013). The extrapolation 
to adult and neonatal humans would suggest 10 to 50-fold lower concentrations for unconjugated 
BPA in blood than as predicted by Mielke and Gundert-Remy (2009) and Edginton and Ritter (2009), 
and leads to the conclusion that the neonatal rat has an impaired metabolism for BPA compared with 
the adult rat whereas in the neonatal primate (i.e. monkey), the metabolism seems more similar to the 
adult primate. 
3.1.3.4. Derivation of PBPK model-based internal dosimetrics for the HED approach 
In order to perform a comparison of BPA dosimetry across species including humans, Yang et al. 
(2013) applied the monkey-based PBPK model of Fisher et al. (2011) for the prediction of internal 
dosimetrics in human newborns and adults, based on a repeated daily oral bolus administration of 
50 µg/kg bw over a period of 5–14 days to ensure periodicity (steady state) of the serum 
concentrations of unconjugated BPA. The authors predicted AUC values of 1.53 and 1.80 nM×h for 
human newborns and adults, respectively. The corresponding Cmax values were 0.23 nM and 0.51 nM, 
respectively. The HED approach, as applied in this opinion, is based on a common oral dose of 
100 µg/kg bw per day, which was used throughout all toxicokinetic key studies in neonetal and adult 
mice, rats, and monkeys. The above mentioned AUC values had therefore to be multiplied by a factor 
of 2 (to adjust for moving from 50 to 100 µg/kg bw) to obtain equivalent-dose AUCs of 3.0 and 3.6 
nM×h for human newborns and adults, respectively (see table 3 and 4 in Section 3.1.5). 
3.1.4. Role of polymorphisms in the kinetics of BPA 
3.1.4.1. Summary of previous evaluations 
The following text is taken from EFSA (EFSA CEF Panel, 2010) with some minor modifications (e.g. 
deletion of references). 
“The enzymes which are involved in BPA conjugation are UDP-glucuronyl-transferases (UGT) and 
sulfotransferases (SULT). In both monkeys and rats, the predominant pathway is glucuronidation, 
with the sulfation reaction representing <20% for monkeys and <5% for rat. Both enzyme families 
consist of different isoforms, which can have different affinities for and capacities to metabolise BPA. 
The various isoforms also demonstrate different ontogenetic patterns. In addition, they show genetic 
polymorphisms. Information on which isoform is involved at dose levels relevant for human exposure 
can be used as valuable input in PBPK modelling in order to identify whether groups of individuals 
can be at higher risks due to the presence of allelic variants with altered activity or a different age-
related enzyme expression level”. 
UDP-glucuronyl-transferases (UGT) 
Among the different recombinant human isoforms, UGT2B15 showed the highest activity over the 
range of BPA concentrations (1-20 μM) tested. Clearly, a role for UGT2B15 is identified and to a 
lesser extent also to 2B7 and 1A8 (EFSA CEF Panel, 2010).  
Polymorphisms have been identified in the UGT2B15 gene. The polymorphism can result in a 
modification of the activity for different substrates, with the UGT2B15*1 allelic variant (wild type) 
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having 2 to 5 fold higher rates of glucuronidation when compared to UGT2B15*2. Polymorphisms of 
UGT 1A9 and 2B7 have been also identified, whose functional consequence is unclear. The 
coefficient of variation for UGT2B15, 1A9 and 2B7 in a large human liver bank is 72, 55 and 45% 
(the lowest among different UGT isoforms), respectively, and therefore, the impact of the 
polymorphic allelic variants is expected to be limited. Due to the redundancy in UGTs for conjugation 
and the overlapping substrate specificity, it is expected that a single polymorphism would not 
significantly affect the total BPA glucuronidation capacity of individuals. At present no specific 
information about ontogeny in humans is available for UGT2B15. Some information is available on 
other UGT isoforms (e.g. UGT1A1, which reaches adult activity at 3-6 months of age, or UGT2B7, 
which is only 5% that of adults at term, but increases to 30% by 3 months of age, and to adult levels 
by 1 year of age). This pattern has been used in human PBPK models to account for possible limited 
UGT activity for BPA conjugation during early life. Notably, most information on UGT ontogeny 
refers to the liver, which is usually endowed with the highest glucuronidation activity. However, in 
the fetus UGT immunoreactivity in liver and kidney tissue is considerably lower when compared with 
the red blood cells. For this reason it has been hypothesised that circulating UGTs may substantially 
contribute to detoxification of xenobiotics in the fetus (EFSA CEF Panel, 2010). 
Sulfotransferases 
Regarding the role of SULT isoform(s) in the conjugation and deactivation of BPA, human 
recombinant SULT1A1 has been identified as the major isoform mediating BPA sulfation in the 
human liver, although recombinant SULT2A1 and 1E1 showed also some activity. The human 
SULT1A1 gene has common single nucleotide polymorphisms resulting in three allelic variants for 
which the differences in specific activity can be up to 10-fold, although they are not necessarily 
translated into the same degree of interindividual variability in in vivo sulfation capacity. The 
differences due to polymorphism are expected to be covered by the interindividual standard 
uncertainty factor. For SULT enzymes no age-dependency has been described and consequently, in 
humans the sulfation activity is comparable at birth and in the adult (EFSA CEF Panel, 2010). 
3.1.4.2. Evaluation of recent studies on polymorphisms 
Two recent studies were identified in which the consequences of UGT polymorphisms for BPA 
glucuronidation were investigated. 
Hanioka et al. (2011) studied the effect of polymorphic forms of human UGT2B15 expressed in insect 
cells in vitro. The study demonstrated that among the 7 allelic variants of the gene investigated, the 
gene product from UGT2B15.1, 2B15.3, 2B15.4, 2B15.6 and 2B15.7 had intrinsic clearances of 140 
to 178 µL × min-1/mg insect cell membrane protein. Two other forms (2B15.2 and 2B15.5) had a 
considerably less intrinsic clearance (17.2 and 6.6 µL x min-1/mg protein, respectively). Since the Km 
values for all isoforms were approximately similar (2.3 to 5.12 µM), the differences in intrinsic 
clearance were mainly related to a large decrease in Vmax, probably as a result of the DNA sequence 
change in the 2B15.2 and 2B15.5 genes (D58Y; 253G>T) as compared to the wild-type (2B15.1). 
Trdan Lušin et al. (2012) studied the glucuronidation of BPA in adult human microsomal 
preparations. For this purpose, they developed a sensitive analytical method using labeled BPA in 
HPLC-MS/MS, which enabled simultaneous determination of unconjugated and conjugated BPA. 
BPA glucuronidation was studied in microsomes prepared from liver, kidneys, intestines and lungs. 
No BPA glucuronidation could be determined in human lung microsomes. In liver, kidneys and 
intestines, the microsomal intrinsic clearances were 950, 40 and 24 µL × min-1/mg microsomal 
protein, corresponding to full tissue intrinsic clearances of 857, 8 and 2 ml × min-1/kg bw, after 
scaling-up of the microsomal data to full organ weight. These authors also investigated the influence 
of a polymorphism of human UGT1A1 on the metabolism of BPA. Although this is not the most 
active form of UGT to contribute to the glucuronidation of BPA (which is UGT2B15), it still has 
significant capacity. For genotyped microsomes containing only wild-type UGT1A1*1, an intrinsic 
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clearance of 1 240 µL × min-1/mg microsomal protein was found and for UGT1A1*1/*28 
(heterozygous) an intrinsic clearance of 1 190 µL × min-1/mg microsomal protein. However, for the 
homozygous UGT1A1*28/*28, the intrinsic clearance was only 320 µL × min-1/mg microsomal 
protein. There were no differences in Km values for the two allelic variants studied. Thus for the three 
different genotypes intrinsic tissue clearances of 1 113, 1 075 and 284 ml × min-1/kg bw were 
calculated. The authors reasoned that this polymorphism of UGT1A1 may have toxicological 
consequences, since the glucuronidation capacity of the liver may be strongly reduced in UGT1A1*28 
homozygous individuals. 
In a recent paper Partosch et al. (2013) used published data on Vmax and Km from 15 different hepatic 
cell donors (Kuester and Sipes, 2007) to simulate the individual blood concentration of unconjugated 
BPA by PBPK modelling. In this human-based PBPK model the estimated highest and lowest peak 
blood concentrations (Cmax) were 4.7-fold different and the Area Under the Curve (AUC) varied with 
a factor of 4.6. In this model, the glucuronidation and the sulfate pathways are negatively correlated: 
in subjects with low glucuronidation capacity the fraction of dose which is metabolised to the sulfate 
conjugate is higher than in subjects with high glucuronidation capacity. The results show that the 
differences are covered by the intraspecies kinetic default assessment factor  
The CEF Panel concluded overall that due to the redundancy of UGTs, a single polymorphism is 
unlikely to significantly affect the total BPA glucuronidation capacity of an individual. The default 
intraspecies uncertainty factors used to derive a health-based guidance value are considered sufficient 
to account for possible differences in rates of metabolism of BPA. 
3.1.5. Inter-species extrapolation of BPA dosimetrics using an HED Approach 
A critical aspect of any risk assessment is the extrapolation of findings from animal toxicology studies 
with BPA to understand the potential for effects in humans. This extrapolation includes uncertainties 
surrounding inter-species and intra-species differences in toxicokinetics and toxicodynamics, which 
are often incorporated by using default uncertainty factors to convert reference points (e.g. BMDL, 
NOAEL) into health-based guidance values (e.g. TDI). Derivation of a human-equivalent dose (HED) 
is an accepted method for linking a critical effect from the dose-response relationship in animals to 
predict a level without harmful effects in humans (US EPA, 2011). 
In derivation of the HED, the exposure related to the critical effect (i.e. a BMDL or an NOAEL) 
found in an animal study is multiplied by a factor that takes account of quantitative differences in 
toxicokinetics between the animal species used in the study and humans. This factor then replaces the 
toxicokinetic component in the interspecies assessment factor. The factor by which this toxicokinetic 
component is replaced can be obtained from allometric scaling, or from comparison of toxicokinetic 
data as explained below. For the interspecies extrapolation, then of the default factor of 10 only a 
factor 2.5 remains to take account of differences in toxicodynamics (see Table 5.5 in WHO/IPCS, 
2009). 
Since target tissue concentrations determine toxicological effects, measurements that define internal 
dosimetrics (e.g. serum AUC, Cmax, time above a critical concentration) are most often used as the 
basis to characterize inter-species differences. In the absence of mechanism of action information that 
relates a specific dosimetric parameter with the toxicodynamic effect(s), the dose metric most often 
used for parent compound effects is the AUC in serum since it is readily measured, incorporates both 
time and concentration elements of exposure, and is predictably related to tissue AUCs. When 
chemical-specific information is not available, empirically derived allometric relationships between 
kinetic and metabolic parameters in different species, typically involving body weight to the ¾ power, 
provide a basis for inter-species extrapolation of internal dosimetrics. Indeed, the US EPA and ECHA 
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use the ratio of bw1/4 (= [bwAnimal/bwHuman]1/4)11 as a default inter-species toxicokinetic dosimetric 
adjustment factor (DAF) for cancer and non-cancer endpoints when chemical-specific data are not 
available or for extrapolation from animals to humans in general (US EPA, 2011; ECHA 2012). 
PBPK modelling is another accepted method for reducing uncertainty associated with extrapolations 
between species and dose in regulatory risk assessment. 
 
The dose-adjusted AUC (i.e. AUC/D with D representing the dose) is a common means for inter-
species extrapolation of dosimetrics at exposure levels where pharmacokinetic processes are not 
saturated. Under these conditions, the Human Equivalent Dose Factor (HEDF) is defined by a 
common relationship between the external dose given to an animal and the resultant AUC and the 
external dose given to a human and its AUC. The HED represents the multiples of the BPA dose (D) 
in an animal species by a specified route and lifestage that a human would require to obtain an 
equivalent AUC from oral administration (D × HEDF = HED). For example, if the same dose (on a 
body weight basis) administered to either an animal or a human produces a 5-fold higher AUC in the 
human, 1/5th the animal dose given to a human would produce the same internal dosimetric. 
Experimentally, AUCs are often determined using the same dose so that the HEDF simplifies to (the 
ratio of) animal AUC/human AUC, which is 0.2 in the previous example.  
For BPA chemical-specific data are available, so that the ratio AUCAnimal/AUCHuman can be derived. 
The studies of Doerge et al. (2010a, b ; 2011a) provide BPA measurements obtained using identical 
experimental protocols for adult and newborn CD-1 mice, Sprague-Dawley rats, and Rhesus 
monkeys. The AUC data for oral and injected BPA are shown in table 3 for a common external dose 
of 100 µg/kg bw per day along with AUCs for human adults that were simulated for the same oral 
dose using the human PBPK model of Yang et al. (2013) which evolved from the monkey-based 
model of Fisher et al. (2011). For adult mice with oral administration, the published AUC value of 
0.1 nM×h (Doerge et al., 2011b) was critically reviewed by the CEF Panel in respect to the 
uncertainty arising from the high proportion of non-detects among the data, and a recalculated AUC 
value of 0.244 nM×h was derived (see Section 3.1.6.1 ). table 3 also lists the respective human-
equivalent, allometric scaling-derived DAFs for adults to convert point of departure doses from 
animal toxicity tests to human-equivalent exposures. table 3 indicates that in an adult mouse, an oral 
dose of 1 mg/kg bw is equivalent to a human dose of 0.068 mg/kg bw (1 mg/kg bw x HEDF of 0.068 
= HED of 0.068 mg/kg bw), i.e. because of the large differences in body weight, a smaller dose is 
required in humans to achieve the same AUC. table 4 shows the comparable data for human infants, 
showing that a neonatal rat injection dose of 1 mg/kg bw per day is equivalent to an oral dose of 310 
mg/kg bw per day to a human infant (i.e. because of the immaturity of Phase II metabolism in 
neonatal rodents but not primates and the bypassing of metabolism in the GI tract after injection). 
These AUC ratios are chemical-specific adjustment factors that replace the typical default uncertainty 
factor for inter-species extrapolation of toxicokinetics. As explained above, then only a factor of 2.5 
would remain to cover the differences in toxicodynamics . For example, the TDI of 50 µg/kg bw per 
day established by EFSA for BPA in 2006 was based on a NOAEL of 5 mg/kg bw per day in 
Sprague-Dawley rats from the Tyl et al. (2002) study. The TDI was obtained by dividing the NOAEL 
by a 100-fold default combined uncertainty factor, which is comprised of factors of 10 for each 
toxicokinetics and toxicodynamics. Using the HED approach with a human-equivalent dose factor 
(HEDF) of 0.72 for orally dosed adult rats (table 3), the HED-derived TDI would be 
(5000×0.72)/(2.5×10) = 144 µg/kg bw per day. The CEF Panel noted that the use of chemical-specific 
adjustment factors represents a refinement in risk assessment, but also noted the uncertainties related 
to the derivation of the HEDF, particularly in the mouse, as discussed further in Section 3.1.6.  
For comparison with the non-chemical specific default approach table 3 also shows the DAFs 
calculated for adult animals based on the EPA default procedure, which is based solely on the animal-
                                                     
11 The ¼ exponent results from the application of the bw−1/4 scaling to doses in units of mg/kg bw per day (rather than mg 
per day). 
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to-human body weight ratio raised to the ¼ power. Comparison with the experimentally derived 
HEDFs  provides some insight about BPA metabolism and disposition affecting dosimetrics beyond 
the predictable body weight effects: 1) in mouse, the HEDF of 0.068 (= 0.244/3.6) is lower than the 
DAF of 0.14, which suggests that mouse has greater metabolic capacity, serving to reduce the AUC; 
2) in rat, the HEDF of 0.72 exceeds the DAF of 0.24, which could reflect the effect of enterohepatic 
recirculation in the rat that serves to extend exposure to BPA; 3) in monkey, the HEDF of 0.42 is 
similar to the DAF of 0.55, which suggests that body weight differences predominate. 
Table 3:  Determination of HEDF for BPA in human adults. HEDF (= AUCAnimal/AUCHuman) 
values were calculated from experimentally determined serum AUCs of unconjugated BPA 
from adult and neonatal animals for a common gavage or injection dose of 100 µg/kg bw and 
from AUCs for human adults and infants that were simulated for the same oral dose using a 
human PBPK model. The HED represent the multiples of BPA dose (D) in an animal species 
by a specified route and lifestage that a human would require to obtain an equivalent AUC 
from oral administration (D × HEDF = HED). For comparison, the comparable dose 
adjustment factors (DAF) are shown which were derived by using the US EPA default of 
animal-to-human body weight ratios raised to the ¼ power. 
Species-Route AUC-Adult 
(nmol × h × l–1) 
HEDF-Adult DAF –Adult  
bw1/4 Scaling  
Mouse-oral 
Mouse – IV injection 
0.244* 
54 
0.068 (= 0.244/3.6) 
15 (= 54 /3.6) 
0.14 = (0.025/70)1/4 
Rat-oral 
Rat – IV injection 
2.6 
95 
0.72 (= 2.6/3.6) 
26 (= 95 /3.6) 
0.24 = (0.25/70)1/4 
Monkey-oral 
Monkey – IV injection 
1.5 
180 
0.42 (= 1.5/3.6) 
50 (=180/3.6) 
0.55 = (6.6/70)1/4 
Human-oral 
PBPK-simulation; 




*  Recalculated AUC value, see Section 3.1.6.1 
Table 4:  Determination of HEDF for BPA in human infants. 
Species-Route AUC-Neonate 
(nmol × h × l–1) 
HEDF-Neonate 
Mouse-oral 
Mouse – SC injection 
26 
26 
8.7 (= 26/3) 
8.7 (= 26/3) 
Rat-oral 
Rat – SC injection 
56 
930 
19 (= 56/3) 
310 (= 930/3) 
Monkey-oral 
Monkey – IV injection 
5.7 
190 








3.1.6. Evaluation of uncertainties affecting the determination of HEDF for BPA 
3.1.6.1. Uncertainty and physiological plausibility of the HEDF for adult mice with oral exposure 
The importance of the HEDF for adult mice with oral exposure for the risk assessment of BPA made 
it necessary to perform a dedicated uncertainty analysis of this parameter and of the underlying AUC 
for adult mice with oral exposure. The following paragraphs summarise the analytical uncertainty in 
the toxicokinetic raw data and describe lower-, middle-, and upper-bound approaches for the 
determination of AUC. The middle-bound AUC estimate was chosen to derive a HEDF for risk 
assessment. Finally, the physiological plausibility of the middle-bound AUC estimate is evaluated. 
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The toxicokinetics in adult mice with oral administration was examined by Doerge et al. (2011b). 
Following the administration by gavage, blood samples were taken at seven time points from 0.25 h to 
24 h. Twelve (new) animals of both sex were used per time point (i.e. 84 animals in total plus 12 
controls). The authors reported that levels of unconjugated BPA that were above the detection limit 
were observed only at the earliest three time points, and only in one or two samples out of the twelve 
determinations at each time. Analysis of the raw data (kindly provided by Daniel R. Doerge, NCTR, 
U.S. FDA, 2013) revealed the following additional information: there was one missing measurement 
at 0.25 h. Moreover, detectable levels of unconjugated BPA that were above the LOD (0.2 nM) were 
observed in 3 of 11 (t = 0.25 h), 2 of 12 (t = 0.5 h), and 1 of 12 (t = 1 h) animals. Finally, five of the 
six detectable observations were in the range of 0.36–0.84 nM, whereas the sixth observation had an 
extreme value of 5.85 nM, which occurred at t = 0.5 h and which was regarded by the authors as an 
outlier to be removed from analysis (Daniel R. Doerge, NCTR, U.S. FDA, 2013, personal 
communication). The impact of this outlier removal is assessed below. 
To reflect the uncertainty that is associated with the estimation  of the AUC due to the high proportion 
of non-detects among the data the CEF Panel decided to derive lower-bound (LB), middle-bound 
(MB), and upper-bound (UB) estimates of the AUC. The following description outlines the 
procedures by which these estimates were derived. 
The lower-bound (LB) approach is based on setting all non-detectable observations of the earliest 
three time points (0.25 h, 0.5 h, 1 h) to zero. The resulting plasma concentration profile, which is 
shown in Figure 3A, yielded an area under the curve from time zero to 1 h (AUC0–1h) of 0.081 nM×h. 
For the area under the curve from 1 h to infinity (AUC1h–∞), a value of 0.026 nM×h was calculated 
from the last concentration value at 1 h and by assuming an exponential decrease with a terminal half-
life t1/2 of 0.6 h which was reported for adult mice with oral administration (Doerge et al., 2011b). 
Summing up the two values yielded an AUC (from time zero to infinity) of 0.108 nM×h. Based on 
this value, a HEDF of 0.030 (= 0.108/3.6) for adult mice with oral administration was derived by 
taking the AUC of 3.6 nM×h for adult humans with oral administration into account (Yang et al., 
2013). Including the outlier at t = 0.5 h (see above) into the calculation would increase the AUC0–1h 
from 0.081 to 0.262 nM×h, which would then result in an AUC (from time zero to infinity) of 0.288 
nM×h and a HEDF of 0.080 which are within the range of uncertainty spanned by the LB and UB 
estimates (see below). 
The middle-bound (MB) approach uses the measurements of the first time point at 0.25 h and sets all 
non-detects to 0.5×LOD (= 0.1 nM) (see Section 4.2.7 in Part I – Exposure assessment). This 
imputation yields a concentration value of 0.253 nM for t = 0.25 h. The next two data points at 0.5 h 
and 1 h are extrapolated from the first data point at 0.25 h by assuming an exponential decrease with a 
half-life of 0.2 h. This half-life was taken from PND 21 mice with gavage (Doerge et al., 2011b) 
(Figure 4C and see below). This extrapolation yields a concentration value of 0.019 nM for t = 1 h. 
The terminal elimination phase at >1 h was assumed to follow an exponential decrease with a half-life 
of 5 h which was based on the evidence from all available toxicokinetic studies on mice with oral 
administration (Figure 4). Specifically, it was reasoned that the time course for unconjugated BPA 
should run in parallel to the time course of total (or conjugated) BPA after a certain time point. Figure 
4 shows several studies with different age groups and oral administration procedures, for which the 
time course could be followed up to 24 h post administration, and for which most terminal half-lives 
for unconjugated and total are in the range of 4–8 h. A value of  5 h was selected. This approach 
yielded values of 0.108 nM×h for AUC0–1h and 0.136 nM×h for AUC1h–∞. The sum of both values 
yields an AUC (from time zero to infinity) of 0.244 nM×h. This AUC gave a HEDF of 0.068 (= 
0.244/3.6). 
The upper-bound (UB) approach is based on toxicokinetic data for PND 21 mice administered by 
gavage (Doerge et al., 2011b) (Figure 4C). As in the experiment with adult mice, blood samples were 
taken at seven time points from 0.25 h to 24 h with 12 (new) animals per time point. The authors 
reported that levels of unconjugated BPA that were above the LOD (0.2 nM) were observed only at 
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the earliest three time points. Analysis of the raw data (provided by Daniel R. Doerge, NCTR, U.S. 
FDA, 2014) revealed that there were two missing measurements at 0.25 h and three missing 
measurements at 0.5 h. Moreover, detectable levels of unconjugated BPA that were above the LOD 
were observed in 10 of 10 animals (t = 0.25 h), 7 of 9 animals (t = 0.5 h), and 1 of 12 (t = 1 h) 
animals. The CEF Panel took account of these non-detects in the following way: The mean plasma 
BPA concentration of 1.279 nM at t = 0.25 h is not affected (no non-detects); for the two non-detects 
at t = 0.5 h, the concentration was set to half the LOD, resulting in a mean plasma BPA concentration 
of 0.553 nM at this time point. The concentration estimate for t = 1 h as given by Doerge et al (2011b) 
was discarded, because it is based on only a single quantifiable data point. Instead, the concentration 
at t = 1 h was estimated to be 0.098 nM by extrapolation from the mean values at t = 0.25 h and t = 
0.5 h, assuming a half-life of 0.2 h for the first hour post dosing. This serum concentration time 
profile was used as a starting point to derive an UB estimate of the AUC in adult mice. For the 
terminal elimination phase at >1 h, an exponential decrease with a half-life of 5 h was assumed (see 
MB approach). This approach yielded values of 0.552 nM×h for AUC0–1h and 0.705 nM×h for AUC1h–
∞. The sum of both values yields an AUC (from time zero to infinity) of 1.257 nM×h. This AUC gave 
a HEDF of 0.349 (= 1.257/3.6). 
To summarize, lower-bound (LB), middle-bound (MB), and upper-bound (UB) estimates of 0.108, 
0.244, and 1.257 nM×h were obtained for the AUC. These estimates translate into HEDF values of 
0.030, 0.068, and 0.349. Of the three AUC estimates, the MB estimate of 0.244 nM×h was chosen to 
derive a HEDF of 0.068 for adult mice with oral administration. 
The physiological plausibility of the chosen AUC estimate for adult mice with oral administration was 
evaluated by taking the AUC values for adult rats, monkeys, and humans and the allometric scaling to 
toxicokinetic parameters with body weight into consideration. The results of toxicokinetic studies 
with IV injection in adult mice (Doerge et al., 2012), rats (Doerge et al., 2010a), and monkeys 
(Doerge et al., 2010b) have shown a close allometric relationship between serum clearance (Cl = 
BW×dose/AUC) and body weight (BW) with an exponent of 0.78, close to the default value of 0.75, 
and a coefficient of 3.6 L/h (Figure 8A). The latter corresponds to the predicted clearance for an 
animal of 1-kg body weight. For toxicokinetic studies with oral administration, the quotient of AUC 
and dose equals the serum clearance divided by the systemically available fraction (= Cl / f). Plotting 
the Cl/f values for mice, rats and monkeys against the respective body weights showed a less close 
allometric relationship (Figure 8B). Fitting this relationship with a restriction of the allometric 
exponent to 0.78 (i.e. the exponent for the IV data) yielded a regression line with a coefficient of 354 
L/h corresponding to an systemically available fraction f (= oral bioavailability) of 1.0% (= 
3.6/354×100%). The fact that the data point for rats is below the regression line suggests additional 
factors contribute to a higher AUC (e.g., enterohepatic recirculation of aglycone BPA; Figure 3B). In 
contrast, the data point for mice is well above the regression line which indicates a lower  AUC for 
mice (see MB estimate in Figure 8B). There is, however, a relatively large uncertainty in the data 
point for mice that is reflected by the LB–UB range in Figure 8B. For adult humans, a Cl/f value was 
calculated from the AUC of 3.6 nM×h (predicted from PBPK modelling; Yang et al., 2013), the oral 
dose of 100 µg/kg bw per day, and the body weight of 75 kg. This Cl/f value for adult humans 
compared well with the prediction made by regression analysis of the animal TK data (Figure 8B). 
 
To conclude, in spite of the analytical difficulties in measuring the serum concentration time course of 
unconjugated BPA in adult mice with gavage administration of 100 µg/kg bw per day, which 
contributed to a great extent to the uncertainty in AUC, there are also physiological reasons related to 
the extensive first-pass metabolism in adult mice. This at least partly explains the (relatively strong) 
discrepancy between observed toxicokinetic values and expected values predicted from default 
allometric considerations. 
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Figure 8:  Allometric scaling of serum clearance values for adult mice, rats, monkeys, and 
humans from oral and IV administration (see also Doerge et al., 2012). For IV data, linear 
regression analysis was performed on log-log coordinates. For oral data, the regression 
analysis was performed with a restriction of the allometric exponent to 0.78 (i.e. the exponent 
for the IV data) and excluding the human data point, which was not experimentally based but 
but based on PBPK modelling (Yang et al., 2013). For further details, see main text. 
3.1.6.2. Main sources of uncertainty in the determination of HEDF in general 
The Human Equivalent Dose Factor (HEDF) is used to account for the toxicokinetic portion of the 
interspecies differences. Multiplying the HEDF by a reference point of a toxicity study yields a 
human equivalent oral dose that can be used for risk assessment. For the present opinion, HEDF 
values were calculated from the area under the curve (AUC) of the serum unconjugated BPA 
concentration in animals and humans (HEDF = AUCAnimal/AUCHuman) under the standard condition of 
a common external dose of 100 µg/kg bw per day. 
AUCAnimal values were obtained from toxicokinetic experiments with oral administration, IV injection 
or SC injection in adult and newborn CD-1 mice, Sprague-Dawley rats, and rhesus monkeys (Doerge 
et al. 2010a,b, 2011a,b, 2012). The AUCHuman values for human adults and infants with oral dosing 
were predicted by PBPK modelling (Yang et al., 2013) using a monkey-based PBPK model (Fisher et 
al., 2011). 
The present evaluation of uncertainties affecting the HEDF is focused on animal and human studies 
with oral administration because these were the most critical and relevant studies for risk assessment. 
Compared to studies with IV or SC bolus injection, oral administration studies are influenced by 
potentially more sources of biological variability due to the different administration procedures (e.g., 
gastrointestinal bolus gavage, oral bolus dosing, exposure via diet). For the present opinion, the 
HEDFs for animal studies with oral dosing were derived from bolus-gavage toxicokinetic studies in 
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animals (Doerge et al. 2010a, b, 2011a, b, 2012), and from a human PBPK model (Yang et al., 2013), 
which originated from a monkey-based PBPK model with bolus-gavage dosing (Fisher et al., 2011). 
The human PBPK model was evaluated against the results of a toxicokinetic study in humans with 
gelatin-capsule administration (Völkel, et al., 2002). 
For HEDF determination, the CEF Panel is of the opinion that toxicokinetic studies in animals and 
humans should be comparable in respect to the administration procedures, and should permit fast 
gastrointestinal absorption. Procedures such as gastrointestinal bolus gavage with aqueous solutions 
or gelatin-capsule administration have the advantage of avoiding important sources of variability 
arising from the use of non-aqueous vehicles such as corn oil and from absorption-delaying digestion 
processes following oral bolus dosing or dietary exposure. The delay in the latter results from the 
inclusion of processes with relatively long time constants (i.e. mechanical and enzymatic food 
digestion, transport of digested food). From the systems analysis point of view, pulsed inputs (i.e. 
gastrointestinal bolus gavage, gelatin-capsule administration) are preferred for toxicokinetic studies to 
reveal the true systems parameter such as the time constants for gastrointestinal absorption, 
distribution, metabolism, and excretion (ADME). Other administration procedures (e.g., use of a corn-
oil vehicle, dietary exposure) are more likely to yield apparent time constants not reflecting 
elementary (first order) ADME processes. Moreover, they are more prone to sources of variability as 
mentioned before. 
The CEF Panel noted that the HEDF determination for animal studies with oral dosing is based on 
administration procedures which are somewhat artificial from the consumer exposure point of view. 
However, these "artificial" procedures apply to the animal and human toxicokinetic studies as well, so 
that the HEDF in itself is consistent. The question of applicability to the human situation arises when 
the HEDF is multiplied with the reference point of a toxicity study to yield a human equivalent dose. 
The question then is whether the type of administration in the toxicity study (e.g. via diet) is 
comparable to the typical exposure situation in humans. The two-generation reproductive toxicity 
study in CD-1 mice by Tyl et al. (2008), for example, exposed the animals via dosed feed. Because of 
the additional physiological (i.e. digestive) processes involved, the time course of the serum 
concentration of unconjugated BPA can be expected to deviate from those observed in toxicokinetic 
studies with gastrointestinal bolus gavage or gelatin capsule administration. Indeed, Sieli et al. (2011) 
reported a change in the shape of the serum concentration-time profile for unconjugated BPA and also 
a delayed time to Cmax when the oral-bolus dosing was changed to dietary exposure. Remarkably, the 
AUCs were comparable between both types of administration. Since the typical exposure to BPA in 
humans is via dietary exposure, there is no reason to question the application of the HEDF to the PoD 
of a toxicity study with dietary exposure. 
Overall, the main sources of uncertainty in the determination of HEDF are (i) the variabilities in the 
experimental animals and in the dosing and sampling procedures, and (ii) the uncertainty about the 
serum concentration-time course of unconjugated BPA in humans as predicted by PBPK modelling. 
These sources of uncertainty influence the AUCAminal and AUCHuman, which are ratioed to yield the 
HEDF. An evaluation of the magnitude of uncertainty of the individual sources of uncertainty is given 
in Appendix D. The overall uncertainty is judged to be within 0.5–2 times the HEDF estimate. A 
specific case is the toxicokinetic study in adult mice with oral administration, for which a dedicated 
uncertainty assessment was performed in Section 3.1.6.1.  
Multiplying the HEDF with the reference point of a toxicity study with oral administration re-raises 
the issue of uncertainty in the extrapolation to the human situation. The question of uncertainty is 
whether the type of oral administration in the toxicity study is comparable to the typical exposure 
situation in humans. The exposure of animals via dosed feed has been shown to lead to a serum 
concentration-time profile for unconjugated BPA which was different from that observed under oral-
bolus dosing (Sieli et al., 2011); the AUC, however, was not affected. Since the typical exposure to 
BPA in humans is via dietary exposure rather than via bolus dosing, there is no reason to assume a 
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large uncertainty when extrapolating from a toxicity study with dietary exposure to the human 
situation. 
3.1.7. Dermal absorption and penetration of BPA and PBPK modelling of aggregated oral 
and dermal exposure 
As described in Section 3.1.5, the CEF Panel made use of the results of PBPK modelling (Fisher et 
al., 2011; Yang et al., 2013) to apply the HED concept for converting doses and reference points 
from animal toxicity studies into human equivalent oral doses, which can directly be compared with 
oral exposure estimates. 
 However, because the dermal route of exposure (mainly due to thermal paper and to some extent 
due to cosmetics) was also an important source of exposure to BPA, it was necessary to carry out an 
assessment of aggregated oral and dermal exposure to BPA, again using PBPK modelling. It should 
be noted that this aggregated assessment did not include the contribution to BPA exposure due to 
inhalation of BPA-containing dust, as this source was considered to contribute only a very small 
fraction of total BPA exposure (< 1%) and no suitable PBPK model was readily available to provide 
an estimate of the internal dose metric arising from inhalation. 
In order to carry out an assessment of aggregated oral and dermal exposure to BPA, it was necessary 
to have information on the dermal absorption and penetration of BPA, in order to quantify how an 
external dermal dose translates into an internal dose metric (e.g., AUC) for unconjugated BPA, the 
toxicologically active compound.  Information of this internal dose metric enables the conversion of 
the external dermal dose into an equivalent oral dose (i.e. an oral dose that would result in the same 
AUC as the dermal dose that it represents) that can be summed up with the oral exposure estimates 
(e.g. from diet) to provide an aggregated exposure estimate that can directly be compared to a health-
based guidance value.  
So far, no toxicokinetic study in humans involving dermal exposure has been carried out, that 
provides information about (i) the extent of dermal absorption of BPA and (ii) the internal dose 
metrics for unconjugated BPA. However, several in vitro studies on cutaneous penetration using pig 
skin and human skin samples and an in vivo study in rats with dermal BPA absorption are available. 
The information available from these in vitro studies can, in principle, be used in PBPK modelling to 
simulate the fate of BPA taken up dermally. The PBPK model of Fisher et al. (2011) does not contain 
an implementation for a dermal input. However, Mielke et al. (2011) developed a PBPK model for the 
oral and dermal exposure, which enables predictions of serum concentration-time profiles and 
estimations of internal dose metrics for unconjugated BPA following oral and dermal exposure. The 
CEF Panel therefore decided to use the PBPK model of Mielke et al. (2011) to simulate the 
aggregated oral and dermal exposure. The implications of using a second PBPK model, in addition to 
the PBPK model of Fisher et al. (2011), which was used for the derivation of the HED, are discussed 
below. 
3.1.7.1. In vitro and in vivo studies on dermal absorption 
Appendix D provides an overview of the experimental studies in vitro and in vivo that have been used 
to derive an estimate of the fraction of an external dermal dose which reaches the systemic circulation, 
while the following section provides the conclusions of the CEF Panel on the extent of dermal 
absorption and penetration, based the data from these studies.  
3.1.7.2. Conclusion on the extent of dermal penetration and absorption 
The available evidence from in vitro dermal absorption studies with human skin explants from breast, 
abdomen, and upper leg, and also from an in vivo dermal absorption study in rats, suggests a 24-h 
dermal absorption of 2.3–8.6%. The upper limit of 8.6% was reported by Demierre et al. (2012) as the 
fraction of the applied dose that passed through human skin explants within 24 h. Demierre et al. 
(2012) additionally reported a skin deposition of ~35% of the applied dose after 24 h, the main 
fraction being located in the most external layers of the stratum corneum. The CEF Panel decided to 
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use a skin absorption of 10% for exposure scenarios with dermal contact to thermal paper. In the EU-
RAR (2008), a dermal absorption of 10% was assumed, based on default considerations with respect 
to lipophilicity and molecular mass. The CEF Panel further decided not to consider the amount 
deposited in the stratum corneum as becoming available for systemic uptake for reasons emerging 
from the PBPK modelling of dermal exposure. 
For the PBPK modelling of exposure scenarios with dermal contact to thermal paper, a BPA depot 
(receiving 100% of the external dermal dose) was assumed in the moisture film on the skin surface. It 
was further assumed (very conservatively) that the BPA depot remains on the skin surface during the 
whole day and that 10% of the initial depot content is absorbed within 24 h. BPA remaining on the 
skin surface after 24 h (i.e. 90% of the inital depot content) is assumed to be completely removed by 
hand washing, and the skin surface depot is then reloaded with 100% of the new dermal dose. In other 
words, the BPA depot is assumed to be periodically replenished to 100% after 24 h by a new dermal 
contact to thermal paper. An important consequence of assuming the BPA depot to be depleted to 
only a small extent within 24 h is that the dermal absorption process is in a steady state with a 
virtually stable and permanent concentration gradient in the stratum corneum, along which BPA is 
diffusing through the skin to reach the systemic circulation. These simplifying and conservative 
assumptions, which were made to keep the PBPK model as simple as possible, show that the fraction 
deposited in the stratum corneum will remain there as a concentration gradient as long as BPA is 
available on the skin surface.  
The CEF Panel decided not to consider skin metabolism in dermal exposure scenarios as the available 
information does not enable derivation of a reliable estimate of the extent of skin metabolism. This 
results in a conservative estimate of the fraction of an external dermal dose of unconjugated BPA 
reaching the systemic circulation. The CEF Panel noted that the assumption of 10% absorption for the 
hand contact to thermal paper is also a further conservative assumption, since (compared to human 
skin explants from breast, abdomen or the dorsal part of the upper leg) the absorption across the skin 
of the palms can be expected to be lower because of the thicker stratum corneum. 
The CEF Panel recognised the potential overestimation of the internal dose metric following dermal 
exposure, resulting from combining conservative assumptions about the following:  
a. the fraction of BPA permeating through the skin, the kinetics following dermal exposure, and 
the absolute amount of total human exposure to BPA that occurs via the dermal route, 
particularly when it is realised that the dietary intake assessments alone already exceed the 
urinary biomonitoring estimates;  
b. the assumption of 10% absorption through the fingers and hand in vivo, which is thicker than 
the skin sections used in the ex vivo studies; and 
c. not considering metabolism in the skin prior to systemic distribution. 
The CEF Panel noted that ongoing human dermal BPA PK and cashier studies at the NIEHS Clinical 
Research Unit will help to resolve much of the uncertainty associated with dermal exposure. The 
above considerations suggest that estimates of internal exposure from the dermal route are both highly 
uncertain and likely to significantly influence the combined estimate of total systemic exposure to 
unconjugated BPA. The model used in the current opinion takes into account these uncertainties 
mentioned above in such a way that it leads to overly conservative internal exposure estimates and 
thus also to overly conservative oral dose equivalents. 
3.1.7.3. PBPK modelling of aggregated oral and dermal exposure 
A PBPK model for the aggregated oral and dermal exposure (Mielke et al., 2011) was used to enable 
estimation of the internal dose metrics for unconjugated BPA for a combined exposure to BPA via 
diet and house dust (oral route) and via thermal paper and cosmetics (dermal route). The model 
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structure is shown in Figure 9A. When re-implementing the PBPK model using the statistical 
computing environment R (R Core Team, 2014) in combination with the deSolve package (Soetaert et 
al., 2010) the model predictions were checked and agreed with those published by Mielke et al. 
(2011). For the present opinion, PBPK model predictions were performed for adult males and children 
(1.5 – 4.5 years), using the model parameters given by Mielke et al. (2011) and Mielke and Gundert-
Remy (2009). These two population groups matched the population groups of adult males (18 – 45 
years) and children (3 – 10 years) which were used in Part I – Exposure assessment. PBPK model 
parameters are given in Table 56 in Appendix D). 
Compared to the published model version (Mielke et al., 2011), the PBPK model was slightly 
modified in respect to the simulation of dermal exposure. For the uptake of BPA from cosmetics, a 
constant uptake rate was assumed, leading to 50% absorption of the external dermal dose within 24 h. 
For the uptake of BPA from thermal paper, it was assumed that thermal paper is touched once a day 
and that BPA migrates into a depot in the moisture film on the skin surface within a short duration of 
5 min. The amount migrating into this skin-surface depot is 100% of the external dermal exposure 
(values taken from Tables 22 and  23 in Part I – Exposure assessment). During each day (= 24 h), 
10% of the initial depot content on the skin surface is assumed to diffuse across the skin barrier into 
the skin compartment according to a first-order process with a time constant k = –
ln(0.9)/(24 h) = 0.00439 h–1 which corresponds to a dermal absorption half-life of 158 h. The value for 
the time constant necessarily results from the assumption of 10% absorption within 24 h. BPA 
remaining on the skin surface after 24 h (i.e. 90% of the inital depot content) is assumed to be 
completely removed by hand washing, and the skin surface depot is then reloaded with 100% of the 
new dermal dose. In other words, the BPA depot is assumed to be periodically replenished to 100% 
after 24 h by a new dermal contact to thermal paper. 
Table 5 shows the oral and dermal doses (DO and DD), which were used for the scenarios with average 
and high exposures of children and adult males to BPA in diet and house dust (oral route) and in 
thermal paper and cosmetics (dermal route). The exposure to and uptake of BPA from the various 
sources was implemented differently in the PBPK model. It comprised a continuous and constant 
dermal uptake of BPA in cosmetics, a single dermal contact to thermal paper per day, and a dietary 
exposure involving 3 meals per day. For reasons of keeping the PBPK model as simple as possible, 
the oral uptake via dust was assumed to be synchronized with dietary uptake. Since internal exposure 
is in the linear range of the toxicokinetics of BPA, this assumption has no influence on the magnitude 
of the calculated AUCs. The dermal uptake via dust was regarded as negligible (see Section 4.5.3 in 
Part I – Exposure assessment). PBPK modelling was used to simulate the serum concentration of 
unconjugated BPA (Figure 9B). The simulation was run for 10 days to reach a steady state. The 
predicted serum concentration-time profile for the last day was used to determine the area under the 
curve (AUC). Table 5 contains the predicted serum AUC values of unconjugated BPA for the oral 
(AUCO) and dermal (AUCD) exposures. Since only a reference dose for external oral exposure is 
available (i.e. a TDI or a t-TDI), for the risk assessment it is necessary to express both oral and dermal 
exposures on the same basis, thus as external oral equivalents. When exposures via both routes are 
converted to external oral equivalents, these can also be summed, resulting in an estimate for 
aggregated exposure. For oral exposure such a conversion is not necessary, since the oral exposures 
are intrinsically external equivalent oral exposures. To convert the external dermal exposure (DD) to 
equivalent oral exposure (D'D), and thus to allow for the calculation of an aggregated (oral plus 
dermal) exposure estimate, the following equation was used:  
DODD DEFD ⋅=′ →     with    . 
EFDO is the dermal-to-oral route equivalence factor which is calculated from the ratio of the dose-
adjusted AUC values. Within each population group and for each dermal source, the obtained EFDO 
values are virtually the same for the average and high exposure scenarios, reflecting linear kinetics. 
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compared to thermal paper, reflecting the assumption of a five-fold higher dermal absorption for 
cosmetics compared to thermal paper. Finally, the EFDO values are smaller for children than for adult 
males (e.g., 0.77 versus 1.20 for thermal paper), possibly resulting from a higher body-weight-specific 
metabolic rate (clearance) for the children. table 6 shows the dermal doses expressed as equivalent 
oral doses for the average and high exposure scenarios for children and adult males. The dermal-to-
oral route conversion was also performed for adolescents using the EFDO values for adult males. 
 
Figure 9:  PBPK modelling of aggregated oral and dermal exposure in humans. PBPK 
modelling of aggregated oral and dermal exposure in humans. (A) Structure of the PBPK 
model for unconjugated BPA (Mielke et al., 2011). (B) Model prediction of the serum 
concentration of unconjugated BPA for the high exposure of adult males involving a oral dose 
of 0.336 µg/kg bw per day (diet plus dust taken up via 3 meals per day), an external dermal 
dose of 0.542 µg/kg bw per day (finger contact to thermal paper once a day), and an external 
dermal dose of 0.004 µg/kg bw per day (exposure to trace amounts of BPA in cosmetics). The 
extent of absorption in this model is 100% for the oral route, but with a first pass effect build 
in in the model so that the systemic availability is reduced. Extent of absorption is 10% for 
the dermal route with contact to thermal paper, and 50% for the dermal route associated with 
cosmetics. For the dermal contact with thermal paper, it is assumed that the depot on the skin 
surface is refilled to 100% of the external dermal exposure, based on the assumption of 1× 
hand washing followed by new contact to thermal paper. For cosmetics, a continuous (stable) 
uptake is assumed. 
Table 5:  PBPK model-based predictions of the area under the curve (AUC) for unconjugated 
BPA in serum. Prediction were made for average and high exposure scenarios for two 
selected population groups. Dermal doses (DD) represent the individual exposures to BPA in 
thermal paper (T) and cosmetics (C) whereas the oral doses (DO) refer to the summed 
exposures from diet and house dust (table 22 and 23 in Part I – Exposure assessment ). Given 
are the predicted AUC values for the oral (AUCO) and dermal (AUCD) exposures as well as 
the values for the dermal-to-oral route equivalence factor (EFDO). 
Exposure 
scenario 




DO DD AUCO AUCD EFDO 
µg (kg bw)–1 d–1 nmol × h × l–1  
Average Adult male 
T 0.127 0.059 0.037 0.021 1.20 C 0.002 0.004 6.02 
Children 1.5 – 4.5 years T 0.293 0.069 0.070 0.013 0.77 
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C 0.002 0.002 3.83 
High 
Adult male T 0.336 0.542 0.098 0.190 1.20 C 0.004 0.007 6.03 
Children 1.5 – 4.5 years T 0.818 0.550 0.195 0.101 0.77 C 0.004 0.004 3.85 
 
Table 6:  PBPK model-based conversion of dermal doses from different sources into equivalent 
oral doses for average and high exposure scenarios for three selected population groups. 
Dermal doses (DD) represent the individual exposures to BPA in thermal paper (T) and 
cosmetics (C). Given are the dermal-to-oral route extrapolation factors (EFDO) which were 
used to translate the dermal doses into equivalent oral doses (D'D). For adolescents, the 
exposure estimates of the adolescent population (10 – 18 years) were used in combination 
with the EFDO values for adult males. 
Exposure 
scenario 
Population group in Dermal 
source 








18 – 45 years Adult male 
T 1.20 0.059 0.071 
C 6.02 0.002 0.012 
Adolescents 
10 – 18 years Adult male 
T 1.20 0.094 0.113 
C 6.02 0.003 0.015 
Children 
3 – 10 years 
Children 
1.5 – 4.5 years 
T 0.77 0.069 0.053 
C 3.83 0.002 0.008 
High 
Adult males 
18 – 45 years Adult male 
T 1.20 0.542 0.650 
C 6.03 0.004 0.024 
Adolescents 
10 – 18 years Adult male 
T 1.20 0.863 1.036 
C 6.03 0.005 0.029 
Children 
3 – 10 years 
Children 
1.5 – 4.5 years 
T 0.77 0.550 0.424 
C 3.85 0.004 0.016 
 
In the tables 5 and 6, the average exposure estimate of 0.059 µg/kg bw per day for adult males is 
based on a transfer of 1.375 µg BPA from thermal paper to the finger tips (surface area per finger tip: 
2 cm2, surface dose: 0.69 µg/cm2), the contact by 3 fingers of one hand only, a single handling event 
per day, and a body weight of 70 kg (1.375 μg × 3 d–1 / 70 kg = 0.059 µg/kg bw per day). The high 
exposure estimate of 0.542 µg/kg bw per day for adult males was obtained by modifying some of the 
above assumptions: contact with two hands (i.e. 6 finger tips in total) and 4.6 handling events per day. 
It is further assumed that each new handling event adds 1.375 µg BPA to the already existing BPA 
depot in the moisture film on the skin surface, resulting in a total daily surface dose of 
4.6×0.69 µg/cm2 = 3.17 µg/cm2. Again, only 10% of this surface dose is assummed to be absorbed 
within 24 h. 
Dermal exposure scenarios for children were based on the transfer of 1.375 µg BPA per finger tip, 
the contact of 3 or 6 fingers, handling events of 0.5 or 2.0 per day, and a body weight of 30 kg. 
The CEF Panel noted that the use of a second PBPK model (Mielke et al., 2011) for converting an 
external dermal exposure into an equivalent oral exposure introduced a (consequential) inconsistency, 
because the PBPK model of Fisher et al. (2011) was selected as the model of choice for deriving the 
HED (see Section 3.1.3.4). The CEF Panel quantified the impact of the functional model differences, 
which turned out to be driven to a major extent by the intestinal first-pass metabolism (present in the 
Fisher model, but absent in the Mielke/Gundert-Remy model) and to a very minor extent by a slight 
difference in intrinsic clearance of the liver. The overall impact is that because of this model 
uncertainty, the dermal-to-oral route equivalence factors (EFDO) could be 7.6-fold higher than the 
equivalence factor used here (see Appendix D).  
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3.1.8. Conclusions on toxicokinetics 
The kinetic data available indicate species- and life stage-dependent differences. Such variability has 
to be considered when data of different species are compared. Conjugation to BPA-glucuronide, 
which is a biologically inactive form, is the major metabolic pathway of BPA in humans and animals. 
A study in humans on high BPA diets (Teeguarden et al., 2011) showed that unconjugated BPA in 
serum was below the LOD of 0.3 ng/ml (= 1.3 nM), confirming under the condition of the study that 
internal exposure to unconjugated BPA is low. The percentage of unconjugated BPA in blood is only 
a few percent of total BPA (sum of conjugated and unconjugated BPA). Based on the analysis of oral 
(gavage) versus intravenous toxicokinetic data, the oral systemic bioavailability of unconjugated BPA 
in rats is 2.8 %, in mice 0.45 % and in monkeys 0.9 % (Doerge et al., 2010a,b, 2011a, b, 2012). The 
concentrations measured in the animal studies and also in the human study render the relevance of 
serum or blood concentrations in humans, which were measured and reported by some authors in the 
literature (see Section 4.6.3 in Part I – Exposure assessment) as rather unplausible. Experimental data 
on the systemic availability of unconjugated BPA in humans has until now not been published. From 
studies on physiologically based pharmacokinetic (PBPK) modelling it can be concluded, that at 
relevant oral exposures (e.g. < 1 µg/kg bw per day) the maximum serum concentrations (Cmax) of 
unconjugated BPA are in the 3.2–160 pg/ml (7–37 pM) range, depending on the model used (Mielke 
and Gundert-Remy, 2009; Edginton and Ritter, 2009; Fisher et al., 2011; Yang et al., 2013). BPA 
does not accumulate in the body even though the concentration of unconjugated BPA is somewhat 
higher in fat compared to serum.  
Some new animal data in particular in mice, rats and monkey give more insight into the kinetics of 
BPA, in particular into the age-dependent maturation of conjugation reactions. Also, diaplacentar 
transfer of BPA has been measured in rat and monkey. Data in rats indicate that in early pregnancy 
transfer to the fetus might be greater compared to later pregnancy after IV injection exposure of BPA 
(fetus/dam concentration ratios: 2.8 at GD 12, 1.2 at GD 16, 0.4 at GD 20). Unconjugated BPA and 
BPA-conjugates are measured in the amniotic fluid of rats and rhesus monkeys at low concentrations. 
BPA is found in milk of rat dams exposed to BPA at a level of 100 ug/kg bw per day in the 
unconjugated and conjugated forms. The amount delivered to the pups is so small that the 
concentrations in pup serum are below 0.2 nM (45.6 pg/ml), and therefore pup exposure via lactation 
is extremely low (1/300 of the maternal dose). These data are in marked contrast to the average 
concentrations reported for human breast milk (unconjugated BPA  ̴  0.3 ng/ml; total BPA 1.1 ng/ml 
)despite the fact that the average human exposure is 1/1000 of the rat exposure exposure (see Chapter 
4.6.4. in Part I – Exposure assessment).  
Polymorphisms have been described for the enzymes relevant for the conjugation of BPA. Since BPA 
conjugation can be carried out by several enzymes, a single polymorphism in one gene, resulting in a 
reduction or loss of enzymatic activity of functional enzymes may result in a change in the plasma 
levels of unconjugated BPA. Since BPA is glucuronidated by two UTGs and is conjugated not only to 
glucuronides but also to sulphates, it can be assumed that the increase in blood concentration is 
modest. This assumption has been confirmed also in the PBPK modelling study by Partosch et al. 
(2013) showing a 4-fold difference in AUC and Cmax between the human PBPK models with the 
highest and the lowest metabolic activity. This difference in sensitivity of BPA in the human 
population is covered by the assessment factors used in the risk assessment of BPA. 
A solid base of toxicokinetic studies in various laboratory animal species (Doerge et al., 2010a,b,c; 
2011a,b; 2012) provide internal dose metrics for neonatal-to-adult stages and for different routes of 
exposure (oral and intravenous/subcutaneous). Moreover, PBPK models have been developed to 
predict the internal exposures in laboratory animals and humans in a route-specific manner. Overall, 
this body of information permits extrapolation to humans and the application of the HED concept for 
providing HEDF which account for the toxicokinetic portion of the interspecies differences. 
Multiplying the HEDF by a reference point of a critical toxicity study yields a human-equivalent oral 
dose that is used for risk assessment. The assessment of the physiological plausibility of the derived 
HEDF values for adult animals with oral dosing revealed a good agreement of the HEDF for monkeys 
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with the allometric scaling-derived DAF. In rats, the HEDF was 3-times higher than the DAF which 
can be explained by the effect of enterohepatic recirculation, serving to extent the exposure to BPA. 
For mice, the HEDF was 2-times lower than the DAF, which suggests a greater metabolic capacity, 
serving to reduce the AUC. The Panel noted that due to limitations in the analytical detectability of 
unconjugated BPA in mouse serum, the HEDF for mice may be conservative by a factor of 5. 
The available evidence from in vitro skin absorption experiments with human, pig and rat skin and 
from in vivo studies on dermal absorption in rats suggests a 24-h dermal absorption for human skin of 
2.3–8.6%. For exposure scenarios with dermal contact to thermal paper, the CEF Panel decided to use 
a skin penetration of 10%. The CEF Panel decided not to consider the amount deposited in the stratum 
corneum as becoming available for systemic uptake for reasons emerging from the PBPK modelling 
of dermal exposure. The CEF Panel further decided not to consider skin metabolism in dermal 
exposure scenarios as the available information does not permit to arrive at a reliable estimate of the 
extent of skin metabolism. Not to consider skin metabolism is a conservative decision. The CEF Panel 
noted that the assumption of 10% dermal absorption for the hand contact to thermal paper is also a 
further conservative decision, since the absorption across the skin of the palms can be expected to be 
lower than in other body parts because of the thicker stratum corneum. For scenarios with aggregated 
oral and dermal exposures, PBPK modelling was used to estimate the internal dose metrics for 
unconjugated BPA and to convert external dermal doses into an equivalent oral doses. 
3.2. General toxicity 
3.2.1. Animal studies 
EU-RAR (2003 and 2008)  
In the original 2003 EU Risk Assessment report, the evaluation of the systemic effects of BPA after 
repeated exposure via the oral route was based on the review of experimental studies in rats, mice and 
dogs. Changes in body weight gain, liver and kidney were identified as the main systemic effects of 
BPA after oral exposure in both rodent species. In a 90-day dietary study in dogs, a no effect level of 
approximately 80 mg/kg bw per day was identified, with increases in relative liver weight being the 
only other finding observed at approximately 270 mg/kg bew/day.  
In the updated report of 2008, a NOAEL of 50 mg/kg bw per day for liver effects from the 2-
generation study in mice by Tyl et al. (2008), rather than the LOAEL of 120 mg/kg/day from the Tyl 
et al. (2002) study identified in 2003 for these effects, was taken forward to the risk characterisation. 
EFSA (2006 and 2010) 
The EFSA 2006 opinion focused on reproductive and endocrine system-related effects of BPA rather 
than systemic toxicity per se, since these endpoints had been recognized as critical endpoints. As 
reported in the opinion’s summary: “The available studies cover the majority of endpoints considered 
relevant for assessment of reproductive effects and other toxicities….The lowest NOAEL of 5 mg/kg 
bw per day derived in the recent two-generation reproductive toxicity study in mice is based on liver 
effects. Toxic effects of repeated administration of BPA on the liver in mice have also been observed 
in previous studies with a LOAEL of 120 mg/kg bw per day, suggesting that liver toxicity is at least as 
sensitive an endpoint for BPA as reproductive and developmental effects. The NOAEL for liver 
toxicity in mice is identical to the derived NOAEL for reproductive toxicity of bisphenol A in rats used 
in the EU RAR, which is based on effects on adult and offspring body weight gain” (EFSA, 2006).  
In 2010, EFSA further confirmed the validity for setting the TDI of the overall NOAEL of BPA of 5 
mg/kg bw per day for systemic effects identified in the multi-generation studies in rats and mice by 
Tyl et al. (2002, 2008). 
FAO/WHO (2011)  
With regard to repeated exposure studies with BPA, the WHO report concluded: “Tyl et al. (2002, 
2008) conducted two large multigenerational studies in rats and mice using dietary administration of 
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BPA over a wide range of doses (1 or 3 μg/kg bw up to 500 or 600 mg/kg bw), allowing for dose–
response assessment. These studies demonstrated effects on the liver, kidney and body weight at doses 
of 50 mg/kg bw and higher. A more recent study by Stump et al. (2010), which also used an expanded 
dose range and the same animal model as that used by Tyl et al. (2002), demonstrated similar 
findings (on common end-points examined), with a lowest NOAEL of 5 mg/kg bw. The liver also 
appeared to be a target organ in a non-rodent model (dog), with a NOAEL of 74 mg/kg bw following 
oral exposure.” 
ANSES (2011 and 2013)  
The 2013 risk assessment by ANSES specifically dealt with the effects identified as “proven” in 
animal studies and “suspected” in humans in the 2011 ANSES report, none of which was related to 
general toxicity effects.    
3.2.2. Studies on general toxicity after oral exposure to BPA considered most significant by 
previous reports published before 2010 
Tyl et al. (2002) exposed CD Sprague-Dawley rats (n = 20 females per group) to dietary BPA in a 
three generation study at 0, 0.015, 0.3, 4.5, 75, 750, 7 500 ppm (giving doses of approximately 0, 
0.02, 0.3, 5, 50 and 500 mg/kg bw per day). The exposure started 10 weeks before mating and 
continued during mating, gestation and lactation until weaning. At weaning (PND21), 30 animals 
/sex/dose were randomly selected as F1 parents, and exposed to BPA as described for the F0 
generation. The selection, number and treatment of the F2 parents were performed as described for the 
F1 parents. Adult systemic toxicity at 750 and 7 500 ppm in all generations included: reduced body 
weights and body weight gains, reduced absolute and increased relative weanling and adult organ 
weight (liver, kidney, adrenals, spleen, pituitary and brain), and mild renal (tubular degeneration) and 
hepatic pathology (in females only). Reproductive organ histology and function were unaffected, 
except for reduced ovarian weights, a significantly reduced number of implantation sites and 
decreased number of pups/litter on PND 0 at 7500 ppm. In the F1, F2 and F3 offspring vaginal 
patency and preputial separation were delayed, associated with reduced body weight. Adult systemic 
NOAEL were 5 mg/kg bw per day and reproductive and postnatal NOAEL were 50 mg/kg bw per 
day.  
Tyl et al. (2008) examined dietary BPA in a CD-1 mice (n=28 per group) two-generation study at 0, 
0.018, 0.18, 1.8, 30, 300, or 3 500 ppm in feed (giving 0, 0.003, 0.03, 0.3, 5, 50, or 600 mg BPA/kg 
bw per day). 17β-oestradiol (0.5 ppm) was used as positive control. There were no BPA related 
effects on adult mating, fertility or gestational indices, ovarian primordial follicle counts, oestrous 
cyclicity, precoital interval, offspring sex ratios or postnatal survival, sperm parameters or 
reproductive organ weights or histology. Systemic effects in adults were increased kidney and liver 
weight, centrilobular hepatocyte hypertrophy, and nephropathy and statistical significant reduction in 
epididymal sperm concentration (15% reduction) in both F0 and F1 males at 3500 ppm (600 mg/kg 
bw per day). Centrilobular hepatocyte hypertrophy was also apparent in F0 males at 50 mg BPA/kg 
bw per day), and kidney weight was statistically significantly increased at this dose level in both F0 
and F1 males, while in F1 males there was also a statistically significant increase in kidney weight in 
animals receiving 0.3 or 5 mg/kg bw per day. Female mice were less sensitive to these effects. 
Increased kidney and liver weight and centrilobular hepatocyte hypertrophy was observed in F0 
females at 3 500 ppm (600 mg/kg bw per day), but nephropathy was not evident on histopathological 
examination, and centrilobular hypertrophy was the only treatment related change reported in the F1 
females. At 3 500 ppm (600 mg/kg bw per day) BPA also reduced F1/F2 weanling body weight, 
reduced weanling spleen and testes weight (with seminiferous tubule hypoplasia). At lower doses 
(0.018 to 30 ppm) there were no treatment related effects in adults or F1/F2 offspring. There are no 
obvious weaknesses in this study.  
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3.2.3. New studies on general toxicity after exposure to BPA published after 2010 
The US National Center for Toxicological Research (NCTR) has recently completed a subchronic 
toxicity study involving pre- and postnatal administration of BPA to Sprague Dawley rats (US 
FDA/NCTR, 2013 and Delclos et al., 2014). The rats were exposed to BPA by gavage at doses of 0, 
2.5, 8, 25, 80, 260, 840, 2 700, 100 000 and 300 000 µg/kg bw per day from GD 6 to the start of 
labour and then directly to the pups from PND 1 to PND 90. Ethinyl oestradiol (EE2) was used as a 
reference substance and given by gavage at doses of 0.5 and 5.0 µg/kg bw per day. Litters were 
adjusted to 10 pups (5 males and 5 females) at PND1. The litter was the unit of analysis and the target 
litter number was 20 per dose group (n = 18-23). Data collection include body weights, weekly food 
consumption, litter parameters, anogenital distances at PND 1 and PND 90, measures of sexual 
development (vaginal opening and time to first estrus, nipple retention, testicular descent, and 
preputial separation, vaginal cytology, clinical chemistry, organ weights and histology.  
Dose-related changes in organ weight was observed with statistically significant effect at the highest 
dose level only in both females and males, with increased liver weight and reduced weights for the 
following organs: heart, ovary, brain (males only), kidney (males only) and spleen (100 000 µg/kg bw 
per day in females and 300 000 µg/kg bw per day in males). Changes in clinical chemistry (e.g. 
cholesterol, leptin, triglycerides) were observed in both sexes and at the two top dose levels.  
Due to the limited number of studies available addressing the endpoint general toxicity, this endpoint 
has not been analysed by the WoE approach. The CEF Panel nevertheless considered that the general 
toxicity effects of BPA were “likely”. 
3.2.4. Conclusion on hazard identification for general toxicity of BPA 
In summary, BPA effects on the kidney and liver weight were reported both in rats and mice in the 
multi-generation studies by Tyl et al. in 2002 and 2008. In male mice the increased kidney weight was 
associated with nephropathy at the highest BPA dose, while the kidney weight changes were less 
marked in female mice and were not associated with nephropathy. Mild renal tubular degeneration 
was also observed in female rats at the highest dose. In contrast, Tyl et al. (2002) and the new 
subchronic rat study including prenatal exposure by US FDA/NCTR, showed reductions in kidney 
weight. The CEF Panel noted that the mechanisms of the effects in the rodent kidney are not yet 
understood including whether these are due to the unconjugated or conjugated form of BPA. As it 
would not be possible to distinguish between effects of conjugated and unconjugated BPA, the CEF 
Panel assumed that the effects in the kidney were caused by unconjugated BPA as a conservative 
approach. Liver weight was increased in rats (relative weight) and mice (both absolute and relative 
weight), the latter species also showing hepatocyte hypertrophy (Tyl et al., 2002; US FDA/NCTR, 
2013 and Delclos et al., 2014). These observations support that changes in the kidney and liver are 
critical endpoints in BPA toxicity, and based on the EFSA evaluations of 2006 and 2010 the CEF 
Panel considered that these effects were “likely” without performing a WoE. These endpoints were 
therefore taken forward for hazard characterisation.  
3.2.5. Hazard characterisation (dose-response relationship) for general toxicity 
Based on the above mentioned robust studies on general toxicity, the reported effects on kidney and 
liver have been taken forward for hazard characterisation. It should be noted that the US FDA/NCTR 
(2013) study is of shorter duration than the studies by Tyl and colleagues and effects indicative of 
general toxicity were only seen at doses higher than those in the Tyl studies, and therefore the latter 
studies have been selected as the basis for hazard characterisation for general toxicity.  
In compliance with the Opinion of the EFSA Scientific Committee on the use of the Benchmark dose 
(BMD) approach in Risk Assessment (EFSA, 2009), the results obtained on general toxicity in the 
reproductive toxicity study with BPA in mice have been subjected to statistical dose-response 
modelling. Given that a NOAEL of 5 mg/kg bw per day was established from both the rat (Tyl et al., 
2002) and mouse (Tyl et al., 2008) studies, but that the HEDs from the mice are much lower that for 
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rats at the same dose levels of BPA, the focus of the BMD analysis was on the study in mice (Tyl et 
al., 2008). The Tyl et al. (2002) rat study had been used to derive a reference point in the previous 
EFSA opinion from 2010, by using the NOAEL of 5 mg/kg bw per day. As stated in the EFSA 
opinion on BMD the NOAEL and BMDL are equally applicable as a reference point: “It has been 
suggested that larger or additional uncertainty factors might be appropriate when a BMDL is used as 
the reference point. The argument used is that the BMDL does not reflect a “no-effect” dose, in 
contrast to the NOAEL. This argument is based on the false assumption that a NOAEL is associated 
with the complete absence of any effect. As discussed (in Section 3.5), the default values of the BMR 
are such that the BMDL on average coincides with the NOAEL. Further, it was shown in section 3.3 
that the potential magnitude of the effect at the NOAEL can be even greater than the specified effect 
size (BMR) associated with the BMD/BMDL. Taking these considerations into account, an additional 
uncertainty factor, beyond those normally applied is not necessary. The health-based guidance value 
derived from the BMDL can be expected to be as protective as the one derived from the NOAEL, i.e, 
on average over a large number of risk assessments. In conclusion, the default values for uncertainty 
factors currently applied to the NOAEL are equally applicable to the BMDL” (EFSA, 2009). 
The toxicological effects used for defining a reference dose were increased liver weight, increased 
kidney weight and centrilobular hepatocyte hypertrophy in the adult F0 and F1 generation in male 
mice (see table 77 in Appendix E).  Since the public consultation the individual data from Tyl et al. 
(2008) have become available, and new BMD calculations on the changes in organ weights have been 
performed based on individual data. 
For all the new dose-response modelling of the mice individual organ weight data (Tyl et al., 2008), 
the statistical package PROAST (version 40.7) has been used, obtained directly from RIVM, through 
personal contact. For the previous dose-response modelling of the histopathological data (liver 
hypertrophy and mammary duct hyperplasia), PROAST version 38.6 was used. This version is no 
longer available at the website (www.proast.nl), but a more recent version (38.9) can be downloaded. 
Using the PROAST package, the 95 % lower confidence limit (one-sided) of the Benchmark dose 
(BMDL) was calculated. For each evaluation, depending on the type of data evaluated, the statistical 
models for continuous data (organ weights) or for quantal data (histopathology) were used. 
A benchmark response (BMR) of 10% was chosen both for the kidney and liver effects, based on the 
view of the CEF Panel that changes in the kidney and liver weight, and hepatocyte hypertrophy of less 
than 10% should not be regarded as adverse. The CEF Panel also took into account that the changes in 
the liver (hepatocyte hypertrophy) were likely to be adaptive in nature, and the pathological changes 
in the kidney were marginal, only observed at the highest dose level and lacked a clear dose-response.  
All the results obtained are reported in detail in Appendix E. table 7 below shows the BMDL10 values 
obtained for liver and kidney effects in the F0 and F1 generations of mice. A lack of dose-response 
relationship was observed for nephropathy in both sexes. Therefore no model was obtained with 
acceptable fit and no BMDL could be calculated for this effects. The CEF Panel noted that there is 
uncertainty regarding the robustness of the BMD modelling for mammary gland hyperplasia, as 
discussed in more detail in Section 3.9.7.  
The analysis revealed large differences in the BMD estimates obtained with the various models and 
the wide BMD confidence intervals, obtained with some of the models (Appendix E). The CEF Panel 
concluded that the dose-response relationship in the US FDA/NCTR study (2013) and Delclos et al. 
(2014) is not suitable to derive with any confidence a reference point for this endpoint. 









External dose level (µg/kg 
bw per day) 
BMDU10 BMDL10 
Tyl et al., Mice (F0) males, Oral feed Increased absolute liver 456 800 213 100 
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2008 with sex and F0/F1 as 
covariate 
weight 
Tyl et al., 
2008 
Mice (F1) males, 
with sex and F0/F1 as 
covariate 
Oral feed Increased relative liver weight 328 700 229 000 
Tyl et al., 
2008 
Mice (F0) males, 
with sex and F0/F1 as 
covariate 
Oral feed Centrilobular hepatocyte hypertrophy 67 200 3 460 
Tyl et al., 
2008 
Mice (F0) males, 
with sex and F0/F1 as 
covariate 
Oral feed 
Increased absolute mean 
kidney weight 
 
91 690 3 420 
Tyl et al., 
2008 
Mice (F0) males, 
with sex and F0/F1 as 
covariate 
Oral feed 
Increased relative mean 
kidney weight 
 
108 900 8 960 
 
Although the lowest BMDL10 from the modelling was observed for hepatocyte hypertrophy, the effect 
of BPA on hepatocyte hypertrophy was regarded by the CEF Panel as adaptive and as a less critical 
effect than the effect in the kidney. In addition, the analysis of the liver weight changes indicated a 
much higher level for the BMD for this endpoint, while a relationship between liver weight changes 
and liver hypertrophy is known to exist. That supports that the observed liver hypertrophy has low 
relevance. For the absolute liver and kidney weight changes in F0 females very wide confidence 
intervals around the BMDs were obtained, because of lack of dose-response information in the data. 
Considering that organ weights are dependent on body weight, adequate dose-response information 
could be identified for relative liver and kidney for all generations and and sexes, when changes in the 
body weight were taken into account. In addition the confidence intervals for the BMD calculations 
were smaller for the relative organ weights, indicating better dose-response relationships and less 
variability in the data for relative organ weights. The CEF Panel has therefore selected the endpoint of 
relative mean kidney weight in the mouse as a reference point, for which a BMDL10 of 8 960 µg/kg 
bw per day was derived.  
3.2.6. Conclusion on hazard characterisation for general toxicity 
BPA was found to affect kidney and liver weight in parental animals and in all the generations of rats 
and mice examined in multi-generation studies. These effects were considered by EFSA (2006, 2010) 
as relevant systemic effects for the identification of a NOAEL. In mice the increased kidney weight 
was associated with nephropathy at the highest BPA dose. Liver weight was increased in rats (relative 
weight) and mice (both absolute and relative weight). The latter species also showed hepatocellular 
hypertrophy. The CEF Panel considered the endpoint “general toxicity” for hazard characterisation, 
using a reference point from the two-generation study in mice, which provided a BMDL10 for mean 
relative kidney weight of 8 960 µg/kg bw per day in male mice of the F0 generation. 
3.3. Reproductive and developmental effects  
3.3.1. Human studies 
3.3.1.1. Summary of previous opinions  
EU-RAR (2003, 2008) 
No human data were reviewed in the 2003 report. In the 2008 report it was stated that no conclusions 
could be drawn from a human study investigating the possible association between recurrent 
miscarriage and BPA exposure.  
EFSA (2006, 2010) 
No human data were reported in the opinion of 2006. 
The 2010 EFSA opinion included evaluation of a number of studies investigating the association 
between BPA exposure and reproductive/developmental disorders in human subjects that had been 
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published since 2007 (Itoh et al., 2007; Padmanabhan et al., 2008; Wolff et al., 2008; Braun et al., 
2009; Cobellis et al., 2009; Yang et al., 2009; Li et al., 2010a, b; Meeker et al., 2010; Mendiola et al., 
2010; Mok-Lin et al., 2010). 
The CEF Panel considered that the available studies were limited by their mostly cross sectional 
design and other methodological issues, and therefore that no relevant conclusions for risk assessment 
could be drawn from them. 
NTP-CERHR (2008) 
No human data were available on developmental effects of BPA and only a few studies focused on 
reproductive endpoints. The NTP expressed the view that the evidence from the limited number of 
studies in humans exposed to BPA was not sufficient to reach conclusions regarding possible 
developmental or reproductive hazard.  
FAO/WHO (2011) 
In respect to male reproduction endpoints, the FAO/WHO report reviewed three epidemiological 
studies (Mendiola et al., 2010, Meeker et al., 2010, Li et al., 2010a) studying the association of 
urinary BPA levels with semen quality. Increased urinary BPA concentrations were associated with 
reduced semen quality in all three studies, although statistical significance was reached in one study 
only. Additional limitations of these studies included their cross-sectional designs and the incomplete 
assessment of occupational co-exposure in one of the three studies. In the case of female reproduction, 
an inverse association between urinary BPA concentration and oocyte yield from women undergoing 
in vitro fertilization treatment in fertility clinics was reported in a small study only (Mok-Lin et al., 
2010), thus preventing any conclusions to be drawn in the absence of data replication. Limited and 
inconsistent evidence for an association of BPA with altered age of pubertal onset in girls was 
identified in two epidemiological studies. Therefore, no conclusions could be drawn by the Expert 
Meeting with repect to an association of BPA with perinatal outcomes. 
ANSES (2011, 2013)  
In the 2011 ANSES report, experts evaluated human studies and stated that effects of BPA on the 
male reproductive system were controversial, that effects of BPA on oocyte maturation were 
suspected based on good quality studies (Mok-Lin et al., 2010, Fujimoto et al., 2010), and that studies 
of other parameters (endometrium, ovaries and pregnancy outcome) were too limited to draw a 
conclusion (ANSES, 2011). Since the adoption of the report on the health effects of BPA in 2011, 
ANSES has reviewed over 20 recently published epidemiological studies, and indicated in their 2013 
risk assessment of BPA that the results of these studies did not change their previous conclusions 
(ANSES, 2013).  
3.3.1.2. Evaluation of recent human studies on BPA exposure and reproductive and developmental 
effects  
This section provides an overview of the human studies on reproductive and developmental effects 
published after July 2010. Some of these studies are also evaluated in relation to hormonal and 
metabolic effects. A detailed description and evaluation of each study is provided separately in 
Appendix B. 
Since the previous EFSA review (2010), 21 studies have been evaluated.  
The studies have been grouped into postulated BPA effects on 1) adult reproduction and health 
(Fujimoto et al., 2011; Bloom et al, 2011a, b; Ehrlich et al., 2012a, b; Krotz et al., 2012; Buttke et al., 
2012; Li et al., 2010a, b; Zhou et al., 2013; Galloway et al., 2010; Kandaraki et al., 2011; Tarantino et 
al., 2013), and 2) gestational/birth outcomes (Cantonwine et al., 2010; Fénichel et al., 2012; Miao et 
al., 2011a, b; Choi et al., 2012; Chevrier et al., 2012; Chou et al., 2011; Philippat et al., 2012; Snijder 
et al., 2013; Lee et al., 2013a).  
1) BPA effects on adult reproduction and health 
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Of seven studies examining BPA exposure in relation to adult reproductive outcomes, five examined 
indicators such as embryo quality, fertilisation and implantation failure in couples undergoing in vitro 
fertilization (IVF). The causes of infertility are very different in those who present for IVF compared 
with both fertile couples and couples seeking investigations and treatment for infertility. 
Notwithstanding the benefits of those undergoing IVF from a research practicability point of view, 
caution must therefore be exercised when extrapolating from an IVF study group to the general 
infertility population, let alone to the fertile population (Hull et al., 1985; Maheshwari et al., 2008; 
HFEA, 2011).  
In a cross-sectional study with 31 women, Fujimoto et al. (2011) found no association between serum 
unconjugated BPA and oocyte fertilization (number of oocytes) in the full study but an inverse 
association was seen in the nine Asian women included in the study.  
In their first cross-sectional study with 27 couples, Bloom et al. (2011a) found no association between 
female serum unconjugated BPA and embryo cell number, but reported weak associations for male 
serum BPA and indicators of embryo quality (lower embryo cell number; p=0.07, lower embryo 
fragmentation score: p=0.009). In their second cross-sectional study with 44 women (some women 
overlapping with the first study), Bloom et al. (2011b) found that higher serum BPA was significantly 
associated with reduced peak oestradiol levels measured as an index of follicular response), but was 
not associated with oocyte fertilization.  
Ehrlich et al. (2012a) collected 1-2 spot urine samples in 137 women during a total of 180 IVF cycles 
and reported a borderline significant association between increasing urinary total BPA quartiles and 
implantation failure (p-trend =0.06). In a subsequent study, partially utilising the same study 
population as Ehrlich et al. (2012a) , Ehrlich et al. (2012b) found that higher urinary total BPA was 
associated with decreasing number of oocytes, decreasing number of normally fertilized oocytes and 
decreasing oestradiol levels (all p<0.01). The women in both studies (Ehrlich et al., 2012a and 2012b) 
were part of a larger prospective cohort study designed to investigate the impact of environmental 
chemicals on fertility and pregnancy outcomes among couples seeking fertility treatment. The authors 
describe the studies as “prospective”, but the time between assessment of exposure and outcome was 
only a few days.  
Krotz et al. (2012a) examined whether phthalates and BPA could be detected in follicular fluid 
following IVF treatment in five women, BPA was undetectable (phthalates were detected).  
The CEF Panel noted that the generalisability of results from IVF studies is uncertain, as women 
undergoing IVF are likely to also be exposed to BPA from medical plastics during an IVF cycle. The 
above studies were limited by timing of the exposure, sample size and study design. Four of the 
studies measured BPA in serum, which may not be a valid measure due to the pervasive 
contamination from plastic.  
A cross-sectional study in occupationally exposed workers in China showed that higher urinary BPA 
was associated with lower sperm concentration, count, vitality and motility, suggesting negative 
impact on human fertility (Li et al., 2011). Of 888 men invited, only 58% participated in the study, 
without reasons for non-participation being known (fertility problem, age, etc.), which may constitute 
a selection bias. The measurements of sperm quality involved 218 individuals. The results are 
comparable to a study evaluated in the EFSA CEF PANEL, 2010 opinion (Meeker et al., 2010).     
In another cross-sectional study from China, Zhou et al. (2013) evaluated the association between 
serum bisphenol A and sex hormone levels in 137 male factory workers who were exposed to BPA at 
the workplace for more than 6 months, and 153 age-matched workers from a tap water factory without 
occupational exposure to BPA. Increasing serum BPA concentration was associated with decreased 
androstenedione levels, decreased free testosterone levels, decreased free androgen index, and 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 74 
increased sex hormone-binding globulin levels. The results are comparable to two studies evaluated in 
the EFSA CEF PANEL, 2010 opinion (Mendiola et al., 2010; Meeker et al., 2010).      
In a cross-sectional study of 715 adult men in the InCHIANTI study in Italy, Galloway et al., 2010 
found that higher levels of urinary BPA was associated with increased serum total testosterone 
concentration (p=0.004), but was not associated with circulating free testosterone (p=0.075) or β-
oestradiol. In women, no associations were found between urinary BPA and total testosterone, free 
testosterone or β-oestradiol, but a positive association was found for sex hormone-binding globulin 
(SHBG) in premenopausal women (p=0.004).  
Two case-control studies examined associations between serum total BPA and existence of polycystic 
ovary syndrome (PCOS) in women. Kandaraki et al., 2011 included 71 PCOS and 100 normal women 
and found that serum BPA was higher in the PCOS group compared with controls (1.05 vs 0.72 
ng/ml, p<0.001).Tarantino et al. (2012) included 40 PCOS and 20 normal women and found that 
higher serum BPA was associated with hepatic steatosis and markers of low-grade inflammation in 
the women with PCOS. The studies have several statistical concerns. Furthermore, the CEF Panel 
considered that serum BPA can be an unreliable measure due to the pervasive contamination from 
plastic. 
Buttke et al. (2012) studied associations between exposures to multiple endocrine-disrupting 
chemicals, including BPA, and age of menarche in adplescent girls in NHANES 2003-2008. Urinary 
total BPA concentration was not associated with age of menarche.   
2)BPA effects on gestational/birth outcomes 
Eleven studies examined BPA exposure in relation to gestational or birth outcomes.  
In a nested case-control subset with 30 cases and 30 controls in a study of environmental toxicants in 
Mexico City, high urinary BPA levels were associated with increased risk of delivery before week 37 
(p<0.05) (Cantonwine et al., 2010).   
Five studies reported significant associations between prenatal BPA exposure and fetal growth, of 
which three showed reduced fetal growth with higher BPA exposure (Miao et al., 2011a, Chou et al., 
2011 and Snijder et al., 2013), one showed weakly increased fetal growth with higher BPA exposure 
(Lee et al., 2013) and one showed increased head circumference with increasing BPA (Philippat et al., 
2012). In a study from China (Miao et al., 2011a), parental exposure to BPA in the workplace during 
pregnancy was associated with decreased birth weight in infants (p=0.02 for maternal occupational 
exposure). The study estimated BPA exposure by combining work place air monitoring and recall of 
employment history and change in work environment. The characterisation of the exposure is 
questionable and confounding by diet or concurring exposure factors was not considered.  
In a cross-sectional study by Chou et al. (2011) total BPA was measured in maternal and umbilical 
cord plasma in 97 mother-newborn pairs in a birth cohort in Taiwan. In male neonates only, high 
maternal BPA was associated with reduced birth weight. The CEF Panel noted that the study was 
limited by cross sectional design and cord blood BPA measurement.  
A prospective study with 219 mother-child pairs within a pregnancy cohort in Rotterdam found no 
significant association between maternal urinary total BPA (prenatal BPA exposure) and fetal weight 
or head circumference (Snijder et al., 2013). However, when the analyses were restricted to 80 women 
for whom three repeat urinary samples were available, the results showed that higher urinary BPA 
was significantly associated with intrauterine growth restriction. The outcome was assessed by fetal 
growth rates based on repeat ultrasound biometry and birth size. The estimated difference between 
altered mean values at birth between the upper and lower category of urinary BPA was –683 g (20.3% 
of mean) for birth weight and –3.9 cm (11.5% of mean) for head circumference. The study found that 
increasing the number of urine samples per subject strengthened the exposure–response estimates. 
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The relatively small sample size limited the power to examine associations with fetal growth in 
different time windows. The statistical analyses included sensitivity analyses and evaluation of the 
effect of the number of measurements per subject on the observed associations. The analyses included 
adjustment for potential confounders, but no dietary factors other than alcohol consumption was 
considered.  
Contrary to the above studies which showed that increased maternal urinary BPA concentrations were 
associated with reduced fetal growth, a prospective study with 757 mother-children pairs in Korea 
found that higher maternal urinary BPA concentration in the third trimester was weakly associated 
with increased birth weight and ponderal index in neonates. The associations differed by gender. No 
associations were found between urinary BPA measured in the first trimester and birth outcome (Lee 
et al., 2013a).  
Philippat et al., 2012 examined urinary BPA and phthalate exposure and birth outcomes in a case-
control study on malformations of the male genitalia nested in two French mother-child cohorts. The 
study sample comprised 191 infants and cases and controls were treated as one group. Increasing 
urinary BPA concentrations were associated with increasing head circumference (p-trend 0.01), and 
also suggested an association with increased birth weight. The study is limited by the choice of study 
group and the clinical relevance of the association between BPA exposure and head circumference is 
not clear.  
In a study from China (Miao et al., 2011b), maternal occupational BPA exposure was associated with 
shortened anogenital distance in 153 boys (p-trend: 0.008). As for the study of birth weight in this 
population (Miao et al,. 2011a) the outcome was compared between groups reflecting maternal 
exposure, paternal exposure or no work place exposure, based on work place air monitoring and recall 
of employment history and change in work environment. The characterisation of the exposure is 
questionable and confounding factors such as diet and/or concurring exposure factors were not 
considered.   
In a study from Fénichel et al. (2012) using a methodologically questionable RIA method to quantify 
cord blood BPA there was no difference in cord-blood BPA between boys with undescended testis 
(n=46) and controls (n=106)).  
A case-controlled study of exposure to five phthalates and BPA in infants with hypospadias and 
controls was conducted in Korea (Choi et al., 2012). Phthalates and total BPA were measured both in 
urine and plasma in 80 children with hypospadias, in 80 control children and in 40 mothers of 
children with hypospadias. Urinary BPA in children was not associated with hypospadias, whereas 
plasma total BPA was higher in children with hypospadias than in controls (P < 0.001). No 
relationship was seen between levels of BPA in urine or plasma in the mothers and the occurrence of 
hypospadias. The study is limited by statistical handling, the measurement of BPA in plasma and very 
limited description of sampling. 
Another case-controlled study from South Korea examined plasma concentrations of several 
endocrine disrupting chemicals in 39 infants with congenital hypothyroidism and 20 controls. There 
was no difference in plasma BPA concentration between patients and controls (P=0.2).   
In a study by Chevrier et al. (2012) maternal urinary BPA was measured twice during pregnancy and 
examined in relation to maternal and infant thyroid function. The study sample comprised 476 women 
in an immigrant Mexican-American population with low socioeconomic status. The results suggested 
that exposure to BPA during pregnancy was related to reduced total T4 in pregnant women and 
decreased TSH in male neonates. The average of the two maternal BPA concentrations was associated 
with reduced TSH in boys (p<0.01) but not in girls. This association was stronger when BPA was 
measured in the third trimester of pregnancy and decreased with interval between BPA and 
measurement of TSH. Iodine status was taken into account, but potential confounders, such as diet 
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and/or concurring exposure factors, were not considered. BPAwas not measured in the urine of the 
neonates.  
3.3.1.3. Summary of BPA exposure and reproductive and developmental effects in humans 
In their 2010 EFSA opinion, the CEF Panel concluded that the studies then available were not 
sufficient to draw any conclusion regarding BPA exposure and reproductive and developmental 
effects in humans. This conclusion was based on studies limited by mostly cross-sectional design, 
small sample size and other methodological weaknesses. Since then, a number of studies have been 
reported, but the limitations noted in the previous opinion are still prevalent. Of 22 new studies, only 
six had a prospective design. Some of the new studies were well powered (i.e. Galloway et al., 2010; 
Li et al., 2011; Miao et al., 2011a), but had large uncertainty in either exposure or outcome 
assessment. There are indications from several prospective studies that BPA exposure during 
pregnancy may have effects on fetal growth (two studies showed reduced fetal growth with increasing 
maternal BPA exposure, while one study reported increased fetal growth). There are also weak 
indications that BPA exposure during pregnancy may be associated with maternal and infant thyroid 
function. It cannot be ruled out, however, that these results are confounded by diet or concurrent 
exposure factors. The associations do not provide sufficient evidence to infer a causal link between 
BPA exposure and reproductive effects in humans.  
3.3.2. Animal studies 
3.3.2.1. Summary of previous reviews of the reproductive and developmental toxicity of BPA 
In recent years, the reproductive and developmental toxicity of BPA has been thoroughly evaluated at 
national, European and international level as reported below. 
EU-RAR (2003, 2008)  
In the original risk assessment report of 2003, it was stated that the effects of BPA on fertility and 
reproductive performance had been investigated in three good quality studies: a 2-generation study 
and a multigenerational study in the rat, and a continuous breeding study in the mouse. These studies 
had shown similar qualitative and quantitative toxicological profiles of BPA for effects on fertility, 
i.e. reductions in litter size, both in rats, i.e. at 500 mg/kg bw per day and mice, i.e. at 600 mg/kg bw 
per day. It was also concluded that there was no convincing evidence that BPA was a developmental 
toxicant in standard development studies in rats (maternal LOAEL and fetal NOAEL of 160 and 640 
mg/kg bw per day, respectively), and mice (maternal and fetfetal NOAELs of 250 and 1,000 mg/kg 
bw per day, respectively). An overall NOAEL of 50 mg/kg bw per day identified from the rat 
multigenerational study was then used for risk characterisation purposes, in relation to effects on 
fertility and provisionally for developmental effects. However, given the uncertainties surrounding the 
potential for BPA to produce adverse effects on development at low doses, the outcome of further 
testing was awaited. 
The 2-generation study in mice conducted by Tyl et al. (2008) provided a comprehensive 
investigation of the reproductive effects of BPA at exposure levels of 0, 0.003, 0.03, 0.3, 5, 50 and 
600 mg/kg bw per day. Fertility was not affected by any BPA dose tested. In the absence of any 
adverse effect of BPA in the μg/kg bw per day dose range on the male reproductive tract 
development, the EU-RAR considered that the study resolved the uncertainties surrounding the 
potential to produce adverse effects on development at low doses. The study results confirmed the 
provisional NOAEL of 50 mg/kg bw per day for reproductive and developmental toxicity, based on 
the effects that were detected at the next dose level of 500-600 mg/kg bw per day, namely slightly 
longer gestation, reduced pup body weight during lactation, a slight increase in the incidence of 
undescended testes at weaning, seminiferous tubule hypoplasia in offspring at weaning, and delayed 
acquisition of preputial separation. 
EFSA (2006); EFSA CEF Panel (2010)  
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In the EFSA 2006 opinion it was stated “In reviewing the earlier and the recently published studies on 
BPA, the Panel noted that some studies indicated differences in behaviour or reproductive parameters 
between control and treated animals at dose levels lower than the previously accepted overall 
NOAEL of 5 mg/kg bw per day. However, the Panel had considerable reservations both about the 
biological significance of the reported observations and the robustness of the studies”. The study by 
Rubin et al., 2001, used as a pivotal study in the risk assessment of ANSES (ANSES, 2013) was 
evaluated in the EFSA opinion 2006, and the AFC Panel noted some shortcomings of the study: “The 
Panel notes that doses were stated to be approximately 0.1 mg and 1.2 mg BPA/kg bw per day, 6 
dams/dose, but it is likely that there was underestimation of exposure due to an assumed low water 
consumption. Offspring exposed to BPA in utero (n= 12 – 28 offspring/group, but only six dams 
treated) exhibited an increase in body weight. In addition, female offspring exposed perinatally to the 
higher dose of BPA exhibited altered patterns of ooestrous cyclicity (changes not defined) and 
decreased levels of plasma LH in adulthood”.  
 
The 2010 EFSA CEF Panel opinion mainly considered peer-reviewed “low dose” in vivo studies 
published between January 2007 and July 2010. The opinion focused upon the oral route of 
administration, developmental exposure and the testing of several doses, including at least one below 
the oral NOAEL of 5 mg/kg bw per day established by Tyl et al., 2008. 
The conclusions of the CEF Panel on reproductive toxicity studies in animals exposed to BPA during 
development applied to both males and females. In particular the CEF Panel concluded: “The studies 
on developmental and reproductive toxicity reporting effects at doses lower than 5 mg/kg bw per day 
including the study by Salian et al. (2009) have severe shortcomings and were considered to be 
invalid. The Panel considers that the valid studies do not raise concern regarding reproductive and 
developmental toxicity of BPA at doses lower than 5 mg/kg bw per day.”  
 
NTP-CERHR (2008) 
The NTP-CERHR monograph stated that there was clear evidence of adverse developmental effects 
on survival and growth at “high” doses of BPA, based on reduced survival in fetuses or new-borns (≥ 
500 mg/kg bw per day), reduced fetal or birth weight or growth of offspring early in life (≥ 300 mg/kg 
bw per day), and delayed puberty in female rats (≥ 50 mg/kg bw per day) and male rats and mice (≥ 
50 mg/kg bw per day). 
With respect to reproductive toxicity, NTP stated that there was some evidence of adverse effects in 
animal studies, based on possible decreased fertility in mice (≥875 mg/kg bw per day), altered 
ooestrous cycling in female rats (≥600 mg/kg bw per day), and cellular effects on the testes of male 
rats (235 mg/kg bw per day). In the case of “low” dose developmental toxicity, the NTP concluded 
that there was limited evidence of adverse effects based on various neural and behaviour alterations 
(≥10 μg/kg bw per day), lesions in the prostate (10 μg/kg bw per day) and mammary glands (2.5–
1000 μg/kg bw per day), altered prostate gland and urinary tract development (10 μg/kg bw per day), 
and early onset of puberty (24 and 200 μg/kg bw per day). 
FAO/WHO (2011)  
Based on a review of the studies published since 2008, the Expert Meeting concluded that there is 
considerable uncertainty as to whether BPA has any effect in rodents on conventional reproductive or 
developmental end-points at doses below 1 mg/kg bw per day by the oral or subcutaneous route. The 
only evidence for adverse reproductive and developmental effects of oral BPA came from studies in 
rats or mice with no relevant evidence from humans, non-human primates or domestic animals. 
Species-related differences, e.g. in timing of developmental periods of sexual differentiation and 
involvement of different hormones, limited a straightforward translation of findings from rodents to 
humans. Important data gaps in the reproductive and developmental toxicology of BPA in 
experimental animals included the lack of a thorough assessment of critical developmental 
reproductive end-points following direct exposure of the neonate to BPA, and of the effects of BPA in 
alternative animal models, including non-human primates, lagomorphs and other non-rodent species, 
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that might be more relevant to human development for a few specific issues (e.g. effects on the 
prostate). 
ANSES (2011 and 2013) 
In the 2011 report, concerning the effects of BPA on the male reproductive system in animal studies, 
ANSES concluded that there were proven alterations of sperm production after 5 weeks exposure 
during adulthood (Chitra et al., 2003 and Herath et al., 2004), suspected reductions in plasma 
testosterone concentrations and altered sexual behaviour due to pubertal exposure. In their 2013 
report, ANSES evaluated several new animal studies on the effects of BPA on the male reproductive 
system (D’Cruz et al., 2012a; Doshi et al., 2011; Kobayashi et al., 2012; Lopez-Casas et al., 2012; 
Nanjappa et al., 2012) and expressed the view that overall these data did not call into question the 
conclusions of the 2011 report. 
In 2011, the ANSES report on the health effects of BPA concluded that in vivo animal studies 
indicated proven effects of BPA on the female reproductive system, consisting of increased 
occurrence of ovarian cysts (Newbold et al., 2007, 2009; Signorile et al., 2010), endometrial 
hyperplasia (Mendoza-Rodríguez et al., 2011; Markey et al., 2005), earlier onset of puberty (Honma 
et al., 2002; Howdeshell et al., 1999; Nikaido et al., 2004; Adewale et al., 2009 and Fernandez et al., 
2009) and changes in the hypothalamic-pituitary-gonadal (HPG) axis (Savabieasfahani et al., 2006; 
Evans et al., 2004; Collet et al., 2010) after pre- and/or early postnatal BPA exposure.  
In 2013, ANSES concluded that the female reproductive toxicity studies in animals published since 
the 2011 ANSES report supported the conclusion that developmental exposure (in utero in the mouse 
and the monkey and early postnatal in the ewe) to low BPA doses could disrupt the meiotic processes 
and cause early folliculogenesis possibly leading to a reduction in the follicular reserve, and unknown 
functional reproductive consequences in the adult. Furthermore, in ANSES’ view certain recent 
studies have reinforced that BPA can disrupt the HPG axis and cause histological changes and 
acceleration of the puberty process during early neonatal exposure. 
3.3.2.2. Studies on reproductive and developmental effects following oral exposure to BPA 
considered by previous reports published before 2010 
The WoE approach that has been taken in the current opinion has necessitated the re-evaluation of a 
number of studies on reproductive and developmental effects of BPA that has already been evaluated 
in the previous risk assessments summarised above, namely the study by Rubin et al. (2001), used as a 
pivotal study for reproductive and developmental toxicity in the ANSES report (ANSES, 2013), the 
studies of Tyl et al. (Tyl et al., 2002; 2008) that were used by EFSA as a basis for the derivation of a 
TDI (EFSA, 2006, 2008; EFSA CEF Panel, 2010) and the study of Salian et al. (2009). These studies 
have been briefly summarised here (more detail is provided in Appendix B) and are also included in 
the WoE section as starting points. 
Rubin et al. (2001) measured the effect of BPA on the offspring of Sprague-Dawley female rats 
exposed to BPA in drinking water at concentrations of 1 mg/l and 10 mg/l (approximately 0.1 and 1.2 
mg BPA/kg bw per day) from GD6 throughout lactation. Patterns of ooestrous cyclicity were 
determined in the female offspring by daily examination of vaginal cytology at 4 and 6 months of age. 
A statistically significant increased body weight of the offspring from day 4-11 was observed in both 
sexes. From day 22 and onwards, only females showed an increased body weight, the effect being 
greater in the 0.1 mg/kg bw per day group than in the 1.2 mg/kg bw per day group. A statistically 
significant and dose-dependent reduction in the percentage of animals with regular cycles and in the 
mean number of regular 4 or 5-day ooestrous cycles per animal was found at the highest BPA 
exposure level. There were some shortcomings in the study performance. The number of mated dams 
(n=6) was low, and it was not reported whether the litter was used as statistical unit.  
In the Tyl et al. (2002) multigenerational dietary study of CD Sprague-Dawley rats, described in detail 
in section 3.2.2, reduced ovarian weights, a significantly reduced number of implantation sites and 
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decreased number of pups/litter on PND 0 were reported in the F0 females at the top dose of 7500 
ppm BPA in the diet (estimated to be equivalent to 500 mg/kg bw per day) compared with controls. In 
the F1, F2 and F3 offspring, at this dose level only, vaginal patency and preputial separation were 
delayed, and associated with reduced body weight. No effects on reproductive organ histology and 
function were reported at lower dose levels of BPA, and the NOAEL for reproductive effects was 
therefore 50 mg/kg bw per day.  
In the Tyl et al. (2008) two-generation dietary study of CD-1 mice, described in detail in section 3.2.2, 
no BPA-related effects were observed on adult mating, fertility or gestational indices, ovarian 
primordial follicle counts, ooestrous cyclicity, precoital interval, offspring sex ratios or postnatal 
survival, sperm parameters or reproductive organ weights or histology. The reproductive/ 
developmental NOAEL was 300 ppm (50 mg/kg bw per day), based on the effect in the testes of 
F1/F2 offspring.  
Salian et al. (2009) performed a 3 generation-study to assess the effects of very low oral doses of BPA 
(1.2 or 2.4 μg/kg bw per day administered by gavage) in Holtzman rats. Fertility was assessed in adult 
F1-3 males by mating them with unexposed females. The authors reported a significant increase in 
post implantation loss in the F3 offspring and a decrease in litter size in F1-3 offspring at both BPA 
concentrations was observed, but a dose-response relationship was only evident for the decrease in 
litter size. Sperm count and motility were significantly reduced in the F1, F2 and F3 male offspring, 
with a dose related reduction in sperm count. A reduction in testicular expression profiles of steroid 
receptors was also reported. 
Tinwell et al. (2002) studied the effects of BPA (0.02, 0.1, 50 mg/kg bw per day) administered by oral 
gavage from GD6-21 on two strains of rat (Sprague-Dawley and Alderley Park). Litter size, sex ratio, 
pup birth weights, timing of puberty, AGD were unaffected in both sexes. In females at PND98 only 
the highest dose affected timing of puberty (delayed) and then only in Alderley Park animals. In males 
at PND90 the only significant effects were at the highest BPA dose, the Alderly Park strain and were 
reduced daily sperm production. 
In a combined, extensive, study with good numbers of litters and offspring, Howdeshell et al. (2008) 
and Ryan et al. (2010a) reported the sexes separately from the same where the same Long Evans 
hooded rats dams, split into two study arms (the second with a more extensive dose range of EE 
positive control groups), received BPA by oral gavage (2, 20, 200 µg/kg bw per day) from GD7 to 
PND18. In males (Howdeshell et al., 2008), only one statistically significant effect was observed: and 
only in the first arm not the second: an increased incidence of testicular degeneration (7/20 males at 
200 µg BPA/kg bw per day vs 1/31 in controls), although without any concomitant effect on testis 
size or sperm numbers. In females (Ryan et al., 2010a), BPA had no significant effect on any 
parameter, including a forced breeding study with the F1 offspring. 
3.3.2.3. Animal studies on reproduction and developmental effects after non-oral exposure published 
before 2010 previously evaluated by EFSA in 2006 or 2010  
These studies have been briefly summarised here (more detail is provided in Appendix B) and are also 
included in the WoE section as starting points. 
 
Studies in mice 
Two studies by Nikaido et al. (2004 and 2005) reported effects of BPA on CD-1 mice offspring after 
maternal exposure at GD15 and in female CD-1 mice after prepubertal exposure at 15 days of age. 
BPA was given subcutaneously in doses of 0.5 (maternal exposure only) and 10 mg/kg bw per day for 
four consecutive days in both experiments. Vaginal opening, ooestrous cyclicity and mammary gland 
development were studied. According to the authors, maternal exposure to BPA did not accelerate 
puberty onset or modify the ooestrous cycle. Effects of perinatal exposure to BPA (25 and 250 ng/kg 
bw per day, but reported as 25 and 250 µg/kg bw per day) from sc administration was investigated 
following administration of BPA by Alzet mini-pumps to CD-1 mice from day 9 of pregnancy until 
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postnatal day 4 (Markey et al., 2005) as reported in EFSA 2006, Appendix B). Decreased vaginal 
weight, small increases in the incorporation of bromodeoxyuridine into DNA of endometrial gland 
epithelial cells, and increased expression of oestrogen receptor-alpha (ERalpha/ESR1) and 
progesterone receptor (PGR) in the luminal epithelium of the endometrium and subepithelial stroma 
were reported in BPA-exposed animals. 
Low-dose effects of BPA on sexual maturation and reproduction of offspring were also investigated 
in female ICR/Jcl mice after sc injection of BPA (2 and 20 µg/kg bw per day), diethylstilboestrol 
(DES, 0.02, 0.2 and 2 µg/kg bw per day) or oil vehicle once a day to pregnant dams from GD11-17 
(Honma et al., 2002). Age at vaginal opening was significantly earlier (reduced from 27.3 in controls 
to 26.2 days) in females exposed to 20 µg/kg bw per day BPA in utero and all DES exposed animals. 
The first vaginal oestrus was earlier (from app. 27.8 to 27.0 days) in female offspring exposed to 20 
µg/kg bw per day BPA and, at all DES dose levels, adult AGD was significantly increased. None of 
the BPA doses affected mating, gestation, pups/litter or pup sex ratio in F1 females. Similarly, in 
Rubin et al. (2006) CD-1 mice were treated on GD8 via osmotic minipumps delivering 50% 
dimethylsufoxide as vehicle control or BPA at doses of 25, 250 ng BPA/kg bw per day until PND16. 
Litters were culled to 4 male and 4 female pups/dam and before PND22-24 tyrosine hydroxylase 
positive neurons in the rostral periventricular preoptic area (AVPV) important for controlling 
ooestrous cyclicity were counted. BPA had no significant effect on pups/litter or sex ratio. The 
number of sections through the AVPV was significantly higher in control female than control male 
brains but not in the BPA exposed groups although the number of sections was significantly reduced 
in BPA-treated females at the highest dose. Similarly, the numbers of tyrosine hydroxylase positive 
neurons were significantly different between male and female offspring in the control and lowest BPA 
dose groups and significantly reduced at the highest BPA dose in females. Taken together the authors 
concluded that this suggests a loss of sexual dimorphism following BPA exposure. 
Effects of exposure of BPA on sperm quality in mice were reported in several non-oral studies. 
Aikawa et al. (2004) reported a decreased percentage of motile sperm and an increased incidence of 
malformed sperm in mice at 10 weeks of age given sc injections of BPA (approximately 0.3 and 30 
mg/kg bw per day) for the first five days after birth. No change in testicular histology was reported.  
Toyama and Yuasa (2004) reported effects in the steps 2-3 spermatids and the acrosomal granule and 
nucleus were deformed, after sc exposure of BPA to new born (n=3-4) mice (0.6 to 66 mg/kg bw per 
day) and rats (0.2 to 120 mg/kg bw per day). However, fully mature animals did not show any of 
these testicular effects and the animals were fertile.  
Studies in rats 
In Kato et al. (2006) Sprague-Dawley male rats were administered 2, 11, 56, 277, 97,000 µg BPA/kg 
bw per day from PND0 (day of birth) -PND9 by subcutaneous injection. Oestradiol (0.9 mg/kg bw per 
day) was used as a positive control and induced effects on most of the parameters assessed. The pups 
were regularly investigated up to adulthood, including necroscopy, on PND 10, 35, 150). The only 
observed effect of reproductive development, morphology and endocrinology was a reduction in the 
proportion of abnormal sperm at two of the BPA doses (one ≤3.6 mg/kg bw per day BPA HED). The 
latter cannot be considered adverse and none of the BPA treated animals displayed any impairment in 
fertility.  
The following studies were not included as starting points in the WoE tables as starting points because 
they did not include at least one BPA dose ≤3.6 mg/kg bw per day HED: Aikawa et al. (2004) and 
Nikaido et al. (2004).  
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3.3.2.4. Animal studies on reproductive and developmental effects of BPA published after 2010 or 
excluded from previous EFSA evaluations  
This section provides an overview of the experimental animal studies on reproductive and 
developmental effects published after 1st August 2010 that met the inclusion criteria set by the CEF 
Panel (see Section 2 and Appendix A). For this endpoint, however, an additional exclusion criterion 
was set for “high dose BPA” studies, as outlined in the following section, Oral Human Equivalent 
Doses. A detailed description and evaluation of each study is provided separately in Appendix B. 
The assessment has considered (a) exposure to BPA during development (via maternal and/or 
lactational routes), where the offspring are the subject of the investigation, and (b) exposure to adult 
(post weaning) animals, followed by assessment of reproductive health and function. Thirty-two 
studies were included in the assessment following the application of inclusion and exclusion criteria 
(see Section 2 and Appendix A). Note that some studies contributed to multiple sections below (adult 
vs developmental exposure, male vs female).  
Oral Human Equivalent Doses 
The CEF Panel noted that the study of Tyl et al. (2002) offered a well-established oral NOAEL of 5 
mg BPA/kg bw per day in the rat, with a higher NOAEL of 50 mg BPA/kg bw per day for 
reproductive effects. For its assessment of this endpoint, therefore, the CEF Panel focussed on studies 
reporting effects on reproductive parameters at dose levels below the NOAEL of 5 mg BPA/kg bw 
per day in the rat. Because of the range of species used in these studies and the various routes of 
administration employed, the CEF Panel decided to calculate an oral HED (see Section 3.1.5) for each 
dose level used in a particular study, using the HED conversion factors shown in table 3. This enabled 
comparison between and integration of information from different studies. Any study employing BPA 
doses with HEDs >3.6 mg BPA/kg bw per day has not been included in the assessment below, unless 
it also included a dose level or dose levels below a HED of 3.6 mg BPA/kg bw per day. The data for 
sheep were not available to calculate the HED and therefore a dose given to a sheep has been 
considered equivalent to the same oral dose given to a human, which led to the inclusion of 1 study 
and exclusion of 1 study. This assumption is supported by allometric scaling considerations. 
As a consequence of this analysis the following 11 studies were excluded from further evaluation 
because the doses used all exceeded the HED of 3.6 mg BPA/kg bw per day: Adewale et al., 2009; 
Aikawa et al., 2004; Crawford et al., 2012; Doshi et al., 2013; El-Beshbishy et al., 2012; Karavan et 
al., 2012; Norazit et al., 2012; Quignot et al., 2012a; Salian-Mehta et al., 2013; Salloum et al., 2013; 
Tainaka et al., 2012. Additionally the following three studies in which BPA was tested as part of a 
mixture of chemicals, but not on its own, were excluded (Christiansen et al., 2012; Xi et al., 2011; 
Manikkam et al., 2013).  
In the following summary of the studies reviewed, dose levels are only given as doses administered to 
the animals by the chosen route. The calculated HED for each dose level in a particular study is given 
in the description of each study in Appendix B. As already indicated the studies below all included a 
dose level or dose levels below a HED <3.6 mg BPA/kg bw per day, and a number of studies also 
included BPA doses with HEDs >3.6 mg BPA/kg bw per day (e.g. the 2013 study of US 
FDA/NCTR/Delclos et al., 2014). Where this was the case, the findings at the higher dose levels have 
also been summarised, in order to provide an overview of high dose effects of BPA on reproductive 
function. 
a) Effects of BPA on reproductive function following exposure during development, 
includingexposure via the mother or direct exposure during post-natal development 
Under this heading, the CEF Panel has assessed 25 studies including at least one BPA HED ≤3.6 
mg/kg bw per day. The following overview of the studies is divided into studies investigating the 
effects of BPA on the male and female reproductive systems respectively, and is further subdivided 
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into studies considered to show (a) no effects attributable to BPA, (b) some limited effects of BPA, (c) 
possibly relevant effects of BPA. 
Male reproductive system  
Ten studies focussing on testis development and/or function (e.g. sperm count and sperm motility) 
and masculinisation (e.g. nipple-retention, ano-genital distance, androgens) have been evaluated. Only 
one of these studies involved an investigation of the functional fertility of the exposed offspring 
(Zhang et al., 2013).  
Four studies showed no significant adverse effects attributable to treatment with BPA on the male 
reproductive system, as follows.  
In the large and well performed study of Ferguson et al. (2011) Sprague Dawley rats were 
administered 2.5 or 25.0 μg/kg bw per day BPA or 5.0 or 10.0 μg/kg bw per day ethinyl oestradiol by 
gavage on GD 6–21 (dams) and PND 1-21 (offspring gavaged individually). No treatment-related 
effects were seen on birth weights of the pups (although pre-weaning body weights decreased), nor on 
anogenital distances (AGD), AGD index, developmental landmarks, or serum hormones. There were 
also no effects on hormonal measures at weaning.   
Larocca et al. (2011) administered 2.5 or 25 μg BPA/kg bw per day to pregnant C57/B16 mice by oral 
gavage from GD 12-PND 21. A positive control (DES, 2 μg/kg bw per day) was included. No BPA-
related effects were seen on pregnancy outcome and on reproductive development of male offspring, 
including testis gene expression and morphology and measures of masculinisation (circulating 
testosterone and AGD).  
Lopez-Casas et al. (2012) exposed CD-1 mice to BPA (0.16; 16 or 64 mg/kg bw per day or 17-beta-
oestradiol (E2: 0.006; 0.012 or 0.048 mg/kg bw per day) via oral administration in the drinking water 
of the dams. The effects of mono-(2-ethylhexyl)-phthalate, zearalenone and lindane were also 
investigated. There were three exposure groups: (A) during the two weeks before mating; (B) 
exposure continued until birth or (C) exposure was continued until four weeks after birth. Body 
weight, testis weight, testicular morphology, apoptosis and testis gene expression were investigated. 
The only effect reported for BPA was an increase in germ cell apoptosis at 64 mg/kg bw per day in 
exposure group (C).  
Horstman et al. (2012) administered BPA (0.02, 0.5, and 400 mg/kg bw per day) in dimethyl 
sulfoxide by subcutaneous injection to pregnant Sprague Dawley rats from GD 8-20. EE was used as 
a positive control. Fetuses were harvested at GD 16, 18 and 20, at which times no effects of BPA or 
EE on testis morphology were observed.  
Three studies reported some limited effects of BPA on the male reproductive system, as follows.  
In Kobayashi et al. (2012), Sprague Dawley rats were administered 3 doses of BPA (0.33, 3.3, 33 
mg/kg in diet, equivalent to 0.02, 0.17 or 1.65 mg/kg bw per day from GD 6 to PND 21. F1 offspring 
were examined at 5 weeks and 3 months postnatally and body and organ weights, AGD, reproductive 
hormones and sperm counts were quantified. The only BPA-related effect in males was a statistically 
significant decrease in epididymal weights in the 3-month old male animals receiving 1.65 mg 
BPA/kg bw per day.  
Nanjappa et al. (2012) administered BPA to pregnant/lactating Long Evans rat dams (2.5 and 25 
μg/kg bw per day by oral gavage up to PND21 and investigated adult male offspring studied at three 
time-points. Stimulation of Leydig cell division was observed in the pre-pubertal period and Leydig 
cell numbers were increased on day 90, but without any overall effect on testosterone levels. 
Increased expression of some developmental/reproductive proteins was also reported (e.g. HSD17B3, 
AMH).  
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In the US FDA/NCTR sub-chronic toxicity study (2013)/Delclos et al. (2014), the experimental 
design of which is reported in Appendix B, at PND 90 the AGD index of Sprague Dawley rat males in 
the 300 000 µg BPA/kg bw per day group was approximately 6.5% greater than that of the vehicle 
control group. Interpretation of this finding was however made difficult by a similar change in the 
male naïve control compared with the vehicle control. Testicular descent was significantly delayed by 
5% in the 260 μg BPA/kg bw per day dose groups. The incidence of seminiferous tubule giant cells 
increased from 0/20 in vehicle controls to 5/23 at the 2.5 µg/kg bw per day dose only. No other effect 
of BPA was reported on male reproductive organ weights, AGD, reproductive endocrinology or 
sperm production. 
A further three studies reported possibly relevant effects of BPA on the male reproductive system, as 
follows. 
In Zhang et al. (2013), postnatal male CD-1 mice were given 0, 20 or 40 µg BPA/kg bw per day by 
subcutaneous injection on PND 3-21, 3-35, 3-49. The authors reported a range of treatment-related 
effects on spermatogenesis, including a significant increase in germ cells in the testis at 3 weeks in 
mice treated with 40 but not 20 µg/kg bw BPA/day, followed by a significant decrease at both 5 and 7 
weeks in mice receiving 20 or 40 µg/kg bw per day BPA. These changes were accompanied by a 
decrease in the population of germ cells entering meiosis. BPA-related increases in diameter of 
seminiferous tubules were reported in mice at 3 weeks, followed by decreases at 5 and 7 weeks. 
Morphological abnormalities were seen in the sperm of the BPA-treated animals, together with 
decreased motility. Changes in gene expression were also reported. Finally, exposure of male mice to 
40 but not 20 µg/kg bw per day BPA followed by mating with untreated females resulted in a 
reduction in offspring body weight and size at PND 14, 21 and 35, together with a reported increased 
rate of dystocia and poor body condition. The CEF Panel concluded that the results of this study 
support an effect of dose levels ≤3.6 mg BPA/kg bw per day HED on postnatal testis development in 
the mouse. 
In Christiansen et al. (2014) Wistar rat dams were administered BPA at dose levels of 0.025, 0.25, 5, 
50 mg/kg bw per day in corn oil from GD7 to PD22. Very few statistically significant effects of BPA 
were observed. Male pup AGD was significantly decreased (7% max) at all except the lowest BPA 
dose and nipple retention increased at the highest dose (4-fold, but dose-dependent). Of the organs 
weighed, the only significant effect was an increase in retroperitoneal fat pad weight in male pups at 
the highest BPA dose. While the decrease in male AGD and increased nipple retention (although only 
statistically significant >3.6 mg BPA/kg bw per day HED) probably is indicative of some impairment 
of masculinisation it is not known from this study whether there is any decrease in subsequent 
fertility.  
In the study of deCatanzaro et al. (2013), adult female CF0-1 mice maintained on either high or low 
phytoestrogen diets received, in 1 g of peanut butter, either vehicle (peanut oil) or 0.175, 1.75, 17.5 µg 
BPA/g peanut butter/day, or, with the high phytoestrogen diet only, 17.5, 175, 1 750 µg BPA/g peanut 
butter/day from GD 9 to PND 1. Pups were weaned on PND 27 and males were maintained on the 
same phytoestrogen diet as their mother until PND 60 or 90. Male offspring AGD, reproductive organ 
weights, capacity to inseminate and urinary hormone levels were measured. In the second study with 
high phytoestogen diet only, none of the BPA doses affected these body/reproductive organ indices 
and urinary testosterone, oestradiol and creatinine were also unaffected. At the 17.5 µg BPA/day dose 
there were reductions in intromission number (also at the 175 µg BPA/day dose) and ejaculations by 
around 50%. The CEF Panel considered that the erratic appearance of mostly minor effects of BPA 
only at the high phytoestrogen dose made the study difficult to interpret in terms of human risk.  
Overall summary of studies investigating the effects of BPA on the male reproductive system and 
involving developmental exposure  
Of the 10 studies evaluated, as described above, four studies were considered to show no adverse 
effects on the male reproductive system attributable to treatment with BPA, three studies reported 
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some limited effects, while three showed one or more consistent effects. Few studies involved 
prolonged post-natal exposure and a number of methodological concerns were raised. Overall the 
CEF Panel considered that there was some evidence, with considerable inter-study variation (in 
quality and outcomes), of an effect on the male reproductive system following developmental 
exposure at dose levels below a HED of 3.6 mg/kg bw per day. The most convincing effects were 
those reported by Christiansen et al. (2014). 
 
Female reproductive system  
The CEF Panel evaluated 17 studies investigating the effects of BPA in females as a result of 
developmental exposure.  
Three rodent studies showed no effects attributable to treatment with BPA on the female reproductive 
system at dose levels below a HED of 3.6 mg/kg bw per day, as follows.  
In the study of Ferguson et al. (2011) described above (and also in Appendix B), there were no BPA-
related effects on birth weight of the pups, although pre-weaning body weights decreased. There were 
no effects of treatment on anogenital distances and AGD index in females, or on developmental 
landmarks or measures of serum hormones. There were also no effects on hormonal measures at 
weaning.  
Xiao et al. (2011) administered daily subcutaneous injections of BPA in sesame oil to provide doses 
of 0, 0.025, 0.5, 10, 40, and 100 mg/kg bw per day from gestation days 0.5-3.5 to C57BL/6 mice and 
examined the effects of BPA on implantation. Although there were significant effects on implantation 
at dose levels of 40 mg BPA/kg bw per day and above, together with increased gestation periods, 
reduced litter size, reduced postnatal survival rate and continued expression of progesterone receptors 
(PGR) in the luminal epithelium of the uteri, no significant effects were observed in mice receiving 
≤3.6 mg BPA/kg bw day HED.  
To examine the effects of BPA on implantation (Berger et al., 2007), mice were exposed via either sc 
injection or two dietary administration routes (not gavage). Subcutaneous injections of BPA (0.016, 
0.047, 0.14, 0.45, 1.3, 3.9, 35.2, 105.5 mg/kg bw per day) in peanut oil were administered daily to 
adult female primiparous CF-1 mice on gestation days 1-4. Oral administration via either (1) dietary 
supplement (calculated daily intake: 36, 278, 550, 453 mg BPA/kg bw per day) or (2) food 
contamination (calculated daily intake: 2,223, 2,293 mg BPA/kg bw per day) was also performed on 
GD1-4. Implantation rate, litter size, number of implantation sites and uterine histology (at the highest 
BPA dose only) were assessed. Although adverse effects on parturition rates and litter size were 
observed at the two highest sc doses, BPA at HED ≤3.6 mg/kg bw per day had no significant effect on 
any of the measures assessed. None of the sc or oral doses had any significant effects at HED ≤3.6 
mg/kg bw per day. 
Seven rodent studies reported some limited effects of BPA on the female reproductive system at dose 
levels below a HED of 3.6 mg/kg bw per day, as follows.  
In Kobayashi et al. (2012), Sprague Dawley rats were administered 3 doses of BPA (0.33, 3.3, 33 
mg/kg in diet, equivalent to 0.02, 0.17 or 1.65 mg/kg bw per day) from GD 6 to PND 21. F1 offspring 
were examined at 5 weeks and 3 months postnatally and body and organ weights, AGD and 
reproductive hormones were quantified. A reduction in female AGD and ovary weight was reported at 
the two higher doses at 5 weeks, but the CEF Panel considered that this finding had no clear 
significance without further data on the reproductive performance, also noting that the effect had 
normalised by 3 months (adulthood).  
Signorile et al. (2010) & Signorile et al. (2012). The 2010 study dosed pregnant female BAlb-C mice 
with 100 or 1000 µg/kg bw per day of BPA by subcutaneous injection throughout pregnancy and up 
to day 7 postnatally. There was no positive control in the 2010 study. While all groups contained 
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animals with ovarian cysts, the incidence was significantly higher in the two BPA-exposed groups (9-
10/20) compared with vehicle controls (2/20) although corpora lutea numbers were unaffected. The 
incidence of endometrial hyperplasia was significantly increased (from 2/20 to 10/20) at the higher 
BPA dose. The authors report that “endometriosis-like” abnormalities were significantly increased in 
incidence by BPA (from 1/20 to 6-7/20). In the 2012 study further morphological analysis of the same 
ovaries as Signorile et al. (2012) ovaries was carried out when the animals were 3 months of age. 
Follicle classes were counted and related to an endometriosis-like phenotype reported in the same 
animals in Signorile et al. (2010). The authors reported a higher incidence of endometriosis-like 
characteristics in animals with fewer primordial and developing follicles and more atretic follicles, 
which were significantly adversely affected by both BPA doses.  
Mendoza-Rodrigues et al. (2011) dosed adult female Wistar rats with BPA (approximately 1.2 mg/kg 
bw per day) via their drinking water from GD6-PND21 in a study without positive controls. The 
female offspring were examined at age 3 months for oestrousooestrous cyclicity and ovarian and 
uterine morphology. Although the ovaries were morphologically normal, the BPA exposed animals 
showed a significantly higher incidence of abnormal cycles. Uterine epithelial and stromal thickness 
increased in the BPA-treated group and more females showed reduced rates of uterine apoptosis. 
Two studies from the same group first studied the effects of immediate post-natal BPA exposure 
(Newbold et al., 2007) and gestational BPA exposure (Newbold et al., 2009). In Newbold et a. (2007), 
doses of 10, 100, 1,000 µg BPA/kg bw per day were administered by subcutaneous injection to 
female CD-1 pups on PND1-5. There was no positive control.  Reproductive tracts were examined at 
18 months post-natal and two statistically significant effects were observed, both at 100 µg BPA/kg 
bw per day: (i) increased incidence of ovarian cysts (from 7/18 in control to 14/20) and (ii) increased 
incidence of cystic endometrial hyperplasia (from 1/18 in control to 9/20). There were no other 
convincing abnormalities. In Newbold et al. (2009), pregnant CD-1 mice were administered BPA at 
0.1, 1, 10, 100, 1,000 µg/kg bw per day by subcutaneous injection, from GD9-16. There was no 
positive control and necroscopies of the F1 females were performed at 16-18 months post-natal. 
Cystic ovaries were seen in all groups and only approached significance (p=0.05) in the 0.068 µg 
BPA/kg bw per day group while uterine abnormalities were not significantly altered by BPA 
exposure. The total number of animals exhibiting reproductive tract lesions, if mesonephric remnants 
were included, was significantly higher at the two lowest doses of BPA. 
In the US FDA/NTCR subchronic toxicity study (2013)/ Delclos et al. (2014) the design of which is 
reported in Appendix B, BPA did not affect the time of vaginal opening in Sprague Dawley rat 
females or the body weight at which the landmark was achieved. Nor was any effect observed on time 
to first oestrus. The dose level of 300,000 μg BPA/kg bw per day significantly increased the 
proportion of animals showing abnormal cycles in a manner similar to that of EE2 and ovarian 
weights (absolute and adjusted for brain weight) were decreased at this dose level, accompanied 
morphologically by depletion of corpora lutea and antral follicles. The CEF Panel noted that there 
were vehicle effects compared with naïve controls, including some very minor alterations in female 
offspring cyclicity. However, there were no statistically significant reproductive effects in female at 
BPA doses ≤3.6 mg/kg bw per day HED on PND90, including an absence of any significant effects 
on AGD, ovarian and uterine morphology, ovarian cyclicity or reproductive endocrinology.  
The only non-rodent studies investigating prenatal BPA exposure were those by Hunt et al. (2012) 
and Veiga-Lopez et al. (2013). Hunt et al. (2012) used pregnant Rhesus macaques to investigate 
reproductive parameters in the female offspring. Two routes of administration were used: (1) oral in 
diet, 400 µg BPA/kg bw per day (single daily dose) or (2) subcutaneous implant tested to yield 2.2-3.3 
ng unconjugated BPA/ml plasma in non-pregnant females (continuous exposure). Two exposure 
windows were investigated for each route: (1) early GD50-100, the onset of meiosis and (2) late 
GD100-term, the period of follicle formation. Only the results for the oral route were considered for 
evaluation because of the inadequate number of animals dosed via the subcutaneous route (only 2 
monkeys in the control group). BPA at 400 µg BPA/kg bw per day was associated with a modest but 
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statistically significant increase in the proportion of multi-oocyte secondary or antral follicles but had 
no significant effect on incidence of meiotic defects reportedly seen in the implant group). The 
significance of the increased incidence of multi-oocyte follicles for subsequent fertility in monkeys or 
humans remains to be conclusively demonstrated, although it is likely negative.  
In Veiga-Lopez et al. (2013) adult Suffolk ewes received 0.5 mg BPA/kg bw per day subcutaneously 
from GD30 to GD90 (total gestation period 147 days) and controls received corn oil alone. BPA 
levels in arterial umbilical blood samples were monitored at GD90. The authors reported that levels of 
unconjugated BPA increased from 0.4 ng/ml in controls to 2.6 ng/ml in BPA-exposed fetuses. 
CYP19A1 and SRD5A1 were reduced at GD65 but not GD90 in BPA exposed ovaries but had no 
effect on the pattern of transcript changes between GD65 and GD90. BPA exposure down-regulated 
45 miRNA at GD65 but only 11 miRNA at GD90. The CEF Panel considered that the consequences 
of these changes are not obvious.  
A further four rodent and one primate studies reported possibly relevant effects of BPA on the female 
reproductive system at dose levels below a HED of 3.6 mg/kg bw per day, as follows.  
A further rodent study by Cabaton et al. (2011) performed an important forced/continuous breeding 
experiment. CD-1 female mice were exposed to BPA via subcutaneous osmotic minipumps (0.025, 
0.25, 2.5 µg/kg bw per day) from GD6-PND16. DES (10ng/kg bw per day) was used as a positive 
control. Female F1 offspring were force-bred from 2 months post-natal for 32 weeks. The lowest and 
highest BPA doses were associated with significantly reduced cumulative pup numbers. At the 
highest BPA dose numbers of litters and the proportion of females with ≥6 litters were significantly 
reduced. 
Cynomolgus monkeys were given BPA (10 µg/kg bw per day) (n=18) or vehicle (n=19) 
subcutaneously by implanted pump prenatally to mothers during pregnancy. No effects of BPA were 
observed on delivery, stillbirth, premature birth, gestational length or body weight of offspring 
(Nakagami et al. 2009).  
Nah et al. (2012) administered a single subcutaneous injection, at dose levels of 0.1, 1, 10, 100 mg 
BPA/kg bw to postnatal female ICR mice on PND 8. Body weight gain, onset of puberty and 
ooestrous cycling were investigated at PND 25, 30, 70. Ovary weights and age of puberty (vaginal 
opening) were reduced significantly at all BPA doses, but other significant effects (ooestrous cycling, 
uterus weight) were only seen at the two higher doses of BPA. However, these differences were not 
seen on PND70.  
In Christiansen et al. (2014) Wistar rat dams were administered BPA at dose levels of 0.025, 0.25, 5, 
50 mg/kg bw per day in corn oil from GD7 to PD22. Very few statistically significant effects of BPA 
were observed in females although female pup AGD was significantly decreased (9% max) at all 
doses (a similar effect was seen in male pups, see above). The CEF Panel considered that the decrease 
in AGD in females at ≤3.6 mg/kg bw per day HED is indicative of an effect of BPA on genital 
development at all doses administered in this study, but the reproductive significance of decreased 
AGD in the females is uncertain. 
The study by Zhang et al. (2012a) was designed to assess the effects of BPA on germ cell cyst 
breakdown and primordial follicle formation in CD1 mice. Pregnant mice were given 0, 20, 40 and 80 
µg BPA/kg bw per day by subcutaneous injection from 12.5 days to 18.5 days postcoitum. The 
ovaries of the female offspring were variously analysed at 13.5, 15.5, 17.5 and 19.5 (=PND1) days 
postcoitum and at PND 3, 5, 7 for meiosis progression, bisulphite sequencing, immunohistochemistry 
and histology for meiosis progression markers. Dose-dependent effects of BPA were observed, with 
retention of oocytes in nests (cysts) and reduced primordial follicle numbers. However, numbers of 
oocytes were higher in the PND3 ovaries, possibly linked with delayed meiosis progression and 
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decreased levels of increasingly methylated Stra8. Progression to meiosis prophase I of oocytes was 
delayed in the 80 µg/kg/day treated group. 
Overall summary of studies investigating the effects of BPA on the female reproductive system and 
involving developmental exposure 
Of the 17 studies evaluated, as described above, four studies were considered to show no effects 
attributable to treatment with BPA on the female reproductive system, seven studies reported some 
limited effects, while six showed one or more consistent effects, with the caveat of very variable study 
quality and outcomes. Few studies involved prolonged post-natal exposure and a number of 
methodological concerns were raised. Overall the CEF Panel considered that there was some evidence 
of an effect on the female reproductive system following developmental exposure at dose levels 
below a HED of 3.6 mg/kg bw per day, with the most convincing effects reported by Christiansen et 
al. (2014).  
Effects of BPA on bone development following developmental exposure  
Pelch et al. (2012) examined the effect of developmental exposure to low doses of diethylstilboestrol 
(DES), BPA or ethinyl oestradiol (EE2) on bone geometry and torsional strength in the offspring at 10 
and 13 weeks of age (females) or 23 weeks (males). C57BL/6 mice were given 0.1 μg/kg bw per day 
diethylstilboestrol, 10 μg/kg bw per day BPA, 0.01, 0.1, or 1.0 μg/kg bw per day ethinyl oestradiol or 
vehicle from gestation day 11 to post-natal day 12 via a mini-osmotic pump. Exposure to DES, BPA 
or low dose EE2 increased adult femur length by small increments (approximately 2.5%). Exposure to 
the highest dose of EE2 did not alter femur length, which the authors considered provided evidence of 
a non-monotonic dose-response. Exposure to EE2 and DES, but not BPA, decreased femur tensile 
strength, while no changes were seen in bone collagen content.  
b) Effects of BPA on reproductive function following exposure during adult life  
Male reproductive system 
The CEF Panel has evaluated seven studies published since 2006, reporting effects on the testis (6 
studies) or prostate (1 study). 
Dobrzynska and Radzikowska (2013) administered 5, 10, 20 or 40 mg BPA/kg bw per day in drinking 
water to male mice for 2 weeks. Decreases in sperm counts, sperm motility, increases in abnormal 
sperm morphology were reported at all BPA doses except 5 mg/kg/day, which only caused a 3% 
increase in abnormal sperm. Increased DNA damage in somatic and germ cells was seen at all BPA 
doses including 5 mg/kg bw per day.   
In the study of Qiu et al. (2013), adult male Sprague-Dawley rats (8 weeks old) were administered 
BPA at dose levels of 0.0005, 0.5, 5 mg/kg bw per day for 8 weeks and examined at the end of the 
dosing period. BPA did not affect organ or body weights, serum biochemistry or hepatonephric 
function. While circulating testosterone was unaffected, BPA reduced intratesticular testosterone at 5 
mg/kg bw per day. This dose also reduced sperm numbers, seminiferous tubule epithelial height, 
numbers of round spermatids and the ratio of round spermatids/Sertoli cells, although sperm motility 
was unaffected. Changes in spermatogenesis-related genes and proteins were also reported. The 
results suggest only limited effects of BPA below 3.6 mg/kg bw per day HED. 
Jin et al. (2013) administered BPA by gavage at a single dose level of 2 µg/kg bw per day to adult 
male Sprague-Dawley rats for 14 days. Separate groups of rats were administered testosterone 
propionate (TP) at 0.1 mg/rat/day or a mixture of BPA+TP. BPA was reported to reduce sperm counts 
and seminiferous tubule numbers of all stage VII germ cells. The BPA-exposed seminiferous tubules 
had an increased apoptotic index that was unaffected by co-administration of TP. Serum and intra-
testicular testosterone were reduced in BPA-exposed animals and the negative effect of BPA on 
sperm counts was partially reversed by TP, as were numbers of mPSc and 7Sd stage VII germ cells. 
BPA-exposed rats had lower follicle-stimulating hormone (FSH) and increased luteinizing hormone 
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(LH), and brain preoptic area GnRH expression was also reduced, while expression of a number of 
testicular genes was increased.  
In the study of Liu et al. (2013), adult (9 weeks old) male Wistar rats were exposed to BPA at dose 
levels of 2, 20, 200 µg/kg bw per day by gavage for 60 days. E2 (10 µg/kg bw per day) administered 
sc was used as a positive control. Treatment continued for 60 days. No effect of BPA on testicular 
parameters was reported at BPA dose levels lower than 200 µg/kg bw per day. BPA (200 µg/kg bw 
per day) and E2 increased stages VII and IX sperm and decreased stage VII sperm, an effect blocked 
by ER antagonism using the ER antagonist fulvestrant. Both BPA (200 µg/kg bw per day) and E2 
reduced the percentage of leptotene and zygotene spermatocytes and increased the proportion of 
pachytene spermatocytes, again blocked by ER antagonist administration. Extensive analysis of germ 
cell meiosis indicated that BPA (200 µg/kg bw per day) and E2 induced disruption of meiosis and 
increased germ cell apoptosis. Despite methodological and reporting deficiencies, the CEF Panel 
noted that the study indicates a potential oestrogenic action of BPA in the adult male rat.  
Tiwari and Vanage (2013) administered 2 dose levels of BPA (10 µg/kg bw per day and 5 mg/kg bw 
per day orally to adult Holtzman male rats once per day for 6 days. The males were then repeatedly 
mated (8 times) with untreated females up to 56 days post-treatment, and treatment-related effects on 
fertility were investigated. The 5 mg/kg bw per day dose reduced implantation/embryo survival 
indices in the offspring of treated males during a single (22-28 days) post treatment interval only, and 
there were no effects on mating or gestation indices. The same dose at the same interval increased 
post-implantation loss but the effect was not statistically significant on the “dominant lethal 
mutation”. Both BPA doses were associated with reduced sperm production, count and motility 
although the latter only achieved significance at the higher dose, which also caused DNA damage to 
the sperms. However, the CEF Panel noted the lack of any effect on fertility, considering the 
implications of the testicular effects to be unclear.  
In a preliminary and inadequately quantified study, El Ghazzawy et al. (2011) administered a single 
low dose level of 20 µg BPA/kg bw per day, ±pomegranate juice and appropriate controls, by oral 
gavage to adult male albino rats for 8 weeks. The authors reported a quantified reduction in caudal 
epididymis sperm numbers (1.8-fold lower in the BPA dose group) and qualitative morphological 
observations were made about caput epididymis and sperm structure and ultrastructure.  
In a well powered, well performed study with valid endpoints, Castro et al. (2013) exposed adult male 
Wistar rats to 0, 25, 50, 300, 600 µg BPA/kg bw per day for 4 days by sc injection. Testosterone 
increased, oestradiol decreased and the testosterone/oestradiol ratio was skewed by exposure to BPA 
at all doses tested.  
Overall summary of studies investigating the effects of BPA on the male reproductive system and 
involving exposure of adult animals 
Of the seven studies published after 2010, six investigated effects of BPA on testicular function 
although only one of these examined whether the changes found impacted on the fertility of the 
animals (and reported no effects). Effects on sperm parameters, hormone levels, testicular gene and 
protein expression were reported in oral studies employing doses in the range of 5 mg/kg bw per day 
(HED of 3.6 mg/kg bw per day), but several authors reported effects at much lower dose levels, in one 
study as low as 2 µg BPA/kg bw per day. Overall the CEF Panel considered that there was some 
limited evidence of an effect on the male reproductive system following developmental exposure at 
dose levels below a HED of 3.6 mg/kg bw per day.  
The CEF Panel noted however that no effect of BPA was reported on male reproductive organ 
weights and sperm production at any dose level in the robust subchronic toxicity study in rats 
conducted by US FDA/NCTR (US FDA/NCTR Report 2013/Delclos et al., 2014), which involved 
exposure during both prenatal and adult life, although testicular descent was significantly delayed by 
approximately 1 and 2 days, respectively, in the 260 and 300,000 μg BPA/kg bw per day dose groups. 
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Similarly, in the multigenerational studies in rats and mice conducted by Tyl et al. (2002, 2008), 
effects were only reported at a dose level of 600 mg/kg bw per day in mice, with a statistically 
significant reduction in epididymal sperm concentration (15% reduction) in males. BPA also reduced 
F1/F2 weanling testis weight (with seminiferous tubule hypoplasia). The NOAEL for reproductive 
effects in both studies was 50 mg/kg bw per day. 
Female reproductive system  
Two studies published after 2006 have been evaluated by the CEF Panel, one investigating BPA 
effects on delivery and placental signalling and one on ovarian effects.  
In Tan et al. (2013) 6-8 week old pregnant female ICR mice were administered 0, 2, 20, 200 mg 
BPA/kg bw per day in ethanol/corn oil by gavage from GD 13 – GD 16. Blood samples and tissues 
were harvested at E17. Mice exposed to 20 and 200 mg/kg bw per day had significantly elevated E2, 
testosterone and CRH although only the highest dose was associated with increased placental crh 
transcript and cyp19a1 was not affected. Placental CREB protein was increased in all BPA groups, as 
was the PKC zeta/gamma ratio, while PKC delta was only affected at the highest dose. The study 
suggests that BPA exposure in pregnant mice may disturb the endocrine and PKC signalling pathways 
in the placenta although limited effects were seen at ≤3.6 mg/kg bw per day HED. 
In a well performed and well powered study Lee et al. (2013b) administered BPA by oral gavage at 
0.001 or 0.1 mg/kg bw per day for 90 days to adult (8 weeks old) female Sprague-Dawley rats. A 
positive control, 0.001 mg oestradiol benzoate (EB)/kg bw per day was included. Circulating E2 and 
T was reduced by both dose levels of BPA and also by EB and the duration of the oestrus phase 
increased. Follicular and corpora luteal atresia was increased by BPA although EB only affected luteal 
atresia as determined by caspase-3 analysis. Theca cell cyp19 was decreased by BPA and StAR 
decreased by BPA and EB. Circulating and pituitary LH levels, but not FSH levels, were increased by 
BPA at both dose levels, without a marked dose-response.  
Summary of studies investigating the effects of BPA on the female reproductive system and involving 
exposure of adult animals 
The two studies evaluated, as described above, showed limited effects of BPA on placental and 
ovarian function at dose levels considerably below a HED of 3.6 mg/kg bw per day.  
3.3.2.5. Summary of reproductive and developmental effects of BPA in animal studies  
Overall, the better -powered, better-conducted studies, especially those including several dose levels 
≤3.6 mg BPA/kg/day HED, reported only limited evidence of effects of in utero exposure to BPA on 
reproductive development. However, on balance, the evidence remains contradictory and highly 
variable between studies. Overall the CEF Panel considered that there was some evidence of an effect 
of BPA on both the male and female reproductive systems following developmental exposure. 
There is also some evidence for effects of exposure of adult animals to BPA on aspects of 
reproductive health/performance, in particular for a possible effect on testicular function in males at 
dose levels below 5 mg/kg bw per day, although again these effects were modest and follow-up to 
establish reduced fertility in adulthood is quite limited. In several cases the assessed studies 
investigated molecular biology endpoints but not functional/morphological endpoints. It appears that 
molecular endpoints often exhibit greater sensitivity to BPA. While these outcomes are considered 
relevant, an adverse phenotypic outcome is of greater significance for risk assessment and it is 
important that studies to be included in risk assessment should report both sets of endpoints. 
The CEF Panel noted that ovarian cysts and endometrial hyperplasia have been reported in female 
animals exposed to BPA in a number of studies published before 2010, and that other assessments 
such as that of ANSES (2011, 2013) have considered the two phenomenon important. Certainly these 
two adverse effects are highly relevant to human reproductive competence and health. However, the 
CEF Panel considered that more recent studies considered for this opinion did not report any 
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significant effects of BPA at an HED ≤3.6 mg/kg bw per day on the incidence of ovarian cysts or 
endometrial hyperplasia. 
Finally, the CEF Panel noted the very wide variability in the incidence and/or magnitude of adverse 
effects, if any, between the studies assessed. There are a number of contributing reasons for this, 
including: (i) use of different species and strains, (ii) use of different ages categories, (iii) onset and 
termination of exposure regimens varies hugely between studies, (iv) widely varying durations of 
exposures to BPA, (v) considerable variation in study quality and statistical power, (vi) extensive 
variations in vehicle and/or solvents used, (vii) diverse selection of end-points assessed, (viii) low 
number of forced/continuous breeding or two-generation  studies, (ix) wide range of cages, bedding 
diets and exposure routes employed, (x) few studies have confirmed in-animal BPA doses levels – i.e. 
how much BPA is reaching target organs? All these factors will contribute to the variability in the 
findings reported in the studies included in this assessment. 
3.3.3. In vitro studies 
Several recent studies (Ye et al., 2011; Guo et al., 2012; Quignot et al., 2012a) on the expression and 
activities of steroidogenic enzymes suggest that BPA has an inhibitory effect only at micromolar 
concentrations. Slight differences in the results from studies using microsomes and cells from 
different species (human, mouse, rat) suggest a cell- and species-specific BPA effects on these 
enzymes. Results from a study using organotypic culture of human fetal testis, N´Tumba-Byn et al. 
(2013), suggests that human fetal testes may have a greater sensitivity to the inhibitory effects of BPA 
(10-8 M) on testosterone production. However, considering that the number of human fetuses in the 
study was low and that the effects of BPA on enzyme activities were only observed at higher 
concentrations the findings of N´Tumba-Byn et al. (2013) still need to be confirmed. Other studies 
were performed on the BPA-induced mechanisms of proliferation in a human ovarian epithelial 
cancer cell line (Ptak et al., 2012) and in mouse spermatogonial cells (Sheng et al., 2011). These cells 
were sensitive to concentrations of BPA at the pico- and nanomolar range, which are still high 
concentration considering internal dose levels, and non-genomic signalling pathways were involved. 
The significance of these in vitro findings has to be further investigated and the impact on the in vivo 
reprotoxic effects of BPA is not yet clear. 
3.3.4. WoE of developmental and reproductive effects of BPA in humans, animals and in 
vitro 
For interpretation of these tables always refer to Appendix A. 
Table 8:  Overall table of WoE evaluation of reproductive and developmental effects of BPA in 
humans and animals. 
Human studies 
Overall conclusion on Likelihood of reproductive effects of BPA in humans:  
An association between BPA and embryo quality and implantation success during IVF, 
semen quality, sex hormones or age of menarche in humans is considered unlikely 
Unlikely 
Overall conclusion on Likelihood of gestational /birth outcomes of BPA in humans:  
There are indications from prospective studies that BPA exposure during pregnancy may be 
associated with effects on fetal growth, and weak indications that BPA exposure during 
pregnancy may be associated with maternal and infant thyroid function. However, it cannot 
be ruled out that the results are confounded by diet or concurrent exposure factors. For fetal 
growth, two studies showed reduced fetal growth, while one study reported increased fetal 
growth with increasing maternal BPA exposure. The associations do not provide sufficient 
evidence to infer a causal link between BPA exposure and reproductive effects in humans. 
Potential effects are considered to be as likely as not.  
As likely as not 
  
Animal studies 
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3.3.5. Conclusions on reproductive and developmental effects 
In relation to reproductive and developmental effects in humans, the CEF Panel concluded that there 
are indications from prospective studies that BPA exposure during pregnancy may be associated with 
disturbed fetal growth, and weak indications that BPA exposure during pregnancy may be associated 
with maternal and infant decreased thyroid function, but it cannot be ruled out that the results are 
confounded by diet or concurrent exposure factors. The associations found in the human studies are 
not sufficient to infer a causal link between BPA exposure and reproductive effects in humans. 
Potential effects are considered to be as likely as not. 
Overall, the better powered, better conducted studies in animals found few consistent effects of in-
utero exposure to BPA on reproductive development at dose levels at or below 3.6 mg BPA/kg/day 
HED. On balance, the evidence remains contradictory and highly variable between studies. The CEF 
Panel noted that there is some evidence for effects of BPA exposure on several parameters indicative 
for changes in the reproductive system in adult male animals at dose levels below 3.6 mg/kg bw per 
day, although these effects were modest. It is not possible to conclude that these changes are reflective 
of changes in reproductive performance, since the studies rarely included a forced/continuous 
breeding phase in adulthood to establish reduced fertility. However, in several multigenerational 
studies no effects were observed at dose levels as low as 3 µg/kg bw per day up to at least 50 mg/kg 
bw per day. 
Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to reproductive 
and developmental effects of BPA at low doses (below the HED of 3.6 mg/kg bw per day). Since the 
likelihood level for this endpoint is less than "likely" (see Appendix A), this endpoint was not taken 
Overall conclusion on Likelihood for reproductive and developmental effects in animals 
when exposed during their adult life (post-pubertal) only at doses ≤ HED of 3.6 mg/kg 
bw per day:  
As more studies emerge with doses ≤3.6 mg BPA/kg bw per day HED, there are increasing 
indications of some negative effects of adult exposure to BPA on gonadal or reproductive 
tract physiology. Very few studies have assessed the effects of long term exposure of adults 
to such doses of BPA (human scenario) on the reproductive gold standard – fertility and 
reproductive ageing. Since only single studies on ovary and prostate gland fit the 
methodological criteria used in this opinion, no conclusion can be drawn on BPA-related 
effects on these organs. Taken together the studies assessed here suggest that BPA at an HED 
of ≤3.6 mg/kg bw per day may have adverse effects on testis function, especially various 
measures of spermatogenesis. There is less evidence to support a conclusion that BPA will 
significantly impair testis morphology or reproductive endocrinology, especially in the 
longer term. 
Note: Alteration of reproductive capacity are likely at high doses (above an HED of 3.6 
mg/kg bw per day) 
As likely as not 
 
Overall conclusion on Likelihood for reproductive and developmental effects in animals 
when exposed during development (prenatally and pre-pubertally) ≤ HED of 3.6 mg/kg 
bw per day: 
Taken overall, there are some data suggesting negative effects of doses of BPA ≤ an HED of 
3.6 mg/kg bw per day on reproductive development in animals. However, the lack of 
agreement between studies results in a high degree of uncertainty. The most consistent 
findings are generally of small magnitude (e.g. reduced male AGD) and often not 
accompanied by associated changes (e.g. disturbed ovarian cyclicity would be expected to be 
associated with ovarian abnormalities). Given difficulties in determining whether molecular 
changes are causal or due to adaptation or morphological changes, the weight given to 
studies presenting molecular findings without accompanying morphological data is low.  The 
single non-human primate ovary study included was hampered by inadequate numbers of 
animals per group. 
Note: Alteration of reproductive development are likely at high doses (above an HED of 
3.6 mg/kg bw per day) 
As likely as not 
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forward for assessing the toxicological reference point, but was taken into account in the evaluation of 
uncertainty for hazard characterisation and risk characterisation (Section 4.3). 
3.4. Neurological, neurodevelopmental and neuroendocrine effects 
3.4.1. Human studies 
3.4.1.1. Summary of previous opinions 
EU-RAR (2003 and 2008)  
No human data were available at the time of these reports. 
EFSA (2006); EFSA CEF Panel (2010)  
No human studies were reviewed in the opinion of 2006. 
The 2010 EFSA opinion included evaluation of a study by Braun et al. (2009) which found that the 
concentration of BPA in maternal urine from early pregnancy was associated with adverse 
externalising behaviour in 2-year old girls. This was the first epidemiological study suggesting an 
association between BPA exposure and neurodevelopmental effects. Several methodological 
limitations were noted and the CEF Panel could not draw any relevant conclusion for risk assessment 
from the study. 
NTP-CERHR (2008) 
No human studies on the effects of human developmental exposure to bisphenol A were then 
available. 
FAO/WHO (2011) 
The Expert meeting reviewed the prospective cohort study by Braun et al. (2009) and concluded that 
the results suggest that prenatal BPA exposures (especially in early pregnancy) are associated with the 
later development of externalizing behaviours, e.g. aggression and hyperactivity, particularly in girls. 
The Expert meeting also indicated replication of this study using large prospective birth cohorts with 
serial measures of urinary BPA during pregnancy as a high-priority research need. 
ANSES (2011, 2013) 
In 2011, the ANSES experts concluded that the human data then available were insufficient to draw a 
conclusion on the effects of BPA on human behaviour. 
The ANSES report evaluated the Braun et al. (2009) study and noted the methodological flaws, which 
limit the value of the study. A study by Miodovnik et al., 2011 was also evaluated in the ANSES 
report. Miodovnik et al.sought to correlate the urinary levels of BPA and of phthalates analysed 
during pregnancy with the sociability of multiethnic city children aged 7 to 9, in 137 children. No 
significant association was found between urinary levels of BPA and social problems assessed by the 
Social Responsiveness Scale (SRS). 
3.4.1.2. Evaluation of recent human studies on BPA exposure and neurological/behavioural, 
neurodevelopmental and neuroendocrine effects 
Six new studies were identified in the literature and evaluated (Miodovnik et al., 2011; Yolton et al., 
2011; Braun et al., 2011; Perera et al., 2012; Harley et al., 2013a; Hong et al., 2013). A detailed 
description and evaluation of each study is provided separately in Appendix B. 
In a group of 404 mother-child pairs, Miodovnik et al. (2011) examined prenatal BPA exposure 
(maternal urinary BPA concentrations) in relation to child social behaviour (Social Responsiveness 
Scale) at age seven- to nine years in a group of inner-city children in New York. The results showed 
suggestive associations for prenatal BPA with autistic spectrum type behaviours, but were not 
statistically significant.  
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Yolton et al. (2011) studied 350 mother/infant pairs and examined maternal urinary BPA 
concentration and infant neurobehaviour measured at five weeks of age using the NICU Network 
Neurobehavioural Scale (NNNS). The NNNS is a tool with proven sensitivity to both overt and subtle 
differences in infant neurobehaviour. There was no significant association with prenatal BPA 
exposure and infant neurobehaviour.  
In 2009 Braun et al. reported that higher prenatal BPA exposure (maternal urinary BPA 
concentrations) was associated with more externalising problem behaviour in girls at age 2 years, but 
not in boys (reviewed by EFSA CEF Panel, 2010). A follow up study by Braun et al. (2011) in the 
same children at age 3 years showed that higher prenatal BPA exposure (as judged by maternal 
urinary BPA) was significantly associated with more anxiety, depression, and hyperactivity 
behaviours in girls, but not in boys. The outcome measures were assessed by parent reports using the 
Behavior Assessment System for Children 2 (BASC-2) and the Behavior Rating Inventory of 
Executed Function-Preschool (BRIEF-P). In this study, no associations were found for children’s 
urinary BPA concentrations and later behaviour. The study by Yolton et al. (2011) and the two studies 
by Braun et al. (2009, 2011) used the same study population (a prospective birth cohort in the 
Cincinnati, Ohio, metropolitan area designed for the study of low-level environmental toxicant 
exposures).   
Perera et al. (2012) investigated the association between prenatal BPA exposure (maternal urinary 
BPA) and child behaviour in children between three and five years of age in 198 mother- child pairs 
in a low-income minority population in New York. In contrast to the studies by Braun et al. (2009 and 
2011), which found associations between prenatal BPA exposure and child behaviour mainly in girls, 
Perera et al. (2012) found that higher prenatal exposure to BPA was significantly associated with 
increased emotional reactivity and aggressive behaviour in boys.On the contrary, in girls prenatal 
BPA exposure was associated with reduced scores for anxiety/depression and aggressive behaviour. 
The associations were adjusted for postnatal BPA exposure (child urinary BPA) and the authors 
suggest that the prenatal period is a critical time window for potential adverse effects of BPA on 
children’s neurodevelopment. Childhood urinary BPA concentration was negatively associated with 
one out of seven syndrome scores (Emotionally Reactive) in the full sample, but no associations were 
seen for any outcome in boys and girls separately. 
Harley et al. (2013a) studied prenatal and early childhood BPA concentrations in urine and behaviour 
in children at age 7 years using data from 292 mothers and children participating in the longitudinal 
birth chohort CHAMACOS, a low income Mexican-American agricultural population in California. 
Children’s behaviour was assessed by maternal and teacher reports (BASC-2 and CADS, scales 
validated in English and Spanish) at age 7 and by direct assessment at age 9 by using the Connors' 
Continuous Performance Test (CPT). Higher urinary BPA concentrations in mothers during 
pregnancy were associated with increased internalising problems, including anxiety and depression, in 
boys (BASC-2), while no associations were found in girls. The findings were consistent using both 
mothers’ and teachers’ report. No associations were seen in boys or girls on the CADS at 7 years or in 
boys or girls with any behaviour at age 9 (CPT).  
Higher urinary BPA concentrations in children at age 5 years were associated with increased 
internalising problems and increased (ADHD) behaviour in both boys and girls and increased 
externalising behaviors, including conduct problems, in girls at age 7 (BASC-2 and CADS). The 
associations with childhood BPA were mainly seen with teacher reports. No associations were seen 
with BPA concentrations at 5 years and any behaviour at age 9 (CPT).   
In a cross-sectional study in Korea with 1008 children aged 8-11 years, Hong et al. (2013) examined 
urinary BPA and behaviour and learning. Behaviour and learning were assessed by the Korean 
version of the Child Behavioural Checklist (CBCL) and the Learning Disability Evaluation Scale 
(LDES). Higher urinary BPA concentrations in the children were associated with higher CBCL total 
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problem score and with lower LDES listening and learning scores. There was no interaction effect 
between urinary BPA concentration and gender. 
A recent review (Rochester, 2013) identified 91 epidemiological studies showing associations 
between environmental BPA exposure and various adverse effects in humans, including 
neurodevelopmental effects. However, the authors concluded that these studies were primarily 
supportive and that a causal relationship was still difficult to obtain (Rochester, 2013).Summary of 
neurological, neurodevelopmental and neuroendocrine effects in humans after prenatal and 
postnatal/childhood BPA exposure 
Although most of the new studies were prospective, the uncertainty related to the relationship between 
exposure to BPA and the outcomes limits the conclusions that can be drawn from studies showing 
associations. In particular, the CEF Panel noted that in the Miodovnik et al. (2011), Braun et al. 
(2011) and Perera et al. (2012) studies, neuropsychological functioning and social function were 
assessed by parents’ reports of child behaviour. Parental reports, even when using validated 
questionnaires/scales, may present more variability than standardised neurodevelopmental scales 
administered by child psychiatrists. The Perera et al. (2012) and Braun et al. (2009, 2011) studies, 
although inconsistent, indicate that prenatal BPA exposure may affect child behaviours in a sex-
dependent manner. In contrast, the Miodovnik et al. (2011) and Yolton et al. (2011) studies did not 
indicate that prenatal BPA exposure was associated with infant or childhood behaviour. In a study 
with 292 mothers and children in the CHAMACOS, Harley et al. (2013a) linked prenatal BPA 
exposure to behavioural problems in boys at age 7. Significant associations were seen for both 
mothers’ and teachers’ reports of child behaviour and the study took into account other environmental 
contaminants, childhood BPA exposure and important covariates reflecting socioeconomic status and 
home environment. This study also found significant associations between higher childhood BPA 
exposure (at age 5 years) and problem behaviours at age 7 years in both boys and girls. However, no 
associations of BPA with any behaviour at age 9 were found when directly assessed (CPT). No 
reliable associations between childhood BPA exposure and behavioural effects were reported in the 
other studies (Braun et al., 2011; Perera et al., 2012; Hong et al., 2013). More prospective studies with 
larger sample size, repeated BPA measurements, inclusion of dietary data and standardized 
neuropsychological testing are needed.  
In summary, there are indications from prospective studies that prenatal BPA exposure (BPA 
exposure during pregnancy) may be associated with child behaviour in a sex-dependent manner. 
However, the associations were not consistent across the studies, and it cannot be ruled out that the 
results are confounded by diet or concurrent exposure factors. The associations do not provide 
sufficient evidence to infer a causal link between BPA exposure during pregnancy or childhood BPA 
exposure and neurodevelopmental effects in humans.  
3.4.2. Animal studies 
3.4.2.1. Summary of previous opinions 
The neurobehavioural effects of developmental exposure to BPA have been reviewed on a number of 
occasions (EU-RAR, 2003, 2008; EFSA, 2006, 2010; NTP-CERHR, 2008; FAO/WHO, 2011; 
ANSES, 2011, 2013). BPA has been tested in rats and mice in a number of experimental in vivo 
models, taking into account medium and long-term behavioural, neurochemical, neuroendocrine and 
gene expression effects, together with shorter term studies in in vitro models. The outcome of these 
reviews is summarised as follows.  
EU-RAR (2003, 2008) 
The EU-RAR reviewed 34 animal studies, published between 1999 and 2007, the majority of which 
used the oral route for BPA exposure. These studies focused on developmental neurotoxicity 
endpoints, including behavioural studies as well as studies assessing the effects of pre- and /or 
postnatal BPA on brain development. Many developmental neurotoxicity endpoints were evaluated: 
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locomotor and exploratory activity; grooming, cognitive, emotional, social, sexual and maternal 
behaviour; behavioural response to pharmacological challenge; brain morphology, 
immunohistochemistry, and receptor/gene expression. The overall assessment draws attention to a low 
level of confidence in the reliability of the studies and a lack of consistency in the results of 
behavioural testing, such that no firm conclusions can be drawn on any of the parameters considered. 
However, the environmental regulatory agencies of three countries, Denmark, Sweden and Norway, 
did not agree with this conclusion, considering that a number of studies on developmental 
neurotoxicity, namely Adriani et al., 2003, Negishi et al., 2004, Carr et al., 2003, and Ryan and 
Vandenberg, 2006, were sufficiently reliable for regulatory use.   
 
NTP-CERHR (2008) 
The NTP-CERHR (2008) monograph reported that perinatal or pubertal exposure to “low” doses of 
BPA may cause neural and behavioural alterations in rats and mice, especially related to the 
development of normal sexual dimorphisms. However, the literature could not be fully interpreted for 
biological or experimental consistency, or for relevance to human health. In summary, the NTP 
considered that there is some concern for effects of BPA at low doses on the developing brain and 
behaviour, but identified the need for additional research to more fully assess its functional and long-
term implications and relevance to humans.  
 
EFSA (2006); EFSA CEF Panel (2010) 
In 2006, EFSA noted that BPA given orally at low doses during gestation and/or lactation was 
reported to cause effects on some of the behavioural endpoints assessed. Overall, however, the AFC 
Panel (2006) considered that there were no consistent treatment-related effects in the behavioural 
endpoints and apparently contradictory observations were published, citing as an example the fact that 
neophobia was found as an effect in one study (Adriani et al., 2003) in females and not in males, 
while in the other study of Negishi et al. (2003) no effect was found in the open field, which should 
show an effect if neophobia is present in male offspring. The AFC Panel also noted methodological 
deficiencies in the available studies. 
The 2010 EFSA opinion included evaluation of toxicological data published between 2007 and July 
2010. For the in vivo animal toxicity studies the focus was on low dose oral studies employing several 
test doses including at least one less than 5 mg/kg bw per day and involving developmental exposure. 
The CEF Panel (2010) noted the impact of BPA on development of sexually dimorphic behaviour as 
addressed in the study by Ryan et al. (2010a), who observed a male-like reduced saccharin preference 
and inhibition of lordosis behaviour in female rat offspring from oestrogen-treated but not from BPA-
treated dams. The CEF Panel (2010) concluded that the effect of BPA on learning and memory 
behaviour as explored in the study of Stump et al. (2009), which was designed according to OECD 
Guideline 426 and focused on learning and memory assessed in the Biel Maze, was inconclusive due 
to large variability in the data.  
The 2010 EFSA CEF Panel opinion also considered that significant methodological shortcomings 
(e.g. small numbers of samples, lack of consideration of the litter effect) applied to a number of 
studies addressing other neurobehavioural endpoints (e.g. learning and memory behaviour, anxiety-
like behaviour and sex-specific behaviour) made the reviewed studies invalid or inadequate for risk 
assessment purposes. Overall the CEF Panel (2010) concluded that currently available data did not 
provide convincing evidence of neurobehavioural toxicity of BPA. The CEF Panel (2010) noted that 
potentially significant biochemical changes, e.g. altered receptor expression in different brain regions, 
such as changes in N-methyl-D-aspartate (NMDA), oestrogen receptors and alteration in the basal 
level of aromatase have been reported. However, in the absence of a correlation with a functional 
adverse effect, the CEF Panel did not consider the available data as convincing evidence of 
neurobehavioural toxicity of BPA. A minority opinion was expressed by a CEF Panel member, based 
on uncertainties raised by some recent animal studies suggesting changes in brain receptor 
programming which may have functional behavioural consequences. 
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An entire Section of the 2010 EFSA CEF Panel opinion was dedicated to a review of a study by 
Stump (2009) who performed a developmental neurotoxicity study with BPA, in accordance with 
OECD guideline 426 and in compliance with GLP. As stated in the EFSA CEF Panel (2010) opinion 
“BPA was administered to pregnant rats via the diet at concentration ranging from 0.15 to 2250 
mg/kg feed equivalent to 0.01-164 mg/kg bw per day during gestation and to 0.03-410 mg/kg bw per 
day during lactation. Dams were evaluated for general signs of toxicity, and offspring were evaluated 
for general toxicity including developmental landmarks and for neurological effects, including 
behaviour and brain histopathology.  
Based on the body weight effects on dams and offspring and also taking into account the occurrence 
of seizures and convulsions in the two highest dose groups, which were not observed at the lower dose 
levels, the study supports the NOAEL which was derived from multigenerational studies in the past (5 
mg/kg bw per day), leading to a TDI of 0.05 mg/kg bw per day. The neurodevelopmental toxicity study 
by Stump (2009) covers motor activity, learning and memory (spatial behaviour), auditory startle 
response, brain histopathology and morphology. The study does not cover some specific aspects of 
learning and memory (i.e. avoidance learning, schedule-controlled behaviour, and impulsiveness), 
anxiety-related behaviour or sexual dimorphic behaviour, but this does not invalidate the study. No 
statistically significant effects were observed in tests on motor activity or auditory startle or in brain 
histopathology and morphology. Stump also concluded that there were no changes in learning and 
memory based on the results of the Biel Maze test. However, the Panel considered that this test on 
learning and memory was inconclusive due to large variability in the data and of limited value in the 
risk assessment of BPA.” 
FAO/WHO (2011) 
The Expert Meeting reported changes in brain biochemical signalling, morphometric and cellular end-
points within sexually dimorphic anatomical structures and neuroendocrine end-points at dietary 
exposures of BPA below 5 mg/kg bw per day. Based on the available data, changes in anxiety-like 
behaviour and convergence of anatomical brain sex differences were identified as end-points 
suggestive of effects with potential human relevance. In particular, the report called for additional 
research to examine anxiety-related behavioural end-points (and the underlying mechanisms) 
following developmental exposure. It recommended to employ multiple validated protocols for testing 
of anxiety-like behaviour at multiple ages using multiple doses in both sexes; to examine the 
association of impacts on brain sex differences with functional (behavioural or physiological) end-
points, and to conduct dose–response analysis for anatomical brain sex differences in both sexes. 
 
ANSES (2011, 2013) 
In 2011, ANSES stated as i) proven the effects of BPA on neurogenesis and brain development due to 
pre or peri-natal exposure including changes in the neurodifferentiation profile, in glutamatergic and 
monoaminergic systems, in the expression of oestrogen receptors α and β and in the number of 
neurons responsive to oxytocin and serotonin, ii) controversial (and thus needing further 
investigation) the effects on anxiety, explorative behaviour and some sexual dimorphisms within this 
framework. Finally, the ANSES report considered as suspected the modification of maternal 
behaviour evidenced in some studies. Altogether, the evidence was considered as sufficient to support 
the developmental neurotoxicity of BPA resulting from pre- and perinatal exposure and this endpoint 
was considered as critical and used for risk characterisation in the 2013 risk assessment.  
In the ANSES risk assessment of 2013 the oral study by Xu et al. (2010) in mice was taken as the key 
study for neurodevelopmental toxicity, where the critical effects were the alteration of memory and 
learning functions paralleled by a decrease in the expression of glutamate NMDA receptors. 
3.4.2.2. Evaluation of recent animal studies on BPA exposure and brain and behavioural effects 
Several studies in the past decade have indicated neurobehavioural effects of developmental exposure 
to BPA. In particular, a number of studies have reported the influence of developmental exposure to 
BPA on anxiety-like behaviours in rodents (e.g. Cox et al., 2010; Tian et al., 2010; Patisaul and 
Bateman, 2008; Ryan and Vanderbergh, 2006; Gioiosa et al., 2007; Fujimoto et al., 2006). The results 
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of these studies were largely inconsistent, possibly because of differences in the doses, exposure 
periods and age at testing used. Both increases and decreases in anxiety levels have been reported, 
with either significant or not significant sex differences. Most of these studies have been thoroughly 
reviewed in the previous opinions listed above, which reached various conclusions regarding the 
neurobehavioural toxicity of BPA. So far limitations in the studies’ design, and inconsistency of 
results made it impossible to establish the reliability of these observations. This section provides an 
overview of the experimental animal studies on brain and behavioural toxicity published after 1st 
August 2010 (EFSA CEF Panel, 2010). A detailed description and evaluation of each study published 
after August 2010 is provided separately in Appendix B. 
a. Effects on anxiety-like behaviour 
Eighteen studies investigating anxiety-like behaviour in rodents following exposure to BPA have been 
identified, the majority being developmental studies with oral administration of BPA to rodent dams 
during gestation and/or lactation. All of the studies included either an open field test procedure or an 
Elevated Plus Maze (EPM) test for evaluation of anxiety-like behaviour. Six studies used both of 
these tests whereas a few used additional tests like free exploratory open field, novelty preference, 
novel home environment, Forced Swimming test, light/dark test/box/transition, or mirrored maze.  
A short review of the identified studies is given below. For study details such as number of animals, 
see Appendix B.  
The study by Diaz Weinstein et al. (2013) reported an increased anxiety-like behaviour of adolescent 
Sprague Dawley rats (7 weeks of age) in the open field (6 min) test and EPM (5 min) tests after 
twelve days of subcutaneous exposure to one dose level of 40 µg/kg bw BPA. BPA exposure affected 
both female and male rats to about the same extent. BPA additionally impaired spatial memory in 
both sexes as evaluated with an object placement procedure, and increased sucrose preference.  
Ferguson et al. (2012) exposed Sprague Dawley dams to low doses of BPA (2.5 or 25 µg/kg bw per 
day) or vehicle by gavage from gestational days 6-21, and then the pups from birth until weaning with 
the same BPA dose also by gavage. A naïve control group was not treated. Offspring were 
behaviourally evaluated in a novelty preference test (PND 29), open field test (PND 40-42), motor 
coordination (PND 43-44), Barnes maze (PND 47-50), acoustic startle response (PND 54, and Morris 
water maze (PND 75-79). In the open field test, males exposed to both doses of BPA were more 
active compared to the vehicle control, while no effect was observed in the females. However, the 
activity of naïve control groups showed approximately the same activity as the BPA treated groups. 
The authors reported that activity in other assessments (e.g., novelty preference) did not indicate 
BPA-induced hyperactivity and thus, that this particular effect deserves replication. Littermates of 
animals used in this study have been investigated for molecular markers for BPA (Cao et al., 2013; He 
et al. 2012, see below). 
Fujimoto et al. (2013) examined anxiety-like behaviour of Wistar rat offspring after postnatal BPA 
exposure through dams milk using an open field test, an Elevated Plus Maze (EPM) and a Forced 
swim task at the age of six, seven and nine weeks, respectively. The first seven days after delivery, 
dams were orally exposed to one dose level of BPA through drinking water (0.1 ppm, equivalent to 
about 24 µg/kg bw per day). Open field results suggested hyperactivity induced by BPA in males and 
thereby eliminating the sex differences seen in controls. BPA did not enhance anxiety-like behaviour 
in the EPM in any sexes, but females were more active than males and the author suggested an 
anxiolytic effect of BPA. In the FST, BPA induced a depression-like response in both sexes since the 
latency time to immobility was decrease in both sexes compared to controls, and the time spent 
immobile was increased in males.  
Gioiosa et al. (2013) attempted to identify specific windows of susceptibility to BPA for anxiety-like 
behaviour by comparing gestational versus lactational exposure in CD-1 mice by use of a cross-
fostering procedure. Dams were orally exposed to one dose level of BPA (10 μg/kg bw per day) from 
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gestational day 11 to lactational day 8. At delivery, offspring were cross-fostered to ensure gestational 
and lactational exposures only. Juvenile offspring (PND 28-30) were assessed in a novelty test, and 
adult offspring (PND 70) both in a free exploratory open field and in an EPM to measure emotional 
response to novelty and anxiety-like behaviour. The control females were less anxious, more active 
and more prone to explore a novel environment than control males and BPA-treated females. The 
direction of the behavioural changes was consistent and the effects of pre- or postnatal exposures were 
similar, although with a greater effect associated with postnatal exposure in females. BPA did not 
have a primary effect per se on the behavioural end points considered, but consistently eliminated the 
sex dimorphism in anxiety-like/exploratory response.  
Inagaki et al. (2012) made use of an acute exposure paradigm and exposed adult female Sprague 
Dawley rats, intact or ovariectomised (OVX), to BPA by subcutaneous injections ranging from 0.4 
µg/kg to 400 µg/kg bw. Some groups received BPA co-administrated with 17-α E2 or 17-β E2. In this 
study, two types of hippocampal-dependent memory tasks, object placement (OP) and object 
recognition (OR), were used. In order to assess influence of anxiety-like behaviour on performance in 
a memory task, rats were tested in the Elevated plus maze. Neither 20 µg E2/kg bw (enhanced OP 
memory) nor 40 µg BPA/kg bw (antagonised E2), alone or in combination, influenced anxiety-like 
behaviour in the Elevated plus maze. Inagaki et al. (2012) also examined learning and memory in the 
Morris water maze and dendritic spine density in the CA1 area of the hippocampus and layer II/III of 
the prefrontal cortex (PFC) (see below). 
Jasarevic et al. (2013) used outbred deer mice (Peromyscus maniculatus bairdii) whose dams were fed 
a diet supplemented with either ethinyl oestradiol or one of three doses of BPA (50 mg, 5 mg, or 50 
µg/kg feed weight) starting from 2 weeks before mating up to the end of the lactation period. 
Compared to controls, adult male offspring exposed to ethinyl oestradiol and to the two upper doses 
of BPA showed increased anxiety-like behaviour in the EMP.  
Jones and Watson (2012) used an EPM and a Forced Swimming test to investigate anxiety-like 
behaviour in adult Long-Evans rats perinatally exposed to BPA. From gestational day 7 until 
lactational day 14, dams were orally exposed to BPA at 5, 50, 500, or 5000 μg/kg bw per day or corn 
oil vehicle (controls) by spontaneously drinking from a syringe. The normal sex differences seen in 
control rats were eliminated in low dose BPA-exposed adults (5 µg/kg bw per day) but not at the 
higher doses in an EMP (see Section 1.2). No significant differences across doses of BPA or sexes 
were seen in the Forced Swimming test. The same study also assessed spatial learning capacities in 
the Morris Water Maze and reported no effects of either BPA doses per se or any interaction of BPA 
with sex.  
Kundakovic et al. (2013) exposed female Balb/c mice orally to BPA (0, 2, 20 or 200 µg/kg bw per 
day; presumably by gavage) from the day of mating to the end of pregnancy. Offspring were tested 
for social behaviour (dam/pup interaction, adolescent home cage, and adult social approach and 
aggression) and anxiety-like behaviour as adults (open field test). BPA exposure induced persistent, 
largely sex-specific effects on anxiety-like behaviour, leading to disruption of sexually dimorphic 
behaviours in adult mice. BPA exposure increased anxiety-like behaviour in females and decreased 
anxiety-like behaviour in males. This study also examined possible epigenetic disturbances of BPA, 
see below.  
Matsuda et al. (2012) assessed the effects of BPA on anxiety-like behaviour (open field test) and brain 
biochemistry in the offspring of C57BL/6J mice exposed subcutaneously from gestational day 10 until 
weaning of the offspring to BPA at 0.25 μg/kg bw per day. Exposure to BPA increased anxiety-like 
behaviour in both juveniles (4 week) and adult (8 week) male offspring, as evaluated by significantly 
decreased the time spent in the centre area of the open field. In brains of adult male offspring, BPA 
significantly altered DA turnover. Similar changes were not seen in the female offspring. This study 
also examined possible neurochemical effects of BPA, see below. 
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Nakamura et al. (2012) reported hypoactivity but no anxiety-like behaviour in ICR/Jcl mice 
perinatally exposed to BPA. Dams were injected subcutaneously with vehicle (sesame oil) or 20 µg 
BPA/kg body weight through gestation and the lactational period. Offspring were tested as juveniles 
and as adults in open field and EPM, and as adults for learning and memory in Morris water maze. 
Patisaul et al., (2012) exposed Wistar rat dams to BPA via drinking water (1 mg/L) from gestation day 
6 through lactation and provided soy-based or soy-free diets. Offspring continued on the same diet 
and BPA exposure regimen via drinking water from weaning until puberty (estimated dose of BPA 
received: between 100 and 1000 µg/kg bw per day). Positive control rats were given ethinyl oestradiol 
(EE, 50 µg/L) and fed a soy-free diet. When fed soy-free diet, BPA-exposed juveniles showed slightly 
increased anxiety-like behaviour in the light/dark box and the EMP, and BPA-exposed adult offspring 
showed disappearance of the normal sexual dimorphism in exploratory behaviour in the EMP. 
Administration of a soy-enriched diet appeared to mitigate the BPA effects. This study also examined 
possible effects of BPA on gene expression in dimorphic brain structures, see below.  
Viberg et al. (2011) reported no anxiety-like behaviour (EMP) in adult NMRI male mice neonatally 
exposed to a single oral dose (gavage) of BPA at 0.32, 3.2 or 4.8 mg/kg bw. However, BPA was 
found to induce hyperactivity and lack of expected habituation profile in males when tested in a novel 
home environment at 2 and 5 months of age (see below). The BPA effects were found not to be 
mediated by alterations in the cholinergic system since all mice responded to nicotine with increased 
activity. At 4 months of age, testing in the Morris water maze for spatial learning showed no effects of 
BPA. In another study (Viberg et al., 2012), the same author reported effects of BPA on brain 
markers, see below. 
Wolstenholme et al. (2011a; 2012) found no changes in anxiety-like behaviour in young C57BL/6J 
mice prenatally exposed to BPA and tested in an EMP (Wolstenholme et al. 2011a, 1.25 mg BPA/kg 
diet; Wolstenholme et al. 2012, 5 mg BPA/kg diet). Wolstenholme et al. (2013) noted no differences 
in the open field for F1 mice, but increased activity in F3 generation of the BPA-line mice compared 
to controls following dietary exposure to BPA of the parenteral generation at 5 mg per kg diet. These 
studies mainly addressed social behaviour but reported also on possible effects of BPA on gene 
expression in dimorphic brain structures, see below.  
Xu et al. (2012) attempted to contrast in ICR mice the effects of gestational vs lactational exposure to 
BPA (0.4 or 4 mg/kg bw per day) by the oral route. Both exposure periods (GD 7-20 or PND 1-14) 
and both doses increased anxiety- and depression-like behaviours in mice of both sexes in one or 
more of the following tests: the EMP, open field test, dark/light transition task and mirrored maze. 
The authors suggested that gestational BPA exposure exhibited stronger effect than lactational on 
anxiety-like behaviour in females. In another study, Xu et al. (2011a) reported abolished (or induced) 
sex difference of BPA compared to controls (sesame oil) in adolescent ICR mice orally exposed 
(intragastric, ig) to BPA at 40, 400 μg/kg/d for eight weeks and thereafter tested in an open field and 
EMP (ca. 90 days old). The mice were additionally tested for learning and memory in the Morris 
water maze and by use of step-down Passive avoidance task (see below). In a further study, Xu et al. 
(2013a) exposed adult ICR mice orally to BPA at 0.4, 4, or 40 mg/kg bw per day, or arachis oil, for 12 
weeks by gavage, and studied anxiety-like behaviour in the open field test. Males spent significantly 
more time in the open area after BPA exposure of 40 mg/kg bw/ day, indicating that BPA reduced 
anxiety-like behaviour in males. No effect of BPA treatment was observed in females. Both Xu et al. 
(2011a) and Xu et al. (2013a) also reported on learning and memory (see below). 
The CEF Panel noted that several of the above studies report increased anxiety-like behaviour in one 
or both sexes after BPA exposure, whereas others found no differences or a decrease of such 
behaviour. The results from different studies were thus considered inconsistent. Additionally, the 
studies were confounded by limitations in study design as indicated in Appendices B and C. 
b. Effects on learning and memory 
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Previous studies have reported that developmental exposure to BPA can interfere with learning and 
memory capacities in different learning tasks in rodents, including spatial learning, passive avoidance 
learning and object recognition (for review see  EFSA CEF Panel, 2010). These studies have 
previously not been considered suitable by EFSA for risk assessment due to methodological 
shortcomings. In addition, Stump et al. (2009; see description of tests applied and results above) did 
not report any effects of BPA on learning and memory as examined in the Biel Maze test, but the CEF 
Panel (EFSA CEF PANEL, 2010) found the study inconclusive.  
In the ANSES risk assessment of 2013, the oral study by Xu et al. (2010b) in mice was taken as the 
key study for neurodevelopmental toxicity, where the critical effects were the alteration of memory 
and learning functions paralleled by a decrease in the expression of glutamate NMDA receptors. 
Therefore this study has been included by the CEF Panel for the current evaluation. In addition to this, 
thirteen studies examining effect of BPA on memory and learning have been identified. Seven of the 
fourteen studies included have investigated effects of BPA following developmental exposure, some 
studies used subchronic exposure in adolescent/adults and a few used acute exposure regimens. The 
majority of the studies used tests like the Morris water maze and/or a passive avoidance task (step 
down), but also object recognition (one new of two objects), object placement (one of two objects in 
new position), modified Barnes maze and fear memory tasks. Several of the studies investigated 
neurochemical markers of the brain in parallel with the functional tests. 
A short review of the identified studies is given below. Studies using exposure to adolescent/adults 
are separated from those which used developmental exposure. For study details such as number of 
animals, see Appendix B. 
b.1 Effects on learning and memory – adolescent/adult exposure  
Diaz Weinstein et al. (2013; see above) reported impaired spatial memory in both sexes adolescent 
SD rats tested in an object placement task following nine days subcutaneous injections of BPA at 40 
µg/kg bw. In line with this, Eilam-Stock et al. (2012) reported impaired visual and spatial memory 
following acute subcutaneous BPA injection (40 μg/kg bw) in adult male rats as evaluated by an 
object recognition and an object placement task. In both tasks, BPA was injected immediately after 
the initial sample trial and memory retention was tested after two hours. These two tasks were 
performed four days apart and groups were switched between tasks so that controls in the object 
recognition task were exposed to BPA in the object placement test and vice versa. Neural brain 
markers were also examined (see below). 
In contrast to the results by Diaz Weinstein et al. (2013) and Eilam-Stock et al. (2012), Inagaki et al. 
(2012) reported that acute subcutaneous injections at 0, 1, 4, 40, 120, 240 and 400 mg BPA/kg bw did 
not impair memory retention in adult ovariectomised female SD-rats in the object recognition and the 
object placement memory tasks, but that BPA blocked the enhancing effects of 17β-oestradiol on 
learning and memory performances at doses from 4 µg/kg in the object placement and at doses from 
40 µg/kg in the object recognition tasks. 17-αE2-induced object placement (OP) memory 
enhancement was inhibited by all doses BPA. The ovariectomised females were exposed to BPA 30 
min before the sample trial and immediately thereafter, and tested every tenth day for about 2 months. 
An additional group of normally cycling rats was exposed to 40 µg BPA/kg bw, which did not affect 
the performance in the object placement task at any phase of the ooestrous cycle. Object recognition 
memory was impaired by BPA only on prooestrous when endogenous E2 levels are highest. Inagaki 
et al. (2012) also examined brain markers, i.e. dendritic spine density in the CA1 area of the 
hippocampus and layer II/III of the prefrontal cortex (see below).  
Kim et al. (2011) exposed 5 week old male mice to BPA (0, 1, 5, 20 mg/kg bw per day) by oral 
gavage for 2 weeks, and assessed learning and memory in the Morris water maze test following seven 
consecutive days of training. The latency time to reach the hidden platform was only significantly 
increased at the highest BPA dose (20 mg/kg bw) at day 7. The total swimming distance was not 
significantly affected by the treatment. Neural brain markers were also examined (see below). 
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Xu et al. (2011a; see above) found no overall effect of oral BPA treatment (0.04, 0.4 mg/kg bw per 
day) for eight weeks and thereafter tested in the Morris water maze. However, at days 3 and 4 of the 
4-days-acquisition part of the Morris water maze test, the BPA low dose males showed a longer 
escape time than control males and as such abolished sex difference within the low dose BPA group. 
In the step-down avoidance test, BPA low dose males showed a shorter latency to step down 
compared to control male and as such induced a sex difference as no effects were seen in females in 
both of these tests. In Xu et al. (2013a; see above) adult ICR mice were orally exposed to BPA (0.4, 4, 
or 40 mg/kg bw per day) or arachis oil for 12 weeks. No learning and memory impairment of BPA 
were reported for females tested in the Morris water maze and the passive avoidance test. For the 
Morris water maze, no effects were seen on the probe day for any BPA doses. In males, BPA at doses 
0.4 and 40 mg/kg/day extended the average escape path length to the hidden platform in Morris water 
maze task during the training days, while no effect were seen at 4 mg/kg bw per day. BPA at the high 
dose of 40 mg/kg bw per day shortened also the step-down latency in males 24 h after a footshock. 
This study examined also neural brain markers (see below).   
b.2 Effects on learning and memory – developmental exposure 
In Ferguson et al. (2012), low doses of BPA (2.5 or 25 µg/kg bw per day) to Sprague Dawley dams by 
oral gavage on gestational days 6-21 and then to the offspring from birth to weaning, did not show 
any significant effects on spatial learning in adolescent/adult offspring neither in the Barnes maze 
(PND 47-50) nor in the Morris water maze (PND 75-79). In agreement, Jones and Watson (2012; see 
above) used the Morris water maze and found no spatial learning effects in adult offspring (PND 90-
150) of Long-Evans rat dams orally exposed to BPA (5, 50, 500, or 5000 μg/kg bw per day) during 
gestation and lactation. Nakamura et al. (2012; see above) reported no effect on learning of perinatal 
exposure to BPA in adult ICR/Jcl mice as evaluated by the Morris water maze. Dams were injected 
subcutaneously with vehicle (sesame oil) or 20 µg BPA/kg body weight through gestation and the 
lactational period. In agreement with the three above mentioned studies, Viberg et al. (2011; see 
above) found no effect on learning and memory (Morris water maze) in 6 month old mice orally 
exposed as neonatal to single doses of BPA (0, 0.32, 3.2 or 4.8 mg/kg bw). This study used 
pharmacological challenge with nicotine in order to elucidate mode of action of BPA (see below). Xu 
et al. (2010b) used the Morris water maze and reported normal memory retention (probe day) in male 
ICR mice perinatally exposed to BPA (0.05, 0.5, 5 and 50 mg/kg bw) tested as weanlings (PND 21-
25) and as adults (PND 56-60), but increased escape lengths (training days) were seen for the upper 
two doses in weanlings and the upper three doses in adult males. In weanlings, BPA at 5 and 50 
mg/kg bw increased error frequency and shortened the step-down latency in males 24 h after a 
footshock, whereas only BPA 50 mg/kg bw did so in adults. This study examined also neural brain 
markers (see below).     
Jang et al. (2012) exposed pregnant C57BL/6 mice by daily intraperitoneal injection to BPA at 0, 0.1, 
1 and 10 mg/kg bw per day from GD6 to GD17. Female BPA offspring were mated with control male 
offspring to obtain F2 generation, which females were subjected for behavioural testing and 
investigated for hippocampal neurogenesis. No group differences were seen in the Morris water maze. 
The passive avoidance test revealed that high-doses BPA (1 mg/kg and 10 mg/kg) decreased the 
latency time in F2-females without a clear dose-response relationship. For the investigation of 
hippocampal neurogenesis in F2-females at postnatal day 44, see below. 
Jasarevic et al. (2013; see above) reported that male deer mice orally exposed during gestation and 
lactation to BPA (0.05, 5 or 50 mg/kg feed, equivalent to 0.25, 25 or 250 µg/kg bw per day) had 
impaired learning performance in the Barnes Maze, while females outperformed males. 
Matsuda et al. (2013) reported that perinatal exposure to BPA (dams were exposed subcutaneously 
(SC) to 250 ng BPA/kg/day during gestation and lactation) enhanced fear memory in juvenile female 
C57BL/6J mice, but not in adult female or males, as evaluated as number of freezing episodes when 
returning to a chamber which gave electrical foot-shock the previous day. This study used a 
pharmacological challenge with sertraline in order to elucidate mode of action of BPA (see below).   
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The CEF Panel noted that several of the above studies report impaired learning and memory of BPA 
exposure in one or both sexes, whereas others found no such differences. The results from different 
studies were thus considered inconsistent. Additionally, the studies were confounded by limitations in 
study design and performances as indicated in Appendices B and C. 
c. Social behaviour 
Previous publications have studying social behaviour after BPA exposure (Gioiosa et al., 2007; 
Palanza et al., 2008; Patisaul and Bateman, 2008; Cox et al., 2010; Tian et al., 2010). Overall, the 
direction of the effects was not consistent and ranged from pro-social effects to reduction of social 
motivation. Although most of these studies have been reviewed by EFSA in 2010, the social 
behaviour endpoint was not addressed separately in the EFSA CEF Panel 2010 opinion. 
Four studies examining the effect of BPA on social behaviour have been identified, and three of these 
are published by the same group. Social behaviours were evaluated by use of e.g. home-cage 
observations, Social interaction test, Social preference test, and a Social approach and aggression task 
by use of stimulus animal. In some of these tests, several parameters are recoded – mostly manually. 
Social behaviour may be influenced by many factors. All four studies applied one or two tests to 
elucidate whether anxiety-like behaviour in the animals influenced  social behaviour or not. A short 
review of the identified studies is given below. For study details such as number of animals, see 
Appendix B. 
Kundakovic et al. (2013, see above) gave BPA (0, 2, 20 or 200 µg/kg bw per day) to pregnant Balb/c 
mice from the day of mating to the end of pregnancy. BPA effect on home-cage social behaviour in 
adolescents offspring of both sexes were increased sniffing and allogrooming at the 2-μg dose 
(compared with vehicle), and reduced chasing in males at the highest dose (to female level). Dyadic 
social interactions with a same-sex stimulus mouse at PND70 showed that BPA had moderate effects 
on aggression and social dominance. This study also examined markers for gene expressions in 
offspring brains (see below). The CEF Panel has assessed this study with regard to NMDR claimed by 
the author (see Section 1.2). 
In the study by Wolstenholme et al. (2011a; see above), C57BL/6J mice dams were given BPA-
supplemented diet during pregnancy (about 1.25 mg BPA/kg diet estimated to be equivalent to 
approximately 120 µg/kg bw per day). A cross-fostering procedure was used to ensure prenatally 
exposure only. The prenatally exposed female offspring showed slightly increased social interactions 
in a free 30-min social interaction test at weaning. The effect of BPA on males was in the same 
direction but less significant. However, BPA did not affect social preference for a stimulus animal 
when compared to an inanimate object when tested a few days later. Expression of selected genes 
involved in neurobehavioural plasticity was also evaluated in this study, see below. 
Wolstenholme et al. (2012; see above) exposed C57BL/6J mice (F0 generation only) to BPA (about 5 
mg/kg diet, equivalent to approximately 1.0 mg/kg bw per day12) through pregnancy. Subsequent 
generations, obtained by breeding brother-sister pairs, were not exposed to dietary BPA. F1 juveniles 
of both sexes underwent evaluation for social interaction on PND 20-21 (10 minutes) and social 
preference on PND 24 (10 minutes), whereas juveniles of the F2 and F4 generation were assessed in 
the free social interaction test. The results on social behaviour throughout the generations were 
inconsistent (social interaction decreased in the F0 generation, but increased in the F2 and F4 
generations). The study also examined effects on gene expression, see below.  
Wolstenholme et al. (2013; see above) exposed C57BL/6J mice (F0 generation only) to BPA (about 5 
mg/kg diet) prior to mating and throughout pregnancy. A cross-fostering procedure was used to 
ensure prenatally exposure only of F1 generation. Subsequent generations, obtained by breeding 
                                                     
12 Time of adoption of the 2010 EFSA Opinion on BPA dealing with hazard identification and characterisation (EFSA CEF 
Panel, 2010). 
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brother-sister pairs, were not exposed to dietary BPA. Juvenile F1 and F3 mice from BPA-exposed-
lines displayed higher levels of investigation than controls during the eight first trials in the Social 
recognition task. In the last trial, F3 male of the BPA exposed line, spent less time with the novel 
stimulus ovarioectomized mouse compared to other groups. When tested, F3-generation mice 
displayed similar olfactory discrimination. 
The CEF Panel noted that examination the effect of BPA on social behaviour may be challenging as 
many environmental and genetically factors influence on the animals and its behaviour. The results 
from these four studies were considered inconsistent, and the studies were confounded by limitations 
in study design as indicated in Appendices B and C. 
a. Effects on sensory-motor functions 
Overall, based on previous opinions, there appears to be no convincing evidence of a consistent BPA-
related effect on sensory-motor function. The OECD guideline for developmental neurotoxicity 
advises sensory-motor function to be examined in detail at least once for the adolescent period and 
once during the young adult period (OECD 426, 2007), and gives the following few examples of tests: 
extensor thrust response, righting reflex, auditory startle habituation, and evoked potentials. Stump 
(2010) covered the auditory startle response as sensory-motor endpoint in offspring at PNDs 20 and 
60 without any statistically significant effects of BPA.  
Two new studies reporting on changes in sensory-motor function following pre and postnatal 
exposure have been included in the present opinion. Ferguson et al. (2012; see above) assessed the 
acoustic (auditory) startle response in adult rats (at PND 54) and found that males of the naïve control, 
both BPA groups and the EE2 group exhibited significantly less response than vehicle control males. 
This effect appeared to be due to an aberrant heightened response in the vehicle control since it also 
was appeared in the naïve control. Wolstenholme et al. (2013; se above) tested F3-generation of BPA-
exposed mice for olfactory discrimination and found no effect of BPA (only parent generation 
exposed). 
The CEF Panel noted that the reported effects of BPA on sensory-motor function in adult male rats, 
not in females, in the Ferguson et al. (2012) were questioned by the author. The auditory startle 
response is not known as a sexually dimorphic behaviour (Meyer, 1998). The results from the 
Ferguson (2012) study were considered inconsistent. However, both studies described above were 
confounded by limitations in study design as indicated in Appendices B and C. 
b. Other effects 
Note that the studies mentioned below are thoroughly described in Appendix B. 
Concerning studies on spontaneously motor activity, Ferguson et al. (2012; see above) found dose-
related effect of BPA (2.5 or 25 µg BPA/kg bw per day) on open field activity of male SD-rats (PND 
40-42), activity being significantly increased relative to vehicle controls, with EE showing a stronger 
response. The author commented that since activity in other tests (e.g., novelty preference) did not 
indicate BPA-induced hyperactivity, this particular effect deserves replication. In the study by 
Fujimoto et al. (2013; see above), open field results suggested hyperactivity induced by lactational 
exposure to BPA (maternal exposure 24 µg/kg/bw day) in males Wistar rats (ca. PND 42) and thereby 
eliminating the sex differences seen in controls. Ishido et al. (2011) assessed the effects of acute 
neonatal (intracisternal on PND 5) exposure of 20 µg BPA to Wistar rats by an automated motor 
activity test at age 4-5 weeks, and found significant but marginal nocturnal hyperactivity. Viberg et al. 
(2011; see above), exposed neonatal (PND 10) male NMRI mice to a single oral dose (gavage) of 
BPA at 0.32, 3.2 or 4.8 mg/kg bw and assessed spontaneous behaviour in a novel home environment 
for 1 hour at 2 and 5 months of age. A dose dependent alteration in activity and habituation profile 
was found, with decreased activity during the first 20 min of the test, and hyperactivity in the last 20-
min period. However, very few litters were studied in the paper by Viberg et al. (2011). In contrast to 
the above mentioned studies, Nakamura et al., (2012; see above) concluded that gestational and 
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lactational BPA exposure (maternal dose 20 µg BPA/kg bw per day) caused hypoactivity in adult 
mice, as evaluated by total travelled distance in an open field and EPM.  
Jones et al. (2011) reported persistent deficit in the sexual behaviour of adult male Long-Evans rat, 
but not females, following perinatal exposure to BPA. Dams were orally exposed to corn oil 
(controls), 5 µg/kg, 50 µg/kg, 500 µg/kg or 5 mg/kg body weight (bw) PBA from gestation day 7 until 
lactation day 14 (3 dams/group). Impairment of sexual performance was reported by the author to 
follow a NMDRC since males perinatally exposed to one of the lower doses BPA (50 μg/kg bw per 
day) seemed more affected than males exposed to the highest dose (5 mg/kg bw per day). This study 
has been included in Chapter 1.2. The CEF Panel noted that BPA may alter the processes affecting 
sexual behaviour due to its estrogenic properties, but that the study identified was confounded by 
limitations in study design as indicated in Appendices B and C. 
c. Morphological, molecular and biochemical changes in the brain 
The EFSA CEF Panel 2010 opinion recognized as potentially significant the biochemical changes. 
However, in the absence of a correlation with a functional adverse effect, the relevance of these 
observations for human health could not be assessed. Fourteen studies addressing functional changes, 
i.e. behavioural endpoints, in parallel with the effects of BPA on brain (effect on neurotransmitters, 
neurogenesis, on gene expression, on the morphology of certain brain regions, etc.) have been 
included (Eilam-Stock et al., 2011; Inagati et al., 2012; Jang et al., 2012; Kim et al., 2011; 
Kundakovic et al., 2013; Matsuda et al., 2012; Matsuda et al., 2013; Patisaul et al., 2012; Viberg et 
al.; 2011; Wolstenholme et al, 2011a; Wolstenholme et al, 2012; Xu et al., 2010b; Xu et al., 2012; Xu 
et al., 2013a). Further, six new studies investigating solely the effects of BPA on animal brains have 
been found (Cao et al., 2012; Cao et al., 2013; He et al; 2013; Komada et al., 2012; Viberg et al., 
2012; Xu et al., 2013b). 
Three studies investigation the possible influence of BPA on neurotransmitters in the brains of 
animals being behaviourally tested (Viberg et al. 2011; Matsuda et al. (2012; 2013)) have been 
identified. Viberg et al. (2011, see above) reported that both BPA (3.2 or 4.8 mg/kg bw) exposed and 
control mice responded with increased activity to administration of nicotine, and therefore the 
observed hyperactivity and lack of expected habituation profile were not mediated by altered 
functionality of the cholinergic system. Matsuda et al., 2012 found decreased levels of dopamine 
metabolites in the brain of male C57BL/6J mice perinatal exposed to BPA (0.25 µg/kg bw) and 
related this to the findings of anxiety-like behaviour of males in the open field (see above). In another 
study with the same exposure regimen (Matsuda et al., 2013,), changes in the serotoninergic system 
(5-HT) were linked to enhance fear memory in juvenile female mice perinatal exposure to BPA.  
Seven studies (Cao et al., 2012b, 2013; Kundakovic et al., 2013; Patisaul et al., 2012; Xu et al., 
2010b; Wolstenholme et al., 2011a; Wolstenholme et al., 2012) have reported changes in the gene 
expression of the oestrogen receptors after BPA exposure, for experimental details see Appendix B.  
The study by Cao et al. (2012b) in neonatal SD-rats shows that subcutaneous injections of BPA (0.05 
mg/kg bw, 50 mg/kg bw) from postnatal day (PND) 0 to PND 2 had regional and sex-specific 
alterations of gene expression of oestrogen receptor alpha (ERα), beta (ERβ) and kisspeptin (Kiss1) in 
anterior and mediobasal hypothalamus that were both decreased or increased in a region-specific 
fashion on PNDs 4 and 10. The responses of BPA were very different from those of oestradiol, 
suggesting that effects of BPA involve mechanisms different from its oestrogenic action. A more 
recent “mode of action” study by Cao et al. (2013) found that new-borns (PND1) of SD-rat dams 
receiving BPA orally (2.5 or 25 µg/kg bw per day, GD6-PND21) showed significant changes in 
oestrogen receptors α and β in hypothalamus and amygdala (in situ hybridisation). The inclusion of a 
group of unhandled pregnant rats highlighted a significant effect of the gavage procedure that appears 
to reduce the baseline ESRs expression in the offspring at birth. Both BPA and ethinyl oestradiol (5 
and 10 µg/kg bw per day) administrations were shown to have the power of counteracting such a 
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“gavage effect”. Sibling animals used by Cao et al. (2013) were assessed for functional outcome by 
Ferguson 2012 (see above) with marginal effects on anxiety-like behaviour and learning and memory. 
Kundakovic et al. (2013, see above) showed in Balb/c mice  exposed to BPA (2, 20, and 200 µg/kg 
bw during pregnancy) induced sex-specific, dose-dependent, and brain region-specific changes in 
expression of genes encoding oestrogen receptors (ERs, ERα, Erβ, Erγ). The effects measured in this 
study appeared to be of different extent and direction depending on BPA dose, suggesting that low 
doses can be more effective in disturbing social behaviour than the higher ones (non-monotonic 
responses), see Section 1.2.  
Patisaul et al. (2012, see above) reported reduced expression of oestrogen receptor beta (Esr2) and 
two melanocortin receptors (Mc3r, Mc4r) in amygdala and elimination of sex differences in Kiss1 
expression in juvenile Wistar rats following perinatal BPA exposure (estimated dose of BPA received: 
between 100 and 1000 µg/kg bw per day in drinking water). No such changes were seen in adult 
offspring. The author linked the genetic changes seen in juveniles to the functional changes of BPA 
seen in anxiety-like behaviour. However, for the transcriptional effects of BPA, a mode of action 
different from the estrogenic activity may be considered, because the positive control (ethinyl 
oestradiol, EE) did not show the same effects.  
Xu et al., (2010b) reported that the expressions of hippocampal oestrogen receptor beta (ERbeta) in 
both PND 21 and PND 56 ICR-mice were markedly down-regulated by perinatal exposure to BPA at 
0.5, 5, and 50 mg/kg bw per day and possible involved in avoidance memory. 
 In Wolstenholme et al. (2012; see above), lower gene expression of several oestrogen receptors, 
vasopressin and oxytocin, were observed in embryotic brains (F1-generation) of C57BL/6J mice (F0-
generation) exposed to BPA (equivalent 1.0 mg BPA/kg bw per day in diet) through pregnancy. In 
this study, a cross-fostering procedure was used to ensure gestational exposure. Furthermore, 
offspring were not given BPA and were mated to produce subsequent generations (F2- to F4-
generations). Embryotic brains of the F4-generation showed decreased vasopressin mRNA and 
oxytocin (only males). The author linked the finding to changes in social behaviour.  
In another study, Wolstenholme et al. (2011a; see above) showed no change in the expression of 
oestrogen receptor genes in embryonic brains of C57BL/6J mice exposed to dietary BPA during 
gestation (about 1.25 mg/kg diet, equivalent to approximately 0.140 mg BPA/kg bw per day), but 
oxytocin receptor gene was reduced in males. Gene expression analysis also revealed that mRNA for 
the glutamate transporter, Slc1a1, was enhanced by exposure to BPA in female brains and that 
expression of two of the three DNA methyltransferase genes, Dnmt1 and Dnmt3a, was modulated by 
BPA. Results were linked to slight increase of social interaction in weanling females. However, no 
effects of BPA were found for social preference at the same age. 
Overall the changes in gene expression of estrogene receptor after BPA exposure are not consistent 
and are also inconsistent with the results from functional tests. In addition the effects are mostly 
inconsistent with the results after treatment with ethinyl oestradiol (EE2), indicating that any proposed 
changes in functional tests have other MOA than changes in the estrogen receptor.  
EFSA CEF PANEL, 2010 reviewed the study by Xu et al., 2010a, which reported inhibition of the 
expression of N-methyl-D-aspartate receptor (NMDAR) subunits in male SD-rats perinatally exposed 
to BPA 0.05, 0.5, 5, 50, 200 mg/kg bw per day without parallel functional testing of the rats (see 
Appendix B). Xu et al., 2010b also reported  decreased hippocampal expression of NMDAR subunits 
NR1, NR2A, NR2B, and of protein expression for ERβ in male offspring of ICR mice orally exposed 
to 0.05, 0.5, 5 and 50mg/kg bw during gestation and lactation. The changes were linked to impaired 
learning and memory in the Morris water maze and passive avoidance (step-down) tests at postnatal 
days 21 and 56.   
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Three new papers by Xu and co-workers (Xu et al. 2012, 2013a, 2013b) have examined the effect of 
BPA in the dose range 0.04 to 40 mg/kg bw on behaviour and brain, and have addressed the same 
hippocampal NMDAR subunits NR1 as Xu et al., 2010b in ICR mice of the same age.  Xu et al., 
(2012; see above) used as cross-fostering design and reported, in contrast to Xu et al. (2010b), no 
effect of BPA on NMDAR subunit NR1 in hippocampus and amygdala of 56 days old male ICR mice 
exposed pre- or postnatally to 0.4 and 4 mg BPA/kg/d, but on AMPAR GluR1 in the same brain areas, 
except at the highest dose in amygdala (both exposure periods) and the highest dose in hippocampus 
(postnatal exposure). In females, NMDAR subunit NR1 in hippocampus and amygdala were 
decreased at the lowest postnatal dose and enhanced at the highest prenatal dose, respectively. The 
AMPAR GluR1 in hippocampus and amygdala was down-regulated in females, except in amygdala at 
the highest postnatal dose. The changes were linked to increased anxiety- and depression-like 
behaviours in mice of both sexes (Xu et al., 2012). Xu et al. (2013b) exposed male ICR mice 
perinatally to 0.04, 0.4 or 4 mg BPA /kg/bw day and found down-regulation of hippocampal NMDR 
subunit NR1 at PND 21 (upper two doses) and PND 56 (all doses), and hippocampal AMPAR subunit 
GluR1 at PND 14, 21, and 56 (upper two doses). No functional tests were done in this study. Xu et al. 
(2013a) exposed adult ICR mice to 0.4, 4 or 40 mg BPA/kg/d for 12 weeks. The lowest and highest 
BPA doses down-regulated hippocampal NMDR subunit NR1 and AMPAR subunit GluR1 in males, 
whereas no effects were seen in females. Slight learning and memory impairments were revealed in 
males and none in females (Xu et al., 2013a).  
Overall, the studies by Xu et al. in mice showed an inconsistent change in hippocampal NMDAR 
subunits between age and sex after exposure to BPA, and no conclusion can be drawn from these 
findings. 
Synaptic density and ultrastructure were investigated in the studies by Xu et al., (2013a, b).  In Xu et 
al. (2013a), the adult male mice orally exposed to BPA (0.4, 4 and 40 mg/kg bw per day) showed 
decreased synaptic density of pyramidal cells in hippocampus CA1 at 0.4 and 40 mg/kg bw per day, 
whereas females at the same dose levels showed increased levels compared to males. The middle 
dose, 4 mg BPA/kg bw per day, showed no such effects. In Xu et al. (2013b), perinatal exposure to 
BPA at 0.04 and 4 mg/kg bw per day, but not at 0.4 mg/kg bw per day, decreased synaptic density in 
hippocampal pyramidal cells in 14 and 56 days old male mice (females not included). No effects of 
BPA on the synaptic width of pyramidal cells in hippocampus CA1 was found, whereas in the Xu et 
al. (2013a) study, it was increased in adult males at all BPA doses compared to controls. The effects 
of BPA on synaptic density were inconsistent between doses and sexes.  
The possible effects of BPA on proteins implicated in the regulation of neurotransmitter release at 
synapses have been addressed by Xu et al. (2013a; 2013b) and Viberg et al., (2012). In Xu et al. 
(2013b) (no functional tests), down-regulation of hippocampal presynaptic synapsin I on PNDs 21 
and 56 were seen in males mice perinatally exposed to BPA (0.4, 4 or 40 mg/kg bw per day), but on 
PND 14 effect was observed only at the high dose. PSD-95, a synaptic marker, in hippocampus was 
reduced on PND 56. In Xu et al. (2013a), the hippocampal expressions of presynaptic synapsin I and 
PSD-95 were significantly down-regulated by BPA at all dose levels (0.4, 4 and 40 mg/kg bw per 
day) in adult male ICR mice, but not in females, which was in parallel with the slight learning and 
memory impairments revealed in males and not in females. Eilam-Stock et al. (2011, see below) also 
reported decreased PSD-95 in brains of SD-rats tested in memory trials following acute BPA 
exposure (40 μg/kg bw) and linked it to memory deficiencies. Viberg et al. (2012) used no functional 
tests, but investigated proteins important for brain development and reported increased cerebral 
synaptophysin (synaptic vesicle protein) in both sexes of adult NMRI mice after a single neonatal 
exposure to 4.8 mg BPA/kg bw, and for male also at 3.2 mg/kg BPA. In adult female, but not in 
males, BPA caused decreased levels of calcium/calmodulin-dependent kinase II (CaMKII), a protein 
important for normal brain development, in both cerebral cortex and hippocampus.  
Five studies have, in addition to other issues, addressed the possible effects of BPA on neurogenesis 
(Eilam-Stock et al., 2011; Inagati et al., 2012; Jang et al., 2012; Kim et al., 2011; Komada et al., 
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2012). Eilam-Stock et al., (2011, see above) reported that acute exposure to BPA at 40 μg/kg bw 
significantly decreased dendritic spine density in pyramidal cells in CA1 and medial prefrontal cortex 
(mPFC) in SD-rats tested in memory trials, but not in untested rats. In the tested rats, BPA also 
significantly decreased PSD-95, a synaptic marker, in the hippocampus and increased cytosolic 
pCREB, a transcription factor, in mPFC. Inagati et al. (2012; see above) reported that BPA did not 
alter E2-dependent increases in dendritic spine density in prefrontal cortex (Golgi impregnation and 
microscopic evaluation) following an acute exposure regimen of 0.4 µg/kg to 400 µg/kg bw BPA 
and/or 17-α E2 or 17-β E2 in adult female SD-rats. However, in the hippocampus, BPA blocked E2-
dependent increases in basal spines at 4 h and was additive with E2 at 30 min. Serum E2-level was 
elevated after an acute E2 injection (20µg/kg), both at 30 min and at 4 h, as analysed by RIA kit. The 
author concluded that BPA can alter E2-dependent functions in adult female and linked the finding to 
effects on learning and memory (see above). Jang et al., 2012 (see above) reported that intraperitoneal 
injection of BPA (10 mg/kg GD6-17) to C57BL/6 mice could adversely affect hippocampal 
neurogenesis in future generations (F2) by modulating the ERK and BDNF–CREB signalling 
cascades. In F2-females at postnatal day 44, BPA lowered the levels of phospho-ERK, brain-derived 
neurotrophic factor (BDNF), and phospho-CREB in hippocampi compared to controls. The findings 
correlated with altered DNA methylation of the CREB regulated transcription co-activator 1 (Crtc1) 
generated in F2-females and were suggested linked to decreased cross-over latency time in the 
passive-avoidance test (see above). Two additional studies (Kim et al., 2011, and Komada et al., 
2012) reported changed neurogenesis after BPA exposure to adult C57BL/6J male mice and fetal 
C57BL/6J mice, respectively. Kim et al., (2011; see above) exposed the adult male mice to 1, 5 and 
20 mg BPA/kg orally by gavage for two weeks. While the high dose (20 mg/kg) decreased 
hippocampal neurogenesis and impaired spatial learning in the Morris water maze, the lower dose 
enhanced hippocampal neurogenesis and had no effect on learning abilities. Komada et al. (2012) 
gavaged pregnant C57BL/6J mice with 200μg/kg bw BPA for 5 days (gestational day (GD) 8.5 - 
13.5). At GD 14, dams were scarified and foetuses subjected to histological evaluation, which showed 
association between BPA and accelerated hippocampal neurogenesis. 
Several biochemical and morphological changes have been reported in the brain after BPA treatment, 
but the results were inconsistent between treatment, age and sex, and no conclusion can be drawn 
regarding the relevance of these effects.  
3.4.2.3. Summary of neurobehavioural effects of BPA in animals after prenatal and postnatal 
exposure 
In their 2010 EFSA opinion, the CEF Panel concluded that the studies available were not sufficient to 
draw any conclusion regarding BPA exposure and neurobehavioural effects. The CEF Panel noted at 
that time that potentially significant biochemical changes, e.g. altered receptor expression in different 
brain regions, such as changes in NMDA, oestrogen receptors and alteration in the basal level of 
aromatase have been reported; however, the relevance of these findings was limited by the lack of 
information on whether functional adverse effects may be associated. 
Eighteen new experimental studies on anxiety-like behaviour of BPA using different tests have been 
identified. Several of the above studies report on increased anxiety-like behaviour after BPA 
exposure, and some report no effect on such behaviour, but the studies are confounded by limitations 
in study design, inappropriate statistics and in addition, the results from different studies are 
inconsistent.  
Fourteen new studies have examined effects of BPA on learning and memory, mostly by use of 
Morris water maze and passive avoidance (step-down) test. Some studies reported significant 
impairment of either learning and/or memory capacities (both in spatial and non spatial learning 
tasks), whereas other did not. The effects of BPA on learning and memory abilities of laboratory 
rodents are not fully consistent, as both positive and negative effects are reported in different papers 
for both for adult and developmental exposure. Seemingly, BPA administration to adult animals 
produces more impairment than developmental exposure to BPA. The studies present methodological 
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shortcomings, such as small sample size, lack of consideration of the litter effect, not properly 
controlled variability of exposure through diet and inadequate statistics.  
Four studies (Wolstenholme et al., 2011a, 2012, 2013; and Kundakovic et al., 2013) evaluated the 
effects of BPA on social behaviour and reported both positive and negative results. The CEF Panel 
noted that the studies have methodological shortcomings (litter effect not properly considered, 
potential variability of exposure not controlled for), although the social behavioural analysis is 
performed in a scientifically-valid way.   
As for the potential effects of BPA on sensory-motor function, two studies (Ferguson et al., 2012; 
Wolstenholme et al. 2013) reported no likely effect as evaluated by auditory startle response and 
olfactory discrimination, respectively.  
Five studies addressing effects on spontaneous motor behaviour (Ferguson et al. 2012; Fujimoto et al. 
2013; Ishido et al., 2011; Nakamura et al., 2012; Viberg et al., 2011) have reported inconsistent 
results but mostly towards increased activity, especially in male rodents. In contrast, Nakamura et al., 
(2012) reported hypoactivity following perinatal BPA-exposure. One of these studies (Ishido et al., 
2011) presents major methodological shortcomings, including small sample size and the use of a 
single administration. The findings of Viberg et al. (2011) indicate very limited changes in motor 
parameters in one test only, while the study by Ferguson et al. (2012) is methodologically sound.   
The EFSA CEF PANEL, 2010 opinion recognized as potentially significant the biochemical changes, 
e.g. altered receptor or protein expression, in different brain regions. A number of new studies address 
the effects of BPA on brain development (effect on neurogenesis and on gene expression, 
neuroendocrine effects, effects on the morphology of certain brain regions, etc.). Several biochemical 
and morphological changes have been reported in the brain after BPA treatment, but the results were 
inconsistent between treatment, age and sex, and no conclusion can be drawn regarding the relevance 
of these effects.  
3.4.3. WoE of neurological, neurodevelopmental or neuroendocrine effects of BPA in 
humans, animals and in vitro 
Whether BPA induces neurological, neurodevelopmental or neuroendocrine effects in humans and 
animals was considered using a tabular format for weighting different lines of evidence (WoE 
evaluation). The overall outcome of this WoE evaluation is presented below, while the WoE 
evaluation tables for these endpoints are presented in full in Appendix C. For interpretation of these 
tables always refer to Appendix A. 
Table 9:  Overall table of WoE evaluation of neurological, neurodevelopmental or 
neuroendocrine effects in humans and animals. 
Human studies 
Overall conclusion on Likelihood of neurodevelopmental effects of BPA in humans:  
There are indications from prospective studies that prenatal BPA exposure (BPA exposure 
during pregnancy) may be associated with child behaviour in a sex-dependent manner. 
However, the associations were not consistent across the studies. It cannot be ruled out that the 
results are confounded by diet or concurrent exposure factors. The associations do not provide 
sufficient evidence to infer a causal link between BPA exposure during pregnancy and 
neurodevelopmental effects in humans. Potential effects are considered to be as likely as not. 
As likely as 
not  
Overall conclusion on Likelihood of neurological/behavioural effects of BPA in humans:  
There are indications from one prospective study that childhood BPA exposure may be 
associated with behavioural problems in both girls and boys. It cannot be ruled out that the 
results are confounded by diet or concurrent exposure factors. The associations do not provide 
sufficient evidence to infer a causal link between childhood BPA exposure and neurological 
effects/behavior in humans. Potential effects are considered to be as likely as not. 
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Animal studies 
Overall conclusion on Likelihood on Anxiety-like behaviour in animals after pre- and/or 
postnatal exposure to BPA: 
Several studies report on increased anxiety-like behaviour in laboratory rodents after exposure 
to BPA. Due to the limitation in study design and statistics, and the inconsistency in the 
reported results, potential effects are considered to be as likely as not.  
As likely as 
not  
 
Overall conclusion on Likelihood on Learning and memory in animals after pre- and/or 
postnatal exposure to BPA: 
The effects of BPA on learning and memory abilities of laboratory rodents are no fully 
consistent, as both positive and negative effects are reported in different papers. The papers 
have methodological shortcomings, such as underpowered sample size, lack of consideration of 
the litter effect, or not properly controlled variability of exposure through diet, and inadequate 
statistics. Potential effects are considered to be as likely as not. 
As likely as 
not 
 
Overall conclusion on Likelihood on Social behaviour in animals after pre- and/or 
postnatal exposure to BPA: 
The few new studies evaluating the effects of BPA on social behaviour as end point have some 
methodological shortcomings (e.g. litter effect not properly red, potential variability of exposure 
not controlled for). Due to the limitation in study design and statistics, and the inconsistency in 
the reported results, potential effects are considered to be as likely as not 
As likely as 
not  
Overall conclusion on Likelihood on Sensory-motor function in animals after pre- and/or 
postnatal exposure to BPA: 
One of the two studies considered reported some positive effects of BPA on sensory-motor 
function in adult male rats, not in females. The auditory startle response is not known as a 
sexually dimorphic behaviour and the study results were considered inconsistent. The potential 
effects are considered to be as likely as not. 
As likely as 
not 
3.4.4. Conclusions on neurological, neurodevelopmental and neuroendocrine effects 
There are indications from prospective studies in humans that prenatal BPA exposure (BPA exposure 
during pregnancy) may be associated with altered child behaviour in a sex-dependent manner. 
However, the associations were not consistent across the studies and it cannot be ruled out that the 
results are confounded by diet or concurrent exposure factors. The associations reported do not 
provide sufficient evidence to infer a causal link between BPA exposure during pregnancy or 
childhood and neurodevelopmental effects in humans.  
A number of new studies report changes that may indicate effects of BPA on brain development 
(effect on neurogenesis and on gene expression, neuroendocrine effects, effects on the morphology of 
certain brain regions, etc.). Whether such changes are mechanistically related to the neurobehavioral 
responses reported following exposure is attempted addressed by some studies but with inconsistent 
results.  
Several new animal studies investigated anxiety-like behaviour, learning and memory, social 
behaviour and sensory-motor function. Some studies report changes in anxiety-like behaviour after 
BPA exposure. Some, but not all, studies reported significant impairment of either learning and/or 
memory capacities. A few studies also report effects on social behaviour and sensory-motor function. 
However, the studies present methodological shortcomings, such as small sample size, lack of 
consideration of the litter effect, not properly controlled variability of exposure through diet and 
inadequate statistics. Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely 
as not” to neurological, neurodevelopmental and neuroendocrine effects of BPA level for this 
endpoint is less than "likely" (see Appendix A), this endpoint was not taken forward for assessing the 
toxicological reference point, but was taken into account in the evaluation of uncertainty for hazard 
characterisation and risk characterisation (Section 4.3).  
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3.5. Immune effects 
3.5.1. Human studies 
3.5.1.1. Summary of previous opinions 
EU-RAR (2003, 2008)  
In an evaluation made in 2003, and updated in 2008 (EU-RAR, 2003, 2008) no information on 
toxicity for the immune system was presented. Concern was expressed for skin sensitisation in 
occupational exposure scenarios where there is the potential for skin contact with high concentrations 
(>30%) of BPA, as there were anecdotal industry reports suggesting that workers handling BPA have 
in the past experienced skin, eye and respiratory tract irritation. The risk assessment indicated that it 
could not be determined whether the reported skin reactions were related to skin sensitisation or 
irritation, but that animal data clearly indicate that BPA is a skin sensitiser, albeit a very weak one, 
being able to sensitise the skin of mice only at concentrations higher than 30%. The assessment also 
concluded that it is unlikely that BPA in foodstuffs poses a risk of skin sensitisation 
EFSA (2006); EFSA CEF Panel (2010) 
In a literature survey by EFSA (2006) and EFSA CEF Panel (2010) no human studies on immune 
effects were available for evaluation. 
NTP-CERHR (2008) 
This monograph only presents a summary of the previous evaluation carried out on this endpoint in 
the EU-RAR of 2003 (see above). 
FAO/WHO (2011)  
In an opinion by FAO/WHO no human data on effects on the immune system were provided. The 
opinion expressed concern that BPA may be a skin sensitiser, but this was based on animal data only. 
ANSES (2011, 2013) 
In the 2011 ANSES report a study published by Clayton et al. (2011) was evaluated. ANSES 
considered that no conclusions on effects of BPA on the immune system could be drawn. In the 2013 
risk assessment no human data on the effects of BPA on the immune system were discussed. 
3.5.1.2. Evaluation of recent human studies on BPA exposure and immune effects 
Since the previous EFSA review (2010), six human studies on possible effects of BPA on the immune 
system were published (Clayton et al., 2011; Savage et al., 2012; Spanier et al., 2012; Vaidya et al., 
2012 and Donohue et al., 2013). A detailed description and evaluation of each study is provided 
separately in Appendix B. 
In the study of Clayton et al. (2011), a survey and laboratory data from the 2003–2006 US NHANES 
were used to evaluate possible associations of urinary BPA levels with serum cytomegalovirus 
(CMV) antibody levels and diagnosis of allergies or hay fever in US adults and children > 6 years of 
age. The exposure was assessed by measuring BPA in spot urines. It is not clear at what time points 
BPA levels, CytomegaloVirus (CMV) titres and allergies were assessed. In analyses adjusted for other 
possible confounders, in the ≥ 18-year age group, higher urinary BPA levels were associated with 
higher CMV antibody titers. In the < 18-year age group, lower levels of BPA were associated with 
higher CMV antibody titers. BPA showed no association with allergy or hay fever diagnosis. The 
authors do not offer an explanation for these contrasting observations, and conclude that additional 
studies should be done to further investigate these findings. 
Spanier et al. (2012) examined prenatal BPA exposure and childhood wheeze from birth to 3 years of 
age in 365 mother – child pairs. The exposure was assessed by measuring BPA in spot urines from 
mothers at 16 and 26 weeks of gestation and at birth. The results were mainly negative: when prenatal 
BPA exposure was modelled as a continuous variable (mean of three values), BPA was not related 
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with childhood wheeze. When urinary BPA was categorized above or below the median value, a 
significant positive relationship with wheeze was found at six months of age, but there was no 
evidence of a persistent positive association by three years of age. The CEF Panel considers this 
categorisation of BPA exposure to be questionable and notes that exposure to BPA after birth was not 
considered.  
In a study by Savage et al. (2012), data were obtained from the NHANES study (survey 2005-2006) 
in which urinary bisphenol A, triclosan, benzophenone-3, propyl, methyl, butyl, and ethyl parabens 
were correlated with specific aeroallergen and food allergen sensitisation in 860 children aged 6-18 
years. The exposure was assessed by measuring in randomly selected urines samples. Serum IgE 
levels were determined according the Phadia ImmunoCAP system for an array of allergens. A subject 
was considered to have aeroallergen or food-specific sensitisation if one specific IgE level was 0.35 
kU/L or greater. Atopic asthma was defined as having doctor-diagnosed asthma and a positive test for 
at least one specific IgE. In contrast to triclosan and propyl and butyl parabens, no associations 
between urinary BPA levels and sensitisation were observed. 
In contrast to the study by Savage, but also based on the NHANES database (survey 2005-2006), 
Vaidya et al. (2012) claimed that urinary BPA is significantly associated with allergic asthma in 
females. Spot urine samples were used to estimate total BPA concentration of eight phenols 
(including BPA) and parabens, and were quantified in 2548 survey participants aged 6 years and over. 
Outcome measures included asthma-related questions, total immunoglobulin E (IgE), and 19 allergen-
specific IgE levels. Allergic asthma was defined as a history of ever having asthma, high eosinophil 
count, and high total IgE or atopy. BPA was associated with a higher likelihood of allergic asthma in 
females but not in males.  
Donohue et al. (2013) examined possible associations of urinary BPA levels with wheeze and asthma 
in a prospective cohort of 568 low-income mothers and children in inner-city New York. Higher 
maternal urinary BPA concentration during 3rd trimester of pregnancy was associated with lower 
occurrence of wheeze at age 5 years, but not with any other outcome measures or time points. 
However, longitudinal analyses of childhood/postnatal BPA concentrations showed that higher BPA 
values were associated with increased occurrence of wheeze and/or asthma at several ages. 
3.5.1.3. Summary of BPA exposure and immunotoxic effects in humans 
For the 2010 EFSA CEF Panel opinion no human studies were available regarding immunotoxic 
effects of BPA exposure in humans. Since then, five studies (Clayton et al., 2011; Savage et al., 2012; 
Spanier et al., 2012 ; Vaidya et al., 2012 and Donohue et al., 2013) were published. Clayton et al. 
(2011) found inconsistent associations between BPA exposure and CMV antibody titres in subjects 
older than 6 years. In three studies (Clayton et al., 2011; Savage et al., 2012 and Spanier et al., 2012), 
no associations of either prenatal BPA exposure or exposure at later age stages with allergy, hay fever 
and wheeze were observed. In contrast, Vaidya et al.(2012) noted an association of urinary BPA 
levels with allergic asthma, and Donohue et al. (2013) found associations between higher postnatal, 
but not prenatal, BPA and increased wheeze and asthma. Based on these studies, there are indications 
that BPA may be linked to immunological outcomes in humans, although in view of the limitations of 
the studies only limited conclusions can be reached and it cannot be ruled out that the results are 
confounded by diet or concurrent exposure factors. The associations do not provide sufficient 
evidence to infer a causal link between BPA exposure during pregnancy or in childhood and immune 
effects in humans.  
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3.5.2. Animal studies 
3.5.2.1. Summary of previous evaluations 
EU-RAR (2003, 2008) 
As indicated earlier the EU-RAR (2003, 2008) concluded that BPA is a very weak skin sensitiser, 
being able to sensitise through the skin of mice only at concentrations higher than 30%. The 
assessment also concluded that it is unlikely that BPA in foodstuffs poses a risk of skin sensitisation.  
EFSA (2006); EFSA CEF Panel (2010) 
The 2006 EFSA opinion did not include any study addressing the immune effects of BPA in 
laboratory animals. 
In 2010, EFSA considered that several studies had reported changes in cytokines, changes in T-cell 
populations and other aspects of immune modulation. However, all the studies suffered from 
shortcomings in experimental design and reporting. Therefore, the CEF Panel concluded that these 
studies could not be taken into consideration for derivation of a TDI. 
NTP-CERHR (2008) 
Only one new animal study (Yoshino et al., 2004) indicating that prenatal exposure to BPA may 
upregulate immune responses in mice was reviewed in this monograph. However, the study was 
considered as inadequate for the evaluation process due to weaknesses. 
FAO/WHO (2011) noted that in utero exposure or exposure at adult age yielded various indications of 
immunomodulation in rodents, such as altered cytokine expression, nitric oxide synthesis by 
macrophages, TNF-α secretion, well as histopathological effects on thymus and spleen, and that these 
data indicate that BPA may modulate the immune system. Yet, the data were inconsistent and the 
expert group concluded that more studies need to be performed using standard protocols to conclude 
on potential adverse immune outcomes of BPA exposure.  
ANSES (2011, 2013) 
ANSES (2011) considered effects on cytokines, notably a shift in the immune response in the 
direction of a Th2 phenotype due to proliferation and activation on Th2-cells and production of 
cytokines as a proven effect. However, it is unknown whether these effects are relevant to humans. 
ANSES did not discuss or bring forward immunotoxicity endpoints for risk characterisation in its 
2013 risk assessment. 
3.5.2.2. Evaluation of recent animal studies on BPA exposure and immune effects 
Since the evaluations described above, four animal studies have been published (Lee et al., 2012; 
Kendziorski et al., 2012; Nakajima et al., 2012; Bauer et al., 2012). A detailed description and 
evaluation of each study is provided separately in Appendix B. 
Lee et al. (2012a) studied adult female mice injected intraperitoneally with 5 mg BPA/kg bw per day 
for 4 weeks. The treatment resulted in increases in several non-specific inflammatory mediators and 
total levels of IgE. These effects were diminished or blocked in the presence of a glycoprotein derived 
from Cudrania tricuspidata Bureau (CTB), investigation of such an inhibitory effect being the main 
purpose of the study. The CEF Panel noted that only one concentration of BPA was used, no 
functional endpoints were investigated and the number of animals was relatively small.  
Kendziorsky et al. (2012) administered BPA in the diet of CD1 and C57Bl mice (n= 5 per group) at 
levels of 0, 0.03, 0.3 or 30 mg/kg diet, (estimated to be equivalent to 4.5, 45 or 4500 µg/kg bw per 
day) from before mating, through gestation, parturition and weaning (in F0 females) and until weeks 
19-23 (F0 females). 17α-ethinyl oestradiol (EE; 0.01, 0.1 or 1.3 mg/kg diet) was also administered to 
separate groups of mice. Reproductive performance was assessed and uterine pathology of the F0 
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females was investigated following sacrifice at weeks 19-23. The authors observed pyometra, i.e. 
inflammation in the uterus in a small minority of C57Bl mice receiving 0.3 mg BPA/kg diet, 
accompanied by changes in uterine morphology. A 5-fold, statistically significantly more pronounced 
presence of macrophages was observed in the uteri of all C57B1 females at this dose. Pyometra was 
also observed in the 15μg/kg-d EE treatment group, but no such changes were seen in CD1 mice. The 
authors concluded that BPA enhances immune responsiveness of the uterus and that heightened 
responsiveness in C57BL/6 females is related to increased susceptibility to pyometra.  
Nakajima et al. (2012) exposed female Balb/c mice to 10 µg/ml BPA in their drinking water from one 
week prior to gestation until the end of the study on day 25 post partum. Pups were sensitised to 
ovalbumin at day 4 after birth and challenged at days 18, 19 and 20 after birth. Airway hyperreactivity 
to methycholine as well as inflammation by evaluating eosinophils in bronchoalveolar lavage were 
assessed in 22 day old pups. Pups exposed in utero or through mothers’ milk in addition to in utero 
exposure showed increased airway hyperreactivity and increased eosinophil numbers in 
bronchoalveolar lavage fluid. Pups exposed only post-natally did not show such effects. The authors 
concluded that prenatal exposure to BPA, followed by postnatal allergic sensitisation and challenge, 
promoted the development of experimental allergic asthma. They suggested that delayed expression 
of BPA-metabolising enzymes may explain, at least in part, the enhanced fetal susceptibility. 
Bauer et al. (2012) administered BPA by gavage to pregnant C57Bl/6 damns from gestation day 6 
until post-natal day 21 to 0, 0.5, 50, or 500 µg BPA/kg/day. To induce allergic inflammation, adult 
offspring were mucosally sensitized with inhaled ovalbumin containing low dose lipopolysaccharide 
or intraperitoneally sensitized using ovalbumin with “alum” (not further specified by the authors), 
followed by ovalbumin aerosol challenge. In the mucosal sensitization model, female offspring 
maternally exposed to > 50 µg BPA/kg/day displayed enhanced lymphocytic and lung inflammation, 
assessed by histopathology, compared to controls. This effect was evident in females but not males. 
There were no clear dose-related effects on cell numbers in broncholveolar lavages of the animals.  
Peritoneally sensitized female but not male mice maternally exposed to < 50 but not 500 µg/kg  
showed a dampened effect on numbers of eosinophils in lung lavage, but there was no clear dose-
response relationship. In the peritoneal model, there was no effect on airway hyperresponsiveness in 
females noted. Unfortunately, this clinical outcome was not measured in the more relevant mucosal 
model. 
3.5.2.3. Summary of the immune effects of BPA in animals 
The CEF Panel concluded that in the study of Lee et al. (2012a) non-specific inflammatory mediators 
and total levels of IgE were affected, but also noted that only one concentration of BPA was used, no 
functional endpoints were investigated and the number of animals was relatively small.  
The CEF Panel notes that in the study of Kendziorski et al. (2012) the relevance of the macrophage 
infiltration in terms of pyometra is not clear, and the conclusion of the authors that BPA enhances 
immune responsiveness is speculative. These considerations do not take away from the fact that 
infiltration of macrophages may be adverse.  
The CEF Panel considers that the study by Nakajima et al. (2012) showed enhancement of ovalbumin 
induced airway hyperreactivity to methycholine as well as increased numbers of eosinophils in 
bronchoalveolar lavage in pups exposed to BPA in utero and through mothers’ milk. The CEF Panel 
notes that also the study by Bauer et al. (2012) indicated enhancement of ovalbumin-induced allergic 
responses, notably inflammation, by oral exposure to BPA, and that a dose-dependence was evident. 
The CEF Panel also noted that in this latter study the inflammation noted was seen in females but not 
males. It should be mentioned that elevated immune responses in female humans as well as female 
animals have been reported pereviously, including innate responses, cytokine responses, and vaccine 
responses (Klein et al., 2010, McLelland and Smith, 2011, Hochstenbach et al., 2012). 
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Whereas the studies lend support to the notion that immunological effects may be elicited by BPA, all 
these studies suffered from shortcomings in experimental design and reporting. Therefore, dose-
response cannot be confidently established. It is currently not clear whether immunotoxicity is an 
endpoint of concern for BPA. The CEF Panel noted that this type of effect is insufficiently covered by 
current testing guidelines, and potential immunotoxicity therefore currently presents an uncertainty 
area in BPA risk assessment, deserving further consideration. 
3.5.3. In vitro studies 
One in vitro study (Pisapia et al., 2012) investigated the effect of several substances including BPA on 
the differentiation of bone marrow dendritic cells isolated from female mice and cultured in hormone-
deficient medium. BPA at 10-7 M, 10-6 M and 10-5 M induced the differentiation of 62%, 70% and 
91% of the cells to the CD11c+ phenotype, respectively. The CEF Panel noted that due to high BPA 
concentrations and the specific culture conditions the relevance of this finding for the in vivo situation 
is not clear. 
3.5.4. WoE of immune effects of BPA in humans, animals and in vitro 
Whether BPA induces immune effects was considered using a tabular format for weighing different 
lines of evidence (WoE evaluation). The overall outcome of this WoE evaluation is presented below, 
while the WoE evaluation tables for these endpoints are presented in full in Appendix C. For 
interpretation of these tables always refer to Appendix A 
Table 10:  Overall table on WoE evaluation of immunotoxic effects of BPA in humans and 
animals  
Human studies 
Overall conclusion on the likelihood of association between BPA exposure and 
developmental immunotoxic effects:  
There are indications that BPA may be linked to immunological outcomes in humans, 
although in view of the limitations of the studies only limited conclusions can be reached 
and it cannot be ruled out that the results are confounded by diet or concurrent exposure 
factors. The associations do not provide sufficient evidence to infer a causal link between 
BPA exposure during pregnancy or in childhood and immune effects in humans.  
As likely as not  
Animal studies 
Overall conclusion on the likelihood of immunotoxic effects of BPA in animals:  
Evidence from the new studies adds to the indications of immunotoxicity of BPA in 
animals reported in previous reviews.  
From -as likely 
as not- to likely 
 
3.5.5. Conclusions on immune effects 
Based on recent human studies, there are indications that BPA may be linked to immunological 
outcomes in humans, although these studies had limitations and confounding factors may have been 
present. A causal link between BPA exposure during pregnancy or in childhood and immune effects 
in humans cannot be established. 
Studies in animals lend support to the possibility of immunological effects of BPA. Most of these 
studies suffered from shortcomings in experimental design and reporting. Although dose-responses 
could not be confidently established in most studies, a dose-related effect was observed in allergic 
lung inflammation.  
Using a WoE approach, the CEF Panel assigned a likelihood level of “-as likely as not- to likely” to 
immunotoxic effects of BPA. Since the likelihood level for this endpoint is less than “likely” (see  
Appendix A), this endpoint was not taken forward for assessing the toxicological reference point, but 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 115 
was taken into account in the evaluation of uncertainty for hazard characterisation and risk 
characterisation (Section 4.3).  
3.6. Cardiovascular effects 
3.6.1. Human studies 
3.6.1.1. Summary of previous opinions 
Studies on obesity and metabolic effects, which may also be linked to cardiovascular outcomes, are 
evaluated in a separate section (3.7). The number of epidemiological studies on cardiovascular 
outcomes and BPA exposure in previous reviews has been limited. The outcomes of these reviews is 
summarised as follows: 
EU-RAR (2003, 2008) 
No cardiovascular effects linked to BPA exposure were reported in the EU-RAR 
EFSA (2006, 2008, 2010) 
No cardiovascular effects linked to BPA exposure were reported in the EFSA opinions of 2006 or 
2008. 
In its 2010 opinion EFSA evaluated two human studies from the National Health and Examination 
Survey (NHANES), which reported associations between BPA exposure (urine) and cardiovascular 
effects (Lang et al., 2008; Melzer et al., 2010). Lang et al. used NHANES data from 2003/04 and 
found that higher BPA concentrations in urine were associated with diabetes and cardiovascular 
diagnoses, but not with other common diseases. Melzer et al. used NHANES data from 2005/06, and 
found that in those years, BPA levels were lower than they had been in 2003/04. Both studies were 
cross sectional, were based on single spot urine samples and self-reported disease. The CEF Panel 
concluded that further (prospective and/or animal) studies would be needed to demonstrate the 
biological plausibility of these findings and to explain the potential underlying mechanism of action. 
A minority opinion stated that “Human studies on the relation between BPA and cardiovascular 
diseases (Lang et al., 2008 and Melzer et al. 2010) provide some indication of possible relevance of 
metabolic effects to humans.” 
FAO/WHO (2011) 
The FAO/WHO report from the expert meeting held in 2010 also evaluated two studies regarding 
BPA exposure and cardiovascular effects (Lang et al., 2008; Melzer et al., 2010) and stated that it was 
not possible to draw any conclusions based on these cross-sectional analyses.  
ANSES (2011, 2013) 
The 2011 ANSES report considered the observed correlations between the highest urinary levels of 
BPA and cardiovascular pathologies (coronary diseases) and diabetes to be indicative of a suspected 
effect, based on the cross-sectional study by Melzer at al. (2010). ANSES did not however take this 
endpoint forward in its risk assessment of 2013, as it focussed on those effects which would enable 
toxicological benchmark doses to be determined, and cardiovascular pathologies were not one of 
these. 
3.6.1.2. Evaluation of recent human studies on BPA exposure and cardiovascular effects 
Since the previous EFSA review (2010), nine studies have been evaluated (Lind and Lind, 2011; 
Melzer et al., 2012a, b; Olsén et al., 2012a; ; Lakind et al., 2012; Teppala et al., 2012; Shankar & 
Teppala, 2012; Shankar et al., 2012a; Bae et al., 2012). A detailed description and evaluation of each 
study is provided separately in Appendix B. 
The studies have been grouped into BPA effects on 1) coronary artery disease (Lind & Lind., 2011; 
Melzer et al., 2012a; Olsén et al., 2012a; Melzer et al., 2012b; Lakind et al., 2012), and 2) metabolic 
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syndrome, hypertension and peripheral artery disease (Teppala et al., 2012; Shankar and Teppala., 
2012; Shankar et al., 2012a; Bae et al., 2012), although these endpoints also overlap. 
1) BPA effects on coronary artery disease/heart attack  
Meltzer et al. (2012a) used a prospective nested case-control design and analysed data for 758 cases 
and 861 controls from a 10 year follow up of the EPIC-Norfolk cohort in the UK. The results showed 
that higher urinary BPA concentrations were associated with increased risk of developing coronary 
artery disease. The longitudinal design increases the weight of the study results as compared to results 
from cross sectional studies. Furthermore, this study is the first to report an association between BPA 
exposure and cardiovascular outcome in a European population. However, the case definition only 
included patients admitted to hospital. Furthermore, confounding by diet was not considered. 
In a cross-sectional study among 1016 elderly men and women in Sweden, Lind and Lind (2011) 
studied associations between serum total BPA and four phthalates and carotid atherosclerosis. Serum 
BPA concentration was not associated with carotid plaque prevalence or intima-media thickness, but 
was associated with echogenicity of the plaques and intima-media (p<0.001).  
In a cross-sectional analysis, Olsén et al. (2012b) examined associations between serum BPA and 
phthalate concentrations and CVD (cardio-vascular disease) risk factors, defined by the Framingham 
risk score, in the same study population of elderly men and women as in the study by Lind and Lind 
(2011). Serum total BPA was not associated with coronary risk defined by the Framingham risk score.  
In a cross-sectional study in the UK comprising 591 patients with suspected cardiovascular risk, 
Melzer et al. (2012b) investigated urinary BPA concentrations and cardiovascular disease based on 
angiography-defined coronary artery stenosis. Higher BPA urinary concentrations were seen in 
patients with severe coronary artery stenosis in comparison to those with no vascular disease.  
Lakind et al. (2012) conducted a re-analysis of more than 4800 participants across four available 
NHANES data sets to investigate associations between BPA exposure and chronic diseases using 
scientifically and clinically supportable exclusion criteria and outcome definitions. Coronary heart 
disease and/or heart attack were among the outcomes examined in the re-analysis. All analyses were 
adjusted for creatinine, age, gender, race/ethnicity, education, income, smoking, heavy drinking, BMI, 
waist circumference, calorie intake, family history of heart attack, hypertension, sedentary time, and 
total cholesterol. When the a-priori selected methods were used to address the research question, no 
associations were found between urinary BPA and heart disease and diabetes. The authors concluded 
that the discrepancy between their findings on cardiovascular disease and those reported previously, 
was in part attributable to differences in exclusion/inclusion criteria.  
2) BPA effects on metabolic syndrome, hypertension and peripheral artery disease 
Studies reporting metabolic syndrome effects of BPA linked with hypertension and cardiovascular 
disease have been included in this section rather than (or as well as) under metabolic effects (Section 
3.7), since hypertension and other factors included in the definition of the metabolic syndrome are 
clearly relevant to this section on cardiovascular effects of BPA.  
Significant associations between urinary BPA and metabolic syndrome and hypertension have been 
reported in four studies (Teppala et al., 2012; Shankar and Teppala, 2012; Shankar et al., 2012a; Bae 
et al., 2012). Shankar and Teppala (2012) and Shankar et al. (2012a) used data from NHANES 
2003/4, while Teppala et al. (2012) used data from NHANES 2003-2008. These studies were cross 
sectional and reported that in comparison to subjects ranked in the lower tertile of urinary BPA, those 
in the upper tertile had increased risk of metabolic syndrome (Teppala et al. 2012), hypertension 
(Shankar and Teppala, 2012) and peripheral arterial disease (Shankar et al., 2012a). A fourth study 
(Bae et al., 2012) was a cross-sectional study in a population of elderly citizens in Seoul, Korea. 
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Although a significant association between urinary BPA levels and hypertension was described, the 
clinical/pathological significance is doubtful. 
3.6.1.3. Summary of BPA exposure and cardiovascular effects in humans 
In their 2010 EFSA opinion, the CEF Panel concluded that the studies available at the time were too 
limited to draw a conclusion regarding BPA exposure and cardiovascular effects in humans. This 
conclusion was based on two cross-sectional studies reporting associations between BPA exposure 
and cardiovascular (and metabolic) outcomes. Since then, several additional studies have examined 
BPA in relation to cardiovascular effects, but all studies except one, were cross-sectional and thus 
unsuitable to study exposure-disease associations on their own. The reanalysis carried out by Lakind 
et al. (2014) does not support the causal inferences suggested in other studies. There are indications 
from one prospective study that BPA exposure may be associated with cardiovascular effects, but it 
cannot be ruled out that the effect is confounded by diet or other factors. This association does not 
provide sufficient evidence to infer a causal link between BPA exposure and cardiovascular effects in 
humans.  
3.6.2. Animal studies 
3.6.2.1. Summary of previous opinions 
Previous evaluations of BPA (EU-RAR, 2003, 2008; EFSA, 2006; NTP-CERHR, 2008; FAO/WHO, 
2011; ANSES, 2011, 2013; EFSA CEF Panel, 2010) have not included any studies on cardiovascular 
effects or cardiotoxicity of BPA in experimental animals. 
3.6.2.2. Evaluation and conclusions of recent animal studies on cardiovascular effects of BPA 
One recent study on cardiovascular effects in animals was identified in the literature, undertaken to 
examine the effects of repeated and acute exposure to BPA on cardio-respiratory reflexes elicited by 
phenylbiguanide (PBG) (Pant et al., 2012). The authors demonstrated that female adult rats fed BPA 
in the diet (2 µg/kg body weight, n=6) showed an attenuation of PBG-induced cardiac and respiratory 
frequency changes (bradycardia, hypotension and tachypnoea) compared with controls. Acute 
exposure of animals to BPA also attenuated PBG-induced cardiac responses significantly, while the 
effect on respiratory rate was identical to controls. The attenuation of the PBG reflex responses by 
BPA in acute experiments was associated with decreased vagal afferent activity. The authors 
suggested that BPA may attenuate protective cardio-respiratory reflexes due to decreased vagal 
afferent activity. The CEF Panel considered that the PBG model does not contribute to the 
understanding of BPA effects in humans, and also noted that in the acute experiment suggesting an 
influence of BPA on vagal nerve afferent activity an extremely high dose of BPA (35 mg/kg bw) was 
given intravenously. 
3.6.3. In vitro studies 
Two recent in vitro studies (Yan et al., 2011; Belcher et al., 2012) were performed with isolated 
rodent ventricular myocytes to investigate the arrhythmogenic effects of E2 and BPA. Rapid effects of 
BPA and E2 (10-12 – 10-6 M) on contractility and Ca2+ signalling were observed in myocytes from 
female but not in male rats. In addition the effects were shown to be ERβ-dependent. However, in 
contrast to the effects in isolated myocytes the induction of arrhythmia by BPA or E2 was observed in 
perfused rat hearts only in the presence of a β-adrenergic agent (isoproterenol). The discrepancy 
between the in vitro and organ experiments indicate that the BPA induction of arrhythmia in vivo 
might be relevant only under specific conditions, e.g. stress. 
Another study (O'Reilly et al., 2012) investigated BPA (10-7 – 10-4 M) effects on the voltage gated 
Na+ channels. BPA-induced blockage of the channel was observed only at and above 10-6 M and, 
therefore, was not considered to be relevant for risk assessment. 
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3.6.4. WoE of cardiovascular effects of BPA in humans 
Whether BPA induces cardiovascular effects was considered using a tabular format for weighting 
different lines of evidence (WoE evaluation). The overall outcome of this WoE evaluation is 
presented below, while the WoE evaluation tables for these endpoints are presented in full in 
Appendix C. For interpretation of this table always refer to Appendix A. No WoE analysis was 
carried out for the one animal study that was evaluated by the CEF Panel.  
Table 11:  Overall table on WoE evaluation of cardiovascular effects of BPA in humans 
Human studies 
Overall conclusion on likelihood of cardiovascular effects of BPA in humans:  
There are indications from one prospective study that BPA exposure may be associated with 
cardiovascular effects, but it cannot be ruled out that the effect is confounded by diet or other 
concurrent exposure factors. This association does not provide sufficient evidence to infer a 
causal link between BPA exposure and cardiovascular effects in humans. Potential effects are 
considered to be as likely as not. 
As likely as 
not 
3.6.5. Conclusions on cardiovascular effects 
In their 2010 EFSA opinion, the CEF Panel concluded that the studies available at the time were too 
limited to draw a conclusion regarding BPA exposure and cardiovascular effects in humans. Since 
then, several additional studies have examined BPA in relation to cardiovascular effects, but all 
studies except one, were cross-sectional and thus unsuitable to study BPA exposure-disease 
associations on their own.  
There are indications from one prospective study that BPA may be associated with such effects but 
overall a causal link between BPA exposure and cardiovascular effects in humans cannot be 
established.  
There are insufficient animal data to suggest that BPA has an effect on cardiac function or causes 
cardiotoxicity.  
Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to 
cardiovascular effects of BPA. Since this likelihood level is less than “likely”, this endpoint was not 
taken forward for risk characterisation. It cannot be ruled out that the observed association between 
exposure to BPA and cardiovascular effect in the epidemiological studies is confounded by diet or 
other concurrent exposure factors. This association does not provide sufficient evidence to infer a 
causal link between BPA exposure and cardiovascular effects in humans. Since there is also a lack of 
information on the dose-relationship for this association, and since there were only very limited 
number of animal studies on this endpoint, this endpoint was not included in the uncertainty analysis. 
3.7. Metabolic effects 
3.7.1. Human studies 
3.7.1.1. Summary of previous opinions 
The number of epidemiological studies on hormonal or metabolic outcomes and BPA exposure in 
previous reviews was limited. Results were reported in studies of cardiovascular outcomes. The 
outcome of these reviews is summarised as follows: 
EU-RAR (2003, 2008) 
The EU-RAR reports do not describe human studies addressing metabolic effects or weight gain.  
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EFSA (2006); EFSA CEF Panel (2010) 
No metabolic effects linked to BPA exposure were reported in the EFSA opinions of 2006 or 2008. 
The EFSA opinion of 2010 included evaluation of two human studies from the USA National Health 
and Examination Survey (NHANES), which reported associations between BPA exposure in urine 
and diabetes and cardiovascular conditions (Lang et al., 2008; Melzer et al., 2010). Lang et al. used 
NHANES data from 2003/04 and found that higher BPA concentrations in urine were associated with 
diabetes and cardiovascular conditions, but not with other common diseases. Melzer et al. used 
NHANES data from 2005/06, and found that in those years, BPA levels were lower than they had 
been in 2003/04. Regarding diabetes: the association between BPA and diabetes was significant in 
pooled data (2003-06), but did not reach significance with the data from 2005/06 alone. Both cross-
sectional studies were based on single spot urine samples and self-reported diabetes and other 
outcomes. The CEF Panel concluded that further (prospective and/or animal) studies would be needed 
to demonstrate the biological plausibility of these findings and to explain the potential underlying 
mechanism of action. 
NTP-CERHR (2008)  
The NTP-CEHR (2008) report did not assess human studies addressing metabolic effects or weight 
gain. 
FAO/WHO (2011) 
The FAO/WHO report from the expert meeting also evaluated the two studies regarding BPA 
exposure and metabolic and cardiovascular effects (Lang et al., 2008; Melzer et al., 2010) and stated 
that it was not possible to draw any conclusions based on these cross-sectional analyses. 
ANSES (2011, 2013) 
The 2011 ANSES report considered the observed correlations between the highest urinary levels of 
BPA and cardiovascular pathologies and diabetes reported by Lang et al. (2008) and Melzer et al. 
(2010) to be indicative of a suspected effect. In the 2013 opinion ANSES did not include further 
human epidemiological studies. 
3.7.1.2. Evaluation of recent human studies on BPA exposure and metabolic effects and hormonal 
disorders 
This section provides an overview of the human studies on metabolic effects and hormonal disorders 
published after July 2010. Although cardiovascular and metabolic outcomes are interrelated, 
cardiovascular outcomes are evaluated in a separate section together with relevant papers on 
metabolic syndrome.  
Since the previous EFSA review (2010), 24 studies have been evaluated (Galloway et al., 2010; 
Brucker-Davis et al., 2011; Carwile and Michels. 2011; Chou et al., 2011; Ning et al., 2011; Shankar 
and Teppala, 2011; Silver et al., 2011; Shankar et al., 2012b; Trasande et al., 2012; Wang et al., 
2012a, b, c; Zhao et al., 2012; Bhandari et al., 2013; Eng et al., 2013; Harley et al., 2013b; Kim and 
Park, 2013; Lakind et al., 2012; Li et al., 2012a, 2013; Mendez and Eftim, 2012; Volberg et al., 2013; 
You et al., 2011; Teppala et al., 2012). The studies evaluated in this section have been grouped 
according to 1) obesity, 2) endocrine/hormonal outcomes, 3) diabetes, and 4) other outcomes. Some 
of these studies addressed more than one metabolic endpoint and/or other toxicological endpoints (e.g. 
cardiovascular effects). Therefore, they are discussed more than once in the sections below, as well as 
in other parts of this opinion. A detailed description and evaluation of each study is provided 
separately in Appendix B. 
 
1) BPA effects on obesity 
Ten studies examined associations between BPA exposure and obesity or obesity-related measures as 
main outcomes, five in adults (Galloway et al., 2010; Carwile and Michels, 2011; Shankar et al., 
2012b; Wang et al., 2012a; Zhao et al., 2012;) and six in children and adolescents (Trasande et al., 
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2012; Wang et al., 2012b; Bhandari et al., 2013; Eng et al., 2013; Harley et al., 2013b; Li et al., 2013). 
All the studies were cross-sectional, but Harley et al. (2013b) included both cross-sectional and 
prospective analyses. 
Shankar et al. (2012b) used NHANES data from years 2003- 2008 for 3967 participants aged 20 years 
or more. The association between urinary levels of BPA and obesity, as defined by BMI and waist 
circumference, was investigated. A positive association was reported between increasing BPA 
concentrations (in quartiles) and obesity defined by BMI and waist circumference, independently of 
confounding factors. Carwile and Michels (2011) used data for 2747 adults from the 2003/04 and 
2005/06 NHANES, and Wang et al. (2012a) used data for 3390 Chinese adults in Shanghai. Both 
studies reported that higher urinary BPA excretion was associated with general and central/abdominal 
obesity. Notably, both the Shankar et al. (2012b) and Carwile and Michels (2011) studies used 
NHANES data, thus raising the question as to whether they report the same association or they are 
independent. 
Galloway et al. (2010) examined associations between 24-hour urinary BPA excretion and serum sex 
hormone concentrations in 715 Italian adults (inCHIANTI cohort). This study reported BPA 
associations with covariates including parameters indicative of obesity. Higher BPA excretion was 
associated with increasing waist circumference and weight, but not with overweight or obesity 
defined by BMI cut-offs as defined by the World Health Organization.  
Zhao et al. (2012) examined urinary BPA exposure and body composition, hormone levels and bone 
mineral density in a cross-sectional study in 246 healthy premenopausal women in Shanghai. BPA 
exposure was not associated with bone mineral density, but weak associations were reported for BPA 
and body weight, BMI, fat mass and serum leptin.  
Trasande et al. (2012) used NHANES data from years 2003-2008 for 2838 children and adolescents 
aged 6-19 year. Children/adolescents in the lowest quartile of urinary BPA had lower estimated 
prevalence of obesity than those in quartiles 2, 3 and 4. Similar patterns of association were found in 
multivariable analyses when BPA was modelled as a continuous variable and BMI z-scores as the 
outcome. In stratified analysis, significant associations between urinary BPA and obesity were found 
among whites, but not among blacks or Hispanics. Bhandari et al. (2013) studied urinary BPA and 
obesity using the same data as Trasande, but with a slightly lower sample size, comprising 2,200 
children and adolescents aged 6-18 years with complete data on all covariates. Obesity was defined as 
the ≥95th percentile of body mass index specific for age and sex. This study also found that higher 
urinary BPA was associated with obesity; compared with children in the lowest quartile of BPA, 
children in the highest quartile had a multivariable or for obesity of 2.55 (95% CI: 1.65, 3.95) (P trend 
< 0.01). The observed positive association was predominantly present in boys and in non-Hispanic 
whites. Wang et al. (2012b) used data for 259 children and adolescents in Shanghai and reported 
significant associations between urinary BPA excretion and obesity. Li et al. (2013) examined urinary 
BPA and obesity in 1,326 school aged children in Shanghai. The habitual diet was assessed by a food 
frequency questionnaire, and 4 dietary quality indicator variables (“unhealthy diet”, “eating junk 
foods”, “eating vegetables”, “eating fruits”) were included among confounding variables. Increasing 
urinary BPA was significantly associated with higher risk of overweight in girls aged 9–12 years only, 
while no association was seen for BMI for girls or boys. Harley et al. (2013b) examined both prenatal 
(maternal urine) and postnatal (childhood urine) BPA exposure in relation to body mass index in 311 
children aged 5 to 9 years in the CHAMACOS cohort. The cross-sectional analysis at age 9 years 
showed that higher urinary BPA was associated with increased BMI, waist circumference, fat mass, 
and overweight/obesity in boys and girls. Contrary to the cross-sectional results, the longitudinal 
analysis showed that higher prenatal exposure (urinary BPA concentration in mothers during 
pregnancy) was associated with lower BMI, body fat, body weight and obesity occurrence in their 
daughters at age 9 years. Among girls, being in the highest tertile of prenatal BPA concentration was 
associated with decreased BMI Z-score (β = -0.47, 95% CI: -0.87, -0.07) and percent body fat (β = -
4.36, 95% CI: -8.37, -0.34) and decreased odds of overweight/obesity (OR) = 0.37, 95% CI: 0.16, 
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0.91) compared to girls in the lowest tertile. These findings were strongest in pre-pubertal girls. 
Urinary BPA concentration at age 5 years was not associated with any anthropometric parameters at 
age 5 or 9 years. 
In a cross-sectional analyses using NHANES data from 2003-2010 Eng et al. (2013) examined urinary 
BPA and BMI in 3370 children and adolescents aged 6-18 years in relation to BMI, waist 
circumference and body fat. In line with previous cross-sectional studies from NHANES higher 
urinary BPA concentration was associated with obesity (BMI>95%). The study population is the same 
as that in Trasande et al. (2013). No associations between urinary BPA and laboratory measures of 
cardiovascular or diabetes risk were found. 
2) BPA effects on endocrine/hormonal outcomes 
Five cross-sectional studies reported endocrine/hormonal outcomes (Galloway et al., 2010; Brucker-
Davis et al., 2011; Chou et al., 2011; Mendez and Eftim, 2012; Wang et al., 2012c) and one 
prospective study (Volberg et al., 2013). Four used total urinary BPA and two used cord blood BPA 
as a measure of the exposure. Galloway et al. (2010) found a weak association between higher urinary 
BPA excretion and increased free testosterone (but no other sex hormones in men), and no 
associations with sex hormones in women.  
Brucker-Davis et al. (2011) conducted a cross-sectional analysis of unspecified BPA in cord blood 
and cord blood thyroid tests in 54 male infants in France. BPA was not associated with free thyroxine 
or free triiodothyronine, but weakly associated (not statistically significant) with lower thyroid 
stimulating hormone (TSH). Chou et al. (2011) examined the relationship between unspecified BPA 
in maternal blood and umbilical cord blood in 97 mother-child pairs in Taiwan and that higher BPA 
was associated with high leptin and low adiponectin in cord blood. The BPA measurement in 
maternal and/or cord blood is not considered a valid measure due to the pervasive contamination from 
plastic. 
Mendez and Eftim (2012) examined the association between urinary BPA exposure and total 
thyroxine in 1887 subjects in the 2007-2008 NHANES and found no association.  
A study in 28 workers from two epoxy-resin factories, professionally exposed to BPA reported 
associations between urinary BPA excretion and clinically abnormal thyroid hormone concentrations 
(Wang et al., 2012c). However, relevant confounding factors such as worker co-exposure to other 
chemicals cannot be excluded. 
Volberg et al. (2013) examined associations between prenatal BPA exposure (maternal urinary BPA 
concentrations during pregnancy) and plasma leptin and adiponectin concentrations in boys and girls 
at age 9 years in 188 mother-children pairs in a Mexican-American prospective cohort in Salinas 
Valleys, USA. Higher maternal BPA concentrations during late pregnancy were associated with 
increased plasma leptin in boys and with increased plasma adiponectin in girls. Associations were 
adjusted for relevant confounders including fast food and sweet snack consumption at 9 years. No 
associations between concurrent BPA concentrations and 9 year old child adiponectin or leptin levels 
were observed. 
3) BPA effects on diabetes outcomes 
Five studies examined urinary BPA and diabetes outcomes (Ning et al., 2011; Shankar and Teppala, 
2011; Silver et al., 2011; Lakind et al., 2012; Kim and Park, 2013). All were cross sectional by design 
and relied on spot urine BPA exposure assessment. The study by Wang et al. (2012a) mentioned 
above found that in addition to being associated with increased prevalence of obesity, higher urinary 
BPA was also associated with increased prevalence of insulin resistance in 3390 Chinese adults aged 
40 years or older. Ning et al. (2011) studied 3423 Chinese adults and defined type-2 diabetes from 
fasting- and 2-h glucose tolerance test and serum insulin levels. Increased risk of type-2 diabetes was 
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seen for participants in the second and fourth BPA quartiles, but not in the third. A study in 1210 
nationally representative Korean adults aged 40-69 years found no association between urinary BPA 
and self-reported type-2 diabetes (Kim and Park, 2013).  
Two cross-sectional studies used NHANES data Shankar and Teppala, 2011; Silver et al., 2011). 
Shankar and Teppala (2011) examined 3967 adults in pooled data from 2003 to 2008 and examined 
type-2 diabetes diagnosed by fasting glucose levels and glycosylated haemoglobin according to the 
latest American Diabetes Associations guidelines. The risk of type-2 diabetes increased with 
increasing quartiles of BPA in a dose-dependent manner.  
Silver et al. (2011) examined 4389 adults and also used pooled data from 2003 to 2008, but defined 
diabetes 2 as glycosylated haemoglobin ≥6.5% or if participants used diabetic medication. A weak 
association between BPA and type-2 diabetes mellitus (T2DM) was seen in 2003-08 pooled data. 
Breaking down by year, the association was only significant in 2003/04, not 2005/06 or 2007/08. 
Results were similar when glycosylated haemoglobin (HbA1c) was used as a continuous outcome.  
It is unclear whether the studies by Silver et al. (2011) and Shankar and Teppala (2011) report the 
same association or are independent studies.Both studies used a population in which the association 
was already described before by Lang et al. (2008) and Melzer et al. (2012). Lakind et al. (2012) 
conducted a re-analysis of the associations between BPA exposure and chronic disease outcomes, 
including diabetes, using four available NHANES data sets, including the same data used in the 
studies above. Scientifically and clinically supportable exclusion criteria and outcome definitions 
were applied. All analyses were adjusted for creatinine, age, gender, race/ethnicity, education, 
income, smoking, heavy drinking, BMI, waist circumference, calorie intake, family history of heart 
attack, hypertension, sedentary time, and total cholesterol. When the a-priori selected methods were 
used to address the research question, no associations were found between urinary BPA and diabetes. 
The authors concluded that the discrepancy between their findings with regard to diabetes and those 
reported previously (Lang et al., 2008; Melzer et al., 2010) was largely explained by the choice of 
case definition. The Lakind et al. (2012) study did not support the associations and causal inferences 
that were suggested in the previous studies, and highlighted that data from cross-sectional studies like 
NHANES surveys are inappropriate for drawing conclusions about relations between short-lived 
environmental chemicals and chronic diseases. 
4) BPA effects on other outcomes 
Li et al. (2012a) examined associations between urinary BPA and low grade albuminuria in the same 
Chinese population that was used to examine obesity (Wang et al., 2012a) and diabetes (Ning et al., 
2011). A weak association for low grade albuminuria with higher urinary BPA was reported but the 
clinical relevance of this is not clear. A study in the NHANES examined whether urinary excretion of 
BPA differed by renal function in subjects without known renal dysfunction (You et al., 2011). 
Urinary excretion of BPA decreased with decreasing renal function, but the association was weak and 
the clinical relevance unclear. Also using cross-sectional data from NHANES 2003-2008, Teppala et 
al. (2012) found that in comparison with subjects ranked in the lower tertile of urinary BPA, those in 
the upper tertile had increased risk of having metabolic syndrome. Metabolic syndrome was defined 
by the presence of at least 3 of 5 criteria; abdominal obesity, hypertension, elevated serum 
triglycerids, glucose intolerance and reduced HDL. 
3.7.1.3. Summary of BPA exposure and metabolic and hormonal effects in humans 
In their 2010 EFSA opinion, the CEF Panel concluded that the studies available at the time were too 
limited to draw a conclusion regarding BPA exposure and metabolic and hormonal effects. This 
conclusion was based on two cross-sectional studies reporting associations between BPA exposure 
and metabolic (and cardiovascular) outcomes. Since then, several additional studies have examined 
BPA in relation to metabolic and hormonal effects, but the majority of all new studies are cross-
sectional and thus not suitable to study exposure-disease associations. The metabolic disorders 
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associated with BPA exposure are suggested to be causally linked to poor diets – usually too much 
sugar, fat and processed food. As diet is the main source of BPA, an obvious possibility is that poorer 
diets are associated with higher exposure to BPA. One prospective study found that higher BPA 
concentration in maternal urine during pregnancy was associated with lower measures of obesity in 
their daughters, and in a second study within the same study population maternal urinary BPA was 
also associated with plasma adiponectin levels in 9-year old boys and girls, corroborating the BMI 
findings. In view of the limitations of using urinary BPA concentrations as a surrogate of exposure, 
the problems of interrelated dietary exposures, mostly cross-sectional designs and inconsistency of the 
results between cross-sectional and prospective studies, the conclusions that can be drawn concerning 
the relationship of BPA exposure and the reported findings are limited. Notwithstanding, there are 
indications from cross-sectional studies that higher BPA may be associated with increased body mass 
in children, and indication from a prospective study that prenatal BPA exposure may be associated 
with reduced body mass and lower plasma adiponectin levels in girls and with higher plasma leptin 
levels in boys. There are no indications of note for other hormonal or metabolic endpoints. A 
systematic literature review of the epidemiological literature on the relation of BPA with obesity and 
markers of glucose metabolism and diabetes concluded that assertions about a causal link between 
BPA and obesity or diabetes are unsubstantiated (Lakind et al., 2014). 
3.7.2. Animal studies 
3.7.2.1. Summary of previous opinions 
EU-RAR (2003, 2008)  
The EU-RAR of 2003, updated in 2008 (EU-RAR, 2003, 2008) did not report any information on 
metabolic effects or obesogenic effects of BPA in animals. Rather, a reduction in weight gain was 
identified with a LOAEL of 650 mg/kg bw per day in the 2-years NTP study with BPA in rats, 
although no such effect was reported in mice. In the EU-RAR (2008) in the 2-generation study (Tyl et 
al., 2005) a dose of 50 mg/kg bw per daywas set as the NOEL based on several endpoints, among 
them being reduced body weight gain.  
EFSA (2006); EFSA CEF Panel (2010) 
In 2006, EFSA did not report any studies showing effects of BPA on the metabolism of experimental 
animals. In 2010, EFSA reviewed a number of studies showing, variously, effects of BPA on insulin 
secretion in mice (Ropero et al., 2008), increased adipogenesis in the female offspring of rats exposed 
prenatally to BPA (mean oral dose 70 µg/kg bw per day) (Somm et al., 2009) and aggravated insulin 
resistance in mice during pregnancy at s.c. doses of 10 or 100 µg/kg/day (Alonso-Magdalena et al., 
2010). EFSA also reviewed the study by Miyawaki et al. (2007) and concluded that the small sample 
size (n=3) invalidated the study. EFSA suggested that the metabolic effects of BPA could be due to 
interactions with peptide hormonal pathways as well as steroid metabolism and function. EFSA noted 
however that the study of Ryan et al. (2010b) showed no indications of increased susceptibility to 
high-fat diet-induced obesity and glucose intolerance in adult mice exposed prenatally to BPA at an 
oral dose of 0.25 µg/kg bw per day. 
NTP-CERHR (2008) 
The NTP-CERHR monograph cited 10 studies in which weight gain was not observed following 
exposure to BPA and five studies in which growth reduction was reported. It reviewed two studies in 
which endpoints related to carbohydrate or lipid regulation were evaluated, those of Alonso-
Magdalena et al. (2006) and Miyawaki et al. (2007) and concluded that “the data are currently too 
limited to conclude that developmental exposure to bisphenol A causes diabetes or other metabolic 
disorders later in life.” NTP-CERHR concluded however that BPA did not have an effect on obesity 
in experimental animals at doses less than 5000 µg/kg bw per day. 
FAO/WHO (2011)  
The FAO/WHO opinion reviewed the studies of Miyawaki et al. (2007), Somm et al. (2009), Alonso-
Magdalena et al. (2010) and Ryan et al. (2010b). The Expert meeting reported that “Findings from 
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these studies include reports of glucose intolerance and hyperinsulinaemia in the 6-month-old male 
offspring of OF-1 mice treated with BPA at 0.01 or 0.1 mg/kg bw per day by subcutaneous injection 
from gestational day (GD) 9 to GD 16 (Alonso-Magdalena et al., 2010); adipocyte hypertrophy and 
increased mass of parametrial white adipose and brown adipose tissue on PND 21 in female offspring 
of Sprague-Dawley rats orally treated with BPA at 0 or approximately 0.07 mg/kg bw per day in 
drinking-water from GD 6 to PND 21 (Somm et al., 2009); and increased cholesterol on PND 31 in 
female offspring of ICR mice orally treated with BPA at approximately 0.26 or 2.6 mg/kg bw per day 
in drinking-water from GD 10 to weaning via the dam and then after weaning with the same drinking-
water treatment as the dam (Miyawaki et al., 2007)”. The opinion concluded that the available data 
suggest that further assessment of the potential effects of BPA on adiposity, glucose or insulin 
regulation, lipids and other end-points related to diabetes or metabolic syndrome is warranted. 
 
ANSES (2011; 2013) 
In 2011, the ANSES experts reviewed the same studies considered by FAO/WHO and EFSA in 2010 
and also the study of Rubin et al. (2001), which had shown obesity in the offspring of Sprague-
Dawley female exposed via drinking water, at approximately 0.1 mg BPA/kg bw per day (low dose) 
or 1.2 mg BPA/kg bw per /day (high dose) from GD6 throughout the period of lactation, persisting 
into adulthood. On this basis, they concluded that effects of BPA on lipogenesis in experimental 
animals (including adipocyte hypertrophy, predisposition to obesity, elevated cholesterol levels and 
triglyceride levels and overexpression of lipogenic proteins following pre-, peri-natal or adult 
exposure were proven. These effects, together with others, were considered as critical and were taken 
forward for risk assessment.  
In the ANSES risk assessment of 2013, the increase in body weight in experimental animal studies 
together with increases in plasma lipids (such as cholesterol and triglycerides) and lipogenesis were 
retained as the critical effects. The ANSES opinion considered the Miyawaki et al. (2007) study in 
ICR mice to be the pivotal study for risk assessment, and derived a LOAEL of 0.26 mg/kg bw per day 
for BPA based on an increase in body weight and cholesterolemia in females. 
3.7.2.2. Evaluation of animal studies on effects of BPA on metabolism (lipogenesis, obesity) or 
effects related to glucose or insulin regulation (diabetes) 
Since the EFSA opinion of 2010, the WHO Expert meeting of 2010 and the ANSES report of 2011, 
several additional experimental studies have reported metabolic effects of BPA (including effects on 
body weight/obesity, lipogenesis or adipogenesis) and/or effects related to glucose or insulin 
regulation. These studies are summarised below, under the various endpoints, together with 
summaries of the relevant earlier studies (Miyawaki et al., 2007; Somm et al., 2009) that were 
considered by the CEF Panel to add to the overall body of evidence for effects in this emerging area. 
A detailed description and evaluation of each study is provided separately in Appendix B  
Studies involving prenatal exposure 
Increased body weight/body weight gain: 
 
a) Studies with BPA exposure alone  
Miyawaki et al. (2007) exposed mice to BPA in drinking water with doses corresponding to 0, 0.26, 
2.72 mg/kg bw per day from GD 10 to PND 21. Body weights of female offspring were increased at 
the low and high dose group, body weights of the males at the high dose group. Adipose tissue weight 
was increased significantly in females at the low dose and in males at the high dose group. In the 
study of Somm et al. (2009) in rats receiving a dose of approximately 70 µg/kg bw per day from GD 6 
until PND 21, body weight on PND 1 was increased in males and females whereas body weight and 
parametrial white fat tissue was increased only in females.  
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Anderson et al. (2013) exposed mice 2 weeks before mating, during gestation and lactation (PND 21) 
to 0, 50 ng, 50 µg or 50 mg of BPA/kg diet, corresponding to 0, 10.75 ng, 10.75 µg, and 10.75 mg/kg 
bw per day. One male and one female/litter were followed until 10 months of age, and were given 
standard diet or diets containing BPA at the same levels as administered to the dams. Increased 
oxygen consumption and carbon dioxide production was found in all BPA-treated animals. The CEF 
Panel noted however that the dose-response relationship was inconsistent. Spontaneous activity was 
increased only in females. Food consumption in females was significantly reduced but without a clear 
dose-response, whereas in males the reduction of food intake did not reach statistical significance. 
Body weight and body fat was not statistically different from control in either sex. In the study of 
Angle et al. (2013) pregnant mice were exposed to five BPA doses (5, 50, 500, 5 000 and 50 000 
µg/kg bw per day) from GD 8 to GD 18. The multiple parameters measured showed an inconsistent 
pattern, with many effects seen on one or more of the parameters at a certain dose, without a 
corresponding effect on a second, pathophysiologically-related parameter. The interpretation of the 
results is not clear, in particular a unifying mode of action is lacking. 
In the study of US FDA/NCTR (2013) Sprague-Dawley rats were treated with BPA administered by 
oral gavage from gestation day 6 through the start of labor. BPA was then given directly to pups from 
PND 1 until termination at PND 90 ± 5 at doses of 2.5, 8, 25, 80, 260, 840, 2 700, 100 000, and 
300 000 μg/kg bw per day. The number of litters per dose group was 18-23. At the dose of 300 mg/kg 
bw per day several effects were noted which were similar to those of the positive control EE2, such as 
preweaning body weight reduction (12 – 16% and 9 – 12% in females and males, respectively), 
reduced retroperitoneal fat pad (females only) on PND 90, and reduced body weight on day 90, 
b) Studies with BPA exposure combined with further intervention  
The publication of Somm et al. (2009) reported on a further treatment modality. Two groups of rats in 
this study were exposed to BPA from GD 6 until PND 21 and were then fed either with a normal diet 
or with a high fat diet from week 4 until week 14. The body weights were higher in both sexes than in 
the controls. However, the weeks in which body weights were higher were not identical in both sexes.   
Xu et al. (2011b) hypothesised that obesity might be due to an increased preference of adult rats for a 
sweet taste, linked to prenatal and postnatal exposure to BPA. Female Sprague Dawley rats were 
exposed to BPA in drinking water at doses of 0.01, 0.1 and 1.0 mg/l from GD 11 to PND 21. All 
females including controls showed a preference for saccharin-containing drinking water compared 
with plain water, without a BPA treatment-related effect, whereas male offspring showed an increased 
preference for only 0.25% (but not for 0.5%) saccharin, and for 15% sucrose, compared with male 
controls. Male offspring from dams receiving 0.1 mg/l BPA and administered 15% sucrose in their 
drinking water postnatally also showed increased body weight gain compared with controls, the 
percentage of body fat was higher, as was their tail blood pressure. The drinking water consumption 
was not reported and hence no clear information on the BPA dose received is available. Further 
methodological flaws of the study are to be noted: the litter effects were not fully taken into 
consideration, the response to saccharin is inconsistent and it is unclear why only the mid dose group 
of BPA-exposed pups was chosen for the sucrose preference test and why only in this group the body 
weight was tested. The flaws limit the conclusions that can be drawn from this study. 
Wei et al. (2011) administered doses of 0, 50, 250 or 1250 µg BPA/kg bw per day orally by gavage in 
corn oil to pregnant Wistar rats from GD 0 to PND 2. The offspring were maintained on either a 
normal or a high fat diet for 16 weeks. The authors only showed the full data set of results for the 50 
µg/kg bw per day dose. Some data for the other doses were reported in the supplemental information. 
Offspring exposed prenatally to 50 µg BPA/kg bw per day and maintained on a normal diet showed 
increased weight gain from week 17 (females) or week 19 (males). Effects were more evident in 
animals fed a high fat diet. No effects of BPA were observed at doses of 250 or 1250 µg BPA/kg bw/ 
day. The amount of fat fed to the animals was twice the normal dietary intake of fat. As in humans the 
recommended intake of fat amounts to 40-45% of the total intake in newborns and 25-30% in adults 
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and adolescents, doubbling the intake would mean that newborns would take only 10-20% food other 
than fat and adults and adolescents would take only 40 -50 % of their daily food as non fat food. It is 
obvious that this is itself a very unhealthy diet. The statistical analysis was flawed; in particular, the 
choice to consider the litter size as a covariate in the ANCOVA analysis was not properly justified. 
The effect is seen only at the lowest dose.  
In addition, there is no convincing evidence that BPA is obesogenic later in life in studies with 
intrauterine and subsequent long-term dosing. 
In the study by MacKay et al. (2013) a normal or high-fat diet was given in adult life to the offspring 
of CD mice exposed from GD 1 and until PND 21 to diets containing 0, 1 or 20 µg BPA/kg feed, 
(equivalent to an average of 0.19 and 3.49 µg/kg bw per day prenatally and 0.36 and 7.2 µg/kg bw per 
day of BPA postnatally). Female offspring of dams receiving 20 µg BPA/kg feed which were fed a 
high fat diet as adults showed increased body weight gain compared with controls and also the DES 
positive control, and also ate more. Male offspring showed no similar BPA-linked effect on body 
weight gain. Males at both levels of BPA showed a dose-related increase in weight in the 
retroperitoneal and intrascapular brown adipose fat pads compared with control and DES-exposed 
mice, and similar effects were seen in female offspring at the higher dose but not at the lower level of 
BPA. The CEF Panel noted however that the magnitude of the effects reported was small and that the 





In the study of Wei et al. (2011) offspring exposed prenatally to 50 µg BPA/kg bw per day and 
maintained on a normal diet showed higher serum insulin levels at week 15 for males and week 26 for 
females but not at doses of 250 and 1 250 µg/kg bw per day. The effect at 50 µg/kg bw per day was 
even more pronounced in animals fed with a high fat diet.  
In contrast, in the study of Anderson et al. (2013) no effects were seen on insulin release when 
offspring were exposed via their dams to doses between 10.75 ng, 10.75 µg, and 10.75 mg BPA/kg 
bw per day throughout gestation and via breast milk, and thereafter by diet until month 10. In the 
study of Angle et al. (2013) with doses of 5, 50, 500, 5 000 and 50 000 µg/kg bw per day, insulin in 
serum was higher than in controls only in the 5 µg/kg bw per day BPA group but not for 50, 500, and 
50 000 µg/kg bw per day. Results for the 5 000 µg/kg bw per day group were not given. In the insulin 
tolerance test the glucose AUC was higher than in the controls in the 5 and 5000 µg/kg bw per day 
group, indicating impaired regulation.  
No effects on insulin were observed in the US FDA/NCTR study (2013) with BPA doses of 2.5, 8, 25, 
80, 260, 840, 2 700, 100 000 and 300 000 μg/kg bw per day. 
Serum leptin  
In the study of Miyawaki et al. (2007) serum leptin was increased only in females of the low dose 
group (0.26 mg/kg bw per day =260 µg/kg bw per day)). 
Wei et al. (2011) administered doses of 0, 50, 250 or 1 250 µg BPA/kg bw per day orally by gavage in 
corn oil to pregnant Wistar rats from GD0 to PND 2. The offspring were maintained on either a 
normal or a high fat diet for 16 weeks. Serum leptin was elevated in the 50 µg BPA/kg bw animals 
compared with controls at week 26, but not in the groups with higher BPA doses. In the study of 
MacKay et al. (2013), with a BPA dose of 3.49 µg/kg bw per day prenatally and 7.2 µg/kg bw per day 
postnatally, females on a high-fat diet postnatally had increased leptin  concentrations with reduced 
proopiomelanocortin mRNA expression in the arcuate nucleus and oestrogen receptor α expression 
patterns. Serum leptin in the study of Angle et al. (2013) was increased at 500 µg/kg bw per day but 
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lower than  control at 50 and 50 000 µg/kg bw per day. A reduced serum leptin concentration was also 
measured in the US FDA/NCTR study (2013) at the highest dose (300 000 µg/kg bw per day). 
It is to be noted that the CEF Panel in its assessment looked at the changes reported  in every study; in 
none of them the observed changes have been discussed related to the results former study and under 
a unifying hyphothesis.  
The CEF Panel considered that, based on the different dose-response of the observed effects in the 
various studies, the effect of BPA on serum leptin is unclear. 
Glucose/Glucose tolerance  
In the subgroups of male rats in the Somm et al. (2009) study that were exposed to BPA (70 µg/kg bw 
per day from GD6 to PND 21) and then fed either with a normal diet or with a high fat diet from week 
4 until week 14, no effect of BPA exposure on glucose and glucose metabolism was found at week 14 
with normal diet and also with high caloric fat diet. In the study by MacKay et al. (2013) male mice 
exposed to a dose of BPA of 3.49 µg/kg bw per day prenatally and 7.2 µg/kg bw per day of BPA 
postnatally showed impaired glucose tolerance on normal or high-fat diet.  
In contrast, in the study of Anderson et al. (2013) in mice no effects were seen on glucose tolerance 
when offspring was exposed via their dams to doses between 10.75 ng, 10.75 µg, and 10.75 mg/kg bw 
per day BPA throughtout gestation and via breast milk, and thereafter by diet until month 10. In the 
study of Angle et al. (2013) in mice glucose tolerance test was impaired in all the doses (5, 50, 500, 
50 000 µg/kg bw per day) with the exception of the highest dose (500 000 µg/kg bw per day). 
In the study of US FDA/NCTR (2013) in Sprague-Dawley rats no effect of BPA on glucose was 
observed with doses of 2.5, 8, 25, 80, 260, 840, 2,700, 100,000, and 300,000 μg/kg bw per day from 
GD 6 until PND 90 by direct gavaging from PND 1.  
In summary, the CEF Panel considered that the results of studies in rats indicated no effect of BPA on 
glucose/glucose tolerance whereas in mice some effects were seen in studies which had 
methodological deficiencies and hence did not demonstrate a convincing effect of BPA on this 
endpoint. 
Studies in adult mice and rats 
 
Increased body weight/body weight gain: 
 
Marmugi et al. (2012) administered BPA in the diet to male CD1 mice for 28 days, dosing (estimated 
by the authors) was equivalent to 0, 5, 50, 500 and 5000 μg/kg bw per day. No effect was seen on 
body weight gain and relative liver weight, but perigonadic white adipose tissue (pWAT weight) was 
significantly increased only in the 50 μg/kg bw per day group.   
In the study of Hassan et al. (2012) exploring mechanistic aspects of BPA effects in the liver, rats 
received BPA (0.1, 1, 10, 50 mg/kg/day) via gavage for four weeks The final body weights in the 0.1 
mg/kg bw per day group showed a significant decrease and the 10 mg/kg bw per day group a 
significant increase compared to the control group. 
In the study of Rönn et al. (2013) intakes of BPA, given in drinking water to female F-344 rats, were 
between 4.6 (week 9) and 5.6 (week 2) µg/kg bw per day at the lowest dose, between 46.3 (week 6) 
and 61.6 (week 3) µg/kg bw per day at the mid dose and 400.3 (week 9) and 595.3 (week 2) µg/kg bw 
per day at the highest dose, according to the authors. Dosing was from five to 15 weeks of age.There 
were no significant effects of BPA on body weight or weight of the perirenal fat pad and no 
differences were seen in total or visceral adipose tissue volumes between the groups. Liver fat content 
was significantly higher in rats receiving the two higher doses of BPA compared with controls (p = 
0.04).   
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Further endpoints 
Insulin 
In the study of Marmugi et al. (2012) in mice, plasma insulin levels were significantly increased 
following oral exposure to 5, 50, and 500 μg BPA/kg bw per day, with the greatest effect (threefold 
increase above the control) being seen at the lowest dose. In the study of Batista et al.(2012), 3-month 
old mice administered a total of 100 µg BPA/kg bw daily by subcutaneous injection (in two 
injections) for 8 days showed higher plasma insulin concentrations in the fed state and increased 
glucose-stimulated insulin secretion in isolated pancreatic islet of Langerhans. In the studies of 
D’Cruz et al. (2012b), in male rats with BPA doses of 0.005, 0.5, 50 and 500 μg/kg bw per day by 
oral gavage for 45 days, plasma insulin was increased and testicular insulin was significantly 
decreased down to the lowest level of BPA exposure of 5 ng/kg bw per day. Jayashree and co-workers 
(Jayashree et al., 2013; Indumathi et al., 2013) in a study in adult male rats found that serum insulin 
was significantly increased in a dose-related manner at oral BPA doses of 20 mg/kg bw per day and 
200 mg/kg bw per day for 30 days. 
Glucose and Glucose tolerance   
In the study of Marmugi et al. (2012) in mice, no significant effect was apparent on plasma glucose 
and total, LDL- or HDL-cholesterol. In the studies of D’Cruz et al. (2012a), in rats, levels of plasma 
glucose were significantly increased across all doses from 500 µg/kg bw per day down to 5 ng/kg bw 
per day, whereas the testicular glucose level significantly decreased, again at all dose levels. In the 
study of Batista et al. (2012), glucose tolerance testing showed that BPA-treated mice were insulin 
resistant and had increased glucose-stimulated insulin release. 
Other effects 
In the study of Marmugi et al. (2012) the group of mice exposed to 500 μg BPA/kg bw per day 
showed a significant increase in plasma triglyceride levels. Furthermore, the results of the microarray 
assays showed a stimulatory effect of BPA on expression of key enzymes involved in lipogenesis, 
cholesterol biosynthesis and, to a lesser extent, enzymes involved in glucose metabolism as well as 
master transcriptional regulators of hepatic lipid and glucose homeostasis with a complex dose-
response pattern.The dose-response relationship is different between the endpoints, even if they are 
biologically related. Hence, the CEF Panel considered that it is difficult to understand the underlying 
mechanism.  
D’Cruz et al. (2012b), in a study in male rats with BPA doses of 0.005, 0.5, 50 and 500 μg/kg bw per 
day by oral gavage for 45 days reported that various insulin signalling molecules were significantly 
decreased in testis in a dose-related manner at all dose levels. Similarly, a dose-dependent and 
significant decrease in testicular superoxide dismutase and catalase activities was measured at all 
doses, and lipid peroxidation was increased, together with decreases in testicular marker proteins and 
key enzymes of steroidogenesis. There was loss of germ cells and decrease in the spermatids in rats 
treated with 500 μg/kg bw per day BPA. The statistics were not properly reported as a one-way 
ANOVA was followed by Tukey’s post test, but the results of the overall ANOVA were not given. 
The use of this statistical approach with such a small sample size is questionable. The reported 
changes in testicular pathology cannot be related to functional deficits. 
The study of Batista et al. (2012) in mice administered a total of 100 µg BPA/kg bw daily by 
subcutaneous injection (in two injections) for 8 days reported that whole-body energy homeostasis, as 
assessed by reduced food intake, reduced locomotor behavior and decreased energy expenditure 
during night, was reduced, although respiratory exchange ratio was unchanged. Changes in a number 
of insulin-signalling pathways were also reported in the study. 
In the studies of Jayashree and co-workers (2013) glucose oxidation was reduced at dose levels of 20 
mg BPA/kg bw per day and 200 mg BPA/kg bw per day, both in liver and in skeletal muscle, and 
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glycogen content of the liver was also reduced. In skeletal muscle, treatment with BPA significantly 
decreased the insulin receptor, protein kinase B and glucose transporter-4 levels (both plasma 
membrane and cytosolic fraction), but did not affect the mRNA levels for these proteins. In the liver 
both mRNA and protein levels were significantly decreased at the highest BPA dose. 
Study in a specific mouse strain  
Bodin and co-workers (2013) investigated possible effects of BPA, administered at 0, 1 and100 mg/l 
BPA in the drinking water of non-obese pre-diabetic (NOD) mice (n = 6-10 per group for different 
parameters) on the development of type 1 diabetes (T1DM). The authors estimated that these levels 
corresponded to intakes of 0, 150 or 15000 μg/kg bw per day in non-diabetic mice. The incidence and 
degree of insulitis in the pancreas was comparable between groups at week 7, but was markedly 
increased compared with controls in 12-weeks-old female mice exposed to 1 mg/l BPA in drinking 
water. Insulitis was less severe in the female animals receiving 100 mg/l and was decreased in male 
mice exposed to BPA compared with controls. Serum glucose levels were increased in the 1 mg/ml 
BPA group, indicating an accelerated onset of T1DM, but this was not seen in the animals exposed to 
100 mg/l BPA. Insulin levels did not differ significantly between the groups and while T4 levels 
increased slightly with increasing BPA intake, this was not statistically significant. Serum levels of 
cytokines and autoantibodies also did not differ between the groups. 
3.7.2.3. Summary of metabolic effects of BPA in animals 
A number of studies in both prenatally- and postnatally exposed rats and mice report effects of BPA 
exposure on metabolic function in terms of glucose or insulin regulation or lipogenesis, and body 
weight. In some of the studies effects were only seen at one dose level which was interpreted by the 
authors as being an evidence for non-monotonicity of the dose-response curve. However dose-
response curves in which effects of different size are present at two low dose levels and a smaller 
effect size at a higher dose level than the two low doses were not observed. Hence, the assumption of 
non-monotonicity is not supported by the data.  
Although some isolated effects may have been assessed as likely effects in evaluating whether the 
effects are clinically relevant for humans an overall assessment has to be performed. It has to be noted 
that the effects observed in the different studies are contradictory and in some of the studies may be 
associated with high fat feed intake which cannot be considered as a good model for human health 
assessment. In addition, there is no convincing evidence that BPA is obesogenic later in life in studies 
with intrauterine and subsequent long-term dosing. In adult animals, body weight was not influenced 
by BPA in the two studies in which it was measured, while fat pad weight was not changed compared 
with controls in one study and increased in the other. Levels of serum glucose were increased in one 
study and unchanged in the other whereas glucose in testis was decreased in one study. Insulin 
plasma/serum levels were increased in BPA-treated animals in two studies in mice and two studies in 
rats over a range of doses from 0.005 µg/kg bw per day up to 30 000 µg/kg bw per day across studies. 
Changes in insulin signalling are reported in several studies, which point at possible mechanisms of 
action for the elevated insulin and might explain the impaired glucose tolerance described in one 
study. However, no long term study confirms the presence of diabetes in the animals. The finding of 
insulin resistance, if existing, seems to be a reversible effect and seems not to indicate the first step in 
developing diabetes mellitus type 2.  
3.7.3. In vitro studies 
Several in vitro studies conducted after 2010 examined the effects of BPA on insulin secretion, 
mitochondrial morphology and function and gene expression in different cell types.  
Insulin secretion stimulated by glucose levels above the normal value in fasting humans (8-17.7 mM 
in the experiments versus 4-5.5 mM) was further increased by treatment with BPA concentrations (10-
10 M, 10-9 M and 2x10-9 M) in mouse and human islets, in primary rat islet cells and in a rat 
insulinoma cell line (Soriano et al., 2012; Song et al., 2012; Lin et al., 2013). Increase was less than 
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twofold with concentrations up to a concentration of 2x10-9. In the presence of 3 mM glucose there 
was either no BPA effect (Soriano et al. 2012) or the insulin secretion was induced at BPA 
concentrations greatly exceeding the concentration which could be expected from human exposure to 
BPA (Song et al., 2012). It remains open whether the results at high glucose levels can be regarded as 
adverse because the increase in insulin secretion is modest even at BPA concentrations in the medium 
of about 100 fold the in vivo human serum concentration. Results from a study using ERβ-/-mice in 
comparison with wild-type mice suggest that BPA´s effects on insulin secretion, KATP channel 
activity and glucose-induced [Ca2+] oscillations in pancreatic β-cells is linked to the presence of ERβ. 
BPA-induced toxicity and apoptosis was associated with changes in the morphology and the 
membrane potential of mitochondria in pancreatic β-cells and insulinoma cells. 
In the human hepatic cell line HepG2 mitochondrial dysfunction along with signs of oxidative stress 
were induced by BPA concentrations of 10-12 M - 10-8 M (Huc et al., 2012). 
In human adipose tissue isolated from children and in preadipocyte/adipocyte cells, BPA at 10-8 M 
increased the expression of 11β-hydroxysteroid-dehydrogenase, PPARγ and lipoprotein lipase and, in 
addition, induced lipid droplet accumulation in adipocytes at terminal differention (Wang et al., 
2012a, b). These data suggest that concentrations of BPA which are more than 1000 fold above 
human concentrations promote adipogenesis in vitro.  
Using transfection gene reporter assays with monkey kidney cells, Sheng et al. (2012) observed a 
BPA (10-9 M to 10-7 M)-induced suppression of thyroid hormone receptor transcription through a non-
genomic pathway. However, the concentrations are beyond the range which could be expected from 
human exposure to BPA, and the relevance of the complex in vitro-transfection data for the in vivo 
situation is unclear. 
3.7.3.1. Summary of metabolic effects of BPA in vitro 
Three studies demonstrated an increase of glucose-stimulated insulin secretion by BPA concentrations 
of 10-10 M – 2x10-9 M in pancreatic cells/tissue. This is a concentration range which is reached with an 
oral dose of 100 µg/kg bw per day in mice (Cmax 1.8x10-10 M in in Doerge et al., 2011b) and in rats 
(Cmax 3.6x10-10 M in Doerge et al., 2010a). Thus, it is likely that nanomolar concentrations of BPA can 
affect insulin secretion in vitro. However, considering the limitations of in vitro studies (e.g. substrate 
and hormone concentrations which often differ from the in vivo situation) the relevance of the above 
mentioned observations for the function of pancreatic β-cells in vivo is currently unclear. 
3.7.4. WoE of metabolic effects in humans, animals and in vitro 
Whether BPA induces metabolic effects was considered using a tabular format for weighting different 
lines of evidence (WoE evaluation). The overall outcome of this WoE evaluation is presented below, 
while the WoE evaluation tables for these endpoints are presented in full in Appendix C. For 
interpretation of these tables always refer to Appendix A. 
Table 12:  Overall table on WoE evaluation of metabolic effects of BPA in humans and animals  
Human studies 
Overall conclusion on likelihood of associations between BPA and obesity in humans 
There are indications from a prospective study that prenatal BPA exposure (maternal urinary 
BPA concentrations) may be associated with reduced body mass in girls, while cross-sectional 
studies indicate associations between childhood BPA exposure and obesity. It cannot be ruled 
out that the results are confounded by diet or concurrent exposure factors. The associations do 
not provide sufficient evidence to infer a causal link between BPA exposure and obesity in 
humans. Potential effects are considered to be as likely as not”. 
As likely as 
not  
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Human studies 
Overall conclusion on likelihood of associations between BPA and hormonal effects in 
humans 
There are indications from one prospective study that maternal BPA exposure may be associated 
with adipokine expression in 9 year old children, but it cannot be ruled out that the result is 
confounded by diet or concurrent exposure factors. The association does not provide sufficient 
evidence to infer a causal link between BPA exposure and hormonal effects in humans. Potential 
effects are considered to be as likely as not.” 
As likely as 
not 
 
Overall conclusion on likelihood of associations between BPA and diabetes effects in 
humans:  
The indications that BPA may be associated with diabetes in humans is unlikely. 
Unlikely 
 
Overall conclusion on likelihood of associations between BPA and metabolic syndrome in 
humans:  
The indication that BPA may be associated with metabolic syndrome in humans is unlikely. 
Unlikely 
 
Overall conclusion on likelihood of associations between BPA and renal effects in humans:  
The indication that BPA may be associated with renal function in humans is unlikely. 
Unlikely 
  
Animal studies  
Overall conclusion on likelihood of metabolic effects in animals exposed postnatally 
Evidence for associations between BPA exposure and metabolic effects in animals exposed 
postnatally is inconsistent. There is reasonable evidence for effects on glucose or insulin 
regulation and/or effects on pancreatic morphology and/or function in shorter term studies, but 
no evidence that BPA is causing diabetes, insulin resistance and increases in weight (obesogenic) 
longer-term. 
As likely as 
not 
Overall conclusion on likelihood of metabolic effects in animals exposed prenatally : 
Since the initial reports that BPA had potential effects on adiposity, glucose or insulin regulation, 
lipids and other end-points related to diabetes or metabolic syndrome in animals exposed 
prenatally, several new studies have been published. There is reasonable evidence for effects on 
glucose or insulin regulation and/or effects on pancreatic morphology and/or function in shorter 
term studies, but no evidence that BPA is causing diabetes, insulin resistance and increases in 
weight (obesogenic) longer-term.    
As likely as 
not  
    
3.7.5. Conclusions on metabolic effects 
Of the reviewed human studies on metabolic effects only two were prospective while 22 were cross-
sectional and thus not suitable on their own to study exposure-disease associations. Inconsistent with 
the results of cross-sectional studies one prospective study found that a higher BPA concentration in 
maternal urine during pregnancy was associated with a lower level of obesity in daughters. A causal 
link between BPA exposure and metabolic effects in humans cannot be established. 
A number of studies in pre- and postnatally exposed rats and mice indicate that BPA exposure could 
have an effect on metabolic function as evidenced by effects on glucose or insulin regulation or 
lipogenesis, and body weight gain (short-term studies). Based on the results from other studies with a 
longer duration (e.g. 90 days) there is no convincing evidence that BPA is obesogenic after 
intrauterine exposure or in longer-term studies. 
Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to metabolic 
effects of BPA. Since the likelihood level for this endpoint is less than "likely" (see  Appendix A), 
this endpoint was not taken forward for assessing the toxicological reference point, but was taken into 
account in the evaluation of uncertainty for hazard characterisation and risk characterisation (Section 
4.3).  
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3.8. Genotoxicity 
3.8.1. Summary of previous opinions on BPA genotoxicity 
The genotoxicity of BPA has been reviewed on a number of occasions (Haighton et al., 2002, EU, 
2003; EFSA, 2006; NTP-CERHR, 2008; EFSA CEF Panel, 2010; FAO/WHO, 2011). BPA has been 
tested in a range of in vitro assays including gene mutation assays in bacteria, yeast and mammalian 
cells, chromosome aberration tests, sister chromatid exchange, cell transformation assays and cell-free 
systems including DNA binding and microtubule disruption. In vivo studies have included 
micronucleus formation, chromosome aberration studies, dominant lethal assay and DNA adduct 
formation.  
EU-RAR (2003 and/or 2008) 
The EU Risk Assessment Report (EU RAR), in reviewing studies published up to 2002 concluded 
that in vitro BPA did not induce gene mutations or structural chromosome aberrations in bacteria, 
fungi or mammalian cells in vitro, but had some aneugenic potential as evidenced by positive findings 
in an in vitro micronucleus test in Chinese hamster V79 cells and in an aneuploidy assay in Syrian 
hamster embryo cells (EU, 2003). The EU RAR noted that the potential of BPA to produce 
aneuploidy was supported by the demonstration of microtubule disruption in the presence of BPA in 
cell-free and cellular systems and also noted that BPA has been reported to produce DNA adducts in a 
post-labelling assay with isolated DNA (EU-RAR, 2003). The EU RAR concluded that the potential 
of BPA to produce aneugenicity in vitro was not expressed in vivo, based on negative findings in a 
guideline mouse micronucleus test supported by a negative result in an inadequately-reported 
dominant lethal study. The authors of the EU RAR further concluded that the finding of DNA adduct 
spots in a postlabelling assay in rats in vivo was unlikely to be of concern, given the lack of evidence 
for mutagenicity and clastogenicity of BPA in cultured mammalian cells. 
NTP-CERHR (2008) 
The NTP-CERHR monograph reviewed the above database and also studies published between 2002 
and 2008 (NTP-CERHR, 2008). The authors noted more recent in vitro studies providing evidence of 
an effect of BPA on meiotic and mitotic cell division, but not induction of aneuploidy. These studies 
included effects on maturation of mouse oocytes, increased frequency of mitotic cells with aberrant 
spindles, and effects on cellular and nuclear division in fertilized sea urchin eggs. NTP-CERHR 
summarised the results of two in vivo studies demonstrating an increase in hyperploid (aneuploid) 
metaphase II oocytes following treatment of peripubertal or pregnant mice with 0.020 mg BPA/kg bw 
per day, without a significant increase in aneuploid embryos. These findings were not however 
reproduced in two subsequent in vivo studies using a similar design. NTP-CERHR concluded that 
“since no impact of such effects on reproduction is reported in animal breeding studies, the 
significance of these findings with regard to human health hazards is not clear” (NTP-CERHR, 
2008).  
EFSA (2006 and 2010) 
EFSA in 2006 noted that BPA is not considered to be genotoxic in bacteria and in mammalian cells, 
based on previous reviews of BPA genotoxicity (EC, 2002; EU-RAR, 2003; Haighton et al., 2002, as 
cited by EFSA, 2006). In the EFSA opinion of 2010, the CEF Panel noted that “Naik and Vijayalaxmi 
(2009) reported that oral administration of BPA as single (10, 50, 100 mg/kg bw) or repeated doses 
(5x10 mg/kg bw) did not increase the incidence of structural chromosomal aberrations or micronuclei 
in bone marrow of Swiss albino mice. Administration of BPA, however, was associated with an 
increased incidence of achromatic lesions (gaps) which cannot be considered as an evidence of a 
clastogenic potential in the absence of a concurrent increase in structural chromosomal aberrations”. 
The CEF Panel concluded therefore that the findings of this study did not alter the 2006 EFSA 
conclusion that BPA has no clastogenic potential in vivo. The CEF Panel noted however that the 
authors also reported that BPA had an effect on spindle structure, which could be interpreted as an 
indication of aneuploidy. The CEF Panel concluded however, “considering the thresholded 
mechanism for aneuploidy induction, the large margin between the doses tested negative in the 
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micronucleus test and the TDI provided adequate reassurance on the lack of aneugenic effects” 
(EFSA CEF Panel, 2010). The 2010 EFSA opinion also summarised the study of Muhlhauser et al. 
(2009), providing data showing a borderline effect of BPA on chromosome alignment or spindle 
abnormalities. The CEF Panel noted that effects of BPA on meiotic spindle can be modulated by the 
amount of phytoestrogens present in the diet, and concluded that “the consequences of these 
cytological effects on chromosome segregation are unknown and therefore these effects cannot be 
considered as markers of aneuploidy”. The CEF Panel also noted the in vivo studies reviewed by 
NTP-CERHR and concluded overall that “these data have no impact on the Panel´s previous 
conclusion on the lack of aneugenic activity of BPA in mouse germ cells.” 
FAO/WHO (2011) 
The report of the 2010 Joint FAO/WHO Expert Meeting on Toxicological and Health Aspects of 
Bisphenol A concluded that “BPA is not a mutagen in in vitro test systems, nor does it induce cell 
transformation. BPA has been shown to affect chromosomal structure in dividing cells in in vitro 
studies, but evidence for this effect in in vivo studies is inconsistent and inconclusive. BPA is not 
likely to pose a genotoxic hazard to humans.” (FAO/WHO, 2011). 
ANSES (2011; 2013) 
No mention of genotoxic effects by BPA was present in either of the two ANSES reports. 
3.8.2. Evaluation of studies on genotoxicity of BPA (2006-2013) 
This section provides an overview of the in vitro and in vivo studies on genotoxicity published after 
the EFSA opinion from 2006 (since this endpoint was not specifically dealt with in the 2010 EFSA 
opinion), that the CEF Panel considered as the most relevant to this evaluation. 
The detailed description and evaluation of each study are provided separately in Appendix B. 
3.8.2.1. In vitro studies 
Masuda et al. (2005) reported negative mutagenicity results of BPA in a bacterial reverse mutation 
assay (Ames test) both in the absence and presence of S9 metabolic activation, using a limited battery 
of tester strains (TA98 and TA100) and a single concentration (1mM), 
In the study by Tiwari et al. (2012) mutagenicity of BPA was determined in an Ames assay using 
tester strains of S. typhimurium TA 98, TA 100 and TA 102 in the presence and absence of S9 
metabolic activation. Negative results were observed at concentrations up to 200 µg/plate, where 
toxicity was observed.  
In the study by Iso et al. (2006), the authors aimed to assess potential DNA damage induced by BPA 
(10 nM-0.1 mM) using the alkaline comet assay and the detection of phosphorylated histone γ-H2AX 
in two non-isogenic human cell lines (MCF-7 and MDA-MB-231) positive and negative for oestrogen 
receptors (ER) respectively. Results reported indicate that BPA was able to induce DNA breakage as 
shown by significant increases in tail length in the alkaline comet assay and significant induction of 
phosphorylated histone γ-H2AX, a marker for induction of DNA double strand breaks. These effects 
were reported to be more pronounced in the ER-positive MCF-7 cells compared to the ER-negative 
MDA-MB-231 ones.  
In the study by Johnson and Parry (2008) the aneugenicity of BPA was investigated in the cytokinesis 
blocked micronucleus assay (CBMA) in human (AHH-1) lymphoblastoid cells over a very narrow 
range of low concentrations (1.5, 3.1, 6.2, 7.7, 9.2, 10.8, 12.3, 18.5, 24.6, and 37.0 µg/ml). For 
mechanistic evaluation of the aneugenic effects of BPA fluorescently labelled antibodies for α and γ-
tubulin were used to visualize the microtubules and the microtubule organizing centers (MTOCs) in a 
V79 Chinese hamster cell line. Results obtained indicated dose-related and statistically significant 
increases of binucleate-micronucleated cells from 12.3 µg/ml and above, with a threshold for 
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induction of micronuclei between 10.8 and 12.3 µg/ml. Induction of aberrations in the mitotic 
machinery, in the form of multiple spindle poles at 8.4 µg/ml BPA and above was also observed. 
Aberrant mitotic divisions were hypothesized to be the mechanism for the generation of micronuclei 
via chromosome loss, thus confirming a threshold mechanism of action for the induction of 
aneuploidy by BPA. 
Tayama et al. (2008) reported positive results for induction of sister chromatid exchanges (SCE’s), 
chromosome aberrations (CA), DNA strand breaks (evaluated by alkaline comet assay) and 
colchicine-mitosis-like (c-mitoses) figures, a marker for spindle disrupting effects in a CHO-K1 cell 
line in vitro following treatment with BPA at dose-levels of 0.1-0.7 mM. Positive findings reported in 
this study for DNA strand breaks (evaluated by alkaline comet assay), chromosomal aberrations and 
SCE were only observed at the highest concentration employed in the presence of a marked 
cytotoxicity. The induction of c-mitoses, which appears to be not influenced by cytotoxicity and 
methods applied, can be considered as a further evidence of a spindle disrupting effect of BPA. 
In the study by Izzotti et al. (2009), BPA was reported to induce dose-related increases of DNA 
adducts as detected by 32P-postlabelling in an acellular sytem constituted by a mixture of calf thymus 
DNA and an exogenous metabolising system containing 10% liver S12 fraction derived from Aroclor 
1254-pre-treated Sprague–Dawley rats. In this investigation, chemical characterisation of DNA 
adducts was not performed.  
In the study by De Flora et al. (2011), BPA was investigated by 32P-postlabelling for induction of 
DNA adducts in two human prostate (PNT1and PC3) cell lines. Results obtained showed formation of 
DNA adducts (4.2 and 2.7 fold increases over control in PNT1 and PC3 cells respectively) following 
metabolic conversion of BPA by PNT1 and PC3 human prostate cell lines. The CEF Panel noted that 
metabolic competence for these cell lines has not been demonstrated and that chemical 
characterisation of the DNA adducts has not been performed.  
In the study by Audebert et al. (2011), BPA was shown to be negative for induction of phosphorylated 
histone γ-H2AX, a marker for induction of DNA double strand breaks in the human cell lines HepG2 
(human hepatocellular carcinoma cells) and LS174T (human epithelial colorectal adenocarcinoma 
cells). The CEF Panel noted that the H2AX assay is not a validated genotoxicity test.  
In the study by Fic et al. (2013) BPA was assessed for its mutagenic and genotoxic potential using the 
Ames test (Salmonella typhimurium strains TA98 and TA 100) in the absence and presence of S9 
metabolic activation and the alkaline comet assay in HepG2 cells at concentrations of 0.1, 1.0 and 
10.0 µM for 4 and 24 hours. BPA was not mutagenic in the Ames test, while in the comet assay it 
induced statistically significant increases in DNA damage only after 24 hours exposure at any of the 
concentrations used. These increases were, however, not concentration-related. 
3.8.2.2. Summary of in vitro studies 
BPA did not induce gene mutation or chromosomal aberrations in bacteria, yeast and mammary cells 
(EFSA, 2006; Masuda et al., 2005; EFSA CEF Panel, 2010; Tiwari et al., 2012). The potential of BPA 
to affect spindle apparatus inducing aneuploidy was clearly demonstrated in a number of reliable 
studies (Johnson and Parry, 2008; Tayama et al., 2008). The compound was shown to induce DNA 
adducts in acellular systems (Izzotti, 2009), in hamster and human cell lines (EFSA, 2006, De Flora et 
al., 2011) and DNA damage in non-isogenic human cell lines (MCF-7 and MDA-MB-231) (Iso et al., 
2006). 
3.8.2.3. In vivo studies 
The study by Masuda et al. (2005), designed to investigate potential genotoxicity from the reaction of 
BPA and nitrite under acidic conditions to simulate the stomach environment, showed that when BPA 
was administered alone at 228 mg/kg bw by oral gavage to male ICR mice it did not induce 
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micronuclei in peripheral blood reticulocytes at the 24, 48 and 72 hour sampling times. Although only 
one dose-level was assessed the CEF Panel considered the study useful for the evaluation of 
genotoxicity.  
Pacchierotti et al. (2008) evaluated potential aneugenic effects of BPA on mouse female germ cells 
following a single treatment at 0.2 and 20 mg/kg bw, or seven daily administrations at 0.04 mg/kg bw 
by oral gavage or administration for seven weeks in drinking water at 0.5 mg/l. The authors also 
examined effects of BPA on male germ and somatic cells (as evidenced by induction of micronuclei 
in bone-marrow cells following six daily administrations of BPA at 0.002, 0.02 and 0.2 mg/kg bw by 
oral gavage). Results obtained for female animals indicated no significant induction of hyperploidy or 
polyploidy in oocytes and zygotes at any dose-level and treatment condition employed. Significant 
increases in the number of metaphase II oocytes with prematurely separated chromatids were 
observed, however these proved to be of no consequences in terms of fidelity of chromosome 
segregation during the second meiotic division as shown by normal chromosome complements of 
zygotes obtained under the same experimental conditions. Similarly, no induction of hyperploidy or 
polyploidy in epydidimal sperms, were observed in male mice. Furthermore, negative results for 
induction of micronuclei in bone marrow cells of male mice were also observed.  
In the study by Izzotti et al. (2009) BPA was investigated for its capability to cause DNA adducts, 
detected by 32P-postlabelling in both liver and mammary cells of female CD-1 mice receiving BPA in 
their drinking water (equivalent to 200 mg/kg bw per day) for 8 consecutive days. Results obtained 
indicated the formation of bulky DNA adducts (two major DNA adducts) in the liver (3.4 fold 
increase over control level) as well as in the mammary cells (4.7 fold increase over control level). The 
authors attributed the formation of adducts to the reactive metabolite BPA-3,4-quinone (BPAQ), 
formed by metabolism of BPA in humans and in experimental animals. 
Naik and Vijayalaxmi (2009)  evaluated potential genotoxic effects of BPA by analyses of 
chromosomal aberrations and micronuclei in bone marrow cells of Swiss albino mice following a 
single administration at 10, 50 and 100 mg/kg bw or five daily administrations at 10 mg/kg bw by oral 
gavage. To further assess for potential interference of BPA with the mitotic spindle apparatus, 
induction of c-mitoses was also evaluated following single administration of BPA by oral gavage at 
10, 50 and 100 mg/kg bw. No significant increases of chromosomal aberrations or micronuclei were 
induced at any dose-level and sampling time used. On the other hand, dose-related and statistically 
significant increases in the frequencies of gaps were observed at all dose-levels assayed at the 48 and 
72 hour sampling time and at the two higher dose-levels (50 and 100 mg/kg bw) at the 24 hour 
sampling time. In addition, BPA also induced c-mitotic effects as shown by the increase of mitotic 
indices and decrease in anaphase at the two higher dose-levels (50 and 100 mg/kg bw) at 24, 48 and 
72 hour sampling times. Despite some methodological deficiencies of the study, the CEF Panel 
concluded that BPA under the reported experimental conditions was not clastogenic and did not elicit 
micronuclei induction which would be indicative of a clastogenic and/or aneugenic potential at dose-
levels employed. Furthermore, the CEF Panel noted that gaps, significantly increased in the 
chromosomal aberration assay, are usually not considered relevant for the evaluation of genotoxicity.  
In the study by De Flora et al. (2011), BPA was assessed for induction of micronuclei in bone marrow 
cells and evaluation of the degree of DNA breakage by means of alkaline comet assay in peripheral 
blood following in vivo treatment of male Sprague-Dawley rats via drinking water for a calculated 
daily exposure to 200 mg/kg bw for 10 consecutive days. Despite some methodological deficiencies 
of the study, the CEF Panel considered the study useful for the evaluation of genotoxicity.   
In the study by Ulutaş et al. (2011) BPA was assessed for its potential genotoxicity in peripheral 
blood nucleated cells of rats by means of the alkaline comet assay following oral administration at 
125 and 250 mg/kg bw per day for four weeks. Results obtained showed statistically significant 
increases of both tail length and tail moment for BPA at the highest dose-level (250 mg/kg bw per 
day) which were, however, not marked. No effect was observed at the lower dose-level (125 mg/kg 
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bw per day). Given methodological deficiencies, the CEF Panel considered that the results obtained 
are of limited value.  
Dobrzyńska and Radzikowska (2013) investigated the effects of BPA alone or in combination with X-
rays for induction of DNA strand breaks by means of DNA tail moment in the alkaline comet assay in 
somatic and germ cells of male mice following administration in drinking water for two weeks. 
Levels in drinking water were designed to achieve BPA intakes of 0, 5, 10, 20 or 40 mg/kg bw per 
day. Two additional groups received either 5 or 10 mg BPA/kg bw per day via drinking water in 
combination with daily radiation doses of 0.05 Gy or 0.10 Gy of X-rays which were not considered in 
this evaluation. BPA induced statistically significant increases of DNA breakage in male germ cells at 
24 hours and 5 weeks from last administration of test compound and in bone marrow, spleen, kidney 
and lung cells at 24 hours from last administration. However, the increases observed were not dose-
related and were obtained following collection of organs/tissues at 24 hours or 5 weeks from last 
administration. The CEF Panel considered that this experimental design is inadequate, since potential 
induced damage may rapidly be repaired and thus may not persist for a long time. Given this, and also 
noting other methodological deficiencies, the CEF Panel considered that no conclusion could be 
drawn from this study. 
In the study by Tiwari et al. (2012) BPA was investigated for induction of micronuclei and structural 
chromosome aberrations in bone marrow cells and primary DNA damage in blood lymphocytes using 
single cell gel electrophoresis (Comet assay). Furthermore, plasma concentrations of 8-
hydroxydeoxyguanosine (8-OHdG), lipid peroxidation and glutathione activity were also evaluated to 
assess potential induction of oxidative DNA damage in rats following oral administration of BPA 
once a day for 6 consecutive days at dose-levels of 2.4 µg, 10 µg, 5 mg and 50 mg/kg bw per day. 
Results obtained showed marked and dose-related increases of both micronuclei and structural 
chromosome aberrations in bone marrow cells of male and female rats exposed to BPA. The observed 
increases achieved statistical significance at dose-levels as low as 10 µg/kg bw per day. Similarly, the 
analysis of primary DNA damage evaluated by comet assay in isolated peripheral blood lymphocytes 
showed marked and dose-related increases which were statistically significant at dose-levels as low as 
10 µg/kg bw per day. The CEF Panel considered that study has major shortcomings including the 
observation of chromosomal aberration incidences which are not compatible with aberrations induced 
by known chemical clastogens and high DNA damage in controls in the absence of evaluation of 
cytotoxicity in the comet assay. 
In the study by Tiwari and Vanage (2013), BPA was investigated for the induction of dominant lethal 
mutations in the different stages of spermatogenesis in the rat. Furthermore, effects of BPA on male 
reproductive functions and potential DNA damage induced in epydidimal sperm, assessed by the 
alkaline comet assay were also investigated. The authors concluded that BPA induced dominant lethal 
mutations during the fourth and sixth weeks after BPA exposure, thus indicating its sensitivity to mid-
spermatid and spermatocyte stages of spermatogenesis, at the highest dose-level employed (5 mg/kg 
bw) and that the positive findings obtained were corroborated by DNA damage observed in the 
epydidimal sperm cells by the alkaline comet assay. Overall, the CEF Panel noted that the conclusion 
raised by the authors are not supported by their experimental data due to experimental shortcomings 
which include a limited number of male animals employed and an inadequate selection of dose-levels 
(only two dose levels with a very large difference between the high and the low dose). In addition, 
negative historical control data were not reported. Thus, overall the result cannot be considered 
reliable. 
3.8.2.4. Summary of in vivo studies 
BPA did not induce chromosomal damage in rodents, evaluated as micronuclei frequency and as 
chromosomal aberrations (Masuda et al., 2005; Pacchierotti et al., 2008; Naik and Vijayalaxmi, 2009; 
De Flora et al., 2011). The potential of BPA to affect the spindle apparatus was shown by the 
increases of c-like metaphases in bone marrow of male mice Naik and Vijayalaxmi, 2009) and of the 
number of metaphase II oocytes with prematurely separated chromatids in female mice after single or 
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multiple treatment with BPA (Pacchierotti et al., 2008). No induction of hyperploidy or polyploidy 
was observed in somatic as well in germinal cells. BPA was shown to induce DNA adducts in liver 
and mammary gland of female mice (Izzotti et al., 2009). 
3.8.3. WoE of the genotoxicity of BPA in vitro and in vivo    
The genotoxicity of BPA was considered using a tabular format for weighting different lines of 
evidence (WoE evaluation). The overall outcome of this WoE evaluation is presented below, while 
the WoE evaluation tables for these endpoints are presented in full in Appendix C. For interpretation 
of these tables always refer to Appendix A. The outcome of the WoE evaluation of in vivo BPA 
genotoxicity is also included in the subsequent carcinogenicity section, given the possible relevance 
of this endpoint in cancer development.  
Table 13:  Overall table on WoE evaluation of genotoxicity 
3.8.4. Conclusions on genotoxicity of BPA 
The genotoxicity of BPA has been reviewed on a number of occasions (Haighton et al., 2002; EU-
RER, 2003; EFSA, 2006; NTP-CERHR, 2008; EFSA CEF Panel, 2010; FAO/WHO, 2011). In the 
present evaluation an overview of the in vitro and in vivo studies on genotoxicity of BPA published 
from 2006-2012 that the CEF Panel considered as the most relevant to the human risk assessment has 
been performed.  
In a number of these studies judged by the CEF Panel as reliable although with limitations, BPA did 
not induce gene mutation in bacteria (Masuda et al., 2005; Tiwari et al., 2012), micronuclei (Masuda 
et al., 2005; Pacchierotti et al., 2008; Naik and Vijayalaxmi , 2009; De Flora et al., 2011) and 
chromosomal aberrations in erythropoietic cells of rodents treated in vivo with BPA (Naik and 
Vijayalaxmi , 2009).  
On the other hand, BPA has been clearly shown to be aneugenic in an in vitro study in mammalian 
cells by Johnson and Parry (2008) who demonstrated induction of micronuclei as a consequence of 
spindle disrupting effects of BPA. Further evidence for spindle disrupting effects of BPA have also 
been indicated by induction of colchicine-like metaphases (C-metaphases) in mammalian cells in vitro 
In vitro studies 
Overall conclusion based on in vitro studies – via non thresholded mechanism: 
BPA has not been shown to induce gene mutations nor chromosomal aberrations in bacteria and 
mammalian cells.  
Unlikely 
Overall conclusion based on in vitro studies – via thresholded mechanism: 
BPA has been clearly shown to be aneugenic through induction of micronuclei caused by spindle 
disrupting effects of BPA identified by the use of fluorescently labelled antibodies for α and γ-
tubulin to visualize the microtubules and the microtubule organizing centers of the mitotic 
spindles (Johnson and Parry 2008). Further evidence for spindle disrupting effects of BPA have 
been also indicated by Tayama et al. (2008) who showed significant increases of colchicine-like 





Overall conclusion based on in vivo studies – via non-thresholded mechanism: 
BPA has not been shown to be clastogenic in vivo (micronuclei and chromosomal aberrations) 
Unlikely 
 
Overall conclusion based on in vivo studies - via thresholded mechanism: 
The potential of BPA to produce aneuploidy in vitro was not expressed in vivo, based on 
negative findings obtained for induction of aneuploidy in female and male mouse germ cells 
(Pacchierotti et al., 2008) and for induction of micronuclei in somatic bone marrow cells 
(Masuda et al., 2005; Pacchierotti et al., 2008;  Naik and Vijayalaxmi , 2009; De Flora et al., 
2011). However, BPA induced dose-related increases of c-like metaphases in mouse bone-
marrow cells ( Naik and Vijayalaxmi , 2009) and significant increases in the number of 
metaphase II oocytes with prematurely separated chromatids (Pacchierotti et al., 2008), pointing 
to potential mitotic spindle disrupting effects of BPA in vivo. 
As likely 
as not  
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(Tayama et al., 2008) and in vivo by induction of prematurely separated chromatids in metaphase II of 
mouse oocytes (Pacchierotti et al., 2008) and c-metaphases in mouse bone marrow cells in vivo (Naik 
and Vijayalaxmi , 2009).  
Overall, these results point to the fact that BPA interacts with mitotic machinery through a mitotic 
spindle disrupting effect for which a threshold mechanism of action is expected, since induction of 
aneuploidy predicted for spindle poisons needs to disable multiple targets of the mitotic machinery 
before a quantitative response can be detected (COM Guidance on a Strategy for Testing of 
Chemicals for Mutagenicity, Department of Health, 2000). 
In addition the CEF Panel concluded that the positive finding  in the postlabelling assays in vitro and 
in vivo was unlikely to be of concern, given the lack of mutagenicity and clastogenicity of BPA in 
vitro and in vivo. BPA is not mutagenic (in bacteria or mammalian cells), nor clastogenic 
(micronuclei and chromosomal aberrations). The potential of BPA to produce aneuploidy in vitro was 
not expressed in vivo.  
Using a WoE approach, the CEF Panel assigned a likelihood level of “unlikely” to BPA genotoxicity.  
3.9. Carcinogenicity 
3.9.1. Human studies 
3.9.1.1. Summary of previous opinions 
EU-RAR (2003, 2008) 
The EU-RAR stated that there are no human data that can contribute to the assessment of whether or 
not BPA is carcinogenic. 
EFSA (2006); EFSA CEF Panel (2010)  
For the 2006 EFSA opinion, the AFC Panel did not identify any human data relevant to the 
assessment of BPA carcinogenicity. 
In the EFSA opinion of 2010, the CEF Panel described the cross-sectional study of Yang et al. (2009) 
in Korean women affected by breast cancer as having several methodological shortcomings and 
insufficient reporting, preventing any conclusion to be drawn on the association between BPA 
exposure and breast cancer. Also, no association between cancer and BPA exposure was reported in 
the Lang study (2008). 
NTP-CERHR (2008)  
The NTP monograph reviewed the results of a study by Hiroi et al. (2004) suggesting that patients 
with endometrial cancer and complex endometrial hyperplasia had lower blood levels of BPA than 
healthy women and women with simple endometrial hyperplasia. Among the strengths and 
weaknesses of the study, the NTP noted that “Because this was a small, cross-sectional study, it is not 
possible to determine whether this association preceded disease, or could have been associated with 
the disease process.” 
FAO/WHO (2011)  
The Expert Meeting noted that no studies of carcinogenicity of BPA in humans have been identified 
in the literature. 
ANSES (2011; 2013) 
In 2011, ANSES concluded that there have been no epidemiological studies published to date 
investigating a possible association between exposure to BPA and prostate disease. The only 
epidemiological study available on the association between BPA exposure and breast cancer, i.e. 
Yang et al. (2009), was considered by ANSES as having major methodological limitations and 
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therefore unsuitable to draw any conclusion. No additional human studies were reviewed by ANSES 
in its 2013 report. 
3.9.1.2. Evaluation of recent human studies on BPA exposure and carcinogenic effects 
Only one new human case-control study has been published since 2010, reporting a positive 
association between meningioma and urinary bisphenol A levels in Chinese adults (Duan et al., 2012). 
The study is very small and there are uncertainties about selection of patients and controls. Urinary 
BPA levels were determined at the time of diagnosis of meningioma and a causal association cannot 
therefore be identified. Confounding factors such as age, gender, body mass index (BMI) and 
hormone replacement therapy (HRT) cannot be excluded; the CEF Panel noted that a higher risk of 
meningioma was observed among current users of oral contraceptives than never users in a large 
European cohort study (Hazard Ratio, 3.61) (Michaud et al., 2010).  
Some of the cases of meningioma had received therapeutic intervention but no details were provided 
in the publication. The results of this small case-control study do not provide significant new 
information about the carcinogenicity of BPA in humans. 
3.9.1.3. Summary of the evidence for carcinogenicity of BPA in humans 
The very few epidemiological studies published to date, investigating a possible association between 
exposure to BPA and incidence of certain cancers, specifically breast cancer (Yang et al., 2009) and 
meningioma (Duan et al., 2012), do not allow any conclusion to be drawn regarding the 
carcinogenicity of BPA in humans. 
3.9.2. Animal studies 
3.9.2.1. Summary of previous reviews of the carcinogenicity of BPA 
The carcinogenicity of BPA has been reviewed on a number of occasions (EU-RER, 2003; EFSA, 
2006; NTP-CERHR, 2008; EFSA CEF Panel, 2010; FAO/WHO, 2011; ANSES, 2011, 2013). BPA 
has been tested for carcinogenic potential in two NTP guideline carcinogenicity studies in rats and 
mice and in a number of experimental carcinogenicity models, together with shorter term rodent 
studies investigating effects in mammary and prostate glands. The outcome of these reviews is 
summarised as follows.  
EU-RAR (2003 and/or 2008) 
The EU RAR concluded that BPA did not have carcinogenic potential, based on the available 
evidence at that time, including two oral carcinogenicity bioassays in rats and mice conducted by the 
NTP. 
NTP-CERHR (2008)  
The NTP-CERHR monograph reviewed the overall database on carcinogenicity of BPA, including a 
number of studies showing that perinatal exposure of rodents to low doses of BPA via the 
subcutaneous route caused proliferative changes in the mammary gland. The report concluded that 
while the findings were not sufficient to conclude that bisphenol A is a rodent mammary gland 
carcinogen or that bisphenol A presents a breast cancer hazard to humans, exposure of rats to BPA 
during gestation may lead to the development of mammary changes in adulthood that could 
potentially progress to tumours. NTP concluded that there was minimal concern for exposures of 
fetuses, infants, and children to BPA, based on the reported effects. NTP-CERHR also concluded that 
there was some concern that perinatal exposure to bisphenol A in rodents may alter prostate and 
urinary tract development, but that the evidence was not sufficient to conclude that bisphenol A is a 
rodent prostate gland carcinogen or that bisphenol A presents a prostate cancer hazard to humans.  
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EFSA (2006); EFSA CEF Panel (2010) 
In 2006, EFSA reported on several studies not reviewed in the EU RAR, examining the effect of BPA 
on tumour induction in experimental carcinogenicity systems. EFSA did not consider that the findings 
reported were indicative of a carcinogenic or a tumour-promoting potential of BPA. 
EFSA in its 2010 opinion reviewed a number of additional studies on proliferative changes in the 
mammary gland following administration of BPA and published subsequent to the NTP-CERHR 
monograph, notably those of Moral et al. (2008), Jenkins et al. (2009) and Betancourt et al. (2010) 
involving the oral route of administration. EFSA concluded that the data reported by these authors 
suggested that either lactational or in utero exposure to BPA may increase the susceptibility of the rat 
mammary gland to cancer induction by experimental carcinogens such as 7,12‑
dimethylbenz(a)anthracene (DMBA). EFSA noted that this could be linked to an enhanced cell 
proliferation/apoptosis ratio, as reported by the authors, and indicated that the effects deserved further 
consideration.  
FAO/WHO (2011) 
The FAO/WHO Expert Meeting concluded that “BPA has been studied in rodent carcinogenicity 
studies with dosing beginning in young adulthood. The studies, although suggestive of increases in 
certain tumour types, were considered not to provide convincing evidence of carcinogenicity. BPA 
exposure during the perinatal period has been reported to alter both prostate and mammary gland 
development in ways that may render these organs more susceptible to the development of neoplasia 
or preneoplastic conditions with subsequent exposures to strong tumour-initiating or tumour-
promoting regimens. In the absence of additional studies addressing identified deficiencies, there is 
currently insufficient evidence on which to judge the carcinogenic potential of BPA.” 
The Expert Meeting also reviewed the body of evidence demonstrating proliferative changes in the 
mammary gland and changes in the prostate gland following perinatal exposures to BPA and 
concluded that the studies had deficiencies in design or execution that prevented a definitive 
evaluation of BPA’s carcinogenic potential, including lack of consideration of litter effects, small 
numbers of animals, study duration and/or additional treatment with a strong initiating or additional 
promoting agent(s). The meeting concluded that there was currently insufficient evidence to judge the 
carcinogenic potential of BPA for the mammary gland, prostate or other organs. 
ANSES 2011, 2013 
In 2011, ANSES considered, in relation to the carcinogenicity of BPA in rodents, that there were 
“proven” effects of BPA on acceleration of structural maturation of the mammary glands in adult 
rodents associated with prenatal or perinatal exposure (Markey et al., 2001; Munoz-de-Toro et al., 
2005; Murray et al., 2007; Moral et al., 2008; Vandenberg et al., 2008); “proven” effects of BPA on 
the development of intraductal hyperplastic lesions in adult animals after pre- or perinatal exposure 
(Durando et al., 2007; Murray et al., 2007); “proven” effects of BPA on the development of 
intraductal hyperplastic lesions in adult animals after pre- or perinatal exposure (Durando et al., 2007; 
Murray et al., 2007); a suspected effect of BPA on the development of neoplastic lesions (intraductal 
carcinoma in situ) after perinatal exposure; a “suspected” effect of BPA on enhanced susceptibility of 
the mammary glands to tumour development later in life (after exposure to a known carcinogenic 
agent) due to pre- or perinatal exposure based on the studies by Jenkins et al. (2009) and Betancourt et 
al. (2010). 
Additionally, ANSES concluded that reported effects of BPA on the prostate in animals were 
“controversial”.  
In 2013, ANSES concluded that “the studies showing the development of neoplastic-type lesions 
(ductal carcinoma) or even an increase in the likelihood of mammary glands subsequently developing 
mammary tumours (during co-exposures to a carcinogenic agent) were to be considered for risk 
assessment. In particular, ANSES used the architectural changes of the mammary gland (Moral et al., 
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2008, oral NOAEL of 25 µg/kg bw per day in prenatally-exposed rats (by the oral route) and ductal 
hyperplasia (Murray et al., 2007; sc LOAEL of 2.5 µg/kg bw per day (no NOAEL could be identified) 
as points of departure for its risk assessment. 
3.9.2.2. Overview of specific animal studies on effects of BPA on cell proliferation and other 
endpoints considered relevant to carcinogenicity after oral or subcutaneous exposure to 
BPA, published before 2010 
The WoE approach that has been taken in the current opinion has necessitated the inclusion of a 
number of key/pivotal studies on the proliferative effects of BPA, particularly on the mammary gland, 
and effects on other endpoints considered relevant to carcinogenicity, already evaluated in the 
previous risk assessments summarised above. These include studies carried out using the oral route of 
exposure (e.g. Moral et al. 2008; Jenkins et al., 2009; Betancourt et al., 2010) and also studies using 
the subcutaneous route of exposure, that were not previously considered in the risk assessments 
carried out by EFSA in 2006 and 2010. These studies have been briefly summarised here and also 
included in the WoE tables presented in Appendix C. 
Proliferative changes in mammary gland 
In reviewing the Moral et al. (2008) study, EFSA CEF Panel (2010) noted that the effects of prenatal 
BPA exposure (25 and 250 µg/kg bw per day applied by gavage on days 10-21 post-conception) on 
mammary gland morphology, proliferation and modification of gene expression were investigated in 
Sprague-Dawley CD rats. The architectural modifications induced by the higher dose of BPA in 
mammary glands of female offspring were transient increases in the total number of epithelial 
structures (day 21 only), (terminal end buds (TEBs), terminal ducts (TDs), alveolar buds (Abs), and 
type 1 lobules (Lob 1) (days 21 and 100, but not at days 35 and 50) and lobule type 1 (day 35 only). 
The proliferative index in the epithelial structures was not affected by BPA treatments. Time- and 
dose-dependent modifications in gene expression profiles were observed after treatment with both 
doses of BPA: modulated (mainly up-regulated) genes related to cell proliferation, apoptosis and 
differentiation, cell communication, signal transduction, immunity, protein metabolism and 
modification.  
In a study examining the effect of lactational exposure to BPA on dimethylbenzanthracene (DMBA)-
induced mammary cancer in female offspring, Jenkins et al. (2009) gavaged nursing Sprague-Dawley 
rats with BPA (0, 25 or 250 μg/kg b.w./day) from lactation day 2 to 20. Increased cell proliferation 
and reduced apoptosis in the mammary gland of female offspring were observed at the high dose 
group at 50 days of age but not at 21 days of age. Consistent with increased proliferation and reduced 
apoptosis, the authors reported changes in expression of a number of proteins linked with apoptosis 
and also changes in progesterone receptor (PR)-A, steroid receptor activator (SRC) 1 to 3, and erbB3. 
The expression of oestrogen receptor (ER)-α was slightly reduced. At 50 days of age, one female 
offspring from each litter of each treatment group was given a single gavage dose of DMBA (30 
mg/kg). BPA-treatment increased the number of tumours (2.84 ± 0.31, 3.82 ± 0.43, and 5.00 ± 0.88 
for control, low and high BPA groups, respectively) with the effect at the high dose group being 
statistically significant. Tumour latency was also reduced (65, 53, 56.5 days for control, low and high 
BPA groups, respectively) with statistically significance at the high dose group. The CEF Panel noted 
however that the study had limitations, as documented in Appendix B.  
In the study by Betancourt et al. (2010), involving prenatal BPA exposure of female Sprague-Dawley 
rats to 0, 25 or 250 μg BPA/ kg bw per day, administered by gavage on GD 10-21, the high BPA dose 
(250 μg BPA/ kg bw per day, GD 10-21) was reported to enhance cell proliferation in mammary 
glands of the offspring (whereas apoptosis was not affected), associated with an increased cancer 
susceptibility and shift of the window for susceptibility for DMBA-induced tumourigenesis in rat 
mammary gland from PND50 to PND100. However, the study revealed similar shortcomings in 
design and reporting as the study by Jenkins et al. (2009), and the CEF Panel concluded at that time 
that these data cannot be taken into consideration for derivation of a TDI for BPA. 
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In relation to studies using the subcutaneous route (s.c.) of administration, EFSA (CEF Panel, 2010) 
had previously noted that “Studies using s.c. application of BPA also indicated that prenatal BPA 
exposure results in an increased cell proliferation/apoptosis ratio in normal tissue as well as 
preneoplastic lesions of rat mammary gland (Durando et al., 2007; Murray et al., 2007; Vandenberg 
et al., 2007; 2008).” The CEF Panel has re-evaluated these studies, and has included them in its WoE 
analysis in reaching a conclusion regarding possible proliferative effects of BPA in the mammary 
gland. Summaries of the design and findings of these studies are provided in Appendix B. 
Additionally, the CEF Panel noted the findings of a number of earlier s.c. studies ((Markey et al., 
2001, 2005; Munoz-de-Toro et al., 2005; Nikaido et al. 2004., 2005; Rubin et al., 2006) on the same 
endpoint, as summarised in Annex 2 of the EFSA opinion of 2006 (EFSA, 2006), and has similarly 
included them in its WoE analysis. 
3.9.2.3. Evaluation of recent animal studies related to potential carcinogenic or proliferative effects 
and/or morphological changes due to BPA 
This section provides an overview of the experimental animal studies relevant to the potential 
carcinogenic effects of BPA or effects on cell proliferation in certain organs that could be related to 
the development of cancer, published after 1st July 2010. A more detailed description and evaluation 
of each study is provided in Appendix B.  
Mammary gland 
Since the previous EFSA review (2010), further studies (Jones et al., 2010; Ayyanan et al., 2011; 
Jenkins et al., 2011; Weber Lozada and Keri, 2011; Kass et al., 2012; Tharp et al., 2012; Acevedo et 
al., 2013; Vandenberg et al., 2013c; US FDA/NCTR, 2013 and Delclos et al., 2014) have reported 
proliferative effects on mammary tissue and/or effects on mammary tumour growth following 
administration of BPA. These studies mainly employed pre- or perinatal administration, with the 
exception of the studies using transgenic mouse models by Jones et al. (2010) and Jenkins and 
colleagues (2011), in which dosing took place during postnatal/adult life. 
The study by Jones et al. (2010) used an adult knockout mouse model of mammary neoplasia that is 
believed to reproduce human susceptibility gene 1 (BRCA1*)-related breast cancer. The results 
indicated that exposure to a low dose of BPA (250 ng/kg bw per day) for 4 weeks using osmotic 
pumps increased mammary epithelial cell proliferation and hyperplasia in adult BRCA1* knockout 
mouse mammary glands compared with wild type mice exposed to vehicle (dimethyl sulphoxide) 
only. However, the CEF Panel noted that the phenotype of the transgenic mice is likely to involve 
morphological and histological changes, making it difficult to compare directly the effect of BPA 
between wild-type and adult Brca1 knockout mouse since the development stage of the mammary 
gland in the transgenic mouse may not be similar to that of an adult mouse. These in vivo results were 
complemented by in vitro mechanistic investigations in MCF-7 cells, supporting the hypothesis that 
loss of BRCA1* function in mammary cells can enhance BPA-induced cell proliferation via 
interference with the ERα signalling pathway.  
The study of Jenkins et al. (2011) examined the susceptibility of female transgenic MMTV-erbB2/neu 
mice to the development of mammary carcinomas after oral exposure to BPA at levels 0, 2.5, 25, 250 
or 2500 μg BPA/l in drinking water during adulthood (PND 56-252), estimated by the authors to be 
equivalent to 0, 0.5, 5, 50 and 500 μg BPA/kg bw per day. The aim of the study was to evaluate the 
effect of chronic administration of low doses of BPA to a strain of mice susceptible to mammary 
carcinoma. The treatment schedule was reported to result in a decreased tumour latency and increased 
tumour multiplicity, enhanced tumour volume and higher incidence of lung metastasis. These effects 
were observed at least in one of the two lower doses but not at levels of 250 or 2500 μg BPA/l 
drinking water. This was considered by the authors to be indicative of a non-monotonic dose-
response. Conversely, an increase was reported in the cell proliferation index of mammary epithelial 
cells evaluated on PND 112, statistically significant from a level of 25 µg BPA/l drinking water, but 
without any further increase at higher dose levels (i.e. 250 and 2500 μg BPA/l in drinking water). The 
mammary epithelial apoptotic index increased at higher doses and achieved a statistical significance 
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only at the top dose of 2500 μg BPA/l in drinking water (equivalent to 500 μg BPA/kg bw per day). 
According to the authors the cell proliferation-to-apoptosis ratio displayed a non-monotonic dose-
response curve that closely mimicked the tumourigenic response, although statistical analysis showed 
that only the BPA dose of 25 μg BPA/l in drinking water (equivalent to 5 µg /kg bw per day) 
produced a significantly greater cell proliferation-to-apoptosis ratio than in controls while the effects 
on mammary tumours (i.e. increase of tumour numbers per mouse, the reduction of tumour latency) 
were already statistically significant at a tenfold lower dose level.    
This study by Jenkins et al. (2011) in transgenic mice addressed similar toxicity endpoints to those 
previously evaluated by the same research group in the DMBA mammary tumour rat model after 
lactational (Jenkins et al., 2009) or prenatal (Betancourt et al., 2010) BPA exposure. These earlier 
findings were reviewed by the CEF Panel in 2010 (EFSA CEF Panel, 2010), and were then 
considered to deserve further consideration. In contrast to the 2011 study, the 2009 Jenkins study in 
the DMBA mammary tumour rat model summarised above did not show a non-monotonic dose-
response for any of the parameters tested. Many of the shortcomings that EFSA had noted in 2010 
concerning study design and reporting of the Jenkins et al. (2009) and Betancourt et al. (2010) studies 
(EFSA CEF Panel, 2010), also apply to the Jenkins et al. (2011) paper, as summarised in the 
comments of the CEF Panel to the more detailed summary of the study provided in Appendix B. The 
time of necropsy of individual animals was not clearly reported; they were only described to be at 252 
days of age or when tumour burden exceeded 10% of body weight. Additionally, there was no 
indication of animal randomisation, which the CEF Panel considered to be of particular importance 
when animals are derived from small transgenic colonies. The CEF Panel also noted that although 
BPA was administered in drinking water, the daily intake of water was only measured in preliminary 
studies and the daily exposure to BPA in the published study was therefore based on estimations.  
The study conducted by Weber Lozada and Keri (2011) used the DMBA mammary tumour mouse 
model to assess the effects of fetal exposure to BPA (via oral gavage of the dams at dose levels of 0, 
25 or 250 μg BPA/kg bw per day) on mammary tumour development in adults. A dose-response in 
the reduction in latency of mammary tumour development was observed in mice treated with BPA 
before birth. Reduced tumour latency after prenatal BPA exposure is in line with the findings of 
Jenkins et al. (2009), although the Jenkins study showed no dose-response relationship for this effect. 
The CEF Panel noted that no information was given on the tumour incidence, or on the number of 
animals that died of other causes than mammary cancer. There are also some concerns about 
methodological issues (incomplete histological evaluation, etc.). Moreover, the CEF Panel noted some 
uncertainties related to the histopathological examination of the induced tumours, which indicated that 
they were all squamous carcinomas and not the characteristic mammary adenocarcinomas found in 
this model. Overall, the CEF Panel considered that the work by Weber Lozada and Keri (2011) has 
limitations that hamper the clear interpretation of the data. 
Two other new rodent studies reviewed used complex protocols in which the morphology, cell 
proliferation and other characteristics of mammary tissue were studied in offspring of mothers treated 
with BPA (Ayyanan et al., 2011; Kass et al., 2012). The CEF Panel considered that the morphological 
endpoints examined in these studies have no clear link to the development of mammary cancer in 
adult rodents or humans, although they provide some support for the hypothesis that BPA causes 
proliferative changes in the mammary gland. However the complexity of these studies, the limited 
numbers of animals, the likely experimental and inter-animal variability as well as lack of any 
exposure data in these studies hamper the clear interpretation of the data. 
The study by Tharp and colleagues (2012) on BPA-related changes in the mammary gland of the 
monkey is notable as it studied mammary gland morphology in five control neonate rhesus monkeys 
and four neonates from mothers given orally 400 μg of BPA per kg of body weight daily from 
gestational day 100 to term. This regimen resulted in 0.68 ± 0.312 ng of unconjugated BPA per ml of 
maternal serum (range: 0.22–1.88 ng/ml), and 39.09 ± 15.71 ng/ml of conjugated BPA (range: 11.42–
94.82 ng/ml), as assessed in a toxicokinetic experiment using deuterated BPA. Morphometric analysis 
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of the mammary glands removed from female offspring at birth showed that there was a statistically 
significant difference between treated and controls in the number of buds/ductal mammary units per 
unit area. Although the CEF Panel acknowledged the value of a study in a primate model, it also 
noted that animal numbers and mammary gland sampling were limited (as expected for a study 
involving primates) and therefore possibly unrepresentative.  
Vandenberg et al. (2013c) concluded that BPA induces proliferative changes in the mammary gland 
of the male CD-1 mouse. BPA was given to pregnant and lactating mice at doses of 0, 0.25, 2.5, 25 or 
250 µg/bw per day via osmotic mini-pumps and mammary glands were examined at several time 
points (3-4, 7-9 and 12-16 months) in the adult offspring. The authors reported that the mammary 
glands of male offspring treated with BPA showed changes in ductal area and branching points 
compared with controls. The authors concluded that their results indicated a non-monotonic dose-
response to BPA, since at 3-4 months animals exposed to 0.25 or 2.5 showed more advanced 
mammary gland development than the controls, but animals receiving 25 or 250 µg/bw per day were 
statistically indistinguishable from controls. Similar effects were seen at later time periods, but the 
pattern of dose-responses changed to monotonic dose curves at 12-16 months. A NOAEL was not 
identified. The CEF Panel noted that the study used few animals per group and limited sampling for 
measurement of the mammary gland development, while this phenomenon demonstrated considerable 
individual variability. Furthermore, the conclusions of the authors were based on slight, but 
statistically significant differences between the groups (for morphological measurements), with 
considerable individual variability in the measured effects as reflected in large standard errors around 
the mean (SEM). In some cases where no visible mammary gland was seen, another sample was 
collected from a litter mate, which the CEF Panel considered as inappropriate. 
In a recent study that examined proliferative changes and development of neoplasia in the mammary 
glands of rats, BPA (0; 0.25; 2.5 or 250 μg/kg bw per day) was administered prenatally only (GD 9 – 
GD 23) or both pre- and perinatally (GD 9 – PND 21) to Sprague Dawley rats via subcutaneously-
implanted osmotic pumps (Acevedo et al., 2013). Mammary gland tissue was collected at PND 50, 
PND 90, PND 140 and PND 200 for histopathological evaluation of proliferative and neoplastic 
changes. Levels of total and unconjugated BPA were measured in the sera of dams, fetuses and 
nursing pups. Mean unconjugated internal dose levels of BPA of 1.25 mg/ml serum were reported in 
dams at the highest dose applied compared to no detectable levels in the controls. No statistically 
significant increase in the mean unconjugated serum levels was observed in fetuses after gestational 
exposure and pups after gestational and lactational exposure with the highest dose of BPA. At PND50 
atypical ductal hyperplasia (ADH) was reported in a varying number of BPA-treated animals in all 
treatment groups (n=5 per group, incidence ranging from 0-60%) without a dose-effect relationship. 
Incidence of ADH was highest at the lowest BPA dose (0.25 μg/kg bw per day) after gestational 
exposure, whereas the same dose group exposed during gestation and lactation did not develop ADH. 
One animal (out of five) had a ductal carcinoma in situ (DCIS) at PND 50. ADH was also evident at 
PND 90, 140 or 200 following gestational or gestational + lactational exposure (n=23-35) and isolated 
mammary adenocarcinomas were observed in most groups, except in controls. One adenocarcinoma 
was observed at PND90 in the 2.5BPA group. However, the incidences of proliferative lesions and 
tumours were not statistically significantly increased in treated animals compared with controls. On 
the basis of these results, the authors concluded that BPA can act as a complete mammary gland 
carcinogen in the rat. The CEF Panel did not agree with this conclusion, noting that a small number of 
rats per group were examined at PND50; that the mean free BPA serum levels in fetuses were not 
significantly increased and those of pups were not detectable (<LOD) even at the highest BPA dose 
given; that overall the incidence of mammary lesions and mammary tumours was low, and data for 
the historical incidence of these lesions was not provided.   
The US National Center for Toxicological Research (US FDA/NCTR) has recently completed a 
subchronic (90-day) toxicity study, conducted under the auspices of the NTP, involving pre- and post-
natal administration of BPA to Sprague Dawley rats (US FDA/NCTR, 2013 and Delclos et al., 2014). 
The study was conducted as a range-finding study for a planned chronic toxicity/carcinogenicity 
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study. At the time of release of the EFSA draft opinion on BPA for consultation, the latter study has 
been started, but is in the very early phases and no results from the study will be available until 2016. 
As indicated in the report of the study, “The major focus of the study was on reproductive tract 
development, and the rationale for concerns regarding potential effects on the prostate and mammary 
gland have been discussed thoroughly in the NTP Brief on BPA (Shelby, 2008); however, evaluation 
of other endpoints were included, including those related to cardiovascular toxicity and obesity.” The 
F1 rats were exposed throughout development in utero (from gestation day 6 up to parturition) and 
pups were directly dosed by gavage from PND 1 up to PND 90±5. Exposure of the mothers was 
stopped after PND 0. BPA doses of 2.5; 8; 25; 80; 260; 860 and 2 700 μg/kg bw per day were 
considered “low dose BPA” and the 100,000 and 300,000 μg/kg bw per day groups were considered 
“high dose BPA”. Vehicle (0.3% carboxymethylcellulose) and naïve control groups were included as 
well as two doses (0.5 and 5.0 μg/kg bw per day) of ethinyl oestradiol (EE2) as an oestrogen reference 
control. Additional groups were exposed from GD 6 to PND 21 for histopathological examination of 
the mammary glands. As is typical for NTP-sponsored studies, all pathological observations were 
subjected to extensive quality control procedures, including a re-reading of slides by a second internal 
pathologist, followed by a second set of review by outside pathologists, and finally a Pathology 
Working Group was convened during which consensus was reached on all diagnoses prior to release 
of the Final Pathology Report.   
Mammary gland duct hyperplasia of minimal severity was reported in the female groups examined at 
PND 21. The incidence of hyperplastic lesions was statistically significant by at least one of the three 
statistical methods used when compared with the vehicle control group in the 2 700 and 100 000 
μg/kg bw per day groups, but not in the 300 000 μg/kg bw per day group. This observation was 
considered possibly treatment-related by the study authors but not by the original study pathologist. 
Mammary gland duct hyperplasia was also reported in the high dose female BPA groups examined at 
PND 90. Using the Poly-k test, the increase in minimal severity mammary gland duct hyperplasia was 
statistically significant in the 300 000 μg/kg bw per day group compared with vehicle controls. A 
significant increase in incidence of mammary gland duct hyperplasia compared with vehicle control 
was seen in the 2 700, 100 000 and 300 000 μg/kg bw per day groups when analysis was carried out 
using the JT/SW or RTE statistical tests. Both of these tests incorporate lesion severity, but only the 
RTE method does not explicitly assume a monotonic dose-response curve (CFSAN, 2013). This 
increase was considered as a possible treatment-related effect by the study authors. BPA did not cause 
duct hyperplasia in the mammary glands of male rats, while conversely the reference oestrogen EE2 
induced hyperplasia in the male but not the female mammary gland. A single mammary gland ductal 
adenocarcinoma (1 out of 260 female rats in the entire study) was seen in the 2.5 µg BPA/kg bw per 
day dose group at PND 90.   
The CEF Panel concluded that the observation of mammary hyperplasia in female rats in this study, 
albeit of minimal severity, was relevant for the risk assessment of BPA, given the findings in other 
studies reported above.  
Prostate gland effects 
EFSA CEF Panel (2010) had previously noted work linking BPA to trans-generational and 
developmental epigenetic changes in rodents, including aberrant expression of growth regulatory 
genes in rat prostate. In the one relevant study reviewed in the current opinion (Prins et al., 2011), the 
Sprague-Dawley rat model of prostate neoplasia was used to study the effects of dosing 10μg/kg bw 
BPA orally or subcutaneously on post-natal days 1, 3 and 5 on the development of prostate cancer in 
rats subsequently given both testosterone and ooestradiol-17β for 16 weeks from postnatal day 90 to 
drive prostatic intra-epithelial neoplasia (PIN) lesions in the prostate. Whilst microscopic evaluation 
suggested that BPA increased the incidence of prostate intraepithelial neoplasia, and (atypical) 
hyperplasia, the histopathology was confounded by the presence of prostatic inflammation. Moreover, 
the degree of cytological pleomorphism (atypia) reported in this study was insufficient to confirm the 
presence of intraepithelial neoplasia.   
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Effects in testes 
In a study in which pregnant and lactating Long-Evans rats were given BPA via gavage from 
gestational day 12 to postpartum day 21, Leydig cell division was stimulated in the prepubertal period 
and increased Leydig cell numbers were shown in the testes of adult male rats at 90 days (Nanjappa et 
al., 2012). The CEF Panel noted that rats are quantitatively far more sensitive to the development of 
Leydig cell tumours than men, since Leydig cell luteinizing hormone releasing hormone 
(gonadotropin-releasing hormone) receptors are unique to rats and also have over 10 times more 
luteinizing hormone receptors than men (Cook et al., 1999). 
Effects on liver 
In the study from Weinhouse et al (2014) mice (10 males and 10 females/group) were treated 
perinatally through maternal diets with 0, 50 ng, 50 ug or 50 mg BPA/kg diet (corresponding to 0, 10 
ng, 10 ug or 10 mg BPA/kg bw per day (calculation based on dam wt) up to weaning (PND 22). Pups 
were maintained on standard phytoestrogen-free control diet for 10 months.  
In the females of the top dose the incidence of combined adenomas and carcinomas with or without 
preneoplastic lesions was significantly increased, but no significant effect was seen in males.  
Liver tumours were also seen in male control mice. Moreover, historical incidence of liver adenomas 
and carcinomas in female was not reported for the isogenic mice.  
3.9.2.4. Summary of the evidence for carcinogenicity, effects on cell proliferation and 
morphological changes induced by BPA in animals 
In their 2010 EFSA opinion, the CEF Panel concluded that the studies then available suggested 
possible enhanced susceptibility to mammary tumours in rodents exposed to BPA during 
development, which deserved further attention. These conclusions were based mainly on the review of 
the studies by Jenkins et al. (2009) and Betancourt et al. (2010) in the rat model of DMBA-induced 
mammary carcinogenesis after either lactational or in utero BPA exposure. The CEF Panel considered 
at that time that these studies had several shortcomings that precluded their use for the derivation of a 
new TDI, and the data had unclear relevance for human health. 
Since then, a number of laboratory animal studies have been reported to show effects on mammary 
tissue (mammary tumour induction, enhancement of mammary tumour growth and/or proliferative 
changes in mammary gland) after prenatal, perinatal and adult exposure to BPA. In relation to 
possible carcinogenic effects of BPA in animals when exposed postnatally/during their adult life, the 
CEF Panel noted that while the study of Jenkins et al. (2011) showed an increased susceptibility of 
adult female transgenic MMTV-erbB2 mice to the development of mammary carcinomas after oral 
exposure to BPA, the study had a number of deficiencies as discussed above, and the result is at 
variance with the lack of any tumorigenic effect in female mice in the 2 year NTP study at high BPA 
doses. The relevance of the findings in this sensitive transgenic mouse model is also uncertain. The 
observation that BPA induces prostatic “intraepithelial neoplasia” in the prostate of rats exposed in the 
immediate postnatal period (Prins et al. 2011) is also of uncertain relevance given the background 
inflammatory changes occurring in the animals and judged deficiencies in the histopathological 
examination. Overall the CEF Panel concluded that these studies do not provide convincing evidence 
that BPA is carcinogenic in animals when exposed postnatally/during their adult life. 
In relation to possible carcinogenic effects of BPA in animals when exposed prenatally, several 
studies including the new study of Weber Lozada and Keri (2011), and the earlier studies of Jenkins et 
al. (2009) and Betancourt (2010) used the DMBA mammary tumour mouse model to assess the 
effects of fetal exposure to BPA on mammary tumour development in adults. The authors reported an 
increased susceptibility to developments of mammary cancer, decreased tumour latency and increased 
tumour multiplicity. The study of Acevedo et al. (2013) reported proliferative changes and 
development of neoplasia within a relatively short time period (up to PND 200) in the mammary 
glands of rats exposed to BPA prenatally or both pre- and perinatally. In contrast the study of 
Ayyanan et al. (2011) did not demonstrate an increased incidence of mammary tumours following 
exposure to BPA over a 1-year period. Overall, however, the CEF Panel concluded that based on the 
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WoE evaluation and the experimental deficiencies in the studies, the findings in these studies do not 
provide convincing evidence that BPA is carcinogenic in animals when exposed pre- or perinatally.    
The other new studies (Jones et al., 2010; Kass et al., 2012; Vandenberg et al., 2013c) examined the 
effects of BPA exposure on mammary gland proliferation in rodents as a possible indicator of 
potential tumourigenesis in this organ. One study (Tharp et al., 2012) reported advancement of 
developmental parameters in the mammary gland of rhesus monkeys, with increased epithelial density 
of terminal endbuds. The US FDA/NCTR subchronic toxicity study provided some evidence of a 
BPA-related effect in the mammary gland of female rats.  
Overall, the CEF Panel concluded that although there were methodological weaknesses in all these 
studies with the exception of the US FDA/NCTR subchronic toxicity study, which was a detailed 
guideline study conducted in accordance with GLP, taken together they provide further evidence that 
BPA may enhance mammary epithelial proliferation in animal models. 
3.9.3. In vitro studies related to carcinogenesis/cell proliferation 
None of the new publications on in vitro-effects of BPA include experimental models for the 
screening of carcinogens, e.g. cell transformation assays. The reported findings rather support recent 
evidence of BPA-mediated induction of cell proliferation and inhibition of apoptotic pathways. A 
reduction of rapamycin- or tamoxifen-induced apoptosis was observed in non-malignant human breast 
epithelial cells at low nanomolar BPA concentrations along with BPA-induced transcriptional changes 
(e.g. increased expression of total and phosphorylated AKT1, down-regulation of p53) which are 
related to the induction of cell growth and are resembling those changes observed in carcinogenic 
progression (Goodson et al., 2011; Dairkee et al., 2013). In a human epithelial breast cell line (HBL-
100) proliferation was induced at 10-10 M BPA (Wu et al., 2012). Increased proliferation was also 
observed in cell cultures of normal human mammary epithelial cells treated with a high nanomolar 
BPA concentration (10-7 M) and changes in DNA methylation associated with tumor development 
(e.g. CDKN2A hypermethylation) were reported at 10-8 M BPA in these cells (Qin et al., 2012a).  
The in vitro studies in mammary epithelial cells suggest that BPA at nanomolar concentrations can 
modulate proliferation-associated signalling pathways. Whilst these changes may also be crucial for 
tumorigenesis, the in vitro findings do not allow for a clear interpretation of the complex 
concentration- and time-dependent pattern of the molecular changes in vivo and thus the relevance of 
in vitro models using artificial culture conditions (e.g. hormone or oxygen concentrations) to the in 
vivo situation is still unclear. In human epithelial ovarian cancer cells (BG-1) BPA (10-9 M – 10-7 M) 
induced growth and the expression of the stromal cell derived factor-1 (CXCL12) (Hall et al., 2012). 
Both the BPA induction of growth and that of CXCL12 were inhibited by the ER antagonist ICI 
182,780 or by transfection of cells with CXCL12 siRNAs indicating that the ER-CXCL12-CXCR4 
signalling pathway is important for the BPA effects in these cells. In breast cancer cells and cancer-
associated fibroblasts, BPA (at 10-7 M and higher) induced proliferation and migration via a G 
protein-coupled receptor pathway (GPR30/GPER) (Pupo et al., 2012). Other in vitro studies using 
human breast (Jung et al., 2011; Lee et al., 2012b; Zhang et al., 2011; Tilghman et al., 2012) and 
ovarian (Hwang et al., 2011) cancer cells reported effects only at high concentrations of BPA (at 10-7 
M and above)) which are out of the inclusion criteria (see Appendix A). 
3.9.4. WoE of the possible carcinogenicity of BPA in humans and animals and its potential to 
cause proliferative changes or advancement of developmental parameters in tissues 
Whether BPA induces and/or promotes carcinogenicity in organs such as mammary gland, prostate 
gland or testis, or causes proliferative changes or advancement of developmental parameters in these 
organs or in vitro that could potentially be linked to development of cancer was considered using a 
tabular format for weighting different lines of evidence (WoE evaluation). The outcome of the WoE 
evaluation of BPA genotoxicity is also included, given the relevance of genotoxicity in the evaluation 
of the possible carcinogenicity of BPA. The overall outcome of this WoE evaluation is presented 
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below, while the WoE evaluation tables for these endpoints are presented in full in Appendix C. For 
interpretation of these tables refer to Appendices A and C. 
Table 14:  Overall table on WoE evaluation of genotoxicity, carcinogenicity and cell 




Overall conclusion on in vivo genotoxicity studies – via non-thresholded mechanism: 
BPA has not been shown to be clastogenic in vivo (micronuclei and chromosomal aberrations). 
Unlikely 
 
Overall conclusion on in vivo genotoxicity studies - via thresholded mechanism: 
The potential of BPA to produce aneuploidy in vitro was not expressed in vivo, based on 
negative findings obtained for induction of aneuploidy in female and male mouse germ cells 
(Pacchierotti et al., 2008) and for induction of micronuclei in somatic bone marrow cells 
(Masuda et al., 2005; Pacchierotti et al., 2008; Naik  and Vijayalaxmi , 2009; De Flora et al., 
2011). However, BPA proved to induce dose-related increases of c-like metaphases in mouse 
bone-marrow cells (Naik  and Vijayalaxmi , 2009) and significant increases in the number of 
metaphase II oocytes with prematurely separated chromatids (Pacchierotti et al., 2008) pointing 
to potential mitotic spindle disrupting effects of BPA in vivo. 




Overall conclusion on carcinogenicity of BPA in humans: The very few epidemiological 
studies published to date, investigating a possible association between exposure to BPA and 
incidence of certain cancers, specifically breast cancer (Yang et al., 2009) and meningioma 
(Duan et al., 2012), do not allow any conclusion to be drawn regarding the carcinogenicity of 
BPA in humans.  
Insufficient 
data for 
application of  
WoE 
approach 
Overall conclusion on carcinogenicity of BPA in animals when exposed during their adult 
life (post-pubertal) only: Effects on mammary gland growth demonstrated in a transgenic 
mouse model with post-pubertal exposure (Jenkins et al., 2011) or on reported prostatic 
“intraepithelial neoplasia” in rats exposed to BPA in the immediate postnatal period (Prins et 
al., 2011) do not provide convincing evidence that BPA is carcinogenic in animals when 
exposed postnatally/during their adult life. 





Overall conclusion on the carcinogenicity of BPA in animals exposed during pre- and 
post-natal (during lactation) development: Recent studies (Jenkins et al., 2009, Betancourt 
et al., 2010; Weber Lozada and Keri, 2011; Acevedo et al, 2013) investigated the potential 
carcinogenic effects of fetal or perinatal exposure to BPA. Given the various weaknesses 
identified in these studies, they do not provide convincing evidence that BPA is carcinogenic in 
animals when exposed during pre- and post-natal (during lactation) development. 





Overall conclusion on proliferative changes of BPA in animals when exposed postnatally/ 
during their adult life: Both Jones et al (2010) and Jenkins (2011) reported an effect on 
mammary gland proliferation in sensitive transgenic or gene knock-out models as well as wild-
type mice (Jones et al. only) given BPA during adulthood, although proliferative effects in 
these mouse models are inconsistent with the lack of any proliferative effect on mammary 
tissue in mice in the two year NTP carcinogenicity study. However, the CEF Panel concluded 
overall that there is some indication that BPA can cause proliferative changes in the mammary 
gland of genetically modified animals when exposed postnatally/in adult life. 
The CEF Panel considered that evidence for proliferative changes induced by BPA in other 
organs (i.e. prostate) is currently too weak to reach a conclusion. 
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3.9.5. Conclusion on carcinogenicity of BPA and proliferative/morphological changes in 
tissues induced by BPA based on evidence from human, animal and in vitro studies 
In summary, BPA is not mutagenic (in bacteria or mammalian cells), or clastogenic (micronuclei and 
chromosomal aberrations). The potential of BPA to produce aneuploidy in vitro was not expressed in 
vivo. The positive finding  in the postlabelling assays in vitro and in vivo is unlikely to be of concern, 
given the lack of mutagenicity and clastogenicity of BPA in vitro and in vivo. 
The CEF Panel concluded that very few epidemiological studies published to date have investigated a 
possible association between exposure to BPA and incidence of certain cancers, specifically breast 
cancer and meningioma. These studies do not allow any conclusion to be drawn regarding the 
carcinogenicity of BPA in humans.  
BPA was not carcinogenic in two standard oral cancer bioassays in rats and mice exposed (from 6-8 
weeks of age) for 2 years. New results do not provide convincing evidence that BPA is carcinogenic 
in animals when exposed during their adult life or when exposed perinatally. 
Using a WoE approach, the CEF Panel assigned a likelihood level of “unlikely to - as likely as not -” 
to carcinogenic effects of BPA. Since the likelihood level for this endpoint is less than “as likely as 
not” (see  Appendix A), this endpoint was not taken into account in the evaluation of uncertainty for 
hazard characterisation and risk characterisation. 
Earlier evidence for BPA effects on cell proliferation and differentiation in the mammary gland and 
other tissues has been supported by recent studies, e.g. a subchronic rat study with prenatal exposure 
to BPA. The proliferative changes in the mammary gland reported in these new studies, including a 
non-human primate study, are insufficient to conclude that there is a link to cancer development in 
later life. However, there might be a possible role of BPA in increasing the susceptibility to mammary 
gland carcinogenesis.  
The proliferative responses and possibly enhanced sensitivity to mammary gland carcinogens seen in 
animal studies might be of relevance for human health and are therefore included in the risk 
assessment. An ongoing long-term study on BPA in rats13, including in utero exposure, may help to 
clarify whether these proliferative changes or changes in differentiation result in an increased 
incidence of tumours in this species. 
                                                     
13 13 See at: http://ntp.niehs.nih.gov/testing/status/agents/ts-10034-y.html 
CELL PROLIFERATION 
Overall conclusion on BPA- induced proliferative changes/ developmental advancement 
in the mammary gland of animals exposed during pre- and/or post-natal (during 
lactation) development or up to PND 90 (gavage):  
The EFSA opinion of 2010 noted potential proliferative effects of fetal or perinatal exposure to 
BPA. Since 2010 additional studies including a study in non-human primates (Ayyanan et al., 
2011, Tharp, 2012, Vandenberg, 2013c, Acevedo, 2013, US FDA/NCTR, 2013 and Delclos et 
al., 2014) have also suggested that BPA can have proliferative effects on mammary tissues and 
strengthen the evidence for an effect of BPA on mammary gland proliferation in animals 
exposed during pre- and post-natal development.  
 
The CEF Panel considered that evidence for proliferative changes induced by BPA in other 
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Using a WoE approach, the CEF Panel assigned a likelihood level of “likely” to BPA induced 
proliferative changes in the mammary gland. Therefore, this endpoint was brought forward for hazard 
characterisation and for uncertainty analysis (Section 4.3).  
The CEF Panel considered that the evidence for proliferative changes induced by BPA in other organs 
(e.g. prostate or testis) is currently too limited to reach a conclusion. 
3.9.6. Hazard characterisation (dose-response relationship) for effects of BPA on the 
mammary gland of animals 
The above analysis indicates, based on a WoE approach, that while there is no convincing evidence 
that BPA is carcinogenic in animals when exposed as adults or during pre- and post-natal (during 
lactation) development, a number of the animal studies reviewed above suggest that BPA can have a 
proliferative/developmental advancement effect on mammary tissue, prostate epithelium and Leydig 
cells and may also have an effect on tumour growth in animal models, particularly in sensitive 
transgenic models or when followed by a treatment with a complete carcinogen. Effects in many of 
these studies are seen at dose levels well below the current NOAEL of 5 mg/kg bw per day BPA, 
although in the recent robust study of US FDA/NTCR (2013) and Delcos et al. (2014), proliferative 
changes were primarily seen at the high dose levels of BPA (100 000 and 300 000 µg/kg bw per day). 
On the basis of the WoE analysis as summarised in table 14 and described in more detail in Appendix 
C, the proliferative effect of BPA on the mammary gland is considered to be a “likely” effect and is 
taken forward for risk characterisation (see Section 5), given the consistency of the effect in a number 
of studies. The proliferative effects reported in the prostate and the testis in several studies were not 
taken forward for hazard/risk characterisation as the CEF Panel considered that the evidence for such 
effects was currently too weak to be used in risk assessment.  
A prerequisite for the risk characterisation step is hazard characterisation, involving examination of a 
possible dose-response relationship for the effect under consideration and identification of a dose 
level at which the effect is not anticipated to occur (NOAEL) or a dose level at which the incidence of 
the effect is considered to be low (LOAEL or BMDL). The CEF Panel has considered the evidence 
for a dose-response relationship for mammary gland proliferation in the studies showing such an 
effect and reviewed in this opinion (Markey et al., 2001; Munoz-de-Toro et al., 2005, Durando et al., 
2007; Murray et al., 2007; Vandenberg et al., 2007; 2008; Moral et al., 2008; Jenkins et al, 2009; 
Betancourt et al., 2010; Jones et al., 2010; Ayyanan et al., 2011; Jenkins et al. 2011; Tharp et al., 
2012; Acevedo et al., 2013; US FDA/NCTR, 2013 and Delclos et al., 2014; Vandenberg et al., 
2013c). Many of these studies showed effects at low doses of BPA, but some of them were single 
dose studies while other studies with multiple doses showed increases in proliferation without a clear 
dose-relationship. Several of the studies (e.g. Markey et al., 2001; Murray et al., 2007; Ayyanan et al. 
2011; Vandenberg et al., 2013c) were reported to show a non-monotonic dose-response curve for 
proliferation (Section 4.3). The CEF Panel considered the effects nonetheless supportive of a BPA-
induced effect on the mammary gland. As shown in table 15 the lowest doses (LOAELs) at which the 
proliferative effects on the mammary gland were reported ranged from 25 ng BPA/kg bw per day 
(Munoz-de-Toro et al., 2005) to 2.7 mg/kg bw per day (US FDA/NCTR, 2013 and Delclos et al., 
2014).  
Table 15:  BPA-induced  proliferative changes  in the mammary gland of various species  
Study Administration, animal species LOAEL/NOAEL 
Acevedo et al., 
2013 
0, 0.25, 2.5, 25 and 250 μg BPA/kg bw per 
day subcutaneously from GD9 to GD23 to 
Sprague Dawley rats 
Atypical ductal hyperplasia (ADH) was 
reported in a few animals in all treatment 
groups without reaching statistical 
significance 
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Study Administration, animal species LOAEL/NOAEL 
Ayyanan et al., 
2011  
 
2.5 µg/L to 5000 µg/L, 0.6, 3, 6, 12, 120, 
600 and 1200 µg BPA/kg bw per day in 
drinking water of C57Bl/6 mice.  
NOAEL for mammary cell number 3 µg 
BPA/kg bw per day, but this was a non-
monotonic LOAEL for increase in 
terminal end buds.  
Betancourt et al., 
2010 
 
0, 25 or 250 μg BPA/ kg bw per day (GD 
10-21) to Sprague-Dawley CD rats rat, cell 
proliferation and gene expression measured 
in high dose and controls only 
Cell proliferation as measured by Ki-67 
expression significantly increased 
compared with control at 250 ug/kg b.w. 
per day, but 25 ug/kg bw dose not 
examined.  
Durando et al., 
2007 
25 μg BPA/kg bw per day administered sc 
by mini-pump from from GD 8 to GD 23 in 
Wistar rats. 
LOAEL 25 μg BPA/kg bw per day.  
US FDA/NCTR, 
2013 and Delclos 
et al., 2014 
2.5, 8, 25, 80, 260, 840, 2700, 100 000, 
300 000 µg BPA/kg bw per day by gavage 
to F0 female Sprague-Dawley rats from GD 
6 up to labour onset and pups from PND 1 
until tissue harvesting, up to PND 90 
LOAEL for ductal hyperplasia 2,700 
µg/kg bw 
Jenkins et al., 2009 
 
0, 25 or 250 μg BPA/kg bw per day by 
gavage to nursing Sprague-Dawley rats from 
lactation day 2 to 20 
Cell proliferation as measured by Ki-67 
expression significantly increased 
compared with control at 250 ug/kg b.w. 
per day, but 25 ug/kg bw dose not 
examined.  
Jenkins et al., 2011 
  
0, 2.5, 25, 250, 2500 μg BPA/L given in 
drinking water to young adult female 
MMTV-erbB2 mice (PND 56-252), 
estimated to be 0, 0.5, 5, 50 and 500 μg 
BPA/kg bw per day. 
Ratio of cell proliferation index to 
apoptotic index was significantly 
increased at the 5 µg BPA/kg bw per day 
dose level only.  
Jones et al., 2010 
  
0.25 μg BPA/kg bw per day for 4 weeks 
using osmotic pumps in adult BRCA* 
knockout mice compared to wild type mice 
Increased epithelial cell proliferation at 
0.25 μg BPA/kg b.w./day 
Markey et al., 2001 
 
0, 25 and 250 ng BPA/kg bw per day 
administered sc by mini-pump to CD-1 mice 
from GD 9 through postnatal day 4. 
LOAEL 25 µg BPA/kg bw per day; No 
dose-response, the reported effect being 
slightly greater at 25 µg BPA/kg bw per 
day 
Moral et al., 2008 25 and 250 ug BPA/kg bw per day 
administered to Sprague-Dawley rats from 
day 10 post-conception to delivery.   




25 and 250 ng BPA/kg bw per day 
administered sc by mini-pump to 
ovarectomised and intact CD-1 mice from 
day 9 of pregnancy through postnatal day 4.  
LOAEL 25 ng BPA/kg bw per day 
Murray et al., 2007 2.5, 25, 250 and 1000 μg BPA/kg bw per 
day administered sc by mini-pump from GD 
9 until postnatal day (PND) 1 in Wistar-
Furth rats.  
LOAEL 2.5 μg BPA/kg bw per day 
Tharp et al., 2012  
 
Rhesus monkeys given orally 400 μg of 
BPA per kg of body weight daily from 
gestational day 100 to term. 
LOAEL 400 μg/kg bw per day.   
Vandenberg et al., 
2007, 2008 
250 ng BPA/kg bw per day administered sc 
by mini-pump from GD 9 to day 18 in CD-1 
mice   
LOAEL 250 ng BPA/kg bw per day.  
Vandenberg et al., 
2013c 
0, 0.25, 2.5, 25 and 250 μg BPA/kg bw per 
day subcutaneously from day 9 of pregnancy 
for 14 days until day 16 of lactation in male 
CD-1 mice  
LOAEL 25 µg/kg bw 
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The CEF Panel considered that none of these studies was sufficiently robust methodologically or 
showed a consistent dose-response to be used as the basis of a revised TDI. In particular the CEF 
Panel noted that the results of the two studies carried out by Nikaido et al. (Nikaido et al., 2004, 2005) 
reported on scores for tissue differentiation. The CEF Panel concluded however that the studies cited 
could be used in the WoE approach to support the conclusion that it is “likely” that pre- and postnatal 
(during lactation) exposure to BPA results in proliferative changes in the female mammary gland in 
animal models, including the Tharp et al. (2012) study in rhesus monkeys, a species that is considered 
to have particular relevance for human health risk assessment (Tab. 14, Appendix C). 
The 2013 US FDA/NCTR subchronic toxicity study, involving prenatal exposure of adequate 
numbers of rats to a very wide range of BPA doses was considered by the CEF Panel to be a detailed 
and methodologically robust study, conducted in accordance with GLP that could be used on its own 
for risk assessment purposes. The CEF Panel noted, however, that the design of the study involved 
two high dose levels of BPA (100 mg/kg bw per day and 300 mg/kg bw per day) and seven “low” 
dose levels, ranging from 2.5 to 2700 μg/kg bw per day, together with a vehicle and a naïve control, 
with a very wide spacing between the high and low dose ranges. The CEF Panel noted also that the 
study was a range-finding study for a subsequent chronic toxicity/carcinogenicity study, and that it 
was not designed for the purpose of establishing a health-based guidance value. 
Nevertheless, the CEF Panel considered that the study provided some evidence for a BPA-related 
effect in the mammary gland of female rats at 100 000 and 300 000 μg/kg bw per day, and possibly 
also at the 2 700 μg/kg bw per day dose level (at PND 21). The table below shows the dose-response 
for these data. The CEF Panel also noted that results of hormone analyses in the high dose BPA 
female rats showed that oestradiol and prolactin levels were significantly higher than vehicle controls, 
effects that could possibly be linked to the mammary gland proliferation seen in these animals.    
Table 16:  Dose-response information for mammary duct hyperplasia in BPA exposed rats (data 
from FDA/NCTR, 2013; Delclos et al, 2014) 
Dose µg/kg bw  
per day 
Summary data on incidence of 
mammary duct hyperplasia in female 
rats at PND 21 (US FDA/NCTR, 2013 and 
Delclos et al., 2014) 
Summary data on incidence of 
mammary duct hyperplasia in female 
rats at PND 90 (US FDA/NCTR, 2013 and 
Delclos et al., 2014) 
Incidence Group size Incidence Group size 
0.0 0 16 7 20 
2.5 2 19 11 23 
8 1 13 6 18 
25 4 19 11 21 
80 1 20 8 20 
260 1 13 8 20 
840 2 18 9 20 
2 700 5 (p < 0.05) 17 11 20 
100 000 6 (p < 0.01) 17 13 20 
300 000 3 12 14 19 (p < 0.01) 
Note: results were not significant compared to vehicle control (poly-k test) except where stated 
The data shown in table 16 were therefore subjected to statistical dose-response modelling in an 
attempt to calculate the BMDL for mammary duct hyperplasia. The report in Appendix V shows the 
outcome of this modelling. Following detailed analysis of the results, the CEF Panel concluded that 
the data could not be used to provide such a BMDL, since the outcome of modelling contained 
considerable uncertainty, shown by relative large differences in the BMDLs calculated from the 
different models, and a wide confidence interval (more than 10 fold difference between the BMD and 
BMDL) for some models (see Section 4). 
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3.9.7. Conclusions on hazard characterisation for effects on the mammary gland in animal 
models 
While the CEF Panel concludes that this endpoint should be considered in the risk assessment of BPA 
since it has been concluded that it is “likely” that prenatal exposure to BPA results in effects on the 
female mammary gland in animal models, the CEF Panel considered that none of these studies were 
sufficiently robust methodologically or showed a consistent dose-response that could be used to 
compare with the current TDI or as the basis of a revised TDI. 
3.10. Mechanisms of action of BPA including epigenetic effects 
3.10.1. Summary of previous reviews on endocrine-mediated action of BPA 
Numerous in vitro and in vivo studies have investigated the mechanisms of action of BPA and have 
been reviewed on a number of occasions (e.g. EFSA, 2006; EFSA CEF Panel, 2010; FAO/WHO, 
2011). Many effects induced by BPA appear to be tissue-, sex- and concentration-specific. For several 
BPA-induced effects “windows of exposure” have been reported. Due to the complexity of BPA´s 
interaction with different hormone receptors and signalling pathways it is challenging to establish 
which specific endocrine mechanism triggers a certain in vivo effect of BPA. As an additional mode 
of action of BPA epigenetic effects have been reported, i.e. changes in DNA methylation, histone 
modification and miRNA expression patterns. Overviews of mechanistic studies aimed at identifying 
the mode of action of BPA have been included in a number of previous evaluations of BPA and are 
summarised as follows. 
EU-RAR (2003, 2008) 
The EU-RAR noted that BPA has oestrogenic activity in vitro and in vivo, its activity being generally 
3-5 orders of magnitude less than that of 17β-oestradiol, and that there was also limited evidence for 
anti-androgenic activity and stimulation of progesterone activity, as well as an increase in prolactin 
release. 
EFSA (2006); EFSA CEF Panel (2010) 
In 2006, the EFSA AFC Panel described several studies showing altered gene expression in target 
organs for BPA, in particular in oestrogen-responsive genes, and also discussed the weak 
oestrogenicity of BPA (and its higher binding affinity for the beta oestrogen receptor as compared to 
the alpha receptor) along with the weak antagonism to thyroid hormone receptors and the weak 
interference with different steps in androgen receptor function in vitro. The AFC Panel noted that the 
in vitro observations in specific cellular systems had an unclear relevance for the risk assessment of 
adverse in vivo effects of BPA. 
In its 2010 opinion, the EFSA CEF Panel considered that effects induced by low BPA concentrations 
(<5 mg/kg bw per day) may be independent of the classical hormone receptor pathway and may be 
alternatively induced by cell membrane-triggered signalling pathway via protein kinases. No 
conclusion could be reached on the implications of the observed biochemical and molecular changes 
and their potential impact on human health. 
In its 2010 opinion EFSA also noted that according to several study reports BPA has been “linked to 
transgenerational and developmental epigenetic changes” in different rodent tissues, e.g. mammary 
glands, prostate, forebrain and reproductive tract. BPA-induced epigenetic alterations were associated 
with histopathological changes in rat prostate (Ho et al., 2006) and functional criteria such as RNA 
and protein expression, and cell turnover in rat prostate and the reproductive tract in mice (Ho et al., 
2006; Bromer et al., 2010). EFSA noted at this time that “a conclusion cannot be reached on the 
implications of the observed biochemical and molecular changes and to establish whether they have 
any impact on human health.” 
NTP-CERHR (2008)  
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The NTP-CERHR monograph noted that a growing number of cellular targets for BPA have been 
identified, including non-nuclear oestrogen receptors such as ncmER, oestrogen-related receptor 
gamma ERR-γ and GPR30, and also the aryl hydrocarbon receptor (AhR). NTP-CERHR noted that 
these receptor interactions “may help explain toxicological effects that are not considered oestrogenic 
or predicted simply based on the lower potency of bisphenol A compared to estradiol.”  
FAO/WHO (2011) 
The FAO/WHO Expert Meeting report includes an extensive review of the biological activities of 
BPA. The report concluded that “available data show that BPA’s biochemical and molecular 
interactions are complex, involving classic estrogen receptors as well as a variety of other receptor 
systems and molecular targets.” The FAO/WHO experts concluded in their review that BPA may 
exert pleiotropic cellular responses and tissue-type specific effects and that at cellular and intracellular 
levels BPA could exhibit non-monotonic dose-responses. At half-maximal activity concentration 
(AC50) values below 10 µmol/l three main gene targets were mentioned, i.e. the oestrogen receptor 1 
(ESR1, also referred to as oestrogen receptor alpha), xenobiotic sensing and metabolizing CYP 
enzymes and genes involved in the down-regulation of inflammatory responses. At higher AC50 
values in excess of 100 µmol/l indications of cell toxicity were generally observed. It was concluded 
that dose-response analyses may be useful to identify the involvement of multiple receptor/signalling 
pathways. 
While noting the oestrogenic activity of BPA, the meeting considered that it should not be considered 
to act only as an estrogen, or even as a selective estrogen receptor modulator (SERM), and concluded 
that “The complexity of BPA’s interactions and concentration ranges at which the observations have 
been made make it challenging to conclude whether a given in vivo finding is biologically plausible 
based on consistency and potency of a response compared with estrogens alone.” The FAO/WHO 
Expert Meeting additionally concluded that “exposure to BPA in utero …has been shown to affect the 
methylation status and expression of several differentially methylated promoters, raising the 
possibility that BPA also acts through mechanisms resulting in alteration of CpG methylation.” 
ANSES (2011; 2013) 
In line with other evaluations, ANSES (2011) reported that in addition to its oestrogenic activity, BPA 
interacts with other cell receptors, including androgen, thyroid hormone and aromatic hydrocarbon 
receptors, the transmembrane oestrogen and GPR30 receptors and can induce expression of the 
nuclear peroxisome proliferation-activated receptor PPARγ. ANSES concluded that “an 
interpretation of the effects of BPA only from the angle of an oestrogeno-mimetic effect would be 
simplistic. The involvement of several of these systems during an exposure to BPA could explain 
certain effects observed at low doses, owing to a possible synergy of action, but also the non-
monotonic dose-response relationships reported in certain studies.” 
3.10.2. Evaluation of recent mechanistic studies relevant to an understanding of the mode or 
modes of action of BPA 
This section provides an overview of a number of in vitro mechanistic studies published after 1st July 
2010 that contribute to the further identification and understanding of the mode or modes of action of 
BPA and hence are relevant to the asssessment of its risks for humans, also in light of the CEF Panel’s 
previous evaluation of BPA in 2010 (EFSA CEF Panel, 2010).  
A more detailed description and evaluation of each study is provided separately in Appendix B. 
An overview on the interaction of BPA with classical ERs and other receptors is given in the 
Background Paper on mechanisms of action of BPA prepared for the FAO/WHO Meeting 2010 by 
Thayer and Belcher (2010). In a recent study by Li et al. (2012b) the cell type-specific BPA-induced 
activation of cell signalling via ERα and ERβ was investigated using three different human cell lines, 
i.e. HeLa cells (cervix epitheloid carcinoma, HepG2 cells (hepatocellular carcinoma) and Ishikawa 
cells (endometrial adenocarcinoma). In the nanomolar range (10-9 M and 10-8 M) BPA increased the 
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ERα activity only in HeLa cells while higher BPA concentrations were needed to induce the ERα 
acitivity in the other two cell lines or the ERβ activity in HeLa cells. Both BPA concentrations 
inhibited the E2-mediated activity via the ERα in Ishikawa cells but not in HeLa cells. Using also two 
other oestrogenic compounds, i.e. a fluorinated BPA and the mycotoxin zearalenone, the authors 
observed compound-specific dose-response curves via both ERs.  
Using transfected Vero (African green monkey kidney) cells Sun and coworkers (2012) reported a 
significant activation of the ERα at and above 4.4x 10-7 M BPA and a significant anti-androgenic or 
anti-thyroidal activity only at 10-fold higher concentrations, confirming the weaker interference of 
BPA with the latter receptors. While studies on the stimulation of growth at high concentrations of 
BPA (>10-7 M) in breast cancer cells (e.g. Lee et al. 2012b) and at lower concentrations (10-12 M and 
above) in spermatogonial GC-1 cells (Sheng and Zhu, 2011) suggest that BPA´s proliferative effect is 
more closely related to ERα than to ERβ, other studies on the contractile effects of BPA (10-9 M) in 
isolated myocytes (Belcher et al., 2012) or on the function of β-cells and islets of Langerhans 
(Soriano et al., 2012) were apparently mediated via the ERβ. A study by Tanabe et al. (2012) 
indicates that BPA´s effect on spinogenesis may be at least partly mediated via the ERγ. In ERα 
expressing cells growth stimulation by BPA (10-9 M) may be associated with the activation of cGMP-
dependent protein kinase PKG and EGFR-ERK pathways (Sheng and Zhu, 2011) while in cells 
lacking the classical oestrogen receptors an induction of ERK1/2 phosphorylation was only observed 
at high BPA concentrations (>10-7 M) (Pupo et al., 2012). Li and coworkers (2012) proposed, based 
on their findings in HepG2 cells, that the p44/42 MAPK activation by BPA is ERα dependent and the 
src pathway is involved in rapid action of BPA. An additional pathway, i.e. the mammalian target of 
rapamycin (mTOR), was studied in human breast epithelial cells treated with BPA (10-10 M to 10-7 M) 
along with a reduction of the tamoxifen- and rapamycin-induced apoptosis (Goodson et al., 2011). 
Based on gene expression experiments in various cell types the EFSA CEF Panel, 2010 opinion 
concluded that particularly at lower BPA concentrations (in the nanomolar range) the BPA-induced 
changes “did not correlate to the estrogenic effects of BPA”. Similarly the Thayer and Belcher 
describe in the FAO/WHO Background Paper (2010) a limited number of “overlapping” expressed 
genes after BPA and E2/EE treatment, indicating substance-specific responsiveness of gene 
expression to oestrogenic substances. This conclusion is further confimed by a study on gene 
expression in human foreskin fibroblasts derived from young patients affected by hypospadia (Qin et 
al., 2012b). The authors report that only a small subset of BPA (10-8 M)-induced genes was also 
affected by E2. Peretz and coworkers (2012) reported that BPA-induced growth inhibition and follicle 
atresia in mouse antral follicles were not inhibited by the ER antagonist ICI 182,780 or increased by 
ER-overexpressing follicles and they therefore concluded that the BPA effects were not mediated via 
the genomic oestrogen signalling pathway.  
For the evaluation of the impact of potential oestrogen-independent signalling pathways in the action 
of BPA, the CEF Panel considered that it may be useful to consider also dose-response analyses. Two 
recent in vitro studies indicate the involvement of PPARγ activation in 3T3-L1 cells after treatment 
with 20 µM BPA (Taxvig et al, 2012) and an increased PPARγ expression in BPA (10-8 M - 8x 10-5 
M)-treated adipose tissue of children (Wang et al., 2013). The CEF Panel noted that the relevance of 
these observations at high BPA concentrations for risk assessment is questionable. 
In several cell models an increased production of reactive oxygen species (ROS) and/or a 
hyperpolarisation of mitochondrial membranes were observed at BPA concentrations in the 
nanomolar range. Huc et al. (2012) reported on an induction of mitochondrial ROS production by 
BPA (10-12 M to 10-4 M) in HepG2 cells with a maximum at 10-9 M after a 72 hour treatment. In rat 
insulinoma cells (immortalized pancreatic cell line) an increase in early apoptotic cells was observed 
at and above 2x10-8 M BPA (48 h) along with a reduction of the mitochondrial mass, disturbed 
mitochondrial membrane potential, increased cytochrome c release and a reduced ATP concentration. 
Western blot analysis of Bax and Bcl-2 expression suggested that apoptosis is mediated via caspase-
dependent mitochondrial pathway (Lin et al., 2013). Song et al. (2012) reported on a BPA-induced 
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decrease in islet viability (>1.1x10-8 M) primary rat pancreatic islet cells and toxic effects on 
mitochondria at 1.1x10-7 M BPA (swollen morphology and a loss of structural integrity) along with a 
reduction of the cytosolic ATP content. 
3.10.3. Epigenetic effects of BPA 
Epigenetic effects of BPA were examined in studies using the Agouti mouse model with pre-
gestational, gestational and lactational BPA exposure (Dolinoy et al., 2007; Anderson et al. 2012). In 
the Agouti mouse model epigenetic changes are correlated with changes in the Agouti gene 
expression which cause a wide variation in coat color ranging from yellow (unmethylated) to brown 
(methylated) and which may also induce other effects including obesity, diabetes and tumorigenesis. 
Maternal BPA exposure resulted in a dose-dependent shift in coat color distribution by decreasing 
methylation at specific CpG sites in the Avy allele. The methylation status found in tail tissue 
correlated with that in liver, kidney and brain of the same individuals, suggesting that BPA-induced 
epigenetic alterations occur in embryonic stem cells. Notably, these BPA-effects could be antagonised 
by supply of methyl-donors via the feed, providing functional support to biochemical data. However, 
in a recent study by Rosenfeld et al. (2013) exposure of Avy/a conceptuses to BPA and genistein 
through maternal diet did not cause any consistent shift in offspring coat color relative to controls. A 
number of different experimental and analytical differences limit the ability to compare the  Rosenfeld 
et al. 2013 study to previous available studies using Agouti mouse model (Dolinoy et al. 2007 and 
Anderson et al. 2012): mainly a different coat color categorization associated with a different 
statistical analysis and  the use of multiparity where the dam age could impair  the evaluation of the 
BPA treatment effect. The CEF Panel noted, that for the time being, the non-consistent results 
concerning BPA-effects on coat color distribution in the Agouti mouse model cannot be explained but 
require further research.As to the human relevance of the agouti gene mutation Avy (viable yellow; 
having an intracisternal A particle (IAP) inserted in the PS1A region), which is the most commonly 
employed in epigenetic studies, it should be emphasised that no comparable retroviral insert is present 
in the human genome and therefore, effects identified in these mice might not translate to humans 
(Rosenfeld, 2010). However, despite these limitations, the CEF Panel concluded that the current data 
on the Agouti mouse model should not be neglected but considered as an indication that BPA in 
principle has the potential to alter the epigenome.   
In different rodent models the subcutaneous or intraperitoneal route of BPA administration were used. 
Ho et al (2006) analysed the prostate upon neonatal BPA exposure (10 µg/kg bw, subcutaneously) and 
provided evidence that BPA can cause epigenetic alterations of genes involved in signal-transduction, 
e.g. a continously enhanced expression of PDE4D4, which may be associated with an increased 
susceptibility to prostate cancer with aging. Notably, this alteration became manifest before 
histopathological changes in the prostate. Using the same experimental model for investigating the 
prostatic epigenome, Tang et al. (2012) reported hypomethylation of the nucleosome binding protein-
1 (Nsbp1)-promoter whereas the physiological, age-related demethylation of Hippocalcin-like 1 
(Hpcal1) was blocked by neonatal BPA exposure. Further evidence suggesting epigenetic effects of 
BPA was provided by Bromer et al. (2010) reporting Hoxa10-hypomethylation (along with a weak 
increase in RNA-expression) in the uterus of offspring upon maternal exposure (5 mg BPA/kg, 
intraperitoneal). Doherty et al. (2010) reported an increased mammary histone H3 trimethylation in 
mice exposed to BPA (maternal dose: 5 mg BPA/kg, i.p. on gestation day 9-26), associated with an 
increased expression of EZH2 protein. A recent study on behavioural effects of low BPA doses (2, 20, 
200 µg/kg bw/ day in utero) in mice showed that BPA affected also DNA methyltransferase 
expression (Dnmt1 and Dnmt3a), DNA methylation of ERα (Esr1 exon A)  and gene expression of 
ERs including Esr1 in a dose-dependent (mainly non-monotonic way), brain region-specific and sex-
specific manner in juvenile offspring (Kundakovic et al., 2013). Surprisingly, reduction of Esr1 
expression correlated with hypomethylation of Esr1 in the hypothalamus of female mice, while it was 
associated with hypermethylation in the male prefrontal cortex. This may indicate that additional 
factors (e.g. local histone modifications or levels of transcription factors as suggested by the authors) 
may contribute to the specific Esr1 expression. The DNA methylation status of this gene was further 
affected by age (neonatal vs. adult hypothalamus) and maternal care which masked some of the BPA-
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induced methylation effects. Overall, these data support the hypothesis that BPA may affect the 
epigenome in several tissues however the results may be critically dependent on the study design and 
further unknown cellular factors. 
The in vivo observations suggesting that BPA cause epigenetic alterations are supported by results 
from cell cultures studies with human cancer cells (Avissar-Whiting et al., 2010; Doherty et al., 2010; 
Weng et al., 2010; Qin et al., 2012a) and rodent cell lines (Ho et al., 2006; Tang et al., 2012). DNA 
methylation levels of genes related to development of most or all tumor types, such as BRCA1, 
CCNA1, CDKN2A (p16), THBS1, TNFRS F10C and TNFRS F10D, were increased in BPA-exposed 
HMEC. Avissar-Whiting et al. (2010) investigated the effect of BPA (0.25 to 25 ng/μl of BPA for six 
days (medium refreshed on day 2 and 4) on microRNAs (miRNAs) in human placental cells. 
Microarray analysis revealed several miRNAs to be significantly altered in response to BPA treatment 
in two cell lines (3A and HR-8). Real-time PCR results confirmed that miR-146a was particularly 
strongly induced and its overexpression in cells led to slower proliferation as well as higher sensitivity 
to the DNA damaging agent, bleomycin. BPA-induced epigenetic changes were also studied in breast 
epithelial cells using mammospheres as a model (Weng et al., 2010). The mammospheres were treated 
with low-dose BPA (4x10-9 M); as a result of exposure to BPA, for instance, the expression of 
lysosomal-associated membrane protein 3 (LAMP3) became epigenetically silenced in breast 
epithelial cells. 
3.10.4. Conclusions on mechanistic studies with BPA including epigenetic effects 
Mechanistic studies published since 2010 continue to support the conclusion that BPA affects a 
number of receptor-dependent and independent signalling pathways, resulting in effects on hormone 
homeostasis and gene expression as well as cytogenetic and epigenetic effects.  
The CEF Panel confirmed its conclusion (EFSA CEF Panel, 2010), that no single clearly defined 
mode of action of BPA can be identified that can contribute substantially to the understanding of the 
potential effects of BPA in humans. However, given that BPA appears to have multiple modes of 
action at the cellular level, and at least some of these MoAs involve cellular responses that are highly 
conserved across species (e.g. binding to oestrogen or androgen receptors), the relevance for humans 
of the variety of effects that have been reported for BPA in mechanistic studies cannot be totally 
discounted. On the other hand, many studies show effects at concentrations that are inappropriately 
high compared with human exposures. They cannot therefore be used in risk assessment. Also, 
whether these in vitro mechanistic studies have in vivo relevance is unclear. 
4. Hazard characterisation: health-based guidance value 
4.1. Critical endpoints  
Section 3 provides a re-evaluation of the potential health hazards of BPA, taking into account the 
scientific literature 2010 – 2012, (see Appendix A)  published since the last evaluation of this 
chemical by EFSA (EFSA CEF Panel, 2010) and also the comprehensive reviews carried out by risk 
assessment bodies worldwide (SCF, 2002; EU-RAR, 2003, 2008; EFSA, 2006, 2008; AIST, 2007, 
2011; NTP-CERHR, 2007, 2008; Health Canada, 2008; EFSA CEF Panel 2010; US FDA, 2010a; 
ANSES, 2011, 2013; FAO/WHO, 2011). Reflecting the key endpoints identified in those reviews, the 
hazard identification phase for BPA included evaluation of the following:    
• General toxicity 
• Reproductive and developmental effects   
• Neurological, neurodevelopmental and neuroendocrine effects 
• Effects on the immune system 
• Cardiovascular effects 
• Metabolic effects  
• Genotoxicity 
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• Carcinogenicity, effects on the mammary gland and cell proliferative effects 
 
The health-based guidance value (TDI) for BPA established by EFSA in 2006 and reconfirmed in 
2008 and 2010  is based on general toxicity in two multi-generation reproductive toxicity studies in 
rodents, in which the critical effects were changes in body and organ weights in adult and offspring 
rats and liver and kidney effects in adult mice, respectively (Tyl et al., 2002; 2008). The TDI of 50 
µg/kg bw per day was derived by application of an uncertainty factor of 100 to the NOAEL of 5 
mg/kg bw per day identified in both studies. In the current re-evaluation, the CEF Panel has 
considered whether any of the studies in the recent scientific literature challenge the validity of this 
TDI and/or provide an alternative basis for derivation of a new TDI. 
The possibility that exposure to BPA is linked to one or more of the effects listed above, following 
pre- and/or postnatal exposure, was evaluated in the current opinion following consideration of the 
results of studies in vitro, in experimental animals and in humans (Section 3). The critical 
toxicological effects (at least "likely effects") for BPA were identified using a WoE approach. 
The CEF Panel considered that the “likely” effects indicative of general toxicity in rats and mice that 
were already described in the EFSA CEF Panel, 2010 opinion should be maintained as a critical 
endpoint for risk assessment of BPA. Additionally the CEF Panel concluded that BPA-induced effects 
on the mammary gland of rats, mice or monkeys exposed pre- or perinatally were “likely” effects”. 
The conclusion on mammary gland effects resulted from the CEF Panel’s evaluation of new evidence 
published since EFSA’s previous risk assessment in 2010 and earlier studies using the subcutaneous 
route of administration (not considered in the EFSA CEF Panel, 2010 opinion). Sections 3.2.5 and 
3.9.6 describe the hazard characterisation step for these two “likely” endpoints, providing an analysis 
of the dose-response relationship and identification of a reference point for the purposes of deriving a 
health-based guidance value.  
The CEF Panel also considered that recent scientific literature has provided additional indications 
(compared with its 2010 evaluation) of reproductive and developmental effects at doses of BPA 
below the NOAEL for general toxicity, and also neurological/ neurodevelopmental/ neuroendocrine, 
immune-modulatory and metabolic effects, as described in Section 3. In light of the methodological 
shortcomings identified in the evaluated studies, the CEF Panel considered that none of these effects 
could be considered as “likely”, following application of a WoE approach. The uncertainty evaluation 
of these effects is described in Section 4.3 below.  
4.2. Outcome of hazard characterisation and derivation of a point of departure for general 
toxicity 
As indicated in sections 3.2.5 and 3.9.6, the CEF Panel has carried out dose-response modelling on 
the data for general toxicity (Tyl et al., 2002, 2008) and proliferative changes in the mammary gland 
(mammary gland duct hyperplasia) (US FDA/NCTR, 2013 and Delclos et al., 2014), following the 
guidance of the Opinion of the EFSA Scientific Committee on the use of the Benchmark Dose (BMD) 
approach in Risk Assessment (EFSA Scientific Committee 2011). Since the public consultation, the 
individual data from Tyl et al. 2008 have become available, and new BMD calculations on the 
changes in organ weights were performed based on individual data. The outcomes of these analyses 
are shown in table 7 in sections 3.2.5 and in more detail in Appendix E.   
The CEF Panel conducted a detailed analysis of the results on proliferative changes in the mammary 
gland reported in the subchronic (90-day) toxicity study involving pre- and post-natal administration 
of BPA to Sprague Dawley rats (US FDA/NCTR, 2013 and Delclos et al., 2014). The analysis 
revealed large differences in the BMD estimates obtained with the various models and the wide BMD 
confidence intervals, obtained with some of the models (Appendix E). The CEF Panel concluded that 
the dose-response relationship in the US FDA/NCTR study (2013) and Delclos et al. (2014) is not 
suitable to derive with any confidence a reference point for this endpoint.  Instead, the CEF Panel 
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considered this and other studies together when taking account of the possibility of mammary gland 
effects in the uncertainty evaluation below (see Section 4.3).  
The kidney weight changes in the mouse (Tyl et al., 2008) showed a good dose-response relationship, 
and consistent results were obtained when sex and generation (F0 and F1) were used as covariates. 
The CEF Panel noted that the modelling for BPA-related kidney weight changes in the mouse (Tyl et 
al., 2008) gave a lower BMDL than for the liver effects in the rat (Tyl et al., 2002). The consistent 
BPA-related increase in kidney weight in this species accompanied by nephropathy at the highest 
dose (Tyl et al., 2008) is considered adverse. Considering that fluctuations in the body weight 
influence organ weights, and that there was greater consistency in the dose-response relationship 
between sexes and generations in the relative kidney weight, the CEF Panel decided to use relative 
rather than absolute kidney weights to derive a reference point. A BMDL10 of 8 960 µg/kg bw per day 
was calculated, based on a 10% increase in the mean relative kidney weight in male mice of the F0 
generation (see Section 3.2.5). This BMDL10 will be used as reference point for the risk assessment. 
After the publication of the 2010 opinion new toxicokinetic data have become available which allow a 
more accurate substance-specific extrapolation of data from animals to humans, using the human-
equivalent dose (HED) approach (see Section 3.1.5 for explanation) and the human-equivalent dose 
factor (HEDF) of 0.068 for oral exposure of adult mice. As explained in Section 3.1.5, the HED is 
defined by a common relationship between the external dose given to an animal and the resultant 
AUC and the external dose given to a human and its AUC. The HED derived from the BMDL10 of 
8 960 µg/kg bw per day is 609 µg/kg bw per day. The CEF Panel decided to use the HED value of 
609 µg/kg bw per day as the reference point for derivation of a health-based guidance value for BPA 
(table 17). 
Table 17:  Outcome of the BMD analysis for effects of BPA on mean relative kidney weight in 















    BMD10 BMDL10 BMDU10  
Tyl et al., 
2008 
Mice (F0) males, 











35 100 – 
36 000 8 960 108 900 609 
** Derived by multiplication of the BMDL10 by  the HEDF of 0.068 for oral exposure of adult mice.  
4.3. Uncertainty in hazard characterisation of other endpoints 
4.3.1. Method for assessing uncertainty 
For the reasons outlined in section 3.2.6, the CEF Panel used the HED of the BMDL for increased  
relative kidney weight in mice as the reference point for establishing a TDI. In setting the TDI, the 
CEF Panel assessed whether an extra factor (besides the uncertainty factors to account for inter- and 
intra-species differences) should be included to account for the uncertainty in the database concerning 
the mammary gland, and the reproductive, neurobehavioural, immune and metabolic systems. 
According to the outcome of the WoE evaluation, an association between BPA and these hazards was 
considered “as likely as not”– with the exception of proliferative changes in mammary gland and 
immunotoxicity, which were respectively assessed as “likely” and from “-as likely as not- to likely”. 
The  CEF Panel considered that the uncertainty about these effects contributes to uncertainty in the 
hazard characterisation for BPA. For each effect a specific set of endpoints and criteria were used for 
inclusion of animal studies in the uncertainty analysis which were as follows:   
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• Proliferative changes in the mammary gland: all studies – both before and after 2010, 
addressing effects on ductal hyperplasia (including terminal end buds and ductal area), 
intraductal hyperplasia and epithelial cell proliferation. 
• Reproductive and developmental toxicity: all publications (new and pre-2010 studies) 
addressing effects on endometrial hyperplasia, ovarian cysts and anogenital distance (AGD) 
at levels below the HED of 3.6 mg/kg bw per day. These endpoints were selected because 
other evaluations regarded these as critical endpoints. 
• Neurobehavioural effects: all studies published after 2010 which contribute more than 
negligibly to the WoE. 
• Immunotoxicity: all animal studies published after 2010. 
• Metabolic effects: all publications addressing effects on glucose and insulin published after 
2010, for which parameters there were clearly indications of effects in in vitro studies. 
The WoE evaluation (Appendix C) allowed an estimation of the overall likelihood that BPA is 
hazardous with respect to certain toxicological endpoints in animal studies, considering the findings 
for all of the dose levels tested (with the exception of reproductive effects for which a cut-off dose 
level was taken as a study inclusion criterion). However, to assess whether an extra UF (and its 
magnitude) in the health-based guidance value would be appropriate to account for uncertainties in 
the database, the following were considered: (i) the likelihood that BPA exposure is associated with a 
certain outcome in animals at particular dose intervals (and especially at doses below the HED for the 
increase in relative mean kidney weight), (ii) the relevance of this effect to humans and (iii) its 
adversity in humans, if it occurs.  
The CEF Panel approached the evaluation of uncertainty in three stages. In the first stage, it carried 
out the following steps for each of the selected types of effect in turn, to assess the likelihood that 
BPA might affect a certain endpoint in animals at each dose interval. 
• The experts reviewed the studies previously considered in the WoE assessment (see bulleted 
list above). 
• The experts extracted key information from each study and collated this in a graphical format 
(Section 4.3.2). The graphs summarise, for each study, the life stage of the animals at 
treatment onset, duration of treatment and sampling time for measurements, the doses tested, 
whether there was a statistically significant effect at any dose. They also show the number 
of strengths and weaknesses of the study, as assessed in the WoE assessment but 
excluding any strengths or weaknesses that did not apply to the effect of interest. In 
addition, they show the CEF Panel’s evaluation of the reliability of the study and its 
relevance to the effect of interest, taking into account all the preceding information. 
When assessing reliability and relevance, the strengths and weaknesses were not 
weighted equally but according to the CEF Panel’s evaluation of their relative 
importance. 
• In order to allow studies for different species using different routes of exposure to be plotted 
on the same dose scale, as well as on the same scale as the reference dose for the increase in 
relative kidney weight – all doses were converted to HED. 
In the next stage of the uncertainty evaluation, the experts met to assess the relevance of each effect to 
humans, and its adversity in humans, if it occurs.  
In the final stage the experts were asked to make judgements about the overall likelihood, in each 
HED dose interval, that BPA has the inherent ability to cause one or more types of effects in animals 
and that it is relevant and adverse in humans, based on the group summaries of the judgements that 
had been made in the earlier stages of the assessment (See Appendix D.III, for details).  
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4.3.2. Outcome of the uncertainty evaluation 
4.3.2.1. Uncertainty in the proliferative changes in mammary gland 
The uncertainties related to the induction of proliferative changes in the mammary gland following 
BPA administration, i.e. intraductal hyperplasia, epithelial cell proliferation and ductal hyperplasia 
(including increase in the number of TEBs), were evaluated taking into account the reliability of the 
study results.  
As shown in figure 10 below, three studies with subcutaneous, pre- or perinatal BPA exposure 
(Durando et al., 2007; Murray et al., 2007; Vandenberg et al., 2008) report on intraductal hyperplasia 
in the mammary gland (i.e. an increase in the relative number of ducts lined by three or more layers of 
epithelial cells), while in two other studies with perinatal BPA exposure (Acevedo et al., 2013; 
Delclos et al., 2014) no such lesions were detected. 
Whilst epithelial cell proliferation is a normal physiological process in certain life stages ( pre-
/perinatal period, pregnancy) and per se does not lead to tumour formation it is generally accepted that 
under certain pathological conditions such as recurrent tissue damage and repair the proliferating 
tissue becomes more susceptible to tumour development. In studies with rats treated with BPA and, 
thereafter, with a well known complete carcinogen (Jenkins et al., 2009; Betancourt et al., 2010) as 
well as in studies with transgenic mice (Jenkins et al. 2011; Jones et al., 2010) increased cell 
proliferation was reported along with tumour formation. In case of the study by Jenkins et al. (2011) – 
who observed cell proliferation in transgenic mice which spontaneously develop tumours – the 
relevance of these findings to whether proliferative changes occur at low BPA doses in normal 
animals was considered medium, taking into account the increased sensitivity of this mouse model to 
tumour development due to over-expression of erbB2. Increase in the number of  terminal end buds as 
well as ductal hyperplasia were reported in several studies even at very low BPA doses (e.g. Ayyanan 
et al., 2011). However, it should be noted that these putative preneoplastic lesions may be  reversible 
and will not in all cases progress to neoplasia. In addition the CEF Panel took into consideration the 
study reliability (e.g. data reporting, methology) which was considered for all studies on BPA-induced 
proliferative effects as low or medium. In the CEF Panel´s evaluation of the reported effects, a low 
study reliability would lead to a high uncertainty, e.g. in case of the low dose effects reported by 
Ayyannan (2011) and Jones (2010). Based on these considerations  and the lower relevance of 
transgenic mice studies, the CEF Panel considers the proliferative effects at a HED below 1 µg 
BPA/kg bw per day as “very unlikely” (VU). The statistical significant effects in the HED range 
between 1 and 100 µg/kg bw per day have to be balanced by the transient nature of the effects (e.g. 
Munoz-de-Toro et al., 2005; Vandenberg et al., 2008, 2013c) and many negative findings which led to 
an expert judgement of “unlikely to -as likely as not (U/ALAN). At a HED above 100 µg BPA/kg bw 
perday the majority of the studies showed statistically significant proliferative effects and therefore 
they were considered as “-as likely as not- to “likely” (ALAN/L) (Figure 10). 
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Figure 10:  Summary plot for the effects of BPA exposure on the proliferative changes in the 
mammary gland: Ductal hyperplasia (including TEBs), intraductal hyperplasia (relative 
number of ducts lined by three or more layers of stratified epithelial cells) and epithelial cell 
proliferation (proliferative index as measured by BrdU, Ki67or PCNA labelling). The left 
hand text indicates the exposure route (oral or subcutaneous, SC). The left hand pane shows 
the experimental design with the horizontal bars showing the timing and duration of exposure 
(while the up-arrows show when the measurements/assessments were made. The central pane 
shows the study results , based on the x-axis showing the human equivalent dose (HED) 
depending upon species, age and route of exposure. The lightly shaded boxes on the x-axis 
show the uncertainty assessment (very unlikely=VU, unlikely=U, as likely as not=ALAN, 
likely=L and combinations thereof). The central pane also shows the sex and species of the 
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animals under consideration (right hand-side of pane) and the nature of the symbols denotes 
critical information: open circles show no significant effect, red/shaded circles show 
significant increase and blue/shaded diamonds show significant decrease (see summaries of 
the studies in Appendix B for details). Numbers under the symbols either denote incidence 
(x/y) or samples size (n=x). The text in the right hand column shows information for each 
study (first author, year), the ratio of strengths/weaknesses of the study (taken from Appendix 
B), the reliability of the study (L=low, M=medium, H=high) and the relevance of the study to 
the biological variable and question being posed in the WoE assessment (L=low, M=medium, 
H=high) (see Appendix C). An asterisk by the study year indicates a study with a carcinogen 
treatment following BPA administration; an author´s name in blue italics indicates a study 
with transgenic mice.  
Relevance and adversity to humans for mammary gland proliferation 
Intraductal hyperplasia is observed in humans and is considered as a precursor of ductal carcinoma 
both in rodents and in humans. Therefore this lesion is of high relevance to predict cancer in the 
human and animal mammary gland and is considered as adverse.   
Ductal hyperplasia and  an increase of the number of TEBs may be regarded as supporting evidence 
for tumour formation along with an increase in the proliferation of epithelial cells. These effects in 
experimental animals are dependent on the study design (e.g. the type of the diet, the administration 
and doses of the substances, the exposure time, the sampling time point). The CEF Panel noted that 
ductal hyperplasia may not always progress to neoplastic lesions but may be reversible. Therefore, the 
relevance of these hyperplastic lesions –  in the absence of intraductal hyperplasia – is questionable 
for humans and the level of adversity of these findings is unknown.  
Increased epithelial cell proliferation in the mammary gland of rodents is linked to prolactin which is 
also associated with an increased breast cancer risk in women (Harvey, 2012). Thus, an increase in 
prolactin levels constitutes an underlying mechanism in the induction of cell proliferation which may 
be indicative and therefore relevant for tumour promotion in both the human and rodent mammary 
gland.   
4.3.2.2. Uncertainties in reprotoxicity 
As shown in Figure 11 below, four studies are included in the assessment of endometrial hyperplasia 
and ovarian cysts. Declos et al. (2014) and Newbold et al. (2009) found no significant effect of BPA 
on the incidence of endometrial hyperplasia at doses ≤3.6 mg/kg bw per day HED while Signorile et 
al. (2010) and Newbold et al. (2007) reported significant increases in the incidences of endometrial 
hyperplasia. The Newbold et al. (2009) study also reported an increase in incidence of ovarian cysts at 
a single dose of BPA with a P-value of 0.05 (marginal significance). Signorile et al. (2010) and 
Newbold et al. (2007) were the weakest of the four studies, with more weaknesses than strengths and 
used the fewest number of doses, with the smallest dose range of BPA. The CEF Panel also noted that 
the duration of BPA exposure in Newbold et al. (2007) was extremely short. 
Six studies are included in the assessment of AGD. Four studies found no significant effect of BPA on 
AGD (de Catanzaro et al., 2013; Delclos et al., 2014; Ferguson et al., 2012; LaRocca et al., 2011). 
However, of the significant effects reported at BPA ≤3.6 mg/kg bw per day HED, only the 
Christianen et al. (2014) reported a clear adverse effect: reduced AGD in male rats. Both Kobayashi et 
al. (2012) and Christiansen et al. (2014) reported a similar significant decline in AGD in females and 
in Kobayashi et al. (2012) the effect was no longer seen in the second, older, age group.  
Taken together these studies show some contradictory and variable results with only Christiansen et 
al. (2014) showing any dose-response relationship although very slight. Taking the WoE overall, 
combined with the uncertainty evaluation process the CEF Panel concluded that up to 1 mg/kg bw per 
day HED (covering doses ≤3.6 mg/kg bw per day HED), the likelihood of BPA inducing negative 
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effects ranged from very unlikely-unlikely to very unlikely-as likely as not. Above 1 mg/kg bw per 
day the likelihood that BPA had an adverse effect climbed to very unlikely-likely and then likely-very 
likely (see Figure 11). The latter conclusion agrees with the opinion of the CEF Panel that at doses 
>3.6 mg/kg bw per day BPA is more likely to have adverse effects on reproductive development and 
function. 
 
Figure 11:  Summary plot for the effects of BPA exposure on the reproductive system: (a) 
endometrial hyperplasia and (b) ovarian cysts. The plot also shows the effect of BPA on (c) 
anogenital distance (AGD) as a read-out of androgen action in-utero/perinatally. The left hand 
text indicates the exposure route (oral or subcutaneous, SC). The left hand pane shows the 
experimental design with the horizontal bars showing the timing and duration of exposure 
(black bar: exposed as adults or during gestation and/or lactation) while the up-arrows show 
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when the measurements/assessments were made. The central pane shows the study results, 
based on the x-axis showing the human equivalent dose (HED) depending upon species, age 
and route of exposure. The down-arrow on the x-axis shows the HED equivalent (3,600 µg 
BPA/kg body weight/day) of the 5.0 mg BPA/kg body weight/day oral exposure NOAEL 
(Tyl et al., 2002).  The lightly shaded boxes on the x-axis show the uncertainty assessment 
(very unlikely=VU, unlikely=U, as likely as not=ALAN, likely=L, very likely=VL and 
combinations thereof). The central pane also shows the sex and species of the animals under 
consideration (right hand-side of pane) and the nature of the symbols denotes critical 
information: open circles show no significant effect, red/shaded circles show significant 
increase and blue/shaded diamonds show significant decrease (see summaries of the studies in 
Appendix B for details). Numbers under the symbols either denote incidence (x/y) or samples 
size (n=x). The text in the right hand column shows information for each study (first author, 
year), the ratio of strengths/weakness of the study (taken from Appendix B), the reliability of 
the study (L=low, M=medium, H=high) and the relevance of the study to the biological 
variable and question being posed in the WoE assessment (L=low, M=medium, H=high) (see 
Appendix C). In the case of Newbold et al., 2009, (b) ovarian cysts, the * denotes a p value of 
p=0.05 rather than significance of p<0.05. 
Relevance and adversity to humans for developmental and reprotoxic effects 
Abnormal endometrial hyperplasia has the same fundamental physiological basis both in women and 
in female animals, including those that do not have a menstrual cycle. Furthermore, abnormal 
endometrial hyperplasia is a common gynaecological condition in women and is also a recognised 
precursor for endometrial carcinoma. Therefore, animal models for endometrial hyperplasia are 
relevant to human health and the occurrence of endometrial hyperplasia in animal models is also 
likely to indicate adverse consequences for women. 
Ovarian cysts and endometriomas occur in various sizes (from small to large) and may be benign 
and/or functional (i.e. hormone producing) and are common in women. In terms of women’s health, 
ovarian cysts/endometriomas, depending on their size and type, are associated with a range of adverse 
outcomes, which include pain and infertility. Therefore, the occurrence of ovarian cysts or 
endometriomas in animal models would be considered both relevant to and adverse for women. 
Anogenital distance (AGD) needs to be considered separately for males and females and the direction 
of change in AGD in terms of adverse effects is opposite between the sexes. Nevertheless, AGD is a 
read-out of androgen action, especially during in utero development, in both animal models and in 
humans. 
In humans and animal models, reduced AGD in males is indicative of reduced masculinisation and 
associated with increased adverse effects in reproductive development (hypospadias and 
cryptorchidism), reduced androgen levels and impaired sperm production and/or fertility. However, 
the magnitude of decrease in AGD that can be clearly associated with a decrease in subsequent 
fertility is more difficult to establish. Nevertheless, there is no doubt that reduced AGD is associated 
with reproductive abnormalities and reduced sperm counts/fertility (Thankamony et al., 2014; 
Mendiola et al., 2011). Therefore, reduced AGD in animal models is relevant to humans and 
indicative of an adverse effect in humans. 
In humans and animal models, increased AGD in females is indicative of excess androgen action. The 
adverse associations in women include reduced fertility and polycystic ovary/polycystic ovarian 
syndrome (PCO/PCOS). Increased AGD in female humans is associated with greater follicle numbers 
in girls (Mendiola et al., 2012) and with prenatal stress in girl infants (Barrett et al., 2013), both 
suggestive of some masculinisation. Therefore, increased AGD in female animal models is relevant to 
humans and indicative of an adverse effect in humans. 
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In contrast, the implications of increased AGD in men/male animal models or reduced AGD in 
women/female animal models are much less clear. While these may be indicative of disturbed 
developmental processes, it is not known whether these effects are adverse either in animal models or 
in humans. Therefore it cannot be stated with any certainty that reduced female AGD or increased 
male AGD are definitely either relevant or adverse to women or men respectively.  
The CEF Panel noted that a fundamental question to be addressed is whether developmental 
exposures to BPA result in reduced fertility. Many studies utilise valid measures of adverse effects of 
developmental exposure on the offspring. However, it has to be recognised that many of these (e.g. 
small but statistically significant changes in AGD or fetal/neonatal reproductive tract weights and/or 
cell numbers) are surrogate measures. There are recognised mismatches between animal species and 
human, such as the fact that sperm counts need to be reduced to a greater extent in rodents than in 
men before fertility is impacted. However, this can be addressed for forced/continuous breeding 
studies (e.g. Cabaton et al., (2011). In the final analysis, a robust approach to assess the actual fertility 
of the individuals exposed during development would be beneficial, especially since human fertility is 
considered as reflective of the combined biologies of the couple. The CEF Panel noted that few of the 
studies it has evaluated in this opinion have performed this analysis. A few studies have noted that the 
reported effects of BPA exposure are transient or reversible, i.e. loss of “adverse” phenotypes with 
increasing age after stopping the exposure (Nah et al., 2011, Kobayashi et al., 2012). This suggests 
some degree of plasticity and demonstrates the important of two generation studies. Furthermore, it 
should be noted that this concept of plasticity has recently also been shown to apply to a degree to 
AGD in male rats (Mitchell et al., 2014). 
4.3.2.3. Uncertainties in neurotoxicity 
Out of all studies included in this opinion, six studies were assessed to have a minor contribution to 
the likelihood that BPA exposure changes response in tests for various neurobehaviour in rodents.  
Due to differences in results reported for female and male animals, two graphs are shown (Figure 12a 
and b, respectively).  
The three studies investigating the possible influence of BPA exposure on anxiety-like behaviour 
(Jasarevic et al., 2013; Wolstenholme et al., 2011a; Xu et al., 2012), used the Elevated Plus Maze 
(EMP) where anxiety-like behaviours were evaluated e.g. as time spent in open and closed arms 
during one 5 to 10 minutes test session. The longer time spent in closed arms, the more anxiety-like 
behaviour, and visa versa, the more time spent in open arms, the less anxiety-like behaviour. One 
study for male and female rodent, respectively, reported increased anxiety-like behaviour of BPA at 
HED 100-103 µg/kg bw per day (males: Jasarevic et al., 2013; female: Xu et al., 2012) whereas the 
other two reported no significant difference compared to controls. However, Jasarevic et al., 2013 
reported effects in males at a lower dose (HED 100 µg/kg bw per day) than the other two studies (HED 
101 -102 µg/kg bw per day). 
One of the three studies investigating anxiety-like behaviour, (Xu et al., 2012) used four different tests 
including the EPM. Additionally, one test for depression-like behaviour (forced swim task) was used. 
In males, prenatal BPA exposure caused anxiety-like behaviour in one test compared to controls. 
Additionally, males were reported to show depression-like behaviour following both exposure periods 
to BPA (Xu et al., 2012). In females, prenatal BPA exposure caused anxiety-like and depression-like 
behaviour in all tests, whereas lactational BPA exposure in three (Xu et al., 2012). 
Disturbed sensory-motor function of BPA in adult male rats, not in females, was reported by 
Fergusson et al., 2012. The effect was evaluated by decreased acoustic startle response compared to 
vehicle controls, but was also seen in the naïve control. The authors presumed that the apparent effect 
of BPA (at HED 100 µg/kg bw per day) was due to an aberrant heightened acoustic startle response in 
the vehicle control, and did not put weight on the results. This consideration is supported by the study 
by Stump (2010) that, among other neurodevelopmental toxicity end points, covered the auditory 
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startle response. No statistically significant effects of BPA on the startle response were found, and 
neither the study’s control data nor the historical control data showed gender related differences in 
auditory startle response. Also in literature auditory startle response is not known as a sexually 
dimorphic behaviour (Meyer, 1998). The expert group concluded disturbed sensory function of BPA 
as likely as not. 
In females, BPA at HED 10-2 to 10-3 µg/kg bw per day produced no effects on learning and memory 
(Fergusson et al., 2012; Jasarevic et al., 2013; Xu et al., 2012). In males, two studies using the same 
test, the Barnes maze, reported no effect (Fergusson et al., 2012) and learning deficit (Jasarevic et al., 
2013) following perinatal BPA exposure. However, the latter found no effect of BPA at the lowest 
dose (HED 10-2 µg/kg bw per day). At the highest dose level (HED 103-104 µg/kg bw per day), 
another study (Xu et al., 2013a) found that BPA given to adult mice impaired learning and memory as 
evaluated by increased escape path length in the Morris water maze and shortened step-down latency 
in the Passive avoidance test. 
In young male mice, no effect of prenatal BPA exposure on social interaction (standard mouse cage) 
and preference (multichamber box) were reported by Wolstenholme et al., 2011a, whereas 
Kundacovic et al. 2013 found reduced chasing in mice at the same age, and increased aggression and 
dominance in adult mice, within the same dose span as Wolstenholme et al., 2011a. In young female 
mice, Kundacovic et al. 2013 found no effect on social behaviour at the same dose level (HED 101 
µg/kg bw per day) as Wolstenholme et al., 2011a; did, but at a lower (HED 10-1 µg/kg bw per day). 
However, as in adult mice, increased aggression and dominance in adult females were seen at the 
highest dose, and decreased in at the lowest dose level (Kundacovic et al. 2013). Both studies reported 
some disturbances in social behaviour at lower BPA doses, but the lack of consistency made the 
expert group to conclude effects on social behaviour in mice as “unlikely to -as likely as not-”  
Based on these results, the expert group concluded for females that at the HEDs from 10-3 to 10-1 it is 
“very unlikely to unlikely” that BPA exerts an effect on neurobehaviour. From HEDs 10-1 to 101 the 
group judged such effects as “unlikely” (female), from HEDs 101 to 103 µg/kg bw per day as 
“unlikely to -as likely as not-”, and from 103 to 104 µg/kg bw per day as “unlikely to likely” (see 
Figure 12a). 
Based on these results, the expert group concluded that at the HEDs for males from 10-3 to 10-1 µg/kg 
bw per day it is “very unlikely to unlikely” that BPA exerts an effect on neurobehaviour. From HEDs 
10-1 to 103 µg/kg bw per day the group judged such effects as “unlikely to -as likely as not-”, and from 
103 to 104 µg/kg bw per day as “-as likely as not- to likely” (see Figure 12b). 
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Figure 12:  Summary plot for the effects of BPA exposure on the neurological system in females 
(a) and males (b): changes in anxiety-like behaviour, sensory-motor function, learning and 
memory and social behaviours. The left hand text indicates the exposure route (oral or 
subcutaneous, SC). The left hand pane shows the experimental design with the horizontal bars 
showing the timing and duration of exposure (black bar: exposed as adults or during gestation 
and/or lactation) while the up-arrows show when the measurements/assessments were made. 
The central pane shows the study results, based on the x-axis showing the human equivalent 
dose (HED) depending upon species, age and route of exposure The central pane shows the 
results for the selected studies, based on the x-axis showing the human equivalent dose (HED) 
depending upon species, age and route of exposure. The lightly shaded boxes on the x-axis 
show the uncertainty assessment (very unlikely=VU, unlikely=U, as likely as not=ALAN, 
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likely=L and combinations thereof). The central pane also shows the sex and species of the 
animals under consideration (right hand-side of pane) and the nature of the symbols denotes 
critical information: open circles show no significant effect, red/shaded circles show 
significant increase and blue/shaded diamonds show significant decrease (see summaries of 
the studies in Appendix B for details). Numbers under the symbols either denote incidence 
(x/y) or samples size (n=x). The text in the right hand column shows information for each 
study (first author, year), the ratio of strengths/weakness of the study (taken from Appendix 
B), the reliability of the study (L=low, M=medium, H=high) and the relevance of the study to 
the biological variable and question being posed in the WoE assessment (L=low, M=medium, 
H=high) (see Appendix C).  
Relevance and adversity to humans for neurotoxic effects 
The traditional domain of toxicology is structural damages to target tissue, i.e. pathology. However, 
toxicants may also cause functional changes, of which behavioural changes represent one type. 
Because a number of chemicals are known to produce developmental neurotoxic effects in humans 
and other species, behavioural changes are regarded as a relevant toxicological endpoint.  
Anxiety disorders are common and relevant disorders in the general human population in the western 
world. Studies of anxiety-like behaviours in experimental animals are difficult to interpret. While 
basic neuronal pathways and modes of actions seem to be the same in mammalians (including 
humans), interpretation of e.g. chemical induced changes in experimental animal behaviour have to be 
done in the context of the animal’s innate behaviour, its physiological state as well as effects such as 
changes of body weight or body temperature. Regarding the animal’s innate behaviour, rodents have 
an innate aversion to open, well-lit spaces and tend to avoid them (while in humans this is not the 
case). Thus, if a mouse spends decreased time in the centre area of an open field task, this might be 
interpreted as increased anxiety-like behaviour but also as a strengthened innate behaviour - the 
mouse being more “cautious”. There is no general agreement on the interpretation of increased 
anxiety-like behaviour in these tests and their relevance to humans. 
Similarly, any sustained chemical-induced impairment of learning ability and/or impairment of 
memory in experimental animals are considered as relevant effects also for humans because the basic 
neuronal pathways and modes of actions are expected to be similar in mammals. However, as 
described for anxiety-like behaviours, caution must be taken to avoid an anthropocentric interpretation 
of any behavioural changes observed in tests with experimental animals. Many behavioural tests for 
experimental animals are linked to the reaction of the limbic system, which controls emotional 
behaviour (i.e. taste aversion or open field aversion in rodents) and is a system which is evolutionary 
well conserved. Despite the fact that emotional behaviour is organised in the same brain structures 
through related neurotransmitters and signalling pathways in many species, the resulting behavioural 
reaction to a given stressor may differ in different species. In conclusion, consistent changes in a 
battery of such behavioural tests are needed to predict behavioural changes in humans, although the 
exact nature of the effect might be different. 
Sensory motor function is highly  conserved and its manifestation (e.g. reflexes, startle response) is 
far less complex compared to e.g. emotional behaviour or learning, and is thus less sensitive to 
interfering factors. Therefore, chemical-induced impairment of sensory motor functions in 
experimental animals should be considered as relevant for humans. 
On the other hand, if changes in a battery of behavioural tests are not consistent or behavioural 
changes are seen only in single tests, the relevance for behavioural effects in humans is questionable. 
Many of the behavioural tests for animals are not sufficiently standardised or validated in terms of 
what the test measures and how well it does so. Many of the tests use motivational factors such as 
rewarding incentives (or punishment) for a specific behaviour, which are also regulated in the limbic 
system and the hypothalamus (e.g. food/water deprivation i.e. hunger/thirst, satiety i.e. stopping 
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eating). As mentioned above, these neuronal centres are tightly linked to emotional behaviour and to 
the hormonal system. A broad variety of factors (including a variety of ingredients in food including 
nutrients and food additives) will influence brain chemistry (and the hormonal system) and 
consequently lead to behavioural changes. Equally, differing testing conditions (e.g. brightness of the 
light, environmental noise, arousing odours etc.) will influence the test outcome and are difficult to 
control. Restraining an animal (e.g. for gavage) has a very different impact in different animal 
species: it leads to high stress in rats but not in dogs because of the innate type of behavioural reaction 
to this stressor. Furthermore, laboratory animals belong to social species, and their behaviour and 
welfare are strongly affected by previous and present social environment. When interpreting results of 
any behavioural test, factors such as as animal group composition and stability, rank and previous 
social experience, should also be taken into account. All these factors hamper comparability and 
consistency of the results of the same test used in different studies when performed under different 
environmental conditions, unless detailed information on the different test conditions is available. It is 
therefore not surprising that there is disagreement among experts about the assessment and 
interpretation of behavioural tests such as tests for anxiety-like behavioural changes or changes in 
social behaviour of experimental animals. 
Overall, there is substantial uncertainty in the interpretation of the results of many behavioural tests. 
For several of these tests (e.g. open field test, social behaviour), the relevance for humans of the 
effects observed in experimental animals is questionable. Only consistent changes in a battery of 
behavioural tests might be predictive for behavioural changes in humans, although the exact nature of 
the effect might be different. Furthermore, the results of functional (behavioural) testing have to be 
evaluated in light of other available information on the test substance such as chemical structure, 
results from in vitro (mechanistic) studies, other toxicity studies, toxicokinetic data, etc. 
Behavioural responses are by definition adaptive reactions to environmental stimuli, accompanied by 
internal signals to maintain homeostasis. These environmental stimuli may be of physical (e.g. bright 
light, noise) or chemical nature (e.g. pheromones). Behavioural changes may become “adverse” when 
they are disruptive of the normal behaviour of a given species, e.g. the loss of the capability to react 
adequately to external stimuli/stressors, sustained (inadequate or stereotypical) behaviour in the 
absence (removal) of stressors. Also, an impairment of the learning ability and/or the impairment of 
the memory may lead to a decrease in the IQ score on a population level, which is clearly an adverse 
effect. Lesions in certain areas of the hypothalamus lead to irreversible loss of regulation of hunger or 
satiety, i.e. leading to starvation and death or gross obesity. Impaired sensory-motor performance may 
also indicate neuronal damage, which is clearly an adverse effect.  
4.3.2.4. Uncertainties in immunotoxicity 
The experiments that showed some signs of induction of pyometra (Kendziorski  et al, 2012) were 
interpreted as not likely to be a consequence of altered resistance to infections, but rather a 
mechanical consequence of access of pathogens to uterus tissue during the hormonal cycle, and 
therefore not an indication of immunotoxic effects of BPA. 
In animal studies by Lee et al. (2012) in which increased levels of total IgE and histamine are found, 
these effects may be interpreted as indications of increased risk of allergy, but they were found in an 
experiment in which only one dose of BPA was applied, and this dose was also higher than in other 
experiments. Studies of Bauer et al (2012) indicated a clear dose dependent facilitation of the severity 
of inflammation in an inhalatory ovalbumin model of respiratory allergy. No effects on eosinophils in 
the lavage were seen while airway hyperreactivity was not tested in this model. Nakajima et al. 2012, 
in an experiment with only one dose, but more or less at the higher dose level as tested by Bauer et al. 
(2012), noted such effects, indicating that BPA may in fact have an influence on respiratory allergy in 
this model. 
In the model used by Bauer et al (2012) in which there was i.p. sensitization to ovalbumin, followed 
by inhalatory challenge, BPA diminished the number of eosinophils in the lavage. These decreased 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 172 
numbers were not associated with a decrement (nor an increment) of airway hyperreactivity. For these 
reasons, the animal data indicating a lowering of eosinophils do not indicate an adverse effects. 
Based on these results, the experts concluded that at the HEDs 10-2, 10-1, 10-0 µg/kg bw per day it is 
“very unlikely” to “unlikely” that BPA exerts an effect on respiratory allergy. From HEDs 10-0 to 10-1 
the group judged such effects as “as likely to not”, and from 10-6 to 106 µg/kg bw per day as “unlikely 
to likely”. It should be noted that at 104 µg/kg bw per day there were no data, and some experts 
considered it inappropriate to give a judgment for that concentration, while others noted that this HED 
is between HED levels where judgments were made on the basis of available data, and felt that effects 
on that intermediate HED could be extrapolated, coming to a judgment of “unlikely to likely” (see 
Figure 13). 
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Figure 13:  Summary plot for the effects of BPA exposure on the immune system: uterus 
inflammation, serum IgE, histamine, and β-hexosaminidase levels, and responses associated 
with sensitization after ovalbumin sensitization The left hand text indicates the exposure route 
of oral or subcutaneous (SC). The left hand text indicates the exposure route (oral or 
subcutaneous, SC). The left hand pane shows the experimental design with the horizontal bars 
showing the timing and duration of exposure (black bar: exposed as adults or during gestation 
and/or lactation) while the up-arrows show when the measurements/assessments were made. 
The central pane shows the study results , based on the x-axis showing the human equivalent 
dose (HED) depending upon species, age and route of exposure The central pane shows the 
results for the selected studies, based on the x-axis showing the human equivalent dose (HED) 
depending upon species, age and route of exposure. The lightly shaded boxes on the x-axis 
show the uncertainty assessment (very unlikely=VU, unlikely=U, as likely as not=ALAN, 
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likely=L and combinations thereof). The central pane also shows the sex and species of the 
animals under consideration (right hand-side of pane) and the nature of the symbols denotes 
critical information: open circles show no significant effect, red/shaded circles show 
significant increase and blue/shaded diamonds show significant decrease (see summaries of 
the studies in Appendix B for details). Numbers under the symbols either denote incidence 
(x/y) or samples size (n=x). The text in the right hand column shows information for each 
study (first author, year), the ratio of strengths/weakness of the study (taken from Appendix 
B), the reliability of the study (L=low, M=medium, H=high) and the relevance of the study to 
the biological variable and question being posed in the WoE assessment (L=low, M=medium, 
H=high) (see Appendix C).  
Relevance and adversity to humans for immunotoxic effects 
In animal studies in which increased levels of total IgE and histamine are found, these effects may be 
interpreted as indications of increased risk of allergy. It should be mentioned that total IgE does not 
necessarily indicate increased specific IgE levels, and that increased levels of IgE, be it specific of 
total levels, do not necessarily indicate allergy. However, if airway hyper-reactivity is found as well, 
this supports the notion of facilitation of respiratory allergy. Increased IgE, inflammation (especially 
eosinophilic inflammation) and airway hyper-reactivity are hall marks of respiratory allergy and 
asthma.  
In case such effects would be evident in humans, in concert they would certainly indicate a risk of 
enhancement of respiratory allergy and asthma. 
In the studies that showed a decreased number of eosinophils in lung lavage, the relevance of these 
effects are difficult to interpret. They do not signify a deleterious effect of respiratory allergy or 
asthma, while they can also not be interpreted as an improvement of such conditions, especially as in 
the studies presented this decrement was not associated with a decrement  (nor an increment) of 
airway hyper-reactivity. For these reasons, the animal data indicating a lowering of eosinophils do not 
indicate an adverse effects, nor would such effect indicate adversity if they were to be evident in 
humans.  
Pyometra is often seen in dogs, but also occurs in humans. It is a pathological condition, i.e. an 
inflammatory condition with involvement of pathogens. It is likely not a consequence of altered 
resistance to infections, but rather a mechanical consequence of access of pathogens to uterus tissue 
during the hormonal cycle. Indications of pyometra in the animal studies is most likely not an 
indication of immunotoxic effects of BPA. 
4.3.2.5. Uncertainties in Metabolic effects 
Analysis of the data in a graphical presentation (Figure 14) showed the results of the 11 studies in 
which parameters of glucose and insulin regulation were measured as relevant endpoints. Six of the 
studies had a low reliability, four studies a medium reliability and one a high reliability. Exposure was 
by the oral route in 10 studies and subcutaneous administration was done in one study. Exposure was 
prenatal (1 study), pre- and post-natal (4 studies) and post-natal (6 studies). 
The doses where effects were seen ranged from 10-3 up to 105 µg/kg bw and these studies showed  
contradictory results. 
In addition, it can be observed that changes in one parameter (e.g. glucose) were not accompanied by 
changes of another parameter (e.g. insulin) in a manner which physiologically or patho-
physiologically could be interpreted in a unifying hypothesis.  
The assessment of the experts is concordant with this graphical presentation of the results; the 
probability that an effect occurs was rated very unlikely (VU) to as likely as not (ALAN) (dose range 
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10-4 – 100 µg/kg bw HED) or to unlikely (UL) (dose range 100 – 101 µg/kg bw HED) or to as likely as 
not (ALAN) (dose range 101 – 104 µg/kg bw HED) to likely (L) (dose range 104 – 106 µg/kg bw 
HED) (see Figure 14). 
The experts assessment indicates the high degree in uncertainty whether there is an effect and if so, at 
which level of exposure it occurs. 
 
Figure 14:  Summary plot for the effects of BPA exposure on the metabolic system: effects on 
glucose and insulin regulation. The left hand text indicates the exposure route (oral or 
subcutaneous, SC). The left hand pane shows the experimental design with the horizontal bars 
showing the timing and duration of exposure (black bar: exposed as adults or during gestation 
and/or lactation) while the up-arrows show when the measurements/assessments were made. 
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The central pane shows the study results , based on the x-axis showing the human equivalent 
dose (HED) depending upon species, age and route of exposure The central pane shows the 
results for the selected studies, based on the x-axis showing the human equivalent dose (HED) 
depending upon species, age and route of exposure. The lightly shaded boxes on the x-axis 
show the uncertainty assessment (very unlikely=VU, unlikely=U, as likely as not=ALAN, 
likely=L and combinations thereof). The central pane also shows the sex and species of the 
animals under consideration (right hand-side of pane) and the nature of the symbols denotes 
critical information: open circles show no significant effect, red/shaded circles show 
significant increase and blue/shaded diamonds show significant decrease (see summaries of 
the studies in Appendix B for details). Numbers under the symbols either denote incidence 
(x/y) or samples size (n=x). The text in the right hand column shows information for each 
study (first author, year), the ratio of strengths/weakness of the study (taken from Appendix 
B), the reliability of the study (L=low, M=medium, H=high) and the relevance of the study to 
the biological variable and question being posed in the WoE assessment (L=low, M=medium, 
H=high) (see Appendix C). oGTT and ipGTT: oral and intraperitoneal glucose tolerance test, 
ipITT: intraperitoneal insulin tolerance test. * This study used a non-obese diabetic mice 
strain. The connected arrows in Bodin (2013) indicate weekly measurements. 
Relevance and adversity to humans for metabolic effects 
In mammalia the regulation of carbohydrate metabolism is similar and there are no data indicating 
that the regulation would be species specific. The endpoints plasma/blood glucose, plasma/serum 
insulin and the response of blood glucose to the oral Glucose Tolerance Test (oGTT) in animals are 
relevant for the human situation.  
In humans, low plasma/blood glucose levels are adverse if clinical symptoms are present (loss of 
consciousness).  High plasma/blood glucose, indicating diabetes mellitus if in an oGTT levels are 
above 200 mg/dl at 2 hrs after glucose intake, is considered adverse.  The relevance of 
elevated/lowered insulin plasma levels in humans is not clear in terms of metabolic situation. High 
insulin levels in humans indicate an insulinoma which is a benign tumour of the pancreas.  
The oGTT is a widely used in humans but it is not established in animals.  
Measurements of insulin after the test dose in an oGTT (in the publication refer to as oGTT response 
insulin) is not done in the diagnostic procedure in humans and no corresponding test in humans is 
known. Hence, the relevance and adversity of findings in animals for humans is not knownThe 
intraperitoneal insulin tolerance test (ipITT) is not done as a diagnostic procedure in humans and no 
corresponding test in humans is known. Hence, the relevance and adversity of findings in animals for 
humans is not known. Measurements of testicular glucose are not done in humans, therefore, the 
relevance and adversity of findings in animals for humans is not known. 
4.3.2.6. Uncertainty analysis for all endpoints considering relevance and adversity to human 
The experts were asked to make judgements about the overall likelihood, in each HED dose interval, 
that BPA has the inherent ability to cause one or more type of effect in animals and that it is relevant 
and adverse in humans, based on the group summaries of the judgements that had been made in the 
earlier stages of the assessment (table 18). The overall assessment was considered by first, 
considering how the likelihoods of causation, human relevance and adversity combine for each effect 
separately and, second, combining likelihood across effects in each dose interval. The judgements 
were then summarised into a range of likelihoods for each dose interval, spanning the range of those 
expressed by individual experts.  
Although the group likelihoods are the same for 101 – 102 and 100 – 101 µg/kg bw per day - both are 
U-ALAN -  there is a clear difference in the individual likelihoods between these two dose intervals, 
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and a clear difference again between 101 – 102 and 102 – 103 (in the latter, 5 of 10 experts considered 
the likelihood could be above 66%) (table 19) 
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Table 18:   Summary of expert judgements of the likelihood that BPA has the inherent ability to cause effects in animals in different dose intervals and 
their human relevance (if they occur in animals) and adversity (if they occur in humans). (For key to likelihoods, see table 59 in Appendix D). Sexes 
were differentiated only for neurobehavioural effects.  
Effect type Human relevance 
Adversity 
in humans 
Likelihood that BPA causes the effect in animals in different dose intervals 
 Human equivalent dose (HED), μg BPA/kg bw per day 
10-4-10-3 10-3-10-2 10-2-10-1 10-1-100 100-101 101-102 102-103 103-104 104-105 105-106 
Mammary proliferation ALAN-L ALAN-L VU VU VU VU U-ALAN U-ALAN ALAN-L ALAN-L ALAN-L ALAN-L 




ALAN VU-L L-VL 












ALAN VU-L VU-L 
Immune system U-L ALAN-L - - VU-U VU-U U-ALAN U-L U-L U-L U-L - 
Neurobehaviour (males) 
U-L U-L 
- VU-U VU-U U-ALAN ALAN ALAN ALAN ALAN-L - - 
Neurobehaviour (females) - VU-U VU-U U U U-ALAN ALAN U-L - - 
-: no data available 
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Table 19:  Expert judgements of the overall likelihood, in each HED dose interval, that BPA has the inherent ability to cause one or more type of effect 
(of the types shown in table 18) in animals and that it is relevant and adverse in humans. (For key to likelihoods, see table 59 in appendix D). 
Expert 
HED Dose interval (μg BPA/kg bw per day) 
10-4-10-3 10-3-10-2 10-2-10-1 10-1-100 100-101 101-102 102-103 103-104 104-105 105-106 
1   U U U-ALAN U-ALAN ALAN ALAN   
2   VU VU-U U-ALAN ALAN ALAN-L ALAN-L   
3   U U U ALAN ALAN ALAN-L L L 
4 VU VU VU VU U U-ALAN ALAN ALAN-L ALAN-L L 
5 VU U U U U ALAN L L L VL 
6   VU-U VU-U U U-ALAN U-ALAN ALAN   
7   U U ALAN ALAN L L L  
8 VU VU-U U U ALAN ALAN ALAN-L L L L 
9   U U ALAN ALAN ALAN-L ALAN-L ALAN ALAN 
10 EU EU VU VU U U U-ALAN ALAN ALAN L 




 ALAN- L (ALAN- L)* 
(ALAN- 
VL)* 
*: For these ranges of doses the experts did not provide a full evaluation because there were not data available for all the endpoints.
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The overall uncertainty evaluation, including the effects on mammary gland as well as reproductive, 
neurobehavioural, immune and metabolic systems  is presented in table 19. The CEF Panel concluded 
that the health-based guidance value should cover  the lowest dose in the dose-range for which the 
likelihood approaches “likely” from the overall uncertainty evaluation, taking into account uncertainty 
of all the evaluated endpoints as well as their relevance and adversity to humans. The uncertainty 
evaluation approached “likely” in the dose (HED) range of 100-1 000 µg/kg bw per day, and therefore 
the CEF Panel decided that the uncertainty in the other effects at the HED of 100 µg/kg bw per day 
and higher should be taken into account when establishing a health-based guidance value.  
The CEF Panel decided that an extra factor should be included to take into account the uncertainty in 
the database (mammary gland, and reproductive, neurobehavioural, immune and metabolic systems). 
Thus, as the reference point was 609 µg/kg bw per day based on the mean relative kidney weight and 
the lower end of the dose-range for which the uncertainty evaluation for other endpoints approached 
“likely” is 100 µg/kg bw per day, a factor of 6 was applied.  
4.4. Health-based guidance value 
In deriving a health-based guidance value, the CEF Panel used an uncertainty factor of 2.5 for inter-
species differences (1 for toxicokinetics and 2.5 for toxicodynamics, reflecting the fact that 
toxicokinetic differences have been addressed by use of the HED approach) and an uncertainty factor 
of 10 for intra-species differences (Ref to SC opinion on the guidance on default values). In addition, 
the CEF Panel considered that the extra factor of 6 should be included to take into account the 
uncertainty in the database, i.e. mammary gland, and reproductive, neurobehavioural, immune and 
metabolic systems (see Section 4.3).  
The CEF Panel applied, therefore, an overall uncertainty factor of 150 to the HED of 609 µg/kg bw 
per day and established a temporary Tolerable Daily Intake (t-TDI) for external oral exposure to BPA 
in humans of 4 µg/kg bw, based on the mean relative kidney weight effect in the mouse. The CEF 
Panel designated the TDI as temporary, pending the outcome of the long-term study in rats involving 
prenatal as well as postnatal exposure to BPA, currently being undertaken by NTP/FDA. This study 
will help resolve the uncertainties in the database.  
5. Risk characterisation  
In this section, the CEF Panel compares the t-TDI of 4 µg/kg bw per day with the exposure estimates 
for BPA.   
The exposure estimates for both oral and dermal exposure (external exposures) are provided for 
different age groups and subpopulations in table 22 (average exposures) and 23 (high exposures) in 
Part I- Exposure assessment.  
For the purpose of risk characterisation, the CEF Panel carried out an assessment of aggregated 
dietary and non-dietary exposure to unconjugated BPA using PBPK modelling. This aggregated 
exposure assessment included the oral-route sources diet, dust and toys (mouthing) as well as the 
dermal-route sources thermal paper and cosmetics. The dermal exposure estimates have been 
expressed as equivalent oral exposures (table 20) in order to provide an aggregated (oral plus dermal) 
exposure scenario for comparison with the t-TDI. This conversion is needed because the reference 
dose for the risk assessment (t-TDI) has been derived for external oral exposure.  
This conversion of the dermal exposures to equivalent oral doses has been carried out by PBPK 
modelling, as described in section 3.1.7.3 of the opinion, with the outcome of the conversion being 
shown in table 5 and table 6 of that section (for average and high exposures). The converted exposure 
estimates are summarised in table 20. It should be noted that the parameters used in the PBPK model 
for aggregated exposure were only available for the two age groups “children (3-10 years)” and “men 
(18-45 years)” (see Section 3.1.7.3). The CEF Panel considered, however, that the dermal equivalent 
oral dose for the age group men 18-45 years is likely to be also representative for the age groups 
“women 18-45 years”, “other adults 45-65 years” and “elderly, very elderly 65 years and over” and 
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adolescents, assuming that the toxicokinetics of BPA in these age groups are not significantly different 
to those of “men (18-45 years)”. The CEF Panel noted that the highest dietary exposure resulted in 
toddlers and children 3-10 years, with very similar values (0.857 and 0.813 µg/kg bw per day, 
respectively). However the non-dietary exposure scenarios derived for “children 3-10 years” were by 
far the highest of any of the child populations (age below 10) identified in table 20, and for the 
purposes of risk characterization, the  exposure estimates for this population could also be used as 
“worst-case” surrogates for infants and children aged below 3 years. Using the above assumptions, 
aggregated exposure was therefore estimated for “children 3-10 years”, adolescents and adult age 
groups. 
Table 20:  Summary table on average (A) and high (H) exposure (µg/kg bw per day) from 
dietary and non-dietary sources to BPA in the different age groups of the general population. 
Dermal doses are expressed as equivalent oral doses as obtained by PBPK modelling,  taken 
from table 22 and 23 in Part I-Exposure assessment (absolute values for dermal exposure), 
and table 5 and table 6 in Section 3.1.7.3. 
Age group Exposure level 
Dietary Non-dietary 
Oral Oral Dermal Sum of 





Infants 1-5 days 
(breastfed) 
A 0.225 - - - - H 0.435 
Infants 6 days - 3 months 
(breastfed) 
A 0.165 0.009 - - 0.009 H 0.6 0.015 0.015 
Infants 4-6 months (breastfed) A 0.145 0.009 - - 0.009 H 0.528 0.015 0.015 
Infants 0-6 months (formula 
fed) 
A 0.03 0.009 - - 0.009 H 0.08 0.015 0.015 
Infants 6-12 months A 0.375 0.009 - - 0.009 H 0.857 0.015 0.015 
Toddlers 1-3 years A 0.375 0.007 - - 0.007 H 0.857 0.012 0.012 
Children 3-10 years A 0.290 0.003 0.053 0.008 0.064 H 0.813 0.005 0.424 0.016 0.445 
Adolescents 10-18 years A 0.159 0.002 0.113 0.015 0.13 H 0.381 0.003 1.036 0.029 1.068 
Women 18-45 years A 0.132 0.0006 0.071 0.012 0.084 H 0.388 0.001 0.650* 0.024* 0.675* 
Men 18-45 years A 0.126 0.0006 0.071 0.012 0.084 H 0.335 0.001 0.650 0.024 0.675 
Other adults 45-65 years A 0.126 0.0006 0.071 0.012 0.084 H 0.341 0.001 0.650* 0.024 0.675* 
Elderly and very elderly 
65 years and over 
A 0.116 0.0006 0.071 0.012 0.084 
H 0.375 0.001 0.650* 0.024* 0.675* 
* It is assumed that the dermal exposures as expressed as equivalent oral doses for the age group men 18-45 years also are 
representative for the age groups women 18-45 years, other adults 45-65 years, and elderly and very elderly 65 years and 
over, assuming that the toxicokinetics are not significantly different between these age groups.  
 
The CEF Panel first compared the estimates for high dietary exposure  for all age groups, as shown in 
table 20, with the t-TDI of 4 µg/kg bw per day. This comparison showed that the dietary exposure in 
all age groups (including all infants and toddler groups) was more than 4-fold below the t-TDI, 
indicating no health concern from dietary exposure alone. The additional contribution from other oral 
sources, like dust and toys mouthing, did not change this conclusion.  
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The CEF Panel then compared the aggregated exposure estimates (dietary plus non-dietary sources 
including dust, toys, cosmetics and thermal paper) for “children 3-10 years”, adolescents and adult age 
groups, as presented in tables 21-23, with the t-TDI. 
Table 21:  Aggregated exposure from diet and non-dietary sources for the population group 
children 3–10 years and adolescents.  
 Children 3–10 years (µg/kg bw per day) 
Adolescents  
(µg/kg bw per day) 
Route of exposure Dietary average (d) Dietary high (D) Dietary average (d) Dietary high (D) 
Non-dietary  
average (n-d) 
0.064 (n-d) 0.290 (d) 
0.354 
0.064 (n-d) 0.813 (D) 
0.877 
0.13 (n-d) 0.159(d) 
0.289 




0.445 (N-D) 0.290 (d) 
0.735 
0.445 (N-D) 0.813 (D) 
1.258 
1.068 (N-D) 0.159 (d) 
1.226 
1.068 (N-D) 0.381 (D) 
1.449 
 
The aggregated exposure estimates presented in table 21 show that even when the high estimates for 
diet and non-dietary sources are combined, the aggregated exposure for children 3–10 years (1.258 
µg/kg bw per day) and adolescents (1.449 µg/kg bw per day) will be approximately 3 fold below the t-
TDI. The CEF Panel noted that the exposure scenarios derived for children 3–10 years are the highest 
of any of the child populations (age below 10) identified in table 20 and the margin between the t-TDI 
and the exposures for the other child populations (i.e. younger than 3 years of age) will therefore be 
greater than that for children 3–10 years.  
The aggregated exposure estimates for children 3–10 years presented in table 21 shows that the largest 
contribution to the aggregated average exposure from diet and average exposure from non-dietary 
sources comes from dietary exposure (82% from diet vs. 18% from non-dietary sources). For the 
aggregated high dietary and high non-dietary exposure, also diet contributes the most (65%). The 
aggregated exposure estimates for adolescents show that the largest contribution to the aggregated 
average dietary and average non-dietary exposure comes from diet (55% vs. 45% from non-dietary 
sources). For the aggregated high dietary and high non-dietary exposure from non-dietary sources, 
non-dietary contribute most (74%). Thermal paper contributed the most to the exposure from non-
dietary sources. 
Table 22:  Aggregated exposure from diet and non-dietary sources for women 18-45 years and 
for men 18-45 years  
 Women 18–45 years (µg/kg bw per day) 
Men 18–45 years 
(µg/kg bw per day) 
Route of exposure Dietary average (d) Dietary high (D) Dietary average (d) Dietary high (D) 
Non-dietary  
average (n-d) 
0.084 (n-d) 0.132 (d) 
0.216 
0.084 (n-d) 0.388 (D) 
472 
0.084 (n-d) 0.126 (d) 
0.210 




0.675 (N-D) 0.132 (d) 
0.807 
0.675 (N-D) 0.388 
(D) 
1.063 
0.675 (N-D) 0.126 (d) 
0.801 
0.675 (N-D) 0.335 (D) 
1.010 
 
The aggregated estimates for high dietary and high non-dietary exposure for women (1.063 µg/kg bw 
per day) and men (1.010 µg/kg bw per day) are mostly identical, and they are lower than those for 
adolescents  and “children 3–10 years”. The CEF Panel noted that the exposure estimates for men and 
women (including pregnant women) are approximately 4-fold lower than the t-TDI of 4 µg/kg bw per 
day. 
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Table 23:  Aggregated exposure from diet and non-dietary sources for other adults 45–65 years 
and for the elderly and very elderly 65 years and over  
 Other adults (45–65 years) (µg/kg bw per day) 
Elderly and very elderly  
(65 years and over)  
(µg/kg bw per day) 
Route of exposure Dietary average (d) Dietary high (D) Dietary average (d) Dietary high (D) 
Non-dietary  
average (n-d) 
0.084 (n-d) 0.126 (d) 
0.210 
0.084 (n-d) 0.341 (D) 
0.425 
0.084 (n-d) 0.116 (d)  
0.200 




0.675 (N-D) 0.126 (d) 
0.801 
0.675 (N-D) 0.341 (D) 
1.016 
0.675 (N-D) 0.116 (d)  
0.791 
0.675 (N-D) 0.376 (D) 
1.051 
 
The aggregated exposure estimates for other adults and the elderly are in the same range as the those 
for women and men, and they are also approximately 4-fold below the t-TDI. 
Overall, the CEF Panel concluded that there is no health concern from high dietary BPA exposure 
alone or from aggregated exposure to BPA from diet and non-dietary sources for any of the age 
groups: even the highest aggregated exposure of 1.449 µg/kg bw per day estimated for adolescents 
was approximately 3-fold lower than the t-TDI of 4 µg/kg bw per day. 
5.1 Uncertainties in the risk characterisation 
5.1.1. Uncertainty in the characterisation of risks from foodstuffs and non-dietary sources 
The CEF Panel considered the uncertainties associated with the characterisation of risks posed by BPA 
in foodstuffs to different age groups. These uncertainties come from two sources, which were assessed 
in earlier sections of the opinion: uncertainties in the identification and characterisation of hazard 
(Section 4.3), and uncertainties in exposure (Section 4.7.2 in Part I- Exposure assessment). In the 
present section, the CEF Panel considered the implications of these uncertainties for risk 
characterisation. table 24 shows the main elements of the uncertainty analysis for women of 
childbearing age. Similar analyses were completed for males aged 18-45, adolescents (aged 10-18), 
and children aged 3-10. These are not shown but gave similar results to those in table 24 and the 
associated figures.  
 
The CEF Panel took account of uncertainties affecting hazard identification and characterisation by 
applying an additional assessment factor of 6 when setting the t-TDI of 4 μg/kg bw per day (Section 
4.4). The CEF Panel expressed its judgement of uncertainties affecting dietary exposure assessment 
using a scale of symbols representing the degree to which real dietary exposures might be higher or 
lower than the CEF Panel’s estimates of exposure of different population groups to BPA from 
foodstuffs (Section 4.7.2 in Part I- Exposure assessment). In order to put this into context with 
exposure from non-dietary sources, including dust, thermal paper and cosmetics, the uncertainty of 
external exposure estimates for those non-dietary sources was also evaluated in the same way. The 
results of those evaluations are summarised in table 24.  
 
The evaluations of uncertainty in dietary exposure assessment using symbols were converted to 
quantitative ranges, by the method described in section 4.7.2 (in Part I- Exposure assessment), in order 
to evaluate their impact on the comparison between exposure estimates and the t-TDI of 4 µg/kg bw 
per day for risk characterisation. This produced an upper and lower bound for the uncertainty of each 
estimate, shown in the right column at the top of table 24.  
 
In order to put the exposures to BPA in foodstuffs into context, the CEF Panel converted its estimates 
of exposure from non-dietary sources, and their uncertainty ranges, into equivalent oral doses. This 
required the use of dermal-to-oral route equivalence factors (EFDO) derived from PBPK modelling, 
which are themselves subject to uncertainty. An important source of uncertainty affecting the EFDO 
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values is the choice of the PBPK model to use: there was about  7.6-fold difference between estimates 
produced using the Mielke/Gundert-Remy model and those that would be obtained if it would be 
possible to use the Fisher model (see Section 3.1.7 and Appendix D). Therefore, to provide an 
indication of the impact of this source of uncertainty on risk characterisation, the conversion of dermal 
exposure estimates to oral equivalents was done first with the Mielke/Gundert-Remy model and then 
with the addition of the factor of about 7.6 representing the difference between the Mielke/Gundert-
Remy and Fisher models (table 24).  
 
Another important source of uncertainty affecting the EFDO values is the absorption fractions which 
were used in PBPK modelling to convert the external doses from thermal paper and cosmetics into 
internal doses (as described at the end of section 3.1.7). It was assumed that 10% of the external dose 
from thermal paper is absorbed. The uncertainty of the dermal absorption factor used for thermal paper 
(0.1) was assessed as – –/+ (×0.2 to ×2), i.e. the true factor is considered to lie between 0.02 and 0.2. 
The uncertainty of dermal absorption factor used for cosmetics (0.5) was also assessed as – –/+ (×0.2 
to ×2), i.e. the true factor might lie between 0.1 and 1. The effect of this uncertainty on the EFDO 
factors can be calculated by applying the same uncertainty ratings (e.g. ×0.2 to ×2 for thermal paper 
exposure) to them.     
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table 24: Evaluation of uncertainties affecting exposure assessment for females aged 18–45 years 
 
The results of these evaluations are presented together with the t-TDI in Figure 15. This shows the 
average and high estimates for dietary exposure for women of childbearing age, together with the 
ranges expressing their uncertainty, and corresponding estimates for the two largest non-dietary 
sources of exposure (thermal paper and cosmetics), expressed as oral equivalents. It can be seen from 
Figure 15 and Table 24 that: 
• The estimates and uncertainty ranges for both average and high dietary exposure are well below 
the t-TDI for all 4 age groups considered (upper bound of high estimate: 0.47 μg/kg bw per day 
for women aged 18–45 years; maximum: 0.98 μg/kg bw per day for children aged 3–10 years).  
• The estimated equivalent oral exposures for non-oral routes (thermal paper and cosmetics) are 
very much more uncertain than the dietary estimates for the oral route, as indicated by the width of 
the dashed lines in Figure 15. 
• The difference in the predictions of the Mielke and Fisher PBPK models (see Section 3.1.7 and 
Appendix D) is also a substantial source of uncertainty when the doses for non-oral routes are 
Source of uncertainty




EXTERNAL EXPOSURE BY EACH ROUTE:
Average Oral exposure 
Average dietary exposure to BPA (μg/kg bw per day) 0.13 –/● 0.066  - 0.16
Average exposure from dust (μg/kg bw per day) 0.0006 – –/● 0.00012  - 0.001
High Oral exposure 
High dietary exposure to BPA (μg/kg bw per day) 0.39 –/● 0.19  - 0.47
High exposure from dust (μg/kg bw per day) 0.001 – – –/+ 0.0001  - 0.002
Average Dermal exposure
Average exposure from dermal contact with thermal paper (μg/kg bw per day) 0.059 – – –/++ 0.006  - 0.29
Average exposure from cosmetics (μg/kg bw per day) 0.002 – –/++ 0.0004  - 0.010
High Dermal exposure
High exposure from dermal contact with thermal paper (μg/kg bw per day) 0.54 – –/++ 0.11  - 2.7
High exposure from cosmetics (μg/kg bw per day) 0.004 – –/++ 0.0008  - 0.020
Dermal absorption fractions
Dermal absorption fraction for thermal paper 0.1 – –/+ 0.02  - 0.2
Dermal absorption fraction for cosmetics 0.5 – –/+ 0.1  - 1
Conversion of dermal exposure to oral equivalent using PBPK modelling
Conversion for thermal paper exposure (ratio) 1.2 not considered
Conversion of cosmetics exposure (ratio) 6.0 not considered
Conversion of dermal exposure including model uncertainty factor of 7.6**
Conversion for thermal paper exposure (ratio) 9.1 not considered
Conversion of cosmetics exposure (ratio) 45.6 not considered
Dermal exposures as oral equivalents converted with & without uncertainty factor
Average exposure from dermal contact with thermal paper (μg/kg bw per day, no factor) 0.071 0.001  - 0.71
Average exposure from dermal contact with thermal paper (μg/kg bw per day, with factor) 0.54 0.011  - 5.4
Average exposure from cosmetics (μg/kg bw per day, without factor) 0.012 0.000  - 0.12
Average exposure from cosmetics (μg/kg bw per day, with factor) 0.091 0.004  - 0.91
High exposure from dermal contact with thermal paper (μg/kg bw per day, without factor) 0.65 0.026  - 6.5
High exposure from dermal contact with thermal paper (μg/kg bw per day, with factor) 4.9 0.20  - 49
High exposure from cosmetics (μg/kg bw per day, without factor) 0.024 0.001  - 0.24
High exposure from cosmetics (μg/kg bw per day, with factor) 0.18 0.007  - 1.8
*Using full width of range implied by the uncertainty symbols (-/+/●) in the third column 
** Model uncertainty factor of 7.6 representing difference between Mielke & Fisher models
Approximate maximum 
plausible range*
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converted to oral equivalents, as can be seen from the distance between the triangles and circles in 
Figure 15.  
• The estimate of high equivalent oral exposure from thermal paper is 4.9 μg/kg bw per day and its 
upper bound (including model uncertainty) is 10-fold higher, due to the combined effects of the 
factor of about7.6 representing PBPK model uncertainty together with the uncertainty of estimated 
external exposure and of the dermal absorption fraction. However, the lower bound is 0.2 μg/kg 
bw per day, a factor of 20 below the estimate, so it is clear that the contribution from thermal 
paper is highly uncertain (factor of 200 overall).  
• The upper bound (including model uncertainty) for high equivalent oral exposure from cosmetics 
reaches 1.8 μg/kg bw per day. This results from the upper bound for the dermal absorption fraction 
(1.0, the maximum possible), the upper bound of the estimated external exposure to cosmetics (a 
factor of 5 above the estimate), and the factor of 7.6 that takes account of the PBPK model 
uncertainty.  
• Similar analyses for men aged 18–45 years, adolescents and children aged 3–10 years gave very 




Figure 15:  Analysis of uncertainty affecting the comparison of the proposed t-TDI of 4 μg/kg bw 
per day with the estimated exposure to BPA in foodstuffs (oral route) for women of 
childbearing age (18–45 years). Also shown are estimates for the largest non-oral sources of 
exposure (thermal paper and cosmetics), converted to oral equivalents by PBPK modelling 
with and without a model uncertainty factor. Note the exposures and t-TDI are plotted on a 
log10 scale, with labels in the natural scale. Dashed lines show approximate ranges for the 
uncertainty of the estimates. 
  
tTDI
0.0001 0.001 0.01 0.1 1 10 100







Key: circles = without model uncertainty factor; 
triangles = with model uncertainty factor
diamonds = dietary (no PBPK model)
FEMALES AGED 18-45
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5.1.2. Uncertainty of aggregate exposure assessment 
Estimates of aggregate equivalent oral exposure were calculated using the following following 
equation: 
 
𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒 𝑒𝑥𝑝𝑜𝑠𝑢𝑟𝑒 = 𝐷𝑖𝑒𝑡𝑎𝑟𝑦 + 𝐷𝑢𝑠𝑡 + 𝑃𝑎𝑝𝑒𝑟 × 𝑃𝑎𝑝𝑒𝑟 𝐸𝐹𝐷→𝑂 + 𝐶𝑜𝑠𝑚𝑒𝑡𝑖𝑐 × 𝐶𝑜𝑠𝑚𝑒𝑡𝑖𝑐 𝐸𝐹𝐷→𝑂 
 
Dermal exposure estimates for thermal paper and cosmetics are converted into equivalent oral 
exposures by source-specific dermal-to-oral route equivalence factors (EFDO). Estimates of (oral 
equivalent) exposures for each of the sources identified in the equation are shown in Table 24, for 
women aged 18–45 years, together with their uncertainty ranges. 
 
As explained in section 4.7.2 (in Part I- Exposure assessment), the exposure assessment is intended to 
estimate, for each population group, the 95th percentile exposure in the EU country where this is the 
highest. For each individual source of exposure, ‘average’ and ‘high’ estimates have been made as 
approximate estimates for the mean and 95th percentile. For estimating aggregate exposure we explore 
different combinations of average and high estimates. Air is a very minor contribution to the aggregate 
exposure and is excluded from all aggregate exposure estimates but would have a negligible influence 
on the total if it were included. Tables 21-23 and Figure 16 show four aggregations of estimates for 
each population group: 
 
1. Averages for both dietary exposure and non-dietary exposure (A1) 
2. High estimates for dietary exposure and averages for non-dietary exposure (A2) 
3. Averages for dietary exposure and high estimates for non-dietary exposure (A3) 
4. High estimates for both dietary and non-dietary exposure (A4). 
Aggregate 1 is an approximate estimate of the average aggregate exposure. It is expected that the 95th 
percentile aggregate exposure will be in the region of the higher of aggregates 2 and 3, and below 
Aggregate 4, which is expected to approximate a 99th percentile or higher. Together aggregates 1-4 
provide an indication of where the 95th percentile exposure is likely to be. To obtain firmer estimates 
of 95th percentile aggregate exposure would require probabilistic exposure modelling, as it will depend 
on the detailed shape and variance of the distributions for each route of exposure and any 
dependencies between them. 
 
In order to evaluate the impact of the uncertainties in the different parts of the exposure assessment on 
the estimates of aggregate exposure, the calculation shown in the equation above was repeated three 
times: once with the CEF Panel’s estimate of each parameter in the equation, once with the upper end 
of the uncertainty range for each parameter, and once with the lower bound of the uncertainty range 
for each parameter. These three calculations were conducted for each of the four aggregates (A1-A4, 
above), providing an estimated aggregate exposure and an uncertainty range for each aggregate.  
 
The results of these calculations are presented together with the t-TDI in Figure 16 (the numerical 
estimates are given in Table 57 in Appendix D). These show four aggregations of average and high 
exposure estimates (aggregates 1-4, as explained above). Each aggregate is estimated twice, once with 
the dermal exposures being converted into equivalent oral exposures without a PBPK model 
uncertainty factor (circles) and the other including a PBPK model uncertainty factor of about 7.6 
(triangles), representing the expected difference in the predictions of Mielke/Gundert-Remy model and 
the Fisher model.  
It can be seen from Figure 16 that: 
 
1) All of the aggregated equivalent oral exposure estimates have wide uncertainty ranges. It can 
be seen from Figure 16 that this is very largely due to the high uncertainty of the contributions 
from thermal paper, which are much more uncertain than the dietary exposure. 
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2) The difference in the predictions of the Mielke/Gundert-Remy and Fisher PBPK models is a 
substantial source of uncertainty (see Section 3.1.7 and Appendix D).  
3) All the estimates of aggregate equivalent oral exposure are below the t-TDI, except for those 
that result from Aggregates 3 and 4 and include the factor of about7.6 for PBPK model 
uncertainty. These estimates are highly uncertain, with two orders of magnitude between the 
lower and upper bounds.  
4) The assessment is dominated by the high uncertainty of the exposure from thermal paper. If 
further investigation confirms that this lies in the lower half of its current uncertainty range, 
then the largest source of exposure would be dietary and Aggregate 2 would be a better guide 
to the true 95th percentile than Aggregate 3. If, on the other hand, further investigation shows 
that thermal paper lies in the upper half of its current uncertainty range, this would be the 
dominant source and Aggregate 3 would be a better guide.    
5) Similar analyses for men aged 18–45 gave a very similar pattern of results to those in Figure 
16. The pattern for adolescents and children aged 3–10 was similar, but shifted a little to the 
right.  
 
Additional uncertainties that were not quantified in the uncertainty analysis are considered in table 58 
(Appendix D), and do not alter the above conclusions. 
  
 
Figure 16:  Comparison of alternative estimates of aggregate equivalent oral exposure for females 
aged 18-45 and their uncertainty. Dashed lines show approximate uncertainty ranges for each 
estimate. The proposed t-TDI of 4 μg/kg bw per day is also shown. A1-A4 denote aggregate 
estimates 1-4, see text for explanation and Appendix D for numerical estimates. 
5.1.3. Conclusion of the uncertainty analysis   
Overall, having evaluated the overall uncertainty of this assessment, the upper bound of the 
uncertainty interval for dietary BPA exposure alone did not exceed the t-TDI for any age group. Upper 
bound for the uncertainty of high but not average aggregate exposure estimates to BPA exceed the t-
TDI but in all cases the lower bounds are considerably lower than the t-TDI. The wide uncertainty 
intervals are caused by uncertainty about the magnitude of external exposure to BPA from thermal 
tTDI
0.01 0.1 1 10 100
Equivalent oral exposure (μg BPA/kg bw per day)
A1. Average dietary + average non-dietary
A2. High dietary + average non-dietary
A3. Average dietary + high non-dietary
A4. High dietary + high non-dietary
Key: circles = without model uncertainty factor; 
triangles = with model uncertainty factor
FEMALES AGED 18-45
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paper, about the fraction of BPA which is absorbed through the skin, and about the choice of PBPK 
model for converting dermal exposures to oral equivalents. 
6. Conclusions 
The CEF Panel was asked to address the risk to public health related to the presence of BPA in 
foodstuffs as well as to estimate exposure from all sources (dietary and non-dietary). The CEF Panel 
felt that from a public health point of view the exposure from food needs to be seen in the context of 
all sources of exposure for the general population. Therefore, the risk characterisation was carried out 
for food-related exposure to BPA and for aggregated exposure, which covers dietary as well as non-
dietary sources. 
6.1. Exposure assessment 
The exposure assessment involved the estimation of consumer exposure in terms of the following 
three different metrics: 
• External exposure to BPA (in Part I - Exposure assessment) 
The assessment of external exposure considered the different routes (ingestion, inhalation, dermal 
uptake) and sources (e.g. diet, drinking water, air, thermal paper). It estimated the source-specific 
doses reaching the physical barriers in the gastrointestinal and respiratory tracts and of the skin. 
Route-specific external exposures to BPA were calculated via the so-called forward modelling 
approach by multiplying source concentrations with the corresponding use frequencies (e.g., food 
intake, handling of thermal paper). 
• Internal exposure to total BPA (in Part I - Exposure assessment) 
The assessment of internal exposure to total BPA considered the route- and source (thermal 
paper/cosmetics)-specific absorption fractions to estimate the doses that passed the physical 
barriers to enter the body. For this purpose the estimates for average and high internal exposure to 
total BPA from all sources and over all routes were combined (Combinations C1-C4). 
These internal doses are expressed as doses of total BPA (as no differentiation is made between 
the unconjugated and conjugated BPA). As BPA is completely eliminated via urine, the sum of 
these internal doses is directly comparable to exposure estimates obtained by the so-called 
backward modelling approach from urinary biomonitoring data. 
• Aggregated exposure to unconjugated BPA (in Part II - Toxicological assessment and risk 
characterisation) 
The assessment of aggregated exposure used PBPK modelling to translate the contributions from 
the relevant sources (diet and house dust for the oral route, thermal paper and cosmetics for the 
dermal route) into a toxicologically relevant dose metric, the area under the curve (AUC) for the 
serum concentration of unconjugated BPA. A translation into AUC is necessary because, in 
contrast to dermally absorbed BPA, BPA absorbed from the gastrointestinal tract is subjected to 
the first-pass metabolism before entering the systemic circulation. Based on the AUC information, 
external dermal exposures (thermal paper, cosmetics) were converted to equivalent oral exposures 
which could then be summed up with the external oral exposures (diet, house dust) to arrive at an 
aggregated exposure estimate. 
The assessment of exposure to BPA from all sources showed that diet is the main source in all 
population groups for external exposure only  Specifically, canned food and non-canned meat and 
meat products are the two main dietary contributors to external BPA exposure in the large majority of 
countries and age classes. The pattern was different for aggregate exposure (see Section 5). 
While canned food as a main source of external dietary exposure to BPA is confirmed by the data 
presented in this opinion, exposure from non-canned meat and meat products and fish had not been 
anticipated until the 2013 report of ANSES on concentrations of BPA in French food. Investigation of 
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these findings is currently under way, but, until further results are available, there is no substantiated 
explanation for the presence of unconjugated BPA in foods of animal origin.  
Among the population older than six months, infants (6-12 months) and toddlers had the highest 
estimated external average (0.375 µg/kg bw per day) and high (0.857 µg/kg bw per day) dietary 
exposure. This was mainly due to their higher consumption of foods and beverages per kilogram body 
weight. The modelled dietary exposure for adolescents, adults (including women of childbearing age) 
and elderly/very elderly ranged from 0.116 to 0.159 µg/kg bw per day for the average external 
exposure and from 0.335 to 0.388 µg/kg bw per day for the high exposure, respectively. Dietary 
exposure to BPA estimated by EFSA in 2006 in the population older than six months was far higher 
(up to 5.3 µg/kg bw per day in toddlers) compared with the current assessment (up to 0.857 µg/kg bw 
per day for the high exposure of toddlers), owing to the lack of data at that time which led to the use of 
very conservative assumptions in relation to both the level of consumption of canned food and the 
estimated BPA concentration in these foods. 
The availability of more data now, as compared to 2006, has allowed the CEF Panel to carry out a 
more refined dietary exposure assessment for infants. According to the current estimate, BPA 
exposure for infants up to six months (0.03 to 0.225 µg/kg bw per day for average external exposure) 
is much lower than that estimated by EFSA in 2006 for infants within six months of age (≤ 
11 µg/kg bw per day)bw per daybw per day. This was due to the use at that time of very conservative 
assumptions in relation to BPA concentration in infant formula and to BPA migration from PC bottles 
to account for the lack of data. 
Dietary external exposure in women of childbearing age (0.132 and 0.388 µg/kg bw per day for 
average and high exposure, respectively) was similar to that in men of the same age (0.126 and 
0.335 µg/kg bw per day for average and high external exposure, respectively). The minimal 
differences may be related to women consuming different food items, as reported in the individual 
surveys. 
The uncertainty around the estimates of dietary exposure was judged as relatively low compared to 
other sources of exposure such as thermal paper. 
Thermal paper was the second largest source of external exposure in all population groups above three 
years of age. The modelled estimates for 3–10 years old children, adolescents, adults (including 
women of childbearing age) and elderly/very elderly ranged from 0.059 to 0.094 µg/kg bw per day for 
the average exposure and from 0.542 to 0.863 µg/kg bw per day for the high external exposure, 
respectively. The CEF Panel considers that more data would be needed for BPA absorption through 
the skin, on skin metabolism and for patterns of thermal paper handling by the general population in 
order to provide a refined estimate of exposure through this source to reduce the uncertainty in the 
estimate. 
In children under the age of three years (except for infants in the first few days of life) dust was the 
second largest source of external exposure to BPA and ranged from 0.009 to 0.015 µg/kg bw per day 
for average and high external exposure, respectively. 
Average external exposure to BPA from other sources such as toys and cosmetics was estimated to be 
less than 0.001 µg/kg bw per day and 0.005 µg/kg bw per day, respectively, in all population groups. 
For the four age classes covering infants from 1 day up to 6 months, the average internal exposure to 
total BPA, as estimated by forward modelling, ranged from 0.042 µg/kg bw per day to 0.226 µg/kg bw 
per day. The average internal exposure for the population older than six months ranged from 0.301 to 
0.387 µg/kg bw per day in children aged 3 to 10 years and infants aged 6 to12 months and from 0.124 
to 0.172 µg/kg bw per day in the elderly/very elderly and adolescents. 
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For the four age classes covering infants from 1 day up to 6 months the high internal exposure to total 
BPA ranged from 0.101 µg/kg bw per day to 0.621 µg/kg bw per day. The high internal exposure for 
populations older than six months ranged from 0.873 to 0.878 µg/kg bw per day in toddlers and infants 
aged 6 to 12 months, and from 0.393 to 0.473 µg/kg bw per day in men and adolescents. 
Internal exposures to total BPA, as estimated by forward modelling, are in good agreement with the 
backward-modelling estimates obtained from urinary biomonitoring, suggesting that it is likely that no 
major exposure sources have been missed for the forward-modelled exposure assessment. It is, 
however, important to highlight the fact that the internal exposure estimation of total BPA includes 
conservative assumptions resulting in likely overestimation of exposure that could in theory have 
hidden other possible sources of exposure. The CEF Panel noted also that there are considerable 
uncertainties in the forward and backward estimates of internal exposure. 
The CEF Panel has carried out an assessment of aggregated dietary  and non-dietary exposure  
tounconjugated BPA using PBPK modelling. This aggregated exposure assessment included diet and 
house dust (the main oral-route sources) as well as thermal paper and cosmetics (the main dermal-
route sources).   
6.2. Hazard identification 
The overall conclusions of the CEF Panel on the hazard identification step for BPA in relation to each 
endpoint considered are summarised in the following sections. 
6.2.1. Toxicokinetics 
• Species- and life stage-dependent differences in the toxicokinetic profile of BPA must be 
considered when comparing toxicokinetic data from different species.  
• Conjugation to BPA-glucuronide is the major metabolic pathway of BPA in humans, non-human 
primates and rodents. Glucuronidated BPA is a biologically inactive form of BPA at the oestrogen 
receptors (ERs), however it cannot be excluded that the glucuronidated form may have effects at 
ER independent sites. BPA can also be conjugated via sulfation to a lower extent.   
• The oral systemic bioavailability of unconjugated BPA in adults is as follows: 2.8 % in rats, 0.45 
% in mice and 0.9 % in monkeys, based on oral versus intravenous toxicokinetic 
dataUnconjugated BPA and BPA-conjugates are observable at low concentrations in the amniotic 
fluid of rats and monkeys in comparison with serum levels. In early pregnancy exposure of the 
fetus might be greater compared with later pregnancy after i.v. exposure to BPA.  
• BPA is present in rat milk from BPA-treated dams in both unconjugated and conjugated forms. In 
rat milk, BPA-glucuronide comprises about 80% of the total BPA concentration. Pup exposure via 
lactation is low, i.e. about 1/300 of the maternal dose. Unconjugated BPA has also been reported 
in human milk. 
• BPA-conjugating enzymes (UDP-glucuronyl-transferases (UGT) and sulfotransferases (SULT)) 
are polymorphic in humans. The default intraspecies uncertainty factors used to derive a health-
based guidance value are considered sufficient to account for possible differences in rates of 
metabolism of BPA between human individuals. 
• A solid base of toxicokinetic studies in various laboratory animal species provides internal dose 
metrics for neonatal-to-adult stages and for different routes of exposure. Moreover, PBPK models 
have been developed to predict the internal exposures in laboratory animals and humans in a 
route-specific manner.  
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• Overall, this body of information permits extrapolation to humans and the application of the 
human equivalent dose (HED) concept for providing HEDs for points of departure derived from 
animal data. This was achieved by estimating human equivalent dose factors (HEDF) from the 
ratio of the Area Under the Curve (AUC) for the test species and AUCs for humans. Available 
experimental evidence indicates a 24-h percutaneous penetration of BPA across human skin of 
2.3–8.6%. For exposure scenarios with dermal contact to thermal paper, the CEF Panel used a 
conservative value of 10% dermal absorptionThe CEF Panel did not consider skin metabolism 
(conservative decision). For scenarios with aggregated oral and dermal exposures, PBPK 
modelling was used to estimate the internal dose metrics (AUCs) for unconjugated BPA, with 
which equivalent oral exposures were subsequently calculated. 
6.2.2. General toxicity 
• BPA was found to affect kidney and liver weight in parental animals and in all the generations of 
rats and mice examined in multi-generation studies. These effects were considered by EFSA 
(2006) and EFSA CEF Panel (2010) as relevant systemic effects for the identification of a 
NOAEL. In mice the increased kidney weight was associated with nephropathy at the highest BPA 
dose. Liver weight was increased in rats (relative weight) and mice (both absolute and relative 
weight). The latter species also showed hepatocellular hypertrophy.  
• The CEF Panel re-confirmed that the changes in the kidney and liver are critical endpoints in BPA 
toxicity and therefore took them forward for hazard characterisation. 
6.2.3. Reproductive and developmental effects 
• Only limited conclusions can be drawn from human studies on the likelihood of associations 
between BPA exposure during pregnancy and disturbed fetal growth, or maternal and infant 
decreased thyroid function. The evidence is not sufficient to infer a causal link between BPA 
exposure and reproductive effects in humans.  
• Data considered in previous EFSA opinions show that BPA is a reproductive toxicant at high dose 
levels. On balance, the evidence from new lower dose (below 3.6 mg/kg bw per day, that 
corresponds to the NOAEL for general toxicity transformed in HED) animal studies for changes in 
reproductive function arising from in utero exposure to BPA remains contradictory and highly 
variable between studies. Furthermore, the biological relevance to humans of some of the effects 
of BPA exposure observed in some animal studies (e.g. reduced ano-genital distance in females) is 
not well understood. The CEF Panel noted that there is some evidence for effects of BPA exposure 
on several parameters indicative for changes in the reproductive system in adult male animals at 
dose levels below 3.6 mg/kg bw per day, although these effects were modest. It is not possible to 
conclude that these changes are reflective of changes in reproductive performance, since the 
studies rarely included a forced/continuous breeding phase in adulthood to establish reduced 
fertility. However, in several multigeneration studies no effects were observed at dose levels as 
low as 3 µg/kg bw per day up to at least 50 mg/kg bw per day.  
• The CEF Panel re-confirmed that BPA is a reproductive toxicant at high dose levels.  
• Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to 
reproductive and developmental effects of BPA at low doses (below the HED of 3.6 mg/kg bw per 
day). Since the likelihood level for this endpoint is less than "likely" (see  Appendix A), this 
endpoint was not taken forward for assessing the toxicological reference point, but was taken into 
account in the evaluation of uncertainty for hazard characterisation and risk characterisation. 
6.2.4. Neurological, neurodevelopmental and neuroendocrine effects 
• There are indications from prospective studies in humans that prenatal BPA exposure (BPA 
exposure during pregnancy) may be associated with altered child behaviour in a sex-dependent 
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manner. However, the associations were not consistent across the studies and it cannot be ruled 
out that the results are confounded by diet or concurrent exposure factors. The associations 
reported do not provide sufficient evidence to infer a causal link between BPA exposure during 
pregnancy or childhood and neurodevelopmental effects in humans.  
• A number of new studies report changes that may indicate effects of BPA on brain development 
(effect on neurogenesis and on gene expression, neuroendocrine effects, effects on the 
morphology of certain brain regions, etc.). Whether such changes are mechanistically related to 
the neurobehavioral responses reported following exposure is attempted addressed by some 
studies but with inconsistent results.  
• Several new animal studies investigated anxiety-like behaviour, learning and memory, social 
behaviour and sensory-motor function. Some studies report changes in anxiety-like behaviour 
after BPA exposure. Some, but not all, studies reported significant impairment of either learning 
and/or memory capacities. A few studies also report effects on social behaviour and sensory-motor 
function. However, the studies present methodological shortcomings, such as small sample size, 
lack of consideration of the litter effect, not properly controlled variability of exposure through 
diet and inadequate statistics. Moreover the results from different studies are inconsistent.  
• Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to 
neurological, neurodevelopmental and neuroendocrine effects of BPA. Since the likelihood level 
for this endpoint is less than "likely" (see Box 1), this endpoint was not taken forward for 
assessing the toxicological reference point, but was taken into account in the evaluation of 
uncertainty for hazard characterisation and risk characterisation.  
6.2.5. Immune effects 
• Based on recent studies, there are indications that BPA exposure may be linked to immunological 
outcomes in humans, although these studies had limitations and confounding factors may have 
been present. A causal link between BPA exposure during pregnancy or in childhood and immune 
effects in humans cannot be established.   
• Studies in animals lend support to the possibility of immunological effects of BPA. Most of these 
studies suffered from shortcomings in experimental design and reporting. Although dose-
responses could not be confidently established in most studies, a dose-related effect was observed 
in allergic lung inflammation.  
• Using a WoE approach, the CEF Panel assigned a likelihood level of “-as likely as not- to likely” 
to immunotoxic effects of BPA. Since the likelihood level for this endpoint is less than "likely" 
(see  Appendix A), this endpoint was not taken forward for assessing the toxicological reference 
point, but was taken into account in the evaluation of uncertainty for hazard characterisation and 
risk characterisation.  
6.2.6. Cardiovascular effects 
• All but one study, among the newly considered human studies in relation to cardiovascular 
effects since the 2010 EFSA opinion, are cross-sectional and thus unsuitable to study BPA 
exposure-disease associations on their own. There are indications from one prospective study that 
BPA may be associated with such effects but overall a causal link between BPA exposure and 
cardiovascular effects in humans cannot be established.  
• There are insufficient animal data to suggest that BPA has an effect on cardiac function or causes 
cardiotoxicity.  
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• Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to 
cardiovascular effects of BPA. Since this likelihood level is less than “likely”, this endpoint was 
not taken forward for risk characterisation. It cannot be ruled out that the observed association 
between exposure to BPA and cardiovascular effect in the epidemiological studies is confounded 
by diet or other concurrent exposure factors. This association does not provide sufficient 
evidence to infer a causal link between BPA exposure and cardiovascular effects in humans. 
Since there is also a lack of information on the dose-relationship for this association, and since 
there were only very limited number of animal studies on this endpoint, this endpoint was not 
included in the uncertainty analysis. 
6.2.7. Metabolic effects 
• Of the reviewed human studies on metabolic effects only two were prospective while 22 were 
cross-sectional and thus not suitable on their own to study exposure-disease associations. 
Inconsistent with the results of cross-sectional studies one prospective study found that a higher 
BPA concentration in maternal urine during pregnancy was associated with a lower level of 
obesity in daughters. A causal link between BPA exposure and metabolic effects in humans cannot 
be established.  
• A number of studies in pre- and postnatally exposed rats and mice indicate that BPA exposure 
could have an effect on metabolic function as evidenced by effects on glucose or insulin regulation 
or lipogenesis, and body weight gain (short-term studies).  Based on the results from other studies 
with a longer duration (e.g. 90 days) there is no convincing evidence that BPA is obesogenic after 
intrauterine exposure or in longer-term studies.  
• Using a WoE approach, the CEF Panel assigned a likelihood level of “as likely as not” to 
metabolic effects of BPA. Since the likelihood level for this endpoint is less than "likely" (see 
Appendix A), this endpoint was not taken forward for assessing the toxicological reference point, 
but was taken into account in the evaluation of uncertainty for hazard characterisation and risk 
characterisation. 
6.2.8. Genotoxicity 
• The available data support that BPA is not mutagenic (in bacteria or mammalian cells), or 
clastogenic (micronuclei and chromosomal aberrations). The potential of BPA to produce 
aneuploidy in vitro was not expressed in vivo. The positive finding in the postlabelling assays in 
vitro and in vivo is unlikely to be of concern, given the lack of mutagenicity and clastogenicity of 
BPA in vitro and in vivo. 
• Using a WoE approach, the CEF Panel assigned a likelihood level of “unlikely” to BPA 
genotoxicity.  
6.2.9. Carcinogenicity 
• Very few epidemiological studies published to date have investigated a possible association 
between exposure to BPA and incidence of certain cancers, specifically breast cancer and 
meningioma. These studies do not allow any conclusion to be drawn regarding the carcinogenicity 
of BPA in humans.  
• BPA was not carcinogenic in two standard oral carcinogenicity studies in rats and mice. In a more 
recent study, female but not male mice, exposed to approximately 10 mg/kg bw per day BPA from 
in utero up to postnatal day (PND) 21, developed significantly more hepatocellular tumours 
(adenomas and carcinomas together) with or without preneoplastic lesions after a stop-exposure 
period of 10 months. Additional rodent studies on perinatal exposure to BPA investigated the 
potential carcinogenic effect in mammary gland. Due to weaknesses in these studies the results do 
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not provide convincing evidence that BPA is carcinogenic to the liver during adult life or in 
mammary gland following perinatal exposure.  
• Using a WoE approach, the CEF Panel assigned a likelihood level of “unlikely to - as likely as not 
-” to carcinogenic effects of BPA. Since the likelihood level for this endpoint is less than "as likely 
as not” (see Appendix A), this endpoint was not taken into account in the evaluation of uncertainty 
for hazard characterisation and risk characterisation. 
6.2.10. Proliferative and morphological changes potentially related to carcinogenesis 
• Earlier evidence for BPA effects on cell proliferation and differentiation in the mammary gland 
and other tissues (e.g. prostate or testis) has been supported by recent studies. The proliferative 
changes in the mammary gland reported in these new studies, including a non-human primate 
study, are insufficient to conclude that there is a link to cancer development in later life. However, 
there might be a possible role of BPA in increasing the susceptibility to mammary gland 
carcinogenesis later in life.  
• The proliferative responses and possibly enhanced sensitivity to mammary gland carcinogens seen 
in animal studies might be of relevance for human health and are therefore included in the risk 
assessment.  
• Using a WoE approach, the CEF Panel assigned a likelihood level of “likely” to BPA induced 
proliferative changes in the mammary gland. Therefore, this endpoint was brought forward for 
hazard characterisation and for uncertainty analysis. 
• The CEF Panel considered that the evidence for proliferative changes induced by BPA in other 
organs (e.g. prostate or testis) is currently too limited to reach any conclusion.  
6.2.11. Mechanistic studies with BPA including epigenetic effects 
• Mechanistic studies published since 2010 continue to support the conclusion that BPA affects a 
number of receptor-dependent and independent signalling pathways, resulting in effects on 
hormone homeostasis and gene expression as well as cytogenetic and in epigenetic effects.  
• The CEF Panel confirmed its conclusion in its opinion of 2010 that no single clearly defined mode 
of action of BPA can be identified that can contribute substantially to the understanding of the 
potential effects of BPA in humans.   
6.3. Hazard characterisation 
• The CEF Panel developed criteria for nonmonotonic dose-responses (NMDRs) and reviewed 
studies reporting a NMDR for BPA. None of the studies fulfil these criteria. Overall the CEF 
Panel concluded that the available data do not provide evidence that BPA exhibits a NMDR for 
the endpoints considered (reproductive/developmental toxicity, neurotoxicity/behavioural effects, 
metabolic effects, proliferative changes in mammary gland).   
• Hazard characterisation was carried out only for those endpoints for which the overall likelihood 
for a specific effect of BPA was considered “likely” in the WoE approach. Dose-response 
relationships were examined for the most reliable studies supporting "likely effects", in order to 
provide a reference point for establishing a health-based guidance value. 
• The CEF Panel has carried out dose-response (Benchmark Dose [BMD]) modelling on the data for 
general toxicity and for the proliferative changes in the mammary gland. The analysis on the 
mammary gland data revealed large differences in the BMD estimates obtained with the various 
models and the wide BMD confidence intervals obtained with some of the models. The CEF Panel 
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concluded that the dose-response data were not suitable to derive with any confidence a reference 
point for this endpoint.   
• The CEF Panel therefore used only the endpoint “general toxicity” for risk characterisation, and 
specifically the mean relative kidney weight in a two generation study in mice, and calculated a 
BMDL10 of 8 960 µg/kg bw per day.  
• Subsequent to the 2010 opinion, new toxicokinetic data have become available which allow a 
more accurate substance-specific extrapolation of data from animals to humans, using the human 
equivalent dose (HED) approach. The human equivalent dose factor (HEDF) of 0.068 for oral 
exposure of adult mice was applied to the BMDL10 of 8 960 µg/kg bw per day, which results in a 
HED of 609 µg/kg bw per day. The CEF Panel decided to use the HED value of 609 µg/kg bw per 
day as the reference point for establishing a health-based guidance value for BPA.  
6.3.1. Uncertainty 
• The overall uncertainty evaluation included the effects on mammary gland as well as reproductive, 
metabolic, neurobehavioural and immune systems. The CEF Panel concluded that the health-based 
guidance value should cover the lowest dose in the dose range for which the likelihood approaches 
“likely” from the overall uncertainty evaluation, taking into account uncertainty of all the 
evaluated endpoints as well as their relevance and adversity to humans. The uncertainty evaluation 
approached “likely” in the (HED) dose range of 100-1000 µg/kg bw per day. The CEF Panel 
therefore decided that the uncertainty regarding the above mentioned effects at the HED of 100 
µg/kg bw per day and higher should be taken into account when establishing a health-based 
guidance value by including an extra factor in establishing the TDI. Thus, as the reference point 
was 609 µg/kg bw per day based on the mean relative kidney weight and the lower end of the 
dose-range for which the uncertainty evaluation for other endpoints approached “likely” is 100 
µg/kg bw per day, a factor of 6 was applied.  
6.3.2.  Health-based guidance value 
• In deriving a health-based guidance value, the CEF Panel used an uncertainty factor of 2.5 for 
inter-species differences (1 for toxicokinetics and 2.5 for toxicodynamics, reflecting the fact that 
toxicokinetic differences have been addressed by use of the HED approach) and an uncertainty 
factor of 10 for intra-species differences. In addition, the CEF Panel considered that the extra 
factor of 6 should be included to take into account the uncertainty in the database, i.e. mammary 
gland and reproductive, neurobehavioural, immune, and metabolic systems.  
• The CEF Panel applied, therefore, an overall uncertainty factor of 150 to the HED of 609 µg/kg 
bw per day and established a temporary Tolerable Daily Intake (t-TDI) for external oral exposure 
to BPA in humans of 4 µg/kg bw, based on the mean relative kidney weight effect in mice. The 
CEF Panel designated the TDI as temporary, pending the outcome of the long-term study in rats 
involving prenatal as well as postnatal exposure to BPA, currently being undertaken by NTP/FDA.  
6.4. Risk characterisation 
• Comparison of the estimates for high dietary exposure for all age groups with the t-TDI of 4 
µg/kg bw per day showed that the dietary exposure in all age groups (including the most exposed 
groups, i.e. 6-12 months infants and toddlers with levels of 0.857 µg/kg bw per day) was more 
than 4-fold below the t-TDI, indicating no health concern from dietary exposure alone. The 
additional contribution from other oral sources, like dust and toys mouthing (high exposure up to 
0.015 µg/kg bw per day), did not change this conclusion. 
• Comparison of the aggregated estimates for exposure to dietary and non-dietary sources of 
“children 3-10 years” and adolescents with the t-TDI showed that even when the high exposure 
estimates for dietary and non-dietary sources are combined, the aggregated exposure for children 
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3-10 years (1.258 µg/kg bw per day) and adolescents (1.449 µg/kg bw per day) will be 
approximately 3-fold below the t-TDI.  
• The aggregated high dietary and non-dietary exposures (including oral and dermal sources) for 
women (1.063 µg/kg bw per day) and men (1.010 µg/kg bw per day) are mostly identical and 
they are lower than those for adolescents and children 3-10 years. The CEF Panel considered that 
these exposure estimates (up to approximately 1 µg/kg bw per day) for men and for women 
including pregnant women and prenatally exposed children, will be approximately 4-fold below 
the t-TDI of 4 µg/kg bw per day. 
• Having evaluated the overall uncertainty of this assessment, the upper bound of the uncertainty 
interval for dietary BPA exposure alone did not exceed the t-TDI for any age group. Upper 
bounds for the uncertainty of high but not average aggregate exposure estimates to BPA exceed 
the t-TDI but the lower bounds are considerably lower than the t-TDI. The wide uncertainty 
intervals are caused by uncertainty about the magnitude of external exposure to BPA from 
thermal paper, about the proportion of the amount of BPA which is absorbed through the skin, 
and about the choice of PBPK model for converting dermal exposures to oral equivalents. 
7. Overall conclusions 
The CEF Panel concludes that the dietary exposure to BPA for the highest exposed groups, which 
include infants children  and adolescents, is below the t-TDI of 4 µg/kg bw per day, indicating that 
there is no  health concern for BPA at the estimated levels of exposure. These conclusions also apply 
to prenatally exposed children and to the elderly.  
In addition, the CEF Panel concludes that the central estimates for aggregated exposure to BPA via the 
dietary and non-dietary sources (dust, toys, cosmetics and thermal paper) for the highest exposed 
groups, which includes infants, children, and adolescents, is also below the t-TDI of 4 µg/kg bw per 
day, indicating that the health concern for BPA is low at the estimated levels of exposure. However, 
the CEF Panel noted that there is considerable uncertainty in the exposure estimate for the non-dietary 
sources. 
8. Recommendations 
Reflecting the uncertainties surrounding this risk assessment of BPA as outlined in the previous 
section, the CEF Panel considers that further research in the following areas would be useful:  
− Further work to refine the Human Equivalent Dose approach used in this opinion to 
extrapolate from experimental results in animals to humans, including further refinement of 
the toxicokinetics of unconjugated BPA in mice   
− Further refinement of the human PBPK modelling applied in the opinion 
− Further studies on the frequency and extent of dermal contact with BPA containing materials 
− Further studies on the extent of dermal absorption following exposure to BPA by the dermal 
route in humans and the toxicokinetics of BPA following dermal absorption in humans and 
experimental animals 
− Mechanistic studies in the kidney to determine the mode of action  of BPA in this organ  
− Further research on the significance of proliferative and morphological changes in mammary 
gland following exposure to BPA and the possible relevance for the development of breast 
cancer 
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− Further research on the potential adverse health effects of BPA for which there are 
uncertainties and that were therefore not definitevely considered as “likely” in this opinion, in 
particular reproductive, neurobehavioural, immunological and metabolic endpoints, using 
validated, robust methodology.  
− Further investigations designed to explore the occurrence of non-monotonic dose-responses 
following in vivo exposure to BPA. 
− Investigations to clarify the extent and the sources of unconjugated BPA in meat and fish.   
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GLOSSARY  
External exposure: the amount of BPA with which the body comes into contact before it is absorbed 
through skin, lungs or GI-tract. 
Internal exposure: the total amount of BPA which is present in the body irrespective of its form (i.e. 
the sum of conjugated plus unconjugatd BPA in the body) 
Aggregated exposure: the sum of unconjugated BPA in the body, irrespective of the route through 
which it entered ther body. The aggregated exposure is the ultimate exposure estimate that will be at 
the basis of the risk assessment. Since the reference dose of BPA (i.e. the t-TDI) is expressed as an 
external oral exposure, aggregated exposure is equal to oral exposure to which contributions to the 
exposure via other routes are added, after conversion of these contributions to their equivalent oral 
exposures, with use of PBPK modelling. 
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APPENDICES  
Appendix A.  Detailed methodology applied to perform hazard identification and 
characterisation and risk characterisation of BPA 
Appendix A describes in detail the methodology applied in this opinion to perform hazard 
identification and characterisation and risk characterisation of BPA. A brief overview of this 
methodology is also presented in section 2 of the scientific opinion. 
Graphical figures showing toxicological data were generated in the statistical computing environment 
R (R Core Team, 2014) in combination with R using the R lattice package (Sarkar et al., 2008). 
 
Identification and selection of evidence relevant to hazard identification and characterisation 
 
For identifying relevant studies for hazard identification and characterisation, different sources of 
evidence were considered as illustrated below. All studies considered for hazard assessment and risk 
characterization are reported in Appendix B. In the next sections details are given on the process for 
identifying and selecting relevant studies. 
The sources of studies considered for hazard identification and characterisation 
Study sources 
Studies that EFSA (EFSA, 2006; EFSA CEF Panel, 2010) or other risk assessment bodies had previously 
identified as crucial for BPA toxicological assessment 
In vitro and in vivo studies on genotoxicity published after the 2006 EFSA opinion  
Studies that were present in the list of the retrieved articles for the preparation of the EFSA opinion of 2010 
(EFSA CEF Panel, 2010), but were not then evaluated because they did not match the inclusion criteria 
established at the time, e.g. non oral studies, exposure during adult age, single dose 
Studies retrieved via a literature search for the period August 2010-December 2012 
Studies included in the report of Réseau Environnement Santé (RES, 2012) on BPA-related risks 
Additional studies becoming available after 2012 
Studies cited in the public consultation (ended on 13 March 2014) comments and original raw data submitted in 
this context (if relevant to the questions addressed by the opinion) 
 
Evidence available until July14 2010 
The background information for this risk assessment was provided by the earlier evaluations of BPA 
by a number of expert bodies (SCF, 2002; EU RAR, 2003; 2008; EFSA, 2006; 2008; 2010; Health 
Canada, 2008; NTP, 2008, US FDA, 2010a, FAO/WHO, 2011; ANSES, 2011; 2013 - see summary in 
Section 1.1). 
For the WoE approach, the conclusions from the EFSA opinions on BPA of 2006 and/or 2010 were 
taken as starting point by the members of the working group on BPA toxicology. 
The working group also revisited some individual studies that EFSA and/or other risk assessment 
bodies had previously identified as crucial for BPA toxicological assessment. These studies were 
included, along with new studies published from August 2010 onwards (see below), in the WoE 
approach, as starting point. 
In vitro and in vivo studies on genotoxicity published after the EFSA opinion from 2006 were also 
considered for this risk assessment, since genotoxicity was not specifically dealt with in the 2010 
                                                     
14 Time of adoption of the 2010 EFSA Opinion on BPA dealing with hazard identification and characterisation (EFSA CEF 
Panel, 2010). 
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EFSA opinion. These studies were identified by performing a thorough literature search and selected 
for relevance in line with the EFSA Scientific opinion on genotoxicity testing strategies applicable to 
food and feed safety assessment (http://www.efsa.europa.eu/en/efsajournal/pub/2379.htm). The studies 
on genotoxicity that were reviewed are reported in Appendix B. 
In addition, studies that were present in the list of the retrieved articles for the preparation of the EFSA 
opinion of 2010, but were not then evaluated because they did not match the inclusion criteria 
established at the time, e.g. non-oral studies, exposure during adult age, single dose studies, were 
identified by the EFSA secretariat and provided to the experts for review. When considered relevant, 
they were included in the WoE approach as “lines of evidence”. 
Evidence available between August 2010 and December 2012 
In addition to the above, EFSA outsourced a thorough literature search15 aiming at identifying as many 
relevant studies as possible published between August 2010 and December 2012. 
The approach to searching was sensitive, i.e. the search terms contained only the term “Bisphenol16” 
or “BPA” without any additional search terms, in order to retrieve as many studies as possible relevant 
to hazard identification and characterisation of BPA and minimize the risk of publication bias. The 
details and results of the searches are reported in table 24 of this Appendix. 
The studies retrieved were screened against pre-defined selection criteria, by the external contractor, 
EFSA secretariat and the members of the EFSA WG on BPA toxicology. The criteria for study 
selection are illustrated below. All studies included in this risk assessment are listed in Appendix B. 
Criteria for study selection 
• Relevant studies were defined as primary research studies17 published in peer-reviewed 
journals in the period August 2010 - December 2012 and dealing with human/animal/in vitro 
toxicity of Bisphenol A (studies dealing with other forms of BPA/metabolites were excluded); 
• Reviews were considered as sources of studies (and not considered in the risk assessment as 
such); 
• Only studies in English were included; 
• Studies not in the field of animal and human health were excluded (e.g. ecotoxicity studies); 
• Studies in the fields of chemistry or physics, where BPA was used or involved in the synthesis 
of other compounds were excluded;  
• Human studies: 
o Biomonitoring studies and epidemiological studies addressing associations between 
BPA exposure and an adverse health outcome in a particular population, all designs 
(e.g. cross-sectional studies were also included); 
o All routes of exposure (also non-oral routes); 
o Including ex vivo studies. 
 
• Animal toxicity studies, including non-oral routes of exposure: 
o single dose studies were included as potential supporting evidence for hazard 
identification; 
o For reproductive and developmental toxicity studies in animals, studies were excluded 
if all the doses used exceeded the oral HED of 3.6 mg BPA/kg bw per day (see list in 
Appendix B). 
                                                     
15 Contract CT/EFSA/CEF/2011/01 – Screening of literature on BPA 
16 It was decided to use “Bisphenol” instead of “Bisphenol A” to avoid excluding studies where in text it wass reported “the 
form A of Bisphenol”. 
17 i.e. studies generating new data, as opposite to “secondary research” studies (i.e. reviews). 
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This was justified on the basis that the study of Tyl et al. (2002) offered a well-established oral 
NOAEL of 5 mg BPA/kg bw per day in the rat, with a higher NOAEL of 50 mg BPA/kg bw per day 
for reproductive effects. Depending on the animal species and route of administration, a correspondent 
oral HED (see Section 3.1.5 and Appendix D) was calculated for each dose level used in a particular in 
vivo study, using the HEDFs for adults and infants. Any study employing BPA doses exceeding the 
HEDs of 3.6 mg BPA/kg bw per day (equivalent to the NOAEL of 5 mg BPA/kg bw per day in the 
rat) was excluded from the assessment, unless it also included a dose level or dose levels (HEDs) < 3.6 
mg BPA/kg bw per day. The data for sheep were not available to calculate the HED and therefore a 
ratio of 1:1 was assumed, which led to the inclusion of 1 study and exclusion of 1 study. Also studies 
addressing the toxicity of BPA in mixtures were condifered relevant to the purpose of this review.  
In the case of the in vitro studies not addressing genotoxicity, an additional exclusion criterion was 
applied, i.e. studies using concentrations equal or above 100 nM were excluded. In vitro studies 
performed at high concentrations of BPA were not considered relevant due to either the induction of 
cytotoxic effects or the use of concentrations not reachable in human serum after BPA intakes at or 
below the current TDI of 50 µg/kg bw per day. Several publications indicate that BPA at or below 10-
100 µM reduces cell viability in vitro, e.g. in human breast cancer cells (Zhang et al., 2011), a murine 
Sertoli cell line (Wang et al., 2012d), stem cell lines (Biemann et al., 2012) or human oocytes (Brienõ-
Enriquezet al., 2012). In addition, based on results from toxicokinetic studies (Doerge et al., 2010a,b, 
and 2011b; Taylor et al., 2011) the CEF Panel is of the view that human BPA intake at the current TDI 
of 50 µg/kg bw per day would lead to unconjugated BPA serum concentrations in the order of 0.1-2 
nM. Human kinetic studies suggested that consumption of food resulted in BPA intakes which were at 
least two orders of magnitude below the TDI (see EFSA CEF Panel (2013) for draft exposure part of 
the BPA opinion). Therefore, based on the above considerations and also taking into account 
potentially different effects of low and high BPA concentrations for some endpoints in in vitro studies 
(non-monotonic dose-response curves, see Section 1.2 on NMDR) and assuming a maximum factor of 
50 applied to the nominal concentration to account for unspecific binding of BPA to cell culture 
devices, it was decided to exclude in vitro studies with nominal concentrations at or higher than 100 
nM BPA for the purpose of this evaluation. 
The results of the literature search were also compared with the compilation of published scientific 
studies on BPA submitted by Réseau Environnement Santé to the European Commission and received 
by EFSA on 19 February 2013. The few publications identified as missing were screened by the EFSA 
secretariat against the relevance criteria illustrated above.The excluded studies and the underlying 
motivations are presented in Appendix B. 
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Table 24:  Details and results of the literature search process (August 2010-December 2012) 
(a):  Two searches run separately using “Bisphenol” and “BPA” in all fields (Text, Abstracts, Keywords, etc). 
(b): The filters “Life Sciences” and “Health Sciences” were applied. c Two searches run separately using “Bisphenol” and “BPA” only in the field “Topic”. The filters with fields dealing with 
“Life Sciences” and “Health Sciences” were applied. 
(c):  Two searches run separately using “Bisphenol” and “BPA” only in the field “Abstract”. 
 
                                                     
18 The Directory of Open Access Journals (DOAJ) is website that lists open access journals and is maintained by Infrastructure Services for Open Access. The project defines open access 
journals as scientific and scholarly journals that meet high quality standards by exercising peer review or editorial quality control and "use a funding model that does not charge readers or their 











Date of the search:  
August 2010-December 2012 (searches 
performed almost every day) 
Date of the search: August 
2010- December 2012 (searches 
performed almost every day) 
Date of the search: 
January 2010- December 
2012 (searches performed 
at least once a month) 
Date of the search: January 2010 - 
December 2012 (searches 
performed almost every day) 
Date of the search: 
January 2010 - 
December 2012 
(searches performed at 
least once a month) 
Search terms (a) 
Bisphenol (Total records retrieved: 1485) 
BPA (Total records retrieved: 808) 
Search terms (a) 
Bisphenol (Total records 
retrieved: 1061) 
BPA (Total records retrieved: 
646) 
Search terms (a), (b) 
Bisphenol (Total records 
retrieved: 1551) 
BPA (Total records 
retrieved: 813) 
Search terms (c) 
Bisphenol (Total records retrieved: 
3542; toxicology: 988) 
BPA (Total records retrieved: 1088; 
toxicology: 545) 
Search terms (c) 
Bisphenol (Total 
records retrieved: 85) 
BPA (Total records 
retrieved: 59) 
Total number of records retrieved: 
2293 
Total number of records 
retrieved: 1707 
Total number of records 
retrieved: 2364 
Total number of records 
retrieved: 4630 (toxicology: 1533) 
Total number of 
records retrieved: 144 
Total number of records retrieved 
after removing duplicates: 1612 
Total number of records 
retrieved after removing 
duplicates: 1192 
Total number of records 
retrieved after removing 
duplicates: 1696 
Total number of records 
retrieved after removing 
duplicates: 3731 (toxicology: 
1003) 
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Evidence available after 2012 
Additional studies made available in 2013 were considered in this review on a case by case basis (see 
Appendix B). Although the CEF Panel acknowledges that these studies may not represent the entire 
body of evidence that has become available after  2012 , these studies were considered based on expert 
judgement because of their relevance to the review questions and/or their methodological soundness. 
Other evidence in the context of the public consultation  
The papers that were mentioned in the comments submitted during the public consultation on the draft 
assessment of BPA health risks (and the full comments themselves) are reported in the EFSA 
Technical report “Outcome of the public consultations on the Draft Scientific Opinion of the EFSA 
Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids on the Risks to Public 
Health related to the presence of Bisphenol A (BPA) in foodstuffs” (EFSA, 2015).  
Among these papers and irrespective of their publication date, those relevant to BPA hazard 
assessment were screened against the reference list in the pre-public consultation draft opinion. The 
missing studies that the Panel considered relevant to address the review questions were included in the 
revised evaluation and treated as all the other evidence as further explained below.  
Upon discretion of the CEF Panel and on the basis of their relevance and methodological soundness, 
original raw data submitted as a result of the public consultation were also considered for the 
assessment.  
1. Assessment of individual studies for BPA toxicological evaluation  
The studies relevant to hazard identification were then grouped according to macro-areas of interest, 
e.g. toxicokinetics and metabolism, general toxicity, reproductive and developmental effects, and 
relative study type, i.e. human, animal or in vitro study (see table 25). The studies selected for 
inclusion in the Opinion were considered by the working group as described in the right column. 
Table 25:  Macro-areas by which the relevant studies for BPA hazard identification were 
grouped and consideration of the studies used for the toxicological evaluation 
Study content How the study was considered 
1. Toxicokinetics and metabolism (human and animal 
studies) 
2. General toxicity (animal studies) 
Appraisal of strengths and weaknesses (see 
Appendix B) 
3. Reproductive and developmental effects (human 
and animal studies) 
4. Neurological, neurodevelopmental and 
neuroendocrine effects (human and animal studies) 
5. Immune effects (human and animal studies) 
6. Cardiovascular effects (human and animal studies) 
7. Metabolic effects (human and animal studies) 
8. Genotoxicity (in vitro and in vivo studies) 
9. Carcinogenicity (human and animal studies) 
 
Appraisal of strengths and weaknesses (see 
Appendix B) and inclusion in the WoE 
approach used for hazard identification (see 
Appendices B and C) 
10. Mechanisms of action of BPA (including 
epigenetics and gene expression studies) 
11. In vitro studies 
Examination and use as supplementary 
information for the toxicological evaluation 
(see Appendix B and Section 3.10) 
 
In particular, the appraisal of the strengths and weaknesses of each study was performed by two 
reviewers from the working group on BPA Toxicology (a rapporteur and a co-rapporteur) and their 
evaluation was presented to and further discussed by the entire working group. During this evaluation, 
studies not relevant to the review questions on the association between BPA and toxicological effects 
were excluded from the WoE approach (as specifically stated in Appendix B). 
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The criteria and principles applied for assessing study strengths and weaknesses are illustrated in the 
following sections. All studies assessed and the overall conclusions on each study are reported in 
Appendix B. 
Criteria and principles for assessing the strengths and weaknesses of human studies 
The CEF Panel took into consideration the following aspects for evaluating epidemiological studies. 
Cross-sectional studies assess exposures and health outcomes at the same time point and are 
inappropriate for making causal inference because reverse causation cannot be ruled out. For example, 
a reported association between BPA exposure and obesity is not sufficient evidence that BPA is a 
cause of obesity; it is a plausible assumption that obese people ingest more food and hence, that they 
ingest more BPA. 
Case-control studies examine multiple exposures in relation to a disease; subjects are defined as cases 
and controls, and exposure histories are compared. Case-control studies generally depend on the 
collection of retrospective data, thus introducing the possibility of recall bias. 
Cohort studies can be either retrospective or prospective. In a prospective cohort study, participants 
are followed over time and exposures are assessed prior to the incidence of the health outcome. In a 
retrospective cohort study, both the exposures and outcomes have already occurred when the study 
begins. Well designed and conducted cohort studies have more weight than case-control and cross-
sectional studies, but for all types of studies it is questionable to relate single BPA measurements to a 
health outcome developing over many years because of BPA’s short half-life. 
Limitations in study design, power, statistical methods, and study population may lead to inconsistent 
results. A study that has a valid exposure assessment, an appropriate sample size, a prospective design, 
a valid and reliable outcome and sound statistical handling provides more robust findings than a small 
study with obvious limitations independent of the statistical outcome.  
The health outcome reported should clearly be identifiable as an adverse event in humans, and it is 
important to evaluate the reliability and validity of the outcome measures used. Often, epidemiological 
studies rely on self-reported information, and this information can be biased. Doctors’ reports and 
health registries are less prone to reporting error, but it is important that the methods include concise 
and transparent information on how outcomes were assessed. The importance of using scientifically 
and clinically supportable exclusion criteria and outcome definitions has been highlighted by Lakind 
et al. (2012). For example, when reanalysing NHANES data, exposure-disease associations between 
BPA exposure and chronic disease outcomes were no longer statistically significant when using a-
priori selected methods to address the research question (Lakind et al., 2012). 
Valid and precise exposure assessment is a major challenge in studies of chemicals and human health 
outcomes. For substances like BPA that are rapidly eliminated, a single measurement, such as a single 
spot urine sample, does not provide a reliable estimate of long term exposure. The time interval 
between the onset of patho-physiological changes that precede the health outcome considered in a 
study and sample collection, on which the exposure assessment is based, is for such substances a 
major factor of concern. If in a study the biological samples were taken at a time that only reflects the 
exposure to the substance in question for a very limited time period before the taking of the samples, it 
is inappropriate to relate the exposure to health outcomes that may take years or decades to develop.  
The special considerations which apply for BPA because of analytical challenges and its 
toxicokinetics which were made for assessing study quality are covered in the Draft Scientific Opinion 
on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs – Part: 
exposure assessment (EFSA CEF Panel, 2013). The criteria and principles for assessing the strengths 
and weaknesses related to the analytical challenges are illustrated in table 24 of this Appendix. 
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In epidemiological studies of exposures and adverse health effects there is the need for sufficient 
confidence that the reported effects are indeed related to the exposure of interest and not confounded 
by correlated factors. Most epidemiological studies use statistical models to adjust for potential 
confounding by demographic, socioeconomic, lifestyle (including diet) and other factors. The 
appropriateness of such models was evaluated when assessing the individual studies. When an 
exposure is associated with an adverse health outcome, the association may in fact be explained by 
another factor, not measured in the study, which actually causes the disease. It is of particular 
importance to adjust the analyses for key confounding factors, of which the two most important in the 
case of BPA are socioeconomic position and dietary intake. The main source of BPA ingestion is from 
food packaging (polycarbonate drink bottles, tinned items etc), and consumption of energy-dense, 
processed (packaged) and tinned food tend to be higher in disadvantaged groups. NHANES data has 
revealed that individuals with lower incomes, who may also be more likely to suffer from other 
disparities in health and exposures, have a greater burden of exposure to BPA (Nelson et al., 2012). 
Even when relevant confounding variables are taken into account, the possibility of unmeasured or 
residual confounding cannot be excluded. Detailed discussion on the points to be considered in 
epidemiological studies is given in Geens et al. (2012) and such points were considered when 
assessing the individual studies. 
Epidemiological studies can demonstrate statistically significant associations between BPA and health 
outcomes, but it should be noted that statistical significance does not imply a causal relationship. 
Criteria for objectively evaluating the level of causality of associations observed in epidemiology have 
been formulated by Bradford Hill (1965) and include consistency, strength of association, dose-
response, time order, specificity, consistency on replication, predictive performance, biological 
plausibility and coherence. 
The strengths and weaknesses considered for appraising epidemiological studies are summarised in 
table 26. 
Table 26:  Criteria applied to assess the strengths and weaknesses of epidemiological studies 
Criteria Interpretation / Assessment  Comments 
 Strengths: Weaknesses:  
Study design 








 Short time frame 
 
Well designed and conducted 
prospective cohort studies have more 
weight than case-control and cross-
sectional studies. 
All cross-sectional studies were 
considered “weak by default” but 
included in the assessment for 
comparison of BPA concentrations 
across different populations and 
because cross-sectional studies can be 
considered as hypothesis- generating 
studies. However, they do not provide 
any meaningful information on 
exposure-disease associations. 
Selection of the 
population  
------ Selection bias (give 
details) 
For cohort studies selection bias was 
considered to arise when the 
comparison groups (exposed and 
unexposed) were not truly comparable.  
For case-control studies selection bias 
was considered to arise when cases 
were not representative of all cases 
within the defined population or 
controls were not representative of the 
population which produced the cases 
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Criteria Interpretation / Assessment  Comments 
 Strengths: Weaknesses:  
Sample size  Large sample size Small sample size 
 
For a non-persistent compound like 
BPA, the large variability in the 
exposure may to some degree be 
compensated by a sufficiently large 
sample size and by including repeated 
measures of exposure. Although the 
exposure estimate may be inaccurate at 
the individual level, ranking of subjects 
within a study population can give a 
fairly accurate indication of exposure at 
the group level. This was considered for 
evaluating study quality. 
Recall period  Reporting by two 
different sources 
(e.g. teachers and 
parents) 
Long recall period 
(retrospective 
collection of data) 
 
 
























creatinine or specific 
gravity) 
At current levels of oral and dermal 
exposure the concentrations of 
unconjugated BPA in 
blood/plasma/serum are typically below 
the LOD of specific analytical methods 
(< 0.1 ng/ml) and cannot be measured 
unless they result from a contamination 











Single spot urine 
BPA measurement 
 
Single measurements are interpreted as 
a weakness due to the short BPA half-
life (< 6 hours) 
 
Repeated measurements are interpreted 





of values below 
LOQ) 
Analytical method 
(SPE LC-MS-MS or 














No quality control 







Unspecific and cross-reactivity with 
other phenols and conjugates 
 
(to avoid sample contamination during 
collection, handling, and analysis)  
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Criteria Interpretation / Assessment  Comments 
 Strengths: Weaknesses:  
BPA 
 
Handling of values 
below LOQ) not 
reported 
Confounding factors ------ Confounding by 




not considered or not 
reported 
 
Study results documentation / study reporting 
Study reporting ------ Insufficient study 
reporting 
 
Statistical modelling  ------ Inappropriate 
statistics (give 
details),  
e.g. incomplete model description, too 
many categories, etc) 
Plausibility of the study design and results 
Clinical relevance  ------ Unclear clinical 
relevance  
e.g. unclear adversity of the effect, 
small effect size, etc) 





e.g. outcome based on self-reported 
information 
Generalisability to 
the total population  




e.g. study performed only in couples 





studies or tests 
Inconsistent results 
amongst different 






Professional exposure may occur by a 
route different from and not relevant to 
the general population. If studies were 
accompanied by urinary BPA measures, 
they were rated less weak than those 
without such measurements 
 
2. Criteria and principles applied for assessing the strengths and weaknesses of animal studies 
Table 27:  Criteria applied to assess the strengths and weaknesses of animal studies 
Criteria Interpretation/assessment Comments 
 Strengths: Weaknesses:  
Test substance identification 
Vehicle  ------ Vehicle not reported  
Test organism characterisation 
Species and strain of the 
animal  
------ Animal species and/or 
strain not reported 
 
Is the age and body 
weight of the test 
organisms given? 
------ Animal age and/or body 
weight not reported  
 
Is the sex of the test ------ Sex of the animals tested  
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Criteria Interpretation/assessment Comments 
 Strengths: Weaknesses:  
organism given?  not reported 
Study design description 
Use of a priori study 
protocol/study plan 
------ Lack of a priori study 
protocol or study plan 
 
Sample size – power of 
the study (number of 
animals) 
Large sample size Small sample size This is based on expert 
judgement 
Control procedures (Were 
negative and/or positive 
controls included (where 
required)?  
Both naïve controls and 
vehicle controls available 
 
Adequate positive 
controls included (if 
appropriate) 




Number of BPA doses   ≥ 3 dose levels tested Single dose level study Not mentioned as a 
strength or weakness if 2 
dose levels were tested 
BPA dose levels  Too wide dose spacing 
 
*Too high dose levels 
tested 
Wide dose spacing makes 
the study inadequate to 
study a dose-response 
relationship 
 
Testing of BPA at very 
high dose levels is not 
informative of effects 
occurring at current 
human exposure levels  
BPA exposure 
assessment 
------ Feed consumption (BPA 
given by the diet) not 
measured 
 
BPA concentration and 
homogeneity in the feed 
mixture not guaranteed 
analytically (BPA given 




BPA) not measured  
The exact BPA doses 
received by the animals 
cannot be established 
Route and type of 
administration / 
administration scheme 
Oral administration via 





via ip injection during 
pregnancy 
Not mentioned if: 
BPA was given via diet 
or drinking water and 
food/water consumption 
was measured;  
BPA was given via sc 
injection; 
 
Maternal dosing via ip 
injection during 
pregnancy was 
considered as a weakness 
due the uncertain fetal 
dosing  
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Criteria Interpretation/assessment Comments 
 Strengths: Weaknesses:  
Oral administration via 
gavage was considered as 
a strength due to exact 




due to animal handling 
Frequency and duration 
of exposure: 
 
Are frequency and 
duration of exposure as 
well as time-points of 
observations explained?  
------ Single acute dose 
administration 
Acute exposure is not 
representative of human 
exposure which is 
prolonged in time 
BPA exposure 
assessment 
BPA measurement in 
biological samples 
 The quality of the 
analysis is also checked 
Test performance  Test performed in one sex 
only 
 
Low number of animals 
tested (in a test) 
 
Blind treatment  
 
Blind treatment or Blind 
evaluation of samples…. 
------ Blind treatment was 
considered as a strength if 
reported, and was not 
mentioned if not reported 
Study results documentation/ Study reporting 
Study reporting ------ Insufficient study 
reporting (give details) 
Details, e.g. number of 
animals tested for each 
test unclear or not 
reported, time points 
unclear, dose levels etc 
Statistical analysis  ------ Inappropriate statistics 
(give details) 
 
Details, e.g. litter effect 
not considered, 
inappropriate analysis 
Plausibility of the study design and results 
Is the study design 
chosen appropriate for 
obtaining the substance-
specific data aimed at?  
------ Study design not 
appropriate to the scope 
 
Diet  Phytoestrogen-free diet 
(e.g. soy free diet) or feed 
content of oestrogens 
negligible at E-screen 
Animal diet and 
phytoestrogen content not 
reported (or poorly 
described) 




Use of non-polycarbonate 
(non-PC cages), and of 
non plastic (e.g. glass) or 
BPA-free water bottles 
 
Use of polycarbonate 
cages (PC) and plastic 
water bottles  
OR  
Type of cages and 
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Criteria Interpretation/assessment Comments 
 Strengths: Weaknesses:  
Quality assurance principles 
GLP/other quality 
assurance system  
 
Study/analysis performed 
under GLP or XX quality 
assurance system 
------  
Protocol according to 
existing guidelines, e.g. 
OECD guidelines or EU 
guidelines (or other e.g. 
national guidance)  
Study/test performed 
according to XX 
guidelines 
------  
Others On a case by case basis On a case by case basis This is based on expert 
judgement 
*“Too high dose levels” is an exclusion criterion for the studies on reproductive and developmental toxicity and therefore this 
weakness is reported only for non reproductive studies. 
3. WoE approach to hazard identification 
The studies appraised against their strengths and weaknesses (see table 26 and 27) were included in 
the WoE approach to perform hazard identification.  
First of all for each toxicological endpoint different questions (Qn) were defined addressing the 
association between BPA and the endpoint (e.g., “does BPA cause ... (type of effect)?”) (See all 
toxicological endpoints and related questions in Appendix C). 
The conclusions from the EFSA opinions on BPA of 2006 and/or 2010 were taken as starting point for 
answering each question. Then the relevant studies were organised into a number of “lines of 
evidence”, addressing different findings that relate to the question concerned. Some lines of evidence 
referred to a single study, whereas others referred to a group of studies addressing the same issue.  
To draw its conclusion for each association question, the CEF Panel first summarised the strengths and 
weaknesses of each line of evidence and pre-2010 assessments in an overall reliability assessment 
(expressed qualitatively on a scale of low, medium or high) and expressed it in terms of weight or 
influence on the likelihood of a positive answer to each question, when considered independently of 
the other lines of evidence.  
Then the CEF Panel evaluated the overall likelihood of a positive answer, taking into account the 
individual influences of all the lines of evidence and considering how they combine.  
The CEF Panel expressed its conclusions in terms of the likelihood that the answer to the question was 
positive in order to take into account uncertainties affecting the balance of evidence. The CEF Panel’s 
conclusion lied on the continuum between a definite negative answer and a definite positive answer. 
The approach described above is generically summarized in table 28. All WoE tables filled in are 
reported in Appendix C. 
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Table 28:  Example of table used in the WoE approach 
Q1: Is BPA…………………..?  
 









Starting point based on previous assessments (EFSA, 
2006; 2010): (summarise conclusions of previous 
assessments relating to this question)  
Strengths:  
Weaknesses:  





or High  
 
 
See table 29 
for key to 
symbols 
Line of Evidence 1: new evidence on ………. 
Strengths:  
Weaknesses:  
   
Line of Evidence 2: increased effect on…… 
Strengths:  
Weaknesses:  
   





The CEF Panel found it helpful to include separate columns in table 28 summarising steps in the 
evaluation of each line of evidence.  
The second column indicates the answer to the question as reported by the study authors (e.g. a 
positive, negative or uncertain answer to the question), i.e. before the CEF Panel assessed strengths 
and weaknesses. 
The third column gives the CEF Panel’s assessment of the reliability based on the evaluation of the 
strengths and weaknesses of each line of evidence, expressed qualitatively on a scale of low, medium 
or high. Note that a low score for reliability does not necessarily imply a poor quality study: e.g. it 
may relate to a well-conducted study with results not reaching statistical significance, but the 
treatment groups are not large enough to be statistically confident there is no effect (see Section on 
‘absence of evidence’ in EFSA 2011). The CEF Panel did not use a fixed formula to assess reliability 
of a study from its number of strengths and weaknesses, because this would not take appropriate 
account of the varying weights of different strengths and weaknesses. Instead, the reliability of the 
evidence as well as the influence on likelihood were agreed based on collective expert judgement 
(starting from a proposal made by the study’s rapporteur and co-rapporteur, that was discussed at least 
at one but more commonly at many WG meetings and that then was reviewed by the CEF Panel 
during Plenary meetings In reaching a collective view varying opinions within the WG and the 
specialist expertise of individual members were taken into account. 
The evaluation of the weight or influence of each line of evidence was then recorded in the right hand 
column using a defined set of symbols as described in table 29. 
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Table 29:  Definition of symbols used for expressing the influence on likelihood of each line of 
evidence in the WoE tables (see Appendix C). 
 Symbols Interpretation 
↑    minor contribution to increasing likelihood 
↑↑   moderate contribution to increasing likelihood 
↑↑↑   major contribution to increasing likelihood 
↓    minor contribution to decreasing likelihood 
↓↓   moderate contribution to decreasing likelihood 
↓↓↓   major contribution to decreasing likelihood 
●   negligible influence on likelihood 
Pairs of symbols indicate uncertainty about the influence, e.g., ●/↑ = between negligible and minor positive 
influence on likelihood. 
 
The number (from one to three) of upward and downward arrows indicates the degree (small, medium, 
high) of the impact of the new evidence to increase or decrease, respectively, the likelihood of a 
positive answer to the question. In developing its judgment on the influence or weight of each line of 
evidence, the CEF Panel took into account all the strengths and weaknesses it identified in the left 
hand column of the WoE table.  
The “dot” is used when the reliability of the new line of evidence is considered as insufficient as to 
have an impact on the likelihood of a positive answer to a question.  When the evidence base was too 
weak to make a firm judgement about the influence, a range of symbols was given to reflect that 
additional uncertainty. For example,●/↑ indicates  between negligible and minor positive influence on 
likelihood. 
A conclusion on the overall likelihood that BPA exposure was associated with a particular effect in 
humans and/or animals was expressed in the bottom row both as a narrative statement and using a 
standard set of likelihood terms (Box below), which was adapted from a similar set used by the 
Intergovernmental Panel on Climate Change (Mastrandrea et al., 2010)  ranging from “very unlikely” 
to “very likely”. Such conclusion was drawn after considering the individual influences of all the lines 
of evidence and the starting point. As already explained above for the assessment of reliability, the 
CEF Panel drew its conclusions on the overall likelihood by expert judgement after a thorough 
discussion process at a Working Group and /or CEF Panel meeting level and not by any standardised 
combination of scores for reliability and influence, which would be simplistic and preclude the 
consideration of other factors. Each likelihood was accompanied by a narrative text briefly 
summarising the rationale for the conclusion, in the bottom row of the WoE table (table 28). 
It is also important to emphasise that the likelihood assessed by the WoE approach refers specifically 
to hazard identification, i.e. it refers to the likelihood of an association between BPA and the effect 
under consideration. It does not refer to the likelihood or frequency of the effect actually occurring in 
humans, which depend on additional factors including the dose-response relationship for the effect 
(considered in hazard characterisation) and the levels of human exposure to BPA (considered in 
exposure assessment).  
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Set of standard terms used for expressing the overall likelihood in the WoE tables from 




From -as likely as not- to likely 
As likely as not 




4. Approach to hazard characterization 
The WoE approach to hazard identification has been used to identify the critical toxicological effects 
("likely effects") for BPA, in relation to specific time windows of exposure. Endpoints were only 
considered for setting a reference point in hazard characterisation, if they were judged “likely” or 
“very likely” in the hazard identification. The possibility of the other, less likely effects was taken into 
account together with the other uncertainties affecting hazard characterisation. 
For effects that were considered "likely” or “very likely", the CEF Panel considered the adversity of 
the effects and their relevance to humans. Uncertainty affecting these considerations was dealt with in 
a conservative way, by retaining effects for hazard characterisation unless there was strong evidence 
that they were not adverse or relevant. 
The most reliable study(ies) supporting “likely” or “very likely" effects were used to study dose-
response relationships and to identify the critical reference point (NOAEL or LOAEL or BMDLs, 
depending on the suitability of the data set) for setting a health-based guidance value.  
To set a TDI (see Section 4 of the opinion), the CEF Panel converted the lowest reference point 
identified from this/these animal studies into a correspondent oral HED (see Section 3 and Appendix 
D), by multiplying it by a factor that takes account of quantitive differences in toxicokinetics between 
the animal species used in the study and humans. This so-called HEDF is calculated from the ratio of 
the AUCs for the test species and AUCs for humans. HEDF, which is based on real data, replaces the 
default uncertainty factor of 4 generally attributed to interspecies kinetic differences. To derive a TDI 
an additional uncertainty factor of 25 is then applied to the HEDF. This default factor should cover for 
(i) the remaining dynamic component of inter-species-related differences, i.e. 2.5, and for (ii) intra-
species-related kinetic and dynamic differences, i.e. 10. 
5. Approach to risk characterization 
To assess the risks (see Sections 5) for consumers from current levels of BPA exposure the TDI is 
compared to estimates for oral exposure for different age groups and subpopulations (both average and 
high dietary exposure scenarios) and with dermal exposure estimates based on PBPK modelling (see 
Part I – Exposure assessment).  
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Appendix B.  All Studies Evaluated 
Toxicokinetics and Metabolism 
Human and animal studies on toxicokinetics and metabolism were appraised against strengths and 
weaknesses but did not undergo WoE analysis. 
(i) Human studies 
Cao X-L, Zhang J, Goodyer CG, Hayward S, Cooke GM and Curran IHA, 2012a. Bisphenol A 
in human placental and fetal liver tissues collected from Greater Montreal area (Quebec) during 
1998–2008. Chemosphere, 89, 505-511. 
 
This ex-vivo human study was aimed at measuring unconjugated and conjugated BPA levels in human 
placental and fetal liver tissues. In the study, human placental samples (n = 128) and fetal liver 
samples (n = 28) were obtained from induced abortions between 1998 and 2008. The determination of 
BPA and its glucuronide (by gas chromatography coupled to a mass selective detector (GC-MSD)) 
was not the primary aim of the tissue collection. Unconjugated BPA was detected in a total of 113 
placental samples. The LOQ was estimated for each placental and liver sample and was on average 
0.99 and 1.4 ng/g, respectively. The unconjugated BPA concentrations ranged from 0.55 ng/g up to 
165 ng/g. The authors also determined BPA-glucuronide by subtracting the concentration of BPA 
(parent compound) from the concentration of total BPA (sum of parent compound and BPA-
glucuronide), obtained after treatment with ß-glucuronidase. The concentration of BPA-glucuronide 
detected in 50 samples varied between 0.1 and 178 ng/g tissue. The ratio of the mean unconjugated 
BPA/BPA-G was 0.73. In fetal liver samples the unconjugated BPA was 1.02–37.7 ng/g (detected in 
20 samples) and that of BPA-glucuronide 1.41–93.9 ng/g (detected in 13 samples out of 16 samples 
analysed). The ratio of the mean unconjugated BPA/BPA-G was 0.47.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in the study: 
Strengths:  
- Container specified (PP vials) 
- Analytical method (SPE GC-MS)  
- Quality control, including blanks 
Weaknesses:  
- Single measurement  
- Quality assurance, precaution to avoid contamination not described  
- Conjugated BPA analysed in a subset of samples  
Overall, the CEF Panel considers that concerning the methodology, there is no indication in the study 
description that special precautions were taken to avoid contamination of the samples during the 
collection process. Also, tissue samples should be handled deep frozen to avoid that the ß-
glucuronidase present in the tissue can release unconjugated BPA from conjugated BPA. It cannot be 
excluded that high levels of unconjugated BPA result from BPA deconjugation during sample 
processing and storage. 
Carwile JL, Ye X, Zhou X, Calafat AM and Michels KB, 2011. Canned soup consumption and 
urinary bisphenol A: a randomized crossover trial. JAMA, 306, 2218-2220.  
The authors carried out a randomized, single-blinded, 2x2 crossover study in 84 volunteers with the 
aim to measure urinary BPA concentration after a week of canned vs. fresh soup consumption. Each 
phase consisted of 5 consecutive days. For the first 5 days, one group consumed a 12-ounce serving of 
a soup that was made of fresh ingredients, whereas the other group consumed a 12-ounce serving of 
canned soup. After a 2 day wash out, treatment assignments were reversed. The ingestion was between 
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12:15 and 2:00 pm; spot urine was collected at day 4 and/or 5 between 3:00 and 6:00 pm. 
Measurements were done by a specific and sensitive method based on solid phase extraction (SPE) 
coupled to isotope dilution high-performance liquid chromatography-tandem mass-spectrometry (ID 
LC-MS-MS). The LOD of the method is 0.4 ng/ml. The concentration measurements were corrected 
for different urine volume by a factor which uses specific gravity measurement of the individual urine. 
Seventy-five volunteers completed the study. The corrected geometric mean concentration of total 
BPA was 1.1 µg/l after intake of fresh soup, and 20.8 µg/l after canned soup consumption. The authors 
commented that the increase in urinary BPA concentrations following canned soup consumption is 
likely a transient peak of yet uncertain duration. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Study design 
- Sample size 
- Container specified (collected in PE vials, stored in PP cryogenic vials) 
- Analytical method (SPE ID LC-MS-MS) 
- Quality control, including blanks 
- Standardized BPA concentration (specific gravity) 
- Consistency in results among different studies 
Weaknesses:  
- Single measurement  
- Quality assurance, precaution to avoid contamination not described  
- Confounding by diet (other than canned soup) and other exposures not considered  
- Generalisability to the overall population  
Overall, the CEF Panel considers that the study design was appropriate, as appropriate was the 
analytical method, and the urine sample collection and storage. The CEF Panel noted that the urinary 
concentrations which were measured in urine are in the same order of magnitude as the urinary 
concentrations reported by the study by Teeguarden et al. (2011; mean: 5.9 µg/l with a broad wide 
range the highest concentration was 125 µg/l).  
Christensen KLM, Lorber M, Koslitz S, Brüning T and Koch HM, 2012. The contribution of 
diet to total bisphenol A body burden in humans Results of a 48 hour fasting study. 
Environment International, 50, 7–14.  
 
The study evaluated the excretion of conjugated BPA in five volunteers during a course of a two day- 
fasting (0–48 hrs). Total BPA concentration in urine was determined by method based on solid phase 
extraction (SPE) coupled to isotope dilution high-performance liquid chromatography-tandem mass-
spectrometry (ID LC-MS-MS). The LOD and the LOQ of the method are 0.05 and 0.1 µg/L, 
respectively. Free BPA was measured in a subset of samples. In four of the five volunteers the amount 
of conjugated BPA excreted in the urine declined during the fasting period to 5 % on the second day 
of the amount on day 1, in one of them urinary excretion increased between 32 and 42 hours without a 
defined exposure. The study shows that even after intake of BPA by meal ceases BPA is still excreted 
from the body indicating (a) non-food exposure towards BPA or (b) excretion of BPA from store 
tissue such as lipid tissues.  
Comments from the CEF Panel:  
 
The CEF Panel identified the following strengths and/or weaknesses in the study: 
Strengths:  
- Study design 
- Multiple measurements (sampling) 
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- Container specified (PP) 
- Analytical method (SPE ID LC-MS-MS) 
- Quality control, including blanks and quality assurance (precaution to avoid contamination 
described) 
- Standardized samples (BPA concentration in urine by creatinine)  
- Confounding by diet and other exposures considered (water, hygiene products, medications) 
Weaknesses:  
- Small sample size (one is an outlier) 
- Selection bias (healthy adult volunteers) 
- Single measurement  
- Generalisability to the overall population (particularly to children) 
Overall, the CEF Panel considers that the study design was appropriate, as appropriate was the 
analytical method, and the urine sample collection and storage.  
Edlow AG, Chen M, Smith NA, Lu C and McElrath TF, 2012. Fetal bisphenol A exposure: 
concentration of conjugated and unconjugated bisphenol A in amniotic fuid in the second and 
third trimesters. Reproductive Toxicology, 34, 1-7. 
 
This study was aimed at determining the levels of free and conjugated BPA in second and third 
trimester amniotic fluid. Amniotic fluid was collected for medical reasons in 20 pregnant women 
between week 15 and 23.9 (second trimester) and in 20 pregnant women in the third trimester. Liquid 
chromatography coupled with mass spectrometry (LC-MS) was used to measure BPA concentrations 
(LOD = 0.1 ng/ml; LOQ: 3LOD) after solid phase extraction (SPE). The method was validated and 
specific investigations were performed to ensure that no cross-contamination took place. In the second 
trimester samples, total BPA levels ranged from non-detectable to 0.75 ng/ml (median 0.47 ng/ml) and 
in 4 out of 20 samples no total BPA was detected. Unconjugated BPA was detected in 9/20 second 
trimester samples, with levels ranged from 0.31 to 0.43 ng/ml (median 0.38 ng/ml). In the third 
trimester samples, total BPA was detected only in 2/20 samples and unconjugated BPA (0.42 ng/ml) 
only in 1/20. When detected, unconjugated BPA comprised 83 % and 91 % of total BPA in second and 
third trimester amniotic fluid, respectively. The authors concluded that the results indicate that 
placental ß-glucuronidase may deconjugate BPA. Deconjugation of BPA by the placenta, and limited 
capacity of the fetal liver to conjugate BPA, may increase fetal exposure to unconjugated BPA. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Repeated measurements (sampling, second and third trimester) 
- Container specified (PETF tube, HDPE caps) 
- Analytical method (SPE LC-MS) 
- Quality control, including blanks and quality assurance (precaution to avoid contamination 
described) 
Weaknesses:  
- Small sample size 
- Single measurement  
- Inability to detect BPA in the majority of third trimester samples  
- Maternal samples (serum or urine) were not collected (maternal exposure not characterized) 
- Unclear clinical relevance  
Overall the CEF Panel notes that the analytical part of the study is done according to the current 
scientific standard, including the check of accuracy, precision (coefficient of variation), BPA stability 
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and the use of blanks. The observed results might be explained by deconjugation of BPA-conjugates in 
the amniotic fluid.  
Geens T, Neels H and Covaci A, 2012. Distribution of bisphenol-A, triclosan and n-nonylphenol 
in human adipose tissue, liver and brain. Chemosphere, 87, 796-802. 
The study of Geens et al. (2012) used human material obtained by autopsies in 11 deceased patients, 
aged 9–62 years, and measured BPA, triclosan and n-nonylphenol in brain, liver and fat. BPA 
measurement was done by gas chromatography coupled with mass spectrometry operated in electron 
negative ionization mode (GC-ECNI/MS) after liquid liquid extraction and derivation to 
pentafluorobenzoyl derivatives. Whereas in brain tissue and fat only unconjugated BPA was 
measured, in liver tissue BPA content was estimated both without (unconjugated BPA) and with 
previous pretreatment with glucuronidase (total BPA, as the sum of unconjugated and its conjugated 
BPA). The resulting median concentrations of unconjugated BPA in tissues were: 2.1 ng/g in fat, 0.6 
ng/g in brain and 1.0 ng/g in liver. In liver, the median concentration of total BPA was 1.0 ng/g.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in the study: 
Strengths:  
- Container specified (PP, BPA free, evaluated for contamination) 
- Analytical method (GC-ECNI/MS) 
- Quality control, including blanks and quality assurance (precaution to avoid contamination 
described) 
Weaknesses:  
- Small sample size 
- Selection bias (deceased patients) 
- Single measurement 
- Collection of sample in hospital settings (less contamination control)  
- Confounding factors (no information on medical treatments of patients before death) 
- Generalisability to the overall population  
- Unclear clinical relevance  
- Inconsistency in results compared to other studies  
Overall the CEF Panel notes that the ratio of the concentrations in different tissues is in fair 
accordance with measurements done by Csanady et al. (2002) in rat tissue incubated with blood 
containing BPA. It should be considered that in experimental studies in humans nearly 100 % of an 
oral dose was excreted in the urine, in the form of metabolites, and only traces of parent compound 
were found. The authors acknowledge that the results of the study partly disagree with the fast 
elimination of BPA and postulate that the reason that unconjugated BPA was detected in the tissues 
was due to deconjugation of the glucuronyl metabolite in the cells, releasing unconjugated BPA. The 
CEF Panel considered that this could not take place in the living organism as the calculated 
tissue/blood partition coefficient (calculated after Schmitt, 2008) is 0.1. This means that only 10 % of 
the blood concentration will go into the tissues, which is due to the high polarity and water solubility 
of BPA-glucuronide. The findings that the authors did not find metabolites, even in the liver tissue, 
might be due to post mortem changes. When the amount of BPA in the human body is calculated, 
based on the data of Geens et al. (2012), the amount is about 82.6 µg or 1.235 µg/kg bw which might 
be in line with high exposure by medical devices used before the death. The authors did not report 
whether the deceased were treated before because of diseases in a hospital. In this case, the amount of 
BPA in the body could be caused because of leaching from medical devices. There were no 
indications of how many persons/age were evaluated in the study.  
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Genuis SJ, Beesoon S, Birkholz D and Lobo RA, 2012. Human Excretion of Bisphenol A: Blood, 
Urine, and Sweat (BUS) Study. Journal of Environmental and Public Health, ID 185731, 10 
pages, doi:10.1155/2012/185731 
This study was designed to assess the relative concentration of BPA in three body fluids—blood, 
urine, and sweat—and to determine whether induced sweating may be a therapeutic intervention with 
potential to facilitate elimination of this compound. Blood, urine, and sweat were collected from 20 
individuals (10 healthy participants and 10 participants with assorted health problems) and analyzed 
for total BPA (after hydrolysis of conjugated BPA). BPA in blood urine and sweat was measured by 
liquid chromatography coupled to tandem mass spectrometer (LC-MS-MS) after hydrolysis and solid 
phase extraction. The LOD of the method was 0.2 ng/ml. BPA was detected at different levels in 
blood, urine, and sweat. In 16 of 20 participants, BPA was identified in sweat, even in some 
individuals with no BPA detected in their serum or urine samples. The authors conclude that 
biomonitoring of BPA through blood and/or urine testing may underestimate the total body burden of 
this potential toxicant. They further conclude that sweat analysis should be considered as an additional 
method for monitoring bioaccumulation of BPA in humans and furthermore that induced sweating 
appears to be a potential method for elimination of BPA. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Container specified for all matrices (glass) 
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks and quality assurance (precaution to avoid contamination 
described) 
Weaknesses:  
- Small sample size 
- Single measurement  
- Collection of samples at different times  
- No distinction between unconjugated and conjugated BPA 
- Concentration in urine not standardized 
- Confounding by diet and other exposures not considered  
- Generalisability to the overall population  
- Unclear clinical relevance 
- Inconsistency in results compared to other studies  
- No possibility of comparison across studies for sweat  
The CEF Panel noted that concentrations in the three body fluids were taken at different times. Thus, it 
is difficult to make a comparison between the concentration in urine (which has been taken as a 
spontaneous sample in the morning), sweat (mainly taken in an infrared sauna) and blood (taken in a 
laboratory). It is not explained why in this study the concentration in the urine was higher than 
reported in other studies and why the two subjects with a measurable serum concentration showed 
levels 10-fold higher that measured in other studies (Teeguarden et al., 2011). 
Gerona RR, Woodruff TJ, Dickenson CA, Pan J, Schwartz JM, Sen S, Friesen M, Fujimoto VY 
and Hunt PA, 2013. BPA, BPA glucuronide, and BPA sulfate in mid-gestation umbilical cord 
serum in a northern California cohort. Environmental Science & Technology, 47, 12477-12485. 
Gerona et al. (2013) used isotope-dilution LC/MS/MS to directly measure concentrations of 
unconjugated BPA, glucuronidated BPA, and sulfated BPA in umbilical cord serum collected from 85 
study participants during elective second trimester pregnancy terminations. The LODs were 0.05 
ng/ml (unconjugated and glucuronidated BPA) and 0.025 ng/ml (sulfated BPA), the LOQ was 0.1 
ng/ml for all three analytes. d16-BPA was used as (surrogate) internal standard for all analytes. 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 252 
Procedural blanks and quality control (QC) materials at low and high concentrations (0.5 and 20 
ng/ml) were included. To reduce the likelihood of contamination, the authors used glass/polypropylene 
containers for sample collection, processing, and storage containers. Umbilical cord blood was drained 
directly into collection tubes during the procedure to avoid contact with medical devices and the 
environment. The authors additionally performed a field blank testing by simulating the sample 
collection, extraction, and analytical run using double-charcoal stripped serum and synthetic human 
serum. No BPA was detected ≥ LOD in any of the sample collection and extraction materials or in any 
of the instruments used in the analysis. The possible contamination from the IV equipment (IV bag, 
needles, and tubing) and medical equipment (gloves, laminaria) used during the termination procedure 
was also evaluated. The analysis of the umbilical cord serum samples revealed detection levels of 
47%, 76%, and 96% for for unconjugated, glucuronidated, and sulfated BPA. The GM concentrations 
were 0.16 ng/ml for unconjugated BPA (range: <LOD–52.26 ng/mL), 0.14 ng/ml for glucuronidated 
BPA (range: <LOD–5.41 ng/mL), and 0.32 ng/ml for sulfated BPA (range: <LOD–12.65 ng/mL). The 
concentration ratio of unconjugated BPA/conjugated BPA ranged from 1:100 to >400:1. The CEF 
Panel noted that extreme concentration ratios such as 400:1 between the unconjugated and conjugated 
BPA forms are not in line with the evidence from toxicokinetic studies in pregnant monkeys (vom 
Saal et al., 2014) and questions the attempts of the authors to have the sample contamination and the 
exposure by medical devices fully under control. The CEF Panel also noted the specific exposure 
situation of pregnant women and fetuses during the termination procedure, which makes an 
extrapolation of the results to pregnant women in general (i.e. outside a hospital setting) questionable. 
Comments from the CEF Panel:  
Comment: They authors describe that they did not found BPA eluting from iv drips. Calafat et al. 
(2009) described that in every of 41 neonatal patients in two hospitals excreted conjugated BPA in the 
urine indicting exposure towards BPA. 
Comment: Umbilical cord blood is a mixture of maternal and fetal blood. The concentrations 
measured in this matrix are henceforth not clearly attributable to the mother or the child 
 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Analytical method (LC-MS/MS)  
Weaknesses: 
- . 
- Insufficient study reporting (the authors state that they tested the medical equipment for 
possible BPA content. They did not describe how they took the samples (at random?) and how 
many replicates they performed).  
 
Kosarac I, Kubwabo C, Lalonde K and Foster W, 2012. A novel method for the quantitative 
determination of free and conjugated bisphenol A in human maternal and umbilical cord blood 
serum using a two-step solid phase extraction and gas chromatography/tandem mass 
spectrometry. Journal of Chromatography B, 898, 90-94.  
The aim was to develop a new analytical method for the analysis of both unconjugated and conjugated 
BPA in human material. Unconjugated BPA was determined after liquid-liquid extraction (LLE) 
followed by a two-step solid-phase extraction (SPE), derivatization by N-methyl-N-
(trimethylsilyl)trifluoro-acetamide (MSTFA) and gas chromatography/tandem mass spectrometry 
(GC/EI-MS/MS). Conjugated BPA was determined after enzymatic deconjugation and bisphenol A-d6 
β-glucuronide served as internal standard. The LOD and LOQ for BPA were 0.026 ng/ml and 0.087 
ng/ml, respectively. Blank levels ranged between <0.026 (LOD) and 0.083 ng/ml, and results were 
corrected for their respective blank samples. Matched human maternal at mid-pregnancy, at delivery 
and umbilical cord blood serum samples were obtained from 12 pregnant women. Total BPA 
concentrations in human maternal serum at mid-pregnancy and at delivery ranged from <0.026 ng/ml 
to 10.425 ng/ml (median 0.548 ng/ml, n=12) and <0.026 ng/ml to 3.048 ng/ml (median 1.461 ng/ml), 
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respectively. Matching umbilical cord blood serum BPA concentrations were in the range of <0.026-
2.569 ng/ml (median 1.823 ng/ml).  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Repeated measurement (mid-term pregnancy and at delivery) 
- Analytical method (LLE SPE GC-MS-MS) 
- Quality control, including blanks and quality assurance (precaution to avoid contamination 
described) 
- Consistency in results among different studies 
Weaknesses:  
- Small sample size 
- Confounding by diet and other exposures not considered 
- Unclear clinical relevance  
The CEF Panel considered that the study has some shortcomings and that the biomonitoring data 
reported have low credibility due to limited reporting in particular with respect to sample coollection 
and handling, and discrepancies with other studies. 
Krotz SP, Carson SA, Tomey C and Buster JE, 2012. Phthalates and bisphenol do not 
accumulate in human follicular fluid. Journal of Assisted Reproduction and Genetics, 29, 773-
777.  
 
The study examined whether phthalates and BPA could be detected in human follicular fluid after 
exposure to medical plastics during an in vitro fertilisation (IVF) cycle. Ovarian follicular fluid was 
prospectively collected from five women, although it is not clear how many follicles were aspirated 
from each woman. Within each woman a single pooled follicular fluid sample was used for BPA and 
phthalate measurement by liquid chromatography tandem mass spectrometry (LC-MS-MS, LOD not 
given). The authors report that no BPA was detectable in any of the five, pooled, follicular fluid 
samples (although phthalates were quantifiable).  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Container specified (glass) 
- Analytical method (SPE LC-MS-MS) 
Weaknesses:  
- Small sample size 
- Single measurement  
- No quality control (including blanks) and quality assurance (precaution to avoid 
contamination not described) 
- Limit of detection not reported 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet and other exposures not considered  
- Generalisability to the overall population 
 
Overall, the CEF Panel considers that the number of participants is very low (n=5). Moreover, the 
authors did not specify whether unconjugated, conjugated or total BPA was measured. BPA was 
below the LOD in all samples, but the LOD was not given and thus the study cannot be compared with 
other studies. However, as a pilot study this shows that BPA is unlikely to accumulate in the 
microenvironment around the oocyte in humans.
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Mose T , Mathiesen L, Karttunen V, Nielsen JKS, Sieppi E, Kummu M, Mørck TA, Myöhänen 
K, Partanen H, Vähäkangas K, Knudsen LE and Myllynen P, 2012. Meta-analysis of data from 
human ex vivo placental perfusion studies on genotoxic and immunotoxic agents within the 
integrated European project NewGeneris. Placenta, 33, 433-439. 
In the EU integrated project NewGeneris, the placental transport of thirteen immunotoxic and 
genotoxic agents was studies in three ex vivo placental perfusion laboratories. In the present 
publication, all placental perfusion data have been re-analyzed and normalized to make them directly 
comparable and rankable. Antipyrine transfer data differed significantly between the studies and 
laboratories, and therefore normalization of data was necessary. An antipyrine normalization factor 
was introduced making the variance significantly smaller within and between the studies using the 
same compound but performed in different laboratories. Non-normalized (regular) and normalized 
data showed a good correlation. The compounds were ranked according to their transplacental transfer 
rate using either antipyrine normalized AUC120 or transfer index (TI120(%)). Based on their results 
the authors concluded that BPA has a high transplacental transfer rate (concentration at the fetal 
site/concentration of the maternal site =1) which is explained by passive diffusion. 
Comments from the CEF Panel:  
The result of the study is comparable to that of a study published earlier (Balakrishnan B, Henare K, 
Thorstensen EB, Ponnampalam AP, Mitchell MD (2010). Transfer of bisphenol A across the human 
placenta. Am J Obstet Gynecol 202:393.e1–e7.) which also reported a factor of 1 for transplacental 
transfer rate. 
Nachman RM, Fox SD, Golden WC, Sibinga E, Veenstra TD, Groopman JD and Lees PSJ, 2013. 
Urinary Free Bisphenol A and Bisphenol A-Glucuronide Concentrations in Newborns. The 
Journal of Pediatrics, 162, 870-872. 
 
The study population consisted of 11 healthy neonates plus 1 young infant (median age 17 days) born 
from healthy non smoking mothers. Urine samples were collected using BPA-free pediatric urine 
collection bags (U-Bag; Hollister, Inc, Libertyville, Illinois) during the neonates’ regular well-child 
care visits. After voiding the urine was transferred on ice to the laboratory, transferred to a pre-cleaned 
glass vial which was stored at -80 °C until analysis. Free and conjugated BPA were determined 
directly in urine by liquid chromatography tandem mass spectrometry (LC-MS-MS) without 
hydrolysis and extraction. The LOD and the LOQ were 0.02 and 0.1 ng/ml, respectively. The average 
concentration of BPA glucuronide, as measured in all of the duplicate urine samples, was 0.87 ± 0.51 
ng/ml (median: 0.66 ng/ml. Unconjugated BPA was not found in any of the urine samples with the 
exception of 1 sample (subject 6) whose replicate sample was a non-detect. With the exception of one 
fully breast feed baby al babies received infant formula. The study demonstrates that neonates and 
infants are capable of conjugating BPA to the BPA-glucuronide. 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Container specified (BPA-free pediatric urine collection bags) 
- Analytical method (LC-MS-MS) 
- Quality control, including blanks and quality assurance (precaution to avoid contamination 
described) 
- Repeated measurements (n=2) 
Weaknesses:  
- Single measurement  
- BPA concentration in urine not standardized 
- Generalisability to the overall population  
Overall the CEF Panel noted that the study was well performed and the results are in accordance with 
what is known from the expression of UTGs in the fetus and neonates. The study showed that BPA-
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glucuronide is the only detectable BPA compound in the urine of the newborn. This finding is not in 
conflict with the results of another study showing that levels of unconjugated BPA might be found.in 
the urine of premature infants in intensive care (Calafat et al., Environ Health Perspect 2009;117:639-
44). Infants in intensive care are exposed to BPA by others than the oral route at doses exceeding the 
doses on the oral route by breast feeding or bottle feeding. As non-oral routes of exposure are 
characterized by lacking presystemic elimination of BPA, the concentration of unconjugated BPA in 
the systemic circulation is higher compared with the oral administration. Hence, levels of 
unconjugated BPA might be found in the urine. The study has a limitation as it did not measure the 
sulphate conjugate of BPA. 
Nahar MS, Liao C, Kannan K and Dolinoy DC, 2012. Fetal Liver Bisphenol A Concentrations 
and Biotransformation Gene Expression Reveal Variable Exposure and Altered Capacity for 
Metabolism in Humans. Journal of Biochemical and Molecular Toxicology, 27, 116-123. 
 
In this study, the internal dose of unconjugated BPA and conjugated BPA was measured and gene 
expression of biotransformation enzymes specific for BPA metabolism was evaluated in 50 first- and 
second-trimester human fetal liver samples. The concentration of unconjugated BPA and conjugated 
BPA concentrations in the fetal livers (measured by liquid chromatography tandem mass spectrometry 
(LC-MS-MS)) varied widely, with unconjugated BPA (geometric mean 2.26 ng/g tissue) exhibiting 
three times higher concentrations than conjugated BPA (geometric mean 0.65 ng/g tissue). As 
compared to gender-matched adult liver controls, UDP-glucuronyltransferase, sulfotransferase, and 
steroid sulfatase genes exhibited reduced expression whereas β-glucuronidase mRNA expression 
remained unchanged in the fetal tissues. According to the authors, the study provides evidence that 
there is considerable exposure to BPA during human pregnancy and that the capacity for BPA 
metabolism is altered in the human fetal liver. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Container specified (PC-free PP tubes) 
- Analytical method (LC-MS-MS) 
- Quality control, including blanks and quality assurance (precaution to avoid contamination 
described, but only for analysis) 
Weaknesses:  
- Single measurement  
- Quality assurance (precaution to avoid contamination during sampling not described) 
- Confounding by diet and other exposures not considered  
- Generalisability to the overall population  
- Inconsistency in results compared with other studies  
Overall the CEF Panel notes that the study results are in marked contrast to what has been observed in 
experimental studies where lower plasma concentrations of BPA was detected in the fetus compared to 
the dams in rats and rhesus monkeys (Doerge et al., 201, and Patterson et al., 2012). The fetal liver 
samples were obtained from the University of Washington Birth Defects Laboratory fetfetal tissue 
bank. The procedures of surgery, the sort of surgical instruments used and the liver sample isolation 
from fetal tissues are not described. Hence, it is open to discuss that the results were mainly due to 
contamination by in hospital processing of the samples. The ratio of 3 of unconjugated/conjugated 
BPA is also a strong indication for sample contamination given the fact that this ratio is 0.1 to 0.01 in 
the experimental study in fetuses of rhesus monkeys. 
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Teeguarden JG, Calafat AM , Ye X, Doerge DR, Churchwell MI, Gunawan R and Graham MK, 
2011. Twenty-four hour human urine and serum profiles of bisphenol A during high-dietary 
exposure. Toxicological Sciences, 123, 48-57. 
 
Teeguarden et al (2011) have reported the results of a clinical exposure study conducted to better 
understand the internal exposure of adult humans to BPA and the relationship between the serum and 
urinary pharmacokinetics of BPA. Blood and urine samples were collected approximately hourly over 
a 24-hour period from 20 adult volunteers who per sitting (breakfast, lunch, and dinner) ingested 100 
% of one of three specified meals comprising standard grocery store food items (including canned 
food). In between the meals the volunteers were only allowed drinking of BPA-free water. Both 
conjugated and total BPA (after enzymatic hydrolysis) were determined in serum samples by solid 
phase extraction coupled to liquid chromatography tandem mass spectrometry (SPE LC-MS-MS). In 
urine samples total BPA only was determined by SPE LC-MS-MS. The LOD of the method was 0.3 
ng/ml in serum and 0.4 ng/ml in urine. The volunteers’ average consumption of BPA, estimated from 
the urinary excretion of total BPA (as the sum of conjugated and unconjugated BPA) was 21 µg (range 
3.3 to 73 µg). Assuming 100 % absorption and urinary excretion and using individual body weights 
this is equivalent to an oral exposure of 0.27 μg/kg body weight (bw) (range, 0.03–0.86), 21 % greater 
than the 95th percentile of aggregate (all routes) daily exposure in the adult US population (0.22 µg/kg 
bw; equivalent to approximately ~15 µg/person). A serum time course of total BPA was observable 
only in individuals with exposures 1.3–3.9 times higher than the 95th percentile of aggregate US 
exposure. Total BPA urine concentration Tmax was 2.75 hours (range, 0.75–5.75 hours) post meal, 
lagging the serum concentration Tmax by ~1 hour. During these high dietary exposures, total BPA 
concentrations in serum were below the LOD for 86 % of the 320 samples collected. Unconjugated 
BPA concentrations were always below the LOD (1.3 nM; 0.3 ng/ml). In six individuals, serum total 
BPA concentrations could be measured (concentrations up to 5.7 nM; 1.3 ng/ml) and the serum levels 
found were, on average, 42 times lower than urine concentrations. For these individuals, serum total 
BPA area under the curve per unit BPA exposure (i.e. normalised to urinary BPA excretion, expressed 
as µg/kg bw) was between 21.5 and 79.0 nM•hr•kg/µg. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size 
- Repeated measurements (sampling)  
- Urine, container specified  
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks and quality assurance (precaution to avoid contamination 
described) 
- Distinction between unconjugated and conjugated BPA in serum samples 
- Repeated measurement (analysis of serum samples by an independent laboratory) 
- Confounding by diet and other exposures considered 
Weaknesses:  
- Serum BPA 
- No distinction between unconjugated and conjugated BPA in urine 
- Single measurement (urine samples) 
-  
Overall the CEF Panel notes that this study endorses the view that no unconjugated BPA in serum and 
only very low levels of conjugated BPA can be found in humans at levels of dietary exposure. The 
study report indicates that exposures to BPA from retrospectively determined dietary exposure (e.g. 
from canned foods) is at the most 73 µg person per day (three meals). The exposures were at the high 
end of the NHANES population-based exposure estimates (spot samples) from the 2005-2006 
NHANES biomonitoring report. The study encompasses quite a large group of human volunteers and 
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is very rigorously controlled with respect to possible sample contamination (e.g. plasma samples were 
analysed in a contra-expertise set-up to identify problems with reproducibility and were further 
analysed if inexplicable results were obtained to identify possible contamination). A limitation of this 
study is the lack of data concerning the content of BPA in the canned food.  
(ii) Animal studies 
Churchwell MI, Camacho L, Vanlandingham MM, Twaddle NC, Sepehr E, Delclos KB, Fisher 
JW, and Doerge DR, 2014. Comparison of life-stage-dependent internal dosimetry for 
bisphenol A, ethinyl estradiol, a reference estrogen, and endogenous estradiol to test an 
estrogenic mode of action in Sprague Dawley rats. Toxicological Sciences, 139, 4-20. 
 
A subchronic BPA exposure study with daily oral administration throughout perinatal and adult life 
was performed in SD rats. As a companion paper to the published evaluation of BPA toxicity (Delclos 
et al., 2014), the present paper evaluated the internal dosimetry in newborn (PND 4), weanling 
(PND 21), and adult (PND 80) animals. Native BPA in 0.3% aqueous carboxymethyl-cellulose (CMC) 
was administered by gavage (2.5–300,000 µg/kg bw per day) to pregnant dams and their offspring. 
Blood samples were collected at ~0.5 h postdosing (time window: 0.25–0.75 h). Unconjugated and 
total BPA concentrations in serum were measured by isotope-dilution LC-MS/MS (LOD: 0.1–1.1 nM, 
see below). Similarly, the internal dosimetries for the reference estrogen ethinyl oestradiol (EE2, dose: 
0.5–5 µg/kg bw per day) and for the endogenous hormones 17β-oestradiol (E2) and testosterone were 
evaluated. Finally, the toxicokinetics following the gavage administration of 100 µg/kg bw of 
deuterated d6-BPA (LOD: 0.2 nM) was analysed in PND 4 rats. 
Several quality control measures were applied which included, among others, the use of (i) 
uncontaminated rat serum for negative control samples and spiked samples, (ii) incurred rat serum 
containing both unconjugated and conjugated BPA to check for the completeness of enzymatic 
hydrolysis for the analysis of total BPA, and (iii) procedural blanks to establish background BPA 
levels from sample preparation. A limit of blank (LOB) was determined daily from procedural blanks 
as mean + 2 SD and subtracted from each serum sample concentration. LOB values ranged from 0.3–
1.1 nM (without enzymatic hydrolysis) to 0.5–1.8 nM (with enzymatic hydrolysis). The LOD was set 
to a signal-to-noise ratio of 3 above the LOB and ranged from 0.1–0.4 nM (without enzymatic 
hydrolysis) to 0.2–1.1 nM (with enzymatic hydrolysis). 
Serum samples from naïve (NC) and vehicle control (VC) rats of all age groups consistently contained 
measurable levels of unconjugated BPA (mean values: 0.1–2 nM) accounting for 17–58% of total 
BPA, which the authors found to be best explained as resulting from contamination by native BPA 
during sample collection and storage. The levels of total BPA in NC and VC rats were consistently 
observed in the 1–10 nM range. Verification measurements were conducted by direct determination of 
glucuronidated BPA (BPA-G) since BPA-G is the predominant BPA conjugate. The presence of BPA-
G in serum indicated an unintentional exposure of the control animals. The concentration of BPA-G in 
NC and VC rats were similar to the levels of conjugated BPA observed in the 2.5 µg/kg bw per day 
dose groups at all ages tested. According to the authors, these findings are best interpreted as resulting 
from similar levels of aggregated exposures. Although several potential BPA inputs (diet, drinking 
water, vehicle, cages, bedding, and dust) were evaluated, the relevant source(s) of BPA to which the 
control animals were supposedly be exposed could not be identified. 
In the BPA-treated rats, increases in serum levels of unconjugated and total BPA above the levels 
measured in control animals were observed at doses above ~80 µg/kg bw per day. In PND 4 rats, the 
fraction of total BPA accounted for by unconjugated BPA plateaued at ~4% in the intermediate dose 
range but increased to >10% at the two highest doses. A lower unconjugated fraction of 1–2% was 
seen in the PND 21 and PND 80 rats. These findings reflected the immaturity, and the saturation at 
high dose levels, of phase II metabolism in PND 4 rats. 
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The analysis of serum toxicokinetics (TK) in PND 4 animals yielded a Cmax for unconjugated d6-BPA 
of 14 nM (observed at the first sampling time point at 0.25 h after dosing), an AUC (i.e. the AUC0–∞) 
of 26.3 nM×h, and a terminal elimination half-life (t1/2) of 4.1 h. Unconjugated BPA represented 4.9% 
of total BPA when determined from the concentrations measured at 0.25 h, and 0.97% when judged on 
the derived AUC values. The TK parameters (Cmax, AUC, and t1/2) were intermediate between those 
reported for PND 3 and PND 10 animals in a previous TK study (Doerge et al., 2010a), in which the 
same rat strain and dose but a different vehicle (10% ethanol in water instead of 0.3% CMC) were 
used. Churchwell et al. (2014) concluded that the results of both TK studies are “consistent with the 
age-dependent development of metabolic and excretory function in neonatal rats that combine to 
decrease internal exposures as maturation proceeds”. 
Serum levels of the reference estrogen EE2 were determined in controls, 0.5 and 5 µg/kg bw-treated 
rats at PND 4, PND 21, and PND 80. As seen with BPA, the internal exposures to unconjugated EE2 
were highest in PND 4 rats. When maximal serum concentrations from the two highest BPA doses 
(100,000 and 300,000 µg/kg bw) and both EE2 doses were compared with concurrent levels of 
endogenous hormone E2, the estrogen receptor α (ERα) binding equivalents were similar to or above 
those of endogenous E2 in male and female rats at all ages tested, suggesting the possibility of ERα-
mediated signaling for the administered EE2, especially at the high EE2 dose, for BPA at the two 
highest doses. 
 
Figure 17:  Serum concentrations of unconjugated and total/glucuronidated BPA at ~0.5 h 
postdosing across all control and dose groups for PND 4, PND 21, and PND 80 rats. The gray-
shaded area indicates the LOD range (0.1–0.4 nM) for unconjugated BPA. The red and blue 
triangle symbols represent the serum concentrations of unconjugated and total BPA as 
measured in the toxicokinetic experiments with PND 4 rats (this study) and PND 21 and 
PND 80 rats (Doerge et al., 2010a) at 0.5 h after gavage administration of 100 µg/kg bw of d6-
BPA. The associated red and blue dashed lines show dose extrapolations under the assumption 
of linear kinetics. NC: naïve control, VC: vehicle control. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Quality control measures (BPA contamination, completeness of enzymatic deconjugation) 
- Life-stage-dependent internal dosimetry for unconjugated and total BPA in all study groups 
- Verification experiments with direct determination of glucuronidated BPA 
- Toxicokinetic analysis in newborns with administration of deuterated BPA 
- Results consistent with linear kinetics and age-dependent maturation of toxicokinetics 
- Internal dosimetry for the reference estrogen EE2 and for endogeneous hormones (E2, testosterone) 
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Weaknesses: 
- Unintended exposure of controls at levels similar to the intended exposure of lowest dose group 
(2.5 µg/kg bw/d) 
- Relevant source(s) of unintended BPA exposure could not be identified 
The CEF Panel noted that the presence of unintended BPA exposure source(s) resulted in similar 
internal levels of unconjugated and conjugated BPA in the control animals and lowest dose group. 
BPA-related toxicity effects, if occurring specifically in the lower dose range, would not be discernible 
in the absence of unexposed controls.  However, as reported by Delclos et al. (2014), the unintended 
exposure did not affect the interpretation of the toxicology study since there were no biologically 
significant effects of BPA observed in the “low dose” range (2.5-2700 µg/kg bw/d).  Similarly, the 
unintended exposure to BPA did not affect identification of significant adverse effects in either of the 
two EE2 dosing groups or the two highest BPA dosing groups.   
Doerge DR, Twaddle NC, Vanlandingham M and Fisher JW, 2010a. Pharmacokinetics of 
bisphenol A in neonatal and adult Sprague-Dawley rats. Toxicology and Applied Pharmacology, 
247, 158-165. 
 
Doerge DR, Twaddle NC, Woodling KA and Fisher JW, 2010b. Pharmacokinetics of bisphenol 
A in neonatal and adult rhesus monkeys. Toxicology and Applied Pharmacology, 248, 1-11. 
 
These two pharmacokinetic studies in rats and monkeys (Doerge et al. 2010a, 2010b) had already been 
revied by EFSA in 2010 as stated below. 
“A very recent pharmacokinetic study by Doerge et al. (2010a) measured by LC/MS/MS serum levels 
of free and conjugated deuterated BPA in neonatal, immature (PND 3, 10 and 21) and adult Sprague-
Dawley rats dosed via oral (gavage) and injection routes (i.v and s.c.). Animals were given a single 
dose of 100 μg/kg b.w. BPA, which was demonstrated to be within the linear range of 
pharmacokinetics, so that extrapolation to lower doses is feasible. The use of labelled BPA (methyl-
d6-BPA) avoided confounding background contamination (from laboratory materials or other 
sources), which was reported by the authors to be as high as 2 ng/ml in buffer blanks. In adult rats, 
direct comparisons of i.v. and oral routes of administration indicate: i) extensive absorption from the 
gastrointestinal tract; ii) rapid elimination of free BPA from the circulation (> 50% of circulating BPA 
was conjugated 5 min after i.v. injection); iii) importance of first-pass conjugation in liver and gut 
after ingestion: indeed, at maximum serum concentration (Cmax), the fraction present as conjugated 
BPA was substantially higher following oral compared to i.v. administration (99.5% vs. 55%). 
Moreover, the higher volume of distribution following i.v. vs. oral administration was due to higher 
distribution of free BPA to tissues. In addition, the occurrence of enterohepatic recirculation of BPA in 
adult rats is reflected by a secondary peak in the concentration of total BPA later in the rat serum 
concentration-time profiles. 
The Cmax of free BPA observed in individual rats ranged from 0.1-0.6 nM (average value of 0.39 ± 
0.19 nM, corresponding to about 89 ng/L) so that internal exposures of adult rats to free BPA are 
below 1% of the total (Cmax = 73 ± 29 nM, corresponding to 16.6 µg total BPA/L). 
A comparison of BPA pharmacokinetics in adult vs. neonatal rats was also performed.  
Oral administration of BPA (100 μg/kg b.w.) to PND 3 pups produced higher Cmax in serum of total 
(6-fold) and free (74-fold) BPA when compared to adults: the fraction present as conjugates was 
93.4% (PND 3) and rapidly increased with age up to 96.9 and 98.9% (PND 10 and 21, respectively), 
indicating a regular development of metabolic and excretory functions toward the adulthood situation 
(99.5% BPA in conjugated form). The percentage of total BPA present in neonatal blood (PND 3) as 
free BPA was very limited (1.4% of AUC, Cmax: 6.6%).  
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Administration of an identical dose (100 μg/kg b.w.) by s.c. injection to PND 3 rats produced 34-fold 
higher Cmax and 17-fold higher AUCs for free BPA compared to oral. The age-related changes 
(described above) after oral administration were not observed after s.c. injection, indicating that even 
in early postnatal pups, which possess lower conjugation activity, the first pass effect is extremely 
relevant. This confirms that the effect due to the route of administration is very relevant, and 
highlights the limitations in interpreting toxicity data from studies in which BPA is administered via 
routes other than the oral one, without any internal dosimetry. 
With a similar study design, free deuterated BPA (100 μg/kg b.w.) was administered to adult and 
neonatal rhesus monkeys orally (PND 5, 35 and 70) and i.v. (PND 77). Free and conjugated BPA were 
measured in the blood (Doerge et al., 2010b).  
In adult rhesus monkeys, results for the first sampling points show that the percentage of free BPA 
was higher following parenteral (i.v) administration (29 ± 19% of total BPA at 5 min post-injection) 
than after oral administration of the same dose (0.21 ± 0.14% of total BPA at 30 min post-gavage). 
This confirms that in monkeys the systemic availability of free BPA is much lower after oral 
administration. When BPA was administered to neonatal non-human primates orally (PND 5, 35 and 
70) or i.v. (PND 77), the toxicokinetic parameters were not statistically significantly different from 
those in adults.  
The CEF Panel noted that following the same oral dose of 100 µg/kg b.w. BPA to adult rat and 
monkeys, free BPA concentrations in both species was similarly low (<1%), the only notable 
difference being the longer elimination half-time in rats, due to the enterohepatic re-circulation in the 
rat. On the contrary, comparing newborn animals, PND3 rats have longer elimination half-time and 
approximately 10 times higher plasma levels of free BPA than PND 5 monkeys, when treated with the 
same oral BPA dose (Doerge, 2010b). These data provide evidence for a different developmental 
profile of hepatic and intestinal conjugation of BPA in rats and monkeys, consistent with literature 
data describing a higher degree of immaturity of rats at birth as compared to primates, in relation to 
UGT activity (Coughtrie et al, 1988; Matsumoto et al, 2002).” 
Doerge DR, Vanlandingham M, Twaddle NC and Delclos KB, 2010c. Lactational transfer of 
bisphenol A in Sprague–Dawley rats. Toxicological Letters, 199, 372–376. 
 
Female pregnant Sprague Dawley rats were given 100 µg/kg bw deuterated BPA using either oral 
administration or IV injection and starting at day of delivery. Conjugated and unconjugated forms of 
BPA were then measured by using liquid chromatography tandem mass spectrometry (LC-MS-MS) in 
milk from lactating dams on PND 7 and in serum from dams and their pups on PND 10. The limit of 
detection (LOD) for deuterated BPA from analysis of 100 µL of either serum or milk was 0.2 nM. All 
samples were collected 1 h after dosing, a time selected to produce nearly maximal levels. In milk and 
serum samples of dams, conjugated material represented most of the BPA present (87 % in milk and > 
99 % in serum). While unconjugated BPA was detected in all dam serum (0.55 nM) and milk (0.87 
nM) samples, none was detected in pup serum (<0.2 nM). Total serum BPA in pups amounted to 0.41 
nM. Doses delivered to pups lactationally, estimated from milk concentrations and body weights, were 
300–fold lower than the dose administered to the dams. Similarly, serum concentrations of total BPA 
in pups were 300–fold lower than those in their dams. Plasma concentrations of total BPA in PND 10 
rat pups were 500–fold lower than peak levels achieved following direct oral delivery of the same dose 
to the same age pups (by comparison with data from another study (Doerge et al., 2010a). According 
to the study authors the significant dose attenuation for the active unconjugated form of BPA, relative 
to that of the dam, suggest that if effects are observed in offspring exclusively due to lactational 
transfer, this would mean that BPA would have high potency for toxicological effects. Alternatively, 
studies that include lactational exposure and report minimal effects from BPA should consider the 
possibility that inadequate internal exposures were achieved during the critical postnatal period (i.e. 
relatively high exposures resulting from e.g. baby bottles is not covered by normal multi-generation 
studies, since during lactation the exposure of neonatal rats is far too low to be comparable). 
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Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Oral administration by gavage 
- Phytoestrogen-free diet (e.g. soy-free diet) 
- Analytical method (LC-MS-MS) 
Weaknesses:  
- Single dose levels study 
- Single acute dose administration 
- Type of cages and drinking bottles not reported 
  
The CEF Panel noted that in the study report some mean values can be found which cannot be 
explained from the reported results for individual animals. However, recalculation of these means 
from the individual data would not change the study outcome. Low lactational exposure has already 
been inferred from the available data in the EFSA opinion of 2010. In fact in this opinion it was 
estimated that rat pups would receive 300–fold lower dose of BPA than the mother animals, which is 
confirmed by the study by Doerge et al (2011b). The use of stable isotope-labeled BPA reassures that 
no contamination by ubiquitous BPA had occurred. 
 
Doerge DR, Twaddle NC, Vanlandingham M and Fisher JW, 2011b. Pharmacokinetics of 
bisphenol A in neonatal and adult CD-1 mice: Inter-species comparisons with Sprague-Dawley 
rats and rhesus monkeys. Toxicology Letters, 207, 298-305. 
 
Adult and neonatal CD-1 mice were administered deuterated BPA (100 µg/kg bw) by oral (gavage) or 
subcutaneous (sc) routes and the concentration of unconjugated and conjugated (inactive) BPA in 
serum were measured at the time points 0.25, 0.5, 1, 2, 4, 8 and 24 hours after dosing by isotopic 
dilution (13C12-BPA) liquid chromatography tandem mass spectrometry (LC-MS-MS). The limit of 
detection (LOD) for deuterated BPA in serum was 0.2 nM (0.05 ng/ml). Pharmacokinetics of BPA 
was measured in neonatal mice at postnatal day (PND) 3, 10 and 21. Neonatal mices were delivered 
and culled to 6 males and 6 females per litter (i.e. 2 litters for each of the 3 neonatal ages providing 
one male and female pup from each litter for each of the post-dose time points). Administration of 
BPA (100 µg/kg bw) by gavage to adult CD-1 mice (n = 12) produced levels of unconjugated BPA 
that were below the LOD in the preponderance of samples at all time points. Levels of unconjugated 
BPA that were above the LOD were observed only at the earliest three time points, and only in one or 
two samples out of the twelve determinations at each time. Oral administration in adults gave a rapid 
absorption phase (max at the first time point) with similar distribution kinetics for unconjugated and 
total BPA. Unlike adult mice, serum levels of unconjugated BPA were consistently detected in pups of 
all ages at early post-dosing time points for both oral and sc administration. Elimination half time after 
oral exposure decreased with postnatal age and became similar to that of adults at PND 21. The 
percentage of Cmax values as the unconjugated BPA form following oral exposure showed 
statistically significant effect of age. On the contrary SC administration showed an almost constant 
Cmax from PND 3 to PND 21. The developmental profile on pharmacokinetics observed in mice (and 
rats) was quite different from neonatal rhesus monkeys in which small insignificant age-related 
differences were observed.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Oral administration by gavage 
- Phytoestrogen-free diet (e.g. soy-free diet) 
- Analytical method (LC-MS-MS) 
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The CEF Panel noted that there is a large difference in Cmax of unconjugated BPA following the oral 
and subcutaneous routes, especially after PND 10. For adult mice (and rats) the unconjugated BPA 
levels were mostly below the detection limit in serum after oral exposure. The use of stable isotope-
labeled BPA reassures that no contamination by ubiquitous BPA had occurred. 
 
Doerge DR, Twaddle NC, Vanlandingham M, Brown RP and Fisher JW, 2011a. Distribution of 
bisphenol A into tissues of adult, neonatal, and fetal Sprague-Dawley rats. Toxicology and 
Applied Pharmacology, 255, 261-270. 
 
Sprague-Dawley rats were administered deuterated BPA (100 µg/kg bw) by oral (gavage) or iv routes. 
The concentration of both unconjugated and conjugated (inactive) BPA in tissues (mammary, liver, 
ovary, uterus, adipose, brain and muscle in adults, liver and brain in fetus) and placental transfer were 
measured by isotopic dilution (13C12-BPA) liquid chromatography tandem mass spectrometry (LC-
MS-MS).The limits of detection (LODs) for deuterated BPA were 0.2 nM in serum and 0.4 pmol/g in 
tissues. Following iv and oral dosing at gestation day (GD) to 12 pregnant rats (n = 6–7), serial blood 
samples were collected at designated time points (5–1440 min for iv, and 30–1440 for oral). For the 
fetfetal collections, whole concepti (n = 4 from each dam) were collected at GD 12 (0.5 hour after iv 
dosing and 24 hours after oral dosing), whole fetus (n = 4 from each dam) were collected at GD 16 
(0.5 hours after iv dosing and 8 hours after oral dosing), and at GD 20 (n = 4 from each dam) fetal 
serum was obtained by cardiac puncture, and liver and brains were removed and flash frozen (0.5 
hours after iv dosing and 8 hours after oral dosing). Amniotic fluid was collected from different ages 
of fetuses. Aliquots of each sample were analysed for both unconjugated BPA and total BPA, the latter 
following incubation with glucuronidase/sulfatase mixture. Thawing and/or cutting of liver samples 
released glucuronidase that converted conjugated BPA to unconjugated. All tissue aliquots were 
therefore processed in the frozen state.  
Administration of BPA by iv to pregnant rats led to rapid distribution (t1/2 = 0.29 ± 0.04 h) and 
elimination (t1/2 = 0.78 ± 0.11 h) of the parent compound from serum. Conjugated BPA were 
eliminated more slowly (t1/2 = 13 ± 7.4 h). Conjugated BPA were eliminated more quickly after oral 
exposure (t1/2 = 7.5 ± 1.9 h) than iv exposure, and the mean pharmacokinetic parameters were similar 
to those previously reported for oral dosing of non-pregnant rats of comparable age. Orally 
administered BPA to pregnant rats resulted in the presence of predominantly BPA-glucuronide (BPA-
G) in fetfetal tissues, while no measurable levels of unconjugated BPA was found in any GD tested. 
The maternal serum levels of unconjugated BPA after oral exposure were close to the LOD. However, 
after iv dosing of BPA to pregnant rats placental transfer were observed for unconjugated BPA into 
fetus after several GD. At GD 20 the ration of unconjugated BPA in fetfetal brain versus maternal 
serum was 4.5 ± 0.9, showing that the fetal brain contained more unconjugated BPA than maternal 
serum at this age. For the fetal tissues/fluids, amniotic fluid, serum and liver, the levels in the fetus 
were lower than in the maternal serum after iv injection of BPA. Oral exposure of BPA to neonatal 
rats postnatal day (PND) 3, 10 and 21 showed measurable concentrations of unconjugated BPA in 
liver, muscle, brain and serum, with highest concentration in the liver of PND 3 (14 nM unconjugated 
BPA). There was a significant age-dependent decrease in the levels of unconjugated BPA in both 
serum and tissues, with 2 nM unconjugated BPA in the liver at PND21. Concentrations of the 
conjugated BPA were considerable higher than the unconjugated in the neonatal tissues after oral 
exposure. 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Oral administration by gavage 
- Analytical method (LC-MS-MS) 
- Phytoestrogen-free diet (e.g. soy-free diet) 
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The CEF Panel noted that no measurable levels of unconjugated BPA were found in the fetuses after 
oral exposure, while unconjugated BPA was transferred to the fetus after iv injection. Also important 
to notice is the sensitive window of the neonatal exposure, with age-decreasing levels of unconjugated 
BPA in the neonates. This has not been observed to the same extent in monkeys, and therefore it can 
be questionable whether the most sensitive time-window for rats is relevant for humans. The use of 
stable isotope-labeled BPA ensures that no contamination by ubiquitous BPA had occurred. 
Doerge DR, Twaddle NC, Vanlandingham M, Fisher JW, 2012. Pharmacokinetics of Bisphenol 
A in serum and adipose tissue following intravenous administration to adult female CD-1 mice. 
Toxicology Letters, 211, 114-119. 
 
In the study liquid chromatography tandem mass spectrometry (LC-MS-MS) was used to measure 
serum concentrations of unconjugated and conjugated BPA in adult female CD-1 mice following 
intravenous (iv) injection of deuterated BPA (100 µg/kg bw). The limits of detection (LODs) for 
deuterated BPA were 0.2 nM (0.05 ng/ml) in serum and 0.4 pmol/g (0.1 ng/g) in tissues. Additionally, 
the unconjugated BPA was measured in adipose tissue. After iv injection, unconjugated BPA had a 
distribution half-life of 0.2 h and a terminal elimination of 0.8 h. Consistent with the degree of 
aqueous solubility, lipid/water solubility ratio, and partitioning from blood into adipose tissue in vivo, 
the levels of unconjugated BPA in mouse adipose tissue rapidly reached a maximal level (0.25 h) that 
did not exceed the serum maximum at the initial sampling time (0.08 h). Terminal elimination of 
unconjugated BPA from adipose tissue (t1/2 = 7.0 h) was similar to that for conjugated BPA in serum 
(t1/2 = 6.6 h) and <0.01 % of the administered dose remained in adipose tissue after 24 h. These 
plasma and tissue kinetics are consistent with rapid equilibria and underscore the non-persistent nature 
of BPA. By comparing the AUC in serum found in this study with the AUC in serum from an earlier 
oral study (Doerge, 2011a) a systemic availability of 2 % resulted after oral administration.  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Phytoestrogen-free diet (e.g. soy-free diet) 
- Analytical method (LC-MS-MS) 
- Distinction between unconjugated and conjugated BPA 
- Type of cages and drinking bottles not reported 
  
The CEF Panel considered that this well performed study adds to the toxicokinetic knowledge on 
BPA. It demonstrates that BPA is not retained in the adipose tissue. The results are plausible and the 
use of stable isotope-labeled BPA reassures that no contamination by ubiquitous BPA had occurred. 
 
Kohda N, Inoue S, Noda T, Saito T, 2012. Effects of Chitosan Intake on Fecal Excretion of 
Bisphenol A and Di(2-ethyl)phthalate in Rats. Bioscience, Biotechnology, and Biochemistry, 76, 
732-736.  
 
The This study investigated the effect of chitosan oral intake on faecal excretion of bisphenol A (BPA) 
in rats. The rats were fed a chitosan diet or a control diet (control group) for 10 days and orally 
administered BPA (100 mg/kg bw) on day 4. Faecal excretion rates of BPA was significantly higher in 
the CHI group than in the control group. Furthermore, accelerated BPA excretion into the faeces was 
observed in the CHI group. 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Use of non-PC cages (metal cages) 
- Analytical method (GC-MS) 
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- Distinction between unconjugated and conjugated BPA  
Weaknesses:  
- Single dose level study 
- Single acute dose administration 
- Test performed in one sex only 
Overall the CEF Panel notes that this study in rats is of no biological significance for humans as in 
man BPA is not excreted in the bile and eliminated in the faeces via this mechanism. 
Marquet F, Payan JP, Beydon D, Wathier L, Grandclaude MC and Ferrari E, 2011. In vivo and 
ex vivo percutaneous absorption of [14C]-bisphenol A in rats: a possible extrapolation to human 
absorption? Archives of Toxicology, 85, 1035-1043. 
 
This study is also described and discussed in Appendix D. 
This is the only in vivo study investigating BPA dermal absorption. The “absorbed dose” of total 14C-
BPA after application of a concentrated acetone solution (4 mg/ml, 500 µL total volume) and a 72 hr 
sample collection interval was 23 % (i.e. fraction of total radioactivity found in urine + faeces + 
carcass). BPA and its conjugated metabolites were determined by HPLC with fluorescence detection. 
The limit of detection (LOD) of the method was 1.5 ng/ml. The disruption by acetone of skin lipid 
structure and the associated barrier function has been described previously (Zhai et al., 1998) so this 
exposure condition is a conservative model for the extent of human exposure from thermal paper. 
Marquet et al (2011) also compared percutaneous fluxes ex vivo from rat and human frozen 
dermatomed skin explants and found the human flux to be approximately 10 % of the rat value under 
identical conditions using the acetone vehicle.  
 
Comment from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Distinction between unconjugated and conjugated BPA 
Weaknesses:  
- Single dose level study 
- Single acute dose administration 
- Test performed in one sex only 
- No information on the use of non-PC cages and of non plastic (e.g. glass) water bottles 
 
Mita L, Baldi A, Diano N, Viggiano E, Portaccio M, Nicolucci C, Grumiro L, Menale C, Mita 
DG, Spugnini EP, Viceconte R, Citro G, Pierantoni R, Sica V, Marino M, Signorile PG and 
Bianco M, 2012. Differential accumulation of BPA in some tissues of offspring of Balb-C mice 
exposed to different BPA doses. Environmental Toxicology and Pharmacology, 33, 9-15. 
 
Pregnant adult Balb-C mice were exposed daily to two different doses of BPA by subcutaneous 
injection (100 µg/kg bw and 1000 µg/kg bw) beginning on gestational day 1 through the seventh day 
after delivery. The mothers were sacrificed on postpartum day 21, and the offspring were sacrificed at 
3 months of age. Control mice were subjected to the same experimental protocol but received saline 
injections. The liver, muscles, hindbrain and forebrain of the offspring were dissected and processed 
using HPLC to assess the level of BPA in the tissues and to determine its dependence on the exposure 
dose and gender. For comparison, the same tissues were dissected from the mothers and analysed. The 
authors reported that: (1) the level of BPA that accumulated in a given tissue was dependent on the 
exposure dose; (2) the rank order of BPA accumulation in the various tissues was dependent on the 
gender of the offspring; (3) the average BPA concentrations in the liver and muscle of the female 
offspring were higher than in the males; and (4) the average BPA concentration in the central nervous 
system (i.e. the hindbrain and forebrain) of the male offspring was higher than in the females. 
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Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
 
Strengths:  
- Phytoestrogen-free diet  
- Use of non-PC cages and of glass water bottles 
Weaknesses:  
- Analytical method (HPLC with fluorescence detection)  
- No distinction between unconjugated and conjugated BPA 
 
Overall the CEF Panel noted that the method used in the study was HPLC with UV and fluorescence 
detection. The authors do not give levels of detection and other information on the precision and 
sensitivity of the method. No mass spectrometry-based analyses have been performed to confirm that 
the peaks are attributed to BPA. The measurements took place in the mother 14 days after the last 
administration and in the pups 2 months and 3 weeks after the administration. Given the half-life of 
BPA in mice of less than 1 hour after PND 21, it is unlikely that the substance which has been 
measured is BPA.  
Nishikawa M, Iwano H, Yanagisawa R, Koike N, Inoue H and Yokota H, 2010. Placental 
transfer of conjugated bisphenol A and subsequent reactivation in the rat fetus. Environmental 
Health Perspectives, 118, 1196-203. 
Nishikawa et al. (2010) studied the transfer of glucuronidated BPA across the placenta by uterine 
perfusion in pregnant SD rats (GD 18.5). 
The uterus was perfused with a solution containing 2 µM glucuronidated BPA for 20 min, followed by 
a 70-min perfusion with a solution not containing glucuronidated BPA, after which the perfusate as 
well as the fetus, amnion, amniotic fluid, placenta, and uterus were collected. HPLC and LC/TOF-MS 
were used for the determination of glucuronidated and unconjugated BPA. Almost all of the 
glucuronidated BPA (113 nmol) was detected in the perfusate leaving the uterine vein. Glucuronidated 
BPA was also detected in the fetus in a small amount (109 pmol, ~0.09% of the total amount) but not 
in the amnion, amniotic fluid, placenta, and uterus. Moreover, unconjugated BPA was detected to a 
small amount in the amniotic fluid (31 pmol) and in the fetus (6 pmol)  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strength:  
- Measurements of BPA and BPA-gucuronide independently in all compartments of the fetus 
- Analytical method (LC/TOF-MS) 
Weaknesses: 
- Study design not appropriate to the scope (only one time point late in pregnancy (GD 18.5)) 
 
Patterson TA, Twaddle NC, Roegge CS, Callicott RJ, Fisher JW and Doerge DR, 2013. 
Concurrent determination of bisphenol A pharmacokinetics in maternal and fetal rhesus 
monkeys. Toxicology and Applied Pharmacology, 267, 41–48. 
 
This paper describes measured concentrations of unconjugated and conjugated BPA in the plasma of 
rhesus dams and in the plasma of fetus after administration of deuterated BPA (100 µg/kg bw) 
intravenously and orally to two groups of dams. The concentrations of unconjugated and conjugated 
BPA were determined in the amniotic fluid and in the placenta by liquid chromatography tandem mass 
spectrometry (LC-MS-MS). The limit of detection (LOD) for deuterated BPA was 0.2 (0.05 ng/ml) in 
serum and 0.4 pmol/g (0.1 ng/g) in tissue. The kinetics in the dams were similar to the findings in a 
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previous study (Doerge et al., 2010). In the fetus, plasma concentrations were several fold lower than 
in the dams and internal exposure as measured by AUC was 0.43 fold of the exposure in dam given 
BPA by the intravenous route. Concentrations in the dams being about 45 600 pg/ml 5 minutes after 
dosing declining to below 22.8 pg/ml 24 hours thereafter. In the fetus, the concentration of 22.8 pg/ml 
is reached already 8 hours after dosing. In amniotic fluid, concentrations of unconjugated BPA were 
detectable (less than 22.8 pg/ml) but clearly lower than the conjugated BPA. The concentrations of 
both, conjugated and unconjugated BPA were several fold lower in the amniotic fluid compared to the 
fetal plasma. In the placenta, unconjugated BPA concentration was 2.7–fold higher than in the plasma 
of the dams and the fraction of the concentrations of the conjugated BPA was 4.5–fold. The data show 
that the fetus is exposed to BPA but to a lower extent than the damns. In the fetus, the ratio of the 
concentrations of conjugated to unconjugated BPA is 3 to 4 in the first half hour and increases with 
time to a factor of 300. This is due to the fact that the unconjugated BPA concentration declined with a 
half life of roughly 5 hours whereas the concentrations of conjugated BPA remained constant within 
the observation period. This finding indicates fetal metabolism. In three fetusses the concentration in 
brain was measured. Highly variable results indicated that BPA id distributed into the brain but the 
concentrations are low.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Oral administration by gavage 
- Analytical method (LC-MS-MS) 
- Distinction between unconjugated and conjugated BPA 
 
Overall the CEF Panel considered that the study is reliable concerning the experimental design and the 
results. It is to be noted that the results were obtained after single dose. However, for unconjugated 
BPA extrapolation to multiple dosing is feasible and indicates that the fetal exposure to BPA is lower 
than the exposure of the dam with a factor of roughly 0.5 which is in contrast to Nahar et al. 2012. In 
addition, no indication is given that the placenta is able to de-conjugated conjugated BPA. The 
concentrations measured in the amniotic fluid are consistent with the concentrations measured in the 
rat model from the same group of scientists, but in contrast to the study of Edlow et al. (2012) in 
amniotic fluid collected from pregnant women where 83–91 % of the conjugated plus unconjugated 
BPA was unconjugated BPA and concentrations were in the ng/ml range at environmental exposure.  
Taylor JA, vom Saal FS, Welshons WV, Drury B, Rottinghaus G, Hunt PA, Toutain P-L, 
Laffont CM and VandeVoort CA, 2011. Similarity of Bisphenol A Pharmacokinetics in Rhesus 
Monkeys and Mice: Relevance for Human Exposure. Environmental Health Perspective, 119, 
422–430. 
 
Taylor et al. (2011) measured unconjugated and conjugated BPA levels in serum from adult female 
rhesus monkeys and adult female mice after oral administration of BPA and compared findings in 
mice and monkeys with prior published data in women. Eleven adult female rhesus macaques were fed 
400 μg/kg bw deuterated BPA (dBPA) daily for 7 days. Levels of serum dBPA were analyzed by 
isotope-dilution liquid chromatography–mass spectrometry (LC-MS, 0.2 ng/ml limit of quantitation) 
over 24 hr on day 1 and on day 7. The same dose of 3H-BPA was fed to adult female CD-1 mice; other 
female mice were administered 3H-BPA at doses ranging from 2 to 100 000 μg/kg bw (4 doses). In 
monkeys, the maximum unconjugated serum dBPA concentration of 4 ng/ml was reached 1 hr after 
feeding and declined to low levels by 24 hr, with no significant bioaccumulation after seven daily 
doses. Mice and monkeys cleared unconjugated serum BPA at virtually identical rates. A linear 
(proportional) relationship between administered dose and serum BPA was observed in mice over a 
50 000-fold dose range. The authors considered that the study demonstrates that for conjugated BPA, 
pharmacokinetics in women, female monkeys, and mice is very similar. The authors further claim that 
based on similarity of plasma conjugated BPA profiles between humans, mice and monkeys, linear 
dose-plasma level kinetics and similarity of conjugated over non-conjugated BPA plasma level ratios 
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between monkeys and mice, it must be assumed that also in humans for comparable exposures to BPA 
comparable plasma levels of unconjugated BPA must be reached. They argue that kinetics in humans, 
monkeys and mice are not so different that extrapolation from rodents to humans would be 
inappropriate.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Analytical method (LC-MS) 
- Use of stainless steel (monkeys) and PP (mice) cages and non plastic water bottles 
Weaknesses:  
- Phytoestrogen content of diet not reported (soy-based diet for mice) 
Overall the CEF Panel noted that the ratio of conjugated/unconjugated BPA determined in this study 
in both mice and monkeys plasma is about 100, which is consistent with the results of other studies. 
The study also confirms that in order to get unconjugated BPA levels of ca. 2 ng/ml external exposures 
are needed in the order of 400 µg/kg bw, or for an adult human being ca. 28 mg per person. The use of 
stable isotope-labeled BPA reassures that no contamination by ubiquitous BPA had occurred.  
Vom Saal FS, VandeVoort CA, Taylor JA, Welshons WV, Toutain PL, Hunt PA. Bisphenol A 
(BPA) pharmacokinetics with daily oral bolus or continuous exposure via silastic capsules in 
pregnant rhesus monkeys: Relevance for human exposures, 2014. Reproductive Toxicology, 45, 
105-16. 
 
In this study, dBPA and its conjugated metabolites were measured in serum in non-pregnant and 
pregnant female rhesus monkeys, their fetuses and amniotic fluid by a reliable isotope-dilution LC/MS 
analysis. dBPA was administered daily by as single oral dose injected into a piece of fruit (400 µg/kg 
bw/d) or by continuous administration by sc implantation of Silastic capsules (release rate not given). 
A concentration time profile was obtained in the animals orally exposed whereas only one 
concentration was measured every other day for 12 days in the animals with continuous 
administration. Concentration time profiles and single concentrations were measured at different time 
points in pregnancy. The average serum unconjugated dBPA concentrations were below 1 ng/ml. 
Using the AUC of the IV route reported previously in rhesus monkeys (i.e. 180 ± 76 nM h/L or 41 ng 
h/mL) for an IV BPA dose of100 µg/kg bw the authors estimated the absolute bioavailability of dBPA 
by the oral route to be about 7.3% in the non-pregnant animals and about 5% for pregnant animals at 
GD 50. At GD 100, when pregnancy was terminated by hysterotomy in a subgroup, the observed 
serum concentrations of unconjugated dBPA in pregnant females were lower relative to pre-pregnancy 
values. Lower concentrations in fetal serum were measured than in maternal serum, 1 hour after oral 
administration, and levels in fetal serum were below LOQ (0.2 ng/ml) at 3 hours after oral 
administration. No parent BPA was detected in the amniotic fluid whereas conjugated BPA was 
present although in much lower concentration than in the fetus. In the maternal deciduas and in the 
fetal placenta dBPA was measured 1 hour after oral administration, and levels of parent compound 
were below LOQ (0.2 ng/ml) in tissues from one animal and at a similar concentration in the tissues 
form the second animal at 3 hours after oral administration. It is to be noted that the ratio of 
conjugated BPA-AUC/unconjugated BPA-AUC was several fold higher after oral administration 
(between 35 and 62) than the ratio for the continuous s.c. administration (between 1 and 4). This is in 
line with high first pass metabolism. The observed differences in pharmacokinetics of dBPA, that were 
evident between pre-pregnancy, early and late pregnancy, reflect changes in maternal physiology 
during pregnancy with a lower absorption rate and higher renal clearance.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study:  
Strengths:  
- Use of  stable isotope-labeled BPA  
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- Analytical method (LC-MS-MS)  
- Distinction between unconjugated and conjugated BPA  
- Oral and sc route of administration (enabling to establish steady state concentration after non-
oral administration) 
Weaknesses: 
- Dose in the sc route study not known 
- No details on the kinetic given as continous administration does not allow the elucidation 
 
The CEF Panel considered that this well performed study adds to the toxicokinetic knowledge on 
BPA. It demonstrates that BPA concentration in fetus is low (lower than the maternal concentration) 
and is not retained in the fetal tissue as well as in placenta. Furthermore, there is only a very low 
concentration of unchanged BPA in the amniotic fluid which renders study results in humans doubtful 
which has measured high concentrations of unchanged BPA in amniotic fluid. It confirms that the 
fetus is able to conjugate BPA (day 50 and older)  and excrete the conjugate into the amniotic fluid.  
The oral administration was by way of a fruit which was hoarded in the cheek. This would explain the 
higher bioavailability in this study (7.3% in non-pregnant and 5% in pregnant animals) compared to 
the findings of the Doerge group (0.94%) as by hoarding the contact time of the BPA with the buccal 
mucosa is prolonged and for the absorbed amount first pass is circumvented. 
The results are plausible and the use of stable isotope-labelled BPA reassures that no contamination by 
ubiquitous BPA had occurred. 
(iii) In vitro studies 
Appraisal of strengths and weaknesses and WoE analysis were not carried out for in vitro studies.  
Demierre AL, Peter R, Oberli A and Bourqui-Pittet M, 2012. Dermal penetration of bisphenol A 
in human skin contributes marginally to total exposure. Toxicology Letters, 213, 305-308. 
This study is also described and discussed in Appendix D. 
The aim of the study was to determine the dermal penetration rate of BPA in human skin by means of 
an in vitro test method according to the OECD Test Guideline 428. The analysis was done under GLP 
conditions. Full thick skin obtained from two human cadavers was frozen at -20 °C for up to one year. 
After thawing, 7 skin sections of 200 µm thickness were cut off from the top and used to perform the 
study. The applied dose was 1.82 µg 14C-BPA/cm2 skin under non-occluded conditions. After 24 hours 
after application 8.6% of the applied dose penetrated into the receptor fluid, whereas 34.9 % of the 
dose was recovered in the stratum corneum, especially in the outer layers. When stripping the skin, 
0.6% of the applied dose was in the skin membrane. The authors considered this latter amount together 
with that present in the receptor fluid as being bioavailable: hence, the total amount bioavailable after 
application to skin is according to the authors 9.3%.  
The CEF Panel considers the study as appropriately performed from a methodological point of view 
and study reporting fit for purpose. The CEF Panel agrees with the interpretation of the results by the 
study authors. Given the good quality of the study and the detail of reporting, the study of Demierre et 
al. (2012) was used as a reference for comparison with the other studies. 
Kaddar N, Harthe C, Dechaud H, Mappus E and Pugeat M, 2008. Cutaneous penetration of 
bisphenol A in pig skin. Journal of Toxicology and Environmental Health-Part a-Current Issues, 
71, 471-473. 
This study is also described and discussed in Appendix D. 
Kaddar and collaborators (2008) analyzed shaved pig skin from the flanks in a static Franz diffusion 
cell. Physiological serum was used as vehicle, and 14C-BPA was applied in a concentration of 10 mg/l. 
The applied surface density was not reported. The experiments were carried out at ~32 °C, either for 
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24 h with repeated sampling in regular intervals (transfer kinetics experiment) or for 2, 5, and 10 h 
with single sampling (skin distribution experiment). For the skin distribution experiment, six replicates 
were used per exposure duration. Additional methodical details (e.g., skin thickness, applied surface 
concentration) were not reported. Analysis of skin distribution after the longest exposure time of 10 h 
showed that 5.4% and 8.8% of the applied dose to be in the epidermis and dermis, respectively. The 
transfer kinetics experiment revealed a lag time of ~3 h and a percutaneous penetration of 4.1% after 
24 h. 
The CEF Panel consider that the study reporting is insufficient due to the omission of several 
methodical details including the applied surface density (µg/cm2) and the skin thickness. As for data 
interpretation, the percutaneous penetration value of 4.1% is in line with the value of 8.6% reported by 
the high quality study of Demierre et al. (2012). 
Marquet F, Payan JP, Beydon D, Wathier L, Grandclaude MC and Ferrari E, 2011. In vivo and 
ex vivo percutaneous absorption of [14C]-bisphenol A in rats: a possible extrapolation to human 
absorption? Archives of Toxicology, 85, 1035-1043. 
 
This study is also described in the previous section on animal studies and discussed in Appendix D. 
In this study, percutaneous BPA absorption was measured in vivo (see in animal studies) in the rat and 
ex vivo both in the rat and humans. Marquet et al. (2011) used a static Franz diffusion cell and 
analyzed viable and non-viable (frozen) human skin from 6 patients undergoing plastic surgery. The 
skin was dermatomed to a thickness of 500 µm, and the skin integrity was checked by measuring the 
transepidermal water loss. Acetone was used as vehicle, and 14C-BPA was applied in a high 
concentration of 4000 mg/l, resulting in a surface density of 200 µg/cm2. The receptor fluid consisted 
of cell culture medium with 2% BSA (BPA solubility ≥300 mg/l). The experiments were conducted at 
32 ± 1 °C for 24 h, and receptor-fluid samples were taken on regular intervals. Permeation 
experiments with 15 non-viable human skin sections revealed a recovery of 95.6% and a maximum 
percutaneous flux of 0.12 µg/cm2/h occurring at the end of the incubation period at 23.5 h. The 
quotient of maximum percutaneous flux and vehicle concentration yielded a permeability coefficient 
of 3.0×10–5 cm/h which was 3.7-fold lower than in Demierre et al. (2012) but still comparable given 
the differences in vehicle type, surface density, and diffusion-cell design. Additional permeation 
experiments with non-viable rat skin under identical conditions revealed a ~12-fold higher 
permeability for rat skin compared to human skin. Finally, the authors used viable human and rat skin 
to estimate the extent of skin metabolism by measuring the BPA metabolites in the receptor fluid after 
24 h of exposure. For both human and rat skin, metabolized BPA accounted for ~3% of the permeant. 
In summary the authors reported an approximately 12-fold difference in permeability between rat skin 
and human skin, with permeability being higher in the rat. In addition, inter- and intra-individual 
variability of up to tenfold was observed in humans. No accumulation of BPA in the skin was found 
during exposure. The skin clearance rate following exposure was estimated at 0.4 µg/cm2/h. 
Mazur CS, Kenneke JF, Hess-Wilson JK and Lipscomb JC, 2010. Differences between human 
and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on 
in vitro kinetic measurements. Drug Metabolism and Disposition, 38, 2232-2238. 
Native hepatic microsomes were used from rat and from human liver and intestine to study the enzyme 
kinetics of glucuronidation of BPA. BPA glucuronidation in liver microsomes were sex dependent. 
Female rat and female human liver microsmomes had a higher V(max) values than that in males. K(m) 
for glucuronidation was much higher in female rats than in humans and male rats. The dissimilar K(m) 
measured for female rat together with inhibition studies suggests that different UDP-
glucuronosyltransferase (UGT) enzyme(s) are involved in BPA glucuronidation in rats, UGT2B7 and 
UGT2B15 being candidates. Human intestinal microsomes (mixed gender) showed little BPA 
glucuronidation activity compared with those from male rat intestine, which in the presence of 
alamethicin, a membrane-disrupting agent, exhibited a V(max) that was nearly 30-fold higher than that 
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for mixed human microsomes. The species- and gender-related metabolic differences observed 
between rat and human liver and intestine provide key information for delineating BPA 
pharmacokinetics needed for human health risk assessment. 
Mazur CS, Marchitti SA, Dimova M, Kenneke JF, Lumen A and Fisher J. (2012) Human and 
Rat ABC Transporter Efflux of Bisphenol A and Bisphenol A Glucuronide: Interspecies 
Comparison and Implications for Pharmacokinetic Assessment. Toxicological Sciences, 128, 317-
25 
 
Mazur et al. investigated the interaction of BPA and BPA-G with human and ABC transporters: P-
glycoprotein (MDR1), multidrug resistance–associated proteins (MRPs), and breast cancer–resistant 
protein (BCRP) in insect cells transfected with the transporters. As the transport is energy dependent, 
using ATP as energy source, ATPase activity can be used to detect whether BPA and BPA-G are 
substrates for the investigated transporters. Based on high ATPase activity, BPA is likely a substrate 
for rat mdr1b but not for human MDR1 or rat mdr1a. Results indicate that BPA is a potential substrate 
for rat mrp2 and human MRP2, BCRP, and MRP3. The metabolite BPA-G demonstrated the highest 
apparent substrate binding affinity for rat mrp2 and human MRP3 but appeared to be a non-substrate 
or potential inhibitor for human MRP2, MDR1, and BCRP and for rat mdr1a, mdr1b, and bcrp. 
Comparison of ABC transporter amino acid sequences revealed differences in putative binding site 
that may explain the observed differences. For BPA transporter activity was shown for transporters 
facilitating transport into the bile and into the intestinal lumen (MDR1, human; MDR1b, rat; MRP2, 
human and rat; BCRP, human and rat). In rat, BPA-G is transported by the same transporters, thus 
facilitating biliary excretion of BPA-G whereas, in human, due to the basolateral location of MRP3, 
BPA-G would be transported into hepatic vein and into the intestinal veins draining into the portal 
vein.  
Overall the CEF Panel notes that this in vitro study provides further information on the interspecies 
differences between human and rodent in toxicokinetics of BPA. Technically, the study is considered 
to be well performed. However, the CEF Panel noted that the lowest concentration tested was 1.95 µM 
(444.6 ng/ml) and the concentration showing some effect was 10 µM (2 280 ng/ml). Both 
concentrations are far above human exposure levels of BPA (Cmax 0.024 ng/ml in humans for an oral 
dose of 1.5 µg/kg bw obtained by simulation; Cmax 0.1 ng/ml in rats for an oral dose of 100 µg/kg 
bw). 
 
Mørck TJ, Sorda G, Bechi N, Rasmussen BS, Nielsen JB, Ietta F, Rytting E, Mathiesen L, 
Paulesu L and Knudsen LE, 2010. Placental transport and in vitro effects of Bisphenol A. 
Reprod Toxicol, 30, 131-137. 
This study is also described and discussed in Appendix D. 
Mørck et al. (2010) used a static Franz diffusion cell and analyzed non-viable human skin from breast-
surgery patients according to the OECD TG 428. Full thickness skin (800–1000 µm) was used, and the 
skin integrity was checked by capacitance measurements. A diluted ethanol solution was used as 
vehicle, and 14C-BPA was applied in a high concentration of 4000 mg/l, resulting in a surface density 
of 259 µg/cm2. The receptor fluid consisted of physiological saline solution containing 5% BSA. The 
experiments were carried out at ~32 °C for 48 h, and receptor-fluid samples were taken in regular time 
intervals. Experiments with 11 skin sections after 48 h incubation showed a percutaneous penetration 
13.0%, a skin deposition of 24.6%, and a recovery of 82.1%. A more detailed analysis of skin 
deposition showed 7.4% and 17.2% of the applied dose to be in the epidermis and dermis, 
respectively. Percutaneous penetration was 13.0%. 
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Trdan Lušin T, Roškar R and Mrhar A, 2012. Evaluation of bisphenol A glucuronidation 
according to UGT1A1*28 polymorphism by a new LC-MS/MS assay. Toxicology, 292, 33-41.  
 
The glucuronidation of BPA in adult human microsomal preparations was studied with a sensitive 
analytical method using labeled BPA in LC-MS/MS, which enabled simultaneous determination of 
aglycone and conjugated BPA. The study was performed in microsomes prepared from liver, kidneys, 
intestines and lungs. No BPA-glucuronidation could be determined in human lung microsomes. In 
liver, kidneys and intestines, the microsomal intrinsic clearances were 950, 40 and 24 µL × min-1/mg 
microsomal protein, corresponding to full tissue intrinsic clearances of 857, 8 and 2 ml × min-1/kg bw, 
after scaling-up of the microsomal data to full organ weight.  
While the liver intrinsic clearance was very high (857 ml min−1 kg body weight−1), the tissue intrinsic 
clearances for the kidney and intestine were less than 1 % of liver intrinsic clearance. Since BPA is a 
UGT1A1 substrate, we postulated that the common UGT1A1*28 polymorphism influences BPA 
glucuronidation, and consequently, BPA detoxification. Hepatic tissue intrinsic clearances for 
UGT1A1*1/*1, UGT1A1*1/*28, and UGT1A1*28/*28 microsomes were 1113, 1075, and 284 ml 
min−1 kg body weight−1, respectively. The in vitro results show that the liver is the main site of BPA 
glucuronidation (Km 8.9 µM, Vmax 8.5 nmol min−1 mg−1) and BPA metabolism may be significantly 
influenced by a person’s genotype (Km 10.0–13.1 µM, Vmax 3.4–16.2 nmol min−1 mg−1).  
These authors also investigated the influence of a polymorphism of human UGT1A1 on the 
metabolism of BPA. Although this is not the most active form of UGT to contribute to the 
glucuronidation of BPA (which is UGT2B15), it still has significant capacity. For genotyped 
microsomes containing only wild-type UGT1A1*1, an intrinsic clearance of 1240 µL × min-1/mg 
microsomal protein was found and for UGT1A1*1/*28 (heterozygous) an intrinsic clearance of 1190 
µL × min-1/mg microsomal protein. However, for the homozygous UGT1A1*28/*28, the intrinsic 
clearance was only 320 µL × min-1/mg microsomal protein. There were no differences in Km values 
for the two allelic variants studied. Thus for the three different genotypes intrinsic tissue clearances of 
1113, 1075 and 284 ml × min-1/kg bw were calculated. The authors reasoned that this polymorphism 
of UGT1A1 may have toxicological consequences, since the glucuronidation capacity of the liver may 
be strongly reduced in UGT1A1*28 homozygous individuals. 
Polymorphisms have been described for the enzymes relevant for the conjugation of BPA. Since BPA 
conjugation can be carried out by several enzymes, a single polymorphism in one gene, resulting in a 
reduced or loss of enzymatic activity of the respective gene product (i.e. the functional enzyme) is not 
anticipated to result in immediate major changes in the plasma levels of aglycone BPA.  
Zalko D, Jacques C, Duplan H, Bruel S and Perdu E, 2011. Viable skin efficiently absorbs and 
metabolizes bisphenol A. Chemosphere, 82, 424-430. 
This study is also described and discussed in Appendix D. 
Zalko et al. (2011) examined the diffusion and metabolism of BPA using viable human skin explants 
from the abdominal region of female donors. The skin was dermatomed to a thickness of 500 µm and 
then seeded in cell culture inserts, where the explants were maintained at the air/liquid interface with 
dermal/epidermal feeding by diffusion of nutrients from the culture medium (1.5 ml) across the insert. 
Ethanol/phosphate buffer 0.1 M pH 7.4 (1:2, v/v) was used as vehicle, and 14C-BPA was applied in a 
surface density of 2.75 µg/cm2. The experiments were carried out at 37 °C, and culture media were 
collected at 24, 48, and 72 h. Experiments with 3 skin sections after 72 h incubation showed a 
percutaneous penetration 45.6%, a skin deposition of 41.5%, a residual amount of 2.5 % on the skin 
surface, and a recovery 92.6%.  
Additional experiments with viable human skin and pig ear skin were carried out to analyze the extent 
of skin metabolism. Major skin metabolites were BPA mono-glucuronide and BPA mono-sulfate, 
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which were reported to account for 73% and 27% of the dose in porcine an human skin after 72 h of 
incubation (percentages are unclear).  
The CEF Panel noted several methodical flaws in the first experimental phase, e.g., use of cell culture 
inserts as diffusion cells, missing skin integrity check, exposure times largely exceeding 24 h, 33% 
ethanol solution as vehicle, which negatively impact the reliability of these estimates for in vitro skin 
absorption. 
Again, the transferability of these results to the in vivo situation in humans is highly questionable. 
First, there was almost a complete depletion of the permeant on the skin surface. Second, the 
concentrations of BPA equivalents in the culture medium (i.e. the receptor compartment) reached 
values well above 1 µM, which is not really the "sink" condition prevailing in vivo with serum 
concentrations for BPA equivalents being generally far below 10 nM. As a consequence, there was no 
longer a directional transport of the permeant from the donor compartment to the receptor 
compartment, and a re-uptake of BPA from the culture medium with subsequent metabolization in the 
skin cannot be excluded. Ignoring these methodical flaws would lead to an overestimation of the 
extent of in vivo skin metabolization. 
(iv) PBPK modelling  
Appraisal of strengths and weaknesses and WoE analysis were not carried out for these PBPK 
modelling studies. Also given the very limited number of studies on this topic, the time period for the 
literature search was extended to earlier than 2010. 
Edginton AN and Ritter L, 2009. Predicting plasma concentrations of bisphenol A in children 
younger than 2 years of age after typical feeding schedules, using a physiologically based 
toxicokinetic model. Environmental Health Perspectives, 117, 645-52.  
The age dependence of the toxicokinetics of BPA and its glucuronidated metabolite, BPA-Glu, has 
been evaluated using a coupled BPA–BPA-Glu physiologically based toxicokinetic (PBTK) model. 
Using information on the concentration-time profile and urinary excretion of the main metabolite 
BPA-Glu gathered from the study in adult humans by Völkel et al. (2005) clearance has been modeled 
by optimization procedures. Based on age dependence of physiologic parameters relevant for 
absorption, distribution, metabolism, and excretion the kinetic of BPA was age-adjusted. In the model 
the metabolism of BPA was modeled with a single metabolite, namely BPA-Glu and metabolism to 
BPA-sulfate has not been taken into consideration. The average steady-state BPA plasma 
concentration in newborns has been simulated to be 11 times greater than that in adults when given the 
same weight-normalized dose mainly due to reduced metabolic clearance mirroring the lower 
expression of the enzyme relevant for glucuronidation, namely UTG 2B 15, in the newborn. Because 
of the rapid development of the glucuronidation process, this ratio dropped to 2 by 3 months of age. 
Because of uncertainty in on the hepatic BPA intrinsic clearance, these values represent preliminary 
estimates. The model predicts a Cmax-value of 50 nM after an oral dose of 5 mg (in the study of 
Völkel et al., 2002 between 54.3 and 87.7 µg/kg bw). 
Comments from the CEF Panel:  
This modelling approach is based on a commercially available modelling tool with a complex 
structural model. The physiological parameters for organ weights and blood flows are taken from 
available literature. The metabolism of BPA was modeled with a single metabolite, namely BPA-glu 
and metabolism to BPA-sulfate has not been taken into consideration as the metabolic clearance of 
BPA is obtained by an optimisation procedure for describing the time course of BPA-Glu with data 
from the study by Völkel et al. (2002). For the situation in adults, the influence of this fact is not 
important as in the adult – at least in persons with an un-impaired glucuronidation capacity - the 
sulfate pathway does contribute the metabolic clearance to only roughly 10%. For the situation in 
subjects with impaired glucuronidation, i.e. the newborn sulfate metabolism plays an important role. 
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Hence, the prediction for the adult with un-impaired glucuronidation capacity but nor for the newborn 
is acceptable.  
Fisher JW, Twaddle NC, Vanlandingham M and Doerge DR, 2011. Pharmacokinetic modeling: 
Prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with 
extrapolation to humans. Toxicology and Applied Pharmacology, 257, 122-136. 
 
A physiologically based pharmacokinetic (PBPK) model was developed for BPA using data from 
intravenous (iv) and oral bolus doses of 100 μg d6-BPA/kg (Doerge et al., 2010b) in adult rhesus 
monkeys. This calibrated PBPK adult monkey model for BPA was then evaluated against published 
monkey kinetic studies with BPA. Using two versions of the adult monkey model based on monkey 
BPA kinetic data from Doerge et al. (2010) and Taylor et al. (2011), the unconjugated BPA 
pharmacokinetics were simulated for human oral ingestion of 5 mg d16-BPA per person (Völkel et al., 
2002). Völkel et al. were unable to detect the unconjugated BPA in plasma, but were able to detect 
BPA metabolites. These human model predictions of the unconjugated BPA in plasma were then 
compared to previously published PBPK model predictions obtained by simulating the Völkel et al. 
kinetic study. The BPA human models as developed here, using two parameter sets reflecting the two 
adult monkey studies, both predicted lower unconjugated levels in human serum than the previous 
human BPA PBPK model predictions. BPA was metabolized at all ages of monkey (PND 5 to adult) 
by the gut wall and liver. However, the hepatic metabolism of BPA and systemic clearance of its 
phase II metabolites appear to be slower in younger monkeys than adults. The authors concluded that 
use of the current non-human primate BPA model parameters provides more confidence in predicting 
the unconjugated BPA in serum levels in humans after oral ingestion of BPA. The authors further 
commented that, based on their models, unconjugated BPA may be present in humans at a level of 8.8 
nM (~ 2 ng/ml).  
  
The study by Fisher et al may be used to predict BPA and BPA-conjugates plasma levels in humans. 
The model comprises 7-compartments for unconjugated BPA (covering 5 compartments important for 
BPA kinetics and 2 compartments representative for target tissues for toxicity) and 1 compartment for 
BPA-conjugates. The model performance in humans could only be tested for the BPA conjugates, 
since no adequate kinetics data on unconjugated BPA in humans are available. The model predicted an 
elimination of > 90 % of an oral dose of 5 mg/person via urine within 12 hrs post dosing. The models 
also predicted at least 2 orders of magnitude difference in BPA conjugate plasma concentration vs. 
unconjugated BPA plasma concentration. Unconjugated BPA levels were also slightly less than 
predicted in previous models in literature (Mielke and Gundert-Remy, 2009; Egington and Ritter, 
2009), which is in line with the data from Teeguarden et al (2011). 
Mielke H, Gundert-Remy U, 2009. Bisphenol A levels in blood depend on age and exposure. 
Toxicological Letters, 190, 32-40.  
 
Two approaches are presented to estimate blood concentrations of Bisphenol A (BPA). Simple kinetic 
principles were applied to calculate steady state plasma concentrations (Css) using the formula Css = f 
x dose/ ke x VD. F is the fraction absorbed; ke is the first order elimination constant which can be 
calculated by ke =ln 2/half-life and VD is the volume of distribution. F was taken from the study of 
Völkel et al. (2005); half-life from data by Tsukioka et al. (2004) (Tsukioka, T., Terasawa, J., Sato, S., 
Hatayama, Y., Makino, T., Nakazawa, H., 2004. Development of analytical method for determining 
trace amounts of BPA in urine samples and estimation of exposure to BPA. J. Environ. Chem. 14, 57–
63); VD from published data by Sun et al. (2002) (Sun, Y., Nakashima, M.N., Takahashi, M., Kuroda, 
N., Nakashima, K., 2002. Determination of bisphenol A in rat brain by microdialysis and column 
switching high-performance liquid chromatography with fluorescence detection. Biomed.Chromatogr. 
16, 319–326.),A physiologically based model was used to simulate the blood concentration time 
profile in several age groups exploring the influence of not yet fully developed metabolic capacity on 
the blood concentrations in the newborn. The structural model consists of 7 compartments and 
metabolism is modeled on two pathways glucuronidation and sulfation. The physiological data were 
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obtained from published sources (Abraham et al. 2005). Metabolism to BPA-G was modeled by 
upscaling in vitro data on KM and Vmax obtained in human hepatozytes and to BPA-S by relating 
activity to the percentage metabolised. The simple kinetic model gave concordant results with the 
more elaborated model. The modelling results are in agreement with experimental results [Völkel, W., 
Colnot, T., Csanady, G.A., Filser, J.G., Dekant, W., 2002. Metabolism and kinetics of bisphenol A in 
humans at low doses following oral administration. Chem. Res. Toxicol. 15, 1281–1287]. The 
predictions also agree with published results obtained with a different physiologically based model. 
According to model simulations, BPA is present in the blood of the normal population at 
concentrations several orders of magnitude lower than most measurements reported in the literature. 
At the same external exposure level, the newborn is predicted to have 3 times greater blood 
concentration than the adult. This is due to the not yet fully developed glucuronidation activity in the 
newborn, not fully compensated by the unimpaired sulfation pathway. The model predicts a Cmax-
value of 50 nM after an oral dose of 5 mg (in the study of Völkel et al., 2002 between 54.3 and 87.7 
µg/kg bw). 
Comments from the CEF Panel:  
As the metabolism of BPA is the main influencing factor for the kinetics the prediction of the model 
depends critically on the in vitro metabolism data and on its upscaling. The model only describes the 
kinetics of BPA and does not include the kinetics of BPA-G. The validity of the model could have 
been increased if it had been extended to BPA-G using available BPA-G experimental data. 
Teeguarden JG, Waechter JM Jr, Clewell HJ 3rd, Covington TR and Barton HA, 2005. 
Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine 
tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. 
Toxicological Sciences, 85, 823-38. 
 
A physiologically based pharmacokinetic (PBPK) model of BPA pharmacokinetics was developed for 
rats and for humans. A uterine tissue compartment was included to allow the correlation of simulated 
estrogen receptor (ER) binding of BPA with increases in uterine wet weight (UWW) in rats. 
Intravenous- and oral-route blood concentration-time course of BPA and its main metabolite, BPA-
glucuronide, were well described by the model. By scaling up the relevant data from rat to human, 
oral-route plasma and urinary elimination kinetics of BPA-glucuronide (BPA-G) in humans were 
covered by the model. The model parameters of metabolism were optimised using the data of Völkel 
et al. 2002. The predicted the concentration time course of BPA-GComparison of metabolic clearance 
rates derived from fitting rat i.v. and oral-route data implied that intestinal glucuronidation of BPA is 
significant. In rats, but not humans, terminal elimination rates were strongly influenced by 
enterohepatic recirculation. The model predicts a Cmax-value of 10 nM after an oral dose of 5 mg (in 
the study between 54.3 and 87.7 µg/kg bw). 
Because of the differences between rat and human concerning biliary excretion and entero-hepatic 
recirculation of BPA/BPA-G the structural model has some weaknesses. More recent and more 
appropriate models are now available. 
Yang X, Doerge DR and Fisher JW, 2013. Prediction and evaluation of route dependent 
dosimetry of BPA in rats at different life stages using a physiologically based pharmacokinetic 
model. Toxicology and Applied Pharmacology, 270, 45-59. 
In this study time a physiologically based pharmacokinetic (PBPK) model was developed for in 
neonatal and adult rats to quantitatively evaluate age-dependent pharmacokinetics of BPA and its 
phase II metabolites. The PBPK model was calibrated in adult rats using studies on BPA metabolism 
and excretion in the liver and gastrointestinal tract, and pharmacokinetic data with BPA in adult rats. 
For immature rats the hepatic and gastrointestinal metabolism of BPA was inferred from studies on the 
maturation of phase II enzymes coupled with serum time course data in pups. The calibrated model 
predicted the measured serum concentrations of BPA and BPA conjugates after administration of 100 
μg/kg of d6-BPA in adult rats (oral gavage and intravenous administration) and postnatal days 3, 10, 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 275 
and 21 pups (oral gavage). The observed age-dependent BPA serum concentrations were partially 
attributed to the immature metabolic capacity of pups. A comparison of the dosimetry of BPA across 
immature rats and monkeys suggests that dose adjustments would be necessary to extrapolate toxicity 
studies from neonatal rats to infant humans. 
Reproductive and Developmental effects 
(i) Human studies 
BPA effects on adult reproduction 
Bloom MS, vom Saal FS, Kim D, Taylor JA, Lamb JD and Fujimoto VY, 2011a. Serum 
unconjugated bisphenol A concentrations in men may influence embryo quality indicators 
during in vitro fertilization. Environmental Toxicology and Pharmacology, 32, 319-323. 
  
This study was a cross-sectional analysis of a subsample of a prospective cohort study of metals and 
assisted reproductive technologies (SMART). In the current study the authors studied the associations 
between serum unconjugated BPA concentrations and indicators of embryo quality in 27 couples 
undergoing in vitro fertilization. Unconjugated BPA was collected according to established procedures 
and measured by HPLC with electrochemical detection (limit of detection, LOD 0.3 ng/ml). The 
measures used as indicators of embryo quality were: embryo cell number (ECN) and embryo 
fragmentation score (EFS). The models were adjusted for female and male unconjugated BPA, age, 
ethnicity and day of embryo transfer for ECN. The authors reported that inverse associations were 
suggested for male BPA with ECN (OR=0.70, p=0.069) and EFS (OR=0.54, p=0.009), but not for 
women. Although the study is suggestive of a negative influence of male BPA exposure on human 
embryo quality the authors acknowledged that the limited sample size and scope of the study make the 
results preliminary.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Quality control, including blanks 
Weaknesses:  
- Cross-sectional design  
- Small sample size 
- Serum BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
- Confounding by diet or by concurring exposure factors (contamination through medical 
treatment during IVF) not considered 
- Generalisability to the overall population 
Overall, the CEF Panel considers that this study has main limitations, e.g. the cross sectional design, 
the small sample size and the use of serum BPA, which is not considered a valid measure of BPA 
exposure. Furthermore, as the study is part of an on-going study of metals, this confounding factor 
should have been taken into account. Potential contamination through medical treatment in IVF is 
likely to occur. A considerable number of BPA values in male (48%) were below the LOD. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
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Bloom MS, Kim D, Vom Saal FS, Taylor JA, Cheng G, Lamb JD and Fujimoto VY, 2011b. 
Bisphenol A exposure reduces the estradiol response to gonadotropin stimulation during in vitro 
fertilization. Fertility and Sterility, 96, 672-677. 
  
The authors examined whether serum unconjugated BPA was associated with follicular response to 
exogenous ovarian stimulation in a cross sectional study of a small group of 44 women undergoing 
IVF treatment. Serum unconjugated BPA was determined by HPLC with electrochemical detection 
(LOD 0.3 ng/ml). The main outcome measures were peak 17β-oestradiol (E2) concentrations, E2 
normalized for mature-sized follicles at the time of the hCG trigger and the number of oocytes 
retrieved during IVF (=antral follicle count, AFC).  
The results showed an inverse association between serum unconjugated BPA and E2 concentration 
and E2 normalized for mature sized follicles, but no association between unconjugated BPA and 
ovarian reserve variables. The results were indicative of a negative association and warrant further 
studies.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Quality control, including blanks 
Weaknesses:  
- Cross-sectional design  
- Small sample size 
- Serum BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
- Confounding by diet or by concurring exposure factors (contamination through medical 
treatment during IVF) not considered 
- Generalisability to the overall population 
 
Overall, the CEF Panel considers that the study has main limitations, e.g. the cross sectional design, 
the small sample size limiting the statistical power of the study and the use of serum BPA, which is 
not considered a valid measure of BPA exposure. In addition, potential contamination through medical 
treatment in IVF is likely to occur. The CEF Panel also noted that this study used the same BPA 
exposure data as the study by Fujimoto et al. (2010), addressing different outcome measures (Fujimoto 
et al., 2010). Concerning the results, BPA correlations were far weaker than physiological correlations 
(see Supplemental Figure 2). Given these overall limitations, this preliminary study is not considered 
as informative on BPA toxicity.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Buttke DE, Sircar K and Martin C, 2012. Exposures to endocrine-disrupting chemicals and age 
of menarche in adolescent girls in NHANES (2003-2008). Environmental Health Perspectives 
120, 1613-1618. 
 
The study examined the relationship between urinary endocrine-disrupting chemical concentrations 
(parabenes, BPA, triclosan, benzophenones, and dochlorophenols) and the age of menarche in 
adolescent girls. The study sample included female participants 12-16 years of age who had completed 
the reproductive health questionnaire and laboratory examination for the Centers for Disease Control 
and Prevention's National Health and Nutrition Examination Survey (NHANES) for years 2003-2008 
(2005-2008 for analyses of phthalates and parabens). Urinary BPA was measured by by on line solid 
phase extraction (SPE) coupled to liquid chromatography isotope dilution tandem mass spectrometry 
(LC-MS-MS, LOD 0.40 ng/ml). Exposures were assessed based on creatinine-corrected natural log 
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urine concentrations of selected environmental chemicals and metabolites found in at least 75% of 
samples in the study sample. The analysis of urinary total BPA and age of menarche included n=441. 
Body mass index, family income-to-poverty ratio, race/ethnicity, mother's smoking status during 
pregnancy and birth weight were evaluated as potential confounders. The weighted mean age of 
menarche was 12.0 years of age. The geometric mean urinary total BPA concentration was 2.25 µg/g 
creatinine. Accounting for BMI and race/ethnicity, 2,5-dichlorophenol (2,5-DCP) and summed 
environmental phenols (2,5-DCP and 2,4-DCP) were inversely associated with age of menarche 
[hazard ratios of 1.10; 95% confidence interval (CI): 1.01, 1.19 and 1.09; 95% CI: 1.01, 1.19, 
respectively]. Other exposures (total parabens, bisphenol A, triclosan, benzophenone-3, total 
phthalates, and 2,4-DCP) were not significantly associated with age of menarche. Hazard ratio for 
BPA was 0.94 (95% CI: 0.80, 1.10).  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross-sectional design  
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet not considered 
 
Overall, the CEF Panel notes that this study evaluated simultaneous exposure to several endocrine-
disrupting chemicals in relation to age of menarche in adolescent girls. Urinary total BPA was not 
associated with age of menarche. Relevant confounders were evaluated, but no dietary variables were 
included. The cross-sectional design limits the interpretation of the results. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Ehrlich S, Williams PL, Missmer SA, Flaws JA, Berry KF, Calafat AM, Ye X, Petrozza JC, 
Wright D and Hauser R, 2012a. Urinary Bisphenol A Concentrations and Implantation Failure 
among Women Undergoing In Vitro Fertilization. Environmental Health Perspectives, 120, 978-
983.  
 
In a study in Boston, USA, 137 women undergoing 180 IVF cycles were studied to investigate the 
potential link between BPA and reproductive outcomes early in the IVF process. In this detailed study 
1 or 2 spot urine samples, the timing of which were determined by clinic visits rather than biological 
hypothesis, were analysed for BPA by on line solid phase extraction (SPE) coupled to isotopic dilution 
liquid chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.4 µg/l), yielding results 
similar to those seen in many other studies. Data were analysed for confounders, covariates and used a 
BPA quantiles approach. Broadly, there was an increased odds of implantation failure with higher 
quartiles of urinary BPA quartiles: 1.02, 1.60, 2.11 for quartiles 2, 3 and 4 respectively compared to 
quartile 1 and a suggestive positive linear dose response association with implantation failure (p-trend 
0.06). .  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Prospective design 
- Urine, container specified (PP cups) 
- Repeated measurements (≤ 2) 
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- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks 
Weaknesses:  
- Short time frame (only days for exposure measurements per treatment cycle) 
- Single spot urine BPA measurements 
- Confounding by diet or by concurring exposure factors (contamination through medical 
treatment during IVF) not considered 
- Generalisability to the overall population 
 
Overall, the CEF Panel considers that this study is well-performed and is suggestive that higher level 
of total BPA is associated with reduced ovarian response in women. However, the generalisability of 
the results is uncertain for the population other than IVF couples. Also women undergoing IVF are 
likely to be exposed to BPA from medical plastics during an IVF cycle. In addition, the presence of 
female factor infertility may be associated with ovarian abnormalities affecting sensitivity to 
exogenous chemicals. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Ehrlich S, Williams PL, Missmer SA, Flaws JA, Ye X, Calafat AM, Petrozza JC, Wright D and 
Hauser R, 2012b. Urinary bisphenol A concentrations and early reproductive health outcomes 
among women undergoing IVF. Human Reproduction, 27, 3583-3592. 
 
Associations between urinary BPA concentrations and early reproductive outcomes were studied 
among 174 women aged 18-45 years undergoing 237 IVF cycles at a fertility center in Boston, USA. 
The study was a follow up of Bloom et al. (2011b), who previously reported an association between 
urinary BPA and decreased ovarian response (peak serum oestradiol (E2) and oocyte count at the time 
of retrieval) in women undergoing IVF. Total urinary BPA (after enzymatic hydrolysis) was 
determined by on line solid phase extraction (SPE) coupled to isotopic dilution liquid chromatography 
tandem mass spectrometry (LC-MS-MS, LOD 0.4 µg/l). The early reproductive outcomes examined 
were measures of ovarian response: oocyte maturation (metaphase II), fertilization, embryo quality 
and cleavage rate. Correlation among the multiple IVF cycles in the same woman were used for 
generalised estimating equations. The geometric mean (SD) for urinary BPA concentrations was 1.50 
(2.22) µg/l. After adjustment for age and other potential confounders (Day 3 serum FSH, smoking, 
BMI), there was a linear dose-response association between increased urinary BPA concentrations and 
decreased number of oocytes (overall and mature), decreased number of normally fertilized oocytes 
and decreased E(2) levels (mean decreases of 40, 253 and 471 pg/ml for urinary BPA quartiles 2, 3 
and 4, when compared with the lowest quartile, respectively; p-value for trend=0.001). The mean 
number of oocytes and normally fertilized oocytes decreased by 24 and 27%, respectively, for the 
highest versus the lowest quartile of urinary BPA (trend test p<0.001 and 0.002, respectively). Women 
with urinary BPA above the lowest quartile had decreased blastocyst formation (trend test P-
value=0.08). The results from this extended study, using IVF as a model to study early reproductive 
health outcomes in humans, indicate a negative dose-response association between urinary BPA 
concentrations and serum peak E2 and oocyte yield. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Prospective design 
- Urine, container specified (PP cups) 
- Repeated measurements (≤ 2) 
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks 
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- Multiple outcome assessment 
Weaknesses:  
- Short time frame (only days for exposure measurements per treatment cycle) 
- Single spot urine BPA measurements 
- Confounding by diet or by concurring exposure factors (contamination through medical 
treatment during IVF) not considered 
- Generalisability to the overall population 
 
Overall, the CEF Panel considers that the scientific soundness of the study was acceptable. According 
to the authors themselves, potential limitations include exposure misclassification due to the very short 
half-life of BPA and its high variability over time and uncertainty about the generalisability of the 
results to the general population of women conceiving naturally and limited sample. In addition, the 
CEF Panel notes that no dietary confounders were considered. The significance of the new scientific 
information is limited to the portion of population that is infertile, not necessarily representing the 
general population. 
This paper is included in the WOE table because of its relevance to one or more review questions 
addressed there. 
Fujimoto VY, Kim D, Vom Saal FS, Lamb JD, Taylor JA and Bloom MS, 2011. Serum 
unconjugated bisphenol A concentrations in women may adversely influence oocyte quality 
during in vitro fertilization. Fertility and Sterility, 95, 1816-1819. 
 
The association between BPA serum levels and oocyte quality during in vitro fertilization were 
investigated. The study sample comprised 31 women undergoing intracytoplasmic sperm injection 
(ICSI) and 26 couples undergoing ICSI or conventional IVF. Serum unconjugated BPA measured in 
fasting blood specimen were obtained from women on the day of oocyte retrieval, and from non-
fasting blood specimen in men. Unconjugated BPA in serum was measured by HPLC with 
electrochemical detection (LOD 0.3 ng/ml). Median serum unconjugated BPA concentrations were 
2.53 ng/ml in women and 0.34 ng/ml in men. Oocyte maturity was defined as number of oocytes in 
metaphase II divided by number of oocytes collected. Oocyte fertilization was defined as the 
proportion of oocytes fertilized. Multiple statistical analyses revealed no association between BPA and 
oocyte maturation in the whole population, but an inverse association was observed in nine Asian 
women separately. However, in all women an inverse association between unconjugated serum BPA 
and normal fertilization was reported, indicating that BPA exposure in female patients may interfere 
with oocyte quality during IVF.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Quality control, including blanks 
Weaknesses:  
- Cross-sectional design  
- Small sample size 
- Serum BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
- Confounding by diet or by concurring exposure factors (contamination through medical 
treatment during IVF) not considered 
- Generalisability to the overall population 
 
Overall, the CEF Panel considers that that the study has many limitations, e.g. the cross sectional 
design, the limited sample size and the use of serum BPA, which is not considered a valid measure of 
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BPA exposure. The CEF Panel noted that the study population (and serum BPA measurements) is the 
same as used in the studies by Bloom et al. (2011a and 2011b). Moreover, important factors, such as 
the particular situation of in vitro fertilization and what it includes, were not considered. For example, 
the quality of oocytes may be affected by hormonal therapy which precedes fertilization. Potential 
contamination through medical treatment in IVF is also likely to occur. Given the above limitations, 
the significance of the results of this preliminary study is doubtful. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Galloway T, Cipelli R, Guralnick J, Ferrucci L, Bandinelli S, Corsi AM, Money C, McCormack 
P and Melzer D, 2010. Daily bisphenol A excretion and associations with sex hormone 
concentrations: results from the InCHIANTI adult population study. Environmental Health 
Perspectives, 118, 1603-1608.  
 
This paper was the first to report human exposure to BPA in a large-scale European population. The 
study comprised 715 adults aged 20 through 74 years in a suburban and rural town population in Italy 
(the InCHIANTI adult population study). Participants each collected one 24-hour urine sample and 
total BPA concentration was measured in the 24-h sample (unconjugated plus conjugated) by on line 
solid phase extraction (SPE) coupled to isotopic dilution liquid chromatography tandem mass 
spectrometry (LC-MS-MS, LOD <0.5 µg/l, LOQ 0.5 µg/l). The BPA collection and analysis was 
appropriate. Fasting blood samples were drawn and the outcomes examined were sex-hormones: 17β-
oestradiol, total testosterone, sex hormone binding globulin (SHBG) and free testosterone. Models 
were adjusted for age, study site, smoking, BMI, weight, waist, and urinary creatinine concentration. 
Other potential confounders were also evaluated. A weak association between urinary BPA and 
testosterone were found in men, in models adjusted for age and study site (p=0.044), and in models 
additionally adjusted for smoking, measures of obesity, and urinary creatinine concentrations 
(β=0.046; 95% CI, 0.015-0.076; p=0.004). No associations were found for other serum hormone 
measures and no associations were found for the primary outcomes among women. However, a 
statistically significant association between BPA and SHBG concentrations was found for the 60 
premenopausal women (p=0.004). The authors concluded that higher BPA exposure may be associated 
with endocrine changes in men.  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size 
- Standardised samples (24-h urine collection) 
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross-sectional design 
- Single exposure measurements 
- Handling of values below LOQ not reported 
- Confounding by concurring exposure factors (concomitant drug treatment) not considered 
- Unclear clinical relevance (small effect size in men) 
- Inconsistency in the results (significant association between BPA exposure and testosterone 
but no association with other hormones) 
 
Overall, the CEF Panel considers that the 24-hour urine collection is a better measure of BPA 
exposure than single spot urine samples and covers to some extent the same time period as the time 
covered by the blood sampled for hormone concentrations. The association with testosterone was 
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weak and the clinical relevance of association is not clear. Concomitant drug treatment was not 
reported. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Kandaraki E, Chatzigeorgiou A, Livadas S, Palioura E, Economou F, Koutsilieris M, Palimeri S, 
Panidis D and Diamanti-Kandarakis E, 2011. Endocrine Disruptors and Polycystic Ovary 
Syndrome (PCOS): Elevated Serum Levels of Bisphenol A in Women with PCOS. The Journal 
of Clinical Endocrinology and Metabolism, 96, 480-484.  
 
Serum BPA was measured in women with polycystic ovarian syndrome (PCOS) and in healthy 
controls in Greece. Associations between BPA and hormonal/metabolic parameters were examined in 
women with PCOS (n=71) and healthy controls (n=100), matched by age and body mass index in a 
University Hospital setting in Greece. The outcome measures were: anthropometric, hormonal, 
metabolic parameters. BPA levels measured by immunoassay (ELISA, measurement range 0.30-100 
ng/ml) were significantly higher in the total PCOS group compared with the controls (1.05±0.56 vs. 
0.72±0.37 ng/ml, p<0.001). PCOS women, lean (PCOS-L) and overweight (PCOS-OW), had higher 
BPA levels compared to the corresponding control group lean (C-L) and overweight (C-OW): (PCOS-
L=1.13±0.63 vs. C-L=0.70±0.36, p<0.001) (PCOS-OW=0.96±0.46 vs. C-OW=0.72±0.39, p<0.05). A 
significant association of testosterone (r=0.192, p<0.05) and androstenedione (r=0.257, p<0.05) with 
BPA was observed. Multiple regression analysis for BPA showed significant correlation with the 
existence of PCOS (r=0.497, p<0.05). BPA was also positively correlated with insulin resistance 
(Matsuda index) in the PCOS group (r=0.273, p<0.05). The fact that the association between BPA and 
PCOS remained when women where stratified for BMI strengthened the finding of higher serum BPA 
in with PCOS in normal ovulating non hyperandrogenemic controls. 
 
Comments from the CEF Panel:  




- Cross-sectional design 
- Serum BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
- Analytical method (ELISA) 
- No quality control (e.g., blanks) and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Handling of values outside measurement range not reported 
- Confounding by diet and concurring exposure factors not considered 
- Generalisability to the overall population (other than women with PCOS) 
 
Overall, the CEF Panel considers that the sample size is quite limited, and although the authors 
reported that cases and controls were matched for age and BMI, no data were presented. Furthermore, 
serum BPA was measured using a commercial ELISA kit, which does not distinguish between 
conjugated and unconjugated BPA. In blood, only unconjugated BPA can be considered a valid 
measure of BPA exposure. The results should be considered as preliminary and need to be confirmed. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Li DK, Zhou Z, Miao M, He Y, Wang J, Ferber J, Herrinton LJ, Gao E and Yuan W, 2011. 
Urine bisphenol-A (BPA) level in relation to semen quality. Fertility and Sterility, 95, 625-630.  
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The aim of the study was to study the association between urinary BPA and semen quality in 218 men 
in China with and without BPA exposure in the workplace. Of 888 men invited only 514 (58%) 
participated in the study and adequate semen specimens were obtained from 236 men. Valid semen 
and urine samples were available from 218 men. Total urinary BPA was determined after hydrolysis 
by HPLC with fluorescence detection (LOD, 0.31 µg/l). For men with occupational exposure to BPA, 
two urine samples were collected at the workplace, one sample pre-shift and one post-shift. For men 
without occupational exposure only one urine sample was collected. Semen quality was determined 
using six common semen quality parameters: volume, total sperm count, concentration, vitality, 
motility (forward movement [grades A + B]), and morphology. After adjustment for potential 
confounders using linear regression, increasing urine BPA level was statistically significantly 
associated with (i) decreased sperm concentration, (ii) decreased total sperm count, (iii) decreased 
sperm vitality, and (iv) decreased sperm motility. Compared with men who did not have detectable 
urine BPA levels, those with detectable urine BPA had more than three times the risk of a lowered 
sperm concentration and lower sperm vitality, more than four times the risk of lower sperm count, and 
more than twice the risk of lower sperm motility. Urinary BPA levels were not associated with semen 
volume or abnormal sperm morphology. The association was noted both in men highly exposed to 
BPA (at the workplace) and men environmentally exposed to lower doses of BPA.  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Repeated measurements (n=2, workers) 
- Standardised samples (pre-shift and post-shift spot urine samples) 
Weaknesses:  
- Cross-sectional studydesign  
- Selection bias of the study population (58% participation rate, without explanation) 
- Single exposure measurements (for men without occupational exposure) 
- Single spot urine BPA measurement 
- No quality control (e.g., blanks) and quality assurance procedures  
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet not considered 
- Occupational exposure (via inhalation) 
 
Overall, the CEF Panel considers that the measurements of sperm quality involved only 218 
individuals. Of 888 men who were invited, only 58% (514) participated in the study, without their 
reasons being known (fertility problem, age, etc.), which may constitute a selection bias. BPA 
occupational exposure mainly occurs via inhalation route, which is of limited value for the general 
population, orally exposed to lower doses of BPA. Another limitation when considering occupational 
exposure to BPA is the potential concurrent exposure to other chemicals and heavy metals (evaluated 
by interview). The cross-sectional design of the study limits the relevance of the results and no casual 
inference can be drawn. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
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Tarantino G, Valentino R, Di Somma C, D’Esposito V, Passaretti F, Pizza G, Brancato V, Orio 
F, Formisano P, Colao A and Savastano S, 2013. Bisphenol A in Polycystic Ovary Syndrome and 
its Association with Liver-Spleen Axis. Clinical Endocrinology, 78, 447-453. 
 
In a cross-sectional analysis comprising cases and controls, the authors examined whether serum BPA 
levels (measured by immunoassay, ELISA, measurement range 0.30-100 ng/ml) were associated with 
low-grade chronic inflammation, hepatic steatosis, and hyperandrogenism in women with Polycystic 
Ovary Syndrome (PCOS) and healthy controls in Naples, Italy. Cases (40 lean and overweight/obese 
premenopausal women with PCOS) and controls (20 healthy age-matched women) were enrolled in 
the years 2009 to 2011 at the Federico II University Hospital in Naples. Higher BPA levels in PCOS 
women were associated with higher grades of insulin resistance, hepatic steatosis, FAI, and 
inflammation, spleen size showed the best correlation (β=0.379, p=0.007). The main finding of this 
study was the association between serum BPA levels and hepatic steatosis and the markers of low-
grade inflammation in women with PCOS, in particular with spleen size, thus unravelling the presence 
of the liver-spleen axis in this syndrome.  
 
Comments from the CEF Panel:  




- Cross-sectional design 
- Small sample size 
- Serum BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
- Analytical method (ELISA) 
- No quality control (e.g., blanks) and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Handling of values outside measurement range not reported 
- Confounding by diet and concurring exposure factors not considered 
- Statistics (unjustified use of non-parametric and parametric models) 
- Generalisability to the overall population (other than women with PCOS) 
 
Overall the CEF Panel notes that the study has major limitations, i.e. the statistical power of the study 
is low, the logic to establish causality between variables is unclear and the use of statistics raises 
concerns. The authors predominantly used univariate statistics and when they used a multivariate 
model, BPA was the outcome, not the predictor. The CEF Panel notes several other concerns: (1) 
controls differed from PCOS patients with regard to several anthropometric parameters (e.g. BMI), 
therefore authors cannot say that the disease increased the levels of BPA; (2) the method of detection 
of BPA in serum (an ELISA kit with low specificity) is not acceptable; furthermore, measures in 
urinary samples would be more adequate from an epidemiological point of view; (3) correlations were 
non-parametric, but the best-fit straight line was reported. Moreover, the multiple regression model is 
parametric, and authors do not justify their choices. Overall, the general soundness of the manuscript 
is quite poor. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Zhou Q, Miao M, Ran M, Ding L, Bai L, Wu T, Yuan W, Gao E, Wang J, Li G and Li DK, 2013. 
Serum bisphenol-A concentration and sex hormone levels in men. Fertility and Sterility, 100, 
478-482. 
 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 284 
A cross-sectional study evaluated the association between serum BPA and sex hormone levels in 290 
male factory workers in China. The participants comprised 137 workers in a petrochemical factory 
who were exposed to BPA at the workplace for more than 6 months, and 153 age-matched workers 
from a tap water factory without occupational exposure to BPA. Blood specimens were collected into 
EDTA tubes, and serum was stored at -80 °C until analysis. Serum BPA was measured by HPLC with 
fluorescence detection (LOD 0.39 µg/l) after enzymatic hydrolysis. Serum total testosterone, 
oestradiol, inhibin B, follicle stimulating hormone, prolactin, sex hormone binding protein, 
androstenedione and free testosterone were measured. The free androgen index (FAI) was calculated 
as Tx100/sex hormone binding globulin. The median serum BPA concentrations in exposed and 
unexposed workers were 3.198 and 0.276 µg/l, respectively. After adjustment for potential 
confounders using linear regression, increasing serum BPA concentration was statistically 
significantly associated with decreased androstenedione levels, decreased free testosterone levels, 
decreased free androgen index, and increased sex hormone-binding globulin levels. Comparison of 
hormone levels between workers exposed and unexposed to BPA showed similar associations. 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Quality control, including blanks 
Weaknesses:  
- Cross-sectional design 
- Small sample size  
- Serum BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
- No distinction between un conjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors (other than occupational exposures) 
not considered 
- Occupational exposure (via inhalation) 
 
Overall, the CEF Panel notes that this study has main limitations, e.g. the cross-sectional design, the 
relatively small sample size and the use of serum BPA, which is not considered a valid measure of 
BPA exposure. BPA occupational exposure mainly occurs via inhalation route, which is of limited 
value for the general population, orally exposed to lower doses of BPA. The study did not evaluate 
other occupational exposures or diet. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
BPA effects on gestational/birth outcomes 
Cantonwine D, Meeker JD, Hu H, Sánchez BN, Lamadrid-Figueroa H, Mercado-García A, 
Fortenberry GZ, Calafat AM and Téllez-Rojo MM, 2010. Bisphenol A exposure in Mexico City 
and risk of prematurity: a pilot nested case control study. Environmental Health, 9, 62.  
 
The aim of this study was to examine urinary BPA concentrations during the last trimester of 
pregnancy and the risk of preterm delivery among a small subset (case-control design) of 60 women 
participating in a pregnancy cohort in Mexico City. Morning spot urine samples (second morning 
void) were collected for 518 non-smoking cohort participants. Of these, 30 cases were selected among 
participants who delivered prior to or during gestational week 37 and 30 controls were selected among 
participants with 38 or more completed gestational weeks. Total urinary BPA (free plus conjugated 
species) was determined by on line solid phase extraction (SPE) coupled to liquid chromatography 
tandem mass spectrometry (LC-MS-MS, LOD 0.4 ng/ml) at the Centers for Disease Control and 
Prevention (CDC). Among the cases, 12 delivered preterm (<37 weeks) and 18 in week 37. BPA was 
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detected in 80.0% (n=48) of the urine samples; total concentrations ranged from <0.4 μg/L to 6.7 
μg/L; uncorrected geometric mean was 1.52 μg/L. The adjusted odds ratio of delivering less than or 
equal to 37 weeks in relation to specific gravity adjusted third trimester BPA concentration was 1.91 
(95% CI 0.93, 3.91, p=0.08). When cases were further restricted to births occurring prior to the 37th 
week (n=12), the odds ratio for specific-gravity adjusted BPA was larger and statistically significant 
(p<0.05). 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Standardised samples (second morning spot samples) 
- Analytical method (SPE LC-MS-MS) 
- Quality controls, including blanks and quality assurance procedures 
Weaknesses:  
- Cross-sectional design  
- Small sample size 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Invalid/imprecise outcome assessment 
- Confounding by diet and concurring exposure factors not considered 
 
Overall the CEF Panel notes that this study is limited by the small sample size and single spot urine 
samples. The association did only reach statistical significance when urinary BPA was adjusted for 
specific gravity and when cases were restricted to delivery prior to week 37. An additional weakness 
was that gestational length was estimated by date of maternally-recalled last menstrual period, which 
is an unreliable measure. It should be noted that the urinary BPA concentrations in the pregnant 
women in Mexico City were similar to urinary concentrations in the US and other developed 
countries. The results suggested that urinary BPA were higher in women who delivered less than or 
equal to 37 weeks of gestation, but due to study limitations the results can only be regarded as 
preliminary. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Chevrier J, Gunier R, Bradman A, Holland NT, Calafat AM, Eskenazi B and Harley KG, 2012. 
Maternal Urinary Bisphenol A during Pregnancy and Maternal and Neonatal Thyroid Function 
in the CHAMACOS Study. Environmental Health Perspectives, 121, 138-144. 
  
This study evaluated whether exposure to BPA during pregnancy was related to thyroid hormone 
levels in pregnant women and neonates. Spot urine samples for measuring BPA was collected during 
the first and second half of pregnancy in 476 women participating in the CHAMACOS study in the 
agricultural Salinas Valley California (immigrant Mexican-American population), USA. Total urinary 
BPA (free plus conjugated species) was determined by on line solid phase extraction (SPE) coupled to 
liquid chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.4 µg/l) at the Centers for 
Disease Control and Prevention (CDC) in Atlanta. The outcomes were: free thyroxine (T4), total T4 
and thyroid-stimulating hormone (TSH) were measured during pregnancy and TSH was measured in 
neonates. The association between the average of the two BPA measurements and maternal thyroid 
hormone levels was not statistically significant. Of the two BPA measurements, only the measurement 
taken closest in time to the TH measurement was significantly associated with a reduction in total T4 
(β=-0.13 µg/dL per log2 unit; 95% CI=-0.25, 0.00). The average of the maternal BPA concentrations 
was associated with reduced TSH in boys (-9.9% per log2 unit; 95% CI=-15.9%, -3.5%) but not in 
girls. Among boys, the relation was stronger when BPA was measured in the third trimester of 
pregnancy and decreased with time between BPA and TH measurements. The results suggest that 
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exposure to BPA during pregnancy was related to reduced total T4 in pregnant women and decreased 
TSH in male neonates. 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Prospective design 
- Urine, container specified (BPA-free urine cups) 
- Repeated measurements (n=2) 
- Analytical method (LC-MS-MS) 
- Quality controls, including blanks and quality assurance procedures 
Weaknesses:  
- Single spot urine BPA measurement 
- Confounding by diet (except iodine) and concurring exposure factors not considered 
- Unclear clinical relevance (association between BPA and T4 only observed in urine samples 
taken during the second half of pregnancy) 
- Generalisability to the overall population (low-income Mexican American population) 
 
Overall the CEF Panel notes that this study considered many relevant confounders, including iodine 
nutrition, but no other contaminants were considered. The study population is likely to be exposed to 
other chemicals in the agricultural Salinas Valley. Spot urine samples from participants were collected 
during the first (12.4±3.8 weeks gestation) and second half (26.2±2.2 weeks gestation) of pregnancy. 
The authors did not include the time between the last BPA measurement and birth in their multivariate 
analysis. Although statistical significant associations were reported, the clinical relevance of the 
findings is not clear. The authors reported that almost all values of maternal and neonatal TH levels 
were not pathological (only 1 abnormal value of TSH among neonates). No measure of BPA in the 
urine of neonates was taken. The association between maternal BPA and total T4 was stronger when 
measured closer together relative to further apart in time, suggesting a transient effect of BPA or 
alternatively, a developmental window of susceptibility. The prospective design of the study 
strengthens the finding. Others strengths are the fair sample size, accurate statistical analysis and a 
general sound discussion. In particular, the use of urinary BPA as continuous variable after 
normalization for creatinine is an important merit. Results were a bit overestimated, in particular the 
association between total T4 and urinary BPA in pregnant women. No measure of BPA in the urine of 
neonates was considered, and the study is not conclusive. However, although associations were weak, 
the clinical relevance of the study may be a cause of concern. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Choi H, Kim J, Im Y, Lee S and Kim Y, 2012. The association between some endocrine 
disruptors and hypospadias in biological samples. Journal of Environmental Science and Health, 
Part A: Toxic Hazardous Substances and Environmental Engineering, 47, 2173-2179. 
 
The levels of endocrine disruptors in the urine and plasma of control (n=80), patient (n=80) and 
patient’ mother (n=40) groups were measured and assayed in this study. The selected target 
compounds were five phthalates (DEHP, DBP, MEHP, MBP and PA), 2 alkylphenols (n-NP and t-OP) 
and BPA, determined by gas chromatography-mass spectrometry (GC-MS, range given for LOD and 
LOQ in urine and plasma) after enzymatic hydrolysis. The mean urinary total BPA was 19.8 ng/ml in 
controls, 51.6 ng/ml in hypospadias and 5.31 ng/ml in mothers. The mean plasma BPA was 2.62 ng/ml 
in controls, 18.3 ng/ml in hypospadias and 9.04 ng/ml in mothers. Urinary BPA in children was not 
associated with hypospadias, whereas plasma BPA was higher in children with hypospadias than in 
controls (p= 7.22e-10). No relationship was seen for levels of BPA in urine or plasma of the mothers 
and hypospadias.  
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Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Urine, container specified (glass) 
- Analytical method (GC-MS) 
Weaknesses:  
- Plasma BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
- Single spot urine BPA measurement 
- No quality control and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not reported 
- Insufficient study reporting (number of patients not clearly reported in the tables) 
- Statistics (use correlations instead of odd ratios) 
- Unreliable outcome (extremely high urinary BPA concentrations) 
 
Overall, the CEF Panel notes that this study has several limitations: (i) the limited description of 
sampling, (ii) the use of serum BPA which is not considered a valid measure of BPA exposure, (iii) 
the lack of distinction between unconjugated and conjugated BPA in plasma, (iv) the extremely high 
urinary BPA concentrations, and (v) the statistical handling and reporting. Concerning statistics, 
correlations were reported, whereas odds ratios (hypospadias yes/no) would have been more 
appropriate. Diagnosis of hypospadias and the numbers of patients reported in the tables was not 
clearly defined, and if all are included it should say so. There is no detail on handling of possible 
confounding factors. The lack of associations in this study is undisputable subject to above limitations. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Chou WC, Chen JL, Lin CF, Chen YC, Shih FC and Chuang CY, 2011. Biomonitoring of 
bisphenol A concentrations in maternal and umbilical cord blood in regard to birth outcomes 
and adipokine expression: a birth cohort study in Taiwan. Environmental Health, 10, 94. 
 
This was a cross-sectional study which analysed BPA in maternal and umbilical cord blood samples in 
97 mother-newborn pairs in a birth cohort in Taiwan, and its association with birth outcomes. 
Unconjugated BPA was determined by HPLC with UV detection (LOD 0.13 ng/ml). The outcomes 
examined were: (i) low birth weight (LBW) defined as birth weight <2600 g, (ii) small for gestational 
age (SGA) defined as birth weight <10th percentile, compared with the birth weight distribution in the 
same gestational week and gender in Taiwan, (iii) high leptin (HLP-9 defined as leptin>90th percentile 
in cord blood, and (iv) low adiponectin (LAD) defined as adiponectin <10th percentile. Geometric 
mean BPA was 2.51 ng/ml in maternal blood and 1.06 ng/ml in umbilical cord blood. In male neonates 
only, high maternal BPA (upper quartile) was associated with increased risk of low birth weight 
babies, small for gestational age babies (SGA) and adverse action of leptin and adiponectin.  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Container specified (plastic-free) 
- Quality control, including blanks and quality assurance procedures  
Weaknesses:  
- Cross-sectional design 
- Blood/plasma and cord blood BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
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- Confounding by diet and concurring exposure factors not considered 
- Inconsistent results amongst different studies 
 
Overall, the CEF Panel notes that this study has several methodological limitations, including the 
cross-sectional design and the excessive categorization of continuous variables. Serum/plasma and 
cord blood BPA measurements cannot be considered a valid measure of BPA exposure. The CEF 
Panel also notes that results are not consistent in abstract and paper. The results regarding maternal 
serum BPA and adverse birth outcomes were weak and can only be regarded as preliminary results. 
Very little separates groups characterised by high and low BPA exposure, and the groups were small. 
The results are only interesting for comparing values for maternal/cord pairs. The association with 
SGA is not convincing. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Fénichel P, Déchaux H, Harthe C, Gal J, Ferrari P, Pacini P, Wagner-Mahler K, Pugeat M and 
Brucker-Davis F, 2012. Unconjugated bisphenol A cord blood levels in boys with descended or 
undescended testes. Human Reproduction, 27, 983-990.  
 
The authors tested whether the concentration of unconjugated BPA measured in cord blood differed 
between male infants with undescended testis (UDT, n=46) and matched controls (n=106). In addition, 
the authors examined associations between unconjugated BPA and 11 steroid and polypeptide 
hormones in the same cord blood samples (e.g. testosterone and inhibin B) and between cord blood 
unconjugated BPA and a range of xenobiotics measured in maternal milk. Blood was collected into 
BPA free tubes from the umbilical cord following placental expulsion. Samples were checked for non-
contamination. Unconjugated BPA was measured using a radioimmunoassay (RIA). There were no 
differences in unconjugated BPA or any of the hormones between the cryptorchid (UTD) (mean: 1.12 
ng/ml) and control boys (mean: 1.26 ng/ml). Unconjugated cord blood BPA was considered as a 
continuous variable. The levels are in line with other studies. In addition to the unconjugated BPA 
measurements by RIA (LOD 0.8 ng/ml), GC-MS measurement was obtained for a subsample of the 
blood samples, and the correlation between the methods were reported (r=0.85).  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Container specified (BPA-free) 
- Quality control, including blanks  
- Consistency in results among different studies 
Weaknesses:  
- Case-control study 
- Cord blood BPA measurement (invalid exposure assessment)  
- Single exposure measurements 
- Analytical method (RIA, no correlation with GC-MS data for values in the low range) 
- Confounding by diet or by concurring exposure factors not reported 
 
Overall, the CEF Panel notes that this study is well powered for the cryptorchid group. The use of 
radioimmunoassay (RIA) for measuring unconjugated BPA is not appropriate and the correlation with 
the additional BPA measured by GC-MS in a subsample is not convincing for values in the low range 
of BPA concentrations. Many variable parameters were compared in the 2 groups, which were not 
separated by maternal or neonatal characteristics. The main finding was that unconjugated cord blood 
BPA at term does not explain cryptorchidism. The statistical modelling was appropriate.  
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This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Jung H, Hong Y, Lee D, Pang K and Kim Y, 2013. The association between some endocrine 
disruptors in human plasma and the occurrence of congenital hypothyroidism. Environmental 
Toxicology and Pharmacology, 35, 278-283. 
 
This study investigated the association between plasma concentrations of endocrine disruptors 
(including BPA) and the occurrence of congenital hypothyroidism in a case-control study in 59 
mother-infant pairs in South Korea. They determined the plasma levels in infants with congenital 
hypothyroidism (n=39) and normal infants (n=20) of the following target compounds: two 
alkylphenolic compounds, bisphenol A, five phthalates, and three isoflavones. Plasma BPA was 
determined by was determined by gas chromatography-mass spectrometry (GC–MS, LOD 0.18 ng/ml, 
LOQ 0.60 ng/ml) after enzymatic hydrolysis. There was no difference in plasma BPA concentrations 
in patients (mean 2.93±4.14 ng/ml) and controls (mean 4.06±7.86 ng/ml), p=0.2201.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Analytical method (GC-MS) 
Weaknesses:  
- Case-control study 
- Plasma BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
- No quality control and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet not considered 
- Statistics (parametric tests applied to variables not normally distributed) 
 
Overall, the CEF Panel notes that this study determined BPA in plasma, which is not considered a 
valid measure of BPA exposure. PPlasma BPA concentration did not differ between cases and 
controls. Although plasma BPA concentrations in patient and controls were not normally distributed, 
differences between the two groups were assessed by parametric tests. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Lee BE, Park H, Hong YC, Ha M, Kim Y, Chang N, Kim BN, Kim YJ, Yu SD and Ha EH, 
2013a. Prenatal bisphenol A and birth outcomes: MOCEH (Mothers and Children's 
Environmental Health) study. International Journal of Hygiene and Environmental Health. 
 
A study in 757 mother-child pairs in Korea examined the relationship between prenatal BPA exposure 
and birth outcomes, including birth weight, birth length, and ponderal index considering gender 
difference. Participants comprised pregnant women participating in a multi-center birth cohort study, 
Mothers and Children's Environmental Health (MOCEH), which was established in Korea in 2006. 
Total urinary BPA was measured after hydrolysis by liquid chromatography tandem mass 
spectrometry (LOD 0.12-0.28 ng/ml). Women were included who had their urinary BPA level 
measured during the third trimester, as well as information on birth outcome, prior medical history, 
psychosocial status, health behaviour, environmental exposure as well as socio-demographic 
characteristics. Furthermore, urinary BPA concentrations were also measured in the first trimester in a 
subsample of the study populations (number not presented). Regression analysis was performed to 
assess the effect of BPA on birth outcome. No associations were found for urinary BPA measured 
during early pregnancy and birth outcomes. For late pregnancy, the geometric mean concentration of 
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BPA was 1.29 μg/l (1.87 μg/g creatinine) during late pregnancy. Contrary to a number of other studies, 
urinary BPA concentrations were higher in women with a higher income level. In unadjusted analysis, 
the correlation between urinary BPA and birth weight was r=0.06, p=0.08, and the correlation with 
ponderal index was r=0.11, p=0.003. In adjusted analysis, the second tertile of maternal BPA exposure 
was associated with an increase in birth weight, relative to the first tertile (p=0.04). This relationship 
was more pronounced in male neonates. Furthermore, prenatal exposure to BPA was associated with 
an increase of ponderal index in the all neonates and especially in female neonates: all neonates, 
second vs first BPA tertile was borderline significant (p=0.07) and third vs first BPA tertile was 
significantly associated (p=0.02). In female neonates, BPA association with ponderal index was 
significant for second vs first tertile (p=0.003), but not for third vs first tertile (p=0.22).  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Prospective design 
- Analytical method (LC-MS-MS) 
- Quality control, including blanks  
Weaknesses:  
- Single exposure measurements 
- Single spot urine BPA measurement 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet and concurring exposure factors not reported 
- Inconsistent results amongst different studies 
 
Overall, the CEF Panel notes that this multi-center birth cohort study showed weak indications that 
prenatal BPA exposure (maternal urinary BPA concentrations in third trimester) was associated with 
increased birth weight and ponderal index, but the associations differed by sex and was generally 
stronger for the second vs the first tertile of BPA exposure than for the third vs the first tertile. The 
study took into consideration a wide range of potential confounding factors. The authors state that 
nutritional and environmental factors were evaluated, but it is not clear how this was handled. 
Furthermore, the study is limited by single spot urine samples in late pregnancy, which may attenuate 
potential associations. Gestational length was estimated by date of maternally-recalled last menstrual 
period, which is an unreliable measure. The gender differences regarding prenatal BPA exposure and 
fetal growth measures are potentially interesting but more studies are needed to elaborate prenatal 
BPA exposure and fetal growth. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Miao M, Yuan W, He Y, Zhou Z, Wang J, Gao E, Li G, Li DK, 2011b. In utero exposure to 
bisphenol-A and anogenital distance of male offspring. Birth Defects Research. Part A, Clinical 
and Molecular Teratology, 91, 867-872.  
 
In utero exposure to BPA modelled according to 6 categories of paternal or maternal occupational or 
non-occupational exposure were examined in relation to anogenital distance (AGD) in boys (n=153). 
BPA exposure was assessed combining air sample monitoring at the workplace, employment history, 
and change in work environment. BPA exposure was divided into 6 categories according to paternal or 
maternal occupational or non-occupational exposure. Urinary BPA (measured by HPLC with 
fluorescence detection, LOD 0.31 ng/ml) was assessed to verify the validity of classification of BPA 
exposure. The results showed that higher BPA exposure was associated with reduced AGD in boys. 
This study is the first epidemiological evidence that parental exposure to BPA in the workplace during 
pregnancy may adversely affect male genital development. 
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Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Container specified (BPA-free) 
Weaknesses:  
- Case-control study  
- Small sample size 
- Invalid/imprecise BPA exposure assessment (air monitoring; combination of paternal and 
maternal exposure) 
- Single exposure measurements 
- Single spot urine BPA measurement 
- No quality control and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Statistics (too many categories) 
- Occupational exposure (via inhalation) 
 
Overall, the CEF Panel notes that there is uncertainty related to BPA exposure association. BPA 
occupational exposure mainly occurs via inhalation route, which is of limited value for the general 
population, orally exposed to lower doses of BPA. In addition, it is not clear how paternal 
occupational exposure was transmitted to pregnant wife. Although the sample size is relatively small, 
BPA exposure was divided into six groups (too many categories). Occupational exposure to BPA may 
coincide with exposure also to other chemicals related to occupational exposure of factory workers. 
The value of AGD as a masculinization index is becoming more apparent, especially where studies to 
link to semen parameters would need to last at least 18 years. Samples size was very small and the 
value of the time weighted average (TWA) is not that clear. The analysis was interesting but needs to 
be expanded with BPA quantitation in maternal samples collected during pregnancy. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Miao M, Yuan W, Zhu G, He X and Li DK, 2011a. In Utero Exposure to Bisphenol-A and its 
Effect on Birth Weight of Offspring. Reproductive Toxicology, 32, 64-68.  
 
Retrospective recall of BPA occupationally exposed and unexposed couples and birth weight of the 
offspring in China. BPA exposure was assessed by combining work place air sample monitoring, 
employment history, and change in work environment. Of 587 children, 93 came from families in 
which mother was occupationally exposed to BPA, 50 came from families in which the father was 
occupationally exposed (father exposure was considered as indirect exposure to mother) and 444 came 
from families without occupational exposure to BPA. Birth weight and gestational lengths, as well as 
maternal height, weight and smoking habits were obtained by an in-person interview of the mother. 
Parental BPA exposure level during the index pregnancy was determined through personal air 
sampling measurements and exposure history. Urinary BPA (measured by HPLC with fluorescence 
detection, LOD 0.31 ng/ml) was assessed to verify the validity of classification of BPA exposure. 
Current urinary BPA analyses confirmed that urine BPA levels showed a gradient reduction from 
exposed women (direct fetal exposure) to spouses of exposed male workers (indirect fetal exposure 
through paternal exposure) to unexposed women. The geometric mean (95% CI) of maternal current 
urine BPA was 15.98 (9.11–28.02), 2.22 (1.49–3.31) and 0.56 (0.70–0.88) μg/g creatinine in currently 
exposed mothers, spouses of exposed fathers and unexposed mothers (including unexposed mothers 
and spouses of unexposed fathers), respectively. After controlling for maternal age at birth, maternal 
weight before pregnancy, calendar year of birth, maternal education, family income and gravidity, 
parental exposure to BPA in the workplace during pregnancy was correlated with decreased birth 
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weight in offspring: compared with offspring from the families without parental BPA exposure in the 
workplace. Birth weight of offspring with paternal BPA exposure was 90.75 g less on average 
(p=0.10), and 168.40 g less for those with maternal BPA exposure (p=0.02). The association remained 
largely the same when analyses were restricted to term births. Likewise, reduced birth weight with 
increasing BPA exposure was found when the exposure was modelled as an 8 hour weighted time 
average.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Prospective design 
- Container specified (BPA-free) 
Weaknesses:  
- Long recall period (up to 16 years) 
- Invalid/imprecise BPA exposure assessment (air monitoring; combination of paternal and 
maternal exposure) 
- Single exposure measurements 
- Single spot urine BPA measurement 
- No quality control and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Inconsistent results amongst different studies 
- Occupational exposure (via inhalation) 
 
Overall, the CEF Panel notes that this study claims to provide human epidemiological evidence that 
parental exposure to BPA in the workplace during pregnancy may be associated with decreased birth 
weight in the offspring. However, the relationship was weak and the biological significance of the 
observed decrease is not clear. Furthermore, occupational exposure to BPA may coincide with 
exposure also to other chemicals related to occupational exposure of factory workers, which may also 
influence fetal growth. The consideration of paternal exposure as indirect exposure of the mother is 
not clear and the authors also acknowledged that misclassification derived from recall error could not 
be ruled out, as the long recall period was up to 16 years. The study is limited by a small sample size 
in the exposed group. Due to the retrospective nature of the study, a weighted time average, rather than 
maternal urine BPA level, was used to classify the exposure dosage during the index pregnancy. 
Further, inaccurate classification of BPA exposure categories could be caused by exposure to BPA 
from consumer products and sources not considered in the study. The analysis was interesting but 
needs to be expanded with BPA quantitation in maternal samples collected during pregnancy. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Philippat C, Mortamais M, Chevrier C, Petit C, Calafat AM, Ye X, Silva MJ, Brambilla C, Pin 
I, Charles MA, Cordier S and Slama R, 2012. Exposure to Phthalates and Phenols during 
Pregnancy and Offspring Size at Birth. Environmental health Perspectives, 120, 464-470.  
 
Exposure to 11 phthalates and nine phenols, including BPA, was examined in relation to offspring size 
at birth in a case-control study of male malformations of the genitalia nested in two French pregnancy 
cohorts. For phenols, data was available for 191 mother-child pairs, comprising 48 cases and 143 
controls. Cases and controls were combined into one study group, with a reweighting approach to 
correct for overrepresentation of congenital abnormalities. Phthalate- and phenol concentrations were 
measured in maternal spot urine samples collected at various gestational ages and times of day. Total 
urinary BPA (free plus conjugated species) was determined by on line solid phase extraction (SPE) 
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coupled to liquid chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.4 ng/ml) at the 
Centers for Disease Control and Prevention (CDC) in Atlanta. BPA concentrations were positively 
associated with head circumference, which increased by 0.3 cm (95% CI: 0.0, 0.7) in association with 
a 1-unit increase in ln-transformed BPA concentration. When BPA was ranked into tertiles, the 
increase in head circumference was 0.8 cm in the highest BPA concentration tertile compared with the 
lowest tertile [95% confidence interval (CI): 0.2, 1.3]. No association was seen for birth length. There 
was no significant trend for either a monotonic or a non-monotonic association with birth weight, 
however, the association for birth weight suggested an inverse U-shape association: birth weight 
increased by 169 g (95% CI: 14, 324) in the second BPA concentration tertile and by 85 g (95% CI: –
62, 233) in the third concentration tertile, compared with the first. For the other phenols, birth weight 
decreased by 77 g (95% CI: –129, –25) and by 49 g (95% CI: –86, –13) in association with a 1-unit 
increase in ln-transformed 2,4-dichlorophenol (DCP) and 2,5-DCP urinary concentrations, 
respectively. Benzophenone-3 (BP3) ln-transformed concentrations were positively associated with 
weight (26 g; 95% CI: –2, 54) and head circumference at birth (0.1 cm; 95% CI: 0.0, 0.2). For 
phthalate metabolites there was no evidence of associations with birth weight. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Analytical method (LC-MS-MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Case-control study design 
- Single exposure measurements 
- Single spot urine BPA measurement  
- Confounding by diet not considered 
- Unclear clinical relevance (small effect size) 
- Inconsistent results amongst different studies 
 
Overall, the CEF Panel notes that this is a case-control study nested in two French pregnancy cohorts. 
As also pointed out by the authors, the BPA concentrations were relatively low in the study group, 
enhancing the analytical uncertainties and hence the potential for exposure misclassification. Other 
limitations include the choice of study group and small sample size, statistical handling and use of 
single spot urine samples. Finally, the clinical relevance of the association between BPA exposure and 
increased head circumference is uncertain. The fairly small numbers (again the issue of how long it 
takes to collect reasonable numbers of human genital malformations must be considered) and 
case/control matching are not supportive. The observed BPA effect is not convincing. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Snijder CA, Heederik D, Pierik FH, Hofman A, Jaddoe VW, Koch HM, Longnecker MP and 
Burdorf A, 2013. Fetal Growth and Prenatal Exposure to Bisphenol A: The Generation R Study 
Environmental Health Perspectives, 121, 393-398. 
 
This study was embedded in a Dutch, population based cohort study and aimed to investigate the 
relation of prenatal BPA exposure with intrauterine growth and to evaluate the effect of the number of 
measurements per subject on observed associations. Spot urine was sampled in early, mid and late 
pregnancy and total (unconjugated and conjugated) BPA was measured by liquid chromatography 
tandem mass spectrometry (LC-MS-MS) at two different laboratories (LOD, 0.26 and 0.05 ng/ml, 
respectively). Ninty-nine had one measurement, 40 had two measurements and 80 had three 
measurements of urinary BPA. Median BPA ranged from 1.1 to1.9 ng/ml. BPA concentrations were 
adjusted for creatinine, and examined by quartiles and as a continuous variable. Linear regression 
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models for repeated measurements of both BPA and fetal growth were used to estimate associations 
between urinary concentrations of creatinine based BPA (BPACB) and intrauterine growth. Two 
outcomes were examined: 1) the SD score of fetal weight per gestational week and 2) the SD score for 
fetal head circumference per gestational week. The results showed that the relationship between 
BPACB and fetal growth was sensitive to the number of BPA measurements per woman. Among 80 
women with three BPA measurements, women with BPACB >4.22 μg/g creatinine (highest quartile) 
had lower growth rates for fetal weight and head circumference than women with BPACB <1.54 μg/g 
creatinine (lowest quartile), with estimated differences in mean values at birth of –683 grams (20.3% 
of mean) and –3.9 cm (11.5% of mean), respectively. When fewer measurements were available per 
woman, the exposure-response relationship became progressively attenuated and statistically non-
significant. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Prospective design 
- Container specified (BPA-free) 
- Repeated measurements (3) 
- Analytical method (LC-MS-MS) 
- Quality control, including blanks and quality assurance procedures 
- Repeated growth measurements 
Weaknesses:  
- Single spot urine BPA measurements 
- Confounding by diet not considered 
- Inconsistent results amongst different studies 
 
Overall, the CEF Panel notes that this prospective study is a well-conducted investigation that used 
repeated measures of BPA exposure and objectively measured outcomes. The statistical modelling is 
sound and BPA was modelled both by quartiles and on the continuous scale. The study demonstrated 
that using three measures of BPA (mean of 3 spot urine samples) resulted in more precise effect 
estimates (narrower confidence intervals) than using fewer BPA measurements, and highlights the 
importance of including repeated urinary samples for assessment of BPA exposure. Many confounders 
were considered, but no dietary variables other than alcohol were included.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
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(ii) Animal studies 
Adewale HB, Jefferson WN, Newbold RR, Patisaul HB, 2009. Neonatal Bisphenol-A exposure 
alters rat reproductive development and ovarian morphology without impairing activation of 
gonadotrophin-releasing hormone neurons. Biology of Reproduction, 81, 690-699. 
 
Long Evans rats received sc injections of vehicle (10% EtOH and 90% sesame oil) or BPA (50 µg/kg 
bw per day or 50 mg/kg bw per day [HED pups, 15.5, 15,500 mg BPA/kg bw per day) daily from 
PND 0 to PND 3. Oestradiol benzoate (EB, 25 µg) and the estrogen receptor alpha (ESR1) agonist 
(PPT, 1 mg/kg bw per day) were used as positive and negative controls respectively. Cross-fostering, 
with litters limited to 12 pups/dam (10 dams in all). Upon weaning, the pups were checked daily for 
day of vaginal opening. The low dose of BPA (50 µg/kg bw per day) showed a significantly earlier 
day of vaginal opening  than the control animals, while the high dose of BPA (50 mg/kg bw per day) 
had no effect on day of vaginal opening. By 15 weeks after day of vaginal opening, only 33% of the 
females exposed to the highest dose BPA (n=9) were still cycling, compared to 86% of the females 
exposed to the low dose of BPA. Females exposed to the high dose of BPA displayed abnormal 
folliculogenesis, containing multinucleated cells. Ovaries from the females exposed to the low dose of 
BPA showed all stages of follicular development. Most of the high dose treated BPA animals were 
acyclic at the time of ovariectomy, and the authors considered it unlikely that these follicles would 
progress to ovulation. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Appropriate positive and negative control (EB and PPT) 
- Phytoestrogen-free diet 
- Good sample size (10-12 female offspring/group) 
Weaknesses:  
- Type of cages and drinking bottle not reported  
 
Overall neither HED dose was ≤3.6 mg BPA/kg bw per day and this largely well-conducted study 
found significant advese effects of the high BPA doses used on  post-natal reproductive development 
and function. 
 
This study is not included in the WoE table because niether of the HED BPA doses used are ≤3.6 mg 
BPA/kg bw per day. 
Berger RG, Hancock T and DeCatanzaro D, 2007. Influence of oral and subcutaneous 
bisphenol-A on intrauterine implantation of fertilized ova in inseminated female mice. 
Reproductive Toxicology, 23, 138-144. 
 
To examine the effects of BPA on implantation, mice were exposed via either sc injection or two 
dietary administration routes (not gavage). Subcutaneous injections of BPA (0.016, 0.047, 0.14, 0.45, 
1.3, 3.9, 35.2, 105.5 mg/kg bw per day [0.24, 0.71, 2.1, 6.75, 19.5, 58.5, 528, 1582.5 mg/kg bw per 
day]) in peanut oil were administered daily to adult female primiparous CF-1 mice on gestation days 
1-4. Oral administration via either (1) dietary supplement (calculated daily intake: 36, 278, 550, 453 
mg BPA/kg bw per day [HED, to dam,  2.49, 18.9, 37.4, 30.8 mg BPA/kg bw per day]) or (2) food 
contamination (calculated daily intake: 2,223, 2,293 mg BPA/kg bw per day [HED to dam, 151, 156 
mg BPA/kg bw per day]) also occurred on GD1-4. Implantation rate, litter size, number of 
implantation sites and uterine histology (at the highest BPA dose only) were assessed. Although 
adverse effects were observed at the two highest doses, BPA at HED ≤3.6 mg/kg bw per day had no 
significant effect on any of the measures assessed. None of the oral doses had any significant effects at 
HED ≤3.6 mg/kg bw per day. 
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Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Number of doses (≥3) 
Weaknesses:  
- Small sample size (mostly <8 animals/group) 
- Type of drinking bottle not reported  
- Study reporting inadequate for the oral studies, very difficult to relate doses to effects to 
statistical analysis. 
 
Overall there were some barriers to interpretation of the study with the BPA dosages requiring 
conversion into mg/kg bw per day prior to calculation of the HED levels. In addition, relating the oral 
BPA doses to specific outcomes was poorly described in the publication. While well performed, the 
low sample numbers and the analysis of uterine histology only at the highest BPA dose means that the 
CEF Panel rated this study as preliminary. 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Cabaton NJ, Wadia PR, Rubin BS, Zalko D, Schaeberle CM, Askenase MH, Gadbois JL, Tharp 
AP, Whitt GS, Sonnenschein C, Soto AM. Perinatal exposure to environmentally relevant levels 
of bisphenol A decreases fertility and fecundity in CD-1 mice. Environmental Health 
Perspectives, 119, 547-552. 
 
This study is one of the rare forced/continuous breeding studies with BPA and as such potentially 
important to obtain insights into potential fecundity effects of BPA in humans. CD-1 female mice 
were exposed to BPA at 0.025, 0.25, 25 µg/kg bw per day [HED: dams 0.38, 3.75, 375 µg/kg bw per 
day] via subcutaneous osmotic minipumps from GD8-PND16. 10 ng/kg bw per day of DES was used 
as a positive control. Cages, bedding and water were assessed for estrogenicity by Escreen and the 
purity, but not the dose level, of BPA confirmed by HPLC-MS. The female F1 pups (1 per litter) at 2 
months of age were housed with unexposed breeder males for 32 weeks, with the F2 pups were 
removed at parturition.  The samples size of 18-21 litters/individuals is good but there is some 
statistical weakness in the detailed analysis of the number of pups delivered to each dam per litter (e.g. 
failure to show statistical significance of correlation coefficients while showing R2, which are for 
linear regressions, furthermore the data  (Fig. 4) do not look appropriate for linear fits. BPA had no 
significant effect on the numbers of live or dead pups, the sex ratio of the pups, time to first delivery of 
F1 dam body weight at 32 weeks. However, the lowest and highest BPA doses were associated with a 
significantly reduced cumulative number of pups. At the highest BPA dose, numbers of litters and % 
of females with ≥6 litters were significantly reduced. The authors conclude that there was a dose-
dependent effect of BPA on reproductive capacity. 
 
Comments from the CEF Panel: 
Sub-cutaneous study via mini-pump 
 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- ≥3 dose levels of BPA 
- Cages, bedding, water, food content of oestrogens negligible at E-screen. 
- Adequate positive controls included (DES) 
- Large sample size (18-21 litters/individuals) 
Weaknesses:  
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- Inappropriate statistics (failure to show statistical significance of correlation coefficients while 
showing R2, which are for linear regressions, furthermore the data  (Fig. 4) do not look 
appropriate for linear fits) 
 
Overall the CEF Panel agreed that cumulative pup numbers were significantly reduced by BPA at the 
highest and lowest doses and by DES, but not by the intermediate BPA dose. Therefore the effect was 
not dose-dependent, raising questions about the role of chance given that all 3 BPA doses were 
considered low, even in terms of HED. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Castro B, Sanchez P, Torres JM, Preda O, Del Moral RG and Ortega E, 2013. Bisphenol A 
exposure during adulthood alters expression of aromatase and 5alpha-reductase isozymes in rat 
prostate. PLoS One, 8, e55905.  
 
Adult male Wistar rats were exposed to 4 dose levels of BPA at 25, 50, 300, 600 µg/kg bw per day 
[HED: Adults males = 650, 1 300, 7 800, 15 600 µg/kg bw per day] for 4 days by sc injection in 
sesame oil. Controls received sesame oil alone and group size was 8. After harvesting circulating 
testosterone and oestradiol were determined and qPCR and Western blot performed to determine 
srd5a1, -a2, -a3 and cyp19a1 transcript and protein levels in the prostate glands. Testosterone 
increased, oestradiol decreased ans the testosterone/oestradiol ratio was skewed by exposure to BPA at 
all doses tested. Prostate levels of srd5a1 and a2 were reduced and a3 and cyp19a1 increased at all 
doses tested. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Number of doses (≥3) 
- Use of non-PC cagesand glass bottles  
Weaknesses: 
- Animal diet poorly described  
 
Overall the CEF Panel noted that this is a well performed study with reasonable and valid enpoints. 
The changes described, especially the skewing of the T/E2 ratio and increased aromatase is considered 
symptomatic of prostate disease. Despite the acute nature of the exposure the study may be of interest 
although a more prolonged exposure paradigm was not included to check whether the effects persisted 
or disappeared with time.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Christiansen S, Axelstad M,  Boberg J and Hass U, 2013. Low dose effects of BPA on early 
sexual development of male and female rats. Reproductive Toxicology, 41, 11. 
 
Mated nulliparous young adult Wistar rats were were allocated to three experimental blocks. Day of 
vaginal plug was GD 1 and GD 23 was called postnatal day1 (PND 1) as the expected day of delivery. 
Four different dose levels of BPA were administered (0.025, 0.25, 5, 50 mg/kg bw per day) in corn oil 
[HED: Dams = 0.018, 0.18, 3.6, 36 mg/kg bw per day; Pups = 0.475, 4.75, 95, 950 mg/kg bw per day]. 
Twenty-two maternal rats were allocated to each treatment group and treatment was by gavage once a 
day from GD 7 to PND 22, excluding the day of delivery. BPA levels in stock solutions were verified 
by analysis. Considerable efforts were made to avoid BPA contamination from the rat environments. 
Animal morpholiogical measures included AGD and nipple retention. On PND 16 and 17 1 male and 
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1 female pup/litter were harvested and a range of organs weighed. 14-20 male pups and 15-20 female 
pups were analysed at each treatment dose. Very few statistically significant effects of BPA were 
observed. Male pup AGD was significantly decreased (7% max) at all except the lowest BPA dose and 
nipple retention increased at the highest dose (4-fold, but dose-dependent). Female pup AGD was also 
significantly decreased (9% max) at all doses. Among the organs weighed, the only significant effect 
was an increase in retroperitoneal fat pad weight in male pups at the highest BPA dose. The authors 
conclude that BPA below the NOAEL of 5 mg/kg bw per day can affect reproductive development in 
the rat. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths in this study: 
Strengths: 
- Large sample size 
- Number of doses (≥3) 
- Oral administration by gavage 
- Phytoestrogen-free diet 




Overall, the CEF Panel noted that the concentrations of BPA in the treatment solutions were verified 
and that statistical analyses were appropriate. The CEF Panel partly agrees with the authors’ 
conclusion. While the decrease in male AGD is indicative of some impairment of masculinization it is 
not known from this study whether there is any decrease in subsequent fertility. The decrease in AGD 
in females is also indicative of an effect of all doses of BPA on genital development, but the 
reproductive significance of shorted AGD in the females is uncertain since increased AGD in young 
women is associated with greater follicle numbers (Mendiola et al., 2012). Reduced female AGD is 
inverse to the expected increase in female AGD associated with ovarian cysts/PCOS in the case of 
increased androgen action.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
DeCatanzaro D, Berger RG, Guzzo AC, Thorpe JB and Khan A, 2013. Perturbation of male 
sexual behaviour in mice (Mus musculus) with a discrete range of bipshenol-A doses in the 
context of high- or low- phytoestrogen diet. Food and Chemical Toxicology, 55, 164-171. 
 
Adult female CF0-1 mice were maintained on either a high or low phytoestrogen certified commercial 
diets. 5 different dose levels of BPA were used in 2 experiments. From GD9 to PND1 the mothers 
received, in the diet in 1 g of peanut butter, either vehicle (peanut oil) or 0.175, 1.75, 17.5 µg BPA/g 
peanut butter/day (experiment 1) [HED: Dams = 0.15, 1.5, 15 µg/kg bw per day]) or, with a high 
phytoestrogen diet only, 17.5, 175, 1750 µg BPA/g peanut butter (experiment 2 [HED: Dams = 15, 
150, 1,500 µg/kg bw per day]). Pups were weaned on PND27 and males maintained on the same diet 
as their mother until PND 60 or 90. Male offspring AGD, reproductive organ weights, capacity to 
inseminate and urinary hormone levels were measured. 1 male per litter, from 12-20 litters, was used 
for each analysis. In experiment 1, the 17.5 µg BPA/day + high phytoestrogen was associated with 
reduced vesicular-coagulating gland weight and increased latency to inseminate, but did not affect 
body, testis or preputial gland weights or AGD. In experiment 2 none of the BPA doses affected these 
body/reproductive organ indices and urinary testosterone, oestradiol and creatinine were also 
unaffected. At the 17.5 µg BPA/day dose there were reductions in intromission number (also at the 
175 dose) and ejaculations by around 50%. 
Comments from the CEF Panel:  
BPA doses were not normalised to body weight  
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The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Large sample size (n=15 dams/group) 





Overall, the CEF Panel noted that numbers and statistical analysis are appropriate but the BPA doses 
are not normalised against body weight. It is not evident what the BPA dose in terms of µg/kg bw per 
day actually were and BPA levels in the rats were not determined. In addition, the erratic appearance 
of mostly minor effects of BPA only at the high phytoestrogen dose makes the study interesting but 
difficult to interpret in terms of human risk.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Delclos KB, Camacho L, Lewis SM, Vanlandingham MM, Latendresse JR, Olson GR, Davis KJ, 
Patton RE, da Costa GG, Woodling KA, Bryant MS, Chidambaram M, Trbojevich R, Juliar 
BE, Felton RP and Thorn BT, 2014. Toxicity Evaluation of Bisphenol A Administered by 
Gavage to Sprague Dawley Rats From Gestation Day 6 Through Postnatal Day 90. Toxicological 
Sciences, 139, 174-197. 
 
In a new study Sprague-Dawley rats were used for a dose-response approach to investigate the effects 
of BPA on a very wide range of pathological, physiological, endocrine, reproductive and 
developmental endpoints. Ethinyl oestradiol was used as a positive control of the estrogenic effects of 
BPA. The dose-matched vehicle control was carboxymethylcellulose, sodium salt. The doses were: (i) 
BPA 2.5, 8, 25, 80, 260, 840, 2 700, 100 000, 300 000 µg/kg bw per day [HED: Dams = 1.8, 5.76, 18, 
57.6, 187, 604, 1 944, 72 000, 216 000 µg/kg bw per day; Pups = 47.5, 152, 475, 1 520, 4 940, 15 960, 
51 300, 1 900 000, 5 700 000 ug/kg bwday although dose to dams was used as conservative], (ii) 
Vehicle, (iii) EE2 0.5, 5 µg/kg bw per day. The study included a naïve control group and doses were 
administered by oral gavage. The protocol ands methods, including statistical analysis were of the high 
quality and robust with treatment, body weight and litter randomisation and appropriate inclusion and 
exclusion criteria established prior to the start of the study. The target unit for analysis was 20 litters 
and 18-23 were achieved. F0 females were dosed from GD 6 up to labour onset and pups from PND 1 
until tissue harvesting, up to PND 90. There were vehicle effects compared with naïve controls, 
including reduced male offspring preweaning survival and reduced male AGD and AGDI (7%). BPA 
doses between 2.5 and 2 700 µg/kg bw per day were considered low doses and these are considered 
here. A significant increase in vaginal metestrus prevalence was found in both BPA 2.5 (P<0.05) and 
BPA 25.0 (P<0.01) relative to the vehicle controls. In addition, a significant change in the oestrous 
pattern was found for BPA 25.0 µg/kg bw per day (P<0.01) relative to controls. Males showed a 
slightly increased incidence of seminiferous tubule giant cells (5/23 at 2.5 µg/kg bw per day vs 0/20 
for vehicle) and delated testis descent (5%, 260 µg/kg bw per day). Reliability of these findings is 
supported by the extensive effects of the 100 000 and 300 000 µg/kg bw per day BPA doses in both 
males and females and the lrgely expected effects of the EE2 positive controls in both sexes. 
In conclusion, at low oral doses of BPA, especially below 2 700 µg/kg bw per day, this study provides 
strong evidence that BPA pre-natal plus post-natal exposure to BPA does not have highly significant 
effects on rat reproductive development and adult reproductive indices. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
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- Large sample size 
- Number of doses (≥3) (especially in the low dose range) 
- Both naïve and vehicle controls available 
- Adequate positive controls included 
- Oral administration via gavage  
- Phytoestrogen-free diet  
- Use of non-PC cages  
- Study/analysis performed under OECD guideline 
- Study/analysis performed under GLP 
- BPA measurements in biological samples 
Weaknesses:  
- BPA contamination of control groups 
 
Overall, the CEF Panel noted that at low oral doses of BPA, especially below 2 700 µg/kg bw per day, 
this study provides strong evidence that BPA pre-natal plus post-natal exposure to BPA does not have 
highly significant effects on rat reproductive development and adult reproductive indices.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Dobrzynska MM and Radzikowska J, 2013. Genotoxicity and reproductive toxicity of bisphenol 
A and X-ray/bisphenol A combination in male mice. Drug and Chemical Toxicology, 36, 19-26. 
 
As stated in the original abstract from the paper: “This study was designed to investigate the effects of 
2 weeks of exposure of male mice to bisphenol A (BPA) alone or in a combination with X-rays on the 
sperm count and quality as well as induction of DNA strand breaks in somatic and germ cells. 
Pzh:SFIS male mice were exposed to X-rays (0.05 and 0.10 Gy) or BPA (5, 10, 20, and 40 mg/kg) or 
to a combination of both (0.05 Gy + 5 mg/kg body weight of BPA and 0.10 Gy + 10 mg/kg of BPA). 
Both X-rays and BPA administered alone decreased sperm count and quality. X-rays induced DNA 
strand breaks in spleen cells, whereas BPA induced DNA strand breaks in lymphocytes and in cells 
from spleen, kidneys, and lung and in germ cells. After combined exposure to both agents, sperm 
count and quality were similar as after exposure to each agent alone and significantly reduced, 
compared to control. Levels of DNA damage in somatic and germ cells after combined exposure to 
lower, as well as higher, doses were significantly reduced, compared to the effects of BPA alone. 
Results confirmed the mutagenic ability of BPA. Combined exposure to X-rays and BPA leads to the 
prevention of DNA damage in somatic and germ cells of mice.” 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Number of doses (≥3)  
Weaknesses:  
- No vehicle controls were tested  
- Drinking water consumption (containing BPA) not measured 
- Animal diet poorly described  
- Animal diet and phytoestrogen content not reported  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
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El Ghazzawy IF, Meleis AE, Farghaly EF, Solaiman A, 2011. Histological study of the possible 
protective effect of pomegranate juice on bisphenol-A induced changes of the caput epididymal 
epithelium and sperms of adult albino rats. Alexandria Journal of Medicine, 47, 125-137.  
 
In what can only be considered a preliminary and inadequately quantified study, a single very low 
dose of BPA administered by oral gavage to adult 13-15 week old male albino rats for 8 weeks. Ten 
rats per group received daily the following treatments by oral gavage: (1) corn oil, (2) corn 
oil+pomegranate juice, (3) 20 µg BPA/kg bw per day [HED: Adult males = 14.4 µg/kg bw per day], 
(4) 20 µg BPA/kg bw per day+ pomegranate juice. A quantified reduction in caudal epididymis sperm 
numbers (1.8-fold lower in BPA only group) was reported and reversed by the anti-oxidant 
pomegranate juice. Qualitative observations were made about caput epididymis and sperm structure 
and ultrastructure. There was no apparent attempt to quantify these observations.  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study:  
Strengths: 
- Oral administration via gavage 
- Use of non-PC cages  
Weaknesses:  
- Single dose level study  
- Animal diet poorly described  
- Insufficient studying reporting (no multiple comparisons statistics)  
 
Overal the CEF Panel noted that this is a single- and low-dose study. While the degeneration of the 
epididymis in BPA-treated animals compared with controls described by the authors seems 
convincing, based on the light and electron micrographs presented, this does not seem to be 
biologically plausible at such a low dose, compared with the results of well-conducted multigeneration 
studies. Statistical analysis was not adequately described. No multi-comparison analysis encompassing 
the protective effects of pomegranate juice was applied. The oxidative stress hypothesis is based on 
these apparent protective effects.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Ferguson SA, Law CD, Jr. and Abshire JS, 2011. Developmental treatment with bisphenol A or 
ethinyl estradiol causes few alterations on early preweaning measures. Toxicological Sciences, 
124, 149-160. 
 
Pregnant Sprague-Dawley rats reared in a low exogenous oestrogen environment were gavaged on 
gestational days 6–21 with 0, 2.5 or 25 µg BPA/kg bw per day [HED: Dams = 1.8, 18 µg/kg bw per 
day, Pups = 47.5, 475 µg/kg bw per day], or 5.0 or 10.0 µg/kg per day ethinyl oestradiol (EE). Litters 
were reduced to four males and four females as far as possible, and the pups were then orally treated 
on postnatal days 1–21 with the same doses. Parameters investigated, starting on postnatal day 1 and 
onwards were anogenital distance (AGD) and anogenital distance index, developmental landmarks 
including bilateral ear canal opening, bilateral eye opening, fur development and nipple retention as 
well as righting reflexes, slant board behaviour. Total brain weights and weights of different 
anatomical zones were measured. On post natal day 21 serum levels of a number of hormone were 
measured; thyroxin, triiodothyronine, oestradiol, testosterone, corticosterone and LH as well as leptin 
and ghrelin. Administration of BPA at 2.5 or 25µg/kg bw per day had no effects on gestational or 
lactational bodyweight in the dams, nor birth weight of the pups although preweaning body weights 
were decreased in both sexes relative to the vehicle control group (maximum 10% decrease in low-
dose BPA postnatal day 5 females). Administration of EE resulted in significant decreases in 
gestational and lactational body weight of the dams, also birth weights and preweaning body weights 
pups. No effect of treatment with these low doses of BPA were observed on anogenital distances and 
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AGD index, developmental landmarks, measures of serum hormones, and whole/regional brain 
weights. Developmental landmarks including age at eye opening, bilateral ear canal opening and fur 
development, and two early behavioral markers, righting reflex and slant board behavior) were not 
altered by BPA treatment. No effects on hormonal measures or brain weights at weaning were seen. 
The authors concluded that these low oral doses of BPA were not associated with early alterations in 
the offspring. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
 Strengths: 
- Large sample size 
- Adequate positive control included 
- Oral administration by gavage 
- Phyoestrogen-free diet 




Overall the CEF Panel noted that this study, by the US FDA, is a robust well controled study, showing 
no effects of BPA. However, it covers endpoints that have not been highlighted by ANSES as of 
particular concern, and covers only 2 low dose levels. Care was taken to avoid confounding factors 
such as not using oily vehicles to avoid their nutritional effects, the cages were made of polysulfone 
checked for BPA release, very careful randomisation and dosing procedures, BPA of defined purity 
and hormones measured at a particular period to avoid confounding diurnal variation. Although the 
positive control ethinyl oestradiol produced significantly decreased gestational and lactational body 
weight, birth weights and pre-weaning body weights, these and other indices were not altered by BPA. 
Thus, developmental BPA treatment at 2.5 or 25.0 mg/kg/day appears to have no effects on gestational 
or lactational body weight, offspring anogenital distance, pre-weaning behaviour or hormone levels 
and whole and regional brain weights measured at weaning. Interestingly, following direct oral 
treatment of the offspring on post-natal days 1–21, the naive control group weighed significantly less 
than the vehicle (aqueous solution of carboxymethylcellulose sodium salt) control group. The reason 
for this was unclear although it was hypothesized that increased thirst in vehicle control offspring of 
the current study may have resulted in increased suckling and potentially increased body weight. 
However, such findings highlight the potential experimental factors that can confound the 
interpretation of group differences in these neonatal studies.  




Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 303 
Honma S, Suzuki A, Buchanan DL, Katsu Y, Watanabe H and Iguchi T, 2002. Low dose effect 
of in utero exposure to bisphenol A and diethylstilbestrol on female mouse reproduction. 
Reproductive Toxicology, 16, 117-122. 
 
This study was aimed primarily at the effects of BPA on female reproduction, but also included some 
data on males. Pregnant ICR-Jci mice were administered BPA at 2,20 µg BPA/kg bw per day [HED: 
dams 30, 300 µg/kg bw per day] from GD11-17. DES (0.02, 02, 2 µg/kg bw per day) was used as a 
psotive control. The offspring of both sexes were assessed at PND 0, 11, 22, 60 and females were 
mated with unexposed males between PND 90 and 120. Body weights, AGD, vaginal histology and 
vaginal opening were examined. BPA had no significant effect on gestation, numbers of live pups or 
pup sex ration. In females BPA reduced body weight at PND 22 and 60 (significant but small effects) 
and increased AGD (2 µg/kg bw per day) at PND 22 although this effect was no longer seen at PND 
60. In males BPA significanrtly reduced body weight at PND60 and while AGD was not affected at 
PND22, at PND60 both BPA doses were associated with significantly increased AGD. Surprisingly, 
DES had similar effects in both sexes (at 1 or more dose levels). BPA (and DES) significantly 
advanced the day of vaginal opening, reduced body weight and age at vaginal opening and increased 
oestrous cycle length. In subgroups of n=10 F1 female mice mated, there were no significant effects of 
BPA (or DES) on mating, pups/litter or pup sex ratio. 
 
Comments from the CEF Panel: 
Some positive control effects were not as expected (DES had similar effects in both sexes (at 1 or 
more dose levels)) 
 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Adequate positive controls included (3 doses of DES) 
- Large sample size (9-10 and 41-51 females, 24-35 males respectively per group) 
Weaknesses:  
- Inappropriate statistics (not clear if data normality was established, use of Student’s t-test, 
analysis of dose-effects bnot stated) 
- Animal diet and phytoestrogens content not reported 
- Type of cages and drinking bottles not reported 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Horstman KA, Naciff JM, Overmann GJ, Foertsch LM, Richardson BD and Daston GP, 2012. 
Effects of transplacental 17-alpha-ethynyl estradiol or bisphenol A on the developmental profile 
of steroidogenic acute regulatory protein in the rat testis. Birth Defects Res B Dev Reprod 
Toxicol, 95, 318-325. 
 
In this study pregnant Sprague Dawley rats were dosed from gestational day 11 with either 17-alpha-
ethynyl oestradiol (EE) in peanut or sesame oil or BPA in dimethyl sulfoxide by subcutaneous 
injection. Doses of EE were 0.001, 0.1 or 10 µg/kg/day or BPA at 0.02, 0.5, 400 mg/kg per day day 
[HED: Dams = 0.52, 13, 10, 400 mg/kg bw per day]. Fetal testes were harvested on gestational days 
16, 18 or 20. They were studied using quantitative reverse transcriptase PCR for changes in 
steroidogenic acute regulatory (StAR) protein transcript levels and immunocytochemistry for StAR 
protein. Neither EE nor BPA exposure caused morphological changes in the developing seminiferous 
tubules or the interstitial region at gestational days 16–20. However, BPA and EE slightly reduced 
StAR mRNA and protein levels at gestational day 18 and 20 but only at the highest doses of 10 
µg/kg/day EE or 400 mg/kg/day BPA. Immunohistochemistry also demonstrated decreases in StAR 
protein levels but again only at the highest doses. 
Comments from the CEF Panel:  
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The CEF Panel identified the following strengths and weaknesses in this study: 
 Strengths: 
- Large sample size  
- Number of doses (≥3) 
- Positive control included 
- Use of non-PC cages 
Weaknesses: 
- Animal diet and phytoestrogen content not reported 
- Insufficient study reporting (some details not completely clear) 
 
Overall the CEF Panel noted that, whilst this study demonstrates the potential effects of neonatal 
exposure to BPA on testicular function of offspring, it seems to be limited to high exposures which are 
probably not directly relevant to human exposures. Notwithstanding the use of EE group as a positive 
control, the precise sample sizes were difficult to interpret from the paper and the 
immunohistochemistry was not very convincing. However, no effects of BPA doses ≤3.6 mg/kg bw 
per day HED were reported.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Howdeshell KL, Furr J, Lambright CR, Wilson VS, Ryan BC and Gray LE, 2008. Gestational 
and lactational exposure to ethinyl estradiol, but not bisphenol a, decreases androgen-dependent 
reproductive organ weights and epididymal sperm abundance in the male long evans hooded 
rat. Toxicological Sciences, 102, 371-382.  
 
In a well-doncducted study of BPA reprotoxicology, Long Evans rats were dosed with BPA at 2, 20, 
200 µg/kg bw per day [HED: 1.44, 14.4, 144 µg/kg/day] by oral gavage from GD7 to PND18 Two 
arms – main study 13-29 dams/ group (0.05, 0.5, 5, 50 µg/kg bw per day) second extended EE group 
(0.05, 0.15, 0.5, 1.5, 5, 15, 50 µg/kg bw per day) study 6-14 dams/group, with the same BPA regime 
for both arms. At PND5 litters were trimmed to n=8 pups max, as far as possible balanced for pup sex 
(4 male, 4 female). 9-38 litters were used per group and the liutter effect was accounted for. Dams and 
male offspring were studied, the females from the same experiment having been reported by Ryan et 
al (2009a). Maternal and pup/weaning body weights and neonatal AGD were measured. Necroscopy 
was performed after PND150 and PND229 and reproductive tract weights, morphology and histology 
as well as external genitalia and nipple retention were assessed. Epidyimyal sperm counts and 
circulating oestradiol, testosterone, corticosterone, total T4, LH and PRL were measured. Apart from 
rwo minor exceptions BPA had no significant effect on AGD, birth or weaning weights, age or weight 
at weaning, growth rates, external genitalia, endoc rine measures, reproductive tract size and 
morphology or any other indeces of reproductive development or function measured. The exceptions 
were: (i) 1/18 males treated with 20 µg/kg bw per day vs 0/31 control males showed ventral prostate 
hyperplasia (dose-related in EE treated positive controls) and (ii) an increased incidence of testisular 
degeneration (without any effect on testis size or sperm numbers) in 7/20 males treated with 200 µg 
BPA/kg bw per day compared with 1/31 controls. These effects were seen only in the first arm of the 
study and not in the second arm. In contrast, the positive control had the expected, dose-dependent 
effects on the parameters measured. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- ≥3 dose levels of BPA 
- Oral administration via gavage Large sample size (9-38 litters/group) 
- Adequate positive controls included (EE) 
Weaknesses:  
- Use of polycarbonate cages (although new) 
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- Animal diet and phytoestrogen content poorly descriped (Purina Rat Chow 5008 has high 
isoflavone content) 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Hunt PA, Lawson C, Gieske M, Murdoch B, Smith H, Marre A, Hassold T, VandeVoort CA, 
2012. Bisphenol A alters early oogenesis and follicole formation in the fetal ovary of the rhesus 
monkey. PNAS, 109 (43), 17525-17530. 
 
Hunt et al. (2012) investigated reproductive parameters in the female fetuses of pregnant Rhesus 
macaques. Two routes of administration were used: (1) oral in diet, 400 µg BPA/kg bw per day [HED: 
Dams = 168 µg/kg bw per day] (single daily dose) or (2) subcutaneous implant tested to yield 2.2-3.3 
ng unconjugated BPA/ml plasma in non-pregnant females (continuous exposure). Deuterated BPA 
was used to allow detection. Two exposure windows were investigated for each route: (1) early GD50-
100, the onset of meiosis and (2) late GD100-term, the period of follicle formation. Offspring ovaries 
were studied: oocyte and quantification of multi-oocyte follicles (late exposure window) and meiotic 
analyses (early exposure window). Only the results for the oral route were considered for evaluation 
because of the inadequate number of animals in the subcutaneous route (only 2 monkeys in the control 
group). BPA ≤3.6 mg/kg bw per day HED was associated with a modest but statistically significant 
increase in the proportion of multi-oocyte secondary or antral follicles but had no significant effect on 
incidence of meiotic defects reportedly seen in the implant group).  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- BPA measurement in animal samples 
- Use of non-PC cages 
Weaknesses: 
- Small sample size 
- Single dose level study 
- BPA concentration and homogenity not guaranteed analytically 
- Diet phytoestrogen content not reported 
 
Overall, the CEF Panel notes that the precise significance of the increased incidence of multi-oocyte 
follicles for subsequent fertility in monkey or human is likely to be adverse but remains to be 
demonstrated. Low animal numbers meant that only the oral dose groups could be assessed reliably.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Jin P, Wang X, Chang F, Bai Y, Li Y, Zhou R, Chen l, 2013. Low dose Bisphenol A impairs 
spermatogenesis by suppressing reproductive hormone production and promoting germ cell 
apoptosis in adult rats. Journal of Biomedical Research, 27 135-144. 
 
Adult male Sprague-Dawley rats in 5 groups of 10 were allocated to treatment groups. A single dose 
level of BPA was used. Animals were treated as follows: (i) BPA in olive oil at 2 µg/kg bw per day, 
(ii) testosterone propionate (TP in DMSO) at 0.1 mg/rat per day, (iii) BPA+DMSO, (iv) BPA+TP, (v) 
the text mentions a baseline group and a vehicle group without specifying which vehicles. BPA was 
administered by oral gavage, TP by subcutaneous injection. BPA treatment was for 14 days, TP 
treatment duration was not specified. Epididymal sperm counts and testicular spermatogenesis were 
assessed by microscopy/histology and TUNEL quantification of seminiferous tubule apoptosis. 
Circulating LH, FSH and testosterone were determined. Brain (preoptic area) GnRH 
immunohistochemistry and qPCR was performed, as well testicular Ar, Fas, FasL, Caspase-3 qPCR. 
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BPA was reported to reduce sperm counts and seminiferous tubule numbers of all stage VII germ 
cells. Serum and iontra-testicular testosterone were reduced in BPA-exposed animals and the negative 
effect of BPA on sperm counts was partially reversed by TP, as were numbers of mPSc and 7Sd stage 
VII germ cells. BPA-exposed rats had lower FSH and increased LH. Following TP replacement the 
level of LH was lower in the BPA rats than in controls. Preoptic area GnRH expression was reduced in 
the BPA exposed group. The BPA-exposed seminiferous tubules had an increased apoptotic index that 
was unaffected by coadministration of TP. Fas, FasL and caspase-3 were increased by BPA exposure. 
The authors conclude that the dose of BPA impaires spermatogenesis by decreasing reproductive 
hormones and activating the Fas/FasL pathway. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths:  
- Oral administration via gavage  
- Use of non-polycarbonate (non-PC cages), and use of glass water bottles  
- Adequate positive controls included  
Weaknesses: 
- Single dose level study  
- Animal diet poorly described  
- Insufficient study reporting (data presentation is unclear) 
 
Overall the CEF Panel noted that the study appears reasonably well performed in places, subject to the 
significant caveat about the group set up and controls. However, the data presentation is confusing and 
erratic in places making interpretation difficult and reduces confidence in the quality and validity of 
the study. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Kato H, Furuhashi T, Tanaka M, Katsu Y, Watanabe H, Ohta Y and Iguchi T, 2006. Effects of 
bisphenol A given neonatally on reproductive functions of male rats. Reproductive Toxicology, 
22, 20-29. 
Neonatal BPA effects on male reproduction were studied in Sprague-Dawley male rats administered 
BPA at 2, 11, 56, 277, 97,000 µg/kg bw per day [HED: neonates 0.62, 3.4, 17.4, 85.9, 30070 mg/kg 
bw per day]. BPA dosage was by daily subcutaneous injection from PND0 (birth) to PND9. A single 
dose level of 0.9 mg/kg bw per day of oestradiol was used as a positive control. 1 male per litter from 
12 dams was used for each treatment group, adjusting for the litter effect. The treatment regime 
required analysis and conversion of doses to mean mg/kg bw per day. The sample size was n=8 and 
therefore adequate although not good and the study was otherwise well conducted and reported. The 
pups were investigated an PND0 (birth), 10, 21, 42, 63, 84, 105, 126, 140, 150 (necroscopy at PND 
10, 35, 150) and preputial separation, semen analysis (numbers, motility and morphology), circulating 
testosterone, copulatory rate, fertility rate, testicular histology, key testis ranscript expression (e.g. 
CYP17A1) and reproductive tract weights and morphology were assessed. At the two lowest doses of 
BPA (i.e. ≤3.6 mg/kg bw per day) and indeed at all BPA doses, there were no significant effects on 
any parameter measured other than a reduction in the proportional of abnormal sperm, not adverse 
outcome. The oestradiol-treated males showed expected estrogen mediated adverse changes, such as 
reduced testis weight. The litters sired by the BPA treated males were no different from controls. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- ≥3 dose levels of BPA 
- Adequate positive controls included (oestradiol) 
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Weaknesses:  
- Type of cages and drinking bottles not reported 
 
The CEF Panel noted that the authors’ statement that the diet (CRF-1, Oriental Yeast Co, Tokyo, 
Japan) is considered relatively low in phytoestrogen. No adverse effects of BPA were observed 
although the fertility test was not using a continuous/forced breeding regume. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Kobayashi K, Kubota H, Ohtani K, Hojo R, Miyagawa M, 2012. Lack of effects for dietary 
exposure of bisphenol A during in utero and lactational periods on reproductive development in 
rat offspring. The Journal of Toxicological Sciences, 37, 565-573. 
 
In order to investigate the effects of both in-utero and lactational BPA exposure on male and female 
offspring reproductive development, the authors exposed female Sprague-Dawley rats (n=10/group) to 
3 doses of BPA (0.33, 3.3, 33 ppm in diet, equivalent to 0.02, 0.17, 1.65 mg/kg bw per day [HED: 
Dams = 0.0144, 0.1224, 1.188 mg/kg bw per day] during gestation and lactation, GD 6–PND 21. F1 
offspring were examined at 5 weeks and 3 months postnatally and body and organ weights, anogenital 
distance, reproductive hormones and sperm counts were quantified. The only BPA-related effect in 
males was a statistically significant decrease in epididymal weights in the 3-month old male animals 
receiving 1.188 mg BPA/kg body weight/day HED. In females, the two highest BPA doses were 
associated with significantly reduced AGD and ovary weights at 5 weeks post-natal although these 
differences had disappeared by the time the animals were 3 months old. 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths:  
- Number of doses (≥3)  
Weaknesses: 
- BPA exposure assessment (Feed consumption (BPA given by the diet) not measured , BPA 
concentration and homogeneity in the feed mixture not guaranteed analytically) 
- Animal diet and phytoestrogen content not reported 
- Insufficient study reporting (some ambiguity about precise dose and/or incidental exposure of 
pups by maternal diet/water)  
 
Overall the CEF Panel noted that the study was reasonably well performed but the exact exposure of 
the animals via the diet is unclear, making the study difficult to compare directly to other studies. The 
litter effect was taken into account.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
LaRocca J, Boyajian A, Brown C, Smith SD, Hixon M, 2011. Effects of in utero exposure to 
Bisphenol A or diethylstilbestrol on the adult male reproductive system. Birth Defects Research, 
Part B. Developmental and Reproductive Toxicology, 92, 526-533. 
 
LaRocca et al. (2011) administered 2.5 or 25 μg BPA/kg bw per day [HED: Dams = 0.08, 0.8 µg/kg 
bw per day] to pregnant mice by oral gavage from GD12-PND21 and the adult male offspring studied. 
A positive control (DES, 2 μg/kg bw per day) was included. Investigation of the effects of BPA on 
pregnancy outcome and on reproductive development of male offspring included testis genes 
expression and morphology and masculinisation (circulating testosterone and AGD). No changes were 
reported for masculinisation, sperm production or germ cell apoptosis in adult testes after exposure to 
either chemical. Adult mRNA levels of genes associated with sexual maturation and differentiation, 
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GATA4 and ID2, were significantly lower only in DES-exposed testes. Overall there was no 
significant effect of BPA ≤3.6 mg/kg bw per day HED. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths:  
- Large sample size  
- Adequate positve controls included 
- Oral administartion by gavage 
Weaknesses : 
- Animal diet and phyoestrogen content not reported  
- Use of polycarbonate cages 
 
Overall, the CEF Panel noted that the study was a reasonably well conducted study in which no effects 
of BPA were reported on testicular function including expression of genes associated with 
steroidogenesis, apoptosis, and Sertoli cell maturation, reported by some other authors to be affected 
by BPA.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Lee SG, Kim JY, Chung JY, Kim YJ, Park JE, Oh S, Yoon YD, Yoo KS, Yoo YH and Kim JM, 
2013b. Bisphenol A Exposure during Adulthood Causes Augmentation of Follicular Atresia and 
Luteal Regression by Decreasing 17beta-Estradiol Synthesis via Downregulation of Aromatase 
in Rat Ovary. Environmental Health Perspectives, 121, 663-669. 
 
Adult (8 wks old) female Sprague-Dawley rats were administered 2 dose levels of BPA by oral gavage 
at 0.001 or 0.1 mg/kg bw per day [HED: Adult females = 0.00072 (0.72 µg), 0.072 (72) mg/kg bw per 
day] for 90 days. The BPA was dissolved in DMSO and the controls received weight matched DMSO 
in corn oil. A positive control, 0.001 mg oestradiol benzoate/kg bw per day was included. Group size 
was 30 for each treatment. After 90 days 18 rats/group were harvested on the day of oestrous while the 
remainer (12/group) were followed for oestrous cycle staging. Uteri, pituitary glands and ovaries were 
examined and plasma E2, T, LH and FSH levels measured and granulosa cells isolated from one 
ovary/rat. Ovarian apoptosis was determined by caspase-3 analysis and steroidogenic enzymes 
measured in theca cells. Circulating E2 and T were reduced by BPA and EB and the duration of the 
estrus phase increased. Follicular and corpora luteal atresia was increased by BPA although EB only 
affected luteal atresia as determined by caspase-3 analysis. Theca cell cyp19 was decreased by BPA 
and StAR decreased by BPA and EB. Circulating and pituitary LH but not FSH were increased by 
BPA. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths:  
- Large sample size 
- Adequate positive controls included  
- Oral administration by gavage 
Weaknesses: 
- Animal diet and phytoestrogen content not reported 
 
Overall the CEF Panel acknowleges that in a well performed and well powered study both doses of 
BPA tested decreased circulating E2 and increased ovarian cell apoptosis, likely partly via decreased 
theca cell steroidogenesis and reduced testosterone which would then explain the increased LH. EB 
did not produce the same phenotype exactly.  
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 309 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Liu C, Duan W, Li R, Xu S, Zhang L, Chen C, He M, Lu Y, Wu H, Pi H, Luo X, Zhang Y, 
Zhong M, Yu Z and Zhou Z, 2013. Exposure to bisphenol A disrupts meiotic progression during 
spermatogenesis in adult rats through estrogen-like activity. Cell Death Dis, 4.  
 
Adult (9 weeks old) male Wistar rats were exposed to 3 BPA dose levels (2, 20, 200 µg/kg bw per 
day) [HED: Adults = 1.44, 14.4, 144 µg/kg bw per day] by oral gavage. 17 β-oestradiol (E2, 10 µg/kg 
bw per day) was administered by subcutaneous injection as a positive control. Both were dissolved in 
ethanol then corn oil. The ER antagonist fulvestrant (ICI) was dissolved in ethanol and used at 500 
µg/kg bw per day, 30 mins prior to gavage where relevant. Solvent control, ICI and E2 groups 
received equivalent cornoil without BPA. Solvent control, BPA and E2 groups were also injected with 
ethanol in cornoil. Treatment continued for 60 days. Groups included colvent control/s, 3 doses of 
BPA only, E2 or ICI only, BPA 200+ICI. After 60 days blood samples and gondas were removed with 
caudal epidymis used for sperm analysis. One testis was used for meiotic chromosol spread and comet 
assay while the otjer epididymis and testis were used for histology (H&E) and PAS-H staining. No 
effect of BPA at less thn 200 µg/kg bw per day was observed. No effects of any dose of BPA on 
sperm characteristics, sperm apoptosis, serum FSH, LH or testosterone were seen although E2 reduced 
testosterone (>3-fold), sperm couns and epididymal weights. The ER antagonist reversed the effects of 
the BPA dose of 200 µg/kg bw per day on sperm counts. The latter dose of BPA and E2 increased 
stages VII and IX sperm and decreased stage VII sperm, an effect blocked by ER antagonism. Both 
200 µg BPA/kg bw per day and E2 reduced the percentage of leptotene and zygotene spermatocytes 
and increased the proportion of pachytene spermatocytes, again blocked by ER antagonist 
administration. Extensive analysis of germ cell meiosis indicated that 200 µg/kg bw per day of BPA 
and E2 induced disruption of meiosis and increased germ cell apoptosis which was blocked by ER 
antagonist. The authors conclude that BPA at 200 µg/kg bw per day disturbs meiosis via estrogenic 
activity and this may contribute to male infertility. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Adequate positive controls included  
- Number of doses (≥3) 
- Use of glass water bottles  
Weaknesses: 
- Animal diet poorly described 
- Study design not appropriate to the scope (description of the study design was poor and 
confusing in terms of exactly what groups received what and which were compared with what 
controls) 
- Inappropriate statistics (only test used was unpaired t-test) 
 
The CEF Panel noted that the description of the study design was poor and unclear in terms of exactly 
what groups received what and which were compared with what controls. Also animals were provided 
with a rodent experimental diet in which it was stated that no phytoestrogens could be detected but this 
was not checked analytically in the study. The statistical analysis was also not adequately described. 
Nevertheless, the study provides insight into a potential estrogenic action of BPA in the adult male.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Lopez-Casas PP, Mizrak SC, Lopez-Fernandez LA, Paz M, de Rooij DG, del Mazo J, 2012. The 
effects of different endocrine disruptor defining compound-specific alterations of gene 
expression profiles in the developing testis. Reproductive Toxicology, 33, 106-115.  
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Lopez-Casas et al. (2012) exposed CD-1 mice to mono-(2-ethylhexyl)-phthalate, zearalenone, lindane, 
bisphenol-A (0.16; 16 or 64 mg/kg bw per day [HED: Dams 0.00048, 0.048, 1.92 mg/kg bw per day]) 
or 17β-oestradiol (E2: 0.006; 0.012 or 0.048 mg/kg bw per day) via oral administration by drinking 
water to mothers. There were 3 exposure groups (A) during the two weeks before mating; (B) 
exposure continued until birth or (C) exposure was continued until four weeks after birth. Body 
weight, testis weight, testicular morphology (including seminiferous tubule and germ cell 
characteristics and germ cell mitosis), and testis apoptosis were investigated. Global testis gene 
changes were quantified using mouse OPERON arrays and confirmed by TaqMan arrays. While some 
morphological effects of MEHP, Lindane and E2 were observed, none were reported for BPA, other 
than an increase in germ cell apoptosis at the highest dose during the longest exposure. BPA caused 
some changes in gene expression considered to be more like those caused by E2 than MEHP or 
lindane.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Number of doses (≥3)  
Weaknesses: 
- Drinking water consumption (containing BPA) not measured  
- Small sample size 
- Animal diet and phytoestrogen content not reported  
- Insufficient study reporting  
 
Overall, the CEF Panel noted that sample size (n as low as 3) in some groups/analyses was inadequate. 
It was also difficult to establish what gene changes were due to BPA. Overall, there was no effect of 
BPA on body weight or testis morphology at ≤5 mg/kg bw per day (≤3.6 mg/kg bw per day HED) 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Markey CM, Wadia PR, Rubin BS, Sonnenschein C and Soto AM, 2005. Long-term effects of 
fetal exposure to low doses of the Xenoestrogen bisphenol-A in the female mouse genital tract. 
Biology of Reproduction, 72, 1344-1351. 
In order to investigate the effect of in-utero exposure to BPA, pregnant CD-1 mouse dams (8 weeks 
old) were implanted, from GD9 to PND4, with subcutaneous osmotic pumps containing BPA at 25, 
250 ng/kg bw per day [HED: 0.65, 6.5 µg/kg bw per day]. There was no positive control but there was 
a vehicle (DMSO) control and the day the vaginal plug was observed was GD1. Litters were culled to 
10 pups/mother on PND7 and weaned on PND20. The female offspring were sacrificed at 3 months of 
age (n=6-10/group, 1 pup/litter) on afternoon of prooestrous and only the best cyclers from the BPA 
groups were studied.  The following were then assessed: genital tract morphology and tissue weights 
BrdU incorporation, apoptosis, ESR1 (Estrogen receptor alpha) and PGR (progesterone receptor) 
expression. The highesr BPA dose significantly reduced absolute and relative vagina, but not uterus, 
weight and decreased the absolute volume of the uterine lamina propria. Uterine but not vaginal BrdU 
incorporation as a marker of DNA systhesis was significantly reduced by the higher BPA dose in the 
glandular epithelium although apoptosis was not altered.  ESR1 and PGR staining and proportion of 
high intensity staining were increased in the uterine luminal epithelium (and stroma, ESR1). In this 
well-conducted study the authors conclude that at doses ≤3.6 mg./kg bw per day, in-utero BPA 
exposure can adversely affect estrogen responsive uterine and vaginal development. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Feed, cages and bedding content of oestrogens negligible at E-screen 
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- Use of  glass water bottles 
Weaknesses:  
- Study design (small sample size:, 6/group in some cases) 
 
In addition, there may be some bias in the study since only the “best cycling” mice were selected for 
study. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Mendoza-Rodriguez CA, Garcia-Guzman M, Baranda-Avila N, Morimoto S, Perrot-Applanat 
M and Cerbon M, 2011. Administration of bisphenol A to dams during perinatal period modifies 
molecular and morphological reproductive parameters of the offspring. Reproductive 
Toxicology, 31, 177-183. 
 
Adult female Wistar rats were individually housed and treated with BPA via drinkiong water to 
achieve a dose of approximately 1.2 mg/kg bw per day [HED: dams 0.86 mg/kg bw per day] from 
GD6 – PND21, with control receiving ethanol vehicle in their water. There was no positive control. 
Offspring body weights were monitored and the males removed at weaning. At 3 months of age thew 
females were monitored for oestrous cyclicity for 4 weeks and sacrificed on day of oestrous 
(n=15/group). The uterine horns and ovaries were fixed for histology, TUNEL analysis and ESR1 
(estrogen receptor alpha) immunohistochemistry. Serum from the females was analysed for oestradiol 
and progesterone. BPA had no significant effect on body weight but significantly reduced the 
proportion of aimals with normal oestrous cycles although the ovaries were morphologically similar 
between groups. BPA increased uterine luminal epithelial and stromal thickness and increased the 
proportion on animals with reduced apoptosis significantly. In terms of ESR1 immunoexpression there 
is some confusion since the figure 5 legend and the image labelling do nbot agree. However, the 
quantitation presented for immunopositive nuclei indicates a significant reduction in ESR1 nuclear 
localisation in both lumional and glandular epithelium. The circulating levels of progesterone and 
oestradiol were not significantly affected by BPA exposure. The authors conclude that perinatal BPA 
via the dam can disturb the reproductive cycle of female offspring. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size  (n=15 pups/group) 
Weaknesses:  
- Single dose level study Study design (small number of litters:n=5 dams/group) 
- Inappropriate statistics  (litter effect not considered)  
- Drinking water consumption (containing BPA) not measured 
- Type of cages /bedding not reported 
- Animal diet not reported 
 
The CEF Panel noted that there was some uncertainty about the presentation of the ESR1 
immunostaining and would need to be convinced that the differences in staining intensity were 
consistent across all animals in each group rather than simply variations in staining intensity. In terms 
of recognition of ESR1 positive nuclei, this would be less certain interms of accurate quantitation in 
the more heavily stained sections. The lack of effect on ovarian histology and steroid hormone profiles 
is surprising given the decrease in the proportion of animals with normal cycles. 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
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Nah WH, Park MJ, Gye MC, 2012. Effects of early prepubertal exposure to bisphenol A on the 
onset of puberty, ovarian weights, and oestrous cycle in female mice. Clinical and Experimental 
Reproductive Medicine, 38, 75-81.  
 
The authors (Nah et al., 2012) investigated the effects of early prepubertal BPA exposure on the onset 
of puberty and reproductive parameters such as oestrous cycle and reproductive organ weights in 
female mice (15 females/dose level group). Female mice were injected subcutaneously at postnatal 
day (PND) 8 with BPA at the dose levels of 0.1, 1, 10, 100 mg/kg in sesame oil [HED: Pups = 0.87, 
8.7, 87, 870 mg/kg bw] or with sesame oil alone. Body weight was measured from PND 10 to 70. 
Vaginal opening and oestrous cycle were monitored from PND 20 to 29. Animals were sacrificed at 
PND 25, 30, and 70, and the ovary and uterus weights were measured. 
An early prepubertal exposure to BPA at PND8 with subcutaneous administration induced a 
significant decreased body weight from PND 18 to 30 at dose levels 10 and 100 mg/kg. An early 
opening of the vagina was observed in all BPA groups, with a mean days of the vaginal opening of 
26.4±0.43 in the 0.1 mg/kg BPA group, 26.2±0.28 in the 1 mg/kg BPA group, 26.2±0.57 in the 10 
mg/kg BPA group, and 25.9± 0.56 in the 100 mg/kg BPA group versus 27.7±0.61 in the control group. 
The number of days of estrus was significantly decreased at the highest tested dose level namely 
100 mg/kg. The number of oestrous cycle after treatment with BPA at PND 8, was slightly decreased 
from 10 mg/kg bw BPA dose level without statistical significance. The ovarian tissue weights were 
significantly lower from 0.1 mg/kg bw and higher versus control group at PND25 but the effect then 
disappeared at later stages. Uterine weights were significantly lower in the higher dose level group 
(100 mg/kg bw of BPA) at PND 30 only. At the adult stage (PND 70), the ovarian and uterine weights 
in the BPA treatment groups were not significantly different from the control group. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Number of doses (≥3) 
Weaknesses: 
- Animal diet and phytoestrogen content not reported  
- Insufficient study reporting  
 
Overall the CEF Panel notes that this study indicated that an early prepubertal exposure to BPA at a 
single day of treatment (PND8) induces an accelerated onset of puberty exhibited with an early 
opening of the vagina from 0.1 mg/kg accompanied with a decreased number of days of estrus at 
100 mg/kg. Only the highest BPA dose had any significant effect on oestrous cyle length or frequency. 
The ovary weights were also affected at PND 25 and 30 but return to normal at adult age. Treatment 
started after completion of many key ovarian developmental events such as primordial follicle 
formation and statistical analysis was weak (final group size was 5). It is unlikely that a single BPA 
dose at PND 8 could induce the significant differences reported. Also the implications for reproductive 
functions are unclear, since the effects were transient and no longer seen at adulthood. The authors did 
not document the purity of the BPA used nor the type of diet provided to the animals, control of the 
water or type of cages. No positive control was used in this study.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Nakagami A, Negishi T, Kawasaki K, Imai N, Nishida Y, Ihara T, Kuroda Y, Yoshikawa Y and 
Koyama T, 2009. Alterations in male infant behaviors towards its mother by prenatal exposure 
to bisphenol A in cynomolgus monkeys (Macaca fascicularis) during early suckling period. 
Psychoneuroendocrinology, 34, 1189-1197. 
 
Normally cycling adult female cynomolgus monkeys (5-13 years old) were housed in stainless steel 
cages, mated and at GD20 subcutaneously implanted osmotic minipumps were used to deliver 10 µg 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 313 
BPA/kg bw per day [HED: 500 µg BPA/kg bw per day]. The vehicle and control were N,N-
dimethylacetamide. The minimumps were placed every 28 days on GD 48, 76, 104, 132. There was no 
positive control. Offspring were housed with their mothers untiol weaning (6-10months). Pregnancy 
rates, abortion/stillbirth, gestation length and birth and PND168 weights recorded. In addition 
behavioural studies were performed of maternal-offspring interactions. BPA administration had no 
significant effect on any pregnancy characterisc measured including abortion/stillbirth, birth weight, 
PND168 weights and weaning. Behavioural observations were also made. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
 Strengths: 
- Large sample size (18/19 mothers/group) 
- Use of non-PC cages  
 
Weaknesses: 
- Diet and water bottles not adequately described 
- Single BPA dose level used 
- Study design (Highly variable animal age and parity not stated) 
 
Overall the CEF Panel noted that this study, showed no significant effect of BPA ≤3.6 mg/kg bw per 
day  during gestation on basic pregnancy statistics in the cynomolgus monkey. The statistical analysis 
for these aspects of the study were satisfactory. Behavioural effects were reported but these wre 
considered in the neurotoxicity section of the EFSA CEF Panel, 2010 and therefore only basic 
pregnancy statistics have been considered here. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Nanjappa MK, Simon L and Akingbemi BT, 2012. The industrial chemical bisphenol A (BPA) 
interferes with proliferative activity and development of steroidogenic capacity in rat Leydig 
cells. Biology of Reproduction, 86, 135, 131-112. 
 
This study was also evaluated in relation to proliferative effects in the testis as reported in the section 
on Carcinogenicity. It is included in this section on developmental and reproductive effects because of 
the reported effects on steroidogenesis.  
This ex-vivo study describes the effects of developmental exposure of male rats to BPA via gavage of 
pregnant and lactating Long Evans dams at 2.5 and 25 μg/kg bw from gestational day 12 to 
postpartum day 21. Although no exposure measurements were performed the authors estimated, based 
on previous data, that maternal exposures to BPA at 2.5 and 25 μg/kg body weight represent BPA 
doses to the offspring of about 8 and 80 pg/kg body weight. Perinatal exposure to BPA did not affect 
litter size, birth weights of pups and pup sex ratio. Body weights, measured at 21, 35 and 90 days of 
age, were equivalent in BPA-exposed and control animals (P > 0.05). Similarly, paired and relative 
testes weights (proportion to body weights) were not affected by BPA. However, Leydig cell division 
was stimulated in the prepubertal period and increased Leydig cell numbers were shown in the testes 
of adult male rats at 90 days.  
 
Comments from the CEF Panel 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Large sample size  
- Oral administration by gavage  
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic water bottles 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 314 
 
Weaknesses: 
- Test performed in one sex only 
 
Overall, the CEF Panel noted that the biological significance of small statistically differences in the 
sophisticated measurements made in this study is unclear, in the context of totally normal pregnancies 
and littering. Particular care has to be taken in extrapolating findings in rat Leydig cells to humans. A 
detailed review of comparative physiology and pathology indicated that rats are quantitatively far 
more sensitive to the development of Leydig cell tumours than men as it appears that Leydig cell 
luteinizing hormone releasing hormone (gonadotropin-releasing hormone) receptors are unique to rats. 
Rats also have over 10 times more luteinizing hormone receptors than men8. However LH (and indeed 
AGD, a masculinisation read-out) was not measured which is an omission given the findings 
presented, and the adaptability of the reproductive axis to small changes in driving signals. It is 
unlikely that this study confirms an adverse effect of BPA exposure on human male reproductive 
function as being likely or not without further work (e.g. determination of whether these rats are in 
fact less fertile). 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Newbold RR, Jefferson WN and Padilla-Banks E, 2007. Long-term adverse effects of neonatal 
exposure to bisphenol A on the murine female reproductive tract. Reproductive Toxicology, 24, 
253-258. 
 
Outbred female CD-1 mice were bred and the pups pooled, separated by sex and all female litters of 8 
pups cross-fostered. From PND1-5 the pups received daily subcutaneous injections of 10, 100, 1,000 
µg/kg bw per day [HED: pups 87, 870, 8,700 µg/kg bw per day]. Corn oil vehicle and corn oil vehicle 
control, but no positive control, were used. Mice were weaned at PND21 and housed in single sex 
cages of 4 animals until sacrifice at 18 months of age. Reproductive tractrs, including ovaries, were 
fixed, H&E stained and exmined by light microscopy. Lesions were further studied in additional 
sections or stained with Masson’s trichrome stain to confirm if leiomyomas were of smooth muscle 
origin. Neonatal BPA treatment ha dno effect on body weights and only two statistically significant 
effects were observed, bith at the HED dose of 870 µg/kg bw per day. Firstly, an increase in incidence 
from control (7/18) to 14/20 animals exhibiting ovarian cysts and secondly an increase in incidence 
from control (1/18) to 9/20 animals exhibiting cystic endometrial hyperplasia. None of the other 
morphological abnormalities showed particularly convincing increases in incidence. The authors 
conclude tht BPA exposure during critical windows of differentiation may have long-term effects on 
reproductive tract development and disease. 
  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size  (16-23/group) 
Weaknesses:  
- Type of cages and water bottles not reported  
- Insufficient study reporting  
- Inappropriate statistics (p value not adjusted to multiple testing) 
 
The CEF Panel noted that several abnormalities also occurred in the control group and that with the 
lack of statistical significance, the wight placed on the non-significant findings by the authors is 
misplaced. In addition, the authors compared their findings with DES but failed to include a DES 
positive control in their study. 
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This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Newbold RR, Jefferson WN and Padilla-Banks E, 2009. Prenatal Exposure to Bisphenol A at 
Environmentally Relevant Doses Adversely Affects the Murine Female Reproductive Tract 
Later in Life. Environmental Health Perspectives, 117, 879-885. 
 
To investigate wheteh in utero exposure to BPA causes adverse effect in female reproductive tracts, 
pregnant CD-1 mice were doses on GD9-16 with 5 dose levels of BPA by daily subcutabeous injection 
(0.1, 1, 10, 100, 1,000 µg/kg bw per day [HED: dams 0.0068, 0.068, 0.68, 6.8, 68 µg/kg bw per day]). 
Corn oil vehicle and corn oil vehicle control, but no positive control, were used. All pups were pooled 
and cross-fostered (4 male, 4 females pups/litter) and at weaning (PND21) the offspring were housed 
in same-sex groups of 4. At 16-18 months of age the mice were further investigated by necroscopy, 
the entire reproductive trascts being fixed and evaluated by light microscopy using at least 5-9 serial 
images for evaluation of each mouse. If required lesions were stained with Trichrome staining. While 
16 offspring/group were used for each exposure, not all could be followed up. BPA had no significant 
effect on litter size and did not affect the frequency of aimals without corpora lutea. Cystic ovaries 
were seen in all groups, approaching significance at the HED of 0.068 µg/kg bw per day (p=0.05). 
Reproted uterine abnormalities were not seen more frequently in BPA-exposed mice. In terms of 
preneoplastic and neoplastic lesions, most BPA dose levels had no statistically significant effects. The 
HED dose of 0.0068 µg/kg bw per day was associated with a slightly higher incidence of reproductive 
tract lesions, while the 0.0068 and 0.068 µg/kg bw per day BPA HED doses increased the total 
number of lesions, which included mesonephric remnants, from 0/16 in control to 5/14 and 4/13 
respectively. The authors conclude tht BPA exposure during critical windows of differentiation may 
have long-term effects on reproductive tract development and disease. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size (13-16) 
Weaknesses:  
- Use of polycarbonate water bottles and polysulphone cages 
- Study design (small number of litters :n=5/group) 
- Inappropriate statistics (p value not adjusted to multiple testing) 
 
The CEF Panel noted that the adverse effects reported were more or less inversely related to dose of 
BPA and while some significant effects of BPA on morphological and./or eoplastic abnormalities were 
reported, the fact that they were only significant at the lowest 2 BPA dose levels only raises questions 
about the role of chance. In addition, the authors compared their findings with DES but failed to 
include a DES positive control in their study. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Otsuka H, Sugimoto M, Ikeda S, Kume S, 2012. Effects of bisphenol A administration to 
pregnant mice on serum Ca and intestinal Ca absorption. Animal Science Journal, 83, 232-237.  
 
This study examined the effects of BPA administration on serum calcium and calcium metabolism of 
the gut and kidney in mice. BPA (2 mg or 20 mg/kg bw per day [HED: Dams = 0.06, 0.6 mg/kg bw 
per day]) was administered by gavage in olive oil to pregnant mice (n= 7) from gestational day 6.5 to 
gestational day 16.5. Controls (n=4 or 5) received vehicle alone or were untreated. On gestational day 
17.5 animals were sacrificed, and determinations were made of serum calcium, alkaline phosphatase 
(ALP) activity in the duodenum and jejunum and vitamin D receptor (VDR) protein expression in the 
duodenum, jejunum and kidney (using enzyme histochemical and immunohistochemical analyses, 
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respectively. Expression of mRNA for VDR, calcium binding protein (CaBP-9k), ECaC2, c-fos, 
VEGF, occludin, junction adherence molecular A (JAM-A) and ALP were examined in specific 
regions of the small intestine and expression of mRNA for CYP27B1 was examined in the kidney, 
using semi-quantitative RT-PCR. Serum calcium was significantly decreased in the mice that had 
received 20 mg BPA/kg bw per day, and slightly but not significantly reduced in the mice receiving 2 
mg/kg bw per day. BPA had no effect on ALP activity and VDR expression in the duodenum and 
jejunum, while expression of mRNA for occludin and JAM-A in the duodenum and ileum and CaBP-
9k and active vitamin D synthesis enzyme (CYP27B1) in the kidney were increased in mice treated 
with 20 mg BPA. No effect of 2 mg BPA/kg bw per day was reported on these various markers of 
calcium metabolism. The authors concluded that administration of 20 mg BPA/kg bw per day during 
gestation results in a decrease in serum calcium, which the authors suggest may be partly due to 
decreased paracellular Ca absorption.  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Oral administration via gavage 
Weaknesses:  
- Type of cages and drinking bottles not reported 
- Animal diet and phytoestrogen content not reported Small sample size ( n=4-7 per treatment 
group) 
- Insufficient study reporting (qPCR – no information on whether the HKG (ACTB) had been 
properly selected) 
- Statistical analysis ( no indication that normality of distribution was checked prior to using 
parametric tests) 
This study did not include a positive control. Changes in serum calcium and markers of calcium 
metabolism were only seen at 20 mg BPA/kg/day (well above 3.6 mg/kg bw per day HED), and were 
of small magnitude.  
 
This study is not included in the WoE table because it is not relevant to any review question. 
 
Pelch KE, Carleton SM, Phillips CL and Nagel SC, 2012. Developmental exposure to 
xenoestrogens at low doses alters femur length and tensile strength in adult mice. Biology of 
Reproduction, 86, 69. 
 
The aim of this study was to examine the effect of developmental exposure to low doses of 
diethylstilboestrol (DES), BPA or ethinyl oestradiol (EE2) on bone geometry and torsional strength. 
C57BL/6 mice were given 0.1 μg/kg/day diethylstilboestrol, 10 μg/kg/day BPA [HED: Dams = 150 
µg/kg bw per day], 0.01, 0.1, or 1.0 μg/kg/day ethinyl oestradiol or vehicle from gestation day 11 to 
post-natal day 12 via a mini-osmotic pump in the dam. Femoral geometry and strength were assessed 
in the offspring at 10 and 13 weeks of age (females) or 23 weeks (males) by μCT scan and torsional 
strength analysis, respectively. Hydroxyproline was also measured, as an indicator of collagen content. 
Exposure to DES, BPA or low dose EE2 increased adult femur length by small increments 
(approximately 2.5%). Exposure to the highest dose of EE2 did not alter femur length, which the 
authors considered provided evidence of a non-monotonic dose-response. Exposure to EE2 and DES, 
but not BPA, decreased femur tensile strength, while no changes were seen in bone collagen content. 
The authors concluded that developmental exposure to environmentally-relevant levels of 
xenoestrogens may negatively impact bone length and strength in adulthood. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Adequate positive controls included Use of non-PC cages and of non plastic water bottles 
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Weaknesses: 
- Animal age and body weight not reported  
- Single dose level study 
- Animal diet phytoestrogen content not reported  
 
Overall the CEF Panel noted that only a single dose of BPA was examined, and the mode of 
administration was subcutaneous infusion by mini-pump, not supported by any evidence of actual 
exposure. The magnitude of effects on femur length was small and the claim of a NMDR for EE2 is 
very tenuous. The study involved a non-standard analysis of bone in a model of uncertain relevance 
for humans. Only a single dose of BPA was examined, and the magnitude of effects on femur was 
small: 2.5% decrease in adult femur length (males) and decrease in energy to failure (males and 
females) with no concomittant effect on tensile strength or collagen content.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Qiu LL, Wang X, Zhang XH, Zhang Z, Gu J, Liu L, Wang Y, Wang X and Wang SL, 2013. 
Decreased androgen receptor expression may contribute to spermatogenesis failure in rats 
exposed to low concentration of bisphenol A. Toxicology Letters, 219, 116-124.  
 
Adult male Sprague-Dawley rats (8 weeks) were administered three dose levels of BPA dissolved in 
ethanol and then cor noil at 0.0005, 0.5, 5 mg/kg bw per day [HED: Adult males = 0.00036, 0.36, 3.6 
mg/kg bw per day] for 8 weeks by oral gavage] for 8 weeks by oral gavage. There were 14 rats/group 
and the control gropup received the same weight-normalised volume of cornoil as the BPA groups. At 
harvesting cardiac blood and testes (and other organs) were collected and used to determine circulating 
and intra-testicular testosterone and sperm analysis using CASA. Testicular histology and 
steroidogenic and spermatogenic transcripts and proteins were analysed. BPA did not affect organ or 
body weights, serum biochemistry or hepatonephric function. While circulating testosterone was 
unaffected, BPA reduced intratesticular testosterone at 5 mg/kg bw per day. This dose also reduced 
sperm numbers although sperm motility was unaffected. This dose also reduced seminiferous tubule 
epithelian height, numbers of round spermatids and the ratio of round spermatids/Sertoli cells. Of the 
spermatogenesis-related genes and proteins, TNP1 and ODF were reduced by BPA at 5 mg/kg bw per 
day, and also at 0.5 mg in the case of TNP1. Of the steroidogenic genes and proteins StAR and 
CYP11A1 were increased at 5 mg/kg bw per day dose while HSD17B, HSD3B and CYP19A1 were 
decreased at 0.5 and 5 mg BPA/kg bw per day. Androgen receptor transcript and protein (but not 
SHBG) were reduced at 0.5 and 5 mg BPA/kg bw per day. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Number of doses (≥3) 
- Oral administration via gavage 
Weaknesses: 
- Animal diet poorly described  
- Study design not appropriate to the scope (corn oil to control rats rather than the vehicle, i.e. 
ethanol further diluted in corn oil) 
- Inappropriate statistics (basic analysis only)  
 
Overall the CEF Panel noted that control rats appeared to receive corn oil only rather than ethanol 
further diluted in corn oil as was the case for the BPA-exposed groups. Statistical analysis was a little 
basic with no mention of data normality etc. Otherwise the study was well performed with group sizes. 
Functional effects were only seen at 5 mg BPA/kg bw per day, with some additional transcript/protein 
effects at 0.5 and 5 mg BPA/kg bw per day. The results do not suggest the occurrence of BPA effects 
below 3.6 mg/kg bw per day HED.  
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This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Rubin BS, Murray MK, Damassa DA, King JC and Soto AM, 2001. Perinatal exposure to low 
doses of bisphenol A affects body weight, patterns of oestrous cyclicity, and plasma LH levels. 
Environmental Health Perspectives, 109, 675-680. 
The study has already been evaluated in the EFSA opinion of 2006 (EFSA, 2006) and included in the 
WoE table as a starting point. 
Rubin et al. (2001) measured the effect of BPA on the offspring (n=12 -34) of Sprague-Dawley female 
rats (n=6) exposed to BPA in drinking water at concentrations of 1 mg/l and 10 mg/l (approximately 
100, 1,200 µg BPA/kg bw per day [HED: dams 72, 864 µg/kg bw per day]) from day GD 6 throughout 
lactation. Water consumption was controlled by measuring the amount of water in the bottles each 
day, and based on the water consumption the exposure was estimated to be approximately 100, 1,200 
µg BPA/kg bw per day. Offsrping were periodically assessed: Males neonatally, 3 and 5 months 
(n=12-18), Females neonatally and 8 and 12-16 months. Body weights (both sexes were tracked and in 
females, vaginal opening, AGD, vaghinal cytology and circulating LH were assessed. A statistically 
significant increased body weight of the offspring from PND 4-11 was observed in both sexes. From 
day 22 and onwards, only females showed an increased body weight, the effect being greater in the 
HED 72 µg/kg bw per day group than in the HED 864 µg/kg bw per day group. Patterns of ooestrous 
cyclicity were determined (n=18-28) by daily examination of vaginal cytology at 4 and 6 months of 
age. A statistically significant and dose-dependent reduction in the percentage of animals with regular 
cycles and in the mean number of regular 4 or 5-day ooestrous cycles per animal was found at the 
highest BPA exposure level. There were no significant effects of BPA on litter size, sex ratios, day of 
vaginal opening, AGD or macroscopic abnormalities of genital tractsAt the higher BPA dose 
circulating LH was reduced significantly in long-term ovariectomised females although the biological 
significance of this is uncertain. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Use of glass water bottles  
- Cages and bedding content of oestrogens negligible at E-screen  
Weaknesses:  
- Animal diet and phytoestrogen content poorly described. 
- Study design (small number of litters (n=6))  
- Litter effect not taken into account 
- Drinking water consumption (containing BPA) not measured 
- Insufficient study reproting 
 
The CEF Panel noted that it was likely that there was underestimation of exposure due to an assumed 
low level of water consumption. 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Rubin BS, Lenkowski JR, Schaeberle CM, Vandenberg LN, Ronsheim PM and Soto AM, 2006. 
Evidence of altered brain sexual differentiation in mice exposed perinatally to low, 
environmentally relevant levels of Bisphenol A. Endocrinology, 147, 3681-3691. 
The study has already been evaluated in the EFSA opinion of 2006 (EFSA, 2006) and included in the 
WoE table as a starting point. 
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CD-1 mice were treated on GD8 via osmotic minipumps delivering 50% dimethylsufoxide as vehicle 
control or BPA at doses of 25, 250 ng BPA/kg bw per day [HED dams: 375, 3,750 ng BPA/kg bw per 
day] until PND16. Litters were culled to 4 male and 4 female pups/dam and weaned on PND22-24. 
Pups used for anatomical and behavioural endpoints were processed before PND22-24 and 27-29 
(before puberty) respectively while those used for behavioural studies were also initially examined at 
6-9 weeks postnatally. Tyrosine hydroxylase positive neurons in the rostral periventricular preoptic 
area (AVPV) important for controlling ooestrous cyclicity were counted. Behavioural studies were 
performed. 
 
BPA had no significant effect on pus/litter or sex ratio. The number of sections through the AVPV was 
significantly higher in control female than control male brains but not in the BPA exposed groups 
although the number of sections was significantly reduced in BPA_treated females at the highest dose. 
Similarly, the number of tyrosine hydroxylase positive neurons were significantly different between 
male and female offspring in the control and lowest BPA dose groups and significantly reduced at the 
highest BPA dose in females. Behavioural studies revealed reported that male offspring behaved more 
like female offspring. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Use of glass water bottles, diet tested negative at E-screen  
- Cages and bedding content of oestrogens negligible at E-screen 
- Good sample size (10-17 offspring/group) used for behavioural studies 
Weaknesses:  
- Study design (sometimes small number of offspring (n=4-8/sex/group) for morphological 
analyses)  
- Litter effect not taken into account 
- Insufficient study reporting (not clear how many dams were used per group) 
 
The CEF Panel noted that the higher dose of BPA in particular was associated with a reduction in the 
sexual dimorphism in tyrosine hydroxylase positive neurons of the AVPV, with the changes in neuron 
numbers being observed in the female offspring. Both BPA doses were ≤HED 3.6 mg/bk bw per day. 
While behavioural effects were reported HED ≤3.6 mg BPA/kg bw per day, this was already 
considered as a starting for neurotoxicity in the EFSA 2006 opinion. 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Ryan BC, Hotchkiss AK, Crofton KM and Gray LE, 2010. In Utero and Lactational Exposure to 
Bisphenol A, In Contrast to Ethinyl Estradiol, Does Not Alter Sexually Dimorphic Behavior, 
Puberty, Fertility, and Anatomy of Female LE Rats. Toxicological Sciences, 114, 133-148. 
 
In a well-doncducted study of BPA reprotoxicology, Long Evans rats were dosed with BPA at 2, 20, 
200 µg/kg bw per day [HED: 1.44, 14.4, 144 µg/kg/day] by oral gavage from GD7 to PND18 Two 
arms – main study 13-29 dams/ group (0.05, 0.5, 5, 50 µg/kg bw per day) second extended EE group 
(0.05, 0.15, 0.5, 1.5, 5, 15, 50 µg/kg bw per day) study 6-14 dams/group, with the same BPA regime 
for both arms. At PND5 litters were trimmed to n=8 pups max, as far as possible balanced for pup sex 
(4 male, 4 female). 9-38 litters were used per group and the liutter effect was accounted for. Dams and 
female offspring were studied, the males from the same experiment having been reported by 
Howdeshell et al (2008). Maternal and pup body weights and neonatal AGD were tracked, the timing 
of vaginal opening and external genitalia and nipples were assessed. A forced/continuous breeding 
study with a subset of females for at lkeast 4 months (fecundity) was performed, as were some 
behavioural studies. BPA had no significant effect on AGD, birth or weaning weights, age or weight at 
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vaginal opening, lordosis quotient, esternal genitalia, number of pups or fertility/fecundity rates and 
also had no effects on sex-specific behaviour. The positive control had the expected, dose-dependent 
effects on the parameters measured. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- ≥3 dose levels of BPA 
- Oral administration via gavage 
- Large sample size (9-38 litters/group) 
- Adequate positive control included (EE2) 
Weaknesses:  
- Use of polycarbonate cages  
- Animal diet and phytoestrogen content poorly descriped (Purina Rat Chow 5008 has high 
isoflavone content) 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Salian S, Doshi T and Vanage G, 2009. Perinatal exposure of rats to bisphenol A affects the 
fertility of male offspring. Life Sciences 85, 742-752. 
 
The study has already been evaluated in the EFSA opinion of 2010 (EFSA CEF Panel, 2010) and 
included in the WoE table as a starting point. 
Salian et al. (2009) performed a 3 generation-study assessing the effects of very low oral doses of BPA 
on the fertility of male Holtzman rats. Eight pregnant rats per group were gavaged with BPA (1.2 or 
2.4 μg/kg bw per day), a vehicle control or diethylstilbestrol (DES; 10 μg/kg bw per day) from GD 12 
to PND 21. Litters were culled to 4/5 male offspring, weaned on PND 22, cohabited (n=24) on PND 
75 with unexposed adult females (n=48) to obtain F2 male generation; by the same procedure, F3 male 
generation was derived. Fertility was assessed in adult F1-3 males by mating them with unexposed 
females (not forced/continuous breeding). Immunohistochemical localization of steroid receptors was 
carried out in the testes of F1, F2 and F3 adults. A significant increase in post implantation loss in the 
F3 offspring (highest BPA dose) and a decrease in litter size in F1-3 offspring at both BPA 
concentrations was observed, but a dose-response relationship was only evident for the decrease in 
litter size. Sperm count and motility were significantly reduced in the F1, F2 and F3 male offspring, 
with a dose related reduction in sperm count. A reduction in testicular expression profiles of steroid 
receptors was also observed. Data on vehicle alone (sesame oil) vs vehicle plus alcohol diluent is not 
shown but stated as not different. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Oral administration via gavage 
- Adequate positive control included (DES) 
Weaknesses:  
- Type of cages not reported  
- Insufficient study reporting (the nature of the diet is unclear: prepared “in house” although 
stated as soy-free).  
- Study design (tsmall  numbers of mated F0 dams per group (n = 8),  
- Litter effect not taken into account   
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The CEF Panel noted that this study had several shortcomings. The effects on tissue weights were lost 
when normalised for body weight, except for F3 seminal vesicle weights. The number of resorptions 
in the controls appears very low with none in the F1 matings and only one single fetus in one female in 
each of the F2 and F3 litters. Thus, the apparent effect of BPA pre and post implantation embryo loss 
may be partly due to atypically low resorption rates in the controls. The CEF Panel found the 
generation persistence of the reported effects of BPA and DES on F1 males into F2 and F3 mle 
reproductive system striking and surprising, with some effects becoming more sever with each 
generation. The explanationis not obvious and this adds to the uncertainty about the effects reported. 
This uncertainty is exacerbated by the retraction of one of the studies cited in Salian et al. 
(Transgenerational epigenetic imprinting of the male germline by endocrine disruptor exposure during 
gonadal sex determination. Chang HS, Anway MD, Rekow SS, Skinner MK. Endocrinology. 2006 
Dec;147(12):5524-41 retracted by the authors (Retraction. Transgenerational epigenetic imprinting of 
the male germline by endocrine disruptor exposure during gonadal sex determination. [No authors 
listed] Endocrinology. 2009 Jun;150(6):2976), which reduces the supporting literature. 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Signorile PG, Spugnini EP, Mita L, Mellone P, D'Avino A, Bianco M, Diano N, Caputo L, Rea F, 
Viceconte R, Portaccio M, Viggiano E, Citro G, Pierantoni R, Sica V, Vincenzi B, Mita DG, 
Baldi F and Baldi A, 2010. Pre-natal exposure of mice to bisphenol A elicits an endometriosis-
like phenotype in female offspring. General and Comparative Endocrinology, 168, 318-325.  
 
In order to investigate whether BPA exposure might be associated with ediometriosis in women, the 
authors conducted a study in mice. Adult BALB-C female mice were mated and injected 
subcutaneously with BPA (in 2% ethanol +saline) from GD1-PND7. The BPA doses were 100, 1,000 
µg/kg bw per day [HED: dams, 1,500, 15,000 µg/kg bw per day]. There was no positive control. All 
pups/treatment were pooled and 5 amle and 5 female pups cross-fostered to each dam. After weaning 
at PND21, the pups were housed in same-sex cages without further treatment and the females were 
sacrified at 3 months (n=20/group). The pelvic organs were fixed and studied using light microscopy 
and immunohistochemistry for ESR1 (estrogen receptor alpha) and HOXA-10. Controls for staining 
were inadequate since they involved simply omitting the primary antibodies. BPA was measured in 
maternal livers by HLPC-GC-MS.  There were no macroscopic defects at either dose of BPA and 
although all groups contained animals with cystic ovaries, the incidence was significantly higher in the 
BPA-exposed animals (9-10/20 vs 2/20), even though there was no effect on the number of corpora 
lutea. The authors report the lowest dose of BPA increases endometrial adenomatous hyperplasia from 
2/10 to 5/20 and atypical endometrial hyperplasia from 0/20 to 3/20, but neither was statistically 
significant. In terms of the “endometriosis-like structures BPAtreatment was associated ith a 
statistically significant increase from 1/20 to 6/20 and 7/20 animals, Although BPA was not detected 
in the control offspring livers, in female offspring in the BPA groups were 0.26±0.06 and 0.24±0.06 
ng BPA/g of tissue, significantly lower that maternal BPA levels in the two groups (0.74±0.13 and 
1.64±0.53 ng BPA/g of tissue). 
 
Comments from the CEF Panel: 
BPA doses and BPA exposure levels in the animals are not internally consistent 
 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Feed content of oestrogens negligible at E-screen  
- Cages/bedding tested by E-screen and of non plastic water bottles used 
- Large sample size(n=20 offspring) 
Weakness:  
- Study design (small number of litters (n=6 litters) 
- Study design not appropriate to the scope (see text below) 
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- Lack of mechanistic plausibility (10 fold difference between BPA doses administered but no 
difference in reported internal BPA levels) 
 
The CEF Panel notes that mice do not get endocmetriosis under natural conditions and the authors did 
not investigate whether BPA enhanced the establishment of human endometrial tissue as a model of 
endometriosis, rather they examined so-called “endometriosis-like” symptoms. In addition, the 
histology shown in the publication and immunohistochemistry was of a poor standard. The 
“endometriosis-like structures might have been endometrial glandular tissue outside the uterus but 
could equally well be embryonic remnants. The data and images presented by the authors do not 
enable a conclusive categorisation to be made. Furthermore, the authors used an unreliable method 
(HPLC with UV-Vis and fluorescence detection), did not report on the quality of the method, the level 
of detection, or the level of quatification. No mention is made with respect to the reproducibility and 
precision of the method. 
 
The last administration of BPA to the mothers was on day 7 after delivery. The mothers were sacrified 
2 weeks later (= 336 hours later). Hence, given the half-life of some hours, it is implausible that BPA 
can be detected after more than 80 half-lifes in the mothers. Similarly, the pups were sacrified at 
month 3 which is 1848 hours after the last dose. It is implausible that BPA would still be present after 
such long time periods with respect to the half-life of BPA. Furthermore, it is to be noted that the 
measured concentrations in the two exposed groups are similar despite the fact that the doses differed 
by a factor of ten. 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Signorile PG, Spugnini EP, Citro G, Viceconte R, Vincenzi B, Baldi F and Baldi A, 2012. 
Endocrine disruptors in utero cause ovarian damages linked to endometriosis. Frontiers in 
Bioscience (Elite Edition), 4, 1724-1730.  
 
This is part of a previously reported study in which pregnant Balb-c mice were treated from day 1 of 
gestation to 7 days after delivery with BPA at 100, or 1 000 μg/kg/day subcutaneously [HED: Dams = 
1,500, 15,000 µg/kg bw per day].7 The vehicle was 2% ethanol in physiological saline. This study 
reported that the ovaries of BPA-treated mice the number of primordial and developing follicles was 
lower than in the untreated animals and the number of atretic follicles was higher in the treated 
animals. This was reported to correlate with animals displaying endometriosis-like phenotype 
previously reported. At the doses of BPA used, the authors concluded that there was a “dose-
dependent” effects on primordial and growing follicle numbers (decreased) and numbers of atreitic 
follicles (increased), indicating the BPA can negatively disturb ovarian follicle characteristics. 
  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths:  
- Feed content of oestrogens negligible at E-screen  
- Cages/bedding tested by E-screen and of non plastic water bottles used 
- Large sample size(n=20 offspring) 
Weaknesses:  
- Study design (small number of litters (n=6 litters) 
- Study design not fit for purpose (see text below) 
- Lack of mechanistic plausibility (10 fold difference between BPA doses administered but no 
difference in reported internal BPA levels) 
 
Overall, the CEF Panel notes that the study was inadequately reported, was not open to unambigious 
reporting and the data were not convincingly presented. Confidence in the findings is therefore low. 
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Review of the images in the previous study clearly shows that the glandular changes reported in the 
fatty tissue near the uterus do not represent endometriosis but merely glandular embryonic rests. It 
should be underlined that endometriosis does not occur naturally in rodents. The other group 
differences reported in the uterus and ovaries appear to be within the normal range of changes that can 
be seen in normal laboratory mice of 3 months of age. There was an attempt to stratify BPA effects of 
ovarian morphology according to evidence of endometriosis-like phenotype, but this is presented in an 
opaque manner and is not convincing. This study is included in the WoE table because of its relevance 
to one or more review questions addressed there. 
 
Tan WJ, Huang H, Wang YF, Wong TY, Wang CC and Leung LK, 2013. Bisphenol A 
differentially activates protein kinase C isoforms in murine placental tissue. Toxicology and 
Applied Pharmacology, 269, 163-168. 
 
Six to 8 week old adult female ICR mice were administered 3 dose levels of BPA: 2, 20, 200 mg/kg 
bw per day [HED: Dams = 0.06, 0.6, 6.0 mg/kg bw per day] in ethanol/corn oil. A vehicle control was 
included. Pregnant mice were treated by daily oral gavage from E13 – E16. Blood samples and tissues 
were harvested at E17. Placentae were analysed for corticotrophin-releasing hormone (CRH), PKC 
and CREB transcript/protein and plasma for oestradiol, testosterone and CRH. Between 3 and 5 mice 
were used for each measurement although the study started with 6-7 mice/group because of premature 
deliveries, although this was only statistically significant when the all data from the different BPA 
doses were pooled. Mice exposed to 20 and 200 mg/kg bw per day had significantly elevated E2, 
testosteron and CRH although only ther highest dose was associated with increased placental crh 
transcript and cyp198a1 was not affected. Placental CREB protein was increased in all BPA groups as 
was the PKC zeta/gamma ratio while PKC delta was only affected at the highest dose. The authors 
conclude that BPA exposure in pregnant mice might increase premature births by disturbing the 
endocrine and PKC signalling pathways in the placenta. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
Number of doses (≥3)  
- Oral administration via gavage 
Weaknesses 
- Animal diet poorly described  
- Small sample size (small group size (3-5) for most measures other than pregnancy loss)  
- Animal diet and phytoestrogen content not reported 
 
Overall the CEF Panel considers this study as underpowered and preliminary although some of the 
findings were potentially of interest. In particular, it is noted that the assessment of early pregnancy 
loss used a good number of animals (>15 mice/dose). On the other side, it is also noted that early 
delivery was assessed in different group to signalling indices and that effect on early delivery was only 
significant when analysing all BPA groups and including group >3.6 mg/kg bw per day. As such, 
these findings need to be reproduced in a much better powered study.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Tinwell H, Haseman J, Lefevre PA, Wallis N and Ashby J, 2002. Normal sexual development of 
two strains of rat exposed in utero to low doses of bisphenol A. Toxicological Sciences, 68, 339-
348. 
 
In a study investigating the effects of BPA exposure in-utero on reproductive development, two strains 
of rat (Sprague-Dawlery and Alderly Park) were exposed by oral gavage to BPA at 20, 100, 50,000 
µg/kg bw per day [HED: dams 14.4, 72, 36,000 µg/kg/day]. Exposure was to pregnant females 
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(n=7/group) from GD6-21. BPA dosing stability and concentration were confirmed by HPLC-MS. On 
PND5 litters were culled to 5 males and 5 females as far as possible, but with litter size limited to 8. 
Sample size (6-7 litters/21-33 individuals/group was good. Maternal and then post weaning diets 
contained 18.5 and 6.5% soya respectively. Vehicle and vehicle control was arachis oil and ethinyl 
oestradiol at 200 µg/kg bw per day was used as the positive control. Pup body weights and timing of 
puberty were monitored and the offspring were assessed by necroscopy at PND90 (males) and 98 
(females). Livers and reproductive ract organs were assessed and the vagina and uteru or testis and 
epididymis were examined histologically. BPA had no significant effect on litter size or sex ratio, 
body weights, AGD in either sex. In feamles BPA had no significant effect on, age (except for highest 
dose in AP females) or body weight at vaginal opening or age at first estrus or any organ weights. In 
males thre was no significant effect of BPA on age or body weight at preputial separation, or any 
organ weights or on histology of the testis or on sperm production (except for the highest BPA dose in 
Ap males). However, the ethinyl oestradiol positive control proved toxic with 2 dams terminated early 
due to severe vaginal bleeding and 2 more at parturition because of liuttering difficulties. The number 
of pups/litters available for assessment were therefore not adequate. Only a few of the expected effects 
were therefore statistically significant, introducing a flaw into an otherwise very well conducted study. 
 
Comments from the CEF Panel: 
Positive control was flawed – toxic 
 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Oral administration via gavage 
- ≤3 BPA dose levels 
- Large sample size (6-7 litters/21-33 individuals/group) 
Weaknesses:  
- Use of polycarbonate cages (PC) 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Tiwari D and Vanage G, 2013. Mutagenic effect of bisphenol A on adult rat male germ cells and 
their fertility. Reproductive Toxicology, 40, 60-68. 
Adult Holtzman male rats were divided into groups of 7 and administered 2 dose levels of BPA (10 
µg/kg bw per day and 5 mg/kg bw per day) [HED: Adults = 7.2, 3 600 (3.6 mg) µg/kg bw per day]) 
orally once per day for 6 days. Controls received the sesame oil vehicle. The males were then 
repeatedly mated (8 times) up to 56 days post-treatment. Mating implantation and lethal mutation rates 
(determined as a ratio of implants: live implants), sperm production, motility, morphology and 
apoptosis were determined. The 5 mg/kg bw per day dose reduced implantation/ebryo survival indices 
during a single (22-28 days) post treatment interval only and there were not effects on mating or 
gestation indices. The same dose at the same interval increased post-implantation loss but had not 
statistical effects, as far as could be determined, on the “dominant lethal mutation). Despite the lack of 
effect of tested fertility, both BPA doses were associated with reduced sperm production, count and 
motliltiy although the latter only achieved significance at the higher dose. Only the higher dose caused 
DNA damage to the sperm. The authors conclude that BPA might be a weak germ cell mutagen. 
 
Comments from the CEF Panel 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Phytoestrogen-free diet (e.g. soy-free diet) 
Weaknesses: 
- Study design not appropriate to the scope (e.g. limited number of animals, absence of negative 
and positive controls, only two dose levels employed and lack of rationale for dose selection) 
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Overall, the the CEF Panel noted that the precise nature of the oral route was not specified. Statistical 
analysis was well performed. There is no effect, especially at the lower dose on actual breeding 
success, which is really the key measure. There are subtle effects on sperm and the lethality measure is 
interesting although not statistically examined. Likely limited implications for human exposure at the 
human age equivalent of 8 weeks post-natal in the rat (late teens). The BPA dose having an effect was 
at 3.6 mg/kg bw per day HED. The results were potentially biased by high background/variability for 
rodent sperm in the alkaline assay. 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Toyama Y and Yuasa S, 2004. Effects of neonatal administration of 17 beta-estradiol, beta-
estradiol 3-benzoate, or bisphenol A on mouse and rat spermatogenesis. Reproductive 
Toxicology, 19, 181-188.  
Neonatal male Wistar rats and ICR mice were injected subcutaneously with BPA at species dependent 
doses ranging between 0.1-10 µg/mouse/injection and 1-600 µg/rat/injection on PND1, 3, 5, 7, 9, 11. 
To determine the relative dosage and calculate the HED, the CEF Panel calculated the doses relatiove 
to body weight and determine and average dose across these 11 days. Therefore, BPA dosage was as 
follows: Mice: 0.014, 0.140, 0.700, 1.401 mg/kg bw per day, Rats: 0.046, 0.461, 4.611, 27.666 µg/kg 
bw per day [HED: Mice: neonates 0.348, 3.48, 6.09, 12.19 mg/kg bw per day; Rats: neonates 14,26, 
142.9, 1,429, 8,577]. Positive controls were oestradiol and oestradiol benzoate and there was a solvent 
(DMSO) vehicle (olive oil) group as controls. Terminal necroscopy was performed every 2 weeks 
from 2-10 weeks and PND 24 and 31 with a single fertility (n=11-12) test at 12 weeks for mice and 15 
weeks for rats (not a forced/continuous reeding test). The testes were weighed (also seminal vesicles 
and body weight) and processed for transmission electron microscopy while the cauda epididymides 
were processed for scanning electron microscopy. These tissues were also examined using light 
microscopy. The highest BPA dose was fatal to rats and excluded. Note that all rat BPA doses were 
higher than the 3.6 mg/kg bw per day HED cut-off dose and therefore the findings ≤3.6 BPA mg/kg 
bw per day are limited to the mouse in the following summary. BPA at the lowest dose had no 
significant effect on any measure. BPA at 3.48 mg/kg bw per day, approaching the cut-off of 3.6 
mg/kg bw per day HED had no significant effects on body, testis or seminal vesicle weights and 
testicular abnormalities appeared at PND21. Multinucleated giant cells and exfoliation of step 8 
spermatids were observed with some mature spermatids being deformed, but not at 3.48 mg/kg bw per 
day. The effects were no longer seen in adulthood and BPA had no significant effect on litter size, pup 
birthweights, gestation length or pup sex ratio, demonstrating that the modest effects on the sperm did 
not impair fertility. Findings for the positive controls were reported as similar as for BPA. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- ≥3 BPA dose levels 
- Adequate positive controls included (oestradiol & oestradiol benzoate) 
Weaknesses:  
- Small sample size ( (n=5), especially for the controls (n=3-4)  
- Inappropriate statistics (litter effect not considered and statistical analysis not described) 
- Type of cages and drinking bottles not reported  
- Animal diet poorly described and insufficient study reporting  
 
The CEF Panel notes that the 3.48 mg BPA/kg bw per day dose in mice had some mild adverse effects 
on gross sperm phenotype but not on electron microscopy identified defects seen with the positive 
controls and the BPA dopses >3.6 mg/kg bw per day. 
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This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Veiga-Lopez A, Luense LJ, Christenson LK and Padmanabhan V, 2013. Developmental 
programming: Gestational bisphenol-A treatment alters trajectory of fetal ovarian gene 
expression. Endocrinology, 154, 1873-1884.  
 
Adult Suffolk ewes were treated by sc injections with a single dose level of BPA: 0.5 mg BPA/kg bw 
per day [HED: dams assumed to be 0.5 mg/kg bw per day in the absence of relevant data] from GD 30 
to 90 (of 147) and controls received corn oil alone. BPA levels in arterial umbilical blood samples 
were monitored at GD 90. Ovaries from 4-5 fetuses/group were obtained at GD 65 and 90. Fetal blood 
BPA was measured using HPLC-ESI-MS/MS using quality assurance methods of BPA blanks and 
13C12-BPA spiking and recovery coirrected by isotopic dilution. RNA recovered from the fetal 
ovaries was analysed for steroidogenic, hormone receptor and ovarian developmental transcript 
expression and screened via 2 human miRNA Panels (Exiqon, n=3 ovaries/group). Free BPA 
increased from 0.4 ng/ml in controls to 2.6 ng/ml in BPA exposed fetuses. CYP19A1 and SRD5A1 
were reduced at 65 but not 90 GD in BPA exposed ovaries but had no effect on the pattern of 
transcript changes between GD 65 and GD 90. BPA exposure downregulated 45 miRNA at GD65 but 
only 11 at GD 90. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- BPA measurement in serum  
Weaknesses: 
- Single dose level study  
- Diet phytoestrogen content not reported  
 
Overall, the CEF Panel notes that this was a well-performed study by a very well known group in the 
field of sheep developmental endocrinology. The consequences of the changes are not obvious and the 
recovery of the two altered transcripts renders the significance of the effect at GD65 uncertain, 
especially since far fewer changes were seen at GD90. Similarly, it is not known whether the miRNA 
changes would have developmental or post-natal consequences. The lack of any morphological data, 
e.g. germ cell numbers, markedly limits the relevance of these findings.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Xiao S, Diao H, Smith MA, Song X, Ye X, 2011. Preimplantation exposure to bisphenol A (BPA) 
affects embryo transport, preimplantation embryo development, and uterine receptivity in mice. 
Reproductive Toxicology, 32, 434-441.  
 
This study examined the effect of BPA on embryo implantation in the mouse. Pregnant C57BL6 
female mice received daily subcutaneous injections of BPA in sesame oil to provide doses of 0, 0.025, 
0.5, 10, 40, and 100 mg/kg bw per day [HED: Dams = 0.375, 7.5, 150, 600, 1 500 mg/kg bw per day], 
from gestation days 0.5–3.5. Additionally, the presence and location of progesterone receptor (PR) 
was determined in the 4.5 gestation day uterus using immunohistochemistry. No implantation sites 
were detected in females receiving 100 mg BPA/kg bw per day on gestation day 4.5, retention of 
embryos in the oviduct and delayed embryo development were observed on day 3.5. Similarly, no 
implantation sites were detected on day 4.5 when untreated healthy embryos were transferred to 
pseudopregnant females treated with 100 mg BPA/kg bw per day. Implantation was delayed in mice 
treated with 40 mg BPA/kg bw per day. Consequential effects of the delayed implantation included 
significantly increased gestation periods, reduced litter size and reduced postnatal survival rate. 
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Altered presence and location of progesterone receptor (PR) was reported in mice treated with either 
100 or 40 mg BPA/kg bw per day Similar effects were not observed in the mice receiving 10 mg/kg 
bw per day or lower. The offspring females (8–12 weeks old) from the dams receiving 40 mg BPA/kg 
bw per day were also mated and examined for BPA-induced effects on reproductive parameters 
including embryo implantation; implantation and other parameters investigated were comparable in 
the offspring from BPA-treated dams was comparable to controls. The authors concluded that high 
doses of BPA adversely affect processes critical for embryo implantation, including embryo transport, 
preimplantation embryo development, and establishment of uterine receptivity. 
Comments from the CEF Panel 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Number of doses (≥3)  
- Adequate positive controls included 
- Use of non-PC cages 
Weaknesses: 
- Animal diet and phytoestrogen content not reported 
 
Overall the CEF Panel noted that this appears to be a relatively well conducted study by the 
subcutaneous route. Group size was variable (4-12 or higher). The 100 mg/kg/day dose was mostly 
lethal, with only the 40 mg/kg/day having effects of real potential interest. There were significant 
effects on implantation at dose levels of 40 mg BPA/kg bw per day and above, together with increased 
gestation periods, reduced litter size, reduced postnatal survival rate and continued expression of 
progesterone receptors (PGR) in the luminal epithelium of the uteri. However, no significant effects 
were observed in mice receiving ≤3.6 mg BPA/kg bw day HED. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Zhang HQ, Zhang XF, Zhang LJ, Chao HH, Pan B, Feng YM, Li L, Sun XF and Shen W, 2012a. 
Fetal exposure to bisphenol A affects the primordial follicle formation by inhibiting the meiotic 
progression of oocytes. Molecular Biology Reports, 39, 5651-5657. 
 
This study was designed to assess the effects of BPA on germ cell cyst breakdown and primordial 
follicle formation in CD1 mice. Pregnant mice were treated orally using Eppendorf pipettes with BPA 
in 0.1% DMSO at doses of 0, 0.02, 0.04, 0.08 mg/kg bw per day [HED: Dams = 0.6, 1.2, 1.8, 2.4 µg/kg 
bw per day] from 12.5-18.5 of pregnancy, Offspring ovaries were variously analysed at 13.5, 15.5, 17.5 
and 19.5 dpc and 3, 5, 7 pnd for meiosis progression, bisulphite sequencing, histology and 
immunohistochemistry for meiosis progression markers. It is not possible to determine the number of 
animals used. Dose-dependent effects of BPA were observed, with retention of oocytes in nests (cysts) 
and reduced primordial follicle numbers. However, numbers of oocytes were higher in the pnd 3 
ovaries, possibly linked with delayed meiosis progression and decreased levels of increasingly 
methylated Stra8. Progression to meiosis prophase I of oocytes was delayed in the 0.08 mg/kg/day 
treated group. 
 
Comments from the CEF Panel  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths:  
- Number of doses (≥3) 
Weaknesses: 
- Animal species and strain not reported  
- Animal age and body weight not reported 
- Animal diet and phytoestrogen content not reported 
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Overall, the CEF Panel notes that this represents a very complex immunohistochemical and 
morphometric evaluation of the tiny ovaries of neonatal mice where the only statistically significant 
differences reported were in the offspring of mice given 0.08 mg/kg/day. The study may suggest a 
potential mechanism by which BPA might reduce female fertility. However, for this study to be 
considered important to understand human ovarian developmental risks associated with BPA it will 
need to be repeated at a higher standard with issues such as samples size addressed.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Zhang GL, Zhang XF, Feng YM, Li L, Huynh E, Sun XF, Sun ZY and Shen W, 2013. Exposure 
to bisphenol A results in a decline in mouse spermatogenesis. Reprod Fertil Dev, 25, 847-859. 
 
This study investigated the effects of BPA administered subcutaneously to male CD-1 mice on 
testicular morphology, sperm quality and morphology and meiotic progression in the germ cells, 
together, sperm quality and DNA, together with effects on expression of oestrogen receptor alpha (ER-
alpha) and gene methylation in the testis. The study also investigated whether these effects on 
spermatogenesis were reflected in the offspring of BPA-treated mice mated with untreated females. 
CD-1 mice (n= 30 per group for histochemical examination of testicular morphology and also effects 
on the F1 generation) were administered 0, 20 or 40 µg/kg bw BPA in 0.1 % DMSO in saline from 
postnatal day (PND) 3 to PND 21 (3 weeks), PND 35 (5 weeks) or PND 49 (7 weeks). The authors 
report a range of effects on spermatogenesis including a significant increase in germ cells in the testis 
at 3 weeks in mice treated with 40 but not 20 µg/kg bw BPA/day, followed by a significant decrease at 
both 5 and 7 weeks in mice receiving 20 or 40 µg/kg bw per day BPA. The decrease in absolute 
number of germ cells was accompanied by a decrease in the population of germ cells entering meiosis 
and parallel changes were reported in differential germ cell types in the testis. BPA-related increases 
in the diameter of the convoluted seminiferous tubules were reported in mice at 3 weeks, followed by 
decreases at 5 and 7 weeks. Morphological abnormalities were seen in the sperm of the BPA-treated 
animals, together with decreased motility. Oestrogen receptor alpha expression was increased in the 
testis of BPA-treated mice, however, BPA had no effect on DNA methylation of genes such as Igf2, 
Igf2r, Peg3 and H19, in germ cells. Finally, exposure of male mice to 40 but not 20 µg/kg bw BPA 
followed by mating with untreated females resulted in a reduction in offspring body weight and size at 
PND 14, 21 and 35, together with a reported increased rate of dystocia and poor body condition. The 
authors conclude that BPA impairs spermatogenesis in the CD-1 mouse and affects the development 
of F1 offspring of these mice. 
 
Comments from the CEF Panel:  




- Insufficient study reporting (lack of experimental details) 
- Animal numbers/group and weights not given 
- Animal diet and phytoestrogen content not reported 
 
Overall, the CEF Panel noted that in the study the dosing period was quite prolonged compared with 
many other studies (daily dosing for up to 7 weeks) and given the repeated exposure to relatively high 
levels of unconjugated BPA, the effects on testis and spermatogenesis are probably not unexpected. 
Based on the descriptions in the paper, the level of confidence in the methodology is not high, e.g. the 
morphological and morphometric analyses do not appear to have been carried out blind, and the 
differentiation of the germ cell population into different cell types is reported with what is considered 
to be spurious accuracy given the methodology described. The lack of effect on DNA methylation of a 
number of genes is in contrast with effects found by the same authors in mouse oocytes. This paper is 
included in the WoE table because of its relevance to one or more questions addressed there. 
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(iii) Excluded in vivo studies 
 
The following studies were excluded from further evaluation because the doses used all exceeded the 
HED of 3.6 mg BPA/kg bw per day.  
 
Reference Calculated HED value for 
administered dose(s) 
(cut-off: HED > 3.6 mg/kg bw 
per day) 
BPA Treatment 
Adewale HB, Jefferson WN, 
Newbold RR, Patisaul HB, 2009. 
Neonatal Bisphenol-A exposure 
alters rat reproductive development 
and ovarian morphology without 
impairing activation of 
gonadotrophin-releasing hormone 
neurons. Biology of Reproduction, 
81, 690-699 
HED (pups) = 15.5, 15,500 mg 
BPA/kg bw per day 
Long Evans rats received sc 
injections of BPA(50 µg/kg bw per 
day or 50 mg/kg bw per day) daily 
from PND 0 to PND 3 
Aikawa H, Koyama S, Matsuda M, 
Nakahashi K, Akazome Y and Mori 
T, 2004. Relief effect of vitamin A 
on the decreased motility of sperm 
and the increased incidence of 
malformed sperm in mice exposed 
neonatally to bisphenol A. Cell and 
Tissue Research, 315, 119-124. 
HED (offspring) = 4.35 and 435 
mg/kg bw per day 
Newborn male mice given daily 
subcutaneous injections of 0.5 or 
50 mg BPA 
 
Crawford BR and Decatanzaro D, 
2012. Disruption of blastocyst 
implantation by triclosan in mice: 
Impacts of repeated and acute doses 
and combination with bisphenol A. 
Reproductive Toxicology, 34, 607-
613. 
HED (Dams) = 930, 1 815 mg/kg 
bw per day]for Adult female CF-1 
mice  
Adult female CF-1 mice with 
N=10-15 animals/group, were 
administered 61 or 121 mg BPA/kg 
bw per day on on GD 1-3 
Doshi T, D'Souza C and Vanage G, 
2013. Aberrant DNA methylation 
at Igf2-H19 imprinting control 
region in spermatozoa upon 
neonatal exposure to bisphenol A 
and its association with post 
implantation loss. Molecular 
Biology Reports, 40, 4747-4757.  
[HED (Neonatal rats) = 124 000 
µg/kg bw per day]. 
Holtzman rats were administered 
by sc injection a single dose of 
BPA:2.4 µg/30 µl that the authors 
state corresponds to 400 µg/kg bw 
per day. 
El-Beshbishy HA, Aly HA, El-
Shafey M, 2012. Lipoic acid 
mitigates bisphenol A-induced 
testicular mitochondrial toxicity in 
rats. Toxicology and Industrial 
Health, 29, 875-887. 
 
HED (Adult rats) = 7.2 mg/kg bw 
per day  
Adult male albino rats were given a 
single BPA dose of 10 mg/kg bw 
per day (suspended in 0.2 ml olive 
oil) orally for 14 successive days to 
8 animals/group. 
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Reference Calculated HED value for 
administered dose(s) 
(cut-off: HED > 3.6 mg/kg bw 
per day) 
BPA Treatment 
Karavan JR and Pepling ME, 2012. 
Effects of estrogenic compounds on 
neonatal oocyte development. 
Reproductive Toxicology, 34, 51-
56. 
 
HED (Neonatal mice) = 43.5, 435 
mg/kg bw per day. 
Female neonatal CD1 mice were 
injected subcutaneously on post-
natal days 1-4 with BPAin peanut 
oil at 5 mg mg/kg/day (or 10 µg per 
pup) or 50 mg/kg/day based on a 
mean pup body weight (or 100 µg 
per pup) 
Norazit A, Mohamad J, Razak SA, 
Abdulla MA, Azmil A, Mohd MA, 
2012. Effects of Soya Bean Extract, 
Bisphenol A and 17β-Estradiol on 
the Testis and Circulating Levels of 
Testosterone and Estradiol Among 
Peripubertal Juvenile Male 
Sprague-Dawley Rats. Sains 
Malaysiana, 41, 63-69.  
 HED (Juvenile rats) = 72 mg/kg 
bw per day 
Juvenile Sprague-Dawley male rats 
(n=6/group) of high dose (100 
mg/kg/bw) were administered by 
oral gavage BPA dissolved in 




Quignot N, Arnaud M, Robidel F, 
Lecomte A, Tournier M, Cren-
Olivé C, Barouki R, Lemazurier E, 
2012b. Characterization of 
endocrine-disrupting chemicals 
based on hormonal balance 
disruption in male and female adult 
rats. Reproductive Toxicology, 33, 
339-352.  
HED (Adult rats) = 144 mg/kg bw 
per day 
Adult male and female Sprague-
Dawley rats were dosed for 2 
weeks by oral gavage with 200 mg 
BPA/kg bw per day with a vehicle 
control of corn oil.  
Tainaka H, Takahashi H, Umezawa 
M, Tanaka H, Nishimune Y, Oshio 
S, Takeda K, 2012. Evaluation of 
the testicular toxicity of prenatal 
exposure to bisphenol A based on 
microarray analysis combined with 
MeSH annotation. The Journal of 
Toxicological Sciences, 37, 539-
548 
HED (Dams) = 75, 1,500 mg/kg 
bw per day 
Female ICR mice (n=6/group) 
received subcutaneous injections of 
5 and 50 mg BPA/kg in cornoil on 
days 7 and 21 of pregnancy.  
Salian-Mehta S, Doshi T and 
Vanage G, 2013. Exposure of 
neonatal rats to the endocrine 
disrupter Bisphenol A affects 
ontogenic expression pattern of 
testicular steroid receptors and their 
coregulators. Journal of Applied 
Toxicology, 34, 307-318. 
HED: (Neonates) = 93,000 
µg/kg/day 
Male Holtzman rats (n=4/group) 
were given a single dose level of 
BPA prepared in ethanol and 
sesame oil (2.4 µg/pup/day which 
the authors state corresponds 
roughly to 300 µg/kg bw per day, 
given a pup weight of 5–6 g. 
Exposure was PND 1-5 by sc 
injection and 8 male pups were 
used per group.  
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Reference Calculated HED value for 
administered dose(s) 
(cut-off: HED > 3.6 mg/kg bw 
per day) 
BPA Treatment 
Salloum BA, Steckler TL, 
Herkimer C, Lee JS and 
Padmanabhan V, 2013. 
Developmental programming: 
Impact of prenatal exposure to 
bisphenol-A and methoxychlor on 
steroid feedbacks in sheep. 
Toxicology and Applied 
Pharmacology, 268, 300-308. 
Assuming an HEDF of 1:1 for the 
sheep in the absence of suitable 
data, this study used a BPA dose 
above 3.6 mg/kg bw per day, i.e. 5 
mg BPA/kg bw per day 
 
Pregnant adult Suffolk ewes were 
administered a single dose level of 
BPA of 5 mg BPA/kg bw per day 
in cotton oil by sc injection from 
GD30-90 (of 147 days gestation). 
 
(iv) In vitro studies 
Appraisal of strengths and weaknesses and WoE analysis were not carried out for in vitro studies.  
Brienõ-Enríquez MA, Robles P, Camats-Tarruella N, García-Cruz R, Roig I, Cabero L, 
Martínez F, Garcia Caldés M (2011) Human meiotic progression and recombination are affected 
by Bisphenol A exposure during in vitro human oocyte development. Human Reproduction, 
26,2807–2818. 
 
The authors studied the effect of 1x10-6-3x10-5M BPA on the meiotic prophase of primary human 
oocytes. Oocytes survival was decreased at 1x10-6M BPA. The percentage of oocytes at pachynema 
decreased at 1x10-6 M BPA and higher concentrations, indicating that normal oocyte development was 
disturbed. Furthermore, MLH1 foci, which were used as a marker for crossing over, were increased at 
and above 10 µM BPA. 
Guo J, Yuan W, Qiu L, Zhu W, Wang C, Hu G, Chu Y, Ye L, Xu Y, Ge RS (2012) Inhibition of 
human and rat 11β-hydroxysteroid dehydrogenases activities by bisphenol A. Toxicology 
Letters, 215,126-130. 
 
The effects of BPA on the enzymatic activity of microsomal 11β-Hydroxysteroid dehydrogenase (11β-
HSD) was studied in human liver and kidney microsomes, rat testis and kidney microsomes and 
primary rat Leydig cells. Both isoforms, 11β-HSD1 and 11β-HSD2 were studied. An IC50 of 1.48x10-5 
and 1.94x10-5M was calculated for human and rat microsomal 11β-HSD1, respectively. No inhibiton 
was detected at 10-8 and 10-7M. Similarly, BPA decreased the 11β-HSD1 activity in intact primary rat 
Leydig cells. However, the BPA concentration was not stated. In addition, BPA reduced the activity of 
both human and rat microsomal 11β-HSD2. 
Lee M-S, Lee Y-S, Lee H-H and Song H-Y, 2012c. Human endometrial cell coculture reduces the 
endocrine disruptor toxicity on mouse embryo development. Journal of Occupational Medicine 
and Toxicology, 7,7. 
 
The authors studied the effect of 10-8-10-4M BPA on the number of developing mouse embryos at 2-
cell stage. Embryos were cultivated for 72 h either in medium, in vehicle or as co-culture on primary 
human endometrial cells. It was concluded that co-cultivation has a beneficial effect on the survival of 
embryos at all BPA concentrations investigated. At 10-4M BPA only embryos in the coculture system 
survived. The description of the experimental set-up is not complete, especially the meaning of 
“vehicle” in table 1. Data on the effects of E2, which was used as control are missing. The statistical 
analysis of the data appear inconclusive. The data indicate that embryo survival is also affected at 
lower BPA concentrations. However, a statistical evaluation is missing. The study suffers from limited 
data reporting and statistics. 
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N’Tumba-Byn T, Moison D, Lacroix M, Lecureuil C, Lesage L, Prud’homme SM, Pozzi-Gaudin 
S, Frydman R, Benachi A, Livera G, Rouiller-Fabre V, Habert R (2012) Differential effects of 
bisphenol A and diethylstilbestrol on human, rat and mouse fetal Leydig cell function. PLoS One 
7(12): e51579. 
 
The authors studied the effect of 10-12-10-5 M BPA on testosterone secretion by fetal human, rat and 
mice testis. 10-5M. BPA did not affect the morphology of testes in any of the species investigated. 
However, testosterone secretion of human Leydig cells showed significant reduction, to 70% of 
control levels, at 10-8M BPA. The strongest effect was detected at 10-5M. At 10-12M BPA had no effect 
on the human fetal testosterone secretion. The absolute amount of released testosterone was 252±38 
pg/h at gestational week 6.5-7.5 and increased more than 50-fold to 13879±4231 pg/h at gestational 
week 9.5-10.5, but was highly variable between testis fragments. Therefore, the toxicological 
relevance of the slight BPA effect is difficult to assess. A significant decrease in testosterone secretion 
only occurred in rat and mouse testis a 10-5M BPA. This decrease was detected in wild type as well as 
in ERα-/- mice, indicating that the effects are independent of the ERα receptor. Furthermore, a decrease 
in testis hormone insulin-like3 (INSL3) mRNA was detected at 10-8M BPA in human testis only. In 
contrast to BPA, DES decreased the testosterone release in rat and mouse testis only. No effects were 
seen at 10-6 and 10-5M DES. 
The results indicate that BPA can affect the development of the human fetal testis, at least in terms of 
testosterone release. However, the results are limited due to the small numbers of human testes. 
 
Ptak A, Gregoraszczuk EL (2012) Bisphenol A induces leptin receptor expression, creating more 
binding sites for leptin, and activates the JAK/Stat, MAPK/ERK and PI3K/Akt signalling 
pathways in human ovarian cancer cell. Toxicology Letters, 210, 332-337. 
 
In human ovarian epithelial carcinoma cells (OVCAR-3) BPA increased cell proliferation at 8.7x10-
10M and higher and leptin receptor expression at 3.5x10-8M and higher concentrations. Inhibitors of 
JAK/Stat, MAPK/ERK and PI3K/Akt pathways decreased the OVCAR-3 cell proliferation, indicating 
that these pathways were potentially involved in the BPA effects. Results from co-treatment 
experiments with leptin (40 ng/ml) and BPA (3.5x10-8M) indicate that both agents activate the same 
intracellular signalling pathways.  
Considering the different expression patterns of leptin receptors in explants of epithelial ovarian 
cancer (reported by others) and OVAR-3 cells the impact of the present findings is unclear. 
Quignot N, Desmots S, Barouki R and Lemazurier E, 2012a. A comparison of two human cell 
lines and two rat gonadal cell primary cultures as in vitro screening tools for aromatase 
modulation. Toxicology in Vitro, 26, 107-118. 
 
The effect of 1x10-7–5x10-5M BPA on the aromatase mRNA expression and enzyme activity was 
studied using two human cell lines (H295R and JEG-3), primary rat granulosa cells and rat Leydig 
cells. No decrease in cell viability was detected up to 5x10-5M BPA. Aromatase expression was 
reduced by 1x10-5M BPA in unstimulated, cAMP or FSH stimulated rat granulosa cells. However, a 
decrease in activity was detected in the cAMP stimulated cells only. In rat Leydig cells 1x10-5M BPA 
resulted in a down-regulation of the aromatase mRNA in unstimulated cells only.  
No change in aromatase mRNA expression was detected in the H295R up to 5x 10-5M PBA, while a 
1.3 fold increase in activity was detected at and above 2.5x10-5M BPA. In contrast a decrease in the 
mRNA and enzyme activity was detected in the JEG-3 cell line at 2.5x10-5 and 5x10-5 M BPA. 
The data confirmed cell- and species-specific effects of BPA on microsomal aromatase activity. This 
was not observed at relevant BPA concentration (< 10-5M). 
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Sheng ZG and Zhu BZ (2011) Low concentrations of bisphenol A induce mouse spermatogonial 
cell proliferation by G-protein-coupled receptor 30 and estrogen receptor-α. Environmental 
Health Perspectives, 119, 1775-1780. 
 
The authors studied the effect of 10-12-10-5M BPA on the proliferation of the spermatogonial cell line 
GC-1. An induction of proliferation/DNA synthesis was observed at all BPA concentrations with a 
maximal proliferation at 10-9M. Proliferation is signalled through cGMP-dependent protein kinase 
(PKG) and epidermal growth factor receptor (EGFR). Based on knock-down and inhibitor 
experiments it was concluded that the ERα receptor was phosphorylated through a cross-talk between 
ERα and the G-protein coupled receptor 30 (GPR30) and MAPK-ERK.  
This is an important mechanistic study on the activation of the ERα via a non-classical pathway.  
Ye L, Zhao B, Hu G, Chu Y, Ge RS (2011) Inhibition of human and rat testicular steroidogenic 
enzyme activities by bisphenol A. Toxicology Letters, 207, 137-142. 
The authors studied the effect of 10-11-10-4M BPA on the enzyme activity of the microsomal 11β-
Hydroxysteroid dehydrogenase (11β-HSD), 17β-Hydroxysteroid dehydrogenase 3 (17β-HSD3), the 
CYP17A1 activity of rat and human testis as well as the testosterone release of rat Leydig cells. The 
IC50 for BPA effects were 7.9x10-6M for 11β-HSD and 2.6x10-5M for human and rat microsomes, 
respectively. The IC50 of the CYP17A1 were 1.9x10-6M and 6.5x10-5M for the human and rat 
microsomes, respectively. In addition, 10-4M BPA inhibited the human 17β-HSD3 by 50%. BPA did 
not affect the testosterone release from rat Leydig cells at concentrations from 10-11 to 10-6 M. At and 
above 10-5 M a decrease in testosterone secretion was detected. The CEF Panel noted that BPA might 
affect testosterone release of rat/mouse Leydig cells at and above 10-5 M (not relevant in vivo). 
  
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 334 
Neurological, neurodevelopmental and neuroendocrine effects 
(i) Human studies 
Braun JM, Kalkbrenner AE, Calafat AM, Yolton K, Ye X, Dietrich KN and Lanphear BP, 2011. 
Impact of early-life bisphenol A exposure on behavior and executive function in children. 
Pediatrics, 128, 873-882.  
 
Braun et al. used a prospective birth cohort of 244 mothers and their 3-year-old children to 
characterize prenatal and childhood BPA exposures by using the mean total BPA concentrations 
(unconjugated plus conjugated) in maternal (16 and 26 weeks of gestation and birth) and child (1, 2, 
and 3 years of age) urine samples, respectively. Urine samples were collected during home visits 
directly into polypropylene specimen cups. Total urinary BPA (free plus conjugated BPA) was 
measured at CDC by on line solid phase extraction (SPE) coupled to isotopic dilution liquid 
chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.4 µg/l). Individual BPA 
concentrations were adjusted for dilution using urinary creatinine concentrations. Behaviour and 
executive function were measured at 3 years by using the Behavior Assessment System for Children 2 
(BASC-2) and the Behavior Rating Inventory of Executive Function-Preschool (BRIEF-P). The 
BASC-2 was considered the main instrument, and is a validated parent-reported assessment of a 
child’s problem behaviours. The authors focused on six subscales: aggression, attention, hyperactivity, 
depression, anxiety and somatisation. BPA was detected in over 85% of the urine samples from 
mothers and in over 97% of those from children, and although child BPA levels fell between the ages 
of 1 to 3, the analyses showed that child BPA concentrations were higher and more variable than those 
of mothers. Addressing potential confounding factors, the study found that each 10-fold increase in 
prenatal BPA concentration was associated with defective behavioural (hyperactivity, aggression, 
anxiety and depression) and emotional regulations (poorer emotional control) mainly in girls. Results: 
Anxiety scale all: β=7.0 (95% CI 1.7, 12), girls only: β=12 (95% CI 4.7, 20). Results Depression scale: 
all: β=4.9 (95% CI 0.0, 9.9), girls only: β=11 (95% CI 3.6, 18). 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Prospective study design 
- Urine, container specified (PP cups) 
- Repeated measurements (3) 
- Standardised samples (urinary creatinine) 
- Analytical method (SPE LC-MS-MS) 
Weaknesses:  
- Small sample size 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet not considered 
- Unclear clinical relevance (small effect size, conflicting results in boys and girls) 
- Imprecise/unreliable outcome (neurobehavioral parameters scored using parent-reported but 
validated methods) 
- Inconsistent results amongst different studies 
Overall, the CEF Panel considers that this study is a follow up of a previous study (Braun et al., 2009) 
which indicated a negative association between prenatal BPA exposures (maternal BPA 
concentrations at gestational week 16) and externalizing behaviours (hyperactivity and aggression) at 
2 years of age, and the associations were more pronounced in girls than in boys. The BASC-2 
instrument was used in both in the 2009 and 2011 studies, and the follow-up study corroborated the 
results of the first study by showing to some degree similar associations and the same sex difference at 
age 3. The study is strengthened by the inclusion of childhood BPA measurements. No associations 
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between childhood urinary BPA (different to maternal urinary BPA) concentration and behaviour or 
executive functions were seen. The study also adjusted for caregiving environment and biomarkers of 
other environmental toxicants (low molecular weight phthalates). Although well designed, it has some 
weaknesses: (i) neurobehavioural parameters were scored on the basis of parent report questionnaires 
(although validated) in the absence of any direct measure of children’s neuropsychological 
development, (ii) use of spot urine samples and (iii) the weak levels of significance.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Harley KG, Gunier RB, Kogut K, Johnson C, Bradman A, Calafat AM and Eskenazi B, 2013a. 
Prenatal and early childhood bisphenol A concentrations and behavior in school-aged children. 
Environ Research, 126, 43-50. 
 
This study investigated associations between prenatal and childhood BPA exposure and behavior in 
school aged children in a prospective study with 292 mother-children pairs in the in the CHAMACOS 
pregnancy cohort in California. Spot urine samples for measuring maternal BPA exposure collected 
from mothers at two time points during pregnancy and at age 5 of the children. Total urinary BPA 
(free plus conjugated BPA) was measured at CDC by on line solid phase extraction (SPE) coupled to 
isotopic dilution liquid chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.4 µg/l). For 
women with two urine samples (n=221) the average was used. BPA concentrations were adjusted for 
dilution using either urinary creatinine or specific gravity. Unadjusted geometric mean BPA was 1.1 
and 2.5 µg/l in mothers and children, respectively. At 7 years of age, the Behavior Assessment System 
for Children 2 (BASC-2) and the Conners’ ADHD/DSM-IV Scales (CADS) were interviewer-
administered to the mother (due to low literacy rates) and self-administered by the child's teacher. 
Answers were summed and compared to national norms to generate T-scores standardized for age and 
sex for three outcomes: inattention, hyperactivity, and ADHD DSM-IV scales. At 9 years of age, 
ADHD behavior was observed directly using the Connors' Continuous Performance Test (CPT), a 
computerized test that assesses reaction time, accuracy, and impulse control by having the child press 
the space bar as quickly as possible when any letter except the letter X appears on the screen. 
Information about possible confounders was obtained from the mothers through interviews in English 
or Spanish by trained interviewers. Maternal urinary concentrations of dialkyl phosphate (DAP) 
metabolites of organophosphate pesticides (DAP metabolites were measured in the same maternal 
urine samples as BPA) and polybrominated diphenyl ether (PBDE) flame retardants were evaluated 
among confounding variables due to study participants coming from an agricultural region and 
because associations between DAP and attention problems have been reported in the study population. 
BPA concentrations were examined on the continuous scale (logarithmic) and by ranked categories. 
For prenatal BPA exposure the results showed that higher urinary BPA concentrations in mothers 
during pregnancy were associated with increased internalizing problem behaviors, i.e. anxiety and 
depression (BASC-2), in their sons at 7 years of age. Each doubling of maternal BPA concentration 
was associated with an increase in internalizing scores of 1.8 points (95%CI: 0.3, 3.3) by maternal 
report and 2.5 points (0.7, 4.4) by teacher’s report. Prenatal BPA concentrations were not associated 
with any behaviors measured on the CADS at 7 years or in boys or girls. Similarly, prenatal BPA 
concentrations were not associated with any behavior at measured by direct observation at age 9 
(CPT). For childhood BPA exposure the results showed that higher urinary BPA concentrations in the 
children at age 5 were associated with increased internalizing problems and increased ADHD 
behaviors in both boys and girls and increased externalizing behaviors, including conduct problems, in 
girls at age 7 years. Each doubling of urinary BPA concentrations at age 5 in girls was associated with 
an increase in ADHD score at age 7 of 1.3 (95%CI: 0.4, 2.2) by maternal report and 1.7 (0.3, 3.1) by 
teacher’s report. No associations were seen with BPA concentrations at 5 years and any behavior at 
age 9 (CPT) in boys or girls.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
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Strengths: 
- Prospective study 
- Urine, container specified (PP cups) 
- Repeated measurements (>1, maternal urine) 
- Standardized samples (urinary creatinine and specific gravity) 
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks 
- Multiple outcome assessment (maternal and teacher-report at age 7 and direct observation at 
age 9) 
Weaknesses:  
- Small sample size 
- Single spot urine BPA measurement 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet not considered 
- Unclear clinical relevance (small effect size, conflicting results in boys and girls) 
- Generalisability to the overall population (low-income Mexican American population) 
- Inconsistent results amongst different studies 
Overall, the CEF Panel considers that this study showed associations between prenatal BPA exposure 
and behavioral problems in boys, and between childhood BPA exposure and behavioral problems in 
both boys and girls at age 7 years. However, no associations were found for prenatal or childhood 
BPA exposure and children’s behavior assessed by direct observation at age 9 years. The mothers and 
children in the study were part of the Center for the Health Assessment of Mothers and Children of 
Salinas (CHAMACOS) in the agricultural Salinas Valley California, which is a deprived immigrant 
Mexican-American population. Almost all children were Hispanic, and more than 70% lived below 
the poverty level. Hence, the generalisability of the results is uncertain. However, the study assessed 
child behavior by multiple observers at school age and included many relevant confounders, including 
mother’s country of birth, maternal education, marital status, maternal language, child’s exact age, 
HOME score, household income, and number of siblings, maternal depression at 7 years, and maternal 
pesticide metabolites during pregnancy. The study is strengthened by the prospective design and that 
the associations were consistent in subgroup and sensitivity analyses. However, the study is limited by 
not all mothers having two urine samples during pregnancy and a relatively small sample size. No 
dietary variables were evaluated.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Hong SB, Hong YC, Kim JW, Park EJ, Shin MS, Kim BN, Yoo HJ, Cho IH, Bhang SY and Cho 
SC, 2013. Bisphenol A in relation to behavior and learning of school-age children. Journal of 
Child Psychology and Psychiatry, and Allied Disciplines, 54, 890-899. 
 
Urinary BPA concentrations and behavioral and learning characteristics were assessed in a cross-
sectional study in a general population of 1 008 children, aged 8–11 years in Korea. Participants were 
recruited from five different administrative regions of which two were urban cities, two were 
industrial cities and one was a rural district. Children were invited from two or three schools in each 
area. Spot urine was collected from each child between 9 and 11 a.m. at school, and total urinary BPA 
(free plus conjugated BPA) measured liquid chromatography isotopic dilution tandem mass 
spectrometry (LC-MS-MS, LOD 0.15 µg/l). BPA concentrations were adjusted for dilution using 
urinary creatinine concentrations. Emotional and behavioural problems of the children were assessed 
by their parents using the Korean version of the Child Behavior Checklist (CBCL) and the Learning 
Disability Evaluation Scale (LDES). Blood levels of lead and urinary levels of phthalates and cotinine 
was also measured and included in the analyses. In addition to the other environmental toxicants, the 
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analyses adjusted for potential confounding by demographic (age, gender, region, parental education, 
parental income and child’s IQ) and obstetric (maternal age at delivery, gestational age, birth weight) 
variables and psychiatric family histories. The median Cr-standardized BPA was 1.28 µg/g creatinine 
(mean 1.32 µg/g creatinine) and median unstandardized BPA was 1.23 µg/l. Higher urinary levels of 
BPA were positively associated with the CBCL total problems score and negatively associated with 
the learning quotient from the LDES. The linear association with the CBCL anxiety/depression score 
and the quadratic association with the LDES listening score were significant after correction for 
multiple comparisons, and the authors concluded that the results suggested a nonmonotonic 
relationship.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Standardized samples (urinary creatinine) 
- Analytical method (LC-MS-MS) 
Weaknesses:  
- Cross-sectional study design 
- Single spot urine BPA measurement 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet not considered 
- Inconsistent results amongst different studies 
Overall, the CEF Panel considers that the main limitation of this study is the cross-sectional design. 
Therefore, the results cannot be used to infer that BPA affects behavior and learning of school-age 
children. A range of confounders were taken into account, but no dietary variables were considered.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Miodovnik A, Engel SM, Zhu C, Ye X, Soorya LV, Silva MJ, Calafat AM and Wolff MS, 2011. 
Endocrine disruptors and childhood social impairment. Neurotoxicology, 32, 261-267.  
 
This study investigates prenatal exposure to two ubiquitous endocrine disruptors, the phthalate esters 
and BPA, and social behaviour in a sample of adolescent inner-city children in New York. Third 
trimester urines of women enrolled in the Mount Sinai Children's Environmental Health Study 
between 1998 and 2002 (n=404) were analysed for phthalate metabolites and BPA. Total urinary BPA 
(free plus conjugated BPA) was measured at CDC by on line solid phase extraction (SPE) coupled to 
isotopic dilution liquid chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.4 µg/l). BPA 
concentrations were adjusted for dilution using urinary creatinine concentrations. Mother-child pairs 
were asked to return for a follow-up assessment when the child was between the ages of 7 and 9 years. 
At this visit, mothers completed the Social Responsiveness Scale (SRS) (n=137), a quantitative scale 
for measuring the severity of social impairment related to Autistic Spectrum Disorders (ASD) in the 
general population. Social responsiveness is based on how the brain processes and responds to 
external social cues. The SRS is a well-validated quantitative instrument which generates a clinically 
relevant standardized total score (T-score) as well as subscales for rating e.g. social awareness, social 
cognition etc. In this study T-scores were calculated separately for males and females. No significant 
associations between prenatal BPA exposure and T-scores was found (β=1.18, 95% CI -0.75, 3.11), 
whereas low molecular weight phthalate metabolite concentrations were associated with greater social 
deficits (T-scores: β=1.53, 95% CI 0.25-2.8), specifically poorer social cognition, social 
communication and social awareness.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
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Strengths: 
- Prospective study design 
- Standardized samples (urinary creatinine) 
- Analytical method (SPE LC-MS-MS) 
Weaknesses:  
- Small sample size 
- Single spot urine BPA measurement 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet not considered 
- Imprecise/unreliable outcome (neurobehavioral parameters scored using parent-reported but 
validated methods) 
- Inconsistent results amongst different studies 
Overall, the CEF Panel considers that one main limitation of this study is the fact that the urine sample 
is a single spot sample in third trimester of pregnancy, and may not adequately reflect long-term 
exposure, but represents only a time point during brain development process. Several factors could 
contribute to a social behaviour assessed at the age of 7-9 years, and it is difficult to establish a 
relevant association between prenatal exposure and a long-term effect taking into account of all the 
possible covariates. The authors examined urinary biomarker concentrations as µg/L as well as after 
correction for dilution as µg/g creatinine. Exposures were examined on the continuous scale and the 
statistical handling was good. The present paper, although it does not attempt to estimate any exposure 
dose by extrapolation from urinary levels of BPA, suggests that there is no association between 
prenatal BPA exposure and effects on social behaviour of children of 7-9 years old.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Perera F, Vishnevetsky J, Herbstman JB, Calafat AM, Xiong W, Rauh V and Wang S, 2012. 
Prenatal Bisphenol A Exposure and Child Behavior in an Inner City Cohort. Environmental 
Health Perspectives, 120, 1190-1194. 
 
This study examined the association between prenatal BPA exposure and child behaviour, adjusting 
for postnatal BPA exposure in a prospective cohort in New York City comprising a low-income 
minority population. Pregnant African American and Dominican women were recruited to the study 
from 1998 through 2003. Inclusion was limited to healthy women aged 18-35 years who did not 
smoke or use other tobacco products or illicit drugs. Prenatal total BPA was measured in spot urine 
samples collected from the mother during pregnancy (mean 34 gestational weeks) and from the 
children between ages of 3 and 4 years. Total urinary BPA (free plus conjugated BPA) was measured 
at CDC by on line solid phase extraction (SPE) coupled to isotopic dilution liquid chromatography 
tandem mass spectrometry (LC-MS-MS, LOD 0.4 µg/l). BPA urinary concentrations were adjusted for 
dilution using specific gravity. Child behavior was assessed using the Child Behavior Check List 
(CBCL) in children between 3 to 5 years of age. Research workers trained in neurodevelopmental 
testing oversaw the completion of the CBCL by the mothers. The study sample comprised 198 mother 
child pairs with complete data on pre- and postnatal BPA measurements, with available data on the 
outcome and with data on potential confounding variables. The results indicated that prenatal exposure 
to BPA affected child behavior, particularly in boys. Prenatal exposure to BPA was dichotomized 
(first three quartiles vs. last quartile) and a weighted association (weighted for recent child BPA 
exposure) was found for high BPA and emotional reactivity (increase, p<0.01, OR=1.62 [95%CI:1.13, 
2.32]) and aggressive behavior (increase, p<0.01, OR=1.29 [CI: 1.0, 1.53]) in boys, and 
anxiety/depression (decrease, p<0.05, OR=0.75 [CI: 0.57, 0.99]) and aggressive behavior (decrease, 
p<0.05, OR=0.82 [CI: 0.70-0.97]) in girls, indicating that girls in the high prenatal BPA exposure 
group had, on average, fewer reported problems in these areas than girls in the low exposure group. 
Postnatal BPA urinary concentration alone had a significant negative effect only on Emotionally 
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Reactive within the entire sample OR=0.76 (CI: 0.59, 0.97), p=0.029, and was not associated with the 
other six sub-scores or the composite scores on internalizing or externalizing problems in the entire 
sample or in boys and girls separately.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Prospective study 
- Standardized samples (specific gravity) 
- Analytical method (SPE LC-MS-MS) 
Weaknesses:  
- Small sample size 
- Single spot urine BPA measurement 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Unclear clinical relevance (small effect size, conflicting results in boys and girls) 
- Imprecise/unreliable outcome (neurobehavioral parameters scored using parent-reported but 
validated methods) 
- Generalisability to the overall population (low-income African American and Dominican 
women)  
- Inconsistent results amongst different studies 
Overall, the CEF Panel considers that the inclusion of both prenatal and postnatal BPA exposure is an 
advantage. The statistical analysis is overall acceptable. BPA exposure was dichotomized, and no 
results for continuous BPA exposure were reported. The associations were weak. The authors 
examined sex-specific effects, but did not sufficiently explain the opposing effects on behaviour in 
girls and boys. This is notable, as the observed sex differences were inconsistent with results reported 
in the two studies by Braun et al. (2009, and 2011), which reported evidence of adverse effects 
predominantly in girls. The study used density but not creatinine to adjust urinary BPA. The authors 
assert in the discussion the uncertainty of the actual fetal exposure related to the use of single spot 
urine samples for measuring BPA.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Yolton K, Xu Y, Strauss D, Altaye M, Calafat AM and Khoury J, 2011. Prenatal exposure to 
bisphenol A and phthalates and infant neurobehavior. Neurotoxicology and Teratology, 33, 558-
566. 
 
This study examined associations between BPA- and phthalates exposures pregnancy and infant 
neurobehavior at 5 weeks. The study used data from the birth cohort in the Cincinnati area (same as 
Braun et al., 2009 and 2011) and included 350 mother/infant pairs. BPA and phthalates were measured 
in spot urine samples collected at gestational weeks 16 and 26. Total urinary BPA (free plus 
conjugated BPA) was measured at CDC by on line solid phase extraction (SPE) coupled to isotopic 
dilution liquid chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.4 µg/l). Urinary BPA 
was adjusted for dilution using urinary creatinine concentrations. Infant neurobehavior was examined 
by the NICU Network Neurobehavioral Scale (NNNS), a tool suited to reveal changes in the 
neurobehavioral development of typical infants. The domains on the NNS scale examined in the study 
included attention, arousal, regulation, handling, movement quality, excitability, lethargy, nonoptimal 
reflexes, asymmetry, hypotonia, stress/abstinence. Detectable BPA was found in over 90% of the 
maternal urine samples at two time points (16 and 26 weeks). The paper considered simultaneous 
exposure to BPA and phthalates, and reported that the correlation between log2 BPA and log2 
phthalate metabolites (DBP, DEHP) at 16 weeks were r=0.50 and r=0.42, respectively, and at 26 
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weeks were r=0.28 and r=0.21, respectively. Some significant associations were found for phthalate 
metabolites at 26 weeks (e.g. DEHP associated with more non-optimal reflexes in males), while no 
significant associations were found between prenatal BPA exposure and infant neurobehaviour 
(domains of NNS scale) (p>0.1 for all).  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Prospective study 
- Repeated measurements (2, maternal urine) 
- Standardized samples (urinary creatinine) 
- Analytical method (SPE LC-MS-MS) 
Weaknesses:  
- Small sample size 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet not considered 
- Inconsistent results amongst different studies 
Overall, the CEF Panel considers that the results of this study show that BPA levels in urine were not 
associated with infants’ neurobehaviour. The statistical analysis is overall acceptable. PBA and 
phthalate metabolites were mutually adjusted, and all models were adjusted for creatinine, infant age 
in days and sex, and confounding by a range of variables were explored, and included demographic 
and socio-economic variables and blood lead levels. Limitations were acknowledged by the authors 
and include: (i) neonatal exposure to BPA and phthalates was not considered, (ii) uncertainty in 
defining gestational age and (iii) use of spot urine samples. The present paper suggests that there is no 
association between prenatal BPA exposure and infant neurobehavior at 5 weeks.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
(ii) Animal studies 
(1) Studies examining effects of BPA on anxiety-like behaviour 
Diaz Weinstein S, Villafane JJ, Juliano N and Bowman RE, 2013. Adolescent exposure to 
Bisphenol-A increases anxiety and sucrose preference but impairs spatial memory in rats 
independent of sex. Brain Research, 1529, 56-65. 
 
This study investigated possible effects of short term BPA exposure on anxiety-like behaviour (open 
field, OF, and elevated plus maze, EMP), spatial memory (Object placement, OP) and sucrose 
preference in adolescent Sprague Dawley rats. Seven week old rats were subcutaneously exposed to 
40 µg/kg BPA or saline daily for 12 days (n= 9 male, 9 female per group). Body weights were 
recorded at arrival and at four additional time points during the treatment period. The animals were 
group housed according to sex and treatment. Behavioural testing were performed on exposure days 6 
(EPM, OF), 9 (OP) and 12 (sucrose preference), respectively. Behavioural measures were obtained in 
real time by experienced persons blinded to the animal treatment. Data were analysed by two-ways 
ANOVA (sex, treatment) with Fisher′s LSD tests for post-hoc analyses. The study reports that 
exposure to BPA statistically significantly increased anxiety-like behaviour (EPM, OF), impaired 
spatial memory (OP) and increased sucrose preference, in both sexes. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
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- Use of glass water bottles 
- Blind evaluation of the observed behaviour 
Weaknesses 
- Single dose level study  
- Study design not appropriate to the scope (behavioural tests performed only once with 
limitation to one trial, subsequent testing in two different tests on the same day) 
- Insufficient study reporting (body weights not measured daily in conjunction with treatment; 
no information on sexual maturation and insufficient information on recording of behavioural 
testing; animal diet and phytoestrogen content not reported) 
- Inappropriate statistics (repeated measures for the same animal are not taken into account; 
cycling is not adjusted for in the analysis; no multiple comparison statistics - Fisher’s 
protected LSD test applied which does not adequately protect from Type 1 Error increase due 
to multiple comparisons) 
 
Overall, the CEF Panel noted that the interpretation of the reported increased sucrose preference in 
BPA-exposed rats is uncertain (the test may have been conducted according to a protocol, but no 
reference is given). Preferentially, behavioural data should be automatically recorded. The value of the 
results obtained from the behavioural testing with elevated plus maze and open field is limited. Both 
of these tests were conducted once only; at the same day, and both were limited to one trial lasting 5- 
and 6-minutes, respectively. Subsequent testing at the same day with the same animals in two different 
tests may potentially influence the animal’s performance in the second test (open field).  
 
The study limitations are considered to lie in uncertainties related to exposure, control of 
environmental BPA-exposure, lack of information of sexual maturation, and shortcomings in the 
statistical analyses. Thus, the underlying cause of the reported statistically significant behavioural 
differences appears unclear.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Ferguson SA, Law CD and Abshire JS, 2012. Developmental treatment with bisphenol A causes 
few alterations on measures of postweaning activity and learning. Neurotoxicology and 
Teratology, 34, 598-606. 
For study details see (2) Studies examining effects of BPA on learning and memory. 
 
Fujimoto T, Kubo K, NishikawaY, Aou S, 2013. Postnatal exposure to low-dose bisphenol A 
influences various emotional conditions. The Journal of Toxicological Sciences, 38(45), 539-546. 
 
Female Wistar rats were exposed to 0.1 ppm BPA in the drinking water (equivalent to about 24 
µg/kg/bw day) or no BPA (controls) from the day of delivery to lactation day 7 (n=5/group). Glass 
bottles were used to control for potential environmental contamination and distilled water replaced the 
tap water during the exposure period. The rats were fed standard chow (CE-2). At delivery, litters 
were culled to four of each sex. Offspring of both sexes (n=16-20/group) were assessed at 6 weeks of 
age in an open field (OF) test, at 7 weeks of age in the Elevated Plus Maze (EPM) and at 9 weeks of 
age in the Forced Swimming test (FST). Data were analysed by 2-way ANOVA (group, sex), followed 
by Fisher’s PLSD test. 
In the OF a main effect of BPA treatment was evident only for duration of rearing, suggesting a 
hyperactivating effect of BPA. In the EPM no main effect of BPA was found, but females exposed to 
BPA were more active than BPA males. In the FST, BPA increased the time spent in immobility in 
male offspring (p < 0.005) and decreased (p < 0.05) latency time to display the depressive-like 
behavioural response (floating while immobile) in both sexes compared to controls.  
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Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Use of glass water bottles 
Weaknesses: 
- Single dose level study 
- Animal diet and phytoestrogen content not reported 
- Study design not appropriate to the scope (small sample size, N = 5 dams and litters per 
treatment group; littermates treated as independent observations) 
- Insufficient BPA-exposure assessment (drinking water consumption (containing BPA) not 
measured) 
- Insufficient study reporting (insufficient information on recording of behaviour testing) 
- Inappropriate statistics(litter effect not considered; no multiple comparison statistics, the 
Fisher’s protected LSD test applied does not adequately protect from Type 1 Error increase 
due to multiple comparisons) 
Overall, the CEF Panel noted that information on control of environmental contamination of BPA 
except for water bottles is lacking (i.e. feed, bedding). The study used one BPA dose level 
administered through drinking water to lactation dams. The authors estimated the BPA intake for dams 
to be 24 µg/kg bw per day, but data are not shown. Only 5 dams and litters per treatment group were 
used and no consideration of the litter factor was included in the statistical analysis. The underlying 
cause of the reported statistically significant behavioural differences appears unclear, e.g. chance 
findings of multiple testing. Additionally, the animals response in a Forced Swimming test is 
discussed and decreased latency to immobility might as well be interpreted as being smart (i.e. being 
picked out of the water).  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Gioiosa L, Parmigiani S, Vom Saal FS, Palanza P, 2013. The effects of bisphenol A on emotional 
behavior depend upon the timing of exposure, age and gender in mice. Hormones and Behavior, 
63, 598-605. 
 
This study was aimed at investigating the behavioural effects of developmental exposure to a low dose 
of BPA with respect to the timing of the exposure, maternal environment, sex and age at testing. 
Starting from the last week of pregnancy (GD 11) to the first postpartum week (PND 8), dams of the 
CD-1 mouse strain daily spontaneously drank either corn oil (control group, n=27) or a solution 
containing 10 µg/kg bw per day BPA (n = 15) from a modified syringe. Mice were reared on a soy-
based standard diet. At birth, the litters were cross-fostered in order to differentiate between pre- and 
postnatal exposure: pups prenatally exposed to BPA were not exposed during lactation, and pups 
postnatally exposed during lactation were not exposed during pregnancy. Offspring of the two sexes 
underwent three diverse experimental paradigms for anxiety-related behaviours: as juveniles (PND 28-
30, n=12-15 group/sex) a novelty test, and at adulthood (PND 70, n=12-15 group/sex) both the free 
exploratory open field and elevated plus maze (EPM) tests. Data were analysed by a two-way (sex, 
group) analysis of variance (ANOVA) with Turkey’s HSD test for post-hoc comparisons. At both 
testing ages, the control females exhibited less anxious-like behaviours, were more active and more 
prone to explore a novel environment than control males. BPA pre- and postnatally exposed females 
showed a behavioural profile more similar to control males than females. In this study, the direction of 
the behavioural changes was affected similarly by the pre- and postnatal exposures, although with a 
greater effect associated with postnatal exposure primarily in females. BPA per se had a main effect 
on free exploratory open field test as both sexes tended to remain near the home area and were less 
prone to explore the environment. In general, in all the three tests applied significant interactions 
between BPA and sex were evident, BPA reducing or reversing sex differences in anxiety-like and 
exploratory behaviours. 
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Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Blind collection and analyses of behavioural data 
Weaknesses: 
- Single dose level study 
- Animal diet and phytoestrogen content not reported (soy-based standard diet used) 
- Use of polycarbonate cages and bottles (new ones) 
- Insufficient BPA-exposure assessment (BPA dose adjusted to body weight seemingly not on a 
daily) 
- Inappropriate statistics(no correction for multiple comparisons applied; comparison between 
the two exposure windows is not appropriate since the same dose is used for either gestational 
or lactational exposure – resulting in a very different internal dose). 
 
Overall, the CEF Panel noted that in this study the group size of offspring for behavioural testing was 
sufficient and the litter effect was considered. Behaviours were recorded by video in the three tests and 
adult female checked for ooestrous phase after testing.  
The CEF Panel also noted that these findings are not consistent with those of Ferguson et al. (2012); 
who used twice the dose (25 μg/kg bw per day) during GD 6-21 without finding any effects of BPA. 
Notably, Gioiosa et al. found stronger impact of BPA in postnatally than in prenatally exposed animals 
(females) although in utero exposure provides the offspring with much higher BPA levels than via 
lactation through dams’ milk.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Inagaki T, Frankfurt M and Luine V, 2012. Estrogen-induced memory enhancements are 
blocked by acute bisphenol A in adult female rats: role of dendritic spines. Endocrinology, 153, 
3357-3367. 
For study details see (2) Studies examining effects of BPA on learning and memory. 
Jasarevic E, Williams SA, Vanda GM, Ellersieck MR, Liao C, Kannan K, Roberts RM, Geary 
DC, Rosenfeld CS, 2013. Sex and dose-dependent effects of developmental exposure to bisphenol 
A on anxiety and spatial learning in deer mice (peromyscus maniculatus bairdii) offspring. 
Hormones and Behavior, 63, 180-189.  
This study was aimed at assessing the behavioural effects of different BPA doses administered in food 
during pregnancy and lactation to outbred deer mice (Peromyscus maniculatus bairdii), a rodent 
species that exhibits well-defined sex- and steroid-dependent behaviours. Dams were fed with a 
phytoestrogen-free diet supplemented with either 7% corn oil, ethinyl oestradiol (0.1 ppb), or one of 
the three doses of BPA (50 mg, 5 mg, 50 μg/kg feed weight) starting from 2 weeks before mating up 
to the end of the lactation period (weaning age of the offspring). Litters with singleton births were 
excluded. To obtain sufficient numbers of offspring, some dams were bred more than once. 
After weaning, the pups were maintained on control diet until they reached sexual maturity and then as 
adults assessed for spatial learning capabilities in a modified Barnes Maze and for anxiety-like and 
exploratory behaviours in an Elevated Plus Maze, EPM. Data obtain from the Barnes maze were 
analysed as a split plot in space and time followed by Fisher's protected LSD, whereas 2-way (sex, 
diet) ANOVA was used to analyse EPM data and a Cohen's d was determined for significant pairwise 
comparisons. Relative to controls, males exposed to the two upper doses of BPA exhibited similar 
behaviour as ethinyl oestradiol-exposed males in the Barnes maze (i.e. inefficient search strategy, 
higher latency to escape maze) and in the EPM (i.e. reduced time spent in open arms of the maze and 
reduced exploratory behaviours). Females exposed to ethinyl oestradiol, but not to BPA, consistently 
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exhibited masculinized spatial abilities, namely they outperformed males in the Barnes maze 
acquisition. According to the author, cycling was not checked for because it is poorly characterized in 
this species. The author measured serum BPA concentrations in controls (below limit of detection) and 
in dams on the BPA diet (5.48 ± 2.07 ng/ml), which was said to be similar to that observed in humans 
(referring to the study of Teeguarden et al., 2011).  
The authors conclude that developmental exposure to environmentally relevant concentrations of BPA 
can affect spatial learning and anxiety-like and explorative behaviour in male offspring in a dose-
dependent manner, and significantly reduce the sex differences present in this species. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Adequate positive controls included 
- Number of BPA doses (3) 
- Use of non-PC cages and water bottles 
- BPA exposure measurement in animal samples (serum) 
 
Weaknesses: 
- Study design not appropriate to the scope (multiple breeding; use of littermates in testing; 
study not controlled for reproductive cycling at testing time; unclear exposure time of the 
respective dams or if the controls were concurrent with the treated animals; possible additional 
dietary exposure of the offspring during late lactation) 
- Insufficient study reporting (no information on normalization for dams’ body weight and feed 
consumption described; maternal amount of feed consumed daily not specified; unclear 
whether offspring may have been exposed directly through feed during late lactation when 
incisors have appeared; total number of dams and their general reproductive outcome not 
given) 
- Insufficient BPA-exposure assessment (see line above) 
- Inappropriate statistics(the litter effect was not adequately addressed in the statistical analysis, 
no multiple comparison statistics - Fisher’s protected LSD test applied which does not 
adequately protect from Type 1 Error increase due to multiple comparisons) 
 
Overall, the CEF Panel noted that in this study three BPA doses and a relatively long exposure period 
were used to mimic chronic exposure (i.e. 2 weeks prior to mating, during gestation and lactation). Pre 
mating exposure implies that the authors assume BPA has no influence on fertility and mating succeed 
index. The study shows an acceptable sample size (n=6-9 dams per group). However, there is 
uncertainty as to the actual BPA doses given to the animals.  
It is also noted that the authors reported that free BPA in serum at the highest dose was similar to that 
found in pregnant women.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
 
Jones BA and Watson NV, 2012. Perinatal BPA exposure demasculinizes males in measures of 
affect but has no effect on water maze learning in adulthood. Hormones and Behavior, 61, 605-
610.  
 
The study aimed to evaluate the effects of perinatal BPA exposure on learning and emotional 
responses in adulthood. Fifteen Long-Evans female rats were mated in house and orally exposed to 
vehicle, 5, 50, 500, or 5000 μg/kg BPA by spontaneously licking oil from a syringe from gestational 
day (GD) 7 to lactational day 14 (n= 3 dams/group, except 500 μg/kg group where n= 2 dams). Litters 
were culled to equal sex ratio of male and female at delivery. Rats were fed standard Purina chow, had 
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access to tap water (dams to water sacks) and were housed in polysulfone cages. Perinatally exposed 
offspring (n=12 rat/sex/group) were examined as adults (PND 90-150) for spatial cognition in the 
Morris Water Maze (MWM), for depression in the Forced Swim Test (FST) and for anxiety-like 
behaviour in the Elevated Plus Maze (EPM).  
No effect of BPA on spatial cognition was observed in the MWM as evaluated by repeated measure 
analysis of variance (ANOVA) and Tukey's HSD post hoc test.  
The EMP data were first analysed by ANOVA within each sex to find effects of BPA dose levels, 
followed by Turkey HSD post hoc test to find specific group differences. Results showed that the 500 
μg/kg females produced more fecal boli than other females, and that the low dose females had higher 
percentage of open arm entries than control females. Amongst males, the low dose males travelled 
longer distance than control males. 
Secondly, for the EPM data, t-tests were used to compare sex differences within each dose group. In 
the control group, female were generally more active than males, except for producing facal boli and 
closed arm enteries.  
The FST-data for day 2 were evaluated by use of repeated measure ANOVA with Tukey's post hoc 
test. ANOVA did not reveal any significant differences across dose within the male groups, nor were 
any of the female BPA groups significantly different from the controls on any parameter, but paired 
comparisons indicated that a number of sex differences in controls appeard to varying degree in the 
different dose groups.  
The authors concluded that the sex differences found between controls were eliminated in the lowest 
BPA dose groups on both the EPM and FST, with a non-monotonic trend.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Number of BPA doses (4) 
- Use of non-PC cages, and of BPA-free water sacks (for dams only) 
Weaknesses: 
- Study design not appropriate to the scope (small number (2-3) of dams per group, littermates 
treated as independent observations, females not controlled for cycling at the time of testing)  
- Insufficient study reporting (unclear reports for the statistical findings in the figures/tables 
presented, especially for FST) 
- Inappropriate statistics(because of the limited number of litters tested (2-3) per dose group, the 
samples size is considered underpowered; litter effect not considered, lack of analysis of the 
two way interaction between treatment and sex, no adjustment of cycling included) 
Overall, the CEF Panel noted that a major weakness of this paper resides in the statistics: each dose 
group contained only 2-3 litters with a total of n=12 males and n=12 females per dose (i.e. eight to 
twelve rats coming from the same litter in each dose group), but the litter effect was not even 
mentioned and a positive control was lacking. The CEF Panel identified statistical shortcomings, in 
particular, the interactions dose x sex were not presented, which would have been useful to evaluate 
the extent of overall BPA effects. Furthermore, despite some significant effects in the Elevated Plus 
Maze test, generally the effect of BPA was small at all the tested doses, and the statistical 
significances of the results appear to be overestimated. A possible U-shaped trend should have been 
confirmed by a higher number of animals (litters), more dose groups and appropriate statistics (see 
Section 1.2). 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Kundakovic M, Gudsnuk K, Franks B, Madrid J, Miller RL, Perera FP, Champagne FA, 2013. 
Sex-specific epigenetic disruption and behavioral changes following low-dose in utero bisphenol 
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A exposure. Proceedings of the National Academy of Sciences of the United States of America, 
110, 9956-9961. 
 
For study details see (3) Studies examining the effects of BPA on social behaviour. 
 
Matsuda S, Matsuzawa D, Ishii D, Tomizawa H, Sutoh C, Nakazawa K, Amano K, Sajiki J, 
Shimizu E, 2012. Effects of perinatal exposure to low dose of bisphenol A on anxiety like 
behavior and dopamine metabolites in brain. Progress in Neuro-Psychopharmacology and 
Biological Psychiatry, 39, 273-279. 
 
Pregnant C57BL/6J mice were subcutaneously injected with vehicle or 250 ng BPA/kg bw per day 
from gestational day (GD) 10 to postnatal day (PND) 20. Every third day from GD 11 to PND 21 the 
dams were weighed. BPA dose was calculated using 30 grams of expected mouse body weight and the 
injection volume was 100 microliters. The vehicle contained 0.01% methanol in phosphate buffered 
saline (pH 7.4). Mice had free access to laboratory chow (CE-2, CLEA Japan, Inc., Tokyo) and tap 
water. Litters were culled to six pups (3 female and 3 male) at PND 2. Offspring was tested in an 
open-field test (10 min) as juveniles (4 weeks) and as adults (8 weeks) (N = 12-15 per sex and group). 
A two-way (sex×group) ANOVA and multiple analyses according to Bonferroni were used for the 
open field test, DA and DOPAC levels, and the DOPAC/DA ratio, whereas one-way (group) was used 
for MAO activity. Correlations between anxiety-like behaviour and DA levels or DA turnover were 
analysed using Pearson's product‐moment correlation test.  
In males, exposure to BPA significantly decreased the time spent in the centre area of the open field in 
both juveniles and adults compared to controls (p < 0.05). A similar effect was not seen in females. 
Locomotor activity was not affected by BPA treatment in either males or females (juvenile or adults).  
One week after testing, adult offspring (N = 4-6) were anesthetized with CO2 and brain samples 
collected. DA and DOPAC levels and the DOPAC/DA ratio were assessed in the dorsal hippocampus 
(HIP), amygdala (AMY), and medulla oblongata (MED) by use of high-performance liquid 
chromatography (HPLC). BPA significantly altered DA turnover only in adult males. Thus, males 
were investigated for the activity of monoamine oxidase (MAO)-B, the enzyme that metabolizes DA 
into DOPAC, and which was reduced in the MED area. The authors conclude that these results suggest 
that an increase in anxiety-like behaviour induced by perinatal exposure to BPA may be related to 
decreases in DA metabolites in the brain.  
Comments from the CEF Panel: 




- Single dose level study  
- Study design not appropriate to the scope (dosing not daily adjusted to body weight; the 
sample sizes for neurochemical assessment were limited (N=4-6) 
- Insufficient study reporting (number of dams lacking, general reproductive outcome and 
information on check for cycling in female offspring not given; type of cages and drinking 
bottles not reported; animal diet and phytoestrogen content not reported 
- Insufficient BPA-exposure assessment (constant during pregnancy and lactation and not 
adjusted to body weight) 
Overall, the CEF Panel noted that parallel examination of neurobiological (dopaminergic markers) and 
functional end points (behaviour, open field) was performed. However,  pregnant mice were given two 
days of habituation from arriving to the laboratory until dosing started. Anxiety–like behaviour was 
tested by an open field procedure and measured as reduced time spent in the centre area. A sufficient 
sample size was used for behavioural testing (n = 8-12), the litter effect is taken into account as pups 
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from the same litter were not used in the same experiments, and the study attempts to correlate 
morphological and functional changes. The main limitation of this study lies in the uncertainty 
regarding exposure, as it appears that dose was not held constant throughout pregnancy and lactation 
and that only a single dose level was tested, using the subcutaneous route.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Nakamura K, Itoh K, Dai H, Han L, Wang X, Kato S, Sugimoto T, Fushiki S, 2012. Prenatal and 
lactational exposure to low-doses of bisphenol A alters adult mice behavior. Brain & 
Development 34 (2012) 57–63 
 
Mated female ICR/Jcl mice were subcutaneously injected vehicle (sesame oil) or 20 µg BPA/kg body 
weight from the day vaginal plugs was observed until weaning of the offspring at postnatal day (PND) 
21 (n=8 dams/group). Litters were culled to 10 pups at delivery. Different offspring subsets of each 
group were used for early (PND 21-24) and late (postnatal week, P10-13W) behavioural testing.  
Offspring were tested early and late (P10W) in open field, early and late (PW11) in elevated plus maze 
(EPM), and late in Morris water maze (female at P12W and male at P13W). Body weights were 
recorded the day prior to early and late testing. Data were analysed two-ways ANOVA (treatment x 
sex) and the Mann-Whitney U test was used for post hoc comparisons.  
At weaning, BPA-exposed mice had lower body weights than controls (n=39-40/sex per group), but 
not at start of late testing (P10W) (n=19-20/sex per group). At early and late testing, no group 
differences were seen in anxiety-like behaviour measured as time spent central areal (open field) or in 
open arms (EMP). At early open field-testing, female in general spent less time in central area than 
males. Both at early (EPM) and late (open field) testing, BPA-exposed mice showed motor 
impairment as the total travelled distance was shorter than controls. At late EMP-testing, females in 
general travelled shorter distances than males. No group differences were shown for the Morris water 
maze data. The authors conclude that gestational and lactational BPA exposure causes hypoactivity in 
adult mice. 
Comments from the CEF Panel: 




- Single dose level study 
- Insufficient study reporting (maternal body weight not given; lack of information on check for 
cycling in female offspring; no information of environmental BPA-control, i.e. animal diet 
and phytoestrogen content, type of cages, bedding and drinking bottles not reported) 
- Insufficient BPA-exposure assessment (constant during pregnancy and lactation and not 
adjusted to body weight) 
- Inappropriate statistics (litter effect not considered) 
The CEF Panel noted that the body weight recordings at weaning indicate that BPA-exposed offspring 
were more strained than controls, whereas no group differences were seen in adult mice. However, 
since different subsets of offspring per group were used for early and late testing, the data are not 
directly comparable. Still, the main limitations of this study are considered to be 1) uncertainty 
regarding exposure, as it appears that dose was held constant and not adjusted to body weight 
throughout pregnancy and lactation and that only a single dose level was tested, using the 
subcutaneous route, and 2) statistical shortcomings as litter effects have been taken into account.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed . 
 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 348 
Patisaul HB, Sullivan AW, Radford ME, Walker DM, Adewale HB, Winnik B, Coughlin JL, 
Buckley B and Gore AC, 2012. Anxiogenic effects of developmental bisphenol A exposure are 
associated with gene expression changes in the juvenile rat amygdala and mitigated by soy. 
PLoS One, 7, e43890.   
The present study focused on the effects of perinatal developmental exposure to BPA and/or soy 
phytoestrogens, respectively, on the ontogeny of sexually dimorphic anxiety-related behaviours in 
juvenile and adult rats. Transcriptional changes for 48 genes involved in modulation of socio-sexual 
behaviours and reported sensitive to oestrogens and/or BPA exposure were analysed in the amygdala, 
a key brain areas for anxiety and fear responses. The mitigating potential of a soy-rich diet on these 
same endpoints was also analysed.  
Mated Wistar dams were exposed to BPA via drinking water (1 mg/L) from gestation (GD 6) during 
lactation and given soy-based or soy-free diets. A group exposed to ethinyl oestradiol (EE, 50 µg/L) 
and fed a soy-free diet served as a positive estrogenic control. From weaning at postnatal day (PND) 
21 through puberty (PND 40), offspring were directly exposed through drinking water and continued 
on the diet (+/- soy) their dams were given. 
Estimation of dams’ exposure to BPA based on water intake without normalization for body weight 
were 35.2-55.6 µg/day (-/+ soy diet) and 71.8-105.6 µg/day (-/+ soy diet) during gestation and 
lactation, respectively. Assessment of dams’ serum BPA and genistein (GEN), a soy phytoestrogen, 
indicated that internal maternal dose was within a human-relevant range (referring to the paper by 
Vandenberg et al. 2007). Positive control dams were estimated to be exposed to about 30 and 1.5 µg 
EE/day during gestation and lactation, respectively. Offspring were directly exposed to BPA through 
drinking water from postnatal day (PND) 21-40, about 18-25 µg/day (-/+ soy) (both sexes). Similarly, 
positive control offspring were estimated to be exposed to about 1 µg EE/day. 
Offspring were tested as juveniles PND 24-28 (Light/dark box and Elevated plus maze, EPM) and as 
adults (EPM) for anxiety-like and exploratory behaviour. Data calculated as percent were analysed by 
logistic regression, elsewhere three-ways ANOVA (gender, exposure, diet) was used with post-hoc t-
tests. Data collected from the EE-group was not incorporated in the overall statistical analysis, but 
might be compared to a group of interest by a t-test. Juvenile behavioural data showed no sex 
differences, thus data were collapsed across sexes.  
BPA induced anxiogenic-like behaviour in juveniles and loss of sexual dimorphisms in adult 
exploratory behaviour, but only in the animals reared on the soy-free diet. In the Light/dark box, BPA 
juveniles (both sexes) fed soy-free diet used significantly higher time to enter the lit chamber 
compared to soy-free controls (400 vs. 300 sec, p<0.05). Similarly, BPA juveniles on the soy-free diet 
made significantly fewer open arm entries (about 2.5) in the EPM than control animals on the same 
diet (about 3.6) (p<0.05). At adulthood, BPA given on soy-free diet did not induce significant 
anxiogenic-like effects in either sex in the Elevated Plus maze, but BPA may for the parameter latency 
of open arm entries be able to eliminate the sex-differences seen for the other parameters in this task. 
Figure 4 in the paper may shows “some consistent sex differences” in all other parameters (F>M) than 
latency. For latency, no sex difference appears for soy, BPA + soy or BPA + soy-free. The soy-free 
control has M>F, and the authors concluded that BPA eliminates this difference.  
Expression analysis performed in juveniles brains (PND 34) revealed a suite of genes, including a 
subset known to mediate sociosexual behaviour, associated with BPA-induced juvenile anxiety. 
Expression of oestrogen receptor beta (Esr2) and two melanocortin receptors (Mc3r, Mc4r) were 
down-regulated while the significant sex differences in Kiss1 expression was eliminated by BPA 
exposure. EE exposure did not completely recapitulate the behavioural and transcriptional effects of 
BPA and soy and mechanisms different from the estrogenic activity of these compounds may be 
considered. The authors conclude that these results collectively show that the behavioural effects of 
BPA can manifest during adolescence, but wane in adulthood, and may be mitigated by a soy-diet. 
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Comments from the CEF Panel 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Positive control included 
- BPA measurement in animal samples (dams’ serum) 
- Phytoestrogen-free diet (one group) 
 
Weaknesses: 
- Single dose level study 
- Insufficient BPA-exposure assessment (estimated based on maternal water intake and not 
normalized to body weight) 
- Lack of constant levels of exposure in time (lactational exposure is much lower than the 
gestational or juvenile exposure).  
- Insufficient study reporting (effects of animal breeding schedule not well described, mating 
was split in four cohorts with no information on distribution of dose groups, insufficient 
reporting of number of dams, unclear whether parallel behavioural testing of different dose 
groups of offspring was performed, duration of testing in EMP not given; type of cages and 
drinking bottles not reported)  
- Inappropriate statistics(unclear if litter effect was properly considered). 
 
Overall, the CEF Panel noted that parallel assessment of molecular markers (ER-beta and Kisspeptin1) 
and functional end points was performed and that the general methods, design and statistical analysis 
are acceptable. Cycling was included, and all females were tested in oestrus (when most active). 
General reproductive outcome (sex ratio) is reported, number of animals in each group and sex are 
shown in graphs. The sample size was consistent (n=43 in BPA groups and n=53 in BPA+soy group, 
with a minimum n=29 rats in the EE group). The behavioural results are sound and consistent in the 
juvenile stage. The protective effects of the soy-enriched diet are interesting although the mechanisms 
by which such effects are brought about are not explained. No effects of BPA appeared in adults 
despite a prolonged exposure period compared to the juvenile. 
An important limitation was the lack of constant levels of exposure in time (lactational exposure is 
much lower than the gestational or juvenile exposure). The exposure to BPA was estimated based on 
water intake and not normalized to body weight for calculation of internal exposure.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Viberg H, Fredriksson A, Buratovic S and Eriksson P, 2011. Dose-dependent behavioral 
disturbances after a single neonatal bisphenol A dose. Toxicology, 290, 187-194.  
The paper by Viberg et al. tested in mice of the NMRI strain the effects of neonatal single oral dose of 
BPA on maturation of spontaneous exploratory behaviour. Pregnant NMRI mice were fed 
standardised pellets and tap water ad libitum prior to and after delivery. Litters were culled to 10-14 
pups within the first 48 hours. 10-day-old pups were exposed to vehicle (10ml 20% fat solution/kg 
bw) or BPA at 0.32, 3.2 or 4.8 mg/kg administered as single oral doses (gavage) (n=15/group and 
minimum 3 litters/group). Male mice were used in the behavioural studies: Spontaneous behaviour in 
a novel home environment was tested for one hour at 2 and 5 months of age (i.e. locomotion, rearing, 
total activity), and the latter age was followed by subcutaneous injection of nicotine to test for 
increased activity (nicotine induced behaviour). Additionally, the male pups were tested in an Elevated 
plus maze at 3 months age, and in Morris water maze at 4 months of age.  
Spontaneous and nicotine-induced behavioural data were evaluated by ANOVA using a split-plot 
design, and for the Elevated plus maze data one-way ANOVA was used. Both these analyses were 
followed by Tukey’s HSD post hoc test. Data from day 1 to day 4 in the Morris water maze test were 
evaluated by general linear model with Tukey’s HSD post hoc test, and data from day 5 was submitted 
to general linear model test with pairwise group testing using Tukey’s HSD post hoc test. 
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In a novel home environment at 2 months of age, the male pups neonatally exposed to the middle or 
high dose of BPA (3.2 or 4.8 mg/kg body weight, respectively) showed a statistically significantly 
decreased activity during the first 20-min period (0-20 min), while during the last 20-min period (40-
60 min) a significantly increased activity was evident, compared to the control animals and the lowest 
dose of BPA (clear dose-response relation). The males exposed to the highest dose of BPA (4.8 mg/kg 
body weight) were significantly more hypoactive during the first 20-min period (0-20 min) and 
significantly more hyperactive during the last 20-min period (40-60 min) compared to the males 
exposed to the middle dose of BPA (3.2 mg/kg body weight). These effects were still present at 5 
months of age. Both BPA and control mice responded with increased activity to administration of 
nicotine, thus showing that the effects of BPA were not mediated by altered functionality of 
cholinergic system. Neither spatial learning (Morris water maze) nor anxiety-like behaviour (Elevated 
plus maze) were affected by BPA treatment.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Number of BPA doses (3) 
Weaknesses: 
- Single acute dose administration  
- Small sample size (3-4 litters/group)  
- Test performed in one sex only 
- Study design not appropriate to the scope (pup body weight recorded only four times during 
the 6 months study; only male pups behaviourally tested and it appears as the same 12-15 
males representing 3-4 litters were used in all four tests; littermates treated as independent 
observations) 
- Insufficient study reporting (number of dams and general reproductive outcome lacking; litters 
said to be standardised by size (12-14 pups) but sex ratio is not given; type of cages and 
drinking bottles not reported)  
- Inappropriate statistics(because of the limited number of litters tested (3-4), the samples size is 
considered underpowered; the litter effect is not properly considered in the statistics) 
- Phytoestrogen content in animal diet not given 
 
Overall, the CEF Panel noted that information on control of environmental contamination of BPA is 
lacking (i.e. cages, feed, water bottles, or bedding). The study reports statistically significant 
hyperactivity and lack of the expected habituation profile in BPA neonatally exposed mice after a 
single administration. The selection of behavioural tests seems appropriate, however given the unusual 
profile of BPA exposed mice both at 2 and 5 months, the lack of motor activity impairments in either 
the Elevated plus maze and the Morris water maze test (testing performed at different ages) is 
suprising. The deficit shown by BPA-treated male mice is specific to the exploration of a novel 
environment, but the authors did not provide any mechanistic explanation. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Wolstenholme JT, Taylor JA, Shetty SR, Edwards M, Connelly JJ, Rissman EF. 2011a. 
Gestational exposure to low dose bisphenol A alters social behavior in juvenile mice. PLoS One, 
6, e25448.  
For study details, see (3) studies examining the effects of BPA on social behaviour 
 
Wolstenholme JT, Edwards M, Shetty SR, Gatewood JD, Taylor JA, Rissman EF, Connelly JJ, 
2012. Gestational exposure to bisphenol A produces transgenerational changes in behaviors and 
gene expression. Endocrinology, 153, 3828-3838. 
For study details, see (3) studies examining the effects of BPA on social behaviour 
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Wolstenholme JT, Goldby JA and Rissman EF, 2013. Transgenerational effects of prenatal 
bisphenol A on social recognition. Hormones and Behavior, 64, 833–839 
For study details, see (3) studies examining the effects of BPA on social behaviour 
 
Xu X, Tian D, Hong X, Chen L, Xie L, 2011. Sex-specific influence of exposure to bisphenol-A 
between adolescence and young adulthood on mouse behaviors. Neuropharmacology. 2011 
Sep;61(4):565-73. doi: 0.1016/j.neuropharm.2011.04.027. Epub 2011 May 5. 
 
This study addresses behavioural changes in adolescence ICR mice orally (intragastric, ig) exposed to 
BPA (40, 400 μg/kg/d) or vehicle (sesame oil) for 8 weeks. Body weights were recoded at the start and 
at the end of the BPA exposure period. Three days after ending of treatment, at the age of 91 days, 
mice (12 per sex per group) were behaviourally tested for anxiety-like behaviour in the open field (3 
minutes) and elevated plus maze (5 minutes), and subsequently for learning and memory in the Morris 
water maze (4 days acquisition and 5th day probe day) and the step-down passive avoidance task (one 
training day with 2 minutes habituation and 5 sec foot-shock when stepping down, with retention for 
stepping down onto the grid floor after 24 h). After the retention test, all mice were tested for 
sensitivity to foot shock and found sufficiently sensitive. 
 
Two-way ANOVAs (sex x group) were used for the data of the open field, elevated plus maze, step-
down passive avoidance, and the probe trial in Morris water maze. Data obtained during the 
acquisition training of the Morris water maze were analysed by repeated measures mixed ANOVAs 
(treatment x training day x sex). Additionally, BPA effect on each gender across groups were 
evaluated separately by 1-way ANOVA (e.g. control males vs. BPA males), as well as sex differences 
within each group (e.g. control females vs. control males, etc.). Post-hoc Student’s t-tests were used 
for comparisons of individual means. Statistical significance was accepted at P < 0.05. 
 
For the open field data, two-ways ANOVA did not find any differences for group or sex, whereas 
paired comparison within treatment groups found sex difference in controls for rearing and grooming 
(males more than females). Corresponding sex differences were not found for the BPA groups, and 
compared to control males, BPA low dose males showed less rearings. In the elevated plus maze, 
control males had higher number of open arm entries and time spent in open arms (i.e. were more 
explorative) than control females. Such activities were reduced in BPA males at both dose levels,  but 
increased in females at the highest BPA dose level (i.e. more explorative/decreased anxiety-like 
behaviour).  
In the Morris water maze, no statistically significant differences were found for the probe day. For the 
four training days, control females showed longer mean escape path-length to the hidden platform (i.e. 
slower learners) than control males. The lowest dose BPA (40 μg/kg/d) extended the average escape 
path-length in males at days three and four, but not in females at any dose levels.  
In the step-down avoidance task, no sex differences in the latency to step down from the platform 24 h 
after receiving a footshock were revealed in the controls, but at the lowest BPA dose level due to 
shortened latency in males compared to control males.  
BPA exposure at both 40 and 400 μg/kg/d markedly reduced the body weight of males, and 40 μg 
/kg/d BPA markedly reduced the body weight of females when compared with the controls of the 
same sex. No changes were found in the serum sex-hormone levels or in the weights of reproductive 
organs for either gender. 
 
Comments from the CEF Panel 
The CEF Panel identified the following strengths/weaknesses in the study: 
  Strengths: 
- Phytoestrogen-free diet 
Weaknesses: 
- Statistical analysis (multiple comparison statistics not considered) 
- Type of cages and drinking bottles not reported 
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Overall, the CEF Panel noted that four behavioural tests were used in order to reveal effects of BPA 
on anxiety-like behaviour and on learning and memory, and that the stage of the female cycle was 
taken into account prior to behavioural testing.  However, performing different tests on subsequent 
days with the same animals may influence the results. Daily administration via gavage provides a 
controlled BPA exposure, but puts also extra stress on the animals which may influence the results 
even in a sex specific manner. Whereas some consistency were shown for sex differences in controls 
in tests for anxiety-like behaviour (male more explorative in open field and elevated plus maze), the 
mode of action of the reported abolished (or induced) sex difference of BPA is unclear and may be a 
result of more unspecific effects on both males and females. This may also apply for the reported lack 
of sex differences for BPA groups in the Morris water maze. The lowest BPA dose seemed to exert 
consistent reducing learning effect in male in the two learning tests; however this effect is at least 
questionable as there was no dose-response observed.  
Some uncertainty as to the BPA exposure remains since the dose was adjusted only weekly and not 
daily to animal body weight, and the control of environmental BPA contamination was limited.     
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Xu X, Hong X, Xie L, Li T, Yang Y, Zhang Q, Zhang G, Liu X, 2012. Gestational and 
Lactational Exposure to Bisphenol-A Affects Anxiety- and Depression-like Behaviors in Mice, 
Hormones and Behavior, 62, 480-490.  
This study aims to investigate the changes of anxiety- and depression-like behaviours. Pregnant ICR 
mice were orally exposed to vehicle (sesam oil), BPA 0.4 or 4 mg/kg either from gestational day 7 to 
20, or from lactational day 1 to 14. Mice fed soy-free feed with free access to feed and water. After 
parturition, litters were culled to 8-10 pups/litter.  
On PND 49, female offspring underwent bilateral ovariectomy. Adult offspring (N=10 sex/group) 
were tested for anxiety- and depression-like behaviours in an open field area (PND 56), a dark–light 
transition (D/LT) task (PND 57), a mirrored maze (MM, PND 58), an elevated plus maze (EPM) tasks 
(PND 59) and a forced swim (FS) task (PND 60). In the FS task, the time spent immobile is 
considered indicative of a depression-like behaviour in mice. The other tests are used to measure 
anxiety-like and explorative behaviours. The remaining mice from 10 litters were used for body 
weight recording and reproductive organ weight measurements (both PND 56) and for western blot 
analyses for NMDA (NR1) and AMPA (GluR1) receptors (PND 56, N=5 litters).  
Behaviours in all tests were automatically recorded with a computer based video tracking system. 
Collected behavioural data were analysed by a mixed repeated analysis of variance (ANOVA), 
including exposure period (gestation and lactation), treatment (0.4, 4 mg/kg/d BPA, control), gender 
(male or female). Two-way ANOVA was used for the Western blot analysis data.  
The results indicated that both gestational and lactational exposures to BPA (both doses) affected body 
weight at the age of 8 weeks (ps< 0.01, direction of effects depending on period of exposure) and 
increased anxiety- and depression-like behaviour in mice of both sexes. The results of locomotor 
activity were inconsistent across tests (e.g. open field, D/LT, MM and EPM). Open field revealed no 
effect of BPA exposure except for increased grooming frequency in female exposed prenatally to high 
dose BPA. The prenatally BPA exposed females exhibited an increased anxiety-like state in the D/LT, 
MM, and EPM tasks, (0.05 > ps < 0.001). The postnatally exposed females and the prenatally exposed 
males exhibited anxiogenic-like behaviour in two tests (D/LT, EMP) whereas the males with 
lactational exposure exhibited an anxiogenic-like behaviour only in EMP. The results of the FS task 
showed that gestational exposure (both doses) increased the immobile time in both sexes (ps < 0.001), 
and the same effect was induced by lactational exposure only with 4 mg/kg/d BPA.  
Western blot analyses showed that both exposure periods inhibited the expression of the AMPA 
receptor subunit GluR1 in the hippocampus and amygdala in mice of both sexes, whereas the level of 
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the NMDA receptor subunit NR1 was increased in the amygdala following gestational exposure but 
was reduced in the hippocampus of the females with lactational exposure (p<0.05). The authors 
suggest that perinatal exposure to BPA increase anxiety- and depression-like behaviours of adult ICR 
mice of both sexes but that gestational exposure exhibits a stronger effect than lactational on anxiety-
like state in females. Down regulation of AMPA and NMDA receptors in the hippocampus and 
amygdala may be associated with BPA-induced behavioural changes. 
Comments from the CEF Panel 
The CEF Panel identified the following strengths/weaknesses in the study: 
  Strengths: 
- Phytoestrogen-free diet 
Weaknesses: 
- Study design not appropriate to the scope (sequence of testing not randomized)  
- Insufficient study reporting (oral route not specified) 
- Type of cages and drinking bottles not reported 
- Statistical analysis (multiple comparison statistics not considered) 
 
Overall, the CEF Panel noted that this study does not detail control of potential environmental sources 
of exposure, except that soy free feed was used. The study aimed to compare the exposure effects of 
two developmental windows. The effects of BPA on the end-points considered were about similar 
irrespectively of exposure period was gestational only or lactational only, although exposure differs by 
orders of magnitude. The sample size for the behavioural measures was adequate (n=10 per sex per 
group) and litter effect was considered (1 pup per litter per sex per group). However, sample size for 
Western blot was limited (n=5), and the sacrificing and brain collection procedures are not detailed. It 
cannot be excluded that only one week recovery after surgery (ovariectomy) and until test start may 
have influenced on the results. The use of different behavioural tests and the attempt to relate 
behaviour with molecular changes at the level of glutamate receptors are considered positive. 
However, testing different tests on subsequent days may influence on the results. Result for 
depression-like behaviour in the FS task seems consistent. Similarly, result for reduction of 
exploration in the EPM and for the anxiogenic-like effects of BPA in females seems to be consistent. 
The behavioural findings might reasonably be related to the molecular changes reported in the 
hippocampus and amygdala as there are experimental data indicating that glutamatergic receptors are 
involved in anxiety/fear responses in rodents.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Xu X, Liu X, Zhang Q, Zhang G, Lu Y, Ruan Q, Dong F and Yang Y, 2013a. Sex-specific effects 
of bisphenol-A on memory and synaptic structural modification in hippocampus of adult mice. 
Hormones and Behavior, 63, 766-775. 
For study details see (2) Studies examining effects of BPA on learning and memory. 
 
(2) Studies examining effects of BPA on learning and memory 
Diaz Weinstein S, Villafane JJ, Juliano N and Bowman RE, 2013. Adolescent exposure to 
Bisphenol-A increases anxiety and sucrose preference but impairs spatial memory in rats 
independent of sex. Brain Research, 1529, 56-65. 
For study details see (1) Studies examining effects of BPA on anxiety-like behaviour 
 
Eilam-Stock T, Serrano P, Frankfurt M, Luine V, 2012. Bisphenol-A impairs memory and 
reduces dendritic spine density in adult male rats. Behavioral Neuroscience, 126, 175-185.  
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This paper examined the effects of a single subcutaneous BPA administration on memory and synaptic 
plasticity in adult (60-70 days old) male Sprague Dawley rats. BPA (40 μg/kg) was administered 
subcutaneously between training and retention testing in an Object recognition (OR) task and an 
Object placement (OP) test, respectively, which measure both visual and spatial memory. The two 
tests were performed 4 days apart and groups were switched between tasks so that controls in the OR 
test was exposed to BPA in the OP test and vice versa. The authors did not expect lingering effects of 
BPA due to short half life.  
 
After at time delay of 11 days the rats were exposed to BPA according to the pattern of the OR-groups 
and underwent a test session. Immediately (40 min) after completion of the learning task, rats were 
decapitated and brains removed for morphological and chemical analyses. Dendritic spine density in 
pyramidal cells in CA1 and medial prefrontal cortex (mPFC) were evaluated by Golgi preparations in 
a subgroup of rats (n=7) receiving the same dose of BPA, while the activity of several proteins 
involved in memory consolidation processes were examined by Western blotting. The behavioural 
data were analysed by two-way repeated measures ANOVA (Group x Object) with post hoc one-
tailed, paired t test between the time spent with new vs. old objects/placements during the recognition 
trial in each of the groups (BPA and control). Apical and basal spine densities were analysed by two-
way ANOVA (group x area) followed by post hoc t-tests. 
 
In BPA exposed rats, significantly impaired object recognition and detection of spatial novelty were 
reported (p<0.05). In the rats which underwent memory trials, BPA significantly decreased spine 
density in both areas evaluated. In the additional group, BPA caused no differences in dendritic spine 
density in any areas and the values were generally lower than in the tested rats. The authors comment 
that in the absence of memory consolidation processes, the increase in spine density is moderate.  
Additionally, BPA significantly decreased PSD-95, a synaptic marker, in the hippocampus and 
increased cytosolic pCREB, a transcription factor, in mPFC. The authors conclude that these findings 
show that a single dose of BPA may block the formation of new memories by interfering with neural 
plasticity processes in the adult brain.  
 
Comments from the CEF Panel: 




- Small sample size (n = 6) 
- Single acute dose administration 
- Single dose level 
- Study design not appropriate to the scope (all test animals were exposed to BPA, no control 
group) 
- Testing performed in one sex only (male) 
- Animal diet and phytoestrogen content not reported 
 
The CEF Panel noted that the study was performed in adult rats using an acute subcutaneous 
administration which limit its value in risk assessment, but that a similar experimental protocol is 
challenging to apply in developing rats due to the complexity of the learning task. Parallel assessment 
of neurobiological markers (decreased spinogenesis and PSD95) in two different brain areas and 
functional effects has been done, but the sample size was rather small (n = 6). The study design imply 
that all animals were exposed to BPA. 
  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
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Ferguson SA, Law CD and Abshire JS, 2012. Developmental treatment with bisphenol A causes 
few alterations on measures of postweaning activity and learning. Neurotoxicology and 
Teratology, 34, 598-606. 
 
Pregnant Sprague-Dawley rats were orally exposed (gavage) on gestational days 6–21 with vehicle, 
2.5 or 25 µg BPA/kg bw per day in 0.3% carboxymethylcellullose (CMC), or 5.0 or 10.0 µg/kg bw per 
day ethinyl oestradiol (EE). Additionally, a naïve control was included as control for potential stress 
induced by oral gavage. The animals were maintained in a low exogenous oestrogen environment. On 
PND 1, litters were culled to four males and four females, and the pups were then orally treated on 
postnatal days 1–21 with the same doses as their dams received. Post-weaning, one offspring/sex/litter, 
providing a number of 11–12/sex/group, were assessed for treatment-related effects in a Novelty 
preference test (PND 29), Open field test (PND 40-42), Motor coordination (PND 43-44), Barnes 
maze (PND 47-50), acoustic startle response (PND 54), and Morris water maze (PND 75-79). 
Behavioural data were analysed by repeated measure analyses (SAS version 9.2, SAS Institute Inc., 
Cary, NC). For datasets in which there was a repeated measure (e.g. test days 1–5 for water maze 
endpoints), within-group correlations were modelled using the heterogeneous AR1 correlation 
structure. For data without normal distributions, a log transform or an ANOVA on ranks (i.e. Kruskal–
Wallis ANOVA) was conducted. 
Some treatment-related effects were evident in both BPA and EE-treated animals, but differences were 
also seen between the naïve and vehicle controls. The main finding with BPA was a dose-related 
effect on open field activity of male offspring, activity being significantly increased relative to vehicle 
controls, with EE showing a stronger response. In the acoustic startle reflex test, males of the naïve 
control, 2.5 µg BPA/kg bw per day, 25 µg BPA/kg bw per day, and 10 µg/kg bw per day EE2 groups 
exhibited significantly less startle response on trials 1–5 than males of the vehicle control group. 
However, there were no significant differences between the BPA and EE2 female groups and the 
same-sex vehicle control group. No effects of BPA were observed on motor coordination, spatial 
learning and memory, although EE did have effects on several of these endpoints.  
Overall the authors concluded that BPA had few consistent effects on neurobehaviour typically 
measured in developmental neurotoxicity studies, in line with the results of earlier oral studies 
investigating the same endpoints. They noted that EE produced some behavioural alterations, although 
these were not substantial. The study is one of a series of studies by the same group of authors, 
investigating possible developmental and neurobehavioural effects of low-dose BPA compared with 
EE. 
  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Large sample size 
- Both naïve and vehicle controls available (to account for the handling of the animal) 
- Adequate positive controls included 
- Use of non-PC cages and of glass water bottles  
Weaknesses: 
- Study design not appropriate to the scope (only low doses BPA used) 
 
Overall the CEF Panel noted that this robust well conducted study shows very limited effects of BPA 
on neurobehavioural endpoints, with the positive control EE, showing more marked, but not 
substantial changes. Direct exposure of the offspring was used in addition to the exposure through 
maternal dosing, which in light of the low maternal dose used is an advantage, as well as the use of 
näive controls makes up for the disadvantage the handling may cause. Multiple tests were performed 
(Novelty preference test (PND 29), Open field test (PND 40-42), Motor coordination (PND 43-44), 
Barnes maze (PND 47-50), Acoustic startle response (PND 54, and Morris water maze (PND 75-79). 
As commented by the authors themselves, the BPA-induced hyperactivity seen in male offspring in 
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the open field test has not been reported in a number of other similar studies (e.g. Stump et al, 2010), 
and other measures examined in the study such as novelty preference, did not show evidence of BPA-
induced hyperactivity. The decreased startle response in the acoustic study compared with vehicle 
controls was also apparent in the naïve control and the apparent effect may be due to an aberrant 
heightened response in the vehicle control. The authors comment that none of the behaviours 
investigated are known to show sexual dimorphism, and BPA has been reported to affect sexual 
dimorphic behaviours. These have been investigated in this series of studies and will be reported in a 
further publication. 
A limitation of this study is the use of very low BPA doses. The inclusion of higher doses would have 
added consistency to the negative results of this study.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there . 
Inagaki T, Frankfurt M and Luine V, 2012. Estrogen-induced memory enhancements are 
blocked by acute bisphenol A in adult female rats: role of dendritic spines. Endocrinology, 153, 
3357-3367. 
 
The aim of this study was to examine effects of acute BPA exposure, alone and in combination with 
oestrogens (17-α or 17-β estradiol, E2), on E2-induced memory enhancement and synaptic plasticity in 
ovariectomized (OVX) and gonadally intact, cycling adult female rats. The study tested effects of BPA 
alone, and in combination with the most effective E2 doses, on recognition memory.  
 
Female Sprague Dawley rat (83 OVX and 18 intact, 3 months of age) were administered BPA at levels 
from 0.4 µg/kg to 400 µg/kg by subcutaneous administration. A positive control was not included but 
some groups of animals received BPA co-administrated with 17α- E2 or 17β- E2. Animals were fed 
low phytoestrogen food. Two types of hippocampal-dependent memory tasks, object placement (OP) 
and object recognition (OR), were done. Ovariectomized rats (n=6-8 per dose level) received BPA 30 
min before a sample trial (viewing objects) and immediately after the sample trial and retention trials 
were performed 4 h later. Retention trials tested discrimination between old and new objects (visual 
memory) or locations (place memory). Those tests were done every 10 days for about 2 months. 
Thereafter, elevated plus maze (EPM) was used to examine whether BPA indirectly may impair 
recognition memory by increasing anxiety levels of the subjects. Prior to EPM testing, OVX rats were 
given 20µg/kg 17-βE2, which enhanced OP memory, and 40 µg/kg bw BPA, which did not affect 
memory but antagonized E2. Spine density and serum E2 level analysis were done 10 days after the 
final behavioural tests in OVX rats. In intact, cycling rats vehicle or BPA (40 µg/kg) was 
administrated immediately after T1 and retention tested 2 hour later. Spine density was assessed at 
times of memory consolidation (30 min) and retention (4 h) after 17β-E2 (20µg/kg) or BPA (40 µg/kg) 
+ 17β-E2 in OVX animals. For memory tests, data were analysed by one-way ANOVA followed by 
Fisher’s least significant differences (LSD) post hoc tests. Ooestrous phase data were tested by two-
way ANOVA (treatment, ooestrous cycle). Data for EPM were tested by one-way ANOVA. For spine 
density, one-way ANOVA with Newman-Keuls post hoc tests were used. 
 
In OVX animals treated with BPA, no statistical significant difference was observed in the spatial OP 
and non spatial OR memory consolidation test. When given immediately after the sample trial, BPA at 
1–400 µg/kg bw, did not alter recognition memory, but doses from 4 µg/kg blocked 17β-E2-dependent 
increases in OP memory enhancement and from 40µg/kg OR memory consolidation. BPA inhibits 17-
αE2-induced OP memory enhancements from 1µg/kg. No inhibition of the 17α-E2-induced OR 
memory enhancements was observed with BPA treatments. No significant effect on anxiety was 
observed in the elevated plus maze with E2 (20 µg/kg) nor BPA (40 µg/kg) or in combination. BPA, 
given to cycling rats at 40 µg/kg (unique dose level tested), reduced OR memory during pro-oestrus 
when 2 h inter trial delays were given. In prefrontal cortex, BPA did not alter E2-dependent increases 
in spine density. In the hippocampus, BPA blocked E2 increases in basal spines at 4 h and was 
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additive with E2 at 30 min. Thus, the authors conclude that doses of BPA alter neural functions 
dependent on E2 in adult female rats. No statistically significant difference between the serum E2 
level analysis were observed between the E2 (20 µg/kg) and the combined E2 (20 µg/kg) and BPA (40 
µg/kg) group.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- BPA measurement in biological samples (serum) 
Weaknesses: 
- Single acute dose administration 
- Test performed in one sex only 
- Insufficient study reporting (study design, doses and number of animals used in the various 
tests appears unclear; except from feed content, no information of environmental 
contamination of BPA is given, i.e. cages, water bottles, or bedding) 
- Inappropriate statistics (considerations of repeated measures of the same animal were not 
included in the statistical analyses, neither multiple endpoint within a test) 
 
Overall the CEF Panel noted that handling and administration of the rats in connection with testing 
may influence the test results.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Jang YJ, Park HR, Kim TH, Yang WJ, Lee JJ, Choi SY, Oh SB, Lee E, Park JH, Kim HP, Kim 
HS, Lee J, 2012. High dose bisphenol A impairs hippocampal neurogenesis in female mice across 
generations. Toxicology, 296, 73-82. 
 
Pregnant female C57BL/6 mice (F0) were exposed to BPA (purity > 99.7%) in corn oil at 0.1, 1 or 10 
mg/kg bw by daily intraperitoneal injection from gestation day 6 to 17. Female offspring (F2) obtained 
from F1 females of various groups mated with F1 control males were examined for hippocampal 
neurogenesis (PND 44) and behaviourally tested by the Morris water maze (PND 56-63) and Passive 
avoidance, the step through test (PND 63-65). F2 mice were 6 weeks old, randomly divided into 4 
groups (n=20 or 22 mice/group). Hippocampal neurogenesis was measured in separate groups of mice 
following treatment with BrdU (100 mg/kg body weight, intraperitoneally, twice a day) during each of 
the 3 days prior to sacrifice (PND 42-44). Data were analysed by analysis of variance (ANOVA) with 
Fisher’s protected least significant difference (PLSD) procedure. 
Exposure of F0 mice to BPA at 10 mg/kg significantly (p < 0.01) decreased hippocampal neurogenesis 
as assessed by measurement of the number of newly generated cells in the hippocampi of F2 female 
mice (n=5 mice/group). Passive avoidance testing revealed that high-doses BPA (1 mg/kg and 10 
mg/kg) significantly (p < 0.05) decreased cross-over latency time in F2 mice (n=5 mice/group) in the 
step through test. However, the MWM (Morris Water Maze) did not show a significant difference 
between the treated mice versus control group (n=5 mice/group). It was found that levels of phospho-
ERK, brain-derived neurotrophic factor (BDNF), and phospho-CREB in hippocampi were 
significantly lower (p < 0.05 – 0.01) in F2 mice at 10 mg/kg (n=5-8 mice/group). The effects of 10 
mg/kg BPA on hippocampal neurogenesis were found to correlate with altered DNA methylation, in 
particular, of the CREB regulated transcription co-activator 1 (Crtc1) generated in F2 mice. The 
authors conclude that BPA exposure of pregnant mice could adversely affect hippocampal 
neurogenesis at 10 mg/kg and cognitive function (1 and 10 mg/kg) in future generations by 
modulating the ERK and BDNF–CREB signalling cascades.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
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Strengths: 
- Number of BPA doses (3)  
Weaknesses: 
- Small sample size 
- Maternal administration via ip injection during pregnancy 
- Test performed in one sex only 
- Low number of animals tested 
- Insufficient study reporting (number of females in the F0 generation was not given; animal 
body weight not given; animal diet and phytoestrogen content not reported; no information of 
environmental contamination of BPA is given, i.e. cages, water bottles, or bedding) 
- Inappropriate statistics(litter effect not considered, no correction for multiple comparisons) 
Overall, the CEF Panel noted that the intraperitoneal route of exposure during pregnancy limits the 
relevance of this study in human risk assessment, since the dose levels are very high when the route of 
exposure is taken into account. The consideration of litter effect is not clearly addressed by the authors 
and the size of the group is quite small, usually 5 mice/group. No positive control was included and 
the number of females in the F0 generation was not given.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Jasarevic E, Williams SA, Vanda GM, Ellersieck MR, Liao C, Kannan K, Roberts RM, Geary 
DC, Rosenfeld CS, 2013. Sex and dose-dependent effects of developmental exposure to bisphenol 
A on anxiety and spatial learning in deer mice (peromyscus maniculatus bairdii) offspring. 
Hormones and Behavior, 63, 180-189.  
For study details see (1) Studies examining effects of BPA on anxiety-like behaviour.  
Jones BA and Watson NV, 2012. Perinatal BPA exposure demasculinizes males in measures of 
affect but has no effect on water maze learning in adulthood. Hormones and Behavior, 61, 605-
610.  
For study details see (1) Studies examining effects of BPA on anxiety-like behaviour. 
 
Kim ME, Park HR, Gong EJ, Choi SY, Kim HS and Lee J, 2011. Exposure to bisphenol A 
appears to impair hippocampal neurogenesis and spatial learning and memory. Food and 
chemical toxicology, 49, 3383-3389. 
 
C57BL/6J male mice (42-days old) were orally (gavage) exposed to vehicle (corn oil) or BPA 1, 5 and 
20 mg/kg bw per day for 2 weeks (n= 5 per group). Neurogenesis (proliferation) was assessed by 
intraperitoneal administration of bromodeoxyuridine (BrdU) 100 mg/kg bw twice a day for the last 3 
consecutive days of BPA treatment, while survival of newly generated cells was assessed in separate 
groups of mice (n=5) given BrdU for 3 consecutive days prior to the commencement of BPA 
treatment. No BPA-related effect on body weight or systemic toxicity was reported. At days 56 to 63, 
learning and memory was assessed in the Morris water maze (7 days of training). Data were analysed 
by one-way analysis of variance (ANOVA) with Fisher’s protected least significant difference 
(PLSD). While the high dose (20 mg/kg) decreased neurogenesis and significantly impaired spatial 
learning in the Morris water maze, the lower dose increased neurogenesis (p<0.01) and had no effect 
on learning abilities. No neuronal loss or damage was observed in the hippocampus after BPA 
treatment of 20 mg/kg as evaluated by examinations of neuron morphologies and determination of 
neuron density in Nissl stained sections. BPA had no effect on brain-derived neurotrophic factor 
(BDNF) levels or reactive oxygen species production in the hippocampus. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
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- Number of doses (3) 
Weaknesses: 
- Small sample size (n = 5- 6 per group) 
- Test performed in one sex only (male) 
- Insufficient study reporting (unclear number of mice used and whether the investigation of 
newly generated cells was performed in separate groups of mice or not; animal diet and 
phytoestrogen content not reported)  
- Inappropriate statistics(Fisher’s protected LSD test applied does not adequately protect from 
Type 1 Error increase due to multiple comparisons) 
 
Overall, the CEF Panel noted that in this study effects were seen only at high doses, not at 5 mg /kg 
bw per day or lower, and even the exposure period was limited adolescent mice at 5 weeks of age are 
still in a very vulnerable developmental phase (middle-late adolescence). The main limitations of this 
study is the reduced sample size (n = 5- 6 per group) and shortcomings in the statistical analyses.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Matsuda S, Matsuzawa D, Ishii D, Tomizawa H, Sutoh C, Sajiki J and Shimizu E, 2013. 
Perinatal exposure to bisphenol A enhances contextual fear memory and affects the 
serotoninergic system in juvenile female mice. Hormonal Behaviour, 63, 709-716. 
 
Pregnant C57BL/6J mice were subcutaneously (SC) injected with vehicle (0.01% methanol in 
phosphate buffered saline) or 250 ng BPA/kg/day from gestational day (GD) 10 to postnatal day 
(PND) 20. Every third day from GD 11 to PND 21 the dams were weighed. BPA dose was calculated 
using 30 gram of expected mouse body weight and the injection volume was 100 microliter. Litters 
were culled to six pups (3 female and 3 male) at PND 2. When the litter size was less than six, foster 
dams were used. Four week (juvenile) and nine weeks (adult) old offspring (N=9-12 sex/group) were 
tested for fear memory or were sacrificed to collect brain tissue.  
Serotonin (5-HT) and 5-HIAA were extracted and analysed by use of high-performance liquid 
chromatography (HPLC) in adult and juvenile mice of both sexes. In brains of juvenile females, the 
gene expressions of 5-HT metabolite-related enzymes and 5-HT receptors were analysed using 
quantitative real-time RT PCR. Three-way ANOVA (age, sex, treatment), followed by post hoc 
Bonferroni analyses, and Student's t-test was used for 5-HIAA and 5-HT and the ratio 5-HIAA/5-HT. 
Fear memory was tested by use of a fear conditioning procedure: Mice were habituated to the test 
chamber for one 20-min session. The following day, after 3-min acclimation period (PRE) mice 
received three foot shocks (2 s, 0.75 mA, foot shock-interval: 60–120 s) through a metal-grid floor and 
returned to their home cage 3 min after the last foot shock (POST) (about 10 min session). The next 
day (TEST), when returned to the chamber for a 3-min session, the number of freezing exhibited was 
recorded as a measure of fear memory by used of a software program (FreezeFrame). Freezing was 
converted to a percentage [(freezing observations / total observations) × 100] for the PRE, POST, and 
TEST periods. Behavioural data were analysed by 3-way ANOVA (age, sex, and treatment) with 
repeated measures (test) and post hoc Bonferroni tests were performed for multiple comparisons.  
Effect of BPA was observed in juvenile females only, which showed higher freezing percentages than 
the vehicle-exposed mice (41.02 ± 4.94% vs. 25.58 ± 3.40%). Thus, juvenile BPA-exposed females 
were divided into two groups which were injected SC from PND 25 to PND 28 with vehicle (N=8) 
and the selective serotonin re-uptake inhibitor sertraline (5 mg/kg, N=11), respectively. Juvenile 
control females were administered vehicle on the same days. Testing for fear memory was performed 
as described above and data were analysed by 2-way repeated-measures ANOVA (treatment and test). 
No main effect of treatment or interaction appeared, but when data for the two BPA groups were 
collapsed a slight effect of BPA vs. control appeared. 
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BPA enhanced fear memory, increased serotonin metabolite (5-HIAA) levels and the ratio 5-HIAA/5-
HT in brain areas and increased the expression levels of Tph2, Slc6a4, and Maoa mRNA in the 
hippocampus of juvenile female mice. The authors conclude by suggesting that perinatal exposure to a 
low dose of BPA may enhance fear memory and the 5-HTergic system in juvenile mice. 
Comments from the CEF Panel:  




- Single dose level (250 ng/kg bw per day BPA) 
- Insufficient study reporting (number of dams and general reproductive outcome not given; no 
information about check for cycling in adult female offspring; no information about 
environmental BPA contamination e.g. feed and bedding) 
- Insufficient BPA-exposure assessment (constant during pregnancy and lactation and not 
adjusted daily to body weight) 
- Animal diet and phytoestrogen content not reported 
- Use of polycarbonate (PC) cages and PC water bottles 
 
The CEF Panel noted that parallel assessment of molecular markers (5-HT and 5-HIAA) and 
functional end points (fear memory) has been performed. PC water bottles were used, but the drinking 
water was checked to be free of BPA. Pregnant mice were given two days of habituation from arriving 
to the laboratory until dosing started. A sufficient sample size of offspring was used for behavioural 
testing (n = 9-12), the litter effect is taken into account as pups from the same litter were not used in 
the same experiments, and the study attempts to correlate neurochemical and functional changes. The 
CEF Panel considers that the main limitation of this study lies in the uncertainty regarding exposure, 
as it appears that the daily PBA dose not was adjusted daily to body weight throughout pregnancy and 
lactation and that only a single dose level was tested, using the subcutaneous route. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Nakamura K, Itoh K, Dai H, Han L, Wang X, Kato S, Sugimoto T, Fushiki S, 2012. Prenatal and 
lactational exposure to low-doses of bisphenol A alters adult mice behavior. Brain & 
Development 34 (2012) 57–63 
For study details see (1) Studies examining effects of BPA on anxiety-like behaviour. 
Viberg H, Fredriksson A, Buratovic S and Eriksson P, 2011. Dose-dependent behavioral 
disturbances after a single neonatal bisphenol A dose. Toxicology, 290, 187-194.  
For study details see (1) Studies examining effects of BPA on anxiety-like behaviour. 
Xu XH, Wang YM, Zhang J, Luo QQ, Ye YP and Ruan Q, 2010a. Perinatal exposure to 
bisphenol-A changes N-methyl-D-aspartate receptor expression in the hippocampus of male rat 
offspring. Environmental Toxicology and Chemistry, 29, 176-181. 
 
This study has already been reviewed by the EFSA CEF Panel in its opinion of 2010 (EFSA CEF 
Panel, 2010). The review done is reported below. 
 
Xu et al. (2010a) gavaged groups of 8 to 9 pregnant Sprague-Dawley rats from GD 7 through PND 21 
with different doses of BPA (0.05, 0.5, 5, 50, 200 mg/kg bw perday). At birth, pups were culled to 
eight and pups were sacrificed to examine the hippocampal region on PND 4, 7, 14, 21, and 56 for 
expression of the N-methyl-D-aspartate receptor (NMDAR) subunits NR1, NR2A and NR2B, of 
oestrogen receptor beta (ERβ), and of aromatase cytochrome P450 (P450arom) protein. All the 
determinations were done only in male pups. At the lower doses of 0.05 to 50 mg/kg bw per day, BPA 
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concentration dependently inhibited the expression of NMDAR subunits. At the highest dose (200 
mg/kg bw per day), the effects of BPA on these subunits were different, with a stronger inhibition of 
NR1 expression and a slighter inhibition of NR2A, NR2B expression when compared with those at the 
lower dosage of BPA. 
According to the authors, these results indicate a change in the composition of NMDARs thereby 
affecting function of the hippocampus such as synaptic plasticity, learning, and memory. Perinatal 
exposure to BPA at doses ≥5 mg/kg b.w./day significantly inhibited the expression of ERβ protein in a 
dose-dependent manner early after birth (on PND 4 and 7). At later time points (from PND 14 to 56) 
the expression of this protein was significantly decreased in comparison with control values only in 
the high dose group (200 mg/kg bw per day). Aromatase was dose-dependently (≥0.05 mg/kg bw per 
day) increased during the first 1-3 postnatal weeks, with no effects being detectable on PND 56. 
The Panel considers that biochemical changes are not sufficient to revise the TDI in the absence of a 
clear link to an adverse outcome (i.e. a functional correlate). In addition, the Panel has identified 
shortcomings mostly in study reporting that bring into doubt the validity of the study. 
Specifically, there is no indication of the number and the identity of the animals used for testing, and 
on whether the statistical analysis was performed on a “per litter” basis. In addition, only one sex was 
tested and there was no reporting on the animal housing conditions, the diet administered and the type 
of bottles used for drinking water. 
Xu XH, Zhang J, Wang YM, Ye YP and Luo QQ, 2010b. Perinatal exposure to bisphenol-A 
impairs learning-memory by concomitant down-regulation of N-methyl-D-aspartate receptors of 
hippocampus in male offspring mice. Hormones and Behavior, 58, 326-333. 
In the ANSES risk assessment of 2013 this oral study by Xu et al. (2010b) in mice was taken as the 
key study for neurodevelopmental toxicity, where the critical effects were the alteration of memory 
and learning functions paralleled by a decrease in the expression of glutamate NMDA receptors. 
Therefore this study has been revisited in depth by the CEF Panel for the current evaluation. 
The purpose of the Xu study was to investigate the effects of perinatal exposure to BPA on 
learning/memory and its mechanism of action, especially focusing on N-methyl-d-aspartate receptor 
(NMDAR) and expression of oestrogen receptor beta (ERβ). BPA at 0.05, 0.5, 5 and 50 mg/kg bw per 
day were given by oral injections to pregnant ICR mice (n=10/group) from gestational day 7 to PND 
21. After parturition (postnatal day 0, PND) litter were culled. At weaning, same sex littermates were 
group housed. At PND 21-25 and 56-60, respectively, male offspring (n=10/group per test time)were 
tested in the Morris water maze (spatial memory task) for four days with four daily sessions followed 
by a probe session the fifth day. At PND 26 and 61, respectively, males (n=10/group) were subjected 
for training session of the step-down passive avoidance task, and retention test sessions were carried 
out 24 h thereafter (i.e. at PNDs 27 and 62). At PND 21 and 56, respectively, male offspring 
(n=10/group) were sacrificed and brains collected and prepared for analyses by gel electrophoresis and 
immunoblotting (Western blot). 
One-way analysis of variance (ANOVA) was applied to the data of the step-down passive avoidance 
test and Western blot. For the Morris water maze, data from the probe trial were analysed by 1-way 
ANOVA, whereas 2-ways ANOVA was used for analyses of effects of treatment and training. For 
comparisons between groups, Tukey's test was used. 
In male offspring, at both test times BPA dose-dependently extended the escape length to find the 
hidden platform in the Morris water maze even the swim velocity were the same. At the early test 
time, the upper two BPA doses were most effective in increasing the escape length, whereas the three 
upper doses did so at PND 56-60. Data from the probe trials revealed normal memory retention in all 
groups.  However, at the probe trial PND 25, BPA at 0.5 mg/kg bw per day decreased the percentage 
of time spent in the quadrant where the platform had been during training in male offspring, whereas 
at PND 60 BPA both at 5 or 5 mg/kg bw per day did so.  
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 362 
The results of step-down passive avoidance test (instrumental conditioning where mice have to inhibit 
an escape response in order to avoid a punishment) showed that the error frequency to step down from 
the platform after receiving foot-shock was significantly increased, and the latency of the step-down 
response onto the grid floor 24h after received foot-shock was reduced by exposure to BPA at 5 and 
50 mg/kg bw per day (P<0.01) in the PND 26 offspring, and at 50 mg/kg bw per day in the PND 61 
offspring (P<0.01).  
Perinatal exposure to BPA significantly inhibited the expressions of NMDAR subunits NR1, NR2A, 
and 2B in the hippocampus during the development stage, especially in PND 56 male mice. Dose-
response was only seen for subunit NR1 in 21 days old males. The expressions of oestrogen receptor 
beta (ERbeta) in both PND 21 and PND 56 mice were markedly down-regulated by BPA at 0.5, 5, and 
50 mg/kg bw per day. The authors conclude that these results indicate that perinatal exposure to BPA 
impairs both spatial memory and avoidance memory. The inhibition of expressions of NMDAR 
subunits and ERbeta in hippocampus during postnatal development stage may be involved. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Number of doses (4) 
- Phytoestrogen-free diet 
Weaknesses: 
- Test performed in one sex only (only male offspring) 
- Insufficient study reporting (reproductive outcome not shown, e.g. maternal bw, no pre-
weaning body weight data shown; information about type of bedding and water bottles 
missing; no indication of the number and the identity of the animals used for testing) 
- Insufficient BPA-exposure assessment (unknown if constant during pregnancy and lactation 
and or adjusted daily to body weight, see line above)  
 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
 
Xu X, Tian D, Hong X, Chen L, Xie L, 2011. Sex-specific influence of exposure to bisphenol-A 
between adolescence and young adulthood on mouse behaviors. Neuropharmacology. 2011 
Sep;61(4):565-73. doi: 0.1016/j.neuropharm.2011.04.027. Epub 2011 May 5. 
 
For study details, see (1) studies examining the effects of BPA on anxiety-like behaviour. 
 
Xu X, Liu X, Zhang Q, Zhang G, Lu Y, Ruan Q, Dong F and Yang Y, 2013a. Sex-specific effects 
of bisphenol-A on memory and synaptic structural modification in hippocampus of adult mice. 
Hormones and Behavior, 63, 766-775. 
 
This study aims to evaluate the effects of long-term exposure to BPA on memory and modification of 
synaptic structure in hippocampus of adult mice. Adult ICR mice were exposed to BPA (0.4, 4, and 
40mg/kg/day) or arachis oil for 12 weeks by oral gavage needle placed at the back of the mouth (22 
mice/group). Body weights were recorded at start and end of treatment. Three days after end of BPA 
exposure, ten mice per group were sacrificed and brains were collected for 1) electron microscopic 
preparations and morphometric measurement (n=6 mice/group) and 2) tissue preparation, gel 
electrophoresis and immunoblotting (n=4 mice/group). Additionally, after termination of treatment (22 
weeks of age) 10-12 mice per group were behaviourally tested in the open field test for locomotor 
activity, and subsequently in two learning tasks, the Morris Water Maze and the Passive Avoidance 
test (step down test).  
Data from acquisition training (days 1–4) in the Morris water maze was analysed by three-way 
repeated analysis of variance (ANOVA) (sex, treatment, day), whereas for the probe trial a two-way 
repeated ANOVA was applied (sex, treatment). The latter was also used for data of the open field, 
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step-down passive avoidance task, body weight, the synaptic density and the synaptic interface 
structure parameters. One-way repeated ANOVA was applied to the data of reproductive organ 
weight, serum steroids, and Western blot analyses. Multiple comparisons within significant 
interactions were performed with the Tukey's HSD test. 
Results showed that BPA increased the frequency of rearing (0.4 and 4 mg/kg bw per day), grooming 
(4, and 40 mg/kg bw per day) and time in the central area (40 mg/kg bw per day) of the open-field in 
males, while BPA at 0.4 mg/kg/day reduced the frequency of rearing in the females. BPA at 0.4 or 40 
mg/kg bw per day extended the average escape path length to the hidden platform in Morris water 
maze task during the training phase but not the probe day, and at 40 mg/kg bw per day shortened the 
step-down latency 24h after foot-shock of the males, but no changes were found in females. In males, 
BPA at the lowest and highest dose reduced numeric synaptic density of pyramidal cells in 
hippocampus CA1 compared to controls, whereas the same doses increased it in BPA females when 
compared to BPA males. BPA had a negative effect on the structural parameters of synaptic interface, 
including an enlarged synaptic cleft (all doses) and reduced length of active zone (lowest dose only) 
and PSD thickness, in the hippocampus of the male mice compared to controls, but not in females. 
Western blot analyses further indicated that BPA (all doses) down-regulated expressions of synaptic 
proteins (synapsin I and PSD-95) and synaptic NMDA receptor subunit NR1 and AMPA receptor 
subunit GluR1 in the hippocampus of the males, but not females. The authors concluded that these 
results suggest that long-term exposure to low levels of BPA in adulthood sex-specifically impair 
spatial and passive avoidance memory of mice. These effects may be associated with the higher 
susceptibility of the hippocampal synaptic plasticity processes, such as remodelling of spinal synapses 
and the expressions of synaptic proteins (e.g. synapsin I and PSD-95) and NMDA and AMPA 
receptors, to BPA in the adult male mice. 
Comments from the CEF Panel 
The CEF Panel identified the following strengths/weaknesses in the study: 
  Strengths: 
- Number of BPA doses (3) 
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic water bottles 
- Blinded evaluation of data from the open field test, not specified for the MWM or for passive 
avoidance 
Weaknesses: 
- Insufficient study reporting (body weight data collected during treatment not shown) 
 
Overall, the CEF Panel noted parallel measurement of synaptic morphology (neural plasticity index) 
and functional endpoints. The cycle stage of females was checked and females in deviating stage 
compared to the majority (di-oestrus) were excluded from the data analyses.  The prolonged treatment 
(about 12 weeks) and use of three dose levels of BPA were noted, however the highest dose was very 
high (40mg/kg bw per day). The effects on learning functions were significant in males only in the 
spatial learning task (MWM) and only for the intermediate and high doses. The effects of BPA on 
passive avoidance (an instrumental learning task not involving spatial learning processes) were also 
limited to males and observed only at the highest dose (40 mg/kg/bw day). The extent of the structural 
changes in the synapses of the hippocampal CA1 areas was limited. Significant reduction in 
expression of the major synaptic proteins analysed was found in males only. The learning impairment 
in males found in the spatial learning task might be possibly linked to the alteration of the synaptic 
structural/molecular properties. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
(3) Studies examining the effects of BPA on social behaviour  
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Kundakovic M, Gudsnuk K, Franks B, Madrid J, Miller RL, Perera FP, Champagne FA, 2013. 
Sex-specific epigenetic disruption and behavioral changes following low-dose in utero bisphenol 
A exposure. Proceedings of the National Academy of Sciences of the United States of America, 
110, 9956-9961.  
Balb C female mice were daily exposed by oral administration to 2, 20, 200 µg/kg BPA or vehicle 
from mating until gestation day (GD) 19. The breeding design generated a minimum of 12 litters per 
treatment [vehicle (n = 14), 2 µg/kg (n = 17), 20 µg/kg (n = 15), and 200 µg/kg (n = 12) BPA]. From 
postpartum days 1 to 6, dam–pup interactions were observed to determine BPA-induced effects on 
maternal behaviour and the effects of postnatal maternal behaviour on the possible BPA-induced 
outcomes in offspring. 
At weaning (PND 28), six male and six female offspring per treatment [one or two pups per litter from 
a minimum of five litters per treatment for each sex; total litters, vehicle (n = 8), 2 µg/kg (n = 7), 20 
µg/kg (n = 8), and 200 µg/kg (n = 7) BPA], were killed and whole brains were dissected (prefrontal 
cortex, hippocampus, hypothalamus) for gene expression and DNA methylation analyses. Remaining 
animals underwent behavioural testing from PND 30 to 70 [male and female offspring from vehicle (n 
= 8–10), 2 µg/kg (n = 10–12), 20 µg/kg (n = 10), and 200 µg/kg (n = 12) BPA litters]. Testing 
included: 1) Home-cage social behaviour in offspring between PND 30 and 40 (60 min by 
observation), 2) an Open field (OF) area at PND 60 (video recording), and 3) Social approach and 
aggression between same sex-mice PND 70 (15 min).  
Data analyses was based on treatment of BPA dosage as a continuous predictor on a logarithmic scale 
(2, 20, 200 µg dose) and use of multilevel models to look for evidence of a curvilinear (quadratic) 
effect of dosage level on offspring gene expression and behaviour as well as on maternal behaviours 
(specifically licking/grooming and archedback nursing) of BPA-treated dams. A complementary two-
way ANOVA (sex and treatment) with Tukeys post hoc test for effects of dose was provided in the 
supporting information to the paper. 
In juvenile offspring, results showed that maternal BPA exposure during pregnancy induced sex-
specific, dose-dependent (linear and curvilinear) and brain region-specific changes in expression of 
genes encoding oestrogen receptors (ERs; ERα and ERβ) and oestrogen-related receptor-γ. Changes in 
ERα and DNA methyltransferase (DNMT) expression in the cortex (males) and hypothalamus 
(females) were associated with DNA methylation changes in the ERα gene.  
Between PND 30 and PND 40, home-cage social behaviour was examined and prenatal BPA 
treatment led to marginal sex-specific changes (huddling and sniffing). Some changes were observed 
in both sexes (allogrooming and hopping). The authors find that the prenatal BPA exposure also 
disrupted sexual dimorphism in play behaviours.  
At PND 60 in the open-field test measured as distance travelled, prenatal BPA exposure was 
associated with a hyperactive phenotype in males at all doses (p<0.01, ANOVA) and hypoactive 
phenotype in females (not statistically significant). BPA exposure at the highest dose increased 
anxiety-like behaviour in females (p<0.05, ANOVA) and decreased anxiety-like behaviour in males 
(not statistically significant) as measured as time spent in inner area. The authors find the open field 
test results to be sexually dimorphic, and that BPA treatment reversed sex differences in these 
behaviours (distance travelled, inner area time).  
At PND 70, prenatal BPA exposure affected dyadic social interactions (sniffing and aggressive 
behaviour) with a same-sex stimulus mouse. For both sexes, BPA had a marginal effect on sniffing but 
the authors find a differential effect by sex at high doses (reversal of sex differences). For both sexes, 
the authors find that prenatal BPA treatment increased the probability of being aggressive/ dominant at 
the highest dose, following a quadratic dose-response curve  
The effects measured in this study appeared to be of different extent and direction depending on BPA 
dose, suggesting that low doses can be more effective than the higher ones (non-monotonic responses). 
The author concluded that although postnatal maternal care was altered in mothers treated with BPA 
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during pregnancy, the effects of in utero BPA were not found to be mediated by maternal care, but that 
increased maternal care partially may attenuate the effects of in utero BPA on DNA methylation. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Number of dose groups (3) 
- BPA measured in biological sample (urine)  
- Use of non-polycarbonate (non-PC cages) 
Weaknesses: 
- Insufficient study reporting (ody weight, litter size and sex- ratio is not given; frequency of 
various postpartum maternal behaviours given without the litter size; the administration to 
dams is not specified except that it is oral; urine collection and analysis not described; the 
sacrificing and brain sampling procedures are not detailed; insufficient information concerning 
the scoring of social/aggressive behaviour; poor description of the social behaviour testing) 
- Inappropriate statistics (lack of accounting for multiple observations within each litter 
[pseudo-replication] in the ANOVA; the application of the multilevel regression model 
showed a large scatter of data within dose-groups [only four] and thus a large number of 
different dose-response curves can be fitted to the data so that it is not possible to conclude on 
the biological relevance for any of them)  
- Animal diet and phytoestrogen content not reported. 
- Type of drinking bottles not reported 
 
Overall, the CEF Panel noted that in this study three dose levels were used, and that the sample size is 
acceptable (n = 10 litters for the behavioural experiments, n = 5-6 in each sex for DNA methylation 
and oestrogen receptors expression in hypothalamus and frontal cortex). The CEF Panel also noted the 
parallel assessment of relevant molecular markers and behaviour as well as the assessment of potential 
effects of BPA on maternal behaviour of dams. The open field behaviour was recorded by video 
whereas for the social measures, data were recorded by observation. Two different tests for social 
behaviour were used (home cage social behaviour in juveniles and dyadic interaction with a same-sex 
stimulus mouse at day 70), but poor description of the testing was given. The paper does not address 
the possible influence of the open field results (motor activity and anxiety-like behaviour) on the 
social behaviour results, whereas maternal care was taken into account. The CEF Panel aknowledge 
that the multilevel (hierarchical) statistical models used take litter effect into account. Furthermore, the 
large scatter within the dose-groups for the behavioural endpoints does not allow concluding on the 
shape of the dose-response curve and even a conclusion that there is no dose-response would be 
compatible with the data (see Section 1.2).  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
Wolstenholme JT, Taylor JA, Shetty SR, Edwards M, Connelly JJ, Rissman EF. 2011a. 
Gestational exposure to low dose bisphenol A alters social behavior in juvenile mice. PLoS One, 
6, e25448.  
This study hypothesised that gestational exposure to BPA in mice affected social behaviour and 
expression of selected genes involved in neurobehavioural plasticity.  
The authors assigned adult female mice of the C57BL/6J strain before mating to either a 
phytoestrogen-free chow (n=11) or the same chow supplemented with 1.25 mg BPA per kg diet 
(n=12). All females consumed their assigned diets (food and water) ad libitum and the authors 
calculated that during the last 10 days of gestation the dams had an intake of approximately 5 µg of 
BPA per dam per day, i.e. approximately 140µg BPA/kg bw per day for a 35 g mouse. The authors 
also adopted a cross-fostering procedure at birth, to avoid any influence of BPA exposure on maternal 
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care (n=20 foster dams). Offspring (BPA = 21 male/18 female, control = 15 male/13 female) were 
subjected to Social interaction test on PND 20 (30 minutes, about 12-14 parameters observed), Social 
preference test on PND 24 (10 minutes, endpoint was time spent with stimulus mouse) and tested in an 
Elevated plus maze tests (EPM, 10 minutes) on PND 22, while gene expression analysis was 
performed on embryo brains (n=5/group). Unconjugated BPA was measured by HPLC in pooled 
serum samples from dams on gestational day 18.5 (4 BPA-dams, 3 controls), and the limit of detection 
(LOD) was 0.5ng/ml. Two-ways ANOVA (sex, diet) followed by Fisher’s exact post hoc test that 
adjusts significance levels and takes multiple comparisons into account, was used for analyses of 
behavioural data.  
BPA-chow diet increased blood level of BPA (0.43±0.002 ng/ml) when compared to control diet 
(0.099±0.014 ng/ml), and it was in the range detected in human maternal blood (0.3 to 18.9 ng/ml). 
Some of the behaviour parameters were observed to be sexually dimorphic, e.g. the non-social items 
exploring and sitting alone where males were more active than females, and the social items side-by-
side sitting where male were spent less time than female. The author suggest that BPA-exposed 
females, but not males, were more interactive compared to same sex controls because they spent more 
time side-by-side interaction, less time self-grooming, showed higher frequency of side-by-side 
behaviours others than grooming as well as of following other mice, and less frequency of self 
grooming (p<0.05). However, BPA did not affect social preference for the stimulus animal in a social 
preference test. In the Elevated Plus Maze task, anxiety-like behaviour evaluated as time spent in the 
open arms and closed arms and the number of crosses between arms was similar in the two groups. 
Gene expression analysis revealed mRNA for the glutamate transporter, Slc1a1, was enhanced by 
exposure to BPA in female brains and that expression of two of the three DNA methyltransferase 
genes, Dnmt1 and Dnmt3a, was modulated by BPA. Notably, expression of oestrogen receptors’ genes 
was not affected by BPA, but oxytocin receptor gene (highly responsive to oestrogen modulation and 
involved in social behaviour) was to some extent reduced in males.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- BPA measurement in animal samples (serum) 
- Phytoestrogen-free diet 
- Scoring blind to treatment 
Weaknesses: 
- Single dose level study 
- Feed consumption (BPA given by the diet) not measured 
- Insufficient study reporting (information of the content of the mixed litters like number of 
pups and sex ratio is missing;; no information of control of environmental contamination of 
BPA, i.e. cages and water bottles) 
- Insufficient BPA-exposure assessment (estimated on the basis of the daily quantity of food 
ingested, see line above) 
- Inappropriate statistics (litter effect not properly considered)   
 
Overall, the CEF Panel noted that the behavioural analysis included two different social behaviour 
tasks and a test specifically suited to reveal differences in general anxiety-like behaviour (elevated 
plus maze). However, the association of the behavioural results at weaning age with the small changes 
in gene expression found at the fetal stage is weak, and findings do not support novel mechanistic 
hypotheses. The main result of the social behaviour domain seems to be that females are more affected 
by gestational BPA exposure than males. The use of foster dams to ensure gestational BPA exposure 
only is considered challenging as it resulted in mixed litters and in some cases tail clipping of the pups 
which may have influenced on their social development and biased the subsequent testing of social 
interaction. Determination of serum levels below LOD was based on estimation by extrapolation of 
the standard curve to zero. The CEF Panel noted that the study has several methodological limitations. 
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This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Wolstenholme JT, Edwards M, Shetty SR, Gatewood JD, Taylor JA, Rissman EF, Connelly JJ, 
2012. Gestational exposure to bisphenol A produces transgenerational changes in behaviors and 
gene expression. Endocrinology, 153, 3828-3838. 
 
This study was aimed at assessing whether BPA exposure during fetal life has transgenerational 
effects on genes and behaviour in C57BL/6J mice. Female mice (n=5 per group, F0) received 
phytoestrogen-free chow with or without BPA (5 mg/kg diet, equivalent to approximately 1 mg 
BPA/kg bw per day based on a conversion factor of 0.2 (EFSA, 2012) seven to ten days before mating 
and throughout gestation. Subsequent generations (F1 to F4) received standard rodent chow containing 
phytoestrogens. F1 brother-sister pairs (BPA n=9, control n=8) were used to produce the 
transgenerational lines. The authors measured unconjugated BPA in three pooled serum samples from 
the F0 dams (two dams in each pool) and detected levels of 4.6, 3.9 and 2.0 ng/ml respectively, which 
the authors noted is comparable to those reported for human serum, 0.3– 4.0 ng/ml. Within 12 h after 
birth, all pups from control and BPA-consuming F0 dams were cross-fostered, i.e. to dams on control 
diet that had given birth within the past 24 hours.  
F1 juveniles of both sexes (about 10 animals per group) underwent evaluation for Social interaction on 
PND 20-21 (10 minutes), Social preference on PND 24 (10 minutes) and tested in an Elevated plus 
maze tests (EPM) on PND 22. Juveniles of the F2 and F4 generation (obtained by breeding brother-
sister pairs) were assessed in the free social interaction test. Expression of several genes (Er-alfa, Er-
beta, membrane bound oestrogen receptor, oestrogen-related receptor gamma, oxytocin, vasopressin 
and their respective receptors) were measured in the brain of 18-day embryos of the F1 and F4 
generation by microarray analysis and quantitative real time Polymerase Chain Reaction (QPCR). 
Two-ways ANOVA (sex, diet) followed by Fisher’s exact post hoc test that adjusts significance levels 
and takes multiple comparisons into account, was used for data analyses. 
Juvenile F1 mice exposed to BPA displayed significantly fewer social interactions as compared with 
control mice (side-by-side interactions and frequency of anogenital investigation), whereas the 
frequency of play solicitation was higher. In juvenile BPA-male, but not female, the social preference 
for an adult male was decreased. In later generations (F2 and F4), the effect of BPA was an increase of 
these social interactions. None of these behaviours appeared to be sexually dimorphic, nor was there 
any interaction between sex and diet. In the EPM no effect of BPA was revealed as the time spent in 
the open arms and closed arms and the numbers of crosses between arms were similar in both groups. 
In the BPA exposed-line, brains from embryos of F1 mice had lower gene transcript levels for several 
oestrogen receptors, oxytocin, and vasopressin as compared with controls; decreased vasopressin 
mRNA persisted into the F(4) generation, at which time oxytocin was also reduced but only in males. 
The authors conclude that exposure to a low dose of BPA during gestation has long-lasting, 
transgenerational effects on mRNA in brain and social behaviours.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- BPA measurement in animal samples (serum) 
- Phytoestrogen-free diet (F0-generation only) 
Weaknesses: 
- Single dose level study 
- Study design not appropriate to the scope (the number of dams in F0 generation was limited)  
- Insufficient study reporting (animal age and body weight not given; no normalization of food 
consumption on body weight, potential variability of exposure; lack of information of control 
of environmental contamination of BPA, i.e. cages, bedding and water bottles; lack of 
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information of mixed litters e.g. number of pups and sex ratio; reproductive outcome of the 
breeding brother-sister pairs done to obtain F2 to F4 generation is not given) 
- Inappropriate statistics (litter effect not properly considered)  
 
The CEF Panel noted the the study addressed association of BPA behavioural effects with expression 
of genes implicated in regulation of social behaviour and related sex dimorphism (ERs, oxytocin and 
vasopressin) in embryos across generations. The CEF Panel however considered the use of foster 
dams to ensure gestational BPA exposure challenging as it resulted in mixed litters and in some cases 
tail clipping of the pups, which may have influenced on their social development and biased the 
subsequent testing of social interactions. Exposure was estimated (20 µg daily) on the basis of the 
quantity of food ingested daily, but it is unclear if the authors calculated the amount of food consumed 
daily by each subject. The study thus has methodological limitations. The results on social behaviour 
throughout the generations were inconsistent (social interaction decreased in the F0 generation but 
increased in the F2 and F4 generations), whereas the effects on gene expression from F1 to F4 
appeared persistent. The CEF Panel acknowledges that variance in appearance of epigenetic 
expression may have influence on the inconsistency.  
This paper is included in the WOE table because of its relevance to one or more questions addressed 
there. 
Wolstenholme JT, Goldby JA and Rissman EF, 2013. Transgenerational effects of prenatal 
bisphenol A on social recognition. Hormones and Behavior, 64, 833–839 
 
Female C57BL/6 mice (F0) received 7-10 days prior to mating and throughout gestation 
phytoestrogen-free chow with (n=22) or without (n=74) BPA at 5 mg BPA per kg chow, which was 
calculated by the author to represent a daily intake of 20 µg BPA per dam. The subsequent F1 to F3 
generations received standard rodent chow containing phytoestrogens and no BPA exposure. Within 
12 h after birth, pups (F1) were cross fostered to control dams to limit BPA exposure to gestation in 
the first generation only. F0 foster dams (n = 48) retained two biological pups not included in the 
study, and received four F1-foster pups from the same litter (control litters n=26, BPA litters n = 22). 
Sibling pairs of F1 and F2 were bred to obtain the F2 and F3 generations (F1, BPA n=9, control n=9, 
F2, BPA n=15, control n=15).  
First (F1) and third (F3) generation juveniles were tested for Social recognition at postnatal day (PND) 
21 and in the open field at PND 23–24. Adult F3 mice of both sexes were tested for olfactory 
discrimination. Each mouse was tested in only one behaviour task and litter was taken into 
consideration. Two-way ANOVA with diet and sex as main factors was used for all behavioural data 
collected, in addition with trials as the repeated measure for social recognition and odour 
discrimination. Fisher’s Exact post-hoc test was used for following up analyses.  
BPA exposed juvenile F1 and F3 mice displayed higher levels of investigation than controls during the 
eight first trials in the Social recognition task. In the last trial, F3 male of the BPA exposed line, spent 
less time with the novel stimulus ovarioectomized mouse compared to other groups. In the open field 
no differences were noted for F1 mice, but increased activity in F3 BPA line age mice compared to 
controls. No group differences appeared for olfactory discrimination (assessed in F3 mice only). The 
authors conclude that these results show that BPA exposure during gestation has long lasting, 
transgenerational effects on social recognition and activity in mice.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Phytoestrogen-free diet (F0 dams) 
Weaknesses: 
- Single dose level study 
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- Insufficient study reporting (information on sex ratio in the F1 litters is missing, as well as 
reproductive outcome of the sibling mating performed to obtain F2 and F3 generations, 
unclear whether the authors actually measured the daily amount of feed consumed for each 
dam or averaged the amount based on previous knowledge; lack of information of control of 
environmental contamination of BPA, i.e. cages, bedding and water bottles) 
- F1-F3 fed chow containing phytoestrogens 
 
Overall, the CEF Panel noted that the use of F0 foster dams to ensure gestational BPA exposure only 
is challenging as it resulted in mixed litters. Compared to the two previous studies of this author (see 
above) it is considered an improvement that the mixed litters were standardized to six pups, and that 
tail clipping for identification purposes were limited to the biological pups which was not included in 
this study. One dose level of 5 mg BPA per kg chow was used, which is equivalent to about 1 mg 
BPA/kg bw per day based on a conversion factor of 0.2 (EFSA, 2012). However, exposure was 
estimated by the authors to be 20 µg daily per dam on the basis of the quantity of daily feed 
consumption, but it is unclear whether the authors actually measured the daily amount of feed 
consumed for each dam or averaged the amount based on previous knowledge. The study thus has 
methodological limitations.  
 
This paper will be included in the WOE table because of its relevance to one or more questions 
addressed there. 
 
(4) Studies examining the effects of BPA on sensory-motor function  
Ferguson SA, Law CD and Abshire JS, 2012. Developmental treatment with bisphenol A causes 
few alterations on measures of postweaning activity and learning. Neurotoxicology and 
Teratology, 34, 598-606. 
For study details see (2) Studies examining effects of BPA on learning and memory 
 
Wolstenholme JT, Goldby JA and Rissman EF, 2013. Transgenerational effects of prenatal 
bisphenol A on social recognition. Hormones and Behavior, 64, 833–839 
For study details see (3) Studies examining effects of BPA on social behaviour 
 
(5) Other studies 
No WoE was performed for the endpoint addressed by these studies. 
Jones BA, Shimell JJ, Watson NV, 2011. Pre- and postnatal bisphenol A treatment results in 
persistent deficits in the sexual behavior of male rats, but not female rats, in adulthood. 
Hormones and Behavior 59, 246–251 
 
Fifteen Long-Evans pregnant dams were orally exposed to corn oil (controls), 5 µg/kg, 50 µg/kg, 500 
µg/kg or 5 mg/kg body weight (bw) PBA by daily drinking from a syringe from gestation day 7 until 
lactation day 14 (3 dams/group). Adult offspring (postnatal day 90 and 120, n=12/group/sex) were 
evaluated for sexual behaviour by use of stimulus animals that were sexually experienced but 
gonadectomized and treated with male/female hormones, respectively.  
Male offspring were tested on three consecutive days to gain sexual experience and then they were 
finally tested seven days after the initial test day, i.e. totally four test days. Data were collected at the 
initial and final test days, representing sexually naïve and sexually experienced males, respectively. 
Test duration was until occurrence of the first mount following ejaculation and maximum 30 min if 
ejaculation failed. For each male the number of anogenital investigations (AGI), mounts and 
intromissions of the stimulus female were noted, as well as the latencies to mount, intromit and 
ejaculate, and the post-ejaculatory interval (PEI; latency to first mount of the next bout of copulation). 
An index of copulatory efficiency (CE: # intromissions/# of mounts) was created by the authors. 
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Consummatory sexual behaviour is referred to as CE and intromissions, and appetitive sexual 
behaviour as PEI and latencies to mount, intromit and ejaculate. 
Females were tested at the day of behavioural ooestrous on two occasions which were separated by the 
duration of one ooestrous cycle (i.e. 4 days). On each test occasion the total number of proceptive 
behaviours as well as the lordosis quotient (i.e. number of lordosis shown per 10 mounts×100) was 
tabulated for each female. The proceptive behaviours (i.e. ear wiggling and hopdarting behaviour) 
were observed until the female had received 10 mounts with pelvic thrusting by the stimulus male. 
Data were analysed by one-way ANOVA with post-hoc Tukey's analyses for testing of specific group 
differences (i.e. comparing all possible pairs of means). The observed non-linear dose response in 
males was sought by the authors to be determined, as a post hoc analysis with the one-way ANOVA, 
whether it exhibited a significant quadratic polynomial component (i.e. displays concavity, a single 
bend either upward or downward). Additionally, the authors transformed different parameters of the 
behavioural endpoints measured in the same animal into a z-score for the evaluation of its 
performance averaged over all parameters (i.e. for each animal and test day, a composite score of the 
recorded data relative to that of the other animals on that test day). Further, in order to ensure that the 
individual characteristics of dams were not significantly affecting the parameters, ANOVA and 
subsequent Tukey's post-hoc tests was used to determine if litter membership had any significant 
effects on the observed behaviours within each dose group. 
No statistically significant differences between groups were found at the initial day of testing, which 
according to the authors might be as expected due to the large variances associated with sexual 
inexperience at the initial days.  
In females, perinatal BPA-exposure did not statistically significantly influence adult sexual behaviour 
at any dose or time tested, and according to the authors a study limitation could be that no male-typical 
behaviours were examined (e.g. partner preference).  
For males, neither AGI nor number of mounts showed any group differences. On day 1, only high 
dose BPA-males differed statistically significantly from other groups with increased consummatory 
behaviour compared to other BPA-groups, and increased appetitive behaviour compared to controls 
and BPA 5 µg/kg bw (latencies) and 50 µg/kg bw (latencies and PEI). On day 4, the statistical picture 
was different. In short, both controls and high dose BPA-males showed increased consummatory 
behaviour compared to 50 µg/kg-group. High dose BPA-males had shorter PEI than 50 µg/kg-males. 
The 50 µg/kg-group showed longer latencies to intromit and ejaculate than controls, 500µg/kg and 
high dose groups. The authors’ conclude that “Males receiving low dose perinatal BPA (50 μg/kg bw 
per day) showed persistent deficits in sexual behavior in adulthood. Males receiving the highest dose 
(5 mg/kg bw per day), however, were indistinguishable from controls with respect to consummatory 
sexual behaviors but showed decreased latencies to engage in those behaviors when sexually naïve, 
with significant non-linear, or U-shaped, dose–response relationships observed on the first and last 
day of testing.” 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Number of BPA doses (4)  
- Blind evaluation of the observed sexual behaviour 
- Non-PC cages used for dams and offspring, and BPA-free water sacks for dams 
Weaknesses: 
- Study design not appropriate to the scope (small number of dams per group (2-3), littermates 
treated as independent observations) 
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- Study reporting (limited information of dams, e.g. body weight, signs of toxicity; number of 
stimulus animals not given, e.g. same number as test animals; test animal body weight and 
developmental landmarks of sexual maturation not reported) 
- Phytoestrogen content in the standard rat chow not reported 
- Inappropriate statistics (litter effect not appropriately addressed; uncertainty whether the 
statistically significant differences were due to dose or other study factors, in particular the 
composite z-score analysis will be sensitive to small differences among dose groups other than 
the dose 
- In the figures it is not reported what the whiskers represent, e.g. SD or SEM. 
- There was no mentioning of the order of the various treatments in the individual animals, i.e. 
when treatments were completed for all animals in a given dose group, and then for the next 
dose group, this could easily give rise to different responses among groups which are 
unrelated to the dose, in particular for behavioural parameters. 
There was no mentioning of the order of the various treatments in the individual animals, i.e. when 
treatments were completed for all animals in a given dose group, and then for the next dose group, this 
could easily give rise to different responses among groups which are unrelated to the dose, in 
particular for behavioural parameters. The CEF Panel noted that control of environmental BPA 
contamination was done by housing rats in polysulfone cages and by use of BPA-free water sacks for 
dams. However, both dams and offspring were fed standard Purina rat chow and no information about 
the bedding used is given. All behaviours were scored by an investigator blind to experimental 
condition. Sexual maturation usually occurs in rats at the age of 2-3 months (60-90 days). In the study, 
rats were tested at the age of 90-120 days and no information about developmental landmarks for 
sexual maturation was reported. Age has been found to be crucial for the sexual maturation of female 
rats, whereas body weight has been found to be more important for the sexual maturation of male rats. 
Differences in sexual maturation might influence the performances. LE-males are recommended to be 
housed individually and not group housed as done in the study. Sexual experience in test males is 
presumed to be present after being presented for stimulus females on three occasions, but no 
information to ensure this is given, e.g. that all males actually had copulated. Studies have shown that 
male rats with no sexual experience exhibit increases in the latencies for intermission and ejaculation 
and PEI period. Since stimulus females were injected 4 h prior to onset of testing for inducing sexual 
receptivity, number of stimulus females is presumably the same as number of test males, but no 
information is given. The underlying cause of the reported statistically significant behavioural 
differences appears unclear, and may be caused e.g. by chance findings of multiple testing.  
The CEF Panel considers the main weakness in this study to be that both male and female test animals 
were littermates representing only 2-3 dams per exposure group. OECD guidance for developmental 
studies states that the statistical unit of measure should be the litter and not the pup (OECD, 2007, Test 
No. 426). The use of littermates leads to p-values that are higher than justified by the data. 
Additionally, the z-score approach implies that statistically significant differences due to other study 
factors than dose are amplified. 
This paper is not included in the WoE table because it is not relevant to any of the questions addressed 
there, but it is included in the section 1.2 on NMDR. 
Ishido M, Masuo Y, Terasaki M and Morita M. 2011. Rat hyperactivity by bisphenol A, but not 
by its derivatives, 3-hydroxybisphenol A or bisphenol A 3,4-quinone. Toxicology Letters, 206, 
300-305.  
 
Ishido et al. intended to assess the effects of acute neonatal exposure to BPA on spontaneous motor 
activity at young adulthood. Approximately 50 male pups were born from 10 pregnant Wistar rat 
females, 5–7 of which were randomly housed. Standard feed and distilled water were available ad 
libitum. Five-day old pups (n = 6 per group) received an intracisternal injection of 10 µl vehicle 
(control) or 20 µg bisphenol A or its derivatives, equivalent to 87 nmol chemical/10 µl vehicle/pup. In 
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4-5 weeks old males, activity was measured at 15-min intervals for 22–24 h under a 12-h light–dark 
cycle by use of a Supermex sensor head which detects body heat and an array of Fresnel lenses placed 
above the cage which monitors motion.  
Administration of BPA induced statistically significant nocturnal hyperactivity in rats at 4-5 weeks of 
age (p<0.05 analysed by Student’s t-test) compared to controls, whereas administration of BPA 
derivates (3-hydroxybisphenol A and bisphenol A 3,4-quinone) did not affect this same endpoint.  
The authors found significant accumulation of BPA (1.385 ng/tissue) in the brain at 8 weeks of age, 
but not of the other compounds. These findings led the authors to suggest that the parent compound 
BPA crosses the immature blood-brain barrier (BBB) and exert long-lasting effects on behaviour with 
mechanisms others than its suggested anti-estrogenic action (i.e. refers to previous paper of the same 
group indicating reduction of brain tyrosine hydroxylase activity after BPA exposure).  
Comments from the CEF Panel: 




- Single dose level study 
- Single acute dose administration 
- Small sample size 
- One sex only (males) 
- Insufficient study reporting (unclear whether one dose level or several dose levels were used; 
animal age and body weight not given; animal diet phytoestrogen content not reported) 
- Inappropriate statistics(litter effect not considered) 
 
Overall, the CEF Panel noted that the main limitations of this study are the limited sample size (n = 6), 
the intracisternal exposure route, the lack of consideration of the litter effect, the small behavioural 
changes found, only 1.3 times higher than controls and only nocturnal and not diurnal activity affected 
by BPA, and the use of a single BPA administration. It is unclear whether one dose level or several 
dose levels were used as it under “Results” refers to other dose levels than described in Materials and 
methods.  
This paper is not included in the WoE table because lack of relevance to one or more questions 
addressed there. 
(6) Studies examining the morphological, molecular and biochemical changes in the brain 
No WoE was performed for the endpoint addressed by these studies. 
 
Cao J, Mickens JA, McCaffrey KA, Leyrer SM, Patisaul HB. 2012. Neonatal Bisphenol A 
exposure alters sexually dimorphic gene expression in the postnatal rat hypothalamus. 
Neurotoxicology, 33, 23--36.  
The goal of this study was to determine if neonatal BPA exposure interferes with sex specific gene 
expression of oestrogen receptor alpha (ERα), ER beta (ERβ) and kisspeptin (Kiss1) in the anterior 
and mediobasal hypothalamus. Time mated Long Evans rats (n=13) delivered pups at postnatal day 
(PND) 0 and the pups were daily exposed to vehicle (10% ethanol in sesame oil), 10μg oestradiol 
benzoate (EB), 50 mg/kg BPA or 50 μg/kg BPA by subcutaneous injection from the day of delivery 
(PND 0) to PND 2 (n=6-9 per sex and group representing a minimum of 3 litters). Litter sizes (9 to 17 
pups) were not standardized for size or sex ratio. All pups within the litter were administered the same 
compound to prevent cross-contamination (3 litters each for vehicle, EB, and low dose BPA, 4 litters 
for high dose BPA). Breeding and rearing procedures included control for potential environmental 
contamination (phytoestrogen free diet, polysulfone cages). At PNDs 4 and 10, pups were sacrificed 
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and their heads subjected for cryosectioning. In situ hybridization histochemistry (ISHH) was used to 
investigate gene expressions. Data was analysed by two-ways ANOVA (sex and exposure). 
Significant interactions were followed by one-way ANOVA to find effect of exposure within each sex. 
Then the Dunnett’s Multiple Comparison post hoc test was used to compare same sex exposure and 
control groups.  
There were no significant impacts of BPA in the mediobasal hypothalamus. Within the anterior 
hypothalamus ERα expression was augmented by BPA in PND 4 females, and then fell to male-
typical levels by PND 10. ERβ expression was not altered by BPA on PND 4, but significantly 
decreased or eliminated in both sexes by PND 10. Kiss1 expression was diminished by BPA in the 
anterior hypothalamus, especially in females. The BPA effects did not mirror those of oestradiol 
benzoate, supporting the view that the interference of BPA with early hypothalamic organization 
involves mechanisms different from its estrogenic action.   
Comments from the CEF Panel: 
The control of environmental BPA contamination includes cages (polysulfone), feed (phytoestrogen 
free), and bedding (woodchip), but the type of water bottles is not mentioned. A positive control, 
oestradiol benzoate, was used. In the study, 13 dams and three litters per dose groups were used. Thus, 
littermates were investigated. Direct exposure to neonatal pups was used and it cannot be excluded 
that handling at delivery to PND 2 may influence gene expression. Considering the BPA dose span, 
0.05 mg/kg bw and 50 mg/kg bw, a dose-response would have been expected, but did not clearly 
appear. In the statistics, the litter effect was not properly considered. 
 
Cao J, Rebuli ME, Rogers J, Todd KL, Leyrer SM, Ferguson SA and Patisaul HB, 2013. 
Prenatal bisphenol A exposure alters sex-specific estrogen receptor expression in the neonatal 
rat hypothalamus and amygdala. Toxicological Sciences, 133, 157-173. 
This study was specifically aimed at assessing whether prenatal BPA exposure altered sex-specific 
ESR1 (ERα) and ESR2 (ERβ) expression in postnatal limbic nuclei. Sprague Dawley rats were mated 
and gavaged on gestational days 6-21 with vehicle, 2.5 or 25 μg/kg bw per day BPA, or 5 or 10 μg/kg 
bw per day ethinyl oestradiol. An additional group was restrained but not gavaged (naïve control). 
Rearing conditions were controlled to avoid any potential source of environmental contamination. 
Offspring (n = 5-8 per sex/group) were sacrificed the day after birth to quantify ESR gene expression 
throughout the hypothalamus and amygdala by in situ hybridization. Data were analysed by two-way 
ANOVA (sex, exposure) followed by and Holm-Sidak multiple comparison tests. Naïve controls were 
not included in the overall analysis, since a separate analysis showed difference between controls and 
naïve controls. 
Relative to the vehicle group, significant effects of BPA, mostly in the direction of the effects 
attributable to ethinyl oestradiol, were observed on ESR1 and ESR2 expressions throughout the 
mediobasal hypothalamus and amygdala in both sexes: the regions more sensitive to BPA effects 
include specific subregions of the amygdala. Significant differences in ESR expression were also 
observed in the mediobasal hypothalamus and amygdala of the naïve control group compared with the 
vehicle group, highlighting the potential for gavage to influence gene expression in the developing 
brain. 
Comments from the CEF Panel:  
Control of environmental BPA contamination was performed including a low phytoestrogen diet and 
glass bottles. This study presents a detailed analysis of ESRs expression in different sub regions of 
hypothalamus and amygdala following prenatal treatment with BPA or ethinyloestradiol (EE). 
Previous studies have consistently reported sex-dimorphic effects of developmental BPA exposure on 
ESR expression. Treatment schedule, route and doses used are relevant, both a positive control (EE) 
and naïve control were included and it was properly controlled for litter effect. The study is large and 
pup samples were from dams bred at different time points. The same litter samples were averaged. 
Advanced statistics comparisons have been used, but it is unclear whether multiple endpoint has been 
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considered. ESR expression is sexually dimorphic but neither BPA nor EE treatments interfere with 
such sex dimorphism. Furthermore is difficult to evidence an effect of BPA per se: both BPA and EE 
appear to enhance ESR expression in most of the sub-regions considered in comparison to vehicle-
treated control. The enhanced ESR expression in naive controls makes the interpretation of the 
findings difficult: gavage per se seems to reduce ESR expression (stress effect) and the estrogenic 
stimulation (either BPA or EE) could somewhat reduce the “gavage” effects with mechanisms which 
are far to be understood. In conclusion the study suggests the estrogenic activity of BPA at very low 
doses shortly after termination of the prenatal exposure. 
 
He Z, Paule MG and Ferguson SA, 2012. Low oral doses of Bisphenol A increase volume of the 
sexually dimorphic nucleus of the preoptic area in male, but not female, rats at postnatal day 21. 
Neurotoxicology and Teratology, 34, 331-337. 
 
He et al. aimed at evaluating the effects of pre- and postnatal treatment with low BPA doses on the 
volume of the sexually dimorphic nucleus of the preoptic area (SDN-POA) of weanling rats. Pregnant 
Sprague-Dawley rats were orally gavaged with vehicle, 2.5 or 25.0 μg BPA/kg bw per day, or 5.0 or 
10.0 μg ethinyl oestradiol (EE)/kg bw per day, on gestational days 6-21. Beginning on the day after 
birth, offspring of both sexes were orally treated with the same dose their dam had received. An 
additional group was restrained but not gavaged (naïve control). On PND 21, offspring (n=10-
15/sex/group; 1/sex/litter) were perfused and volume evaluation was conducted blind to treatment. 
SDN-POA outline was delineated using calbindin D28K immunoreactivity. Low-phytoestrogen diet 
was given. Average SDN-POA volumes were analysed by two-way ANOVA (exposure, sex) and the 
Holm–Sidak method was used for interaction comparisons to the vehicle controls. Correction for 
anogenital distance (AGD) was not included in the statistical analyses. 
Pairwise comparisons of the significant treatment by sex interaction indicated that neither BPA doses 
affected female SDN-POA volume. However, females treated with 5.0 or 10.0μg/kg EE exhibited 
volumes that were larger than same-sex controls, respectively (p<0.001). Males treated with either 
BPA dose or 10.0μg/kg/day EE had larger volumes than same-sex controls (p<0.006). These data 
indicate that BPA can have sex-specific effects on SDN-POA volume and that these effects manifest 
as larger volumes in males. 
Comments from the CEF Panel: 
Control of environmental BPA contamination was performed including a low phytoestrogen diet and 
glass bottles. A positive control was used (EE), but it was not properly positive for males. The effect 
of the highest dose used of EE was very similar to that of BPA, suggesting the use of other positive 
controls. The authors explained this as being due to the existence of an upper limit in males (e.g. a 
saturation value). Litter effect, statistical power (at least n=10 rats per group, 1/sex/litter) and vehicle 
controls were properly considered. The presence of a higher dose of BPA would have been important 
in assessing whether the effect is U-shaped. A weakness of this study is the consideration of a single 
histological endpoint at PND 21 and the lack of testing for functional effects of reproductive and sex 
dimorphic behaviours. 
 
Komada M, Asai Y, Morii M, Matsuki M, Sato M, Nagao T. 2012. Maternal bisphenol A oral 
dosing relates to the acceleration of neurogenesis in the developing neocortex of mouse fetuses. 
Toxicology, 295, 31-38.  
The study by Komada et al. was aimed at describing the effects of gestational exposure to BPA on the 
hippocampal neurogenesis of the fetal mouse. Young C57BL/6J mice were bought and then mated in 
house. The presence of a seminal plug was denoted embryonic days (E) 0. The mice had free access to 
standardised pellets and drinking water in glass bottles prior to and after mating. The pregnant mice 
were given corn oil or 200 μg/kg BPA by oral gavage from E 8.5 to E 13.5. At E 14.5, dams were 
killed and fetuses were subjected to histological evaluation (pups representing 6 litters per group). 
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Prior to killing of the dams, CldU and IdU were injected 24 h and 1 h, respectively, in order to 
elucidate the histological fetal changes.  
Data presented by the authors indicated that maternal exposure to 200 μg/kg BPA was associated with 
accelerated neurogenesis and hyperplasia of cortical plate during telencephalon development, as 
demonstrated by increases of the thickness of the plate. Moreover, BPA-fetuses showed a reduction of 
neural stem/progenitor cells as a result of the promotion of neurogenesis in the dorsal telencephalon. 
Through immunostaining, the authors demonstrated that BPA exposure is specifically associated with 
the acceleration of neurogenesis of neural progenitor cells (IPCs) in the sub-ventricular zone (SVZ) 
and the differentiation of radial glial cells (RGCs) of dorsal telencephalon. In the BPA-treated group, 
the cell cycle was prolonged compared to controls.  
Comments from the CEF Panel:  
Environmental contamination of BPA is addressed as information about water bottles of glass, use of 
polypropylene cages and corncob bedding is given. The authors claim that BPA affects neuronal 
proliferation at critical developmental phases, likely by interfering with the important neurotrophic 
role of steroids and related receptors in brain development. There is however no specific statistical 
analysis Section, making it difficult to understand what is reported (SEM or SD) in figures. In 
addition, both male and female fetuses were considered, but no discussion of a sex effect (either 
significant or insignificant) is reported. Finally, it is impossible to evaluate whether the maternal factor 
has been considered, although on the basis of the number of treated pregnant females and of offspring 
of both sexes examined, it appears that there are at least four fetuses for each treated dams in the final 
experimental groups.  
Viberg H and Lee I, 2012. A single exposure to Bisphenol A alters the levels of important 
neuroproteins in adult male and female mice. NeuroToxicology, 33, 1390-1395.   
 
The aim of the study was to evaluate whether a single exposure to BPA during the brain growth spurt 
can alter the adult levels of proteins important for normal brain development (CaMKII and 
synaptophysin). Pregnant NMRI mice were fed standardised pellets and tap water ad libitum prior to 
and after delivery. Litters were culled to 10-14 pups within the first 48 hours. On PND10, male pups 
were given 0.32, 3.2 or 4.8 mg/kg bw and female mice were given 4.8 mg/kg bw in a single dose via 
metal gastric tube. Controls were gavaged vehicle (10ml 20% fat solution/kg bw). Males were 
sacrificed 24 h or 5 months after the BPA exposure (n=6 males), but females only after 5 months 
(n=8-9). The cerebral cortex and hippocampus brain regions were dissected out and frozen in liquid 
nitrogen and stored until protein analysis for CaMKII, GAP-43, synaptophysin and tau. Male data 
were analysed by one-way ANOVA and Newman–Keul’s post hoc test (GraphPad Prism 5.01). The 
collected data from the adult females was analysed by Student’s t-test. For neonatally mice, no 
statistically significant group differences for synaptic proteins in the cerebral cortex or the 
hippocampus appeared. For adult males, no group differences for synaptic proteins were shown in 
hippocampus or for CaMKII, GAP-43 and tau protein levels in the cerebral cortex, but for increased 
cerebral synaptophysin at the two higher BPA doses (3.2 or 4.8 mg/kg bw). For adult females, BPA 
caused increased synaptophysin in cerebral cortex and decreased CaMKII in both cerebral cortex and 
hippocampus. No other treatment effects were seen in females. According to the authors, the findings 
of this study indicate that a single neonatal exposure to BPA, on postnatal day 10, during the peak of 
the brain growth spurt, can alter the adult levels of proteins important for normal brain development 
(CaMKII and synaptophysin). These alterations are induced in both male and female mice and effects 
are seen in both hippocampus and cerebral cortex.  
 
Comments from the CEF Panel:  
Information on control of environmental contamination of BPA is lacking (i.e. cages, feed, water 
bottles, or bedding). The number of dams and their general reproductive outcome including pup sex 
ratio is not given. The litters were standardised with regard to size (12-14 pups) but sex ratio is not 
given. Chosen doses were relevant, although the exposure was single dose. Sample size was limited 
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for males (n=6), and acceptable for females (n=8-9) but it is unclear whether each sample represented 
one litter. In the statistics, the litter effect is not taken into consideration, thus the results presented 
may be questioned. 
Xu X, Xie L, Hong X, Ruan Q, Lu H, Zhang Q, Zhang G, Liu X, 2013b. Chemosphere. Perinatal 
exposure to bisphenol-A inhibits synaptogenesis and affects the synaptic morphological 
development in offspring male mice. Chemosphere, 91, 1073-1081. 
 
This study was aimed at evaluating whether perinatal exposure to BPA has effects on hippocampal 
synaptogenesis in exposed offspring. Pregnant ICR mice were orally exposed by injection from 
gestational day 7 through PND 21 to BPA at doses of 4, 0.4 or 0.04 mg/kg/bw day. Only male pups 
coming from 6 different litters (n= 6 male/group) were used in the study. Offspring were sacrificed on 
PND 14, 21 or 56 and brain processed for measurement of synaptic density and synaptic interface 
structure by the electron microscopy. The expression of Synapsin 1, PSD 95 and the levels of NMDA 
receptor subunit NR1, AMPA receptor subunit GluR1 were measured by immunoblotting in the 
synaptic fraction (n= 4 male/group). Synaptic density and the synaptic interface structure parameters 
were evaluated by two-way (age, exposure) repeated measure analysis of variance (ANOVA). One-
way analysis of variance was applied to the Western blot data. Difference between groups was tested 
by use of Tukey’s test. 
Results showed that the numeric synaptic density of pyramidal cells of hippocampal CA1 area was 
significantly reduced by BPA (main effect of the treatment p < 0.001). The higher dose of BPA 
reduced synaptic density at all three ages considered, while the lower dose reduced this same measure 
at PND 14 and 56. No effects of the intermediate dose were found. The reduced numeric density was 
paralleled by alteration of synaptic ultrastructural parameters, i.e. curvature of synaptic interface, 
width of synaptic cleft and thickness of Post Synaptic Density (PSD), affected by BPA exposure in a 
dose-dependent fashion. PSD was reduced by BPA exposure while the synaptic cleft was enlarged and 
the length of the active synaptic zone reduced: the authors hypothesize that BPA affects not only 
synaptogenesis but possibly the efficacy of CA1 neurotransmission. The expression of synapsin-1, 
PSD 95 (both markers of synaptic functionality) as well as the expression of glutamate receptor 
subunits appeared significantly down-regulated on PND 14, 21 and 56 (AMPA receptors) and PND 21 
and 56 (NMDA receptors). These findings replicate those already reported in a previous study of the 
same group (Xu et al., 2010) where a reduced expression of NMDA receptor subunits in the 
hippocampus on PND 21 and 56 was associated with impaired memory capabilities in BPA exposed 
mouse offspring. 
 
Comments from the CEF Panel:  
Information on control of potential sources of environmental BPA contamination is lacking (i.e. cages, 
feed, water bottles, or bedding). Route of exposure is oral but it is unclear whether “oral injection” 
refers to the use of gavage or not. The litter effect is considered, the sample size is acceptable for the 
electronic measurements (n=6) but rather small for the immunoblotting studies (n=4). Only male 
offspring are examined which leaves possible sex differences behind. This study follows previous 
studies of the same group and was focused on the effects of perinatal BPA exposure on hippocampal 
synaptogenesis, synaptic protein and glutamate neurotransmission.  
(iii) In vitro studies 
Appraisal of strengths and weaknesses and WoE analysis were not carried out for in vitro studies.  
Seki S, Aoki M, Hosokawa T, Saito T, Masuma R, Komori M and Kurasaki M, 2011. Bisphenol-
A suppresses neurite extension due to inhibition of phosphorylation of mitogen-activated protein 
kinase in PC12 cells. Chemico-Biological Interactions, 194, 23-30. 
Seki and co-workers assessed the morphological changes in nerve growth factor (NFG)-induced 
differentiation caused by bisphenol-A in a PC12 cell system. In addition, to clarify whether BPA 
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affects the early and late stages of the NGF-signalling pathway in cell differentiation, changes of 
phosphorylation of MAP kinases and cAMP-response element binding protein (CREB) in PC12 cells 
treated with and without BPA in medium containing NGF were investigated using Western blot 
analysis. The results indicate that BPA significantly inhibited phosphorylation of CREB and ERK1/2 
MAPK. When a BPA concentration of 10 ng/ml (corresponding to 50 nM) was added to medium 
containing NGF, it inhibited neurite extension.  
Tanabe N, Yoshino H, Kimoto T, Hojo Y, Ogiue-Ikeda M, Shimohigashi Y and Kawato S, 2012. 
Nanomolar dose of bisphenol A rapidly modulates spinogenesis in adult hippocampal neurons. 
Molecular and Cellular Endocrinology, 351, 317-325.  
The study by Tanabe et al. aimed at assessing the effects of BPA on spinogenesis in rat derived 
hippocampal slices. In addition to BPA concentrations ranging from 1 nM to 10 µM, the authors also 
assessed the effect of different compounds (hydroxytamoxifen, an antagonist of both estrogen-related 
receptor gamma (ERRγ) and estrogen receptors (ERα/ERβ), ICI, an antagonist of ERα/ERβ, the MAP 
kinase inhibitor PD98059, and the blocker of NMDA receptors, MK-801) to obtain insight into the 
mechanisms implicated in BPA modulation of spinogenesis. Spinogenesis was significantly enhanced 
by BPA added to isolated hippocampal slices obtained from untreated adult Wistar male rats. The 
results suggest that the action of BPA on ERRγ may contribute to the observed rapid effect on 
spinogenesis. Finally, the authors also measured BPA concentration in hippocampus through mass-
spectrometry, finding an average concentration of 14.6 ± 1.8 ng/g wet weight (64 ± 8 nM) from 4 
animals.  
Although the findings presented by the authors are preliminary and should be confirmed in vivo, the 
study shows that internal BPA concentration in the nanomolar range may change density and 
morphology of spinogenesis of hippocampal neurons from adult rats. The reported BPA concentration 
in the hippocampus is surprisingly high considering that rats after oral treatment with 100 µg/kg bw 
have unconjugated BPA serum concentrations of 0.1 mg/ml (0.5 nM; Doerge et al., 2011b).  
Warita K, Mitsuhashi T, Ohta KI, Suzuki S, Hoshi N, Miki T and Takeuchi Y, 2013. In vitro 
evaluation of gene expression changes for gonadotropin-releasing hormone 1, brain-derived 
neurotrophic factor, and neurotrophic tyrosine kinase, receptor, type 2, in response to bisphenol 
A treatment. Congenital Anomalies (Kyoto), 53, 42-45. 
The present short communication reports effects of bisphenol A (BPA) on gene expressions of 
embryonic mouse hypothalamic cells by using the cell line mHypoE-N44. Normal maturation of the 
hypothalamic-pituitary-gonadal axis in fetuses is, among other thing, dependent on proper 
development of the hypothalamic neurons that release gonadotropin-releasing hormone 1 (GNRH1). 
Additionally, most embryonic GNRH1 neurons express neurotrophic tyrosine kinase, receptor, type 2 
(NTRK2), which is the high-affinity receptor of brain-derived neurotrophic factor (BDNF) that 
supports the survival of a variety of embryonic neural types. 
BPA was dissolved in dimethyl sulfoxide (DMSO; final concentration, 0.1%). The vehicle DMSO 
(0.1%) showed no cell toxicity or effects on cell survival or ability to divide. Cells exposed to DMSO 
0.1% served as controls, and each exposure experiment was performed in three replicate wells.  
mHypoE-N44 cells were incubated with 0.02, 0.2, 2, 20, and 200 µM BPA for 3 hours and evaluated 
for Gnrh1 gene expression by use of reverse transcription polymerase chain reaction (RT-PCR) with 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) mRNA as internal positive control. Equivalently, 
mHypoE-N44 cells were examined for gene expressions of Bdnf and its high-affinity receptor Ntrk2 
after incubation with 200 µM BPA for 3, 6 and 12 hours. Statistical analyses were performed using 
one-way analysis of variance (ANOVA) and Bonferroni–Dunn post-hoc tests. 
Results showed that cells treated for 3 hours with the highest concentration of BPA, 200µM, expressed 
statistically significant decreased levels of Gnrh1 compared to control cells. In cells treated with 200 
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µM BPA for 6 and 12 hours, the mRNA level for brain-derived neurotrophic factor (Bdnf) was 
significantly decreased, whereas that for neurotrophic tyrosine kinase, receptor, type 2 (Ntrk2) did not 
change. 
The authors’ conclude that these results indicate that Gnrh1 gene expression in mice fetuses is not 
affected by exposure to less than 20 µM BPA and that the adverse effects of BPA on the BDNF-
NTRK2 neurotrophin system are induced by decreased mRNA level of the ligand BDNF, not of its 
receptor. 
Immune effects 
(i) Human studies 
Clayton EMR, Todd M and Aiello AE, 2011. The impact of Bisphenol A and Triclosan on 
Immune Parameters in the US population, NHANES 2003-2006. Environmental Health 
Perspectives, 119, 390-396. 
Clayton et al. (2011) examined possible associations of urinary BPA levels with serum 
cytomegalovirus (CMV) antibody levels and diagnosis of allergies or hay fever in US adults and 
children >6 years of age (n=3 728), for which the survey and laboratory data from the 2003–2006 US 
NHANES were used. The exposure was assessed by measuring BPA in spot urines. Total (free and 
conjugated) urinary BPA was measured by solid phase extraction (SPE) coupled with liquid 
chromatography–tandem mass spectrometry (LC–MS–MS, LOD 0.36 ng/ml) at the Center for Disease 
Control and Prevention (CDC). CMV-specific IgG was measured using an enzyme-linked 
immunosorbent assay (ELISA) and CMV-specific IgG optical density was reported [measured in 
arbitrary units (AU) per milliliter] and used as a continuous outcome variable. CMV seropositivity 
was defined by NHANES based on this optical density measure. A diagnosis of allergy or hay fever 
was determined by two questions in the NHANES interview. Respondents were asked: “Has a doctor 
or other health professional ever told you that you have allergies/hay fever?” A respondent was coded 
as having allergies or hay fever if the response to either question was yes. Multivariate ordinary least 
squares linear regression models were used to examine the association of BPA with CMV antibody 
titers, and multivariate logistic regression models to investigate the association of these chemicals with 
allergy or hay fever diagnosis. Statistical models were stratified by age (<18 years and ≥18 years). In 
analyses adjusted for age, sex, race, body mass index, creatinine levels, family income, and 
educational attainment, in the ≥18-year age group, higher urinary BPA levels were associated with 
higher CMV antibody titers (p<0.001). In the <18-year age group, lower levels of BPA were 
associated with higher CMV antibody titers (p<0.05). BPA showed no association with allergy or hay 
fever diagnosis. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses: 
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet or by concurring exposure factors not considered or not reported 
- Unclear clinical relevance (inconsistent results between groups stratified by age) 
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The authors do not offer an explanation for these contrasting observations, and conclude that 
additional studies should be done to further investigate these findings. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Donohue KM, Miller RL, Perzanowsky MS, Just AC, Hoepner MS, Arunajadai S, Canfield S, 
Resnick D, Calafat AM, Perera FP and Whyatt RM, 2013. Prenatal and postnatal bisphenol A 
exposure and asthma developoment among innet-city children. Journal of Allergy and Clinical 
Immunology, 131, 736-742. 
 
Donohue et al. (2013) examined possible associations of urinary BPA levels with wheeze and asthma 
in a prospective cohort of 568 Dominican (65%) and African American (35%) mothers and children in 
New York. Total (free plus conjugated) was determined by solid phase extraction (SPE) coupled with 
liquid chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.4 ng/ml) at the Center for 
Disease Control and Prevention (CDC). BPA concentration in spot urine samples was measured in the 
pregnant women in the third trimester of pregnancy (n=375), and in the children at 3 (n=408), 5 
(n=401), and 7 (n=318) years of age. Women were screened to avoid enrollment of active smokers. 
Wheeze questionnaire were administered in the last 12 months at the ages of 5, 6, and 7 years, and 
asthma was determined by a physician at ages between 5 and 12 years, using the following criteria: 
respiratory symptoms, FEV1 measurements, IgE measurements, asthma medication. FENO (fraction of 
exhaled nitric oxide) measurements were done at ages between 5 and 11 years. Maternal prenatal 
urinary BPA levels were lower than all BPA levels measured in children and did not correlate with 
child urinary BPA.  
Results for prenatal BPA: Contrary to what was hypothesized, the prenatal urinary BPA concentration 
was associated inversely with wheeze at age 5 years (odds ratio [OR], 0.7; 95% CI, 0.5–0.9; p=0.02), 
but no associations were found for prenatal BPA values with wheeze at age 6 or 7 years or with 
asthma at ages between 5 and 12 years or with serotopy at age 7 years. Results for postnatal BPA: 
urinary BPA concentrations at age 3 years were associated positively with wheeze at ages 5 years 
(OR, 1.4; 95% CI, 1.1–1.8; p=0.02) and 6 years (OR, 1.4; 95% CI, 1.0–1.9; p=0.03). BPA 
concentrations at age 7 years were associated with wheeze at age 7 years (OR, 1.4; 95% CI, 1.0–1.9; 
p=0.04) and FENO values (β=0.1; 95% CI, 0.02–0.2; p=0.02). BPA concentrations at ages 3, 5, and 7 
years were associated with asthma (OR, 1.5 [95% CI, 1.1–2.0], p=0.005; OR, 1.4 [95% CI, 1.0–1.9], 
p=0.03; and OR, 1.5 [95% CI, 1.0–2.1], p=0.04, respectively). No associations with seratopy at 7 years 
were noted. Although the strength of the associations is modest, this is the first cohort study to report 
an association between childhood urinary BPA concentrations and asthma in children. There negative 
correlation between maternal BPA and wheeze at 5 years was unexpected. Only few children had all 
the repeated measures (n=82). 
CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study: 
Strengths: 
− Longitudinal follow up 
− Large sample size 
− Repeated measurements 
− Analytical method (LC-MS-MS) 
− Quality control, including blanks and quality assurance procedures 
− Multiple outcome assessment for asthma 
Weaknesses: 
− Single spot urine BPA measurements 
− Confounding by diet or by concurring exposure factors not considered 
- Inconsistency of results between groups 
− Inconsistent results amongst different studies  
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Overall the CEF Panel notes that the odd ratio’s observed were modest, and as for all observational 
studies, unmeasured confounding might have biased the results. Potential confounding for diet was not 
considered. Yet, the findings are in agreement with other evidence that BPA may be associated with 
adverse respiratory outcomes. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Savage JH, Matsui EC, Wood RA and Keet CA, 2012. Urinary levels of triclosan and parabens 
are associated with aeroallergen and food sensitization. Journal of Allergy and Clinical 
Immunology, 130, 453-460. 
 
The aim of this study was to determine the association between urinary endocrine-disrupting 
compounds (EDCs), namely BPA, triclosan, benzophenone-3, propyl, methyl, butyl, and ethyl 
parabens, with specific aeroallergen and food allergen sensitization. Data were obtained from the 
2005–2006 National Health and Nutrition Examination Survey (NHANES) and urinary BPA, 
triclosan, benzophenone-3, propyl, methyl, butyl, and ethyl parabens and specific IgE levels were 
available for 860 children aged 6–18 years. Urinary BPA and other EDCs were measured by liquid 
chromatography tandem mass spectrometry (LC-MS-MS, LODs 0.1–2.0 ng/ml). Aeroallergen and 
food sensitizations were defined as having at least one positive (≥0.35 kU/L) specific IgE level to an 
aeroallergen or a food. Analyses were adjusted for urinary creatinine level, age, sex, ethnicity, and 
poverty index ratio. In contrast to triclosan and propyl and butyl parabens, no associations between 
urinary BPA levels and sensitization were observed.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
− Large sample size 
− Analytical method (LC-MS-MS) 
− Quality control, including blanks and quality assurance procedures 
− Multiple outcome assessment for allergen sensitisation 
Weaknesses: 
− Cross-sectional study design 
− Single spot urine BPA measurement 
− Confounding by diet or by concurring exposure factors not considered 
− Inconsistent results amongst different studies  
 
Overall the CEF Panel notes that the manuscript is interesting and the scientific soundness is 
acceptable in light of the limitations related to the cross-sectional design and single spot urine samples. 
The fact that urinary BPA was not significantly related to aeroallergen and food sensitization is a 
negative but quite relevant result. 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Spanier AJ, Kahn RS, Kunselman AR, Hornung R, Xu Y, Calafat AM and Lanphear BP, 2012. 
Prenatal Exposure to Bisphenol A and Child Wheeze from Birth to Three Years. Environmental 
Health Perspectives, 120, 916-920. 
 
Spanier et al. (2012) examined prenatal BPA exposure and childhood wheeze from birth to 3 years of 
age in 365 mother–child pairs. The exposure was assessed by measuring BPA in spot urines from 
mothers at 16 and 26 weeks of gestation and at birth. Total (free plus conjugated) was determined by 
solid phase extraction (SPE) coupled with liquid chromatography tandem mass spectrometry (LC-MS-
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MS, LOD 0.4 ng/ml) at the Center for Disease Control and Prevention (CDC). Tobacco exposure was 
measured by means of serum concentration of a metabolite of nicotine. Childhood wheeze was 
surveyed every 6 months from birth to 3 years by trained research assistants at home visits or by 
phone, using questions parallel to the NHANES wheeze question. Questions included the number of 
wheeze attacks, and the outcome was dichotomized to no wheeze versus any wheeze at each time 
point. The results were mainly negative. When prenatal BPA exposure was modelled as a continuous 
variable (mean of three values), BPA was not related with childhood wheeze. However, when urinary 
BPA was categorized above or below the median value, a significant positive relationship with wheeze 
was found at six months of age, but there was no evidence of a persistent positive association by three 
years of age.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
− Longitudinal follow up 
− Large sample size 
− Repeated measurements 
− Analytical method (LC-MS-MS) 
− Quality control, including blanks and quality assurance procedures 
− Multiple outcome assessment for wheeze 
Weaknesses: 
− Single spot urine BPA measurements 
− Confounding by diet or by concurring factors (other than active smoking during pregnancy) 
not reported 
− Unclear clinical relevance (relevance of wheeze difficult to interpret in the absence of effects 
on sensitisation) 
− Inconsistent results amongst different studies  
 
Overall the CEF Panel notes that the study is generally sound, but the CEF Panel considers that this 
categorization of BPA exposure to be questionable and notes that exposure after birth was not 
considered. The relevance of wheeze is of difficult interpretation in the absence of effects on 
sensitisation. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Vaidya SV and Kulkarni H, 2012. Association of Urinary Bisphenol A Concentration with 
Allergic Asthma: Results from the National Health and Nutrition Examination Survey 2005-
2006. The Journal of Asthma, 49, 800-806. 
 
Vaidya et al.(2012) examined whether urinary BPA concentration was associated with allergic asthma 
using data from the National Health and Nutrition Examination Survey 2005–2006 survey. The sample 
size was large (n=2548). Total (free plus conjugated) was determined by solid phase extraction (SPE) 
coupled with liquid chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.4 ng/ml). The 
exposure was spot urine BPA measurement, allergic asthma was defined as a history of asthma ever, 
high eosinophil count, and high total IgE or atopy. The results showed that 10-fold increase in BPA 
was independently associated with a higher likelihood of allergic asthma in females [odds ratio 
(OR)=2.21, p=0.032] but not in males (OR=0.83, p=0.474). These findings were reaffirmed when 
allergic asthma was defined based on atopy rather than total IgE (OR=2.45, p=0.001 in females and 
OR=0.83, p=0.605 in males). Urinary BPA was significantly associated with sensitization to various 
specific allergens in a dose-response manner.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and weaknesses in this study: 
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Strengths: 
− Large sample size 
− Analytical method (LC-MS-MS) 
− Quality control, including blanks and quality assurance procedures 
− Multiple outcome assessment for asthma 
Weaknesses: 
− Cross-sectional study design 
− Single spot urine BPA measurement 
− Not adjusted urine samples 
− Confounding by diet or by concurring factors not reported 
− Unclear clinical relevance (gender-related differences) 
− Inconsistent results amongst different studies  
 
Overall the CEF Panel notes that the relevance of this study is limited by several methodological 
issues (cross-sectional study and single spot urines) and statistical handling. Urinary BPA 
measurements were not adjusted for creatinine or specific gravity data and log of BPA was used as 
dependent variable in spite of several samples <LOD. Differences were found between included and 
excluded subjects, but the differences were not considered clinically meaningful. The authors 
acknowledged the main limitations of the study. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
(ii) Animal studies 
Bauer S, Roy A, Jason E, Chapman T, Georas S. Lawrence BP. The effects of maternal exposure 
to bisphenol A on allergic lung inflammation into adulthood. Toxicological Sciences, 130, 82-93. 
  
Bauer et al. (2012) administered BPA by gavage to pregnant C57Bl/6 damns from gestation day 6 
until post-natal day 21 to 0, 0.5, 50, or 500 µg BPA/kg/day. To induce allergic inflammation, adult 
offspring were mucosally sensitized with inhaled ovalbumin containing low dose lipopolysaccharide 
or intraperitoneally sensitized using ovalbumin with “alum” (not further specified by the authors), 
followed by ovalbumin aerosol challenge. In the mucosal sensitization model, female offspring 
maternally exposed to > 50 µg BPA/kg/day displayed enhanced lymphocytic and lung inflammation, 
assessed by histopathology, compared to controls. This effect was evident in females but not males. 
There were no clear dose-related effects on cell numbers in broncholveolar lavages of the animals.  
Peritoneally sensitized female but not male mice maternally exposed to < 50 but not 500 µg/kg  
showed a dampened effect on numbers of eosinophils in lung lavage, but there was no clear dose-
response relationship. In the peritoneal model, there was no effect on airway hyperresponsiveness in 
females noted. Unfortunately, this clinical outcome was not measured in the more relevant mucosal 
model. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths:  
− Number of doses (≥3) 
− Phytoestrogen –free diet 
− Oral administration via gavage 
− BPA measurement in biological samples  
Weaknesses:  
− Study design not appropriate to the scope (Lower end of the dose-response was performed in a 
separate experiment) 
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Overall, the CEF Panel considered that the inflammation seen in the mucosal model in females is an 
adverse effect, indicative of stimulation of allergic asthma. It is not known why females but not males 
show these effects. The effect seems subtle, as effects on eosinophils in the lavage could not be 
detected, but  airway hyperreactivity was not assessed in that model. In the peritoneal sensitization 
model, the females showed dampened eosinophil numbers after inhalation challenge to ovalbumin in 
the lung lavage, but only below 50 μg/kg bw per day, and not at the highest concentration. Hence, 
there is no clear dose-response relationship, while the CEF Panel considers this intraperitoneal model 
less relevant for allergic asthma.  
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Kendziorski JA, Kendig EL, Gear RB, Belcher SM, 2012. Strain specific induction of pyometra 
and differences in immune responsiveness in mice exposed to 17α-ethinyl estradiol or the 
endocrine disrupting chemical bisphenol A. Reproductive Toxicology, 34, 22-30.  
Kendziorsky et al. (2012) administered BPA in the diet of CD1 and C57Bl mice (n= 5 per group) at 
levels of 0, 0.03, 0.3 or 30 mg/kg diet, (estimated to be approximately equivalent to 0, 4, 30-40 or 
4000 µg BPA/kg bw per day) from before mating, through gestation, parturition and weaning (in F0 
females) and until weeks 19-23 (F0 females). 17α-ethinyl oestradiol (EE; 0.01, 0.1 or 1.3 mg/kg diet) 
was also administered to separate groups of mice (n=4), equivalent to approximate intakes of 0, 1.2-
1.4, 12-15 or 1160 µg DES/kg bw/ day. Reproductive performance was assessed and uterine pathology 
of the F0 females was investigated following sacrifice at weeks 19-23.  
The authors observed pyometra, i.e. inflammation in the uterus in in a small minority of C57Bl mice 
receiving 0.3 mg BPA/kg diet, accompanied by changes in uterine morphology. A 5-fold, statistically 
significantly more pronounced presence of macrophages was observed in the uteri of all C57B1 
females at this dose. Pyometra was also observed in the 15μg/kg-d EE treatment group, but no such 
changes were seen in CD1 mice. The authors concluded that BPA enhances immune responsiveness of 
the uterus and that heightened responsiveness in C57BL/6 females is related to increased susceptibility 
to pyometra.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Positive control included 
- Number of doses (≥3) 
- Phytoestrogen –free diet 
Weaknesses: 
- Small sample size 
Overall, the CEF Panel noted that the relevance of the macrophage infiltration in terms of pyometra is 
not clear, and the conclusion of the authors that BPA enhances immune responsiveness is speculative. 
The pyometra was observed only in a minority of animals at highest dose. These notions do not take 
away from the fact that infiltration of macrophages may be adverse. A clear deficiency in the study is 
that a dose-response relationship has not been established, although it is not totally clear from the 
paper whether uterine changes were investigated in the animals receiving 30 mg BPA/kg diet.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Lee J, Lee SJ, Lim KT and 2012a. CTB glycoprotein (75kDa) inhibits IgE releasing, TNF-α and 
IL-6 expressed by bisphenol A in vivo and in vitro. Food and Chemical Toxicology, 50, 2109-
2117. 
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Lee et al. (2012a) described studies in which adult female BALB/c mice (n=6) were injected 
intraperitoneally with 5 mg BPA/kg body weight per day for 4 weeks. The treatment resulted in 
increases in several non-specific inflammatory mediators and total levels of IgE. These effects were 
diminished or blocked in the presence of a glycoprotein derived from Cudrania tricuspidata Bureau 
(CTB), investigation of such an inhibitory effect being the main purpose of the study.  
In the in vitro part of the study, the authors examined the effects of BPA (50 µM) on extracellular 
signal-regulated kinases (ERK) and p38 mitogen-activated protein kinase (MAPK), activator protein 
(AP)-1, expressions of pro-inflammatory cytokines, nitric oxide (NO) production and cyclooxygenase 
(COX)-2 in pre-mast cells (RBL-2H3 cells) BPA was found to stimulate expression of these various 
markers, indicative of an immunomodulatory effect. CTB glycoprotein blocked or partially inhibited 
the stimulatory effect of BPA. 
 
Comments from the CEF Panel: 




- Study design not appropriate to the scope (no functional endpoints assessed) 
 
Overall the CEF Panel considers that while BPA had a number of effects that may be seen as 
immunomodulatory, only one concentration of BPA was used, no functional endpoints were 
investigated and the number of animals was relatively small.  
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Nakajima Y, Goldblum RM, Midoro-Horiuti T, 2012. Fetal exposure to bisphenol A as a risk 
factor for the development of childhood asthma: an animal model study. Environmental Health, 
11, 8.  
Nakajima et al. (2012) exposed female Balb/c mice to 10 µg/ml BPA in their drinking water from one 
week prior to gestation until the end of the study on day 25 post partum. Some pups were left with 
their mothers, but other pups were switched to unexposed mothers within the first 48 hours of life, so 
that exposure took place during the entire study period, only prenatally, or only postnatally. Pups were 
sensitized to ovalbumin at day 4 after birth and challenged at days 18, 19 and 20 after birth. Airway 
hyperreactivity to methycholine as well as inflammation by evaluating eosinophils in bronchoalveolar 
lavage were assessed in 22 day old pups. Pups exposed in utero or through mother’s milk in addition 
to in utero exposure showed increased airway hyperreactivity and increased eosinophil numbers in 
bronchoalveolar lavage fluid. Pups exposed only post-natally did not show such effects. The authors 
concluded that prenatal exposure to BPA, followed by postnatal allergic sensitisation and challenge, 
promoted the development of experimental allergic asthma. They suggested that delayed expression of 
BPA-metabolising enzymes may explain, at least in part, the enhanced fetal susceptibility. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
- Small sample size 
- Test performed in one sex only 
- Single dose level study (to show effects on total IgE non-specific inflammatory mediators).  
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Overall the CEF Panel considers that this study shows enhancement of ovalbumin-induced airway 
hyper-reactivity in mice and increased numbers of eosinophils in bronchoalveolar lavage after pre- and 
postnatal exposure to BPA, but no dose-response relationship was assessed. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
(iii) In vitro studies 
Appraisal of strengths and weaknesses and WoE analysis were not carried out for in vitro studies.  
Pisapia L, Del Pozzo G, Barba P, Caputo L, Mita L, Viggiano E, Russo GL, Nicolucci C, Rossi S, 
Bencivenga U, Mita DG and Diano N, 2012. Effects of some endocrine disruptors on cell cycle 
progression and murine dendritic cell differentiation. General and Comparative Endocrinology, 
178, 54-63. 
 
Pisapia and coll. investigated the effect of several substances including BPA on the differentiation of 
bone marrow dendritic cells isolated from female mice and cultured in hormone-deficient medium. 
BPA at 10-7 M, 10-6 M and 10-5 M induced the differentiation of 62%, 70% and 91% of the cells to the 
CD11c+ phenotype, respectively. The CEF Panel noted that due to high BPA concentrations and the 
specific culture conditions the relevance of this finding for the in vivo situation is not clear. 
Cardiovascular effects 
(i) Human studies 
BPA effects on coronary artery disease/heart attack  
Lakind JS, Goodman M and Naiman DQ, 2012. Use of NHANES Data to Link Chemical 
Exposures to Chronic Diseases: A Cautionary Tale. PLoS One. 2012;7(12):e51086.  
The authors reanalysed data from four datasets in the National Health and Nutrition Examination 
Survey (NHANES). Data on urinary BPA and health outcomes from 2003-2004, 2005-2006, 2007-
2008, and 2009–2010 were available. The aim was to examine the consistency of the association 
between urinary BPA measures and diabetes, coronary heart disease (CHD), and/or heart attack across 
datasets when consistent scientifically and clinically defined criteria were applied. The study sample 
included n=4811 for CVD, n=4811 for heart attack and n=4823 for diabetes. Samples were analysed 
by on line solid-phase extraction (SPE) coupled with liquid chromatography tandem mass 
spectrometry (LC-MS-MS, LOD 0.4 ng/mL). All multivariable analyses were controlled for a priori 
selected potential confounders including, but not limited to, those used in the previous studies. The 
models included the following covariates: creatinine, age, gender, race/ethnicity, education, income, 
smoking, body mass index, waist circumference, heavy drinking, family history of diabetes (in the 
analyses of diabetes) or heart attack/angina (in the analyses of CHD and heart attack), hypertension, 
sedentary activity, blood cholesterol, and daily energy intake. Urinary BPA was not significantly 
associated with adverse health outcomes for any of the NHANES surveys, with ORs (95% CIs) 
ranging from 0.996 (0.951–1.04) to 1.03 (0.978–1.09) for CHD, 0.987 (0.941–1.04) to 1.04 (0.996–
1.09) for heart attack, and 0.957 (0.899–1.02) to 1.01 (0.980–1.05) for diabetes. When the data from 
Strengths: 
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic bottles 
Weaknesses:  
- Animal age and body weight not given 
- Small sample size 
- Single dose level study 
- Study design not appropriate to the scope (administration via drinking water, but water 
consumption not measured) 
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four surveys were pooled, the ORs (95% CIs) for the full model that included all covariates were 
1.004 (0.998–1.009) for CHD, 1.002 (0.998–1.007) for heart attack, and 0.995 (0.982–1.007) for 
diabetes. The choice of covariates had only minor effect on point estimates. The authors concluded 
that the discrepancy between their findings on diabetes and those reported previously was largely 
explained by the choice of case definition. For discrepancy between results of this study and previous 
findings for CHD, the authors concluded that this was in part attributable to differences in inclusion 
criteria. In the current study, no subjects were excluded based on very high BPA concentrations.  
The authors provided an example of reverse causality obscuring possible conclusions from cross-
sectional studies: “In all analyses, cholesterol levels were statistically significantly inversely 
associated with heart attack and CHD. Given the well-documented positive association between 
cholesterol and heart disease from prospective studies, the most logical explanation for the observed 
result is reverse causation, i.e. it is likely that diagnoses of heart attack or CHD, which preceded the 
cholesterol measurements in NHANES, likely triggered changes in lifestyle or use of medications that 
resulted in lower cholesterol levels.” 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size 
- Urine, container specified 
- Standardised samples (urinary creatinine included in the model as independent variable) 
- Analytical method (SPE LC-MS-MS)  
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross-sectional study design  
- Single spot urine BPA measurement  
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered  
- Inconsistency in results among different studies  
Overall, the CEF Panel considers that this study shows how relatively minor decisions made a priori 
(clinical definition of diabetes and inclusion of participants with higher levels of BPA) affected the 
previously reported results and conclusions of associations between urinary BPA exposure and chronic 
disease. This study does not add to the evidence as to whether or not BPA is a risk factor for chronic 
disease, but highlights that using data from cross-sectional studies like NHANES surveys to draw 
conclusions about relations between short-lived environmental chemicals and chronic diseases is 
inappropriate.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Lind PM and Lind L, 2011. Circulating levels of Bisphenol A and Phthalates are related to 
Carotid Atherosclerosis in the Elderly. Atherosclerosis, 218, 207-213.  
 
The authors investigated whether circulating levels of BPA and phthalate metabolites were related to 
atherosclerosis. The study was carried out as a cross-sectional analysis of 1 016 subjects all aged 70, 
within a population-based cohort in Sweden. BPA and 10 phthalate metabolites were measured in 
serum by solid phase extraction (SPE) coupled with liquid chromatography tandem mass spectrometry 
(LC-MS-MS, LOD 0.2 ng/mL). Atherosclerosis was defined by the prevalence of overt plaques and 
echogenectity (grey scale median, GSM) of carotid artery plaques recorded by ultrasound in both of 
the carotid arteries. Additionally, the thickness (IMT) and echogenicity (IM-GSM) of the intima-
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 387 
media complex were measured. BPA was not significantly associated with the number of arteries with 
plaque or intima-media thickness, while these associations were significant for mono-methyl phthalate 
(MMP). High levels of BPA as well as some phthalates were associated with an echogenic IM-GSM 
and plaque GSM, suggesting a role for plaque-associated chemicals in atherosclerosis. The models 
were adjusted for multiple CV risk factors.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size 
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross-sectional design 
- Selection bias (Caucasians aged > 70, better health conditions) 
- Serum BPA measurement (invalid exposure measurement) 
- Single BPA measurements  
- No distinction between unconjugated and conjugated BPA 
- Handling of values below LOQ not reported 
- Confounding by diet or by concurring exposure factors not considered  
- Generalisability to the total population  
- Inconsistency in results among different studies 
Overall, the CEF Panel considers that the significant relationship between serum level of BPA and 
echogenicity of the intima-media complex and plaque echogenicity in 1 016 subjects aged 70 is 
potentially interesting, but the study has main limitations (e.g. cross-sectional design and invalid 
exposure assessment using serum BPA without distinction between unconjugated and conjugated 
BPA). The four phthalates and BPA were analyzed separately, and the relationship between the 
measured substances would be interesting. 
The CEF Panel notes that no formal adjustment for multiple testing was made and the explanation for 
not performing it provided by the authors is not convincing. Further covariates for which information 
was available were not adjusted for in the models (e.g. myocardial infarction, drugs other than statins); 
the authors neither describe nor discuss this choice. Some of the CV risk factors included in the 
analysis for adjustment were collected via administration of a questionnaire (e.g. smoking, statin use); 
there is a possibility for information bias due to self-reporting.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Melzer D, Osborne NJ, Henley WE, Cipelli R, Young A, Money C, McCormack P, Luben R, 
Khaw KT, Wareham NJ and Galloway TS, 2012a. Urinary Bisphenol: A Concentration and 
Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Circulation, 
125, 1482-1490.  
 
This is an observational nested case-control prospective study using data from a 10 year follow up of 
the EPIC-Norfolk cohort in the UK to examine associations between urinary BPA concentration and 
later coronary artery disease (CAD). Total BPA (unconjugated and conjugated) was determined in 
spot urine, by solid phase extraction (SPE) coupled with liquid chromatography tandem mass 
spectrometry (LC-MS-MS, LOQ 0.50 ng/mL). The results showed that higher urinary concentrations 
of total BPA were associated with increased risk of developing coronary artery disease defined as 
hospital admittance or death because of myocardial infarction). One SD (4.45 ng/mL) increase in 
urinary total BPA in a partly adjusted model resulted in and increased risk of OR: 1.13 (95%CI: 1.02–
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1.24) and in a fully adjusted model of OR: 1.11 (95% CI: 1.00–1.23, p=0.058). Blood and urine 
samples were taken between March 1993 and April 1998. Follow-up was until first endpoint event or 
December 2003. The longest observation interval between urine sampling (and estimation of BPA 
concentrations in urine) and observation of the endpoint (if not the endpoint occurred in between) is 10 
years 9 months; the shortest is 5 years 8 months.  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Longitudinal follow up 
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Single spot urine BPA measurement  
- Confounding by diet or by concurring exposure factors not considered 
- Unclear clinical relevance (small effect size) 
- Generalisability to the overall population  
Overall the CEF Panel notes that the longitudinal design in a European population can be seen as a 
major strength in comparison to previously reported cross-sectional associations in more highly 
exposed US study populations. BPA exposure was measured in spot urine samples with limited 
information on the conditions of sampling, except that the BPA measures were from single-spot urine 
specimens and that urine samples were taken at the same time of day for each respondent. However, 
the authors reported that they followed WHO guidelines as regards biomonitoring of BPA exposure as 
well as GLP and inclusion of reagent blanks.  
The endpoint in this study was CAD, and the authors only identified cases that were admitted to the 
hospital or died because of myocardial infarction. Validation of diagnoses was only performed in the 
cases of myocardial infarction. CAD is a disease where patients do not necessarily need to be admitted 
to a hospital. Hence, the possibility is given that subjects in the control group have a CAD which was 
not leading to a hospital admission. The authors excluded subjects with diabetes. Several statistical 
models were reported, of which only the fully adjusted model D is acceptable because in partly 
adjusted models the known risk factors were not taken into consideration. If adjusted for BMI, 
cigarette smoking, average of the 2 systolic blood pressure readings (in mm Hg), total cholesterol, 
low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and level of 
physical activity the odds ratio decreased to 1.11 (CI 1.00–1.23), p=0.058. It is also of interest to note 
that removal of the cases of the first three years in the post hoc sensitivity analysis changed the odds 
ratio to 1.12 (CI 1.00–1.26) p=0.05. The authors indicate that they measured C-reactive protein (also 
associated with CAD) but they did not explain why the measurements were not included into the 
model. However, this seems not to be of influence in the post hoc analysis.  
The discussion part infers from kinetic data in rodents to the human situation which is not 
scientifically correct given the fact that in rodents enterohepatic recirculation influences the terminal 
half-life whereas in humans BPA is not undergoing enterohepatic recirculation. Hence, their 
conclusion that under normal condition of food intake single spot urinary concentration of total BPA is 
a valuable estimate for intake is not substantiated and is in contrast to experimental findings 
mimicking normal conditions of food intake (Teeguarden et al., 2011). The study may be confounded 
by the fact that CAD cases were only cases with hospital admission thus not including cases in 
outpatient care (whether this omission is distributed equally between cases and controls is unclear and 
here the fact that they did not match the controls may play a role). The association observed in the 
study was weak.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
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Melzer D, Gates P, Osborn NJ, Henley WE, Cipelli R, Young A, Money C, McCormack P, 
Schofield P, Mosedale D, Grainger D and Galloway TS, 2012b. Urinary Bisphenol A 
concentration and angiography-defined coronary artery stenosis. PLoS One. 2012 ;7(8):e43378. 
doi: 10.1371/journal.pone.0043378. Epub 2012b Aug 15. 
 
The study aim was to estimate associations between BPA exposure assessed in spot urine and 
angiographically graded coronary atherosclerosis in 591 patients participating in The Metabonomics 
and Genomics in Coronary Artery Disease (MaGiCAD) study in Cambridgeshire UK. Total BPA 
(unconjugated and conjugated) was determined in spot urine, by solid phase extraction (SPE) coupled 
with liquid chromatography tandem mass spectrometry (LC-MS-MS, LOQ 0.50 ng/ml). Total BPA 
was compared with grades of severity of coronary artery disease (CAD) on angiography. Linear 
models were adjusted for BMI, occupational social class and diabetes status. Severe (one to three 
vessel) CAD was present in 385 patients, 86 had intermediate disease (n=86) and 120 had normal 
coronary arteries. The (unadjusted) median urinary BPA concentration was 1.28 ng/mL in patients 
with normal coronary arteries and 1.53 ng/mL in patients with severe CAD. Compared to those with 
normal coronary arteries (n=120), urinary BPA concentration was significantly higher in those with 
severe CAD (n=385) (OR per uBPA SD=5.96 ng/mL OR=1.43, CI 1.03 to 1.98, p=0.033), and near 
significant for those with intermediate disease (n=86) (OR=1.69, CI 0.98 to 2.94, p=0.061). Patients 
with severe CAD were further divided into three groups with scores denoting disease in 1, 2 or three 
vessels (148 with 1 VD, 123 with 2VD, 114 with 3VD). Significant associations with BPA were seen 
only for patients with 1VD and 3VD. 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Longitudinal follow up 
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Single spot urine BPA measurement  
- Confounding by diet or by concurring exposure factors not considered 
- Generalisability to the overall population  
- Inconsistent results amongst different studies 
Overall, the CEF Panel considers that the finding of higher BPA exposure in those with severe 
coronary artery stenosis compared to those with no vessel disease is potentially interesting, despite the 
relative weak associations and the limitations concerning the clinical usefulness of the criteria used to 
classify severe and intermediate patients. Whereas nearly the same number of patients were in one the 
three groups (1 VD, 2VD, 3 VD), there was no association between the group of patients with 2 VD 
and uBPA (OR per SD uBPA 1.2 (0.7–2.04)), indicating an unknown influence in the statistical model 
used. In addition, it should be critically noted that the scoring category used has not been identical 
with the one used in the original paper and that the cumulative assessment of one to three vessel 
disease might be made from a statistical point of view but is without clear clinical relevance. 
Classification of all other coronary lesions as intermediate if the criteria were not met is also clinically 
not justified. BPA was used as a continuous variable, but analytical aspects were sufficiently justified. 
Urinary BPA varied from below levels of detection to 69.4 ng/mL, with a median of 1.28 ng/mL 
(unadjusted) in patient with normal coronary arteries, and 1.53 ng/mL in those severe disease, while 
median concentration in the intermediate group was higher (1.77 ng/mL). Urinary BPA was associated 
with severe disease in a model adjusted for age, sex, BMI category, occupational social class and 
diabetes status, but potential confounding by diet was not considered. The authors modelled urinary 
BPA as a continuous variable, but the standard deviation was very high (5.96 ng/mL) and it could be 
questioned whether it was appropriate to use the SD increase as the independent value in OR 
calculation. Such an increase is higher than the most part of the performed measures. Urinary BPA 
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values were not normalized to urinary creatinine level, but for blood urea creatinine ratio, thus they are 
not comparable to values of other studies available in the peer-reviewed literature. This is a very 
important limitation. The authors discuss the limitation related to use of spot urine samples, and say it 
is “likely that the use of single spot samples would, if anything, result in a smaller (diluted) estimate of 
the strength of the association between BPA and CAD”. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Olsén L, Lind L and Lind PM, 2012. Associations between circulating levels of bisphenol A and 
phthalate metabolites and coronary risk in the elderly. Ecotoxicology and Environmental Safety, 
80, 179-183.  
 
This is a cross sectional study (n=1 016 with an age >70) that examined associations between serum 
concentrations of total BPA and coronary risk. The study dates were not reported. Blood samples were 
taken to measure lipids including LDL-, HDL-cholesterol and triglycerides as well as glucose (fasting 
state). Blood pressure was measured and a self-reported questionnaire was used to assess smoking 
habits, history of cardiovascular diseases and drug use. From these data the Framingham risk score 
was determined. The blood sample was also used to measure phthalate and its metabolites as well as 
total BPA by solid phase extraction (SPE) coupled with liquid chromatography tandem mass 
spectrometry (LC-MS-MS, LOD 0.2 ng/ml) after enzymatic hydrolysis. The authors evaluated 
whether the circulating levels of the chemicals or their metabolites were related to one of the risk 
factors for coronary heart disease, and found no associations.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Large sample size 
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks 
Weaknesses:  
- Cross-sectional design 
- Selection bias (age >70) 
- Serum BPA measurement (invalid exposure measurement)  
- Single BPA measurements  
- No distinction between unconjugated and conjugated BPA 
- Handling of values below LOQ not reported 
- Confounding by diet or by concurring exposure factors not considered  
- Generalisability to the total population  
- Inconsistency in results among different studies 
Overall, the CEF Panel notes that the study sample is the same as in the study by Lind and Lind 
(2011), and many of the limitations noted above relate to the Olsén study. The study, which did not 
find a correlation between the serum concentration of BPA and the risk factors, cannot be taken as 
dismissing a correlation.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
BPA effects on metabolic syndrome, hypertension, and peripheral artery disease 
Bae S, Kim JH, Lim YH, Park HY and Hong YC, 2012. Associations of Bisphenol A Exposure 
With Heart Rate Variability and Blood Pressure. Hypertension, 60, 786-793. 
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The aim of the study was to investigate the associations of urinary BPA with heart rate variability and 
blood pressure. The study comprised 560 non-institutionalized elderly citizens recruited in Seoul 
during the years 2008–2010. All of the participants were ≥60 years old. The participants took medical 
examinations ≤5 times. Heart rate variability, blood pressure and spot urine BPA concentration, were 
measured at each time. Hypertension was defined as systolic blood pressure (SBP) ≥140 mm Hg or 
diastolic blood pressure (DBP) ≥90 mm Hg A total of 1 511 observations from 521 participants were 
included in the analyses. Total BPA was measured by solid phase extraction (SPE) coupled with liquid 
chromatography tandem mass spectrometry (LC-MS-MS, LOD 0.01 µg/l) after enzymatic hydrolysis. 
When urinary BPA was modelled on the continuous scale, urinary BPA was negatively associated 
with the heart rate (p<0.001) and positively associated with blood pressure (SBP: p=0.073, DBP: 
p=0.038). When urinary BPA was divided into quartiles, no significant association was found for 
comparison of the fourth quartile compared with the first quartile of urinary BPA concentration. 
However, the association was statistically significant when the analyses were restricted to participants 
who did not report previous history of hypertension (n=258), with adjusted OR: 2.35 (95% CI, 1.33–
4.17). The association was stronger in women than in men.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Urine, container specified 
- Standardized samples (urinary creatinine) 
- Analytical method (SPE LC-MS-MS)  
Weaknesses:  
- Cross-sectional study design  
- Selection bias (age ≥60) 
- Single spot urine BPA measurement 
- No quality control (e.g., blanks) and quality assurance procedures  
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered  
- Generalisability to the total population 
Overall, the CEF Panel notes that, although some significant associations between urinary BPA levels 
and hearth rate variability and hypertension were described, the clinical/pathological significance 
remains doubtful. Fasting blood glucose and alcohol consumption was included among adjusting 
variables, but other dietary information was not considered. The study has a fair sample size. 
However, according to the authors the sample size became small after stratification by the previous 
history of hypertension and sex. The study is limited by use of single spot urine samples and cross- 
sectional design. The generalisability of the study population is also questionable. The authors 
sometime overestimated the results, in particular those of clinical relevance.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Shankar A and Teppala S, 2012. Urinary Bisphenol A and Hypertension in a Multiethnic 
Sample of US Adults. Journal of Environmental and Public Health, 2012, Article ID 481641, 5 
pages.  
 
This is a cross-sectional study that examined the association between urinary BPA levels in 1 380 
subjects from the National Health and Nutritional Examination Survey 2003–2004 and hypertension, 
defined as blood pressure-reducing medication use and/or blood pressures >140/90 mm Hg (n=580). 
Complete data was available for 1 380 participants, of whom 580 had hypertension. Total BPA was 
measured in spot urine samples by solid phase extraction (SPE) coupled with liquid chromatography 
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tandem mass spectrometry (LC-MS-MS, LOD 0.36 ng/mL). The results showed a positive association 
between increasing levels of urinary BPA and hypertension independent of confounding factors such 
as age, gender, race/ethnicity, smoking, body mass index (BMI), diabetes mellitus and total serum 
cholesterol levels. Compared to tertile 1 (referent), the multivariate-adjusted odds ratio (95% 
confidence interval) of hypertension associated with tertile 3 was 1.50 (1.12–2.00); p-trend=0.007. 
The association was consistently present in subgroup analyses by race/ethnicity, smoking status, BMI, 
and diabetes mellitus.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Analytical method (SPE LC-MS-MS or GC-MS)  
- Quality control, including blanks and quality assurance procedures 
Weaknesess:  
- Cross-sectional study design 
- Single spot urine BPA measurement 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Generalisability to the total population 
Overall, the CEF Panel notes that the hypertension endpoint was measured (method adequate) and the 
diagnostic criteria used were appropriate. Age, gender, race/ethnicity, smoking status, alcohol intake 
(g/day), level of education, history of diabetes and oral hypoglycemic intake or insulin administration 
were assessed using a questionnaire. The authors adjusted for the following confounding factors; age, 
gender, race/ethnicity, smoking, body mass index (BMI), diabetes mellitus and total serum cholesterol 
levels, but no dietary data were included. The CEF Panel also notes that the study has main 
limitations, e.g. the use of single spot urine samples to assess total BPA exposure and the cross-
sectional design, which makes the study unsuitable for causal inference.  
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Shankar A, Teppala S and Sabanayagam C, 2012a. Bisphenol A and Peripheral Arterial 
Disease: Results from the NHANES. Environmental Health Perspectives, 120, 1297-1300.  
 
The authors analysed data from the US NHANES 2003/04 with a sample size of 745 subjects. The aim 
of the study was to investigate the potential association between single spot urine BPA concentrations 
and peripheral arterial disease (PAD) defined as ankle-brachial index <0.9 (n=63). Total BPA was 
measured in spot urine samples by solid phase extraction (SPE) coupled with liquid chromatography 
tandem mass spectrometry (LC-MS-MS, LOD 0.36 ng/ml). Urinary total BPA was categorized into 
tertiles (<1.4 ng/ml, 1.4-3.5 ng/ml, >3.5 ng/ml). The results showed a significant, positive association 
between increasing levels of urinary total BPA and PAD before and after adjustment for confounders 
(age, gender, race/ethnicity, education, smoking, body mass index (BMI), diabetes mellitus, 
hypertension, urinary creatinine, estimated glomerular filtration rate, and serum cholesterol levels). 
The multivariable-adjusted odds ratio (95% confidence interval) for PAD associated with the highest 
versus lowest tertile of urinary BPA was 2.69 (1.02–7.09); p-trend=0.01.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Analytical method (SPE LC-MS-MS)  
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
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- Cross-sectional study design 
- Single spot urine BPA measurement 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Generalisability to the total population 
Overall, the CEF Panel notes that the study suggests that total BPA may be involved in inducing 
cardiovascular related diseases as a minor risk factor. However, the study has limitations and the 
cross-sectional design makes it unsuitable for causal inference. The authors acknowledged in their 
discussion that the study is limited by its cross sectional design, possible residual confounding by 
socioeconomic status, and the use of single a spot urine sample. Potential confounding by diet is also a 
limitation. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Teppala S, Madhavan S and Shankar A, 2012. Bisphenol A and Metabolic Syndrome: Results 
from NHANES. International Journal of Endocrinology, 2012, Article ID 598180, 5 pages.  
http://www.ncbi.nlm.nih.gov/pubmed/23251154 
 
The authors examined the association between urinary BPA concentrations and metabolic syndrome 
(MetS) in 2 104 participants (≥18 years) in the National Health and Nutrition Examination Survey 
2003–2008 (NHANES) in a cross-sectional study. BPA exposure (total BPA) was measured in spot 
urine samples by solid phase extraction (SPE) coupled with liquid chromatography tandem mass 
spectrometry (LC-MS-MS, LOD 0.36 ng/ml). MetS was defined based on the revised Adult Treatment 
CEF Panel III (ATP III) guidelines. A total of 741 participants were found to be positive for 3 or more 
of the 5 measured components and were considered to have MetS: (1) abdominal obesity (waist 
circumference:≥102 cm in men and ≥88 cm in women), (2) hypertension (systolic blood pressure 
≥130mm of Hg, diastolic blood pressure ≥85 mm of Hg, use of medications for elevated blood 
pressure), (3) elevated serum triglycerides (≥150 mg/dl), (4) glucose intolerance (fasting serum 
glucose ≥100 mg/dl, medications for diabetes), and (5) reduced HDL (<40 mg/dl for men and <50 
mg/dl for women). The results showed that increasing levels of urinary BPA were positively 
associated with MetS, independent of confounders such as age, gender, race/ethnicity, smoking, 
alcohol intake, physical activity, and urinary creatinine. Compared to tertile 1 (referent), the 
multivariable adjusted odds ratio (95% confidence interval) of MetS in tertile 3 was 1.51 (1.07–2.12); 
p-trend was 0.02. The potential biological mechanism suggested by the authors is the endocrine 
disrupting and estrogen-like effects of BPA reported in animal studies. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Standardised samples (urinary creatinine included in the model as independent variable) 
- Analytical method (SPE LC-MS-MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross-sectional study 
- Single spot urine BPA measurement 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Generalisability to the overall population 
Overall, the CEF Panel notes that this is the first reporting a positive association between BPA and 
MetS in humans. As acknowledged by the authors, it is not possible to draw cause effects from the 
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observed associations due to the cross sectional nature of the study. The authors also acknowledged 
the potential confounding role of diet, as the main source of BPA exposure in humans is consumption 
of food and beverages known to be associated with MetS. 
This paper is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
(ii) Animal studies 
Pant J, Pant MK and Deshpande SB, 2012. Bisphenol A attenuates phenylbiguanide-induced 
cardio-respiratory reflexes in anaesthetized rats. Neuroscience Letters 530, 69– 74. 
 
The study was undertaken to examine the effects of repeated and acute exposure to BPA on cardio-
respiratory reflexes elicited by phenylbiguanide (PBG). In chronic experiments, adult female Albino 
rats of Charles Foster strain were fed with pellets containing BPA (2 µg/kg body weight, (n=6) or 
without BPA (time-matched control, n=6) for 30 days. Food pellets containing BPA were prepared by 
dissolving BPA in vegetable oil and then mixed with wheat flour and water. Blood pressure, ECG and 
respiratory excursions were recorded under urethane anaesthesia. PBG (10 µg/kg bw) was injected 
through the jugular vein to evoke reflexes in these animals. In acute experiments, BPA was dissolved 
in 100% ethanol. In these latter experiments, the PBG reflexes were obtained before and after injecting 
BPA (35 mg/kg body weight dissolved in ethanol) (n=7) with ethanol (0.1%) treated animals (n=5) as 
controls. Vagal afferent activity was recorded in rats (numbers not given) given 35 mg/kg bw BPA 
intravenously. Other rats served as controls. Measurements were done pre-BPA-dosing and post-BPA-
dosing. In time-matched control rats, PBG produced bradycardia, hypotension and tachypnoea over 60 
seconds. Changes were calculated with the value obtained before PBG dosing as reference. The 
maximal changes were a decrease to 50–65% of the reference value. In BPA treated group, the PBG-
induced heart rate and respiratory frequency changes were attenuated. Acute exposure of animals to 
BPA also attenuated the PBG-induced responses significantly whereby the effect on respiratory rate 
was identical with the influence of ethanol (control group). The attenuation of the PBG reflex 
responses by BPA in acute experiments was associated with decreased vagal afferent activity. The 
present results may suggest that BPA attenuates the protective cardio-respiratory reflexes due to 
decreased vagal afferent activity. 
Comments from the CEF Panel: 




- Test performed in one sex only 
- Insufficient study reporting, e.g. number of animals tested,  
- Animal diet and phytoestrogen content not reported  
- Environmental contamination (use of PC cages and/or plastic drinking bottles) not reported 
Overall the CEF Panel considers that this study does not contribute to the understanding of BPA 
effects in humans based on the following. First, the PBG model does not mimic any situation in 
humans. Second, in the BPA experiment suggesting an influence of BPA on vagal nerve afferent 
activity an extremely high dose of BPA (35 mg/kg bw) dissolved in ethanol was given intravenously. 
The authors describe in the text that earlier experiments had shown that doses up to 30 mg/kg bw did 
not influence vagal nerve afferent activity. 
No WoE analysis was carried out for the one animal study that was evaluated by the CEF Panel.  
(iii) In vitro studies 
Appraisal of strengths and weaknesses and WoE analysis were not carried out for in vitro studies.  
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Belcher SM, Chen Y, Yan S, Wang HS (2012) Rapid estrogen receptor-mediated mechanisms 
determine the sexually dimorphic sensitivity of ventricular myocytes to 17β-estradiol and the 
environmental endocrine disruptor Bisphenol A. Endocrinology, 153, 712-720. 
 
This study extends earlier findings of this group (Yan S, Chen Y, Dong M, Song W, Belcher SM and 
Wang HS, 2011. Bisphenol A and 17β-oestradiol promote arrhythmia in the female heart via alteration 
of calcium handling. PLoS One, 6:e25455) and reports on concentration-dependent effects of 10-12 – 
10-6 M BPA on the contraction of primary female ventricular myocytes. E2 (10-12 – 10-6 M), the 
selective β-agonist DNP (10-11 – 10-7 M) and the β-adrenergic agonist isoproterenol (ISO, 10-8 M) 
were used as positive controls. A significant increase in fractional shortening during contraction was 
detected at all BPA concentrations in myocytes from female rats with a maximum effect at 10-9 M 
(inverse U-shaped curve) comparable to the effects of E2, ISO and DNP. No effects were detected in 
myocytes from male rats and gonadectomised animals (male and female). Binding of BPA to 
membrane ERβ receptors was required to increase the fractional shortening during contraction. 
Blockade of ERβ abolished the stimulatory effect while a selective ERα agonist decreased the effects. 
Exposures of female myocytes to BPA and E2 (10-9 M each) in triggered cells resulted in spontaneous 
after-contractions, determined by intracellular Ca2+ transients indicating proarrhytmic effects. An ERβ 
blocker and an ERα agonist reduced these effects. In addition, BPA and E2 effects on myocytes were 
also studied in myocytes from female wild-type (WT) and in ERβ-/- mice: Whilst ISO induced 
contractility in WT and ERβ-/- myocytes BPA and E2 induction were only observed in WT cells. 
The results suggest that induction of contractility and arrhythmogenesis in female myocytes is 
dependent on the ERβ while ERα has opposite effects. However, the underlying molecular 
mechanisms related to the balance between ERα/ ERβ and the relevance of this balance in the 
complex in vivo situation remain to be determined.  
 
O'Reilly AO, Eberhardt E, Weidner C, Alzheimer C, Wallace BA and Lampert A, 2012. 
Bisphenol A binds to the local anesthetic receptor site to block the human cardiac sodium 
channel. PLoS One, 7, e41667. 
 
The effect of 10-7 – 10-4 M BPA on the human cardiac voltage gated Na+ channel hNav1.5, expressed 
in HEK293 cells was studied. BPA blocked the channel at and above 10-6 M with a Kd of 25.4 µM. All 
further experiments were performed at 30 µM or 100 µM BPA. The local anaesthetic mexiletine and 
BPA share the same binding site of hNav1.5. Molecular docking simulations allowed to visualize 
binding and to identify relevant molecular structures. 
 
The CEF Panel concluded that BPA effects on the voltage gated Na+ channels did not occur at relevant 
concentrations and were observed in an artificial system (overexpression of Na+ channel in a cell line). 
 
Yan S, Chen Y, Dong M, Song W, Belcher SM and Wang HS, 2011. Bisphenol A and β-estradiol 
promote arrhythmia in the female heart via alteration of calcium handling. PLoS One, 6, 
e25455. 
 
Rapid arrhythmogenic effects of 10-9 M BPA and/or E2 on the activity of rat hearts and of primary 
rodent myocytes were investigated. More than 20 % of female rat myocytes showed increased after-
contraction in the presence of BPA or E2. This correlated with Ca2+ after-transients. The number of 
after-contractions increased to 40% in the presence of BPA and E2. In contrast, BPA induced only 
infrequently arrhythmias in the isolated heart. However, during catecholamine-induced stress of the 
heart, BPA and E2 (at 10-9 M each) increased the frequency of ventricular beats by 4 folds. Arrhythmia 
of the myocytes is based on altered Ca2+ handling between the sarcoplasmic reticulum and the cytosol. 
In addition, using female WT and ERβ-/- mouse myocytes the BPA-effects on spontaneous Ca 
transients were only observed in ERβ expressing WT myocytes. 
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The CEF Panel noted that treatment with BPA/E2 increases arrhythmic contractions in female heart 
only during catecholamine-induced stress. The discrepancy between the arrhytmogenic BPA effects on 
the whole organ and the isolated myocytes and the consequences for the in vivo situation are unclear. 
Metabolic effects 
(i) Human studies 
Obesity outcomes 
Bhandari R, Xiao J and Shankar A, 2013. Urinary Bisphenol A and Obesity in US Children. 
American Journal of Epidemiology, 177, 1263–1270.  
 
Using the same data as Trasande et al. (2012) from the National Health and Nutrition Examination 
Survey (NHANES) 2003–2008, Bhandari et al. examined the cross–sectional association between 
urinary BPA and obesity in children aged 6–18 years (n=2 200), with special focus on analyzing the 
associations separately by race/ethnicity and gender. The primary exposure was urinary BPA and the 
outcome was obesity, defined as the ≥95th percentile of body mass index specific for age and sex. 
Measures of BPA concentration included BPA parent compound and conjugated metabolites. Urinary 
BPA was measured by using solid–phase extraction (SPE) coupled with liquid chromatography 
tandem mass spectrometry (LC–MS–MS, LOD 0.36 ng/ml). Quality assurance and quality control 
ensured that samples were not contaminated during collection, handling, and analysis. Urinary BPA 
was categorized into quartiles (<1.5 ng/ml, 1.5–2.7 ng/ml, 2.8–5.4 ng/ml, >5.4 ng/ml) and also 
analyzed as a continuous variable, after log transformation due to skewed distribution. 
A positive association between increasing levels of urinary BPA and obesity was seen, independent of 
age, sex, race/ethnicity, education, physical activity, serum cotinine, and urinary creatinine. The 
multivariable adjusted OR was 1.25 (95% CI: 1.09, 1.43 when log BPA was considered). When BPA 
was ranked into quartiles the results showed: compared with children in the lowest quartile of BPA 
(<1.5 ng/ml), children in the highest quartile (>5.4 ng/ml) had a multivariable OR for obesity of 2.55 
(95% CI: 1.65, 3.95) (ptrend < 0.01). The observed positive association was predominantly present in 
boys (OR = 3.80, 95% CI: 2.25, 6.43) (ptrend < 0.001) and in non–Hispanic whites (OR = 5.87, 95% CI: 
2.15, 16.05) (ptrend < 0.01). 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses: 
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet or by concurring exposure factors not considered or not reported 
- Inconsistent results amongst different studies (cross sectional studies vs longitudinal study; 
different gender–related effects in cross sectional studies) 
Overall the CEF Panel noted that NHANES data from 2003 to 2008 were used for this study as well as 
for the study by Trasande et al. (2012), and while Trasande used data for n=2 838, the study sample in 
the current study consisted of 2 664 children (6–18 years), of which 2 200 had complete data on all 
covariates.The authors reported differences in association between urinary BPA and obesity reported 
for gender and race. However, as also noted by the authors, due to the cross–sectional nature, no 
causal inference can be drawn from this study.  
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This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Carwile JL and Michels KB, 2011. Urinary bisphenol A and obesity: NHANES 2003–2006. 
Environmental Research, 111, 825–830. 
 
Carwile and Michels examined urinary BPA in relation to general and central obesity in 2 747 adults 
using pooled data from the 2003–2004 and 2005–2006 National Health and Nutrition Examination 
Surveys. Total (free and conjugated) urinary BPA was measured by solid phase extraction (SPE) 
coupled with liquid chromatography–tandem mass spectrometry (LC–MS–MS, LOD 0.36 ng/ml) at 
the Center for Disease Control and Prevention (CDC) in Atlanta. Quality control procedures included 
reagent blanks and samples of pooled human urine spiked with BPA at low– and high concentrations. 
For BPA values below the lower level of detection, LLOD/square root of 2 was assigned. Urinary 
BPA was adjusted for creatinine. Participants weight, height and waist circumference were objectively 
measured by trained health technicians. Elevated waist circumference was defined according 
established criteria and BMI was divided into overweight (<25 BMI ≤29.9) and obese (BMI≥30). 
Relative to those in the lowest BPA quartile, participants in the upper BPA quartiles were more likely 
to be classified as obese (quartile 2 odds ratio (OR): 1.85, 95% confidence interval (CI): 1.22, 2.79; 
quartile 3 OR: 1.60, 95% CI: 1.05–2.44; quartile 4 OR: 1.76, 95% CI: 1.06–2.94). Higher BPA 
concentration was also associated with abdominal obesity (quartile 2 OR: 1.62, 95% CI: 1.11, 2.36; 
quartile 3 OR: 1.39, 95% CI: 1.02–1.90; quartile 4 OR: 1.58, 95% CI: 1.03–2.42). 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet or by concurring exposure factors not considered 
- Inconsistent results amongst different studies 
Overall the CEF Panel notes that although a range of covariates were taken into account, e.g., age, sex, 
race, education, and smoking, no dietary variables were considered among adjustment variables. Due 
to the cross–sectional design, reverse causality cannot be ruled out as higher urinary levels of BPA 
could be a consequence of diet rather than a cause. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Eng DS, Lee JM, Gebremariam A, Meeker JD, Peterson K and Padmanabhan V, 2013. 
Bisphenol A and chronic disease risk factors in US children. Pediatrics, 132, e637–645.  
 
Eng et al. (2013) examined the cross–sectional association between urinary BPA levels and obesity in 
3 370 US children aged 6–18 years, with chronic disease risk factors as endpoints. This study used 
mostly the same data as Trasande et al. (2012) and Bhandari et al. (2013) (National Health and 
Nutrition Examination Survey 2003–2008), and in addition data from the latest NHANES wave 
(2009–2010). Concentrations of BPA were measured at the Atlanta Centers for Disease Control and 
Prevention (CDC), by using online solid–phase extraction (SPE) coupled with liquid chromatography 
isotope dilution tandem mass spectrometry with peak focusing (LC–MS–MS). The limit of detection 
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was 0.4 ng/ml, and the coefficient of variation ranged from 6% to 16% for BPA. In NHANES, BPA 
concentrations below the level of detection were assigned a value of 0.3 ng/ml. The endpoints 
measured in children were: BMI, waist–circumference (WC), WC–to–hip–Ratio, percent body fat, 
cholesterol, HDL, fasting LDL, fasting TG, homeostasis model assessment of insulin resistance 
(HOMA–IR) and fasting glucose. Adjustments were made for relevant covariates (eg, demographics, 
urine creatinine, tobacco exposure, and soda consumption). 
Height, weight and waist circumference was measured by trained examiners. Total body percent fat 
was measured by whole body DXA scans conducted on a subset of individuals 8 years and older. 
Cholesterol, TG, and HDL cholesterol were measured in serum, and LDL cholesterol level was 
calculated from measured values of TC, TG, and HDL cholesterol based on the Friedewald equation, 
Fasting glucose and insulin was measured. Homeostasis model assessment was used as a surrogate 
measure of insulin resistance in nondiabetic children. The primary exposure, urinary BPA level was 
examined by quartiles. The results showed higher odds of obesity (BMI >95th percentile) with 
increasing quartiles of BPA for quartiles 2 vs 1 (odds ratio [OR] 1.74, 95% confidence interval [CI] 
1.17–2.60, p=0.008), 3 vs 1 (OR 1.64, 95% CI 1.09–2.47, p=0.02), and 4 vs 1 (OR 2.01, 95% CI 1.36–
2.98, p=0.001). With increasing BPA quartiles the results also showed higher odds of having an 
abnormal waist circumference–to–height ratio (quartiles 2 vs 1 [OR 1.37, 95% CI 0.98–1.93, p=0.07], 
3 vs 1 [OR 1.41, 95% CI 1.07–1.87, p=0.02], and 4 vs 1 [OR 1.55, 95% CI 1.12–2.15, p=0.01]). No 
significant associations of BPA were found with any other chronic disease risk factors. 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses: 
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet or by concurring exposure factors not considered or not reported 
- Inconsistent results amongst different studies (cross sectional studies vs longitudinal study; 
different gender–related effects in cross–sectional studies) 
In addition to the above, the CEF Panel noted that no associations were found between BPA and 
laboratory measures of cardiovascular and diabetes risk. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Galloway T, Cipelli R, Guralnik J, Ferrucci L, Bandinelli S, Corsi AM, Money C, McCormack P 
and Melzer D, 2010. Daily bisphenol A excretion and associations with sex hormone 
concentrations: results from the InCHIANTI adult population study. Environmental Health 
Perspectives 118, 1603–1608. 
 
This paper was the first to report human exposure to BPA in a large–scale European population. The 
study comprised 715 adults aged 20 through 74 years in a suburban and rural town population in Italy 
(the InCHIANTI adult population study). Total (unconjugated plus conjugated) BPA concentrations 
were measured by solid phase extraction (SPE) coupled with liquid chromatography tandem mass 
spectrometry (LC–MS–MS, LOQ 0.50 ng/ml) in compliance with Good Laboratory Practice in 24–hr 
urine samples collected in plastic bottles. Fasting blood samples were drawn and the outcomes 
examined were sex–hormones: 17β–oestradiol, total testosterone, sex hormone binding globulin 
(SHBG) and free testosterone. Models were adjusted for age, study site, smoking, BMI, weight, waist 
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and urinary creatinine concentration. Other potential confounders were also evaluated. A weak 
association between urinary BPA and testosterone were found in men, in models adjusted for age and 
study site (p=0.044), and in models additionally adjusted for smoking, measures of obesity, and 
urinary creatinine concentrations (beta = 0.046; 95% CI, 0.015–0.076; p = 0.004). No associations 
were found for other serum hormone measures and no associations were found for the primary 
outcomes among women. However, an association between BPA and SHBG concentrations was seen 
in the 60 premenopausal women. The authors concluded that higher BPA exposure may be associated 
with endocrine changes in men. This study reported BPA associations with covariates including 
parameters indicative of obesity.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size (European population) 
- Standardised samples (24–h urine collection) 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Confounding by diet or by concurring exposure factors (drugs) not considered 
- Handling of values below LOD not reported 
- Inconsistent results amongst different studies 
Overall the CEF Panel notes that the 24–hour urine collection is a better measure of BPA exposure 
than single spot urine samples and covers to some extent the same time period as the time covered by 
the blood sampled for hormone concentrations. The association with testosterone was weak and the 
clinical relevance of association is not clear. Higher BPA excretion was associated with increasing 
waist circumference and weight, but not with overweight or obesity defined by BMI cut–offs as 
defined by the World Health Organization.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Harley KG, Schall RA, Chevrier J, Tyler K, Aguirre H, Bradman A, Holland NT, Lustig RH, 
Calafat AM and Eskenazi B, 2013b. Prenatal and postnatal bisphenol A exposure and body mass 
index in childhood in the CHAMACOS cohort. Environmental Health Perspectives, 121, 514–
520.  
 
In this study the authors examined whether prenatal and postnatal urinary BPA concentrations were 
associated with body mass index (BMI), waist circumference, percent body fat, and obesity in 9 year–
old children (n=311) in the CHAMACOS longitudinal cohort study. BPA was measured in spot urine 
samples collected from mothers twice during pregnancy and from children at 5 and 9 years of age. Of 
601 pregnant women enrolled in the study, a total of 527 were followed through the birth of a 
singleton, live–born infant. BPA measurements in spot urine collected during pregnancy were 
available for 498 mothers and 402 children had at least one measure of BMI between age 2 and 9 
years. Urine samples were collected in polypropylene urine cups, aliquoted into glass vials, and frozen 
at 80 °C until shipment to the CDC for analysis. Analysis of field blanks showed no detectable 
contamination by BPA using this collection protocol. Solid phase extraction (SPE) coupled to high 
performance liquid chromatography–isotope dilution tandem mass spectrometry (LC–MS–MS) was 
used to measure total urinary BPA concentration (conjugated plus unconjugated). The limit of 
detection (LOD) was 0.4 μg/l. Concentrations below the LOD for which a signal was detected were 
reported as measured. 
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Prenatal urinary BPA concentrations were associated with decreased BMI at age 9 in girls but not 
boys. Among girls, being in the highest tertile of prenatal BPA concentrations was associated with 
decreased BMI Z–score (β=–0.47, 95% Confidence Interval (CI): –0.87, –0.07) and percent body fat 
(β=–4.36, 95% CI: –8.37, –0.34) and decreased odds of overweight/obesity (Odds Ratio (OR) = 0.37, 
95% CI: 0.16, 0.91) compared to girls in the lowest tertile. These findings were strongest in pre–
pubertal girls. Urinary BPA concentrations at age 5 years were not associated with any anthropometric 
parameters at age 5 or 9 years, but BPA concentrations at age 9 were positively associated with BMI, 
waist circumference, fat mass, and overweight/obesity at age 9 in boys and girls. Consistent with other 
cross–sectional studies, higher urinary BPA concentrations at age 9 were associated with increased 
adiposity at 9 years. However, increasing BPA concentrations in mothers during pregnancy were 
associated with decreased BMI, body fat, and overweight/obesity among their daughters at age 9.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Prospective study design 
- Urine, container specified (PP cups) 
- Repeated measurements (>1) 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Small sample size 
- Single spot urine BPA measurement 
- Confounding by concurring exposure factors not considered 
- Unclear clinical relevance (small effect size) 
- Generalisability to the overall population (low–income Mexican American population) 
- Inconsistent results amongst different studies (cross sectional studies vs longitudinal study; 
different gender–related effects in cross–sectional studies) 
Overall, Overall, the CEF Panel notes that this is a well conducted study that examined both cross–
sectional and longitudinal associations between BPA exposure and body mass index in children. 
Concomitant exposure to other contaminants was considered in the CHAMACOS cohort, a study in 
the agricultural Salinas Valley California comprising an immigrant Mexican–American population. 
BPA was measured in child urines at age 5 and 9 and examined in addition to maternal exposure. 
Dietary factors were also considered among the covariates, including soda consumption during 
pregnancy, and fast food and sweet snack consumption in children. Contrary to what was expected, 
higher BPA concentrations in mothers during pregnancy were associated with decreased BMI, body 
fat and overweight and obesity in children, but only in girls. The results from the longitudinal analyses 
weaken the hypothesis that BPA exposure leads to overweight in children. Although dietary factors 
were included among covariates, the study highlights that cross–sectional associations cannot be used 
for drawing any causal inferences.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Li D–K, Miao M, Zhou Z, Wu C, Shi H, Liu X and Wang S, 2013. Urine Bisphenol A level in 
relation to obesity and overweight in school–age children. PLoS ONE 8(6): e65399.  
 
The aim of the study was to examine associations between urinary BPA and overweight/obesity in 
school–age children. The study population comprised 1 326 children in grades 4–12 from three 
schools (one elementary, one middle, and one high school) in Shanghai, China. Spot urine samples 
(non–fasting) were collected from each participant. The collection time ranged from 9 am to 4 pm. All 
urine kits were made of BPA free materials. For each urine sample, the total urine BPA concentration 
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(free plus conjugated species) was measured using HPLC with fluorescence detection. The limit of 
detection (LOD) was 0.31 µg/l. Anthropometric measurements including weight, height, hip 
circumference, waist circumference, and skinfold thickness were taken by trained staff members at the 
time when urine BPA samples were collected. Body weight was used as the primary measure of 
overweight/obesity, and other measures including hip circumferences, waist circumference, waist to 
height ratio, skinfold thickness, and BMI were used as secondary measurements to verify the findings 
based on weight. The 90th percentile age– and gender–specific distribution for the anthropometric 
measures was used as a cutoff for overweight. 
Median urinary BPA in the study population was 0.98 µg/l. Risk factors for childhood obesity were 
included as potential confounders. A food frequency questionnaire with 24 questions was administered 
to all participating students to determine their dietary patterns (e.g., frequency of eating junk food, 
unbalanced diet such as eating favourite foods only, and habit of eating fruits/vegetables). Information 
on physical activities (e.g., average daily time on playing video/computer games and participating in 
sports or other physical activities), parental overweight, and children’s current depression status using 
the published Children's Depression Inventory (CDI) was also collected.  
No association between urinary BPA and overweight was found for boys. For girls, increasing urinary 
BPA concentration was associated with overweight. After adjustment for potential confounders, a 
higher urine BPA level (>2 mg/l), at the level corresponding to the median urine BPA level in the US 
population, was associated with more than two–fold increased risk of having weight >90th percentile 
among girls aged 9–12 (adjusted odds ratio (aOR) = 2.32, 95% confidence interval: 1.15–4.65). The 
association showed a dose–response relationship with increasing urine BPA level associated with 
further increased risk of overweight [The adjusted risk of overweight: OR: 5.18 (95%CI: 1.68–15.9) 
for BPA above>90th percentile vs BPA<50th percentile (p–trend p=0.006).  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Urine, container specified (BPA–free) 
Weaknesses:  
- Cross sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Not adjusted urine samples  
- No quality control (e.g., blanks) and quality assurance procedures  
- No distinction between unconjugated and conjugated BPA 
- Invalid outcome (weight) 
- Inconsistent results amongst different studies (cross sectional studies vs longitudinal study; 
different gender–related effects in cross–sectional studies) 
Overall, the CEF Panel notes that the outcome variable “weight” used in this study is not appropriate. 
In the age range under study, BMI z–scores should be used. In any case, also BMI (gender and age–
adjusted) would be better than weight. Another weakness is the lack of measures of pubertal status, 
relevant to the outcome in the age range considered. The authors should be commended for taking into 
account dietary patterns and other risk factors of childhood obesity. The sample size was fair. Contrary 
to the results from the US, which showed a stronger association between urinary BPA and overweight 
in boys, this study found a significant association between urinary BPA levels and overweight only in 
girls. The study is interesting, but the cross–sectional design is a major limitation and the results 
cannot be used to infer any causal relationship between BPA exposure and obesity.  
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This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Shankar A, Teppala S and Sabanayagam C, 2012b. Urinary Bisphenol A levels and measures of 
obesity: results from the National Health and Nutrition Examination Survey 2003–2008. ISRN 
Endocrinology 2012:965243. doi: 10.5402/2012/965243.  
 
Shankar et al. (2012c) examined the association between urinary BPA levels and obesity in 3 967 
participants aged greater than 20 years in the National Health and Nutritional Examination Survey 
(NHANES) 2003–2008. Total BPA was measured in spot urine samples by solid phase extraction 
(SPE) coupled with liquid chromatography tandem mass spectrometry (LC–MS–MS, LOD 0.36 
ng/ml). Height, weight, and waist circumference were measured by trained technicians. Obesity was 
defined as (1) body mass index (BMI) ≥30 kg/m2 and (2) waist circumference (WC) ≥102 cm in men 
and ≥88 cm in women. Urinary BPA levels were examined in quartiles. A positive association was 
reported for increasing levels of urinary BPA and both measures of obesity, independent of potential 
confounding factors including smoking, alcohol consumption, and serum cholesterol levels. The 
adjusted OR for upper quartile compared to the lower quartile (referent) for BMI–based obesity was 
1.69 (1.30–2.20); p–trend <0.0001 and for WC–based obesity was 1.59 (1.21–2.09); p–trend=0.0009. 
The association between BPA and both measures of obesity was consistently present across gender 
and race–ethnic groups. Of 4792 eligible participants, the authors excluded subjects with self–reported 
cardiovascular disease (n=495) and also subjects with missing data (n=330) on covariates (including 
level of education, smoking status, serum glucose levels, systolic or diastolic blood pressure, body 
mass index (BMI) or cholesterol levels), resulting in 3 967 participants (51.7% women) in the final 
analysis.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements  
- Single spot urine BPA measurement 
- Not adjusted urine samples 
- Confounding by diet or by concurring exposure factors not considered 
- Insufficient study reporting (urinary BPA stratified in quartiles, but no justification provided) 
- Inconsistent results amongst different studies 
Overall the CEF Panel noted that BPA concentrations in urine were stratified in quartiles, without an 
explicit justification by the authors. Due to the cross–sectional design and the lack of consideration of 
dietary variables no conclusions can be drawn as to the causality between BPA exposure and obesity. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Trasande L, Attina TM and Blustein J, 2012. Association between urinary bisphenol A 
concentration and obesity prevalence in children and adolescents. JAMA, 308, 1113–1121. 
 
This study also used data from NHANES, and the study sample comprised 2 823 children and 
adolescents (age 6 through 19 years) from 2003–2008. Spot urine BPA was measured by solid phase 
extraction (SPE) coupled with liquid chromatography–tandem mass spectrometry (LC–MS–MS, LOD 
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0.3 ng/ml) at CDC and quality control procedures included reagent blanks and samples of pooled 
human urine spiked with BPA at low– and high concentrations. For BPA concentrations below the 
level of detection, the value of 0.3 ng/ml was assigned. Body mass index was converted to sex– and 
age– standardized z–scores and modelled as a continuous variable as well as dichotomized to classify 
participants as overweight (>85th percentile) or obese (>95th percentile). The results showed that 
urinary BPA was significantly associated with obesity. Controlling for race/ethnicity, age, caregiver 
education, poverty to income ratio, sex, serum cotinine level, caloric intake, television watching, and 
urinary creatinine level, children in the lowest urinary BPA quartile had a lower estimated prevalence 
of obesity (10.3% [95% CI, 7.5%–13.1%]) than those in quartiles 2 (20.1% [95% CI, 14.5%–25.6%]), 
3 (19.0% [95% CI, 13.7%–24.2%]), and 4 (22.3% [95% CI, 16.6%–27.9%]). It should be noted that 
the relationship with obesity was not dose–dependent (quartile 2–3–4 had similar OR). Similar 
patterns of association were found in multivariable analyses examining the association between 
quartiled urinary BPA concentration and BMI z score and in analyses that examined the logarithm of 
urinary BPA concentration and the prevalence of obesity. In stratified analysis, significant associations 
between urinary BPA concentrations and obesity were found among whites (p<0.001) but not among 
blacks or Hispanics.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures  
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Inconsistent results amongst different studies (cross sectional studies vs longitudinal study; 
different gender–related effects in cross–sectional studies) 
Overall the CEF Panel notes that this is a well conducted study that examined BPA exposure both by 
quartiles and as a continuous variable. Additional strengths of the study include body measurements 
obtained by trained health technicians. Furthermore, a broad range of variables, including caloric 
intake, was included in the adjusted analyses. However, the cross–sectional nature of the study makes 
it inappropriate for drawing any causal inference.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Wang T, Li M, Chen B, Xu M, Xu Y, Huang Y, Lu J, Chen Y, Wang W, Li X, Liu Y, Bi Y, Lai S 
and Ning G, 2012a. Urinary Bisphenol A (BPA) concentration associates with obesity and insulin 
resistance. The Journal of Clinical Endocrinology and Metabolism, 97, E223–E227.  
 
Wang et al. examined in a cross sectional study urinary BPA and obesity and insulin resistance in 
3 390 Chinese adults in a district from Shanghai, China. Questionnaire, clinical and biochemical 
measurements, and urinary BPA concentration were determined. Morning spot urine samples were 
collected and total (unconjugated and conjugated) BPA was measured by liquid chromatography 
tandem mass spectrometry (LC–MS–MS, LOQ 0.30 ng/ml). The authors report that if urinary BPA 
concentrations were below the limit of quantification (0.30 ng/ml) they assigned the value of 0.15 
ng/ml. The outcome measures were objectively measured. Weight, height, waist circumference and 
blood pressure were measured by nurses. All participants were subjected to a 75 g oral glucose 
tolerance test, and blood samples were collected at 0 and 2 hours. Urinary BPA levels measured were 
divided into quartiles, and logistic regression model analysis revealed a positive association between 
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the fourth quartile of BPA concentration (>1.43 ng/ml) and generalized obesity with an OR value of 
1.50 (CI95%: 1.15–1.97), and a positive association with abdominal obesity (OR: 1.28; CI95%: 1.03–
1.60). Furthermore, this study also reported a positive association with insulin resistance (OR: 1.37; 
CI95%: 1.06–1.77). The associations between BPA and obesity were adjusted for age, sex, urinary 
creatinine, smoking, alcohol drinking, education, systolic blood pressure, HDL–cholesterol, LDL–
cholesterol, total cholesterol, triglycerides, ALT, GGT, CRP, fasting plasma glucose, and fasting 
serum insulin. The association between BPA and insulin resistance was additionally adjusted for BMI.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Standardized urine samples (morning spot samples) 
- Analytical method (SPE LC–MS–MS) 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- No quality control, including blanks or quality assurance procedures reported 
- No distinction between conjugated and unconjugated BPA 
- Confounding by diet or concurring exposure factors not considered 
- Inconsistent results amongst different studies 
Overall the CEF Panel notes that this study has a very high sample size and used objectively measured 
anthropometric data. However, the cross–sectional design hampers the reliability of the study as 
dietary behaviour could be a common cause of both overweight/insulin resistance and higher BPA 
concentrations.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Wang HX, Zhou Y, Tang CX, Wu JG, Chen Y and Jiang QW, 2012b. Association between 
bisphenol a exposure and body mass index in Chinese school children: a cross–sectional study. 
Environ Health. 2012 Oct 19;11:79. doi: 10.1186/1476–069X–11–79 
 
Wang et al. examined urinary BPA and obesity in a cross–Section study in 259 Chinese children and 
adolescents (age 8 to 15) in Changning district in Changhai city. All urine samples were morning spot 
samples. Total (unconjugated and conjugated) BPA was measured by solid phase extraction (SPE) 
coupled with ultra performance liquid chromatography–tandem mass spectrometry (UPLC–MS–MS, 
LOD 0.07 ng/ml). Weight and height were objectively measured and body mass index (BMI) was 
modelled as a continuous outcome. Urinary BPA concentration was associated with increasing BMI as 
a continuous variable in all subjects (adjusted for age and sex). There were sex and age related 
variations. The authors claim that adjusting urinary BPA for creatinine is not appropriate and instead 
they conducted the analyses with and without adjusting urinary BPA for specific gravity. The results 
did not differ. Furthermore, the authors converted urinary BPA to estimated dietary BPA exposure, 
which resulted in similar results as for the urinary BPA concentrations. In this sample, the geometric 
mean (95% CI) urinary BPA corrected by standard gravity was 0.40 ng/ml (0.33, 0.49) and the 
estimated daily intake was 0.33 µg/day (0.27, 0.45 µg/day). Without correction for standard gravity 
the values were slightly higher (0.45 ng/ml and 0.37 µg/day) for urinary and estimated dietary intake, 
respectively.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study:  
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Strengths: 
- Urine, container specified (glass) 
- Standardized urine samples (first morning spot samples) 
- Analytical method (SPE LC–MS–MS) 
Weaknesses: 
- Cross–sectional study design 
- Small sample size 
- Single exposure measurements 
- Single spot urine BPA measurement 
- No quality control, including blanks and quality assurance procedures 
- No distinction between conjugated and unconjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Inconsistent results amongst different studies (cross sectional studies vs longitudinal study; 
different gender–related effects in cross–sectional studies) 
Overall the CEF Panel notes that this study showed additional strengths, i.e. the body weight and 
height were measured by trained technicians and that all spot urine samples were first morning urines, 
which is preferable to random spot urines. The authors report that they calculated daily BPA intakes 
based on individual body weights and urinary BPA concentrations, but no equation as to how this is 
done was provided. The low urinary BPA and low estimated daily intakes (much lower than the 
recommended TDI) should be noted. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
 
Zhao H, Bi Y, Ma L, Zhao L, Wang T, Zhang L, Tao B, Sun L, Zhao Y, Wang W, Li X, Xu M, 
Chen J, Ning G and Liu J, 2012. The effects of bisphenol A (BPA) exposure on fat mass and 
serum leptin concentrations have no impact on bone mineral densities in non–obese 
premenopausal women. Clinical Biochemistry, 45(18), 1602–1606. 
 
The aim of this study was to examine the relationships between urinary BPA exposure, body 
composition, hormone levels and bone mineral density in 246 healthy premenopausal women from 
Shangai aged 20 years and older. The study was cross–sectional and BPA exposure was measured 
second morning urine spot samples. The serum and urine samples were stored at −80 °C until analysis. 
Urine samples were available from 251 individuals for BPA measurement, and 246 of these samples 
had measurable BPA levels above the lowest detection limit (0.3 ng/ml). Urinary BPA levels were 
determined by enzymatic hydrolysis using a sensitive and selective liquid chromatography tandem 
mass spectrometry method (LC–MS–MS, LOQ 0.30 ng/ml). None of the subjects enrolled in this 
study suffered from any diseases or took any medications that were likely to affect bone metabolism or 
body weight. 
Body mass index (BMI), fat mass, fat–free mass and bone mineral density (BMDs) were measured by 
Dual–energy x–ray absorptiometry (DXA). Independent variables: serum oestradiol, leptin, 
osteocalcin, urinary BPA and N–telopeptide of type I collagen (NTx).  
Urinary BPA was positively associated with fat mass (r=0.193, p=0.006) and leptin (r=0.236, p=0.001) 
but not with fat–free mass after adjusting for age and BMI. Urinary BPA was not associated with 
serum oestradiol levels, BMDs or other bone parameters. Mean urinary BPA concentration was 2.27 
ng/ml, and women with urinary BPA <LOD were excluded.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
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Strengths: 
- Standardized urine samples (second morning samples) 
- Analytical method (SPE LC–MS–MS) 
Weaknesses: 
- Cross–sectional study design 
- Small sample size 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Not adjusted urine samples 
- No quality control, including blanks or quality assurance procedures reported 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Inconsistent results amongst different studies 
In addition to the limitations listed above the CEF Panel noted that no adjustment to urinary BPA 
creatinine was made. Several models were used to understand potential associations between 
variables, and BPA was considered as independent or dependent variable. Finally, a discussion about 
the normality of variables (urinary BPA in particular) is lacking. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there.  
Hormonal outcomes 
 
Brucker–Davis F, Ferrari P, Boda–Buccino M, Wagner–Mahler K, Pacini P, Gal J, Azuar P and 
Fenichel P, 2011. Cord blood thyroid tests in boys born with and without cryptorchidism: 
correlations with birth parameters and in utero xenobiotics exposure. Thyroid, 21, 1133–1141.  
 
The sample comprised 53 boys from the control group in a case–control study of cryptorchidism. The 
aim of the study was to examine associations between exposure to a range of xenobiotics (including 
BPA) in cord blood (and maternal breast milk) and birth parameters including cord blood thyroid tests. 
BPA was measured only in cord blood by RIA and no distinction is given between conjugated and 
unconjugated BPA. The median (range) unspecified BPA was 0.9 ng/ml (0.2–3.3 ng/ml). A weak 
negative correlation was reported between cord blood BPA and thyroid stimulating hormone (TSH), 
with r=–0.25, p=0.077).  
 
Comments from the CEF Panel:  




- Case–control study 
- Small sample size 
- Cord blood BPA measurement (invalid exposure measurement) 
- Single exposure measurements  
- Analytical method (RIA) 
- No quality control (e.g., blanks) and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Handling of values below LOQ not reported 
- Confounding by diet not considered 
- Inconsistent results amongst different studies 
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Overall the CEF Panel notes that the study has major limitations. It is not clear which form of BPA 
was measured (total, unconjugated or conjugated BPA). In blood, only unconjugated BPA can be 
considered a valid measure of BPA exposure. The sample size was small and the finding needs to be 
confirmed in a larger sample.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Chou WC, Chen JL, Lin CF, Chen YC, Shih FC and Chuang CY, 2011. Biomonitoring of 
bisphenol A concentrations in maternal and umbilical cord blood in regard to birth outcomes 
and adipokine expression: a birth cohort study in Taiwan. Environmental Health, 10, 94.  
 
This cross–sectional study was also evaluated in relation to developmental and reproductive effects of 
BPA. It is included in this Section because maternal BPA concentrations were studied versus maternal 
hormone expression as well as in relation to prenatal growth retardation. BPA was determined in 
maternal and umbilical cord blood samples by HPLC with UV detection (LOD 0.13 ng/ml) in 97 
mother–newborn pairs in a birth cohort in Taiwan and association with birth outcomes was 
investigated. In male neonates only, high maternal BPA (upper quartile) was associated with increased 
risk of low birth weight babies, small for gestational age babies. The results reported for adverse 
action of leptin (high leptin (HLP) defined as >90th percentile and low adiponectin (LAD) defined as 
<10th percentile) in highest versus lowest quartile of maternal BPA exposure given in the abstract 
differed from the results given in the main text. Abstract: HLP: OR: 1.67, 95% CI: 1.12–2.25 and 
LAD: OR: 1.12, 95% CI: 1.52–3.97. Text: HLP: OR: 3.03, 95% CI: 2.09–4.54 and LAD: OR: 1.67, 
95% CI: 1.12–2.25).  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Quality control, including blanks  
Weaknesses:  
- Case–control study 
- Small sample size 
- Maternal blood and umbilical cord blood BPA measurement (invalid exposure measurement) 
- Single exposure measurements 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by other exposure factors not considered 
- Insufficient study reporting (discrepancies between the abstract and the text) 
- Inappropriate statistics (excessive categorization of continuous variables) 
- Unclear clinical relevance 
Overall the CEF Panel notes that the study has major limitations. Discrepancy between results 
reported in the abstract and main text raise question to the results altogether. Furthermore, the study 
has several statistical limitations including excessive categorization of continuous variables. The 
results regarding maternal BPA and adverse birth outcomes, including adverse action of leptin and 
adiponectin, were weak and can only be regarded as preliminary results. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Galloway T, Cipelli R, Guralnik J, Ferrucci L, Bandinelli S, Corsi AM, Money C, McCormack P 
and Melzer D, 2010. Daily bisphenol A excretion and associations with sex hormone 
concentrations: results from the InCHIANTI adult population study. Environmental Health 
Perspectives 118, 1603–1608. 
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This paper was the first to report human exposure to BPA in a large–scale European population. The 
study comprised 715 adults aged 20 through 74 years in a suburban and rural town population in Italy 
(the InCHIANTI adult population study). Participants each collected one 24–hour urine sample. Total 
BPA (unconjugated plus conjugated) concentration in the 24–h sample was measured by solid phase 
extraction (SPE) coupled with liquid chromatography tandem mass spectrometry (LC–MS–MS, LOQ 
0.50 ng/ml). The BPA collection and analysis was appropriate. Fasting blood samples were drawn and 
the outcomes examined were sex–hormones: 17β–oestradiol, total testosterone, sex hormone binding 
globulin (SHBG) and free testosterone. Models were adjusted for age, study site, smoking, BMI, 
weight, waist, and urinary creatinine concentration. Other potential confounders were also evaluated. 
A weak association between urinary BPA and testosterone were found in men, in models adjusted for 
age and study site (p=0.044), and in models additionally adjusted for smoking, measures of obesity, 
and urinary creatinine concentrations (β=0.046; 95% CI, 0.015–0.076; p=0.004). No associations were 
found for other serum hormone measures and no associations were found for the primary outcomes 
among women. However, an association between BPA and SHBG concentrations was seen in the 60 
premenopausal women. The authors concluded that higher BPA exposure may be associated with 
endocrine changes in men. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size (European population) 
- Standardised samples (24–h urine collection) 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Confounding by diet or by concurring exposure factors (drugs) not considered 
- Handling of values below LOD not reported 
- Unclear clinical relevance 
- Inconsistent results amongst different studies 
Overall the CEF Panel notes that the 24–hour urine collection is a better measure of BPA exposure 
than single spot urine samples and covers to some extent the same time period as the time covered by 
the blood sampled for hormone concentrations. The association with testosterone was weak and the 
clinical relevance of association is not clear. Concomitant drug treatment was not reported. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Mendez W Jr and Eftim SE, 2012. Biomarkers of perchlorate exposure are correlated with 
circulating thyroid hormone levels in the 2007–2008 NHANES. Environmental Research, 118, 
137–144. 
 
This study only marginally examined BPA and the aim of the study was to examine the relationship 
between biomarkers of perchlorate exposure and serum thyroid hormone levels in 1 887 subjects in the 
2007–2008 NHANES. The models included covariates related to gender, age, ethnicity, income, 
smoking status, medications, BPA and other goitrogenic ions and phthalate ester metabolites. Total 
(unconjugated plus conjugated BPA) and thyroid hormones were analysed according to NHANES 
procedures. Subjects who were pregnant, had thyroid disease or used thyroid medication were 
excluded. The geometric mean BPA in spot urine was 2.0 ng/ml. Urinary BPA was not associated with 
total thyroxine (T4) in men or in women.  
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Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet or by concurring exposure factors not considered 
- Inconsistent results amongst different studies 
Overall the CEF Panel notes that the statistical analyses were sound, but the relevance of the finding is 
limited by the cross–sectional design. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Volberg V, Harley K, Calafat AM, Davé V, McFadden J, Eskenazi B and Holland N, 2013. 
Maternal bisphenol a exposure during pregnancy and its association with adipokines in 
Mexican–American children. Environmental Molecular Mutagenesis, 54, 621–628.  
 
The study examined maternal urinary BPA concentrations from spot urine samples in early and late 
pregnancy and in children at age 9 years, and plasma leptin and adiponectin at age 9 years. The study 
sample included 188 mother–child pairs from the CHAMACOS cohort, a study in the agricultural 
Salinas Valley California comprising an immigrant Mexican–American population. BPA was 
measured in urinary spot samples by solid phase extraction (SPE) coupled with liquid chromatography 
tandem mass spectrometry (LC–MS–MS, LOD 0.4 µg/l) during early (12.6±3.9 weeks gestation) and 
late (26.3±2.5 weeks gestation) pregnancy and in 9–year–old children. The results showed that BPA 
concentrations during late pregnancy were associated with increased plasma leptin in boys (β=0.06, 
p=0.01), controlling for maternal pre–pregnancy body mass index (BMI), pregnancy soda 
consumption, and smoking, years in US prior to pregnancy, maternal education, household poverty 
status, child BMI and child soda, fast food and sweet snack consumption at 9 years. Furthermore, BPA 
concentrations during early pregnancy were associated with plasma adiponectin levels in girls (β=3.71, 
p=0.03). No significant relationships between concurrent BPA concentrations and 9–year child 
adiponectin or leptin.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Prospective study design 
- Urine, container specified (PP cups) 
- Repeated measurements (n=2, maternal urine) 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Small sample size 
- Single spot urine BPA measurement 
- Confounding by concurring exposure factors not considered 
- Unclear clinical relevance (effects in boys and girls) 
- Generalisability to the overall population (low–income Mexican American population) 
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Overall, the CEF Panel notes that the study is based on the same study population as in the study by 
Harley et al., 2013b, which examined cross–sectional and longitudinal associations between BPA 
exposure and BMI in 9 year old children. The results of the current study complement the Harley et al. 
study. The authors report that plasma adiponectin levels were inversely correlated with 9–year child 
BMI (r=–0.38, p<0.001) and plasma leptin levels were positively correlated with 9–year child BMI 
(r=0.82, p<0.001). The strengths of this study are the prospective design and that adjustment variables 
included the dietary variables: soda consumption during pregnancy and child soda, fast food and sweet 
snack consumption at 9 years. Concomitant exposure to other contaminants was however, not 
considered. Limitations of the study include the short–term nature of the BPA exposure measurement 
and the limited generalisability of results obtained from the immigrant, low SES population from an 
agricultural community.  
Wang F, Hua J, Chen M, Xia Y, Zhang Q, Zhao R, Zhou W, Zhang Z and Wang B, 2012c. High 
urinary bisphenol A concentrations in workers and possible laboratory abnormalities. 
Occupational and Environmental Medicine. Occupational and Environmental Medicine, 69, 
679–684. 
 
This cross–sectional study examined associations between urinary BPA in spot samples and biological 
markers in blood or urine, including markers of liver function, glucose homeostatis, thyroid function, 
and cardiovascular disease in 28 workers in two epoxy resin factories in China. Total (free and 
conjugated) BPA was measured by solid phase extraction (SPE) followed by isotopic dilution liquid 
chromatography tandem mass spectrometry (LC–MS–MS). The levels of total urinary BPA in exposed 
workers were about ten times higher than in the general population. The geometric mean BPA 
concentration was 55.7 ng/ml (geometric standard deviation, GSD: 5.48) or 32.0 µg/g creatinine 
(GSD: 4.42). The concentrations differed between workers in different positions in the factories, 
reflecting higher exposure in manual labour workers than in office workers. Higher urinary BPA 
concentrations were associated with clinically abnormal concentrations of free triiodothyronine (FT3), 
free thyroxine (FT4), total triiodothyronine (TT3), total thyroxine (TT4), thyroid stimulating hormone, 
glutamic–oxaloacetic transaminase and gamma–glutamyl transaminase. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Analytical method (SPE LC–MS–MS) 
Weaknesses:  
- Cross–sectional study design 
- Small sample size 
- Single exposure measurements 
- Single spot urine BPA measurement 
- No quality control and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Generalisability to the overall population 
- Inconsistent results amongst different studies 
- Occupational exposure 
Overall the CEF Panel notes that the study is limited by a very small sample size. Another concern is 
occupational exposure to other chemicals in these factory workers. Occupational exposure to BPA 
warrants further examination.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
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Diabetes outcomes 
Kim K and Park H, 2013. Association between urinary concentrations of bisphenol A and type 2 
diabetes in Korean adults: A population–based cross–sectional study. International Journal of 
Hygiene and Environmental Health, 216, 476–471.  
 
In a cross–sectional study in Korea, associations between urinary BPA and type 2 diabetes was studied 
in 1 210 adults (age 40–69 years) in Korea, and was based on the 2009 Korean National Human 
Biomonitoring study. The mean age was 53.4 years. Spot urine samples were collected at different 
times throughout the day and creatinine levels were used to correct for urine dilution. After hydrolysis 
and liquid liquid extraction, total BPA was measured by isotopic dilution gaschromatography mass 
spectrometry (GC–MS, LOD 0.05 ng/ml, LOQ 0.20 ng/ml). The criteria for type 2 diabetes were 
based on self–reported and doctor–diagnosed type 2 diabetes. The geometric mean urinary BPA 
concentrations were 2.03 ng/ml among those not diagnosed with type 2 diabetes and 2.40 ng/ml 
among those diagnosed with type 2 diabetes. However, after adjusting for potential confounders, 
higher BPA concentrations were not significantly associated with type 2 diabetes. When adjusted for 
creatinine, age, sex, body mass index, education, cigarette smoking, income, and place of residence, 
the odds ratio for being in the highest versus lowest quartile of BPA was 1.71 (95%CI: 0.89, 3.26), 
p=0.374.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (GC–MS) 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- No quality control and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Inconsistent results amongst different studies 
Overall the CEF Panel notes that the study was well conducted. Height and weight were objectively 
measured. The fact that spot urine samples were collected at different times throughout the day could 
give a more correct population median. However, as the cross–sectional design and self–reported 
outcome measure limits the relevance of the study for risk assessment. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Lakind JS, Goodman M and Naiman DQ, 2012. Use of NHANES Data to Link Chemical 
Exposures to Chronic Diseases: A Cautionary Tale. PLoS One. 2012;7(12):e51086. 
 
This same study has also been reviewed in the section on cardiovascular effects – human studies. 
The authors reanalysed data from four datasets in the National Health and Nutrition Examination 
Survey (NHANES). Data on urinary BPA and health outcomes from 2003–2004, 2005–2006, 2007–
2008, and 2009–2010 were available. The aim was to examine the consistency of the association 
between urinary BPA measures and diabetes, coronary heart disease (CHD), and/or heart attack across 
datasets when consistent scientifically and clinically defined criteria were applied. The study sample 
included n=4811 for CVD, n=4811 for heart attack and n=4823 for diabetes. Samples were analysed 
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by on line solid–phase extraction (SPE) coupled with liquid chromatography tandem mass 
spectrometry (LC–MS–MS, LOD 0.4 ng/ml). All multivariable analyses were controlled for a priori 
selected potential confounders including, but not limited to, those used in the previous studies. The 
models included the following covariates: creatinine, age, gender, race/ethnicity, education, income, 
smoking, body mass index, waist circumference, heavy drinking, family history of diabetes (in the 
analyses of diabetes) or heart attack/angina (in the analyses of CHD and heart attack), hypertension, 
sedentary activity, blood cholesterol, and daily energy intake. Urinary BPA was not significantly 
associated with adverse health outcomes for any of the NHANES surveys, with ORs (95% CIs) 
ranging from 0.996 (0.951–1.04) to 1.03 (0.978–1.09) for CHD, 0.987 (0.941–1.04) to 1.04 (0.996–
1.09) for heart attack, and 0.957 (0.899–1.02) to 1.01 (0.980–1.05) for diabetes. When the data from 
four surveys were pooled, the ORs (95% CIs) for the full model that included all covariates were 
1.004 (0.998–1.009) for CHD, 1.002 (0.998–1.007) for heart attack, and 0.995 (0.982–1.007) for 
diabetes. The choice of covariates had only minor effect on point estimates. The authors concluded 
that the discrepancy between their findings on diabetes and those reported previously was largely 
explained by the choice of case definition. For discrepancy between results of this study and previous 
findings for CHD, the authors concluded that this was in part attributable to differences in inclusion 
criteria. In the current study, no subjects were excluded based on very high BPA concentrations.  
The authors provided an example of reverse causality obscuring possible conclusions from cross–
sectional studies: “In all analyses, cholesterol levels were statistically significantly inversely 
associated with heart attack and CHD. Given the well–documented positive association between 
cholesterol and heart disease from prospective studies, the most logical explanation for the observed 
result is reverse causation, i.e. it is likely that diagnoses of heart attack or CHD, which preceded the 
cholesterol measurements in NHANES, likely triggered changes in lifestyle or use of medications that 
resulted in lower cholesterol levels.” 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size 
- Urine, container specified 
- Analytical method (SPE LC–MS–MS)  
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross–sectional study design  
- Single exposure measurements 
- Single spot urine BPA measurement  
- Confounding by diet or by concurring exposure factors not considered  
- Inconsistency in results among different studies  
Overall, the CEF Panel considers that this study shows how relatively minor decisions made a priori 
(clinical definition of diabetes and inclusion of participants with higher levels of BPA) affected the 
previously reported results and conclusions of associations between urinary BPA exposure and chronic 
disease. This study does not add to the evidence as to whether or not BPA is a risk factor for chronic 
disease, but highlights that using data from cross–sectional studies like NHANES surveys to draw 
such conclusions about relations between short–lived environmental chemicals and chronic diseases is 
inappropriate. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Ning G, Bi Y, Wang T, Xu M, Xu Y, Huang Y, Li M, Li X, Wang W, Chen Y, Wu Y, Hou J, 
Song A, Liu Y and Lai S, 2011. Relationship of Urinary Bisphenol A Concentration to Risk for 
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Prevalent Type 2 Diabetes in Chinese Adults: A Cross–sectional Analysis. Annals of Internal 
Medicine, 155, 368–374. 
 
The association between urinary BPA and diabetes was investigated in 3 423 Chinese adults in 
Baoshan disctrict in Shanghai. Total (free and conjuagted) urinary BPA was determined in morning 
spot urine samples by liquid chromatography isotopic dilution tandem mass spectrometry (LC–MS–
MS, LOQ 0.30 ng/ml). Overall, BPA concentration was lower (median 0.81 ng/ml) than in data from 
NHANES (median 2.0 ng/ml). Dividing participants into quartiles of BPA exposure, the data showed 
that risk of diabetes was higher in people in the second and fourth quartiles of exposure, but not the 
third. The overall trend was not significant. The adjusted odds ratio (OR) of type 2 diabetes for 
participants in the second quartile of BPA (0.48 to 0.81 ng/ml) was 1.30 [95% CI, 1.03 to 1.64] and in 
the fourth quartile (>1.43 ng/ml) was OR, 1.37 [CI, 1.08 to 1.74]. The adjusted odds ratio in the third 
quartile (0.82 to 1.43 ng/ml) was 1.09 [CI, 0.86 to 1.39], and a test of the trend of the association was 
not statistically significant. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (LC–MS–MS) 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Not adjusted urine samples 
- No quality control, including blanks and quality assurance procedures 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Inconsistent results amongst different studies 
Overall the CEF Panel notes that the statistical modelling included adjustment for a wide range of risk 
factors including blood lipids, blood pressure, waist circumference etc, but as acknowledged by the 
authors themselves, the study did not take into account any potential confounding by diet such as for 
example consumption of sugared drinks from plastic bottles. It should be noted that even if significant 
associations were found for the second and third BPA quintile, the authors conclude that the data do 
not support the previous finding of an association between urinary BPA and self–reported diabetes in 
NHANES (Lang et al., 2008). The study sample and BPA measurements seem to be the same as used 
in Wang et al. (2012a) who reported on urinary BPA concentration in relation to general and 
abdominal obesity. The main limitation is however the cross–sectional design. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Shankar A and Teppala S, 2011. Relationship between Urinary Bisphenol A Levels and Diabetes 
Mellitus. The Journal of Clinical Endocrinology and Metabolism, 96, 3822–3826. 
 
Shankar et al. analysed NHANES data (n=3967), and found that pooled data from 2003–2008 showed 
a positive association between single spot urine BPA concentrations and diabetes, using fasting 
glucose levels and glycosylated haemoglobin to define diabetes mellitus according to the latest 
American Diabetes Associations guidelines. The risk of type 2 diabetes (insulin–resistent diabetes) 
increased with increasing quartiles of BPA in a dose–dependent manner. In the fully adjusted model 
the OR for highest versus lowest quartile was 1.68, 95%CI: 1.22–2.30. The trend of association was 
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significant. The association was present among normal weight as well as overweight and obese 
subjects.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet or by concurring exposure factors not considered 
- Inconsistent results amongst different studies 
Overall the CEF Panel notes that strengths of the study include a large sample size and objective 
outcome measures. However, it is limited by the cross–sectional design and cannot be considered 
relevant for establishing a link between BPA exposure and increased risk of diabetes type 2.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Silver MK, O'Neill MS, Sowers MR and Park SK, 2011. Urinary Bisphenol A and Type–2 
Diabetes in US Adults: Data from NHANES 2003–2008. PloS One, 6, e26868.  
 
Silver et al. used the 2003–2008 NHANES data, and used a different definition of diabetes 2 by 
whether or not participants (n=4389) used diabetic medication, or had high long–term blood glucose 
levels (HbA1c ≥6.5%). Total BPA (free and conjugated) was measured by solid phase extraction 
(SPE) coupled with liquid chromatography tandem mass spectrometry (LC–MS–MS, LOD 0.36 
ng/ml). The results showed an overall weak positive association between BPA and diabetes in 2003–
2008 pooled data (adjusted OR for a two fold increase in BPA: 1.08 (95% CI: 1.02, 1.16), while 
breaking down by year, the association was only significant in 2003–2004 (n=1,364, OR=1.23 (95% 
CI, 1.07 to 1.42), not 2005–2006 (n=1 363, OR=1.05 (95% CI, 0.94 to 1.18)), or 2007–2008 (n=1,662, 
OR = 1.06 (95% CI, 0.91 to 1.23)). Similar patterns of associations between BPA and continuous 
HbA1c were also observed. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study:  
Strengths: 
- Large sample size 
- Analytical method (LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet or by concurring exposure factors not considered 
- Inconsistent results amongst different studies 
Overall the CEF Panel notes that as for the study by Shankar et al. (2011) the main strengths of the 
study are a large sample size and an objective outcome measures. However, the study is limited by the 
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cross sectional design and cannot be considered relevant for establishing a link between BPA exposure 
and increased risk of diabetes type 2.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Wang T, Li M, Chen B, Xu M, Xu Y, Huang Y, Lu J, Chen Y, Wang W, Li X, Liu Y, Bi Y, Lai S 
and Ning G, 2012a. Urinary Bisphenol A (BPA) concentration associates with obesity and insulin 
resistance. The Journal of Clinical Endocrinology and Metabolism, 97, E223–E227.  
 




Li M, Bi Y, Qi L, Wang T, Xu M, Huang Y, Xu Y, Chen Y, Lu J, Wang W and Ning G, 2012. 
Exposure to bisphenol A is associated with low–grade albuminuria in Chinese adults. Kidney 
International, 81,1131–1139. 
 
In the same population of Chinese adults as the study by Wang et al. (2012a) and Ning et al. (2011), Li 
et al. examined urinary BPA in relation to renal disease defined by albuminuria in 3 055 adults. 
Morning spot urine samples were collected and total (unconjugated and conjugated) BPA was 
measured by liquid chromatography tandem mass spectrometry (LC–MS–MS, LOQ 0.30 ng/ml). The 
results showed that urinary BPA was an independent determinant of the urinary albumin–to–creatinine 
ratio significantly associated with an increased risk of low–grade albuminuria. The adjusted odds ratio 
(OR) and 95% confidence interval (95%CI) for the third quartile of BPA relative to the lowest was 
OR: 1.20 (1.06–1.37), and for the fourth quartile was OR: 1.23 (1.13–1.34). The association was not 
modified by conventional risk factors such as age, gender, smoking, alcohol consumption, body mass 
index, hypertension, diabetes, and the estimated glomerular filtration rate. The univariate correlation 
between log–BPA and log–albumin was very weak (r=0.09).  
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size 
- Urine, container specified 
- Standardised samples (first morning spot samples) 
- Analytical method (LC–MS–MS) 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- No quality control, including blanks or quality assurance procedures reported 
- No distinction between unconjugated and conjugated BPA 
- Confounding by diet or by concurring exposure factors not considered 
- Unclear clinical relevance 
Overall, the CEF Panel notes that the study is sound and the statistical analysis adequate, but the 
clinical relevance of the results are not clear. Furthermore, the study is limited by the cross sectional 
design and single spot urines. 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
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Teppala S, Madhavan S and Shankar A, 2012. Bisphenol A and Metabolic Syndrome: Results 
from NHANES. International Journal of Endocrinology, 2012, 598180, 5 pages.  
http://www.ncbi.nlm.nih.gov/pubmed/23251154 
 
The authors examined the association between urinary BPA concentrations and metabolic syndrome 
(MetS) in 2 104 participants (≥18 years) in the National Health and Nutrition Examination Survey 
2003–2008 (NHANES) in a cross–sectional study. BPA exposure (total BPA) was measured in spot 
urine samples by solid phase extraction (SPE) coupled with liquid chromatography tandem mass 
spectrometry (LC–MS–MS), and the lower limit of detection (LOD) for BPA concentrations was 0.36 
ng/ml. MetS was defined based on the revised Adult Treatment Panel III (ATP III) guidelines. A total 
of 741 participants were found to be positive for 3 or more of the 5 measured components and were 
considered to have MetS: (1) abdominal obesity (waist circumference:≥102 cm in men and ≥88 cm in 
women), (2) hypertension (systolic blood pressure ≥130mm of Hg, diastolic blood pressure ≥85mm of 
Hg, use of medications for elevated blood pressure), (3) elevated serum triglycerides (≥150 mg/dl), (4) 
glucose intolerance (fasting serum glucose ≥100mg/dl, medications for diabetes), and (5) reduced 
HDL (<40 mg/dl for men and <50 mg/dl for women). The results showed that increasing levels of 
urinary BPA were positively associated with MetS, independent of confounders such as age, gender, 
race/ethnicity, smoking, alcohol intake, physical activity, and urinary creatinine. Compared to tertile 1 
(referent), the multivariable adjusted odds ratio (95% confidence interval) of MetS in tertile 3 was 
1.51 (1.07–2.12); p–trend was 0.02. The potential biological mechanism suggested by the authors is 
the endocrine disrupting and estrogen–like effects of BPA reported in animal studies. 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet or by concurring exposure factors not considered 
- Generalisability to the overall population 
Overall, the CEF Panel notes that this is the first reporting a positive association between BPA and 
MetS in humans. The finding of higher BPA exposure in participants with MetS is potentially 
interesting. However, as acknowledged by the authors, it is not possible to draw cause effects from the 
observed associations due to the cross–sectional nature of the study. The authors also acknowledged 
the potential confounding role of diet, as the main source of BPA exposure in humans is consumption 
of food and beverages known to be associated with MetS.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
You L, Zhu X, Shrubsole MJ, Fan H, Chen J, Dong J, Hao CM and Dai Q, 2011. Renal function, 
Bisphenol A, and Alkylphenols: Results from the National Health and Nutrition Examination 
Survey (NHANES 2003–2006). Environmental Health Perspectective, 119, 527–533. 
 
You et al. used the 2003–2006 NHANES data for 2 573 adults without known renal diseases to 
examine whether urinary excretion of BPA and alkyphenols differed by renal function. Renal function 
was measured by glomerular filtration rate (eGFR) estimated by using the Modification of Diet in 
Renal Disease (MDRD) Study equation and newly developed Chronic Kidney Disease Epidemiology 
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Collaboration (CKD–EPI) equation. Mildly decreased renal function or undiagnosed chronic kidney 
disease (CKD) was found in 58% of the study population. Total urinary BPA (unconjugated plus 
conjugated) was measured in spot urine samples by solid phase extraction (SPE) coupled with liquid 
chromatography isotopic dilution tandem mass spectrometry (LC–MS–MS, LOD 0.36 ng/ml). The 
adjusted geometric means for urinary BPA excretion decreased with decreasing renal function 
(decreasing levels of GFR), primarily in females, by using the most widely used equation in the clinic 
and epidemiologic studies (MDRD equation). On the other hand, through a newly developed CKD–
EPI equation, the association was not significant.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Large sample size 
- Analytical method (SPE LC–MS–MS) 
- Quality control, including blanks and quality assurance procedures 
Weaknesses:  
- Cross–sectional study design 
- Single exposure measurements 
- Single spot urine BPA measurement 
- Confounding by diet or by concurring exposure factors not considered 
- Unclear clinical relevance (small effect size) 
Overall, the CEF Panel notes that despite the high number of subjects considered, the association 
between BPA urinary levels and renal function impairment was very low, and no threshold doses were 
proposed. The study is limited by the cross sectional design and single spot urines.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
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(ii) Animal studies 
Studies involving prenatal exposure 
 
Anderson OS, Peterson KE, Sanchez BN, Zhang Z, Mancuso P and Dolinoy DC, 2013. Perinatal 
bisphenol A exposure promotes hyperactivity, lean body composition, and hormonal responses 
across the murine life course. FASEB Journal, 27, 1784-1792. 
 
Anderson et al. (2013) exposed mice during gestation and lactation to 0, 50 ng, 50 µg or 50 mg of 
BPA/kg of diet. The authors state that the mice were obtained from a colony maintained with sibling 
mating and forced heterozygosity for the viable yellow agouti (Avy) allele for 220 generations, 
resulting in a genetically invariant background. Following parturition, a subset of a/a wild-type 
animals, 1 male and 1 female/litter, was followed until 10 months of age on standard diet (n = 20 
offspring); 50 ng BPA/kg diet (n = 20 offspring); 50 µg BPA/kg diet (n = 21 offspring); or 50 mg 
BPA/kg diet (n = 18 offspring). Offspring energy expenditure, spontaneous activity, and body 
composition was assessed at 3, 6, and 9 months of age, and hormone levels were measured at 9 and 10 
months of age. The authors found increased energy expenditure as evidenced by increased oxygen 
consumption and carbon dioxide production in all BPA-treated animals compared with controls. The 
CEF Panel noted however that the dose-response relationship was inconsistent over the period of the 
study and overall the results were difficult to interpret. For example, energy expenditure as measured 
by oxygen consumption was only significantly increased at 3 months in female offspring whose dams 
had been exposed to 50 mg BPA/kg of diet (p = 0.004, and was still significantly increased at 6 
months, while other treated groups showed a non-significant dose related trend, while at 9 months 
only the animals whose dams had been exposed to 50 ng/kg diet showed a significant increase in 
oxygen consumption. Males overall showed no such increases until 9 months (significant compared 
with controls at 50 µg or 50 mg of BPA/kg of diet). Carbon dioxide production was inconsistent in 
females, but was significant increased compared to controls in males at 3 months only by doses of 50 
µg/kg bw per day and 50 mg/kg bw per day. Spontaneous activity was increased, but only in females, 
and again showed an inconsistent dose-response. Food consumption in females was reduced to a 
statistically significant extent but without a clear dose:response (significant only in females whose 
dams had received 50 µg or 50 ng of BPA/kg of diet at 6 months and in the 50 µg BPA/kg of diet 
group at 9 months, with no significant differences being seen at 3 months. In males the reduction of 
food intake was not statistically significant at any time period. Body weight and body fat were overall 
not statistically different from controls and glucose tolerance and insulin release were also unchanged.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
 
Overall, the CEF Panel noted that the results of this study, in a genetically specific mouse strain, are in 
contrast to the findings of a number of other studies showing effects on body weight gain and on 
glucose tolerance and insulin resistance. The study is considered broadly acceptable, with adequate 
numbers of animals per group, although the intakes of BPA were not specifically calculated. It is not 
however possible to derive an indication of a dose-response, and no NOAELs or LOAELs can be 
derived from the study because of the inconsistency of the results. The biochemical basis for the 
results seen is not obvious. For these reasons, and also because of the specificity of the genetic model, 
 
Strengths: 
- Number of doses (≥3) 
- Use of non-PC cages  
- Phytoestrogen-free diet 
 
Weaknesses:  
- Insufficient study reporting (administration via diet but intakes of BPA not specifically 
calculated) 
- Inappropriate statistics 
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the general applicability of the results is debatable. It is to be noted that the standard diet for the 
animals was phytoestrogen free as explicitly stated in the publication.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Angle BM, Do RP, Ponzi D, Stahlhut RW, Drury BE, Nagel SC, Welshons WV, Besch-Williford 
CL, Palanza P, Parmigiani S, Vom Saal FS and Taylor JA, 2013. Metabolic disruption in male 
mice due to fetal exposure to low but not high doses of bisphenol A (BPA): Evidence for effects 
on body weight, food intake, adipocytes, leptin, adiponectin, insulin and glucose regulation. 
Reproductive Toxicology, 42, 256-268. 
 
Angle et al. (2013) orally exposed CD-1 mice in utero to a range of BPA concentrations (5, 50, 500, 
5000 and 50000 µg/kg bw per day) from. 
 
Angle et al. (2013) orally exposed CD-1 mice in utero to a range of BPA concentrations (5, 50, 500, 
5000 and 50000 µg/kg bw per day) from GD9 to GD18. The study duration was 17-19 weeks. The 
study results were only obtained in males. The authors studied as much as 19 parameters which were 
measured even at different time points. Statistically significant effects were seen in 11 of the 
parameters measure using an alternative, non-monotonic dose-response model after the standard 
ANOVA gave statistical significant results in 10 out of the 19 parameters. Statistical results with the 
same significantly positive outcome between the two statistical models were obtained in 7 parameters. 
The effects with statistical significance were those on body weight (at week 3 and week 19), energy 
intake (at 3-4 and 4-5 weeks), gonadal and abdominal fat pad weights, gonadal adipocytes number and 
volumes, liver weight, glucose tolerance and serum concentrations of insulin. Non-monotonic dose-
response relationships were reported for many outcomes.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
 
Overall, the CEF Panel noted that only males were evaluated for glucose and insulin tolerance test. 
Multiple endpoints were measured which are either time related (e.g. body weight in longitudinal 
follow up) or mechanism related (e.g. release of hormones such a leptin from fat tissue the weight of 
which had also been assessed). The authors used two different statistical models for dose-response 
modelling and they explored which statistical model would fit their data better. From this procedure it 
is obvious that the study results are not to be seen as confirmatory but as exploratory. In addition, 
given the multiple outcomes and multiple time periods examined, the statistical adjustment procedure 
for the multiple comparisons had to be explained. As this information is not provided, the question 
remains open whether appropriate adjustment was made. There were discrepancies with an effect seen 
between weeks 4 and 5 e.g. for BPA 500 which disappear between week 5 and 7. Weight at 19 weeks 
was not statistically significantly changed in both of the statistical models they used in contrast to what 
is suggested in the article. Discrepancies were also found for effects seen on fat weight. Whereas for 
renal fat pad weight significant differences versus control were reported for 5 µg/kg bw per day, for 
500 µg/kg bw per day and for 5000 µg/kg bw per day but not for 50 µg/kg bw per day and for 50000 
µg/kg bw per day the only significant difference reported for cell number in renal fat pad was at the 
dose of 500 µg/kg bw per day and the only statistical difference reported for renal adipocyte volume 
Strenghts: 
- Number of doses (≥3) 
- Adequate positive controls included 
- Use of non-PC cages 
 
Weaknesses:  
- Study design not appropriate to the scope (only males tested for glucose and insulin tolerance 
tests) 
- Statistical analysis (insufficient study reporting) 
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was for 5000 µg/kg bw per day. Serum leptin was statistically significantly elevated only at 500 µg/kg 
bw per day but serum adiponectin was unchanged at the dose whereas it was decreased at 50 µg/kg bw 
per day and 5000 µg/kg bw per day. In total, the multiple parameters measured showed an inconsistent 
pattern with many effects seen for one parameter at a certain dose at which however no effect was 
observed for a second, pathophysiological related parameter. The interpretation of the results is not 
clear, in particular a unifying mode of action approach is lacking.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Mackay H, Patterson ZR, Khazall R, Patel S, Tsirlin D and Abizaid A, 2013. Organizational 
Effects of Perinatal Exposure to Bisphenol-A and Diethylstilbestrol on Arcuate Nucleus 
Circuitry Controlling Food Intake and Energy Expenditure in Male and Female CD-1 Mice. 
Endocrinology, 154, 1465-1475. 
 
In the study of MacKay et al. (2013) CD mice were exposed throughout pregnancy (from GD 1) and 
lactation to diets containing 0, 1 or 20 µg BPA/kg. Diethylstilbestrol (DES) was used as a positive 
control. The authors estimated that the mice consumed an average of 0.19 and 3.49 µg/kg bw per day 
of BPA in the low and high BPA treatments prenatally and an average of 0.36 and 7.2 µg/kg bw per 
day of BPA postnatally. Offspring were weaned initially onto a normal diet, then as adults exposed to 
either a normal or high-fat diet (HFD). Two males and two females from each litter at each dose level 
made up cohort 1 (n= 3-5 per sex per treatment and diet), in which whole-body energy expenditure 
was measured at 3 months of age (before HFD) and again at 5 months of age (after HFD). Glucose 
tolerance tests were performed in the cohort after 60 days of HFD exposure. The animals were killed 
at 5.5 months at which time the adipokines IL-6, insulin, leptin, and resistin were measured in blood 
and perigonadal, retroperitoneal, sc fat pads, and interscapular brown adipose tissue (BAT) were 
dissected and weighed. Cohort 2 was used for brain histochemical investigations. Female offspring 
receiving 20 µg BPA/kg diet and fed a high fat diet as adults showed increased body weight gain 
compared with controls and also the DES positive control, and also ate more. They had increased 
adiposity and leptin concentrations with reduced proopiomelanocortin mRNA expression in the 
arcuate nucleus and estrogen receptor α expression patterns similar to those seen in males, which the 
authors considered was suggestive of a masculinising effect of BPA. Male offspring showed no 
similar BPA-linked effect on body weight gain, however males at both levels of BPA showed 
significantly increased weight of the retroperitoneal and intrascapular brown adipose fat pads 
compared with control and DES-exposed mice, and similar effects were seen in female offspring at the 
higher dose level of BPA. Effects were more pronounced or only significant in the animals receiving 
high fat diets. Males exposed to the high dose of BPA showed impaired glucose tolerance on both 
diets.They also showed reduced proopiomelanocortin fiber innervation into the paraventricular 
nucleus of the hypothalamus, and when exposed to HFD, they demonstrated increased neuropeptide Y 
and Agouti-related peptide expression in the arcuate nucleus (ARC). The authors concluded that 
exposure to BPA leads to sexually dimorphic alterations in the structure of hypothalamic energy 
balance circuitry, leading to increased vulnerability for developing diet-induced obesity and metabolic 
impairments, such as glucose intolerance. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Adequate positive controls included 
- Use of non-PC cages 
Weaknesses:  
- Small sample size 
- Insufficient study reporting (uncertainty about estimated intakes due to very low (< 1 ng/kg 
bw per day) dietary level and homogeneity of the diet not checked) 
- Statistical analysis (litter effect not completely controlled) 
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Overall the CEF Panel notes that the actual intakes of BPA were only estimated, the litter effect was 
not completely controlled, numbers of animals per test group were small. Results between males and 
females were inconsistent and the magnitude of the effects seen was small. The obesity-inducing diet 
is a very high-fat diet (60 % Kcal from fat), thus raising doubts about its relevance to the development 
of human obesity. In addition, as in rodents adipose tissue is developing particularly during the last 
week of gestation and during early postnatal life and this process essentially takes place before birth in 
bigger mammals the findings might not be directily relevant fo the human situation. Furthermore, it is 
to be noted that the phytoestrogen content of the diet was apparently not tested.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Miyawaki J, Sakayama K, Kato H, Yamamoto H and Masuno H, 2007. Perinatal and postnatal 
exposure to bisphenol a increases adipose tissue mass and serum cholesterol level in mice. 
Journal of Atherosclerosis and Thrombosis, 14, 245-252. 
 
This study was already considered in the 2010 EFSA opinion, and was used in the 2013 ANSES 
opinion to derive a LOAEL for BPA based on body weight and cholesterol increase in females. Below 
the extract from the 2010 EFSA opinion: 
“The effects of peri- and postnatal exposure to BPA on adipose tissue mass were investigated by 
Miyawaki et al. (2007). Groups of 3 pregnant ICR mice were exposed to BPA in drinking water (0, 1 
or 10 μg/ml, resulting in 0, 0.26, 2.72 mg/kg b.w./day) from GD 10 to end of lactation. Offspring were 
exposed up to PND 31 and groups of 16 to 25 offspring per sex and dose group were evaluated. Body 
weights of female offspring were increased at the low and high dose group, body weights of the males 
at the high dose group. Adipose tissue weight was increased significantly in females at the low dose 
and in males at the high dose group. Serum leptin was increased only in females of the low dose 
group. Total cholesterol was increased only in females with the highest increase in the low dose group. 
Serum triacylglycerol and non-esterified fatty acid levels were increased and serum glucose levels 
decreased only in males of the low dose group. The low number of dams per group invalidates this 
study”.  
The study has some flaws e.g. the sample size is small, inconsistencies in the results as in females 
body weight increases at both doses but adipose tissue only at the lower dose. It is to be noted that 
there is no evidence for a dose-response relationship and in addition, the phytoestrogen content of the 
diet was apparently not tested.  
US FDA/NCTR, 2013. Evaluation of the toxicity of bisphenol A (BPA) in male and female 
Sprague-Dawley rats exposed orally from gestation day 6 through postnatal day 90. Experiment 
E02176.01 
 
Delclos KB, Camacho L, Lewis SM, Vanlandingham MM, Latendresse JR, Olson GR, Davis KJ, 
Patton RE, da Costa GG, Woodling KA, Bryant MS, Chidambaram M, Trbojevich R, Juliar 
BE, Felton RP and Thorn BT, 2014. Toxicity Evaluation of Bisphenol A Administered by 
Gavage to Sprague Dawley Rats From Gestation Day 6 Through Postnatal Day 90. Toxicological 
Sciences, 139, 174-197. 
 
In this study, Sprague-Dawley rats (Sprague-Dawley/CD23/NCTR BR) were used to investigate the 
effects of BPA on a very wide range of pathological, physiological, endocrine, reproductive and 
developmental endpoints in a very broad dose interval. Ethinyl oestradiol was used as a positive 
control of the estrogenic effects of BPA. The dose-matched vehicle control was 
carboxymethylcellulose, sodium salt. The doses were: (i) BPA 2.5, 8, 25, 80, 260, 840, 2700, 100 000, 
300 000 µg/kg bw per day, (ii) Vehicle, (iii) EE2 0.5, 5 µg/kg bw per day. The study included a naïve 
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control group and doses were administered by oral gavage. The protocol and methods, including 
statistical analysis were of the high quality and robust with treatment, body weight and litter 
randomisation and appropriate inclusion and exclusion criteria established prior to the start of the 
study. The target unit for analysis was 20 litters and 18-23 were achieved. F0 females were dosed from 
GD 6 up to labour onset and pups from PND 1 until tissue harvesting, up to PND 90. 
Metabolic endpoints were body weight, weekly food consumption. At PND 90 the following 
parameters were considered: glucose, TG, cholesterol, insulin, leptin, cardiac troponins. 0.5 and 5 
µg/kg bw per day ethinyl-oestradiol (EE2) served as estrogenic controls. At the dose of 300 mg/kg bw 
day several effects were noted which were similar to those of EE2: 1. preweaning body weight 
reduction (12 – 16 % and 9 – 12 % in females and males, respectively), 2. Reduced retroperitoneal fat 
pad (females only) on PND 90, 3. Reduced body weight on day 90, 4. Reduced leptin in males (33 %) 
and females (56 %), 5. Reduced cholesterol in males and females. No effects were seen on 
triglycerides and insulin. A significant dose trend for glucose was due to an 11 % lower mean glucose 
level in the 2,700 μg BPA/kg bw per day. However, this changed level was not significantly different 
from the vehicle control group, p = 0.189). 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses the study: 
Strengths: 
- Large sample size  
- Both naïve and vehicle controls available 
- Adequate positive controls included 
- Measurement of BPA concentration in the serum 
- Number of doses (≥3) 
- Oral administration by via gavage 
- Phytoestrogen-free diet 
- Use of non-PC cages 
- Study performed according to OECD guidelines, under GLP US FDA/NCTR, 2013 and 
Delclos et al., 2014 
Weaknesses: 
- Unintended exposure of  the control groups (see Churchwell et al, 2014) 
 
Overall, the CEF Panel noted that this GLP study, performed according to OECD standards, evaluated 
a wide range of nine dose levels, seven below and two above the dose of 5 mg/kg bw per day in 
former assessments defined as the reference point. The highest dose had an influence on several 
parameters. It is to be noted that the study duration was 90 days (13 weeks) with permanent dosing. 
Phytooestrogen levels in food were monitored to be in the low range. As the number of litters is 
sufficiently large the study has a fair sensitivity to detect effects.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Somm E, Schwitzgebel VM, Toulotte A, Cederroth CR, Combescure C, Nef S, Aubert ML and 
Huppi PS, 2009. Perinatal Exposure to Bisphenol A Alters Early Adipogenesis in the Rat. 
Environmental Health Perspectives, 117, 1549-1555. 
 
This study was already considered in the 2010 EFSA opinion where it is stated “Perinatal exposure to 
BPA (1 mg/l in drinking water from GD 6 to PND 21) in rats (Somm et al., 2009) was reported to 
increase adipogenesis in female offspring at weaning”.  
Body weight on PND 1 was increased in both males and females, whereas body weight and pWAT 
was increased in females only on PND 21. Furthermore, BPA exposed animals fed with high fat 
caloric diet had increased body weights compared to controls on high fat caloric diet (feeding from 
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week 4 until week 14) from week 9 to week 14 in males and in week 4 and 5 as well as week 8 to 
week 11 in females. No effects were seen on glucose metabolism in a sub-study performed only in 
males. 
Comments from the CEF Panel:  
The study was performed with a single dose only (app. 70 µg/kg bw per day). Phytoestrogen content 
in food was measured as was also the water content of BPA. The effects on body weights and pWAT 
were only seen in females as was expression of genes involved in adipogenesis. The statistical 
procedures are not clearly described and might be flawed. 
Wei J, Lin Y, Li Y, Ying C, Chen J, Song L, Zhou Z, Lv Z, Xia W, Chen X and Xu S, 2011. 
Perinatal Exposure to Bisphenol A at Reference Dose Predisposes Offspring to Metabolic 
Syndrome in Adult Rats on a High-Fat Diet. Endocrinology, 152, 3049-3061. 
 
Wei et al. (2011) gave doses of 0, 50, 250 or 1 250 µg BPA/kg bw per day orally by gavage in corn oil 
to pregnant Wistar rats from GD 0 to PND 21. The offspring (n=16 per group, 2 from each of 8 litters) 
were maintained on either a normal or a high fat diet for 16 weeks), with monitoring of body weight, 
blood parameters (triglycerides, cholesterol, low- and high-density lipoprotein), glucose tolerance test, 
insulin tolerance test were investigated periodically through the experimental period, while 
morphology and function of the pancreas was assessed at termination at week 27. No effects of BPA 
were observed at doses of 250 or 1250 µg BPA/kg bw per day. Offspring exposed prenatally to 50 µg 
BPA/kg bw per day and maintained on a normal diet showed increased weight gain from week 17 
(females) or week 19 (males). No significant differences in fasting blood glucose levels were seen in 
animals exposed to 50 µg BPA/kg bw per day when compared to controls, while serum insulin levels 
were higher at week 15 and 26 for males and week 26 for females. Effects were more evident in the 50 
µg BPA/kg bw per day animals fed a high fat diet, with body weight gain being increased compared 
with controls at weeks 7 (males) and 9 (males). BPA (50 µg /kg bw per day) was associated with 
changes in blood lipid parameters compared with controls in both males and females fed a high fat diet 
and in males fed a normal diet. Serum leptin was elevated in BPA-treated animals compared with 
controls at week 26. The animals also had a higher body fat percentage and showed hypertrophy of 
adipocytes. Mitochondrial structure and insulin granule characteristics in pancreatic β-cells were 
altered by BPA at 50 µg/kg bwper day, both at weaning (week 3) and at termination (week 27) and 
mRNA expression of islet-associated transcription factors were reduced compared to controls. The 
authors suggested that BPA exposure predisposed the offspring to metabolic disturbances, possibly 
indicating the presence of metabolic syndrome, and noted that low dose BPA (50 µg/kg bw per day) 
was more effective than high doses, suggesting a non-monotonic dose-response relationship.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses the study: 
Strengths: 
- Number of doses (≥3) 
- Oral administration by gavage 
- Use of non-PC cages and non plastic water bottles 
Weaknesses:  
- Small sample size 
- Insufficient study reporting (number of animals used for each end-point was variable and not 
always clear) 
- Statistical analysis (litter effect not completely controlled) 
- Animal diet phytoestrogen content not reported 
 
Overall the CEF Panel noted that this was a reasonably well designed oral study, but but how litter 
effect was taken into consideration is not fully described and remains unclear. Results appeared to 
show a non-monotonic dose-response, with effects only seen at 50 µg BPA/kg bw per day. 
Mechanisms for leptin and serum insulin increase are not well explained. Statistical analysis was 
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flawed; in particular, the choice to consider the litter size as a covariate in the ANCOVA analysis was 
not properly justified. Moreover, the number of animals used for each end-point was variable and not 
always clear. For some parameters, sample size (n=3) was low. The phytoestrogen content of the diet 
was apparently not tested. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Xu X, Tan L, Himi T, Sadamatsu M, Tsutsumi S, Akaike M and Kato N, 2011b. Changed 
preference for sweet taste in adulthood induced by perinatal exposure to bisphenol A-A 
probable link to overweight and obesity. Neurotoxicology and Teratology, 33, 458-463. 
 
Xu et al. (2011b) suggested that an increased preference of adult rats for a sweet taste, potentially 
resulting in obesity, could be linked to prenatal exposure to BPA. Female Sprague Dawley rats were 
exposed to BPA in drinking water at doses of 0.01, 0.1 and 1.0 mg/L from GD 11 to lactation day 21. 
The sweet preference of the offspring for 0.25 % or 0.5 % saccharin compared with water was 
assessed on week 7 after birth, while preference for 15 % sucrose compared with water was assessed 
on PND 42, 70 and 140 (in rats perinatally exposed to 0.1 mg/L compared with controls only). Body 
fat percentage and tail blood pressure were measured at the end of the study. A significant sex 
difference in preference for a sweet taste was evident in both BPA-treated and non-BPA treated 
offspring, with all females showing a preference for saccharin-containing drinking water compared 
with plain water and no evidence of a treatment-related effect. However male offspring showed an 
increased preference for 0.25 % (but not for 0.5 %) saccharin compared with male controls. Prenatal 
treatment of dams with 0.1mg/L BPA in drinking water treatment increased sucrose preference in 
males at postnatal day (PND) 70 and 140 (p<0.05 and p<0.001, compared to control respectively) but 
decreased sucrose preference in females at PND 140 (p<0.05, compared to control). This tendency 
was reversed in BPA-treated females compared with controls, implying the feminization of males and 
masculinization of females. Male offspring from dams receiving 0.1 mg/L BPA and administered 
15 % sucrose in their drinking water postnatally also showed increased body weight gain compared 
with controls at PND 140 (p<0.001), their percentage of body fat as imaged by X-ray CT Scan was 
higher (p<0.001) as was their tail blood pressure (p<0.05). 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses the study: 
 
Strengths: 
- Number of doses (≥3) 
- Use of non-PC cages 
 
Weaknesses: 
- Insufficient study reporting (administration via drinking water but no information on 
consumption) 
- Statistical analysis (litter effect not completely controlled) 
- Study design not appropriate to the scope (only one BPA dose was assessed postnatally 
 
Overall, the CEF Panel noted that BPA was administered in drinking water, and no information was 
provided about the actual daily intakes based on drinking water consumption. Pups were selected 
randomly for assessment, litter effects were therefore not taken fully into account. Numbers of pups 
investigated for each endpoint was 4-6 pups/gender, which was acceptable. The inconsistency in the 
response to saccharin (preference for 0.25 % but not for 0.5 % saccharin) is noted, interpretation of the 
saccharin preference results was difficult, limiting overall the conclusions that can be drawn from the 
study. The choice of only the middle dose of BPA pups for the sucrose preference test based on the 
dose-response for saccharin preference is difficult to justify. It is impossible to evaluate the dose-
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response effect for body weight because only one BPA dose was assessed postnatally. The 
phytoestrogen content of the diet was apparently not tested.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Studies in adult mice and rats 
 
Batista TM, Alonso-Magdalena P, Vieira E, Amaral ME, Cederroth CR, Nef S, Quesada I, 
Carneiro EM and Nadal A, 2012. Short-term treatment with bisphenol-A leads to metabolic 
abnormalities in adult male mice. PLoS One, 7, e33814. 
 
In the study of Batista et al. (2012), 3-month old Swiss albino OF1 mice (n=6-12 in different tests) 
were administered a total of 100 µg BPA/kg bw daily by subcutaneous injection (in two injections) for 
8 days. Control mice received vehicle (corn oil) alone. Whole body energy homeostasis was assessed 
with in vivo indirect calorimetry, while responses of insulin sensitive peripheral tissues as measured 
by plasma insulin levels, glucose tolerance testing, secretion of insulin from isolated pancreatic islets 
and insulin signaling assays Mice treated with BPA and assessed at the end of the treatment period 
showed higher plasma insulin concentrations in the fed state and increased glucose-stimulated insulin 
secretion in isolated pancreatic islet of Langerhans, in addition to changes in insulin signaling. 
Glucose tolerance testing showed that BPA-treated mice were insulin resistant and had increased 
glucose-stimulated insulin release. Whole-body energy homeostasis, as assessed by reduced food 
intake, reduced locomotor behavior and decreased energy expenditure during night, was reduced, 
although respiratory exchange ratio was unchanged. Insulin-stimulated tyrosine phosphorylation of the 
insulin receptor b subunit and the mitogen-activated protein kinase (MAPK) signaling pathway was 
impaired in the skeletal muscle of BPA-treated mice and both skeletal muscle and liver showed an 
upregulation of IRS-1 protein by BPA. The authors concluded that BPA slows down whole body 
energy metabolism and disrupts insulin signaling in peripheral tissues, supporting the hypothesis that 
BPA may be a risk factor for the development of type 2 diabetes.  
Comments from the CEF Panel: 





- Single dose level study 
- Test performed in one sex only 
- Insufficient study reporting (number of animals tested is unclear for each endpoint) 
- Animal diet and phytoestrogen content not reported. 
 
Overall the CEF Panel noted that this is a single dose study. The results suggest an effect of BPA on 
insulin homeostasis and signalling, reported also by other authors. The study may be considered 
supportive for effects of BPA on insulin/glucose metabolism.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Bodin J, Bolling AK, Samuelsen M, Becher R, Lovik M and Nygaard UC, 2013. Long-term 
bisphenol A exposure accelerates insulitis development in diabetes-prone NOD mice. 
Immunopharmacology and Immunotoxicology, 35, 349-358. 
 
Bodin and co-workers investigated possible effects of BPA, administered at 0, 1 and100 mg/l BPA in 
the drinking water of non-obese diabetic (NOD) mice (n = 6-10 per group for different parameters) on 
the development of type 1 diabetes (T1DM). This mouse strain is used as a animal model of 
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spontaneous diabetes development, due to a high level of beta cell apoptosis leading to increased 
insulitis. The authors estimated from parallel measurements of water consumption in non-diabetic and 
diabetic mice that these levels of BPA in drinking water corresponded to intakes of 0, 150 or 15000 
μg/kg bw per day in non-diabetic mice. Intakes in diabetic mice at the end of the study were estimated 
to reach 200–1650 μg/kg bw per day in diabetic mice in the 1.0 mgBPA/l group due to the higher 
water consumption in these animals. Plasma glucose was measured at weekly intervals from week 7 to 
week 30, by which time the mice had become diabetic. The development of insulitis was followed by 
histological examination of the pancreas at 7 and 12 weeks and changes in serum autoantibodies, 
cytokines, insulin and thyroxine (T4) levels were also investigated at these time intervals. Serum 
insulin was additionally measured at week 28 of the study. Incidence and degree of insulitis in the 
pancreas was comparable between groups at week 7. It was markedly increased compared with 
controls in 12-weeks-old female mice exposed to 1 mg/l BPA in drinking water, but was less severe in 
the female animals receiving 100 mg/l and was decreased in male mice exposed to BPA compared 
with controls. Increased apoptosis and reduced numbers of tissue resident macrophages were seen in 
the pancreatic islets of female mice prior to the development of insulitis. Serum glucose levels were 
increased in the 1 mg/ml BPA group indicating an accelerated onset of T1DM, but this was not seen in 
the animals exposed to 100 mg/l BPA. Insulin levels did not differ significantly between the groups 
and while T4 levels increased slightly with increasing BPA intake, this was not statistically significant. 
Serum levels of cytokines and autoantibodies also did not differ between the groups. The authors 
suggested that the higher level of BPA could be protective against diabetes development in female 
mice, while a protective effect was seen for male mice for both BPA concentrations. The authors 
concluded that long-term BPA exposure at a dose three times higher than the tolerable daily intake of 
50 mg/kg, appeared to accelerate spontaneous insulitis and diabetes development in NOD mice, with 
some evidence of a non-monotonic dose-response. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses the study: 
Strengths: 
- Phytoestrogen-free diet 
- Use of non-PC cages 
 
Overall, the CEF Panel concluded that the relevance of the findings in this strain of diabetes-prone 
mice for development of diabetes in a normal population is debatable, particularly in the light of the 
inconsistent dose-response and the absence of effects on plasma insulin. Furthermore, the results are 
quite inconsistent and mainly negative. Indeed, the tendency toward an accelerated development of 
diabetes, observed only in females exposed to the lower dose BPA is not statistically significant. The 
immunological markers whose impairment should lead to the development of diabetes, according to 
the authors’ hypothesis are non different between the study groups. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
D’Cruz SC, Judendradass R and Mathur PP, 2012a. Bisphenol A Induces Oxidative Stress and 
Decreases Levels of Insulin Receptor Substrate 2 and Glucose Transporter 8 in Rat Testis. 
Reproductive Sciences, 19, 163-172.  
D’Cruz SC, Jubendradass R, Jayakanthan M, Amala Rani SJ and Mathur PP, 2012b. Bisphenol 
A impairs insulin signaling and glucose homeostasis and decreases steroidogenesis in rat testis: 
an in vivo and in silico study. Food and Chemical Toxicology, 50, 1124-1133. 
 
Note: these papers are reviewed together as they address the same endpoints, the second-listed study 
providing an extension of the endpoints investigated in the first. 
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In the studies of D’Cruz et al. (2012a, b) male Wistar rats (n = 6 per group) were given doses of BPA 
ranging from 0.005, 0.5, 50 and 500 μg/kg bw per day by oral gavage for 45 days. In the first study, 
levels of plasma glucose and insulin, testicular glucose and peroxide and enzymes involved in glucose 
metabolism were investigated, together with levels of insulin signaling molecules, glucose transporter-
2 (GLUT-2). The second study investigated testicular levels of insulin, insulin signaling molecules, 
GLUT-2, antioxidant enzymes and steroidogenesis were investigated at the end of the treatment 
period. 17-β-oestradiol (50 μg/kg bw per day) was used as a positive control. Levels of plasma glucose 
and insulin were significantly increased down to the lowest level of BPA exposure of 5 ng/kg bw per 
day, whereas the testicular glucose level significantly decreased, again at all dose levels. Similar 
responses were seen with the positive control, 17-β-oestradiol. There was also a significant decline in 
the activities of hexokinase and phosphofructokinase in the testis of rats treated with BPA. Levels of 
insulin and various insulin signalling molecules as determined by Western blot analysis were 
significantly decreased in rat testis of BPA-treated rats in a dose-related manner down to an exposure 
level of 5 ng/kg bw per day. Similarly, a dose-dependent and significant decrease in testicular 
superoxide dismutase and catalase activities was measured following BPA exposure at all doses, and 
lipid peroxidation was increased, together with a dose-dependent increase in the level of hydrogen 
peroxide, decreases in testicular marker proteins and key enzymes of steroidogenesis. The authors 
reported testicular damage as evidenced by loss of germ cells and decrease in the spermatids in rats 
treated with 500 μg BPA, as well as in the positive control, and immunolocalization of GLUT-8 
protein in the testis revealed decreased expression of this protein in spermatocytes and developing 
spermatids of rats exposed to BPA. The authors concluded that low doses of BPA affect insulin 
signaling and glucose, possibly leading to impairment of testicular function.  
Comments from the CEF Panel: 
Comment: The standard deviation is much smaller than normal variability 
 
The CEF Panel identified the following strengths/weaknesses in the studies: 
 
Overall, the CEF Panel noted that, despite the relatively small number of animals used at each dose 
level and the relative complexity of some of the assays undertaken, the dose-response reported, 
persisting down to a dose level of 5 ng/kg bw per day, was perfect. The statistics are not properly 
reported as one-way ANOVA followed by Tukey’s post test, but the results of the overall ANOVA are 
not given. The use of this statistics with such a small sample size is questionable. The reported 
changes in testicular pathology cannot be related to functional deficits.  
These papers are included in the WoE table because of their relevance to one or more review questions 
addressed there. 
Hassan ZK, Elobeid MA, Virk P, Omer SA, ElAmin M, Daghestani MH and AlOlayan EM, 
2012. Bisphenol A induces hepatotoxicity through oxidative stress in rat model. Oxid Med Cell 
Longev, 2012, 194829. 
 
Strengths: 
- Adequate positive controls included 
- Number of doses (≥3)  
- Oral administration by via gavage 
- Use of non-PC cages 
 
Weaknesses:  
- Test performed in one sex only 
- Small number of animals  
- Inappropriate statistics (considering the small number of animals) 
- Animal diet and phytoestrogen content not reported 
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The study investigates at the cellular level whether BPA causes hepatotoxicity by induction of 
oxidative stress in liver. As indices of oxidative stress liver content of glutathione, superoxide 
dismutase, glutathione peroxidase, glutathione-S-transferase, glutathione reductase and catalase 
activity were measured. Five rats per group received BPA (0.1, 1, 10, 50 mg/kg/day) via gavage for 
four weeks. One additional group of five rats served as control group and received water. In addition, 
gene expression profile in liver tissue was measured by real-time PCR. The final body weights in the 
0.1 mg/kg bw group showed a significant decrease and the 10 mg/kg bw group a significant increase 
compared to control group. Serum ALT, ALP and bilirubin were significantly elevated in the 10 
mg/kg bw and the 50 mg/kg bw group indicating liver cell damage. Levels of reduced glutathione, 
superoxide dismutase, glutathione peroxidase, glutathione-S-transferase, glutathione reductase and 
catalase activity were found in the 50mg BPA group compared to controls. Likewise, the activity of 
antioxidant genes was reduced as confirmed by real time PCR in which the expression levels of these 
genes in liver tissue were significantly decrease compared to control. The data from this study are 
compatible with the assumption that BPA generates ROS and reduces antioxidant gene expression that 
these effects are causative for the observed hepatotoxicity of BPA. 
 
Comment from the CEF Panel: 
The study seems well performed although the number of animals per group is small and the statistical 
testing was performed without adjustment for multiple testing. In addition the description of the 
methods is not given in detail. The phytoestrogen content of the diets was apparently not tested. 
Nevertheless, the findings are pointing to a dose dependent hepatotoxic effect of BPA which was 
observed in other studies with identical doses (50 mg/kg bw per day, Tyl et al., 2008). The mechanism 
by which the hepatotoxicity is mediated seems to be oxidative stress as evidenced by biochemical 
indices and by the expression levels of antioxidant genes in the liver.  
 
Indumathi D, Jayashree S, Selvaraj J, Sathish S, Mayilvanan C, Akilavalli N, Balasubramanian 
K, 2013. Effect of bisphenol-A on insulin signal transduction and glucose oxidation in skeletal 
muscle of adult male albino rat. Human and Experimental Toxicology, 32, 960-971.  
 
Jayashree S, Indumathi D, Akilavalli N, Sathish S, Selvaraj J, Balasubramanian K, 2013. Effect 
of Bisphenol-A on insulin signal transduction and glucose oxidation in liver of adult male albino 
rat. Environmental Toxicology and Pharmacology, 35, 300-310. 
 
Note : these papers are reviewed together as they address the same endpoints in different tissues 
Jayashree and co-workers investigated the effects of bisphenol-A on insulin signal transduction and 
glucose oxidation in skeletal muscle and liver of adult male Wistar rats (Jayashree et al. 2013; 
Indumathi et al., 2013). BPA was administered orally by gavage once daily for 30 days at dose levels 
of 0, 20 or 200 mg/kg bw, in corn oil. Group size was six animals. At the end of the treatment period 
serum insulin was significantly increased in a dose-related manner in both groups of BPA-treated 
animals (the authors also demonstrated a decrease in serum testosterone levels) but fasting blood 
glucose level remained unaltered. Glucose oxidation was reduced at both dose levels in liver and in 
skeletal muscle, and glycogen content of the liver was also reduced. In skeletal muscle, treatment with 
BPA at both 20 or 200 mg/kg bw significantly decreased the insulin receptor, protein kinase B and 
glucose transporter-4 levels (both plasma membrane and cytosolic fraction), but did not affect the 
mRNA levels for these proteins. In the liver both m-RNA and protein levels were significantly 
decreased at the highest BPA-exposed group. The authors concluded that BPA can affect glucose 
oxidation and hepatic glycogen reserves through defective insulin signal transduction.  
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the studies: 
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Strengths: 
- Oral administration by via gavage (Indumathi et al., 2013, Jayashree et al., 2013) 
- Use of non-PC cages (Indumathi et al., 2013, Jayashree et al., 2013) 
Weaknesses:  
- Small sample size (Indumathi et al., 2013, Jayashree et al., 2013) 
- Test performed in one sex only (Indumathi et al., 2013, Jayashree et al., 2013) 
- Animal diet and phytoestrogen content not reported (Indumathi et al., 2013, Jayashree et al., 
2013) 
 
Comments from the CEF Panel:  
Overall, the CEF Panel noted that in these studies a relatively small number of animals were used at 
each dose level, the dose levels were quite high and the diet was apparently not checked for 
phytoestrogen content.  
These studies are included in the WoE table because of their relevance to one or more review 
questions addressed there. 
Marmugi A, Ducheix S, Lasserre F, Polizzi A, Paris A, Priymenko N, Bertrand-Michel J, Pineau 
T, Guillou H, Martin PG and Mselli-Lakhal L, 2012. Low doses of bisphenol A induce gene 
expression related to lipid synthesis and trigger triglyceride accumulation in adult mouse liver. 
Hepatology, 55, 395-407. 
 
Marmugi et al. (2012) administered BPA (0, 0.05, 0.5, 5 or 50 mg/kg diet, estimated by the authors to 
be equivalent to 0, 5, 50, 500 and 5000 μg/kg b.w. per day) to male CD1 mice (n=6 per group) for 28 
days. At the end of the experimental period, the authors measured body weight gain, liver weight and 
weight of perigonadic white adipose tissue (pWAT), hepatic lipid content and fatty acid composition, 
plasma levels of insulin, triglycerides, glucose, total cholesterol, low- or high-density lipoprotein 
(LDL, HDL) cholesterol were measured, and the the effects of BPA on gene expression in the liver 
was assessed using microarrays. No effect was seen on body weight gain and relative liver weight, but 
pWAT weight was significantly increased in mice receiving 50 μg/kg bw per day (but not at higher 
dose levels). Plasma insulin levels were significantly increased following exposure to 5, 50, and 500 
μg BPA/kg bw per day, with the greatest effect being seen at the lowest dose. No significant effect 
was apparent on plasma glucose and total, LDL- or HDL-cholesterol, but mice exposed to 500 μg 
BPA/kg bw per day showed a significant increase in plasma triglyceride levels. The results of the 
microarray assays showed a stimulatory effect of BPA on expression of key enzymes involved in 
lipogenesis, cholesterol biosynthesis and, to a lesser extent, enzymes involved in glucose metabolism. 
The authors suggest that effects seen showing a non-monotonic dose-response since a stronger 
response was seen in the liver of mice receiving 50 μg/kg bw per day than those receiving mice 
receiving 5000 μg/kg bw per day. The authors suggest that exposure to low doses of BPA may 
influence de novo fatty acid synthesis through increased expression of lipogenic genes, thereby 
contributing to hepatic steatosis. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Number of doses (≥3)  
- Protocols according to EU guideline  
Weaknesses:  
- Test performed in one sex only 
- Small sample size 
- Feed consumption (BPA given by the diet) not measured 
- Inappropriate statistics: insufficient studying reporting 
- Animal diet and phytoestrogen content not reported 
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Overall, the CEF Panel notes that this study appears to confirm the effects reported by several other 
studies on lipogenesis, in adult animals, but the lack of a dose-response/non-monotonic dose-response 
has to be further confirmed. The numbers of animals involved per group are considered to be low. In 
the statistics no mention to multiple comparisons that should have been performed for all the 
measurements reported in Figure 1 of the study. The TDI dose induced more changes in gene 
expression as compared to the other doses and control.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
 
Ronn M, Kullberg J, Karlsson H, Berglund J, Malmberg F, Orberg J, Lind L, Ahlstrom H and 
Lind PM, 2013. Bisphenol A exposure increases liver fat in juvenile fructose-fed Fischer 344 
rats. Toxicology, 303, 125-132. 
  
Rönn et al. (2013) administered BPA (0.025, 0.25 or 2.5 mg BPA/L, equivalent in drinking water 
containing 5 % fructose to female F-344 rats (n= 12 per group) from five to 15 weeks of age. The 
intakes of BPA, according to the authors, were between 4.6 (week 9) and 5.6 (week 2) µg/kg bw per 
day (mean 5.1 µg/kg bw per day) at the lowest dose, between 46.3 (week 6) and 61.6 (week 3) µg/kg 
bw per day (mean 54.3 µg/kg bw per day) at the mid dose and 400.3 (week 9) and 595.3 (week 2) 
µg/kg bw per day (mean 487.3 µg/kg bw per day) at the highest dose. The authors assessed effects on 
adipose tissue volume and liver fat content in the BPA-exposed groups by magnetic resonance 
imaging (MRI) compared with a control group also given fructose solution. They also measured 
cholesterol, triglycerides and apolipoprotein A-1a, changes in body weight and weight of the perirenal 
fat pad. There were no significant effects of BPA exposure on body weight or weight of the perirenal 
fat pad and no differences were seen in total or visceral adipose tissue volumes between the groups. 
However liver fat content was significantly higher in BPA-exposed rats (0.25 and 2.5 mg BPA/L; 
corresponding to 54.3 µg/kg bw per day 487.3 µg/kg bw per day) than in fructose controls (p = 0.04). 
BPA exposure also increased the apolipoprotein A-I levels in plasma (p < 0.0001) which indicates a 
favourable modification in the lipid profile because it is the main component of the high density 
lipoprotein (HDL). 
 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths:  
- Number of doses (≥3)  
- Oral administration by via gavage  
- Phytoestrogen-free diet  
- Use of non-PC cages  
Weaknesses:  
- Test performed in one sex only  
- Study design not appropriate to the scope (not fully appropriate for obtaining the substance 
specific data aimed at (BPA exposure combined with fructose)  
 
Overall the CEF Panel notes that this is considered to be quite a robust study, with an adequate 
number of animals per group, which notably does not show a marked effect of BPA on lipogenesis 
other than a marginal effect on liver fat levels. However the methodology used (MRI) may have 
limitations in relation to sensitivity to detect subtle effects. It should be noted that in humans 
apolipoprotein A I is part of the high density lipoproteins (HDL), for which is agreement that increases 
have a beneficial effect.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
(iii) In vitro studies 
Appraisal of strengths and weaknesses and WoE analysis were not carried out for in vitro studies.  
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Huc L, Lemarié A, Guéraud F and Héliès-Toussaint C, 2012. Low concentrations of bisphenol A 
induce lipid accumulation mediated by the production of reactive oxygen species in the 
mitochondria of HepG2 cells. Toxicology In Vitro, 26, 709-717. 
 
HepG2 cells (human hepatocellular carcinoma) were treated with 10-4-10-12 M BPA for 1-3 days and 
changes of the mitochondrial membrane potential, oxidative stress, generation of reactive aldehydes 
(4-hydroxynonenal) and lipid accumulation were determined. In addition, the release of IL-8, IL-6 and 
TNFα was monitored. Mitochondrial ROS production was detected mainly at 48 and 72 h after 
treatment in 20-30% of all cells. An inverse U-shaped increase in cytosolic superoxide anions was 
detected 72 h after treatment with a maximum at 10-9 M in up to 20% of all cells. In addition 
mitochondrial hyperpolarisation was seen in a time and concentration-dependent manner in up to 60% 
of all cells. In the presence of free fatty acids the number of cells with more lipid droplets increased 
from 6 % to 15 % within 72 h. Recently it has been shown that BPA increases the lipid synthesis in 
hepatocytes in vivo (Marmugi et al., 2012). In the latter study key enzymes of the lipid metabolism 
showed an inverse U-shaped kinetic, suggesting that the data of the present study are of physiological 
relevance. A release of IL-8 and TNFα was detected after 72 h only at a high BPA concentration, i.e. 
10-5 M. 
Lin Y, Sun X Qiu L, Wei J, Huang Q, Fang C, Ye T, Kang M, Shen H and Dong S, 2013. 
Exposure to bisphenol A induces dysfunction of insulin secretion and apoptosis through the 
damage of mitochondria in rat insulinoma (INS-1) cells. Cell Death and Disease 4, e460. 
 
The authors studied the effect of 2x10-9 - 2x10-6 M BPA on the immortalized rat pancreatic cell line 
INS-1. A significant time- and concentration-dependent toxicity (MTT assay) was observed - even at 
the lowest BPA concentration at 48 hours treatment. In addition, BPA at 2x10-9 M increased insulin 
secretion at 16.7 mM glucose. A significant increase in early apoptotic cells was observed at and 
above 2x10-8 M BPA (48 h) along with a reduction of the mitochondrial mass, disturbed mitochondrial 
membrane potential, increased cytochrome c release and a reduced ATP concentration. Western blot 
analysis of Bax and Bcl-2 expression suggests that apoptosis is mediated via caspase-dependent 
mitochondrial pathway. 
INS-1 cells seem to be very sensitive to BPA effects on mitochondrial membranes resulting in 
apoptosis. The BPA induced effects – except for insulin secretion and expression of two related genes 
- were concentration-dependent with a maximum at high BPA concentrations which were clearly toxic 
and not relevant for risk assessment (>10-7 M). It remains to be clarified whether or not this cell model 
is relevant for toxic effects of BPA on pancreatic β-cells in vivo. 
 
Linehan C, Gupta S, Samali A and O'Connor L, 2012. Bisphenol A-mediated suppression of 
LPL gene expression inhibits triglyceride accumulation during adipogenic differentiation of 
human adult stem cells. PLoS One, 7, e36109. 
 
Triglyceride accumulation and gene expression weres studied during differentiation of 3T3-L1 pre-
adipocytes. Whilst the effective BPA concentration (8x10-5 M) was too high to be relevant for risk 
assessment, lower concentrations of BPA of 8x10-8 and 8x10-6 M did not affect adipogenic 
differentiation or triglyceride accumulation in these cells. 
Sheng ZG, Tang Y, Liu YX, Yuan Y, Zhao BO, Chao XJ and Zhu BZ, 2012. Low concentrations 
of bisphenol A suppress thyroid hormone receptor transcription through a nongenomic 
mechanism. Toxicology and Applied Pharmacology, 259, 133-142. 
 
The authors studied the effect of 10-9-10-7 M BPA on the thyroid receptor (TR) activation in the 
presence and absence of physiological concentrations of T3 (10-10 M) and T4 (10-7 M). These effects 
were studied on CV-1 cells derived from cercopithecus aethiops monkey kidneys, lacking TR and 
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293T cells. After transfection gene reporter assays were used to study involved signalling 
mechanisms. The authors showed that BPA suppressed the T3/T4- and the steroid receptor coactivator 
(SRC-1)-enhanced TR transcription probably by disrupting the T3 /T4-mediated activation of the 
β3integrin/c-Src/MAPK/TR-β1 pathway.  
Whilst BPA is known to bind to both the TR-α and TR-β only with low affinity the present findings 
with low BPA concentrations suggest a BPA-induced suppression of TR transcription by recruitment 
of nuclear receptor co-repressor (N-CoR) to TR-β. The relevance of the findings from the complex 
transfection experiments for the in vivo situation is unclear.  
 
Song L, Xia W, Zhou Z, Li Y, Lin Y, Wei J, Wei Z, Xu B, Shen J, Li W and Xu S, 2012. Low-
level phenolic estrogen pollutants impair islets morphology and β-cells function in isolated rat 
islets. Journal of Endocrinology, 215, 303-311. 
 
The authors studied the effect of 4.4x10-10 – 1.1x10-6 M BPA and 4 phenolic estrogen pollutants on 
primary rat pancreatic islet cells. A concentration–dependent decrease in islet viability (MTT assay) 
was detected at 1.1x10-8 M BPA and higher. At 1.1x10-7 M BPA the mitochondria of treated β-cells 
were remarkably swollen and showed a loss of structural integrity, the cytosolic ATP content was 
reduced. Incubations in the presence of 16.7 mM glucose resulted in a significant increase in the 
insulin release at 4.4x10-10 to 1.1x10-8 M BPA while it was significantly decreased at higher BPA 
concentrations. Additionally gene expression was studied at 1.1x10-7 M BPA: except for Ucp2, most 
of the studied genes showed reduced gene expression. According to recent publications (Chan et al., 
1999, 2001) overexpression of UCP2 is associated with reduced ATP generation in mitochondria of β-
cell lines and has been shown to promote proton keakage across the mitochondrial membrane (Rial et 
al., 1999).  
The CEF Panel noted that except a very slight increase in insulin secretion in the presence of a high 
glucose concentration (16.7 mM) all other BPA-induced effects, i.e. on insulin secretion (at 3 mM 
glucose), on mitochondria and gene expression, were observed at (sub)toxic BPA concentrations. 
Therefore, the relevance of these in vitro observation remain questionable. 
Soriano S, Alonso-Magdalena P, García-Arévalo M, Novials A, Muhammed SJ, Salehi A, 
Gustafsson JA, Quesada I, Nadal A (2012) Rapid insulinotropic action of low doses of bisphenol-
A on mouse and human islets of Langerhans: role of estrogen receptor β. PLoS One, 7, e31109. 
 
The authors studied the effect of 10-10 - 10-7 M BPA on the insulin secretion of primary human and 
murine pancreatic β-cells at 8 mM glucose. BPA increased the insulin secretion at all investigated 
concentrations in mouse islets. For the following investigations 10-9 M BPA was used. While BPA 
increased the insulin secretion (at 8 mM Glc) in islets and reduced the KATP channels activity in β-cells 
from three human cadaveric organ donors and wild type (WT) mice, no such effects was observed in 
β-cells from ERβ-/- mice. This occurred in parallel with an frequency increase of [Ca2+]i oscillations, 
again in β-cells from WT mice, only. At 3 mM glucose the observed in vitro effects were absent. The 
negative results on insulin release with cells from from ERβ-/- mice and the stimulation of insulin 
release with the specific ERβ agonist DPN in human cells suggest a crucial role of from ERβ in the 
BPA-induction of insulin release. 
In this study E2 was not included as a positive control was included, however it was claimed in the 
discussion Section that BPA and E2 were equally potent. With regard to the in vivo situation the 
impact of E2 on the BPA effects in isolated islets/β-cells would be interesting. 
The number of experiments/cells is – where indicated at all – low (n=5), however the reported effects 
are consistent and are in line with earlier observations from the same research group. The impact of 
such an artificial cell system on the risk assessment of BPA is unclear. 
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Wang J, Sun B, Hou M, Pan X and Li X, 2013. The environmental obesogen bisphenol A 
promotes adipogenesis by increasing the amount of 11β-hydroxysteroid dehydrogenase type 1 in 
the adipose tissue of children. International Journal of Obesity, 37, 999-1005. 
 
The authors studied the effect of BPA on human adipose tissue, obtained after surgical interventions. 
The expression of 11β-hydroxysteroid dehydrogenase (11β-HSD1), PPARγ, and of lipoprotein lipase 
(LPL) significantly increased after 24 h of incubation at 10-8 M, 10-6 M and 8x10-5 M BPA. In 
addition, the 11-βHSD1 enzyme activity increased in adipose tissue. After stimulation with BPA the 
gene expression of 11β-HSD1 show a similar response in human pre-adipocytes and adipocytes. 
However, expression levels were higher in adipocytes, compared to pre-adipocytes. The presence of 
BPA during differentiation of pre-adipocytes to adipocytes resulted in significant higher number of 
lipid droplets at 10-8 M and 8x10-5 M and an increased expression of PPARγ and LPL. The 11β-HSD1 
inhibitor CXB significantly reduced the effects of BPA on the increased expression of 11β-HSD1, 
PPARγ and LPL. In addition, mifepristone (RU486) a glucocorticoid receptor antagonist significantly 
reduced the expression of 11β-HSD1 in pre-adipocytes. 
Genotoxicity 
The selection for relevance as well as the review criteria applied to in vitro and in vivo genotoxicity 
studies differed from those used for animal and in vitro studies on other endpoints, since they were in 
line with the EFSA scientific opinion on genotoxicity testing strategy principles  
(i) In vitro studies 
Audebert M, Dolo L, Perdu E, Cravedi JP and Zalko D, 2011. Use of the γH2AX assay for 
assessing the genotoxicity of bisphenol A and bisphenol F in human cell lines. Archives of 
Toxicology, 85, 1463-1473. 
 
In this study the authors investigated the capability of established human cell lines, ACHN (human 
kidney adenocarcinoma cells), HepG2 (human hepatocellular carcinoma cells) and LS174T (human 
epithelial colorectal adenocarcinoma cells) to biotransform bisphenol A (BPA) and bisphenol F (BPF). 
The potential genotoxicity of BPA and BPF was assessed using a novel genotoxicity assay based on 
the detection of phosphorylated histone γ-H2AX, which forms foci that appears immediately after 
DNA damage and recruit protein responsible for repair of DNA damage. A description of the 
experimental procedure followed to detected histone γ-H2AX is missing and no information on 
antibodies employed is reported. BPA was shown to be metabolized by HepG2 and LS174T cell lines. 
Intestinal cells showed stronger biotransformation capabilities than liver cells, in terms of production 
of the glucuronide- and the sulphate-conjugates (phase II metabolites). On the other hand, ACHN cell 
line was not able to metabolize BPA. Relevant metabolites were separated and quantified by radio-
HPLC. Following treatment with BPA at dose-levels of 1, 5, 10, 50 and 100 for 24 hours no increases 
of γ-H2AX were observed in any concentration assayed. To avoid false-positive genotoxic signals 
induction of histone γ-H2AX was assessed at dose-levels with at least 80 % cell viability. 
Comments from the CEF Panel:  
Overall the CEF Panel notes that the study was not specifically designed for risk assessment purposes 
but rather for basic research objectives. The work shows serious uncertainties mainly related to 
genotoxicity evaluation.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
Fic A, Žegura B, Sollner Dolenc M, Filipič M and Peterlin Mašič L, 2013. Mutagenicity and 
DNA damage of bisphenol A and its structural analogues in HepG2 cells. Arhiv Za Higijenu 
Rada i Toksikologiju, 64, 3-14. 
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This study was aimed at assessing the mutagenic and genotoxic potential of bisphenol A (BPA) using 
the Ames test (Salmonella typhimurium strains TA98 and TA 100) in either the absence or presence of 
S9 metabolic activation and the alkaline comet assay in the HepG2 cells treated with BPA at dose-
levels of 0.1, 1.0 and 10.0 µM for 4 and 24 hours. BPA was not mutagenic in the Salmonella 
typhimurium strains TA98 and TA 100 both in the absence and presence of S9 metabolism, while in 
the comet assay it induced a significant, but not dose-related increase in DNA damage only after 24-
hour exposure.  
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in this study: 
Strengths: 
- Adequate number of concentrations in presence and absence of metabolic activation (S9) 
Weaknesses: 
- Limitations of the experimental design in the Ames test (e.g. limited number of Salmonella 
Typhimurium strains) 
- Inconsistent results in the comet assay (e.g. not dose-related increase in DNA damage ) 
 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
Iso T, Watanabe T, Iwamoto T, Shimamoto A and Furuichi Y, 2006. DNA damage caused by 
bisphenol A and estradiol through estrogenic activity. Biological & Pharmaceutical Bulletin, 29, 
206-210. 
 
This study was aimed at assessing potential DNA damage induced by BPA and oestradiol using the 
alkaline comet assay and the detection of phosphorylated histone γ-H2AX, a marker for induction of 
DNA double strand breaks, in human cell lines positive and negative for estrogen receptors (ER) 
(MCF-7 and MDA-MB-231, respectively). ER-positive and ER-negative cells were treated with BPA 
at 10-4, 10-6 and 10-8 M up to 24 hours. In a time course analysis of DNA damage, cells were treated at 
10-4 M and damage was analysed after 1, 3 and 24 hours. Results obtained indicate significant 
increases of DNA breakage (increases in tail length) at the two highest levels assayed following 3 hour 
treatment and in the time course study in any of the sampling time used. Increases were also noted for 
induction of phosphorylated histone γ-H2AX in MCF-7 cells. 
Comments from the CEF Panel:  
The CEF Panel identified the following weaknesses in this study: 
- Results are not clearly reported  
- Inconsistent results in ER-negative and ER-positive cells (different genomic stability) 
Overall the CEF Panel notes that the methods implemented are not sufficiently robust to support the 
results reported in the study. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
Johnson GE and Parry EM, 2008 Mechanistic investigations of low dose exposures to the 
genotoxic compounds bisphenol-A and rotenone. Mutation Research, 651, 56-63. 
 
In this mechanistic study the aneugenicity of two known spindle poisons model compounds, namely 
rotenone and bisphenol A (BPA), has been investigated following low dose-exposure to mammalian 
cells, using the cytokinesis blocked micronucleus assay (CBMA) and immunofluorescence methods to 
visualize modifications of the microtubule organizing centers (MTOCs) of the mitotic spindles. For 
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induction of micronuclei BPA was added over a tight range of very narrowed low concentrations (1.5, 
3.1, 6.2, 7.7, 9.2, 10.8, 12.3, 18.5, 24.6, and 37.0 µg/ml) to cultures of human (AHH-1) 
lymphoblastoid cell line for a complete cell cycle (22-26 hours dependent upon any cell cycle delay) 
in the presence of 3 µg/ml of the actin-inhibitor cytochalasin-B. A minimum of five separate 
experiments were performed. For mechanistic evaluation of the aneugenic effects of BPA, 
fluorescently labelled antibodies were used to visualize microtubules (α-tubulin) and MTOCs (γ-
tubulin) in V79 culture because they are fibroblast cells which grow by attachment to the vessel 
surface which is an important feature in the study of the fidelity of mitoses. BPA in this case was 
added to V79 cells growing on sterile glass microscope slides placed in Petri dishes at concentrations 
4.2, 4.9, 5.6, 7.0, 8.4, 9.8, 11.2 and 14 µg/ml for 20 hours (i.e. one cell cycle for V79). Results 
obtained for induction of micronuclei indicated dose-related and statistically significant increases of 
binucleate-micronucleated cells from 12.3 µg/ml with a clear threshold for induction of micronuclei 
(NOEL at 10.80 µg/ml and LOEL at 12.3 µg/ml). A NOEL and LOEL for percentage of binucleate 
cells (i.e. relative proportion of mononucleated to binucleate cells, as a measure of cell viability) was 
also observed at 9.2 µg/ml and 10.8 µg/ml BPA respectively. Similarly for induction of aberrations in 
the mitotic machinery a NOEL was observed at 7.0 µg/ml and a LOEL at 8.4 µg/ml BPA in V79 cells. 
Aberrant mitotic divisions, in the form of multiple spindle poles may be the mechanism for the 
production of chromosome loss into micronuclei. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths in this study: 
- Sound experimental design and well documented study  
- Adequate selection and spacing of dose-levels  
Overall the CEF Panel notes that the conclusions of this study are very informative concerning the 
interaction of BPA with microtubule organizing centers (MTOCs) of the mitotic spindle and 
consequent induction of micronuclei. Furthermore, this study clearly demonstrates a threshold level 
for induction of micronuclei (NOEL at 10.80 µg/ml) and for induction of aberrations in the mitotic 
machinery (NOEL at 7.0 µg/ml) in mammalian cells, thus confirming thresholds of action for the 
induction of aneuploidy predicted for spindle poisons since multiple targets of the mitotic machinery 
need to be disabled before a quantitative response can be detected. The results obtained support the 
concept of a potential threshold-based hazard and risk assessment for BPA. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
Tayama S, Nakagawa Y and Tayama K, 2008. Genotoxic effects of environmental estrogen-like 
compounds in CHO-K1 cells. Mutation Research, 649, 114-25. 
 
In this study, the authors evaluated the genotoxicity of some environmental estrogen-like compounds 
including bisphenol A (BPA) using sister chromatid exchanges (SCEs), chromosome aberration (CA) 
and DNA strand breaks (comet) assays in CHO-K1 cell line in vitro. For CA and SCEs six 
concentrations of BPA ranging from 0.1 to 0.6 mM were added to CHO-K1 cells for 3 hours. 
Following treatments cells were further incubated for 27 hours in the presence of 5-bromo-2’-
deoxyuridine (BrdU) until preparation of slides for both SCE and CA from the same culture. For 
comet assay seven concentrations of BPA ranging from 0.1 to 0.7 mM were added to CHO-K1 for 1 
hour and following washes of test compound cells were processed for comet assay using a silver-
staining method and manual microscopic analysis. Results reported by the authors indicate positive 
effects for both SCE and chromosome aberrations at the two highest (0.5 and 0.6 mM) and at the 
highest concentrations (0.6 mM) respectively. Significant increases of c-mitotic effects were also 
reported at highest concentrations0.3-0.6 mM. For comet assay significant increases of DNA breakage 
were only reported at the highest concentration (0.7 mM). For chromosome aberrations, the sampling 
time used (27 hours) far exceeded the recommended 1.5 cell cycle which is 18-21 hours for cell line 
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used. Furthermore, cells were recovered in the presence of (BrdU) needed to detect SCE in the same 
cell culture which induces, although at low level, DNA single strand breaks which can influence 
production of chromosomal aberrations. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in this study: 
Strengths: 
- Adequate range of concentrations 
- Three genotoxic endpoints (DNA breakage, SCE and CA) 
- Concentration-related and statistically significant increases of c-metaphases 
Weaknesses: 
- Limitations in the experimental design (e.g. sampling times, staining procedures, cells 
recovered in the presence of BrdU) 
- Positive effects only at high dose-level in the presence of cytotoxicity which generates false 
positives 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
(ii) In vivo studies 
De Flora S, Micale RT, La Maestra S, Izzotti A, D'Agostini F, Camoirano A, Davoli SA, Troglio 
MG, Rizzi F, Davalli P and Bettuzzi S, 2011. Upregulation of clusterin in prostate and DNA 
damage in spermatozoa from Bisphenol A-treated rats, and formation of DNA adducts in 
cultured human prostatic cells. Toxicological Sciences, 122, 45-51. 
 
This study evaluated a variety of biomarkers, including the analysis of micronuclei in bone marrow 
cells and evaluation of the degree of DNA breakage by measurement of tail moment in the alkaline 
comet assay in peripheral blood lymphocytes, in male Sprague-Dawley rats treated with BPA via 
drinking water for a calculated daily intake of 200 mg/kg bw for 10 consecutive days. Furthermore, 
they investigated the formation of DNA adducts in two human prostate (PNT1and PC3) cell lines in 
vitro treated with BPA at 200 µM for PNT1 and at 250 µM for PC3 for 24 hours. Results obtained in 
vivo did not show induction of micronuclei in bone marrow cells and DNA breakage as measured by 
determination of tail moment in the comet assay. In vitro, results obtained showed formation of DNA 
adducts (4.2 and 2.7 fold increases over control in PNT1 and PC3 cells respectively). 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in this study: 
Strengths: 
- Sound approach and experimental design 
Weaknesses: 
- Limitations in the experimental design (e.g. single dose level, number of cells examined) 
Overall the CEF Panel notes that—despite some limitations (e.g. 1 000 PCE/animal scored for 
micronuclei instead of 2 000 PCE/animal recommended; 100 cells analyzed for each test point in the 
comet assay instead of 150 recommended; only one dose-level used)—the methods implemented in 
the in vivo study to evaluate micronuclei induction in bone marrow cells and the degree of DNA 
breakage in peripheral blood lymphocytes by comet assay, are sufficiently robust to support the results 
reported which were judged informative for purposes of risk assessment.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
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Dobrzyńska MM and Radzikowska J, 2013. Genotoxicity and reproductive toxicity of bisphenol 
A and X-ray/bisphenol A combination in male mice. Drug and Chemical Toxicology, 36, 19-26.  
 
This study investigated the effects of BPA alone or in combination with X-rays on the sperm and 
induction of DNA strand breaks in somatic and germ cells of mice. Male Pzh:SFIS mice received BPA 
orally in drinking water for two weeks. Levels in drinking water were designed to achieve BPA 
intakes of 0, 5, 10, 20 or 40 mg/kg bw per day. Two additional groups received either 5 or 10 mg 
BPA/kg bw per day via drinking water in combination with daily radiation doses of 0.05 Gy or 0.10 
Gy of X-rays. These latter groups were not considered relevant for the present evaluation. For comet 
assay animals were sacrificed 24 hours after the last treatment and DNA tail moment was employed to 
assess the levels of DNA breakage induced in cells isolated from liver, spleen, bone marrow, lungs, 
and kidneys through mechanic disaggregation of organs and filtered by adequate meshes. Results 
obtained indicate that BPA induced statistically significant increases of DNA tail moment in bone 
marrow, spleen, kidney and lung cells at any of the dose-level assayed. No DNA breakage was 
detected in liver cells.  
Comments from the CEF Panel: 
The CEF Panel identified the following weaknesses in this study: 
Strenghts: 
- Number of doses (≥3)  
Weaknesses: 
- Limitations in the experimental design (e.g. cytotoxicity not evaluated, absence of historical 
control values, inadequate sampling times) 
- Poor study report 
- No vehicle controls were tested  
- Drinking water consumption (containing BPA) not measured 
- Animal diet poorly described  
- Animal diet and phytoestrogen content not reported  
 
Overall the CEF Panel notes that the methods implemented are not sufficiently robust to support the 
results reported in the study. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Izzotti A, Kanitz S, D'Agostini F, Camoirano A and De Flora S, 2009. Formation of adducts by 
bisphenol A, an endocrine disruptor, in DNA in vitro and in liver and mammary tissue of mice. 
Mutation Research, 679, 28-32.  
 
This study was aimed a) to investigate the sensitivity threshold of DNA-adduct detection by 32P-
postlabelling in an acellular system and b) to evaluate the formation of DNA adducts, detected by 32P-
postlabelling in both liver and mammary cells of female CD-1 mice receiving BPA in their drinking 
water (200 mg/kg bw) for 8 consecutive days. Calf thymus DNA (dissolved in bi-distilled water, final 
concentration of 200 µg/ml), BPA dissolved in DMSO (and further diluted in bi-distilled water to final 
concentrations of 6.2 and 100 µM) and an exogenous S9 mix (metabolizing system containing 10 % 
liver S12 fractions derived from aroclor-1254-pretreated Sprague-Dawley rats) were incubated at 37 
°C for 30 minutes. Results obtained indicated that the reaction of BPA in the presence of exogenous 
metabolizing system S9 mix resulted in a dose-related formation of bulky DNA adducts (two major 
and five minor DNA adducts detected in autoradiographic plates) with a detection limit of 10 ng for 
test compound. In vivo, administration of BPA to mice via drinking water under the mentioned 
experimental conditions resulted in the formation of bulky DNA adducts (two major DNA adduct) in 
the liver (3.4 fold increase over control level) as well as in the target mammary cells (4.7 fold increase 
over control level). 
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Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in this study: 
Strengths: 
- Sound approach and experimental design 
Weaknesses: 
- Speculative conclusions 
The results of this study confirm the ability of BPA to form DNA adducts both in vitro, in the acellular 
system previously described, and in vivo in liver and in target mammalian epithelial cells (for the first 
time). The authors attribute the adduct formation to the reactive metabolite BPA-3,4-quinone (BPAQ). 
BPA is metabolised in humans and in experimental animals, to its glucuronide and to hydroxylated 
derivatives, mainly 3-hydroxy-BPA (BPA catechol), which is finally oxidized to BPAQ. The 
conclusions raised by authors, although plausible from a theoretical point of view, in practice are 
rather speculative since the chemical identity of DNA adducts has not been characterized. This aspect 
is important for the outcome of this assay since different methods of DNA extraction can generate 
unspecific covalent binding to DNA. However, the CEF Panel considers that the methods 
implemented are sufficiently robust to support the results reported in the study. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
Masuda S, Terashima Y, Sano A, Kuruto R, Sugiyama Y, Shimoi K, Tanji K, Yoshioka H, Terao 
Y and Kinae N, 2005. Changes in the mutagenic and estrogenic activities of bisphenol A upon 
treatment with nitrite. Mutation Research, 585, 137-146. 
 
In this study, the authors investigated the possible generation of genotoxicity from the reaction of BPA 
and nitrite under acidic conditions to simulate stomach environment. Genotoxicity of BPA alone at a 
concentration of 1 mM was also evaluated in an Ames test using TA 98 and TA 100 tester strains in 
either the absence or presence of S9 metabolic activation and in an in vivo micronucleus test in male 
ICR mice using peripheral blood reticulocytes at 228 mg/kg bw once by oral gavage. Peripheral blood 
was collected at 24, 48 and 72 hours after administration of test compound. Results obtained indicated 
that BPA alone did not exhibit any mutagenicity in the Ames test and did not induce any increase in 
micronucleated erythrocytes at any sampling time.  
Comments from the CEF Panel:  
The CEF Panel identified the following weaknesses in this study: 
Weaknesses: 
- Ames test limited to two strains 
- Limitations in the experimental design (e.g. single concentration/dose)  
 
Although the experiment was performed with the use of a single dose-level, the CEF Panel considers 
the negative results obtained at reasonably high dose-levels (228 mg/kg bw) in the in vivo peripheral 
blood micronucleus assay as informative for risk assessment purposes. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
Naik P and Vijayalaxmi KK, 2009. Cytogenetic evaluation for genotoxicity of bisphenol-A in 
bone marrow cells of Swiss albino mice. Mutation Research, 676, 106-112. 
 
This study evaluated potential genotoxic effects of BPA by induction of chromosomal aberrations and 
micronuclei in bone marrow cells of Swiss albino mice. To further assess for potential interference of 
BPA with mitotic spindle apparatus, induction of c-mitoses was also performed. The test compound 
was administered orally in a 2 % acacia gum suspension at dose-levels of 10, 50 and 100 mg/kg bw to 
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groups of three male and three female mice, as single acute dose. Cumulative dose-level experiments 
were also performed at the lowest (10 mg/kg bw) dose-level for 5 consecutive days. In single 
treatment schedule, sampling of bone marrow was performed at 6, 24, 48 and 72 hours from beginning 
of treatment for both micronucleus and chromosome aberration assays. In cumulative treatment 
schedule, bone marrow was sampled in both assays 24 hour after the last administration of BPA. For 
induction of c-mitoses, the same dose levels used for micronucleus and chromosome aberration assays 
were applied as single dose and sampling of bone marrow was performed at 2, 6, 12, 24, 48 and 72 
hours. Results showed that no significant increases of chromosomal aberrations or micronuclei were 
induced at any dose-level and sampling time used. On the other hand, significant increases in the 
frequencies of gaps were observed in all dose-levels assayed at the 48 and 72 hour sampling time and 
at the two higher dose-levels (50 and 100 mg/kg bw) at the 24 hour sampling time. The authors did not 
provide a suitable explanation for increase of gap frequencies but discussed findings from literature. 
One of the most relevant quoted by Xu and Adler (1990) considered such a finding not relevant for 
clastogenicity but associated this effect with potential interference with chromosome condensation 
along with potential effect on the mitotic spindle apparatus. In addition, BPA also induced c-mitotic 
effects through increases of mitotic indices and decrease in anaphase for both higher dose-level at 24, 
48 and 72 hour sampling times. 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in this study: 
Strengths: 
- Sound approach and experimental design 
Weaknesses: 
- Minor limitations in the experimental design (e.g. top dose too low, sub-optimal dose and 
exposure to colchicine) 
The study complies with current recommendations with the exception that the highest dose-level 
selected was much lower than the feasible one (2000 mg/kg bw). In addition, the number of six 
animals employed (three male and three females) compensated the fact that a minimum of 5 males 
should have been used. Treatment with colchicine to accumulate cells at metaphase stage was shorter 
(1.5 hours) than recommended (5-6 hours). However, the CEF Panel considers that the methods 
implemented are sufficiently robust to support the results reported in the study and concluded that 
BPA under the reported experimental conditions was not clastogenic and did not elicit micronuclei 
induction thus excluding potential aneugenic effects at dose-levels employed. Furthermore, significant 
increases of achromatic lesions (gaps) are not considered relevant for clastogenicity and in this case 
could have been the result of different plausible factors which include flaming of cytogenetic slides 
during their preparation and use of lower concentration of colchicine (2.5 mg/kg bw instead of 4) for 
shorter time (1.5 hours instead of recommended 5-6 hours). Induction of c-mitotic effects may be 
related to interference of BPA with microtubule organising centres (MTCOs) of mitotic spindles in 
mammalian cells as reported by Johnson and Parry (2008). 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Pacchierotti F, Ranaldi R, Eichenlaub-Ritter U, Attia S and Adler I-D, 2008. Evaluation of 
aneugenic effects of bisphenol A in somatic and germ cells of the mouse. Mutation Research, 
651, 64-70.  
 
This study aimed to assess potential aneugenic effects of BPA on mouse male and female germ cells 
and somatic cells (male bone marrow cells), following acute in vivo exposure following different time 
periods. Cytogenetic effects on first and second meiotic divisions in the oocytes were evaluated 
following administration with BPA to female mice by oral gavage once at 0.2 and 20 mg/kg bw for 7 
days with daily dose-levels of 0.04 mg/kg bw or for 7 weeks in drinking water at concentration of 0.5 
mg/l. To further assess potential aneugenic effects of BPA on the second meiotic division of mouse 
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oocytes, analysis of chromosome complement of zygotes generated from mating of similarly BPA-
treated females with untreated males was also performed. Evaluation of induction of aneuploidy in the 
first and second meiotic division of mouse spermatocytes was performed on the 22nd day after 
treatment of male mice with BPA by oral gavage on 6 consecutive days at 0.002, 0.02 and 0.2 mg/ kg 
bw. This study design was based on previous experiments with 5-bromo-2’-deoxyuridine (BrdU) to 
assess meiotic delay in spermatocytes. Furthermore, evaluation of potential aneugenic effects on 
somatic cells was performed by analysis of micronuclei in bone marrow cells of male mice treated on 
two consecutive days by oral gavage with 0.002, 0.02 and 0.2 mg/ kg bw and collected 24 hours after 
last administration of test compound. Results obtained for female animals indicated no significant 
induction of hyperploidy or polyploidy in oocytes and zygotes at any dose-level and treatment 
condition employed. Significant increases in the number of metaphase II oocytes with prematurely 
separated chromatids proved to be of no consequences in terms of fidelity of chromosome segregation 
during the second meiotic division as shown by normal chromosome complements of zygotes obtained 
under the same experimental conditions. In male mice no delay of meiotic divisions was observed 
following six daily administration of 0.2 mg/kg bw BPA in the BrdU assay. Similarly, no induction of 
hyperploidy or polyploidy in epydidimal sperms hybridized with DNA probes specific for mouse 
chromosome 8, X and Y 22 days after six oral doses of BPA. Furthermore, no induction of 
micronuclei in the bone marrow polychromatic erythrocytes of m male mice was observed following 
treatment on two consecutive days by oral gavage with 0.002, 0.02 and 0.2 mg/kg bw of BPA. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths/weaknesses in this study: 
Strengths: 
- Sound approach and experimental design 
Weaknesses: 
- Inappropriate dose selection: high dose-levels for single or 7 daily administration apparently 
low (20 and 0.2, mg/kg bw respectively) 
Overall the CEF Panel notes that the study is well conducted. The CEF Panel also notes that the dose-
levels used in this study were selected to further evaluate increases of meiotic abnormalities observed 
in untreated female mice from an experimental colony which was temporally correlated with the 
accidental release of BPA from polycarbonate cages and bottles damaged by inadvertent treatment 
with harsh alkaline detergents as reported by Hunt et al. (2003) not according to recommendations for 
genotoxicity testing. However, information provided by this study is important in terms of risk 
assessment based on potential human exposure levels, since for aneugenic effects which are reported 
for BPA in in vitro studies, a non genotoxic effect level (NOGEL) can be defined. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Tiwari D, Kamble J, Chilgunde S, Patil P, Maru G, Kawle D, Bhartiya U, Joseph L and Vanage 
G, 2012. Clastogenic and mutagenic effects of bisphenol A: An endocrine disruptor. Mutation 
Research/Genetic Toxicology and Environmental Mutagenesis, 743, 83-90. 
 
This study was aimed to assess potential genotoxic effects of Bisphenol A (BPA) in rats following oral 
administration of test compound once a day for 6 consecutive days at dose-levels of 2.4 µg, 10 µg, 5 
mg and 50 mg/kg bw by measuring induction of micronuclei and structural chromosome aberrations in 
bone marrow cells and primary DNA damage in blood lymphocytes using single cell gel 
electrophoresis (comet assay). Furthermore, plasma concentrations of 8-hydroxydeoxyguanosine (8-
OHdG), lipid peroxidation and glutathione activity were evaluated to assess potential induction of 
oxidative DNA damage. In the same study, mutagenicity was evaluated in the standard Salmonella 
plate test (Ames test) strains TA98, TA100 and TA102 at increasing concentrations from 6.25 µg to 
200 µg both in the absence and presence of rat liver S9. No mutagenic response was observed in any 
of the tester strains at the various concentrations tested in absence and presence of metabolic 
activation. Results obtained for genotoxicity endpoints show marked dose-related increases of both 
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micronuclei and structural chromosome aberrations in bone marrow cells of male and female rats 
exposed to BPA. The observed increases achieved statistical significance at dose-levels as low as 10 
µg/kg bw per day. Similarly, primary DNA damage evaluated by comet assay, in isolated peripheral 
blood lymphocytes showed marked and dose-related increases which were statistically significant at 
dose-levels as low as 10 µg/kg bw per day.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in this study: 
Strengths: 
- Ames test well conducted 
Weaknesses: 
- Ames test: limitations in the experimental design (e.g. three strains only) 
- Micronucleus: limitations in the experimental design (e.g. inappropriate staining procedures) 
- Chromosomal aberrations: experimental procedures questionable (e.g. inappropriate selection 
of sampling time; mitotic index as a measure of cytotoxicity not determined; sub-optimal 
exposure to colchicine) 
- Incidence and type of chromosome aberrations generally not compatible with those seen with 
other chemical agents 
- Comet assay: limitations in the experimental design (e.g. number of cells examined, 
cytotoxicity not evaluated/reported) and poor reporting (e.g. sampling times not reported) 
- Plasma 8-OHdG concentrations: inconsistent results when compared with the comet assay 
outcome (significant increases were observed in the comet assay at dose-levels as low as 10 
µg/kg bw but not in plasma concentration of 8-OHdG), low sensitivity of the analytical 
method (ELISA) 
Based on the listed observations, the CEF Panel concludes that the methods implemented are not 
sufficiently robust to support the results reported in the study.  
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Tiwari D and Vanage G, 2013. Mutagenic effect of Bisphenol A on adult rat male germ cells and 
their fertility. Reproductive Toxicology, 40, 60-68. 
 
This study investigated the induction by BPA of dominant lethal mutations in the different stages of 
spermatogenesis in the rat. Furthermore, the effects of BPA on male reproductive functions and 
potential DNA damage induced in epydidimal sperm, assessed by the alkaline comet assay were 
investigated. The male rats were treated by oral gavage with BPA at dose-levels of 10 µg/kg bw and 5 
mg/kg bw over a period of six days. Negative control were treated with vehicle. Each male of a 
specific treatment group (e.g. vehicle, 10 µg/kg bw, 5 mg/kg bw) was cohabited with two female per 
week (e.g. a total number of fourteen per group per mating interval) over a period of eight weeks. The 
mated females were then sacrificed on the day 15th of their gestation. The authors concluded that BPA 
induced dominant lethal mutations during the fourth and sixth weeks after BPA exposure, thus 
indicating its sensitivity to mid-spermatid and spermatocyte stages of spermatogenesis, at the highest 
(5 mg/kg bw) dose-level employed and that, the positive findings obtained were corroborated by DNA 
damage observed in the epydidimal sperm cells by the alkaline comet assay.  
Comments from the CEF Panel: 
The CEF Panel identified the following weaknesses in this study: 
- Limitations in the experimental design (e.g. limited number of animals, absence of negative 
and positive controls, only two dose levels employed and lack of rationale for dose selection) 
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- Results potentially biased by high background/variability for rodent sperm in the alkaline 
assay 
- No dose-related increases in dominant lethal mutations 
- Absence of negative historical control data 
Overall, the CEF Panel noted that the conclusion drawn by authors is not supported by experimental 
data. Similarly, positive findings obtained in the epididymal sperm using the alkaline comet assay 
appear to be biased by high background/variability for sperm, which might have been influenced by 
the elevated number of alkali labile sites present in rodent sperm as shown in the literature (see also 
Speit et al., Mutat Res. 2009; 681, 3-12). On this basis, and in the absence of negative historical 
control values, significant increases in DNA breaks over concurrent control values might not be 
indicative of genotoxic activity of BPA in sperm cells. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Ulutaş OK, Yıldız N, Durmaz E, Ahbab MA, Barlas N and Çok I, 2011. An in vivo assessment of 
the genotoxic potential of bisphenol A and 4-tert-octylphenol in rats. Archives of Toxicology, 85, 
995-1001. 
 
The authors aimed to assess potential genotoxicity of bisphenol A (BPA) in peripheral blood nucleated 
cells of rats by comet assay. Groups of 6 rats were dosed orally for 4 weeks at dose-levels of 125 and 
250 mg/kg bw. Control group animals (5 animals) were administered orally with corn oil for four 
weeks. At the end of treatment peripheral blood cells were collected via cardiac puncture and stored at 
4°C until preparation of slides for comet assay. Authors showed significant increases of both tail 
length and tail moment for BPA only at the highest dose-level (250 mg/kg bw per day) employed,  
Comments from the CEF Panel: 
The CEF Panel identified the following weaknesses in this study: 
- Limitations in the experimental design (e.g. inappropriate/not clearly reported sampling times, 
number of cells examined, cytotoxicity not evaluated/reported) 
On this basis, the methods implemented were thought not to be sufficiently robust to support the 
results reported in the study. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there. 
Carcinogenicity 
(i) Human studies 
Duan B, Hu X, Zhao H, Qin J, and Luo J, 2012. The relationship between urinary bisphenol A 
levels and meningioma in Chinese adults. International Journal of Clinical Oncology,18, 492-
497. 
 
The study represents a small case-control study in which urinary BPA concentrations in 243 male and 
female patients with neuroradiology-confirmed diagnosis of meningioma were compared with those in 
258 matched healthy controls undergoing medical examinations at the same hospital in Wuhan, China. 
The specimens and data of patients were collected from 2009 to 2010. Total urinary BPA were 
measured using solid-phase extraction (SPE) coupled with high-performance liquid chromatography–
mass spectrometry (LC–MS, no details given). A comprehensive quality control system, including 
reagent blanks, was used to ensure that samples were not contaminated during handling, storage, and 
analysis. The authors reported a positive association between increased concentrations of BPA in spot 
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urine samples (unadjusted) and meningioma independent of confounding factors that they identified: 
gender, age, race, body mass index (BMI), hormone replacement therapy (HRT) use and family 
history of cancer. Compared to quartile 1 (referent), the multivariate-adjusted odds ratio of 
meningioma associated with quartile 4 was 1.45 (95 % CI, 1.02–1.98) (p trend=0.03). 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Quality control, including blanks and quality assurance procedures 
- Analytical method (LC-MS) 
Weaknesses: 
- Case-control study 
- Potential selection bias (details on the selection of patients and controls not provided) 
- Single exposure measurements 
- Single spot urine BPA measurement  
- Not adjusted urine samples 
- No distinction between conjugated and unconjugated BPA 
- Handling of values below LOD not reported 
- Confounding by diet or by concurring exposure factors (medication) not reported 
- Unclear clinical relevance 
 
Overall the CEF Panel notes that the study by Duan and colleagues is very small and there are 
uncertainties about the selection of patients and controls. Additional confounding factors other than 
those considered, e.g. age, gender, BMI and HRT cannot be excluded. Some of their cases of 
meningioma had been treated therapeutically but no details are given. No detailed data about the 
concentrations of BPA measured in urine are provided and numbers are very small for comparisons of 
single measurement of BPA concentration in a random urine sample. The results of this small case-
control do not significantly add to the information about factors involved in the development of 
meningioma, which is unlikely to be linked to chemical exposure.  
No WoE analysis was carried out for the one human case-control study that was evaluated by the CEF 
Panel.  
(ii) Animal studies 
To note: in this section, strengths and weaknesses of studies published after 2010 and not previously 
reviewed by EFSA have been provided as “Comments from the CEF Panel” under each study. For 
studies reviewed in previous risk assessments of EFSA, the comments of the reviewing Panel (EFSA 
2006; EFSA CEF Panel,  2010) have been provided in the format used at that time, without always 
specifically listing strengths and weaknesses. These are however included in Appendix B in summary 
form.   
Acevedo N, Davis B, Schaeberle CM, Sonnenschein C and Soto AM, 2013. Perinatally 
Administered bisphenol A acts as a mammary gland carcinogen in rats. Environmental Health 
Perspectives, 121, 1040-1046. 
BPA (0; 0.25; 2.5 or 250 μg/kg bw per day) was administered s.c. to Sprague-Dawley rats (dams N=9-
12/dose/exposure period) via osmotic pumps prenatally (GD 9 – GD 23) and pre- and perinatally (GD 
9 – PND 21). Cages, water bottles, and bedding tested negligible for estrogenicity by the E-SCREEN 
assay. Food was supplied ad libitum. Estrogenicity of the feed (Harlan Teklad 2018 Rodent Diet, 
Harlan Teklad, Indianapolis, IN) was measured at 8–15 fmol of estrogen equivalents per gram. 
Mammary glands from BPA-exposed offspring were examined at four time points for preneoplastic 
and neoplastic lesions. To assess circulating BPA levels, pregnant rats were exposed to vehicle or 250 
μg BPA/kg bw per day during gestation only or during gestation/lactation and sera were analyzed from 
dams, fetuses, and nursing pups for total and unconjugated BPA. Serum was either treated with β-
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glucuronidase/sulfatase to estimate the concentration of total BPA (conjugated plus unconjugated), or 
processed without enzymatic treatment to estimate the concentration of unconjugated BPA. Serum 
concentrations were quntified using on-line solid phase extraction coupled to high performance liquid 
chromatography–isotope dilution tandem mass spectrometry (LOD: 0.3 ng/mL; LOQ: 0.9 mg/mL).  
The authors reported that total and unconjugated BPA were detected in sera from 100% of dams and 
fetuses and 33% of pups exposed to 250 μg BPA/kg bw per day. Mammary gland tissue was collected 
at PND 50 (N=5-6), PND 90, PND 140 and PND 200 (N=27-33). The incidences of ductal 
hyperplasias were assessed as described by Murray et al (2007). TEB, intraductal hyperplasias, 
atypical ductal hyperplasias and ductular CIS were identified. At PND50 some animals of the group 
exposed during gestation (except in the 25 BPA group) showed atypical ductal hyperplasia. Incidences 
of atypical ductal hyperplasias (ADH) were highest at the lowest BPA dose (0.25 μg/kg bw per day) 
after gestational exposure (no dose-response relationship), whereas the 0.25 BPA group exposed 
during gestation and lactation did not develop such lesion. Incidences of proliferative lesions and 
tumours did not increase statistically significantly in the treated offspring (n=23-35) at PND 90, 140 or 
200 following gestational or gestational + lactational exposure. However, single adenocarcinoma were 
observed in most groups, except in controls. One adenocarcinoma was already observed at PND 90 in 
the 2.5 BPA group.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study: 
Strengths: 
- Number of animals per group at PND 90, 140 and 200 
- Number of doses (4) 
- Phytoestrogen-content of the diet measured and low 
- Cages, water bottles, and bedding tested and negligible for estrogenicity  
- BPA exposure determination by LC-MS-MS (dams, fetuses and pups) 
Weaknesses: 
- Low number of rats/group at PND 50 when proliferation was to be assessed  
- No quantitative proliferation measurement (only hystopathological examination) 
 
The CEF Panel noted that a low number of rats showing ductal hyperplasia (1-3) and a very low 
number (1/5) demonstrated a ductular CIS at PND 50 or carcinomas at PND 90, 140 or 200. 
Serum levels of unconjugated BPA in dams of the 250 BPA group were 1.25 ng/ml. This value is 
about 5 fold higher than serum levels after oral administration of BPA, i.e. 0.1 ng/ml in rats treated 
with 100 μg/kg bw (Doerge et al., 2010a; 2011b) and more than 2 fold higher than in mice and 
monkeys treated with 400 μg/kg bw (Taylor et al., 2011). Mean serum levels were 0.6 ng/ml in fetuses 
and < LOD in pups after additional lactational exposure in the present paper. The authors consider the 
levels of free BPA in the dams comparable to those in humans. However, Teeguarden et al. (2013) 
calculated the free BPA levels in human serum to be in the (sub)picomolar range. Thus there is a 
discrepancy of at least a factor of 1000. 
This paper is included in the WoE table because of its relevance to one or more questions addressed 
there.  
Ayyanan A, Laribi O, Schuepbach-Mallepell S, Schrick C, Gutierrez, M Tanos, T Lefebvre, G 
Rougemont, J Yalcin-Ozuysal O and Brisken C, 2011. Perinatal exposure to bisphenol A 
increases adult mammary gland progesterone response and cell number. Molecular 
Endocrinology 25, 1915-1923. 
 
In this study designed to investigate whether exposure to low doses of BPA during pregnancy and 
lactation has the potential to alter mammary gland hormone response of female offspring later on in 
life, C57Bl/6 mice (breeding pairs) were administered BPA (prediluted in dimethylsulphoxide) in their 
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drinking water at doses ranging from 2.5 µg/L to 5000 µg/L. Based on selected measurement of 
drinking water intake this range corresponded to doses of 0.6, 3, 6, 12, 120, 600 and 1200 µg/kg/day. 
Diethylstilboestrol at doses of 0.12 or 1.2 µg/kg/day was used as a positive control (mode of dosing 
not given). The resultant female offspring (exposed in utero and postnatally through milk) were 
transferred to a BPA- and DES-free environment at weaning (day 24). For each BPA concentration, 
four different mothers were used to achieve a final n=18-20 female offspring for evaluation during the 
study. C57BL6/J mice were bred in a BPA-free environment using polysulfone cages and bottles, 
autoclaved water, and no paper towels. 
Two inguinal mammary glands were taken from female offspring at post-natal day 30, one for 
microscopical analysis of a whole mount preparation, the other for measurement of mRNA expression 
of progesterone receptor, amphiregulin and SLP1. One offspring from each of four mothers was 
examined in each dose group, in triplicate. Total mammary epithelial cell numbers were measured 
using a cell counter from pooled mammary tissue from mice at 3 months.  
The authors reported that intakes of 3, 120 or 1200_µg BPA/kg bw per day BPA resulted in dose-
dependent increases in PR and SLPI mRNA expression, statistically significant and comparable in 
magnitude to DES (0.12 µg/kg bw per day) only in the offspring of mothers exposed to 1200 µg 
BPA/kg bw per day. Neither BPA nor DES affected mRNA expression, while amphiregulin mRNA 
expression showed a non-significant trend toward a nonmonotonic response. A significant increase in 
terminal end buds (TEB) was measured in the 3 µg BPA/kg bw per day offspring only, with some 
evidence of a non-monotonic dose-response over all BPA groups. Total mammary cell numbers were 
significantly increased (approximately 50% higher) compared with controls in the offspring of 
mothers receiving both low doses of BPA (6 or 12 µg/kg bw per day) and high doses (600 or/1200 
µg/kg bw per day). Mammary glands from the offspring of DES-exposed females (1.2 µg/kg bw per 
day) showed a 70% increase in cell number. Finally PR-positive cells within the luminal epithelial 
population were significantly increased in the offspring of mothers receiving 6 µg BPA/kg bw per day, 
as well as mRNA expression of Wnt-4, but not RANKL.  
Overall, in this complex experiment these authors showed small statistically significant increases in 
the mammary terminal end buds in BPA-treated mice, together with increases in mammary cell 
numbers and the mRNA encoding mediators implicated in control of cell proliferation. The changes 
were reported to be analogous to those seen in the DES-treated mice. 
The authors concluded that perinatal exposure to low doses of BPA can have long-term, measurable 
biological effects on the mouse mammary gland of the offspring, which could facilitate the 
development of breast neoplasia in later life. The authors state that specific groups of mice, followed 
up for over a year did not develop palpable mammary tumours, indicating that BPA exposure is not 
sufficient to cause mammary carcinomas, but no further details are provided in the publication.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study: 
Strengths: 
- Large sample size 
- Adequate positive control included (DES) 
- Environment BPA free from weaning onwards 
Weaknesses  
- Insufficient data reporting (e.g. DES administration) 
- Study design not appropriate to the scope (low number of animals tested for histological 
examination) 
- Insufficient study reporting (mode of dosing for diethylstilboestrol not given) 
- Individual drinking water consumption not measured (doses calculated on average body 
weight and water consumption) 
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The CEF Panel noted that offspring were killed at ages when reproductive cycling occurs and this was 
not assessed or controlled. Cycling can be variable dependant on a number of factors including 
housing conditions, whether housed singly or in groups and this was also not detailed in the methods. 
This could significantly influence outcomes. Microscopic analysis was performed on a very limited 
number of glands in relatively few animals. Whilst the neonatal mouse model may show 
developmental alterations to mammary gland growth with oestrogenic agents (Bern et al., 1987), the 
relevance of the findings for the assessment of mammary cancer risk in humans is unclear. The actual 
exposure to BPA was not measured but only estimated from the average water intake and average 
body weight, and the mode of administration of diethylstilboestrol not given so it is difficult to 
compare BPA treated groups with those of the positive control.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Betancourt AM, Eltoum IA, Desmond RA, Russo J and Lamartiniere CA, 2010. In utero 
Exposure to Bisphenol A Shifts the Window of Susceptibility for Mammary Carcinogenesis in 
the Rat. Environmental Health Perspectives, 118, 1614-1619. 
 
Betancourt et al. (2010) also used the model of DMBA-induced mammary carcinogenesis, 
administering BPA in utero by gavaging pregnant Sprague-Dawley rats with 0, 25 or 250 μg BPA/ kg 
b.w./day (GD 10-21). Female offspring of BPA treated dams did not differ from controls with respect 
to body weight development, vaginal opening and on PND 50, serum concentration of 17ß-oestradiol, 
progesterone as well as estrus cyclicity. On PND 50, expression of oestrogen receptor (ER)-α, PR-A 
and bcl-2 was reduced. On PND 100, ER-α and bcl-2 were upregulated, PR-A was at similar levels to 
controls. As to SRC-1,-2 and -3, only SRC-3 was increased on PND 50, but all members of the SRC-
family were up-regulated on PND 100. Cell proliferation (n=6/group) and apoptosis (n=5/group) were 
measured in the mammary gland of the offspring of controls and the high BPA-dose group on 
PND100 (before DMBA treatment). Upon prenatal BPA exposure, proliferation of epithelial cells was 
increased but apoptosis was not affected. Consistent with increased cell proliferation expression of the 
following proteins was increased in the high dose group at PND100: EGFR, phosphorylated -IGF-1R, 
phosphorylated –c-Raf, phosphorylated pERKs 1/2, phosphorylated ErbB2, phosphorylated Akt. For 
tumourigenesis studies, one female offspring per litter was given a single gavage of 30 mg DMBA/kg 
b.w. on PND 50 (31, 29 and 33 rats in the control, low- and high-dose groups, respectively) or on PND 
100 (30 and 28 rats in the control, and high-dose groups, respectively). Offspring were palpated twice 
weekly to monitor tumour development and underwent necropsy at 12 month of age or when tumour 
burden exceeded 10% of body weight. DMBA administration at PND50 of rats which received 
prenatal BPA-treatment (both 25 and 250 μg/kg bw) did not result in an increase in the number of 
tumours per animal (2.94 ± 0.48, 2.38 ± 0.42, and 2.88 ± 0.4 for control, low and high BPA groups, 
respectively). The tumour latency was not reduced (109 ± 11, 116 ± 14, 106 ± 14 days for control, low 
and high BPA groups, respectively). DMBA administration at PND 100 caused a significant increase 
in tumour (benign and malignant combined) incidence (53 to 83%) along with a non-significant 
increase in tumour multiplicity (1.96 ± 0.53 to 2.53 ± 0.55). The latency period was reduced from 267 
to 189.5 days. Finally, a significant greater proportion of DMBA-induced tumours classified as grade 
II (Bloom-Richardson system for human breast tumours; control: 3 of 13 tumours (23%); BPA high 
dose group: 9 of 20 tumours (45%)) was observed. The authors concluded that the high BPA dose 
(250 μg BPA/kg b.w.) enhanced cell proliferation in mammary glands of the offspring, associated with 
an increased cancer susceptibility and shift of the window for susceptibility for DMBA-induced 
tumourigenesis in rat mammary gland from PND 50 to PND 100. Cell proliferation was increased in 
the epithelial cells of mammary tubular ducts of 100 day old rats prenatally exposed to 250 μg BPA 
(not 25 μg BPA) compared to controls (p<0.05). Apoptosis in these rats was not altered. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
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Strengths 
- Large sample size (not applicable to proliferation) 
- Oral administration by gavage 
- Use of non-PC cages and of non plastic bottles 
Weaknesses 
- Low sample size for proliferation assessement 
- Only one dose-level tested for cell proliferation 
- Insufficient study reporting (e.g timing of necrospy) (not relevant for proliferation) 
- Animal diet and phytoestrogen content not reported 
 
The study revealed similar shortcomings in design and reporting as the study by Jenkins et al. (2009), 
i.e. measurement uncertainties involved in tumour data collection by palpation, time of necropsy of 
individual animals not exactly reported but given as “at 12 months of age or when tumour burden 
exceeded 10% of body weight”. The CEF Panel further noted that only a single tumour from each 
animal was randomly selected for histopathological analysis and concluded that thus not all tumours 
were histologically characterised and graded according to the Bloom Richardson grading system, 
which is rather unusual. The CEF Panel concluded that these data can be used as supporting evidence 
of the induction of proliferation by BPA.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Durando M, Kass L, Piva J, Sonnenschein C, Soto AM, Luque EH and Munoz-de-Toro M, 2007. 
Prenatal bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar 
rats. Environmental Health Perspectives, 115, 80-86. 
 
Pregnant Wistar rats were exposed to 25 μg BPA/kg bw per day or to DMSO (vehicle control) from 
GD 8 (corresponding to the beginning of organogenesis in the fetus) by s.c. implantation of Alza 
Osmotic pumps. Both BPA and DMSO were released continuously for 14 days (GD 8 up to GD 23). 
Offspring were delivered on GD 23 and weaned from their mothers on PND 21. According to the 
design of the study, exposure to BPA was only prenatally and not during lactation. Animals were 
sacrificed at PND 30 and PND 50 and at adulthood (PND 110 and PND 180). In a separate 
experiment, female offspring from the DMSO group received at PND50 a single i.p. dose of either 25 
mg N-nitroso-N-methylurea (NMU) or 50 mg/kg bw NMU, and female offspring from the 25BPA 
group received 25 mg NMU. This resulted in 3 groups: DMSO + 25 mg/kg MNU (n=16); DMSO + 50 
mg/kg MNU (n=10) and 25 BPA + 25 mg/kg MNU (n=21). Cell proliferation was determined by i.p. 
injection of all rats with BrdU (6 mg/100 g bw). Apoptosis was determined by TUNEL technique. At 
PND 50, but not at PND 30, cell proliferation was increased and apoptosis decreased in mammary 
gland epithelium. At PND 110 and 180, a significant increase in hyperplastic ducts in rats in utero 
exposed to BPA was observed in comparison to DMSO-treated controls. Tumour incidence after 
NMU administration at PND180 was 0% for the DMSO 25 MNU group and 83% for the DMSO 50 
MNU group. Females treated in utero with DMSO and at PND50 with 25 mg/kg MNU showed no 
changes in number of hyperplastic ducts at PND 110, whereas at PND 180 a significant increase was 
found. Furthermore, in rats in utero treated with BPA, the 25NMU dose at PND 50 caused a 
significant increase in hyperplastic ducts at PND180, but not at PND 110. Moreover 2/15 of the BPA 
NMU group developed cribiform CIS. Rats treated with DMSO and 50 mg/kg NMU developed 
invasive adenocarcinomas in 7/10 animals. The authors concluded that prenatal exposure to BPA 
increases the sensitivity to endogenous estrogen. At PND 180, BPA exposed rats treated with 25 mg 
NMU at PND 50 exhibited a significantly higher number of ductal hyperplasias compared to animals 
not exposed to BPA and treated with NMU. Based on this observation the authors suggested that in 
utero BPA exposure increased the susceptibility of the mammary gland to develop preneoplastic and 
neoplastic lesions as a response to NMU exposure. The authors further concluded that the results 
obtained with this widely accepted surrogate model of human breast carcinogenesis, strengthen the 
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arguments linking the increased incidence of endocrine-dependent human tumours, to in utero 
exposure to minimal doses of xenoestrogens such as BPA.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Use of non-PC cages and of non plastic bottles 
Weaknesses: 
- Single dose level study 
- Animal diet and phytoestrogen content not measured 
- Low No of animals tested for histological examination  
 
The CEF Panel noted that that only one dose of BPA is used and, moreover, the exact dose to which 
the offspring was exposed during gestation was not determined. The CEF Panel also noted that it is 
unclear whether the animal model used is relevant for the human situation, taking the differences in 
toxicokinetics of BPA in experimental animals and humans into consideration. (see also the serum 
levels in BPA exposed monkeys in the study of Tharp). The CEF Panel agreed with the conclusion of 
the authors that rats which are in utero exposed to BPA exhibited an increase in cell proliferation and a 
decrease in apoptosis in mammary gland epithelium at PND 50, which in the present study lead to an 
increased number of hyperplastic ducts at PND110 and PND180. Therefore the CEF Panel concluded 
that the results of this study can be used as supportive evidence of the induction of proliferation by 
BPA. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Jenkins S, Raghuraman N, Eltoum I, Carpenter M, Russo J and Lamartiniere CA 2009. Oral 
exposure to bisphenol A increases dimethylbenzanthracene-induced mammary cancer in 
rats. Environmental Health Perspectives, 117, 910-915. 
 
In a study examining the effect of lactational exposure to BPA on dimethylbenzanthracene (DMBA)-
induced mammary cancer in female offspring, Jenkins et al. (2009) gavaged nursing Sprague-Dawley 
rats with BPA (0, 25 or 250 μg/kg b.w./day) from lactation day 2 to 20. All female offspring (5-8 per 
litter) and enough males were retained to yield 10 offspring/litter. Cell proliferation and apoptosis 
were measured in the mammary gland of the female offspring (n=5/group) at 21 days of age (at end of 
BPA treatment) and at 50 days of age (before DMBA exposure). Increased cell proliferation and 
reduced apoptosis in the mammary gland of female offspring were observed in the high dose group at 
50 days of age but not at 21 days of age. Consistent with increased proliferation and reduced 
apoptosis, expression of the following proteins was increased in the high dose group: Akt and 
phosphorylated Akt (pAkt; proteins linked with apoptosis), progesterone receptor (PR)-A, steroid 
receptor activator (SRC) 1 to 3, and erbB3. The expression of the oestrogen receptor (ER)-α was 
slightly reduced. At 50 days of age, one female offspring from each litter of each treatment group was 
given a single dose of DMBA (30 mg/kg b.w.) by gavage which was expected to result in a low 
number of mammary adenocarcinomas. In total, 32, 34, and 24 female offspring in the control (no 
BPA during lactation), low and high BPA group, respectively, received DMBA. Offspring were 
palpated twice weekly to monitor tumour development and underwent necropsy at 12 month of age or 
when tumour burden exceeded 10% of body weight. BPA-treatment increased the number of tumours 
(not further specified between adenoma and carcinoma) per animal (2.84 ± 0.31, 3.82 ± 0.43, and 5.00 
± 0.88 for control, low and high BPA groups, respectively) with the effect at the high dose group 
being statistically significant. The authors reported that there was “no change in the carcinomas 
score”. Tumour latency was also reduced (65, 53, 56.5 days for control, low and high BPA groups, 
respectively) with statistically significance at the high dose group.  
Comments from the CEF Panel:  
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The CEF Panel noted the following: (a) the toxicokinetic studies showed that only minimal fraction of 
BPA administered to dams is transferred to breast milk. Therefore, the exposure of the pups to BPA 
under this condition is anticipated to be very low, however, information on internal BPA levels is 
lacking. (b) The score of carcinoma formation which would indicate tumour progession is not 
changed. (c) When considering the results of the study on tumour latency, the measurement 
uncertainties involved in the data collection (palpation) should be taken into account. In conclusion, 
the shortcomings in the study design, and the absence of a significant dose: response, the uncertainty 
regarding the exposure of the offspring to BPA, and the limitations in reporting preclude these results 
to be used for risk assessment of BPA and the re-evaluation of the existing TDI. However, the CEF 
Panel noted that a dose-related response of BPA on cell proliferation and apoptosis in the mammary 
gland was reported in the study and this deserves further considerations. Consistent finding: cell 
proliferation was increased and apoptosis decreased by BPA at PND 50 but not after PND 21 days. 
The CEF Panel concluded that the present study cannot be used for the assessment of cancer risk but 
as supporting evidence of the induction of proliferation by BPA following lactational as well as in 
utero exposure. 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Oral administration by gavage 
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic bottles 
Weaknesses: 
- Only one dose level tested for proliferation measurement 
- Low No of animals tested for histological examination 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Jenkins S, Wang J, Eltoum I, Desmond R and Lamartiniere CA, 2011. Chronic oral exposure to 
bisphenol A results in a nonmonotonic dose-response in mammary carcinogenesis and 
metastasis in MMTV-erbB2 mice. Environmental Health Perspectives, 119, 1604-1609.,  
 
The effect of chronic, oral exposure to BPA during adulthood was investigated on the development of 
mammary tumours in a transgenic mouse model which spontaneously develops tumours through over-
expression of wild type erbB2 (MMTV-erbB2). Female MMTV-erbB2 mice (n= 36-76, control n=94) 
were administered BPA at levels of 0, 2.5, 25, 250, 2500 µg BPA/L in drinking water, from PND 56 
until PND 112 (for mechanism of action) or PND 252 (for tumorigenesis). The authors roughly 
estimated that the intakes of BPA were 0.5, 5, 50 or 500 µg/kg bw per day, in the absence of actual 
consumption data, based on their pilot data that showed that 20 g mice drink 4 ml of water per day. 
Drinking water of all groups, including the control group, contained 0.05% by volume of the vehicle, 
ethanol. A positive (oestrogenic) control was not included. Animals were fed AIN-76A diet 
(phytoestrogen-free; Dyets, Inc., Bethlehem, PA), housed in polypropylene cages, and provided glass 
water bottles. 
To assess tumour development, mice were killed at 252 days of age or before when tumours exceeded 
10% of body weight. The tumour endpoints used in the study were number of tumours/animal and 
tumour volume/animal. Tumours were assessed histologically and lung metastases were also counted 
in a blinded manner. The authors assessed tumour volume by measurement of tumour dimensions. 
Selected mice were sacrificed at 112 days of age to measure mammary cell proliferation, apoptosis 
and protein expression (n = 5-17 mice/treatment) of a number of growth factor-related proteins in 
mammary epithelial cells.  
The authors reported a statistically significant increase in numbers of tumours/mouse (multiplicity) 
and also in the percentage of mice with lung metastases at estimated intakes of 0.5 or 5 µg BPA/kg bw 
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per day. In addition latency time to first tumour was also reduced at both dose levels and tumour 
volume was significantly increased in mice receiving 5 µg BPA/kg bw per day. No such effects were 
reported at the higher dose levels. The evaluation of histopathology showed no difference in tumour 
differentiation. Cell proliferation was stimulated at intakes of 5 µg BPA/kg bw per day and above, 
while a significant increase in apoptosis was reported at the highest dose level of 500 µg/kg bw per 
day only. The ratio of cell proliferation index to apoptotic index was significantly increased at the 5 µg 
BPA/kg bw per day dose level only. At the molecular level, doses of 5 μg BPA but not 500 μg 
BPA/kg bw per day were reported to increase phosphorylation of erbB2, erbB3, insulin-like growth 
factor 1 receptor, and Akt in the mammary gland. The authors concluded that oral administration of 
BPA accelerated mammary cancer development and progression in the mouse in a non-monotonic 
fashion and that the ratio of cell proliferation and apoptosis indices and alterations in protein 
expression were predictive of the potential of varying doses of BPA to alter tumorigenesis in the 
experimental model. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study: 
Strengths: 
- Adequate number animals/group 
- Number of doses (4) 
- Slides were blind-evaluated  
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic bottles 
Weaknesses: 
- Low number of animals for some dose groups 
- Exposure via drinking water: exact doses received are not therefore known  
 
The CEF Panel additionally noted several uncertainties, outlined as follows. The transgenic model is 
reported to develop mammary tumours in 50% of animals at 205 days of age and over 70% of all 
tumour bearing mice develop lung metastases if they survive to 240 days of age (data from Jackson 
Laboratories). The authors did not include a positive control group, and used non-standard 
measurements of tumour endpoints not usually used in animal cancer studies. In a model with such 
rapidly growing tumours tumour volume, tumour numbers and metastases are highly variable and 
difficult to measure because individual tumours rapidly become confluent. Measurement of volume of 
tumours embedded within the mammary fat pad is also subject to significant error. The exact number 
of animals that developed tumours and those that remained tumour free is not given and an analysis 
that took into account the different times at which the animals were killed was not conducted. Thus the 
small differences seen may simply be the result of usual variability in this model, albeit that the 
authors reported a non-monotonic dose-response for tumour induction, particularly as they gave no 
indication of how they randomised entry of mice into the study, crucial when animals are obtained 
from small colonies. According to the authors, the evaluation of histopathology showed no difference 
in tumour grade (stage of differentiation). No mention is made of hyperplasia and pre-neoplastic 
(dysplastic) mammary changes that are important in any histopathological evaluation of neoplasia. 
Interestingly the results of cell proliferation and apoptosis assays showed a simple dose-response with 
higher doses showing greater responses particularly of apoptosis, quite different from the reported 
tumour data. These increased responses were not however statistically significant, other than the 
apoptotic response at the highest dose, while the increased proliferative responses showed a plateau. 
The relevance of these findings for mammary cancer development is uncertain.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Jones LP, Sampson A, Hang HJ, Kim HJ, Yi YW, Babus JK, Wang A and Bae I, 2010: Loss of 
BRCA1 leads to an increased sensitivity to bisphenol A. Toxicology Letters, 199(3), 261-268. 
- Insufficient data reporting (e.g. data on tumour incidence and histopathology incomplete)  
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This study used a mouse model of breast cancer susceptibility gene 1 (BRCA1) related mammary 
cancer as well as MCF7 cells with the BRCA1 gene knocked down by interfering RNA. The aim was 
to study whether loss of BRCA1 function in mammary epithelium would enhance BPA-mediated cell 
proliferation and whether the effects were mediated through the ERα signalling pathway. Three month 
old Brca1 knockout mice maintained on a C57Bl/6 genetic background were used along with non-
transgenic C57Bl/6 controls. Mice were implanted with osmotic pumps to deliver either 50% dimethyl 
sulphoxide vehicle or 250 ng BPA/kg/day dissolved in vehicle for four weeks at a flow rate of 0.22 
µL/h. There were 13 mice/group, although the number of wild type mice was not clarified. Mammary 
glands were processed for whole mount analysis and histology and immunohistochemistry for cell 
proliferation (PCNA). The proliferative index was determined on one section from each mouse 
counting a total of 1000 cells. Seven mice/group were used for this assessment. The authors also 
treated MCF7cells with loss of BRCA1 function with 1 µM of BPA for 0, 1, 2, 3 days or various 
concentrations (0, 10, 100, or 1000 nM) of BPA for 72 h. Cell proliferation with or without tamoxifen 
or ICI182780 and ERα target gene expression was studied in these cells.The results suggested that 
exposure to BPA in vitro enhanced proliferation in cells with loss of BRCA1 in a dose-and time-
dependent manner more that in cells without BRCA1 loss and this was linked to ERα signalling. 
Additionally, BPA exposure in vivo at 250 ng/kg increased mammary epithelial cell proliferation and 
hyperplasia in adult Brca1 knockout mouse mammary glands more than in wild type mice. 
Comments from the CEF Panel:  
The relevance to cancer development of these differences in proliferation between BPA and vehicle 
treated cells and mammary glands in these mice are unclear. Whilst BPA led to increased growth 
response in MCF7 cells with loss of BRCA1 and mammary epithelium in mice with a deficiency in 
Brca1, both ordinary MCF7 cells and wild type mice were also affected. Whilst mechanistically 
interesting, the data do not add significantly to the assessment of the carcinogenic potential of BPA 
based on the NTP two year studies. 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Use of phytoestrogen-free diet and of non plastic bottles 
Weaknesses: 
- Low number of animal/group for proliferation 
- Single dose level study 
- Type of cages not reported 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Kass L, Altamirano GA, Bosquiazzo VL, Luque EH, and Munoz-de-Toro M, 2012: Perinatal 
exposure to xenoestrogens impairs mammary gland differentiation and modifies milk 
composition in Wistar rats. Reproductive Toxicology, 33, 390-400 
 
This study was aimed at evaluating the effects of perinatal (gestation + lactation) exposure to BPA or 
DES on F1 mammary gland differentiation. Pregnant Wistar rats were given BPA or DES in drinking 
water from gestational day 9 through to weaning. The concentration of BPA in drinking water was 2.5 
µg/L or 250 µg/L or 25 µg DES/L, corresponding to theoretical doses of 0.5 µg BPA/kg bw per day, 
50 µg BPA/kg bw per day or 5 µg diethylstilboestrol/kg bw per day, respectively. The control group 
was exposed to a vehicle solution (0.001% ethanol in water). 10-12 dams/group were used and litters 
of eight F1 pups (four males and four females) were left with F0 lactating mothers until weaning on 
LD21, when the female offspring (exposed in utero and postnatally through milk) were transferred to a 
BPA- and DES-free environment. Randomly chosen 90-day-old F1 females from each BPA group 
were then bred to non-BPA-exposed males, and after pregnancy confirmation, one F1 female per litter 
from each treatment group was assigned to a particular experimental time point group (GD18, GD21 
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and lactation day 14). Reproductive performance parameters of the F1 dams was assessed, mammary 
gland samples were taken on GD 18 and GD 21, and during lactation, milk yield and milk protein 
composition were assessed. Blood was also taken at these time intervals for hormone analysis. The 
mammary glands of mated offspring were investigated on gestational days 18 or 21. Conventional 
histology and immunohistochemistry for levels of progesterone receptor (PR), oestrogen receptor α 
and β and phosphorylated Stat5a/b (pStat5a/b) were used as well as assessment of lactation, milk 
yield, milk protein composition. The authors reported a decrease in α-lactalbumin and β-casein levels 
in milk, accompanied by reduced prolactin receptor and Stat5a/b expression on gestational day 18. On 
gestational day 21, slightly delayed histological mammary gland differentiation was reported in both 
BPA and diethylstilboestrol-treated groups compared with controls. No effect of BPA was observed 
on any of the reproductive parameters investigated in the female offspring, including numbers of 
corpora lutea, implantation sites and resorption sites. 
Comments from the CEF Panel: 
The CEF Panel concluded that this study displays many potential experimental variables that render 
the result difficult to interpret. The actual doses of BPA are uncertain for there was no monitoring of 
water intake or serum BPA levels. A subjective method was used to histologically examine single 
mammary glands from each animal. This is very limited as mammary glands in rodents are very 
dispersed in the abdominal and thoracic fat and show a variable distribution. The illustrations provided 
are unconvincing of a significant effect because all appear to show histology that is within the limits to 
be expected in normal lactating rats. Moreover, the relevance of any putative changes in lactating 
glands for cancer assessment is unclear. In the view of the CEF Panel, the data do not in themselves 
lend support to an effect of treatment of mammary gland differentiation and any implications for 
assessment of the carcinogenic potential of BPA.  
Markey CM, Luque EH, de Toro MM, Sonnenschein C and Soto AM, 2001. In utero exposure to 
bisphenol a alters the development and tissue organization of the mouse mammary gland. 
Biology of Reproduction, 65, 1215-1223. 
 
Munoz-de-Toro M, Markey CM, Wadia PR, Luque EH, Rubin BS, Sonnenschein C and Soto 
AM, 2005. Perinatal exposure to bisphenol-A alters peripubertal mammary gland development 
in mice. Endocrinology, 146, 4138-4147. 
 
As reported in EFSA, 2006, in a series of publications from Markey, Munoz-de-Toro et al. the effects 
of perinatal exposure to BPA (25 and 250 ng BPA/kg bw per day, but initially reported as 25 and 250 
ug/kg bw per day ), administered sc by Alzet mini-pumps from day 9 of pregnancy for 14 days 
through postnatal day 4, n = 6 -10 per group) on the peripubertal development of the mammary gland, 
the genital tract and on brain sexual differentiation was investigated in CD-1 mice  
Markey et al. (2001) reported that mammary glands of BPA-exposed mice compared with controls 
showed differences in the rate of ductal migration into the stroma at 1 month of age and a significant 
increase in the percentage of ducts, terminal ducts, terminal end buds, and alveolar buds at 6 mo of 
age. The percentage of cells that incorporated BrdU was significantly decreased within the epithelium 
at 10 days of age and increased within the stroma at 6 months of age. The response was very similar at 
25 and 250 µg/kg bw per day, with 25 µg/kg bw per day showing a slightly greater response.  
Strenghts: 
- Cages and bedding tested negative for estrogenicity 
- Use of use of phytoestrogen-free diet  
Weaknesses: 
- Low number of animals/group for proliferation 
In Munoz-de-Toro et al. (2005), it was reported that BPA exposure enhanced the mammary gland 
sensitivity to oestradiol in ovariectomized CD-1 mice. At 30 d of age in intact mice, there was a 
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significant increase in the number of TEBs relative to the area occupied by the ductal tree in the 
animals exposed to 250 ng BPA/kg bw·d, compared with that in the vehicle-treated controls (P = 
0.008), whereas the increase in the 25 ng BPA/kg bw·d approached significance (P = 0.054). 
Similarly, when these data were expressed as TEB area relative to ductal tree area, a significant 
increase was observed at 250 ng BPA/kg bw·d with respect to the vehicle-treated control (P < 0.05). a 
significant decline in the number of apoptotic cells in TEBs of both treated groups (25 ng BPA/kg 
bw·d, P < 0.001; 250 ng BPA/kg bw·d, P < 0.05) was seen relative to the controls.There was a 
positive correlation between ductal length and the age at first proestrus. The age at first proestrus was 
reduced by BPA. A significant increase of progesterone receptor-positive ductal epithelial cells 
localised in clusters was also reported in BPA-treated animals. Lateral branching was significantly 
enhanced at 4 months of age in mice exposed to 25 ng BPA/kg bw per day. A decreased wet weight of 
the vagina, small increases in the incorporation of bromodeoxyuridine into the DNA of endometrial 
gland epithelial cells, and increased expression of oestrogen receptor-alpha (ERalpha) and 
progesterone receptor in the luminal epithelium of the endometrium and subepithelial stroma were 
reported in BPA-exposed animals. Changes were in the range of 20 to 40 % of control values, but 
positive controls and controls without Alzet pumps were not included and the selection of animals for 
assessment was based on ooestrous cyclicity. Apparently, results on other parameters determined in 
this animal study were reported separately.  
 
Comments from the AFC Panel (EFSA, 2006): 
The AFC Panel noted absence of dose-response for many changes reported or the evaluation of 
samples for only one dose level. 
Strenghts: 
- Food tested negative for estrogenicity 
- Cages and bedding tested negative for estrogenicity 
Weaknesses:  
- Low/unclear number of animals for the dose-groups 
These studies are included in the WoE table because of their relevance to one or more review 
questions addressed there. 
Moral R, Wang R, Russo IH, Lamartiniere CA, Pereira J and Russo J, 2008. Effect of prenatal 
exposure to the endocrine disruptor bisphenol A on mammary gland morphology and gene 
expression signature. Journal of Endocrinology 196, 101–112. 
  
In this study pregnant Sprague-Dawley rats were gavaged with 25 µg BPA/kg bw or 250 µg BPA/kg 
bw on days 10-21 post conception. Controls were given sesame oil vehicle only and there were 10 
animals per group. The 4th pair of mammary glands from the offspring (8-10/group) was assessed for 
morphological changes in whole mount preparations and for cell proliferation in sections at days 21, 
35, 50 and 100. Frozen mammary tissue was pooled from controls and each treatment group for gene 
expression analysis using microarrays and real-time (RT)-PCR. 
High-dose BPA exposure was reported to induce small architectural modifications in the mammary 
glands, mainly in the number of undifferentiated epithelial structures but the proliferative index (as 
determined by BrdU) was not affected. Low and high doses of BPA were reported to alter the gene 
expression profile of mammary tissue but in a somewhat inconsistent manner: low dose had the 
highest effect by 50 days, while high dose had the most influence on gene expression by 100 days. At 
the low dose, up-regulated genes were related to the immune system and at the high dose, genes 
related to differentiation were upregulated. 
 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
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Strengths: 
- Large sample size 
- Oral administration by gavage 
- Phytoestrogen-free diet 
Weaknesses: 
- Types of cages and drinking bottles not reported 
- Time-points for BrdU is not indicated 
 
As with other studies of this type it is difficult to assess the relevance of these observations. The 
differences reported were small, and there was neither control of dosing nor evidence of actual 
exposure achieved. The authors did not report any precautions to avoid BPA exposure from containers 
or other environmental sources. However, the study results were used for the evaluation of 
proliferation induced by BPA. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Murray TJ, Maffini MV, Ucci AA, Sonnenschein C and Soto AM, 2007. Induction of 
mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A 
exposure. Reproductive Toxicology 23, 383–390. 
 
As reported in the EU RAR (2008), “Murray et al. (2007) examined the effect of prenatal BPA 
exposure on in situ induction of mammary tumours in rats. From GD 9 (GD 1 = day of vaginal sperm) 
through PND 1 (PND 0 = day of birth) Wistar-Furth rat dams received subcutaneous osmotic pumps 
of 0, 0.0025, 0.025, 0.250, or 1 mg/kg bw per day BPA. Number of dams treated was not reported. 
Based on a limited amount of information provided on the number of offspring examined, it appears 
that ≤ 6 dams/group were treated. Pup viability was assessed on PND 1. On PND 2 pups were sexed 
and litters were culled to 8 pups. Anogenital distance was measured on PND 4. Litters were weighed 
during the lactation period. Female offspring were monitored for body weight and vaginal opening in 
the post-weaning period. Female offspring were killed on PND 50 or PND 95. Mammary glands were 
collected and whole-mounted or sectioned for histopathological examination. Morphometric analyses 
were conducted to examine possible presence of preneoplastic lesions. Mammary glands were 
examined for ER-α and Ki-67 protein by an immunohistochemistry technique. One female/litter was 
included in the histological examinations. Apparently, ≤6 offspring/group were examined 
histopathologically. The number of offspring examined for the other endpoints was not reported. It 
was not clear if dams or offspring were considered the statistical unit. BPA exposure did not affect 
offspring viability, sex ratio, age at vaginal opening, or female anogenital distance. Anogenital 
distance was reduced on PND 4 in males from the 0.250 mg/kg bw per day group. Cribriform 
structures classified as carcinomas-in-situ were observed in the 0.25 and 1 mg/kg bw per day groups. 
The incidence of these structures in the controls and lower dose groups were not reported”.  
Comments from the Panel (current CEF Panel, EFSA, 2014): 
The CEF Panel noted that although the study authors classified the cribriform structures as carcinoma 
in situ because of their hallmarks, it is difficult to establish whether or not these histopathological 
findings are clear neoplastic lesions of the mammary gland. The study authors concluded that fetal 
BPA exposure at dose levels of 0.250 and 1 mg/kg bw per day in rats is able to induce development of 
preneoplastic and neoplastic mammary lesions. The CEF Panel does not agree with this conclusion. 
Putative preneoplastic lesions have been observed but no neoplastic lesions. Moreover, due to the 
small sample size, lack of clarity on the statistical analysis, absence of a dose-response relationship 
and uncertainty about the incidence of the cribriform-like lesions in the controls it is difficult to 
establish whether the effects reported were due to chance or were real treatment-related effects. In 
addition, because of the uncertainty about the significance of the cribriform structures, it is unclear 
whether real neoplasia actually occurred. The incidence of hyperplastic ducts was increased in all dose 
groups at PND 50 (at PND 95 the incidence of hyperplastic ducts was overall lower than at PND 50, 
only the incidence of hyperplastic ducts in the 2.5 BPA group was significantly higher than controls 
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p=0.038); the study authors noted that the effect at PND 50 was quantitatively similar in all dose 
groups (i.e. 3–4-fold increase). Notwithstanding the lack of dose-response relationship the CEF Panel 
concluded that the results of this study can be used as supporting evidence of the induction of 
proliferation by BPA. 
The CEF Panel identified the following methodological strengths and weaknesses in this study: 
Strengths: 
- Number of doses (4) 
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic bottles 
Weaknesses: 
- Insufficient study reporting (No of animals) 
- Inappropriate statistics (lack of clarity) 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Nanjappa MK, Simon L, and Akingbemi BT, 2012. The industrial chemical bisphenol a (BPA) 
interferes with proliferative activity and development of steroidogenic capacity in rat Leydig 
cells. Biology of Reproduction, 86(5): 135, 1-12  
 
This is a study in which pregnant and lactating Long-Evans rats were given BPA in olive oil vehicle 
via gavage at 2.5 and 25 μg/kg bw per day from gestational day 12 to postpartum day 21, followed by 
examination of the testicular Leydig cells of the male offspring. Although no exposure measurements 
were performed the authors estimated based on previous data that maternal exposures to BPA at 2.5 
and 25 μg/kg body weight represent BPA doses to the offspring of about 8 and 80 pg/kg body weight. 
Proliferative activity of Leydig cells was assessed using [3H]thymidine incorporation using progenitor 
Leydig cells isolated from male rats at the end of BPA exposure. Leydig cell proliferation was also 
examined at 90 days in tissue sections from 3 to 5 rats in the model where rats are treated with the 
Leydig cell toxin ethane dimethylsulfonate. 
Perinatal exposure to BPA did not affect litter size, birth weights of pups and pup sex ratio. Body 
weights, measured at 21, 35 and 90 days of age, were equivalent in BPA-exposed and control animals. 
Similarly, paired and relative testes weights (proportion to body weights) were not affected by BPA. 
However Leydig cell division was stimulated in the prepubertal period and increased Leydig cell 
numbers were shown in the testes of adult male rats at 90 days. 
Comments from the CEF Panel:  
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Phytoestrogen free-diet 
- Use of non-PC cages and of non plastic bottles 
Weaknesses: 
- Results interpretation (biological relevance debatable) 
 
The CEF Panel noted that this rat strain is highly disposed to Leydig cell proliferation. Also particular 
caution is required when extrapolating findings in rat Leydig cells to humans. A detailed review of 
comparative physiology and pathology indicated that rats are quantitatively far more sensitive to the 
development of Leydig cell tumours than men as Leydig cell luteinizing hormone releasing hormone 
(gonadotropin-releasing hormone) receptors are unique to rats. Rats also have over 10 times more 
luteinizing hormone receptors than men (Cook et al. 1999). Thus this study is unlikely to have any 
relevance for assessment of the carcinogenic potential of BPA.  
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This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Nikaido Y, Yoshizawa K, Danbara N, Tsujita-Kyutoku M, Yuri, T, Uehara N and Tsubura A. 
2004. Effects of maternal xenoestrogen exposure on development of the reproductive tract and 
mammary gland in female CD-1 mouse offspring. Reproductive Toxicology, 18, 803-11. 
 
Nikaido Y, Danbara N, Tsujita-Kyutoku M, Yuri T, Uehara N and Tsubura A, 2005. Effects of 
prepubertal exposure to xenoestrogen on development of estrogen target organs in female CD-1 
mice. In Vivo, 19, 487-494. 
 
As reported in EFSA, 2006,“Nikaido et al. (2004) compared the effects of genistein (GEN), 
resveratrol (RES), zearalenone (ZEA), BPA and diethylstilboestrol (DES) on reproductive and 
mammary gland development in female CD-1 mice. Beginning on GD 15, pregnant mice (n = 6) were 
administered 0.5 or 10 mg/kg/day GEN, RES, ZEA or BPA, and 0.5 or 10 microg/kg/day of DES by 
daily subcutaneous injection for four consecutive days. Vaginal opening was monitored, 6 animals per 
group of offspring were autopsied at 4, 8, 12 and 16 weeks of age and ooestrous cyclicity was 
monitored from 9 to 11 weeks of age. Maternal exposure to BPA did not accelerate puberty onset or 
modify the ooestrous cycle. Mammary gland differentiation was accelerated in mice after BPA at 4 
weeks of age, According to the publication, mice treated with GEN, RES, BPA or DES spent more 
time in diestrus; but BPA did not induce statistically significant changes. A publication from the same 
author apparently using the same protocol reported absence of BPA-effects on mammary gland and 
oestrous cycle when given as 4 daily subcutaneous injections (dose of 10 mg BPA/kg bw per day) to 
female CD-1 mice beginning at 15 days of age. (Nikaido et al., 2005).” 
 
Comments from the AFC Panel (2006): 
The AFC Panel noted that a statistical evaluation of the BPA effects on the mammary gland was not 
performed, and that conflicting results were obtained in the two studies 
These studies are included in the WoE table because of their relevance to one or more review 
questions addressed there. 
Prins GS, Ye SH, Birch L, Ho SM and Kannan K, 2011. Serum bisphenol A pharmacokinetics 
and prostate neoplastic responses following oral and subcutaneous exposures in neonatal 
Sprague-Dawley rats. Reproductive Toxicology, 31, 1-9 
 
This study reports the effects of subcutaneous injection or oral dosing of 10 μg BPA/kg bw on post-
natal days 1, 3 and 5 on the development of prostate cancer in a rat model. In this model rats are given 
both testosterone and oestradiol-17β (by implants of Silastic capsules packed with both the hormones) 
for 16 weeks from postnatal day 90 to drive prostatic intra-epithelial neoplasia (PIN) lesions in the 
prostate lobes. BPA was dissolved in 95% ethanol and solubilized in α-tocopherol stripped corn oil at 
a final administered concentration of 10 μg/ml. Solutions were made and stored using glass containers 
and any plastic products used for the collection and storage of blood and sera samples were 
polypropylene. Serum BPA in PND3 rats was measured using HPLC–MS–MS. Unconjugated and 
total BPA at Cmax were 1.77 and 2.0 ng/ml, respectively following injection and 0.26 and 1.02 ng/ml, 
respectively following oral exposure. The AUC0–2 for unconjugated and total BPA was 4.1-fold and 
1.8-fold greater, respectively, in s.c. vs. oral delivery. Twenty pregnant rats were used to obtain 180 
male pups divided equally between treatment groups which allowed 15-25 males per sub group. At 28 
weeks of age, the animals were killed and prostate glands were conventionally fixed and serially 
sectioned at four levels for each organ so that 12-16 sections analysed for prostatic intraepithelial 
neoplasia for each animal.  
Care was taken to avoid contamination by using non-polycarbonate cagesand double-deionized water 
was supplied from glass bottles. Animals were fed ad libitum a soy-free, phytoestrogen-reduced diet. 
The author report that post-natal BPA treatment increased prostatic intraepithelial neoplasia (PIN) 
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equally in both subcutaneous and orally dosed animals compared to controls. Prostate glands from 
treated animals also had a higher incidence of inflammation than controls. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study: 
Strengths: 
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic bottles 
- BPA determination in animal samples 
Weaknesses: 
- A single dose level study 
- Possible confounding (BPA exposure was followed by testosterone and oestradiol-17β) 
 
The CEF Panel also noted that it would be uncommon for true neoplasia to develop within 28 weeks in 
rats treated with hormones or non-genotoxic chemicals. In a previous study of this model by Bosland 
and colleagues, early neoplastic change occurred much later - at least after one year (Bosland et al., 
1995). Moreover, so called PIN is difficult to distinguish from reactive epithelial alterations. The 
photomicrographs of PIN reported in this study are unconvincing evidence of true neoplastic change 
as they do not show sufficient degree of cytological atypia. The rat prostate normally shows variable 
cytological patterns and the reported findings are much more likely to be reactive responses to the 
prostatic inflammation also reported in rats in this study.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Tharp AP, Maffini MV, Hunt PA, VandeVoort CA, Sonnenschein C and Soto AM, 2012. 
Bisphenol A alters the development of the rhesus monkey mammary gland. Proceedings of the 
National Academy of Sciences of the United States of America, 109, 8190-8195. 
 
This paper describes the effects of dosing BPA at a low dose to pregnant rhesus monkeys from 
gestational day 100 to term and the examination of the mammary glands of offspring. It was part of an 
on-going study to investigate the effects of BPA on ovarian function, and this study involved 
examination of the mammary glands from five control neonates and four neonates from mothers dosed 
with BPA. The dose of BPA given to mothers was 400 µg/kg/day given orally in a solution in ethanol, 
delivered within the centre of a small piece of fruit. Control mothers received fruit treated with vehicle 
(100 µl ethanol) only. The authors showed that this gave rise to average unconjugated BPA in 
maternal serum, near the time of spontaneous birth, approximately 4 hours after oral dosing, of 0.68 ± 
0.312 ng/ml. Both neonatal mammary glands were surgically excised 1-3 days after birth from each of 
the four offspring of treated mothers and five control offspring, and one gland was whole-mounted for 
morphometric analysis, while the other was processed for histological analysis, using 
immunohistochemical staining for smooth muscle actin, keratin 14, keratin 18, ERα and ERβ in 
conventional sections. All examinations were carried out without prior knowledge of the prior 
treatment of the animals.  
Morphometric analysis revealed a larger epithelial area, more ductal extension and branching points 
and a higher number of buds per ductal unit in treated compared with controls in the whole mount 
preparations. Only the difference in the number of buds/ductal mammary unit was statistically 
significant (p=0.027). These differences were ascribed to treatment with BPA because they were 
morphologically similar to those reported in mice by the same workers. No differences were observed 
in receptor status between controls and treated as indicated by the immunohistochemical staining 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
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Strengths: 
- Oral administration 
- BPA measurements in biological fluids 
Weaknesses:  
- Small sample size 
- Single dose level study 
- Statistics (because of limited sample size) 
- Animal diet and phytoestrogen content not measured 
 
The CEF Panel acknowledged that a primate study is judged to have particular relevance for humans 
however also noted that very little is known about the mammary gland at birth in rhesus monkeys. So 
few individuals were used in this study and the variability among the measurements was such that it 
seems inappropriate to conclude the results were the result of BPA administration and not simply 
individual biological variation within the context of a high and changing endogenous sex hormone 
environment. The role of sex steroid receptors has not been explored with respect to in utero 
mammary development in monkeys but given the high exposure of the primate fetus to oestrogens, 
progestogens, prolactin, and placental lactogen, it is likely that the fetal mammary gland is relatively 
insensitive to these hormonal stimuli (Cline 2007; Cline and Wood 2008). Moreover, following 
parturition there is a rapid reduction in sex hormone stimuli so that the neonatal mammary gland 
shows rapid regression. The mammary tissue was collected 1-3 days after birth, which is sufficiently 
non-standardised to represent another uncertain variable. Gestation periods may vary by a day or two 
between pregnancies and organ development may have been slightly different between the animals 
used.The results therefore can only be considered very preliminary and their relevance for the 
assessment of carcinogenic potential of BPA cannot be assessed. The CEF Panel concluded 
nonetheless that the results of this study can be used as supportive evidence of the induction of 
proliferation by BPA. 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
US FDA/NCTR, 2013. Evaluation of the toxicity of bisphenol A (BPA) in male and female 
Sprague-Dawley rats exposed orally from gestation day 6 through postnatal day 90. Experiment 
E02176.01, Technical report of March 2013 
 
Delclos KB, Camacho L, Lewis SM, Vanlandingham MM, Latendresse JR, Olson GR, Davis KJ, 
Patton RE, da Costa GG, Woodling KA, Bryant MS, Chidambaram M, Trbojevich R, Juliar 
BE, Felton RP and Thorn BT, 2014. Toxicity Evaluation of Bisphenol A Administered by 
Gavage to Sprague Dawley Rats From Gestation Day 6 Through Postnatal Day 90. Toxicological 
Sciences, 139, 174-197. 
 
In this study, Sprague-Dawley rats (Sprague-Dawley/CD23/NCTR BR) were used for a dose-response 
approach to investigate the effects of BPA on a very wide range of pathological, physiological, 
endocrine, reproductive and developmental endpoints. Ethinyl oestradiol was used as a positive 
control of the estrogenic effects of BPA. The dose-matched vehicle control was 
carboxymethylcellulose, sodium salt. The doses were: (i) BPA 2.5, 8, 25, 80, 260, 840, 2700, 100 000, 
300 000 µg/kg bw per day, (ii) Vehicle, (iii) EE2 0.5, 5 µg/kg bw per day. The study included a naïve 
control group and doses were administered by oral gavage. The protocol and methods, including 
statistical analysis were of the high quality and robust with treatment, body weight and litter 
randomisation and appropriate inclusion and exclusion criteria established prior to the start of the 
study. The target unit for analysis was 20 litters and 18-23 were achieved. F0 females were dosed from 
GD 6 up to labour onset and pups from PND 1 until tissue harvesting, up to PND 90. Additional 
groups were exposed from GD 6 to PND 21 for histopathological examination of the mammary 
glands. 
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Mammary gland duct hyperplasia of minimal severity was reported in the female groups examined at 
PND 21. The incidence of hyperplastic lesions was statistically significant by at least one of the three 
statistical methods used when compared with the vehicle control group in the 2 700 and 100 000 μg/kg 
bw per day groups, but not in the 300 000 μg/kg bw per day group. This observation was considered 
possibly treatment-related by the study authors but not by the original study pathologist. Mammary 
gland duct hyperplasia was also reported in the high dose female BPA groups examined at PND 90. 
Using the Poly-k test, the increase in minimal severity mammary gland duct hyperplasia was 
statistically significant in the 300 000 μg/kg bw per day group compared with vehicle controls. A 
significant increase in incidence of mammary gland duct hyperplasia compared with vehicle control 
was seen in the 2700, 100 000 and 300 000 μg/kg bw per day groups when analysis was carried out 
using the JT/SW or RTE statistical tests. Both of these tests incorporate lesion severity, but only the 
RTE method does not explicitly assume a monotonic dose-response curve (CFSAN, 2013a). Taking 
the incidences, the statistical testing results, and all pathologists and study authors opinions together, 
the authors of the NTP report (Gu and Mitkus, 2013), concluded that the evidence for duct hyperplasia 
in the mammary gland of females on either PND 21 or PND 90 was weak. They considered it an 
equivocal finding that may be the reflection of normal variability and/or a reflection of limits in tissue 
processing. BPA did not cause duct hyperplasia in the mammary glands of male rats, while conversely 
the reference estrogen EE2 induced hyperplasia in the male but not the female mammary gland. A 
single mammary gland ductal adenocarcinoma (1 out of 260 female rats in the entire study) was seen 
in the 2.5 µg BPA/kg bw per day dose group at PND 90. The CEF Panel considered that the 
observation of mammary hyperplasia in female rats in this study albeit of minimal severity was 
relevant for the risk assessment of BPA, given the findings in other studies reported above. In the 
100 000 and 300 000 µg/kg bw per day female BPA groups, significantly higher plasma levels of 
oestradiol and prolactin were found whereas the EE2 values were only mildly elevated in comparison 
to controls. The CEF Panel concluded that this may point to a BPA treatment-related effect in females. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths/weaknesses in the study: 
Strengths: 
- Large sample size  
- Both naïve and vehicle controls available 
- Adequate positive controls included 
- Measurement of BPA concentration in the serum 
- Number of doses (9) 
- Oral administration by gavage 
- Phytoestrogen-free diet  
- Use of non-PC cages 
- Study performed according to OECD guidelines, under GLP  
Weaknesses: 
- Inconsistent results within groups (females not sensitive to EE2 effects) 
- Unintended exposure of  the control groups (see Churchwell et al, 2014) 
- No quantitative proliferation measurement (only hystological examination) 
 
Overall, the CEF Panel noted that this GLP study, performed according to OECD standards, evaluated 
a wide range of dose levels, seven below and two above the dose of 5 mg/kg bw per day in former 
assessments defined as the reference point. The highest dose had an influence on several parameters. It 
is to be noted that the study duration was 90 days (13 weeks) with permanent dosing. Phytooestrogen 
levels in food were monitored to be in the low range. As the number of litters is sufficiently large the 
study has a fair sensitivity to detect effects.  
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
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Vandenberg LN, Maffini MV, Wadia PR, Sonnenschein C, Rubin BS and Soto AM, 2007. 
Exposure to environmentally relevant doses of the xenoestrogen bisphenol-A alters development 
of the fetal mouse mammary gland. Endocrinology, 148, 116-127. 
Female CD-1 mice (8 wk of age) were exposed to BPA from gestational day 8 (GD8) until GD18 via 
s.c. implanted  Alzet osmotic pumps designed to deliver either 50% dimethylsulfoxide (vehicle 
control) or 0.25 μg BPA/kg bw per day dissolved in the vehicle. At GD18, the fetuses were delivered 
singly by cesarean section and decapitated. One mammary gland was whole mounted and its 
contralateral gland was embedded in paraffin for light microscopy and immunohistochemistry (Ki67 
for cell proliferation and Bax for apoptosis analyses). Exposure of dams to 0.25 μg BPA significantly 
increased ductal area (increased size of the epithelial cords) and ductal extensions. There was no 
statistically significant difference in the number of terminal end buds and cell proliferation (Ki67) 
between BPA-exposed and control mice. A significant decrease in apoptosis was seen in the inner cord 
cells of BPA-exposed mice relative to controls, whereas there was no such an effect in the outer cells 
of the BPA-exposed animals. 
In the stroma, BPA exposure promoted the maturation of the fat pad and altered the localization of 
collagen, which is suggested by the authors to be responsible for the altered growth and cell size 
observed in the epithelium. 
Comments from the CEF Panel:The CEF Panel concluded that the results indicate that exposure of 
dams to 0.25 μg BPA from GD8 until GD18 did not cause epithelial proliferation or an increase in the 
number of TEBs in the mammary glands of female fetuses. 
The CEF Panel identified the following strenths and weaknesses in this study: 
Strenghts: 
- Sample size (40 controls and 36 BPA treated fetuses) for histological parameters 
- Cages, bedding and food tested negligible for estrogenicity 
Weaknesses: 
- Small sample sizes for proliferation (8 controls and 7 BPA-treated) and apoptosis assessment 
(n=4) 
- Only one dose  
- Short exposure period  
 
The study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Vandenberg LN, Maffini MV, Schaeberle CM, Ucci AA, Sonnenschein C, Rubin BS and Soto 
AM, 2008. Perinatal exposure to the xenoestrogen bisphenol-A induces mammary intraductal 
hyperplasias in adult CD-1 mice. Reproductive Toxicology, 26, 210-219. 
 
CD-1 mice were exposed to BPA from gestational day 8 (GD8) until PND16 via s.c. implanted Alzet 
osmotic pumps designed to deliver dimethylsulfoxide (DMSO vehicle control). Exposure groups 
comprised: 0, 0.25 (0.25BPA); 2.5 (2.5BPA) or 25 (25BPA) μg BPA/kg bw per day. At 3, 9, and 12-
15 months of age, female offspring were killed. Morphometry was performed on whole-mount 
mammary glands. Cell proliferation was determined by Ki67 staining. The ERα and progesterone 
receptor (PR) was determined in normal and “beaded ducts” (ducts with a beaded aspect caused by 
epithelial cells in the lumen; comparable with the intraductal hyperplasias as described by Murray et 
al, 2007).  
3-Month old mice of the 0.25BPA group showed a significant increase in the volume of alveolar buds 
compared to controls. At 9 months of age the volume frcation of the alveolar buds was significantly 
increased in the 2.5BPA group. The volume fraction of TD did not vary regardless of treatment. 
Immunohistochemical analysis of Ki67, ERα or PR did not indicate quantitative differences among the 
groups. At 9 months of age (but not at 3 or at 12-15 months of age, where the number of animals 
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examinded was ranging between 4 and 11) the incidence of beaded ducts was significantly increased 
in all BPA treated groups compared to controls, however without a dose-response relationship (5/20; 
3/12 and 6/20 vs 0/18 in 0.25; 2.5 and 25BPA groups vs controls, respectively). ERα staining beaded 
ducts was not qualitatively different form non-beaded ducts. However, the epithelial cells in 
intraductal hyperplasias were often positive for PR. Cell proliferation was almost 5x higher in beaded 
ducts than in normal ducts and alveolar ducts. The authors concluded that the results at 3 months of 
age indicate that exposure from GD8 up to PND16 to BPA alters the development of the mammary 
gland. Specifically, 0.25BPA females showed an increase in alveolar buds compared to controls. The 
authors further concluded that the most novel observation reported was the development of intraductal 
hyperplasias in BPA treated mice.  
Comments from the CEF Panel: 
The CEF Panel concluded that the results can be used as supporting evidence of proliferation induced 
by BPA. 
The CEF Panel identified the following strengths and weaknesses in this study: 
Strengths: 
- Number of doses (3) 
- Phytoestrogen-free diet 
- Use of non-pc cages and of non plastic bottles 
Weaknesses: 
- Small sample size in some of the dose groups  
- Unclear reporting of the results 
 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Vandenberg LN, Schaeberle CM, Rubin BS, Sonnenschein C and Soto AM, 2013c. The male 
mammary gland: a target for the xenoestrogen bisphenol A. Reproductive Toxicology, 37, 15-23. 
 
In this study, BPA was given to pregnant (GD8 up to delivery) and lactating mice (PND1 up to 
PND16) and mammary glands were examined at several time points in the adult offspring. In this 
experiment doses given to pregnant female CD-1 mice were 0.25, 2.5, 25 or 250 µg/bw per day via 
osmotic mini-pumps. Dams were allowed to litter and litters culled to 8 pups per mother. A single 
male offspring was killed at 3-4, 7-9 and 12-16 months of age and one mammary gland from each 
(from 5 to 20 animals/time point) was whole mounted and examined following Carmine-alum 
staining. In some cases where no visible gland was seen another sample was collected from a litter 
mate. Glands from animals exposed to 0.25 and 2.5 µg/bw per day had significantly more branching 
points and males exposed to 2.5 µg/bw per day had increased ductal area relative to controls. In the 
most severely affected group (2.5 µg/bw per day BPA), the mean number of branching points and 
ductal area represented 4.5- and 7.7-fold increases, respectively, compared to controls. At 7-9 months 
of age, a non-monotonic relationship between dose and mammary gland morphology was still present, 
but had shifted such that animals in the 2.5 µg/bw per day and 25 µg/bw per day groups were 
significantly different from controls; however, lower doses (0.25 µg/bw per day) and higher doses 
(250 µg/bw per day) were statistically indistinguishable from controls. The authors suggest that 
mammary glands of male offspring treated with BPA showed changes in ductal area and branching 
points compared with controls and that the response was non-monotonic. They suggested this might 
have relevance for gynaecomastia reported in men. 
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study: 
Strengths: 
- Number of doses (4) 
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic bottles 
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Weaknesses: 
- Number of animals low 
- Limited sampling methodology 
- Unclear reporting of the results 
 
The CEF Panel noted that the authors draw conclusions based on minor statistical significant 
differences in a study that used few animals and very limited sampling. The CEF Panel noted in 
particular the considerable individual variability in the measured effects as reflected in large standard 
errors around the mean (SEM).Moreover, a dose-response relationship (based on the nominal doses) 
was not observed. In some cases where no visible gland was seen another sample as collected from a 
litter mate, which the CEF Panel considered as inappropriate.   
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Weber Lozada K and Keri RA, 2011. Bisphenol A increases mammary cancer risk in two 
distinct mouse models of breast cancer. Biology of Reproduction, 85, 490-497. 
 
Female FVB/N mice were administered by gavage, vehicle (mineral oil), 25 or 250 µg BPA/kg/day 
from postcoital day 8 and until parturition. The first experiment studied vaginal opening and 
mammary gland development using groups of 5 mice from at least three litters. In the second 
experiment, mammary cancer susceptibility was studied in female offspring given (n = 10) 7,12-
dimethyl benz[a]anthracene (DMBA) (1 mg/100µl corn oil) at week 5 and 6 weeks of age. These mice 
were palpated weekly to detect mammary tumours. Tumour latency was measured using Kaplan-
Meier survival analyses. Upon the detection of tumours, mice were killed and tumours collected. Mice 
that were sick or died during the experiment from other causes than mammary cancer were censored 
from the study. In the third experiment NCR nu/nu female mice (n > 5) were ovariectomized at 8 
weeks of age and implanted with a placebo (37.5 mg/60 day release), 17β-oestradiol (1.7 mg/60 day 
release), or low dose BPA pellet (37.5 mg pellet/60 day release). After recovery from surgery, 1 x 106 
oestrogen sensitive cancer MCF-7 cells were subcutaneously injected into the flanks of the mice. 
Tumour latency was then assessed by weekly palpation and tumour growth was monitored by weekly 
measurement with callipers. A small group (n = 3) of the mice with injections of MCF-7 cells were 
also treated with the oestrogen receptor modulator tamoxifen (1 mg/mouse/day) by oral gavage for 5 
continuous days per week. 
Female FVB/N mice exposed prenatally to vehicle control exhibited vaginal opening on day 22-24, 
while mice exposed to BPA exhibited accelerated vaginal opening on day 21-22. The difference in 
vaginal opening was statistically significant. At no time point examined was there any notable 
morphological difference in mammary gland development observed between the BPA and vehicle 
treated offspring. The high dose BPA group exhibited a mean tumour latency of 50.8 weeks, and the 
lower BPA dose group exhibited a mean tumour latency of 69.3 weeks. Only one vehicle treated 
mouse developed a DMBA-induced tumour at week 111. A statistically significant difference in 
tumour latency in both the low and high BPA dose treatment group was reported. Numbers of animals 
that developed tumours in each group (incidence) were not reported, or the numbers of animals that 
died from other reasons than mammary tumours.  
From the experiment with injection of MCF-7 cells, 5 of 7 mice in the 17β-oestradiol treated group, 5 
of 6 mice in the BPA treated group and 0 of 7 mice in the placebo treated group formed tumours. On 
average the tumours form in the 17β-oestradiol treated group were 3 times larger in volume than the 
tumours from the BPA treated group 9 weeks post tumour cell implantation. Tumour regression was 
observed by tamoxifen in all mice from both 17β-oestradiol and BPA treated groups.  
Comments from the CEF Panel: 
The CEF Panel identified the following strengths and/or weaknesses in this study: 
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Strengths: 
- Adequate positive control included 
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic bottles 
Weaknesses: 
- Small sample size 
- Insufficient study reporting (e.g. tumour incidence, no information on the number of animals 
that died of other causes than mammary cancer)  
 The CEF Panel noted uncertainties related to interpretation of the results of this paper, since it does 
not report the tumour incidence, a more relevant measure of effects on carcinogenicity. In addition no 
information is given on the number of animals that died of other causes than mammary cancer. This 
may have influenced results as it is probable that most animals in the control group died of other 
causes as only one animal in this group developed a carcinoma. Although tumours were verified 
histologically, they were all squamous carcinomas whereas DMBA given orally to mice and rats is 
reported to produce mainly adenocarcinomas that resemble those occurring in women (Qing et al. 
1997; Costa et al., 2004; Mansour et al., 2012). There is no explanation for this. Moreover, 
histological evaluation was incomplete as it did not include study of preneoplastic changes that also 
occur in the mammary gland in the DMBA rat model. Such neoplasms therefore may have developed 
from the skin rather mammary tissue and would be inappropriate for mammary tumour risk 
assessment. It should also be noted that BPA is not genotoxic and that any observed effect on tumour 
latency or growth is a threshold phenomenon (EFSA CEF Panel, 2010). 
This study is included in the WoE table because of its relevance to one or more review questions 
addressed there. 
Weinhouse C, Anderson OS, Bergin IL, Vandenbergh DJ, Gyekis JP, Dingman MA, Yang J and 
Dolinoy DC, 2014. Dose-Dependent Incidence of Hepatic Tumors in Adult Mice following 
Perinatal Exposure to Bisphenol A. Environmental Health Perspectives, 122, 485-491. 
Isogenic mice characterized by a resistance to hepatic tumors (genetically 75-93% C57BL/6J) were 
used in this study to evaluate the incidence of hepatic lesions following perinatal exposure to BPA. 
Ten wild type Agouti a/a female mice/group  were exposed to BPA 2 weeks before mating (with 
males heterozygote Agouti Avy/a briefly exposed to diets containing  BPA during the mating period), 
during gestation and lactation (PND 21) through the diet (phytoestrogen-free AIN-93G diet (diet 
95092, with 7% corn oil substituted for 7% soybean oil) supplemented with 0, 50 ng, 50 µg or 50 mg 
BPA/kg diet, corresponding to approximately 0, 10 ng, 10 µg, or 10 mg BPA/kg bw per day 
(calculated based on dam bw). One male and one female wild type (a/a) per litter, which were then 
given a standard phytoestrogen-free control diet, were followed until 10 months of age and tested for 
known risk factors for hepatocellular carcinoma, including bacterial and viral infections.  
The authors report statistically significant trends in the dose-response in neoplastic lesions (adenomas 
+ carcinomas) with or without preneoplastic lesions in females, but not in males. Furthermore, there 
was a statistically significant trend in adenomas, in neoplastic lesions (adenomas + carcinomas) and in  
neoplastic combined with preneoplastic lesions in all mice (males and females together) exposed to 10 
mg/kg bw per day.  
 
Comments from the CEF Panel: 
Comment:_ The relevance of the isogenic mouse model for human health may be low.  
 
The CEF Panel identified the following strengths and/or weaknesses in this study: 
Strengths: 
- Number of BPA doses (3) 
- Phytoestrogen-free diet 
- Use of non-PC cages 
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- BPA measurement in biological samples (total liver measurement) 
Weaknesses: 
- Small sample size (low number of animals/group)  
- Insufficient reporting (no reporting on historical incidence of liver adenomas and carcinomas 
in isogenic mice)  
 
The CEF Panel noted that the tumours already developed at an early time point, therefore raising the 
question as to the possible outcome at later stages (> 20 months). 
(iii) In vitro studies related to proliferation 
Appraisal of strengths and weaknesses and WoE analysis were not carried out for in vitro studies.  
Dairkee et al., 2012/2013. Bisphenol-A-induced inactivation of the p53 axis underlying 
deregulation of proliferation kinetics, and cell death in non-mallignant human breast epithelial 
cells. Carcinogenesis 34, 703-712 
 
The study extends previous work of this group using non-cancerous human high risk donor breast 
epithelial cells (HRBEC) (Goodson et al., 2011). BPA (only one concentration: 10-7 M) induced in 
sponaneously immortalized HRBEC lines and the ER-positive breast cancer cell line, T47D, molecular 
changes associated with reduced apoptosis (downregulation of p53, p21WAF1 and BAX) and increased 
proliferation (PCNA, cyclins and phosphorylated pRb) and the ERα:ERβ ratio. Additionally, BPA 
reduced tamoxifen-induced apoptosis in these cell lines and induced proliferation in the cell lines and 
primary HRBEC cultures resulting in extended proliferation of the latter cells. The observed effects 
were inhibited by concomitant treatment of HRBEC cells by curcumin (10-7 M).  
 
Comments from the CEF Panel: 
In conclusion, the results demonstrate the antagonistic interaction of BPA and the anti-oestrogens 
tamoxifen and curcumin. Considering also potential interactions of BPA with the hormonal 
environment in the body, the expression of BPA effects in vivo is complex and difficult to simulate in 
vitro. The use of only one relatively high BPA concentration is an additional limiting factor in the 
present study. 
 
Goodson WH , Luciani MG, Sayeed SA, Jaffee IM, Moore DH and SH Dairkee, 2011. Activation 
of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk 
women. Carcinogenesis 32, 1724-1733. 
 
This in vitro study used pairwise comparisons of 16 independent epithelial cells from the unaffected 
breast of patients at high-risk of breast cancer with and without BPA exposures (10-10 M to 10-7 M). 
The authors report induction of genes and proteins in the PI3K-mTOR pathway—AKT1, RPS6 and 
4EBP1 and a concurrent reduction in the tumour suppressor, phosphatase and tensin homolog gene 
protein. The altered regulation of these mTOR pathway proteins in BPA-treated cells led to marked 
resistance to rapamycin, the defining mTOR inhibitor, as observed in 17β-oestradiol (5x10-9 M)-
treated cells. Moreover, these cells pretreated with BPA were reported to surmount anti-oestrogenic 
effects of tamoxifen showing dose-dependent apoptosis evasion and induction of cell cycling. 
 
Comments from the CEF Panel: 
Whilst this study has the merit of using normal human breast epithelial cells taken from cancer 
patients, the interpretation of relevance for humans still suffers from all the constraints inherent in in 
vitro studies. This is particularly difficult in this context where dosing xeno-oestrogenic agents takes 
place in an artificial environment devoid of the normal oestrogenic and sex hormone environment. 
Whilst this study suggests that BPA at very low concentrations may have the potential to affect these 
pathways in mammary epithelial cells, the relevance to the in vivo situation is not clear. 
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Hall JM, Korach KS, 2012. Endocrine disrupting chemicals promote the growth of ovarian 
cancer cells via the ER-CXCL12-CXCR4 signaling axis. Molecular Carcinogenesis, 52, 715-725. 
 
The authors studied the effect of 10-5-10-9 M BPA on cell proliferation and CXCL12 chemokine 
expression using a human epithelial ovarian cancer cell line (BG-1). BPA induced cell proliferation, 
increased the expression of CXCL12 and its release into the culture medium. Previously it has been 
shown that the CXCR4 receptor activation after binding of CXCL12 leads to cell proliferation. Using 
different biochemical approaches and a relatively high BPA concentration (10-7 M) the authors 
demonstrated that proliferation of this cell line is linked to the ER-CXCL12-CXCR4 signalling axis. 
 
Lee HR, Hwang KA, Park MA, Yi BR, Jeung EB and Choi KC, 2012b. Treatment with 
bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration 
of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-
dependent signaling pathway. International Journal of Molecular Medicine, 29, 883-890. 
 
In this study with the oestrogen responsive human brest cancer cell line MCF-7 BPA or methoxychlor 
were used to follow the proliferative responses and cell-cycle-related genes. Both compounds were 
shown to induce cell proliferation by the up-regulation of genes that promote the cell cycle and the 
downregulation of anti-proliferative genes, especially ones affecting the G1/S transition via oestrogen 
receptor α signalling.  
The authors argue that these results confirm the carcinogenicity of these endocrine disrupting 
chemicals in vitro. However these results merely illustrate an in vitro effect of these agents in a cell 
line that originates from a cancer. Its relevance to cancer development in the complex in vivo situation 
is speculative. 
Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, Rosano C and 
Maggiolini M, 2012. Bisphenol A Induces Gene Expression Changes and Proliferative Effects 
through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts. Environmental 
Health Perspectives, 120, 1177-1182. 
 
SKBR3 breast cancer cells and cancer-associated fibroblasts, which lack the classical estrogen 
receptors, were used to study the involvement of the G protein-coupled receptor (GPR30/GPER) 
pathway. Induction of ERK1/2 phosphorylation was shown in both cell types only by high 
concentrations of BPA (10-7 and 10-6 M) and was abolished by silencing GPER (by shGPER). BPA 
(10-7 M) induction of the expression of GPER target genes (c-FOS, EGR-1 and CTGF) was also 
inhibited by shGPER. This rapid activation of the GPER signalling pathway has also been reported in 
other cell-types (human seminoma cells, mouse spermatogonial cells). These data expand the 
knowledge of BPA signalling via membrane G-proteins. 
Qin X-Y, Fukuda T, Yang L, Zaha H, Akanuma H, Zeng Q, Yoshinaga J and Sone H, 2012a. 
Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary 
epithelial cells. Cancer Biology Therapy 13, 1-11. 
This study reports the effect of BPA cellular proliferation and senescence in a human mammary cell 
line derived from normal mammary epithelial cells (HMEC). Oestradiol (10-9 M) served as positive 
control. Exposure to BPA (10-8 M and 10-7 M) for 1 week at the early stage at passage 8 increased the 
proliferation and sphere size of these cells at the later stage up to passage 16, suggesting that BPA has 
the capability to modulate cell growth in breast epithelial cells comparable to the treatment with 17β-
oestradiol (E2, 10-9 M). The number of human heterochromatin protein-1γ positive cells, which is a 
marker of senescence, was also increased among BPA-treated cells. Consistent with these findings, the 
protein levels of both p16 and cyclin E, which are known to induce cellular senescence and promote 
proliferation, respectively, were also increased at 10-7 M BPA. DNA methylation levels of a number of 
genes related to development tumours were also increased in treated cells. DNA methylation levels of 
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genes related to development of most or all tumor types, such as BRCA1, CCNA1, CDKN2A (p16), 
THBS1, TNFRS F10C and TNFRS F10D, were increased in BPA-exposed HMEC. The authors 
concluded that the findings in the HMEC model suggested that the genetic and epigenetic alterations 
by BPA might damage HMEC function and result in complex activities related to cell proliferation 
and senescence, playing a role in mammary carcinogenesis. 
Whereas the study shows genetic and epigenetic alterations induced by BPA in this cell model, its in 
vivo relevance is uncertain. The conclusion from the results of this study is hampered by the use of 
only two BPA concentrations and only one time point for expression of mRNA and protein (passage 
11, i.e. 3 weeks after treatment), which is insufficient to obtain a maximal response. 
Wu S, Wei X, Jiang J, Shang L and Hao W, 2012. Effects of bisphenol A on the proliferation and 
cell cycle of HBL-100 cells. Food and Chemical Toxicology, 50, 3100-3105. 
 
Proliferation, progression through cell cycle and cyclin D1 expressio were studied in normal human 
breast cells (HBL-100). Surprisingly, BPA induced growth at a 100-fold lower concentration, i.e. at 
10-10 M, in these cells than E2. The BPA effect was not completely blocked by the ER antagonist ICI 
182780. Additionally BPA induced cyclin D1 expression but no ERα expression. 
 
Zhang W, Fang Y, Shi X, Zhang M, Wang X and Tan Y, 2011.  Effect of bisphenol A on the 
EGFR-STAT3 pathway in MCF-7 breast cancer cells. Molecular Medicine Reports, 5, 41-47. 
 
This study explored the effect of BPA on the EGFR-STAT3 pathway in MCF-7 breast cancer cells. It 
was shown that the optimal concentration and time point of BPA-induced proliferation in MCF-7 cells 
was 10-6 M and 24 hours, respectively (However, due to poor data presentation the dose-response 
curve cannot be interpreted). BPA significantly increased the expression of STAT3 at a concentration 
of 10-6 M following treatment for 48 h and the expression of STAT3 was down-regulated after 
blocking EGFR. It was argued that STAT3 expression, which is a major factor in the pathway of BPA-
induced proliferation and STAT3 activation, contributes to BPA-induced breast cancer cell 
proliferation. 
 
Comments from the CEF Panel: 
Again whilst this study shows the potential of BPA to induce cellular changes in vitro, it does not 
provide evidence of their potential to do so in vivo. 
In vitro studies/Mechanisms of action 
 
Appraisal of strengths and weaknesses and WoE analysis were not carried out for in vitro and/ or 
mechanistic studies. 
 
Brannick KE, Craig ZR, Himes AD, Peretz JR, Wang W, Flaws JA and Raetzman LT, 
2012. Prenatal Exposure to Low Doses of Bisphenol A Increases Pituitary Proliferation 
and Gonadotroph Number in Female Mice Offspring at Birth. Biology of Reproduction, 
87, 82.  
 
This study investigated whether prenatal exposure of mice to low doses of BPA results in changes in 
pituitary development and cellular specification. Pregnant female mice (described as from a mixed 
FVB, C57BL/6 background, with up to 8 mice per treatment group) were dosed orally (by gavage) 
with 0, 0.5 or 50 µg/kg bw per day of BPA dissolved in ethanol and diluted in corn oil. Dosing took 
place from GD 10.5 to GD 18.5 and pups were examined at PND 1 for effects of BPA on cell 
proliferation, cell differention and parameters of hormone synthesis. Six to eight individual pituitaries 
were examined from each treatment, obtained from pups from five to seven different litters per 
treatment group. BPA induced cell proliferation in the pituitary of female, but not male, offspring as 
evidenced by the results of quantitative histochemistry to detect mKi67-immunoreactive cells and 
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measurement of mKi67 mRNA levels. The effect was more marked at 0.5 µg/kg bw per day of BPA 
compared with 50 µg/kg bw per day of BPA. The number of gonadotrophs (as measured by cells 
expressing LHb and FSHb) also increased in female offspring from BPA-treated females; female mice 
exposed to 0.5 µg/kg bw per day BPA had increased mRNA levels of gonadotropins and the 
gonadotropin-receptor hormone (GNRH) receptor (Gnrhr), while a decrease in gonadotropin mRNA 
levels, Gnrhr and Nr5a was seen in females that had been exposed to 50 µg/kg bw per day of BPA. 
Proliferating cells, expressing mKi67 did not also express LHb and FSHb, as demonstrated by double-
labelling immunohistochemistry, but proliferating progenitor cell s were demonstrated to frequently be 
SOX2-positive. No changes were seen in mRNA levels of marker hormones produced by 
corticotropes, somatotropes, and thyrotropes, and notably no effect of BPA was seen on prolactin 
(PRL) expression on PND 1. The authors demonstrated however (using CD-1 mice) that PRL 
expression did not commence until PND 5 and was not fully expressed until adulthood. The authors 
conclude that exposure to BPA affects pituitary gonadotroph development in female mice but not in 
males, and postulate that this may be due to an effect of BPA on the sexually dimorphic development 
of the anteroventral periventricular nucleus (AVPV) of the hypothalamus, leading to altered pituitary 
function. 
The results of this study are mechanistically interesting, suggesting a BPA-mediated effect on pituitary 
development which is sexually dimorphic and may explain/underlie some of the effects seen on 
reproductive parameters in female rodents exposed prenatally to BPA. The authors suggest that the 
effect of BPA on the pituitary may be oestrogenic – use of a positive control would have helped 
understand the results of the study. Although the number of animals used was relatively small, the 
methodology appears robust. 
 
Goodson WH, Luciani MG, Sayeed SA, Jaffee IM, Moore DH and Dairkee SH 2011. Activation 
of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk 
women. Carcinogenesis, 32, 1724-1733. 
 
Non-malignant breast epithelial cells were obtained in this study by random periareolar fine needle 
aspiration from the unaffected contralateral breast of high-risk women undergoing breast surgery. 
Sixteen independent samples were expanded in vitro and exposed to BPA at concentrations between 
10-10 M and 10-7 M or to 17β-oestradiol (5x10-9 M). There was a dose-dependent inhibition of 
tamoxifen-induced apoptosis by BPA – even at the lowest concentration in these cells. The dose-
dependent reversal of tamoxifen-induced growth inhibition by BPA could also be observed using 
BrdU labelling of the cells. Additionally, BPA-induced molecular changes in the mammalian target of 
rapamycin (mTOR) pathway were associated with significant reduction in rapamycin-induced 
apoptosis. Similar changes were observed with the xenoestrogen methylparaben. The finding with 
BPA supports other observations that BPA increases the cell proliferation/apoptosis ratio in normal 
tissue as well as preneoplastic lesions of rat mammary gland (see EFSA CEF Panel, 2010, p75: reports 
by Betancourt et al., 2010 and others). The authors observed also a decline of endogenously 
accumulated reactive oxygen species (not dose-dependent) in these cells, while usually an induction of 
oxidative stress by BPA is reported (e.g. Rashid et al., 2009 cited in EFSA CEF Panel, 2010). 
Considering that the lowest BPA concentration (10-10 M) was still active (LOEC) this in vitro model 
using human breast epithelial cells can be regarded as very sensitive to xenoestrogens. 
Hall JM and Korach KS, 2012. Endocrine disrupting chemicals promote the growth of ovarian 
cancer cells via the ER-CXCL12-CXCR4 signaling axis. Molecular Carcinogenesis, 52, 715–725. 
 
The authors studied the effect of 10-5-10-9 M BPA on cell proliferation and CXCL12 chemokine 
expression using the BG-1 cell line (human epithelial ovarian cancer). The authors reported that BPA 
induces cell proliferation, increases the expression of CXCL12 and its release into the culture medium. 
Previously it has been shown that the CXCR4 receptor activation after binding of CXCL12 induces 
also cell proliferation. Using different biochemical approaches and a BPA concentration of 10-7 M the 
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authors reported that proliferation of this cell line is regulated also throught the ER-CXCL12-CXCR4 
signalling axis. 
Huc L, Lemarié A, Guéraud F and Héliès-Toussaint C, 2012. Low concentrations of bisphenol A 
induce lipid accumulation mediated by the production of reactive oxygen species in the 
mitochondria of HepG2 cells. Toxicology In Vitro, 26, 709-717. 
 
See study description in Appendix B  under section “Metabolic effects – In vitro studies” 
 
Hwang K-A, Park SH, Yi BR and Choi KC, 2011. Gene alterations of ovarian cancer cells 
expressing estrogen receptors by estrogen and bisphenol a using microarray analysis. 
Laboratory Animal Research, 27, 99-107. 
 
This study presents a microarray analysis supported by examination of mRNA levels of selected genes 
in ovarian adenocarcinoma cell line after exposure to exposed to 17β-oestradiol (10-7 M) or BPA (10-5 
M). This cell line expresses oestrogen receptor α. Altered genes reported included RAB31_member 
Ras oncogene family, cyclin D1, cyclin-dependent kinase 4, insulin-like growth factor-binding protein 
4 and anti-mullerian hormone. This paper presents an in vitro method for screening chemicals with 
weak oestrogenic properties.  
 
Jung J-W, Park S-B, Lee S-J, Seo M-S, Trosko JE and Kang K-S, 2011. Metformin represses 
self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-
mediated OCT4 expression. PLoS ONE 6(11): e28068. 
 
This mechanistic study investigated the potential of metformin, an oral anti-diabetic drug to reduce the 
risk to breast cancers using a human breast carcinoma cell line, MCF-7, grown in 3-dimensional 
mammospheres, representing breast cancer stem cells. The cells were also treated with TCDD, BPA or 
17-β-oestradiol or the anti-oestrogen ICI182,780. Using OCT4 expression (which functions as a 
transcription factor) as a marker for the cancer stem cells, the number and size were measured in these 
cells. TCDD (100 nM), BPA and the oestrogen (10 nM) increased the number and size of the 
mammospheres. Metformin reduced the expression of OCT4 in 17-β-oestradiol & TCDD treated 
mammospheres but not in those treated with BPA, suggesting different mechanisms of action of the 
BPA on human breast carcinoma cells. 
Lee HK, Kim TS, Kim CY, Kang IH, Kim MG, Kyung Jung K, Kim HS, Han SY, Yoon HJ and 
Rhee GS, 2012d. Evaluation of in vitro screening system for estrogenicity: comparison of stably 
transfected human estrogen receptor-α transcriptional activation (OECD TG455) assay and 
estrogen receptor (ER) binding assay. The Journal of Toxicological Sciences, 37, 431-437. 
 
The authors compared 4 different in vitro screening systems for estrogenicity using 7 different 
industrial chemicals: “Yeast assay”, “E-screen assay”, “ER binding assay” and the “STTA assay” 
(OECD TG455). All assays gave comparable results. The authors concluded that the OECD TG455 
might be a useful screening test for endocrine disruptors. 
Li Y, Burns KA, Arao Y, Luh CJ and Korach KS, 2012a. Differential Estrogenic Actions of 
Endocrine-Disrupting Chemicals Bisphenol A, Bisphenol AF and Zearalenone through Estrogen 
Receptor α and β in Vitro. Environmental Health Perspectives, 120, 1029-1035. 
 
Three different cell lines, HepG2 (human hepatocellular carcinoma), HeLa (human cervix epitheloid 
carcinoma) and Ishikawa (human endometrical adenocarcinoma) were used to study effects of 10-6-
10-9 M BPA on signalling through ERα and ERβ. The authors concluded that the estrogenic activity is 
cell type and concentration dependent. In some experimental set-ups 10-9 M BPA increased ERα 
activity. Also antagonizing effects of BPA in combination with E2 (17β-oestradiol) were detected. 
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Using specific kinase inhibitors the authors concluded that BPA activates not only the MAPK 
pathway. Other signalling pathways like src might also be relevant. Finally the authors used different 
ERα constructs to study the mechanism of receptor binding and gene activation. 
Nanjappa MK, Simon L, and Akingbemi BT, 2012. The industrial chemical bisphenol A (BPA) 
interferes with proliferative activity and development of steroidogenic capacity in rat Leydig 
cells. Biology of Reproduction 86, 135, 1-12. 
 
The study indicates that low perinatal BPA doses (2.5 and 25 µg/kg bw per day at GD 12 to PND 21) 
given orally (gavage) to pregnant and lactating Long Evans rats (n=14?) stimulated growth of Leydig 
cells in male offspring (3H-thymidine incorporation). This was associated with an up-regulation of the 
expression of cell cycle proteins (e.g., PCNA, cyclin D3). The mitogenic BPA effect is possible 
mediated in part also by protein kinases (e.g., MAPK3/1), growth factor receptors (IGF1RB, EGFR) 
and Sertoli cell-secreted paracrine factor anti-Mullerian hormone. A slight induction of proliferation 
was also confirmed in vitro using 10-8 M but not with 10-11 M BPA. The effects on cell number and 
PCNA expression were not dose-dependent. A decreased Leydig cell testosterone production was 
observed at PND 21, 35 and 90 but changes in serum testosterone levels were not significant. The 
reduced hormone production was associated with a BPA induced suppression of LH receptors and the 
hydrosteroid dehydrogenase enzyme (HSD17B3) in Leydig cells. The authors suggest that BPA 
impaired postnatal Leydig cell differentiation but the effect on serum testosterone levels might be 
counterbalanced by a higher proliferation of Leydig cells. The unchanged testosterone serum levels 
observed in this study are not in line with earlier findings of Akingbemi et al. (2004) using rats treated 
with 2.4 µg BPA/kg bw per day from PND 21 – 35.  
 
The limited effect (<40%) on adult (PND 90) Leydig cell testosterone production was not dose-
dependent and is not expected to have an impact on sperm production in accordance with the absence 
of such effects at low doses in the Tyl-study (2002). Despite some limitations (two BPA doses only, 
no positive control) the consistent effects of BPA on proliferation and the associated biochemical 
changes at the low dose, which is relevant for human exposure, are challenging. It is noted that BPA at 
low doses (given perinatally) is frequently reported to stimulate proliferation in different tissues or 
cells.  
 
Nanjappa MK, Simon L and Akingbemi BT, 2012. The Industrial Chemical Bisphenol A (BPA) 
Interferes with Proliferative Activity and Development of Steroidogenic Capacity in Rat Leydig 
Cells. Biology of Reproduction, 86, 135, 131-112. 
 
This is an ex-vivo study which describes the effects of developmental exposure of male rats to BPA 
via gavage of pregnant and lactating Long Evans dams at 2.5 and 25 μg/kg body weight from 
gestational day 12 to postpartum day 21. Although no exposure measurements were performed the 
authors estimated based on previous data that maternal exposures to BPA at 2.5 and 25 μg/kg body 
weight represent BPA doses to the offspring of about 8 and 80 pg/kg body weight. Perinatal exposure 
to BPA did not affect litter size, birth weights of pups and pup sex ratio. Body weights, measured at 
21, 35 and 90 days of age, were equivalent in BPA-exposed and control animals (P > 0.05). Similarly, 
paired and relative testes weights (proportion to body weights) were not affected by BPA. However 
Leydig cell division was stimulated in the prepubertal period and increased Leydig cell numbers were 
shown in the testes of adult male rats at 90 days.  
 
It is difficult to judge the biological significance of small statistically differences in the sophisticated 
measurements made in this study in the context of totally normal pregnancies and littering. Particular 
care has to be taken in extrapolating findings in rat Leydig cells to humans. A detailed review of 
comparative physiology and pathology indicated that rats are quantitatively far more sensitive to the 
development of Leydig cell tumours than men as it appears that Leydig cell luteinizing hormone 
releasing hormone (gonadotropin-releasing hormone) receptors are unique to rats. Rats also have over 
10 times more luteinizing hormone receptors than men8. However LH (and indeed AGD, a 
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masculinisation read-out) was not measured which is a strange omission given the findings presented, 
and the adaptability of the reproductive axis to small changes in driving signals. It is unlikely that this 
study confirms an adverse effect of BPA exposure on human male reproductive function as being 
likely or not without further work (e.g. determination of whether these rats are in fact less fertile). 
 
Sangai NP, Verma RJ and Trivedi MH, 2012. Testing the efficacy of quercetin in mitigating 
bisphenol A toxicity in liver and kidney of mice. Toxicology and Industrial Health, 28, 28. 
 
The study was performed to evaluate the effect of quercetin (a flavone) on the toxicological effects of 
bisphenol A in liver and kidney of mice. Groups of Swiss albino mice (adult, males) received 120 
mg/kg bw per day and 240 mg/kg bw per day BPA for 30 days with and without quercetin. In the 
context of this evaluation the results obtained with quercetin are not of interest but the findings with 
120 mg/kg bw per day and 240 mg/kg bw per day BPA are of interest. Oral administration of BPA for 
30 days caused significant and dose-dependent decrease in body weight. Absolute and relative organ 
weights increased in liver and kidney of mice compared with vehicle control. Histopathological 
findings included hepatocellular necrosis, cytoplasmic vacuolization and decrease in hepatocellular 
compactness in liver and distortion of the tubules, increased vacuolization, necrosis and 
disorganization of glomerulus in the kidney.BPA treatment caused, when compared with vehicle 
control, a statistically significant reduction in the activities of a series of enzymes, such as catalase, 
superoxide dismutase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase. The 
content of glutathione and total ascorbic acid was reduced whereas significant increase was found in 
malondialdehyde levels. The results show that high doses of BPA (120 mg/kg bw per day and 240 
mg/kg bw per day) caused oxidative damage in liver and kidney of mice. The phytoestrogen content of 
the diet was apparently not tested. 
The study is well performed and gives some insight into the toxicological effects of BPA in liver and 
kidney. Based on the findings of the authors oxidative damage is one of the mechanisms/mode of 
action playing a role in BPA organ toxicity. However, the mechanisms remain far from being 
elucidated. 
Sun H, Si C, Bian Q, et al., 2012. Developing in vitro reporter gene assays to assess the hormone 
receptor activities of chemicals frequently detected in drinking water. Journal of Applied 
Toxicology, 32, 635-641.  
 
The authors studied the effect of 4.4x 10-9 – 10-6 M BPA on the activation of the estrogen receptor 
(ERα), the androgen receptor (AR) and the thyroid hormone receptor (TR) using transfected Vero 
(African green monkey kidney) cells. No toxic effects of BPA were detected at the investigated 
concentration range. A significant activation of the ERα was detected at and above 4.4x 10-7 M BPA. 
The authors calculated that 20 % of the maximal ERα activation was reached at 2.8x10-6 M BPA.  
A significant anti-androgenic activity was detected at 4.4x10-6 M BPA. The authors calculated that 
1.3x10-6 M BPA would result in a reduction of the AR receptor by 20%, which was activated with 50 
ng/l testosterone. Similarly, 4.4x10-6 M BPA would result in 20% reduction of the TR activity, which 
was activated by 0.5 µg/l T3. No receptor activation/antagonism was observed at relevant BPA 
concentrations. 
Peretz J, Craig ZR and Flaws JA, 2012. Bisphenol A inhibits follicle growth and induces atresia 
in cultured mouse antral follicles independently of the genomic estrogenic pathway. Biology of of 
Reproduction, 87, 1-11. 
 
The study aimed at determining whether BPA can affect cell cycle regulators and/or induce atresia in 
ovarian antral follicles and whether this is via genomic estrogenic signalling. FVB mice, both ESR1 
over-expressing and control were used, with 2-3 mice/experiment and 8-16 
follicles/treatment/experiment. BPA exposure was in-vitro using well established antral follicle culture 
methods. BPA was diluted in culture medium to achieve final concentrations in media = 1, 10, 100 µg 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 471 
BPA/ml. Treatments included co-treatments of BPA variously with E2 (10 nM) and ICI 182,780 ESR 
antagonist. Culture duration was 24-120 hrs. Endpoints were follicle growth and atresia, expression of 
cell cycle proliferation and apoptosis transcripts. BPA inhibited follicle growth and induced follicle 
atresia, effects that were not reversed by oestradiol or ESR antagonist and not increased in ESR-
overexpressing follicles. The study concludes that the genomic estrogen signalling pathway is not 
involved in transducing the adverse effects of BPA.  
The concentrations used in this study are higher than those relevant in vivo and those at which most 
effects were observed were far above human exposure levels. 
Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, Rosano C and 
Maggiolini M, 2012. Bisphenol A Induces Gene Expression Changes and Proliferative Effects 
through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts. Environmental 
Health Perspectives 120, 1177-1182. 
 
See study description in Appendix B  under Section “Carcinogenicity – In vitro studies”. 
Qin XY, Kojima Y, Mizuno K, Ueoka K, Muroya K, Miyado M, Zaha H, Akanuma H, Zeng Q, 
Fukuda T, Yoshinaga J, Yonemoto J, Kohri K, Hayashi Y, Fukami M, Ogata T, Sone H, 2012b. 
Identification of novel low-dose bisphenol A targets in human foreskin fibroblast cells derived 
from hypospadias patients. PLoS One, 7, e36711. 
 
DNA microanalysis was used to identify novel targets of low concentrations of BPA (10-8 M) in 
human foreskin fibroblasts cells derived from child hypospadias patients. In addition to BPA E2 (10-11 
M) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD at 10-9 M) were used. Among the 71 genes 
differentially expressed after BPA treatment only a small subset was also affected by E2. Using real-
time PCR it could be confirmed that the expression of one of the most effectively down-regulated 
genes, i.e. metallopeptidase 11 (MMP11) was only 40% in BPA-treated cells. While MMP11 was 
shown to be overexpressed in several human cancers, the authors speculated that its down-regulation 
might be associated with abortive penile development. 
Tilghman SL, Bratton MR, Segar HC, Martin EC, Rhodes LV, Li M, McLachlan JA, Wiese TE, 
Nephew KP and Burow ME, 2012. Endocrine disruptor regulation of microRNA expression in 
breast carcinoma cells. PLoS ONE 7(3): e32754. 
 
This study that uses the human MCF-7 breast cancer cell line, which is oestrogen receptor positive and 
hormone sensitive investigate the cellular effects of both DDT and BPA. It shows that DDT and BPA 
can potentiate oestrogen receptor transcriptional activity, resulting in an increased expression of 
receptor target genes, including progesterone receptor, bcl-2, and trefoil factor 1. While these 
compounds and oestrogen similarly altered the expression of multiple microRNAs in MCF-7 cells, 
including miR-21, differential patterns of microRNA expression were induced by DDT and BPA 
compared to oestrogen. This study shows the oestrogenic potential of BPA and the DDT in vitro.  
 
Vo TTB, An B-S, Yang H, Jung E-M, Hwang I, and Jeung E-B, 2012. Calbindin-D9k as a 
sensitive molecular biomarker for evaluating the synergistic impact of estrogenic chemicals on 
GH3 rat pituitary cells. International Journal of Molecular Medicine, 30, 1233-1240. 
The authors studied the effect of 10-7, 10-6 and 10-5 M BPA in combination with equal concentrations 
of 4-nonylphenol (NP), 4-tert octylphenol (OP) and isobutylparabene (IBP) on the concentration and 
expression of the cytosolic calcium-binding protein calbindin, which was used as indictor of endocrine 
activation. Mixtures of BPA+NP, BPA+NP+OP and BPA+NP+IBP increased the gene and protein 
expression of calbindin significantly, compared to incubations with single substances. These effects 
were lower after preincubation with fulvestrant, an anti-estrogen compound. 
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The expression of the progesterone receptor (PR) significantly increased after incubation with 
mixtures of BPA+NP+OP or BPA+NP+IBP (10-5-10-7 M), compared to the exposure of each chemical 
alone. 
Wang J, Sun B, Hou M, Pan X and Li X, 2013. The environmental obesogen bisphenol A 
promotes adipogenesis by increasing the amount of 11β-hydroxysteroid dehydrogenase type 1 in 
the adipose tissue of children. International Journal of Obesity, 37, 999-1005. 
 
See study description in Appendix B  under section “Metabolic effects - In vitro studies”. 
Wu S, Wei X, Jiang J, Shang L and Hao W, 2012. Effects of bisphenol A on the proliferation and 
cell cycle of HBL-100 cells. Food and Chemical Toxicology, 50, 3100-3105. 
 
Proliferation, progression through cell cycle and cyclin D1 expression were studied in normal human 
breast cells (HBL-100). In these cells BPA induced growth at a 100-fold lower concentration, i.e. at 
10-10 M, than E2. The BPA effect could not be completely blocked by the ER antagonist ICI 182780. 
Additionally BPA induced cyclinD1 expression but no ERα expression. According to these data the 
proliferation of HBL-100 cells is a sensitive endpoint to BPA.  
(i) Toxicokinetic/metabolism issues 
Coughlin JL, Thomas PE and Buckley B, 2012. Inhibition of genistein glucuronidation by 
bisphenol A in human and rat liver microsomes. Drug Metabolism and Disposition, 40, 481-485. 
 
The authors addressed the influence of BPA on the in vitro metabolism (microsomal glucuronidation) 
of an endocrine-active substance, i.e. genistein. This issue may be particularly relevant for risk 
assessment of mixtures of endocrine disrupters. The BPA-induced inhibition of glucuronidation of 
genistein was studied in human liver microsomes (pooled from 50 donors, mixed gender) and rat liver 
microsomes (pooled from 100 female and 100 male Wistar rats). Non-competitive and competitive 
inhibition was observed in human and rat liver microsomes, respectively. However, for these 
experiments only one high BPA concentration (25 µM) was used. Additionally, a concentration range 
of 5 to 250 µM BPA was used to establish an IC50 value of 37 µM BPA for the inhibition of genistein 
(100 µM) metabolism. In conclusion, these findings refer to high in vitro BPA concentrations. 
Trdan Lusin T, Roskar R and Mrhar A, 2012. Evaluation of bisphenol A glucuronidation 
according to UGT1A1*28 polymorphism by a new LC-MS/MS assay. Toxicology, 292, 33-41. 
The paper describes a novel method for biomonitoring BPA exposure using an internal standard 
(BPAGd16) and a LC-MS/MS method for simultaneous determination of BPA and its metabolite.* 
Using this analytical approach the authors confirmed the high metabolic capacity of human liver 
microsomes, i.e. 400-fold higher compared to intestinal microsomes. No metabolic activity was 
detected in lung microsomes. Therefore, it can be assumed that BPA intake by inhalation (which is not 
known to have a relevant contribution to human BPA exposure) would result in “unconjugated BPA” 
in the blood. In addition the authors addressed the impact of UGT1A1*28 polymorphism on BPA 
metabolism using genotyped human liver microsomes (wild-type homozygotes, heterozygotes and 
polymorphic homozygotes). Based on differences in the glucuronidation efficiency (Vmax) this 
polymorphism could contribute to a minor extent to differences in BPA elimination which is more 
actively triggered by UGT2B15 isoforms (Hanioka et al., 2008).  
Overall, this paper does not change the view on the toxicokinetics of BPA expressed by the CEF Panel 
in its Opinions (EFSA 2006, 2008, 2010). 
(ii) Gene expression 
Humans 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 473 
Hanna CW, Bloom MS, Robinson WP, Kim D, Parsons PJ, Vom Saal FS, Taylor JA, Steuerwald 
AJ, Fujimoto VY, 2012. DNA methylation changes in whole blood is associated with exposure to 
the environmental contaminants, mercury, lead, cadmium and bisphenol A, in women 
undergoing ovarian stimulation for IVF. Human Reproduction, 27, 1401-1410. 
 
Blood concentrations of mercury, lead, cadmium and unconjugated BPA (uBPA) were examined in 
relation to DNA methylation in 43 women undergoing ovarian stimulation for IVF. Blood and urine 
were collected on the day of oocyte retrieval. Unconjugated BPA was quantified in serum of 35 
women with median values of 2.4 µg/l (0.0-67). This is in contrast to values reported by Teeguarden et 
al. (2011) for persons with high BPA exposure via canned food (intake = urinary excretion/24 hrs: 
<0.3 µg/kg bw per day): the peak serum concentrations of unconjugated BPA were between 0.001 and 
0.11 nM corresponding to 0.23 – 25 ng/l. Tayler et al. (2011) reported a serum concentration of 
unconjugated BPA in monkeys of 0.5 µg/l after oral intake of 400 µg/kg bw per day. Candidate CpG 
sites were identified using a Diff score >|13| (p=0.005) and an absolute difference of 10% which were 
confirmed using bisulfite pyrosequencing. BPA exposure was divided into higher and lower exposure 
groups by median concentrations. Women with higher BPA exposure had significantly lower 
methylation of promotor CpG site at the TSP50 gene, and BPA exposure was inversely correlated to 
methylation (r=-0.51, p=0.001). The negative correlation suggests that increased BPA exposure may 
be associated with increased expression of TSP50. The TSP50 gene encodes “testis specific protease 
50” expressed in the testis. In vitro studies showed that TSP50 is related to cell proliferation. Knock-
down of TSP50 resulted in a decreased cell proliferation (Zhou et al. 2010) and overexpression 
increased cell proliferation (Song et al. 2011). Increased TSP50 has also been observed in female 
breast cancer tissue.  
 
No confounding factors were considered. BPA values for samples measured <LOD were generated by 
extrapolation from the standard curve, and where no evidence for the presence of BPA at any 
concentrations existed, BPA values were assigned a value of zero. This could influence the results. 
The authors themselves discuss the limitations of their study due to its pilot nature. In addition to the 
issues above they mention: no correction for multiple comparisons, heterogeneity of the sample with 
regard to infertility diagnosis, no adjustment for factors that might potentially alter methylation as well 
as body burdens of Hg, Pb, Cd (unmeasured confounding), assessment in whole peripheral blood 
(varying cell types). 
Melzer D, Harries L, Cipelli R, Henley W, Money C, McCormack P, Young A, Guralnik J, 
Ferruci L, Bandinelli S, Corsi AM, Galloway T, 2011. Bisphenol A Exposure is Associated with 
In-Vivo Estrogenic Gene Expression in Adults. Environmental Health Perspectives, 119, 1788-
1793. 
 
The study investigated associations between urinary BPA exposure and in vivo expression of six 
estrogen receptor, estrogen-related receptor, and androgen receptor genes in peripheral blood 
leukocytes in 96 adult men in an Italian population based cohort. Urinary BPA concentration (mean 
3.65 ng/ml) was in the normal range (NHANES 2003/4: 2.7 ng/ml). Positive associations were found 
between urinary BPA and ESR2 (estrogen receptor type beta) and ESRRA (estrogen related receptor 
alpha) expression.  
 
The study is sound despite the relatively low sample size and this study presents new results. 
Considering that the BPA induced pattern of gene expression is cell-specific (EFSA Opinion, 2010, 
p73) the relevance for ERS2 (ERβ) expression in blood leukocytes is unclear. While BPA exposure 
increases ERβ in breast cancer cells, it was unaffected by BPA (1 nM) in prostate cancer cells with 
wild-type androgen receptor (AR) and was down-regulated by 1 nM BPA in AR-mutant prostate 
cancer cells (Hess-Wilson et al., 2007). Considering also the fast metabolism of BPA the time-
dependence of the expression changes in ERβ would be interesting. Finally, the question has to be 
answered whether or not such small changes (i.e. 65% higher mean ESR2 expression in upper-tertile 
BPA excretors) could be biologically meaningful. Although the clinical significance of these results is 
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unknown, the activation in humans suggests that BPA could be a xenoestrogen in this population 
representative sample. The results need to be replicated and expanded in a larger sample.  
Singh S, Li SS, 2012. Bisphenol A and phthalates exhibit similar toxicogenomics and health 
effects. Gene, 494, 85-91. 
 
This paper compares toxicogenomics and adverse effects on human health of BPA exposure with 
those of phthalates by using the Comparative Toxicogenomics Database (CTD) in order to find 
biomarkers of toxicity. The CTD include data on a huge set of interactions between chemicals and 
genes/proteins from several species, gene/protein-disease direct relationships, and chemical-disease 
direct relationships. The authors identified 1932 –BPA-gene/protein interactions, and among them 
estrogen receptor 1 and 2 appeared most frequently.  
The comparative toxicogenomics and health effects between BPA and the five most frequently curated 
phthalates revealed 89 common genes/proteins that may serve as biomarkers to assess their toxicity. It 
is noted however, that most phthalates (e.g. DEHP) have very poor or no estrogenic activity but act via 
other modes of action (e.g. Borch et al., 2006). Therefore, the relevance of a common mode of action 
of phthalates and BPA particularly on estrogen receptors is questionable. 
Animals 
Doshi T, Mehta SS, Dighe V, Balasinor N, Vanage G, 2011. Hypermethylation of estrogen 
receptor promoter region in adult testis of rats exposed neonatally to bisphenol A. Toxicology, 
289, 74-82. (AUG-11) 
 
A single BPA dose (2.4 µg/pup/day which the authors state corresponds roughly to 300 µg/kg bw per 
day), was administered by subcutaneous injection to male Holtzman rats on the first 5 days 
postnatally. The testes were collected on day 125 (adult) and increased Dnmt expression and Esr1 and 
Esr2 promoter region hypermethylation were observed.  
This limited but well performed study of epigenetic effects on the rat testis suggests that BPA 
exposure during fetal/neonatal life could disrupt estrogen receptor mediated signalling at least in part 
by Esr hypermethylation and might be a mechanism contributing to disrupted testis development in 
rodents caused by BPA. The acute nature of the exposure (and the fact that adverse effects on the 
testes do not appear to have been checked) renders extrapolation to the human difficult. 
 
Horstman et al. 2012. Effects of transplacental 17-α-ethynyl estradiol or bisphenol A on the 
developmental profile of steroidogenic acute regulatory protein in the rat testis. Birth Defects 
Research (Part B) 00:1–8  
 
In this study pregnant Sprague Dawley rats were dosed from gestational day 11 with either oestradiol 
or BPA by the subcutaneous route. Doses of oestradiol were 0.001, 0.1 or 10 µg/kg/day or BPA at 
0.02, 0.5, 400 mg/kg/day. Fetal testes were harvested on gestational days 16, 18 or 20. They were 
studied using quantitative reverse transcriptase PCR for changes in steroidogenic acute regulatory 
(StAR) protein transcript levels and immunocytochemistry for StAR protein. Neither oestradiol nor 
BPA exposure caused morphological changes in the developing seminiferous tubules or the interstitial 
region at gestational days16–20. However, BPA and oestradiol slightly reduced StAR mRNA and 
protein levels at gestational day 18 and 20 but only the highest doses of 10 µg/kg/day oestradiol or 400 
mg/kg/day BPA. Immunohistochemistry also demonstrated decreases in StAR protein levels but again 
only at the highest doses. Whilst this study demonstrates the potential effects of neonatal exposure to 
BPA on testicular function of offspring, this seems to be limited to high exposures which are probably 
not relevant to human exposures. 
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(iii) Epigenetics 
In vivo studies on epigenetic effects of BPA 
Anderson OS, Nahar MS, Faulk C, Jones TR, Liao C, Kannan K, Weinhouse C, Rozek LS and 
Dolinoy DC, 2012. Epigenetic responses following maternal dietary exposure to physiologically 
relevant levels of bisphenol A. Environmental and Molecular Mutagenesis, 53, 334-342. 
 
Anderson et al. (2012) tested the effect of 3 doses of BPA given via the diet (50 ng BPA/kg feed, 50 
µg BPA/kg feed, 50 mg BPA/kg feed) before and during pregnancy until lactation day 22 using the 
viable yellow agouti (Avy) mouse model. Virgin a/a dams (aged 6 weeks) were treated orally with BPA 
via a phytoestrogen-free diet for 2 weeks, before mating with Avy/a males. All animals were housed in 
polycarbonate-free cages and provided ad libitum access to diet and BPA-free water. Dams remained 
on the assigned diet throughout pregnancy and lactation The Avy/a offspring were examined on PND 
22. Nine to 14 litters were used per each experimental group, and therefore the sample size was 
acceptable. Analysis of coat color phenotype replicated previous results showing that the distribution 
of 50 mg BPA/kg Avy/a offspring shifts toward yellow by decreasing DNA methylation in the 
retrotransposon upstream of the Agouti gene. Maternal exposure to 50 µg or 50 ng BPA/kg, however, 
resulted in altered coat color distributions in comparison with control, but no DNA methylation effects 
at the Agouti gene were noted. DNA methylation at the CDK5 activator-binding protein (CabpIAP) 
metastable epiallele shows hypermethylation in the 50 µg BPA/kg - offspring, compared with controls. 
Free and conjugated BPA concentrations were analyzed 
in a subset of d22 mouse liver samples (1 pup per litter) from each BPA exposure and control group as 
well as in 51 human fetal liver samples. Total BPA concentrations in human fetal liver ranged from 
below LOQ to 96.8 ng/g. Comparison of exposed mouse liver BPA levels to human fetal liver BPA 
levels led the authors to state that the three experimental exposures were physiologically relevant. The 
authors concluded that perinatal BPA exposure affects offspring phenotype and epigenetic regulation 
across multiple doses.  
 
Bromer JG, Zhou Y, Taylor MB, Doherty L and Taylor HS, 2010. Bisphenol-A exposure in 
utero leads to epigenetic alterations in the developmental programming of uterine estrogen 
response. FASEB Journal, 24, 2273-2280. 
Bromer at al. (2010) studied whether an epigenetic mechanism underlies BPA-mediated alterations in 
Hoxa10 expression. Pregnant CD-1 mice (housed in polypropylene cages) were treated with BPA (5 
mg/kg bw, intraperitoneal) or vehicle control on days 9–16 of pregnancy. Food (Purina chow) and 
water were given ad libitum (no other information were given as to the estrogenicity of the diet or the 
type of water bottles). For statistical analysis a Student’s t-test not corrected for multiple comparisons 
was used. Hoxa10 mRNA and protein expression were increased by 25% in the reproductive tract of 
mice exposed in utero. Bisulfite sequencing revealed that cytosine-guanine dinucleotide methylation 
was decreased from 67 to 14% in the promoter and from 71 to 3% in the intron of Hoxa10 after in 
utero BPA exposure. Decreased DNA methylation led to an increase in binding of ER-alpha to the 
Hoxa10 ERE both in vitro as and in vivo as determined by EMSA and chromatin immunoprecipitation, 
respectively. Diminished methylation of the ERE-containing promoter sequence resulted in an 
increase in EREdriven gene expression in reporter assays. The authors concluded that altered 
methylation is a mechanism of BPA-induced altered developmental programming and that permanent 
epigenetic alteration of ERE sensitivity to estrogen may be a general mechanism through which 
endocrine disruptors exert their action.  
 
Chao HH, Zhang XF, Chen B, Pan B, Zhang LJ, Li L, Sun XF, Shi QH and Shen W, 2012. 
Bisphenol A exposure modifies methylation of imprinted genes in mouse oocytes via the estrogen 
receptor signaling pathway. Histochemistry and Cell Biology, 137, 249-259.  
 
BPA-induced effects on DNA methylation and oocyte maturation were studied in postnatally exposed 
(s.c. injection of 0, 20 and 40 µg/kg) female CD-1 mice. No information on housing condition, diet 
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and water bottles were given. A hypomethylation of 3 gene (insulin like growth factor 2 receptor, Peg3 
and H19) was observed along with a dose-dependent reduction in the mRNA expression of 4 
methyltransferases. BPA-induced hypomethylation was abolished by an ER inhibitor. ER-alpha but 
not ER-betha mRNA and protein expression were significantly up-regulated in BPA-treated cells. 
Additionally, BPA induced an abnormal ratio of spindle assembling in meiosis I, which was not 
increased by dose.  
Dolinoy DC, Huang D and Jirtle RL, 2007. Maternal nutrient supplementation counteracts 
bisphenol A-induced DNA hypomethylation in early development. Proceedings of the National 
Academy of Sciences of the United States of America, 104, 13056-13061. 
Dolinoy et al. (2007) analysed the effect of maternal nutrient supplementation on bisphenol A-induced 
DNA hypomethylation using the agouti (Avy) mouse model. Virgin a/a females, 8–10 weeks of age, 
were assigned to receive one of four diets: (a) modified AIN-93G diet (control), (b) modified AIN-
93G containing 50 mg BPA/kg diet; (c) modified AIN-93G diet containing 50 mg BPA/kg diet and 
supplemented 250 mg genistein/kg diet (d) modified AIN-93G diet with 50 mg BPA/kg diet and 
supplemented with methyl donor compounds (4.3 mg folic acid/kg diet, 0.53 mg vitamin B12/kg diet, 
5 g betaine/kg diet, 7.97 g choline chloride/kg diet). As doses were given as BPA-concentration in the 
diet, BPA-intake was not adjusted to body weight. Diets were provided 2 weeks before mating with 
Avy/a males and throughout pregnancy and lactation. No information on cage and drinking bottle 
material was provided. The offspring was examined on PND 22. The sample size was acceptable. 
Maternal exposure to BPA shifted the coat color distribution of viable yellow agouti (Avy) mouse 
offspring toward yellow by decreasing CpG methylation in an intracisternal A particle retrotransposon 
upstream of the Agouti gene. CpG methylation was also decreased at another metastable locus, the 
CDK5 activator-binding protein (CabpIAP). DNA methylation at the Avy locus was similar in tissues 
from the three germ layers, supporting that epigenetic patterning during early stem cell development is 
sensitive to BPA exposure. Maternal dietary supplementation with either methyl donors like folic acid 
or the phytoestrogen genistein counteracted BPA-induced hypomethylation. The authors concluded 
that early developmental exposure to BPA can change offspring phenotype by stably altering the 
epigenome, an effect that can be counteracted by maternal dietary supplements.  
Doherty LF, Bromer JG, Zhou Y, Aldad TS and Taylor HS, 2010. In utero exposure to 
diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary 
gland: an epigenetic mechanism linking endocrine disruptors to breast cancer. Horm Cancer, 1, 
146-155. 
Doherty et al. (2010) studied the effect of BPA on expression and function of Enhancer of Zeste 
Homolog 2 (EZH2), a histone methyltransferase that has been linked to breast cancer risk and 
epigenetic regulation of tumorigenesis, in MCF-7 cells and in mammary glands of mice exposed in 
utero. DES served as positive control. Treatment of MCF-7 cells with BPA (2.5×10E−4, 2.5×10E−5, 
2.5×10E−6, 2.5×10E−7, 2.5×10E−8M) or DES (5×10E−6, 5×10E−7, 5×10E−8, 5×10E−9, 5×10E−10 
M) led to a 3- and 2-fold increase in EZH2 mRNA expression, respectively as well as increased EZH2 
protein expression. Histone H3 trimethylation was increased in MCF-7 cells treated with BPA or DES. 
Student’s t-test was not corrected for multiple comparisons. For the in in vivo studies, environmental 
contamination was controlled by means of the use of standard polypropylene cages but no information 
was given on drinking bottles. Mice exposed to DES in utero (maternal dose: 10 μg DES/kg bw, 
intraperitoneal on gestation day 9-26) showed a >2-fold increase in EZH2 expression in adult 
mammary tissue compared with controls. EZH2 protein was elevated in mammary tissue of mice 
exposed to DES or BPA (maternal dose: 5 mg BPA/kg, i.p. on gestation day 9-26). Mice exposed to 
BPA or DES in utero also showed increased mammary histone H3 trimethylation. The authors 
suggested that developmental programming of EZH2 is a novel mechanism by which in utero 
exposure to BPA and DES leads to epigenetic regulation of the mammary gland. 
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Doshi T, D'Souza C, Dighe V and Vanage G, 2012. Effect of neonatal exposure on male rats to 
bisphenol A on the expression of DNA methylation machinery in the postimplantation embryo. 
Journal of Biochemical and Molecular Toxicology, 26, 337-343. 
Doshi et al. (2012) addressed the mechanism involved in resorption of rat embryos (postimplantation 
loss; POL) as a result of BPA treatment (PND 1-5). Neonatal male pups received 5 subcutaneous 
injections of BPA (400 µg/kg bw) for the first 5 days of life (PND 1-5) or sesame oil (vehicle). On , 
PND 75 BPA-treated and control males (12/group) were mated with normal cycling female (n=24). 
Animals were fed a diet of soy-free, in-house-prepared rat pellets, and water ad libitum throughout the 
study. No information was provided on cages and drinking water bottle material. Pregnant rats were 
sacrificed on GD 20. qPCR expression data were measured on “BPA resorbed embryos”. The authors 
reported that neonatal exposure of male rats to BPA downregulated the gene expression of Dnmts and 
related transcription factors in resorbed embryos as compared with the viable embryo, and suggested 
that BPA may have altered the sperm epigenome, which might have affected the embryo development 
leading to an increase in the postimplantation loss. The expression levels were calculated in relation to 
endogenous control ribosomal L19 gene. However, the authors neither provided data on endogenous 
L19 expression levels in controls as compared to BPA-treated, nor a comment on the degree of 
resorption/ tissue lysis, preventing the validity of the relative expression values from being estimated.  
Ho S-M, Tang W-Y , Belmonte de Frausto J and Prins GS, 2006. Developmental exposure to 
estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically 
regulates phosphodiesterase type 4 variant 4. Cancer Research 66, 5624-5632.  
Ho et al. (2006) studied the effect of neonatal exposure of rats to BPA (0.1 g/pup; 10 g/kg bw) on the 
occurrence of prostate intraepithelial neoplasia (PIN) and DNA methylation pattern.  17ß-oestradiol-3-
benzoate (high dose: 25 µg EB/pup=2500g/kg bw; low dose: 0.1 g/pup=10 µg/kg bw) served as 
positive control. The compounds were administered subcutaneously on PND 1, 3 and 5. The sample 
size was acceptable and environmental contamination was controlled (new polysulfone cages, water in 
glass bottles, low exposure to phytoestrogens (12 ppm), one feed batch for whole experiment). At 
PND 90, an increased in the incidence and score of prostate intraepithelial hyperplasia (PIN), 
associated with an increased prostatic cell turnover was observed in BPA treated rats. For 
phosphodiesterase type 4 variant 4 (PDE4D4), an enzyme responsible for cyclic AMP breakdown, a 
specific methylation cluster was reported in the 5-flanking CpG island. In normal prostate, this site 
gradually was hypermethylated with aging, resulting in loss of gene expression. Neonatal exposure to 
BPA resulted in continued, elevated PDE4D4 expression. Studies with a normal prostatic epithelial 
cell line (NbE-1) and a rat cancer cell line (AIT) confirmed that site-specific methylation is involved 
in transcriptional silencing of the PDE4D4 gene and showed hypomethylation of this gene in prostate 
cancer cells. The PDE4D4 alterations in BPA-exposed prostates were distinguishable before 
histopathologic changes of the gland. The authors concluded that low-dose exposures to BPA affect 
the prostate epigenome during development and thereby promote prostate disease with aging. 
Rosenfeld CS, Sieli PT, Warzak DA, Ellersieck MR, Pennington KA and Roberts RM, 2013. 
Maternal exposure to bisphenol A and genistein has minimal effect on Avy/a offspring coat color 
but favors birth of agouti over nonagouti mice. Proceedings of the National Academy of Sciences 
of the United States of America, 110, 537-542. 
Rosenfeld et al. (2013) fed groups of C57/B6 a/a females, which are nonagouti, either a 
phytoestrogen-free control diet or one of six experimental diets: diets 1–3 contained BPA (50 mg, 5 
mg, and 50 μg BPA/kg food, respectively); diet 4 contained genistein (G; 250 mg/kg food); diet 5 
contained G plus BPA (250 and 50 mg/kg food, respectively); and diet 6 contained 0.1 μg of ethinyl 
oestradiol (EE)/kg food. Mice were bred to Avy/a males over multiple parities. In all, 2,824 pups from 
426 litters were born. None of the diets provided any significant differences in relative numbers of 
brown, yellow, or intermediate coat color Avy/a offspring. However, BPA plus G (P < 0.0001) and EE 
diets (P = 0.005), but not the four others, decreased the percentage of black (a/a) to Avy/a offspring 
from the expected Mendelian ratio of 1:1. The authors concluded that – in contrast to Anderson et al. 
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2012, Dolinoy et al. 2006 (genistein), 2007(BPA)- the present study indicates that exposure of Avy/a 
conceptuses to genistein and BPA through maternal diet did not cause any consistent shift in offspring 
coat color relative to controls. However, Rosenfeld noted that two diets likely to promote an enriched 
estrogenic environment (BPA plus genistein; ethinyloestradiol) distorted the anticipated 1:1 ratio of 
agouti Avy/a to nonagouti a/a offspring in a/a × Avy/a crosses in favor of the latter. This effect became 
more pronounced with parity and according to the authors, possibly because the expression of the 
paracrine agouti-regulated protein (AGRP; synom. agouti signaling protein (ASIP)) provides a short-
term, competitive advantage in utero.  
Tang WY, Morey LM, Cheung YY, Birch L, Prins GS and Ho SM, 2012. Neonatal exposure to 
estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes 
and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life. 
Endocrinology, 153, 42-55. 
Tang et al. (2012) studied the effects of neonatal BPA treatment (10 µg/kg bw, subcutaneous injection 
on PND 1, 3 and 5) at PND 10, 90 and 200 in male Sprague-Dawley rats. Animals were housed in new 
polysulfone cages, and given deionized water from glass bottles, and fed with a single feed lot of soy-
free, phytoestrogen-reduced diet containing 12 ppm phytoestrogens as determined by high 
performance liquid chromatography. Litter effects were properly avoided. The promoter of 
nucleosome binding protein-1 (Nsbp1) was found to be hypomethylated. Hippocalcin-like 1 (Hpcal1) 
was reported to be progressively demethylated during aging but this age-related process was found to 
be blocked by neonatal BPA exposure, resulting in silencing of RNA-expression. Early and persistent 
overexpression were reported for DNA methyltransferases (Dnmt 3a/b) and methyl CpG binding 
protein (Mbd2/4), which was not a function of DNA methylation at their promoters. The authors 
suggested that their lifelong aberrant expression implicates them in early-life reprogramming and 
prostate carcinogenesis during adulthood.  
Yaoi T, Itoh K, Nakamura K, Ogi H, Fujiwara Y and Fushiki S, 2008. Genome-wide analysis of 
epigenomic alterations in fetal mouse forebrain after exposure to low doses of bisphenol A. 
Biochem Biophys Res Commun, 376, 563-567. 
Yaoi et al. (2008) studied the effect of maternal exposure to BPA (20 µg BPA/kg of body weight , 
subcutaneous injection once daily from E0; dams sacrificed at E12.5 or E14.5) on the epigenome in 
mouse forebrain. The CpG methylation status was scanned in 2500 NotI loci, representing 48 
(de)methylated unique loci. Methylation status in most of them was primarily developmental stage-
dependent. Each of almost all cloned NotI loci was located in a CpG island (CGI) adjacent to 5′ end of 
the transcriptional unit. The mRNA expression of two functionally related genes changed with 
development as well as the exposure to BPA, namely: 1. Vps52, encoding a protein constituting a 
protein complex involved in the Golgi-associated retrograde transport system; 2. LOC72325, encoding 
a hypothetical protein with a functional domain (Vps9) that catalyzes nucleotide exchange on a small 
GTPase, Rab5. In both genes, changes at the transcriptional level correlated with the changes in NotI 
methylation status. The authors concluded that epigenetic alterations in promoter-associated CGIs 
after exposure to BPA may underlie some effects on brain development.  
 
 
Zhang XF, Zhang LJ, Feng YN, Chen B, Feng YM, Liang GJ, Li L and Shen W, 2012b. 
Bisphenol A exposure modifies DNA methylation of imprint genes in mouse fetal germ cells. 
Molecular Biology Reports, 39, 8621-8628. 
 
Zhang et al. treated pregnant mice from 0.5 day post coitum with BPA at doses of 0, 40, 80 and 160 
µg BPA/kg body weight/day (orally via (Eppendorf pipette) until 12dpc. DNA methylation of 
imprinting genes, Igf2r, Peg3 and H19, was decreased with the increase of BPA concentration in fetal 
mouse germ cells. The relative mRNA levels of Nobox were lower in BPA-treated group compared to 
control (BPA free) in female fetal germ cells, but in male fetal germ cells, a significant higher in 
Nobox expression was observed in BPA-treated group compared to control. Decreased mRNA 
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expression of specific meiotic genes including Stra8 and Dazl were obtained in the female fetal germ 
cells. The authors concluded that BPA exposure can affect the DNA methylation of imprinting genes 
in fetal mouse germ cells. 
 
Cell culture studies on epigenetic effects of BPA 
Avissar-Whiting M, Veiga KR, Uhl KM, Maccani MA, Gagne LA, Moen EL and Marsit CJ, 
2010. Bisphenol A exposure leads to specific microRNA alterations in placental cells. Reprod 
Toxicol, 29, 401-406. 
 
Avissar-Whiting et al. (2010) investigated the effect of BPA (0,25 to 25 ng/μL of BPA for six days 
(medium refreshed on day 2 and 4) on microRNAs (miRNAs) in human placental cells. miRNA 
microarray was performed following BPA treatment in three immortalized cytotrophoblast cell lines 
(3A, first-trimester villous cells; TCl-1, third trimester extravillous cells; HTR-8, first trimester 
extravillous cells) and the results validated using quantitative real-time PCR. For functional analysis, 
overexpression constructs were stably transfected into cells that were then assayed for changes in 
proliferation and response to toxicants. Microarray analysis revealed several miRNAs to be 
significantly altered in response to BPA treatment in two cell lines (3A and HR-8). Real-time PCR 
results confirmed that miR-146a was particularly strongly induced and its overexpression in cells led 
to slower proliferation as well as higher sensitivity to the DNA damaging agent, bleomycin. The 
authors concluded that BPA can alter miRNA expression in placental cells, a potentially novel mode 
of BPA toxicity.  
Fernandez SV and Russo J, 2010. Estrogen and xenoestrogens in breast cancer. Toxicology and 
Pathology, 38, 110-122. 
Fernandez previously demonstrated that BPA was able to induce the transformation in vitro of human 
breast epithelial cells. While the normal-like human breast epithelial cell line, MCF-10F, formed 
tubules in collagen (3-D cultures), treatment with BPA (10E-5 M and 10E-6 M BPA) reduced the cells 
tubules production (73% and 80%, respectively) and produced some spherical masses (27% and 20%, 
respectively). In the present study, expression and DNA methylation analyses were performed in these 
cells after exposure to BPA. These cells showed an increased expression of BRCA1, BRCA2, BARD1, 
CtIP, RAD51 and BRCC3, all of which are genes involved in DNA repair, as well as the 
downregulation of PDCD5 and BCL2L11 (BIM), both of which are involved in apoptosis. 
Furthermore, DNA methylation analysis showed that the BPA exposure induced the hypermethylation 
of BCL2L11, PARD6G, FOXP1 and SFRS11, as well as the hypomethylation of NUP98 and CtIP 
(RBBP8). The authors concluded that normal human breast epithelial cells exposed to BPA have 
increased expressions of genes involved in DNA repair in order to overcome the DNA damage 
induced by this chemical.  
 
Hashimoto S, Shiomoto K, Okada K and Imaoka S, 2012. The binding site of bisphenol A to 
protein disulphide isomerase. Journal of Biochemistry, 151, 35-45. 
 
In this mechanistic study, protein disulphide isomerase (PDI) was isolated as a binding protein of BPA 
in the rat brain. The authors determined and characterized the binding sites of BPA to PDI. The BPA-
binding domain was identified with ab, b'a'c, a, b, b' and a'c fragment peptides of PDI by surface 
plasmon resonance spectroscopy. BPA interacted with ab, b'a 'c, a and b', suggesting that a and b' 
domains are important in their interaction. Second, ab, b'a'c, a,b,b',a', abb'a', abb', b'a', Δb' and a'c 
fragment peptides were used for their isomerase activity with RNase as a substrate. BPA could inhibit 
the activity of peptide fragments including b', suggesting that b' domain contributes to inhibition of 
catalytic activity of PDI by BPA. The authors investigated the BPA-binding capacity of PDI by amino 
acid substitution. PDI lost the BPA-binding activity by the mutation of H258 and mutation of Q245 
and N300 also decreased its activity. Furthermore, acidic condition increased the BPA-binding activity 
of PDI. Based on their findings, the authors concluded that the charge of these amino acid especially, 
H258, is important for the BPA binding to PDI.  
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Qin X-Y , Fukuda T , Yang L, Zaha H, Akanuma H, Zeng Q, Yoshinaga J and Sone H, 2012b. 
Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary 
epithelial cells. Cancer Biology Therapy 13, 1-11. 
 
See study description in Appendix B under section “Carcinogenicity – In vitro studies/Mechanisms of 
action”. 
Weng YI, Hsu PY, Liyanarachchi S, Liu J, Deatherage DE, Huang YW, Zuo T, Rodriguez B, 
Lin CH, Cheng AL and Huang TH, 2010. Epigenetic influences of low-dose bisphenol A in 
primary human breast epithelial cells. Toxicology and Applied Pharmacology, 248, 111-121. 
 
Weng et al. (2010) examined the effect of BPA epigenetic changes in breast epithelial cells using 
mammospheres as a model. Breast progenitor cells from noncancerous human mammary tissues were 
enzymatically dissociated and grown into floating spherical colonies so called mammospheres. These 
mammospheres enriched in breast progenitor cells were exposed to BPA (4 nM), or DMSO for 3 
weeks. DES (70 nM) served as positive control. The differentiated cells were studied using 
immunofluorescence with anti-ERα antibody, gene expression microarrays and reverse transcription-
quantitative PCR. The effect of BPA on the ERα signaling pathway and global gene expression 
profiles was investigated. Compared to control cells, nuclear internalization of ERα was observed in 
epithelial cells pre-exposed to BPA. The authors identified 170 genes with expression changes in 
response to BPA. Functional analysis confirmed that gene suppression was mediated in part through 
an ERα-dependent pathway. As a result of exposure to BPA or other oestrogen-like chemicals, the 
expression of lysosomal-associated membrane protein 3 (LAMP3) became epigenetically silenced in 
breast epithelial cells. Furthermore, increased DNA methylation in the LAMP3 CpG island positively 
correleated with ERα-positive breast tumours. This study shows potential epigenetic alterations to 
progenitor mammary cells in response to BPA in vitro. 
(iv) Excluded studies 
Excluded in vivo mixture studies 
The following animal studies in which BPA was tested as part of a mixture of chemicals were 
excluded a priori from the evaluation.  
• Christiansen S, Kortenkamp A, Axelstad M, Boberg J, Scholze M, Jacobsen PR, Faust M, 
Lichtensteiger W, Schlumpf M, Burdorf A and Hass U, 2012. Mixtures of endocrine 
disrupting contaminants modelled on human high end exposures: an exploratory study in rats. 
International Journal of Andrology, 35, 303-316. 
• Manikkam M, Tracey R, Guerrero-Bosagna C and Skinner MK, 2013. Plastics Derived 
Endocrine Disruptors (BPA, DEHP and DBP) Induce Epigenetic Transgenerational 
Inheritance of Obesity, Reproductive Disease and Sperm Epimutations. PLoS One, 8, e55387.  
• Xi W, Wan HT, Zhao YG, Wong MH, Giesy JP, Wong CK, 2011. Effects of perinatal 
exposure to bisphenol A and di(2-ethylhexyl)-phthalate on gonadal development of male 
mice. Environmental Science and Pollution Research International, 19, 2515-2527. 
Excluded in vitro studies 
Studies using high concentrations of BPA (>10-6 M) which were not considered by the CEF Panel as 
relevant for risk assessment and therefore excluded from this review. 
• Aoki T and Takada T, 2012. Bisphenol A modulates germ cell differentiation and retinoic acid 
signaling in mouse ES cells. Reproductive Toxicology, 34, 463-470. 
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• Bulzomi P, Bolli A, Galluzzo P, Acconcia F, Ascenzi P and Marino M, 2012. The naringenin-
induced proapoptotic effect in breast cancer cell lines holds out against a high bisphenol a 
background. IUBMB Life, 64, 690-696. 
• Huang H, Tan W, Wang CC and Leung LK, 2012. Bisphenol A induces corticotropin-
releasing hormone expression in the placental cells JEG-3. Reproductive Toxicology, 34, 317-
322. 
• Kang NH, Hwang KA, Kim TH, Hyun SH, Jeung EB and Choi KC, 2012. Induced growth of 
BG-1 ovarian cancer cells by 17β-oestradiol or various endocrine disrupting chemicals was 
reversed by resveratrol via downregulation of cell cycle progression. Molecular Medicine 
Reports, 6, 151-156. 
• Li Z, Zhang H, Gibson M and Li J, 2012. An evaluation on combination effects of phenolic 
endocrine disruptors by estrogen receptor binding assay. Toxicology in Vitro, 26, 769-774. 
• Lee MS, Lee YS, Lee HH and Song HY, 2012c. Human endometrial cell coculture reduces 
the endocrine disruptor toxicity on mouse embryo development. Journal of Occupational 
Medicine and Toxicology 7, 7. 
• Taxvig C, Dreisig K, Boberg J, Nellemann C, Blicher Schelde A, Pedersen D, Børgesen M, 
Mandrup S and Vinggaard AM, 2012. Differential effects of environmental chemicals and 
food contaminants on adipogenesis, biomarker release and PPARγ activation. Molecular and 
Cellular Endocrinology, 361, 106-115. 
Excluded studies (Jan 2012 - Sept 2012) from the list submitted by “Réseau Environnement Santé” 
(RES, 2012) 
The compilation of published scientific studies on BPA submitted by Réseau Environnement Santé 
(RES, 2012) to the European Commission was compared with EFSA’s comprehensive literature 
database. The few publications identified as missing were screened against the relevance criteria 
defined in Appendix I. As a result of this screening the following studies were excluded from this 
review for the motivations indicated. 
• Maserejian NN, Trachtenberg FL, Hauser R, McKinlay S, Shrader P, Tavares M and Bellinger 
DC, 2012. Dental Composite Restorations and Psychosocial Function in Children. Pediatrics, 
130, E328-E338.  
Reason: bisGMA-based dental composite restorations, not directly BPA. 
• Kuan YH, Huang FM, Li YC and Chang YC, 2012a. Proinflammatory activation of 
macrophages by bisphenol A-glycidyl-methacrylate involved NF kappa B activation via 
PI3K/Akt pathway. Food and chemical toxicology, 50, 4003-4009.  
Reason: bisGMA-based dental composite restorations, not directly BPA. 
• Lee S, Kim YK, Shin TY and Kim SH, 2013c. Neurotoxic Effects of Bisphenol AF on 
Calcium-Induced ROS and MAPKs. Neurotoxicity Research, 23, 249-259.  
Reason: BPAF, not directly BPA. 
• O'Boyle NM, Delaine T, Luthman K, Natsch A and Karlberg A-T, 2012. Analogues of the 
Epoxy Resin Monomer Diglycidyl Ether of Article Bisphenol F: Effects on Contact Allergenic 
Potency and Cytotoxicity. Chemical Research in Toxicology, 25, 2469-2478. 
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Reason: DGEBF, not directly BPA. 
• Chevalier N, Vega A, Bouskine A, Siddeek B, Michiels J-F, Chevallier D and Fenichel P, 
2012. GPR30, the Non-Classical Membrane G Protein Related Estrogen Receptor, Is 
Overexpressed in Human Seminoma and Promotes Seminoma Cell Proliferation. PLoS One, 7. 
Reason: Not dealing with BPA. 
• Feng Y, Yin J, Jiao Z, Shi J, Li M and Shao B, 2012. Bisphenol AF may cause testosterone 
reduction by directly affecting testis function in adult male rats. Toxicology Letters, 211, 201-
209. 
Reason:  BPAF, not directly BPA. 
• Liao C, Liu F and Kannan K, 2012. Bisphenol S, a New Bisphenol Analogue, in Paper 
Products and Currency Bills and Its Association with Bisphenol A Residues. Environmental 
Science & Technology, 46, 6515-6522.  
Reason: BPS, not directly BPA. 
• Trentham-Dietz A, Sprague BL, Wang J, Hampton JM, Buist DSM, Bowles AE, Sisney G, 
Burnside E, Hemming J and Hedman C, 2012. Phenol Xenoestrogens and Mammographic 
Breast Density. Cancer Epidemiology Biomarkers & Prevention, 21, 561-562. 
Reason: Only a Congress Abstract 
• Liu X, Matsushima A, Nakamura M, Costa T, Nose T and Shimohigashi Y, 2012. Fine spatial 
assembly for construction of the phenol-binding pocket to capture bisphenol A in the human 
nuclear receptor estrogen-related receptor gamma. Journal of Biochemistry, 151, 403-415. 
Reason: Structural biology and biophysics, no toxicity 
• Blasiak J, Synowiec E, Tarnawska J, Czarny P, Poplawski T and Reiter RJ, 2012. Dental 
methacrylates may exert genotoxic effects via the oxidative induction of DNA double strand 
breaks and the inhibition of their repair. Molecular Biology Reports, 39, 7487-7496. 
Reason: Bis-GMA, not directly BPA. 
• Li YC, Kuan YH, Huang FM and Chang YC, 2012d. The role of DNA damage and caspase 
activation in cytotoxicity and genotoxicity of macrophages induced by bisphenol-A-
glycidyldimethacrylate. International Endodontic Journal, 45, 499-507. 
Reason: Bis-GMA, not directly BPA. 
• Kuan YH, Li YC, Huang FM and Chang YC, 2012b. The upregulation of tumour necrosis 
factor-α and surface antigens expression on macrophages by bisphenol A-glycidyl-
methacrylate. International Endodontic Journal, 45, 619-626.  
Reason: Bis-GMA, not directly BPA. 
• Rowas SA, Haddad R, Gawri R, Al Ma'awi AA, Chalifour LE, Antoniou J and Mwale F, 
2012. Effect of in utero exposure to diethylstilbestrol on lumbar and femoral bone, articular 
cartilage, and the intervertebral disc in male and female adult mice progeny with and without 
swimming exercise. Arthritis Res Ther, 14. 
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Reason: Not dealing with BPA. 
• Michelsen VB, Kopperud HB, Lygre GB, Bjorkman L, Jensen E, Kleven IS, Svahn J and Lygre 
H, 2012. Detection and quantification of monomers in unstimulated whole saliva after treatment 
with resin-based composite fillings in vivo. European Journal of Oral Sciences, 120, 89-95. 
Reason: Bis-GMA, not directly BPA. 
• Hsu WY, Wang VS, Lai CC and Tsai FJ, 2012. Simultaneous determination of components 
released from dental composite resins in human saliva by liquid chromatography/multiple-
stage ion trap mass spectrometry. Electrophoresis, 33, 719-725. 
Reason: No directly BPA 
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Appendix C.  WoE approach to hazard identification 
A detailed description of the approach taken to the hazard identification is given in the methodological 
section (Appendix A). After being grouped by macro-areas of interest, e.g. reproductive and 
developmental effects, and relative study type, i.e. human, animal or in vitro study  the relevant studies 
were appraised on their strengths and weaknesses and included in a structured WoE approach to 
hazard identification to identify the critical toxicological effects (“likely” or “very likely” effects) for 
BPA. A tabular format was developed to facilitate the consistent treatment of the whole body of 
human and animal evidence and transparently document the WoE analysis. 
For each toxicological endpoint, different questions (Q1, Q2, etc.) were formulated to address the 
association between BPA and the endpoint (e.g. “does BPA cause ... (type of effect)?”. These were 
placed in the first column on the top left handside of the WoE table. Under each question (first 
column) the conclusions from the 2006 and/or 2010 EFSA opinions on BPA were taken as a “starting 
point” for an answer. The new studies relevant to each question (see Appendices B and C) were 
organised into a number of “lines of evidence” in order to address the different findings that relate to 
the question concerned. Some lines of evidence referred to a single study, whereas others referred to a 
group of studies addressing the same issue. In the same first column the CEF Panel also summarised 
the strengths and weaknesses of each study and/or line of evidence, and those of the pre-2010 EFSA 
assessments. 
The second column of the WoE tables reports the “answer to the question as reported by the study 
authors“ (e.g. a positive, negative or uncertain answer to the question), irrespectively of the CEF 
Panel’s consideration of  the study strengths and weaknesses. 
The third column of the tables gives the CEF Panel’s assessment of the “reliability”of each line of 
evidence, expressed qualitatively on a scale of low, medium or high. The CEF Panel considered 
strengths and weaknesses when judging the reliability of each line of evidence. Notably, there was not 
a pre-defined outcome of a study reliability based on its number of strengths and weaknesses, given 
their different relative weight. The reliability of the evidence was agreed based on collective expert 
judgement (starting from a proposal made by the study’s rapporteur and co-rapporteur, that was 
discussed at least at one but more commonly at many WG meetings and that then was reviewed by the 
CEF Panel during Plenary meetings). 
In the fourth column the weight or influence of each line of evidence on the “likelihood” of a positive 
answer to each question is expressed using a defined set of symbols (see  table 30) when considered 
independently of the other lines of evidence. The number (from one to three) of upward and 
downward arrows indicates the degree (small, medium, high) of the impact of the new evidence to 
increase or decrease, respectively, the likelihood of a positive answer to the question. The “dot” is 
used when the reliability of the new line of evidence is considered as insufficient as to have an impact 
on the likelihood of a positive answer to a question. Pairs of symbols indicate uncertainty about the 
influence, e.g. ●/↑ indicate  between negligible and minor positive influence on likelihood. 
Table 30:  Definition of symbols used for expressing the influence on likelihood of each line of 
evidence in the WoE tables  
Symbols Interpretation 
↑    minor contribution to increasing likelihood 
↑↑   moderate contribution to increasing likelihood 
↑↑↑   major contribution to increasing likelihood 
↓    minor contribution to decreasing likelihood 
↓↓   moderate contribution to decreasing likelihood 
↓↓↓   major contribution to decreasing likelihood 
●   negligible influence on likelihood 
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A conclusion on the overall likelihood that BPA exposure was associated with a particular effect in 
humans and/or animals was expressed in the bottom row both as a narrative statement and using a 
seven level-scale of likelihood terms, ranging from “very unlikely” to “very likely” (see box below). 
Note that, on this scale, "As likely as not" means a level of likelihood between "Unlikely" and 
"Likely", where it is about equally likely that BPA causes, or does not cause, the effect.  
Such conclusion was drawn after considering the individual influences of all the lines of evidence and 
the starting point. As for the judgement of the reliability of each line of evidence, also the assessment 
of the overall likelihood resulted from from a complex and collective expert judgement, as opposed to 
the  application of a pre-defined formula.   
Set of standard terms used for expressing the overall likelihood in the WoE tables (adapted from 




From -as likely as not- to likely 
As likely as not 
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WoE of reproductive and developmental effects 
Whether BPA has the potential to cause developmental and reproductive effects in humans and animals was considered using a tabular format for weighing 
different lines of evidence (WoE evaluation). The WoE evaluation tables for these endpoints are presented in full below. 
Human studies 
Table 31:  Assessment of the likelihood of associations between BPA exposure and developmental and reproductive effects in humans. 
Q1: Is there an association between BPA exposure and reproductive and health effects in humans?  Answer to the 
question as 














(see Table 28) 
Starting point based on previous assessments (EFSA CEF Panel, 2010). Eight studies investigating the 
association between BPA exposure and reproductive disorders in human adults (Itoh et al., 2007; Braun et al., 2009; 
Cobellis et al., 2009; Yang et al., 2009; Li et al., 2010a, b; Meeker et al., 2010; Mendiola et al., 2010; Mok-Lin et al., 
2010). 
 









Line of Evidence 1: Associations with embryo quality and implantation success during IVF 
Several studies reported inverse associations between increasing BPA levels in serum or urine and one or more 
parameters of embryo quality and implantation (Fujimoto et al., 2010; Bloom et al., 2011a; 2011b; Ehrlich et al., 
2012a; 2012b).  
 
Strengths:  
− Prospective study design (Ehrlich et al., 2012a; 2012b) 
− Urine, contained specified (Ehrlich et al., 2012a; 2012b) 
− Repeated measurements (≥ 2) (Ehrlich et al., 2012a; 2012b) 
− Standardised samples (specific gravity) (Ehrlich et al., 2012a; 2012b) 
− Analytical method (LC-MS-MS) (Ehrlich et al., 2012a; 2012b) 
− Quality controls, including blanks (all studies) 
Weaknesses:  
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− Short time frame (only days) (Ehrlich et al., 2012a; 2012b) 
− Small sample size (Fujimoto et al., 2010; Bloom et al., 2011a; b) 
− Serum BPA measurement (Fujimoto et al., 2010; Bloom et al., 2011a, b) 
− Single exposure measurements (Fujimoto et al., 2010; Bloom et al., 2011a; b) 
− No distinction between unconjugated and conjugated BPA (Ehrlich et al., 2012a; 2012b) 
− Potential BPA exposure by diet or by concurring exposure factors (contamination through medical 
treatment during IVF) not reported (all studies) 
− Poor generalisability for the population other than IVF couples (all studies) 
Line of Evidence 2: Associations with semen quality. One study showed association with semen quality in 
occupationally and environmentally exposed workers (Li et al., 2011) 
 
Comment: Confounding by multiple chemical exposures was evaluated 
 
Strengths: 
− Standardised samples (urinary creatinine or specific gravity) 
Weaknesses:  
− Cross-sectional study design 
− Selection bias of the study population (58 % participation rate, without explanation) 
− Single spot urine BPA measurement (for men without occupational exposure) 
− No quality control and quality assurance procedures  
− No distinction between unconjugated and conjugated BPA 
− Confounding by diet not considered 









Line of Evidence 3: Associations with sex hormones. 
One study showed weak association with testosterone in men only, no associations with other sex hormones 
examined and no associations with sex hormones in women (Galloway et al., 2010). One study showed associations 
with sex hormones in men (Zhou et al., 2013) 
 
Strenghts:  
− Standardised samples (24-h urine collection, urinary creatinine) (Galloway et al., 2010) 
− Analytical method (SPE LC-MS-MS) (Galloway et al., 2010) 
− Quality control, including blanks (all studies) 
Weaknesses: 
− Cross-sectional study design (all studies)  
− Small sample size (Zhou et al., 2013) 
− Serum BPA measurement (Zhou et al., 2013) 
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− Confounding by diet or by concurring exposure factors not reported (all studies) 
− Unclear clinical relevance due to small effect size in men (Galloway et al., 2010) 
− Inconsistency in the results, significant association between BPA exposure and testosterone but no 
association for other hormones (Galloway et al., 2010) 
− Occupational exposure (Zhou et al., 2013) 
Line of Evidence 4: Associations with age of menarche. One study showed no association (Buttke et al., 2012) 
 
Comment: Confounding by multiple chemical exposures was evaluated 
 
Strengths:  
− Standardised samples (urinary creatinine) 
− Analytical method (SPE LC-MS-MS) 
Weaknesses:  
− Cross-sectional study design 
− Single spot urine BPA measurement 
− No distinction between unconjugated and conjugated BPA 





Line of Evidence 5: Associations with hormones and metabolic parameters in women with polycystic ovary 
syndrome (PCOS). Two studies reported associations (Kandaraki et al., 2010; Tarantino et al., 2012). 
 
Weaknesses:  
− Cross-sectional study design (all studies) 
− Small sample size (Tarantino et al., 2012) 
− Serum BPA measurement (all studies) 
− Single exposure measurements (all studies) 
− Analytical method (ELISA) (all studies) 
− No quality control and quality assurance procedures (all studies) 
− No distinction between unconjugated and conjugated BPA (all studies) 
− Statistics (unjustified use of non-parametric and parametric models) (Tarantino et al., 2012) 










Overall conclusion on Likelihood:  
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Q2: Is there an association between BPA exposure and gestational /birth outcomes?  Answer to the 
question as 














(see Table 28) 
Starting point based on previous assessments (EFSA CEF Panel, 2010).  
Two studies investigated the association between BPA exposure and birth outcomes (Padmanabhan et al., 2008; 









Line of Evidence 1: Associations with preterm delivery. The only study identified on this issue showed 
association with urinary BPA (Cantonwine et al., 2010) 
 
Strenghts: 
− Standardised samples (specific gravity and creatinine) 
− Analytical method (SPE LC-MS-MS) 
− Quality controls, including blanks 
Weaknesses: 
− Cross-sectional study design 
− Small sample size 
− Single spot urine BPA measurements 
− No distinction between unconjugated and conjugated BPA  
− Invalid/imprecise outcome assessment 










Line of Evidence 2: Associations with fetal growth. Three studies showed associations with growth restriction 
(Miao et al., 2011a; Snijder et al., 2013; Chou et al., 2011) and two studies showed associations with increased 
growth (Lee et al., 2013a; Philippat et al., 2012).  
 
Strengths:  
− Prospective study design (Miao et al., 2011a; Snijder et al., 2013; Lee et al., 2013a) 
− Repeated measurements (Snijder et al., 2013) 
− Container specified (Miao et al., 2011a; Snijder et al., 2013; Chou et al., 2011) 
− Standardised samples (urinary creatinine) (Miao et al., 2011a; Snijder et al., 2013; Lee et al., 2013a; 
Philippat et al., 2012) 
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− Quality controls, including blanks (Lee et al., 2013a; Chou et al., 2011) 
− Repeated growth measurement (Snijder et al., 2013) 
Weaknesses:  
− Cross-sectional study design (Chou et al., 2011) or case-control study (Philippat et al., 2012) 
− Long recall period (Miao et al., 2011a) 
− Blood/plasma and cord blood BPA measurement (Chou et al., 2011) 
− Single exposure measurements (Miao et al., 2011a; Lee et al., 2013a; Chou et al., 2011; Philippat et al., 
2012) 
− No distinction between unconjugated and conjugated BPA (all studies) 
− Confounding by diet and concurring exposure factors not considered (all studies) 
− Unclear clinical relevance (small sample effect size) (Philippat et al., 2012) 
− Inconsistent results, some showed growth restriction (Miao et al., 2011a; Snijder et al., 2013; Chou et al., 
2011) some showed increased growth (Lee et al., 2013a; Philippat et al., 2012) 
− Occupational exposure (Miao et al., 2011a) 
Line of Evidence 3: Associations with cryptorchidism. The only study identified on this issue showed no 
association (Fénichel et al., 2012) 
 
Comment: Sound statistical modelling 
 
Strengths:  
− Container specified (BPA-free) 
− Quality control, including blanks 
− Consistency in results among different studies 
Weaknesses:  
− Cross-sectional study design 
− Single exposure measurement 
− Analytical method (RIA, no correlation with GC-MS data for values in the low range)  










Line of Evidence 4: Associations with anogenital distance, congenital hypothyroidism and hypospadia. One 
study showed association with anogenital distance (Miao et al., 2011b), one study showed no association with 
congenital hypothyroidism (Jung et al., 2013) and one showed inconsistent associations with hypospadias (Choi et 
al., 2012)  
 
Strengths: 
− Container specified (BPA-free) (Choi et al., 2012; Miao et al, 2011b) 
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Weaknesses: 
− Case-control study design (Choi et al., 2012; Jung et al., 2013; Miao et al., 2011b) 
− Small sample size (Miao at al., 2011b) 
− Invalid/imprecise BPA exposure assessment combination of paternal and maternal occupational exposure 
through inhalation (Miao at al., 2011b)  
− Plasma PBA measurement (Choi et al., 2012; Jung et al., 2013) 
− Single spot urine BPA measurement (Choi et al., 2012) 
− No distinction between conjugated and unconjugated BPA (Choi et al., 2012; Jung et al., 2013) 
− Confounding by diet and concurring exposure factors not considered (all studies) 
− Insufficient study reporting (Choi et al., 2012) 
− Statistics (Miao at al., 2011b; Jung et al., 2013; Choi et al., 2012) 
− Occupational exposure (Miao at al., 2011b) 
Line of Evidence 5: Associations with maternal and infant thyroid function. The only study identified on this 
issue showed associations with reduced TSH in neonates and reduced T4 in mothers (Chevrier et al., 2012) 
 
Comment: Iodine status (nutritional) was taken into account 
 
Strengths: 
− Prospective study design 
− Urine, container specified (BPA-free) 
− Repeated measurements 
− Standardised samples (creatinine) 
− Analytical method (SPE LC-MS-MS) 
− Quality controls, including blanks 
Weaknesses: 
− No distinction between unconjugated and conjugated BPA 
− Confounding by diet (except nutrition iodine) and concurring exposure factors not considered 
− Unclear clinical relevance (association between BPA and T4 observed in urine samples taken during the 










Overall conclusion on Likelihood:  
There are indications from prospective studies that BPA exposure during pregnancy may be associated with fetal growth, and weak indications that 
BPA exposure during pregnancy may be associated with maternal and infant thyroid function. However, it cannot be ruled out that the results are 
confounded by diet or concurrent exposure factors. For fetal growth, two studies showed reduced fetal growth, while one study reported increased fetal 
growth with increasing maternal BPA exposure. The associations do not provide sufficient evidence to infer a causal link between BPA exposure and 
reproductive effects in humans.   
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Animal studies 
Table 32:  Assessment of the likelihood that BPA causes developmental and reproductive toxicity in animals when exposed during their adult life (post-
pubertal) only. 
NOTE: The cut-off of 5 mg/kg/day from Tyl et al. (2002) is used below as a rodent NOAEL. This figure has been translated into an HED of 3.6 mg/kg bw per day. 
All monkey, mouse and rat exposures have been converted into an HED using the values in Table 3 and studies with an effect ≤3.6 mg BPA/kg bw per day have been 
included below. The equivalent data for sheep are not available and the BPA doses for those studies have been used at equivalence for HED. 
Q1: Does adult exposure to BPA at doses equal to, or below the HED NOAEL equivalent of 3.6 mg/kg/bw per 
day disturb reproductive capacity? 
(Dobrzynska and Radzikowska , 2013; Castro et al. 2013; Qiu et al. 2013; Jin et al. 2013; Liu et al., 2013; Tiwari 
and Vanage 2013; Lee et al., 2013b; Tan et al. 2013; El Ghazzawy et al. 2011) 
















Starting point based on previous assessments (EFSA CEF Panel, 2010): Conclusion on developmental and 
reproductive toxicity 
Tyl et al. (2002)  
CD Sprague-Dawley rats (n= 20 pregnant females) were exposed to dietary BPA in a three generation study at 0, 
0.015, 0.3, 4.5, 75, 750, 7500 ppm (giving doses of approximately 0, 0.02, 0.3, 5, 50 and 500 mg/kg bw per day). 
Adult systemic toxicity at 750 and 7500 ppm in all generations included: reduced body weights and body weight 
gains, reduced absolute and increased relative weanling and adult organ weight (liver, kidney, adrenals, spleen, 
pituitary and brain), and female mild renal and hepatic pathology. Reproductive organ histology and function were 
unaffected, except for reduced ovarian weights, a significantly reduced number of implantation sites and decreased 
number of pups/litter on PND 0 at 7500 ppm. Adult oral NOAEL was 5 mg/kg bw per day.  
Tyl et al. (2008) 
In a two-generation study dietary BPA was given to CD-1 mice (n=28) at 0, 0.018, 0.18, 1.8, 30, 300, or 3500 ppm 
in feed (giving 0, 0.003, 0.03, 0.3, 5, 50, or 600 mg BPA/kg bw per day). 17β-oestradiol (0.5 ppm) was used as 




Line of Evidence 1: new evidence on the effects of BPA on the adult testis 
(1) Dobrzynska and Radzikowska, 2013; (2) Qiu et al., 2013; (3) Jin et al., 2013; (4) Liu et al., 2013; (5) Tiwari and 
Vanage, 2013; (6) El Ghazzawy et al., 2011. 
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- Number of doses (≥3) (Liu et al., 2013, Qiu et al., 2013, Dobrzynska and Radzikowska, 2013) 
- Adequate positive controls included (Liu et al., 2013, Jin et al., 2013) 
- Oral administration via gavage (El Ghazzawy et al., 2011, Liu et al., 2013, Qiu et al., 2013, Jin et al., 2013) 
- Use of non-PC cages (El Ghazzawy et al., 2011, Jin et al., 2013) 
- Use of glass bottle (Liu et al., 2013, Jin et al., 2013) 
- Phytoestrogen-free diet (e.g. soy-free diet) (Tiwari and Vanage, 2013) 
Weaknesses: 
- Single dose level study (El Ghazzawy et al., 2011, Jin et al., 2013) 
- No vehicle controls were tested (Dobrzynska and Radzikowska, 2013) 
- Drinking water consumption (containing BPA) not measured (Dobrzynska and Radzikowska, 2013) 
- Animal diet poorly described (El Ghazzawy et al., 2011, and Liu et al., 2013: animals were provided with a 
rodent experimental diet in which no phytoestrogens could be detected – this was not checked in the study, 
Qiu et al., 2013, Jin et al., 2013, Dobrzynska and Radzikowska, 2013) 
- Study design not appropriate to the scope (Qiu et al., 2013: control rats appeared to receive corn oil only 
rather than ethanol further diluted in corn oil as was the case for the BPA-exposed groups, Liu at al., 2013: 
description of the study design was poor and confusing in terms of exactly what groups received what and 
which were compared with what controls) 
- Inappropriate statistics (El Ghazzawy et al., 2011: no multiple comparisons statistics, Qiu et al., 2013: basic 
statistical analysis, Liu at al., 2013: statistics not adequate) 
- Insufficient study reporting (Jin et al., 2013: data presentation is confusing) 
Line of Evidence 2: new evidence on the effects of BPA on the adult prostate gland 
(7) Castro et al., 2013: The changes described in the rat, especially the skewing of the T/E2 ratio and increased 
aromatase is considered symptomatic of prostate disease. 
 
Comment: Dose-response to some BPA effects 
Comment: Data presented do not prove prostate disease 
Comment: Very short exposure (4 days) – acute response 
 
Strengths:  
- Number of doses (≥3)  
- Use of non-PC cages and of glass bottles  
Weaknesses:  
- Insufficient study reporting (animal diet poorly described) 
Positive Medium ● 
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Line of Evidence 3: new evidence on the effects of BPA on increased incidence of early delivery and disturbed 
endocrine and placental signaling. 
(8) Tan et al., 2013: Study in mice: increased plasma T, E2, CRH placental CREB and PKC. 
 
Comment: Majority of effects reported >3.6 mg/kg bw per day 
Comment: Assessment of early pregnancy loss used a good number of animals (>15 mice/dose) 
Comment: Effect on early delivery only significant when analysing all BPA groups and including group >3.6 mg/kg 
bw per day 
Comment: early delivery assessed in different group to signalling indices 
 
Strengths: 
- Number of doses (≥3),  
- Oral administration via gavage  
Weaknesses: 
- Animal diet poorly described Small sample size (small group size (3-5) for most measures other than 
pregnancy loss)  
- Animal diet and phytoestrogen content not reported  
Positive Low ● 
Line of Evidence 4: new evidence on the effects of BPA on the adult ovary 
(9) Lee et al., 2013b: Study in rat: decreased circulating E2 and T associated with increased LH and increased 
ovarian cell apoptosis and decreased theca cell steroidogenesis. 
 
Strengths: 
- Large sample size  
- Adequate positive controls included  
- Oral administration by gavage  
Weaknesses: 
-  Animal diet and phyoestrogen content not reported  
Positive High ↑↑ 
Overall conclusion on Likelihood that BPA causes reproductive toxicity in animals when exposed during their adult life (post-pubertal) only  
As more studies emerge with doses ≤3.6 mg BPA/kg bw per day HED, there are increasing indications of some negative effects of adult exposure to 
BPA on gonadal or reproductive tract physiology. Very few studies have assessed the effects of long term exposure of adults to such doses of BPA 
(human scenario) on the reproductive gold standard – fertility and reproductive ageing. Since only single studies on ovary and prostate gland fit the 
methodological criteria used in this opinion, no conclusion can be drawn on BPA-related effects on these organs. Taken together the studies assessed 
here suggest that BPA at a HED of ≤3.6 mg/kg bw per day may have adverse effects on testis function, especially various measures of spermatogenesis. 
There is much less evidence to support a conclusion that BPA will significantly impair testis morphology or reproductive endocrinology, especially in 
the longer term. 
Note: Alteration of reproductive capacity are likely at high doses (above an HED of 3.6 mg/kg bw per day) 
As likely as not 
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Table 33:  Assessment of the likelihood that BPA causes developmental and reproductive toxicity in animals exposed during pre- and post-natal (during 
lactation) development. 
NOTE: the NOAEL HED of 3.6 mg/kg bw per day refers to the dose administered to the MOTHER if fetus or neonate is exposed through the mother. If the neonate 
is exposed separately post-natally prior to tissue harvesting, then the dose will be higher as a calculated HED than if the neonate is treated only via lactation through 
the dam. 
 
Q2: Does developmental (fetal and/or prepubertal period) exposure to BPA at oral doses equal to or below 
the NOAEL of 5 mg/kg bw per day (HED equivalent 3.6 mg/kg bw per day) impair reproductive development 
and/or function in adulthood? (Ferguson et al., 2011, Hunt et al., 2012, Kobayashi et al., 2012, Larocca et al., 
2011, Lopez-Casas et al., 2012, Nanjappa et al., 2012, US FDA/NCTR, 2013 and Delclos et al., 2014, Christiansen 
et al., 2014, Horstman et al., 2012, Veiga-Lopez et al., 2013, Zhang et al., 2012a, 2013, de Catanzaro et al., 2013, 
Nah et al., 2011, Pelch et al., 2012, Xiao et al., 2011; Signorile et al., 2012, Nakagami et al., 2009, Mendoza-
Rodriguez et al., 2011, Newbold et al., 2007, Newbold et al., 2009, Signorile et al., 2010, Berger et al., 2007, 
Cabaton et al., 2011) 

















Starting point based on previous assessments (EFSA, 2006; EFSA CEF Panel, 2010): Conclusion on 
developmental and reproductive toxicity (including anogenital distance, fertility, endometrial hyperplasia and 
ovarian cysts). 
   
Tyl et al., 2002  
CD Sprague-Dawley rats (n= 20 pregnant females) were exposed to dietary BPA in a three generation study at 0, 
0.015, 0.3, 4.5, 75, 750, 7500 ppm (giving doses of approximately 0, 0.02, 0.3, 5, 50 and 500 mg/kg bw per day). 
Adult systemic toxicity at 750 and 7500 ppm in all generations included: reduced body weights and body weight 
gains, reduced absolute and increased relative weanling and adult organ weight (liver, kidney, adrenals, spleen, 
pituitary and brain), and female mild renal and hepatic pathology. Reproductive organ histology and function were 
unaffected, except for reduced ovarian weights, a significantly reduced number of implantation sites and decreased 
number of pups/litter on PND 0 at 7500 ppm. Adult oral NOAEL were 5 mg/kg bw per day. 
 
Tyl et al., 2008 
 Dietary BPA in CD-1 mice (n=28) two-generation study at 0, 0.018, 0.18, 1.8, 30, 300, or 3500 ppm in feed (giving 
0, 0.003, 0.03, 0.3, 5, 50, or 600 mg BPA/kg bw per day). 17β-oestradiol (0.5 ppm) was used as positive control. 
Reproductive/developmental NOAEL in the offspring was 300 ppm (50 mg/kg bw per day) based on the effect in 
the testes of F1/F2 offspring. 
Negative High ↓↓↓ 
 
Rubin et al., 2001 
Exposure of Sprague-Dawley female rats to BPA at 100, 1,200 µg BPA/kg bw per day from day GD 6 throughout 
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reduction in the percentage of females with regular cycles and in the mean number of regular 4 or 5-day ooestrous 
cycles per animal. There were no significant effects of BPA on litter size, sex ratios, day of vaginal opening, AGD 
or macroscopic abnormalities of genital tracts.  
 
Strengths:  
- Use of glass water bottles  
- Cages and bedding content of oestrogens negligible at E-screen  
Weaknesses:  
- Animal diet and phytoestrogen content poorly described. 
- Study design not appropriate to the scope   (small number of litters (n=6) 
- Litter effect not taken into account 
- Drinking water consumption (containing BPA) not measured 
- Insufficient study reporting 
Salian et al., 2009  
A 3 generation-study where pregnant rats were gavaged with 1.2 or 2.4 μg BPA/kg bw per day, resulting in a 
significant increase in post implantation loss in the F3 offspring and a decrease in litter size in F1, F2 and F3 
offspring Sperm count and motility were significantly reduced in the F1, F2 and F3 male offspring, with a dose 
related reduction in sperm counts.  
Strengths:  
- Oral administration via gavage 
- Adequate positive control included (DES) 
Weaknesses:  
- Type of cages not reported  
- Insufficient study reporting (the nature of the diet is unclear: prepared “in house” although stated as soya-
free)  
- Study design not appropriate to the scope   (small numbers of mated F0 dams per group (n = 8)  




Howdeshell et al., 2008 
Long Evans rats were dosed with BPA at 2, 20, 200 µg/kg bw per day by oral gavage from GD7 to PND18. Apart 
from two minor exceptions BPA had no significant effect on AGD, birth or weaning weights, age or weight at 
weaning, growth rates, external genitalia, endoc rine measures, reproductive tract size and morphology or any other 
indices of reproductive development or function measured.  
 
Strengths:  
- ≥3 dose levels of BPA 
- Oral administration via gavage  
Negative Low/Medium ↓ 
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- Large sample size (9-38 litters/group) 
- Adequate positive controls included (EE) 
Weaknesses:  
- Use of polycarbonate cages (although new) 
- Animal diet and phytoestrogen content poorly described  
Ryan et al., 2010a 
Long Evans rats were dosed with BPA at 2, 20, 200 µg/kg bw per day by oral gavage from GD7 to PND18. BPA 
had no significant effect on AGD, birth or weaning weights, age or weight at vaginal opening, lordosis quotient, 
external genitalia, number of pups or fertility/fecundity rates and also had no effects on sex-specific behaviour.  
 
Strengths:  
- ≥3 dose levels of BPA 
- Oral administration via gavage 
- Large sample size (9-38 litters/group) 
- Adequate positive control included (EE) 
Weaknesses:  
- Use of polycarbonate cages  
- Animal diet and phytoestrogen content poorly described 
Negative Low/Medium ↓ 
Tinwell et al., 2002 
Two strains of rat (Sprague-Dawlery and Alderly Park) were exposed by oral gavage to BPA at 20, 100, 50,000 
µg/kg bw per day from GD6-21. BPA had no significant effect on litter size or sex ratio, body weights, AGD in 
either sex. In females BPA had no significant effect on, age or body weight at vaginal opening or age at first estrus 
or any organ weights. In males there was no significant effect of BPA on age or body weight at preputial separation, 
or any organ weights or on histology of the testis or on sperm production.  
 
Strengths:  
- Oral administration via gavage 
- ≤3 BPA dose levels 
- Large sample size (6-7 litters/21-33 individuals/group) 
Weaknesses:  
- Use of polycarbonate cages (PC) 
Negative Medium ↓↓ 
Markey et al., 2005 
Pregnant CD-1 mouse dams were implanted, from GD9 to PND4, with subcutaneous osmotic pumps containing 
BPA at 25, 250 ng/kg bw/ The highest BPA dose significantly reduced absolute and relative vagina, but not uterus, 
weight and decreased the absolute volume of the uterine lamina propria. Uterine but not vaginal DNA synsthesis 
Positive Low/Medium ↑ 
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was significantly reduced by the higher BPA dose in the glandular epithelium although apoptosis was not altered. 
ESR1 and PGR staining and proportion of high intensity staining were increased in the uterine luminal epithelium 
(and stroma, ESR1).  
 
Strengths:  
- Feed, cages and bedding content of oestrogens negligible at E-screen 
- Use of glass water bottles 
Weaknesses:  
- Study design not appropriate to the scope   (small sample size:, 6/group in some cases) 
Honma et al., 2002 
Pregnant ICR-Jci mice were administered BPA at 2,20 µg BPA/kg bw per day from GD11-17. BPA had no 
significant effect on gestation, numbers of live pups or pup sex ration. In females BPA reduced body weight at PND 
22 and 60 and increased AGD at PND22 although this effect was no longer seen at PND60. BPA significantly 
advanced the day of vaginal opening, reduced body weight/age at vaginal opening and increased oestrous cycle 
length, but had no significant effects on mating, pups/litter or pup sex ratio. In males BPA significantly reduced 
body weight at PND60 and while AGD was not affected at PND22, at PND60 BPA was associated with 
significantly increased AGD.  
 
Strengths:  
- Adequate positive controls included (3 doses of DES) 
- Large sample size (9-10 and 41-51 females, 24-35 males respectively per group) 
Weaknesses:  
- Inappropriate statistics (not clear if data normality established, use of Student’s t-test, analysis of dose-
effects not stated) 
- Animal diet and phytoestrogens content not reported  




Toyama and  Yuasa 2004.  
Neonatal male Wistar rats and ICR mice were injected subcutaneously with BPA on PND1, 3, 5, 7, 9, 11(Mice: 
0.014, 0.140, 0.700, 1.401 mg/kg bw per day, Rats: 0.046, 0.461, 4.611, 27.666 µg/kg bw per day) [All rat BPA 
doses were higher than the 3.6 mg/kg bw per day HED cut-off dose and therefore the findings ≤3.6 BPA mg/kg bw 
per day are limited to the mouse. BPA at the lowest dose had no significant effect on any measure. BPA at 3.48 
mg/kg bw per day, approaching the cut-off of 3.6 mg/kg bw per day HED had no significant effects on body, testis 
or seminal vesicle weights and no significant effect on litter size, pup birthweights, gestation length or pup sex ratio. 
 
Strengths:  
- ≥3 BPA dose levels 
Negative Low ↓ 
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- Adequate positive controls included (oestradiol & oestradiol benzoate) 
Weaknesses:  
- Small sample size ( (n=5), especially for the controls (n=3-4)  
- Inappropriate statistics (litter effect not considered and statistical analysis not described) 
- Type of cages and drinking bottles not reported  
- Animal diet poorly described  
- Insufficient study reporting  
Kato et al., 2006 
Neonatal Sprague-Dawley male were rats administered BPA at 2, 11, 56, 277, 97,000 µg/kg bw per day by daily 
subcutaneous injection from PND0 (birth) to PND9. At all BPA doses, there were no significant effects on any 
parameter measured other than a reduction in the proportional of abnormal sperm, not adverse outcome. The litters 
sired by the BPA treated males were no different from controls.  
 
Strengths:  
- ≥3 dose levels of BPA 
- Adequate positive controls included (oestradiol) 
Weaknesses:  
- Type of cages and drinking bottles not reported 
Negative Low/Medium ↓ 
Rubin et al., 2006 
CD-1 mice were treated from D8-PND16 via osmotic minipumps with 25, 250 ng BPA/kg bw per day. BPA had no 
significant effect on pups/litter or sex ratio. Sexual dimorphism of the rostral periventricular preoptic area was 
significantly reduced by changes in the female but, contradictorally, behavioural studies reported that male offspring 
behaved more like female offspring. 
 
Strengths:  
- Use of glass water bottles, diet tested negative at E-screen  
- Cages and bedding content of oestrogens negligible at E-screen 
- Good sample size (10-17 offspring/group) used for behavioural studies 
Weaknesses:  
- Study design not appropriate to the scope   (sometimes small number of offspring (n=4-8/sex/group) for 
morphological analyses)  
- Litter effect not taken into account 




Line of Evidence 1: new evidence on the effect of BPA on testis development and/or function (e.g. sperm 
count and sperm motility) and masculinisation (e.g. nipple-retention, anogenital distance, androgens) 
Uncertain From Low to 
High 
↑/↓ 
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(1) US FDA/NCTR, 2013 and Delclos et al., 2014, (2) Christiansen et al., 2014, (3) Kobayashi et al., 2012, (4) 
Ferguson et al., 2011, (5) Lopez-Casas et al., 2012, (6) Nanjappa et al., 2012, (7) Larocca et al., 2011, (8) Horstman 
et al., 2012, (9) deCatanzaro et al., 2013, (10) Zhang et al., 2013.  
 
Comment: Of the 10 studies included, four found no significant effect of BPA ≤3.6 mg/kg bw per day HED on male 
reproductive development: Larocca et al., 2011, Lopez-Casas et al., 2012, Ferguson et al., 2012, Horstman et al., 
2012. Three found limited negative effects of BPA ≤3.6 mg/kg bw per day HED on male reproductive development:   
US FDA/NCTR, 2013 and Delclos et al., 2014 (slightly delayed testis descent, seminiferous tubule giant cells, each 
at different single doses), Kobayashi et al., 2012 (reduced epididymis weights), Nanjappa et al., 2012 (increased 
Leydig cell numbers but no change in testosterone). Three found clear negative effects of BPA ≤ 3.6 mg/kg bw per 
day HED on male reproductive development: deCatanzaro et al., 2013 (only in conjunction with high phytoestrogen 
diet: reduced vascular-coagulating gland weight and increased latency to inseminate), Christiansen et al., 2014 
(decreased AGD, dose-dependent increase in nipple retention, latter not significant ≤3.6 mg/kg bw per day) while 
four of the other studies showed no significant reduction in male AGD, Zhang et al., 2013 (reduced sperm number, 
survival and viability). 
 
Strengths: 
- Large sample size (US FDA/NCTR, 2013 and Delclos et al., 2014, Ferguson et al., 2011, Christiansen et 
al., 2014, Nanjappa et al., 2012, LaRocca et al., 2011 Horstman et al., 2012, deCatanzaro et al., 2013) 
- Number of doses (≥3) (US FDA/NCTR, 2013 and Delclos et al., 2014: especially in the low dose range, 
Kobayashi et al., 2012, Christiansen et al., 2014, Lopez-Casas et al., 2012, Horstman et al., 2012, 
deCatanzaro et al., 2013) 
- Both naïve and vehicle controls available (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Adequate positive controls included (Ferguson et al., 2011, LaRocca et al., 2011,  US FDA/NCTR, 2013 
and Delclos et al., 2014) 
- Oral administration via gavage (US FDA/NCTR, 2013 and Delclos et al., 2014, Ferguson et al., 2011, 
Christiansen et al., 2014, Nanjappa et al., 2012, LaRocca et al., 2011) 
- Phytoestrogen-free diet (US FDA/NCTR, 2013 and Delclos et al., 2014, Ferguson et al., 2011, Christiansen 
et al., 2014, Nanjappa et al., 2012) 
- Use of non-PC cages (US FDA/NCTR, 2013 and Delclos et al., 2014, Ferguson et al., 2011, Christiansen et 
al., 2014, Nanjappa et al., 2012, Horstman et al., 2012, deCatanzaro et al., 2013) 
- Study/analysis performed under OECD guideline, under GLP (US FDA/NCTR, 2013 and Delclos et al., 
2014) 
Weaknesses: 
- Feed consumption (BPA given by the diet) not measured (Kobayashi et al., 2012) 
- BPA concentration and homogeneity in the feed mixture not guaranteed analytically (Kobayashi et al., 
2012) 
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- Drinking water consumption (containing BPA) not measured (Lopez-Casas et al., 2012) 
- Small sample size (Lopez-Casas et al., 2012) 
- Insufficient study reporting and/or inappropriate statistics (Lopez-Casas et al., 2012, Kobayashi et al. 2012, 
Horstman et al., 2012, Zhang et al., 2013)  
- Animal diet and phytoestrogen content not reported (Kobayashi et al., 2012, Lopez-Casas et al., 2012, 
LaRocca et al., 2011, Horstman et al., 2012, Zhang et al., 2013) 
- Use of polycarbonate cages or cage type not reported (LaRocca et al., 2011) 
- Dietary confounder in the study – e.g. BPA effects seen with high phytoestrogen diet (deCatanzaro et al., 
2013) 
- Unintended exposure of the control groups (US FDA/NCTR, 2013 and Delclos et al., 2014, see Churchwell 
et al, 2014) 
Line of Evidence 2: new evidence on the effect of BPA on male reproductive development observed to lead to 
impaired fertility and offspring neonatal growth. 
(10) Zhang et al. 2013.  




- Prolonged treatment duration (Zhang et al., 2013)  
Weaknesses: 
- Insufficient study reporting (lack of experimental details and/or statistical analyses), (Zhang et al., 2013). 
- Study design not appropriate to the scope  (lack of a positive control), ( Zhang et al., 2013) 
- Animal diet and phytoestrogen content not reported (Zhang et al., 2013) 
Uncertain Low ↓/↑ 
Line of Evidence 3: new evidence on the effect of BPA on ovary development (e.g. follicle and oocyte number) 
and female morphology/function (e.g. oestrogens, endometrial hyperplasia, cycstic ovaries, anogenital 
distance) 
(1) US FDA/NCTR, 2013 and Delclos et al., 2014, (2) Christiansen et al., 2014, (3) Kobayashi et al., 2012, (4) 
Ferguson et al., 2011, (11) Veiga-Lopez et al., 2013, (12) Hunt et al., 2012, (13) Zhang et al., 2012a , (14) Nah et al., 
2011, (15) Signorile et al., 2012, (16) Mendoza-Rodriguez et al., 2011, (17) Newbold et al., 2007, (18) Newbold et 
al., 2009, (19) Signorile et al., 2010.  
 
Comment: Of the 13 studies included, one found no significant effect of BPA ≤3.6 mg/kg bw per day HED on 
female reproductive development: Ferguson et al. 2012. Seven found limited negative effects of BPA ≤3.6 mg/kg 
bw per day HED on female reproductive development: US. FDA/NCTR, 2013 and Delclos et al., 2014 (oestrous 
cyclicity abnormalities at two BPA doses), Hunt et al., 2012 (increased proportion of multi-oocyte follicles), Veiga-
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et al., 2012 (reduced female AGD, normalised at adulthood), Signorile et al., 2010 (increased incidence of ovarian 
cysts) Signorile et al., 2012 (reduced numbers of follicles, increased numbers of atretic follicles), Newbold et al., 
2009 (2 BPA doses associated with endometrial abnormalities). Five found clear negative effects of BPA ≤3.6 
mg/kg bw per day HED on female reproductive development: Christiansen et al., 2014 (reduced AGD at all doses),  
Zhang et al., 2012a (increased retention of oocye nests, reduced numbers of primordial follicles, delayed meiotic 
progression), Nah et al., 2011 (reduced ovary weights and delayed puberty), Newbold et al., 2007 (increased 
incidence of ovarian cycts and endometrial hyperplasia at a single BPA dose), Mendoza-Rodruigez et al., 2011 
(abnormalities in oestrous cyclicity and increased evidence of endometrial hyperplasia). 
Comment: Significance of reduced AGD is not clear – i.e. suggests and effect but whether adverse is not currently 
known (Christiansen et al., 2014, Kobayashi et al., 2012). 3 of the other studies found no significant effect on female 
AGD and in the case of Kobayashi et al., 2012 the effect (reduced AGD) was lost as the animals matured. 
Comment: Signs of adaptation/loss of BPA effects in adulthood (Nah et al., 2011, Kobayashi et al., 2012) 
Comment: In Hunt et al., 2012 only the results for the oral route were considered for evaluation because of the 
inadequate number of animals dosed via the subcutaneous route (only 2 monkeys in the control group)  
Comment: In Nah et al., 2011 the administration of BPA on one single day (then followed) reduced confidence in 
the absence of a repeat study. 
Comment: Most of the significant effects of BPA ≤3.6 mg/kg body weight/day HED were from the studies with the 
strengths/weaknesses ratios skewed more heavily towards weaknesses. 
Comment: With regard to endometrial hyperplasia/abnormalities some studies showed a statistically significant 
increase (Mendoza-Rodriguez et al., 2011, Newbold et al., 2009) but findings were not statistically significant in  
Signorile et al. (2010). Signorile et al (2010; 2012) report unconvincing “endometriosis-like” features. 
Comment: An increased incidence of ovarian cysts were observed by Signorile et al., 2010 and Newbold et al., 2007 
but not significantly in Newbold 2009 and not in Signorile et al. (2012) which reported changes in follicle types. 
Comment: Aberrations in oestrous/ovarian cyclicity were reported (Mendoza-Rodriguez et al., 2011, Newbold et al., 
2007, US FDA/NCTR, 2013 and Delclos et al., 2014). Other studies found no significant effects in cyclicity 
(Newbold et al., 2009) 
 
Strengths: 
- Large sample size (US FDA/NCTR, 2013 and Delclos et al., 2014, Ferguson et al. 2012, Christiansen et al., 
2014, Mendoza-Rodriguez et al., 2011, Newbold et al., 2007, Newbold et al., 2009, Signorile et al., 2010, 
Signorile et al., 2012) 
- Number of doses (≥3) (US FDA/NCTR, 2013 and Delclos et al., 2014: especially in the low dose range, 
Kobayashi et al., 2012, Christainsen et al., 2013, Zhang et al., 2012a, Nah et al., 2011) 
- Both naïve and vehicle controls available (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Adequate positive controls included (Ferguson et al., 2011) 
- BPA measurement in serum (Hunt et al., 2012, Veiga-Lopez et al., 2013) 
- Oral administration via gavage (US FDA/NCTR, 2013 and Delclos et al., 2014, Ferguson et al., 2011, 
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Christiansen et al., 2014) 
- Phytoestrogen-free diet (US FDA/NCTR, 2013 and Delclos et al., 2014, Ferguson et al., 2011, Christiansen 
et al., 2014)  
- Cages and diet/water tested by E-screen (Signorile et al., 2010, Signorile et al., 2012) 
- Use of non-PC cages (US FDA/NCTR, 2013 and Delclos et al., 2014, Ferguson et al., 2011, Christiansen et 
al., 2014, Hunt et al., 2012) 
- Study/analysis performed under OECD guideline (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Study/analysis performed under GLP (US FDA/NCTR, 2013 and Delclos et al., 2014) 
Weaknesses: 
- Animal species and strains not reported (Zhang et al., 2012a) 
- Animal age and body weight not given (Zhang et al., 2012a, Signorile et al., 2010, Signorile et al., 2012) 
- Small sample size (Hunt et al., 2012), small litter number (Signorile et al., 2010, Signorile et al., 2012) 
- Plastic cages used or tyope not reported (Newbold et al., 2007, Newbold et al., 2009) 
- Feed/water consumption (BPA given by the diet/water) not measured (Kobayashi et al., 2012, Mendoza-
Rodriguez et al., 2011) 
- BPA concentration and homogeneity in the feed mixture not guaranteed analytically (Kobayashi et al., 
2012) 
- Single dose level study (Hunt et al., 2012, Veiga-Lopez et al., 2013, Mendoza-Rodriguez et al., 2011) 
- Insufficient study reporting/inappropriate statistics (Kobayashi et al. 2012, Zhang et al., 2012a, Nah et al., 
2011, Signorile et al., 2012, Mendoza-Rodriguez et al., 2011, Newbold et al., 2007, Newbold et al., 2009)  
- Internal inconsistencies in data (Signorile et al., 2010, 2012). 
- Animal diet and phytoestrogen content not reported (Kobayashi et al., 2012, Nah et al., 2011, Zhang et al., 
2012a, Mendoza-Rodriguez et al., 2011) 
- BPA concentration and homogeneity not guaranteed analytically (Hunt et al., 2012) 
- Diet phytoestrogen content not reported (Hunt et al., 2012, Veiga-Lopez et al., 2013) 
- Unintended exposure of the control groups (US FDA/NCTR, 2013 and Delclos et al., 2014, see Churchwell 
et al, 2014) 
Line of Evidence 4: new evidence on the effect of BPA on implantation and early development or survival of 
the conceptus or female fertility. 
(21) Xiao et al., 2011, (22) Berger et al., 2007, (23) Nakagami et al., 2009: No effects on implantation, 
development/survival or uterine PGR expression at ≤3.6 mg BPA/kg bw per day. (24) Cabaton et al., 2011: 
significantly reduced cumulative number of pups. 
 
Strengths:  
- Number of doses (5, but only one ≤3.6 mg/kg bw per day, Xiao et al., 2011, Berger et al., 2007)  
- Positive controls included (Xiao et al., 2011, Cabaton et al., 2011) 
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- Good sample size (Nakagami et al., 2009) 
Weaknesses: 
- Animal diet and phytoestrogen content not given (Xiao et al., 2011, Nakagami et al., 2009)  
- Small sample size (n=4 animals, Xiao et al., 2011, n<8 animals, Berger et al., 2007)  
- Drinking bottle type not reported (Berger et al., 2007, Nakagami et al., 2009) 
- Some statistical flaws (Cabaton et al., 2011)  
- Single dose level (Nakagami et al., 2009) 
Line of Evidence 5: new evidence on the effect of BPA on bone in subsequent adulthood. 
(25 Pelch et al., 2012: extremely small effect on male femur length and larger reduction in energy to failure (males 
and females) but not torsional strength or collagen content 
 
Strengths: 
- Positive control included  
- Use of non-PC cages and of non plastic water bottles 
Weaknesses: 
- Animal age and body weight not given  
- Single dose level study  
- Animal diet phytoestrogen content not reported  
Uncertain Low • 
Overall conclusion on Likelihood:  
Taken overall there are some data suggesting negative effects of doses of BPA ≤ an HED of 3.6 mg/kg bw per day on reproductive development in 
animals. However, the disagreement between studies on whether there is an effect, how extensive the effect is and whether the effect is lost as the 
animal matures into adulthood renders a high degree of uncertainty (e.g. disturbed oestrous cyclicity without any effect on ovarian morphology of 
circulating hormones). The most consistent findings are generally of small magnitude and often not accompanied by associated changes (e.g. reduced 
AGD in males would be expected to be associated with reduced testosterone). In addition, a number of studies present molecular findings without 
accompanying morphological data. Given the difficulty in determining whether such molecular changes are due to adaptation, causal or just a result of 
modest morphological changes, weight given to such studies must be reduced. There was only a single non-human primate study included and this was 
hampered by inadequate numbers of animals per group and reported only a single sex. The most convincing evidence for adverse effects are reduced 
(by 7%) male AGD in Christiansen et al., 2014 but four other studes found no effect. Therefore our overall conclusion reflects the contradictory nature 
and highly variable quality of the data and the high levels of uncertainty. 
As likely as not 
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Table 34:  Summary of the WoE assessment of the likelihood that BPA causes reproductive and developmental effects  
Humans 
Overall conclusion on Likelihood of reproductive effects of BPA in humans:  




Overall conclusion on Likelihood of gestational /birth outcomes of BPA in humans:  
There are indications from prospective studies that BPA exposure during pregnancy may be associated with effects on fetal growth, and weak 
indications that BPA exposure during pregnancy may be associated with effects on maternal and infant thyroid function. However, it cannot be ruled out 
that the results are confounded by diet or concurrent exposure factors. For fetal growth, two studies showed reduced fetal growth, while one study 
reported increased fetal growth with increasing maternal BPA exposure. The associations do not provide sufficient evidence to infer a causal link 
between BPA exposure and reproductive effects in humans. Potential effects are considered to be as likely as not.”  
As likely as not 
Animals 
Overall conclusion on Likelihood for reproductive and developmental effects in animals when exposed during their adult life (post-pubertal) 
only at doses ≤ HED of 3.6 mg/kg bw per day:  
As more studies emerge with doses ≤3.6 mg BPA/kg bw per day HED, there are increasing indications of some negative effects of adult exposure to 
BPA on gonadal or reproductive tract physiology. Very few studies have assessed the effects of long term exposure of adults to such doses of BPA 
(human scenario) on fertility/fecundity and reproductive ageing. Since only single studies on ovary and prostate gland fit the methodological criteria 
used in this opinion, no firm conclusion can be drawn on BPA-related effects on these organs. Taken together the studies assessed here suggest that BPA 
at an HED of ≤3.6 mg/kg bw per day may have adverse effects on testis function, especially various measures of spermatogenesis. There is much less 
evidence to support a conclusion that BPA will significantly impair testis morphology or reproductive endocrinology, especially in the longer term. 
Note: Alterations of reproductive capacity are likely at high doses (above an HED of 3.6 mg/kg bw per day) 
As likely as not 
 
Overall conclusion on Likelihood for reproductive and developmental effects in animals when exposed during development (prenatally and 
pre-pubertally) ≤ HED of 3.6 mg/kg bw per day: 
Taken overall, there are some data suggesting negative effects of doses of BPA ≤ an HED of 3.6 mg/kg bw per day on reproductive development in 
animals. However, the lack of agreement between studies and the highly variable quality of the studies renders a high degree of uncertainty. The most 
consistent findings are generally of small magnitude (e.g. reduced male AGD) and often not accompanied by associated changes (e.g. abnormal 
oestrous cyclicity in females would be expected to associate with ovarian or endocrine effects of BPA in the same groups). Given difficulties in 
determining whether molecular changes are causal or due to adaptation or morphological changes, the weight given to studies presenting molecular 
findings without accompanying morphological data is low. The single non-human primate study of the effects of BPA on the fetal ovary included was 
hampered by inadequate numbers of animals per group. The likelihood rating of the studies reflects the variability of the data. 
Note: Alterations of reproductive development are likely at high doses (above an HED of 3.6 mg/kg bw per day) 
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WoE of neurological, neurodevelopmental and neuroendocrine effects 
Whether BPA has the potential to cause neurological, neurodevelopmental and neuroendocrine effects in humans and animals was considered using a tabular 
format for weighing different lines of evidence (WoE evaluation). The WoE evaluation tables for these endpoints are presented in full below.  
Human studies 
Table 35:  Assessment of the likelihood of associations between BPA exposure and neurological, neurodevelopmental or neuroendocrine effects in 
humans.  
Q1: Is there an association between prenatal BPA exposure and neurodevelopmental effects? Answer to the 
question as 














Starting point based on previous assessments (EFSA CEF Panel, 2010). 
The only study identified on this issue showed associations between BPA exposure and externalizing behaviour in 2 
year old girls (Braun et al., 2009).  
 
Weaknesses: Although the study provided some indication of possible effects on neurodevelopment in girls, EFSA 
concluded that the study had methodological limitations and that it was not possible to draw a conclusion for risk 




Line of Evidence 1: Prenatal BPA exposure and neurodevelopmental effects.  
In total five prospective studies. One study showed significant associations in boys only (Harley et al., 2013a), two 
studies showed no associations in boys or girls (Miodovnik et al., 2011, Yolton et al., 2011), one study showed 
associations in girls only (Braun et al., 2011) and one study showed significant but different/conflicting associations 
in boys and girls, i.e. in boys higher prenatal BPA was associated with increased behavioural problems while in girls 
higher BPA was associated with decreased problems in girls (Perera et al., 2012). 
 
Comment:  
Adjustment for other environmental chemicals (Yolton et al., 2011; Braun et al., 2011; Miodovnik et al., 2011; 
Harley et al., 2013a) 
 
Strengths:  
− Prospective study design (all studies) 
− Urine, container specified (Braun et al., 2011; Harley et al., 2013a) 
Positive Medium  
 
↑ 
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− Repeated measurements for maternal (Yolton et al., 2011; Braun et al., 2011; Harley et al., 2013a) and 
children urine (Braun et al., 2011)  
− Standardised samples (all studies) 
− Analytical method (LC-MS-MS) (all studies) 
− Quality controls, including blanks (Harley et al., 2013a) 
− Multiple outcome assessment (maternal and teacher-report at age 7 and direct observation at age 9) (Harley 
et al., 2013a) 
Weaknesses:  
− Small sample size (all studies) 
− Single spot urine BPA measurement (Miodovnik et al., 2011; Perera et al., 2012) 
− No distinction between unconjugated and conjugated BPA (all studies) 
− Confounding by diet (all studies) or other chemicals (Perera et al., 2012) not considered  
− Unclear clinical relevance (small effect size, conflicting results in boys and girls) (Braun et al., 2011; Perera 
et al., 2012; Harley et al., 2013a) 
− Imprecise/unreliable outcome (parent-reported but validated methods only) (Miodovnik et al., 2011; Braun 
et al., 2011; Perera et al., 2012) 
− Generalisability to the overall population (Perera et al., 2012; Harley et al., 2013a) 
− Inconsistent results amongst different studies (all studies) 
Overall conclusion on Likelihood of neurodevelopmental effects of BPA in humans:  
There are indications from prospective studies that prenatal BPA exposure (BPA exposure during pregnancy) may be associated with child behaviour in 
a sex-dependent manner. However, the associations were not consistent across the studies. It cannot be ruled out that the results are confounded by diet 
or concurrent exposure factors. The associations are not sufficient evidence to infer a causal link between BPA exposure during pregnancy and 
neurodevelopmental effects in humans. Potential effects are considered to be as likely as not. 
 
As likely as not  
 
Q2: Is there an association between childhood BPA exposure and neurological/behavioural effects? Answer to the 
question as 















Line of Evidence 1: Childhood BPA exposure and neurological effects.  
Three prospective studies, of which one found no associations between urinary BPA levels in children and 
behavioural effects (Braun et al., 2011) one found an association with 1 of 7 outcomes (Perera et al., 2012), and one 
found associations in both boys and girls (Harley et al., 2013a). A cross-sectional study with boys and girls analysed 
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− Adjustment for other environmental chemicals (Braun et al., 2011; Harley et al., 2013a). 
 
Strengths:  
− Prospective study design (Braun et al., 2011; Perera et al., 2012; Harley et al., 2013a) 
− Urine, container specified (Braun et al., 2011; Harley et al., 2013a) 
− Repeated measurements for maternal (Braun et al., 2011; Harley et al., 2013a) and children urine (Braun et 
al., 2011)  
− Standardised samples (all studies) 
− Analytical method (LC-MS-MS) (all studies) 
− Quality controls, including blanks (Harley et al., 2013a) 
− Multiple outcome assessment (maternal and teacher-report at age 7 and direct observation at age 9) (Harley 
et al., 2013a) 
Weaknesses:  
− Cross-sectional study design (Hong et al., 2013) 
− Small sample size (Braun et al., 2011; Perera et al., 2012; Harley et al., 2013a) 
− Single spot urine BPA measurement (Perera et al., 2012; Hong et al., 2013) 
− No distinction between unconjugated and conjugated BPA (all studies) 
− Confounding by diet not considered (all studies) 
− Imprecise/unreliable outcome (parent-reported but validated methods) (Braun et al., 2011; Perera et al., 
2012) 
− Generalisability to the overall population (Perera et al., 2012; Harley et al., 2013a) 
− Inconsistent results amongst different studies (all studies) 
Overall conclusion on Likelihood of neurological/behavioural effects of BPA in humans:  
There are indications from one prospective study that childhood BPA exposure may be associated with behavioural problems in both girls and boys. It 
cannot be ruled out that the results are confounded by diet or concurrent exposure factors. The associations do not provide sufficient evidence to infer a 
causal link between childhood BPA exposure and neurological effects/behavior in humans. Potential effects are considered to be as likely as not. 
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Animal studies 
Table 36:  Assessment of the likelihood that BPA produces neurobehavioural changes in laboratory rodents after pre- and/or postnatal exposure to BPA. 
 
Q1: Is there any evidence that BPA exposure changes response in tests for anxiety-like behaviour in 
rodents? 
Answer to the 
question as reported 
by the study authors 














Starting point based on previous assessments (EFSA, 2006; EFSA CEF Panel, 201019) 
Overall, no consistent pattern in the data on anxiety-like behaviour across species and gender. Uncertainties 
include study design limitations, inclusion of only one sex, age at examination (EFSA, 2006). In 2010, the CEF 
Panel concluded that currently available data addressing neurobehavioural endpoints (e.g. learning and memory 
behaviour, anxiety-related behaviour and gender-specific behaviour) does not provide convincing evidence of 
neurobehavioural toxicity of BPA (EFSA CEF Panel, 2010).  
Some Positive Low 
 
● 
Line of evidence 1: New studies on Anxiety-like behaviour (Diaz Weinstein et al., 2013; Ferguson et al., 2012; 
Fujimoto et al., 2013; Gioiosa et al., 2013; Inagaki et al., 2012; Jasarevic et al. 2013; Jones and Watson, 2012; 
Kundakovic et al., 2013; Matsuda et al. 2012; Nakamura et al., 2012; Patisaul et al., 2012; Viberg et al., 2011; 
Wolstenholme et al., 2011a; Wolstenholme et al., 2012; Wolstenholme et al., 2013; Xu et al. (2011); Xu et al. 
2012; Xu et al., 2013a): 
   
Diaz-Weinstein et al., 2013 
Comment: Adolescent rats exposed daily by subcutaneous injection to BPA for 12 days 
Comment: anxiety-like behaviour tested in open field and elevated plus maze 
 
Strengths: 
- Use of glass water bottles  
- Blind evaluation of the observed behaviour 
Weaknesses: 
- Single dose level study  
- Study design not appropriate to the scope (behavioural tests performed only once with limitation to one 
trial, subsequent testing in two different tests on the same day) 
Positive Low • 
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- Insufficient study reporting (body weights not measured daily in conjunction with treatment; no 
information on sexual maturation and insufficient information on recording of behavioural testing; 
animal diet and phytoestrogen content not reported) 
- Inapproriate statistics (repeated measures for the same animal are not taken into account, cycling is not 
adjusted for in the analysis; no multiple comparison statistics - Fisher’s protected LSD test applied 
which does not adequately protect from Type 1 Error increase due to multiple comparisons) 
Ferguson et al., 2012 (see Q2 and Q4 for other endpoints) 
Comment: Pre- and postnatal exposure by maternal administration of BPA (gavage), plus direct postnatal 
exposure to pups (gavage) 
Comment: Motor activity of naïve controls similar to that of BPA –treated groups 
Comment: Multiple tests performed (Novelty preference test (PND 29), open field test (PND 40-42), motor 
coordination (PND 43-44), Barnes maze (PND 47-50), acoustic startle response (PND 54), and Morris water 
maze (PND 75-79). Here open field test is addressed. 
 
Strengths: 
- Large sample size 
- Both naïve and vehicle controls available (to account for the handling of the animal) 
- Adequate positive controls included 
- Use of non-PC cages and of glass water bottles  
Weaknesses: 
- Study design not appropriate to the scope  (only low doses of BPA used) 
Negative/uncertain 
(males only) 
Low  • 
Fujimoto et al., 2013 
Comment: lactational BPA-exposure (maternal dosing via drinking water) 
Comment: Two different tests used to investigate anxiety-like behaviour (open field  at 6 weeks of age, Elevated 
plus maze at 7 weeks of age) 
 
Strengths: 
- Use of glass water bottles 
Weaknesses: 
- Single dose level study 
- Animal diet and phytoestrogen content not reported  
- Study design not appropriate to the scope  (small sample size, N = 5 dams and litters per treatment 
group, littermates treated as independent observations) 
- Insufficient BPA-exposure assessment (drinking water consumption (containing BPA) not measured) 
- Insufficient study reporting (insufficient information on recording of behavioural  testing) 
- Inappropriate statistics (litter effect not considered; no multiple comparison statistics - Fisher’s protected 
Positive Low • 
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LSD test applied which does not adequately protect from Type 1 Error increase due to multiple 
comparisons) 
Gioiosa et al., 2013  
Comment: Crossfostering design, pre- or postnatal exposure only (maternal dosing by spontaneous consumption 
of oil-based solution from a modified syringe) 
Comment: Three different tests used to investigate anxiety-like behaviour (novelty test in juveniles, open-field 
and EPM at adulthood) 
 
Strengths: 
- Blind collection and analyses of behavioural data 
Weaknesses: 
- Single dose level study 
- Animal diet and phytoestrogen content not reported (soy-based standard diet used) 
- Use of polycarbonate cages and bottles (new ones) 
- Insufficient BPA-exposure assessment (BPA dose adjusted to body weight seemingly not on a daily 
basis) 
- Inappropriate statistics (no correction for multiple comparisons applied; comparison between the two 
exposure windows is not appropriate since the same dose is used for either gestational or lactational 
exposure – resulting in very different internal dose) 
Positive/Uncertain Low • 
Inagaki et al., 2012 (see also Q2)  
Comment: Single subcutaneous administration to adult cycling female rats 
Comment: Parallel assessment of learning/memory and relevant neurobiological marker (spinogenesis) in two 
different brain areas 
Comment: Elevated plus maze (EPM) was used to examine whether BPA indirectly may impair recognition 
memory by increasing anxiety levels of the rats 
 
Strengths: 
- BPA measurement in biological samples (serum) 
Weaknesses: 
- Single acute dose administration 
- Test performed in one sex only 
- Insufficient study reporting (study design not properly described, doses and number of animals for the 
various tests is unclear; except from feed content, no information of environmental contamination of 
Negative Low • 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 512 
BPA is given, i.e. cages, water bottles, or bedding) 
- Inappropriate statistics (considerations of repeated measures of the same animal not included in the 
analyses, nor multiple endpoint within a test) 
Jasarevic et al., 2013 (see also Q2) 
Comment: Deer mice with pre- and postnatal exposure (maternal dosing via feed 2 week prior to mating) 
Comment: Indication of weak dose-response reaching a plateau at the 2 top doses (≥5 mg/kg bw per day).  
Comment: Anxiety-like behaviour evaluated by elevated plus maze (EPM) 
 
Strengths: 
- Adequate positive controls included 
- Number of BPA doses (3) 
- Use of non-PC cages and glass water bottles 
- BPA exposure measurement in animal samples (serum) 
Weaknesses: 
- Study design not appropriate to the scope  (multiple breeding; use of littermates in testing; study not 
controlled for reproductive cycling at testing time; unclear exposure time of the respective dams or if the 
controls were concurrent with the treated animals; possible additional dietary exposure of the offspring 
during late lactation)  
- Feed consumption (BPA given by the diet) not measured 
- Insufficient study reporting (no information on normalization for dams’ body weight; maternal amount 
of feed consumed daily not specified; unclear whether offspring may have been exposed directly through 
feed during late lactation when incisors have appeared; total number of dams and their general 
reproductive outcome not given) 
- Inappropriate statistics (litter effect not considered; no multiple comparison statistics - Fisher’s protected 




 Low  •/↑ 
Jones and Watson, 2012 (see also Q2) 
Comments: Pre- and postnatal exposure (maternal oral dosing by licking oil drops)  
Comment: three behavioural tests performed (Morris Water Maze, Forced Swim Test (FST) and for anxiety-like 
behaviour in the Elevated Plus Maze, EPM) 
 
Strengths: 
- Number of BPA doses (4) 
- Use of non-PC cages, and of BPA-free water sacks (for dams) 
Weaknesses: 
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independent observations; females not controlled for cycling at the time of testing)  
- Insufficient study reporting (unclear reports for the statistical findings in the figures/tables presented, 
especially for FST) 
- Inappropriate statistics (because of the limited number of litters tested (2-3) per dose group, the samples 
size is considered underpowered; litter effect not considered, lack of analysis of the two way interaction 
between treatment and sex; no adjustment of cycling included) 
Kundakovic et al. 2013 (see Q3 for another endpoint) 
Comment: Gestational exposure (maternal oral administration of BPA during pregnancy only) 
Comment: Parallel assessment of relevant molecular markers (oestrogen receptors and DNA methylation for ER 
genes)  
Comment: The large scatter within the dose-groups for the behavioural endpoints does not allow to conclude on 
the shape of the dose-response curve and even a conclusion that there is no dose-response would be compatible 
with the data 
Comment: Two different tests for social behaviour used (home cage social behaviour in juveniles and dyadic 
interaction with a same-sex stimulus mouse at PND 70) 
Comment: Anxiety-like behaviour tested in open field (OF) area at PND 60 (video recording) 
 
Strengths: 
- Number of BPA doses (3) 
- BPA measured in biological sample (urine)  
- Use of non-polycarbonate (non-PC) cages 
Weaknesses: 
- Insufficient study reporting (general reproductive information like maternal body weight, litter size and 
sex- ratio is not given; frequency of various postpartum maternal behaviours given without the litter 
size; the administration to dams is not specified except that it is oral; urine collection and analysis not 
described; the sacrificing and brain sampling procedures are not detailed; insufficient information 
concerning the scoring of social/aggressive behaviour; poor description of the social behaviour testing) 
- Inappropriate statistics (lack of accounting for multiple observations within each litter [pseudo-
replication] in the ANOVA; the application of the multilevel regression model showed a large scatter of 
data within dose-groups [only four] and thus a large number of different dose-response curves can be 
fitted to the data so that it is not possible to conclude on the biological relevance for any of them) 
- Animal diet and phytoestrogen content not reported  
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Matsuda et al., 2012 
Comment: Pre- and postnatal exposure (maternal dosing via subcutanous route) 
Comment: Parallel examination of neurobiological (dopaminergic markers) and functional end points (anxiety-




- Single dose level study 
- Study design not appropriate to the scope  (dosing not daily adjusted to body weight; limited sample size 
(n=4-6) for neurochemical assessment) 
- Insufficient study reporting (number of dams lacking, general reproductive outcome and information on 
check for cycling in female offspring not given; type of cages and drinking bottles not reported; animal 
diet and phytoestrogen content not reported) 
- Insufficient BPA-exposure assessment (constant during pregnancy and lactation and not adjusted to 
body weight) 




Nakamura et al., 2012 (see also Q2) 
Comment: Pre- and postnatal exposure by maternal administration of BPA (subcutaneously) 





- Single dose level study 
- Insufficient study reporting (maternal body weight not given; lack of information on check for cycling in 
female offspring; no information of environmental BPA-control, i.e. animal diet and phytoestrogen 
content, type of cages, bedding and drinking bottles not reported) 
- Insufficient BPA-exposure assessment (constant during pregnancy and lactation and not adjusted to 
body weight) 
- Inappropriate statistics (litter effect not considered) 
Negative Low ● 
Patisaul et al., 2012 
Comment: Pre- and postnatal exposure (maternal dosing via drinking water, plus direct exposure of offspring via 
drinking water until PND 40) 
Comment: BPA-exposed dams were given soy-free or soy-based diets 
Comment: cycling taken into account; including only females in the same estral phase to avoid variability 
Comment: Parallel assessment of molecular markers (ER-beta and Kisspeptin1) and functional end points 
Positive 
 
 Low  • 
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Comment: anxiety-like behaviour evaluated by light/dark box and Elevated plus maze 
 
Strengths: 
- Positive control included (estrogenic) 
- BPA measurement in animal samples (dams’ serum)  
- Phytoestrogen-free diet (one group) 
Weaknesses: 
- Single dose level study 
- Insufficient BPA-exposure assessment (estimated based on maternal water intake and not normalized to 
body weight) 
- Lack of constant levels of exposure in time (lactational exposure is much lower than the gestational or 
juvenile exposure).  
- Insufficient study reporting (effects of animal breeding schedule not well described, mating was split in 
four cohorts with no information on distribution of dose groups, insufficient reporting of number of 
dams, unclear whether parallel behavioural testing of different dose groups of offspring was performed, 
duration of testing in EMP not given; type of cages and drinking bottles not reported)  
- Inappropriate statistics (unclear if litter effect was properly considered).  
Viberg et al., 2011 (also see Q2) 
Comment: single oral administration by gavage on PND 10 to males only  
Comment: anxiety-like behaviour (Elevated plus maze) was not affected by BPA treatment (tested at 3 month)  
 
Strengths: 
- Number of dose groups (3) 
Weaknesses 
- Single acute dose administration 
- Small sample size (3-4 litters/group) 
- Test performed in one sex only 
- Study design not appropriate to the scope   (pup body weight recorded only four times during the 6 
months study; only male pups behaviourally tested and it appears as the same 12-15 males representing 
3-4 litters were used in all four tests; littermates treated as independent observations) 
- Insufficient study reporting (number of dams and general reproductive outcome lacking; litters said to be 
standardised by size (12-14 pups) but sex ratio is not given; type of cages, bedding and drinking bottles 
not reported)  
- Inappropriate statistics (because of the limited number of litters tested (3-4), the samples size is 
considered underpowered; the litter effect is not properly considered in the statistics) 
Negative  Low • 
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- Phytoestrogen content in animal diet not given 
Wolstenholme et al., 2011a 
Comment: Prenatal exposure (maternal exposure via feed prior to mating and through gestation) 
Comment: To ensure prenatal exposure only and exclude BPA-induced differences of maternal care, foster-dams 
were used implying mixed litters and tail clipping of pups, which might both be a strength and a weakness 
Comment: Parallel assessment of relevant neurobiological (oxytocin) and functional endpoints 
Comment: anxiety-like behaviour evaluated by elevated plus maze (EPM)  
 
Strengths: 
- BPA measurement in animal samples (serum) 
- Phytoestrogen-free diet 
- Scoring blind to treatment 
Weaknesses: 
- Single dose level study 
- Feed consumption (BPA given by the diet) not measured 
- Type of cages and drinking bottles not reported 
- Insufficient study reporting (information of the content of the mixed litters, like number of pups and sex 
ratio is missing) 
- Inappropriate statistics (litter effect not considered)  
Negative   
 
 
Low  •/↓ 
 
Wolstenholme et al., 2012 
Comment: The study addressed association of BPA behavioural effects with expression of genes implicated in 
regulation of social behaviour and related sex dimorphism (ERs, oxytocin and vasopressin) in embryos. 
Comment: transgenerational effects (F2 and F4) were addressed 
Comment: anxiety-like behaviour evaluated by elevated plus maze (EPM)  
 
Strengths: 
- BPA measurement in animal samples (F0 dams, serum) 
- Phytoestrogen-free diet (F0-generation only) 
Weaknesses: 
- Single dose level study 
- Study design not appropriate to the scope   (the number of dams in F0 generation was limited)  
- Insufficient study reporting (animal age and body weight not given; no normalization of food 
consumption on body weight, potential variability of exposure; lack of information of control of 
environmental contamination of BPA, i.e. cages, bedding and water bottles; lack of information of 
mixed litters e.g. number of pups and sex ratio; reproductive outcome of the breeding brother-sister pairs 
done to obtain F2 to F4 generation is not given) 
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line above) 
- Inappropriate statistics (litter effect not considered)   
Wolstenholme et al., 2013 (see also Q3 and Q4) 
Comment: Transgenerational study (F0-F3) where F0 dams were exposed to BPA via feed 
Comment: Cross-fostering design (F0 to F1) to ensure prenatal BPA exposure to F1 generation 
Comment: At postnatal day (PND) 24, F1 and F3 mice were tested in an open field  
 
Strengths: 
- Phytoestrogen-free diet (F0 dams) 
Weaknesses: 
- Single dose level study 
- Insufficient study reporting (information on sex ratio in the F1 litters is missing, as well as reproductive 
outcome of the sibling mating performed to obtain F2 and F3 generations, unclear whether the authors 
actually measured the daily amount of feed consumed for each dam or averaged the amount based on 
previous knowledge; lack of information of control of environmental contamination of BPA, i.e. cages, 
bedding and water bottles) 
- F1-F3 fed chow containing phytoestrogens) 
Positive Low to 
Medium 
● 
Xu et al., 2011 (see also Q2) 
Comment: Adolescent mice orally exposed to BPA for 8 weeks; behavioural testing started at day 91  
Comment: four behavioural tests used (open field, Elevated plus maze, Morris water maze, passive avoidance 
(step down)) 
Comment: index of anxiety-like behaviour given; unclear abolished (or induced) sex difference of BPA 
 
Strengths: 
- Phytoestrogen-free diet 
Weaknesses: 
- Inappropriate statistics (multiple comparison statistics not considered) 





Xu et al., 2012 
Comment: Prenatal or postnatal exposure (maternal oral dosing presumably by gavage) 
Comment: Degree of effects are similar irrespectively of exposure period was gestational only or lactational only 
(exposure differs by orders of magnitude) 
Comment: Multiple functional test PND 56-60: Open field, Dark/light transition, Mirrored maze, Elevated plus 
maze, Forced swim task, and assessment of neurobiological end points (AMPA and NMDA receptors)   
Comment: Multiple tests performed to address the same endpoint and results consistent in 5 different tests for 
females and 3 different tests for males  
Comment: Use of ovariectomized mice which underwent surgery 1 week before testing for anxiety-like behaviour 
Positive 
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Strengths: 
- Phytoestrogen-free diet 
Weaknesses: 
- Study design not appropriate to the scope   (the sequence of testing was not randomized) 
- Insufficient study reporting (two doses of BPA (4 and 0.4 mg/kg bw per day) were administered through 
the oral route without specifying how, presumably by gavage  
- Type of cages and drinking bottles not reported 
- Inappropriate statistics (multiple comparison statistics not considered) 
Xu et al., 2013a (see Q2 for other endpoint) 
Comment: Adult exposure by oral administration (gavage) for 12 weeks 
Comment: the highest BPA dose 40mg/kg per day is high 
Comment: anxiety-like behaviour evaluated by open field. Dose dependency for medium and high dose males in 
the measures of grooming  
Comment: Parallel measurement of synaptic morphology (neural plasticity index) and functional endoints 
 
Strengths: 
- Number of BPA doses (3) 
- Phytoestrogen-free diet 
- Use of non-PC cages and of non-plastic water bottles 
- Blinded evaluation of data from the open field test, not specified for the MWM or for passive avoidance 
Weaknesses: 
- Insufficient study reporting (body weight data collected during treatment not shown) 
Positive  Low  • 
Overall conclusion on Likelihood on Anxiety-like behaviour in animals after pre- and/or postnatal exposure to BPA: 
Several studies report on increased anxiety-like behaviour in laboratory rodents after exposure to BPA. Due to the limitation in study design and statistics, 
and the inconsistency in the reported results, potential effects are considered to be as likely as not.  
 
As likely as 
not 
 
Q2: Is there any evidence that BPA exposure affects learning and memory?  Answer to the 
question as reported 
by the study authors 













Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 519 
Starting point based on previous assessments (EFSA, 2006; EFSA CEF Panel, 2010) 
Overall the CEF Panel concluded that currently available data addressing neurobehavioural endpoints (e.g. 
learning and memory behaviour, anxiety-related behaviour and gender-specific behaviour) does not provide 
convincing evidence of neurobehavioural toxicity of BPA (EFSA CEF Panel, 2010). The Stump (2010) study was 
inconclusive with respect to the learning and memory endpoint. The Panel considered that the biochemical 
changes in Xu et al., 2010a (in rats) were not sufficient to revise the TDI in the absence of a clear link to an 






Line of evidence 1: new studies on impairment of learning and memory following BPA exposure (Diaz-
Weinstein et al., 2013; Eilam- Stock et al., 2012; Ferguson et al., 2012; Inagaki et al., 2012; Jang et al., 2012; 
Jasarevic et al. 2012; Jones and Watson, 2012; Kim et al., 2011; Matsuda et al., 2013, Nakamura et al., 2012; 
Viberg et al., 2011; Xu et al., 2010b; Xu et al., 2011; Xu et al., 2013a) 
   
Diaz-Weinstein et al., 2013 (also see Q1) 
Comment: Adolescent rats exposed daily by subcutaneous injection to BPA for 12 days 
Comment: spatial memory was tested (object placement task) 
 
Strengths: 
- Use of glass water bottles  
- Blind evaluation of the observed behaviour 
Weaknesses: 
- Single dose level study  
-  not appropriate to the scope   not appropriate to the scope (behavioural tests performed only once with 
limitation to one trial, subsequent testing in two different tests on the same day) 
- Insufficient study reporting (body weights not measured daily in conjunction with treatment; no 
information on sexual maturation and insufficient information on recording of behavioural testing; 
animal diet and phytoestrogen content not reported) 
- Inappropriate statistics (repeated measures for the same animal are not taken into account, cycling is not 
adjusted for in the analysis; Fisher’s protected LSD test applied which does not adequately protect from 
Type 1 Error increase due to multiple comparisons) 
Positive Low • 
Eilam-Stock et al., 2012 
Comment: Single subcutaneous administration in adult male rats 
Comment: Parallel assessment of neurobiological markers (decreased spinogenesis and PSD95) in two different 
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- Small sample size (n = 6) 
- Single acute dose administration 
- Single dose study level 
- Study design not appropriate to the scope   (all test animals were exposed to BPA, no control group) 
- Test performed in one sex only (male) 
- Animal diet and phytoestrogen content not reported 
Ferguson et al., 2012 (see Q1 and Q4 for other endpoint) 
Comment: Pre- and postnatal exposure by maternal administration of BPA (gavage), plus direct postnatal 
exposure to pups (gavage) 
Comment: Motor activity of naïve controls similar to that of BPA –treated groups 
Comment: Multiple tests performed (Novelty preference test (PND 29), Open field test (PND 40-42), Motor 
coordination (PND 43-44), Barnes maze (PND 47-50), Acoustic startle response (PND 54), and Morris water 
maze (PND 75-79). Here Barnes maze and Morris water maze is addressed 
 
Strengths: 
- Large sample size 
- Both naïve and vehicle controls available (to account for the handling of the animal) 
- Adequate positive controls included 
- Use of non-PC cages and of glass water bottles  
Weaknesses: 
- Study design not appropriate to the scope  (only low doses of BPA used) 
Negative High  ↓ 
Inagaki et al., 2012 (see also Q1) 
Comment: Single subcutaneous administration to adult cycling female rats 
Comment: parallel assessment of learning/memory and relevant neurobiological marker (spinogenesis) in two 
different brain areas 
 
Strengths: 
- BPA measurement in biological samples (serum) 
Weaknesses: 
Positive Low • 
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- Single acute dose administration 
- Test performed in one sex only 
- Insufficient study reporting (study design not properly described, doses and number of animals for the 
various tests is unclear; except from feed content, no information of environmental contamination of 
BPA is given, i.e. cages, water bottles, or bedding) 
- Inappropriate statistics (considerations of repeated measures of the same animal not included in the 
analyses, nor multiple endpoint within a test) 
Jang et al., 2012 
Comment: Gestational exposure of the F0 dams by intraperitoneal injection (i.p.) in a multigeneration study 
Comment: highest dose 10 mg/kg bw i.p. 
Comment: use of Morris water maze (no effect) and Passive Avoidance (with effect) 




- Number of BPA doses (3)  
Weaknesses: 
- Small sample size 
- Maternal administration via ip injection during pregnancy 
- Test performed in one sex only 
- Low number of animals tested 
- Insufficient study reporting (number of females in the F0 generation was not given; animal body weight 
not given; animal diet and phytoestrogen content not reported; no information of environmental 
contamination of BPA is given, i.e. cages, water bottles, or bedding) 







Jasarevic et al., 2013 (also see Q1) 
Comment: Deer mice with pre- and postnatal exposure (maternal dosing via feed 2 week prior to mating) 
Comment: Indication of weak dose-response reaching a plateau at the 2 top doses (≥5 mg/kg bw per day).  
Comment: anxiety-like behaviour evaluated by elevated plus maze (EPM) and spatial learning capabilities in a 
modified Barnes Maze as adults 
 
Strengths: 
- Adequate positive controls included 
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- Use of non-PC cages and glass water bottles 
- BPA exposure measurement in animal samples (serum) 
Weaknesses: 
- Study design not appropriate to the scope (exposure pre mating may influence on reproductive outcome; 
multiple breeding; use of littermates in testing; study not controlled for reproductive cycling at testing 
time; unclear exposure time of the respective dams or if the controls were concurrent with the treated 
animals; possible additional dietary exposure of the offspring during late lactation)  
- Insufficient study reporting (no information on normalization for dams’ body weight and feed 
consumption described; maternal amount of feed consumed daily not specified; unclear whether 
offspring may have been exposed directly through feed during late lactation when incisors have 
appeared; total number of dams and their general reproductive outcome not given) 
- Inappropriate statistics (the litter effect was not adequately considered; no multiple comparison statistics; 
Fisher’s protected LSD test applied which does not adequately protect from Type 1 Error increase due to 
multiple comparisons) 
Jones and Watson, 2012 (see also Q1) 
Comments: Pre- and postnatal exposure (maternal oral dosing by licking oil drops)  
Comment: three behavioural tests performed (Morris Water Maze, Forced Swim Test (FST) and for anxiety-like 
behaviour in the Elevated Plus Maze, EPM) 
 
Strengths: 
- Number of BPA doses (4) 
- Use of non-PC cages, and of BPA-free water sacks (for dams) 
Weaknesses: 
- Study design not appropriate to the scope (small number (2-3) of dams per group; littermates treated as 
independent observations; females not controlled for cycling at the time of testing)  
- Insufficient study reporting (unclear reports for the statistical findings in the figures/tables presented, 
especially for FST) 
- Inappropriate statistics (because of the limited number of litters tested (2-3) per dose group, the samples 
size is considered underpowered; litter effect not considered, lack of analysis of the two way interaction 
between treatment and sex; no adjustment of cycling included) 
Positive Low  
 
• 
Kim et al., 2011 
Comment: Two weeks exposure orally by gavage in young adult mice 
Comment: Parallel assessment of neuroanatomical markers and functional effects 
Comment: effects seen only at high dose (20mg/kg bw), not at 5mg /kg bw per day or the lower 1 mg/kg bw  
Positive  
 
Low  • 
 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 523 
Strengths: 
- Number of doses (3) 
Weaknesses: 
- Small sample size (n = 5- 6 per group) 
- Test performed in one sex only (male) 
- Insufficient study reporting (unclear number of mice used and whether the investigation of newly 
generated cells was performed in separate groups of mice or not; animal diet and phytoestrogen content 
not reported  
- Inappropriate statistics (Fisher’s protected LSD test applied does not adequately protect from Type 1 
Error increase due to multiple comparisons) 
Matsuda et al., 2013 
Comment: Pre- and postnatal exposure (maternal dosing via subcutanous route) 






- Single dose level (250 ng/kg bw per day BPA) 
- Insufficient study reporting (number of dams and general reproductive outcome not given; no 
information about check for cycling in adult female offspring) 
- Insufficient BPA-exposure assessment (constant during pregnancy and lactation and not adjusted daily 
to body weight; no information about environmental BPA contamination, e.g. feed and bedding is given) 
- Animal diet and phytoestrogen content not reported 






Nakamura et al., 2012 (see also Q1) 
Comment: Pre- and postnatal exposure by maternal administration of BPA (subcutaneously) 





- Single dose level study 
- Insufficient study reporting (maternal body weight not given; lack of information on check for cycling in 
female offspring; no information of environmental BPA-control, i.e. animal diet and phytoestrogen 
content, type of cages, bedding and drinking bottles not reported) 
Negative Low ● 
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- Insufficient BPA-exposure assessment (constant during pregnancy and lactation and not adjusted to 
body weight) 
- Inappropriate statistics (litter effect not considered) 
Viberg et al., 2011 (also see Q1) 
Comment: single oral administration by gavage on PND 10 to males only  
Comment: Spatial learning task (Morris water maze) performed at 6 months of age showed no BPA effect 
Strengths: 
- Number of dose groups (3) 
Weaknesses 
- Single acute dose administration 
- Small sample size (3-4 litters/group) 
- Test performed in one sex only 
- Study design not appropriate to the scope   (pup body weight recorded only four times during the 6 
months study; only male pups behaviourally tested and it appears as the same 12-15 males representing 
3-4 litters were used in all four tests; littermates treated as independent observations) 
- Insufficient study reporting (number of dams and general reproductive outcome lacking; litters said to be 
standardised by size (12-14 pups) but sex ratio is not given; type of cages and drinking bottles not 
reported)  
- Inappropriate statistics (because of the limited number of litters tested (3-4), the samples size is 
considered underpowered; the litter effect is not properly considered in the statistics) 
- Phytoestrogen content in animal diet not given 




Xu et al., 2010b 
Comment: Pre- and postnatal exposure by oral maternal administration of BPA  
Comment: Two behavioural tests performed, Morris water maze and step-down passive avoidance test 
 
Strengths: 
- Number of doses (4) 
- Phytoestrogen-free diet 
Weaknesses: 
- Test performed in one sex only (male) 
- Insufficient study reporting (reproductive outcome not shown, e.g. maternal bw, no pre-weaning body 
weight data shown; information about type of bedding and water bottles missing) 
- Insufficient BPA-exposure assessment (unknown if constant during pregnancy and lactation or adjusted 
daily to body weight)  
Positive (males only) Low to 
Medium 
● 
Xu et al., 2011 (see also Q1) 
Comment: Adolescent mice orally exposed to BPA for 8 weeks; behavioural testing starts at day 91  
Positive Low ● 
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Comment: four behavioural tests used (Open field, Elevated plus maze, Morris water maze, Passive avoidance 
(step down)) 
Comment: unclear abolished (or induced) sex difference of BPA 
 
Strengths 
- Phytoestrogen-free diet 
Weaknesses 
- tics (multiple comparison statistics not considered) 
- Type of cages and drinking bottles not reported 
Xu et al., 2013a (see Q1 for other endpoint) 
Comment: Adult exposure by oral administration (gavage) for 12 weeks 
Comment: Parallel assessment of synaptic morphology (neural plasticity index) and functional end points. 
Comment: Two learning tasks used: the Morris Water Maze and the Passive Avoidance test (step down test). 
 
Strengths: 
- Number of BPA doses (3) 
- Phytoestrogen-free diet 
- Use of non-PC cages and of non plastic water bottles 
- Blinded evaluation of data from the open field test, not specified for the MWM or for passive avoidance 
Weaknesses: 
- Insufficient study reporting (body weight data collected during treatment not shown)  




Overall conclusion on Likelihood on Learning and memory in animals after pre- and/or postnatal exposure to BPA: 
The effects of BPA on learning and memory abilities of laboratory rodents are no fully consistent, as both positive and negative effects are reported in 
different papers. The papers have methodological shortcomings, such as underpowered sample size, lack of consideration of the litter effect, or not properly 
controlled variability of exposure through diet, and inadequate statistics. Potential effects are considered to be as likely as not. 
 
As likely as 
not 
 
Q3: Is there any evidence that BPA exposure affects social behaviour in the animal species tested? Answer to the 
question as reported 
by the study authors 














Starting point based on previous assessments: EFSA opinion did not assess social behaviour separately 
from anxiety. Other reviews (FAO/WHO, 2011) 
Several studies reviewed suggest an effect of developmental exposure to BPA on social responses in rodents 
(increased aggression in males and defeminisation of social/affiliative behaviour in females). In general these 
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Line of evidence 1: New studies on social behaviour (Kundakovic et al., 2013; Wolstenholme et al., 2011a; 
Wolstenholme et al., 2012; Wolstenholme et al., 2013;):  
   
Kundakovic et al., 2013 (see also Q1) 
Comment: Gestational exposure (maternal oral administration of BPA during pregnancy only) 
Comment: Parallel assessment of relevant molecular markers (oestrogen receptors and DNA methylation for ER 
genes)  
Comment: The large scatter within the dose-groups for the behavioural endpoints does not allow concluding on 
the shape of the dose-response curve and even a conclusion that there is no dose-response would be compatible 
with the data 
Comment: Anxiety-like behaviour tested in Open field (OF) area at PND 60 (video recording) 
Comment: Two different tests for social behaviour used (home cage social behaviour in juveniles and dyadic 
interaction with a same-sex stimulus mouse at PND 70) 
 
Strengths: 
- Number of BPA doses (3) 
- BPA measured in biological sample (urine)  
- Use of non-polycarbonate (non-PC cages) 
Weaknesses: 
- Insufficient study reporting (type of bedding not given; general reproductive information like maternal 
body weight, litter size and sex- ratio is not given; frequency of various postpartum maternal behaviours 
given without the litter size; the administration to dams is not specified except that it is oral; urine 
collection and analysis not described; the sacrificing and brain sampling procedures are not detailed; 
insufficient information concerning the scoring of social/aggressive behaviour; poor description of the 
social behaviour testing) 
- Inappropriate statistics" (lack of accounting for multiple observations within each litter [pseudo-
replication] in the ANOVA; the application of the multilevel regression model showed a large scatter of 
data within dose-groups [only four] and thus a large number of different dose-response curves can be 
fitted to the data so that it is not possible to conclude on the biological relevance for any of them)  
- Animal diet and phytoestrogen content not reported 
- Type of drinking bottles not given 
Positive Low  ●/↑ 
 
 
Wolstenholme et al., 2011a. (also see Q1) 
Comment: Prenatal exposure (maternal exposure via feed prior to mating and through gestation); cross-fostering 
design 
Comment: To ensure prenatal exposure only and exclude BPA-induced differences of maternal care, foster-dams 
were used implying mixed litters and tail clipping of pups, which might both be a strength and a weakness 
Comment: Parallel assessment of relevant neurobiological (gene expression ER, oxytocin) and functional end 
points. 
Comment: Social interaction test on PND 20, social preference test on PND 24. 
Positive Low  
 
↑/• 
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Strengths: 
- BPA measurement in animal samples (serum) 
- Phytoestrogen-free diet 
- Scoring blind to treatment 
Weaknesses: 
- Single dose level study 
- Feed consumption (BPA given by the diet) not measured 
- Type of cages and drinking bottles not reported 
- Insufficient study reporting (information of the content of the mixed litters, like number of pups and sex 
ratio is missing) 
- Inappropriate statistics (litter effect not properly considered)  
Wolstenholme et al., 2012 
Comment: The study addressed association of BPA behavioural effects with expression of genes implicated in 
regulation of social behaviour and related sex dimorphism (ERs, oxytocin and vasopressin) in embryos. 
Comment: transgenerational effects (F2 and F4) were addressed. 
Comment: Social interaction on PND 20-21, social preference on PND 24. 
Strengths: 
- BPA measurement in animal samples (F0 dams, serum) 
- Phytoestrogen-free diet (F0-generation only) 
Weaknesses: 
- Single dose level study 
- Study design not appropriate to the scope (the number of dams in F0 generation was limited)  
- Insufficient study reporting (animal age and body weight not given; no normalization of food 
consumption on body weight, potential variability of exposure; lack of information of control of 
environmental contamination of BPA, i.e. cages, bedding and water bottles; lack of information of 
mixed litters e.g. number of pups and sex ratio; reproductive outcome of the breeding brother-sister pairs 
done to obtain F2 to F4 generation is not given) 
- Insufficient BPA-exposure assessment (estimated on the basis of the daily quantity of food ingested, see 
line above) 








Wolstenholme et al., 2013 (see also Q1) 
Comment: Transgenerational study (F0-F3) where F0 dams were exposed to BPA via feed 
Comment: cross-fostering design F0 to F1 to ensure prenatal BPA exposure to F1 generation 
Comment: F1 and F3 tested at postnatal day (PND) 21 for social recognition  
 
Strengths 
Positive Low to 
Medium 
● 
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- Phytoestrogen-free diet (F0 dams) 
Weaknesses 
- Single dose level study 
- Insufficient study reporting (information on sex ratio in the F1 litters is missing, as well as reproductive 
outcome of the sibling mating performed to obtain F2 and F3 generations, unclear whether the authors 
actually measured the daily amount of feed consumed for each dam or averaged the amount based on 
previous knowledge; lack of information of control of environmental contamination of BPA, i.e. cages, 
bedding and water bottles) 
- F1-F3 fed chow containing phytoestrogens 
The few new studies evaluating the effects of BPA on social behaviour as end point have some methodological shortcomings (e.g. litter effect not properly 
red, potential variability of exposure not controlled for). Due to the limitation in study design and statistics, and the inconsistency in the reported results, 
potential effects are considered to be as likely as not. 
 
As likely as 
not  
Q4: Is there any evidence that BPA exposure affects sensory-motor function? Answer to the 
question as reported 
by the study authors 












Starting point based on previous assessments (EFSA, 2006; EFSA CEF Panel, 2010). 
Overall the Panel concluded that currently available data did not provide convincing evidence of sensory-motor 
function of BPA. The study by Stump (20) covered among other neurodevelopmental toxicity end points, the 




Line of evidence 1: new studies on changes in sensory-motor function (Ferguson et al., 2012; Wolstenholme 
et al., 2013): 
   
Ferguson et al., 2012 (see Q1 and Q2 for other endpoint tested) 
Comment: Pre- and postnatal exposure by maternal administration of BPA (gavage), plus direct postnatal 
exposure to pups (gavage) 
Comment: Motor activity of naïve controls similar to that of BPA –treated groups 
Comment: Multiple tests performed (Novelty preference test (PND 29), Open field test (PND 40-42), Motor 
coordination (PND 43-44), Barnes maze (PND 47-50), Acoustic startle response (PND 54), and Morris water 
maze (PND 75-79). Here acoustic startle response are addressed. 
 
Strengths: 
- Large sample size 
- Both naïve and vehicle controls available (to account for the handling of the animal) 
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- Use of non-PC cages and of glass water bottles  
Weaknesses: 
- Study design not appropriate to the scope  (only low doses of BPA used) 
Wolstenholme et al., 2013 (see also Q1 and Q3) 
Comment: Transgenerational study (F0-F3) where F0 dams were exposed to BPA via feed 
Comment: cross-fostering design F0 to F1 to ensure prenatal BPA exposure to F1 generation 
Comment: F3 mice of both sexes were tested for olfactory discrimination as adults  
 
Strengths: 
- Phytoestrogen-free diet (F0 dams) 
Weaknesses: 
- Single dose level study 
- Insufficient study reporting (information on sex ratio in the F1 litters is missing, as well as reproductive 
outcome of the sibling mating performed to obtain F2 and F3 generations, unclear whether the authors 
actually measured the daily amount of feed consumed for each dam or averaged the amount based on 
previous knowledge; lack of information of control of environmental contamination of BPA, i.e. cages, 
bedding and water bottles) 
-  F1-F3 fed chow containing phytoestrogens 
Negative Low to 
Medium 
● 
Overall conclusion on Likelihood on Sensory-motor function in animals after pre- and/or postnatal exposure to BPA: 
One of the two studies considered reported some positive effects of BPA on sensory-motor function in adult male rats, not in females. The auditory startle 
response is not known as a sexually dimorphic behaviour and the study results were considered inconsistent. The potential effects are considered to be as 
likely as not. 
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Table 37:   Summary of the WOE assessment of the likelihood that BPA causes neurodevelopmental or neurological/behavioural effects  
Humans 
Overall conclusion on Likelihood of neurodevelopmental effects of BPA in humans:  
There are indications from prospective studies that prenatal BPA exposure (BPA exposure during pregnancy) may be associated with child behaviour in 
a sex-dependent manner. However, the associations were not consistent across the studies. It cannot be ruled out that the results are confounded by diet 
or concurrent exposure factors. The associations are not sufficient evidence to infer a causal link between BPA exposure during pregnancy and 
neurodevelopmental effects in humans. Potential effects are considered to be as likely as not. 
As likely as not  
 
Overall conclusion on Likelihood of neurological/behavioural effects of BPA in humans:  
There are indications from one prospective study that childhood BPA exposure may be associated with behavioural problems in both girls and boys. It 
cannot be ruled out that the results are confounded by diet or concurrent exposure factors. The associations are not sufficient evidence to infer a causal 
link between childhood BPA exposure and neurological effects/behavior in humans. Potential effects are considered to be as likely as not. 
 
As likely as not  
 
Animals 
Overall conclusion on Likelihood on Anxiety-like behaviour in animals after pre- and/or postnatal exposure to BPA: 
Several studies report on increased anxiety-like behaviour in laboratory rodents after exposure to BPA. Due to the limitation in study design and 
statistics, and the inconsistency in the reported results, potential effects are considered to be as likely as not. 
As likely as not 
 
Overall conclusion on Likelihood on Learning and memory in animals after pre- and/or postnatal exposure to BPA: 
The effects of BPA on learning and memory abilities of laboratory rodents are no fully consistent, as both positive and negative effects are reported in 
different papers. The papers have methodological shortcomings, such as underpowered sample size, lack of consideration of the litter effect, or not 
properly controlled variability of exposure through diet, and inadequate statistics. Potential effects are considered to be as likely as not. 
As likely as not 
 
Overall conclusion on Likelihood on Social behaviour in animals after pre- and/or postnatal exposure to BPA: 
The few new studies evaluating the effects of BPA on social behaviour as end point have some methodological shortcomings (e.g. litter effect not 
properly red, potential variability of exposure not controlled for). Due to the limitation in study design and statistics, and the inconsistency in the 
reported results, potential effects are considered to be as likely as not 
As likely as not  
Overall conclusion on Likelihood on Sensory-motor function in animals after pre- and/or postnatal exposure to BPA: 
One of the two studies considered reported some positive effects of BPA on sensory-motor function in adult male rats, not in females. The auditory 
startle response is not known as a sexually dimorphic behaviour and the study results were considered inconsistent. The potential effects are considered 
to be as likely as not. 
As likely as not 
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WoE of immune effects 
Whether BPA has the potential to cause immune effects in humans and animals was considered using a tabular format for weighing different lines of evidence 
(WoE evaluation). The WoE evaluation tables for this endpoints are presented in full below.  
Human studies 
Table 38:  Assessment of the likelihood of associations between BPA exposure and developmental immunotoxic effects in humans 
Q1: Is there an association between BPA exposure and developmental immunotoxic effects?   Answer to the 
question as 















Starting point based on previous assessments (EFSA, 2006, 2010): No human studies on immune effects were 
available for evaluation. 
   
Line of Evidence 1: Associations with developmental immunotoxic effects, resistance to infection: the 
association with cytomegalovirus is positive in <18 years, and negative in >18 y (Clayton et al., 2011)  
 
Strengths: 
− Large sample size 
− Analytical method (LC-MS-MS) 
− Quality control and quality assurance procedures 
Weaknesses: 
− Cross-sectional study design 
− Single exposure measurements 
− Single spot urine BPA measurement 
− Confounding by diets or by concurring exposure factors not considered 




Line of Evidence 2: Associations with developmental immunotoxic effects, allergy. 
Association with wheeze at 6 months of age (Spanier et al., 2012), and with asthma in females (Vaidya et al., 2012), 
no association with wheeze at other time points, no association with asthma in males, no association with 
sensitization (Savage et al., 2012). Urinary BPA in pregnant mothers associated with lower risk of wheeze, while 
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Strengths:  
− Longitudinal follow-up (Spanier et al., 2012; Donohue et al., 2013). 
− Large sample size (all studies) 
− Repeated measurements (Spanier et al., 2012; Donohue et al., 2013) 
− Analytical method (LC-MS-MS) (all studies) 
− Quality control and quality assurance procedures (all studies) 
− Multiple outcome assessment, for wheeze (Spanier et al., 2012), asthma (Donohue et al., 2013, Vaidya et 
al., 2012) and allergen sensitisation (Savage et al., 2012). 
Weaknesses: 
− Cross-sectional study design (Vaidya et al., 2012; Savage et al., 2012)  
− Single spot urine BPA measurements (all studies) 
− Not adjusted urine samples (Vaidya et al., 2012) 
− Confounding by diet or other exposures not considered (all studies) 
− Unclear clinical relevance: small effect size (Donohue et al., 2013), relevance of wheeze difficult to 
interpret in the absence of sensitization effects (Spanier et al., 2012), inconsistent results between groups 
(Vaidya et al., 2012; Donohue et al., 2013).  
− Inconsistent results amongst different studies (all studies)  
Overall conclusion on the likelihood of association between BPA exposure and developmental immunotoxic effects:  
There are indications that BPA may be linked to immunological outcomes in humans, although in view of the limitations of the studies only limited 
conclusions can be reached and it cannot be ruled out that the results are confounded by diet or concurrent exposure factors. The associations do not 
provide sufficient evidence to infer a causal link between BPA exposure during pregnancy or in childhood and immune effects in humans.  
As likely as not  
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Animal studies 
Table 39:  Assessment of convincing associations between BPA exposure and developmental immunotoxic effects in animals.  
Q1: Is BPA immunotoxic in animals? 
 
Answer to the 
question as 
reported by the 
study authors 
(Positive, Negative 











Starting point based on previous assessments (EFSA CEF Panel, 2010): Based on the studies reviewed, the CEF 
Panel concludes that BPA showed indications of effects on immune parameters.  
Weakness: All studies suffered from shortcomings 
Weakness: Results were inconsistent 
Some positive Low 
 
●/↑ 
Line of Evidence 1: new evidence on immunotoxic effects induction in adult life (Lee et al., 2012a; Kendziorski et 
al., 2012) 
Comment:  no functional endpoints assessed (Lee et al., 2012a) 
 
Strengths: 
- Positive control included (Kendziorski et al., 2012) 
- Number of doses (≥3) (Kendziorski et al., 2012) 
- Phytoestrogen –free diet (Kendziorski et al., 2012) 
Weaknesses: 
- Animal body weight not given (Kendziorski et al., 2012) 
- Small sample size (Lee et al., 2012a; Kendziorski et al., 2012) 
- Single dose level study (to show effects on total IgE non-specific inflammatory mediators) (Lee et al., 
2012a) 




Line of Evidence 2: new evidence on immunotoxic effects induction during pre- and post-natal (during lactation) 
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- Phytoestrogen-free diet (Nakajima et al., 2012; Bauer et al., 2012) 
- Use of non-PC cages and of non plastic bottles Nakajima et al., 2012) 
- Oral administration by gavage (Bauer et al., 2012) 
- Number of doses (4 doses for the lung lavage) (Bauer et al., 2012) 
 
Weaknesses:  
- Animal age not given (Nakajima et al., 2012) 
- Animal body weight not given (Nakajima et al. 2012) 
- Small sample size for the endpoint studied  (3 to 11 animals/group) (Nakajima et al., 2012; Bauer et al., 
2012) 
- Single dose level study  Nakajima et al., 2012 
- Study design not appropriate to the scope   (administration via drinking water, but water consumption not 
measured) (Nakajima et al., 2012) 
 
Overall conclusion on the likelihood of immunotoxic effects of BPA in animals:  
Evidence from the new studies adds to the indications of immunotoxicity of BPA in animals reported in previous reviews.  
ALAN to Likely          
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WoE of cardiovascular effects 
Whether BPA has the potential to cause cardiovascular effects in humans was considered using a tabular format for weighing different lines of evidence (WoE 
evaluation). The WoE evaluation tables for this endpoints are presented in full below.  
Human studies 
Table 40:  Assessment of the likelihood of associations between BPA exposure and cardiovascular effects in human studies.  
Q1: Question: Is there an association between BPA exposure and cardiovascular effects? Answer to the 
question as 















Starting point based on previous assessments (EFSA CEF PANEL, 2010):  
Two cross-sectional epidemiological studies showed statistically significant associations between BPA exposure and 
coronary heart disease (Lang et al., 2008, Melzer et al., 2010).  
 
Weakness:  
- Although the studies provided some indication of possible cardiovascular effects in humans, EFSA 





A prospective study showed that higher urinary BPA was associated with increased risk of developing myocardial 
infarction (Melzer et al., 2012a) and a prospective study showed that higher urinary BPA was associated with 
increased risk of coronary artery stenosis (Meltzer atl al., 2012b) 
 
Comment: Outcome definitions only included cases admitted to hospital (Melzer et al., 2012a). Urinary BPA values 
were normalized to blood urea creatinine ratio, while other studies use urinary creatinine level for normalization 
(Melzer et al., 2012b). 
 
Strengths:  
− Longitudinal follow up  
− Analytical method (SPE LC-MS-MS) 
− Quality control, including blanks and quality assurance procedures 
Weaknesses:  
− Small sample size (Meltzer atl al., 2012b) 
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− Single spot urine BPA measurement 
− Confounding by diet or by concurring exposure factors not considered 
− Generalisability to the overall population 
Line of Evidence 2: Associations with coronary artery disease/heart attack in cross-sectional studies. Two 
studies found no association (Olsén et al., 2012; Lakind et al., 2012), one showed no associations with two and 
significant associations with two outcome measures (Lind and Lind., 2011) 
 
Comment: A-priori defined inclusion and exclusion criteria, outcome definitions and confounders (Lakind et al., 
2012) 
Comment: Total energy intake included among confounders (Lakind et al., 2012): 
 
Strengths: 
− Large sample size (Lakind et al., 2012; Lind and Lind., 2011; Olsén et al., 2012) 
− Urine, container specified (Lakind et al., 2012) 
− Standardized samples (urinary creatinine included in the model as independent variable) (Lakind et al., 
2012) 
− Analytical method (SPE LC-MS-MS) (all studies) 
− Quality control, including blanks and quality assurance procedures (all studies) 
Weaknesses:  
− Cross-sectional design (Lind and Lind., 2011; Olsén et al., 2012; Lakind et al., 2012) 
− Selection bias (Lind and Lind., 2011; Olsén et al., 2012) 
− Serum BPA measurement (invalid exposure measurement) (Lind and Lind., 2011; Olsén et al., 2012) 
− Single exposure measurements (all studies) 
− No distinction between unconjugated and conjugated BPA (Lind and Lind., 2011; Olsén et al., 2012; 
Lakind et al., 2012) 
− Handling of values below LOQ not reported (Lind and Lind., 2011; Olsén et al., 2012) 
− Confounding by diet or by concurring exposure factors not considered (all studies) 
− Generalisability to the total population (Lind and Lind., 2011; Olsén et al., 2012) 





Line of Evidence 3: Associations with metabolic syndrome. One study showed association with presence of 
metabolic syndrome (Teppala et al., 2012) 
 
Strengths: 
− Standardised samples (urinary creatinine included in the model as independent variable) 
− Analytical method (SPE LC-MS-MS) 
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− Cross-sectional study 
− Single spot urine BPA measurement 
− No distinction between unconjugated and conjugated BPA 
− Confounding by diet or by concurring exposure not considered  
− Generalisability to the overall population  
Line of Evidence 4: Associations with hypertension and peripheral artery disease. Two studies found 
association with hypertension (Shankar and Teppala., 2012; Bae et al., 2012) and one study with peripheral arterial 
disease (Shankar et al., 2012). 
 
Strengths:  
− Urine, container specified (Bae et al., 2012) 
− Standardised samples (Bae et al., 2012) 
− Analytical method (SPE LC-MS-MS) (all studies) 
− Quality control, including blanks and quality assurance procedures (Shankar and Teppala., 2012; Shankar et 
al., 2012) 
Weaknesses:  
− Cross-sectional study design (all studies) 
− Selection bias (Bae et al., 2012) 
− Single spot urine BPA measurement (all studies) 
− No quality control (e.g., blanks) and quality assurance procedures (Bae et al., 2012) 
− No distinction between unconjugated and conjugated BPA (all studies) 
− Confounding by diet or by concurring exposure factors not considered (all studies) 




Overall conclusion on Likelihood:  
There are indications from one prospective study that BPA exposure may be associated with cardiovascular effects, but it cannot be ruled out that 
the effect is confounded by diet or other concurrent exposure factors. This association does not provide sufficient evidence to infer a causal link 
between BPA exposure and cardiovascular effects in humans. Potential effects are considered to be as likely as not. 
As likely as not 
Table 41:   Overall table on WoE evaluation on cardiovascular effects of BPA in humans 
Overall conclusion on likelihood of cardiovascular effects of BPA in humans:  
There are indications from one prospective study that BPA exposure may be associated with cardiovascular effects, but it cannot be ruled out that the effect is 
confounded by diet or other concurrent exposure factors. This association does not provide sufficient evidence to infer a causal link between BPA exposure and 
cardiovascular effects in humans. 
 
As likely 
as not  
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WoE of metabolic effects 
Whether BPA has the potential to cause metabolic effects in humans and animals was considered using a tabular format for weighing different lines of 
evidence (WoE evaluation). The WoE evaluation tables for this endpoints are presented in full below.  
Human studies 
Table 42:  Assessment of the likelihood of associations between BPA exposure and metabolic and hormonal effects in humans.  
Q1: Is there an association between BPA exposure and obesity? Answer to the 
question as 















Starting point based on previous assessments (EFSA CEF PANEL, 2010): No association with obesity in one 
cross-sectional study (Lang et al., 2008). 
 




Line of Evidence 1: Association with obesity in adults  
Four studies showed significant associations (Carwile and Michels, 2011; Shankar et al., 2012b; Wang et al., 2012a; 
Zhao et al., 2012), and one study showed no associations (Galloway et al., 2010) 
 
Comment: Study populations not only in the US (Galloway et al., 2010; Wang et al., 2012a; Zhao et al., 2012) 
Comment: Inconsistent modelling of BPA exposure across studies 
 
Strengths: 
− Large sample size (Galloway et al., 2010; Carwile and Michels, 2011; Shankar et al., 2012b; Wang et al., 
2012a)  
− Standardised samples: 24-h urine collection, (Galloway et al., 2010), morning spot samples (Wang et al., 
2012a) or second morning spot samples (Zhao et al., 2012) 
− Analytical method (SPE LC-MS-MS) (all studies) 
− Quality control and quality assurance procedures (Galloway et al., 2010; Carwile and Michels, 2011; 
Shankar et al., 2012b) 
Weaknesses:  
− Cross-sectional study design (all studies) 
− Small sample size (Zhao et al., 2012) 
Mainly Positive Low 
 
● 
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− Single spot urine BPA measurement (Carwile and Michels, 2011; Shankar et al., 2012b; Wang et al., 2012a; 
Zhao et al., 2012) 
− Single exposure measurements (all studies) 
− Single spot urine BPA measurement (Carwile and Michels, 2011; Shankar et al., 2012b; Wang et al., 2012a; 
Zhao et al., 2012) 
− Not adjusted urine samples (Shankar et al., 2012b; Zhao et al., 2012) 
− No quality control and quality assurance procedures (Wang et al., 2012a; Zhao et al., 2012) 
− No distinction between unconjugated and conjugated BPA (Wang et al., 2012a; Zhao et al., 2012) 
− Handling of values below LOQ not reported (Galloway et al., 2010) 
− Confounding by diet and/or by concurring exposure factors not considered (Carwile and Michels, 2011; 
Shankar et al., 2012b; Wang et al., 2012a; Zhao et al., 2012) 
− Insufficient study reporting (urinary BPA stratified in quartiles, but no justification provided) (Shankar et 
al., 2012b) 
− Inconsistent results amongst different studies (all studies) 
Line of Evidence 2: Association with obesity in children and adolescents  
Cross-sectional studies showed that higher BPA was associated with increased obesity (Trasande et al., 2012; Wang 
et al., 2012b; Bhandari et al., 2013; Eng et al., 2013; Harley et al., 2013b; Li et al., 2013) while a longitudinal 
analysis showed that higher prenatal BPA was association with lower body mass in girls (Harley et al., 2013b)  
 
Comments: 
− Study populations not only in the US (Wang et al., 2012b; Li et al., 2013) 
− Evaluation of total caloric intake assessed (Trasande et al., 2012)  
− Evaluation of dietary behaviour (Li et al., 2013) 
Strengths: 
− Prospective study design (Harley et al., 2013b) 
− Large sample size (Trasande et al., 2012; Bhandari et al., 2013; Eng et al., 2013; Li et al., 2013) 
− Urine, container specified (Harley et al., 2013b; Li et al., 2013) 
− Repeated measurements (Harley et al., 2013b) 
− Standardised samples: first morning spot samples (Wang et al., 2012b) 
− Analytical method (LC-MS-MS) (Trasande et al., 2012; Wang et al., 2012b; Bhandari et al., 2013; Eng et 
al., 2013; Harley et al., 2013b) 
− Quality control and quality assurance procedures (Trasande et al., 2012; Bhandari et al., 2013; Eng et al., 
2013; Harley et al., 2013b) 
Weaknesses: 
− Cross-sectional study design (Trasande et al., 2012; Wang et al., 2012b; Bhandari et al., 2013; Eng et al., 
2013; Li et al., 2013) 
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− Single exposure measurements (Trasande et al., 2012; Wang et al., 2012b; Bhandari et al., 2013; Eng et al., 
2013; Li et al., 2013) 
− Single spot urine BPA measurement (all studies) 
− Not adjusted urine samples (Li et al., 2013) 
− No quality control and quality assurance procedures (Wang et al., 2012b; Li et al., 2013) 
− No distinction between unconjugated and conjugated BPA (Wang et al., 2012b; Li et al., 2013) 
− Confounding by diets or by concurring exposure factors not considered (Wang et al., 2012b; Bhandari et al., 
2013; Eng et al., 2013; Harley et al., 2013b) 
− Inconsistent results amongst different studies (different gender-related effects in cross-sectional studies) 
− Inconsistent results between cross sectional and longitudinal studies (higher BPA was associated with 
higher body mass in cross-sectional analyses, while the longitudinal analysis showed no associations in 
boys and that higher BPA was associated with lower body mass in girls) 
Overall conclusion on likelihood of associations between BPA and obesity in humans 
There are indications from a prospective study that prenatal BPA exposure (maternal urinary BPA concentrations) may be associated with reduced 
body mass in girls, while cross-sectional studies indicate associations between childhood BPA exposure and obesity. It cannot be ruled out that the 
results are confounded by diet or concurrent exposure factors. The associations do not provide evidence to infer a causal link between BPA 
exposure and obesity in humans. Potential effects are considered to be as likely as not.” 
 
As likely as not  
Q2: Is there an association between BPA exposure and hormonal effects?  Answer to the 
question as 















Starting point based on previous assessments (EFSA CEF PANEL, 2010): 
One cross-sectional study reported a significant association between urinary BPA and serum hormones in men 
recruited through an infertility clinic (Meeker et al., 2010).  
 





Line of Evidence 1: Associations with sex hormones 
The only study identified on this issue showed weak association with testosterone in men only, no associations with 
other hormones examined and no associations in women (Galloway et al., 2010) 
 
Strengths: 
− Large sample size 
− Standardised sample (24-h urine collection)  
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− Quality control, including blanks 
Weaknesses:  
− Cross-sectional study design 
− Single exposure measurements 
− Confounding by diet or by concurring exposure factors (drugs) not considered  
− Handling of values below LOD not reported 
− Unclear clinical relevance  
− Inconsistent results amongst different studies 
Line of Evidence 2: Associations with thyroid hormones 
One study showed no association with thyroid hormones (Mendez and Eftim, 2012). Two studies showed 
associations (Brucker-Davies et al., 2011; Wang et al., 2012c) 
 
Strengths: 
− Large sample size (Mendez and Eftim, 2012) 
− Analytical method (LC-MS-MS) (Mendez and Eftim, 2012; Wang et al., 2012c) 
− Quality control, including blanks (Mendez and Eftim, 2012) 
Weaknesses:  
− Cross-sectional study design (all studies) 
− Small sample size (Brucker-Davies et al., 2011; Wang et al., 2012c) 
− Cord blood BPA measurement (invalid exposure assessment) (Brucker-Davies et al., 2011) 
− Single exposure measurements (all studies) 
− Single spot urine BPA measurement (Mendez and Eftim, 2012; Wang et al., 2012c) 
− Analytical method (RIA) (Brucker-Davies et al., 2011) 
− No quality control and quality assurance procedures (Brucker-Davies et al., 2011; Wang et al., 2012c) 
− No distinction between unconjugated and conjugated BPA (Brucker-Davies et al., 2011; Wang et al., 
2012c) 
− Handling of values below LOQ not reported (Brucker-Davies et al., 2011) 
− Confounding by diet (all studies) or by concurring exposures (Mendez and Eftim, 2012; Wang et al., 2012c) 
not considered 
− Generalisability to the overall population (Wang et al., 2012c) 
− Inconsistent results among st different studies (all studies) 







Line of Evidence 3: Associations with adipokine expression 
One cross-sectional study showed associations with adverse action of leptin and adiponectin (Chou et al., 2011), and 
one prospective study found that maternal urinary BPA was associated with higher plasma leptin in 9 year old boys 
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Comment: 
− Pregnancy soda consumption and child soda, fast food and sweet snack consumption were evaluated among 
confounders (Volberg et al., 2013) 
Strengths:  
− Prospective study (Volberg et al., 2013) 
− Urine, container specified (Volberg et al., 2013) 
− Repeated measurements (n=2, maternal urine) (Volberg et al., 2013) 
− Analytical method (LC-MS-MS) (Volberg et al., 2013) 
− Quality controls, including blanks (all studies) 
 
Weaknesses: 
− Cross-sectional study design (Chou et al., 2011) 
− Limited sample size (all studies) 
− Blood and cord blood BPA measurement (invalid exposure assessment) (Chou et al., 2011) 
− Single exposure measurements (Chou et al., 2011) 
− Single spot urine measurement (Volberg et al., 2013) 
− No distinction between unconjugated and conjugated BPA (Chou et al., 2011)  
− Confounding by diet (Chou et al., 2011) or by concurring exposure factors (all studies) 
− Insufficient study reporting (inconsistency between abstract and text) (Chou et al., 2011) 
− Statistics (excessive categorisation) (Chou et al., 2011) 
− Unclear clinical relevance (all studies) 
− Generalisability to the overall population (Volberg et al., 2013) 
Overall conclusion on likelihood of associations between BPA and hormonal effects in humans 
There are indications from one prospective study that maternal BPA exposure may be associated with adipokine expression in 9 year old children, but it 
cannot be ruled out that the result is confounded by diet or concurrent exposure factors. The association does not provide sufficient evidence to infer a 
causal link between BPA exposure hormonal effects in humans.  Potential effects are considered to be as likely as not.” 
As likely as not 
 
Q3: Is there an association between BPA exposure and diabetes?  Answer to the 
question as 















Starting point based on previous assessments (EFSA CEF PANEL, 2010): Two cross-sectional epidemiological 
studies showed statistically significant associations between BPA exposure and diabetes (Lang et al., 2008, Melzer et 
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Weakness: Although the studies provided some indication of possible effects on diabetes incidence in humans, EFSA 
concluded that the cross-sectional design of the studies limited the reliability and likelihood of a causal association. 
Line of Evidence 1: Associations with diabetes or insulin resistance 
Three studies showed associations (Ning et al., 2011; Silver et al., 2011; Shankar et al., 2011) and two studies did 
not show associations with diabetes (Kim and Park, 2013; Lakind et al., 2012). One study showed association with 
insulin resistance (Wang et al., 2012a) 
 
Comments:  
− Study populations not only in the US (Ning et al., 2011; Wang et al., 2012a; Kim and Park, 2013) 
− A-priori defined inclusion and exclusion criteria, outcome definitions and confounders (Lakind et al., 2012) 
− Some studies relied on self-reported diabetes incidence (Shankar et al., 2011; Kim and Park, 2013) 
 
Strengths:  
− Large sample size (all studies) 
− Urine, container specified (Lakind et al., 2012) 
− Standardised samples: morning spot samples (Wang et al., 2012a) 
− Analytical method (GC-MS or LC-MS-MS) (all studies) 
− Quality controls, including blanks and quality assurance procedures (Silver et al., 2011; Shankar et al., 
2011; Lakind et al., 2012; Wang et al., 2012a) 
Weaknesses:  
− Cross-sectional study design (all studies)  
− Single exposure measurements (all studies) 
− Single spot urine BPA measurement (all studies) 
− Not adjusted urine samples (Ning et al., 2011) 
− No quality controls and quality assurance procedures (Ning et al., 2011; Kim and Park, 2013) 
− No distinction between unconjugated and conjugated metabolites (Ning et al., 2011; Wang et al., 2012a; 
Kim and Park, 2013) 
− Confounding by diet or by concurring factors not considered (all studies) 





Overall conclusion on likelihood of associations between BPA and diabetes effects in humans:  
The indications that BPA may be associated with diabetes in humans are unlikely. 
Unlikely 
  
Q4: Is there an association between BPA exposure and metabolic syndrome?  Answer to the 
question as 
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Uncertain)   
Line of Evidence 1: Associations with metabolic syndrome. The only study identified on this issue showed 
association with presence of metabolic syndrome (Teppala et al., 2012) 
 
Strengths: 
− Large sample size 
− Analytical method (SPE LC-MS-MS) 
− Quality control, including blanks and quality assurance procedures 
Weaknesses:  
− Cross-sectional study  
− Single exposure measurements 
− Single spot urine BPA measurement 
− Confounding by diet or by concurring exposure factors not considered 





Overall conclusion on likelihood of associations between BPA and metabolic syndrome in humans:  
The indication that BPA may be associated with metabolic syndrome in humans is unlikely. 
Unlikely 
 
Q5: Is there an association between BPA exposure and renal function?   Answer to the 
question as 















Line of Evidence 1: Associations with renal function 
Two studies showed associations (Li et al., 2012a; You et al., 2011). 
 
Strengths:  
− Large sample size (all studies) 
− Urine, container specified (Li et al., 2012a) 
− Standardised sample: first morning spot samples (Li et al., 2012a) 
− Analytical method (LC-MS-MS) (all studies) 
− Quality control and quality assurance procedures (You et al., 2011) 
Weaknesses: 
− Cross-sectional study design (all studies) 
− Single exposure measurements (all studies) 
− Single spot urine BPA measurement (all studies) 
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− Confounding by diet or by concurring exposure factors not considered (all studies) 
− Unclear clinical relevance (all studies) 
Overall conclusion on likelihood of associations between BPA and renal effects in humans:  




Table 43:  Assessment of the likelihood of associations between BPA exposure and metabolic effects in animals when exposed during their adult life 
(postnatally). 
Q1: Does BPA affect metabolic function as evidenced by effects on glucose or insulin regulation in adult 
animals (exposed postnatally) 
Answer to the 
question as 
















Starting point: EFSA CEF Panel, 2010, reported the study of Ropero et al., 2008 showing effects of BPA on insulin 
secretion in mice.  
 





Line of Evidence 1: A number of recent studies show effects on glucose or insulin regulation and/or effects on 
pancreatic morphology and/or function (Batista et al. (2012 subcutaneous injection); D’Cruz et al., 2012a, b; 
Marmugi et al., 2012; Jayashree et al. 2013/ Indumathi et al., 2013; Bodin et al., 2013; US FDA/NCTR, 2013 and 
Delclos et al., 2014)  
 
Comment: the US FDA/NCTR, 2013 and Delclos et al., 2014 subchronic toxicity study showed no effect, but the 
animals were exposed both pre and post-natally 
Comment: The standard deviation is much smaller than normal variability (D’Cruz, 2012a,b) 
 
Strengths:  
- Large sample size (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Adequate positive controls included (D’Cruz et al., 2012a,b; US FDA/NCTR, 2013 and Delclos et al., 
2014) 
- Both naïve and vehicle controls available (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Adequate positive controls included (US FDA/NCTR, 2013 and Delclos et al., 2014, D’Cruz et al., 
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2012a,b) 
- Number of doses (≥3) (D’Cruz et al., 2012a,b, Marmugi et al., 2012, US FDA/NCTR, 2013 and Delclos et 
al., 2014 – especially in the low dose range) 
- Oral administration by via gavage (D’Cruz et al., 2012a,b, Indumathi et al., 2013, Jayashree et al., 2013, US 
FDA/NCTR, 2013 and Delclos et al., 2014) 
- Phytoestrogen-free diet (Bodin et al., 2013, US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Use of non-PC cages (D’Cruz et al., 2012b, Jayashree et al., 2013, Indumathi et al., 2013, Bodin et al., 
2013, US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Protocols according to EU guideline (Marmugi et al., 2012) 
- Study performed according to OECD guidelines, under GLP (US FDA/NCTR, 2013 and Delclos et al., 
2014) 
Weaknesses:  
- Small sample size (D’Cruz et al., 2012a,b, Marmugi et al., 2012, Indumathi et al., 2013, Jayashree et al., 
2013) 
- Test performed in one sex only (Batista et al., 2012, D’Cruz et al., 2012a,b, Marmugi et al., 2012, 
Indumathi et al., 2013, Jayashree et al., 2013) 
- Single dose level study (Batista et al., 2012) 
- Feed consumption (BPA given by the diet) not measured (Marmugi et al., 2012) 
- Inappropriate statstics (considering the small number of animals) (D’Cruz et al., 2012a,b) 
- Insufficient study reporting (Batista et al., 2012: number of animals tested is unclear for each endpoint) 
- Inappropriate statistics: insufficient studying reporting (no multiple comparisons statistics) (Marmugi et al., 
2012;  
- Animal diet and phytoestrogen content not reported (Batista et al., 2012, D’Cruz et al., 2012a,b, Marmugi et 
al., 2012, Indumathi et al., 2013, Jayashree et al., 2013) 
- Unintended exposure of  the control groups (US FDA/NCTR, 2013 and Delclos et al., 2014, see Churchwell 
et al, 2014) 
Overall conclusions: Although 5 studies with major weaknesses reported effects. One strong study (US 
FDA/NCTR, 2013 and Delclos et al., 2014) found no effect of BPA. 
  As likely as not 
Q2: Does BPA affect metabolic function as evidenced by effects on adipose tissue in animals exposed in adult 
life? 
Answer to the 
question as 
















Starting point: not addressed in previous EFSA opinions     
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Line of Evidence 1 (Marmugi et al., 2012; Ronn et al., 2013; US FDA/NCTR, 2013 and Delclos et al., 2014) 
There is some evidence of such effects in the studies of Marmugi et al., 2012, in which in the 50 µg/kg bw per day 
group perigonadic white adipose tissue was increased. Rönn et al. (2013) no changes in visceral fat and perirenal fat 
were observed but they described effects on lipids which are not considered adverse. They observed steatosis of the 
liver. 
 
Comment: the US FDA/NCTR, 2013 and Delclos et al., 2014 subchronic toxicity study,showed no effect up to 100 
000 µg/kg bw per day, but the animals were exposed both pre and post-natally. 
 
Strengths:  
- Large sample size (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Adequate positive controls included (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Both naïve and vehicle controls available (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Number of doses (≥3) (Marmugi et al., 2012, US FDA/NCTR, 2013 and Delclos et al., 2014 – in the low 
dose range, Ronn et al., 2013) 
- Oral administration by via gavage (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Phytoestrogen-free diet (US FDA/NCTR, 2013 and Delclos et al., 2014, Ronn et al., 2013) 
- Use of non-PC cages (US FDA/NCTR, 2013 and Delclos et al., 2014, Ronn et al., 2013) 
- Protocols according to EU guideline (Marmugi et al., 2012) 
- Study performed according to OECD guidelines, under GLP (US FDA/NCTR, 2013 and Delclos et al., 
2014) 
Weaknesses:  
- Animal body weight not given (Marmugi et al., 2012) 
- Small sample size (Marmugi et al., 2012) 
- Test performed in one sex only (Marmugi et al., 2012, Ronn et al., 2013) 
- Feed consumption (BPA given by the diet) not measured (Marmugi et al., 2012) 
- Inappropriate statistics: insufficient studying reporting (no multiple comparisons statistics) (Marmugi et al., 
2012) 
- Study design not appropriate to the scope (Ronn et al., 2013: not fully appropriate for obtaining the 
substance specific data aimed at (BPA exposure combined with fructose)  
- Animal diet and phytoestrogen content not reported (Marmugi et al., 2012) 
- Unintended exposure of  the control groups (US FDA/NCTR, 2013 and Delclos et al., 2014, see Churchwell 







Overall conclusions: Two new studies reporting effects have major weaknesses; one strong study reports no effects. 
therefore no reliable conclusions can be drawn. 
  Unlikely 
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Q3: Does BPA increase obesity in animals exposed postnatally?  Answer to the 
question as 















Starting points: Long term regulatory studies on BPA (e.g. NTP, 1982; Tyl et al., 2002, 2008) have not shown 
obesity/excessive weight gain over the duration of the studies.  
There are no new studies showing long-term obesity. 
Negative High ↓↓↓ 
Line of Evidence 1: Associations with changes in body weight  
(Marmugi et al., 2012; Rönn et al., 2013; US FDA/NCTR, 2013 and Delclos et al., 2014) 
 
Strengths:  
- Large sample size (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Both naïve and vehicle controls available (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Adequate positive controls included (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Number of doses (≥3) (Marmugi et al., 2012, US FDA/NCTR, 2013 and Delclos et al., 20143 – in the low 
dose range, Ronn et al., 2013) 
- Oral administration by gavage (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Phytoestrogen-free diet (US FDA/NCTR, 2013 and Delclos et al., 2014, Ronn et al., 2013) 
- Use of non-PC cages (US FDA/NCTR, 2013 and Delclos et al., 2014, Ronn et al., 2013) 
- Protocols according to EU guideline (Marmugi et al., 2012) 
- Study performed according to OECD guidelines, under GLP (US FDA/NCTR, 2013 and Delclos et al., 
2014) 
Weaknesses:  
- Animal body weight not given (Marmugi et al., 2012) 
- Small sample size (Marmugi et al., 2012) 
- Test performed in one sex only (Marmugi et al., 2012, Ronn et al., 2013) 
- Feed consumption (BPA given by the diet) not measured (Marmugi et al., 2012) 
- Inappropriate statistics: insufficient studying reporting (no multiple comparisons statistics) (Marmugi et al., 
2012) 
- Study design not appropriate to the scope (Ronn et al., 2013: not fully appropriate for obtaining the 
substance specific data aimed at (BPA exposure combined with fructose)  
- Animal diet and phytoestrogen content not reported (Marmugi et al., 2012) 
- Unintended exposure of  the control groups (US FDA/NCTR, 2013 and Delclos et al., 2014, see Churchwell 
et al, 2014) 
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Overall conclusions: : There is no reliable evidence that BPA is obesogenic.  Unlikely 
Overall conclusion on likelihood of metabolic effects in animals exposed postnatally Evidence for associations between BPA exposure and 
metabolic effects in animals exposed postnatally is inconsistent. There is reasonable evidence for effects on glucose or insulin regulation and/or effects 
on pancreatic morphology and/or function in shorter term studies, but no evidence that BPA is causing diabetes, insulin resistance and increases in 
weight (obesogenic) longer-term.  
 As likely as not 
 
Table 44:  Assessment of the likelihood of associations between BPA exposure and metabolic effects in animals when exposed prenatally. 
Q1: Does BPA affect metabolic function as evidenced by effects on glucose or insulin regulation in animals 
exposed prenatally? 
Answer to the 
question as 
















Starting point: EFSA CEF Panel, 2010 reported a study showing aggravated insulin resistance in mice during 
pregnancy (Alonso-Magdalena et al., 2010). In contrast the study of Ryan et al. (2010b) showed no indications of 
increased susceptibility to high-fat diet-induced obesity and glucose intolerance in adult mice exposed prenatally to 
BPA. 
 
Comment: Inconsistent results between the two studies 
 







Line of Evidence 1: Recent studies showing effects on glucose or insulin regulation and/or effects on pancreatic 
morphology and/or function.  
 
Comment: Two new studies have shown effects on several of these parameters (Wei et al., 2011, MacKay et al, 
2013), whereas the results of Anderson et al. (2013) and the US FDA/NCTR, 2013 and Delclos et al., 2014 
subchronic toxicity study (2013) did not show such effects. The study of Angle et al. (2013) reported several 
physiologically related effects which are inconsistent because changes in one parameter are not paralleled by 
expected changes in other physiological inter-related parameters measured. The US FDA/NCTR study (US 
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and Delclos et al., 2014 – especially in the low dose range) 
- Oral administration by gavage (Wei et al., 2011, US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Adequate positive controls included (Angle et al., 2013, US FDA/NCTR, 2013 and Delclos et al., 
2014MacKay et al., 2013 ) 
- Both naïve and vehicle controls available (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Phytoestrogen-free diet (Anderson et al., 2013, US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Use of non-PC cages (Anderson et al., 2013, MacKay et al., 2013, Wei et al., 2011, US FDA/NCTR, 2013 
and Delclos et al., 2014; Angle et al., 2013) 
- Study performed according to OECD guidelines, under GLP (US FDA/NCTR, 2013 and Delclos et al., 
2014) 
Weaknesses: 
- Animal body weight not given (Andersen et al., 2013, Angle et al., 2013, MacKay et al., 2013) 
- Small sample size (MacKay et al., 2013, Wei et al., 2011) 
- Insufficient study reporting (Anderson et al., 2013: administration via diet but intakes of BPA not 
specifically calculated, MacKay et al., 2013: uncertainty about estimated intakes due to very low (< 1 
ng/kg bw per day) dietary level and homogeneity of the diet not checked, Angle at al., 2013: insufficient 
study reporting, Wei et al., 2011: number of animals used for each end-point was variable and not always 
clear) 
- Inappropriate statistics (Andersen et al., 2013: validity of statistical analysis not clear, MacKay et al., 2013 
and Wei et al., 2011: litter effect not completely controlled) 
- Study design not appropriate to the scope   (Angle et al., 2013: only males tested for glucose and insulin 
tolerance tests) 
- Animal diet phytoestrogen content not reported (Angle et al., 2013, Wei et al., 2011) 
- Unintended exposure of  the control groups (US FDA/NCTR, 2013 and Delclos et al., 2014, see 

















Overall conclusions: Although three studies with major weaknesses reported effects, these were not consistent 
between the studies. One weak study (Anderson et al., 2013) and one strong study (US FDA/NCTR, 2013 and 
Delclos et al., 2014) found no effect of BPA. 
  Unlikely to -as 
likely as not- 
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Starting point: EFSA (2010) reported studies showing increased adipogenesis in the offspring of rats and mice 
exposed prenatally to BPA (Somm et al., 2009; Miyawaki et al, 2007).  
 
Comment: No dose-response in female (Miyawaki et al., 2007)  
Comment: Only effects in females (Somm et al., 2009) 
 
Weakness: single dose level study (Somm et al., 2009) 
Weakness: small sample size (Miyawaki et al., 2007) 
Weakness: litter effect not considered (Miyawaki et al.,, 2007) 




Line of Evidence 1: Two new studies have reported effects on fat weight in animals exposed prenatally to BPA 
only for one out of three doses (Wei et al., 2011, and only for high fat diet MacKay et al, 2013). One strong study 
(US FDA/NCTR, 2013 and Delclos et al., 2014) does not report effects up to 100 000 µg/kg bw per day.  
 




- Number of doses (≥3) (Wei et al., 2011, US FDA/NCTR, 2013 and Delclos et al., 2014 – especially in the 
low dose range) 
- Oral administration by gavage (Wei et al., 2011, US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Adequate positive controls included (US FDA/NCTR, 2013 and Delclos et al., 2014MacKay et al., 2013 ) 
- Both naïve and vehicle controls available (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Phytoestrogen-free diet (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Use of non-PC cages (MacKay et al., 2013, Wei et al., 2011, US FDA/NCTR, 2013 and Delclos et al., 
2014) 




- Animal body weight not given (MacKay et al., 2013) 
- Small sample size (MacKay et al., 2013, Wei et al., 2011) 
- Insufficient study reporting (MacKay et al., 2013: uncertainty about estimated intakes due to very low (< 1 
ng/kg bw per day) dietary level and homogeneity of the diet not checked, Wei et al., 2011: number of 
animals used for each end-point was variable and not always clear) 
- Inappropriate statistics (MacKay et al., 2013 and Wei et al., 2011: litter effect not completely controlled) 
- Animal diet phytoestrogen content not reported (Wei et al., 2011) 
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- Unintended exposure of  the control groups (US FDA/NCTR, 2013 and Delclos et al., 2014, see 
Churchwell et al, 2014) 
Overall conclusions: Two new studies reporting effects have major weaknesses and one strong study does not 
report effects.  
  As likely as not 
Q3: Does BPA affect metabolic function as evidenced by effects on energy expenditure? 
 
 
 Answer to the 
question as 















Starting point: not addressed in previous EFSA opinions    
Line of Evidence 1: New evidence on energy expenditure. Anderson et al., (2013), MacKay et al., (2013) 
reported an effect on energy expenditure 
 
Comment: Only a specific genetic strain of mouse was used 
Comment: no underlying mechanistic explanation  
 
Strengths: 
- Number of doses (≥3) (Anderson et al., 2013)  
- Adequate positive controls included (MacKay et al., 2013) 
- Use of non-PC cages (Anderson et al., 2013, MacKay et al., 2013) 
- Phytoestrogen-free diet (Anderson et al., 2013) 
Weaknesses:  
- Animal body weight not given (Anderson et al., 2013, MacKay et al., 2013) 
- Small sample size (MacKay et al., 2013) 
- Insufficient study reporting (Anderson et al., 2013: administration via diet but intakes of BPA not 
specifically calculated, MacKay et al., 2013: uncertainty about estimated intakes due to very low (< 1 
ng/kg bw per day) dietary level and homogeneity of the diet not checked) 
- Inappropriate statistics (Anderson et al., 2013: inappropriate statistical analysis, MacKay et al., 2013: litter 













Overall conclusions: The studies report an effect which could be of interest. However, the studies have 
weaknesses. In addition, the paradigms used (special strain; high fat diet) render the interpretation of the findings 
with respect to human health difficult. 
   As likely as not 
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Q4: Does BPA cause obesity in animals exposed prenatally?  Answer to the 
question as 















 Starting point: Long term regulatory studies on BPA (Tyl et al. 2002, 2008) together with the study of Ryan et al. 
2010, have not shown obesity/excessive weight gain over the duration of the studies. The study of Rubin et al. 
(2001) showed increased weight gain in BPA-exposed animals later in life 
 
Weakness: Ryan et al. was a single dose level study 





Line of Evidence 1: There are no new long term studies. New studies have reported effects on body weight (e.g. 
MacKay et al., 2013; Wei et al., 2011; Xu et al., 2011b)), but conflicting results have been obtained in other studies 
(e.g. Anderson et al., 2013, US FDA/NCTR, 2013 and Delclos et al., 2014)  
Comment: High fat diets used in some studies cannot be considered as a good model for human health, also type of 
fat not specified  
 
Strengths:  
- Number of doses (≥3) (Anderson et al., 2013, Wei et al., 2011, US FDA/NCTR, 2013 and Delclos et al., 
2014 – especially in the low dose range, Xu et al., 2011b) 
- Oral administration by gavage (Wei et al., 2011, US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Adequate positive controls included (US FDA/NCTR, 2013 and Delclos et al., 2014MacKay et al., 2013 ) 
- Both naïve and vehicle controls available (US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Phytoestrogen-free diet (Anderson et al., 2013, US FDA/NCTR, 2013 and Delclos et al., 2014) 
- Use of non-PC cages (Anderson et al., 2013, MacKay et al., 2013, Wei et al., 2011, US FDA/NCTR, 2013 
and Delclos et al., 2014, Xu et al., 2011b) 
- Study performed according to OECD guidelines, under GLP (US FDA/NCTR, 2013 and Delclos et al., 
2014) 
- Study performed under GLP (US FDA/NCTR, 2013 and Delclos et al., 2014) 
Weaknesses: 
- Small sample size (MacKay et al., 2013, Wei et al., 2011) 
- Insufficient study reporting (Anderson et al., 2013: administration via diet but intakes of BPA not 
specifically calculated, MacKay et al., 2013: uncertainty about estimated intakes due to very low (< 1 
ng/kg bw per day) dietary level and homogeneity of the diet not checked, Wei et al., 2011: number of 
animals used for each end-point was variable and not always clear, Xu et al., 2011b: administration via 
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- Statistical analysis (Anderson et al., 2013: validity of statistical analysis not clear, MacKay et al., 2013, 
Wei et al., 2011 and Xu et al., 2011b: litter effect not completely controlled) 
- Animal diet phytoestrogen content not reported (Wei et al., 2011) 
- Study design not appropriate to the scope   (only one BPA dose was assessed postnatally). 
- Unintended exposure of  the control groups (US FDA/NCTR, 2013 and Delclos et al., 2014, see 
Churchwell et al, 2014) 
Overall conclusions: There are new studies on pre- and perinatal exposure towards BPA, some, not all of which indicate some effects on body weight. 
The studies have measured multiple endpoints at several time points and in the studies with positive outcome the procedure in which way the statistical 
adjustment was made is not clear, so that it is uncertain whether the results are chance findings. The positive studies used experimental paradigms 
(special strain, extremely high fat diet, sucrose) which do not represent the human situation.  
Unlikely to -as 
likely as not- 
Overall conclusion on likelihood of metabolic effects in animals exposed prenatally: 
Since the initial reports that BPA had potential effects on adiposity, glucose or insulin regulation, lipids and other end-points related to diabetes or 
metabolic syndrome in animals exposed prenatally, several new studies have been published. There is reasonable evidence for effects on glucose or 
insulin regulation and/or effects on pancreatic morphology and/or function in shorter term studies, but no evidence that BPA is causing diabetes, insulin 
resistance and increases in weight (obesogenic) longer-term.  
As likely as not  
Table 45:  Summary of the WoE assessment of the likelihood that BPA causes metabolic effects 
Humans  
Overall conclusion on Likelihood of associations between BPA and obesity in humans 
There are indications from a prospective study that prenatal BPA exposure (maternal urinary BPA concentrations) may be associated with reduced body 
mass in girls, while cross-sectional studies indicate associations between childhood BPA exposure and obesity. It cannot be ruled out that the results are 
confounded by diet or concurrent exposure factors. The associations do not provide sufficient evidence to infer a causal link between BPA exposure and 
obesity in humans. No firm conclusions can be drawn on the likelihood. 
As likely as not  
 
Overall conclusion on Likelihood of associations between BPA and hormonal effects in humans 
There are indications from one prospective study that maternal BPA exposure may be associated with adipokine expression in 9 year old children, but it 
cannot be ruled out that the result is confounded by diet or concurrent exposure factors. The association does not provide sufficient evidence to infer a 
causal link between BPA exposure hormonal effects in humans. No firm conclusions can be drawn on the likelihood. 
As likely as not 
 
Overall conclusion on Likelihood of associations between BPA and diabetes effects in humans:  
The indications that BPA may be associated with diabetes in humans are unlikely. 
Unlikely 
  
Overall conclusion on Likelihood of associations between BPA and metabolic syndrome in humans:  
The indication that BPA may be associated with metabolic syndrome in humans is unlikely. 
Unlikely 
 
Overall conclusion on Likelihood of associations between BPA and renal effects in humans:  
The indication that BPA may be associated with renal function in humans is unlikely. 
Unlikely 
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Animals 
Overall conclusion on likelihood of metabolic effects in animals exposed postnatally Evidence for associations between BPA exposure and 
metabolic effects in animals exposed postnatally is inconsistent. There is reasonable evidence for effects on glucose or insulin regulation and/or effects 
on pancreatic morphology and/or function in shorter term studies, but no evidence that BPA is causing diabetes, insulin resistance and increases in 
weight (obesogenic) longer-term. 
 
As likely as not 
Overall conclusion on Likelihood for metabolic effects in animals exposed prenatally: 
Since the initial reports that BPA had potential effects on adiposity, glucose or insulin regulation, lipids and other end-points related to diabetes or 
metabolic syndrome in animals exposed prenatally, several new studies have been published. There is reasonable evidence for effects on glucose or 
insulin regulation and/or effects on pancreatic morphology and/or function in shorter term studies, but no evidence that BPA is causing diabetes, insulin 
resistance and increases in weight (obesogenic) longer-term.  
As likely as not  
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WoE of genotoxicity 
Whether BPA has the potential to cause genotoxicity in vitro and in vivo was considered using a tabular format for weighing different lines of evidence (WoE 
evaluation). The WoE evaluation tables for these endpoints are presented in full below.  
In vitro studies 
Table 46:  Assessment of the likelihood that BPA exposure is genotoxic in vitro.  
Q1: Is BPA genotoxic in vitro via a non-threshold mechanism?  
 
Answer to the 
question as 













Starting point based on previous assessments (EU-RAR, 2003; EFSA CEF Panel, 2010): 
EFSA in 2006 noted that BPA is not considered to be genotoxic in bacteria and in mammalian cells, based on 
previous reviews of BPA genotoxicity (EU-RAR, 2003; Haighton et al., 2002). EFSA (2010) did not consider 







Line of Evidence 1: New evidence of direct damage to DNA (Induction of gene mutation in bacteria e.g.) 
Gene mutation in the Ames test (Masuda et al., 2005; Tiwari et al., 2012; Fic et al., 2013) 
 
Strengths: 
− Ames test well conducted (Tiwari et al., 2012) 
− Adequate number of concentrations in presence and absence of metabolic activation (S9) (Fic et al., 2013) 
Weaknesses:  
− Limited number of strains (all studies) 









Line of Evidence 2: New evidence of direct damage to DNA (DNA breakage, DNA adducts, induction of 
phosphorylated histone γ-H2AX, etc.) 
Six studies evaluated DNA breakage (Iso et al., 2006; Tayama et al., 2008; Fic et al., 2013), DNA adducts (Izzotti 
et al., 2009; De Flora et al., 2011) and induction of phosphorylated histone γ-H2AX (Iso et al., 2006; Audebert et 
al., 2011) in different cell lines 
 
Strengths: 
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− Three genotoxic endpoints (DNA breakage, SCE and CA) (Tayama et al., 2008) 
Weaknesses:  
− Experimental procedures questionable: staining procedures (Tayama et al., 2008), single dose level, 
number of cells examined (De Flora et al., 2011) 
− Results not clearly reported (Iso et al., 2006) 
− Inconsistent results in ER-negative and ER-positive cells (different genomic stability) (Iso et al., 2006) 
− Inconsistent results in the comet assay (e.g. increase in DNA damage not dose-related) (Fic et al., 2013) 
Line of Evidence 3: New evidence of damage at chromosome level (Chromosome aberrations, micronuclei, 
SCEs) 
Induction of chromosomal aberrations and SCEs in CHO-K1 cell line (Tayama et al., 2008) 
 
Strengths: 
− Adequate range of concentrations 
− Three genotoxic endpoints (DNA breakage, SCE and CA)  
− Concentration-related and statistically significant increases of c-metaphases 
Weaknesses: 
− Experimental procedures questionable: sampling times, cells recovered in the presence of BrdU 









Overall conclusion based on in vitro studies – via non thresholded mechanism: 
BPA has not been shown to induce gene mutations nor chromosomal aberrations in bacteria and mammalian cells.  
Unlikely 
 
Q2: Is BPA genotoxic in vitro via a threshold mechanism?  Answer to the 
question as 













Starting point based on previous assessments (EU RAR, 2003EFSA, 2006 
The EU RAR (EU, 2006) reported the potential of BPA to induce aneuploidy by the evidence of microtubule 
disruption in cell-free system and induction of micronuclei in hamster cell lines. EFSA (2010) did not review in 






Line of Evidence 1: New evidence of genotoxicity in vitro via a threshold mechanism: Aneuploidy 
(microtubule effects, chromosome loss, non-disjunction, induction of c-metaphases etc.) 
 
Evaluation of aneuploidy by analysis of micronuclei in cytochalasin binucleate cells and aberration of mitotic 
machinery by analysis of multiple spindle poles in human lymphoblastoid cells AHH1 and Chinese hamster V79 
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In vivo studies  
Table 47:  Assessment of the likelihood that BPA exposure is genotoxic in vivo.  
Strengths:  
− Sound experimental design and well documented study  
− Adequate selection and spacing of concentrations  
 
Clear induction of “c-like metaphases”, a biomarker of spindle disrupting effects (Tayama et al., 2008) 
 
Strengths:  
− Concentration-related and statistically significant increases of c-metaphases  
Weaknesses:  




















Overall conclusion based on in vitro studies – via thresholded mechanism: 
BPA has been clearly shown to be aneugenic through induction of micronuclei caused by spindle disrupting effects of BPA identified by the use of 
fluorescently labelled antibodies for α and γ-tubulin to visualize the microtubules and the microtubule organizing centers of the mitotic spindles 
(Johnson and Parry 2008). Further evidence for spindle disrupting effects of BPA has been also indicated by Tayama et al. (2008) who showed 
significant increases of colchicine-like metaphases (c-metaphases) in CHO-K1 cells. 
 Very Likely 
 
Q1: Is BPA genotoxic in vivo via a non-threshold mechanism?  
 
















Starting point based on previous assessments (EFSA, 2006; 2010): 
The EFSA 2006 opinion noted that BPA is not considered to be genotoxic based on previous reviews of BPA 
genotoxicity (EC, 2002; EU, 2003; Haighton et al., 2002). In vivo studies had been considered by the EU RAR, 










Line of Evidence 1: New evidence of genotoxicity in vivo via a non-threshold mechanism involving direct 
damage to DNA (DNA breakage, DNA adducts etc.) 
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Strength: 
− Sound approach and experimental design  
Weaknesses:  
− Experimental procedures questionable: single dose level, number of cell examined  
 
Four studies evaluated DNA breakage (Ulutaş et al., 2011; Tiwari et al., 2012; Dobrzyńska and Radzikowska, 2013 
2013) and DNA adducts (Izzotti et al., 2009) 
 
Strength: 
− Sound approach and experimental design (Izzotti et al., 2009) 
Weaknesses:  
− Methodological shortcomings: absence of historical control values (Dobrzyńska and Radzikowska, 2013); 
number of cell examined (Ulutaş et al., 2011); cytotoxicity not evaluated, inadequate sampling times 
(Ulutaş et al., 2011; Tiwari et al., 2012; Dobrzyńska and Radzikowska, 2013) 
− Poor study report (Tiwari et al., 2012; Dobrzyńska and Radzikowska, 2013)  
 
Alkaline comet assay in the epididymal sperm (Tiwari and Vanage, 2013)  
 
Weaknesses:  
− Experimental procedures questionable (e.g. limited number of animals, absence of negative and positive 
controls, only two dose levels employed and lack of rationale for dose selection) 
− Results potentially biased by high background/variability for rodent sperm in the alkaline assay 
− No dose-related increases in dominant lethal mutations  

















































Line of Evidence 2: New evidence of genotoxicity in vivo via a non-threshold mechanism involving damage 
at chromosome level (Chromosome aberrations, micronuclei, SCE’s) 
 
Analysis of micronuclei in peripheral blood reticulocytes (Masuda et al., 2005) and bone marrow cells of rodents 
(Masuda et al., 2005; Pacchierotti et al., 2008;  Naik and Vijayalaxmi , 2009; De Flora et al., 2011); analysis of 
chromosomal aberrations in bone marrow cells of rodents ( Naik and Vijayalaxmi , 2009) 
 
Strength:  
− Sound approach and experimental design (Pacchierotti et al., 2008; Naik et al., 2009; De Flora et al., 2011) 
Weaknesses:  
− Limitations in the experimental design: single concentration/dose (Masuda et al., 2005); top dose too low 
(Pacchierotti et al., 2008; Naik et al., 2009), sub-optimal dose and exposure to colchicine ( Naik and 
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− Experimental procedures questionable: single dose level, number of cells examined (De Flora et al., 2011) 
 
Analysis of micronuclei and chromosomal aberrations in bone marrow cells of rodents (Tiwari et al., 2012) 
 
Weaknesses:  
− Incidence and type of chromosome aberrations generally not compatible with those seen with other 
chemical agents;  
− Methodological shortcomings: inappropriate staining procedures (micronuclei), inappropriate selection of 
sampling time; mitotic index as a measure of cytotoxicity not determined; sub-optimal exposure to 
colchicine (chromosomal aberrations) 
 




− Experimental procedures questionable; limited number of male animals employed; absence of negative and 
positive controls, inadequate selection of dose-levels (only two dose levels employed and lack of rationale 
for dose selection) 
− Results potentially biased by high background/variability for rodent sperm in the alkaline assay 
− No dose-related increases in dominant lethal mutations 





































Overall conclusion based on in vivo studies – via non-thresholded mechanism: 
BPA has not been shown to be clastogenic in vivo (micronuclei and chromosomal aberrations). 
Unlikely 
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Starting point based on previous assessments (EFSA, 2006; 2010): EFSA (2006) could not conclusively 
evaluate a study by Hunt et al, 2003, showing meiotic disturbances in mouse oocytes, due to deficiencies in the 
authors’ analysis and overall weakness of effects, and did not indicate concern for aneugenicity in vivo. EFSA 
(2010) considered two additional studies (micronucleus study of Naik and Vijayalaxmi, 2009, Mulhauser et al, 
2009 study on mouse oocytes), both showing some effects on spindle structure. EFSA noted the thresholded 
mechanism for aneuploidy induction and the large margin between the doses tested and the TDI and concluded that 
the findings of these studies did not alter the previous EFSA conclusion on the lack of aneugenic activity of BPA 









Line of Evidence 1: New evidence of genotoxicity in vivo via a thresholded mechanism: Aneuploidy 
(microtubule effects, chromosome loss, non-disjunction, induction of c-metaphases etc.) 
   
 
No effects for induction of aneuploidy; Significant increases in the number of metaphase II oocytes with 
prematurely separated chromatids of no consequences in terms of fidelity of chromosome segregation during the 
second meiotic division (Pacchierotti et al., 2008): 
 
Strength:  
− Sound approach and experimental design 
Weakness:  
− Inappropriate dose selection: high dose-levels for single or 7 daily administration apparently low (20 and 










Induction of “c-like metaphases” a biomarker of spindle disrupting effects (  Naik and Vijayalaxmi , 2009) 
 
Strength:  
− Sound approach and experimental design 
Weakness: 
− Minor limitations in the experimental design: top dose too low, sub-optimal dose and exposure to colchicine 
Positive High ↑ 
Overall conclusion based on in vivo studies via a thresholded mechanism: 
The potential of BPA to produce aneuploidy in vitro was not expressed in vivo, based on negative findings obtained for induction of aneuploidy in 
female and male mouse germ cells (Pacchierotti et al., 2008) and for induction of micronuclei in somatic bone marrow cells (Masuda et al., 2005; 
Pacchierotti et al., 2008;  Naik and Vijayalaxmi , 2009; De Flora et al., 2011). However, BPA induced dose-related increases of c-like metaphases in 
mouse bone-marrow cells ( Naik and Vijayalaxmi , 2009) and significant increases in the number of metaphase II oocytes with prematurely separated 
chromatids (Pacchierotti et al., 2008) pointing to potential mitotic spindle disrupting effects of BPA in vivo. 
 
As likely as not  
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WoE of carcinogenicity and proliferative changes 
Whether BPA has the potential to cause carcinogenicity or proliferqtive changes in tissues was considered using a tabular format for weighing different lines 
of evidence (WoE evaluation). The WoE evaluation tables for these endpoints are presented in full below.  
Animal studies 
WoE of the carcinogenicity of BPA in animals and its potential to cause proliferative changes in tissues, that could potentially be linked to development of 
cancer 
Table 48:  Assessment of the likelihood that BPA is carcinogenic in animals  
Q1: Is BPA genotoxic?  
Overall conclusion on in vivo studies – via non-thresholded mechanism: 
BPA has not been shown to be clastogenic (micronuclei and chromosomal aberrations). 
Unlikely 
 
Overall conclusion based on in vivo studies via a thresholded mechanism: 
The potential of BPA to produce aneuploidy in vitro was not expressed in vivo, based on negative findings obtained for induction of aneuploidy in female 
and male mouse germ cells (Pacchierotti et al., 2008) and for induction of micronuclei in somatic bone marrow cells (Masuda et al., 2005; Pacchierotti et 
al., 2008; Naik and Vijayalaxmi , 2009; De Flora et al., 2011). However, BPA induced dose-related increases of c-like metaphases in mouse bone-marrow 
cells (Naik and Vijayalaxmi , 2009) and significant increases in the number of metaphase II oocytes with prematurely separated chromatids (Pacchierotti 
et al., 2008) pointing to potential mitotic spindle disrupting effects of BPA in vivo. 
 
As likely as not 
 
Q2: Is BPA carcinogenic in animals when exposed during their adult life (post-pubertal) only?  Answer to the 
question as 













Starting point based on previous assessments (EFSA, 2006; EFSA CEF Panel, 2010): BPA did not show any 
significant carcinogenic activity in 2 standard oral cancer bioassays in rats and mice (NTP, 1982) 
 
Comment: Although there were differences between treated groups and controls in some tumour types and NTP had 
concluded that the data were suggestive of a carcinogenic effect on the haematopoietic system , reviews of the study by 
the EU RAR and EFSA concluded that these were not toxicologically significant (the main tumour type showing a 
dose:response relationship, haemopoetic tumours, is of unlikely relevance in humans) 
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Strengths: 
− Number of doses (4) 
− Large sample size 
− Phytoestrogen-free diet 
− Use of non-pc cages and of non plastic bottles 
Weaknesses: 
− Drinking water consumption not measured: exact doses received not known 
− Insufficient data reporting (e.g. Data on tumour incidence and histopathology incomplete, type of epithelial 
cells undergoing proliferation was not specified, time of necropsy not defined) 
Line of evidence 2: effects on tumour induction in the prostate (Prins et al., 2011) 
Comments: unusual early appearance of neoplastic lesions in this model after a very short period of treatment; “prostatic 
intraductal neoplasia” is a possible response to the prostatic inflammation, not sufficient degree of cellular atypia to be 
compatible with neoplasia 
 
Strengths: 
− Phytoestrogen-free diet 
− Use of non-PC cages and of non plastic bottles 
− BPA determination in animal samples 
Weaknesses: 
− Single dose level study 
− Possible confounding (BPA exposure was followed by testosterone and oestradiol-17β) 
Positive 
 
Low  ● 
Overall conclusion on carcinogenicity of BPA in animals when exposed during their adult life (post-pubertal) only: Effects on mammary gland 
growth demonstrated in a transgenic mouse model with post-pubertal exposure (Jenkins et al., 2011) or on prostatic “intraepithelial neoplasia” in rats 
exposed to BPA in the immediate postnatal period (Prins et al. 2011) do not provide convincing evidence that BPA is carcinogenic in animals when 
exposed postnatally/during their adult life. 
Unlikely to -
as likely as 
not- 
 
Q3: Is BPA carcinogenic in animals exposed during pre- and post-natal (during lactation) development? 
 
Answer to the 
question as 













Carcinogenicity other than mammary carcinogenicity: Starting point on based on previous assessments (EFSA, 
2006): Based on studies reviewed by EFSA in the 2006 opinion the AFC Panel concluded that transplacental and 
lactational exposure to BPA did not affect the incidence of preneoplastic and neoplastic lesions in prostate and seminal 
vesicle, and had no effects on age-related morphological changes of the reproductive and endocrine organs and uterine 
carcinogenesis up to 15 months of age (Ichihara et al., 2003; Yoshida et al., 2004), Nor did BPA promote thyroid cancer 
Negative  Medium ↑/↓↓ 
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in a thyroid carcinogenesis model (Takagi et al., 2002). 
 
In the EFSA CEF PANEL, 2010 opinion studies that addressed proliferative changes in the mammary glands were 
evaluated, including  Jenkins et al., 2009 and Betancourt et al., 2010. The CEF Panel noted that: “at the highest dose 
level studied there is a shift of the ratio between cell proliferation and apoptosis in favour of cell multiplication in the 
mammary gland. In view of the mechanistical data obtained upon in utero exposure in other studies  and the 
implications of an increased cell proliferation/apoptosis ratio in carcinogenesis, the effects reported by Jenkins and 
Betancourt deserve further consideration.” 
 
In several studies, including those addressing prenatal exposure, no putative pre-neoplastic or neoplastic lesions in the 
liver were observed (EFSA, 2006; EFSA CEF Panel, 2010; US FDA/NCTR, 2013 and Delclos et al, 2014). 
Line of Evidence 1: effects of BPA on tumour induction in the mammary glands (incidence, multiplicity and/or 
latency of tumours) (Weber Lozada and Keri, 2011; Acevedo et al., 2013) 
Comment: The tumours identified in the study reported by Weber Lozada and Keri (2011) were all squamous 
carcinomas whereas DMBA given orally to mice and rats is reported to produce mainly adenocarcinomas. 
 
Strengths: 
− Large sample size in most group (Acevedo et al., 2013) 
− Adequate positive control included (Weber Lozada and Keri, 2011) 
− Phytoestrogen-free diet (all) 
− Use of non-PC cages and of non plastic bottles diet (all) 
− BPA measurements in biological fluids (dams, fetuses and pups) (Acevedo et al., 2013) 
Weaknesses: 
− Small sample size (Acevedo et al., 2013; Weber Lozada and Keri, 2011) 











Line of Evidence 2: effects of BPA on tumour induction in the liver (Weinhouse et al., 2014) 
Comment: Liver tumours were also seen in male control mice 
 
Strengths: 
− Number of BPA doses (3) 
− Phytoestrogen-free diet 
− Use of non-PC cages 
− BPA measurement in biological samples (total liver measurement) 
Weaknesses:  
− Small sample size (low number of animals/group) 
− Insufficent reporting (no clear reporting on historical incidence of liver adenomas and carcinomas in female) 
Positive Low to 
Medium 
● 
Overall conclusion on the carcinogenicity of BPA in animals exposed during pre- and post-natal (during lactation) development: Recent studies Unlikely to -as 
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(Jenkins et al., 2009, Betancourt et al., 2010; Weber Lozada and Keri, 2011; Acevedo et al., 2013; Weinhouse et al, 2014) investigated the potential 
carcinogenic effects of fetal or perinatal exposure to BPA. Given the various weaknesses identified in these studies, they do not provide convincing 
evidence that BPA is carcinogenic in animals when exposed during pre- and post-natal (during lactation) development. 
likely as not-  
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Table 49:  Assessment of the likelihood that BPA induces proliferative changes in animal tissues  
















Starting point based on previous assessments (EFSA, 2006): Findings from the NTP bioassay (NTP, 1982): 
Histological examination of mammary tissue from all necropsied animals (rats and mice) revealed no evidence of 
non-neoplastic proliferative changes in either species.  
Negative High ↓↓↓ 
Line of Evidence 1: BPA induces mammary epithelial cell proliferation and hyperplasia (Jones et al., 2010; 
Jenkins et al. 2011) 
Comment: The Brca1 mouse model of Jones et al. and the female transgenic MMTV-erbB2 model in mice of 
Jenkins are not representative of the general population but in the case of the former might reflect increased 
sensitivity of the subpopulation with defective Brca1 gene. 
Comment: small changes in proliferation and hyperplasia of mammary gland epithelium cells in sensitive mouse 
models (Jones et al., 2010; Jenkins et al. 2011) 
 
Strengths: 
− Number of doses (Jenkins et al., 2011) 
− Large sample size (Jenkins et al., 2011) 
− Phytoestrogen-free diet (Jenkins et al., 2011; Jones et al., 2010) 
− Use of non-pc cages and of non plastic bottles (Jenkins et al., 2011) 
− Slides were blind-evaluated (Jenkins et al., 2011) 
Weaknesses: 
− Single dose level study (Jones et al., 2010) 
− Low number of animal/group for proliferation-drinking water consumption not measured: exact doses 
received not known (Jenkins et al., 2011) 
− Insufficient data reporting (e.g. No of animals with tumour and histopathology incomplete) (Jenkins et al., 
2011) 
− Type of cages not evaluated (Jones et al., 2010) 
Positive Medium ●/↑ 
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Line of Evidence 2: BPA effects on (atypical) hyperplasia (in addition to “intraepithelial neoplasia”) in the 
prostate of rats exposed postnatally (Prins et al., 2011) 
 
Comment: The early appearance of neoplastic lesions in this model after a very short period of treatment is unusual 
 
Strengths: 
− Phytoestrogen-free diet 
− Use of non-PC cages and of non plastic bottles 
− BPA determination in animal samples 
Weaknesses: 
− Single dose level study 
− Possible confounding (BPA exposure was followed by testosterone and oestradiol-17β) 
Positive Low • 
Overall conclusion on proliferative changes of BPA in animals when exposed postnatally/ during their adult life: Both Jones et al (2010) and 
Jenkins (2011) reported an effect on mammary gland proliferation in sensitive transgenic or gene knock-out models as well as wild-type mice (Jones et 
al. only) given BPA during adulthood, although proliferative effects in these mouse models are inconsistent with the lack of any proliferative effect on 
mammary tissue in mice in the two year NTP carcinogenicity study. However, the CEF Panel concluded overall that there is some indication that BPA 
can cause proliferative changes in the mammary gland of genetically modified animals when exposed postnatally/in adult life. 
 
The CEF Panel considered that evidence for proliferative changes induced by BPA in other organs (i.e. prostate) is currently too weak to reach a 
conclusion. 
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Q2: Does BPA induce proliferative changes in the mammary gland of animals exposed during pre- and/or 
post-natal (during lactation) development or up to PND 90 (gavage)? 
















Starting point based on previous assessments (EFSA, 2006, 2010): Based on the reviewed studies (Avecedo et al. 
2013, Betancourt et al, 2010; Durando et al, 2007; Jenkins et al, 2009; Moral et al. 2008; Murray et al, 2007; 
Vandenberg et al, 2007, 2008) the implications of cell proliferation in the mammary gland and the significance of an 
increased cell proliferation/apoptosis ratio deserve further consideration. Additionally, the Panel noted the findings 
of a number of earlier s.c. studies (Nikaido et al, 2004, 2005; Markey et al, 2001, 2005; Munoz-de-Toro et al, 2005, 
Rubin et al, 2006) supporting this conclusion.  
Comment: No dose-effect relationship observed (Jenkins et al, 2009; Betancourt et al, 2010; Durando et al, 2007; 
Murray et al, 2007; Vandenberg et al, 2007) 
Comment: Differences in architecture/histology was very small (Moral et al, 2008) 
 
Strength:  
− Number of doses (Avecedo et al, 2013; Vandenberg et al., 2008; Murray et al, 2007) 
− Large sample size (Betancourt et al, 2010, not for proliferation assessment; Moral et al. 2008; Vandenberg 
et al.,  2007) 
− Oral administration by gavage (Jenkins et al, 2009; Betancourt et al, 2010; Moral et al. 2008) 
− Phytoestrogen-free diet (Jenkins et al, 2009; Vandenberg et al., 2008; Betancourt et al, 2010; Moral et al. 
2008;  Murray et al, 2007, Markey et al, 2001) 
− Use of non-PC cages and of non plastic bottles (Jenkins et al, 2009; Durando et al, 2007; Vandenberg et al, 
2008; Betancourt et al, 2010; Murray et al, 2007) 
− Study design not appropriate to the scope (Comprehensive histology of TEB, AB and Lobules type 1 
(Moral et al., 2008) 
− Food tested negative for estrogenicity (Munoz de Toro et al., 2005) 
− Cages and bedding tested negative for estrogenicity (Markey et al, 2001; Munoz de Toro et al., 2005; 
Vandenberg et al, 2007) 
Weaknesses: 
− Only one tumour/animal selected for histopathology (Betancourt et al, 2010) 
− Only one dose-level tested for cell proliferation (Betancourt et al., 2013; Jenkins et al., 2009; Vandenberg 
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− Tubular epithelium not further specified (not TED (Betancourt et al., 2010) 
− Cell proliferation and apoptosis was measured at 12 months of age in TEB only (Jenkins et al., 2009) 
− No quantitative proliferation measurement (only hystopathological examination) (Avecedo et al., 2013) 
− Low number of animals/group for proliferation (Markey et al, 2001; Avecedo et al, 2013; Betancourt et al, 
2010; Vandenberg et al, 2007) 
− Low number of animals tested for histological examination) (Jenkins et al., 2009) 
− Low/unclear number of animals for the dose-groups (Munoz de Toro et al., 2005) 
− Time-points for BrdU is not indicated (Moral et al., 2008) 
− Short exposure period (Vandenberg et al, 2007) 
Line of Evidence 1: Changes in number of mammary (terminal end) buds volume fraction of (alveolar) buds, 
and/or (atypical) intraductal epithelial hyperplasia/proliferation (Ayyanan et al., 2011, Tharp et al., 2012, 
Vandenberg, 2013c; US FDA/NCTR 90-day study, 2013, Acevedo et al., 2013)  
Comment: Increase in TEBs at one low dose only; small changes (Ayyanan et al., 2011) 
Comment: No dose-response relationship (Acevedo et al., 2013, Vandenberg et al., 2013c) 
 
Strengths: 
− Number of doses in some of the dose groups (U.S FDA/NCTR, 2013; Vandenberg et al, 2013; Acevedo et 
al., 2013) 
− Large sample size (US FDA/NCTR, 2013 and Delclos et al., 2014; Ayyanan et al., 2011 ) 
− Large sample size in most group (Acevedo et al., 2013) 
− Both naive and vehicle controls available (US FDA/NCTR, 2013 and Delclos et al., 2014) 
− Oral administration by gavage (US FDA/NCTR, 2013 and Delclos et al., 2014; Tharp et al, 2012) 
− Measurement of BPA concentration in the serum (US FDA/NCTR, 2013 and Delclos et al., 2014) 
− Primate study judged to have particular relevance for humans (Tharp et al., 2012) 
− Diet with low content or free of phytoestrogens (US FDA/NCTR, 2013 and Delclos et al., 2014; Ayyanan 
et al., 2011; Vandenberg et al, 2013c; Acevedo et al., 2013) 
− Use of non-pc cages and of non plastic bottles (US FDA/NCTR, 2013 and Delclos et al., 2014; Ayyanan et 
al., 2011; Vandenberg et al, 2013c; Acevedo et al., 2013) 
− Study performed according to GLP regulations (US FDA/NCTR, 2013 and Delclos et al., 2014) 
− BPA measurements in biological fluids (Tharp et al, 2012; Acevedo et al., 2013) 
− Mammary glands were analyzed in a treatment-blind manner (Tharp et al., 2012, US FDA/NCTR, 2013 and 
Delclos et al., 2014) 
− Study performed according to OECD guidelines, under GLP (US FDA/NCTR, 2013 and Delclos et al., 
2014) 




Low to High  
 
↑↑ 
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− Re-evaluation of the lesions by a pathology working group (US FDA/NCTR, 2013 and Delclos et al., 2014) 
Weaknesses: 
−  Small sample size (Tharp et al, 2012; Vandenberg et al, 2013c; Acevedo et al., 2013; Ayyanan et al., 2011) 
− Single dose level study (Tharp et al, 2012) 
− Statistics (because of limited sample size) (Tharp et al, 2012) 
− Inconsitent results within groups (females not sensitive to EE2 effects) (US FDA/NCTR, 2013 and Delclos 
et al., 2014) 
− Drinking water consumption not measured (Ayyanan et al., 2011) 
− Animal diet and phytoestrogen content not measured (Tharp et al, 2012) 
− Low No of animals tested for histological examination (Ayyanan et al., 2011) 
− Unclear/insufficient study reporting (Vandenbergh et al., 2013c; Ayyanan et al., 2011) 
− Reproductive cycling not controlled (Ayyanan et al., 2011, Tharp et al., 2012) 
− Unintended exposure of  the control groups (US FDA/NCTR, 2013 and Delclos et al., 2014, see 
Churchwell et al, 2014)  
Line of Evidence 2: BPA has been reported to cause Leydig cell division in the prepubertal period and 
increased Leydig cell numbers were shown in the testes of adult male rats at 90 days (Nanjappa et al., 2012). 
 
Comment Rat strain highly disposed to Leydig cell proliferation 
 
Strengths: 
− Phytoestrogen free-diet 
− Use of non-pc cages and of non plastic bottles 
− Multiple tests to address the same endpoint 
− Correlation between morphological and functional changes assessed 
Weaknesses: 
− Results interpretation (biological relevance debatable) 
Positive Low ● 
Overall conclusion on induction of proliferative changes by BPA in animals exposed during pre- and/or post-natal (during lactation) 
development or up to PND 90 (gavage):  
The EFSA opinion of 2010 noted potential proliferative effects of fetal or perinatal exposure to BPA. Since 2010 additional studies including a study in 
non-human primates (Ayyanan et al., 2011, Tharp, 2012, Vandenberg, 2013c, Acevedo, 2013, US FDA/NCTR, 2013 and Delclos et al., 2014) have also 
suggested that BPA can have proliferative effects on mammary tissues and strengthen the evidence for an effect of BPA on mammary gland 
proliferation in animals exposed during pre- and post-natal development.  
 
The CEF Panel considered that evidence for proliferative changes induced by BPA in other organs (e.g. testis: Nanjappa et al., 2012) is currently too 
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Table 50:   Summary of the WoE assessment of the likelihood that BPA is carcinogenic in animals  
 
 
Table 51:   Summary of the WoE assessment of the likelihood that BPA causes cell proliferation in tissues of animals exposed post- or pre-natally  
Overall conclusion on proliferative changes of BPA in animals when exposed postnatally/ during their adult life: Both Jones et al (2010) and 
Jenkins (2011) reported an effect on mammary gland proliferation in sensitive transgenic or gene knock-out models as well as wild-type mice (Jones et 
al. only) given BPA during adulthood, although proliferative effects in these mouse models are inconsistent with the lack of any proliferative effect on 
mammary tissue in mice in the two year NTP carcinogenicity study. However, the CEF Panel concluded overall that there is some indication that BPA 
can cause proliferative changes in the mammary gland of genetically modified animals when exposed postnatally/in adult life. 
 
The Panel considered that evidence for proliferative changes induced by BPA in other organs (i.e. prostate) is currently too weak to reach a conclusion. 




Overall conclusion on BPA- induced proliferative changes/ developmental advancement in the mammary gland of animals exposed during pre- 
and/or post-natal (during lactation) development or up to PND 90 (gavage):  
The EFSA opinion of 2010 noted potential proliferative effects of fetal or perinatal exposure to BPA. Since 2010 additional studies including a study in 
non-human primates (Ayyanan et al., 2011, Tharp, 2012, Vandenberg, 2013c, Acevedo, 2013, US FDA/NCTR, 2013 and Delclos et al., 2014) have also 
suggested that BPA can have proliferative effects on mammary tissues and strengthen the evidence for an effect of BPA on mammary gland 
proliferation in animals exposed during pre- and post-natal development.  
 
The CEF Panel considered that evidence for proliferative changes induced by BPA in other organs (e.g. testis: Nanjappa et al., 2012) is currently too 






Overall conclusion on carcinogenicity of BPA in animals when exposed during their adult life (post-pubertal) only: Effects on mammary gland 
growth demonstrated in a transgenic mouse model with post-pubertal exposure (Jenkins et al., 2011) or on reported prostatic “intraepithelial neoplasia” in 
rats exposed to BPA in the immediate postnatal period (Prins et al., 2011) do not provide convincing evidence that BPA is carcinogenic in animals when 
exposed postnatally/during their adult life. 
Unlikely to -as 
likely as not- 
 
Overall conclusion on the carcinogenicity of BPA in animals exposed during pre- and post-natal (during lactation) development: Recent studies 
(Jenkins et al., 2009, Betancourt et al., 2010; Weber Lozada and Keri, 2011; Acevedo et al, 2013) investigated the potential carcinogenic effects of fetal 
or perinatal exposure to BPA. Given the various weaknesses identified in these studies, they do not provide convincing evidence that BPA is 
carcinogenic in animals when exposed during pre- and post-natal (during lactation) development. 
Unlikely to as 
like as not 
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Appendix D.  Uncertainty analysis: (I) Dermal absorption (II) HEDF (III) Hazard 
characterisation 
(i) Dermal penetration and absorption studies and uncertainties affecting the assessment of 
BPA absorption from dermal contact with thermal paper  
In vitro studies on dermal penetration 
Five in vitro studies on dermal penetration are available (Table 52 of this Appendix). The most recent 
study by Demierre et al. (2012) used non-viable (defrosted) human skin in a flow-through Franz cell 
system and performed the experiments according to the OECD test guideline 428 for in vitro skin 
absorption. Skin samples were obtained from the dorsal part of the upper leg from two human 
deceased donors, and seven skin sections dermatomed to a thickness of 200 µm were analysed. Skin 
integrity was checked with 3H-water, yielding permeability coefficients within the acceptance range. 
Water was used as vehicle for the donor solution, and radiolabelled 14C-BPA was applied in 
concentration of 193.6 mg/l slightly below the, aqueous solubility limit of ~250 mg/l. The applied 
surface density was 1.82 µg/cm2. The donor chamber was covered with permeable tape (non-occluded 
conditions) to mimic real exposure conditions. Physiological saline was used as receptor fluid. The 
experiments were conducted at 30–32 °C for 24 h, and the receptor fluid was collected initially in 1 h 
and 2 h intervals. After 24 h incubation, the percutaneous penetration (i.e. the relative amount present 
in the receptor fluid) was 8.6%, the skin deposition 35.5%, and the recovery 101.5 %. Consecutive 
stripping of the stratum corneum (SC) with adhesive tape (15 tape strips) recovered 34.9% of the 
external dose in the SC with the main portion located in the most external SC layers. The kinetics of 
cumulative percutaneous penetration revealed a lag time of 1 h and a maximum penetration flux of 
0.022 µg/cm2/h, reflecting the penetration rate under steady-state conditions in the initial linear phase 
from 1–4 h. In the later time period, the penetration rate decreased to a ~6-fold lower level in the 
terminal linear phase from 11–24 h, indicating a change in the diffusion process, which is possibly 
(but not necessarily exclusively) resulting from the evaporation of the aqueous vehicle (applied 
volume 6 µl) on the skin surface. Dividing the maximum percutaneous penetration flux by vehicle 
concentration yielded a permeability coefficient (a dose-independent measure) Kp of 11×10–5 cm/h. 
Given the good quality of the study and the detail of reporting, the CEF Panel used the study of 
Demierre et al. (2012) as a reference for comparison with the other studies. 
Marquet et al. (2011) used a static Franz diffusion cell and analyzed viable and non-viable (defrosted) 
human skin from 6 patients undergoing plastic surgery. The skin was dermatomed to a thickness of 
500 µm, and the skin integrity was checked by measuring the transepidermal water loss. Acetone was 
used as vehicle, and 14C-BPA was applied in a high concentration of 4000 mg/l, resulting in a surface 
density of 200 µg/cm2. The receptor fluid consisted of cell culture medium with 2% BSA (BPA 
solubility ≥300 mg/l). The experiments were conducted at 32 ± 1 °C for 24 h, and receptor-fluid 
samples were taken on regular intervals. Permeation experiments with 15 non-viable human skin 
sections revealed a recovery of 95.6% and a maximum percutaneous flux of 0.12 µg/cm2/h occurring 
at the end of the incubation period at 23.5 h. The quotient of maximum percutaneous flux and vehicle 
concentration yielded a permeability coefficient of 3.0×10–5 cm/h, which was 3.7-fold lower than in 
Demierre et al. (2012) but still comparable given the differences in vehicle type, surface density, and 
diffusion-cell design. Additional permeation experiments with non-viable rat skin under identical 
conditions revealed a ~12-fold higher permeability for rat skin compared to human skin. Finally, the 
authors used viable human and rat skin to estimate the extent of skin metabolism by measuring the 
BPA metabolites in the receptor fluid after 24 h of exposure. For both human and rat skin, metabolised 
BPA accounted for ~3% of the permeant. 
Mørck et al. (2010) used a a static Franz diffusion cell and analyzed non-viable human skin from  
breast-surgery patients according to the OECD TG 428. For experimental details, the authors referred 
to the paper of Nielsen et al. (2009) from which some of information described below was taken. Full 
thickness skin (800–1000 µm) was used, and the skin integrity was checked by capacitance 
measurements. A diluted ethanol solution was used as vehicle, and 14C-BPA was applied in a high 
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 573 
concentration of 4000 mg/l, resulting in a surface density of 259 µg/cm2. The receptor fluid consisted 
of physiological saline solution containing 5% BSA. The experiments were carried out at ~32 °C for 
48 h, and receptor-fluid samples were taken at regular time intervals. Experiments with 11 skin 
sections after 48 h incubation showed a percutaneous penetration of 13.0%, a skin deposition of 
24.6%, and a recovery of 82.1%. A more detailed analysis of skin deposition showed 7.4% and 17.2% 
of the applied dose to be in the epidermis and dermis, respectively, which is in contrast to Demierre et 
al. (2012) who found the main portion of the skin deposition to be located in the stratum corneum of 
the epidermis. The CEF Panel noted that the percutaneous penetration of 13.0% is in good agreement 
with the 8.6% determined by Demierre et al. (2012) if the different incubation times (48 h vs. 24 h) are 
accounted for. 
Kaddar et al. (2008) analyzed shaved pig skin from the flanks in a static Franz diffusion cell. 
Physiological serum was used as vehicle, and 14C-BPA was applied in a concentration of 10 mg/l. The 
applied surface density was not reported, but the applied dose of 0.7 µg was comparable to the dose of 
1.16 µg applied by Demierre et al. (2012). The experiments were carried out at ~32 °C, either for 24 h 
with repeated sampling in regular intervals (transfer kinetics experiment) or for 2, 5, and 10 h with 
single sampling (skin distribution experiment). For the skin distribution experiment, six replicates 
were used per exposure duration. Additional methodical details (e.g., skin thickness, applied surface 
concentration) were not reported. Analysis of skin distribution after the longest exposure time of 10 h 
showed that 5.4% and 8.8% of the applied dose to be in the epidermis and dermis, respectively, which 
is in contrast to human-skin study of Demierre et al. (2012) where the main portion of skin deposition 
was in the stratum corneum of the epidermis. The transfer kinetics experiment revealed a lag time of 
~3 h and a percutaneous penetration of 4.1% after 24 h, which the CEF Panel noted was in good 
agreement with the 8.6% determined by Demierre et al. (2012) when taking the different skin types 
into account. 
Zalko et al. (2011) examined the diffusion and metabolism of BPA using viable human skin explants 
from the abdominal region of female donors. The skin was dermatomed to a thickness of 500 µm and 
then seeded in cell culture inserts, where the explants were maintained at the air/liquid interface with 
dermal/epidermal feeding by diffusion of nutrients from the culture medium (1.5 ml) across the insert. 
Ethanol/phosphate buffer 0.1 M pH 7.4 (1:2, v/v) was used as vehicle, and 14C-BPA was applied in a 
surface density of 2.75 µg/cm2. The experiments were carried out at 37 °C, and culture media were 
collected at 24, 48, and 72 h. Experiments with 3 skin sections after 72 h incubation showed a 
percutaneous penetration 45.6%, a skin deposition of 41.5%, a residual amount of 2.5 % on the skin 
surface, and a recovery 92.6%. The CEF Panel noted that the reported skin penetration and deposition 
are not reliable estimates for in vitro skin absorption since several methodical features (e.g. use of cell 
culture inserts as diffusion cells, missing skin integrity check, exposure times largely exceeding 24 h, 
33% ethanol solution as vehicle) did not conform with the OECD TG 428. Additional experiments 
with viable human skin and pig ear skin were carried out to analyze the extent of skin metabolism. 
Major skin metabolites were BPA mono-glucuronide and BPA mono-sulfate, which were reported to 
account for 73% and 27% of the dose in porcine and human skin after 72 h of incubation. The CEF 
Panel considered that the transferability of these results to the in vivo situation in humans as 
questionable. First, there was almost a complete depletion of the permeant on the skin surface. Second, 
the concentrations of BPA equivalents in the culture medium (i.e. the receptor compartment) reached 
values well above 1 µM, which is not really the "sink" condition prevailing in vivo with serum 
concentrations for BPA equivalents being generally far below 10 nM. As a consequence, there was no 
longer a one-directional transport of the permeant from the donor compartment to the receptor 
compartment, and a re-uptake of BPA from the culture medium with subsequent metabolism in the 
skin cannot be excluded. The CEF Panel considered that ignoring these methodical flaws would lead 
to an overestimation of the extent of in vivo skin metabolism. 
In conclusion, a consistent picture of in vitro skin absorption of BPA emerged from the available 
studies with the exception of Zalko et al. (2011), which was not further considered for the 
methodological reasons given above. The CEF Panel regarded the study of Demierre et al. (2012) as a 
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key study and considered other acceptable studies as supporting evidence. Demierre et al. (2012) used 
water as the vehicle, which is more comparable to a consumer exposure scenario to thermal paper than 
e.g. acetone or diluted ethanol solutions, and the applied surface density of 1.82 µg/cm2 is comparable 
to exposure estimates as derived for thermal paper (1.375–5.5 µg BPA per ~2 cm2 finger tip). The 
experiment was conducted for 24 h, which again is comparable to a scenario with a daily exposure to 
thermal paper. Demierre et al. (2012) reported a percutaneous penetration of 8.6% and a skin 
deposition of 35.5% after 24 h. It is important to note that a somewhat depleted but still large portion 
of the applied dose (57%) remained on the skin after 24 h. The relatively high fraction of 35.5% in the 
skin is physiologically plausible as a steep concentration gradient is needed in the stratum corneum 
(SC), along which BPA can diffuse from the skin surface to the deeper skin layers. That this high 
fraction is present in the SC was corroborated by tape stripping of successive corneocyte layers 
(Demierre et al., 2012) and by the findings of Biedermann et al. (2010). Seemingly contradictory 
findings by Mørck et al. (2010) and Kaddar et al. (2008) concerning the distribution between the 
epidermis and dermis would need to be considered in terms of dermis thickness and the extent of 
deviation from the sink condition in the receptor compartment. In Demierre et al. (2012), the specific 
permeation kinetics with an initial high penetration rate and a subsequent low penetration rate are 
suggestive of effects arising from finite dosing (i.e. partial depletion of the dose on the skin surface) 
and/or evaporation of the aqueous vehicle (→ reduced hydration of the SC), which both are realistic 
conditions applicable to consumer exposure. In spite of differences in the diffusion-cell design, skin 
type, vehicle type and applied dose, the in vitro studies of Marquet et al. (2011), Mørck et al. (2010), 
and Kaddar et al. (2008) support the percutaneous penetration estimate of 8.6 % of Demierre et al. 
(2012), although tending to somewhat lower values: a rough calculation based on the comparison of 
permeability coefficients or the normalization of percutaneous penetration to 24 h incubation yielded 
estimates of 2.3 % (Marquet et al., 2011) and 6.5 % (Mørck et al., 2010) for human skin, and of 4.1 % 
(Kaddar et al., 2008) for pig skin. 
Given a percutaneous penetration of <10%, a skin deposition in the stratum corneum of ~35%, and a 
residual amount on the skin surface of >50% after 24 h incubation, the question arises as to whether or 
not the amount that is deposited in the skin may reach the systemic circulation. The CEF Panel noted 
that if a simple consumer scenario with a repeated single daily exposure to thermal paper is 
considered, and if it is further assumed that any BPA remaining on the skin surface after 24 h is 
removed (e.g. by hand washing, sloughing or by touching things) before the next dose is applied, then 
a stationary state will prevail, with a more or less stable concentration gradient in the stratum corneum 
(SC), along which BPA diffuses across the skin to reach the circulation. As a consequence, it is the 
<10% fraction of the external dermal dose that reaches the systemic circulation within the time period 
of 24 h.  
Concerning the metabolic capacity of the skin, there were two in vitro dermal penetration studies 
providing information on BPA metabolism. Marquet et al. (2011) analysed human and rat skin and 
reported that metabolized BPA accounted for ~3% of the permeant, which is a negligible fraction. 
Zalko et al. (2011) reported that skin metabolites accounted for 73% (pig skin) and 27% (human skin) 
of the dose. This study was not further considered because of methodological shortcomings. The CEF 
Panel noted that the available information does not permit to arrive at a reliable estimate of the extent 
of skin metabolism. For the estimation of internal exposure from dermal exposure to thermal paper, it 
was conservatively assumed that no considerable skin metabolisation occurs. 
In vivo studies on percutaneous absorption 
The study of Marquet et al. (2011) in rats is the only in vivo study of BPA dermal absorption. The 
absorbed dose of total 14C-BPA after application of a concentrated acetone solution (4000 mg/l, 500 µl 
total volume) in a surface density of 200 µg/cm2 and a 72 hr sample collection interval was 23% (i.e. 
fraction of total radioactivity found in urine + feces + carcass). The total recovery was in the range of 
90–100% of the administered dose. There was a linear relationship between the cumulative absorption 
and exposure time over the experimental period of 0–30 h, and the slope of this line corresponded to 
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an absorption flux of 2.5 µg/cm2/h. The quotient of absorption flux and vehicle concentration yielded a 
permeability coefficient of 62.5×10–5 cm/h. 
Marquet et al. (2011) also compared the maximum percutaneous fluxes ex vivo from rat and human 
frozen dermatomed skin explants and found the human flux to be 8% of the rat value under identical 
conditions using the acetone vehicle. Using this figure as an “interspecies factor” permits extrapolation 
of the in vivo rat permeability coefficient of 62.5×10–5 cm/h to humans. This extrapolation yielded an 
in vivo human permeability coefficient of 5.0×10–5 cm/h, which is somewhat lower than but still 
comparable to the value of 11×10–5 cm/h determined by Demierre et al. (2012) for human skin 
ex vivo. This additional plausibility check not only corroborates the findings of Demierre et al. (2012) 
but also suggests a 24-h percutaneous penetration that is approximately half the value of 8.6% reported 
by Demierre et al. (2012). 
Table 52:  Overview of in vitro studies on percutaneous penetration of BPA. Data are given as 
means ± SD. 
Parameter Kaddar et al. 
(2008) 
Mørck et al. 
(2010) 
Marquet et al. 
(2011) 
Zalko et al. 
(2011) 
Demierre et al. 
(2012) 













dorsal part of the 
upper leg 
from 2 human 
cadavers. 
Number of skin 
sections 
6 (?) 11 15 3 7  
Skin viability  non-viable non-viable (and 
viable) 
viable skin non-viable 
Skin Section 
thickness 
 800–1000 µm 500 µm 500 µm 200 µm 
Exposed area  2.12 cm2 1.76 cm2 6.2 cm2 (ø28 
mm) 
0.64 cm2 
Applied volume 70 µl 32.6 µl  60 µl 6 µl 
Applied volume 
per area 
 15.4 µl/cm2 50 µl/cm2 9.7 µl/cm2 9.4 µl/cm2 
Applied 
concentration 
10 mg/l 3995 mg/l (= 
17.5 mM) 
4000 mg/l 284 mg/l 194 mg/l 
Applied surface 
density 
 259 µg/cm2 200 µg/cm2 2.75 µg/cm2 1.82 µg/cm2 
Applied dose 0.7 µg 452 µg 352 µg 17 µg 1.16 µg 
Temperature 32.0 ± 0.1 °C ≈32 °C 32 ± 1 °C 37 °C 30–32 °C 




OECD TG 428 
static Franz 
diffusion cell 





























receptor fluid  physiol. saline + 
BSA 




24 h 48 h 24 h 72 h 24 h 
Recovery 84.3 ± 9.0 % at 82.1 % 96.5 ± 1.9 % 92.6 ± 5.8 % 101.5 ± 1.6 % 
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Parameter Kaddar et al. 
(2008) 
Mørck et al. 
(2010) 
Marquet et al. 
(2011) 
Zalko et al. 
(2011) 
Demierre et al. 
(2012) 
10 h 
Skin deposition  24.6 ± 5.8 %  41.5 ± 10.8 % 35.5 ± 6.6 % 
Percutaneous 
penetration 





8.6 ± 2.1 % 
Maximum 
penetration flux 
  0.12 µg/cm2/h  0.022 µg/cm2/h 
Permeability 
coefficient Kp 
  3.0×10–5 cm/h  11×10–5 cm/h 
Remark also data for 2, 5 
and 10 h, 





Nielsen et al. 
(2009) 
additional data 
for rat skin, 
information on 
metabolites 








Evaluation of uncertainties affecting the assessment of dermal absorption of BPA after dermal 
exposure to BPA from thermal paper  
This evaluation of uncertainties surrounding the estimate for dermal absorption of BPA starts with a 
definition and clarification of the processes involved. Dermal / percutaneous absorption is the 
movement of a chemical from the outer surface of the skin into the circulatory system leading to 
systemic exposure (EFSA, 2011). Dermal penetration is the movement of a chemical from the outer 
surface of the skin into the epidermis, but not necessarily into the circulatory system (EFSA, 2011). 
The study of Biedermann et al. (2010) on the transfer of BPA from thermal paper to the skin and the 
dermal penetration study of Demierre et al. (2011) suggest that ~30% of the external dermal exposure 
may penetrate into the skin and become available for subsequent systemic uptake. Demierre et al. 
(2011) also showed that 8.6% of the applied dose passed through the human skin within 24 h. Given 
the uncertainties around this value, and taking the evidence from the other dermal absorption studies 
into account, a dermal absorption fraction of 10% was assumed in the present opinion for the exposure 
scenarios with dermal contact to thermal paper. This is considered as fairly realistic. Further 
specifications in the PBPK modelling of these exposure scenarios comprised (i) the assumption of a 
BPA depot (receiving 100% of the external dermal dose) in the moisture film on the skin and (ii) the 
assumption of a first order process for dermal absorption. To keep the PBPK model as simple as 
possible (in terms of the number of assumptions and parameters), it was further assumed 
(conservatively) that the BPA depot remains on the skin surface during the whole day and that 10% of 
the initial depot content is absorbed within 24 h. BPA remaining on the skin surface after 24 h (i.e. 
90% of the initial depot content) is assumed to be completely removed (e.g. by hand washing, abrasion 
etc.), and the skin surface depot is then reloaded with 100% of the new dermal dose. The impact of 
this assumption, which could potentially result in severe underestimation of the contribution of dermal 
exposure, is however limited, as discussed in the uncertainty table (Table 53) below. In other words, 
the BPA depot is assumed to be periodically replenished to 100% after 24 h by a new dermal contact 
to thermal paper. An important consequence of assuming the BPA depot to be depleted to only a small 
extent within 24 h is that the dermal absorption process is in a steady state with a virtually stable and 
permanent concentration gradient in the stratum corneum (SC), along which BPA is diffusing through 
the skin to reach the systemic circulation. In the PBPK modelling of internal exposure (i.e. serum 
concentration of unconjugated BPA) resulting from dermal contact to dermal paper, it was made sure 
that the modelled system was in a steady steady state by running the simulation for 10 days. For the 
HEDF calculations the AUC value from day 10 was used. 
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Given the above specifications, the amount of BPA absorbed per unit time and area J (µg cm–2 h–1) is 
described according to a first-order process as 
AXkJ ⋅= , 
where k is the first-order rate constant (h–1), X is the amount of BPA (µg) in the skin surface depot, and 
A is the skin surface area (cm2). 
The assumption of a first-order process for dermal absorption and of 10% absorption during 24 h leads 
to a rate constant (k) of –ln(0.9)/24 h = 0.00439 h–1. For the external dermal dose that is loaded into the 
skin surface depot (X/A), an average estimate of 0.69 μg/cm2 was derived e.g. for adult males based on 
the transfer of 1.375 µg BPA from thermal paper to the finger tips (surface area per finger tip: 2 cm2) 
following a single handling event per day. The high estimate of 3.17 μg/cm2 for adult males was based 
on 4.6 handling events per day and by further assuming that each new handling event adds 
0.69 μg/cm2 to the already existing BPA depot on the skin surface. 
Table 53 contains the evaluation of uncertainties surrounding the rate constant estimate (k) and the 
built-up and maintenance of the BPA depot (X/A). Concerning the BPA depot, the uncertainty 
assessment is focussed on the uncertainty in the surface dose X/A and not on the uncertainty in the 
individual parameters X (amount) and A (exposed surface area) as these are treated in the uncertainty 
evaluation of the external dermal exposure (see Appendix H in Part I-Exposure assessment). The scale 
used to evaluate the impact of the source of uncertainty on the estimates of dermal absorption is shown 
in Figure 18. Plus symbols indicate the real value could be higher than the estimate, while minus 
symbols indicate the real value could be lower than the estimate. The evaluations are approximate 
expert judgements and should not be interpreted as precise estimates. 
 
Figure 18:  Scale used for evaluating the impact of uncertainties on estimates of total exposure to 
BPA.  
Table 53:  Assessment of the uncertainty in the dermal absorption fraction, as reflected by the 
first order rate constant k, and in the BPA depot in the moisture film on the skin surface, as 
reflected by the variable X/A, as related to the dermal exposure to BPA in thermal paper (See 
Figure 18). 
Source of uncertainty Variable affected Uncertainty 
of the 
estimate 
Extent of dermal absorption 
Available evidence from in vitro dermal absorption studies with 
human skin explants from breast, abdomen, and upper leg suggests a 
24-h dermal absorption for human skin of 2.3–8.6%. The upper limit 
was reported by Demierre et al. (2012) as the fraction of the applied 
dose that passed through human skin explants within 24 h. By taking 
the amount of BPA in the viable part of the epidermis into account, 
Demierre et al. (2012) reported a bioavailable fraction of 9.6%, which 
was rounded up in the present opinion to 10% to reflect the 
k 
(first-order rate 
constant for 10% 
dermal absorption 
during 24 h) 
– / ● 
• + ++ +++ − − − − − − 
+/ - 20% x 1/2 x 1/5 2x 5x x 1/10 10x 
Real value  higher than estimate 
(under - estimation) 
Real value  lower than estimate 
(over - estimation) 
++++ − − − − 
>10x < x 1/10 
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Source of uncertainty Variable affected Uncertainty 
of the 
estimate 
uncertainties around this number. The impact of uncertainty is judged 
to be within the range of 0.5–1.2 times the estimate. 
Skin viability and skin metabolism  
The non-viability of the human skin explants in Demierre et al. 
(2011) may influence the extent of the dermal absorption. However, it 
is generally accepted that the non-viable SC is the main diffusion 
barrier for absorption (EFSA, 2011), so that the effect on 
percutaneous diffusion can be assumed to be small. The tape-
stripping results of Demierre et al. (2011) support the assumption that 
the SC is the main diffusion barrier. Skin metabolism, however, may 
reduce the extent of dermal absorption of unconjugated BPA. 
 
There are two in vitro dermal absorption studies on skin metabolism. 
Marquet et al. (2011) analysed human and rat skin and reported ~3% 
of the permeant being metabolized BPA. Zalko et al. (2011) reported 
that skin metabolites accounted for 73% (pig skin) and 27% (human 
skin) of the applied dose. The available information did not permit to 
arrive at a reliable estimate of extent of skin metabolism. Not 
considering skin metabolism may overestimate the amount of 
unconjugated BPA that reaches the systemic circulation. This 
uncertainty is within the range of 1/2–1 times the estimate. 
k – / no impact 
Thickness of the Stratum corneum (SC)  
Dermal absorption studies normally use the back (in vivo studies) or 
breast/abdomen or upper leg (in vitro studies), which are considered 
to provide realistic dermal absorption values (EFSA, 2011). The 
thickness of the SC is several times greater in the palms than in other 
parts of the body (Egawa et al., 2007; US EPA, 2011; EFSA, 2011). 
The extent of dermal absorption across the skin of the finger tips may 
therefore be smaller than across other body part such as those 
normally used for dermal absorption studies. The impact of 
uncertainty is judged to be within the range of 1/5–1/2 times the 
estimate. 
k – – 
Age-related differences in dermal absorption 
Possible minor differences in skin absorption due to age appear to be 
limited to certain skin areas only and do not call for any correction 
factor or any specific default figures to be applied (EFSA, 2011).  
k No impact 
Sweating and skin hydration  
Sweating and skin hydration were reported to increase dermal 
absorption < 2 fold (EFSA, 2011). Two variables are affected. 
Compared to dry fingers, sweaty fingers have a thicker moisture film 
on the skin surface, which would enable a larger BPA depot on the 
skin surface (X/A). This potential effect is already covered under 
"Wet and oily/greasy fingers". An increased hydration of the Stratum 
corneum (SC) could increase the diffusion of BPA through the SC. 
However, this potential effect is already covered by the dermal 
absorption fraction of 10% (from which the first-order rate constant k 
was derived), because the aqueous vehicle that was used in the in-
vitro dermal penetration study of Demierre et al. (2012), likely 
resulted in an increased skin hydration. The impact of uncertainty is 
judged to be within the range of 1–1.5 times the estimate. 
k 
X/A 
(BPA depot in the 
moisture film on the 
skin surface) 
● to ●/+ 
Saturation of BPA in the skin moisture film 
Biedermann et al. (2010) reported a BPA transfer from thermal paper 
to dry finger tips of 1.13 µg BPA per finger. They also showed that 
the BPA load to the skin did not increase when the paper was touched 
for longer times or repeatedly. This could suggest a saturation of BPA 
in the skin moisture film. 
X/A 
(BPA depot in the 
moisture film on the 
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Further evidence for a saturation effect can be derived from analyses 
of the film thickness of liquids on the skin. E.g., the contact of dry 
hands with water and subsequent full wipe of the hands resulted in an 
aqueous water film on the skin of ~20 µm thickness (US EPA, 2011). 
Taking the aqueous solubility of BPA of 250 mg/l into account, the 
maximum BPA load into this aqueous surface film would be 0.5 
µg/cm2 or about 1 µg per finger tip when assuming a surface area of 
2 cm2 per finger tip. This agrees well with the observed transfer of 
1.13 µg BPA per finger in Biedermann et al. (2010) and of 11.3 µg to 
8 fingers (= 1.41 µg per finger) in Lassen et al. (2011) under dry-hand 
conditions. So, if the skin moisture film is already saturated, the BPA 
depot would not increase with further touching of thermal paper. This 
limitation would specifically affect the dermal absorption of high 
dermal doses. The impact is judged to be within the range of 1/2–1 
times the estimate. 
–  
Wet and oily/greasy fingers  
Biedermann et al. (2010) reported a limited transfer of BPA from 
thermal paper to dry fingers but a comparatively increased transfer to 
wet or oily fingers. Similarily, Lassen et al. (2011) reported a ~9-fold 
higher BPA transfer to humid fingers compared to dry fingers. 
 
The comparatively higher BPA transfer from thermal paper into an 
oily or greasy surface film can be explained by the higher solubility 
of the lipophilic BPA and also by a possibly thicker surface film. A 
higher BPA concentration in the skin surface film increases the 
dermal absorption. For wet or sweaty fingers, however, the BPA 
concentration in the skin surface film remains limited by the aqueous 
solubility. Compared to the dry-finger scenario, the main difference 
in the humid-finger scenario is the larger depot volume on the skin 
surface and, consequently, the reduced depletion of the BPA depot. 
 
For a chronic daily exposure to BPA in thermal paper, the assumption 
of having always wet or greasy/oily fingers when touching thermal 
paper is unlikely for the general population. The impact of 
uncertainty is judged to be within the range of 1–2 times the estimate. 
X/A ● / + 
Hand washing and desquamation 
Processes such as hand washing and desquamation (i.e. shedding of 
the outermost skin layers) that could additionally deplete the BPA 
depot on the skin surface have not been taken into account in the 
scenarios for dermal absorption. Not considering these effects leads 
to an overestimation of dermal absorption. The impact of uncertainty 
is judged to be within the range of 1/2 times to –20% of the estimate. 
X/A – 
Replenishment of the skin surface depot 
Another simplification concerns neglecting a possible built-up of the 
BPA amount on and in the skin (i.e. scenarios with contact to thermal 
paper repeated on consecutive days). Biedermann et al. (2010) 
determined that 2 h after finger contact to thermal paper only 70% of 
applied substance could be removed from the finger tips with ethanol, 
which is in accordance with the in vitro dermal penetration study of 
Demierre et al. (2012), where ~15% of applied surface dose were 
found in most external SC layer (tape strip 1), which can be regarded 
as potentially extractable and therefore to belong to the BPA depot, 
and where ~20% of BPA were found in the deeper parts of the SC 
(tape strip 2-10). Therefore, if it is assumed that a maximum of 30% 
BPA penetrates the skin, of which 10% are internally absorbed, 20% 
X/A + 
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Source of uncertainty Variable affected Uncertainty 
of the 
estimate 
may still be present in deeper layers of the SC. The second dosing 
would therefore initially raise the amount on and in the skin to 120%. 
On the second day 20% of these 120% (i.e. 24%) would remain in the 
skin, which raises the dose on the third day to 124%. After around 5 
days a plateau of around 126% will be reached. The impact of 
uncertainty of daily dosing on consecutive days therefore is judged to 
be slightly larger than 20% in the direction of underestimation. 
Overall assessment: 
The main sources of uncertainty in the first-order rate constant (k) for 10% dermal absorption 
during 24 h resulting from the dermal exposure to BPA in thermal paper are (i) the extent of 
dermal absorption and (ii) the increased thickness of the Stratum corneum (SC) of the finger 
tips. The combined impact of both factors is judged to be within the range of 1/5–1/2 times 
the estimate (– –). Based on this proposed uncertainty range, the experts were asked to make 
their personal judgements. Five experts gave their personal view on that; some shifted the 
upper limit of the proposed uncertainty range to a higher value, others specified a somewhat 
different uncertainty range (Table 54). The differences among the experts’ individual 
judgements are covered by the uncertainty range of 1/5–2 times the estimate (– – / +). 
 
The main sources of uncertainty in the BPA depot in the moisture film on the skin surface 
(X/A) are (i) the potential saturation of BPA in the skin moisture film, (ii) the possibility of 
having wet or oily/greasy fingers, (iii) hand washing and desquamation, and (v) the 
replenishment of the skin surface depot. The combined impact of all factors is judged to be 
within the range of 1/2–2 times the estimate (– / +). This uncertainty is already covered by 
the uncertainty evaluation of external dermal exposure given in Appendix H in Part I-













the skin depot 
X/A: 
– / + 
 
Table 54:  Individual expert judgements of the uncertainty around the dermal absorption fraction 
of 0.1 (= 10%) relating to the dermal exposure to BPA in thermal paper. Each expert was 
asked to consider the proposed uncertainty range of 1/5–1/2 times the estimate (– –) and to 
make a personal judgement about the uncertainty range (See Figure 18 for key to symbols). 




The description of dermal absorption as a first-order process is an abstraction of 
the real process and includes simplifying assumptions. The upper uncertainty 
limit is therefore increased to equal the estimate of 10% dermal absorption. A 
further increase of the upper uncertainty limit to 2–5 times the estimate is 
regarded as overly conservative as it would generate a substantial disagreement in 
the internal exposure estimates as obtained by biomonitoring and forward 
exposure modelling. 
– – / ● 
2 
 
The study of Biedermann et al. (2010) on the transfer of BPA from thermal paper 
to the skin and the dermal penetration study of Demierre et al. (2011) suggest that 
~30% of the external dermal exposure may penetrate into the skin and may 
become available for subsequent systemic uptake. This should be covered to some 
extent by the uncertainty range. In addition, skin contact to ethanolic solutions  
may increase dermal uptake. Overall, the uncertainty around the dermal 
absorption fraction of 0.1 is assessed as –/+ (×1/2 – ×2). 
– / + 
3 The 10% dermal absorption is conservative and sufficient as an upper uncertainty 
limit. 
– – / ● 
4 From the controlled exposure study to BPA in thermal paper (Ehrlich et al., 
2014), it can be estimated that 0.112 µg/kg bw per day is excreted in urine above 
the background excretion level after handling thermal paper without gloves for 
2 hours (see Section 3.1.2.4). The forward exposure modelling (see Section 
4.5.3.3 in Part I-Exposure assessment) estimated the average external exposure to 
– / + 
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Expert Reasoning Uncertainty of 
the estimate 
be 0.06 µg/kg bw per day (= 3 fingers × 1.4 µg per finger × 1 occasion/day/70 kg) 
and the high external exposure to be 0.55 µg/kg bw per day (= 2×3 fingers [both 
hands] × 1.4 µg per finger × 4.6 occasions/day/70 kg). Assuming 10% dermal 
absorption, these external exposure estimates translate into internal exposures of 
0.006 µg/kg bw per day (average) and 0.055 µg/kg bw per day (high). The 
amount of 0.112 µg/kg/day (according to Ehrlich et al., 2014) is still 2-fold higher 
than the calculated internal high exposure. Thus, 10% dermal absorption is a 
rather plausible estimate without an extreme uncertainty. Overall, the uncertainty 
around the dermal absorption fraction of 0.1 is assessed as –/+ (×1/2 – ×2). 
5 Given the information and the stengths/weaknesses of the various studies, the 
estimate of 10% as central estimate for the dermal absorpion is realistic to 
conservative, but not over-conservative. However, one shows that 30% of the 
dermal load may be present in the skin. For this 30% the reloading 
(replenishment) principle is applicable, and has been addressed in the reloading / 
replenishing uncertainty discussion. Consequently, the impact of this depot and 
the reloading of it was quantified to be around 20–30% (under-estimation). 
Assuming that the dermal uptake can be 5 times higher than what we currently 
assume (i.e. a ++ score) is very conservative, taking into account that several 
other studies, among which the reliable study by Demiere et al. (2011), have 
measured less intensive absorption than the 10% that we already assume as 
central estimate. It seems that an upper limit for the dermal absorption factor of 
15–20% (i.e. 1.5 to 2 times as high as we have used) would be sufficient to cover 
the uncertainty in this parameter. For the lower bound, 5% absorption (i.e. 1/2 
times the estimate) seems a reasonable assumption. 
– / + 
 
(ii) Evaluation of uncertainties affecting the determination of Human-Equivalent Dose Factor 
(HEDF) for BPA 
Table 55 contains the evaluations of uncertainties affecting the determination of the average HEDF. 
The scale used to evaluate the impact of the source of uncertainty is shown in Figure 19. Plus symbols 
indicate the real value could be higher than the estimate, while minus symbols indicate the real value 
could be lower than the estimate. These evaluations are approximate expert judgements and should not 
be interpreted as precise estimates. 
 
Figure 19:  Scale used for evaluating the impact of uncertainties on estimates of total exposure to 
BPA.  
  
• + ++ +++ − − − − − − 
+/ - 20% x 1/2 x 1/5 2x 5x x 1/10 10x 
Real value  higher than estimate 
(under - estimation) 
Real value  lower than estimate 
(over - estimation) 
++++ − − − − 
>10x < x 1/10 
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Table 55:  Evaluation of uncertainties affecting the determination of the average Human-
Equivalent Dose Factors (HEDF = AUCAnimal/AUCHuman) for BPA. See Figure 19 here above  
for key to symbols. 
Source of uncertainty Variable affected Impact on the 
HEDF 
Analytical uncertainty for serum concentrations of unconjugated 
BPA (CBPA) above the LOD.  
Recovery: Not a problem since all studies used isotope-dilution mass 
spectrometry with recovery correction. Repeatability (CV): <20%. 
Accuracy: < ±20%. These percentages refer to the uncertainty in the 
measurement of CBPA at a single time point. A serum concentration-
time profile consists of 3–8 data points, so that the imprecision in the 
measurement of a single concentration value will average out when 
calculating the AUC. The overall impact of the analytical uncertainty 
on the AUC estimate is regarded to be within ±20%. 
AUCAnimal (nM×h) ● 
Contamination of serum samples.  
Not a problem since all studies used isotope-labelled (deuterated) 
BPA for administration. 
AUCAnimal (nM×h) none 
Inter-individual variability and uncertainties in experimental 
procedures and toxicokinetic analysis 
Variability in the experimental animals and in the dosing and 
sampling procedures results in a variability in the individual 
AUCAnimal values. An additional source of variability is the 
toxicokinetic analysis, which is based on the application of the 
trapezoidal area method to estimate the AUC for the observed serum 
concentration-time profile but which additionally includes the 
extrapolation to the AUC from zero time to infinity. For this 
extrapolation, the elimination rate constant and the last observed 
quantifiable CBPA are required, both of which are associated with 
uncertainties. All these sources of variability are covered by the 
reported standard deviation (SD) of AUCAnimal. Based on the 
estimates for the mean and the SD, and on the number of animals, a 
relative standard error (RSE) can be calculated as a measure of 
uncertainty around the mean AUCAnimal. RSE values of 34–37% can 
be derived for adult rats and monkeys with oral administration and 
for PND 77 monkeys with oral administration. In addition, RSE 
values of 4–21% can be derived for adult rats and monkeys with IV 
injection. Translating these RSE values into naive 95% confidence 
intervals (i.e. 1.96×RSE), and taking into account a log-normal 
distribution for the serum concentration values as a reasonable 
assumption, the true mean AUCAnimal value for given tested species is 
judged to be within the range of 0.5–2 times the estimated mean 
AUCAnimal. 
Experimental designs can incorporate sequential blood sampling from 
individual animals of sufficient body size and blood volumes (e.g., 
rats and monkeys) to calculate individual serum concentration-time 
profiles that are used to produce group mean PK parameters and 
reliable estimates of inter-animal variability. On the other hand, 
studies in small animals that have insufficient blood volumes for 
repeated withdrawals (e.g., mice), samples can only be collected from 
multiple animals at each time point to calculate an average serum 
concentration-time profile that is used to produce a single set of PK 
parameters. In this experimental design, no statistical analysis is 
possible except for Cmax and estimation of inter-animal variability in 
other PK parameters is not possible. An example for the latter case is 
the AUCAnimal for adult mice with oral administration. A detailed 
uncertainty discussion for this case is given in Section 3.1.6.1. 
AUCAnimal (nM×h) –/+ 
Uncertainty due the laboratory-specific bias AUCAnimal (nM×h) ● 
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Source of uncertainty Variable affected Impact on the 
HEDF 
The administration procedure can have a significant effect on the 
AUCAminal estimate. For HEDF determination, it is noted that the 
administration procedures in animal and human toxicokinetic studies 
should be comparable. The animal toxicokinetic studies of Doerge et 
al. (2010a/b, 2011a/b, 2012) used gastrointestinal bolus gavage with 
aqueous vehicle solutions, which permitted fast gastrointestinal 
absorption and excluded potential sources of variability associated 
with digestive processes. The obtained values for AUCAnimal (and 
AUCHuman, see below) are therefore internally consistent. There are no 
known or suspected sources of bias apart from those already 
mentioned (i.e. analytical uncertainty and contamination). If present, 
it would affect all the data in the same way. 
Uncertainty about the serum concentration-time course of 
unconjugated BPA as predicted by PBPK modelling 
The AUCHuman values for human adults and infants were obtained 
from PBPK modelling (Yang et al., 2013) by using a monkey-based 
PBPK model with bolus-gavage dosing (Fisher et al., 2011). The 
human PBPK model was evaluated against the results of a 
toxicokinetic study in humans with gelatine-capsule administration 
(Völkel, et al. 2002), which is consistent with the administration 
procedure used in the animal studies. A sensitivity analysis revealed 
the volume of the liver, the hepatic and small-intestine metabolism, 
and the oral uptake rate constant to be sensitive in predicting the 
unconjugated BPA concentration in serum. The impact of this 
uncertainty is judged within the range of 0.5–2 times the estimated 
mean AUCHuman. 
AUCHuman (nM×h) –/+ 
Overall assessment:  
The main sources of uncertainty in the determination of HEDF are (i) the variabilities in the 
experimental animals and in the dosing and sampling procedures, and (ii) the uncertainty 
about the serum concentration-time course of unconjugated BPA in humans as predicted by 
PBPK modelling (Fisher et al., 2011; Yang et al., 2013). These sources of uncertainty 
influence the AUCAminal and AUCHuman, which are ratioed to yield the HEDF. The overall 
uncertainty is judged to be within the range of 0.5–2 times the estimate. A specific case is the 
toxicokinetic study in adult mice with oral administration, for which a dedicated uncertainty 
assessment was performed (see Section 3.1.6.1).  
Multiplying the HEDF with the reference point of a toxicity study with oral administration 
re-raises the issue of uncertainty in the extrapolation to the human situation. The question of 
uncertainty is whether the type of oral administration in the toxicity study is comparable to 
the typical exposure situation in humans. The exposure of animals via dosed feed has been 
shown to lead to a serum concentration-time profile for unconjugated BPA which was 
different from that observed under oral-bolus dosing (Sieli et al., 2011); the AUC, however, 
was not affected. Since the typical exposure to BPA in humans is via dietary exposure, there 
is no reason to assume a large uncertainty when extrapolating from a toxicity study with 
dietary exposure to the human situation. 
–/+ 
(iii)  Additional results from the uncertainty analysis for aggregate exposure  
The main results of the uncertainty analysis for aggregate exposure is reported in Section 5.1.2. This 
section reports additional results from specific parts of that analysis. 
Parameters for PBPK modelling 
Table 56:  Parameter values for the male adult were taken from Mielke et al. (2011). Parameter 
values for the children were taken from Mielke and Gundert-Remy (2009). In the latter 
publication, the muscle and skin tissues were combined to a single muscle/skin compartment. 
Additional information from Edginton and Ritter (2009) was used for assigning organ 
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weights and blood flow rates to the muscle and skin compartments of the children. The values 
for the extent of absorption for the oral and dermal routes were those set in the present 
opinion. 
Parameter / Age group Children 
1.5–4.5 years 
Male adult 
Body weight (kg) 19 73 
Organ weights (g)   
Adipose tissue 5500 18200 
Liver 570 1800 
Brain 1310 1450 
Kidney 110 310 
Muscle 0.86×6170 29200 
Skin 0.14×6170 2708 
Other vessel-rich organs 1141 3768 
Skeleton 2090 9330 
Blood flow rates (l/h)   
Fat 9.7 19.5 
Brain 55.8 46.8 
Kidney 27.1 74.1 
Muscle 0.55×26.7 65.8 
Skin 0.45×26.7 20 
Other vessel-rich organs 29.8 56.5 
Skeleton 2.9 7.8 
Liver 52 99.5 







Other vessel-rich organs 1.43 
Skeleton 0.5 
Metabolic parameters  
Glucuronidation Km (µM) 8.5 
Glucuronidation Vmax (nmol min–1 g liver–1) 54.9 
Sulfation = 0.08 × Vmax / Km 0.08 × 54.9 / 8.5 
Absorption half-life (h)  
Oral route 0.25 
Dermal route (Thermal paper) 158 
Extent of absorption (fraction of the dose)  
Oral route 
Dermal route (Thermal paper) 
1.0 
0.1 
Dermal route (Cosmetics) 0.5 
 
 
Uncertainty in PBPK modelling 
The PBPK model of Mielke et al. (2011), hereinafter called the Mielke/Gundert-Remy model, was 
used to convert an external dermal exposure into an equivalent oral exposure (see Section 3.1.7.3). 
The use of the Mielke/Gundert-Remy model introduced an uncertainty, because the PBPK model of 
Fisher et al. (2011) was selected as the model of first choice for deriving the HED (see Section 
3.1.3.4). The structure of both models is described in the Sections 3.1.3.1 and 3.1.7.3. In the following, 
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the functional differences of both models are described and the overall impact of these differences on 
the dermal-to-oral route equivalence factor (EFDO) is quantified. 
Whereas intrinsic liver clearance in both models is similar, a difference exists in the implementation of 
the first-pass metabolism. This leads to different systemic availabilities of BPA following oral 
exposure. In the Fisher model the first pass takes place in the gut wall and in the liver, which reduces 
the systemic availability of unconjugated parent compound to about 1.3 % of the oral dose. The 
Mielke/Gundert-Remy-Modell contains only the hepatic first pass, because the intestinal metabolism 
was considered to be so small to be negligible, being less than 10% of the liver clearance according to 
the in vitro data of Trdan Lušin et al. (2012). Compared to the Fisher model, the Mielke/Gundert-
Remy model predicts a higher systemic availability of about 10 %. More precisely, for a defined oral 
exposure, the Mielke/Gundert-Remy model predicts an area under the curve (AUC) for the serum 
concentration of unconjugated BPA which is 8.1-fold higher than the AUC predicted by the Fisher 
model (Yang et al., 2013, and calculation by the experts using the Mielke/Gundert-Remy model). 
Accordingly, AUCoral.MGR / AUCoral.F = 8.1. 
For the dermal exposure, the magnitude of the AUC depends on how much of the dermal dose is 
assumed to penetrate the skin and to enter the blood. The present opinion assumed 10 % dermal 
absorption for the exposure to BPA in thermal paper and 50 % dermal absorption for the exposure to 
BPA in cosmetics. For a dermal absorption fraction being equal in both PBPK models, the AUC 
predicted by the Fisher model is slightly lower (by a factor of 0.94) than AUC predicted by the 
Mielke/Gundert-Remy model (the value of 0.94 is the ratio of the intrinsic liver clearances of the two 
models). Accordingly, AUCdermal.F / AUCdermal.MGR = 0.94. 
Having quantified the model differences in the internal dose metric (AUC) for defined oral and dermal 
exposures, it becomes possible to evaluate the model uncertainty in the dermal-to-oral route 
equivalence factor (EFDO) which was used to convert an external dermal exposure into an equivalent 
oral exposure (see Section 3.1.7.3). EFDO values were calculated by using the Mielke/Gundert-Remy 
model (see Section 3.1.7.3). Using the Fisher model instead of the Mielke/Gundert-Remy model 
would have resulted in 7.6-fold higher EFDO values. This difference arises from the fact that (i) the 
AUC for oral exposure is considerably higher in the Mielke/Gundert-Remy model than in the Fisher 
model and that (ii) the AUC for dermal exposure is only slightly higher in the Mielke/Gundert-Remy 
model than in the Fisher model: 
(AUCdermal.F / AUCdermal.MGR) × (AUCoral.MGR / AUCoral.F) = 0.94 × 8.1 ≈ 7.6 
 
Uncertainty regarding the relative contribution of different sources to aggregate exposure 
Estimates of aggregated exposure were presented graphically in Figure 16 (Section 5.1.2). The 
numerical results are shown in Table 57.  
 
Table 57:  Evaluation of uncertainties affecting assessment of aggregate equivalent oral exposure 
for females aged 18-45. Based on estimates for individual sources of exposure from Table 24 
in the Section 5.1.1).  
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The importance of the uncertainty regarding the exposure from thermal paper and the choice of the 
PBPK model is apparent from the results and discussion in Section 5.1.2. This is further emphasised 
when the contributions of the main sources of exposure are expressed as a percentage of the aggregate, 
shown in Figure 20. Average exposures were expressed as  a percentage of the aggregate of averages 
(Aggregate 1), and high exposures as a percentage of the aggregate of high exposures (Aggregate 4). 
Upper bound estimates were calculated by substituting the upper bound for the source of interest into 
both the numerator and denominator when calculating its percentage contribution. Figure 20 shows 
that the contribution from cosmetics tends to be small either with or without the factor of about 7.6 for 
model uncertainty, whereas this factor is critical in determining the relative contributions of the dietary 
exposure and thermal paper. The dietary route is important if the Mielke/Gundert-Remy model is more 
realistic, but less important if the Fisher model is more realistic. If the high estimates for thermal paper 
prove realistic, however, this source will then dominate under either model.       
AGGREGATE EXPOSURES:
Average Dietary + Average Non-Dietary
Estimate with Mielke PBPK model (μg/kg bw per day) 0.22
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.068  - 0.99
Estimate with Mielke model + model uncertainty factor (μg/kg bw per day) 0.76
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.08  - 6.4
High Dietary + Average Non-Dietary
Estimate with Mielke PBPK model (μg/kg bw per day) 0.47
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.20  - 1.3
Estimate with Mielke model + model uncertainty factor (μg/kg bw per day) 1.0
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.21  - 6.7
Average Dietary + High Non-Dietary
Estimate with Mielke PBPK model (μg/kg bw per day) 0.81
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.093  - 6.9
Estimate with Mielke model + model uncertainty factor (μg/kg bw per day) 5.3
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.27  - 51
High Dietary + High Non-Dietary
Estimate with Mielke PBPK model (μg/kg bw per day) 1.1
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.22  - 7.2
Estimate with Mielke model + model uncertainty factor (μg/kg bw per day) 5.5
 -   range based on uncertainties for each route of exposure (μg/kg bw per day) 0.40  - 52
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Figure 20:   Relative contribution of the main sources of exposure to BPA for females aged 18-
45, expressed as a percentage of aggregate equivalent oral exposure. Average exposures were 
expressed as  a percentage of the aggregate of averages (Aggregate 1), with and without 
inclusion of the PBPK model uncertainty factor. High exposures were expressed as a 
percentage of the aggregate of high exposures (Aggregate 4).  Dashed lines show approximate 
uncertainty ranges for each estimate. 
 
Additional uncertainties affecting the assessment 
Section 5.1.2 brings together qualitative and quantitative evaluations of uncertainty in all parts of the 
aggregate exposure assessment, and quantitatively examines their impact on risk characterisation (a 
form of sensitivity analysis). Uncertainties in the hazard assessment were taken into account 
quantitatively in deriving the t-TDI.  However, it is also important to consider, at least qualitatively, 
the potential impact of other uncertainties that have not been included in the quantitative evaluations 
(EFSA, 2006, 2009). Additional uncertainties identified by the CEF Panel in this case are summarised 
and evaluated in Table 58.  
Overall, the CEF Panel concludes that these additional uncertainties are smaller than those examined 
in the quantitative uncertainty analysis and are not sufficiently large to alter the main conclusion, 
which is that most uncertainty is associated with assessing exposure from thermal paper. 
Table 58:  Qualitative evaluation of additional uncertainties affecting the assessment. 
Source of uncertainty Evaluation of impact 
Uncertainty within the Fisher PBPK model 
(separate from the difference between it and the 
Mielke/Gundert-Remy model) 
May cause over or underestimation of the AUC by a 
factor of 2. Limited overall impact because it would 
affect the exposure and hazard assessments in 
opposite ways and hence tend to cancel out.  
Uncertainty in extrapolating the Mielke/Gundert-
Remy model, calibrated for adult males, to other age 
groups 
May cause over or underestimation of the AUC by a 
factor of 2. This will have a minor influence on the 
results, compared to the difference between the 
Fisher and Mielke/Gundert-Remy models (a factor 
0% 20% 40% 60% 80% 100%







FEMALES AGED 18-45Key: circles = without model uncertainty factor; 
triangles = with model uncertainty factor
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of 7.6). 
Human equivalent oral dose factor (HEDF) used in 
setting the t-TDI.  
Assessed in Section 3.1.6.1 as –/++ for oral studies 
with adult mice and in Appendix D II as +/- for all 
other studies. This is not expected to cause large 
uncertainty in the human toxicity assessment 
(Appendix D). 
Dependencies between the uncertainties analysed 
quantitatively  
Difficult to assess qualitatively, but unlikely to 
change the conclusion that uncertainty in exposure 
and risk characterisation is dominated by the dermal 
route. 
The inhalation and dust absorption fractions were 
both assumed to be 1.  
The true fractions will be lower, by an uncertain 
amount. However this will have little impact 
because the contributions of these sources are very 
minor. 
Absorption fraction of 1 assumed for dietary 
exposure. 
1 is an upper bound. The true value is expected to be 
between 0.8 and 1 
Using full range of uncertainty scale intervals when 
converting to numerical ranges 
Will overstate assessors’ judgement of uncertainty 
to varying degrees, but within the same interval on 
the uncertainty scale. 
Assessment of aggregate exposure by examining 
different combinations of average and high 
exposures.  
Combining average and high exposures is unlikely 
to cause underestimation of the 95th percentile 
overall, since using only high estimates causes little 
increase in the total.   
Evaluation of uncertainty of aggregate exposure by 
combining upper bounds of all sources of exposure 
to give aggregate upper bound, and lower bounds of 
all sources to give aggregate lower bound. 
Will over-estimate the uncertainty of the aggregate 
exposure estimates, possibly by a substantial 
amount. This will exaggerate the degree by which 
the upper bounds exceed the t-TDI. However, this 
will not change the CEF Panel’s main conclusions 
regarding the uncertainty of the risk 
characterisation, since the central estimates with and 
without model uncertainty (excluding other 
uncertainties) already span the t-TDI for Aggregate 
3 (Figure 16), and most of the overall uncertainty 
derives from only two sources (estimation of 
thermal paper exposure and PBPK model 
uncertainty).  
The evaluations used for some uncertainties were 
considered in less detail than others. 
 
The effect of this is likely to be small compared to 
the large uncertainties in estimating thermal paper 
exposure. The uncertainty ranges for average 
exposures may be somewhat over-estimated, since 
some were assumed to be similar to those for high 
exposure, which would generally be more uncertain. 
Exposure from inhalation is excluded from the 
estimates of aggregate exposure. 
Average and high exposure from inhalation are both 
negligible compared to other sources, even when 
uncertainties affecting that route (- -/+) are taken 
into account. 
 
(iv) Uncertainty analysis of hazard characterisation for the mammary gland, and the 
reproductive, neurobehavioural, immune and metabolic systems 
For the reasons outlined in section 3.2.6, the CEF Panel used the HED of the BMDL for increased  
relative kidney weight in mice as the reference point for establishing a TDI. In setting the TDI, the 
CEF Panel assessed whether an extra factor (besides the uncertainty factors to account for inter- and 
intra-species differences) should be included to account for the uncertainty in the database concerning 
the mammary gland, and the reproductive, neurobehavioural, immune and metabolic systems. 
According to the outcome of the WoE evaluation, an association between BPA and these hazards was 
considered “as likely as not”– with the exception of proliferative changes in mammary gland and 
immunotoxicity, which were assessed respectively as “likely” or “-as likely as not- to likely”. The  
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CEF Panel considered that the uncertainty about these effects contributes to uncertainty around in the 
hazard characterisation for BPA. For each effect a specific set of endpoints and criteria were used for 
inclusion of animal studies in the uncertainty analysis which were as follows: 
 
• Proliferative changes in the mammary gland: all studies – both before and after 2010, 
addressing effects on ductal hyperplasia (including terminal end buds and ductal area), 
intraductal hyperplasia and epithelial cell proliferation. 
• Reproductive and developmental toxicity: all publications (new and pre-2010 studies) 
addressing effects on endometrial hyperplasia, ovarian cysts and anogenital distance (AGD) at 
levels below the HED of 3.6 mg/kg bw per day. These endpoints were selected because other 
evaluations regarded these as critical endpoints. 
• Neurobehavioural effects: all studies published after 2010 which contribute more than 
negligibly to the WoE. 
• Immunotoxicity: all animal studies published after 2010. 
• Metabolic effects: all publications addressing effects on glucose and insulin published after 
2010, for which parameters there were clearly indications of effects in in vitro studies. 
The WoE evaluation (Appendix C) allowed an estimation of the overall likelihood that BPA is 
hazardous with respect to certain toxicological endpoints in animal studies, considering the findings 
for all of the dose levels tested (with the exception of reproductive effects for which a cut-off dose 
level was taken as a study inclusion criterion). However, to assess whether an extra UF (and its 
magnitude) in the health-based guidance value would be appropriate to account for uncertainties in the 
database, the following were considered: (i) the likelihood that BPA exposure is associated with a 
certain outcome in animals at particular dose intervals (and especially at doses below the HED for the 
increase in relative mean kidney weight), (ii) the relevance of this effect to humans and (iii) its 
adversity in humans, if it occurs.  
The CEF Panel approached the evaluation of uncertainty in three stages. In the first stage, it carried 
out the following steps for each of the selected types of effect in turn, to assess the likelihood that BPA 
might affect a certain endpoint in animals at each dose interval. 
1. The experts reviewed the studies previously considered in the WoE assessment (see bulleted 
list above). 
2. The experts extracted key information from each study and collated this in a graphical format 
(Section 4.3.2). The graphs summarise, for each study, the life stage of the animals at 
treatment onset, duration of treatment and sampling time for measurements, the doses tested, 
whether there was a statistically significant effect at any dose.  They also show the number of 
strengths and weaknesses of the study, as assessed in the WoE assessment but excluding any 
strengths or weaknesses that did not apply to the effect of interest. In addition, they show the 
CEF Panel’s evaluation of the reliability of the study and its relevance to the effect of interest, 
taking into account all the preceding information. When assessing reliability and relevance, 
the strengths and weaknesses were not weighted equally but according to the CEF Panel’s 
evaluation of their relative importance. 
3. In order to allow studies for different species using different routes of exposure to be plotted 
on the same dose scale scale, as well as on the same scale as the reference dose for the 
increase in relative kidney weight – all doses were converted to HED. 
4. An expert elicitation procedure21 was conducted to ensure that all the experts were familiar 
with making probabilistic judgements before they were engaged in assessing likelihoods for 
the endpoint of interest. Experts used a defined scale of likelihood categories (Table 59), 
based on a similar table used by the Intergovernmental Panel on Climate Change (Mastrandrea 
                                                     
21 A simplified expert elicitation process was performed, based on the procedure described in the EFSA (2014) guidance 
document.  
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et al, 2010). Experts were offered the option to use more than one category if they wished to 
express a broader range of likelihoods, or to respond with a question mark (‘?’) if they felt 
unable to give any estimate.   
Table 59:  Terms and abbreviations used to express likelihood in the uncertainty evaluation for 
hazard characterisation (from Mastrandrea et al. 2010). 
Virtually certain (VC) 99 - 100% probability 
Very likely (VL) 90 - 100% probability 
Likely (L) 66 - 100% probability 
As likely as not (ALAN) 33 to 66% probability 
Unlikely (U) 0 - 33% probability 
Very unlikely (VU) 0 - 10% probability 
Exceptionally unlikely (EU) 0 - 1% probability 
 
The experts were then asked to review the graphical summary of studies (e.g. Figure 10) and assess 
the likelihood that BPA has the inherent ability to cause effects in each logarithmic interval of the dose 
scale (expressed as HED), which is indicated at the bottom of the graph, for one or more combinations 
of the animal species tested, exposure period and measurement time. For neurobehavioural endpoints, 
the experts considered it necessary to assess likelihoods separately for males and females, otherwise 
both sexes were considered together. The participants did not assume that likelihoods necessarily 
increase with increasing dose, but rather assessed the likelihood in each dose interval based on the 
evidence shown for that interval, taking account also of evidence in the adjacent dose intervals if they 
considered that appropriate. After discussion of the methodology with the CEF Panel, it was decided 
to only assess likelihoods for dose intervals within the range of the studies considered. 
The assessment was conducted in three rounds. In the first round, each WG member made his 
assessment of the likelihoods. These were collectively displayed in a table, and discussed, focussing 
mainly on dose intervals where the differences between estimates were largest, and the reasoning for 
the estimates. In a second round, members were asked to review their individual assessments of the 
likelihoods in the light of the discussion. The second round estimates were again collected and the 
highest and lowest estimates in each dose interval were combined to form a provisional range, 
expressing the variation of estimates within the group. In a third round, these ranges were discussed, 
and adjusted if appropriate to represent the range of opinion in the group. The final ranges were added 
to the graph for each endpoint, where they are shown below the dose scale on the horizontal axis (e.g. 
Figure 10). 
The steps described above were carried our separately for all of the 5 effects being considered.  
In the next stage of the uncertainty evaluation, the experts met to assess the relevance of each effect to 
humans, and its adversity in humans, if it occurs. This stage was carried out for all 5 effects together. 
For each effect, a list of evidence and reasoning relevant to assessing its human relevance, and a 
second list for adversity: evidence for and against, and sources of uncertainty, had been prepared in 
advance and discussed and amended, if needed, at the meeting. Participants took note of the EFSA 
Scientific Committee’s definition22 of biological relevance (EFSA, 2011). The experts then made 
judgements about the likelihood of relevance and adversity for each effect using the same scale of 
likelihood terms as before (Table 59). The likelihoods were conditional, i.e. the likelihood of each 
effect being relevant in humans if it occurred in animals, and the likelihood of each effect being 
adverse in humans, if it occurred in humans. The experts expressed their judgements. The judgements 
                                                     
22The Scientific Committee definition is: ‘A biologically relevant effect can be defined as an effect considered by expert 
judgement as important and meaningful for human, animal, plant or environmental health. It therefore implies a change 
that may alter how decisions for a specific problem are taken.’ It was noted that ‘important and meaningful’ could 
considered in the judgements made in this Opinion about adversity, while the judgements about human relevance refer to 
occurrence in humans, rather than importance. 
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were elicited in two rounds. In the first round, individuals judgements were collected and displayed on 
screen for discussion by the group, focussing especially on the judgements where the likelihoods 
differed most between experts. In the second round, the experts again made individual judgements, 
which were collected and a summary was produced, in which the range of individual likelihoods was 
assigned to each judgement. The results of all these assessments are presented in Tables 60-75.  
The final stage of the uncertainty evaluation was conducted in the same meeting as the preceding 
stage. The experts were asked to make judgements about the overall likelihood, in each HED dose 
interval, that BPA has the inherent ability to cause one or more type of effect in animals and that it is 
relevant and adverse in humans, based on the group summaries of the judgements that had been made 
in the earlier stages of the assessment (summarised in Table 18). The overall assessment was 
considered by, first, considering how the likelihoods of causation, human relevance and adversity 
combine for each effect separately and, second, combining likelihood across effects in each dose 
interval. The judgements were then summarised into a range of likelihoods for each dose interval, 
spanning the range of those expressed by individual experts. The experts then discussed which dose 
levels would need to be covered by an uncertainty factor, taking account of the group’s conclusions 
regarding the likelihood of BPA having the inherent ability to cause human-relevant adverse effects in 
each dose interval. This led to further discussion, in which account was taken of the range of 
individual likelihood judgements in each dose interval and their associated probabilities (based on 
table 59). A final vote was then taken, which showed unanimous agreement on the final conclusion 
(see Section 4.3.2).  
INDIVIDUAL and GROUP ASSESSMENT of the LIKELIHOODS FOR DIFFERENT 
EFFECTS IN ANIMALS 
 
Reproductive effects  
 
The precise question to consider for each dose interval is as follows:  
“What is the likelihood that BPA has the capability to cause reproductive effects (of one or more of 
the types listed in the summary graph) in this dose interval, for one or more combinations of the 
animal species tested, exposure period and measurement time. In other words, if large, well-conducted 
experiments were done for the same species with a range of combinations of exposure period and 
time, what is the likelihood that one or more of the types of reproductive effect listed in the summary 
graph would be found in this dose interval?” 
Table 60:  First round estimates of the likelihood that BPA has the capability to cause 
reproductive effects (of one or more of the types listed in the summary graphic) in each dose 
interval, for one or more combinations of the animal species tested, exposure period and 
measurement time.  
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10-1-100 100-101 101-102 102-103 103-104 104-105 105-106 
Expert 1 VU VU VU ALAN ALAN L L L 
Expert 2 VU VU VU U U U U L 
Expert 3 U U U ALAN ALAN ALAN ALAN L 
Expert 4 U VU VU ALAN ALAN ALAN ALAN L 
Expert 5 U VU VU U U to 
ALAN 
ALAN ALAN  ALAN 
Expert 6 U U U U ALAN ALAN ALAN L 
Expert 7 VU VU VU VU ALAN ALAN L VL 
Expert 8 U U U ALAN ALAN ALAN ALAN L 
Expert 9 VU VU VU VU VU VU VU VL 
Table 61:  Second round estimates and group assessment (bottom two rows) of the likelihood 
that BPA has the capability to cause reproductive effects (of one or more of the types listed in 
the summary graphic) in each dose interval, for one or more combinations of the animal 
species tested, exposure period and measurement time.  
Dose interval 
(μg BPA/kg 







101-102 102-103 103-104 104-105 105-106 
Expert 1 VU VU VU ALAN ALAN ALAN L L 
Expert 2 VU VU VU U U U U L 
Expert 3 U U U ALAN ALAN ALAN ALAN L 
Expert 4 VU VU VU U ALAN ALAN ALAN L 
Expert 5 U VU VU U U to ALAN ALAN ALAN to 
U 
L 
Expert 6 U U U U ALAN ALAN ALAN L 
Expert 7 VU VU VU VU U to ALAN ALAN L VL 
Expert 8 U U U ALAN ALAN ALAN ALAN L 
Expert 9 VU VU VU VU VU VU VU VL 
Group 
evaluation 




The precise question to consider for each dose interval is as follows:  
“What is the likelihood that BPA causes neurobehavioural effects (of one or more of the types listed in 
the summary graph) in this dose interval, for one or more combinations of animal species that were 
tested, exposure period and measurement time?. In other words, if large, well-conducted experiments 
were done with a wide range of combinations of species, exposure periods and time, what is the 
likelihood that one or more of the types of neurobehavioural effect listed in the summary graph would 
be found in this dose interval?” 
 
Table 62:  First round estimates of the likelihood that BPA has the capability to cause 
neurobehavioural effects (of one or more of the types listed in the summary graphic) in each 
dose interval, for one or more combinations of animal species, exposure period and 





10-3-10-2 10-2-10-1 10-1-100 100-101 101-102 102-103 103-104 104-105 
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Expert 1 U? U? U ALAN ALAN ALAN L? VL 
Expert 2 U? U? ALAN ALAN L L L? VL? 
Expert 3 VU VU VU U U U U-ALAN  
Expert 4 EU EU U ALAN ALAN ALAN L  
Expert 5 VU U U ALAN ALAN-L ALAN-L ALAN-L  
Expert 6 VU U ALAN ALAN L L L VL? 
Expert 7 U ALAN ALAN ALAN ALAN ALAN ALAN-L U? 
 
Table 63:  Second round estimates and group assessment (bottom two rows) of the likelihood 
that BPA has the capability to cause neurobehavioural effects (of one or more of the types 
listed in the summary graphic) in each dose interval, for one or more combinations of animal 





10-3-10-2 10-2-10-1 10-1-100 100-101 101-102 102-103 103-104 104-105 
Expert 1 VU VU U ALAN ALAN ALAN L VL 
Expert 2 VU VU ALAN ALAN L L L VL 
Expert 3 VU VU VU U U/ALAN U/ALAN ALAN  
Expert 4 VU VU U ALAN ALAN ALAN L  
Expert 5 VU VU- U ALAN ALAN-L ALAN-L ALAN-L  
Expert 6 VU VU U ALAN ALAN ALAN L  
Expert 7 U U-
ALAN 





ALAN ALAN ALAN ALAN-L  
 
  
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 594 
Table 64:  First round estimates of the likelihood that BPA has the capability to cause 
neurobehavioural effects (of one or more of the types listed in the summary graphic) in each 
dose interval, for one or more combinations of animal species, exposure period and 





10-3-10-2 10-2-10-1 10-1-100 100-101 101-102 102-103 103-104 104-105 
Expert 1 U? 
 
U? U ALAN ALAN ALAN ALAN VL 
Expert 2 U? U? U U U ALAN L VL? 
Expert 3 VU VU VU VU U U U  
Expert 4 EU EU U U ALAN ALAN U  
Expert 5 VU U U U ALAN ALAN ALAN  
Expert 6 VU U ALAN ALAN L L L?  
Expert 7 U U ALAN ALAN ALAN ALAN U?  
Table 65:  Second round estimates and group assessment (bottom two rows) of the likelihood 
that BPA has the capability to cause neurobehavioural effects (of one or more of the types 
listed in the summary graphic) in each dose interval, for one or more combinations of animal 





10-3-10-2 10-2-10-1 10-1-100 100-101 101-102 102-103 103-104 104-105 
Expert 1 VU VU U ALAN ALAN ALAN ALAN VL 
Expert 2 VU VU U U U ALAN L VL 
Expert 3 VU VU VU VU U U U  
Expert 4 VU VU U U ALAN ALAN U  
Expert 5 VU VU U U ALAN ALAN ALAN  
Expert 6 VU VU U U ALAN ALAN L?  
Expert 7 U U U-ALAN ALAN ALAN ALAN U?  
Group 
evaluation 
VU-U VU-U U U U-ALAN ALAN U-L  
 
Immune effects  
 
The precise question to consider for each dose interval is as follows:  
“What is the likelihood that BPA has the capability to cause immune effects (of one or more of the 
types listed in the summary graph) in this dose interval, for one or more combinations of the animal 
species tested, exposure period and measurement time. In other words, if large, well-conducted 
experiments were done for the same species with a range of combinations of exposure period and 
time, what is the likelihood that one or more of the types of immune effect listed in the summary graph 
would be found in this dose interval?” 
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Table 66:  First round estimates of the likelihood that BPA has the capability to cause immune 
effects (of one or more of the types listed in the summary graphic) in each dose interval, for 
one or more combinations of the animal species tested, exposure period and measurement 
time. 
Dose interval 
(μg BPA/kg bw 
per day) 
10-2-10-1 10-1-100 100-101 101-102 102-103 103-104 104-105 
Expert 1 VU VU ALAN U L ? ALAN 
Expert 2 VU VU ALAN ALAN L ? ALAN 
Expert 3 VU-to U VU-to U ALAN ALAN to L ALAN ALAN ALAN 
Expert 4 U U ALAN to L L L ALAN to L ALAN to L 
Expert 5 VU VU ALAN ALAN L L L 
Expert 6 U U ALAN ALAN ALAN ? ALAN to L 




ALAN to L ? ALAN 
Expert 8 VU VU ALAN ALAN to L ALAN to L ? ALAN to L 
Expert 9 EU EU VU VU VU ? U to 
ALAN 
Expert 10 U U ALAN ALAN to L ALAN to L ? ? 
Expert 11 U U ALAN ALAN ALAN ? ALAN 
Expert 12 ALAN ALAN ALAN ALAN ALAN ? ALAN 
Expert 13 VU VU ALAN ALAN L ?/L L 
 
Table 67:  Second round estimates and group assessment (bottom two rows) of the likelihood 
that BPA has the capability to cause immune effects in each dose interval, for one or more 
combinations of the animal species tested, exposure period and measurement time. 
Dose interval 
(μg BPA/kg 
bw per day) 
10-2-10-1 10-1-100 100-101 101-102 102-103 103-104 104-105 
Expert 1 VU VU ALAN U L ? ALAN 
Expert 2 VU VU ALAN ALAN L ? ALAN 
Expert 3 VU to U VU to U ALAN ALAN  ALAN to 
L 
? ALAN 




Expert 5 VU VU ALAN ALAN L L L 
Expert 6 VU VU ALAN ALAN ALAN ? ALAN to 
L 
Expert 7 VU VU U to 
ALAN  
ALAN ALAN to 
L 
? ALAN 




? ALAN to 
L 
Expert 9 VU VU U U U ? U to 
ALAN 








Expert 11 U U ALAN ALAN ALAN ALAN ALAN 
Expert 12 U U ALAN ALAN ALAN ? ALAN 
Expert 13 VU VU ALAN ALAN L ALAN ALAN 
Group 
evaluation 
VU to U VU to U U to 
ALAN 
U to L U to L U to L U to L 
 
Metabolic effects  
The precise question to consider for each dose interval is as follows:  
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“What is the likelihood that BPA has the capability to cause metabolic effects (of one or more of the 
types listed in the summary graph) in this dose interval, for one or more combinations of animal 
species, exposure period and measurement time. In other words, if large, well-conducted experiments 
were done for the same species with a range of combinations of exposure period and time, what is the 
likelihood that one or more of the types of metabolic effect listed in the summary graph would be 
found in this dose interval?” 
Table 68:  First round estimates of the likelihood that BPA has the capability to cause metabolic 
effects (of one or more of the types listed in the summary graphic) in each dose interval, for 


















101-102 102-103 103-104 104-105 105-106 
Expert 1 U U U U U ALAN ALAN L ALAN U 
Expert 2 VU U U U U U U U U U 
Expert 3 VU VU VU VU VU VU VU VU VU VU 
Expert 4 VU U U U U U U to 
ALAN 
ALAN ALAN ALAN 
Expert 5 U U U ALAN U ALAN ALAN U to 
ALAN 
L ALAN 
Expert 6 VU VU U U U U U U ALAN ALAN 
Expert 7 U U U U U ALAN ALAN ALAN L L 






















Table 69:  Second round estimates and group assessment (bottom two rows) of the likelihood 
that BPA has the capability to cause metabolic effects (of one or more of the types listed in 
the summary graphic) in each dose interval, for one or more combinations of the animal 
species tested, exposure period and measurement time.  
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101-102 102-103 103-104 104-105 105-106 









Expert 2 VU U U U U U U U U U 
Expert 3 VU VU VU VU VU VU VU VU U U 
Expert 4 VU U U U U U U to 
ALAN 
ALAN ALAN ALAN 





Expert 6 VU U U U U U U U ALAN ALAN 
















































VU to L VU to 
L 
 
Proliferative changes in mammary gland 
The precise question to consider for each dose interval is as follows:  
 “What is the likelihood that BPA has the capability to cause proliferative changes in mammary gland 
(of one or more of the types listed in the summary graph) in this dose interval, for one or more 
combinations of animal species, exposure period and measurement time. In other words, if large, well-
conducted experiments were done for the same species with a range of combinations of exposure 
period and time, what is the likelihood that one or more of the types of proliferative changes in 
mammary gland listed in the summary graph would be found in this dose interval?”  
 
Table 70:  First round estimates of the likelihood that BPA has the capability to cause 
proliferative changes in mammary gland (of one or more of the types listed in the summary 
graphic) in each dose interval, for one or more combinations of the animal species tested, 
exposure period and measurement time.  
Dose interval (μg 
BPA/kg bw per 
day) 
<10-1 10-1-100 100-101 101-102 102-103 103-104 104-105 105-106 
Expert 1 U U U U ALAN ALAN L L 
Expert 2 VU U U U ALAN ALAN L L 
Expert 3 VU U ALAN ALAN L L L L 
Expert 4 VU U ALAN ALAN L L L L 
Expert 5 VU U ALAN ALAN L L U U 
Expert 6 VU U U U ALAN ALAN ALAN ALAN 
 
Table 71:  Second round estimates and group assessment (bottom two rows) of the likelihood 
that BPA has the capability to cause proliferative changes in mammary gland (of one or more 
of the types listed in the summary graphic) in each dose interval, for one or more 
combinations of the animal species tested, exposure period and measurement time.  
Dose interval (μg <10-1 10-1- 100-101 101-102 102-103 103-104 104-105 105-106 
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BPA/kg bw per 
day) 
100 
Expert 1 VU VU U U ALAN ALAN ALAN ALAN 
Expert 2 VU VU U U ALAN ALAN ALAN ALAN 
Expert 3 VU U ALAN ALAN L L L L 
Expert 4 VU U ALAN ALAN L L ALAN ALAN 
Expert 5 VU U ALAN ALAN L L ALAN ALAN 
Expert 6 VU U U U ALAN ALAN ALAN ALAN 
Overall group 
assessment 
VU VU U/ALAN U/ALAN ALAN/L ALAN/L ALAN/L ALAN/L 
 
Table 72:  Summary of second round group assessments of the likelihood that BPA has the 
capability to cause each of the effects considered in the uncertainty analysis, in each dose 
interval, for one or more combinations of the animal species tested, exposure period and 
measurement (compiled from the bottom rows of Tables 60, 62, 64, 66, 68 and 70 
ENDPOINT 
BPA DOSE INTERVALS Human equivalent dose (HED) 
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Relevance of effects to humans 
The precise question considered for each effect is as follows:  
 “What is the likelihood of this effect being relevant in humans, if it occurred in animals?”  
 
Table 73:  First round estimates of the likelihood of each effect being relevant in humans, if it 
occurred in animals. 











Expert 1 ALAN ALAN ALAN U TO ALAN U TO ALAN 
Expert 2 ALAN TO L ALAN ALAN ALAN U 
Expert 3 L ALAN TO L ALAN TO L ALAN ALAN 
Expert 4 L L ALAN ALAN TO L ALAN 
Expert 5 L L ALAN TO L L U TO ALAN 
Expert 6 ALAN ALAN TO L ALAN TO L ALAN TO L ALAN TO L 
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Expert 7 VL VL VL VL ALAN 
Expert 8 L L L L ALAN 
Expert 9 L L ALAN L ALAN 
Expert 10 L ALAN ALAN U TO ALAN U TO ALAN 
 
Table 74:  Second round estimates of the likelihood of each effect being relevant in humans, if it 
occurred in animals. The overall range of the individual estimates is shown in the bottom 
row.  










ural effects  
Expert 1 ALAN TO L ALAN TO L ALAN TO L U TO ALAN U TO ALAN 
Expert 2 ALAN TO L ALAN ALAN ALAN U 
Expert 3 L ALAN TO L ALAN TO L ALAN TO L ALAN TO L 
Expert 4 L L ALAN ALAN TO L ALAN 
Expert 5 L L ALAN TO L L U TO ALAN 
Expert 6 ALAN TO L ALAN TO L ALAN TO L ALAN TO L ALAN TO L 
Expert 7 L L L ALAN TO L ALAN 
Expert 8 L L L L ALAN 
Expert 9 L L ALAN L ALAN 
Expert 10 L ALAN ALAN U TO ALAN U TO ALAN 
Range ALAN - L ALAN - L ALAN - L U - L U - L 
 
Adversity of effects in humans 
The precise question considered for each effect is as follows:  
Table 75:   “What is the likelihood of this effect being adverse in humans, if it occurred in 
humans?” First round estimates of the likelihood of each effect being adverse in humans, if it 
occurred in humans.  











Expert 1 U TO ALAN ALAN ALAN ALAN U TO ALAN 
Expert 2 L ALAN ALAN ALAN U TO ALAN 
Expert 3 L L L L ALAN TO L 
Expert 4 L L ALAN ALAN TO L ALAN 
Expert 5 L L ALAN TO L ALAN ALAN 
Expert 6 ALAN L ALAN ALAN ALAN 
Expert 7 ALAN L U TO L ALAN U TO ALAN 
Expert 8 L L L L ALAN 
Expert 9 L L ALAN ALAN TO L ? 
Expert 10 VL VL ALAN TO L ALAN TO L ALAN 
 
Table 76:  Second round estimates of the likelihood of each effect being adverse in humans, if it 
occurred in humans. The overall range of the individual estimates is shown in the bottom 
row.  
Expert Mammary Effects on Metabolic Effects on Neurobehaviou
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ral effects  
Expert 1 ALAN TO L ALAN TO L ALAN TO L ALAN TO L U TO ALAN 
Expert 2 L ALAN TO L ALAN TO L ALAN TO L U TO ALAN 
Expert 3 L L L L ALAN TO L 
Expert 4 L L ALAN ALAN TO L ALAN 
Expert 5 L L ALAN TO L ALAN ALAN 
Expert 6 ALAN L ALAN ALAN ALAN 
Expert 7 ALAN L U TO L ALAN U TO ALAN 
Expert 8 L L L L ALAN 
Expert 9 L L L L L 
Expert 10 L L ALAN TO L ALAN TO L ALAN 
Range ALAN TO L ALAN TO L U TO L ALAN TO L U TO L 
 
  
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 601 
 
Appendix E.  Report on BMD calculations on general toxicity and proliferative changes in the 
mammary gland 
General introduction 
In this Annex the results of the BMD modelling for “likely”effects (kidney and liver effects; 
proliferative changes in mammary gland) are presented. For the liver and kidney effects data as 
reported in two rodent multigeneration studies (Tyl et al., 2002 and Tyl et al., 2008) have been 
considered (Part A). For the evaluation of mammary duct hyperplasia, the data from the recent US 
FDA/NCTR study (2013) have been used (Part B). 
For all the new dose-response modelling of the individual organ weight data (Tyl et al, 2008), the 
statistical package PROAST (version 40.7) has been used, obtained directly from RIVM, through 
personal contact. For the previous dose-response modelling of the histopathological data (liver 
hypertrophy and mammary duct hyperplasia), PROAST version 38.6 has been used. This version is no 
longer available at the website (www.proast.nl), but a more recent version (38.9) can be downloaded. 
Using the PROAST package, the 95 % lower confidence limit (one-sided) of the Benchmark dose 
(BMDL) was calculated. For each evaluation, depending on the type of data evaluated, the statistical 
models for continuous data (organ weights) or for quantal data (histopathology) were used.  
All evaluations were carried out with the following setting: 
• Benchmark dose-response (BMR, or CES = critical effect size) 10 % extra risk for all effects  
• No restrictions for model parameters to limit e.g. steepness of the fitted dose-response curves. 
For all evaluations a P-value for goodness of fit of 0.05 was used as criterion to decide on 
acceptability of modelling output. 
PART A 
Report on BMD calculation on general toxicity from Tyl et al. (2008)  
In compliance with the Opinion of the EFSA Scientific Committee on the use of the Benchmark dose 
(BMD) approach in Risk Assessment (EFSA, 2009), the results obtained on general toxicity in the 
reproductive toxicity studies with BPA in rats (Tyl et al., 2002) and mice (Tyl et al., 2008) were 
submitted to statistical dose-response modelling. From these studies kidney weight accompanied by 
nephropathy (mice), liver weight  (mice and rats) and histological changes in liver have been identified 
as critical effects (see Section 3.2.4). Given that a NOAEL of 5 mg/kg bw per day has been 
established from both the rat (Tyl et al., 2002) and the mouse  study (Tyl et al., 2008), but that the 
HEDFs for the mouse are much lower than for rats, the focus of the BMD analysis was on the Tyl et 
al. (2008) study in mice.  
 
The necessary data (see Table 77) were retrieved from the paper (Tyl et al., 2008), the supplementary 
file available through the respective journal‘s website and the full study report with individual data, 
which were kindly provided to EFSA shortly after the end of the public consultation (March 2014). 
1.1 Experimental data  
The BMD and BMDL were estimated using data collected by Tyl et al. (2008). For the body and organ 
weights individual data from the full study report  (Tyl et al., 2008) were used. The data on the 
histological changes (centrilobular hepatocellular hypertrophy) were taken from the publication and 
the supplementary data (Tyl et. al., 2008). The information used is presented in Table 77 in a 
summarised form. Since left and right kidney weights are not independent variables, the kidney 
weights have been evaluated as mean kidney weight per animal (i.e. left + right kidney weight divided 
by 2). Relative kidney weights are the mean kidney weights divided by the body weight. Relative liver 
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weight is liver weight divided by body weight. A lack of dose-response relationship was observed for 
nephropathy in both sexes. Therefore no model was obtained with acceptable fit and no BMDL could 
be calculated for this effects.  
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Table 77:  Critical general toxicological effects in mice in the adult F0 and F1 generations from Tyl et al. (2008). 
Generation / Sex        Endpoint    BPA mg/kg bw per day 
  0 0.003  0.03  0.3  5  50  600  
ORGAN WEIGHTS& 
F0-males Number of animals 55 28  28  28  28  28  27  
 Absolute liver weight (g)  2.123±0.204 2.168±0.271 2.180±0.297 2.215±0.218 2.246±0.223 2.226±0.243 2.498±0.324@ 
 Relative  liver weight (% bw) 5.399±0.414 5.419±0.601 5.545±0.369 5.490±0.413 5.573±0.367 5.628±0.478 6.317±0.883 
 Abs mean kidney weight (g)  0.386±0.041 0.385±0.051 0.383±0.045 0.397±0.041 0.408±0.064 0.417±0.043 0.464±0.110@ 
 Rel mean kidney weight (% 
bw)  
0.983±0.097 0.961±0.112 0.979±0.119 0.985±0.100 1.008±0.113 1.057±0.113 1.171±0.110 
         
F1-parental males# Number of animals 54  27  27  28  28  27  27  
 Absolute liver weight (g)  2.074±0.289*  2.121±0.204@  2.088±0.226  2.158±0.256  2.105±0.247  2.139±0.271@ 2.428±0.449  
 Relative  liver weight (% bw) 5.311±0.432 5.289±0.277 5.249±0.435 5.467±0.509 5.450±0.375 5.551±0.387 6.480±1.037 
 Abs mean kidney weight (g)  0.368±0.049  0.396±0.069  0.382±0.049  0.393±0.034  0.408±0.053  0.402±0.035 0.432±0.059 
 Rel mean kidney weight (% 
bw)  
0.947±0.105  0.988±0.0139  0.963±0.112  1.000±0.108 1.058±0.117  1.042±0.099 1.153±0.131 
         
F0-females Number of animals 56  28  27  27  27  28  28  
 Absolute liver weight (g)  2.733±0.481  2.871±0.451  2.752±0.510  2.785±0.421  2.603±0.270  2.710±0.465  3.293±0.802  
 Relative  liver weight (% bw) 7.808±1.061 8.088±0.821 7.750±1.034 7.857±0.820 7.491±0.508 7.837±1.051 9.162±1.705 
 Abs mean kidney weight (g)  0.307±0.045  0.311±0.039  0.320±0.038  0.319±0.035  0.323±0.028  0.321±0.043  0.350±0.044  
 Rel mean kidney weight (% 
bw)  
0.881±0.111  0.878±0.078  0.908±0.095  0.904±0.075  0.933±0.084  0.936±0.141  0.985±0.118  
         
F1-parental 
females# 
Number of animals 55  28  27  27  26  27  27  
 Absolute liver weight (g)  2.939±0.0507  2.889±0.512  2.845±0.492  3.089±0.476  2.825±0.470  2.776±0.585  3.1065±0.711 
 Relative  liver weight (% bw) 7.951±0.823 7.690±0.922 7.815±0.917 8.078±0.871 7.756±0.832 7.549±0.985 8.727±1.543 
 Abs mean kidney weight (g)  0.324±0.039  0.311±0.031  0.318±0.037  0.348±0.035  0.321±0.044 0.323±0.041  0.334±0.051  
 
 
Rel mean kidney weight (% 
bw)  
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Generation / Sex        Endpoint    BPA mg/kg bw per day 
  0 0.003  0.03  0.3  5  50  600  
 
HISTOPATHOLOGICAL OBSERVATIONS$ 
 Centrilobular hepatocyte hypertrophy  
F0-males   6/56 (10.7)  1/10 (10)  2/10 (20)  2/10 (20)  0/10 (0)  4/10 (40)  10/10 (100)  
F1-males   7/55 (12.7)  0/10 (0)  0/10 (0)  4/10 (40)  2/10 (20)  1/10 (10)  4/10 (40)  
F0-females   1/56 (1.8)  0/10 (0)  0/10 (0)  0/10 (0)  0/10 (0)  1/10 (10)  6/10 (60)  
F1-females   2/55 (3.6)  0/10 (0)  0/10 (0)  0/10 (0)  0/10 (0)  3/11 (27.3)  7/10 (70)  
 Nephropathy  
F0-males   12/56 (21.4)  0/10 (0.0)  3/10 (30.0)  2/10 (20.0)  2/10 (20.0)  1/10 (10.0)  4/10 (40.0)  
F1-parental males   6/55 (10.9)  2/10 (20.0)  0/10 (0.0)  1/10 (10.0)  2/10 (20.0)  0/10 (0.0)  4/10 (40.0)  
F1-retained males   8/50 (16.0)  1/10 (10)  0/10 (0.0)  0/10 (0.0)  2/10 (20.0)  0/10 (0.0)  3/10 (10.0)  
 
& mean ± SD; # animals were randomly selected from the dose groups, but it is not clear if littermates could be present in each selected group. Brother-sister combinations for mating were not 
allowed. $ number observed/ number examined (percentage); @ N=28; * N=55. 
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1.2 Results 
1.2.1 Kidney Data 
BMD assessment for absolute mean kidney weight 
Table 78 shows the BMD confidence intervals for the absolute mean kidney weights for the four 
subgroups male/female F0/F1, using generation and sex as a covariate. Figure 21 shows the associated 
data and the dose-response curves for the two models that described the data most adequately (i.e. 
Exponential and Hill model 3). The data for the F1 females contained insufficient information, which 
resulted in a very wide confidence interval around the BMD. Also for the other groups (F0 
males/females and F1 males) rather wide confidence intervals around the BMD were obtained. 
Nevertheless, from this analysis the F0 males were found to be the most sensitive group, with a BMD 
of 22 (Exponential 3) or 22.4 (Hill 3) mg/kg bw per day, a BMDL of 3.42 mg/kg bw per day and a 
BMDU of 91.69 mg/kg bw per day (encompassing the results of both models).  
 
Figure 21:   Dose-response modelling for absolute mean kidney weight. CED (critical effect dose) 
is the BMD for a 10% increase in absolute mean kidney weight. Green crosses: females F1; 
blue diamonds: males F1; black circles: females F0; red triangles: males F0. Horizontal axis: 
log dose; Vertical axis: absolute mean kidney weight (g). 
Table 78:   Summary of the results obtained for the models fitted considering generations F0 and F1 
and sex for absolute mean kidney weight changes.  
 
Model used Full Exp 3 Hill 3 
N° of parameter 29 10 10 
LL* 576.65 563.88 564.02 
F0-Female 
BMD10 NA 231 225 
BMDL10 NA 36.23 36.27 
BMDU10 NA 2342 2294 
F0-Male 
BMD10 NA 22 22.4 
BMDL10 NA 3.42 3.55 



















 version: 40.7  
 loglik    563.88  
 var-    0.0163  
 a-F0f    0.307  
 a-F0m    0.379  
 a-F1f    0.32  
 a-F1m    0.374  
 CED-F0f    231  
 CED-F0m    22  
 CED-F1f    209000  
 CED-F1m    85.7  
 d-    0.212  
   CES    0.1  
 conv :  1  
 scaling factor on x :  1  
 dtype :  1  
    selected :  all  
 removed:  
    nonatione  
    covariate: Generation.sex  
   CEDL-F0f    36.23  
 CEDU-F0f    2342  
 CEDL-F0m    3.42  
 CEDU-F0m    91.26  
 CEDL-F1f    2061  
 CEDU-F1f    Inf  
 CEDL-F1m    10.91  
 CEDU-F1m    526.3 



















 version: 40.7  
 loglik    564.02  
 var-    0.0162  
 a-F0f    0.307  
 a-F0m    0.379  
 a-F1f    0.32  
 a-F1m    0.374  
 CED-F0f    225  
 CED-F0m    22.4  
 CED-F1f    234000  
 CED-F1m    86.6  
 d-    0.202  
   CES    0.1  
 conv :  1  
 scaling factor on x :  1  
 dtype :  1  
    selected :  all  
 removed:  
    none  
    covariate: Generation.sex  
   CEDL-F0f    36.27  
 CEDU-F0f    2294  
 CEDL-F0m    3.546  
 CEDU-F0m    91.69  
 CEDL-F1f    2063  
 CEDU-F1f    Inf  
 CEDL-F1m    11.62  
 CEDU-F1m    521.7 
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BMDU10 NA 91.26 91.69 
F1-Female 
BMD10 NA 209000 234000 
BMDL10 NA 2061 2063 
BMDU10 NA ∞ ∞ 
F1-Male 
BMD10 NA 85.7 86.6 
BMDL10 NA 10.91 11.62 
BMDU10 NA 526.3 521.7 
* LL: Log-likelihood 
 
 
BMD assessment for relative mean kidney weight 
Table 79 shows the BMD confidence intervals for the relative mean kidney weights for  the four 
subgroups male/female F0/F1, using generation and sex as a covariate. Figure 22 shows the associated 
data and the dose-response curves for the two models that described the data most adequately (i.e. 
Exponential and Hill model 3). In comparison with the analysis for absolute mean kidney weight, the 
data for the F1 females contained now sufficient information to estimate a BMD with a fairly narrow 
confidence interval. Also for the other groups (F0 males/females and F1 males) similar narrow 
confidence intervals around the BMD were obtained. By correcting the individual kidney weights for 
the individual body weights an additional source of uncertainty has been removed. From this analysis 
the F1 males were found to be the most sensitive group, with a BMD of 34.8 (Exponential 3) or 36.7 
(Hill3) mg/kg bw per day, a BMDL of 8.96 mg/kg bw per day and a BMDU of 108.9 mg/kg bw per 
day (encompassing the results of both models). 
 
 
Figure 22:   Dose-response modelling for relative mean kidney weight. CED (critical effect dose) 
is the BMD for a 10% increase in relative mean kidney weight. Green crosses: females F1; 
blue diamonds: males F1; black circles: females F0; red triangles: males F0. Horizontal axis: 
log dose; Vertical axis: Relative mean kidney weight. 
  
 m3-ab 
 version: 40.7  
 loglik    702.56  
 var-    0.0118  
 a-F0f    0.00882  
 a-F0m    0.0096  
 a-F1f    0.00867  
 a-F1m    0.00955  
 CED-F0f    334  
 CED-F0m    35.1  
 CED-F1f    1570  
 CED-F1m    34.8  
 d-    0.244  
   CES    0.1  
 conv :  1  
 scaling factor on x :  1  
 dtype :  1  
    selected :  all  
 removed:  
    none  
    covariate: Generation.sex  
  

























 CEDL-F0f    86.78  
 CEDU-F0f    1930  
 CEDL-F0m    10.68  
 CEDU-F0m    96.44  
 CEDL-F1f    287.4  
 CEDU-F1f    37800  
 CEDL-F1m    8.956  
 CEDU-F1m    106.2 


























 version: 40.7  
 loglik    702.61  
 var-    0.0118  
 a-F0f    0.00881  
 a-F0m    0.0096  
 a-F1f    0.00867  
 a-F1m    0.00955  
 CED-F0f    332  
 CED-F0m    36  
 CED-F1f    1560  
 CED-F1m    36.7  
 d-    0.233  
   CES    0.1  
 conv :  1  
 scaling factor on x :  1  
 dtype :  1  
    selected :  all  
 removed:  
    none  
    covariate: Generation.sex 
   CEDL-F0f    87.41  
 CEDU-F0f    1926  
 CEDL-F0m    11.07  
 CEDU-F0m    97.32  
 CEDL-F1f    283.9  
 CEDU-F1f    40790  
 CEDL-F1m    9.738  
 CEDU-F1m    108.9 
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Table 79:   Summary of the results obtained for the models fitted considering generations F0 and F1 
and gender for relative mean kidney weights changes. 
 
Model used Full Exp 3 Hill 3 
N° of parameter 29 10 10 
LL* 714.07 702.44 702.61 
F0-Female 
BMD10 NA 334 332 
BMDL10 NA 86.78 87.41 
BMDU10 NA 1930 1926 
BMD10/BMDL10 NA 3.85 3.8 
F0-Male 
BMD10 NA 35.1 36 
BMDL10 NA 10.68 11.1 
BMDU10 NA 96.44 97.3 
BMD10/BMDL10 NA 3.29 3.24 
F1-Female 
BMD10 NA 1570 1560 
BMDL10 NA 287.4 283.9 
BMDU10 NA 37800 40790 
BMD10/BMDL10 NA 5.46 5.49 
F1-Male 
BMD10 NA 34.8 36.7 
BMDL10 NA 8.96 9.7 
BMDU10 NA 106.2 108.9 
BMD10/BMDL10 NA 3.88 3.78 
* LL: Log-likelihood 
 
1.2.2 Liver Data 
BMD assessment for absolute liver weight 
Table 80 shows the BMD confidence intervals for the absolute liver weights for  the four subgroups 
male/female F0/F1, using generation and sex as a covariate. Figure 23 shows the associated data and 
the dose-response curves for the two models that described the data most adequately (i.e. Exponential 
and Hill model 2). The data for the F1 females contained insufficient information, which resulted in a 
very wide confidence interval around the BMD. For the other groups (F0 males/females and F1 males) 
rather narrow confidence intervals around the BMD were obtained. From this analysis the F0 males 
were found to be the most sensitive group, with a BMD of 290.3 (Exponential 2) or 300.4 (Hill 2) 
mg/kg bw per day, a BMDL of 213.1 mg/kg bw per day and a BMDU of 456.8 mg/kg bw per day 
(encompassing the results of both models). 
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Figure 23:  Dose-response modelling for absolute liver weight. CED (critical effect dose) is the BMD 
for a 10% increase in absolute liver weight. Green crosses: females F1; blue diamonds: males F1; 
black circles: females F0; red triangles: males F0. Horizontal axis: log dose/1000; Vertical axis: 
absolute liver weight (g). Panels E2 and H2 show the dose-response curves calculated with 
Exponential model 2 and Hill model 2, respectively. 
Table 80:  Summary of the results obtained for the models fitted considering generations F0 and F1 
and gender for absolute liver weight changes. 
 
 
Model used Full Exp 2 Hill 2 
N° of parameter 32 12 12 
LL*  434.85  425.9  425.96 
F0-Female 
BMD10 NA 290.3 300.4 
BMDL10 NA 213.1 227.2 
BMDU10 NA 455.4 456.8 
BMD10/BMDL10 NA 1.36 1.32 
F0-Male 
BMD10 NA 334.3 343.1 
BMDL10 NA 266.9 278.9 
BMDU10 NA 447.1 450.6 
BMD10/BMDL10 NA 1.25 1.23 
F1-Female 
BMD10 NA 995 967.9 
BMDL10 NA 1.00E-15 1.00E-15 
BMDU10 NA ∞ ∞ 
BMD10/BMDL10 NA 9.95E+17 9.679E+17 
F1-Male 
BMD10 NA 358.7 366.3 
BMDL10 NA 272.1 283.8 
BMDU10 NA 526.1 525.9 
BMD10/BMDL10 NA 1.32 1.29 

























 E2-CED: y = a*exp(bx) 
 version: 40.7  
 loglik    425.94  
 var-F0f    0.0329  
 var-F0m    0.0121  
 var-F1f    0.0395  
 var-F1m    0.0161  
 a-F0f    2.7  
 a-F0m    2.16  
 a-F1f    2.85  
 a-F1m    2.09  
 CED-F0f    0.29  
 CED-F0m    0.334  
 CED-F1f    0.995  
 CED-F1m    0.359  
   CES    0.1  
 conv :  1  
 scaling factor on x :  1000  
 dtype :  1  
    selected :  all  
 removed:  
    none  
   covariate:  Generation.sex  
 CEDL-F0f    0.2131  
 CEDU-F0f    0.4554  
 CEDL-F0m    0.267  
 CEDU-F0m    0.4471  
 CEDL-F1f    0  
 CEDU-F1f    Inf  
 CEDL-F1m    0.2721  
 CEDU-F1m    0.5261 





















 H2-CED: a * (1 - x/(b+x)) 
 version: 40.7  
 loglik    425.96  
 var-F0f    0.0329  
 var-F0m    0.0121  
 var-F1f    0.0395  
 var-F1m    0.0161  
 a-F0f    2.7  
 a-F0m    2.16  
 a-F1f    2.85  
 a-F1m    2.09  
 CED-F0f    0.3  
 CED-F0m    0.343  
 CED-F1f    0.968  
 CED-F1m    0.366  
   CES    0.1  
 conv :  1  
 scaling factor on x :  1000  
 dtype :  1  
    selected :  all  
 removed:  
    none  
   covariate:  Generation.sex  
 
 CEDL-F0f    0.2272  
 CEDU-F0f    0.4568  
 CEDL-F0m    0.2789  
 CEDU-F0m    0.4506  
 CEDL-F1f    0  
 CEDU-F1f    Inf  
 CEDL-F1m    0.2838  
 CEDU-F1m    0.5259 
covariate:  Generation.sex  
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BMD assessment for relative liver weight 
Table 81 shows the BMD confidence intervals for the relative liver weights for  the four subgroups 
male/female F0/F1, using generation and sex as a covariate. Figures 24 shows the associated data and 
the dose-response curves for the two models that described the data most adquately (i.e. Exponential 
and Hill model 2). In comparison with the analysis for absolute liver weight, the data for the F1 
females contained now sufficient information to estimate a BMD with a fairly narrow confidence 
interval. Also for the other groups (F0 males/ females and F1males) similar narrow confidence 
intervals around the BMD were obtained. Obviously, by correcting the individual liver weights for the 
individual body weights an additional source of uncertainty has been removed. From this analysis, the 
F1 males were found to be the most sensitive group, with a BMD of 266 (Exponential 2) or 278.9 (Hill 
2) mg/kg bw per day, a BMDL of 229 mg/kg bw per day and a BMDU of 328.7 mg/kg bw per day 





Figure 24:   Dose-response modelling for relative liver weight changes. CED (critical effect dose) 
is the BMD for a 10% increase in relative liver weight. Green crosses: females F1; blue 
diamonds: males F1; black circles: females F0; red triangles: males F0. Horizontal axis: log 
dose; Vertical axis: relative liver weight. Panels E2 and H2 show the dose-response curves 
calculated with Exponential model 2 and Hill model 2, respectively. 
  
 






















 E2-CED: y = a*exp(bx) 
 version: 40.7  
 loglik    723.93  
 var-F0f    0.0172  
 var-F0m    0.00732  
 var-F1f    0.0167  
 var-F1m    0.00771  
 a-F0f    0.0773  
 a-F0m    0.0546  
 a-F1f    0.0777  
 a-F1m    0.0534  
 CED-F0f    0.321  
 CED-F0m    0.34  
 CED-F1f    0.508  
 CED-F1m    0.266  
   CES    0.1  
 conv :  1  
 scaling factor on x :  1000  
 dtype :  1  
    selected :  all  
 removed:  
    none  
    covariate: Generation.sex  
   CEDL-F0f    0.249  
 CEDU-F0f    0.4526  
 CEDL-F0m    0.2823  
 CEDU-F0m    0.426  
 CEDL-F1f    0.3482  
 CEDU-F1f    0.9407  
 CEDL-F1m    0.229  
 CEDU-F1m    0.3186 
 






















 H2-CED: a * (1 - x/(b+x)) 
 version: 40.7  
 loglik    723.85  
 var-F0f    0.0172  
 var-F0m    0.00733  
 var-F1f    0.0167  
 var-F1m    0.00771  
 a-F0f    0.0773  
 a-F0m    0.0546  
 a-F1f    0.0777  
 a-F1m    0.0535  
 CED-F0f    0.33  
 CED-F0m    0.348  
 CED-F1f    0.507  
 CED-F1m    0.279  
   CES    0.1  
 conv :  1  
 scaling factor on x :  1000  
 dtype :  1  
    selected :  all  
 removed:  
    none  
   
 CEDL-F0f    0.2615  
 CEDU-F0f    0.455  
 CEDL-F0m    0.2936  
 CEDU-F0m    0.4307  
 CEDL-F1f    0.355  
 CEDU-F1f    0.9154  
 CEDL-F1m    0.2431  
 CEDU-F1m    0.3287 
 covariate: Generation.sex  
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Table 81:  Summary of the results obtained for the models fitted considering generations F0 and F1 
and gender for relative liver weight changes. 
 
Model used Full Exp 2 Hill 2 
N° of parameter 32 12 12 
LL* 735.14 723.93 723.85 
F0-Female 
BMD10 NA 321.2 330.1 
BMDL10 NA 249 261.5 
BMDU10 NA 452.6 454.9 
BMD10/BMDL10 NA 1.29 1.26 
F0-Male 
BMD10 NA 339 348.2 
BMDL10 NA 282.3 293.7 
BMDU10 NA 426 430.7 
BMD10/BMDL10 NA 1.2 1.19 
F1-Female 
BMD10 NA 508 506.6 
BMDL10 NA 348.2 355 
BMDU10 NA 940.7 915.4 
BMD10/BMDL10 NA 1.46 1.43 
F1-Male 
BMD10 NA 266 278.9 
BMDL10 NA 229 243.1 
BMDU10 NA 318.6 328.7 
BMD10/BMDL10 NA 1.16 1.15 
* LL: Log-likelihood 
 
 
BMD assessment for centrilobular hepatocellular hypertrophy 
Table 82 shows the BMD confidence intervals for centrilobular hypertrophy of liver cells for the F0 
males. As can be seen in Figure 25, all four goups were analysed, but the F0 males gave the lowest 
BMD values. Since histopathological data are quantal rather than continous, for these data additional 
(“classical”models were also included in the assessment (the “classical models” cannot be used to 
evaluate  continuous data). From this analysis, the lowest BMDL of 3.46 mg/kg bw per day was 
obtained with the Gamma model. The BMD ranged from 12.8 to 43.5 mg/kg bw  per day and the 
highest BMDU of 67.2 was obtained with Exponential model 5. 
Table 82:   Dose-response modelling results for centrilobular hepatocellular hypertrophy. 
model.list npar loglik accepted bmd bmdl bmdu ab.txt sens.lev 
null 1 -184 NA NA NA    
full 28 -118 NA NA NA    
two.stage 9 -128 yes 13.6 6.19 39.2 ab F0m 
log.logist 9 -129 yes 13.3 4.26 34.9 ab F0m 
Weibull 9 -128 yes 12.5 3.60 36.2 ab F0m 
log.prob 9 -128 yes 13.1 4.43 33.3 ab F0m 
gamma 9 -128 yes 12.6 3.46 35.5 ab F0m 
logistic 8 -131 yes 21.4 12.70 66.4 ab F0m 
LVM:E5- 10 -127 yes 43.5 7.27 67.2 ab F0m 
LVM:H2- 8 -129 yes 12.8 6.02 29.7 ab F0m 
data: mouse; response: Centr_hyperthrophy; covariate: gnrtn*sex; CED: 0.1 extra risk; constraint: no; P-value GoF: 0.05  
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Figure 25:   Dose-response curves for centrilobular hepatocellular hypertrophy. CED (critical 
effect dose) is the BMD for a 10% increase in incidence of hepatocellular hypertrophy. Green 
crosses: males F1; blue x-es: females F1; black circles: males F0; red triangles: females F0. 
Horizontal axis: log dose; Vertical axis: fraction responding. 
In general, models from both exponential and Hill families were fitting the dose-response data for 
the absolute and relative liver and kidney weight changes well, except for the absolute liver and 
kidney weight changes in F0 females, where very wide confidence intervals around the BMDs 
were obtained, because of lack of dose-response information in the data. However, considering 
that organ weights are dependent on body weight, after correction for body weight (i.e. by 
calculation of relative organ weights) also for the F0 females adequate dose-response information 
could be identified in these studies, and for the relative organ weight changes the information in 
the F0 female groups has been included. 
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PART B 
Dose-response modelling on mammary duct hyperplasia after exposure to BPA from the US 
FDA/NCTR (2013) / Delclos et al. (2014)   
In compliance with the Opinion of the EFSA Scientific Committee on the use of the Benchmark dose 
(BMD) approach in Risk Assessment (EFSA, 2011), the results obtained on mammary duct 
hyperplasia in a subchronic toxicity study with BPA in rats have been submitted to statistical dose-
response modelling. A full study report with the individual data (US FDA/NCTR, 2013 and Delclos et 
al., 2014) was available for dose-response modelling. In the study, animals were administered BPA by 
oral gavage from GD 6 through the start of labour and then directly to pups from PND 1 until 
termination at PND 90 at the doses of 0, 2.5, 8, 25, 80, 260, 840, 2 700, 100 000 and 300 000 µg/kg 
bw per day.  
Microscopic evaluation of the mammary gland was performed at PND 21 and PND 90. An increase in 
the incidence of mammary duct hyperplasia in females was observed at both times, with statistically 
significant effects at the BPA doses of 2 700 and 100 000 µg/kg bw per day at PND 21 and at the 
doses of 2 700, 100 000 and 300 000 µg/kg bw per day at PND 90. The severity of the duct 
hyperplasia was minimal in all the observed findings and in all dose groups.  
 
BMD calculations were performed for mammary duct hyperplasia at both PND 21 and PND 90, and 
with PND 21 and PND 90 as a covariate.  
Table 83:   Dose-response information for mammary duct hyperplasia in BPA exposed rats (data 
from FDA/NCTR, 2013; Delclos et al, 2014) 
 Summary data on incidence of 
mammary duct hyperplasia in female 
rats at PND 21 (US FDA/NCTR, 2013 
and Delclos et al., 2014) 
SUMMARY DATA ON INCIDENCE OF 
MAMMARY DUCT HYPERPLASIA IN FEMALE 
RATS AT PND 90 (US FDA/NCTR, 2013 
AND DELCLOS ET AL., 2014) 
Dose (µg/kg bw per day) Incidence Group size Incidence Group size 
0.0 0 16 7 20 
2.5 2 19 11 23 
8 1 13 6 18 
25 4 19 11 21 
80 1 20 8 20 
260 1 13 8 20 
840 2 18 9 20 
2 700 5 17 11 20 
100 000 6 17 13 20 
300 000 3 12 14 19 
 
The severity of the mammary duct hyperplasia was also reported and was minimal hyperplasia for all 
the observations in all doses. This will therefore not influence the BMD calculations. 
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BMD calculation on mammary duct hyperplasia females with PND 21 and PND 90 as covariate 
Table 84:  Summary of BMD analysis on mammary duct hyperplasia. The column “covar” indicates 
which parameters were found to differ significantly between the subgroups. The column “level” 
indicates which subgroup was found to be most sensitive. 
Results from benchmark dose calculations for mammary duct hyperplasia in female rats with PND 21 and 
PND 90 as covariate (US FDA/NCTR, 2013 and Delclos et al., 2014) 
Model covar npar loglike accept BMD BMDL10 BMDU level 
null NA 1 -233.24 -- NA NA NA -- 
full NA 20 -194.76 -- NA NA NA -- 
Two-stage a 4 -204.14 yes 62 200 36 100 147 000 -- 
Log-logistic a 4 -199.97 yes 17.3 0.15 197 -- 
Weibull b 4 -210.14 no 1.00E-06 NA NA PND 90 
Log-prob a 4 -200.08 yes 16.8 0.184 162 -- 
Gamma a 4 -199.89 yes 14.9 0.085 220 -- 
Logistic ab 4 -205.33 yes 46 100 28800 113000 PND 90 
LMV:E5- a 5 -199.84 yes 943 2.09E-06 3 020 PND 90 
LVM:H5- a 5 -200.26 yes 1.3 4.70E-06 2 390 PND 90 
BMR: 0.1 extra risk; P-value GoF: 0.05; constraint: no 
 
From the data provided in Table 84 the CEF Panel concluded that given the wide differences in the 
results obtained with various models (see also Figure 26) and wide confidence intervals, obtained with 
some of the models, the dose-response information in the FDA/NCTR study is too limited to derive 
with any confidence BMDL for this endpoint. 
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Figure 26:   The various models fitted to mammary duct hyperplasia, observed in the two 
subgroups (PND21 (black circles) and PND 90 (red triangles) females). Some models did not 
distinguish between the two subgroups with respect to sensitivity; for other models the PND 
90 females turned out to be the most sensitive subgroup. Horizontal axis: log dose; Vertical 
axis: fraction responding. 
Conclusions of the BMD calculation on general toxicity and on mammary duct hyperplasia 
The summary Table 85 below shows the BMDL10 values obtained for liver and kidney effects in the 
F0 and F1 generations of mice. A lack of dose-response relationship was observed in the effect on 
nephropathy in both sexes. Therefore no model was obtained with acceptable fit and no BMDL10 
could be calculated for these toxic effects. 
A benchmark response (BMR) of 10% was chosen both for the kidney and liver effects, based on the 
view of the CEF Panel that changes in the kidney and liver weight, and hepatocyte hypertrophy of less 
than 10% should not be regarded as adverse. The CEF Panel also took into account that the adaptive 
nature of the liver changes and that pathological changes in the kidney were marginal and were only 
observed at the highest dose level.  
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Table 85:  Dose-response relationships for general toxicity of BPA in mice (Tyl et al., 2008) 
Group Toxic end point BMDL10$ BMD10$ BMDU10$ 
F0 males Absolute mean kidney weight 3.42 22 – 22.4 91.69 
F1 males Relative mean kidney weight 8.96 35.1 - 36 108.9 
F0 males Absolute liver weight 213.1 290.3 -300.4 456.8 
F1 males Relative liver weight 229 266 – 278.9 328.7 
F0 males Centrilobular hepatocellular 
hypertrophy 
3.46@1 12.8 – 43.5@2 67.2@3 
$: values expressed as mg/kg bw per day; for the BMDL and BMDU the lower and upper bound values are 
given, irrespective of the model with which they were obtained; for the BMD the two values for the two separate 
models are given. @1: lowest of 7 models, @2: range of 7 models, @3: highest of 7 models 
Although the lowest BMDL10 from the modelling was observed for hepatocyte hypertrophy, the effect 
of BPA on hepatocyte hypertrophy was regarded by the CEF Panel as adaptive and as a less critical 
effect than the effect in the kidney. In addition, the analysis of the liver weight changes indicated a 
much higher level for the BMD for this endpoint, while a relationship between liver weight changes 
and liver hypertrophy is known to exist. That supports that the liver hypertrophy observed here has 
only marginal relevance if any at all. The CEF Panel has therefore selected the endpoint of relative 
mean kidney weight in the mouse, for which a BMDL10 of 8 960 µg/kg bw per day was derived. This 
BMDL can be used as a PoD in the risk characterisation. 
The CEF Panel noted that there is uncertainty regarding the robustness of the BMD modeling for on 
mammary duct hyperplasia. This is further discussed in section 3.9.6. of the main text. The CEF Panel 
concluded that given the wide differences in the results obtained with the various models and the wide 
confidence intervals, obtained with some of the models, the dose-response information in the 
FDA/NCTR study is too limited to derive with any confidence BMDL for this endpoint. 
  
Scientific opinion on BPA: Part II –Toxicological assessment and risk characterisation 
 
EFSA Journal 2015;13(1):3978 616 
ABBREVIATIONS 
ABC Atp-Binding Cassette 
Abs Alveolar Buds 
ACHN Human Kidney Adenocarcinoma Cells 
ADHD Attention Deficit Hyperactivity Disorder  
ADME Absorption, Distribution, Metabolism And Excretion 
AFC Panel Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food  
AFSSA Agence Française de Sécurité Sanitaire des Aliments  
AGD Ano Genital Distance 
AGRP Agouti-Regulated Protein 
AhR Aryl Hydrocarbon Receptor 
AIST Japanese Institute of Advanced Industrial Science and Technology  
ALARA As Low As Reasonably Achievable 
ALP Alkaline Phosphatase 
AMPA Α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid 
AMY Amygdala 
ANOVA Analysis of Variance 
ANSES French Agency For Food, Environmental And Occupational Health And Safety 
ARC Arcuate Nucleus 
ASD Autistic Spectrum Disorders 
ASIP Agouti Signaling Protein 
ATP III Adult Treatment Panel Iii 
AUC Area Under The Curve 
AVPV Anteroventral Periventricular Nucleus  
BASC-2 Behaviour Assessment System For Children 2 
BAT Brown Adipose Tissue 
BBB Blood-Brain Barrier 
BCRP Breast Cancer–Resistant Protein 
BDNF Brain-Derived Neurotrophic Factor 
BfR Federal Institute For Risk Assessment  
BMD Benchmark Dose 
BMDL Benchmark Dose (Lower Confidence Limit) 
BMI Body Mass Index 
BMR Benchmark Response 
BPA Bisphenol A 
BPADS BPA Disulfate 
BPAG BPA-Glucuronide 
BrdU Bromodeoxyuridine 
BRCA Breast Cancer  
BRIEF-P Behaviour Rating Inventory of Executive Function-Preschool 
BUS Blood, Urine, and Sweat  
bw  Body Weight  
CA Chromosome Aberration 
CAD Coronary Artery Disease 
CADS Conners’ Adhd/Dsm-Iv Scales 
CASA Computer-Assisted Sperm Analysis 
CBCL Child Behavioural Checklist 
CBMA Cytokinesis Blocked Micronucleus Assay 
CBX Hemisuccinateester Carbenoxolone 
CDC Center For Disease Control And Prevention 
CDI Children Depression Inventory 
CED Critical Effect Dose 
CEF Panel Panel on Food Contact Materials, Enzymes, Flavourings And Processing Aids  
CERHR Center for the Evaluation of Risks to Human Reproduction 
CES Critical Effect Size 
CFSAN Center for Food Safety and Applied Nutrition 
CHD Coronaryheart Disease 
CI Confidence Interval 
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration 
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Cmax Maximum concentration 
CMV Cytomegalo Virus 
COX Cyclooxygenase 
CPT Continuous Performance Test 
CREB Camp-Response Element Binding Protein 
CRH Corticotrophin-Releasing Hormone 
Css Calculate Steady State Plasma Concentrations 
CTB Cudrania Tricuspidata Bureau  
CV Cardiovascular 
CVD Cardiovascular Disease 
CYP Cytochrome P450 
DA Dopamine 
DAF Dosimetric Adjustment Factor 
DAP Dialkyl Phosphate 
DBP Diastolic Blood Pressure 
2,5-DCP 2,5-Dichlorophenol 
DD Dermal Doses 
DEHP Di(2-Ethylhexyl)Phthalate 
DES Diethylstilboestrol 
D/LT Dark–Light Transition 
DMBA Dimethylbenzanthracene 
DMEM Dulbecco's Modified Eagle's Medium 
DMNT DNA Methyltransferases 
DMSO Dimethylsulfoxide  
DNA Desoxyribonucleic Acid  
DNEL Derived No Effect Level 
DNMT DNA Methyltransferase 
DO Oral Doses 
DOAJ Directory of Open Access Journals  
DOPAC 3,4-Dihydroxyphenylacetic Acid 
DOV Day Of Vaginal Opening 
DXA 
E2 
Dual-Energy X-Ray Absorptiometry 
Oestradiol 
EC European Commission 
ECG Electrocardiogram 
ECHA European Chemical Agency 
ECN Embryo Cell Number 
EDCs Endocrine-Disrupting Compounds 
EE, EE2 Ethinyl Oestradiol  
EEC European Economic Commission 
EFS Embryo Fragmentation Score 
EFSA European Food Safety Authority 
EGFR Epidermal Growth Factor Receptor 
EHR Enterohepatic Recirculation  
ELISA Enzyme-Linked Immunosorbent Assay 
EPA Exposure Factors Handbook 
EPM Elevated Plus Maze 
ER Estrogen Receptor 
ERα Estrogen Receptor Alpha 
ERRγ Estrogen-Related Receptor Gamma 
ERβ Estrogen Receptor Beta 
ERK Extracellular Signal-Regulated Kinases 
ESR Estrogen Receptor Beta 
EU  European Union  
EU-RAR European Union -Risk Assessment Report  
EZH2 Enhancer of Zeste Homolog 2 
FAO/WHO Food and Agriculture Organization /World Health Organization  
FBS Fetal Bovine Serum 
FDA Food and Drug Administration  
FENO Fraction of Exhaled Nitric Oxide 
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FEV Forced Expired Volume 
FLD  Fluorescence Detection  
FS Forced Swim 
FSANZ Food Standard Australia New Zealand  
FSH Folliculum Stimulant Hormon 
FST Forced Swimming Test 
GC  Gas Chromatography  
GC-ECNI/MS Gas Chromatography Coupled With Mass Spectrometry Operated In Electron Negative 
Ionization Mode 
GC/EI-MS/MS Gas Chromatography/Tandem Mass Spectrometry 
GC-MSD Gas Chromatography Coupled to a Mass Selective Detector 
GD Gestational Day 
GEN Genistein 
GFR Glomerular Filtration Rate 
GI Gastrointestinal 
GLP Good Laboratories Practice 
GluR1 Glutamate Receptor 1 
GnRH Gonadotropin-Receptor Hormone 
GPR30 G-Protein Coupled Receptor 
GSD Geometric Standard Deviation 
GSM Grey Scale Median 
HbA1c Glycated Hemoglobin 
HDL High Density Lipoproteins 
HED Human Equivalent Dose  
HEDF Human Equivalent Dose Factor 
HepG2 Human Hepatocellular Carcinoma Cells 
HFD High-Fat Diet 
HFEA Human Fertilisation and Embryology Authority 
HIP Hippocampus 
HLP High Leptin 
Hpcal1 Hippocalcin-Like 1 
HPLC High-Performance Liquid Chromatography 
HPLC-ESI-
MS/MS 
High Performance Liquid Chromatography – Electrospray Tandem Mass Spectrometry  
HPLC-MS/MS High-Performance Liquid Chromatography Tandem Mass Spectrometry  
HRBEC High Risk Donor Breast Epithelial Cells  
HRT Hormone Replacement Therapy 
HSD Hydroxysteroid Dehydrogenase 
IAP Intracisternal A Particle 
ICSI Intracytoplasmic Sperm Injection 
ID LC-MS-MS Isotope Dilution High-Performance Liquid Chromatography-Tandem Mass-Spectrometry 
IgE Immunoglobuline E 
IM-GSM Intima–Media Complex-Grey Scale Median 
IMT Intima-Media Thickness 
INSL3 Insulin-Like3 
ISHH In Situ Hybridization Histochemistry 
ISI Institute For Scientific Information 
IV Intravenous 
IVF In Vitro Fertilization  
JAK/Stat Janus Kinase/Signal Transducer And Activator Of Transcription   
JAM-A Junction Adherence Molecular A 
JRC Joint Research Center 
Kiss1 Kisspeptin 
LAD Low Adiponectin  
LAMP3 Lysosomal-Associated Membrane Protein 3 
LBW Low Birth Weight  
LC Liquid Chromatography  
LC-ED Liquid Chromatography With Electrochemical Detection 
LC-MS Liquid Chromatography Coupled With Mass Spectrometry 
LC/MS/MS Liquid Chromatography Coupled To Tandem Mass Spectrometer 
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LD Lactation Day 
LDES Learning Disability Evaluation Scale 
LDL Low-Density Lipoprotein 
LH Luteinizing Hormone 
LLE Liquid-Liquid Extraction 
LLOD Lower Level Of Detection 
LOAEL Lowest Observed Adverse Effect Level 
LOD  Limit Of Detection  
LOQ  Limit Of Quantification  
LPL Lipoprotein Lipase 
MaGiCAD Metabonomics And Genomics In Coronary Artery Disease 
MAO Monoamine Oxidase 
MAPK Mitogen-Activated Protein Kinase 
Mc3r, Mc4r Melanocortin Receptors 
MDR Multidrug Resistance 
MDRD Modification of Diet In Renal Disease 
MED Medulla oblongata 
MEHP Mono-(2-Ethylhexyl) Phthalate 
MEP Monoethyl Phthalate 
MiBP Monoisobutyl Phthalate 
MLH Mutl Homolog 
MM Mirrored Maze 
MMP Mono- Methyl Phthalate 
MN-PCE Micronucleated Polychromatic Erythrocytes 
MOA Mode of Action 
MOCEH  Mothers and Children's Environmental Health 
MOEs Margins of Exposure  
mPFC Medial Prefrontal Cortex 
mPSc Mid-Pachytene Spermatocytes 
mRNA Messenger RNA 
miRNA Microrna 
MRI Magnetic Resonance Imaging 
MRP Multidrug Resistance-Associated Proteins 
MSTFA N-Methyl-N-(Trimethylsilyl)Trifluoro-Acetamide 
MTOCs Modification Of The Microtubule Organizing Centers 
MTOCs Microtubule Organizing Centers 
MWM Morris Water Maze 
NCTR National Center For Toxicological Research  
ND Non-Detectable 
NFG Nerve Growth Factor 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences  
NMDA N-Methyl-D-Aspartate 
NMDAR N-Methyl-D-Aspartate Receptor  
NMDR Non-Monotonic Dose-Response 
NMDR Non-Monotonic Dose-Response  
NNS Network Neurobehavioral Scale 
NO Nitric Oxide 
NOAEL No Observed Adverse Effect Level 
NOD Non-Obese Pre-Diabetic 
NP Nonylphenol 
NTP National Toxicology Program 
ODF Outer Dense Fiber Protein  
OECD Organisation for Economic Co-Operation and Development  
OF Open Field 
OFT Open-Field Test 
OJ Official Journal 
OP Object Placement 
OP Octylphenol 
OR Object Recognition 
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OR Odds Ratio 
OVAR Epithelial Ovarian Cancer 
OVCAR Ovarian Epithelial Carcinoma Cells 
OVX Ovariectomized 
OW Overweight 
PAD Peripheral Arterial Disease 
PBDE Polybrominated Diphenyl Ether 
PBG Phenylbiguanide 
PBPK  Physiologically Based Pharmacokinetic Modelling  
PBTK Physiologically Based Toxicokinetic 
PC  Polycarbonate  
PCOS Polycystic Ovarian Syndrome 
pCREB p-Camp Response Element-Binding Protein 
PDE4D4 Phosphodiesterase Type 4 Variant 4 
PDI Protein Disulphide Isomerase 
PGR Progesterone Receptor 
PI3K/Akt Phosphatidylinositide 3-Kinases/Protein Kinase B 
PIN Prostate Intraepithelial Neoplasia 
PIVUS Prospective Investigation of the Vasculature in Uppsala Seniors 
PK Protein Kinase 
PKC Protein Kinase C 
PKG Protein Kinase G 
PLSD Protected Least Significant Difference 
PND Postnatal Days 
POL Postimplantation Loss 
PP  Polypropylene  
PR Progesterone Receptor 
PRL Prolactin  
PSD Post Synaptic Density 
PVC Poly Vinyl Chloride 
pWAT Perigonadic White Adipose Tissue 
QPCR Quantitative Real Time Polymerase Chain Reaction 
RES Resveratrol  
RGCs Radial Glial Cells 
RIA Radioimmunoassay 
RSE Relative Standard Error 
RT Real-Time 
SBP Systolic Blood Pressure  
SC’s Sister Chromatid Exchanges 
SCENIHR  Scientific Committee On Emerging And Newly Identified Health Risks  
SC Subcutaneous 
SCF Scientific Committee On Food 
s.d. Standard Deviation 
SD Standard Deviation 
SDN-POA Sexually Dimorphic Nucleus Of The Preoptic Area 
SEM Standard Error Of The Mean  
SERM Estrogen Receptor Modulator 
SGA Small For Gestational Age  
SHBG Sex Hormone-Binding Globulin 
SMART Study Of Metals And Assisted Reproductive Technologies 
SML Specific Migration Limit  
SPE Solid Phase Extraction 
SRC Steroid Receptor Activator  
SRD5A1 Steroid 5-Alpha- Reductase Type I  
SRS Social Responsiveness Scale 
StAR Steroidogenic Acute Regulatory 
SULT Sulfotransferases 
SVZ Sub-Ventricular Zone 
TEBs Terminal End Buds 
TED Tubular Epithelium 
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TDI Tolerable Dailay Intake 
t-TDI  Temporary- Tolerable Daily Intake 
TDs Terminal Ducts 
TNP Transition Protein 
TP Testosterone Propionate 
TR Thyroid Receptor 
TSH Thyroid-Stimulating Hormone 
TUNEL Terminal Deoxynucleotidyl Transferase Dutp Nick End Labeling  
TWA Time Weighted Average  
UF Uncertainty Factor  
UGT UDP-Glucuronyl-Transferase 
UNEP United Nations Environment Programme  
UTD Undescended Testes 
UWW Uterine Wet Weight 
VD Volume of Distribution 
VDR Vitamin D Receptor 
VEGF Vascular Endothelial Growth Factor 
WoE Weight of Evidence  
WT Wild-Type 
ZEA Zearalenone  
 
